{"title": "PDF", "author": "PDF", "url": "https://www.seimc.org/contenidos/gruposdeestudio/gesida/dcientificos/documentos/2011/gesidadcyrc2011-Documentoconsenso-TAR-adulto-verordenador.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nDocumento \u00a0de\u00a0consenso \u00a0de\u00a0Gesida/Plan \u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0respecto\u00a0\nal\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0adultos\u00a0infectados \u00a0por\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0\ninmunodeficiencia \u00a0humana\u00a0\u00a0\n(Actualizaci\u00f3n \u00a0enero\u00a02011)\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nPanel\u00a0de\u00a0expertos\u00a0de\u00a0Gesida\u00a0y\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n iiDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n iiiPanel:\u00a0\nCoordinadores: \u00a0\u00a0\nFernando \u00a0Lozano1\u00a0\nHospital\u00a0de\u00a0Valme.\u00a0Sevilla\u00a0\nPere\u00a0Domingo \u00a0Pedrol1\u00a0\nHospital\u00a0de\u00a0la\u00a0Santa\u00a0Creu\u00a0i\u00a0Sant\u00a0Pau.\u00a0Barcelona \u00a0\nRosa\u00a0Polo2\u00a0\nSecretar\u00eda \u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida.\u00a0Ministerio \u00a0de\u00a0Sanidad,\u00a0Pol\u00edtica\u00a0Social\u00a0e\u00a0Igualdad. \u00a0Madrid\u00a0\nRedactores: \u00a0\nKoldo\u00a0Aguirrebengoa1\u00a0\nHospital\u00a0de\u00a0Cruces,\u00a0Bilbao\u00a0Juan\u00a0Berenguer1\u00a0\nHospital\u00a0Gregorio\u00a0Mara\u00f1\u00f3n, \u00a0Madrid\u00a0\nPere\u00a0Domingo \u00a0Pedrol1\u00a0\nHospital\u00a0de\u00a0la\u00a0Santa\u00a0Creu\u00a0i\u00a0Sant\u00a0Pau.\u00a0Barcelona \u00a0M\u00aa\u00a0Jos\u00e9\u00a0Galindo2\u00a0\nHospital\u00a0Cl\u00ednico\u00a0Universitario, \u00a0Valencia\u00a0\nHernando \u00a0Knobel2\u00a0\nHospital\u00a0del\u00a0Mar,\u00a0Barcelona \u00a0Esteban\u00a0Mart\u00ednez2\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona \u00a0\nCelia\u00a0Miralles2\u00a0\nHospital\u00a0Xeral,\u00a0Vigo\u00a0Daniel\u00a0Podzamczer1\u00a0\nHospital\u00a0Univ.\u00a0de\u00a0Belvitge,\u00a0L\u00b4Hospitalet. \u00a0\u00a0Barcelona \u00a0\nAntonio\u00a0Rivero1\u00a0\nHospital\u00a0Reina\u00a0Sof\u00eda,\u00a0C\u00f3rdoba\u00a0Jes\u00fas\u00a0Santos2\u00a0\nHospital\u00a0Univ.\u00a0Virgen\u00a0de\u00a0la\u00a0Victoria.\u00a0M\u00e1laga\u00a0\nJes\u00fas\u00a0Sanz2\u00a0\nHospital\u00a0de\u00a0la\u00a0Princesa,\u00a0Madrid\u00a0Montserrat \u00a0Tuset2\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona \u00a0\nConsultores: \u00a0\nJose\u00a0R.\u00a0Arribas1\u00a0\nHospital\u00a0La\u00a0Paz,\u00a0Madrid\u00a0Julio\u00a0Arrizabalaga1\u00a0\nHospital\u00a0Donostia, \u00a0San\u00a0Sebasti\u00e1n \u00a0\nVicente\u00a0Boix1\u00a0\nHospital\u00a0General,\u00a0Alicante\u00a0Bonaventura \u00a0Clotet1\u00a0\nHospital\u00a0Germans\u00a0Trias\u00a0i\u00a0Pujol,\u00a0Badalo na\u00a0\nVicente\u00a0Estrada1\u00a0\nHospital\u00a0Cl\u00ednico,\u00a0Madrid\u00a0Federico\u00a0Garc\u00eda1\u00a0\nHospital\u00a0Universitario \u00a0San\u00a0Cecilio,\u00a0Granada\u00a0\u00a0\nJos\u00e9\u00a0M\u00aa\u00a0Gatell1\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona \u00a0F\u00e9lix\u00a0Guti\u00e9rrez1\u00a0\nHospital\u00a0General\u00a0Universitario, \u00a0Elche\u00a0\nJosep\u00a0Maria\u00a0Llibre1\u00a0\nHospital\u00a0Germans\u00a0Trias\u00a0Pujol,\u00a0Badalona \u00a0Jos\u00e9\u00a0M\u00aa\u00a0Mir\u00f31\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona \u00a0\nSantiago\u00a0Moreno1\u00a0\nHospital\u00a0Ram\u00f3n\u00a0y\u00a0Cajal,\u00a0Madrid\u00a0Federico\u00a0Pulido1\u00a0\nHospital\u00a0Doce\u00a0de\u00a0Octubre,\u00a0Madrid\u00a0\nVicente\u00a0Soriano1\u00a0\nHospital\u00a0Carlos\u00a0III,\u00a0Madrid\u00a0\u00a0\n\u00a0\nRedactor \u00a0General\u00a0\nJos\u00e9\u00a0L\u00f3pez\u00a0Aldeguer1\u00a0\nHospital\u00a0La\u00a0Fe,\u00a0Valencia\u00a0\n1.\u00a0Miembros \u00a0del\u00a0Panel\u00a0propuestos \u00a0por\u00a0Gesida;\u00a02.\u00a0\u00cddem,\u00a0propuestos \u00a0por\u00a0el\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n iv\u00a0\n\u00a0\nAgradecimiento: \u00a0\nLa\u00a0Junta\u00a0Directiva\u00a0de\u00a0Gesida\u00a0y\u00a0la\u00a0Secretar\u00eda \u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0agradecen \u00a0\nlas\u00a0aportaciones \u00a0y\u00a0opiniones \u00a0de\u00a0los\u00a0doctores\u00a0Marisa\u00a0\u00c1lvarez,\u00a0\u00c0ngels\u00a0Andreu,\u00a0Angel\u00a0\nBurgos,\u00a0Mar\u00eda\u00a0Coronado, \u00a0Manuel\u00a0Cotarelo,\u00a0Jorge\u00a0del\u00a0Romero,\u00a0Pedro\u00a0Ferrer,\u00a0Oscar\u00a0L.\u00a0\nFerrero,\u00a0Clara\u00a0Guti\u00e9rrez, \u00a0Henar\u00a0Hevia,\u00a0Francisco \u00a0Ledesma, \u00a0Juan\u00a0E.\u00a0Losa,\u00a0Enrique\u00a0\nRedondo\u00a0y\u00a0Rafael\u00a0Rubio\u00a0que\u00a0han\u00a0contribuido \u00a0a\u00a0mejorar\u00a0la\u00a0redacci\u00f3n \u00a0y\u00a0enriquecer \u00a0el\u00a0\ncontenido \u00a0del\u00a0documento \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n vQu\u00e9\u00a0hay\u00a0de\u00a0nuevo\u00a0en\u00a0estas\u00a0gu\u00edas\u00a0\n\u00a0\nSecciones \u00a0nuevas\u00a0\n\u2010 Tratamiento \u00a0antirretroviral \u00a0en\u00a0pacientes \u00a0con\u00a0eventos\u00a0tipo\u00a0C.\u00a0Se\u00a0comenta\u00a0el\u00a0\nTAR\u00a0en\u00a0pacientes \u00a0diagnosticados \u00a0simult\u00e1neamente \u00a0de\u00a0infecci\u00f3n\u00a0VIH\u00a0y\u00a0un\u00a0\neventi\u00a0tipo\u00a0C\u00a0(p\u00e1g.\u00a039)\u00a0\n\u2010 VIH\u00a0en\u00a0la\u00a0mujer.\u00a0Se\u00a0ha\u00a0modificado \u00a0el\u00a0cap\u00edtulo\u00a0relativo\u00a0a\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0\ntransmisis\u00f3n \u00a0materno\u2010fetal\u00a0que\u00a0ahora\u00a0se\u00a0refiere\u00a0al\u00a0\u201cTratamiento \u00a0\nantirretroviral \u00a0en\u00a0la\u00a0mujer,\u00a0en\u00a0el\u00a0embarazo \u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0\nmaterno\u2010fetal\u201d\u00a0(p\u00e1g.\u00a085)\u00a0\n\u2010 Prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH.\u00a0El\u00a0cap\u00edtulo\u00a0relativo\u00a0a\u00a0la\u00a0profilaxis\u00a0\npostexposici\u00f3n \u00a0se\u00a0ha\u00a0modificado \u00a0incluyendo \u00a0tanto\u00a0aspectos\u00a0de\u00a0profilaxis\u00a0\npreexposici\u00f3n \u00a0como\u00a0postexposici\u00f3n \u00a0ocupacional \u00a0o\u00a0no\u00a0(p\u00e1g.\u00a090)\u00a0\n\u00a0\nActualizaciones \u00a0consideradas \u00a0clave:\u00a0\n\u2010 Se\u00a0aconseja\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0el\u00a0paciente\u00a0asintom\u00e1tico \u00a0\ncuando\u00a0los\u00a0CD4\u00a0desciendan \u00a0por\u00a0debajo\u00a0de\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0(Tabla\u00a03,\u00a0p\u00e1g\u00a0104)\u00a0\n\u2010 Respecto\u00a0a\u00a0los\u00a0f\u00e1rmacos \u00a0que\u00a0debe\u00a0incluir\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0\ninicial,\u00a0se\u00a0modifica\u00a0el\u00a0esquema\u00a0en\u00a0columnas \u00a0(de\u00a0familias\u00a0de\u00a0f\u00e1rmacos) \u00a0por\u00a0\ncombinaciones \u00a0concretas \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0los\u00a0resultados \u00a0de\u00a0los\u00a0ensayos\u00a0\nefectuados \u00a0con\u00a0esas\u00a0pautas\u00a0(Tabla\u00a04,\u00a0p\u00e1g\u00a0105)\u00a0\n\u2010 Entre\u00a0las\u00a0pautas\u00a0recomendadas \u00a0para\u00a0el\u00a0tratamiento \u00a0de\u00a0inicio,\u00a0se\u00a0diferencia \u00a0\nentre\u00a0las\u00a0que\u00a0hubo\u00a0consenso \u00a0global\u00a0del\u00a0panel\u00a0frente\u00a0a\u00a0las\u00a0que\u00a0no\u00a0lo\u00a0hubo\u00a0\n(Tabla\u00a04,\u00a0p\u00e1g\u00a0105).\u00a0\n\u2010 Se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0f\u00e1rmacos \u00a0coformulados \u00a0para\u00a0facilitar\u00a0la\u00a0adherencia \u00a0\n(P\u00e1g\u00a025\u00a0y\u00a0Tabla\u00a04,\u00a0p\u00e1g\u00a0105)\u00a0\n\u00a0\nOtras\u00a0actualizaciones \u00a0\n\u2010 Tratamiento \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0con\u00a0s\u00edntomas\u00a0graves\u00a0(p\u00e1g\u00a014)\u00a0\n\u2010 Determinaci\u00f3n \u00a0genot\u00edpica \u00a0del\u00a0tropismo\u00a0(p\u00e1g\u00a010)\u00a0\n\u2010 Pautas\u00a0de\u00a0tratamiento \u00a0libres\u00a0de\u00a0an\u00e1logos\u00a0(p\u00e1g\u00a038)\u00a0\n\u2010 Consideraciones \u00a0sobre\u00a0los\u00a0estudios\u00a0de\u00a0resistencia \u00a0(p\u00e1g\u00a044)\u00a0\n\u2010 Se\u00a0aportan\u00a0en\u00a0cada\u00a0cap\u00edtulo\u00a0los\u00a0datos\u00a0relevantes \u00a0de\u00a0los\u00a0ensayos\u00a0y\u00a0estudios\u00a0\nnuevos\u00a0en\u00a0pacientes \u00a0con\u00a0o\u00a0sin\u00a0tratamiento \u00a0previo\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n vi\u00cdndice\u00a0\n\u00a0\nResumen \u00a0\u00a0\u00a0 1\u00a0\n1.\u00a0Introducci\u00f3n \u00a0 \u00a0\n1.1.\u00a0Metodolog\u00eda \u00a0\u00a0\u00a0\u00a0\u00a0 2\u00a0\n1.2.\u00a0Principios \u00a0generales \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3\u00a0\n2.\u00a0Par\u00e1metros \u00a0para\u00a0guiar\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0 \u00a0\n2.1.\u00a0Linfocitos \u00a0CD4\u00a0 4\u00a0\n2.2.\u00a0Carga\u00a0viral\u00a0plasm\u00e1tica \u00a0del\u00a0VIH\u00a0 5\u00a0\n2.3.\u00a0Niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0f\u00e1rmacos\u00a0 6\u00a0\n2.4.\u00a0Resistencia \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0 6\u00a0\n2.5.\u00a0Determinaci\u00f3n \u00a0del\u00a0HLA\u00a0B*5701\u00a0 9\u00a0\n2.6.\u00a0Determinaci\u00f3n \u00a0del\u00a0tropismo \u00a0 10\u00a0\n3.\u00a0Infecci\u00f3n \u00a0aguda\u00a0por\u00a0VIH\u00a0 11\u00a0\n4.\u00a0Tratamiento \u00a0antirretroviral \u00a0inicial\u00a0 \u00a0\n4.1.\u00a0Cu\u00e1ndo\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0 14\u00a0\nEvaluaci\u00f3n \u00a0del\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0 15\u00a0\nRespuesta \u00a0cl\u00ednica\u00a0(progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte)\u00a0 15\u00a0\nIncidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0VIH\u00a0 16\u00a0\nSubgrupos \u00a0de\u00a0mayor\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0 17\u00a0\nRespuesta \u00a0inmunol\u00f3gica \u00a0 17\u00a0\nToxicidad \u00a0de\u00a0tratamiento \u00a0antirretroviral \u00a0 18\u00a0\nTAR\u00a0en\u00a0parejas\u00a0serodiscordantes \u00a0 18\u00a0\n4.2.\u00a0\u00bfQu\u00e9\u00a0combinaci\u00f3n \u00a0de\u00a0antirretrovirales \u00a0debe\u00a0utilizarse? \u00a0 \u00a0\nCriterios\u00a0para\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0las\u00a0pautas\u00a0de\u00a0antirretrovirales \u00a0 19\u00a0\nConsideraciones \u00a0sobre\u00a0elecci\u00f3n\u00a0de\u00a0un\u00a0NN\u00a0o\u00a0un\u00a0IP\u00a0\u00a0 19\u00a0\n4.3.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0 \u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0AN\u00a020\u00a0\nRecomendaciones \u00a0sobre\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0 25\u00a0\nCombinaciones \u00a0de\u00a0TAR\u00a0con\u00a0tres\u00a0an\u00e1logos\u00a0 26\u00a0\nEnsayos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0tres\u00a0AN\u00a0\u00a0 26\u00a0\nRecomendaciones \u00a0sobre\u00a0las\u00a0combinaciones \u00a0de\u00a03\u00a0AN\u00a0 27\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n vii\u00a0\n4.4.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\u00a0 \u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0NVP\u00a0 28\u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0EFV\u00a0 29\u00a0\nConsideraciones \u00a0sobre\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0un\u00a0r\u00e9gimen\u00a0con\u00a0NVP\u00a0o\u00a0EFV\u00a0\u00a0\u00a0\u00a0\u00a032\u00a0\nRecomendaciones \u00a0sobre\u00a0no\u00a0nucle\u00f3sidos \u00a0 32\u00a0\n4.5.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0 32\u00a0\nEnsayos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0sobre\u00a0IP\u00a0 33\u00a0\nRecomendaciones \u00a0sobre\u00a0IP\u00a0 36\u00a0\n4.6.\u00a0Inhibidores \u00a0del\u00a0correceptor \u00a0CCR5\u00a0 \u00a0\nEnsayos\u00a0que\u00a0avalan\u00a0recomendaciones \u00a0sobre\u00a0inhibidores \u00a0de\u00a0CCR5\u00a0\u00a0\u00a0\u00a037\u00a0\nRecomendaciones \u00a0sobre\u00a0Inhibidores \u00a0CCR5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 37\u00a0\n4.7.\u00a0Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0 \u00a0\nEnsayo\u00a0que\u00a0avala\u00a0la\u00a0recomendaci\u00f3n \u00a0de\u00a0inhibidores \u00a0integrasa \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 38\u00a0\nRecomendaciones \u00a0sobre\u00a0Inhibidores \u00a0integrasa \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 38\u00a0\n4.8.\u00a0Pautas\u00a0libres\u00a0de\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0 38\u00a0\nEnsayo\u00a0que\u00a0avala\u00a0la\u00a0recomendaci\u00f3n \u00a0de\u00a0pautas\u00a0libres\u00a0de\u00a0AN\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 38\u00a0\nRecomendaciones \u00a0sobre\u00a0Inhibidores \u00a0integrasa \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 39\u00a0\n4.9.\u00a0TAR\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0con\u00a0eventos\u00a0C\u00a0 39\u00a0\nRecomendaciones \u00a0sobre\u00a0TAR\u00a0y\u00a0eventos\u00a0C\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40\u00a0\n5.\u00a0Modificaci\u00f3n \u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0 \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5.1.\u00a0Fracaso\u00a0del\u00a0TAR\u00a0 40\u00a0\nFactores\u00a0que\u00a0influyen\u00a0en\u00a0el\u00a0fracaso\u00a0terap\u00e9utico \u00a0 40\u00a0\nCriterios\u00a0de\u00a0cambio\u00a0de\u00a0TAR\u00a0por\u00a0fracaso\u00a0virol\u00f3gico \u00a0 41\u00a0\nObjetivo\u00a0del\u00a0tratamiento \u00a0tras\u00a0un\u00a0fracaso\u00a0virol\u00f3gico \u00a0 42\u00a0\n5.1.1.\u00a0Cambio\u00a0de\u00a0TAR\u00a0tras\u00a0fracaso\u00a0precoz\u00a0 44\u00a0\n5.1.2.\u00a0Cambio\u00a0de\u00a0TAR\u00a0en\u00a0el\u00a0fracaso\u00a0avanzado \u00a0(TAR\u00a0de\u00a0rescate)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 46\u00a0\nInhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0potenciados \u00a0 46\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0 50\u00a0\nInhibidores \u00a0de\u00a0la\u00a0uni\u00f3n\u00a0 52\u00a0\nInhibidores \u00a0correceptor \u00a0CCR5\u00a0 53\u00a0\nInhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\u00a0 54\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n viiiOpciones \u00a0en\u00a0pacientes \u00a0con\u00a0m\u00faltiples \u00a0fracasos\u00a0virol\u00f3gicos \u00a0 56\u00a0\nReplicaci\u00f3n \u00a0viral\u00a0baja\u00a0en\u00a0pacientes \u00a0multitratados \u00a0 57\u00a0\nSuspensi\u00f3n \u00a0del\u00a0TAR\u00a0 58\u00a0\nRecomendaciones \u00a0de\u00a0cambio\u00a0de\u00a0TAR\u00a0por\u00a0fracaso\u00a0virol\u00f3gico \u00a0\u00a0\u00a0\u00a058\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5.2.\u00a0Simplificaci\u00f3n \u00a0del\u00a0TAR\u00a0\u00a0 59\u00a0\nReducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos\u00a0 59\u00a0\nReducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0y/o\u00a0de\u00a0dosis\u00a0 63\u00a0\nSimplificaci\u00f3n \u00a0a\u00a0reg\u00edmenes \u00a0de\u00a0administraci\u00f3n \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0 66\u00a0\nOtros\u00a0tipos\u00a0de\u00a0simplificaci\u00f3n \u00a0 69\u00a0\nRecomendaciones \u00a0sobre\u00a0simplificaci\u00f3n \u00a0 71\u00a0\n6.\u00a0Adherencia\u00a0 71\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recomendaciones \u00a0sobre\u00a0adherencia \u00a0 74\u00a0\n7.\u00a0Efectos\u00a0adversos\u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0 75\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recomendaciones \u00a0 78\u00a0\n8.\u00a0Interacciones \u00a0farmacocin\u00e9ticas \u00a0y\u00a0farmacodin\u00e1micas \u00a0 79\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recomendaciones \u00a0 81\u00a0\n9.\u00a0Hepatopat\u00eda \u00a0cr\u00f3nica\u00a0y\u00a0tratamiento \u00a0antirretroviral \u00a0\u00a0\u00a0 82\u00a0\nInfecci\u00f3n\u00a0VIH,\u00a0TAR\u00a0e\u00a0historia\u00a0natural\u00a0hepatitis\u00a0cr\u00f3nica\u00a0(VHB\u00a0y\u00a0VHC)\u00a0 82\u00a0\nToxicidad \u00a0hep\u00e1tica\u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0 82\u00a0\nUso\u00a0de\u00a0antirretrovirales \u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0 83\u00a0\nTAR\u00a0en\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0C\u00a0 84\u00a0\nTratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0B\u00a0en\u00a0pacientes \u00a0coinfectados \u00a0 85\u00a0\n10.\u00a0TAR\u00a0en\u00a0la\u00a0mujer,\u00a0el\u00a0embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0materno\u00a0fetal\u00a085\u00a0\nConsideraciones \u00a0especiales \u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0mujer\u00a0 85\u00a0\nRecomendaciones \u00a0 87\u00a0\nTAR\u00a0en\u00a0el\u00a0embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0transmisi\u00f3n \u00a0materno\u2010fetal\u00a0 87\u00a0\nRecomendaciones \u00a0 89\u00a0\n11.\u00a0Prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0 90\u00a0\nPapel\u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0 90\u00a0\nProfilaxis\u00a0pre\u00a0exposici\u00f3n \u00a0 91\u00a0\nProfilaxis\u00a0post\u2010exposici\u00f3n \u00a0ocupacional \u00a0 91\u00a0\nProfilaxis\u00a0post\u2010exposici\u00f3n \u00a0no\u00a0ocupacional \u00a0 93\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n ix12.\u00a0Otras\u00a0estrategias \u00a0y\u00a0nuevos\u00a0f\u00e1rmacos \u00a0 95\u00a0\nInterrupciones \u00a0supervisadas \u00a0del\u00a0tratamiento \u00a0 95\u00a0\nTratamientos \u00a0inmunomediados \u00a0 97\u00a0\nInmunizaciones \u00a0terap\u00e9uticas \u00a0 98\u00a0\nNuevos\u00a0antirretrovirales \u00a0 98\u00a0\n13.\u00a0Coste\u00a0comparativo \u00a0de\u00a0combinaciones \u00a0de\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\u00a0\u00a0\u00a0 99\u00a0\n14.\u00a0Tablas\u00a0\u00a0 101\u00a0\n15.\u00a0Bibliograf\u00eda \u00a0 186\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Documento \u00a0de\u00a0consenso \u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n xAbreviaturas \u00a0usadas:\u00a0\n\u00a0\n3TC\u00a0 Lamivudina \u00a0\nABC\u00a0 Abacavir\u00a0\nAN\u00a0 Inhibidores \u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0nucle\u00f3sido\u00a0 o\u00a0nucle\u00f3tido\u00a0\nAPV\u00a0 Amprenavir \u00a0\nATV\u00a0 Atazanavir \u00a0\nBID\u00a0 Pauta\u00a0de\u00a0tratamiento \u00a0administrada \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda\u00a0\nCVP\u00a0 Carga\u00a0viral\u00a0 plasm\u00e1tica \u00a0\nd4T\u00a0 Estavudina \u00a0\nddI\u00a0 Didanosina \u00a0\nDRV\u00a0 Darunavir \u00a0\nEFV\u00a0 Efavirenz\u00a0\nEMA\u00a0 European \u00a0Medicines \u00a0Agency\u00a0\nENF\u00a0 Enfuvirtida \u00a0\nETR\u00a0 Etravirina \u00a0\nETS\u00a0 Enfermedades \u00a0de\u00a0transmisi\u00f3n \u00a0sexual\u00a0\nFAR\u00a0 F\u00e1rmacos \u00a0antirretrovirales \u00a0\nFPV\u00a0 Fosamprenavir \u00a0\nFTC\u00a0 Emtricitabina \u00a0\nIDV\u00a0 Indinavir\u00a0\nIF\u00a0 Inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\nIInt\u00a0 Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nIP\u00a0 Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0\nIP/r\u00a0 Inhibidor\u00a0de\u00a0la\u00a0proteasa\u00a0(IP)\u00a0potenciado\u00a0 con\u00a0ritonavir\u00a0\nIST\u00a0 Interrupci\u00f3n \u00a0estructurada \u00a0del\u00a0tratamiento \u00a0\nITT\u00a0 An\u00e1lisis\u00a0 por\u00a0intenci\u00f3n \u00a0de\u00a0tratamiento \u00a0\nIU\u00a0 Inhibidores \u00a0de\u00a0la\u00a0uni\u00f3n\u00a0al\u00a0receptor\u00a0CCR5\u00a0\nLPV\u00a0 Lopinavir\u00a0\nMVC\u00a0 Maraviroc \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n xiNFV\u00a0Nelfinavir \u00a0\nNN\u00a0 Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0an\u00e1logos\u00a0\nNVP\u00a0Nevirapina \u00a0\nOT\u00a0 An\u00e1lisis\u00a0\u201cen\u00a0tratamiento\u201d \u00a0\nQD\u00a0 F\u00e1rmaco\u00a0o\u00a0pauta\u00a0de\u00a0tratamiento \u00a0administrada \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0\nRHS\u00a0Reacci\u00f3n\u00a0de\u00a0hipersensibilidad \u00a0\nRAL\u00a0Raltegravir \u00a0\nRTV\u00a0Ritonavir\u00a0\nSQV\u00a0Saquinavir \u00a0\nTAR\u00a0Tratamiento \u00a0antirretroviral; \u00a0\u00eddem.\u00a0de\u00a0alta\u00a0eficacia\u00a0\nTDF\u00a0Tenofovir \u00a0DF\u00a0\nTLOVR\u00a0Tiempo\u00a0hasta\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0la\u00a0eficacia\u00a0virol\u00f3gica \u00a0\nTPV\u00a0Tipranavir \u00a0\nZDV,\u00a0AZT\u00a0Zidovudina \u00a0 \nDocumento \u00a0de\u00a0consenso \u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1Resumen \u00a0\nObjetivo: \u00a0Actualizar \u00a0las\u00a0recomendaciones \u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0(TAR)\u00a0\npara\u00a0los\u00a0adultos\u00a0infectados \u00a0por\u00a0el\u00a0VIH.\u00a0\nM\u00e9todos: \u00a0Estas\u00a0 recomendaciones \u00a0se\u00a0han\u00a0 consensuado\u00a0 por\u00a0un\u00a0panel\u00a0 de\u00a0expertos\u00a0del\u00a0\nGrupo\u00a0de\u00a0Estudio\u00a0de\u00a0Sida\u00a0 y\u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida.\u00a0Para\u00a0ello\u00a0se\u00a0han\u00a0 revisado\u00a0\nlos\u00a0resultados \u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0ensayos\u00a0cl\u00ednicos,\u00a0estudios\u00a0de\u00a0cohortes\u00a0y\u00a0de\u00a0\nfarmacocin\u00e9tica \u00a0publicados \u00a0en\u00a0revistas\u00a0biom\u00e9dicas \u00a0(PubMed\u00a0y\u00a0Embase)\u00a0o\u00a0presentados \u00a0\nen\u00a0congresos. \u00a0Se\u00a0han\u00a0 definido\u00a0tres\u00a0niveles\u00a0de\u00a0evidencia \u00a0seg\u00fan\u00a0la\u00a0procedencia \u00a0de\u00a0los\u00a0\ndatos:\u00a0estudios\u00a0aleatorizados\u00a0 (nivel\u00a0A),\u00a0de\u00a0cohortes\u00a0o\u00a0de\u00a0caso\u2010control\u00a0(nivel\u00a0B),\u00a0u\u00a0\nopini\u00f3n\u00a0de\u00a0expertos\u00a0(nivel\u00a0C).\u00a0En\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0situaciones \u00a0se\u00a0ha\u00a0establecido \u00a0\nrecomendar, \u00a0considerar \u00a0o\u00a0no\u00a0recomendar\u00a0 el\u00a0TAR.\u00a0\nResultados: \u00a0El\u00a0TAR\u00a0con\u00a0combinaciones \u00a0de\u00a0tres\u00a0f\u00e1rmacos \u00a0constituye \u00a0el\u00a0tratamiento \u00a0de\u00a0\ninicio\u00a0de\u00a0elecci\u00f3n\u00a0 de\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0por\u00a0el\u00a0VIH.\u00a0Se\u00a0recomienda\u00a0 iniciar\u00a0el\u00a0TAR\u00a0en\u00a0los\u00a0\npacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0sintom\u00e1tica. \u00a0Se\u00a0incluyen\u00a0directrices \u00a0sobre\u00a0el\u00a0inicio\u00a0de\u00a0\nlos\u00a0enfermos \u00a0con\u00a0un\u00a0evento\u00a0infeccioso \u00a0tipo\u00a0C.\u00a0En\u00a0los\u00a0pacientes \u00a0asintom\u00e1ticos \u00a0el\u00a0inicio\u00a0\nde\u00a0TAR\u00a0se\u00a0basar\u00e1\u00a0en\u00a0los\u00a0resultados \u00a0de\u00a0determinaci\u00f3n\u00a0 de\u00a0linfocitos\u00a0CD4\u00a0(CD4/\u00b5L), \u00a0en\u00a0la\u00a0\ncarga\u00a0viral\u00a0plasm\u00e1tica\u00a0 (CVP)\u00a0y\u00a0en\u00a0las\u00a0comorbilidades \u00a0del\u00a0paciente: \u00a01)\u00a0Si\u00a0los\u00a0linfocitos\u00a0\nCD4\u00a0son\u00a0inferiores \u00a0a\u00a0350\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0iniciar\u00a0el\u00a0TAR;\u00a0\u00a02)\u00a0En\u00a0caso\u00a0de\u00a0que\u00a0los\u00a0\nlinfocitos\u00a0CD4\u00a0se\u00a0encuentren \u00a0entre\u00a0350\u00a0y\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda\u00a0 el\u00a0tratamiento \u00a0\nsalvo\u00a0en\u00a0casos\u00a0de\u00a0n\u00famero\u00a0estable\u00a0de\u00a0CD4,\u00a0CVP\u00a0baja\u00a0o\u00a0poca\u00a0predisposici\u00f3n \u00a0del\u00a0paciente; \u00a0\n3)\u00a0Si\u00a0los\u00a0linfocitos\u00a0CD4\u00a0son\u00a0superiores \u00a0a\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0en\u00a0general\u00a0se\u00a0puede\u00a0diferir\u00a0el\u00a0\ntratamiento, \u00a0pero\u00a0se\u00a0puede\u00a0considerar \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0cirrosis\u00a0hep\u00e1tica,\u00a0 hepatitis\u00a0\ncr\u00f3nica\u00a0por\u00a0virus\u00a0C,\u00a0hepatitis\u00a0B\u00a0que\u00a0requiera\u00a0tratamiento, \u00a0riesgo\u00a0cardiovascular \u00a0\nelevado,\u00a0nefropat\u00eda \u00a0VIH,\u00a0CVP\u00a0superior\u00a0a\u00a0100000\u00a0copias/mL, \u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0inferior\u00a0\na\u00a014%,\u00a0 edad\u00a0superior\u00a0a\u00a055\u00a0a\u00f1os\u00a0y\u00a0en\u00a0parejas\u00a0serodiscordantes \u00a0con\u00a0riesgo\u00a0de\u00a0\ntransmisi\u00f3n \u00a0sexual.\u00a0El\u00a0esquema\u00a0terap\u00e9utico \u00a0debe\u00a0incluir\u00a02\u00a0inhibidores \u00a0de\u00a0la\u00a0\ntranscriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido\u00a0 o\u00a0nucle\u00f3tido\u00a0 (AN)\u00a0y\u00a01\u00a0inhibidor\u00a0de\u00a0la\u00a0\ntranscriptasa \u00a0inversa\u00a0no\u00a0an\u00e1logo\u00a0(NN)\u00a0o\u00a02\u00a0AN\u00a0y\u00a01\u00a0inhibidor\u00a0de\u00a0la\u00a0proteasa\u00a0potenciado\u00a0\ncon\u00a0 ritonavir\u00a0(IP/r)\u00a0 aunque\u00a0son\u00a0posibles\u00a0otras\u00a0combinaciones. \u00a0Se\u00a0han\u00a0seleccionado \u00a0y\u00a0\npriorizado\u00a0 por\u00a0consenso\u00a0 combinaciones \u00a0concretas \u00a0de\u00a0f\u00e1rmacos\u00a0algunas\u00a0 de\u00a0ellas\u00a0\ncoformuladas.\u00a0 El\u00a0objetivo\u00a0 del\u00a0TAR\u00a0es\u00a0conseguir \u00a0una\u00a0CVP\u00a0indetectable. \u00a0La\u00a0adherencia \u00a0al\u00a0\nTAR\u00a0juega\u00a0un\u00a0papel\u00a0 fundamental \u00a0en\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0respuesta \u00a0antiviral.\u00a0Las\u00a0opciones\u00a0\nterap\u00e9uticas \u00a0tras\u00a0los\u00a0fracasos\u00a0del\u00a0TAR\u00a0son\u00a0limitadas\u00a0 pero\u00a0con\u00a0los\u00a0estudios\u00a0genot\u00edpicos \u00a0\nse\u00a0puede\u00a0conseguir \u00a0el\u00a0objetivo\u00a0 de\u00a0CVP\u00a0indetectable \u00a0con\u00a0 los\u00a0f\u00e1rmacos\u00a0disponibles. \u00a0La\u00a0\ntoxicidad\u00a0es\u00a0un\u00a0factor\u00a0cada\u00a0vez\u00a0menos\u00a0limitante\u00a0del\u00a0TAR\u00a0cuyos\u00a0beneficios \u00a0superan\u00a0los\u00a0\nposibles\u00a0perjuicios.\u00a0 Tambi\u00e9n\u00a0 se\u00a0comentan \u00a0los\u00a0criterios\u00a0de\u00a0TAR\u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda,\u00a0 en\u00a0\nla\u00a0mujer,\u00a0el\u00a0embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0materno\u2010fetal,\u00a0as\u00ed\u00a0como\u00a0la\u00a0\nprofilaxis\u00a0pre\u00a0y\u00a0postexposici\u00f3n \u00a0(laboral\u00a0o\u00a0no)\u00a0y\u00a0el\u00a0manejo\u00a0de\u00a0la\u00a0coinfecci\u00f3n \u00a0del\u00a0VIH\u00a0con\u00a0\nlos\u00a0virus\u00a0VHC\u00a0y\u00a0VHB.\u00a0\nConclusiones: \u00a0La\u00a0cifra\u00a0 de\u00a0linfocitos\u00a0CD4,\u00a0la\u00a0CVP\u00a0y\u00a0las\u00a0comorbilidades \u00a0del\u00a0paciente\u00a0son\u00a0\nlos\u00a0factores\u00a0de\u00a0referencia \u00a0m\u00e1s\u00a0 importantes\u00a0 para\u00a0iniciar\u00a0el\u00a0TAR\u00a0en\u00a0pacientes\u00a0\nasintom\u00e1ticos. \u00a0Por\u00a0otra\u00a0 parte,\u00a0el\u00a0n\u00famero\u00a0considerable \u00a0de\u00a0f\u00e1rmacos\u00a0disponibles, \u00a0los\u00a0\nm\u00e9todos\u00a0m\u00e1s\u00a0sensibles\u00a0de\u00a0monitorizaci\u00f3n \u00a0de\u00a0la\u00a0CVP,\u00a0y\u00a0la\u00a0posibilidad \u00a0de\u00a0determinar\u00a0 la s\u00a0\nresistencias \u00a0hacen\u00a0que\u00a0las\u00a0estrategias \u00a0terap\u00e9uticas \u00a0deban\u00a0ser\u00a0mucho\u00a0m\u00e1s\u00a0\nindividualizadas \u00a0para\u00a0conseguir \u00a0en\u00a0cualquier \u00a0circunstancia \u00a0el\u00a0objetivo\u00a0 de\u00a0CVP\u00a0\nindetectable. \u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 2\u00a0\n1.\u00a0INTRODUCCION \u00a0\nEl\u00a0tratamiento \u00a0antirretroviral \u00a0(TAR)\u00a0evoluciona \u00a0con\u00a0tal\u00a0rapidez\u00a0que\u00a0exige\u00a0una\u00a0frecuente \u00a0\nactualizaci\u00f3n \u00a0de\u00a0sus\u00a0recomendaciones. \u00a0Desde\u00a0que\u00a0en\u00a01995\u00a0el\u00a0Plan\u00a0Nacional\u00a0Sobre\u00a0el\u00a0\nSida\u00a0(PNS)\u00a0y\u00a0su\u00a0Consejo\u00a0Asesor\u00a0Cl\u00ednico\u00a0editaran\u00a0las\u00a0primeras\u00a0\u201cRecomendaciones \u00a0de\u00a0\ntratamiento \u00a0antirretroviral \u00a0en\u00a0el\u00a0adulto\u201d1,\u00a0este\u00a0organismo \u00a0junto\u00a0al\u00a0Grupo\u00a0de\u00a0Estudio\u00a0de\u00a0\nSida\u00a0(Gesida)\u00a0de\u00a0la\u00a0SEIMC\u00a0han\u00a0actualizado \u00a0estas\u00a0recomendaciones \u00a0con\u00a0periodicidad \u00a0\nanual,\u00a0public\u00e1ndolas \u00a0en\u00a0la\u00a0revista\u00a0Enfermedades \u00a0Infecciosas \u00a0y\u00a0Microbiolog\u00eda \u00a0Cl\u00ednica\u00a0o\u00a0\nen\u00a0sus\u00a0respectivas \u00a0p\u00e1ginas\u00a0web2.\u00a0Otras\u00a0instituciones \u00a0y\u00a0sociedades \u00a0cient\u00edficas \u00a0elaboran\u00a0y\u00a0\nactualizan \u00a0sus\u00a0propias\u00a0recomendaciones \u00a0sobre\u00a0el\u00a0empleo\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0\nantirretrovirales \u00a0(FAR)3,\u00a04.\u00a0\u00a0\nEl\u00a0objetivo\u00a0de\u00a0este\u00a0documento \u00a0es\u00a0dar\u00a0a\u00a0conocer\u00a0a\u00a0la\u00a0comunidad \u00a0cient\u00edfica\u00a0y\u00a0a\u00a0los\u00a0\nprofesionales \u00a0que\u00a0tratan\u00a0a\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0el\u00a0estado\u00a0del\u00a0arte\u00a0del\u00a0TAR\u00a0en\u00a0\nel\u00a0momento \u00a0de\u00a0su\u00a0actualizaci\u00f3n. \u00a0Se\u00a0incluyen\u00a0algunos\u00a0aspectos\u00a0del\u00a0tratamiento \u00a0que\u00a0\ntanto\u00a0Gesida\u00a0y\u00a0el\u00a0PNS,\u00a0en\u00a0colaboraci\u00f3n \u00a0con\u00a0otras\u00a0sociedades \u00a0cient\u00edficas \u00a0han\u00a0elaborado \u00a0\nin\u00a0extenso,\u00a0a\u00a0las\u00a0que\u00a0se\u00a0remite\u00a0al\u00a0lector\u00a0interesado \u00a0en\u00a0el\u00a0tema.\u00a0\u00a0\u00a0\u00a0\n\u00a01.1.\u00a0Metodolog\u00eda \u00a0\nEl\u00a0Panel\u00a0est\u00e1\u00a0formado\u00a0por\u00a0un\u00a0grupo\u00a0de\u00a0cl\u00ednicos\u00a0expertos\u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0pacientes \u00a0\ninfectados \u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0en\u00a0el\u00a0uso\u00a0de\u00a0los\u00a0FAR.\u00a0Estos\u00a0profesionales \u00a0\nhan\u00a0sido\u00a0designados \u00a0\npor\u00a0la\u00a0Junta\u00a0Directiva\u00a0de\u00a0Gesida\u00a0y\u00a0la\u00a0Secretar\u00eda \u00a0del\u00a0PNS\u00a0y\u00a0aceptado \u00a0voluntariamente. \u00a0\nLos\u00a0miembros \u00a0se\u00a0han\u00a0dividido\u00a0en\u00a0grupos\u00a0formados \u00a0por\u00a0un\u00a0redactor\u00a0y\u00a0dos\u00a0consultores \u00a0\npara\u00a0actualizar \u00a0cada\u00a0cap\u00edtulo\u00a0de\u00a0las\u00a0recomendaciones. \u00a0Tres\u00a0miembros \u00a0del\u00a0panel\u00a0act\u00faan\u00a0\ncomo\u00a0coordinadores \u00a0y\u00a0uno\u00a0como\u00a0redactor\u00a0general.\u00a0\nPara\u00a0la\u00a0actualizaci\u00f3n \u00a0de\u00a0estas\u00a0gu\u00edas\u00a0cada\u00a0redactor\u00a0ha\u00a0revisado\u00a0los\u00a0datos\u00a0m\u00e1s\u00a0relevantes \u00a0\nde\u00a0las\u00a0publicaciones \u00a0cient\u00edficas \u00a0(PubMed\u00a0y\u00a0Embase; idiomas: espa\u00f1ol, ingl\u00e9s y \nfranc\u00e9s)\u00a0o\u00a0las\u00a0comunicaciones \u00a0de\u00a0los\u00a0congresos \u00a0recientes\u00a0de\u00a0la\u00a0materia.\u00a0Con\u00a0esta\u00a0\nrecopilaci\u00f3n \u00a0el\u00a0redactor\u00a0de\u00a0cada\u00a0grupo\u00a0actualiza\u00a0su\u00a0cap\u00edtulo,\u00a0somete\u00a0sus\u00a0aportaciones \u00a0a\u00a0\nlos\u00a0consultores \u00a0consensuando \u00a0las\u00a0aportaciones. \u00a0Cada\u00a0cap\u00edtulo\u00a0se\u00a0remite\u00a0a\u00a0los\u00a0\ncoordinadores \u00a0y\u00a0finalmente \u00a0se\u00a0ensamblan \u00a0en\u00a0el\u00a0documento \u00a0en\u00a0el\u00a0que\u00a0se\u00a0resaltan\u00a0en\u00a0\namarillo\u00a0las\u00a0novedades. \u00a0El\u00a0documento \u00a0se\u00a0consensua \u00a0en\u00a0una\u00a0reuni\u00f3n\u00a0presencial \u00a0de\u00a0los\u00a0\ncoordinadores \u00a0y\u00a0redactores. \u00a0Tras\u00a0ello\u00a0se\u00a0expone\u00a0durante\u00a0un\u00a0periodo\u00a0de\u00a0tiempo\u00a0en\u00a0la\u00a0\nweb\u00a0de\u00a0las\u00a0entidades \u00a0promotoras \u00a0para\u00a0que\u00a0los\u00a0profesionales \u00a0a\u00a0los\u00a0que\u00a0va\u00a0dirigido\u00a0y\u00a0\nquien\u00a0est\u00e9\u00a0interesado \u00a0pueda\u00a0sugerir\u00a0matices\u00a0o\u00a0cambios\u00a0que\u00a0el\u00a0Panel\u00a0puede\u00a0o\u00a0no\u00a0\naceptar\u00a0a\u00a0posteriori .\u00a0\nLa\u00a0jerarquizaci\u00f3n \u00a0de\u00a0la\u00a0evidencia \u00a0est\u00e1\u00a0ligada\u00a0a\u00a0la\u00a0solidez\u00a0del\u00a0dise\u00f1o\u00a0de\u00a0cada\u00a0estudio\u00a0y\u00a0es\u00a0\nesencial\u00a0si\u00a0sus\u00a0resultados \u00a0van\u00a0a\u00a0matizar\u00a0una\u00a0recomendaci\u00f3n \u00a0de\u00a0pr\u00e1ctica\u00a0cl\u00ednica.\u00a0En\u00a0este\u00a0\nconsenso \u00a0la\u00a0gradaci\u00f3n \u00a0de\u00a0la\u00a0evidencia \u00a0se\u00a0ha\u00a0efectuado \u00a0seg\u00fan\u00a0una\u00a0modificaci\u00f3n \u00a0de\u00a0las\u00a0\nrecomendaciones \u00a0de\u00a0la\u00a0IDSA5:\u00a0nivel\u00a0A,\u00a0estudios\u00a0aleatorizados \u00a0y\u00a0controlados; \u00a0nivel\u00a0B,\u00a0\nestudios\u00a0de\u00a0cohortes\u00a0o\u00a0de\u00a0casos\u00a0y\u00a0controles; \u00a0y\u00a0nivel\u00a0C,\u00a0estudios\u00a0descriptivos \u00a0u\u00a0opini\u00f3n\u00a0\nde\u00a0expertos. \u00a0\u00a0\nSe\u00a0debe\u00a0recordar\u00a0que\u00a0los\u00a0datos\u00a0sobre\u00a0TAR\u00a0cambian\u00a0frecuentemente, \u00a0por\u00a0lo\u00a0que\u00a0los\u00a0\nlectores\u00a0deben\u00a0consultar \u00a0con\u00a0regularidad \u00a0otras\u00a0fuentes\u00a0de\u00a0informaci\u00f3n. \u00a0\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 31.2.\u00a0Principios \u00a0generales \u00a0\nTras\u00a0m\u00e1s\u00a0de\u00a020\u00a0a\u00f1os\u00a0de\u00a0estudios\u00a0cl\u00ednicos\u00a0con\u00a0FAR\u00a0efectuados \u00a0en\u00a0todos\u00a0los\u00a0estadios\u00a0\nevolutivos \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0utilizando \u00a0los\u00a0f\u00e1rmacos \u00a0en\u00a0distintas\u00a0\ncombinaciones \u00a0pueden\u00a0establecerse \u00a0los\u00a0siguientes \u00a0principios: \u00a0\n1.\u00a0El\u00a0TAR\u00a0se\u00a0basa\u00a0en\u00a0combinaciones \u00a0de\u00a0al\u00a0menos\u00a0tres\u00a0f\u00e1rmacos \u00a0lo\u00a0que\u00a0retrasa\u00a0la\u00a0\nprogresi\u00f3n \u00a0cl\u00ednica\u00a0(morbilidad \u00a0e\u00a0ingresos\u00a0hospitalarios), \u00a0reduce\u00a0\u00a0los\u00a0costes\u00a0y\u00a0aumenta\u00a0la\u00a0\nsupervivencia6,\u00a07.\u00a0Se\u00a0han\u00a0establecido \u00a0pautas\u00a0eficaces\u00a0con\u00a0menos\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos \u00a0\nen\u00a0esquemas \u00a0de\u00a0simplificaci\u00f3n \u00a0y\u00a0rescate\u00a0que\u00a0no\u00a0est\u00e1n\u00a0autorizadas \u00a0por\u00a0las\u00a0autoridades \u00a0\nsanitarias \u00a0como\u00a0tratamiento \u00a0de\u00a0inicio.\u00a0\n2.\u00a0La\u00a0adherencia \u00a0al\u00a0TAR\u00a0desempe\u00f1a \u00a0un\u00a0papel\u00a0primordial \u00a0en\u00a0el\u00a0grado\u00a0y\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0\nrespuesta \u00a0antiviral8.\u00a0Por\u00a0ello\u00a0es\u00a0imprescindible \u00a0que\u00a0cada\u00a0centro\u00a0hospitalario \u00a0tenga\u00a0una\u00a0\nestrategia \u00a0para\u00a0mejorar\u00a0el\u00a0cumplimiento \u00a0del\u00a0TAR\u00a0mediante \u00a0una\u00a0estrecha\u00a0colaboraci\u00f3n \u00a0\nentre\u00a0todos\u00a0los\u00a0profesionales \u00a0implicados. \u00a0\n3.\u00a0La\u00a0situaci\u00f3n\u00a0cl\u00ednica,\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0la\u00a0CVP\u00a0son\u00a0los\u00a0elementos \u00a0b\u00e1sicos\u00a0para\u00a0\nestablecer \u00a0las\u00a0decisiones \u00a0terap\u00e9uticas \u00a0y\u00a0monitorizar \u00a0la\u00a0efectividad \u00a0del\u00a0TAR.\u00a0Los\u00a0\nlinfocitos\u00a0CD4\u00a0y\u00a0la\u00a0CVP\u00a0son\u00a0los\u00a0par\u00e1metros \u00a0imprescindibles \u00a0para\u00a0la\u00a0toma\u00a0de\u00a0decisiones. \u00a0\nAmbos\u00a0son\u00a0factores\u00a0predictores \u00a0independientes \u00a0de\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0enfermedad \u00a0y\u00a0\nde\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0enfermedades \u00a0que\u00a0en\u00a0principio\u00a0no\u00a0se\u00a0cre\u00edan\u00a0relacionados \u00a0con\u00a0el\u00a0VIH.\u00a0\nAdem\u00e1s,\u00a0la\u00a0primera\u00a0indica\u00a0el\u00a0riesgo\u00a0de\u00a0padecer\u00a0eventos\u00a0oportunistas \u00a0y\u00a0se\u00f1ala\u00a0el\u00a0\nmomento \u00a0de\u00a0iniciar\u00a0las\u00a0profilaxis\u00a0de\u00a0las\u00a0infecciones \u00a0oportunistas. \u00a0Existe\u00a0una\u00a0buena\u00a0\ncorrelaci\u00f3n \u00a0entre\u00a0las\u00a0respuestas \u00a0virol\u00f3gica, \u00a0inmunol\u00f3gica \u00a0y\u00a0cl\u00ednica\u00a0(restauraci\u00f3n \u00a0de\u00a0la\u00a0\ninmunidad \u00a0celular,\u00a0retraso\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0y\u00a0aumento\u00a0de\u00a0supervivencia)9,\u00a010.\u00a0\n4.\u00a0El\u00a0objetivo\u00a0del\u00a0tratamiento \u00a0es\u00a0reducir\u00a0la\u00a0CVP\u00a0por\u00a0debajo\u00a0de\u00a0los\u00a0l\u00edmites\u00a0de\u00a0detecci\u00f3n \u00a0\n(<50\u00a0copias/mL) \u00a0y\u00a0mantenerla \u00a0suprimida \u00a0el\u00a0mayor\u00a0tiempo\u00a0posible.\u00a0\u00a0\n5.\u00a0La\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0es\u00a0un\u00a0fen\u00f3meno \u00a0inevitable \u00a0cuando\u00a0el\u00a0VIH\u00a0se\u00a0expone\u00a0a\u00a0la\u00a0\npresi\u00f3n\u00a0selectiva\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0contin\u00faa\u00a0su\u00a0replicaci\u00f3n. \u00a0La\u00a0detecci\u00f3n \u00a0de\u00a0\nresistencias \u00a0por\u00a0m\u00e9todos\u00a0genot\u00edpicos \u00a0es\u00a0muy\u00a0\u00fatil\u00a0en\u00a0el\u00a0fracaso\u00a0virol\u00f3gico. \u00a0\u00a0\n6.\u00a0Con\u00a0las\u00a0pautas\u00a0actuales\u00a0de\u00a0TAR\u00a0es\u00a0posible\u00a0la\u00a0restauraci\u00f3n \u00a0del\u00a0sistema\u00a0inmune\u00a0\ncuantitativa \u00a0y\u00a0cualitativamente \u00a0independientemente \u00a0de\u00a0la\u00a0inmunodepresi\u00f3n \u00a0de\u00a0\npartida11,\u00a012.\u00a0La\u00a0recuperaci\u00f3n \u00a0es\u00a0lenta\u00a0y\u00a0constante \u00a0mientras\u00a0el\u00a0TAR\u00a0sea\u00a0efectivo\u00a0y\u00a0es\u00a0m\u00e1s\u00a0\ndif\u00edcil\u00a0a\u00a0partir\u00a0de\u00a0un\u00a0determinado \u00a0grado\u00a0de\u00a0deterioro \u00a0y\u00a0en\u00a0la\u00a0edad\u00a0avanzada. \u00a0\n7.\u00a0En\u00a0diciembre \u00a0de\u00a02010\u00a0disponemos \u00a0de\u00a023\u00a0FAR\u00a0comercializados \u00a0que\u00a0pertenecen \u00a0a\u00a0seis\u00a0\nfamilias\u00a0lo\u00a0que\u00a0posibilita\u00a0estrategias \u00a0terap\u00e9uticas \u00a0individualizadas. \u00a0\u00a0\n8.\u00a0La\u00a0toxicidad\u00a0de\u00a0los\u00a0FAR\u00a0a\u00a0medio\u00a0y\u00a0largo\u00a0plazo\u00a0es\u00a0un\u00a0factor\u00a0limitante\u00a0que\u00a0obliga\u00a0a\u00a0\nbuscar\u00a0nuevas\u00a0opciones\u00a0terap\u00e9uticas \u00a0manteniendo \u00a0la\u00a0potencia\u00a0antiviral13.\u00a0\n9.\u00a0Hay\u00a0diversas\u00a0pautas\u00a0de\u00a0TAR\u00a0que\u00a0son\u00a0similares\u00a0en\u00a0cuanto\u00a0a\u00a0potencia\u00a0antirretroviral. \u00a0\nLa\u00a0elecci\u00f3n\u00a0depender\u00e1 \u00a0de\u00a0los\u00a0efectos\u00a0secundarios, \u00a0adherencia, \u00a0tratamientos \u00a0previos,\u00a0\nresistencias \u00a0cruzadas, \u00a0interacciones \u00a0farmacol\u00f3gicas, \u00a0disponibilidad \u00a0y\u00a0coste,\u00a0as\u00ed\u00a0como\u00a0las\u00a0\npreferencias \u00a0del\u00a0m\u00e9dico\u00a0o\u00a0paciente. \u00a0\u00a0\n10.\u00a0La\u00a0recomendaci\u00f3n \u00a0de\u00a0iniciar\u00a0el\u00a0TAR\u00a0s\u00f3lo\u00a0cuando\u00a0los\u00a0CD4\u00a0llegan\u00a0a\u00a0un\u00a0dintel\u00a0\ndeterminado \u00a0se\u00a0debe\u00a0fundamentalmente \u00a0al\u00a0temor\u00a0a\u00a0los\u00a0efectos\u00a0secundarios13,\u00a0a\u00a0las\u00a0\ndificultades \u00a0de\u00a0adherencia8\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0resistencias14.\u00a0Tambi\u00e9n\u00a0ha\u00a0\ninfluido\u00a0en\u00a0esta\u00a0actitud\u00a0la\u00a0imposibilidad \u00a0de\u00a0erradicar\u00a0el\u00a0VIH15,\u00a016\u00a0y\u00a0de\u00a0restaurar \u00a0la\u00a0\nrespuesta \u00a0inmunoespec\u00edfica \u00a0frente\u00a0al\u00a0mismo17,\u00a018.\u00a0Sin\u00a0embargo, \u00a0la\u00a0mejor\u00eda\u00a0gradual\u00a0de\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 4las\u00a0pautas\u00a0de\u00a0inicio\u00a0en\u00a0cuanto\u00a0a\u00a0tolerancia \u00a0y\u00a0simplicidad, \u00a0la\u00a0evidencia \u00a0de\u00a0un\u00a0efecto\u00a0\nnegativo\u00a0directo\u00a0del\u00a0VIH\u00a0per\u00a0se,\u00a0as\u00ed\u00a0como\u00a0el\u00a0incremento \u00a0de\u00a0opciones\u00a0de\u00a0rescate\u00a0tras\u00a0un\u00a0\nfracaso\u00a0virol\u00f3gico \u00a0ha\u00a0reabierto \u00a0el\u00a0debate\u00a0sobre\u00a0este\u00a0tema\u00a0y\u00a0algunos\u00a0expertos\u00a0abogan\u00a0\npor\u00a0recomendaciones \u00a0menos\u00a0restrictivas \u00a0para\u00a0iniciar\u00a0el\u00a0tratamiento. \u00a0\n11.\u00a0La\u00a0complejidad \u00a0creciente \u00a0del\u00a0TAR\u00a0implica\u00a0que\u00a0el\u00a0cuidado\u00a0de\u00a0los\u00a0pacientes \u00a0debe\u00a0\nefectuarse \u00a0por\u00a0personal\u00a0especializado \u00a0que\u00a0tenga\u00a0los\u00a0conocimientos \u00a0y\u00a0los\u00a0medios\u00a0\nadecuados19.\u00a0\n12.\u00a0La\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0es\u00a0un\u00a0aspecto\u00a0fundamental \u00a0que\u00a0no\u00a0debe\u00a0\nolvidarse\u00a0nunca\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0diaria\u00a0y\u00a0que\u00a0debe\u00a0introducirse \u00a0de\u00a0forma\u00a0\nsistem\u00e1tica \u00a0en\u00a0la\u00a0educaci\u00f3n \u00a0sanitaria\u00a0de\u00a0los\u00a0pacientes \u00a0y\u00a0las\u00a0personas\u00a0de\u00a0su\u00a0entorno.\u00a0\n\u00a0\n2.\u00a0PARAMETROS \u00a0PARA\u00a0GUIAR\u00a0EL\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\nEl\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0la\u00a0CVP\u00a0son\u00a0los\u00a0par\u00e1metros \u00a0que\u00a0se\u00a0utilizan\u00a0para\u00a0indicar\u00a0el\u00a0\nTAR,\u00a0monitorizar \u00a0su\u00a0eficacia\u00a0y\u00a0tomar\u00a0decisiones \u00a0respecto\u00a0a\u00a0cambios.\u00a0\u00a0\nExisten\u00a0otros\u00a0par\u00e1metros \u00a0que,\u00a0aunque\u00a0no\u00a0intervienen \u00a0directamente \u00a0en\u00a0el\u00a0inicio\u00a0del\u00a0\nTAR,\u00a0se\u00a0deben\u00a0realizar\u00a0igualmente \u00a0en\u00a0la\u00a0evaluaci\u00f3n \u00a0inicial\u00a0o\u00a0en\u00a0el\u00a0seguimiento \u00a0ya\u00a0que\u00a0\npueden\u00a0matizar\u00a0las\u00a0decisiones \u00a0terap\u00e9uticas \u00a0(Tabla\u00a01).\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n2.1.\u00a0Linfocitos \u00a0CD4\u00a0\nEl\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0es\u00a0el\u00a0marcador \u00a0principal\u00a0de\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0\nla\u00a0infecci\u00f3n\u00a0VIH\u00a0y\u00a0necesidad \u00a0de\u00a0TAR.\u00a0Un\u00a0objetivo\u00a0del\u00a0TAR\u00a0es\u00a0la\u00a0restauraci\u00f3n \u00a0\ninmunol\u00f3gica \u00a0y\u00a0la\u00a0forma\u00a0m\u00e1s\u00a0pr\u00e1ctica\u00a0de\u00a0valorarlo\u00a0es\u00a0midiendo \u00a0el\u00a0incremento \u00a0de\u00a0los\u00a0\nCD4,\u00a0que\u00a0es\u00a0evidente\u00a0en\u00a0las\u00a0primeras\u00a0semanas\u00a0de\u00a0tratamiento12,\u00a020,\u00a021.\u00a0Adem\u00e1s\u00a0del\u00a0\nn\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0se\u00a0restaura\u00a0la\u00a0respuesta \u00a0proliferativa \u00a0frente\u00a0a\u00a0mit\u00f3genos \u00a0y\u00a0\nant\u00edgenos \u00a0memoria\u00a0pudiendo \u00a0retirar\u00a0las\u00a0profilaxis\u00a0de\u00a0infecciones \u00a0oportunistas20\u201023.\u00a0\nParalelamente \u00a0al\u00a0aumento\u00a0de\u00a0los\u00a0linfocitos\u00a0CD4,\u00a0hay\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0los\u00a0CD8\u00a0y\u00a0\notros\u00a0marcadores \u00a0de\u00a0activaci\u00f3n \u00a0del\u00a0sistema\u00a0inmune20,\u00a022.\u00a0\nEl\u00a0aumento\u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0es\u00a0lento\u00a0pero\u00a0constante \u00a0en\u00a0el\u00a0tiempo.\u00a0No\u00a0hay\u00a0datos\u00a0que\u00a0\ndefinan\u00a0cu\u00e1l\u00a0es\u00a0la\u00a0respuesta \u00a0inmunol\u00f3gica \u00a0adecuada. \u00a0Se\u00a0admite,\u00a0seg\u00fan\u00a0estudios\u00a0de\u00a0\ncin\u00e9tica\u00a0celular,\u00a0que\u00a0durante\u00a0el\u00a0primer\u00a0a\u00f1o\u00a0deber\u00eda\u00a0existir\u00a0un\u00a0aumento\u00a0m\u00ednimo\u00a0de\u00a050\u2010\n100\u00a0CD4/\u03bcL24.\u00a0No\u00a0es\u00a0raro\u00a0observar\u00a0una\u00a0discordancia \u00a0entre\u00a0respuesta \u00a0virol\u00f3gica \u00a0e\u00a0\ninmunol\u00f3gica: \u00a0pacientes \u00a0que\u00a0mantienen \u00a0una\u00a0cifra\u00a0de\u00a0CD4\u00a0estable\u00a0o\u00a0que\u00a0disminuye \u00a0a\u00a0\npesar\u00a0de\u00a0tener\u00a0una\u00a0CVP\u00a0no\u00a0detectable25\u201028.\u00a0En\u00a0esta\u00a0situaci\u00f3n\u00a0puede\u00a0existir\u00a0carga\u00a0viral\u00a0\ndetectable \u00a0en\u00a0tejido\u00a0linf\u00e1tico\u00a0por\u00a0un\u00a0TAR\u00a0sub\u00f3ptimo27.\u00a0Sin\u00a0embargo, \u00a0esta\u00a0linfopenia \u00a0\npuede\u00a0deberse\u00a0a\u00a0otras\u00a0causas\u00a0como\u00a0hipertensi\u00f3n \u00a0portal,\u00a0toxicidad\u00a0farmacol\u00f3gica, \u00a0etc.\u00a0\nEn\u00a0este\u00a0sentido,\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0en\u00a0cirr\u00f3ticos \u00a0se\u00a0pueda\u00a0usar\u00a0el\u00a0porcentaje \u00a0de\u00a0CD4\u00a0\npara\u00a0la\u00a0toma\u00a0de\u00a0decisiones29,\u00a030,\u00a0aunque\u00a0tambi\u00e9n\u00a0en\u00a0estos\u00a0pacientes \u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0\nha\u00a0demostrado \u00a0ser\u00a0el\u00a0mejor\u00a0predictor \u00a0de\u00a0riesgo31.\u00a0Por\u00a0otra\u00a0parte,\u00a0se\u00a0ha\u00a0comunicado \u00a0la\u00a0\nposibilidad \u00a0de\u00a0suspender \u00a0la\u00a0profilaxis\u00a0frente\u00a0a\u00a0\u00a0P.\u00a0jiroveci,\u00a0en\u00a0pacientes \u00a0con\u00a0<200\u00a0\nCD4/\u03bcL\u00a0si\u00a0la\u00a0CVP\u00a0est\u00e1\u00a0suprimida \u00a0lo\u00a0que\u00a0orienta\u00a0a\u00a0que\u00a0la\u00a0supresi\u00f3n \u00a0viral\u00a0continuada \u00a0debe\u00a0\nser\u00a0necesaria \u00a0para\u00a0la\u00a0reconstituci\u00f3n \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0inmune32.\u00a0\nEn\u00a0los\u00a0pacientes \u00a0asintom\u00e1ticos \u00a0deben\u00a0medirse\u00a0los\u00a0linfocitos\u00a0CD4\u00a0cada\u00a03\u20106\u00a0meses\u00a0y\u00a0ante\u00a0\nun\u00a0hallazgo\u00a0que\u00a0oriente\u00a0a\u00a0tomar\u00a0una\u00a0decisi\u00f3n\u00a0terap\u00e9utica, \u00a0debe\u00a0repetirse\u00a0en\u00a03\u20104\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 5semanas33,\u00a034.\u00a0Se\u00a0aconseja\u00a0la\u00a0repetici\u00f3n \u00a0del\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0antes\u00a0de\u00a0tomar\u00a0\nla\u00a0decisi\u00f3n\u00a0de\u00a0iniciar\u00a0el\u00a0TAR.\u00a0\u00a0\nRecomendaci\u00f3n \u00a0sobre\u00a0linfocitos \u00a0CD4\u00a0\n\u0083 Se\u00a0debe\u00a0controlar\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0ya\u00a0que\u00a0es\u00a0el\u00a0par\u00e1metro \u00a0m\u00e1s\u00a0\nimportante \u00a0para\u00a0decidir\u00a0el\u00a0inicio\u00a0del\u00a0TAR\u00a0(nivel\u00a0B).\u00a0\u00a0\n\u00a0\n2.2.\u00a0Carga\u00a0viral\u00a0plasm\u00e1tica \u00a0del\u00a0VIH\u00a0\nEl\u00a0objetivo\u00a0del\u00a0TAR\u00a0es\u00a0suprimir\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0de\u00a0modo\u00a0r\u00e1pido\u00a0y\u00a0duradero. \u00a0La\u00a0CVP\u00a0\ndesciende \u00a0r\u00e1pidamente \u00a0(1\u20102\u00a0log10)\u00a0al\u00a0inicio\u00a0del\u00a0TAR\u00a0y\u00a0el\u00a0nadir,\u00a0que\u00a0se\u00a0alcanza\u00a0a\u00a0las\u00a04\u20108\u00a0\nsemanas, \u00a0se\u00a0correlaciona \u00a0con\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0respuesta35\u201038.\u00a0Los\u00a0pacientes \u00a0con\u00a0CVP\u00a0\nmuy\u00a0elevadas\u00a0pueden\u00a0tardar\u00a0hasta\u00a024\u00a0semanas\u00a0en\u00a0conseguir \u00a0niveles\u00a0<50\u00a0copias/mL39.\u00a0\nEl\u00a0objetivo\u00a0de\u00a0supresi\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0es\u00a0llegar\u00a0a\u00a0una\u00a0cifra\u00a0inferior\u00a0a\u00a050\u00a0copias/mL, \u00a0cifra\u00a0con\u00a0\nla\u00a0que\u00a0se\u00a0ha\u00a0comprobado \u00a0que\u00a0no\u00a0se\u00a0seleccionan \u00a0mutaciones40,\u00a041\u00a0y\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0\nrespuesta \u00a0virol\u00f3gica \u00a0es\u00a0mucho\u00a0mayor\u00a0(frente\u00a0a\u00a0los\u00a0mantienen \u00a0CVP\u00a0entre\u00a050\u00a0y\u00a0500\u00a0\ncopias/mL)36.\u00a0En\u00a0los\u00a0pacientes \u00a0con\u00a0CVP\u00a0controlada \u00a0se\u00a0ha\u00a0observado \u00a0ocasionalmente \u00a0\nbrotes\u00a0transitorios \u00a0de\u00a0viremia\u00a0de\u00a0bajo\u00a0nivel\u00a0(blips)42\u00a0que\u00a0vuelve\u00a0espont\u00e1neamente \u00a0a\u00a0ser\u00a0\nindetectable \u00a0sin\u00a0ning\u00fan\u00a0cambio\u00a0en\u00a0el\u00a0tratamiento. \u00a0La\u00a0patogenia \u00a0de\u00a0los\u00a0blips\u00a0no\u00a0est\u00e1\u00a0\nclara\u00a0y\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0inmune\u00a0por\u00a0infecciones \u00a0intercurrentes \u00a0\nestimular\u00edan \u00a0las\u00a0c\u00e9lulas\u00a0cr\u00f3nicamente \u00a0infectadas \u00a0(reservorios) \u00a0con\u00a0aparici\u00f3n \u00a0transitoria \u00a0\nde\u00a0CVP43.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0estudios\u00a0no\u00a0relacionan \u00a0los\u00a0blips\u00a0con\u00a0fracaso\u00a0virol\u00f3gico44\u201047,\u00a0\naunque\u00a0un\u00a0peque\u00f1o\u00a0porcentaje \u00a0pueden\u00a0desarrollar \u00a0fracaso\u00a0virol\u00f3gico \u00a0con\u00a0aparici\u00f3n \u00a0de\u00a0\nmutaciones \u00a0de\u00a0resistencia48,\u00a049.\u00a0\u00a0\nLos\u00a0criterios\u00a0de\u00a0respuesta \u00a0y\u00a0fracaso\u00a0virol\u00f3gicos \u00a0son:\u00a0\nRespuesta \u00a0virol\u00f3gica :\u00a0Descenso \u00a0de\u00a0la\u00a0CVP\u00a0>1\u00a0log\u00a0a\u00a0las\u00a04\u00a0semanas\u00a0de\u00a0TAR\u00a0y\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0a\u00a0las\u00a016\u201024\u00a0semanas. \u00a0\nFracaso\u00a0virol\u00f3gico :\u00a0Cualquiera \u00a0de\u00a0las\u00a0siguientes \u00a0situaciones \u00a0a)\u00a0CVP\u00a0detectable \u00a0a\u00a0las\u00a024\u00a0\nsemanas\u00a0de\u00a0TAR,\u00a0o\u00a0b)\u00a0si\u00a0tras\u00a0alcanzar\u00a0una\u00a0CVP\u00a0indetectable \u00a0(<50\u00a0copias/mL), \u00a0\u00e9sta\u00a0\nvuelve\u00a0a\u00a0ser\u00a0detectable \u00a0en\u00a0dos\u00a0determinaciones \u00a0consecutivas. \u00a0\nEs\u00a0conveniente \u00a0medir\u00a0la\u00a0CVP\u00a0a\u00a0las\u00a04\u00a0semanas\u00a0de\u00a0inicio\u00a0del\u00a0TAR\u00a0para\u00a0comprobar \u00a0la\u00a0\nrespuesta \u00a0virol\u00f3gica \u00a0y\u00a0como\u00a0medida\u00a0indirecta\u00a0de\u00a0adherencia. \u00a0Posteriormente \u00a0la\u00a0\ndeterminaci\u00f3n \u00a0se\u00a0har\u00e1\u00a0cada\u00a03\u20106\u00a0meses.\u00a0Si\u00a0la\u00a0medida\u00a0de\u00a0la\u00a0CVP\u00a0se\u00a0efect\u00faa\u00a0tras\u00a0un\u00a0\nproceso\u00a0viral\u00a0intercurrente \u00a0o\u00a0vacunaci\u00f3n \u00a0puede\u00a0haber\u00a0brotes\u00a0transitorios \u00a0de\u00a0la\u00a0CVP50.\u00a0\nRecomendaciones \u00a0sobre\u00a0carga\u00a0viral\u00a0plasm\u00e1tica \u00a0\n\u0083 Se\u00a0debe\u00a0conocer\u00a0la\u00a0CVP\u00a0ya\u00a0que\u00a0es\u00a0un\u00a0criterio\u00a0secundario \u00a0para\u00a0el\u00a0inicio\u00a0del\u00a0TAR,\u00a0\ncomplementario \u00a0al\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0(nivel\u00a0A)\u00a0\n\u0083 Se\u00a0debe\u00a0controlar\u00a0la\u00a0eficacia\u00a0del\u00a0TAR\u00a0mediante \u00a0la\u00a0CVP\u00a0que\u00a0es\u00a0el\u00a0par\u00e1metro \u00a0principal\u00a0\npara\u00a0evaluar\u00a0la\u00a0misma,\u00a0definir\u00a0su\u00a0fracaso\u00a0y\u00a0para\u00a0tomar\u00a0decisiones \u00a0de\u00a0cambio\u00a0(nivel\u00a0\nB)\u00a0\u00a0\n\u0083 Debe\u00a0utilizarse\u00a0una\u00a0t\u00e9cnica\u00a0de\u00a0determinaci\u00f3n \u00a0de\u00a0CVP\u00a0cuyo\u00a0dintel\u00a0de\u00a0detecci\u00f3n \u00a0sea\u00a0\n<50\u00a0copias/mL \u00a0y\u00a0usar\u00a0siempre\u00a0la\u00a0misma\u00a0t\u00e9cnica\u00a0(nivel\u00a0B)\u00a0\n\u0083 Si\u00a0se\u00a0van\u00a0a\u00a0tomar\u00a0decisiones \u00a0terap\u00e9uticas \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0un\u00a0resultado, \u00a0se\u00a0debe\u00a0\nconfirmar \u00a0la\u00a0CVP\u00a0con\u00a0una\u00a0segunda\u00a0determinaci\u00f3n \u00a0(nivel\u00a0B)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 6\u00a0\n2.3.\u00a0Niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0f\u00e1rmacos \u00a0\nLas\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0de\u00a0algunos\u00a0FAR\u00a0se\u00a0correlacionan \u00a0con\u00a0su\u00a0eficacia\u00a0o\u00a0\ntoxicidad\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0\npodr\u00eda\u00a0ser\u00a0\u00fatil\u00a0para\u00a0optimizar \u00a0su\u00a0uso51.\u00a0\nSe\u00a0conocen\u00a0determinadas \u00a0situaciones \u00a0cl\u00ednicas\u00a0o\u00a0factores\u00a0que\u00a0pueden\u00a0inducir\u00a0\nvariaciones \u00a0importantes \u00a0en\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0los\u00a0FAR\u00a0lo\u00a0que\u00a0justificar\u00eda \u00a0su\u00a0\ndeterminaci\u00f3n52.\u00a0Entre\u00a0ellos\u00a0est\u00e1n\u00a0el\u00a0sexo,\u00a0edad,\u00a0peso\u00a0y\u00a0superficie \u00a0corporal,\u00a0los\u00a0niveles\u00a0\nde\u00a0alfa1\u2010glucoprote\u00edna \u00a0y\u00a0variaciones \u00a0en\u00a0las\u00a0isoformas \u00a0del\u00a0citocromo \u00a0P450,\u00a0las\u00a0\ninteracciones \u00a0medicamentosas, \u00a0el\u00a0embarazo, \u00a0la\u00a0insuficiencia \u00a0hep\u00e1tica\u00a0o\u00a0renal.\u00a0\u00a0\nLa\u00a0monitorizaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0se\u00a0limita\u00a0a\u00a0NN\u00a0e\u00a0IP\u00a0ya\u00a0que\u00a0la\u00a0\ndeterminaci\u00f3n \u00a0de\u00a0la\u00a0forma\u00a0activa\u00a0de\u00a0los\u00a0AN\u00a0(intracelular) \u00a0presenta\u00a0una\u00a0variabilidad \u00a0\ninter\u00a0e\u00a0intrapaciente \u00a0tan\u00a0amplia\u00a0que\u00a0dificulta\u00a0su\u00a0uso\u00a0cl\u00ednico.\u00a0\u00a0\nEl\u00a0valor\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0IP\u00a0con\u00a0respecto\u00a0a\u00a0su\u00a0eficacia\u00a0ha\u00a0perdido\u00a0vigencia\u00a0desde\u00a0que\u00a0se\u00a0\nutilizan\u00a0potenciados \u00a0aunque\u00a0ha\u00a0aumentado \u00a0su\u00a0valor\u00a0para\u00a0reducir\u00a0toxicidad. \u00a0Los\u00a0datos\u00a0\nque\u00a0relacionaban \u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0IP\u00a0y\u00a0eficacia\u00a0se\u00a0obtuvieron \u00a0en\u00a0los\u00a0estudios\u00a0de\u00a0\ndesarrollo \u00a0donde\u00a0se\u00a0utilizaron \u00a0en\u00a0monoterapia53.\u00a0Los\u00a0estudios\u00a0en\u00a0reg\u00edmenes \u00a0de\u00a0\ncombinaci\u00f3n \u00a0han\u00a0mostrado \u00a0resultados \u00a0dispares,\u00a0variando\u00a0seg\u00fan\u00a0l\u00ednea\u00a0de\u00a0tratamiento \u00a0\n(sin\u00a0terapia\u00a0previa\u00a0frente\u00a0a\u00a0pretratados), \u00a0f\u00e1rmacos \u00a0acompa\u00f1antes \u00a0(otros\u00a0IP\u00a0o\u00a0NN)\u00a0o\u00a0\npotenciaci\u00f3n \u00a0con\u00a0RTV54\u201060.\u00a0En\u00a0cuanto\u00a0a\u00a0toxicidad, \u00a0se\u00a0ha\u00a0demostrado \u00a0una\u00a0relaci\u00f3n\u00a0entre\u00a0\nniveles\u00a0plasm\u00e1ticos \u00a0y\u00a0algunos\u00a0efectos\u00a0secundarios \u00a0como\u00a0alteraciones \u00a0\ngastrointestinales, \u00a0hipertrigliceridemia \u00a0y\u00a0parestesias \u00a0(RTV),\u00a0alteraciones \u00a0renales\u00a0(IDV),\u00a0\nhepatotoxicidad \u00a0(NVP),\u00a0colesterol \u00a0total\u00a0y\u00a0triglic\u00e9ridos \u00a0(LPV/r)61\u201065.\u00a0Igualmente \u00a0hay\u00a0datos\u00a0\nque\u00a0sugieren\u00a0que\u00a0los\u00a0pacientes \u00a0que\u00a0alcanzan\u00a0concentraciones \u00a0m\u00e1s\u00a0elevadas\u00a0de\u00a0EFV\u00a0\ntienen\u00a0mayor\u00a0riesgo\u00a0de\u00a0s\u00edntomas\u00a0neuropsiqui\u00e1tricos66,\u00a067.\u00a0\nLas\u00a0limitaciones \u00a0del\u00a0uso\u00a0rutinario\u00a0de\u00a0niveles\u00a0plasm\u00e1ticos \u00a0en\u00a0la\u00a0cl\u00ednica\u00a0diaria\u00a0son\u00a0\nm\u00faltiples, \u00a0por\u00a0una\u00a0parte\u00a0no\u00a0existen\u00a0estudios\u00a0prospectivos \u00a0que\u00a0demuestren \u00a0su\u00a0utilidad\u00a0\nen\u00a0mejorar\u00a0la\u00a0eficacia\u00a0y\u00a0por\u00a0otra,\u00a0la\u00a0ausencia\u00a0de\u00a0rangos\u00a0terap\u00e9uticos \u00a0asociados \u00a0a\u00a0\nrespuesta \u00a0terap\u00e9utica \u00a0o\u00a0la\u00a0posibilidad \u00a0de\u00a0reducir\u00a0reacciones \u00a0adversas. \u00a0Otra\u00a0limitaci\u00f3n \u00a0\nes\u00a0la\u00a0no\u00a0disponibilidad \u00a0de\u00a0la\u00a0t\u00e9cnica\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0laboratorios. \u00a0\n\u00a0\nRecomendaci\u00f3n \u00a0sobre\u00a0niveles\u00a0de\u00a0f\u00e1rmacos \u00a0\n\u0083 La\u00a0medici\u00f3n \u00a0de\u00a0niveles\u00a0podr\u00eda\u00a0ser\u00a0de\u00a0ayuda\u00a0en\u00a0el\u00a0manejo\u00a0de\u00a0situaciones \u00a0cl\u00ednicas\u00a0\nconcretas \u00a0(interacciones \u00a0farmacol\u00f3gicas, \u00a0TAR\u00a0en\u00a0trasplante \u00a0de\u00a0\u00f3rgano,\u00a0delgadez\u00a0u\u00a0\nobesidad\u00a0m\u00f3rbidas, \u00a0insuficiencia \u00a0hep\u00e1tica\u00a0o\u00a0renal)\u00a0(nivel\u00a0C)\u00a0\n\u00a0\n2.4.\u00a0Resistencia \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\nLa\u00a0tasa\u00a0de\u00a0mutaci\u00f3n \u00a0espont\u00e1nea \u00a0de\u00a0los\u00a0retrovirus \u00a0se\u00a0estima\u00a0en\u00a0un\u00a0nucle\u00f3tido \u00a0por\u00a0cada\u00a0\n104\u00a0\u00f3\u00a0105\u00a0nucle\u00f3tidos \u00a0y\u00a0copia\u00a0de\u00a0la\u00a0cadena\u00a0del\u00a0ARN68\u201070.\u00a0Por\u00a0otro\u00a0lado,\u00a0la\u00a0vida\u00a0media\u00a0de\u00a0\nlos\u00a0linfocitos\u00a0CD4\u00a0infectados \u00a0que\u00a0replican\u00a0activamente \u00a0es\u00a0de\u00a0un\u00a0d\u00eda\u00a0y\u00a0se\u00a0estima\u00a0que\u00a0la\u00a0\nvida\u00a0media\u00a0del\u00a0virus\u00a0en\u00a0plasma\u00a0es\u00a0de\u00a06\u00a0horas71\u201074.\u00a0La\u00a0conjunci\u00f3n \u00a0de\u00a0esta\u00a0alta\u00a0tasa\u00a0de\u00a0\nerror\u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0y\u00a0de\u00a0la\u00a0r\u00e1pida\u00a0renovaci\u00f3n \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0produce\u00a0\nun\u00a0c\u00famulo\u00a0de\u00a0gran\u00a0cantidad\u00a0de\u00a0variantes\u00a0virales,\u00a0que\u00a0reciben\u00a0el\u00a0nombre\u00a0de\u00a0cuasi\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 7especies.\u00a0El\u00a0n\u00famero\u00a0de\u00a0variantes\u00a0gen\u00e9ticas \u00a0distintas\u00a0presentes \u00a0en\u00a0un\u00a0momento \u00a0dado\u00a0\nen\u00a0un\u00a0individuo \u00a0infectado \u00a0se\u00a0estima\u00a0entre\u00a05\u00a0x105\u00a0y\u00a05\u00a0x1010.\u00a0\nLas\u00a0mutaciones \u00a0que\u00a0confieren \u00a0resistencia \u00a0pueden\u00a0existir\u00a0en\u00a0estas\u00a0cuasi\u00a0especies,\u00a0pero\u00a0\nrepresentan \u00a0una\u00a0proporci\u00f3n \u00a0m\u00ednima\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0hasta\u00a0que\u00a0se\u00a0ve\u00a0sometida \u00a0a\u00a0la\u00a0\npresi\u00f3n\u00a0selectiva\u00a0del\u00a0TAR73.\u00a0As\u00ed\u00a0pues,\u00a0el\u00a0tratamiento \u00a0conllevar\u00e1 \u00a0que\u00a0las\u00a0variantes\u00a0\nresistentes \u00a0se\u00a0conviertan \u00a0en\u00a0poblaci\u00f3n \u00a0dominante \u00a0al\u00a0cabo\u00a0de\u00a0semanas\u00a0o\u00a0meses\u00a0si\u00a0no\u00a0se\u00a0\nsuprime\u00a0la\u00a0replicaci\u00f3n \u00a0viral75\u201077.\u00a0\nNo\u00a0todas\u00a0las\u00a0mutaciones \u00a0tienen\u00a0la\u00a0misma\u00a0importancia. \u00a0Para\u00a0cada\u00a0FAR\u00a0existen\u00a0unas\u00a0\nllamadas\u00a0\u201cprincipales\u201d, \u00a0cuya\u00a0presencia \u00a0est\u00e1\u00a0estrechamente \u00a0ligada\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0\nresistencia \u00a0y\u00a0que\u00a0reducen\u00a0la\u00a0eficiencia \u00a0biol\u00f3gica\u00a0del\u00a0virus\u00a0(fitness)\u00a0y\u00a0otras\u00a0\u201csecundarias\u201d \u00a0\nque,\u00a0en\u00a0menor\u00a0medida,\u00a0tambi\u00e9n\u00a0contribuyen \u00a0a\u00a0la\u00a0resistencia \u00a0y\u00a0que,\u00a0en\u00a0general,\u00a0act\u00faan\u00a0\nmodificando \u00a0la\u00a0capacidad \u00a0replicativa \u00a0viral.\u00a0\n\u00a0Detecci\u00f3n \u00a0de\u00a0resistencias \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\nLas\u00a0variantes\u00a0resistentes \u00a0pueden\u00a0detectarse \u00a0mediante \u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0o\u00a0\nfenot\u00edpicas\n78.\u00a0Las\u00a0genot\u00edpicas \u00a0detectan\u00a0cambios\u00a0espec\u00edficos \u00a0en\u00a0los\u00a0genomas\u00a0de\u00a0las\u00a0\nenzimas\u00a0diana\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0(transcriptasa \u00a0inversa,\u00a0proteasa, \u00a0integrasa, \u00a0envuelta), \u00a0\nmientras\u00a0que\u00a0las\u00a0t\u00e9cnicas\u00a0fenot\u00edpicas \u00a0determinan \u00a0la\u00a0respuesta \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0\nmayoritaria \u00a0a\u00a0concentraciones \u00a0crecientes \u00a0de\u00a0los\u00a0distintos\u00a0f\u00e1rmacos. \u00a0Ambas\u00a0comparten \u00a0\nlimitaciones \u00a0como\u00a0la\u00a0dificultad \u00a0de\u00a0detecci\u00f3n \u00a0cuando\u00a0la\u00a0poblaci\u00f3n \u00a0mutada\u00a0es\u00a0<20%\u00a0de\u00a0la\u00a0\npoblaci\u00f3n \u00a0viral\u00a0o\u00a0la\u00a0CVP\u00a0es\u00a0<1000\u00a0copias/mL78,\u00a0aunque\u00a0t\u00e9cnicas\u00a0recientes\u00a0van\u00a0\nreduciendo \u00a0ambas\u00a0limitaciones. \u00a0Las\u00a0pruebas\u00a0de\u00a0resistencias \u00a0deben\u00a0realizarse \u00a0durante\u00a0\nel\u00a0TAR79\u00a0activo\u00a0ya\u00a0que\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0resistente \u00a0ser\u00e1\u00a0sustituida \u00a0por\u00a0otra\u00a0sensible\u00a0a\u00a0\nlas\u00a0pocas\u00a0semanas\u00a0de\u00a0retirar\u00a0los\u00a0f\u00e1rmacos. \u00a0Los\u00a0resultados \u00a0de\u00a0estas\u00a0pruebas\u00a0se\u00a0deben\u00a0\ninterpretar \u00a0teniendo\u00a0presente\u00a0los\u00a0estudios\u00a0previos\u00a0de\u00a0resistencia, \u00a0\u00a0la\u00a0historia\u00a0\nterap\u00e9utica \u00a0y\u00a0la\u00a0adherencia. \u00a0\nLas\u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0y\u00a0fenot\u00edpicas \u00a0tienen\u00a0ventajas\u00a0y\u00a0desventajas \u00a0que\u00a0las\u00a0hacen\u00a0\ncomplementarias \u00a0entre\u00a0s\u00ed78.\u00a0Las\u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0son\u00a0m\u00e1s\u00a0sencillas,\u00a0r\u00e1pidas\u00a0y\u00a0\naccesibles \u00a0para\u00a0la\u00a0mayor\u00a0parte\u00a0de\u00a0laboratorios \u00a0y\u00a0permiten \u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0mutaciones \u00a0\ncentinela\u00a0antes\u00a0de\u00a0que\u00a0se\u00a0detecten\u00a0cambios\u00a0de\u00a0susceptibilidad \u00a0en\u00a0las\u00a0pruebas\u00a0\nfenot\u00edpicas. \u00a0Su\u00a0mayor\u00a0limitaci\u00f3n \u00a0estriba\u00a0en\u00a0la\u00a0dificultad \u00a0de\u00a0establecer \u00a0una\u00a0correlaci\u00f3n \u00a0\ngenot\u00edpica \u2010fenot\u00edpica \u00a0y,\u00a0sobre\u00a0todo,\u00a0en\u00a0las\u00a0dificultades \u00a0de\u00a0interpretaci\u00f3n \u00a0para\u00a0algunos\u00a0\nf\u00e1rmacos. \u00a0Adem\u00e1s,\u00a0su\u00a0aplicaci\u00f3n \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0diaria\u00a0requiere\u00a0el\u00a0conocimiento \u00a0previo\u00a0\npor\u00a0parte\u00a0del\u00a0cl\u00ednico\u00a0de\u00a0la\u00a0influencia \u00a0que\u00a0tiene\u00a0cada\u00a0mutaci\u00f3n \u00a0detectada \u00a0en\u00a0la\u00a0eficacia\u00a0\nde\u00a0cada\u00a0f\u00e1rmaco.\u00a0Las\u00a0t\u00e9cnicas\u00a0fenot\u00edpicas \u00a0tienen\u00a0la\u00a0ventaja\u00a0de\u00a0informar\u00a0del\u00a0efecto\u00a0neto\u00a0\nde\u00a0las\u00a0distintas\u00a0concentraciones \u00a0sobre\u00a0la\u00a0sensibilidad \u00a0real\u00a0de\u00a0la\u00a0cepa\u00a0predominante \u00a0a\u00a0\nlos\u00a0FAR,\u00a0hayan\u00a0sido\u00a0utilizados \u00a0o\u00a0no.\u00a0Existe\u00a0una\u00a0buena\u00a0correlaci\u00f3n \u00a0entre\u00a0las\u00a0dos\u00a0t\u00e9cnicas\u00a0\nexistentes \u00a0en\u00a0la\u00a0actualidad, \u00a0Virologic\u00a0Phenosense \u00a0y\u00a0Virco\u00a0Antivirogram80.\u00a0Sus\u00a0mayores\u00a0\ndesventajas \u00a0son\u00a0el\u00a0coste,\u00a0la\u00a0disponibilidad \u00a0limitada\u00a0y\u00a0demora\u00a0en\u00a0la\u00a0obtenci\u00f3n \u00a0de\u00a0\nresultados. \u00a0Para\u00a0superar\u00a0estas\u00a0desventajas \u00a0se\u00a0ha\u00a0desarrollado \u00a0el\u00a0fenotipo\u00a0virtual81,\u00a0\nobtenido\u00a0a\u00a0partir\u00a0de\u00a0una\u00a0base\u00a0de\u00a0datos\u00a0que\u00a0tiene\u00a0miles\u00a0de\u00a0muestras \u00a0analizadas \u00a0por\u00a0\nambas\u00a0t\u00e9cnicas.\u00a0Ante\u00a0un\u00a0determinado \u00a0genotipo\u00a0el\u00a0sistema\u00a0busca\u00a0todos\u00a0los\u00a0genotipos \u00a0\ncoincidentes \u00a0en\u00a0la\u00a0base\u00a0de\u00a0datos\u00a0\u00a0y\u00a0calcula\u00a0el\u00a0fenotipo\u00a0medio\u00a0de\u00a0estos\u00a0pacientes. \u00a0En\u00a0\nuna\u00a0modificaci\u00f3n \u00a0posterior\u00a0(VircoType\u00ae) \u00a0se\u00a0a\u00f1ade\u00a0informaci\u00f3n \u00a0de\u00a0predicci\u00f3n \u00a0de\u00a0la\u00a0\nrespuesta: \u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0respuesta \u00a0m\u00e1xima\u00a0o\u00a0reducida\u00a0y\u00a0ausencia\u00a0de\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 8respuesta \u00a0(puntos\u00a0de\u00a0corte\u00a0cl\u00ednicos).\u00a0Se\u00a0ha\u00a0demostrado \u00a0que\u00a0existe\u00a0una\u00a0buena\u00a0\ncorrelaci\u00f3n \u00a0entre\u00a0ambos\u00a0m\u00e9todos80,\u00a081\u00a0sobre\u00a0todo\u00a0con\u00a0los\u00a0NN\u00a0y\u00a0menos\u00a0con\u00a0los\u00a0AN.\u00a0La\u00a0\ncorrelaci\u00f3n \u00a0es\u00a0bastante\u00a0m\u00e1s\u00a0deficiente \u00a0en\u00a0pacientes \u00a0multitratados. \u00a0\u00a0\nNumerosos \u00a0trabajos\u00a0han\u00a0estudiado, \u00a0en\u00a0pa\u00edses\u00a0desarrollados, \u00a0la\u00a0prevalencia \u00a0de\u00a0\nresistencias \u00a0primarias \u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0cr\u00f3nica.\u00a0Se\u00a0sabe\u00a0que\u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0las\u00a0mutaciones \u00a0puede\u00a0detectarse \u00a0durante\u00a0a\u00f1os\u00a0y\u00a0que\u00a0su\u00a0prevalencia \u00a0ha\u00a0\naumentado \u00a0llegando\u00a0a\u00a0superar\u00a0el\u00a010%\u00a082\u201084.\u00a0En\u00a0Espa\u00f1a\u00a0en\u00a0un\u00a0estudio\u00a0multic\u00e9ntrico \u00a0de\u00a0\npacientes \u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0se\u00a0encontr\u00f3\u00a0que\u00a0el\u00a014%\u00a0de\u00a0las\u00a0cepas\u00a0ten\u00eda\u00a0mutaciones \u00a0\nprimarias85,\u00a0pero\u00a0datos\u00a0m\u00e1s\u00a0recientes\u00a0muestran \u00a0una\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0prevalencia \u00a0en\u00a0los\u00a0\ndiagn\u00f3sticos \u00a0nuevos\u00a0a\u00a010%86,\u00a087.\u00a0Y\u00a0a\u00fan\u00a0m\u00e1s\u00a0recientemente \u00a0la\u00a0prevalencia \u00a0de\u00a0\ntransmisi\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0en\u00a0poblaci\u00f3n \u00a0no\u00a0tratada\u00a0en\u00a0el\u00a0periodo\u00a02004\u2010\n2008\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos \u00a0de\u00a0la\u00a0cohorte\u00a0prospectiva \u00a0de\u00a0adultos\u00a0de\u00a0la\u00a0red\u00a0de\u00a0Sida\u00a0\n(CoRIS)\u00a0se\u00a0ha\u00a0estimado \u00a0en\u00a0el\u00a08,4%88.\u00a0Por\u00a0ello\u00a0se\u00a0debe\u00a0realizar\u00a0una\u00a0prueba\u00a0genot\u00edpica \u00a0en\u00a0\nel\u00a0momento \u00a0del\u00a0diagn\u00f3stico. \u00a0Un\u00a0estudio\u00a0coste\u2010eficacia\u00a0relativo\u00a0a\u00a0la\u00a0ventaja\u00a0de\u00a0efectuar\u00a0\nla\u00a0prueba\u00a0genot\u00edpica \u00a0a\u00a0todos\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0TAR,\u00a0\nha\u00a0demostrado \u00a0que\u00a0la\u00a0misma\u00a0es\u00a0coste\u2010eficaz\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0preservar \u00a0f\u00e1rmacos\u00a0y\u00a0que,\u00a0por\u00a0\ntanto,\u00a0deber\u00eda\u00a0incluirse\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0habitual89,\u00a090.\u00a0Se\u00a0deber\u00eda\u00a0considerar \u00a0repetir\u00a0el\u00a0\ngenotipado \u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0TAR\u00a0en\u00a0caso\u00a0de\u00a0diferir\u00a0\u00e9ste\u00a0por\u00a0la\u00a0posibilidad \u00a0de\u00a0haber\u00a0\nsufrido\u00a0una\u00a0reinfecci\u00f3n. \u00a0\nEn\u00a0Espa\u00f1a\u00a0una\u00a0de\u00a0las\u00a0actividades \u00a0de\u00a0la\u00a0plataforma \u00a0de\u00a0resistencias \u00a0de\u00a0la\u00a0Red\u00a0de\u00a0SIDA\u00a0ha\u00a0\nsido\u00a0el\u00a0establecimiento \u00a0de\u00a0una\u00a0base\u00a0de\u00a0datos\u00a0de\u00a0secuencias \u00a0de\u00a0pacientes \u00a0en\u00a0fracaso\u00a0\nvirol\u00f3gico, \u00a0atendidos \u00a0en\u00a0numerosos \u00a0centros\u00a0hospitalarios \u00a0espa\u00f1oles. \u00a0Expertos\u00a0de\u00a0esta\u00a0\nplataforma \u00a0han\u00a0elaborado \u00a0un\u00a0algoritmo \u00a0de\u00a0interpretaci\u00f3n, \u00a0que\u00a0se\u00a0actualiza\u00a0\nanualmente, \u00a0y\u00a0\u00a0que\u00a0permite\u00a0la\u00a0predicci\u00f3n \u00a0de\u00a0la\u00a0resistencia \u00a0\u201con\u00a0line\u201d.\u00a0Se\u00a0puede\u00a0acceder\u00a0\na\u00a0dicho\u00a0algoritmo \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0p\u00e1gina\u00a0web\u00a0de\u00a0la\u00a0Red\u00a0de\u00a0Investigaci\u00f3n \u00a0en\u00a0SIDA.\u00a0\nUna\u00a0de\u00a0las\u00a0principales \u00a0limitaciones \u00a0de\u00a0los\u00a0estudios\u00a0de\u00a0resistencias \u00a0consiste\u00a0en\u00a0que,\u00a0por\u00a0\nel\u00a0momento, \u00a0no\u00a0son\u00a0capaces\u00a0de\u00a0detectar\u00a0mutaciones \u00a0que\u00a0no\u00a0representan \u00a0m\u00e1s\u00a0del\u00a015\u2010\n20%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral.\u00a0Aunque\u00a0se\u00a0han\u00a0desarrollado \u00a0algunas\u00a0tecnolog\u00edas \u00a0(PCR\u00a0alelo\u00a0\nespec\u00edfica, \u00a0secuenciaci\u00f3n \u00a0de\u00a0genomas\u00a0individuales, \u00a0o\u00a0secuenciaci\u00f3n \u00a0masiva\u00a0de\u00a0\ngenomas\u00a0\u00fanicos\u2010UDS\u2010)\u00a0que\u00a0permiten \u00a0detectar\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0en\u00a0niveles\u00a0de\u00a0\nhasta\u00a0el\u00a00,1\u20101%,\u00a0en\u00a0la\u00a0actualidad \u00a0no\u00a0est\u00e1n\u00a0disponibles \u00a0para\u00a0su\u00a0uso\u00a0en\u00a0rutina\u00a0y\u00a0no\u00a0se\u00a0\nconoce\u00a0con\u00a0precisi\u00f3n\u00a0\u00a0la\u00a0utilidad\u00a0de\u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0estas\u00a0poblaciones \u00a0minoritarias \u00a0que\u00a0\nse\u00a0escapan\u00a0al\u00a0estudio\u00a0genot\u00edpico \u00a0convencional91\u201098.\u00a0\n\u00a0\nSignificado \u00a0cl\u00ednico\u00a0de\u00a0las\u00a0resistencias \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\nCon\u00a0el\u00a0uso\u00a0de\u00a0la\u00a0CVP\u00a0en\u00a0el\u00a0seguimiento \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0se\u00a0ha\u00a0\nevidenciado \u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0aparici\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencias \u00a0y\u00a0fracaso\u00a0\nvirol\u00f3gico. \u00a0Sin\u00a0embargo\u00a0este\u00a0fen\u00f3meno \u00a0no\u00a0es\u00a0homog\u00e9neo \u00a0para\u00a0todos\u00a0los\u00a0f\u00e1rmacos \u00a0ya\u00a0\nque\u00a0es\u00a0muy\u00a0claro\u00a0en\u00a0los\u00a0AN\u00a0y\u00a0NN\u00a0pero\u00a0existen\u00a0datos\u00a0contradictorios \u00a0con\u00a0los\u00a0IP\u00a0con\u00a0los\u00a0\nque\u00a0se\u00a0ha\u00a0constatado \u00a0fracaso\u00a0virol\u00f3gico \u00a0sin\u00a0evidencia \u00a0de\u00a0resistencias99.\u00a0En\u00a0este\u00a0sentido\u00a0\nse\u00a0ha\u00a0definido\u00a0el\u00a0fen\u00f3meno \u00a0de\u00a0resistencia \u00a0celular\u00a0ya\u00a0que\u00a0se\u00a0han\u00a0detectado \u00a0la\u00a0existencia \u00a0\nde\u00a0bombas\u00a0de\u00a0expulsi\u00f3n \u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0la\u00a0membrana \u00a0de\u00a0los\u00a0linfocitos\u00a0y\u00a0otras\u00a0c\u00e9lulas.\u00a0Se\u00a0\nhan\u00a0descrito\u00a0el\u00a0MDRP\u20101\u00a0(glicoprote\u00edna \u2010P)\u00a0para\u00a0los\u00a0IP\u00a0y\u00a0la\u00a0MDRP\u20104\u00a0para\u00a0los\u00a0AN100.\u00a0Se\u00a0\ndesconoce \u00a0la\u00a0relevancia \u00a0cl\u00ednica\u00a0de\u00a0estos\u00a0hallazgos. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 9Los\u00a0estudios\u00a0prospectivos \u00a0y\u00a0aleatorizados \u00a0que\u00a0han\u00a0utilizado\u00a0las\u00a0pruebas\u00a0de\u00a0resistencias \u00a0\npara\u00a0el\u00a0manejo\u00a0del\u00a0fracaso\u00a0virol\u00f3gico \u00a0comparan \u00a0la\u00a0eficacia\u00a0del\u00a0cambio\u00a0de\u00a0TAR\u00a0cuando\u00a0\nse\u00a0realiza\u00a0seg\u00fan\u00a0las\u00a0distintas\u00a0pruebas\u00a0de\u00a0resistencia \u00a0(genotipo, \u00a0fenotipo\u00a0o\u00a0fenotipo\u00a0\nvirtual)\u00a0con\u00a0o\u00a0sin\u00a0consejo\u00a0de\u00a0expertos\u00a0o\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0historia\u00a0terap\u00e9utica \u00a0previa\u00a0y/o\u00a0\nla\u00a0experiencia \u00a0cl\u00ednica\u00a0de\u00a0los\u00a0m\u00e9dicos101\u2010109.\u00a0Un\u00a0metaan\u00e1lisis \u00a0de\u00a0los\u00a0primeros\u00a0estudios\u00a0\ncomunicados \u00a0puso\u00a0de\u00a0manifiesto \u00a0que\u00a0el\u00a0uso\u00a0del\u00a0genotipo\u00a0para\u00a0dise\u00f1ar\u00a0el\u00a0TAR\u00a0de\u00a0\nrescate\u00a0frente\u00a0al\u00a0est\u00e1ndar\u00a0(historia\u00a0terap\u00e9utica \u00a0y\u00a0experiencia \u00a0del\u00a0m\u00e9dico)\u00a0se\u00a0asociaba\u00a0\ncon\u00a0un\u00a0control\u00a0virol\u00f3gico \u00a0significativamente \u00a0mayor\u00a0a\u00a0los\u00a03\u00a0y\u00a06\u00a0meses110.\u00a0Estas\u00a0\ndiferencias \u00a0no\u00a0se\u00a0observaron \u00a0en\u00a0los\u00a0estudios\u00a0que\u00a0compararon \u00a0los\u00a0m\u00e9todos\u00a0fenot\u00edpicos \u00a0\nfrente\u00a0al\u00a0manejo\u00a0est\u00e1ndar110.\u00a0Por\u00a0otro\u00a0lado,\u00a0no\u00a0se\u00a0han\u00a0detectado \u00a0diferencias \u00a0cuando\u00a0se\u00a0\nhan\u00a0comparado \u00a0el\u00a0fenotipo\u00a0virtual\u00a0y\u00a0el\u00a0fenotipo\u00a0real108,\u00a0109.\u00a0Se\u00a0requieren \u00a0pues\u00a0m\u00e1s\u00a0\ndatos\u00a0para\u00a0aclarar\u00a0el\u00a0papel\u00a0de\u00a0las\u00a0pruebas\u00a0fenot\u00edpicas \u00a0para\u00a0guiar\u00a0el\u00a0TAR.\u00a0\nRecomendaciones \u00a0sobre\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0\n\u0083 Se\u00a0deben\u00a0estudiar\u00a0las\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0ya\u00a0que\u00a0su\u00a0conocimiento \u00a0permite\u00a0\nun\u00a0mejor\u00a0uso\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0(nivel\u00a0A)\u00a0\n\u0083 Se\u00a0considera \u00a0indicada\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0las\u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0de\u00a0detecci\u00f3n \u00a0de\u00a0\nresistencias \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0asistencial \u00a0en\u00a0las\u00a0situaciones \u00a0expuestas \u00a0en\u00a0la\u00a0Tabla\u00a02\u00a0\n(Nivel\u00a0B)\u00a0\n\u00a0\n\u00a0\n2.5.\u00a0Determinaci\u00f3n \u00a0del\u00a0HLA\u00a0B*5701\u00a0\nLa\u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad \u00a0(RHS)\u00a0a\u00a0ABC\u00a0es\u00a0un\u00a0s\u00edndrome \u00a0multiorg\u00e1nico \u00a0que\u00a0se\u00a0\nmanifiesta \u00a0con\u00a0una\u00a0combinaci\u00f3n \u00a0variable\u00a0de\u00a0fiebre,\u00a0mialgias,\u00a0s\u00edntomas\u00a0respiratorios \u00a0y\u00a0\ngastrointestinales \u00a0y\u00a0un\u00a0exantema \u00a0de\u00a0intensidad \u00a0creciente, \u00a0pudiendo \u00a0ser\u00a0fatal\u00a0en\u00a0caso\u00a0\nde\u00a0continuar \u00a0con\u00a0el\u00a0f\u00e1rmaco\u00a0o\u00a0reintroducirlo. \u00a0\u00a0Suele\u00a0aparecer\u00a0durante\u00a0las\u00a0primeras\u00a06\u00a0\nsemanas\u00a0de\u00a0tratamiento, \u00a0se\u00a0presenta\u00a0en\u00a0el\u00a05\u20108%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0toman\u00a0ABC\u00a0y\u00a0es\u00a0\nla\u00a0causa\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0su\u00a0discontinuaci\u00f3n111.\u00a0Se\u00a0sabe\u00a0que\u00a0la\u00a0RHS\u00a0es\u00a0m\u00e1s\u00a0frecuente \u00a0\nen\u00a0la\u00a0poblaci\u00f3n \u00a0blanca\u00a0y\u00a0se\u00a0dispone\u00a0de\u00a0una\u00a0prueba\u00a0cut\u00e1nea\u00a0(parche)\u00a0para\u00a0su\u00a0\nconfirmaci\u00f3n. \u00a0\nEstudios\u00a0farmacogen\u00e9ticos \u00a0han\u00a0identificado \u00a0que\u00a0la\u00a0RHS\u00a0ocurre\u00a0en\u00a0las\u00a0personas\u00a0\nportadoras \u00a0del\u00a0alelo\u00a0HLA\u00a0B*5701.\u00a0En\u00a0un\u00a0ensayo\u00a0(PREDICT) \u00a0en\u00a0el\u00a0que\u00a0los\u00a0pacientes \u00a0se\u00a0\naleatorizaron \u00a0a\u00a0comenzar \u00a0TAR\u00a0con\u00a0ABC\u00a0o\u00a0comenzarlo \u00a0s\u00f3lo\u00a0si\u00a0el\u00a0HLA*5701 \u00a0era\u00a0negativo, \u00a0\nse\u00a0valor\u00f3\u00a0la\u00a0RHS\u00a0por\u00a0datos\u00a0cl\u00ednicos\u00a0que\u00a0se\u00a0confirmaron \u00a0con\u00a0una\u00a0prueba\u00a0cut\u00e1nea\u00a0\n(confirmaci\u00f3n \u00a0inmunol\u00f3gica). \u00a0La\u00a0prevalencia \u00a0del\u00a0HLA\u00a0B*5701\u00a0en\u00a0esta\u00a0cohorte\u00a0era\u00a0del\u00a0\n5,6%.\u00a0La\u00a0genotipificaci\u00f3n \u00a0del\u00a0HLA\u00a0B*5701\u00a0redujo\u00a0la\u00a0incidencia \u00a0de\u00a0sospecha \u00a0cl\u00ednica\u00a0de\u00a0\nRHS\u00a0(3,4%\u00a0frente\u00a07,8%)\u00a0y\u00a0la\u00a0inmunol\u00f3gica \u00a0(0%\u00a0frente\u00a0a\u00a02,7%)\u00a0siendo\u00a0el\u00a0valor\u00a0predictivo \u00a0\nnegativo\u00a0de\u00a0esta\u00a0prueba\u00a0del\u00a0100%112.\u00a0Se\u00a0ha\u00a0validado\u00a0esta\u00a0prueba\u00a0en\u00a0poblaci\u00f3n \u00a0negra\u00a0\nconfirmando \u00a0los\u00a0resultados113.\u00a0\nEl\u00a0ABC\u00a0no\u00a0debe\u00a0utilizarse\u00a0en\u00a0personas\u00a0portadores \u00a0del\u00a0alelo\u00a0HLA\u00a0B*5701.\u00a0Si\u00a0el\u00a0HLA\u00a0\nB*5701\u00a0es\u00a0negativo\u00a0no\u00a0se\u00a0descarta\u00a0la\u00a0posibilidad \u00a0de\u00a0RHS\u00a0y\u00a0debe\u00a0informarse \u00a0y\u00a0controlar\u00a0\nestos\u00a0pacientes \u00a0respecto\u00a0a\u00a0la\u00a0RHS\u00a0cuando\u00a0se\u00a0inicia\u00a0tratamiento \u00a0con\u00a0ABC.\u00a0\n\u00a0\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 10Recomendaciones \u00a0sobre\u00a0determinaci\u00f3n \u00a0del\u00a0HLA\u00a0B*5701\u00a0\n\u0083 Se\u00a0deben\u00a0determinar \u00a0el\u00a0HLA\u00a0B*5701\u00a0a\u00a0todos\u00a0los\u00a0pacientes \u00a0en\u00a0el\u00a0momento \u00a0del\u00a0\ndiagn\u00f3stico \u00a0o\u00a0cuando\u00a0vayan\u00a0a\u00a0comenzar \u00a0TAR\u00a0con\u00a0ABC\u00a0(Nivel\u00a0A)\u00a0\n\u0083 Si\u00a0el\u00a0HLA\u00a0B*5701\u00a0es\u00a0positivo\u00a0no\u00a0se\u00a0debe\u00a0prescribir \u00a0ABC\u00a0(Nivel\u00a0A)\u00a0\n\u0083 Si\u00a0el\u00a0HLA\u00a0B*5701\u00a0es\u00a0negativo\u00a0no\u00a0se\u00a0puede\u00a0descartar \u00a0completamente \u00a0la\u00a0RHS,\u00a0por\u00a0lo\u00a0\nque\u00a0se\u00a0debe\u00a0informar\u00a0al\u00a0paciente\u00a0y\u00a0vigilar\u00a0su\u00a0posible\u00a0aparici\u00f3n \u00a0(Nivel\u00a0A)\u00a0\n\u0083 Si\u00a0se\u00a0prescribe \u00a0ABC\u00a0sin\u00a0conocer\u00a0el\u00a0HLA\u00a0B*5701,\u00a0se\u00a0debe\u00a0informar\u00a0al\u00a0paciente\u00a0y\u00a0estar\u00a0\nalerta\u00a0para\u00a0detectar\u00a0s\u00edntomas\u00a0de\u00a0la\u00a0RHS\u00a0(Nivel\u00a0C)\u00a0\n\u00a0\n2.6.\u00a0Determinaci\u00f3n \u00a0del\u00a0tropismo \u00a0del\u00a0VIH\u00a0\nEl\u00a0VIH\u00a0entra\u00a0en\u00a0la\u00a0c\u00e9lula\u00a0diana\u00a0por\u00a0un\u00a0mecanismo \u00a0que\u00a0incluye\u00a0el\u00a0reconocimiento \u00a0del\u00a0\nreceptor\u00a0CD4,\u00a0seguido\u00a0de\u00a0la\u00a0uni\u00f3n\u00a0a\u00a0uno\u00a0de\u00a0los\u00a0correceptores \u00a0CCR5\u00a0o\u00a0CXCR4\u00a0y\u00a0a\u00a0\ncontinuaci\u00f3n \u00a0se\u00a0produce\u00a0la\u00a0fusi\u00f3n\u00a0de\u00a0las\u00a0membranas \u00a0con\u00a0paso\u00a0del\u00a0ARN\u00a0del\u00a0VIH\u00a0a\u00a0la\u00a0\nc\u00e9lula\u00a0invadida.\u00a0Los\u00a0inhibidores \u00a0del\u00a0CCR5\u00a0(MVC,\u00a0vicriviroc) \u00a0son\u00a0f\u00e1rmacos \u00a0que\u00a0bloquean \u00a0\neste\u00a0receptor\u00a0impidiendo \u00a0la\u00a0entrada\u00a0del\u00a0VIH\u00a0en\u00a0la\u00a0c\u00e9lula114.\u00a0\nTras\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0pacientes \u00a0albergan\u00a0virus\u00a0que\u00a0usan\u00a0el\u00a0\ncorreceptor \u00a0CCR5\u00a0(R5).\u00a0Si\u00a0no\u00a0se\u00a0inicia\u00a0un\u00a0tratamiento \u00a0el\u00a0virus\u00a0evoluciona \u00a0a\u00a0cepas\u00a0que,\u00a0\nen\u00a0mayor\u00a0o\u00a0menor\u00a0proporci\u00f3n, \u00a0utilizan\u00a0el\u00a0correceptor \u00a0CXCR4\u00a0(X4),\u00a0pudiendo \u00a0encontrar \u00a0\nigualmente \u00a0cepas\u00a0duales\u00a0o\u00a0mixtas\u00a0(D/M)\u00a0que\u00a0pueden\u00a0usar\u00a0ambos\u00a0correceptores. \u00a0Este\u00a0\ncambio\u00a0se\u00a0relaciona\u00a0con\u00a0un\u00a0descenso \u00a0de\u00a0CD4\u00a0y\u00a0aumento\u00a0de\u00a0la\u00a0inmunodepresi\u00f3n \u00a0ya\u00a0que\u00a0\nse\u00a0consideran \u00a0m\u00e1s\u00a0patog\u00e9nicas115.\u00a0En\u00a0los\u00a0pacientes \u00a0multitratados \u00a0con\u00a0CVP\u00a0detectable \u00a0\nlas\u00a0cepas\u00a0X4\u00a0o\u00a0D/M\u00a0son\u00a0m\u00e1s\u00a0prevalentes, \u00a0pudiendo \u00a0llegar\u00a0a\u00a0superar\u00a0el\u00a050%\u00a0en\u00a0caso\u00a0de\u00a0\nCD4\u00a0<100\u00a0c\u00e9lulas/\u00b5L116,\u00a0117.\u00a0\nActualmente \u00a0existe\u00a0una\u00a0t\u00e9cnica\u00a0fenot\u00edpica \u00a0para\u00a0la\u00a0detecci\u00f3n \u00a0del\u00a0tropismo\u00a0(TrofileTM,\u00a0\nMonogram \u00a0Biosciences, \u00a0USA)\u00a0que\u00a0se\u00a0realiza\u00a0en\u00a0un\u00a0solo\u00a0centro\u00a0(California, \u00a0USA)\u00a0y\u00a0que\u00a0\nllega\u00a0a\u00a0detectar\u00a0la\u00a0poblaci\u00f3n \u00a0X4\u00a0o\u00a0D/M\u00a0cuya\u00a0proporci\u00f3n \u00a0supere\u00a0el\u00a00.3%\u00a0en\u00a0una\u00a0CVP\u00a0\n\u22651000\u00a0copias/mL \u00a0(prueba\u00a0ultrasensible)118.\u00a0Este\u00a0ensayo , presenta\u00a0limitaciones \u00a0t\u00e9cnicas\u00a0\ny\u00a0log\u00edsticas\u00a0que\u00a0dificultan \u00a0su\u00a0utilizaci\u00f3n \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica.\u00a0Los\u00a0ensayos\u00a0genot\u00edpicos \u00a0\n(secuenciaci\u00f3n \u00a0de\u00a0la\u00a0regi\u00f3n\u00a0V3)\u00a0se\u00a0presentan \u00a0como\u00a0una\u00a0alternativa \u00a0m\u00e1s\u00a0econ\u00f3mica, \u00a0\nr\u00e1pida\u00a0y\u00a0factible\u00a0de\u00a0desarrollar \u00a0en\u00a0cualquier \u00a0laboratorio \u00a0especializado \u00a0de\u00a0VIH\u00a0que\u00a0\ncuente\u00a0con\u00a0tecnolog\u00eda \u00a0para\u00a0realizar\u00a0estudios\u00a0genot\u00edpicos. \u00a0Los\u00a0primeros\u00a0estudios\u00a0de\u00a0\ncorrelaci\u00f3n \u00a0entre\u00a0m\u00e9todos\u00a0genot\u00edpicos \u00a0y\u00a0TrofileTM\u00a0mostraron, \u00a0en\u00a0general,\u00a0una\u00a0baja\u00a0\nsensibilidad \u00a0de\u00a0los\u00a0primeros\u00a0para\u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0variantes\u00a0X4\u2010tr\u00f3picas119.\u00a0\nPosteriormente, \u00a0la\u00a0introducci\u00f3n \u00a0de\u00a0mejoras\u00a0en\u00a0la\u00a0interpretaci\u00f3n \u00a0de\u00a0algunos\u00a0algoritmos \u00a0\ngenot\u00edpicos \u00a0y\u00a0de\u00a0estrategias \u00a0de\u00a0combinaci\u00f3n \u00a0de\u00a0los\u00a0mismos119\u2010122,\u00a0ha\u00a0conseguido \u00a0\nmejorar\u00a0notablemente \u00a0la\u00a0sensibilidad \u00a0de\u00a0estos\u00a0para\u00a0detectar\u00a0variantes\u00a0X4\u2010tr\u00f3picas\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0el\u00a0ensayo\u00a0de\u00a0TrofileTM.\u00a0Recientemente, \u00a0en\u00a0un\u00a0an\u00e1lisis\u00a0retrospectivo \u00a0\nde\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0con\u00a0MVC\u00a0MOTIVATE \u00a0y\u00a0MERIT\u00a0en\u00a0pacientes \u00a0pretratados \u00a0y\u00a0sin\u00a0\ntratamiento \u00a0previo\u00a0respectivamente, \u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0las\u00a0herramientas \u00a0\ngenot\u00edpicas \u00a0y\u00a0el\u00a0ensayo\u00a0de\u00a0TrofileTM\u00a0son\u00a0comparables \u00a0en\u00a0la\u00a0predicci\u00f3n \u00a0de\u00a0respuesta \u00a0\nvirol\u00f3gica \u00a0a\u00a0MVC123,\u00a0124.\u00a0Estos\u00a0datos\u00a0ponen\u00a0de\u00a0manifiesto \u00a0la\u00a0viabilidad \u00a0de\u00a0la\u00a0utilizaci\u00f3n \u00a0\nde\u00a0m\u00e9todos\u00a0genot\u00edpicos \u00a0para\u00a0la\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0viral\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica,\u00a0\naunque\u00a0el\u00a0m\u00e9todo\u00a0genot\u00edpico \u00a0no\u00a0est\u00e1\u00a0homologado. \u00a0En\u00a0Marzo\u00a02010\u00a0un\u00a0grupo\u00a0de\u00a0\ninvestigadores \u00a0nacionales, \u00a0con\u00a0experiencia \u00a0en\u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0tropismo\u00a0viral,\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 11iniciaron\u00a0una\u00a0serie\u00a0de\u00a0reuniones \u00a0que\u00a0han\u00a0culminado \u00a0en\u00a0la\u00a0publicaci\u00f3n \u00a0de\u00a0una\u00a0\u00a0revisi\u00f3n,\u00a0\nen\u00a0la\u00a0que\u00a0se\u00a0detallan\u00a0las\u00a0recomendaciones \u00a0que\u00a0este\u00a0grupo\u00a0estima\u00a0adecuadas \u00a0para\u00a0la\u00a0\ndeterminaci\u00f3n \u00a0genot\u00edpica \u00a0del\u00a0tropismo\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica125.\u00a0Este\u00a0grupo,\u00a0recomienda \u00a0\nla\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0del\u00a0VIH\u00a0en\u00a0todos\u00a0los\u00a0pacientes \u00a0que\u00a0hayan\u00a0fracasado \u00a0a\u00a0\ncualquier \u00a0l\u00ednea\u00a0de\u00a0tratamiento \u00a0y\u00a0vayan\u00a0a\u00a0iniciar\u00a0un\u00a0tratamiento \u00a0de\u00a0rescate.\u00a0La\u00a0\ninformaci\u00f3n \u00a0del\u00a0tropismo\u00a0(tropismo \u00a0R5/tropismo \u00a0X4)\u00a0debe\u00a0de\u00a0estar\u00a0disponible \u00a0\nrutinariamente \u00a0junto\u00a0con\u00a0el\u00a0estudio\u00a0de\u00a0resistencias \u00a0a\u00a0todos\u00a0los\u00a0antiretrovirales \u00a0con\u00a0el\u00a0\nfin\u00a0de\u00a0facilitar\u00a0la\u00a0selecci\u00f3n\u00a0del\u00a0tratamiento \u00a0de\u00a0rescate\u00a0m\u00e1s\u00a0\u00f3ptimo.\u00a0En\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo\u00a0s\u00f3lo\u00a0se\u00a0recomienda \u00a0valorar\u00a0la\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0cuando\u00a0\nse\u00a0va\u00a0a\u00a0iniciar\u00a0el\u00a0TAR\u00a0en\u00a0determinadas \u00a0situaciones \u00a0cl\u00ednicas\u00a0(resistencias \u00a0primarias, \u00a0\ntoxicidad\u00a0a\u00a0f\u00e1rmacos\u00a0de\u00a0primera\u00a0l\u00ednea)\u00a0en\u00a0las\u00a0que\u00a0un\u00a0f\u00e1rmaco\u00a0antagonista \u00a0del\u00a0receptor\u00a0\nCCR5\u00a0pueda\u00a0considerarse \u00a0una\u00a0buena\u00a0opci\u00f3n\u00a0terap\u00e9utica. \u00a0Entre\u00a0las\u00a0recomendaciones \u00a0\nmetodol\u00f3gicas \u00a0se\u00a0aconseja\u00a0partir\u00a0de\u00a0un\u00a0volumen\u00a0de\u00a0plasma\u00a0\u2265500\u00a0\u00b5l,\u00a0\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a03\u00a0\nRT\u2010PCR\u00a0o\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0una\u00a0\u00fanica\u00a0PCR\u00a0si\u00a0se\u00a0incrementa \u00a0posteriormente \u00a0la\u00a0\nsensibilidad \u00a0de\u00a0los\u00a0algoritmos \u00a0de\u00a0interpretaci\u00f3n. \u00a0Geno2pheno \u00a0y\u00a0PSSM\u00a0son\u00a0\nconsiderados \u00a0los\u00a0algoritmos \u00a0de\u00a0interpretaci\u00f3n \u00a0m\u00e1s\u00a0adecuados. \u00a0En\u00a0muestras \u00a0con\u00a0carga\u00a0\nviral\u00a0indetectable \u00a0o\u00a0inferior\u00a0a\u00a0500\u00a0copias/mL, \u00a0la\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0viral\u00a0se\u00a0\npuede\u00a0realizar\u00a0a\u00a0partir\u00a0de\u00a0ADN\u00a0proviral.\u00a0En\u00a0subtipos\u00a0no\u2010B,\u00a0la\u00a0sensibilidad \u00a0para\u00a0detectar\u00a0\nvariantes\u00a0X4\u2010tr\u00f3picas\u00a0es\u00a0menor\u00a0que\u00a0en\u00a0subtipos\u00a0B.\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0tropismo \u00a0viral\u00a0\n\u0083 Se\u00a0recomienda \u00a0siempre\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0una\u00a0prueba\u00a0de\u00a0tropismo\u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0\ntratamiento \u00a0con\u00a0un\u00a0f\u00e1rmaco\u00a0que\u00a0bloquee\u00a0el\u00a0receptor\u00a0CCR5\u00a0(nivel\u00a0A)\u00a0\n\u0083 Se\u00a0recomienda \u00a0la\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0del\u00a0VIH\u00a0en\u00a0todos\u00a0los\u00a0pacientes \u00a0que\u00a0\nhayan\u00a0fracasado \u00a0a\u00a0cualquier \u00a0l\u00ednea\u00a0de\u00a0tratamiento \u00a0y\u00a0vayan\u00a0a\u00a0iniciar\u00a0un\u00a0tratamiento \u00a0\nde\u00a0rescate\u00a0(nivel\u00a0A)\u00a0\n\u0083 La\u00a0informaci\u00f3n \u00a0del\u00a0tropismo\u00a0(tropismo \u00a0R5/tropismo \u00a0X4)\u00a0debe\u00a0de\u00a0estar\u00a0disponible \u00a0\nrutinariamente \u00a0junto\u00a0con\u00a0el\u00a0estudio\u00a0de\u00a0resistencias \u00a0a\u00a0todos\u00a0los\u00a0antiretrovirales \u00a0con\u00a0\nel\u00a0fin\u00a0de\u00a0facilitar\u00a0la\u00a0selecci\u00f3n\u00a0del\u00a0tratamiento \u00a0de\u00a0rescate\u00a0m\u00e1s\u00a0\u00f3ptimo\u00a0(nivel\u00a0A)\u00a0\n\u0083 En\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0s\u00f3lo\u00a0se\u00a0recomienda \u00a0valorar\u00a0la\u00a0determinaci\u00f3n \u00a0\ndel\u00a0tropismo\u00a0cuando\u00a0se\u00a0va\u00a0a\u00a0iniciar\u00a0el\u00a0TAR\u00a0en\u00a0determinadas \u00a0situaciones \u00a0cl\u00ednicas\u00a0\n(resistencias \u00a0primarias, \u00a0toxicidad\u00a0a\u00a0f\u00e1rmacos\u00a0de\u00a0primera\u00a0l\u00ednea)\u00a0en\u00a0las\u00a0que\u00a0un\u00a0\nantagonista \u00a0del\u00a0receptor\u00a0CCR5\u00a0pueda\u00a0considerarse \u00a0una\u00a0buena\u00a0opci\u00f3n\u00a0terap\u00e9utica \u00a0\n(nivel\u00a0C)\u00a0\n\u00a0\u00a0\u00a0\n3.\u00a0INFECCI\u00d3N \u00a0AGUDA\u00a0POR\u00a0VIH\u00a0\nLa\u00a0primoinfecci\u00f3n \u00a0por\u00a0el\u00a0VIH\u00a0es\u00a0sintom\u00e1tica \u00a0en\u00a0m\u00e1s\u00a0de\u00a0la\u00a0mitad\u00a0de\u00a0los\u00a0casos,\u00a0pero\u00a0\npuede\u00a0pasar\u00a0desapercibida \u00a0ya\u00a0que\u00a0sus\u00a0s\u00edntomas\u00a0son\u00a0los\u00a0de\u00a0una\u00a0virosis\u00a0com\u00fan126\u2010130.\u00a0El\u00a0\ncuadro\u00a0cl\u00ednico\u00a0es\u00a0similar\u00a0a\u00a0la\u00a0mononucleosis \u00a0o\u00a0a\u00a0una\u00a0meningoencefalitis \u00a0viral130.\u00a0Los\u00a0\ns\u00edntomas\u00a0y\u00a0signos\u00a0m\u00e1s\u00a0comunes\u00a0son\u00a0fiebre,\u00a0adenopat\u00edas, \u00a0mialgias,\u00a0exantema, \u00a0\nsudoraci\u00f3n \u00a0nocturna\u00a0y\u00a0artralgias131.\u00a0Debe\u00a0\u00a0sospecharse \u00a0en\u00a0toda\u00a0persona\u00a0con\u00a0s\u00edntomas\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 12compatibles \u00a0\u00a0con\u00a0o\u00a0sin\u00a0conducta \u00a0de\u00a0riesgo.\u00a0Las\u00a0determinaciones \u00a0necesarias \u00a0para\u00a0el\u00a0\ndiagn\u00f3stico \u00a0difieren\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica.\u00a0Como\u00a0en\u00a0esta\u00a0fase\u00a0todav\u00eda\u00a0no\u00a0hay\u00a0\nanticuerpos \u00a0(per\u00edodo\u00a0ventana)\u00a0debe\u00a0determinarse \u00a0la\u00a0CVP132\u00a0que\u00a0se\u00a0detecta\u00a0a\u00a0partir\u00a0de\u00a0\nla\u00a0primera\u00a0semana,\u00a0precede\u00a0a\u00a0los\u00a0s\u00edntomas\u00a0y\u00a0tiene\u00a0una\u00a0sensibilidad \u00a0y\u00a0especificidad \u00a0del\u00a0\n100%\u00a0y\u00a097%\u00a0respectivamente \u00a0(debe\u00a0ser\u00a0una\u00a0CVP\u00a0alta\u00a0ya\u00a0que\u00a0si\u00a0es\u00a0inferior\u00a0a\u00a010000\u00a0\ncopias/mL \u00a0puede\u00a0ser\u00a0un\u00a0falso\u00a0positivo). \u00a0La\u00a0CVP\u00a0suele\u00a0estar\u00a0muy\u00a0elevada\u00a0(>6\u00a0log10)\u00a0en\u00a0la\u00a0\ninfecci\u00f3n\u00a0aguda\u00a0y\u00a0se\u00a0relaciona\u00a0con\u00a0la\u00a0intensidad \u00a0de\u00a0las\u00a0manifestaciones \u00a0cl\u00ednicas.\u00a0La\u00a0\nseroconversi\u00f3n \u00a0se\u00a0detecta\u00a01\u20102\u00a0semanas\u00a0m\u00e1s\u00a0tarde131.\u00a0La\u00a0t\u00e9cnica\u00a0de\u00a0Western\u00a0blot\u00a0con\u00a0la\u00a0\nque\u00a0se\u00a0confirma\u00a0el\u00a0diagn\u00f3stico \u00a0puede\u00a0ser\u00a0negativa\u00a0o\u00a0indeterminada \u00a0y\u00a0deber\u00e1\u00a0repetirse\u00a0\nunas\u00a0semanas\u00a0despu\u00e9s\u00a0del\u00a0comienzo \u00a0de\u00a0los\u00a0s\u00edntomas\u00a0para\u00a0confirmar \u00a0su\u00a0positivizaci\u00f3n. \u00a0\nEl\u00a0t\u00e9rmino\u00a0infecci\u00f3n\u00a0aguda\u00a0(diagn\u00f3stico \u00a0antes\u00a0de\u00a0la\u00a0seroconversi\u00f3n) \u00a0no\u00a0debe\u00a0\nconfundirse \u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0que\u00a0es\u00a0la\u00a0que\u00a0tiene\u00a0menos\u00a0de\u00a0seis\u00a0meses\u00a0de\u00a0\nevoluci\u00f3n130.\u00a0\u00a0\nDesde\u00a0la\u00a0descripci\u00f3n \u00a0de\u00a0los\u00a0primeros\u00a0casos\u00a0de\u00a0infecci\u00f3n\u00a0aguda\u00a0se\u00a0sabe\u00a0que\u00a0la\u00a0\nprogresi\u00f3n \u00a0a\u00a0sida\u00a0es\u00a0m\u00e1s\u00a0r\u00e1pida\u00a0en\u00a0los\u00a0pacientes \u00a0sintom\u00e1ticos. \u00a0En\u00a0estudios\u00a0de\u00a0cohortes\u00a0\nque\u00a0han\u00a0analizado \u00a0la\u00a0historia\u00a0natural\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0VIH\u00a0se\u00a0ha\u00a0evidenciado \u00a0que\u00a0la\u00a0\nprogresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte\u00a0se\u00a0asociaba\u00a0a\u00a0factores\u00a0iniciales\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0como\u00a0la\u00a0\ngravedad \u00a0de\u00a0la\u00a0sintomatolog\u00eda \u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda133\u00a0(mayor\u00a0riesgo\u00a0a\u00a0mayor\u00a0n\u00famero\u00a0\nde\u00a0s\u00edntomas), \u00a0descenso \u00a0inicial\u00a0de\u00a0CD4\u00a0(mayor\u00a0riesgo\u00a0si\u00a0<500)134,\u00a0nivel\u00a0de\u00a0CVP\u00a0a\u00a0partir\u00a0\ndel\u00a04\u00ba\u00a0mes\u00a0(mayor\u00a0progresi\u00f3n \u00a0si\u00a0setpoint\u00a0>100\u00a0000\u00a0copias/mL)133,\u00a0y\u00a0al\u00a0ADN\u00a0proviral\u00a0\ninicial\u00a0(mayor\u00a0progresi\u00f3n \u00a0si\u00a0es\u00a0>3,4\u00a0log10\u00a0copias/mill\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0mononucleares \u00a0en\u00a0\nsangre\u00a0perif\u00e9rica)134.\u00a0\u00a0\nEl\u00a0TAR\u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0puede\u00a0tener\u00a0ventajas\u00a0e\u00a0inconvenientes130,\u00a0135.\u00a0Las\u00a0ventajas\u00a0\nte\u00f3ricas\u00a0ser\u00edan\u00a0acortar\u00a0la\u00a0duraci\u00f3n\u00a0y\u00a0gravedad \u00a0de\u00a0los\u00a0s\u00edntomas, \u00a0suprimir\u00a0la\u00a0replicaci\u00f3n \u00a0\nviral,\u00a0reducir\u00a0el\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0(muy\u00a0elevado\u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda)127,\u00a0136\u00a0\nreducir\u00a0la\u00a0diversidad \u00a0viral\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0infectadas \u00a0(reservorio) \u00a0\u00a0y\u00a0preservar \u00a0o\u00a0\nrestaurar \u00a0el\u00a0sistema\u00a0inmunitario \u00a0y\u00a0la\u00a0inmunidad \u00a0espec\u00edfica \u00a0frente\u00a0al\u00a0VIH,\u00a0tanto\u00a0\nproliferativa \u00a0(mediada \u00a0por\u00a0los\u00a0linfocitos\u00a0CD4)\u00a0como\u00a0citot\u00f3xica \u00a0(mediada \u00a0por\u00a0los\u00a0\nlinfocitos\u00a0CD8+)126,\u00a0137\u2010141,\u00a0lo\u00a0que\u00a0podr\u00eda\u00a0permitir\u00a0el\u00a0control\u00a0inmunol\u00f3gico \u00a0de\u00a0la\u00a0\nreplicaci\u00f3n \u00a0viral,\u00a0modificar \u00a0la\u00a0historia\u00a0natural,\u00a0disminuir \u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0y\u00a0\nmejorar\u00a0el\u00a0pron\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH.\u00a0Por\u00a0el\u00a0contrario, \u00a0las\u00a0principales \u00a0\ndesventajas \u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0fase\u00a0aguda\u00a0son\u00a0la\u00a0exposici\u00f3n \u00a0a\u00a0los\u00a0antirretrovirales \u00a0sin\u00a0un\u00a0\nbeneficio \u00a0cl\u00ednico\u00a0demostrado, \u00a0su\u00a0duraci\u00f3n\u00a0indefinida \u00a0(ya\u00a0que\u00a0con\u00a0las\u00a0pautas\u00a0de\u00a0TAR\u00a0que\u00a0\nhasta\u00a0ahora\u00a0se\u00a0han\u00a0utilizado\u00a0no\u00a0se\u00a0erradica\u00a0la\u00a0infecci\u00f3n126,\u00a0\u00a0ni\u00a0se\u00a0restaura\u00a0el\u00a0tejido\u00a0\nlinf\u00e1tico\u00a0asociado\u00a0a\u00a0mucosas142),\u00a0el\u00a0riesgo\u00a0de\u00a0efectos\u00a0secundarios \u00a0y\u00a0desarrollo \u00a0de\u00a0\nresistencias, \u00a0la\u00a0posible\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0y\u00a0el\u00a0tratamiento \u00a0innecesario \u00a0de\u00a0\nlos\u00a0no\u00a0progresores. \u00a0\u00a0\u00a0\nEn\u00a0la\u00a0actualidad \u00a0el\u00a0inicio\u00a0del\u00a0TAR\u00a0durante\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0reciente\u00a0es\u00a0\ncontrovertido143,\u00a0144\u00a0ya\u00a0que\u00a0su\u00a0potencial \u00a0beneficio \u00a0a\u00a0largo\u00a0plazo\u00a0es\u00a0desconocido. \u00a0La\u00a0\ninformaci\u00f3n \u00a0disponible \u00a0se\u00a0ha\u00a0obtenido\u00a0de\u00a0series\u00a0peque\u00f1as, \u00a0generalmente \u00a0sin\u00a0grupo\u00a0\ncontrol,\u00a0en\u00a0pa\u00edses\u00a0desarrollados, \u00a0con\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0subtipo\u00a0B\u00a0y\u00a0con\u00a0pautas\u00a0\nde\u00a0TAR\u00a0similares\u00a0a\u00a0las\u00a0utilizadas \u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica.\u00a0No\u00a0hay\u00a0estudios\u00a0publicados \u00a0que\u00a0\nhayan\u00a0evaluado\u00a0si\u00a0otras\u00a0pautas\u00a0(TAR\u00a0con\u00a0inhibidores \u00a0de\u00a0la\u00a0entrada\u00a0y/o\u00a0de\u00a0la\u00a0integrasa) \u00a0\npueden\u00a0ser\u00a0m\u00e1s\u00a0efectivas\u00a0en\u00a0este\u00a0escenario. \u00a0Hasta\u00a0ahora\u00a0no\u00a0se\u00a0ha\u00a0demostrado \u00a0un\u00a0\nbeneficio \u00a0cl\u00ednico\u00a0en\u00a0t\u00e9rminos\u00a0de\u00a0reducir\u00a0la\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte143,\u00a0aunque\u00a0en\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 13alg\u00fan\u00a0estudio\u00a0se\u00a0ha\u00a0visto\u00a0una\u00a0mejor\u00a0evoluci\u00f3n \u00a0inmunol\u00f3gica \u00a0y\u00a0virol\u00f3gica \u00a0en\u00a0pacientes \u00a0\ntratados145\u2010147.\u00a0\u00a0\nEn\u00a0cualquier \u00a0caso,\u00a0si\u00a0se\u00a0decide\u00a0iniciar\u00a0TAR\u00a0las\u00a0pautas\u00a0recomendadas \u00a0son\u00a0las\u00a0mismas\u00a0que\u00a0\nen\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0y\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0a\u00a0IP\u00a0o\u00a0NN\u00a0similar146,\u00a0148\u2010150.\u00a0\u00a0Como\u00a0en\u00a0la\u00a0\ninfecci\u00f3n\u00a0cr\u00f3nica\u00a0siempre\u00a0debe\u00a0efectuarse \u00a0un\u00a0test\u00a0de\u00a0resistencias, \u00a0se\u00a0vaya\u00a0a\u00a0iniciar\u00a0TAR\u00a0\no\u00a0no,\u00a0por\u00a0la\u00a0posibilidad \u00a0de\u00a0transmisi\u00f3n \u00a0de\u00a0cepas\u00a0resistentes. \u00a0En\u00a0pacientes \u00a0con\u00a0\nmultirresistencia \u00a0se\u00a0debe\u00a0realizar\u00a0un\u00a0tropismo\u00a0viral\u00a0porque\u00a0se\u00a0han\u00a0descrito\u00a0cepas\u00a0con\u00a0\nfenotipo\u00a0dual\u00a0(R5\u00a0y\u00a0X4)\u00a0y\u00a0una\u00a0r\u00e1pida\u00a0progresi\u00f3n \u00a0a\u00a0sida151\u2010153.\u00a0Dado\u00a0que\u00a0la\u00a0prevalencia \u00a0de\u00a0\ncepas\u00a0con\u00a0resistencia \u00a0a\u00a0NN\u00a0es\u00a0mayor\u00a0que\u00a0a\u00a0IP\u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0\nreciente85,\u00a0154,\u00a0si\u00a0se\u00a0decide\u00a0iniciar\u00a0TAR\u00a0y\u00a0todav\u00eda\u00a0no\u00a0est\u00e1\u00a0disponible \u00a0el\u00a0resultado \u00a0del\u00a0\nestudio\u00a0de\u00a0resistencias \u00a0es\u00a0preferible \u00a0comenzar \u00a0con\u00a0una\u00a0pauta\u00a0basada\u00a0en\u00a0IP.\u00a0Se\u00a0ha\u00a0\nobservado \u00a0que\u00a0la\u00a0prevalencia \u00a0de\u00a0lipodistrofia \u00a0y\u00a0dislipemia \u00a0y\u00a0otros\u00a0efectos\u00a0adversos\u00a0\nasociados \u00a0al\u00a0TAR\u00a0es\u00a0similar\u00a0a\u00a0la\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica150,\u00a0155\u2010157.\u00a0\nPara\u00a0evitar\u00a0el\u00a0TAR\u00a0indefinido \u00a0y\u00a0conseguir \u00a0los\u00a0objetivos\u00a0mencionados \u00a0previamente \u00a0se\u00a0\nhan\u00a0planteado \u00a0diversas\u00a0estrategias130,\u00a0135:\u00a01)\u00a0Administrar \u00a0el\u00a0TAR\u00a0durante\u00a0un\u00a0periodo\u00a0\nlimitado\u00a0de\u00a0tiempo;\u00a0\u00a02)\u00a0Administrarlo \u00a0de\u00a0forma\u00a0intermitente, \u00a0a\u00a0fin\u00a0de\u00a0potenciar \u00a0la\u00a0\nrespuesta \u00a0VIH\u2010espec\u00edfica \u00a0y\u00a0controlar\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0sin\u00a0FAR;\u00a03)\u00a0Combinar \u00a0el\u00a0TAR\u00a0con\u00a0\ninmunosupresores \u00a0(hidroxiurea, \u00a0ciclosporina \u00a0A,\u00a0\u00e1cido\u00a0micofen\u00f3lico) \u00a0o\u00a0citoquinas \u00a0(IL\u20102);\u00a0\ny,\u00a04)\u00a0Asociar\u00a0TAR\u00a0y\u00a0vacunas\u00a0terap\u00e9uticas. \u00a0Sin\u00a0embargo, \u00a0ninguna\u00a0de\u00a0estas\u00a0estrategias \u00a0ha\u00a0\nconseguido \u00a0que\u00a0el\u00a0sistema\u00a0inmune\u00a0controle\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0de\u00a0forma\u00a0sostenida \u00a0en\u00a0\nausencia\u00a0de\u00a0TAR,\u00a0por\u00a0lo\u00a0que\u00a0en\u00a0la\u00a0actualidad \u00a0si\u00a0se\u00a0inicia\u00a0el\u00a0tratamiento \u00a0durante\u00a0la\u00a0\ninfecci\u00f3n\u00a0aguda\u00a0probablemente \u00a0se\u00a0deba\u00a0mantener \u00a0de\u00a0forma\u00a0indefinida. \u00a0\nLa\u00a0eficacia\u00a0del\u00a0TAR\u00a0durante\u00a0un\u00a0periodo\u00a0variable\u00a0se\u00a0ha\u00a0evaluado\u00a0principalmente \u00a0en\u00a0\nestudios\u00a0de\u00a0cohortes\u00a0en\u00a0los\u00a0que\u00a0se\u00a0han\u00a0comparado \u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0\nreciente\u00a0tratados\u00a0frente\u00a0a\u00a0no\u00a0tratados.\u00a0Los\u00a0resultados \u00a0de\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estos\u00a0estudios\u00a0\nno\u00a0han\u00a0conseguido \u00a0demostrar \u00a0un\u00a0beneficio \u00a0cl\u00ednico,\u00a0virol\u00f3gico \u00a0ni\u00a0inmunol\u00f3gico \u00a0a\u00a0las\u00a048\u2010\n144\u00a0semanas\u00a0de\u00a0interrumpir \u00a0el\u00a0tratamiento, \u00a0mientras\u00a0que\u00a0en\u00a0otros,\u00a0s\u00f3lo\u00a0una\u00a0peque\u00f1a\u00a0\nproporci\u00f3n \u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0mostraban \u00a0un\u00a0setpoint\u00a0de\u00a0CVP\u00a0m\u00e1s\u00a0bajo,\u00a0mejores\u00a0\ncifras\u00a0de\u00a0CD4\u00a0o\u00a0manten\u00edan \u00a0la\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH148,\u00a0158\u2010170.\u00a0Habr\u00e1\u00a0\nque\u00a0esperar\u00a0a\u00a0los\u00a0resultados \u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados \u00a0que\u00a0est\u00e1n\u00a0en\u00a0marcha\u00a0\n(estudio\u00a0SPARTAC) \u00a0para\u00a0poder\u00a0valorar\u00a0adecuadamente \u00a0los\u00a0potenciales \u00a0beneficios \u00a0de\u00a0\nesta\u00a0estrategia \u00a0terap\u00e9utica. \u00a0\u00a0\nLa\u00a0administraci\u00f3n \u00a0de\u00a0TAR\u00a0intermitente \u00a0con\u00a0el\u00a0fin\u00a0de\u00a0potenciar \u00a0la\u00a0respuesta \u00a0VIH\u00a0\ninmunoespec\u00edfica \u00a0para\u00a0controlar\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0no\u00a0ha\u00a0conseguido \u00a0buenos\u00a0\nresultados, \u00a0siendo\u00a0testimonial \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0manten\u00eda \u00a0la\u00a0respuesta \u00a0\ninmune\u00a0y\u00a0el\u00a0control\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0sin\u00a0TAR\u00a0a\u00a0las\u00a096\u00a0semanas141,\u00a0171,\u00a0172.\u00a0Adem\u00e1s\u00a0\nesta\u00a0estrategia \u00a0de\u00a0interrupci\u00f3n \u00a0estructurada \u00a0no\u00a0est\u00e1\u00a0exenta\u00a0de\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0\nresistencias173,\u00a0174.\u00a0\u00a0\u00a0\nLa\u00a0estrategia \u00a0de\u00a0asociar\u00a0al\u00a0TAR\u00a0citoquinas \u00a0como\u00a0interfer\u00f3n \u2010pegilado\u00a0o\u00a0IL\u20102,\u00a0a\u00a0fin\u00a0de\u00a0\ndisminuir \u00a0el\u00a0reservorio \u00a0viral\u00a0y\u00a0mejorar\u00a0la\u00a0respuesta \u00a0inmunitaria175\u2010177\u00a0tampoco\u00a0ha\u00a0\nconseguido \u00a0sus\u00a0objetivos. \u00a0Se\u00a0han\u00a0efectuado \u00a0estudios\u00a0con\u00a0interfer\u00f3n \u00a0pegilado178\u00a0o\u00a0\ninmunosupresores \u00a0(hidroxiurea, \u00a0ciclosporina, \u00a0\u00e1cido\u00a0micofen\u00f3lico) \u00a0para\u00a0reducir\u00a0la\u00a0\nactivaci\u00f3n \u00a0del\u00a0sistema\u00a0inmune\u00a0y\u00a0controlar\u00a0la\u00a0replicaci\u00f3n \u00a0viral174,\u00a0179\u2010182.\u00a0Algunos\u00a0de\u00a0estos\u00a0\nestudios\u00a0solamente \u00a0han\u00a0podido\u00a0demostrar \u00a0mayor\u00a0toxicidad\u00a0sin\u00a0aumentar \u00a0la\u00a0eficacia.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 14Finalmente, \u00a0las\u00a0vacunas\u00a0terap\u00e9uticas \u00a0asociadas \u00a0o\u00a0no\u00a0a\u00a0TAR\u00a0con\u00a0el\u00a0fin\u00a0de\u00a0restaurar\u00a0o\u00a0\npotenciar \u00a0la\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH\u00a0tampoco\u00a0han\u00a0mostrado \u00a0mejores\u00a0\nresultados. \u00a0Se\u00a0sab\u00eda\u00a0que\u00a0en\u00a0modelos\u00a0animales\u00a0algunas\u00a0vacunas\u00a0hab\u00edan\u00a0sido\u00a0\nsatisfactorias183,\u00a0184,\u00a0pero\u00a0los\u00a0resultados \u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0doble\u00a0ciego\u00a0en\u00a0humanos \u00a0\nhan\u00a0sido\u00a0desalentadores185\u2010187.\u00a0Tanto\u00a0el\u00a0estudio\u00a0QUEST185\u00a0(TAR\u00a0frente\u00a0a\u00a0TAR\u00a0m\u00e1s\u00a0\nvacuna\u00a0ALVAC\u2010HIV,\u00a0y\u00a0frente\u00a0a\u00a0TAR\u00a0m\u00e1s\u00a0vacuna\u00a0ALVAC\u2010HIV\u00a0m\u00e1s\u00a0Remune\u00a9)\u00a0como\u00a0en\u00a0el\u00a0\nensayo\u00a0cl\u00ednico\u00a0que\u00a0compar\u00f3\u00a0diferentes \u00a0dosis\u00a0de\u00a0una\u00a0vacuna\u00a0que\u00a0usaba\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0\nviruela\u00a0aviar\u00a0con\u00a0los\u00a0genes\u00a0gag/pol\u00a0del\u00a0VIH\u00a0insertados186,\u00a0como\u00a0en\u00a0el\u00a0estudio\u00a0ACTG\u00a0\nA5187\u00a0(TAR\u00a0frente\u00a0a\u00a0TAR\u00a0m\u00e1s\u00a0vacuna\u00a0HIV\u00a0DNA)\u00a0187,\u00a0las\u00a0respuestas \u00a0virol\u00f3gica \u00a0e\u00a0\ninmunoespec\u00edfica \u00a0fueron\u00a0similares\u00a0al\u00a0grupo\u00a0placebo.\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0infecci\u00f3n \u00a0aguda\u00a0\n\u0083 En\u00a0general,\u00a0no\u00a0se\u00a0recomienda \u00a0iniciar\u00a0TAR\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0\nreciente\u00a0(nivel\u00a0B)130,\u00a0135\u00a0\n\u0083 Se\u00a0recomienda \u00a0iniciar\u00a0TAR\u00a0en\u00a0pacientes \u00a0con\u00a0primoinfecci\u00f3n \u00a0grave:\u00a0infecci\u00f3n\u00a0\nsintom\u00e1tica \u00a0con\u00a0afectaci\u00f3n \u00a0neurol\u00f3gica \u00a0\u00a0(meningoencefalitis, \u00a0s\u00edndrome \u00a0de\u00a0Guillain\u2010\nBarr\u00e9,\u00a0etc)\u00a0o\u00a0afectaci\u00f3n \u00a0grave\u00a0de\u00a0cualquier \u00a0otro\u00a0\u00f3rgano\u00a0o\u00a0aparato\u00a0(hepatitis, \u00a0\nmiopericarditis, \u00a0trombocitopenia, \u00a0etc),\u00a0infecci\u00f3n\u00a0sintom\u00e1tica \u00a0prolongada \u00a0(m\u00e1s\u00a0de\u00a07\u00a0\nd\u00edas\u00a0de\u00a0duraci\u00f3n), \u00a0infecci\u00f3n\u00a0sintom\u00e1tica \u00a0con\u00a0eventos\u00a0cl\u00ednicos\u00a0definitorios \u00a0de\u00a0sida,\u00a0\ninmunodepresi\u00f3n \u00a0celular\u00a0avanzada \u00a0(linfocitos \u00a0CD4\u00a0<200/\u00b5L\u00a0(nivel\u00a0C)153\u00a0\n\u0083 Se\u00a0debe\u00a0considerar \u00a0iniciar\u00a0el\u00a0tratamiento \u00a0en\u00a0los\u00a0casos\u00a0en\u00a0los\u00a0que\u00a0exista\u00a0un\u00a0alto\u00a0\nriesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0(nivel\u00a0C)136\u00a0\n\u0083 Se\u00a0debe\u00a0efectuar\u00a0siempre\u00a0una\u00a0prueba\u00a0de\u00a0resistencias \u00a0al\u00a0diagn\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0\naguda,\u00a0se\u00a0vaya\u00a0a\u00a0iniciar\u00a0TAR\u00a0o\u00a0no\u00a0(nivel\u00a0B)85,\u00a0151,\u00a0152\u00a0\n\u0083 Si\u00a0se\u00a0decide\u00a0iniciar\u00a0TAR\u00a0las\u00a0pautas\u00a0recomendadas \u00a0son\u00a0las\u00a0mismas\u00a0que\u00a0en\u00a0la\u00a0\ninfecci\u00f3n\u00a0cr\u00f3nica\u00a0(nivel\u00a0C)146,\u00a0148\u2010150.\u00a0Si\u00a0no\u00a0se\u00a0dispone\u00a0del\u00a0resultado \u00a0del\u00a0estudio\u00a0de\u00a0\nresistencias \u00a0es\u00a0preferible \u00a0comenzar \u00a0con\u00a0una\u00a0pauta\u00a0basada\u00a0en\u00a0un\u00a0IP/r\u00a0(nivel\u00a0C)\u00a0)85,\u00a0154\u00a0\n\u0083 En\u00a0los\u00a0pacientes \u00a0no\u00a0tratados\u00a0se\u00a0recomienda \u00a0evaluar\u00a0los\u00a0criterios\u00a0de\u00a0TAR\u00a0a\u00a0partir\u00a0de\u00a0\nlos\u00a06\u00a0meses,\u00a0cuando\u00a0ya\u00a0la\u00a0infecci\u00f3n\u00a0es\u00a0cr\u00f3nica\u00a0(nivel\u00a0A)\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n4.\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0INICIAL\u00a0\nEn\u00a0los\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo,\u00a0se\u00a0debe\u00a0valorar\u00a0individualmente \u00a0cu\u00e1ndo\u00a0iniciar\u00a0\nel\u00a0TAR\u00a0y\u00a0qu\u00e9\u00a0combinaci\u00f3n \u00a0de\u00a0f\u00e1rmacos \u00a0utilizar,\u00a0sopesando \u00a0siempre\u00a0las\u00a0ventajas\u00a0e\u00a0\ninconvenientes \u00a0de\u00a0cada\u00a0opci\u00f3n.\u00a0La\u00a0disposici\u00f3n \u00a0y\u00a0la\u00a0motivaci\u00f3n \u00a0del\u00a0paciente\u00a0para\u00a0\niniciarlo\u00a0es\u00a0un\u00a0factor\u00a0cr\u00edtico\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0tomar\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0empezar. \u00a0\n\u00a04.1.\u00a0Cu\u00e1ndo\u00a0iniciar\u00a0el\u00a0TAR\u00a0\nSe\u00a0dispone\u00a0de\u00a0combinaciones \u00a0de\u00a0FAR\u00a0que\u00a0bloquean \u00a0de\u00a0forma\u00a0duradera\u00a0la\u00a0replicaci\u00f3n \u00a0\nviral\u00a0en\u00a0plasma\u00a0y\u00a0tejido\u00a0linf\u00e1tico\u00a0permitiendo \u00a0la\u00a0restauraci\u00f3n, \u00a0al\u00a0menos\u00a0parcial,\u00a0del\u00a0\nsistema\u00a0inmunol\u00f3gico\n6,\u00a011,\u00a0188.\u00a0En\u00a0ediciones \u00a0previas\u00a0de\u00a0estas\u00a0gu\u00edas\u00a0se\u00a0hac\u00eda\u00a0\u00e9nfasis\u00a0en\u00a0la\u00a0\ninfluencia \u00a0en\u00a0el\u00a0balance\u00a0riesgo/beneficio \u00a0del\u00a0TAR\u00a0de\u00a0la\u00a0toxicidad\u00a0a\u00a0medio\u2010largo\u00a0plazo\u00a0de\u00a0\nlos\u00a0FAR,\u00a0los\u00a0problemas \u00a0de\u00a0adherencia, \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias, \u00a0las\u00a0interacciones \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 15medicamentosas \u00a0y\u00a0el\u00a0impacto\u00a0en\u00a0la\u00a0calidad\u00a0de\u00a0vida8.\u00a0Aunque\u00a0todos\u00a0estos\u00a0factores\u00a0\nsiguen\u00a0siendo\u00a0muy\u00a0importantes, \u00a0es\u00a0justo\u00a0reconocer \u00a0que\u00a0el\u00a0n\u00famero\u00a0de\u00a0opciones\u00a0\nterap\u00e9uticas, \u00a0la\u00a0eficacia,\u00a0la\u00a0seguridad \u00a0y\u00a0la\u00a0simplicidad \u00a0de\u00a0las\u00a0combinaciones \u00a0de\u00a0\nantirretrovirales \u00a0han\u00a0aumentado \u00a0marcadamente \u00a0durante\u00a0los\u00a0\u00faltimos\u00a0cinco\u00a0a\u00f1os189.\u00a0\nAdem\u00e1s,\u00a0debido\u00a0fundamentalmente \u00a0al\u00a0uso\u00a0de\u00a0IP/r,\u00a0el\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0\nmultirresistencia \u00a0ha\u00a0disminuido \u00a0considerablemente. \u00a0\nGracias\u00a0al\u00a0TAR\u00a0se\u00a0ha\u00a0reducido\u00a0dr\u00e1sticamente \u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0y\u00a0muerte\u00a0de\u00a0los\u00a0\npacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH.\u00a0A\u00a0pesar\u00a0de\u00a0todos\u00a0estos\u00a0avances\u00a0la\u00a0esperanza \u00a0de\u00a0vida\u00a0\ndel\u00a0paciente\u00a0infectado \u00a0por\u00a0el\u00a0VIH\u00a0que\u00a0recibe\u00a0TAR\u00a0\u00a0est\u00e1\u00a0acortada\u00a0con\u00a0respecto\u00a0a\u00a0la\u00a0de\u00a0la\u00a0\npoblaci\u00f3n \u00a0general190,\u00a0191.\u00a0Se\u00a0ha\u00a0comunicado \u00a0que\u00a0s\u00f3lo\u00a0los\u00a0pacientes \u00a0que\u00a0han\u00a0recibido\u00a0\nTAR\u00a0durante\u00a0al\u00a0menos\u00a06\u00a0a\u00f1os\u00a0y\u00a0han\u00a0alcanzado \u00a0una\u00a0cifra\u00a0de\u00a0CD4\u00a0>500\u00a0c\u00e9lulas/\uf06dL\u00a0tienen\u00a0\nuna\u00a0mortalidad \u00a0similar\u00a0a\u00a0la\u00a0poblaci\u00f3n \u00a0general192.\u00a0\u00a0\nEl\u00a0aumento\u00a0de\u00a0la\u00a0eficacia,\u00a0seguridad \u00a0y\u00a0simplicidad \u00a0del\u00a0TAR\u00a0junto\u00a0con\u00a0el\u00a0reconocimiento \u00a0\nde\u00a0que\u00a0a\u00fan\u00a0existe\u00a0margen\u00a0de\u00a0mejora\u00a0en\u00a0el\u00a0aumento\u00a0de\u00a0la\u00a0esperanza \u00a0de\u00a0vida\u00a0del\u00a0\npaciente\u00a0infectado \u00a0por\u00a0VIH\u00a0ha\u00a0vuelto\u00a0a\u00a0plantear\u00a0el\u00a0debate\u00a0sobre\u00a0un\u00a0inicio\u00a0m\u00e1s\u00a0\ntemprano \u00a0del\u00a0TAR.\u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0del\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0\nLa\u00a0CVP\u00a0y\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0son\u00a0marcadores \u00a0independientes \u00a0de\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0\ninfecci\u00f3n\u00a0por\u00a0el\u00a0VIH193,\u00a0194.\u00a0\u00a0\nExiste\u00a0evidencia, \u00a0basada\u00a0en\u00a0ensayos\u00a0cl\u00ednicos\u00a0y\u00a0estudios\u00a0observacionales, \u00a0que\u00a0apoya\u00a0el\u00a0\ninicio\u00a0del\u00a0TAR\u00a0en\u00a0pacientes \u00a0con\u00a0linfocitos\u00a0CD4\u00a0<350\u00a0c\u00e9lulas/\u00b5L. \u00a0Sin\u00a0embargo, \u00a0y\u00a0a\u00a0pesar\u00a0\nde\u00a0sus\u00a0limitaciones, \u00a0existen\u00a0estudios\u00a0de\u00a0cohortes\u00a0observacionales, \u00a0de\u00a0pacientes \u00a0\ntratados\u00a0o\u00a0no,\u00a0que\u00a0pueden\u00a0ayudar\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0decidir\u00a0el\u00a0inicio\u00a0del\u00a0TAR\u00a0en\u00a0personas\u00a0con\u00a0\ninfecci\u00f3n\u00a0VIH\u00a0asintom\u00e1ticas. \u00a0\nEl\u00a0debate\u00a0actual\u00a0se\u00a0centra\u00a0en\u00a0torno\u00a0a\u00a0si\u00a0es\u00a0necesario \u00a0iniciar\u00a0TAR\u00a0con\u00a0cifras\u00a0de\u00a0linfocitos\u00a0\nCD4\u00a0superiores \u00a0a\u00a0350\u00a0c\u00e9lulas/\u00b5L. \u00a0Los\u00a0datos\u00a0que\u00a0sustentan \u00a0este\u00a0debate\u00a0provienen \u00a0de\u00a0\ncohortes\u00a0de\u00a0pacientes \u00a0en\u00a0las\u00a0que\u00a0se\u00a0ha\u00a0evaluado\u00a0la\u00a0mortalidad, \u00a0la\u00a0progresi\u00f3n \u00a0a\u00a0sida,\u00a0la\u00a0\nincidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0definitorias \u00a0de\u00a0sida,\u00a0la\u00a0recuperaci\u00f3n \u00a0inmunol\u00f3gica \u00a0y\u00a0la\u00a0\ntoxicidad\u00a0del\u00a0tratamiento \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0previa\u00a0al\u00a0inicio\u00a0del\u00a0\nTAR.\u00a0Los\u00a0estudios\u00a0de\u00a0cohortes\u00a0tienen\u00a0importantes \u00a0problemas \u00a0metodol\u00f3gicos \u00a0como\u00a0el\u00a0\nsesgo\u00a0de\u00a0prescripci\u00f3n \u00a0que\u00a0hacen\u00a0que\u00a0la\u00a0calidad\u00a0de\u00a0la\u00a0evidencia \u00a0sea\u00a0menor\u00a0que\u00a0la\u00a0\nproveniente \u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados. \u00a0\n\u00a0\n\u00a0\nRespuesta \u00a0cl\u00ednica\u00a0(progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte)\u00a0\u00a0\nHay\u00a0datos\u00a0muy\u00a0limitados\u00a0sobre\u00a0la\u00a0comparaci\u00f3n \u00a0de\u00a0la\u00a0mortalidad \u00a0y/o\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0\nen\u00a0pacientes \u00a0que\u00a0empiezan \u00a0TAR\u00a0por\u00a0encima\u00a0o\u00a0por\u00a0debajo\u00a0de\u00a0350\u00a0CD4/\u00b5L.\u00a0\u00a0\u00a0\nEn\u00a0un\u00a0an\u00e1lisis\u00a0conjunto\u00a0de\u00a0varias\u00a0cohortes\u00a0que\u00a0incluy\u00f3\u00a0m\u00e1s\u00a0de\u00a021000\u00a0pacientes, \u00a0la\u00a0\nprogresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte\u00a0fue\u00a0significativamente \u00a0mayor\u00a0en\u00a0los\u00a0que\u00a0iniciaban\u00a0el\u00a0TAR\u00a0\nentre\u00a0251\u2010350\u00a0CD4/\u00b5L\u00a0(HR,\u00a01,28,\u00a0IC\u00a095%\u00a0entre\u00a01,04\u00a0y\u00a01,57)\u00a0que\u00a0los\u00a0que\u00a0lo\u00a0empezaron \u00a0\nentre\u00a0351\u2010450.\u00a0Igualmente \u00a0en\u00a0el\u00a0primer\u00a0grupo\u00a0se\u00a0observ\u00f3\u00a0una\u00a0mayor\u00a0mortalidad \u00a0y\u00a0a\u00fan\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 16mayor\u00a0diferencia \u00a0cuando\u00a0se\u00a0analizaba \u00a0conjuntamente \u00a0sida\u00a0o\u00a0muerte\u00a0(HR\u00a01,13;\u00a0IC\u00a095%\u00a0\nentre\u00a00,80\u00a0y\u00a01,60)9.\u00a0\u00a0\nEn\u00a0la\u00a0cohorte\u00a0PISCIS\u00a0de\u00a0Catalu\u00f1a\u00a0y\u00a0Baleares\u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte\u00a0tras\u00a0\ninicio\u00a0de\u00a0TAR\u00a0fue\u00a0significativamente \u00a0menor\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0lo\u00a0iniciaron\u00a0con\u00a0cifras\u00a0\nde\u00a0CD4\u00a0\u2265350\u00a0c\u00e9lulas/\u00b5L \u00a0que\u00a0en\u00a0los\u00a0que\u00a0empezaron \u00a0entre\u00a0200\u2010350\u00a0CD4/\u00b5L\u00a0(HR\u00a01,85;\u00a0IC\u00a0\n95%,\u00a01,03\u00a0a\u00a03,33),\u00a0o\u00a0<200\u00a0CD4/\u00b5L\u00a0(HR\u00a02,97;\u00a0IC\u00a095%,\u00a01,91\u00a0a\u00a04,63)10.\u00a0\nEn\u00a0un\u00a0suban\u00e1lisis \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0>350\u00a0CD4/\u00b5L\u00a0del\u00a0ensayo\u00a0SMART\u00a0\u00a0que\u00a0no\u00a0estaban\u00a0\nrecibiendo \u00a0TAR\u00a0al\u00a0inicio\u00a0del\u00a0estudio,\u00a0los\u00a0aleatorizados \u00a0a\u00a0demorar\u00a0el\u00a0TAR\u00a0hasta\u00a0alcanzar\u00a0\nla\u00a0cifra\u00a0de\u00a0250\u00a0CD4\u00a0/\u00b5L\u00a0tuvieron\u00a0mayor\u00a0riesgo\u00a0de\u00a0enfermedades \u00a0oportunistas \u00a0y/o\u00a0\nmuerte\u00a0por\u00a0causas\u00a0no\u00a0directamente \u00a0relacionadas \u00a0con\u00a0sida\u00a0que\u00a0quienes\u00a0iniciaron\u00a0TAR\u00a0\ninmediatamente \u00a0con\u00a0cifras\u00a0de\u00a0CD4\u00a0\u2265\u00a0350\u00a0c\u00e9lulas/\u00b5L195.\u00a0\u00a0\nPor\u00a0\u00faltimo,\u00a0en\u00a0un\u00a0an\u00e1lisis\u00a0paralelo\u00a0de\u00a017.517\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0\nasintom\u00e1tica \u00a0en\u00a0EE.UU\u00a0y\u00a0Canad\u00e1\u00a0(estudio\u00a0NA\u2010ACCORD), \u00a0se\u00a0estratificaron \u00a0dichos\u00a0\npacientes \u00a0en\u00a0funci\u00f3n\u00a0del\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0(>351\u00a0a\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0o\u00a0>\u00a0500\u00a0\nc\u00e9lulas/\u00b5L) \u00a0en\u00a0el\u00a0momento \u00a0de\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0antirretroviral. \u00a0En\u00a0cada\u00a0grupo\u00a0se\u00a0\ncompar\u00f3\u00a0el\u00a0riesgo\u00a0relativo\u00a0de\u00a0muerte\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0tratamiento \u00a0\ncuando\u00a0el\u00a0recuento\u00a0de\u00a0CD4\u00a0era\u00a0superior\u00a0a\u00a0cualquiera \u00a0de\u00a0los\u00a0dos\u00a0puntos\u00a0de\u00a0corte\u00a0\n(tratamiento \u00a0precoz)\u00a0con\u00a0el\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0difirieron \u00a0el\u00a0tratamiento \u00a0hasta\u00a0que\u00a0el\u00a0\nrecuento\u00a0de\u00a0CD4\u00a0cay\u00f3\u00a0por\u00a0debajo\u00a0de\u00a0dichos\u00a0puntos\u00a0de\u00a0corte\u00a0(tratamiento \u00a0diferido).\u00a0El\u00a0\nprimer\u00a0an\u00e1lisis\u00a0incluy\u00f3\u00a08362\u00a0pacientes, \u00a02084\u00a0(25%)\u00a0que\u00a0iniciaron\u00a0tratamiento \u00a0entre\u00a0351\u00a0\ny\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a06278\u00a0(75%)\u00a0que\u00a0difirieron \u00a0el\u00a0tratamiento. \u00a0Tras\u00a0ajuste\u00a0por\u00a0a\u00f1o\u00a0de\u00a0\ntratamiento, \u00a0cohorte,\u00a0y\u00a0caracter\u00edsticas \u00a0cl\u00ednicas\u00a0y\u00a0demogr\u00e1ficas \u00a0se\u00a0hall\u00f3\u00a0un\u00a0incremento \u00a0\ndel\u00a0riesgo\u00a0de\u00a0muerte\u00a0del\u00a069%\u00a0comparando \u00a0el\u00a0grupo\u00a0de\u00a0tratamiento \u00a0precoz\u00a0con\u00a0el\u00a0de\u00a0\ntratamiento \u00a0diferido\u00a0(RR\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TAR\u00a0diferido:\u00a01,69;\u00a0IC\u00a095%,\u00a01,26\u00a0a\u00a02,26;\u00a0p\u00a0\n<0,001).\u00a0En\u00a0un\u00a0segundo\u00a0an\u00e1lisis\u00a0con\u00a09155\u00a0pacientes, \u00a02220\u00a0(24%)\u00a0iniciaron\u00a0TAR\u00a0\nprecozmente \u00a0(>500\u00a0c\u00e9lulas/\u00b5L) \u00a0y\u00a06935\u00a0(76%)\u00a0difirieron \u00a0el\u00a0TAR.\u00a0Se\u00a0hall\u00f3\u00a0un\u00a0incremento \u00a0\ndel\u00a0riesgo\u00a0relativo\u00a0de\u00a0muerte\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TAR\u00a0diferido\u00a0del\u00a094%\u00a0(RR\u00a01,94;\u00a0IC\u00a095%,\u00a0\n1,37\u00a0a\u00a02,79;\u00a0p\u00a0<0,001)196.\u00a0\nPor\u00a0\u00faltimo,\u00a0en\u00a0un\u00a0ensayo\u00a0cl\u00ednico,\u00a0controlado, \u00a0aleatorizado, \u00a0abierto,\u00a0llevado\u00a0a\u00a0cabo\u00a0en\u00a0\nHait\u00ed\u00a0se\u00a0incluyeron \u00a0816\u00a0pacientes \u00a0mayores\u00a0de\u00a018\u00a0a\u00f1os\u00a0a\u00a0iniciar\u00a0TAR\u00a0(AZT+3TC+EFV) \u00a0\nentre\u00a0200\u00a0y\u00a0350\u00a0c\u00e9lulas\u00a0CD4/\u00b5L\u00a0o\u00a0diferirlo\u00a0hasta\u00a02\u00a0semanas\u00a0despu\u00e9s\u00a0del\u00a0diagn\u00f3stico \u00a0\ncl\u00ednico\u00a0de\u00a0SIDA\u00a0o\u00a0que\u00a0su\u00a0recuento\u00a0de\u00a0CD4\u00a0descendiera \u00a0por\u00a0debajo\u00a0de\u00a0200\u00a0c\u00e9lulas/mL. \u00a0El\u00a0\nestudio\u00a0fue\u00a0interrumpido \u00a0prematuramente \u00a0tras\u00a0un\u00a0an\u00e1lisis\u00a0interino\u00a0planeado \u00a0que\u00a0\nmostr\u00f3\u00a06\u00a0muertes\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0200\u00a0a\u00a0350\u00a0c\u00e9lulas/\u00b5L \u00a0frente\u00a0a\u00a023\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\npacientes \u00a0que\u00a0difirieron \u00a0TAR.\u00a0Adem\u00e1s,\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TAR\u00a0diferido\u00a0se\u00a0diagnosticaron \u00a0el\u00a0\ndoble\u00a0de\u00a0casos\u00a0de\u00a0tuberculosis \u00a0que\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0inicio\u00a0inmediato197.\u00a0\nEn\u00a0resumen, \u00a0los\u00a0estudios\u00a0de\u00a0cohorte\u00a0sugieren\u00a0que\u00a0existe\u00a0una\u00a0relaci\u00f3n\u00a0progresiva \u00a0entre\u00a0\nla\u00a0inmunodeficiencia \u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0muerte\u00a0y/o\u00a0progresi\u00f3n \u00a0a\u00a0sida.\u00a0Comparado \u00a0con\u00a0los\u00a0\npacientes \u00a0que\u00a0empiezan \u00a0el\u00a0TAR\u00a0con\u00a0>350\u00a0CD4/\uf06dL,\u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0est\u00e1\u00a0\nclaramente \u00a0aumentado \u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0lo\u00a0empiezan \u00a0por\u00a0debajo.\u00a0\u00a0\n\u00a0\nIncidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0VIH\u00a0\nRecientemente \u00a0los\u00a0estudios\u00a0de\u00a0cohortes\u00a0han\u00a0puesto\u00a0\u00e9nfasis\u00a0en\u00a0el\u00a0riesgo\u00a0de\u00a0aparici\u00f3n \u00a0\nde\u00a0enfermedades \u00a0que\u00a0hasta\u00a0el\u00a0momento \u00a0no\u00a0se\u00a0hab\u00edan\u00a0considerado \u00a0relacionadas \u00a0con\u00a0la\u00a0\ninmunosupresi\u00f3n \u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0no\u00a0prevenibles \u00a0con\u00a0el\u00a0empleo\u00a0de\u00a0TAR.\u00a0Estas\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 17enfermedades \u00a0son\u00a0de\u00a0tipo\u00a0cardiovascular \u00a0(infarto\u00a0de\u00a0miocardio, \u00a0ictus),\u00a0afectaci\u00f3n \u00a0de\u00a0\n\u00f3rganos\u00a0(insuficiencia \u00a0renal,\u00a0hepatopat\u00eda \u00a0descompensada) \u00a0y\u00a0aparici\u00f3n \u00a0de\u00a0c\u00e1nceres\u00a0no\u00a0\ndefinitorios \u00a0de\u00a0sida\u00a0(todo\u00a0tipo\u00a0excepto\u00a0sarcoma\u00a0de\u00a0Kaposi,\u00a0linfoma\u00a0no\u00a0hodgkiniano \u00a0y\u00a0\ncarcinoma \u00a0cervical\u00a0invasor).\u00a0\nHay\u00a0que\u00a0resaltar\u00a0que\u00a0para\u00a0los\u00a0pacientes \u00a0que\u00a0empiezan \u00a0TAR\u00a0con\u00a0m\u00e1s\u00a0de\u00a0200\u00a0CD4/\u00b5L\u00a0la\u00a0\nincidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0VIH\u201d\u00a0es\u00a0tan\u00a0frecuente \u00a0como\u00a0las\u00a0\ndefinitorias \u00a0de\u00a0sida198.\u00a0Por\u00a0lo\u00a0tanto,\u00a0es\u00a0muy\u00a0relevante \u00a0investigar \u00a0estrategias \u00a0\nencaminadas \u00a0a\u00a0disminuir \u00a0la\u00a0incidencia \u00a0de\u00a0los\u00a0dos\u00a0tipos\u00a0de\u00a0complicaciones \u00a0y\u00a0no\u00a0s\u00f3lo\u00a0de\u00a0\nlas\u00a0relacionadas \u00a0cl\u00e1sicamente \u00a0con\u00a0la\u00a0inmunosupresi\u00f3n. \u00a0El\u00a0TAR\u00a0podr\u00eda\u00a0ejercer\u00a0un\u00a0efecto\u00a0\nbeneficioso \u00a0sobre\u00a0las\u00a0complicaciones \u00a0no\u2010sida\u00a0mediante \u00a0el\u00a0control\u00a0del\u00a0estado\u00a0pro\u00a0\ninflamatorio \u00a0y\u00a0la\u00a0activaci\u00f3n \u00a0inmune\u00a0que\u00a0se\u00a0asocian\u00a0a\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0persistente. \u00a0\u00a0\nEn\u00a0la\u00a0cohorte\u00a0D.A.D.199\u00a0y\u00a0en\u00a0la\u00a0cohorte\u00a0CASCADE200\u00a0se\u00a0ha\u00a0comunicado \u00a0que\u00a0existe\u00a0una\u00a0\ndisminuci\u00f3n \u00a0progresiva \u00a0del\u00a0riesgo\u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0VIH\u00a0a\u00a0\nmedida\u00a0que\u00a0aumenta\u00a0la\u00a0cifra\u00a0de\u00a0c\u00e9lulas\u00a0CD4.\u00a0Los\u00a0pacientes \u00a0que\u00a0presentan \u00a0el\u00a0menor\u00a0\nriesgo\u00a0de\u00a0desarrollar \u00a0enfermedades \u00a0no\u00a0definitorias \u00a0de\u00a0sida\u00a0son\u00a0los\u00a0que\u00a0mantienen \u00a0una\u00a0\ncifra\u00a0de\u00a0CD4\u00a0mayor\u00a0de\u00a0350\u00a0c\u00e9lulas/\u03bcL.\u00a0\u00a0\nEn\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0\u00a0SMART201\u00a0la\u00a0incidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0sida\u00a0\naument\u00f3\u00a0significativamente \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0pacientes \u00a0que\u00a0suspendieron \u00a0el\u00a0TAR\u00a0cuando\u00a0\nla\u00a0cifra\u00a0de\u00a0CD4\u00a0era\u00a0menor\u00a0de\u00a0350\u00a0c\u00e9lulas/\u03bcL.\u00a0En\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0FIRST198\u00a0tambi\u00e9n\u00a0se\u00a0\nha\u00a0puesto\u00a0de\u00a0manifiesto \u00a0una\u00a0relaci\u00f3n\u00a0entre\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0\nenfermedades \u00a0no\u00a0definitorias \u00a0de\u00a0sida,\u00a0siendo\u00a0menor\u00a0el\u00a0riesgo\u00a0en\u00a0aquellos\u00a0pacientes \u00a0\nque\u00a0mantuvieron \u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0por\u00a0encima\u00a0de\u00a0350\u00a0c\u00e9lulas/\u03bcL.\u00a0\n\u00a0\nSubgrupos \u00a0de\u00a0mayor\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0\nVarios\u00a0estudios10,\u00a0202,\u00a0203\u00a0han\u00a0demostrado \u00a0que\u00a0diversos\u00a0subgrupos \u00a0de\u00a0pacientes \u00a0tienen\u00a0\nun\u00a0mayor\u00a0riesgo\u00a0de\u00a0mortalidad \u00a0y/o\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0independientemente \u00a0de\u00a0la\u00a0cifra\u00a0\nde\u00a0CD4\u00a0antes\u00a0de\u00a0iniciar\u00a0TAR.\u00a0El\u00a0uso\u00a0de\u00a0drogas\u00a0por\u00a0v\u00eda\u00a0parenteral, \u00a0la\u00a0coinfecci\u00f3n \u00a0por\u00a0\nvirus\u00a0de\u00a0la\u00a0hepatitis\u00a0C,\u00a0el\u00a0sexo\u00a0masculino \u00a0y\u00a0la\u00a0edad\u00a0avanzada \u00a0se\u00a0asocian\u00a0a\u00a0un\u00a0mayor\u00a0\nriesgo\u00a0de\u00a0progresi\u00f3n. \u00a0\u00a0Aunque\u00a0no\u00a0se\u00a0ha\u00a0establecido \u00a0claramente \u00a0un\u00a0corte\u00a0de\u00a0edad\u00a0a\u00a0\npartir\u00a0del\u00a0cual\u00a0sea\u00a0m\u00e1s\u00a0beneficioso \u00a0iniciar\u00a0TAR,\u00a0los\u00a0estudios\u00a0de\u00a0cohorte\u00a0sugieren\u00a0que\u00a0el\u00a0\nriesgo\u00a0de\u00a0progresi\u00f3n \u00a0est\u00e1\u00a0aumentado \u00a0por\u00a0encima\u00a0de\u00a0los\u00a055\u201060\u00a0a\u00f1os\u00a0de\u00a0edad204.\u00a0\u00a0\nSe\u00a0ha\u00a0estudiado \u00a0la\u00a0relaci\u00f3n\u00a0de\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0al\u00a0inicio\u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0\nsupervivencia \u00a0en\u00a0un\u00a0grupo\u00a0de\u00a0pacientes \u00a0cuyos\u00a0CD4\u00a0estaban\u00a0entre\u00a0200\u00a0y\u00a0350\u00a0c\u00e9lulas/\u00b5L. \u00a0\nLa\u00a0supervivencia \u00a0era\u00a0m\u00e1s\u00a0corta\u00a0si\u00a0la\u00a0proporci\u00f3n \u00a0era\u00a0<5%\u00a0(HR\u00a04,46)\u00a0o\u00a0entre\u00a05\u201014%\u00a0(HR\u00a0\n2,43)\u00a0que\u00a0si\u00a0era\u00a0\u00a0\u226515%\u00a0(p<0,01)205.\u00a0Sin\u00a0embargo, \u00a0en\u00a0la\u00a0cohorte\u00a0PISCIS\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\nCD4\u00a0no\u00a0fue\u00a0un\u00a0factor\u00a0independiente \u00a0asociado\u00a0con\u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n10.\u00a0\u00a0\n\u00a0\nRespuesta \u00a0inmunol\u00f3gica \u00a0\u00a0\nHay\u00a0datos\u00a0contradictorios \u00a0sobre\u00a0si\u00a0existe\u00a0un\u00a0l\u00edmite\u00a0en\u00a0la\u00a0reconstituci\u00f3n \u00a0inmunol\u00f3gica \u00a0\nde\u00a0los\u00a0pacientes \u00a0que\u00a0reciben\u00a0TAR.\u00a0La\u00a0cohorte\u00a0del\u00a0Hospital\u00a0Johns\u00a0Hopkins\u00a0y\u00a0la\u00a0cohorte\u00a0\nATHENA205,\u00a0206\u00a0con\u00a0un\u00a0seguimiento \u00a0de\u00a0hasta\u00a07\u00a0a\u00f1os\u00a0despu\u00e9s\u00a0del\u00a0inicio\u00a0de\u00a0TAR\u00a0sugieren\u00a0\nque\u00a0la\u00a0posibilidad \u00a0de\u00a0alcanzar\u00a0recuentos \u00a0de\u00a0CD4\u00a0normales \u00a0depende\u00a0del\u00a0n\u00famero\u00a0inicial.\u00a0\nEn\u00a0estas\u00a0dos\u00a0cohortes\u00a0s\u00f3lo\u00a0los\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0TAR\u00a0con\u00a0>350\u00a0CD4\u00a0se\u00a0\naproximaron \u00a0a\u00a0la\u00a0normalizaci\u00f3n \u00a0cuantitativa; \u00a0sin\u00a0embargo\u00a0los\u00a0datos\u00a0de\u00a0Eurosida207\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 18sugieren\u00a0que\u00a0se\u00a0puede\u00a0normalizar \u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4,\u00a0independientemente \u00a0del\u00a0nadir\u00a0\nalcanzado, \u00a0si\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0persiste\u00a0suprimida \u00a0por\u00a0debajo\u00a0de\u00a050\u00a0copias/mL \u00a0de\u00a0\nforma\u00a0prolongada. \u00a0\u00a0\u00a0\n\u00a0\nToxicidad \u00a0del\u00a0TAR\u00a0\nUn\u00a0argumento \u00a0para\u00a0diferir\u00a0el\u00a0TAR\u00a0es\u00a0evitar\u00a0la\u00a0toxicidad\u00a0asociada\u00a0al\u00a0empleo\u00a0de\u00a0\nantirretrovirales. \u00a0Hay\u00a0pocos\u00a0estudios\u00a0actuales\u00a0que\u00a0hayan\u00a0evaluado\u00a0la\u00a0incidencia \u00a0de\u00a0\nefectos\u00a0adversos\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0antes\u00a0del\u00a0inicio\u00a0del\u00a0TAR.\u00a0Un\u00a0estudio\u00a0\nreciente\u00a0sugiere\u00a0que\u00a0la\u00a0incidencia \u00a0de\u00a0neuropat\u00eda \u00a0perif\u00e9rica, \u00a0anemia\u00a0e\u00a0insuficiencia \u00a0renal\u00a0\nno\u00a0est\u00e1\u00a0aumentada \u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0inician\u00a0TAR\u00a0con\u00a0cifras\u00a0de\u00a0CD4\u00a0mayores\u00a0de\u00a0350\u00a0\nc\u00e9lulas/\u03bcL208.\u00a0De\u00a0hecho\u00a0la\u00a0incidencia \u00a0de\u00a0neuropat\u00eda \u00a0perif\u00e9rica, \u00a0anemia,\u00a0insuficiencia \u00a0\nrenal\u00a0y\u00a0lipodistrofia \u00a0fue\u00a0menor\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0TAR\u00a0por\u00a0encima\u00a0de\u00a0350\u00a0\nCD4/\u03bcL\u00a0que\u00a0en\u00a0quienes\u00a0empezaron \u00a0entre\u00a0200\u00a0y\u00a0350\u00a0CD4/\u03bcL.\u00a0\n\u00a0\nTAR\u00a0para\u00a0evitar\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0(parejas\u00a0serodiscordantes) \u00a0\nAlgunos\u00a0expertos\u00a0han\u00a0sugerido\u00a0que\u00a0en\u00a0parejas\u00a0serodiscordantes \u00a0que\u00a0mantienen \u00a0\nrelaciones \u00a0sexuales\u00a0no\u00a0protegidas, \u00a0el\u00a0tratamiento \u00a0del\u00a0miembro\u00a0infectado \u00a0a\u00a0fin\u00a0de\u00a0\ncontrolar\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0(carga\u00a0viral\u00a0indetectable) \u00a0puede\u00a0constituir \u00a0una\u00a0indicaci\u00f3n \u00a0\nde\u00a0TAR.\u00a0En\u00a0un\u00a0metaan\u00e1lisis \u00a0reciente\u00a0que\u00a0incluy\u00f3\u00a05021\u00a0parejas\u00a0heterosexuales \u00a0y\u00a0461\u00a0\neventos\u00a0de\u00a0trasmisi\u00f3n, \u00a0la\u00a0tasa\u00a0global\u00a0de\u00a0transmisi\u00f3n \u00a0para\u00a0pacientes \u00a0en\u00a0TAR\u00a0fue\u00a0de\u00a00,46\u00a0\n(IC\u00a095%,\u00a00,19\u00a0a\u00a01,09)\u00a0por\u00a0100\u00a0pacientes \u2010a\u00f1o.\u00a0La\u00a0tasa\u00a0de\u00a0trasmisi\u00f3n \u00a0desde\u00a0un\u00a0sujeto\u00a0en\u00a0\nTAR\u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0fue\u00a0de\u00a00\u00a0con\u00a0un\u00a0IC\u00a097,5%\u00a0superior\u00a0de\u00a01,27\u00a0por\u00a0100\u00a0\npersonas\u2010a\u00f1o,\u00a0lo\u00a0que\u00a0equivale\u00a0en\u00a0estas\u00a0parejas\u00a0a\u00a0un\u00a0episodio\u00a0de\u00a0transmisi\u00f3n \u00a0por\u00a079\u00a0\npersonas\u2010a\u00f1o.\u00a0\u00a0Si\u00a0el\u00a0sujeto\u00a0no\u00a0tomaba\u00a0TAR\u00a0la\u00a0tasa\u00a0de\u00a0transmisi\u00f3n \u00a0era\u00a0del\u00a00,16\u00a0(IC\u00a095%,\u00a0\n0,02\u00a0a\u00a01,13)\u00a0por\u00a0100\u00a0personas\u2010a\u00f1o.\u00a0No\u00a0hab\u00edan\u00a0suficientes \u00a0datos\u00a0para\u00a0estratificar \u00a0el\u00a0\nriesgo\u00a0de\u00a0transmisi\u00f3n \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0presencia \u00a0de\u00a0ETS,\u00a0uso\u00a0de\u00a0cond\u00f3n\u00a0o\u00a0coito\u00a0vaginal\u00a0\no\u00a0anal209.\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0inicio\u00a0del\u00a0TAR\u00a0\n\u0083 El\u00a0inicio\u00a0del\u00a0TAR\u00a0debe\u00a0basarse\u00a0en\u00a0tres\u00a0elementos: \u00a0los\u00a0s\u00edntomas, \u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0y\u00a0\nla\u00a0CVP\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0infecci\u00f3n \u00a0sintom\u00e1tica \u00a0(eventos\u00a0B\u00a0o\u00a0C)\u00a0se\u00a0recomienda \u00a0iniciar\u00a0el\u00a0TAR\u00a0en\u00a0\ntodos\u00a0los\u00a0casos\u00a0(nivel\u00a0A)\u00a0\n\u0083 Si\u00a0la\u00a0infecci\u00f3n \u00a0es\u00a0asintom\u00e1tica \u00a0el\u00a0inicio\u00a0del\u00a0TAR\u00a0se\u00a0basa\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4,\u00a0la\u00a0\nCVP\u00a0o\u00a0en\u00a0determinadas \u00a0comorbilidades \u00a0o\u00a0caracter\u00edsticas \u00a0del\u00a0paciente\u00a0(Tabla\u00a03):\u00a0\n\u0083 Si\u00a0linfocitos\u00a0CD4\u00a0<350\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0el\u00a0TAR\u00a0(nivel\u00a0B)\u00a0\n\u0083 Si\u00a0los\u00a0linfocitos\u00a0CD4\u00a0est\u00e1n\u00a0entre\u00a0350\u00a0y\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0el\u00a0TAR,\u00a0\naunque\u00a0se\u00a0puede\u00a0diferir\u00a0su\u00a0inicio\u00a0en\u00a0determinadas \u00a0situaciones, \u00a0como\u00a0la\u00a0\npresencia \u00a0de\u00a0un\u00a0recuento\u00a0de\u00a0CD4\u00a0estable,\u00a0CVP\u00a0baja\u00a0o\u00a0poca\u00a0predisposici\u00f3n \u00a0del\u00a0\npaciente\u00a0(nivel\u00a0B)\u00a0\n\u0083 Si\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0es\u00a0mayor\u00a0de\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0diferir\u00a0\nel\u00a0TAR\u00a0en\u00a0general,\u00a0Sin\u00a0embargo\u00a0debe\u00a0ser\u00a0considerado \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 19comorbilidades \u00a0(cirrosis\u00a0hep\u00e1tica,\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0virus\u00a0C,\u00a0hepatitis\u00a0B\u00a0con\u00a0\nindicaci\u00f3n \u00a0de\u00a0tratamiento, \u00a0CVP\u00a0>105\u00a0copias/mL, \u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0<14%,\u00a0\nedad\u00a0>55\u00a0a\u00f1os,\u00a0riesgo\u00a0cardiovascular \u00a0elevado\u00a0y\u00a0nefropat\u00eda \u00a0VIH)\u00a0(nivel\u00a0B)\u00a0\n\u0083 En\u00a0parejas\u00a0serodiscordantes, \u00a0debe\u00a0valorarse \u00a0cuidadosamente \u00a0el\u00a0inicio\u00a0de\u00a0TAR\u00a0\npara\u00a0disminuir \u00a0la\u00a0transmisi\u00f3n \u00a0por\u00a0v\u00eda\u00a0heterosexual \u00a0(nivel\u00a0B).\u00a0En\u00a0ning\u00fan\u00a0caso\u00a0\nello\u00a0debe\u00a0suponer\u00a0la\u00a0abstenci\u00f3n \u00a0de\u00a0otras\u00a0medidas\u00a0para\u00a0impedir\u00a0la\u00a0transmisi\u00f3n \u00a0\ndel\u00a0VIH\u00a0\n\u0083 A\u00a0pesar\u00a0de\u00a0las\u00a0consideraciones \u00a0previas,\u00a0el\u00a0inicio\u00a0del\u00a0TAR\u00a0debe\u00a0valorarse\u00a0siempre\u00a0\nindividualmente. \u00a0Antes\u00a0de\u00a0tomar\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0iniciarlo\u00a0deben\u00a0confirmarse \u00a0la\u00a0cifra\u00a0\nde\u00a0CD4\u00a0y\u00a0de\u00a0CVP.\u00a0Adem\u00e1s,\u00a0debe\u00a0prepararse \u00a0al\u00a0paciente, \u00a0ofertando \u00a0las\u00a0distintas\u00a0\nopciones, \u00a0adaptando \u00a0el\u00a0esquema\u00a0terap\u00e9utico \u00a0al\u00a0estilo\u00a0de\u00a0vida,\u00a0comorbilidades, \u00a0\nposibles\u00a0interacciones \u00a0y\u00a0valorando \u00a0el\u00a0riesgo\u00a0de\u00a0mala\u00a0adherencia \u00a0\n\u00a04.2.\u00a0\u00bfQu\u00e9\u00a0combinaci\u00f3n \u00a0de\u00a0antirretrovirales \u00a0debe\u00a0utilizarse? \u00a0\nEl\u00a0tratamiento \u00a0de\u00a0elecci\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0el\u00a0momento \u00a0actual\u00a0consiste\u00a0en\u00a0\nuna\u00a0combinaci\u00f3n \u00a0de\u00a0al\u00a0menos\u00a0tres\u00a0f\u00e1rmacos \u00a0que\u00a0incluyan\u00a0dos\u00a0AN\u00a0y\u00a0un\u00a0IP/r\u00a0o\u00a0un\u00a0NN\u00a0\n(tabla\u00a04).\u00a0Con\n\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estas\u00a0combinaciones \u00a0se\u00a0puede\u00a0conseguir \u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0en\u00a0>70%\u00a0de\u00a0casos\u00a0a\u00a0las\u00a048\u00a0semanas210.\u00a0\n\u00a0Criterios\u00a0para\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0las\u00a0pautas\u00a0antirretrovirales \u00a0\nSe\u00a0consideran \u00a0\u201cpautas\u00a0preferentes\u201d \u00a0las\u00a0combinaciones \u00a0avaladas\u00a0por\u00a0el\u00a0mayor\u00a0n\u00famero\u00a0\nde\u00a0ensayos\u00a0cl\u00ednicos\u00a0con\u00a0eficacia\u00a0y\u00a0durabilidad \u00a0\u00f3ptimas,\u00a0tolerancias \u00a0aceptables \u00a0y\u00a0f\u00e1ciles\u00a0\nde\u00a0usar.\u00a0Otras\u00a0pautas\u00a0que\u00a0han\u00a0demostrado \u00a0eficacia,\u00a0pero\u00a0con\u00a0menor\u00a0n\u00famero\u00a0de\u00a0\npacientes, \u00a0menor\u00a0duraci\u00f3n\u00a0de\u00a0los\u00a0estudios,\n\u00a0mayor\u00a0toxicidad\u00a0o\u00a0complejidad \u00a0en\u00a0su\u00a0\nposolog\u00eda \u00a0se\u00a0han\u00a0considerado \u00a0\u201cpautas\u00a0alternativas\u201d. \u00a0Se\u00a0dispone\u00a0de\u00a0m\u00faltiples \u00a0pautas\u00a0\nantirretrovirales \u00a0de\u00a0eficacia\u00a0similar.\u00a0En\u00a0este\u00a0contexto\u00a0este\u00a0comit\u00e9\u00a0quiere\u00a0destacar\u00a0la\u00a0\nimportancia \u00a0creciente \u00a0del\u00a0coste\u2010efectividad \u00a0de\u00a0los\u00a0FAR\u00a0para\u00a0establecer \u00a0las\u00a0pautas\u00a0\npreferentes. \u00a0\u00a0\n\u00a0\nConsideraciones \u00a0sobre\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0un\u00a0NN,\u00a0un\u00a0IP/r\u00a0o\u00a0IInt\u00a0\u00a0\nLa\u00a0elecci\u00f3n\u00a0de\u00a0una\u00a0u\u00a0otra\u00a0familia\u00a0ofrece\u00a0ciertas\u00a0ventajas\u00a0sobre\u00a0otras:\u00a01)\u00a0Menos\u00a0\ninteracciones \u00a0farmacocin\u00e9ticas \u00a0y\u00a0mejor\u00a0perfil\u00a0metab\u00f3lico \u00a0con\u00a0NN\u00a0o\u00a0IInt;\u00a02)\u00a0Mayor\u00a0\nbarrera\u00a0gen\u00e9tica\u00a0de\u00a0los\u00a0IP/r\u00a0para\u00a0el\u00a0desarrollo \u00a0de\u00a0resistencias; \u00a03)\u00a0Menor\u00a0coste\u00a0de\u00a0los\u00a0\nNN.\u00a0El\u00a0momento \u00a0id\u00f3neo\u00a0del\u00a0uso\u00a0de\u00a0los\u00a0NN\u00a0es\u00a0el\u00a0primer\u00a0tratamiento \u00a0ya\u00a0que\u00a0en\u00a0pautas\u00a0\nde\u00a0rescate\u00a0tienen\u00a0menos\u00a0actividad\u00a0que\u00a0otros\u00a0componentes \u00a0del\u00a0r\u00e9gimen.\u00a0\u00a0\nLa\u00a0ventaja\u00a0principal\u00a0de\u00a0los\u00a0IInt\u00a0es\u00a0su\u00a0favorable \u00a0perfil\u00a0de\u00a0seguridad \u00a0y\u00a0sus\u00a0desventajas \u00a0son\u00a0\nla\u00a0menor\u00a0experiencia \u00a0y\u00a0el\u00a0precio.\u00a0\u00a0\nRecomendaci\u00f3n \u00a0sobre\u00a0combinaciones \u00a0de\u00a0FAR\u00a0en\u00a0tratamiento \u00a0de\u00a0inicio\u00a0\u00a0\u00a0\n\u0083 Pueden\u00a0utilizarse\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a02\u00a0AN+1\u00a0NN\u00a0\u00f3\u00a02\u00a0AN+1\u00a0IP/r\u00a0o\u00a02\u00a0AN+IInt\u00a0como\u00a0\ntratamiento \u00a0de\u00a0inicio\u00a0(los\u00a0f\u00e1rmacos \u00a0preferentes \u00a0se\u00a0detallan\u00a0m\u00e1s\u00a0adelante). \u00a0Una\u00a0\nalternativa \u00a0v\u00e1lida\u00a0cuando\u00a0no\u00a0se\u00a0pueden\u00a0tomar\u00a0IP\u00a0o\u00a0NN\u00a0es\u00a0combinar \u00a03\u00a0AN\u00a0\n(ZDV/3TC/ABC) \u00a0o\u00a02\u00a0AN+\u00a0MVC\u00a0(nivel\u00a0A)\u00a0(Tabla\u00a04)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 20\u00a0\n4.3.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0\nEn\u00a0Espa\u00f1a\u00a0est\u00e1n\u00a0comercializados \u00a06\u00a0AN:\u00a0zidovudina \u00a0(ZDV),\u00a0didanosina \u00a0(ddI),\u00a0estavudina \u00a0\n(d4T),\u00a0lamivudina \u00a0(3TC),\u00a0emtricitabina \u00a0(FTC)\u00a0y\u00a0abacavir\u00a0(ABC).\u00a0Tambi\u00e9n\u00a0se\u00a0dispone\u00a0de\u00a0\nun\u00a0an\u00e1logo\u00a0de\u00a0nucle\u00f3tido, \u00a0tenofovir\u00a0(TDF).\u00a0A\u00a0efectos\u00a0pr\u00e1cticos, \u00a0la\u00a0abreviatura \u00a0AN\u00a0\nincluye\u00a0tambi\u00e9n\u00a0al\u00a0TDF\u00a0en\u00a0esta\u00a0gu\u00eda.\u00a0Las\u00a0principales \u00a0caracter\u00edsticas \u00a0de\u00a0los\u00a0AN\u00a0se\u00a0\ndescriben \u00a0en\u00a0Tabla\u00a054,\u00a0211,\u00a0212.\u00a0Las\u00a0combinaciones \u00a0TDF+FTC, \u00a0ABC+3TC\u00a0y\u00a0ddI+3TC\u00a0pueden\u00a0\nadministrarse \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda;\u00a0de\u00a0ellas\u00a0las\u00a0dos\u00a0primeras\u00a0se\u00a0presentan \u00a0en\u00a0un\u00a0solo\u00a0\ncomprimido. \u00a0\u00a0\u00a0\n\u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0AN\u00a0\u00a0\nGilead\u00a0903\u00a0\u00a0\nEl\u00a0estudio\u00a0Gilead\u00a0903\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0TDF\u00a0frente\u00a0a\u00a0d4T\u00a0\nadministrados \u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0EFV\u00a0y\u00a03TC\u00a0en\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo.\u00a0Los\u00a0602\u00a0\npacientes \u00a0incluidos\u00a0ten\u00edan\u00a0una\u00a0media\u00a0de\u00a0CD4\u00a0de\u00a0276\u2010283\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0de\u00a0CVP\u00a0de\u00a04,91\u00a0\nlog10\u00a0copias/mL. \u00a0En\u00a0un\u00a0an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar,\u00a0a\u00a0las\u00a0144\u00a0semanas, \u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0era\u00a0del\u00a067,9%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF\u00a0y\u00a0\n62,5%\u00a0en\u00a0el\u00a0de\u00a0d4T.\u00a0Entre\u00a0los\u00a0tratados\u00a0con\u00a0TDF\u00a0fue\u00a0menos\u00a0frecuente \u00a0tanto\u00a0la\u00a0toxicidad\u00a0\nglobal\u00a0relacionada \u00a0con\u00a0disfunci\u00f3n \u00a0mitocondrial \u00a0(6%\u00a0frente\u00a0a\u00a028%)\u00a0como\u00a0la\u00a0neuropat\u00eda \u00a0\nperif\u00e9rica \u00a0(3%\u00a0frente\u00a0a\u00a010%)\u00a0o\u00a0lipodistrofia \u00a0(3%\u00a0frente\u00a0al\u00a019%).\u00a0Asimismo, \u00a0este\u00a0grupo\u00a0\ntuvo\u00a0un\u00a0mejor\u00a0perfil\u00a0lip\u00eddico.\u00a0Por\u00a0tanto,\u00a0este\u00a0estudio\u00a0apoy\u00f3\u00a0el\u00a0uso\u00a0de\u00a0TDF\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0\nfrente\u00a0al\u00a0d4T\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0como\u00a0terapia\u00a0de\u00a0inicio213.\u00a0\u00a0\n\u00a0Gilead\u00a0934\u00a0\u00a0\nEl\u00a0estudio\u00a0aleatorizado \u00a0Gilead\u00a0934\u00a0compar\u00f3\u00a0TDF+FTC\u00a0QD\u00a0frente\u00a0a\u00a0ZDV+\u00a03TC\u00a0BID\u00a0\ncombinados \u00a0con\u00a0EFV.\u00a0Se\u00a0incluyeron \u00a0517\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo\u00a0con\u00a0CVP\u00a0basal\u00a0de\u00a05\u00a0\nlog\n10\u00a0y\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0233\u2010241\u00a0c\u00e9lulas/\u00b5L, \u00a0seg\u00fan\u00a0grupo\u00a0de\u00a0tratamiento. \u00a0En\u00a0el\u00a0\nan\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0fue\u00a0del\u00a081%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0y\u00a0del\u00a070%\u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0ZDV+3TC\u00a0(p=0,005). \u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0\nde\u00a077%\u00a0frente\u00a0a\u00a068%,\u00a0respectivamente \u00a0(p=0,034). \u00a0Los\u00a0linfocitos\u00a0CD4\u00a0aumentaron \u00a0190\u00a0\nc\u00e9lulas/\u00b5L \u00a0en\u00a0el\u00a0grupo\u00a0TDF+FTC\u00a0frente\u00a0a\u00a0158\u00a0c\u00e9lulas/\u00b5L \u00a0en\u00a0el\u00a0de\u00a0ZDV+3TC\u00a0(p=\u00a00,002).\u00a0\nHubo\u00a0menos\u00a0efectos\u00a0adversos\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0(4%\u00a0frente\u00a0al\u00a09%;\u00a0\u00a0p\u00a0=\u00a00,016)\u00a0y\u00a0\nmenos\u00a0suspensiones \u00a0de\u00a0tratamiento \u00a0por\u00a0reacciones \u00a0adversas\u00a0(4%\u00a0frente\u00a0a\u00a09%;\u00a0p=\u00a0\n0,016).\u00a0El\u00a06%\u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0ZDV+3TC\u00a0tuvo\u00a0anemia\u00a0frente\u00a0al\u00a00%\u00a0en\u00a0los\u00a0\ntratados\u00a0con\u00a0TDF+FTC. \u00a0El\u00a0incremento \u00a0del\u00a0colesterol \u00a0fue\u00a0m\u00e1s\u00a0bajo\u00a0y\u00a0el\u00a0volumen\u00a0de\u00a0grasa\u00a0\nen\u00a0extremidades \u00a0m\u00e1s\u00a0alto\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0(diferencias \u00a0significativas)214.\u00a0A\u00a0las\u00a0\n144\u00a0semanas\u00a0de\u00a0seguimiento \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0era\u00a0\nde\u00a075%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0y\u00a058%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ZDV+3TC\u00a0(p=0,004), \u00a0pero\u00a0sin\u00a0\ndiferencias \u00a0en\u00a0la\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(p=0,08).\u00a0En\u00a0caso\u00a0de\u00a0fracaso\u00a0virol\u00f3gico, \u00a0la\u00a0\nmutaci\u00f3n \u00a0M184V/I\u00a0fue\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ZDV+3TC215.\u00a0La\u00a0respuesta \u00a0\ninmunol\u00f3gica \u00a0fue\u00a0algo\u00a0mejor\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0TDF+FTC\u00a0(312\u00a0frente\u00a0a\u00a0271\u00a0c\u00e9lulas/\u00b5L; \u00a0\np=\u00a00,09).\u00a0Por\u00a0otra\u00a0parte,\u00a0\u00a0la\u00a0cantidad\u00a0de\u00a0grasa\u00a0en\u00a0extremidades \u00a0fue\u00a0mayor\u00a0en\u00a0el\u00a0grupo\u00a0\nde\u00a0TDF+FTC\u00a0(7,9\u00a0frente\u00a0a\u00a05,4\u00a0kg,\u00a0p\u00a0<0,001)216.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 21\u00a0\nCNA30024 \u00a0\u00a0\nEl\u00a0estudio\u00a0CNA30024 \u00a0es\u00a0un\u00a0ensayo\u00a0aleatorizado, \u00a0doble\u00a0ciego\u00a0que\u00a0compara\u00a0la\u00a0eficacia\u00a0y\u00a0\ntolerancia \u00a0de\u00a0ZDV\u00a0frente\u00a0a\u00a0ABC\u00a0(ambos\u00a0BID)\u00a0combinados \u00a0con\u00a03TC\u00a0y\u00a0EFV.\u00a0Se\u00a0incluyeron \u00a0\n649\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo\u00a0con\u00a0una\u00a0CVP\u00a0basal\u00a0media\u00a0de\u00a04,76\u20104,81\u00a0log10\u00a0copias/mL \u00a0y\u00a0\nuna\u00a0media\u00a0de\u00a0linfocitos\u00a0CD4\u00a0de\u00a0256\u2010267\u00a0c\u00e9lulas/\u00b5L. \u00a0En\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0eficacia\u00a0\nvirol\u00f3gica \u00a0fue\u00a0similar\u00a0en\u00a0ambos\u00a0grupos.\u00a0Alrededor \u00a0del\u00a070%\u00a0alcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar).\u00a0Sin\u00a0embargo, \u00a0el\u00a0incremento \u00a0de\u00a0CD4\u00a0fue\u00a0\nsignificativamente \u00a0superior\u00a0en\u00a0el\u00a0grupo\u00a0tratado\u00a0con\u00a0ABC\u00a0(mediana, \u00a0205\u00a0frente\u00a0a\u00a0155\u00a0\nc\u00e9lulas/\u00b5L). \u00a0Un\u00a08%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0tomaron\u00a0ABC\u00a0desarroll\u00f3 \u00a0reacci\u00f3n\u00a0de\u00a0\nhipersensibilidad. \u00a0Bas\u00e1ndose \u00a0en\u00a0los\u00a0resultados \u00a0de\u00a0este\u00a0estudio\u00a0se\u00a0considera \u00a0que\u00a0ABC\u00a0es\u00a0\nequivalente \u00a0a\u00a0ZDV\u00a0en\u00a0eficacia\u00a0antiviral,\u00a0aunque\u00a0debe\u00a0tenerse\u00a0en\u00a0cuenta\u00a0el\u00a0riesgo\u00a0de\u00a0\naparici\u00f3n \u00a0de\u00a0la\u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad217.\u00a0\n\u00a0\nCNA30021 \u00a0\u00a0\nEl\u00a0estudio\u00a0CNA30021 \u00a0es\u00a0un\u00a0ensayo\u00a0aleatorizado \u00a0que\u00a0compara\u00a0la\u00a0eficacia\u00a0del\u00a0ABC\u00a0QD\u00a0\nfrente\u00a0a\u00a0BID.\u00a0Incluy\u00f3\u00a0770\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo.\u00a0Los\u00a0pacientes \u00a0recibieron \u00a0ABC,\u00a0600\u00a0\nmg\u00a0QD,\u00a0o\u00a0ABC,\u00a0300\u00a0mg\u00a0BID,\u00a0adem\u00e1s\u00a0de\u00a03TC\u00a0(300\u00a0mg\u00a0QD)\u00a0+\u00a0EFV\u00a0(600\u00a0mg\u00a0QD).\u00a0A\u00a0las\u00a048\u00a0\nsemanas\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0que\u00a0alcanzaron \u00a0<50\u00a0copias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0\nintenci\u00f3n \u00a0de\u00a0tratar)\u00a0fue\u00a0de\u00a066%\u00a0en\u00a0la\u00a0rama\u00a0QD\u00a0y\u00a0de\u00a068%\u00a0en\u00a0la\u00a0rama\u00a0BID.\u00a0El\u00a0estudio\u00a0\ndemostr\u00f3 \u00a0la\u00a0equivalencia \u00a0de\u00a0las\u00a0dos\u00a0pautas\u00a0de\u00a0administraci\u00f3n \u00a0de\u00a0ABC.\u00a0Las\u00a0reacciones \u00a0\nde\u00a0hipersensibilidad \u00a0a\u00a0ABC\u00a0(grado\u00a03\u20104)\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0la\u00a0rama\u00a0QD\u00a0que\u00a0en\u00a0la\u00a0\nBID\u00a0(5%\u00a0frente\u00a0a\u00a02%)218.\u00a0\u00a0\n\u00a0\nABCDE\u00a0\nEl\u00a0ABCDE\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0abierto\u00a0que\u00a0incluy\u00f3\u00a0237\u00a0pacientes \u00a0aleatorizados \u00a0a\u00a0recibir\u00a0\nABC\u00a0o\u00a0d4T\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a03TC\u00a0+\u00a0EFV.\u00a0En\u00a0la\u00a0semana\u00a096\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0\ncon\u00a0CVP<50\u00a0copias/mL \u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0ABC\u00a0(60,9%\u00a0frente\u00a0a\u00a047,5%,\u00a0p\u00a0=\u00a0\n0,05).\u00a0El\u00a0grupo\u00a0tratado\u00a0con\u00a0d4T\u00a0presentaba \u00a0lipoatrofia \u00a0cl\u00ednicamente \u00a0aparente\u00a0(para\u00a0\nm\u00e9dico\u00a0y\u00a0paciente) \u00a0en\u00a0el\u00a038,3%,\u00a0significativamente \u00a0superior\u00a0al\u00a04,8%\u00a0de\u00a0los\u00a0que\u00a0\nrecibieron \u00a0ABC219.\u00a0\n\u00a0PREDICT\u00a0\nEl\u00a0ensayo\u00a0cl\u00ednico\u00a0PREDICT\u00a0ha\u00a0demostrado \u00a0que\u00a0la\u00a0incidencia \u00a0de\u00a0reacci\u00f3n\u00a0de\u00a0\nhipersensibilidad \u00a0a\u00a0ABC\u00a0puede\u00a0disminuir \u00a0dr\u00e1sticamente \u00a0mediante \u00a0la\u00a0genotipificaci\u00f3n \u00a0\ndel\u00a0HLA\u2010\u00a0B*5701\n112.\u00a0En\u00a0este\u00a0ensayo\u00a0cl\u00ednico\u00a0la\u00a0prueba\u00a0de\u00a0genotipificaci\u00f3n \u00a0del\u00a0HLA\u2010\nB*5701\u00a0tuvo\u00a0un\u00a0valor\u00a0predictivo \u00a0negativo\u00a0del\u00a0100%\u00a0para\u00a0descartar \u00a0la\u00a0reacci\u00f3n\u00a0de\u00a0\nhipersensibilidad \u00a0a\u00a0ABC\u00a0confirmada \u00a0mediante \u00a0prueba\u00a0cut\u00e1nea.\u00a0\u00a0\n\u00a0FTC\u00a0301\u2010A\u00a0\nEl\u00a0FTC\u00a0301\u2010A\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0doble\u00a0ciego\u00a0que\u00a0compara\u00a0la\u00a0eficacia\u00a0y\n\u00a0\ntolerancia \u00a0de\u00a0FTC\u00a0frente\u00a0a\u00a0d4T,\u00a0ambos\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0ddI+EFV.\u00a0Se\u00a0incluyeron \u00a0571\u00a0\npacientes \u00a0sin\u00a0terapia\u00a0previa\u00a0con\u00a0una\u00a0media\u00a0de\u00a0linfocitos\u00a0CD4\u00a0de\u00a0312\u2010324\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 22una\u00a0media\u00a0de\u00a0CVP\u00a0de\u00a04,8\u00a0log10.\u00a0A\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0para\u00a0los\u00a0grupos\u00a0de\u00a0FTC\u00a0y\u00a0d4T\u00a0fue\u00a0de\u00a074%\u00a0y\u00a058%\u00a0(p<0,0001). \u00a0El\u00a0\nincremento \u00a0de\u00a0los\u00a0linfocitos\u00a0CD4\u00a0fue\u00a0mayor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0FTC\u00a0(168\u00a0frente\u00a0a\u00a0134\u00a0\nc\u00e9lulas/\u00b5L; \u00a0p<0,05).\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0discontinuaron \u00a0por\u00a0efectos\u00a0\nadversos\u00a0fue\u00a0mayor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0d4T+ddI\u00a0(16,6\u00a0frente\u00a0a\u00a07,4%;\u00a0p=0,0028). \u00a0Los\u00a0\npacientes \u00a0tratados\u00a0con\u00a0d4T+ddI\u00a0tuvieron\u00a0mayor\u00a0incidencia \u00a0de\u00a0neuropat\u00eda \u00a0perif\u00e9rica, \u00a0\ndiarrea\u00a0y\u00a0n\u00e1useas220.\u00a0\u00a0\n\u00a0Gesida\u00a03903\u00a0\nEl\u00a0Gesida\u00a03903\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0abierto\u00a0que\u00a0estudia\u00a0la\u00a0eficacia\u00a0de\u00a0la\u00a0\ncombinaci\u00f3n \u00a0ddI+3TC\u00a0en\u00a0pauta\u00a0QD.\u00a0En\u00a0este\u00a0ensayo\u00a0se\u00a0compararon \u00a0ddI\u00a0(400\u00a0mg\u00a0QD\u00a0o\u00a0\n250\u00a0mg\u00a0si\u00a0peso\u00a0<60\u00a0Kg,\u00a0tomado\u00a0con\u00a0o\u00a0sin\u00a0comida)\u00a0+\u00a03TC\u00a0(300\u00a0mg\u00a0QD)\u00a0frente\n\u00a0a\u00a0ZDV/3TC\u00a0\n(coformulados, \u00a0300/150mg \u00a0BID)\u00a0en\u00a0369\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo.\u00a0Todos\u00a0los\u00a0pacientes \u00a0\nrecibieron \u00a0adem\u00e1s\u00a0EFV\u00a0600\u00a0mg\u00a0QD.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP\u00a0<50\u00a0copias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar)\u00a0fue\u00a070%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ddI+3TC\u00a0y\u00a0\n63%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ZDV+3TC\u00a0(diferencia \u00a07,1%;\u00a0IC\u00a095%,\u00a02,39\u00a0a\u00a016,59%,\u00a0p=0,154). \u00a0El\u00a0\nestudio\u00a0demostr\u00f3 \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ddI+3TC\u00a0frente\u00a0a\u00a0ZDV+3TC. \u00a0La\u00a0discontinuaci\u00f3n \u00a0\ndel\u00a0tratamiento \u00a0\u00a0por\u00a0efectos\u00a0adversos\u00a0fue\u00a0menor\u00a0el\u00a0grupo\u00a0de\u00a0ddI+3TC\u00a0(14,\u00a08%\u00a0frente\u00a0a\u00a0\n26%,\u00a0p=0,046), \u00a0as\u00ed\u00a0como\u00a0la\u00a0toxicidad\u00a0hematol\u00f3gica \u00a0y\u00a0la\u00a0anemia\u00a0(1%\u00a0y\u00a06%;\u00a0p=0,003). \u00a0No\u00a0\nhubo\u00a0diferencias \u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0recuperaci\u00f3n \u00a0inmunol\u00f3gica, \u00a0ni\u00a0en\u00a0la\u00a0prevalencia \u00a0de\u00a0\nlipoatrofia \u00a0y/o\u00a0lipoacumulaci\u00f3n, \u00a0valorada\u00a0por\u00a0criterio\u00a0del\u00a0investigador221.\u00a0\u00a0\n\u00a0\nACTG\u2010384\u00a0\nEl\u00a0ACTG\u2010384\u00a0es\u00a0un\u00a0estudio\u00a0que\u00a0valora\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0las\u00a0distintas\u00a0\ncombinaciones \u00a0de\u00a0AN\u00a0cuando\u00a0se\u00a0asocian\u00a0a\u00a0un\u00a0tercer\u00a0f\u00e1rmaco\u00a0(NN\u00a0o\u00a0IP).\u00a0Este\u00a0ensayo\u00a0\ncl\u00ednico\u00a0aleatorizado \u00a0se\u00a0plantea\u00a0responder \u00a0a\u00a0tres\u00a0preguntas: \u00a01\u00ba)\u00a0\u00bfes\u00a0mejor\u00a0empezar\u00a0con\u00a0\nddI+d4T\u00a0o\u00a0ZDV+3TC\u00a0como\u00a0combinaci\u00f3n \u00a0de\u00a0AN?;\u00a02\u00ba)\u00a0\u00bfEs\u00a0mejor\u00a0empezar\u00a0con\u00a0un\u00a0IP\u00a0(NFV)\u00a0\no\u00a0un\u00a0NN\u00a0(EFV)?,\u00a03\u00ba)\u00a0\u00bfEs\u00a0mejor\u00a0utilizar\u00a0combinaciones \u00a0secuenciales \u00a0de\u00a0tres\u00a0FAR\u00a0o\u00a0una\u00a0\ncombinaci\u00f3n \u00a0de\u00a0cuatro?\u00a0Se\u00a0incluyeron \u00a0980\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo\u00a0con\u00a0una\u00a0mediana\u00a0\nde\u00a0linfocitos\u00a0CD4\u00a0de\u00a0278\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0una\u00a0CVP\u00a0basal\u00a0de\u00a04,9\u00a0log10\u00a0copias/mL. \u00a0Los\u00a0brazos\u00a0\ndel\u00a0estudio\u00a0fueron:\u00a01\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0EFV\u00a0\u2192\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0NFV;\u00a02\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0NFV\u00a0\u2192\u00a0ZDV\u00a0\n+\u00a03TC\u00a0+\u00a0EFV;\u00a0\u00a03\u00ba)\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0\u2192\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0NFV;\u00a04\u00ba)\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0NFV\u00a0\u2192\u00a0d4T\u00a0+\u00a0ddI\u00a0\n+\u00a0EFV;\u00a05\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0EFV\u00a0+\u00a0NFV;\u00a06\u00ba)\u00a0ZDV\u00a0+3TC\u00a0+\u00a0EFV\u00a0+\u00a0NFV.\u00a0El\u00a0punto\u00a0de\u00a0valoraci\u00f3n \u00a0\nfinal\u00a0primario\u00a0fue\u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0de\u00a0dos\u00a0reg\u00edmenes \u00a0secuenciales \u00a0de\u00a0tres\u00a0FAR\u00a0\no\u00a0el\u00a0primer\u00a0fracaso\u00a0de\u00a0reg\u00edmenes \u00a0de\u00a04.\u00a0La\u00a0mediana\u00a0de\u00a0seguimiento \u00a0fue\u00a0de\u00a02,3\u00a0a\u00f1os.\u00a0\u00a0\nDesafortunadamente \u00a0el\u00a0dise\u00f1o\u00a0factorial\u00a0fue\u00a0frustrado \u00a0por\u00a0el\u00a0hecho\u00a0\u00a0de\u00a0que\u00a0las\u00a0\ncombinaciones \u00a0de\u00a0AN\u00a0no\u00a0fueron\u00a0independientes \u00a0del\u00a0efecto\u00a0del\u00a0tercer\u00a0f\u00e1rmaco.\u00a0La\u00a0\nactividad\u00a0de\u00a0EFV\u00a0fue\u00a0diferente \u00a0cuando\u00a0se\u00a0combin\u00f3\u00a0con\u00a0ZDV\u00a0+\u00a03TC\u00a0que\u00a0con\u00a0ddI\u00a0+\u00a0d4T,\u00a0y\u00a0\nla\u00a0actividad\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0ZDV\u00a0+\u00a03TC\u00a0vari\u00f3\u00a0dependiendo \u00a0si\u00a0se\u00a0combinaba \u00a0\ninicialmente \u00a0con\u00a0EFV\u00a0o\u00a0NFV.\u00a0Por\u00a0estas\u00a0razones\u00a0el\u00a0an\u00e1lisis\u00a0factorial\u00a0no\u00a0se\u00a0pudo\u00a0realizar.\u00a0\nSin\u00a0embargo, \u00a0de\u00a0los\u00a0datos\u00a0de\u00a0este\u00a0estudio\u00a0se\u00a0pueden\u00a0hacer\u00a0varias\u00a0observaciones: \u00a01\u00ba)\u00a0\nEn\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0primer\u00a0fracaso\u00a0virol\u00f3gico, \u00a0es\u00a0significativamente \u00a0\nmejor\u00a0iniciar\u00a0la\u00a0terapia\u00a0con\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0que\u00a0con\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0EFV\u00a0o\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0\nNFV.\u00a02\u00ba)\u00a0Si\u00a0la\u00a0terapia\u00a0se\u00a0inicia\u00a0con\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV,\u00a0no\u00a0existe\u00a0beneficio \u00a0significativo \u00a0al\u00a0\na\u00f1adir\u00a0NFV\u00a0como\u00a0cuarto\u00a0f\u00e1rmaco;\u00a03\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0producen \u00a0m\u00e1s\u00a0efectos\u00a0t\u00f3xicos\u00a0que\u00a0ZDV\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 23+\u00a03TC.\u00a0Los\u00a0resultados \u00a0de\u00a0este\u00a0estudio\u00a0avalar\u00edan\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0\ncomo\u00a0terapia\u00a0de\u00a0inicio222,\u00a0223.\u00a0\n\u00a0ACTG\u00a05175\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ZDV+\u00a03TC\u00a0+\u00a0EFV\u00a0se\u00a0ha\u00a0comparado \u00a0con\u00a0TDF\u00a0+\u00a0FTC\u00a0+\u00a0EFV\u00a0y\u00a0con\u00a0ddI\u00a0+\u00a0FTC\u00a0\n+\u00a0ATV\u00a0(sin\u00a0potenciar \u00a0con\u00a0ritonavir) \u00a0en\u00a01571\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0en\u00a0el\u00a0\nensayo\u00a0cl\u00ednico\u00a0ACTG\u00a05175\n224.\u00a0Despu\u00e9s\u00a0de\u00a0una\u00a0mediana\u00a0de\u00a0seguimiento \u00a0de\u00a072\u00a0semanas, \u00a0\nel\u00a0comit\u00e9\u00a0de\u00a0control\u00a0y\u00a0seguridad \u00a0del\u00a0estudio\u00a0decidi\u00f3\u00a0suspender \u00a0el\u00a0grupo\u00a0de\u00a0tratamiento \u00a0\ncon\u00a0ddI\u00a0+\u00a0FTC\u00a0+\u00a0ATV\u00a0debido\u00a0a\u00a0una\u00a0tasa\u00a0significativamente \u00a0mayor\u00a0de\u00a0fracaso\u00a0\nterap\u00e9utico. \u00a0\u00a0\n\u00a0\nHEAT\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ABC/3TC\u00a0se\u00a0ha\u00a0comparado \u00a0con\u00a0la\u00a0combinaci\u00f3n \u00a0TDF/FTC\u00a0en\u00a0688\u00a0\npacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0en\u00a0el\u00a0estudio\u00a0HEAT.\u00a0Todos\u00a0los\u00a0pacientes \u00a0recibieron \u00a0\nadem\u00e1s\u00a0LPV/r\u00a0c\u00e1psulas\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0Los\u00a0datos\u00a0disponibles \u00a0a\u00a048\u00a0y\u00a096\u00a0semanas225\u00a0\navalan\u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ABC/3TC\u00a0frente\u00a0a\u00a0TDF/FTC\u00a0cuando\u00a0se\u00a0administran \u00a0junto\u00a0a\u00a0\nLPV/r\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0Tras\u00a096\u00a0semanas\u00a0de\u00a0seguimiento \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP\u00a0<50\u00a0copias/mL \u00a0(intenci\u00f3n \u00a0de\u00a0tratar)\u00a0fue\u00a0del\u00a060%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ABC/3TC\u00a0y\u00a0del\u00a058%\u00a0\nen\u00a0el\u00a0grupo\u00a0de\u00a0TDF/FTC.\u00a0La\u00a0tasa\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0confirmado \u00a0fue\u00a0del\u00a012%\u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0ABC\u00a0y\u00a011%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF.\u00a0Tampoco \u00a0hubo\u00a0diferencias \u00a0significativas \u00a0en\u00a0el\u00a0\nsubgrupo \u00a0de\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0tratamiento \u00a0con\u00a0m\u00e1s\u00a0de\u00a0100.000\u00a0copias/mL \u00a0\naunque\u00a0el\u00a0estudio\u00a0no\u00a0tiene\u00a0poder\u00a0para\u00a0demostrar \u00a0la\u00a0no\u2010inferioridad \u00a0de\u00a0ABC/3TC\u00a0en\u00a0\npacientes \u00a0con\u00a0CVP\u00a0elevadas. \u00a0\n\u00a0ACTG\u00a05202\u00a0\nEl\u00a0estudio\u00a0ACTG\u00a05202\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0factorial\u00a0que\u00a0compara\u00a0ABC/3TC\u00a0y\u00a0TDF/FTC\u00a0\nen\u00a01857\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0detalles\u00a0de\u00a0este\u00a0estudio\u00a0en\u00a0el\u00a0\ncap\u00edtulo\u00a0de\u00a0EFV\u00a0frente\u00a0a\u00a0IP/r).\u00a0Los\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0adem\u00e1s\u00a0a\u00a0recibir\u00a0\nATV/r\u00a0\no\u00a0EFV.\u00a0En\u00a0el\u00a0subgrupo \u00a0de\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0el\u00a0TAR\u00a0con\u00a0una\u00a0CVP\u00a0>100000\u00a0\ncopias/mL \u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0m\u00e1s\u00a0corto\u00a0en\u00a0los\u00a0que\u00a0recibieron \u00a0\nABC/3TC\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0efectos\u00a0adversos\u00a0grado\u00a03\u20104\u00a0fue\u00a0mayor.\u00a0Despu\u00e9s\u00a0de\u00a0una\u00a0\nmediana\u00a0de\u00a0seguimiento \u00a0de\u00a060\u00a0semanas, \u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0fracaso\u00a0\nvirol\u00f3gico \u00a0fue\u00a0del\u00a014%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ABC/3TC\u00a0y\u00a0del\u00a07%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF/FTC\u00a0\n(P=0,0003). \u00a0Si\u00a0el\u00a0paciente\u00a0hab\u00eda\u00a0alcanzado \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0entonces\u00a0no\u00a0hubo\u00a0\ndiferencias \u00a0en\u00a0cuanto\u00a0a\u00a0fracaso\u00a0posterior\u00a0independientemente \u00a0de\u00a0la\u00a0pareja\u00a0de\u00a0\nnucle\u00f3sidos \u00a0recibida226.\u00a0Con\u00a0posterioridad \u00a0hemos\u00a0conocido\u00a0que\u00a0en\u00a0el\u00a0estrato\u00a0de\u00a0CVP\u00a0\n<100000\u00a0copias/mL, \u00a0no\u00a0hay\u00a0diferencias \u00a0entre\u00a0ambos\u00a0\u201ccombos\u201d \u00a0independientemente \u00a0\nde\u00a0que\u00a0se\u00a0administren \u00a0con\u00a0EFV\u00a0o\u00a0ATV/r227.\u00a0\n \nMetaan\u00e1lisis \u00a0que\u00a0compara\u00a0la\u00a0base\u00a0de\u00a0nucle\u00f3sidos \u00a0ABC+3TC\u00a0con\u00a0TDF+FTC\u00a0\nEn\u00a0un\u00a0reciente\u00a0metaan\u00e1lisis \u00a0se\u00a0analizaron \u00a0datos\u00a0de\u00a012\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0los\u00a0que\u00a0se\u00a0\nutilizaron \u00a0TDF/FTC\u00a0(3399)\u00a0o\u00a0ABC/3TC\u00a0(1769)\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0inhibidores \u00a0de\u00a0\nproteasa\u00a0potenciados \u00a0con\u00a0ritonavir.\u00a0En\u00a0los\u00a0ensayos\u00a0que\u00a0utilizaban \u00a0LPV/r,\u00a0ATV/r\u00a0y\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 24FAPV/r\u00a0como\u00a0tercer\u00a0f\u00e1rmaco,\u00a0la\u00a0tasa\u00a0de\u00a0respuesta \u00a0(por\u00a0ITT,\u00a0tiempo\u00a0hasta\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0\u00a0\nrespuesta \u00a0virol\u00f3gica, \u00a0ITT\u2010TOLVR),\u00a0fue\u00a0significativamente \u00a0inferior\u00a0para\u00a0ABC/3TC\u00a0que\u00a0\npara\u00a0TDF/FTC\u00a0(68,8%\u00a0frente\u00a0a\u00a076,1%,\u00a0P\u00a0=\u00a00,0015).\u00a0En\u00a0pacientes \u00a0con\u00a0carga\u00a0viral\u00a0basal\u00a0\ninferior\u00a0a\u00a0100.000\u00a0copias/mL \u00a0la\u00a0diferencia \u00a0fue\u00a0de\u00a070,1%\u00a0para\u00a0ABC/3TC\u00a0frente\u00a0a\u00a080,6%,\u00a0\npara\u00a0TDF/FTC\u00a0P\u00a0=\u00a00,0161),\u00a0mientras\u00a0que\u00a0en\u00a0los\u00a0que\u00a0ten\u00edan\u00a0una\u00a0carga\u00a0basal\u00a0superior\u00a0a\u00a0\n100.000\u00a0copias/mL, \u00a0la\u00a0diferencia \u00a0fue\u00a0borderline \u00a0(67,5%\u00a0frente\u00a0a\u00a071,5%,\u00a0P\u00a0=\u00a00,0523)228.\u00a0\u00a0\n\u00a0\nEstudio\u00a0ASSERT\u00a0\nEl\u00a0estudio\u00a0ASSERT\u00a0es\u00a0un\u00a0estudio\u00a0multic\u00e9ntrico, \u00a0abierto,\u00a0que\u00a0compar\u00f3\u00a0los\u00a0perfiles\u00a0de\u00a0\nseguridad \u00a0de\u00a0TDF/FTC\u00a0y\u00a0ABC/3TC, \u00a0ambos\u00a0administrados \u00a0con\u00a0EFV\u00a0en\u00a0pacientes \u00a0HLA\u2010\nB*5701\u00a0negativos. \u00a0Los\u00a0cambios\u00a0de\u00a0filtrado\u00a0glomerular \u00a0fueron\u00a0similares\u00a0en\u00a0ambas\u00a0\nramas,\u00a0mientras\u00a0que\u00a0la\u00a0excreci\u00f3n \u00a0urinaria\u00a0de\u00a0beta\u20102\u2010microglobulina \u00a0y\u00a0de\u00a0prote\u00edna\u00a0que\u00a0\nse\u00a0une\u00a0al\u00a0retinol\u00a0fue\u00a0significativamente \u00a0mayor\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC.\u00a0Una\u00a0mayor\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0recib\u00edan\u00a0TDF/FTC\u00a0(71%)\u00a0comparado \u00a0con\u00a0los\u00a0que\u00a0recib\u00edan\u00a0\nABC/3TC\u00a0(59%)\u00a0alcanzaron \u00a0una\u00a0carga\u00a0viral\u00a0<50\u00a0copias/mL \u00a0(diferencia \u00a011,6%;\u00a0IC\u00a095%,\u00a02,2\u00a0\na\u00a021,1)229.\u00a0\n\u00a0Cohortes\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0AN\u00a0\u00a0\nD.A.D.\u00a0\nEn\u00a0la\u00a0cohorte\u00a0D.A.D.\u00a0se\u00a0ha\u00a0comunicado \u00a0que\u00a0el\u00a0uso\u00a0reciente\u00a0(pero\u00a0no\u00a0el\u00a0acumulado) \u00a0de\u00a0\nABC\u00a0(definido\u00a0como\u00a0estar\u00a0recibi\u00e9ndolo \u00a0en\u00a0el\u00a0momento \u00a0actual\u00a0o\u00a0haberlo\u00a0suspendido \u00a0\ndurante\u00a0los\u00a0\u00faltimos\u00a06\u00a0meses)\u00a0se\u00a0asoci\u00f3\u00a0con\u00a0un\u00a0incremento \u00a0de\u00a01,9\n\u00a0veces\u00a0en\u00a0el\u00a0riesgo\u00a0de\u00a0\npadecer\u00a0un\u00a0infarto\u00a0de\u00a0miocardio \u00a0(comparado \u00a0con\u00a0los\u00a0pacientes \u00a0que\u00a0no\u00a0han\u00a0utilizado\u00a0\nrecientemente \u00a0ABC).\u00a0Esta\u00a0asociaci\u00f3n \u00a0persist\u00eda\u00a0despu\u00e9s\u00a0del\u00a0ajuste\u00a0por\u00a0otros\u00a0factores\u00a0de\u00a0\nriesgo.\u00a0El\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio \u00a0no\u00a0aument\u00f3\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0\nrecibido\u00a0ABC\u00a0hac\u00eda\u00a0m\u00e1s\u00a0de\u00a06\u00a0meses.\u00a0El\u00a0aumento\u00a0del\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio \u00a0fue\u00a0\nm\u00e1s\u00a0relevante \u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0cl\u00ednico\u00a0en\u00a0aquellos\u00a0pacientes \u00a0que\u00a0ya\u00a0tienen\u00a0un\u00a0\nriesgo\u00a0cardiovascular \u00a0alto\u00a0seg\u00fan\u00a0la\u00a0ecuaci\u00f3n\u00a0de\u00a0Framingham. \u00a0En\u00a0este\u00a0estudio\u00a0tambi\u00e9n\u00a0\nse\u00a0encontr\u00f3\u00a0un\u00a0incremento \u00a0significativo \u00a0del\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio \u00a0asociado\u00a0al\u00a0\nuso\u00a0reciente\u00a0de\u00a0ddI\u00a0si\u00a0bien\u00a0la\u00a0magnitud \u00a0de\u00a0la\u00a0asociaci\u00f3n \u00a0fue\u00a0menor230.\u00a0\u00a0\n\u00a0\nSMART\u00a0\nEl\u00a0estudio\u00a0SMART,\u00a0que\u00a0tambi\u00e9n\u00a0ha\u00a0evaluado\u00a0la\u00a0asociaci\u00f3n \u00a0entre\u00a0uso\u00a0de\u00a0ABC\u00a0y\u00a0riesgo\u00a0de\u00a0\nenfermedad \u00a0cardiovascular \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0pacientes \u00a0aleatorizados \u00a0a\u00a0continuar \u00a0la\u00a0\nterapia\u00a0antirretroviral \u00a0se\u00a0ha\u00a0observado \u00a0una\u00a0asociaci\u00f3n \u00a0significativa \u00a0entre\u00a0estar\u00a0\nrecibiendo \u00a0ABC\u00a0y\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0de\u00a0padecer\u00a0infarto\u00a0de\u00a0miocardio \u00a0(HR\u00a04,3),\u00a0\nsiendo\u00a0m\u00e1s\u00a0evidente\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0ya\u00a0ten\u00edan\u00a0m\u00faltiples \u00a0factores\u00a0de\u00a0riesgo\u00a0o\u00a0con\u00a0\nalteraciones \u00a0electrocardiogr\u00e1ficas \u00a0en\u00a0el\u00a0momento \u00a0basal231.\u00a0\u00a0\n\u00a0\nOtras\u00a0Cohortes\u00a0\nEn\u00a0una\u00a0revisi\u00f3n\u00a0de\u00a0m\u00faltiples \u00a0ensayos\u00a0de\u00a0ABC\u00a0(9639\u00a0pacientes,7485 \u00a0personas\u2010a\u00f1o\u00a0de\u00a0\nseguimiento) \u00a0no\u00a0se\u00a0ha\u00a0encontrado \u00a0una\u00a0asociaci\u00f3n \u00a0entre\u00a0uso\u00a0de\u00a0este\u00a0AN\u00a0y\u00a0riesgo\u00a0de\u00a0\ninfarto\u00a0de\u00a0miocardio232.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 25\u00a0\nResumen \u00a0de\u00a0los\u00a0datos\u00a0de\u00a0ensayos\u00a0y\u00a0cohortes\u00a0\nLa\u00a0pauta\u00a0TDF+FTC\u00a0es\u00a0m\u00e1s\u00a0eficaz\u00a0y\u00a0tiene\u00a0menos\u00a0riesgo\u00a0de\u00a0lipoatrofia \u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0\nZDV+3TC. \u00a0La\u00a0combinaci\u00f3n \u00a0ABC+3TC\u00a0tiene\u00a0una\u00a0eficacia\u00a0similar\u00a0a\u00a0ZDV+3TC\u00a0con\u00a0menor\u00a0\nriesgo\u00a0de\u00a0lipoatrofia \u00a0y\u00a0ha\u00a0demostrado \u00a0la\u00a0no\u00a0inferioridad \u00a0frente\u00a0a\u00a0la\u00a0pauta\u00a0TDF+3TC\u00a0\ncuando\u00a0ambas\u00a0se\u00a0administran \u00a0con\u00a0LPV/r.\u00a0Es\u00a0posible\u00a0que\u00a0el\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nsea\u00a0mayor\u00a0con\u00a0la\u00a0pauta\u00a0ABC+3TC\u00a0que\u00a0con\u00a0la\u00a0pauta\u00a0TDF+3TC\u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0\nelevadas\u00a0cuando\u00a0ABC+3TC\u00a0se\u00a0administra \u00a0con\u00a0efavirenz\u00a0o\u00a0ATV/r.\u00a0No\u00a0se\u00a0han\u00a0realizado\u00a0\ngrandes\u00a0estudios\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0TDF+3TC\u00a0con\u00a0un\u00a0IP\u00a0como\u00a0tratamiento \u00a0inicial,\u00a0pero\u00a0\ns\u00ed\u00a0de\u00a0TDF+FTC\u00a0(con\u00a0ATV/r,\u00a0FPV/r,\u00a0LPV/r,\u00a0DRV/r\u00a0y\u00a0SQV/r).\u00a0No\u00a0existe\u00a0experiencia \u00a0de\u00a0\nensayos\u00a0cl\u00ednicos\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0ABC+3TC\u00a0con\u00a0NVP,\u00a0pero\u00a0s\u00ed\u00a0con\u00a0ATV/r,\u00a0LPV/r,\u00a0\nFPV/r233\u2010235.\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ddI+3TC\u00a0asociada\u00a0a\u00a0EFV\u00a0no\u00a0es\u00a0inferior\u00a0a\u00a0ZDV+3TC+ \u00a0EFV221.\u00a0No\u00a0hay\u00a0datos\u00a0\nsobre\u00a0el\u00a0riesgo\u00a0de\u00a0lipoatrofia \u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0ddI+3TC\u00a0medida\u00a0por\u00a0DEXA.\u00a0No\u00a0existe\u00a0\nexperiencia \u00a0de\u00a0las\u00a0combinaciones \u00a0ddI+FTC\u00a0con\u00a0NVP\u00a0ni\u00a0con\u00a0IP.\u00a0La\u00a0combinaci\u00f3n \u00a0d4T+3TC\u00a0\nha\u00a0demostrado \u00a0su\u00a0eficacia\u00a0en\u00a0m\u00faltiples \u00a0estudios,\u00a0pero\u00a0produce\u00a0m\u00e1s\u00a0alteraciones \u00a0del\u00a0\nmetabolismo \u00a0de\u00a0los\u00a0l\u00edpidos,\u00a0lipodistrofia \u00a0y\u00a0neuropat\u00eda \u00a0perif\u00e9rica \u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0\nTDF+3TC. \u00a0\u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0AN\u00a0\nCombinaciones \u00a0preferentes \u00a0\n\u0083 Las\u00a0combinaciones \u00a0de\u00a0AN\u00a0de\u00a0elecci\u00f3n\u00a0para\u00a0reg\u00edmenes \u00a0de\u00a0inicio\u00a0son\u00a0TDF/FTC\u00a0o\u00a0\nABC/3TC. \u00a0Se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0nucle\u00f3sidos \u00a0coformulados \u00a0\u00a0(nivel\u00a0A)\u00a0\n\u0083 ABC/3TC\u00a0tiene\u00a0mayor\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0que\u00a0TDF/FTC\u00a0cuando\u00a0se\u00a0\nadministra \u00a0combinado \u00a0con\u00a0EFV\u00a0(nivel\u00a0A)\u00a0\n\u0083 ABC+3TC\u00a0debe\u00a0ser\u00a0empleado \u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0elevadas\u00a0\n(>100.000 \u00a0copias/mL) \u00a0(nivel\u00a0A)\u00a0\nCombinaciones \u00a0alternativas \u00a0\n\u0083 Combinaciones \u00a0de\u00a0AN\u00a0alternativas \u00a0son\u00a0TDF+3TC, \u00a0ddI+3TC\u00a0(nivel\u00a0A)\u00a0y\u00a0ddI+FTC,\u00a0\naunque\u00a0de\u00a0esta\u00a0\u00faltima\u00a0s\u00f3lo\u00a0existen\u00a0datos\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico,\u00a0por\u00a0lo\u00a0que\u00a0su\u00a0perfil\u00a0\nde\u00a0seguridad \u00a0no\u00a0est\u00e1\u00a0firmemente \u00a0establecido \u00a0\n\u0083 Otras\u00a0combinaciones \u00a0alternativas \u00a0son\u00a0\u00a0ZDV/3TC\u00a0y\u00a0ZDV+ddI\u00a0214,\u00a0216\u00a0\nCombinaciones \u00a0no\u00a0recomendadas \u00a0\n\u0083 No\u00a0se\u00a0recomiendan \u00a0las\u00a0combinaciones \u00a0d4T+ddI\u00a0por\u00a0toxicidad, \u00a0TDF+ddI\u00a0por\u00a0\ntoxicidad\u00a0y\u00a0menor\u00a0eficacia236\u2010240,\u00a0ZDV+d4T\u00a0por\u00a0antagonismo, \u00a0FTC+3TC\u00a0por\u00a0similar\u00a0\nperfil\u00a0de\u00a0resistencias \u00a0y\u00a0pocos\u00a0beneficios \u00a0cl\u00ednicos\u00a0(Tabla\u00a04)\u00a0\n\u00a0\nEn\u00a0resumen, \u00a0la\u00a0elecci\u00f3n\u00a0final\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0AN\u00a0deber\u00e1\u00a0individualizarse \u00a0teniendo\u00a0\nen\u00a0cuenta\u00a0las\u00a0caracter\u00edsticas \u00a0del\u00a0f\u00e1rmaco,\u00a0la\u00a0situaci\u00f3n\u00a0cl\u00ednica\u00a0y\u00a0preferencias \u00a0del\u00a0\npaciente. \u00a0Las\u00a0pautas\u00a0sencillas\u00a0facilitan\u00a0la\u00a0adherencia. \u00a0Estas\u00a0incluyen\u00a0FAR\u00a0que\u00a0se\u00a0\nadministran \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0(ABC,\u00a0ddI,\u00a0FTC,\u00a03TC\u00a0y\u00a0TDF)\u00a0con\u00a0especial\u00a0preferencia \u00a0por\u00a0las\u00a0\ncoformuladas \u00a0en\u00a0dosis\u00a0fijas\u00a0(TDF/FTC\u00a0o\u00a0ABC/3TC). \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 26\u00a0\nCombinaciones \u00a0de\u00a0TAR\u00a0con\u00a0tres\u00a0AN\u00a0\nLas\u00a0combinaciones \u00a0de\u00a03\u00a0AN\u00a0han\u00a0demostrado \u00a0eficacia\u00a0virol\u00f3gica \u00a0e\u00a0inmunol\u00f3gica \u00a0en\u00a0\nvarios\u00a0estudios.\u00a0\nExiste\u00a0una\u00a0coformulaci\u00f3n \u00a0con\u00a0la\u00a0asociaci\u00f3n \u00a0ZDV+3TC+ABC \u00a0que\u00a0permite\u00a0su\u00a0\nadministraci\u00f3n \u00a0en\u00a0forma\u00a0de\u00a0un\u00a0comprimido \u00a0BID,\u00a0pauta\u00a0atractiva\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0\nvista\u00a0de\u00a0la\u00a0adherencia. \u00a0Otros\u00a0estudios\u00a0comparan \u00a0esta\u00a0combinaci\u00f3n \u00a0con\u00a0pautas\u00a0que\u00a0\ncontienen \u00a0\u00a0IP\u00a0o\u00a0NN.\u00a0\n\u00a0Ensayos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0tres\u00a0AN\u00a0\nACTG\u00a0A5095\u00a0\nEl\u00a0ACTG\u00a0A5095\u00a0es\u00a0un\u00a0estudio\u00a0aleatorizado \u00a0y\u00a0controlado \u00a0con\u00a0placebo\u00a0que\u00a0eval\u00faa\u00a0la\u00a0\neficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0tres\u00a0reg\u00edmenes: \u00a01\u00ba)\u00a0ZDV/3TC/ABC \u00a0(Trizivir\u00ae); \u00a02\u00ba)\u00a0ZDV/3TC+EFV; \u00a0\ny\u00a03\u00ba)\u00a0ZDV/3TC/ABC+EFV \u00a0en\u00a0pacientes\n\u00a0sin\u00a0terapia\u00a0previa.\u00a0Se\u00a0incluyeron \u00a01.147\u00a0pacientes \u00a0\ncon\u00a0una\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0238\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0de\u00a071434\u00a0copias/mL. \u00a0Tras\u00a0una\u00a0\nmediana\u00a0de\u00a0seguimiento \u00a0de\u00a032\u00a0semanas, \u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0ZDV/3TC/ABC \u00a0\ntuvieron\u00a0mayor\u00a0fracaso\u00a0virol\u00f3gico \u00a0(21%\u00a0frente\u00a0al\u00a011%\u00a0en\u00a0los\u00a0otros\u00a0grupos)\u00a0y\u00a0en\u00a0un\u00a0\ntiempo\u00a0m\u00e1s\u00a0corto\u00a0(p<0,001), \u00a0independientemente \u00a0del\u00a0nivel\u00a0de\u00a0CVP.\u00a0Dado\u00a0que\u00a0a\u00a0las\u00a048\u00a0\nsemanas\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<200\u00a0copias/mL \u00a0era\u00a0del\u00a074%\u00a0en\u00a0el\u00a0grupo\u00a0\ncon\u00a03\u00a0AN\u00a0y\u00a089%\u00a0en\u00a0los\u00a0otros\u00a0dos\u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar)\u00a0el\u00a0comit\u00e9\u00a0de\u00a0\nseguridad \u00a0recomend\u00f3 \u00a0que\u00a0el\u00a0grupo\u00a0de\u00a0ZDV/3TC/ABC \u00a0se\u00a0interrumpiese, \u00a0continuando \u00a0el\u00a0\nestudio\u00a0de\u00a0forma\u00a0ciega\u00a0con\u00a0los\u00a0pacientes \u00a0en\u00a0los\u00a0brazos\u00a0que\u00a0conten\u00edan \u00a0EFV241.\u00a0Estos\u00a0\nresultados \u00a0han\u00a0hecho\u00a0que\u00a0se\u00a0replantee \u00a0el\u00a0papel\u00a0del\u00a0ZDV/3TC/ABC \u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0\ninicio\u00a0y\u00a0se\u00a0considere \u00a0una\u00a0alternativa \u00a0a\u00a0otras\u00a0opciones\u00a0m\u00e1s\u00a0eficaces.\u00a0\u00a0\nA\u00a0los\u00a0tres\u00a0a\u00f1os\u00a0de\u00a0seguimiento, \u00a0la\u00a0pauta\u00a0ZDV/3TC/ABC+EFV \u00a0no\u00a0demostr\u00f3 \u00a0ser\u00a0superior\u00a0a\u00a0\nla\u00a0pauta\u00a0ZDV/3TC+EFV. \u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<200\u00a0y\u00a0<50\u00a0copias/mL \u00a0en\u00a0\nlas\u00a0dos\u00a0ramas\u00a0del\u00a0estudio\u00a0fue\u00a090%\u00a0y\u00a092%\u00a0(p=0,59)\u00a0y\u00a085%\u00a0y\u00a088%\u00a0(p=0,39)\u00a0\nrespectivamente. \u00a0El\u00a0ensayo\u00a0A5095\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0adici\u00f3n\u00a0de\u00a0un\u00a0tercer\u00a0AN\u00a0a\u00a0un\u00a0\nr\u00e9gimen\u00a0que\u00a0incluya\u00a02\u00a0AN\u00a0y\u00a0EFV\u00a0no\u00a0incrementa \u00a0la\u00a0respuesta \u00a0virol\u00f3gica242.\u00a0\u00a0\n\u00a0\nCNA3005 \u00a0\nEl\u00a0CNA3005 \u00a0es\u00a0un\u00a0estudio\u00a0controlado \u00a0con\u00a0placebo,\u00a0doble\u00a0ciego\u00a0y\u00a0de\u00a0equivalencia \u00a0que\u00a0\ncompar\u00f3\u00a0ZDV/3TC+ABC \u00a0\u00a0frente\u00a0a\u00a0ZDV/3TC+IDV. \u00a0La\u00a0principal\u00a0conclusi\u00f3n \u00a0fue\u00a0que\u00a0ambos\u00a0\nreg\u00edmenes \u00a0eran\u00a0equivalentes \u00a0para\u00a0alcanzar\u00a0CVP\u00a0<400\u00a0copias/mL, \u00a0pero\u00a0en\u00a0los\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0>100.000 \u00a0copias/mL, \u00a0el\u00a0r\u00e9gimen\u00a0con\u00a0ABC\u00a0era\u00a0inferior\u00a0al\u00a0de\u00a0IDV\u00a0para\u00a0conseguir \u00a0\nCVP\u00a0inferior\u00a0a\u00a050\u00a0copias/mL243.\u00a0\u00a0\n\u00a0\nCLASS\u00a0\nEl\u00a0estudio\u00a0CLASS\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0virol\u00f3gica \u00a0de\u00a0una\u00a0pauta\u00a0basada\u00a0en\u00a0NN\u00a0(EFV),\u00a0\nfrente\u00a0a\u00a0un\u00a0IP/r\u00a0(APV/r)\u00a0o\u00a0una\u00a0pauta\u00a0con\u00a0tres\u00a0AN\u00a0(d4T),\u00a0todos\u00a0ellos\u00a0combinados \u00a0con\u00a0\nABC\u00a0y\u00a03TC.\u00a0Los\u00a0datos\u00a0preliminares \u00a0de\u00a0la\u00a0semana\u00a048\u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0\ntratamiento) \u00a0mostraron \u00a0la\u00a0superioridad \u00a0de\u00a0la\u00a0pauta\u00a0de\u00a0EFV\u00a0frente\u00a0a\u00a0las\u00a0otras\u00a0(pacientes \u00a0\ncon\u00a0CVP\u00a0<50\u00a0copias/mL \u00a076%,\u00a059%\u00a0y\u00a062%,\u00a0respectivamente)244.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 27\u00a0\nESS30009 \u00a0\nEl\u00a0estudio\u00a0ESS30009 \u00a0compar\u00f3\u00a0la\u00a0administraci\u00f3n \u00a0QD\u00a0de\u00a03\u00a0AN\u00a0(TDF+3TC+ABC) \u00a0frente\u00a0a\u00a0la\u00a0\ncombinaci\u00f3n \u00a0de\u00a0ABC+3TC+EFV. \u00a0Se\u00a0observ\u00f3\u00a0una\u00a0falta\u00a0de\u00a0respuesta \u00a0virol\u00f3gica \u00a0temprana \u00a0\n(descenso \u00a0de\u00a0CVP\u00a0\u22652\u00a0log10\u00a0en\u00a0la\u00a0semana\u00a08\u00a0o\u00a0incremento \u00a0de\u00a01\u00a0log10\u00a0sobre\u00a0el\u00a0nadir\u00a0\nalcanzado) \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0pacientes \u00a0con\u00a03\u00a0AN.\u00a0Entre\u00a0los\u00a0pacientes \u00a0que\u00a0llegaron\u00a0a\u00a0la\u00a0\nsemana\u00a012,\u00a0se\u00a0consider\u00f3 \u00a0no\u00a0respondedores \u00a0al\u00a049%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a03\u00a0AN\u00a0y\u00a05%\u00a0en\u00a0el\u00a0\ngrupo\u00a0con\u00a0EFV\u00a0(p<0,001). \u00a0El\u00a0an\u00e1lisis\u00a0genot\u00edpico \u00a0de\u00a0los\u00a014\u00a0aislados\u00a0de\u00a0los\u00a0no\u2010\nrespondedores \u00a0(brazo\u00a0con\u00a03\u00a0AN)\u00a0mostraron \u00a0la\u00a0mutaci\u00f3n \u00a0M184V\u00a0y\u00a08\u00a0de\u00a0ellos\u00a0ten\u00edan\u00a0la\u00a0\nK65R,\u00a0que\u00a0puede\u00a0reducir\u00a0la\u00a0susceptibilidad \u00a0a\u00a0TDF\u00a0y\u00a0ABC245.\u00a0\n\u00a0Otros\u00a0\nEn\u00a0un\u00a0estudio\u00a0piloto\u00a0con\u00a0ddI+3TC+TDF, \u00a0el\u00a091%\u00a0de\u00a0los\u00a0pacientes \u00a0tuvieron\u00a0un\u00a0fracaso\u00a0\nvirol\u00f3gico \u00a0(descenso \u00a0de\u00a0la\u00a0CVP\u00a0\u22642\u00a0log\n10\u00a0en\u00a0la\u00a0semana\u00a012).\u00a0La\u00a0mutaci\u00f3n \u00a0M184I/V\u00a0se\u00a0\ndetect\u00f3\u00a0en\u00a0el\u00a095%\u00a0de\u00a0los\u00a0pacientes \u00a0y\u00a0el\u00a050%\u00a0ten\u00edan\u00a0tambi\u00e9n\u00a0la\u00a0K65R.\u00a0\u00a0\nEn\u00a0otro\u00a0estudio\u00a0se\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0d4T+ddI+ABC \u00a0frente\u00a0a\u00a0SQV+RTV \u00a0\n(400/400mg \u00a0BID)+ZDV+3TC \u00a0frente\u00a0a\u00a0NFV+NVP+ZDV+3TC. \u00a0Se\u00a0incluyeron \u00a0180\u00a0pacientes, \u00a0\ncon\u00a0una\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0161\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0de\u00a05\u00a0log10.\u00a0A\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<20\u00a0copias/mL \u00a0fue\u00a0inferior\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0tres\u00a0AN\u00a0\n(43%,\u00a062%\u00a0y\u00a069%,\u00a0respectivamente), \u00a0los\u00a0efectos\u00a0secundarios \u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0\neste\u00a0grupo246.\u00a0\u00a0\nAdem\u00e1s,\u00a0en\u00a0un\u00a0estudio\u00a0multic\u00e9ntrico \u00a0espa\u00f1ol\u00a0no\u00a0comparativo \u00a0en\u00a0el\u00a0que\u00a0se\u00a0inici\u00f3\u00a0TAR\u00a0a\u00a0\npacientes \u00a0con\u00a04\u00a0AN\u00a0(Trizivir\u00ae+TDF)\u00a0y\u00a0seguido\u00a0hasta\u00a0la\u00a0semana\u00a096,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0era\u00a0del\u00a063%\u00a0(ITT)\u00a0y\u00a087%\u00a0(OT).\u00a0Los\u00a0resultados \u00a0fueron\u00a0\nmejores\u00a0si\u00a0la\u00a0CVP\u00a0era\u00a0<5\u00a0log10\u00a0o\u00a0los\u00a0CD4\u00a0>250\u00a0c\u00e9lulas/\u00b5L247.\u00a0\nEl\u00a0estudio\u00a0TIMS\u00a0compar\u00f3\u00a0en\u00a0113\u00a0pacientes \u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a04\u00a0AN\u00a0(Trizivir\u00ae+TDF)\u00a0\nfrente\u00a0a\u00a0ZDV+3TC+EFV. \u00a0Tras\u00a048\u00a0semanas\u00a0de\u00a0seguimiento \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0era\u00a0del\u00a067%\u00a0(ITT)\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a04\u00a0AN\u00a0y\u00a0del\u00a067%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\nZDV+\u00a03TC\u00a0+\u00a0EFV248.\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0combinaciones \u00a0de\u00a03\u00a0AN\u00a0\n\u0083 Un\u00a0r\u00e9gimen\u00a0con\u00a0ZDV/3TC/ABC \u00a0con\u00a0o\u00a0sin\u00a0TDF\u00a0deber\u00eda\u00a0ser\u00a0usado\u00a0solamente \u00a0cuando\u00a0\nno\u00a0pueda\u00a0usarse\u00a0otra\u00a0pauta\u00a0m\u00e1s\u00a0potente\u00a0(nivel\u00a0A)\u00a0\u00a0\n\u0083 No\u00a0se\u00a0recomienda \u00a0utilizar\u00a0d4T+ddI+ABC \u00a0(nivel\u00a0A).\u00a0El\u00a0comit\u00e9\u00a0recomienda \u00a0no\u00a0utilizar\u00a0\nen\u00a0ning\u00fan\u00a0momento \u00a0pautas\u00a0con\u00a03\u00a0AN\u00a0con\u00a0ABC/3TC+TDF \u00a0o\u00a0ddI+3TC+TDF \u00a0(nivel\u00a0A)\u00a0\n\u0083 No\u00a0deben\u00a0usarse\u00a0otras\u00a0combinaciones \u00a0de\u00a03\u00a0AN\u00a0en\u00a0una\u00a0pauta\u00a0de\u00a0TAR\u00a0porque\u00a0no\u00a0\nexiste\u00a0experiencia \u00a0\n\u00a0\n4.4.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0(NN)\u00a0\u00a0\nEn\u00a0Espa\u00f1a\u00a0hay\u00a03\u00a0NN\u00a0comercializados: \u00a0nevirapina, \u00a0efavirenz\u00a0y\u00a0etravirina. \u00a0Sus\u00a0principales \u00a0\ncaracter\u00edsticas \u00a0se\u00a0describen \u00a0en\u00a0la\u00a0Tabla\u00a06211,\u00a0212.\u00a0Son\u00a0inductores \u00a0de\u00a0algunos\u00a0isoenzimas \u00a0\ndel\u00a0citocromo \u00a0P450\u00a0pudiendo \u00a0interaccionar \u00a0con\u00a0otros\u00a0f\u00e1rmacos. \u00a0EFV\u00a0se\u00a0administra \u00a0en\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 28pauta\u00a0QD\u00a0(1\u00a0comprimido \u00a0de\u00a0600\u00a0mg/d\u00eda)\u00a0y\u00a0NVP\u00a0se\u00a0puede\u00a0administra \u00a0tanto\u00a0en\u00a0pauta\u00a0\nBID\u00a0(200\u00a0mg/\u00a012\u00a0horas)\u00a0o\u00a0QD\u00a0(400\u00a0md/d);\u00a0durante\u00a0los\u00a0primeros\u00a014\u00a0d\u00edas\u00a0se\u00a0administra \u00a01\u00a0\ncomprimido \u00a0al\u00a0d\u00eda.\u00a0ETR\u00a0se\u00a0administra \u00a0en\u00a0BID\u00a0(200\u00a0mg/12\u00a0horas)\u00a0o\u00a0QD\u00a0(400\u00a0mg/24\u00a0\nhoras).\u00a0ETR\u00a0no\u00a0est\u00e1\u00a0aprobada \u00a0por\u00a0la\u00a0EMA\u00a0para\u00a0tratamiento \u00a0de\u00a0inicio.\u00a0\n\u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0NVP\u00a0\nPautas\u00a0con\u00a0NVP\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a0IP\u00a0\nCombine\u00a0\nEn\u00a0el\u00a0ensayo\u00a0Combine\u00a0se\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0de\u00a0NVP\u00a0frente\u00a0a\u00a0NFV249.\u00a0Es\u00a0de\u00a0destacar\u00a0\nque\u00a0el\u00a0ensayo\u00a0no\u00a0ten\u00eda\u00a0suficiente \u00a0poder\u00a0estad\u00edstico \u00a0para\u00a0evaluar\u00a0la\u00a0equivalencia \u00a0entre\u00a0\nambas\u00a0pautas.\u00a0El\u00a0n\u00famero\u00a0de\u00a0pacientes \u00a0incluidos\u00a0con\u00a0CVP\u00a0elevada\u00a0(>100000 \u00a0copias/mL) \u00a0\nfue\u00a0bajo\u00a0y\u00a0no\u00a0se\u00a0observaron \u00a0diferencias \u00a0entre\u00a0NVP\u00a0y\u00a0NFV.\u00a0En\u00a0una\u00a0recopilaci\u00f3n \u00a0de\u00a0\ndiversos\u00a0estudios\u00a0con\u00a0NVP\u00a0en\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo\u00a0el\u00a083%\u00a0de\u00a0los\u00a0que\u00a0ten\u00edan\u00a0CVP\u00a0\n>100000\u00a0copias/mL \u00a0ten\u00edan\u00a0CVP\u00a0indetectable \u00a0a\u00a0los\u00a06\u00a0meses250.\u00a0\n\u00a0\nARTEN\u00a0\nEn\u00a0el\u00a0ensayo\u00a0ARTEN\u00a0se\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0NVP\u00a0administrada \u00a0una\u00a0o\u00a0dos\u00a0\nveces\u00a0al\u00a0d\u00eda\u00a0frente\u00a0a\u00a0ATV/r,\u00a0ambos\u00a0combinados \u00a0con\u00a0TDF/FTC251.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0ensayo\u00a0\ncl\u00ednico\u00a0aleatorizado, \u00a0abierto\u00a0y\u00a0multic\u00e9ntrico \u00a0que\u00a0incluy\u00f3\u00a0569\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0\nprevio.\u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0se\u00a0defini\u00f3\u00a0por\u00a0la\u00a0presencia \u00a0de\u00a0CVP\u00a0detectable \u00a0(>50\u00a0\ncopias/mL) \u00a0a\u00a0las\u00a024\u00a0semanas\u00a0del\u00a0estudio\u00a0y\u00a0el\u00a0margen\u00a0de\u00a0no\u00a0inferioridad \u00a0se\u00a0estableci\u00f3 \u00a0\nen\u00a0\u201012%.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0carga\u00a0viral\u00a0basal\u00a0>100.000 \u00a0copias/mL \u00a0fue\u00a0\nsuperior\u00a0al\u00a060%\u00a0en\u00a0los\u00a0tres\u00a0grupos\u00a0de\u00a0tratamiento. \u00a0A\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0fue\u00a0del\u00a065%\u00a0y\u00a067%\u00a0para\u00a0NVP\u00a0y\u00a0ATV/r\u00a0respectivamente \u00a0\n(IC\u00a095%,\u00a0\u20105,9%\u00a0a\u00a09,8%;\u00a0p=0,63)\u00a0en\u00a0al\u00a0an\u00e1lisis\u00a0basado\u00a0en\u00a0el\u00a0objetivo\u00a0primario,\u00a0mientras\u00a0\nque\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0por\u00a0TLVOR\u00a0fue\u00a0del\u00a070%\u00a0y\u00a074%\u00a0respectivamente \u00a0(IC\u00a095%,\u00a0\u201010,4%\u00a0a\u00a0\n4,5%;\u00a0p=0,44)251.\u00a0En\u00a0pacientes \u00a0con\u00a0>100.000 \u00a0copias/mL \u00a0de\u00a0CVP\u00a0basal,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\nindetectabilidad \u00a0para\u00a0NVP\u00a0y\u00a0ATV/r\u00a0fueron\u00a0del\u00a060%\u00a0y\u00a052%,\u00a0respectivamente.  \n\u00a0\nOCTANE\u00a01\u00a0y\u00a02\u00a0\nLos\u00a0estudios\u00a0OCTANE\u00a0comparan \u00a0el\u00a0tratamiento \u00a0con\u00a0NVP\u00a0frente\u00a0a\u00a0LPV/r,\u00a0ambas\u00a0con\u00a0\nTDF/FTC,\u00a0en\u00a0mujeres\u00a0con\u00a0CD4\u00a0<200\u00a0c\u00e9lulas/\u00b5L \u00a0de\u00a0varios\u00a0pa\u00edses\u00a0africanos. \u00a0El\u00a0objetivo\u00a0\nera\u00a0el\u00a0tiempo\u00a0desde\u00a0la\u00a0aleatorizaci\u00f3n \u00a0hasta\u00a0la\u00a0muerte\u00a0o\u00a0fracaso\u00a0virol\u00f3gico \u00a0(definido\u00a0\ncomo\u00a0descenso \u00a0de\u00a0CVP\u00a0<1\u00a0log\u00a0en\u00a0la\u00a0semana\u00a012\u00a0o\u00a0CVP\u00a0>400\u00a0copias/mL \u00a0en\u00a0la\u00a0semana\u00a024)\u00a0\nEn\u00a0el\u00a0OCTANE\u00a01\u00a0se\u00a0aleatorizaron \u00a0234\u00a0mujeres\u00a0que\u00a0hab\u00edan\u00a0recibido\u00a0al\u00a0menos\u00a0una\u00a0dosis\u00a0\nde\u00a0NVP\u00a0en\u00a0\u00a0los\u00a06\u00a0meses\u00a0previos\u00a0para\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0trasmisi\u00f3n \u00a0madre\u2010hijo.\u00a0El\u00a0estudio\u00a0\nse\u00a0interrumpi\u00f3 \u00a0a\u00a0las\u00a066\u00a0semanas\u00a0de\u00a0seguimiento \u00a0al\u00a0documentarse \u00a0que\u00a0LPV/r\u00a0era\u00a0m\u00e1s\u00a0\neficaz\u00a0que\u00a0NVP\u00a0y\u00a0con\u00a0menos\u00a0efectos\u00a0adversos252.\u00a0\nEl\u00a0OCTANE\u00a02\u00a0se\u00a0design\u00f3\u00a0para\u00a0buscar\u00a0equivalencia \u00a0(definida\u00a0como\u00a0IC\u00a095%,\u00a0HR:\u00a00,5\u00a0a\u00a02,0)\u00a0\nentre\u00a0las\u00a0dos\u00a0ramas.\u00a0Se\u00a0aleatorizaron \u00a0500\u00a0mujeres\u00a0(249\u00a0a\u00a0NVP\u00a0y\u00a0251\u00a0a\u00a0LPV/r)\u00a0que\u00a0no\u00a0\nhab\u00edan\u00a0tomado\u00a0NVP.\u00a0Las\u00a0caracter\u00edsticas \u00a0basales\u00a0eran\u00a0similares. \u00a0El\u00a0seguimiento \u00a0medio\u00a0\nfue\u00a0de\u00a0118\u00a0semanas. \u00a0Se\u00a0perdieron \u00a014\u00a0mujeres\u00a0de\u00a0la\u00a0rama\u00a0de\u00a0NVP\u00a0y\u00a06\u00a0de\u00a0la\u00a0de\u00a0LPV/r.\u00a0El\u00a0\nobjetivo\u00a0del\u00a0estudio\u00a0lo\u00a0consiguieron \u00a042\u00a0(17%)\u00a0mujeres\u00a0de\u00a0la\u00a0rama\u00a0de\u00a0NVP\u00a0y\u00a050\u00a0(20%)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 29del\u00a0LPV/r\u00a0(HR\u00a00,85;\u00a0IC\u00a095%,\u00a00,56\u00a0a\u00a01,29)\u00a0cumpliendo \u00a0criterios\u00a0de\u00a0equivalencia \u00a0(an\u00e1lisis\u00a0\npor\u00a0ITT).\u00a0Se\u00a0\u00a0analizaron \u00a0por\u00a0separado \u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0y\u00a0la\u00a0mortalidad \u00a0(15%\u00a0frente\u00a0a\u00a0\n17%\u00a0y\u00a02%\u00a0frente\u00a0a\u00a03%)\u00a0de\u00a0las\u00a0ramas\u00a0con\u00a0NVP\u00a0y\u00a0LPV/r.\u00a0Globalmente \u00a093\u00a0mujeres\u00a0\ndiscontinuaron \u00a0el\u00a0tratamiento \u00a0(70\u00a0[28%]\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0NVP\u00a0y\u00a023\u00a0[9%]\u00a0en\u00a0la\u00a0de\u00a0LPV/r).\u00a0\nLo\u00a0hicieron\u00a0por\u00a0efectos\u00a0adversos\u00a0relacionados \u00a0con\u00a0el\u00a0f\u00e1rmaco\u00a035\u00a0(14%)\u00a0de\u00a0las\u00a0tratadas\u00a0\ncon\u00a0NVP\u00a0y\u00a0ninguna\u00a0de\u00a0las\u00a0de\u00a0LPV/r253.\u00a0\n\u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0EFV\u00a0\nPautas\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a0IP\u00a0\nACTG\u00a05202\u00a0\nEl\u00a0estudio\u00a05202\u00a0es\u00a0un\u00a0estudio\u00a0aleatorizado, \u00a0ciego,\u00a0que\u00a0se\u00a0dise\u00f1\u00f3\u00a0para\u00a0comparar \u00a0en\u00a0el\u00a0\ntratamiento \u00a0inicial\u00a0un\u00a0NN\u00a0(EFV)\u00a0con\u00a0un\u00a0IP/r\u00a0(ATV/r)\u00a0junto\u00a0a\u00a0uno\u00a0de\u00a0los\u00a0dos\u00a0AN\u00a0\ncoformulados \u00a0(ABC/3TC \u00a0o\u00a0TDF/FTC). \u00a0La\u00a0hip\u00f3tesis\u00a0del\u00a0estudio\u00a0era,\u00a0por\u00a0una\u00a0parte,\u00a0\ncomparar \u00a0la\u00a0equivalencia \u00a0de\u00a0ATV/r\u00a0a\u00a0EFV\u00a0cuando\u00a0se\u00a0combinan \u00a0con\u00a0ABC/3TC\u00a0o\u00a0FTC/TDF\u00a0\ny,\u00a0por\u00a0otra,\u00a0comparar \u00a0la\u00a0equivalencia \u00a0de\u00a0ABC/3TC\u00a0a\u00a0FTC/TDF\u00a0cuando\u00a0se\u00a0combinan \u00a0con\u00a0\nEFV\u00a0o\u00a0ATV/r.\u00a0El\u00a0objetivo\u00a0del\u00a0estudio\u00a0era\u00a0triple.\u00a0Respecto\u00a0a\u00a0la\u00a0eficacia,\u00a0tiempo\u00a0hasta\u00a0el\u00a0\nfracaso\u00a0virol\u00f3gico; \u00a0respecto\u00a0a\u00a0la\u00a0seguridad, \u00a0tiempo\u00a0hasta\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0un\u00a0efecto\u00a0\nadverso\u00a0tipo\u00a03\u00a0\u00f3\u00a04;\u00a0y\u00a0respecto\u00a0a\u00a0la\u00a0tolerancia, \u00a0tiempo\u00a0hasta\u00a0la\u00a0modificaci\u00f3n \u00a0del\u00a0\ntratamiento \u00a0al\u00a0que\u00a0se\u00a0fue\u00a0aleatorizado. \u00a0Se\u00a0aleatorizaron \u00a01850\u00a0pacientes \u00a0a\u00a0cada\u00a0uno\u00a0de\u00a0\nlas\u00a0cuatro\u00a0ramas\u00a0estratificando \u00a0los\u00a0pacientes \u00a0por\u00a0CVP\u00a0(>\u00a0\u00f3\u00a0<\u00a0100000\u00a0copias/mL). \u00a0\nEl\u00a0comit\u00e9\u00a0de\u00a0seguimiento \u00a0y\u00a0seguridad \u00a0del\u00a0estudio\u00a0en\u00a0enero\u00a0de\u00a02008\u00a0modific\u00f3\u00a0el\u00a0estudio\u00a0\nante\u00a0el\u00a0hallazgo\u00a0de\u00a0mayor\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0las\u00a0ramas\u00a0con\u00a0ABC/3TC\u00a0del\u00a0estrato\u00a0con\u00a0\nCVP\u00a0altas\u00a0discontinuando \u00a0estas\u00a0ramas,\u00a0no\u00a0el\u00a0resto\u00a0del\u00a0estudio226.\u00a0\nLos\u00a0resultados \u00a0finales,\u00a0presentados \u00a0en\u00a0un\u00a0congreso, \u00a0mostraron \u00a0que\u00a0no\u00a0hubo\u00a0diferencia \u00a0\nen\u00a0cuanto\u00a0a\u00a0la\u00a0eficacia\u00a0entre\u00a0ATV/r\u00a0y\u00a0EFV\u00a0independientemente \u00a0de\u00a0los\u00a0AN\u00a0que\u00a0les\u00a0\nacompa\u00f1aran. \u00a0Entre\u00a0los\u00a0pacientes \u00a0que\u00a0fracasaron, \u00a0el\u00a0n\u00famero\u00a0de\u00a0mutaciones \u00a0de\u00a0\nresistencia \u00a0para\u00a0AN\u00a0y\u00a0NN\u00a0fue\u00a0mayor\u00a0en\u00a0las\u00a0ramas\u00a0con\u00a0EFV\u00a0(no\u00a0hubo\u00a0mutaciones \u00a0\nprimarias \u00a0a\u00a0ATV).\u00a0El\u00a0incremento \u00a0de\u00a0CD4\u00a0fue\u00a0algo\u00a0mayor\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0TDF/FTC.\u00a0En\u00a0\ncuanto\u00a0a\u00a0los\u00a0an\u00e1lisis\u00a0de\u00a0seguridad \u00a0y\u00a0tolerancia, \u00a0no\u00a0hubo\u00a0diferencia \u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0\nTDF/FTC,\u00a0pero\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0ABC/3TC\u00a0el\u00a0tiempo\u00a0hasta\u00a0la\u00a0modificaci\u00f3n \u00a0del\u00a0tratamiento \u00a0\nfue\u00a0menor\u00a0con\u00a0ATV/r\u00a0que\u00a0con\u00a0EFV.\u00a0El\u00a0incremento \u00a0de\u00a0los\u00a0l\u00edpidos\u00a0fue\u00a0menor\u00a0en\u00a0la\u00a0rama\u00a0\nde\u00a0TDF/FTC\u00a0y\u00a0en\u00a0cuanto\u00a0al\u00a0aclaramiento \u00a0de\u00a0creatinina \u00a0aument\u00f3\u00a0discretamente \u00a0en\u00a0\ntodas\u00a0las\u00a0ramas,\u00a0excepto\u00a0en\u00a0ATV/r+TDF/FTC \u00a0en\u00a0la\u00a0que\u00a0descendi\u00f3 \u00a0discretamente227.\u00a0Se\u00a0\nhan\u00a0comunicado \u00a0resultados \u00a0de\u00a0un\u00a0subestudio \u00a0metab\u00f3lico \u00a0(cambios\u00a0en\u00a0grasa\u00a0y\u00a0densidad\u00a0\nmineral\u00a0\u00f3sea)\u00a0que\u00a0se\u00a0exponen\u00a0en\u00a0cap\u00edtulos\u00a0posteriores. \u00a0\n\u00a0\u00a0\nACTG\u00a05142\u00a0\nEl\u00a0estudio\u00a0ACTG\u00a05142\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0cuyo\u00a0objetivo\u00a0era\u00a0valorar\u00a0la\u00a0\neficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0tres\u00a0reg\u00edmenes \u00a0de\u00a0tratamiento: \u00a0LPV/r+2\u00a0AN,\u00a0EFV+2\u00a0AN\u00a0y\u00a0LPV/r+\u00a0\nEFV.\u00a0Se\u00a0incluyeron \u00a0753\u00a0pacientes \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0182\u00a0\nc\u00e9lulas/\u00b5L\u00a0y\u00a0CVP\u00a0de\u00a0\n100.000\u00a0copias/mL. \u00a0Los\u00a0puntos\u00a0finales\u00a0de\u00a0valoraci\u00f3n \u00a0fueron:\u00a01\u00ba)\u00a0Fracaso\u00a0virol\u00f3gico: \u00a0a)\u00a0\nfracaso\u00a0temprano: \u00a0imposibilidad \u00a0de\u00a0reducir\u00a0la\u00a0CVP\u00a0>1\u00a0log10\u00a0o\u00a0rebrote\u00a0antes\u00a0de\u00a0la\u00a0\nsemana\u00a032;\u00a0y\u00a0b)\u00a0fracaso\u00a0tard\u00edo:\u00a0imposibilidad \u00a0de\u00a0suprimir\u00a0la\u00a0CVP\u00a0por\u00a0debajo\u00a0de\u00a0200\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 30copias/mL \u00a0o\u00a0rebrote\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0semana\u00a032.\u00a02\u00ba)\u00a0Finalizaci\u00f3n \u00a0del\u00a0r\u00e9gimen:\u00a0fracaso\u00a0\nvirol\u00f3gico \u00a0o\u00a0suspensi\u00f3n \u00a0relacionada \u00a0con\u00a0la\u00a0toxicidad. \u00a0En\u00a0la\u00a0semana\u00a096\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0sin\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0de\u00a067,\u00a076\u00a0y\u00a073%\u00a0para\u00a0los\u00a0grupos\u00a0de\u00a0LPV/r+2\u00a0AN,\u00a0\nEFV+2\u00a0AN\u00a0y\u00a0LPV/r+EFV \u00a0respectivamente. \u00a0En\u00a0este\u00a0corte,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP\u00a0<200\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a0de\u00a086,\u00a093,\u00a092\u00a0%\u00a0para\u00a0cada\u00a0rama\u00a0de\u00a0tratamiento \u00a0(p=0,041, \u00a0\nLPV\u00a0frente\u00a0a\u00a0EFV),\u00a0y\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0de\u00a077,\u00a089\u00a0y\u00a083%,\u00a0respectivamente \u00a0\n(p=0,003; \u00a0LPV\u00a0frente\u00a0a\u00a0EFV).\u00a0El\u00a0incremento \u00a0de\u00a0linfocitos\u00a0CD4\u00a0\u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0brazos\u00a0\nque\u00a0conten\u00edan \u00a0LPV/r\u00a0frente\u00a0al\u00a0brazo\u00a0de\u00a0EFV\u00a0(p\u00a0=\u00a00,01\u00a0frente\u00a0EFV+2\u00a0AN.\u00a0Los\u00a0datos\u00a0de\u00a0\nresistencias \u00a0indican\u00a0que\u00a0en\u00a0caso\u00a0de\u00a0fracaso\u00a0virol\u00f3gico, \u00a0es\u00a0m\u00e1s\u00a0probable\u00a0que\u00a0aparezcan \u00a0\nresistencias \u00a0a\u00a0dos\u00a0clases\u00a0de\u00a0f\u00e1rmacos \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0EFV+2\u00a0AN\u00a0que\u00a0en\u00a0los\u00a0grupos\u00a0de\u00a0\nLPV/r,\u00a0mientras\u00a0que\u00a0hipertrigliceridemia \u00a0fue\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0\nLPV/r+EFV. \u00a0En\u00a0resumen, \u00a0el\u00a0estudio\u00a0ACTG\u00a05142,\u00a0demuestra \u00a0que\u00a0tanto\u00a0la\u00a0eficacia\u00a0\nvirol\u00f3gica \u00a0como\u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0son\u00a0mejores\u00a0con\u00a0la\u00a0pauta\u00a0de\u00a0EFV\u00a0+\u00a0\n2\u00a0AN\u00a0y\u00a0el\u00a0incremento \u00a0de\u00a0los\u00a0linfocitos\u00a0CD4\u00a0es\u00a0mayor\u00a0en\u00a0los\u00a0brazos\u00a0con\u00a0LPV/r254.\u00a0\u00a0\n\u00a0\nEstudio\u00a0DMP\u2010006\u00a0\nEn\u00a0el\u00a0estudio\u00a0DMP\u2010006\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0EFV,\u00a0combinado \u00a0con\u00a0ZDV\u00a0y\u00a03TC\u00a0tiene\u00a0una\u00a0\nmayor\u00a0eficacia\u00a0virol\u00f3gica \u00a0(48\u00a0y\u00a0144\u00a0semanas) \u00a0que\u00a0IDV+ZDV+3TC255.\u00a0\u00a0\n\u00a0\nACTG\u00a0384\u00a0\nEn\u00a0el\u00a0estudio\u00a0ACTG\u00a0384\u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0EFV+ZDV+3TC \u00a0es\u00a0m\u00e1s\u00a0\neficaz\u00a0que\u00a0un\u00a0r\u00e9gimen\u00a0con\u00a0NFV+ZDV+3TC \u00a0o\u00a0\u00a0NFV+ddI+d4T222.\u00a0\n\u00a0FOCUS\u00a0\nEn\u00a0el\u00a0ensayo\u00a0FOCUS\u00a0se\u00a0compar\u00f3\u00a0una\u00a0pauta\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0SQV/r\u00a0(1600/100, \u00a0QD)\u00a0en\u00a0\n152\u00a0pacientes \u00a0sin\u00a0terapia\u00a0previa.\u00a0La\u00a0pauta\u00a0con\u00a0EFV\u00a0fue\u00a0m\u00e1s\u00a0eficaz\u00a0en\u00a0la\u00a0semana\u00a048\u00a0(CVP\u00a0\n<50\u00a0copias/mL, \u00a071\u00a0%\u00a0frente\u00a0a\u00a051%)\u00a0y\u00a0present\u00f3\u00a0menos\u00a0toxicidad\n256.\u00a0\n\u00a0\nCLASS\u00a0\nEn\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0CLASS\u00a0se\u00a0compar\u00f3\u00a0una\u00a0pauta\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0otra\u00a0con\u00a0APV/r.\u00a0La\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0del\u00a094%\u00a0en\u00a0el\u00a0primer\u00a0grupo\u00a0y\u00a0del\u00a0\n73%\u00a0en\u00a0el\u00a0segundo244.\u00a0\n\u00a0\nBMS\u2010034\u00a0\nEn\u00a0el\u00a0estudio\u00a0BMS\u00a0AI424\u2010034\u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0ATV\u00a0(400\u00a0mg,\u00a0QD)\u00a0+\u00a0ZDV\u00a0+\u00a03TC\u00a0fue\u00a0tan\u00a0\neficaz\u00a0como\u00a0EFV\u00a0+\u00a0ZDV\u00a0+\u00a03TC\u00a0\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo257.\u00a0Sin\u00a0embargo\u00a0los\u00a0\nresultados \u00a0de\u00a0este\u00a0estudio\u00a0son\u00a0dif\u00edciles\u00a0de\u00a0interpretar \u00a0por\u00a0un\u00a0error\u00a0en\u00a0la\u00a0determinaci\u00f3n \u00a0\nde\u00a0la\u00a0CVP\u00a0relacionado \u00a0con\u00a0el\u00a0procesamiento \u00a0y\u00a0tipo\u00a0de\u00a0tubos\u00a0empleados \u00a0para\u00a0el\u00a0\ntransporte \u00a0de\u00a0muestras. \u00a0\u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 31Pautas\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a03\u00a0AN\u00a0\nACTG\u00a0A5095\u00a0\nComo\u00a0ya\u00a0se\u00a0ha\u00a0comentado \u00a0previamente, \u00a0el\u00a0estudio\u00a0ACTG\u2010A5095\u00a0demostr\u00f3 \u00a0que\u00a0las\u00a0\ncombinaciones \u00a0de\u00a0f\u00e1rmacos\u00a0de\u00a02\u00a0familias\u00a0(EFV+ZDV/3TC \u00a0o\u00a0EFV+ZDV/3TC/ABC) \u00a0son\u00a0m\u00e1s\u00a0\neficaces\u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a03\u00a0AN\u00a0(ZDV/3TC/ABC)241.\u00a0\u00a0\n\u00a0\nPautas\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a0NVP\u00a0\nEstudio\u00a02NN\u00a0\nEl\u00a0estudio\u00a02\u00a0NN258,\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0abierto,\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0\ntolerancia \u00a0de\u00a04\u00a0pautas\u00a0con\u00a0EFV,\u00a0NVP\u00a0(400\u00a0mg\u00a0QD),\u00a0NVP\u00a0(200\u00a0mg\u00a0BID)\u00a0y\u00a0EFV+NVP, \u00a0\ncombinados \u00a0todos\u00a0con\u00a0d4T+3TC. \u00a0Se\u00a0incluyeron \u00a01216\u00a0pacientes \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0\nCD4\u00a0de\u00a0190\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0de\u00a04,7\u00a0log10\u00a0copias/mL. \u00a0Se\u00a0consider\u00f3 \u00a0fracaso\u00a0de\u00a0\ntratamiento \u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0(descenso \u00a0de\u00a0CVP\u00a0<1\u00a0log10\u00a0en\u00a0la\u00a0semana\u00a012\u00a0o\u00a0dos\u00a0\ndeterminaciones \u00a0de\u00a0CVP\u00a0>50\u00a0copias/mL \u00a0a\u00a0partir\u00a0de\u00a0la\u00a0semana\u00a024\u00a0o\u00a0una\u00a0CVP\u00a0\u226550\u00a0\ncopias/mL \u00a0en\u00a0la\u00a0semana\u00a048),\u00a0la\u00a0progresi\u00f3n \u00a0cl\u00ednica\u00a0a\u00a0estadio\u00a0C\u00a0o\u00a0muerte\u00a0y\u00a0el\u00a0cambio\u00a0de\u00a0\ntratamiento. \u00a0En\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0fracaso\u00a0de\u00a0tratamiento \u00a0\nfue\u00a043,6%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0NVP\u00a0QD;\u00a043,7%\u00a0en\u00a0el\u00a0de\u00a0NVP\u00a0BID,\u00a037,8%\u00a0en\u00a0el\u00a0de\u00a0EFV,\u00a0y\u00a053,1%\u00a0\nen\u00a0el\u00a0de\u00a0NVP+EFV. \u00a0La\u00a0diferencia \u00a0de\u00a05,9%\u00a0(IC\u00a095%,\u00a0\u2010\u00a00,9\u00a0a\u00a012,8)\u00a0entre\u00a0las\u00a0ramas\u00a0con\u00a0NVP\u00a0\nBID\u00a0y\u00a0EFV\u00a0no\u00a0fue\u00a0significativa, \u00a0por\u00a0lo\u00a0que\u00a0no\u00a0pudo\u00a0demostrarse \u00a0la\u00a0equivalencia \u00a0dentro\u00a0\nde\u00a0los\u00a0l\u00edmites\u00a0del\u00a010%.\u00a0No\u00a0hubo\u00a0diferencias \u00a0entre\u00a0los\u00a0grupos\u00a0con\u00a0NVP\u00a0(QD\u00a0o\u00a0BID).\u00a0El\u00a0\nfracaso\u00a0de\u00a0tratamiento \u00a0fue\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0la\u00a0rama\u00a0NVP+EFV\u00a0que\u00a0en\u00a0la\u00a0de\u00a0EFV\u00a0\n(15,3%,\u00a0p=0,0003), \u00a0pero\u00a0no\u00a0hubo\u00a0diferencias \u00a0significativas \u00a0respecto\u00a0al\u00a0grupo\u00a0de\u00a0NVP\u00a0\nQD\u00a0(9,5%;\u00a0p=0,05).\u00a0Tampoco \u00a0hubo\u00a0diferencias \u00a0entre\u00a0las\u00a0distintas\u00a0ramas\u00a0con\u00a0respecto\u00a0a\u00a0\nla\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL: \u00a070%\u00a0con\u00a0NVP\u00a0QD,\u00a065%\u00a0con\u00a0NVP\u00a0\nBID,\u00a070%\u00a0con\u00a0EFV\u00a0y\u00a0\u00a062,7%\u00a0con\u00a0EFV+NVP\u00a0(ITT).\u00a0En\u00a0el\u00a0subgrupo \u00a0con\u00a0CVP\u00a0alta\u00a0(>100000 \u00a0\ncopias/mL) \u00a0el\u00a0fracaso\u00a0de\u00a0tratamiento \u00a0fue\u00a0de\u00a019,9%\u00a0en\u00a0la\u00a0rama\u00a0NVP\u00a0QD,\u00a015,8%\u00a0en\u00a0la\u00a0de\u00a0\nNVP\u00a0BID,\u00a08,2%\u00a0en\u00a0la\u00a0de\u00a0NVP+EFV\u00a0y\u00a05,9%\u00a0en\u00a0la\u00a0de\u00a0EFV\u00a0(p=0,004). \u00a0El\u00a0incremento \u00a0de\u00a0\nlinfocitos\u00a0CD4\u00a0fue\u00a0el\u00a0mismo\u00a0en\u00a0las\u00a04\u00a0ramas.\u00a0Los\u00a0efectos\u00a0adversos\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0\nen\u00a0el\u00a0grupo\u00a0de\u00a0NVP+EFV\u00a0y\u00a0la\u00a0toxicidad\u00a0hepatobiliar \u00a0fue\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0el\u00a0de\u00a0NVP\u00a0QD\u00a0\nque\u00a0en\u00a0los\u00a0otros.\u00a0Se\u00a0registraron \u00a025\u00a0muertes\u00a0de\u00a0las\u00a0que\u00a02\u00a0se\u00a0atribuyeron \u00a0a\u00a0NVP.\u00a0Como\u00a0\nconclusi\u00f3n \u00a0de\u00a0este\u00a0estudio\u00a0se\u00a0puede\u00a0decir\u00a0que\u00a0la\u00a0eficacia\u00a0fue\u00a0similar\u00a0en\u00a0los\u00a0tres\u00a0brazos\u00a0\nque\u00a0conten\u00edan \u00a0un\u00a0NN.\u00a0La\u00a0eficacia\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0NVP\u00a0+\u00a0EFV\u00a0es\u00a0inferior\u00a0a\u00a0la\u00a0que\u00a0\ncontiene\u00a0solamente \u00a0EFV.\u00a0\u00a0\nA\u00a0la\u00a0hora\u00a0de\u00a0valorar\u00a0los\u00a0resultados \u00a0de\u00a0este\u00a0estudio,\u00a0debe\u00a0tenerse\u00a0en\u00a0cuenta\u00a0que\u00a0en\u00a0el\u00a0\u00a0\ndise\u00f1o\u00a0se\u00a0especific\u00f3 \u00a0que\u00a0ser\u00eda\u00a0cl\u00ednicamente \u00a0significativa \u00a0una\u00a0diferencia \u00a0de\u00a0fracaso\u00a0\nterap\u00e9utico \u00a0inferior\u00a0al\u00a010%\u00a0entre\u00a0las\u00a0dos\u00a0pautas\u00a0(semana\u00a048).\u00a0Los\u00a0resultados \u00a0indicaron, \u00a0\nsin\u00a0embargo, \u00a0que\u00a0no\u00a0pod\u00eda\u00a0descartarse \u00a0una\u00a0diferencia \u00a0mayor\u00a0ya\u00a0que\u00a0seg\u00fan\u00a0el\u00a0intervalo\u00a0\nde\u00a0confianza \u00a0del\u00a095%\u00a0la\u00a0eficacia\u00a0de\u00a0EFV\u00a0sobre\u00a0NVP\u00a0puede\u00a0superar\u00a0el\u00a010%.\u00a0En\u00a0un\u00a0an\u00e1lisis\u00a0\nde\u00a0sensibilidad \u00a0en\u00a0el\u00a0que\u00a0s\u00f3lo\u00a0se\u00a0incluyeron \u00a0los\u00a0pacientes \u00a0que\u00a0tomaron\u00a0la\u00a0medicaci\u00f3n \u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\u00e9xito\u00a0terap\u00e9utico \u00a0fue\u00a0significativamente \u00a0mayor\u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0EFV\u00a0que\u00a0en\u00a0el\u00a0de\u00a0NVP\u00a0BID.\u00a0\u00a0\n\u00a0\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 32Resumen \u00a0sobre\u00a0ensayos\u00a0de\u00a0NN\u00a0\nSe\u00a0ha\u00a0demostrado \u00a0que\u00a0pautas\u00a0con\u00a0EFV\u00a0o\u00a0NVP\u00a0son\u00a0m\u00e1s\u00a0eficaces\u00a0que\u00a0pautas\u00a0con\u00a03\u00a0AN.\u00a0\nIgualmente \u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0una\u00a0pauta\u00a0con\u00a0EFV\u00a0es\u00a0m\u00e1s\u00a0eficaz\u00a0que\u00a0con\u00a0algunos\u00a0IP\u00a0\n(IDV,\u00a0NFV,\u00a0SQV/r,\u00a0APV/r,\u00a0LPV/r).\u00a0ATV/r\u00a0es\u00a0no\u00a0inferior\u00a0a\u00a0EFV.\u00a0Sin\u00a0embargo, \u00a0no\u00a0se\u00a0ha\u00a0\ndemostrado \u00a0en\u00a0ning\u00fan\u00a0ensayo\u00a0cl\u00ednico\u00a0que\u00a0NVP\u00a0sea\u00a0m\u00e1s\u00a0eficaz\u00a0que\u00a0un\u00a0IP\u00a0pero\u00a0s\u00ed\u00a0no\u00a0\ninferior\u00a0a\u00a0ATV/r.\u00a0Por\u00a0\u00faltimo,\u00a0la\u00a0comparaci\u00f3n \u00a0entre\u00a0los\u00a0dos\u00a0NN\u00a0no\u00a0ha\u00a0permitido \u00a0obtener\u00a0\nconclusiones \u00a0definitivas. \u00a0\u00a0\n\u00a0Consideraciones \u00a0sobre\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0un\u00a0r\u00e9gimen\u00a0con\u00a0NVP\u00a0o\u00a0EFV\u00a0\n1)\u00a0EFV\u00a0ha\u00a0demostrado \u00a0su\u00a0eficacia\u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0>100000\u00a0copias/mL \u00a0o\u00a0muy\u00a0\ninmunodeprimidos \u00a0(50\u2010100\u00a0linfocitos\u00a0CD4/\u00b5L)\n259,\u00a0260\u00a0y\u00a0es\u00a0capaz\u00a0de\u00a0suprimir\u00a0la\u00a0carga\u00a0\nviral\u00a0en\u00a0tejido\u00a0linf\u00e1tico\u00a0de\u00a0forma\u00a0similar\u00a0a\u00a0reg\u00edmenes \u00a0con\u00a0IP261.\u00a0\u00a0\n2)\u00a0EFV\u00a0est\u00e1\u00a0contraindicado \u00a0en\u00a0embarazadas \u00a0(riesgo\u00a0de\u00a0teratogenicidad) \u00a0y\u00a0deber\u00eda\u00a0\nevitarse\u00a0en\u00a0mujeres\u00a0que\u00a0quieran\u00a0quedarse \u00a0embarazadas \u00a0o\u00a0que\u00a0no\u00a0utilicen\u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0seguros.\u00a0EFV\u00a0puede\u00a0producir\u00a0mareos,\u00a0trastornos \u00a0de\u00a0la\u00a0concentraci\u00f3n \u00a0y\u00a0\nsomnolencia, \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0deber\u00e1\u00a0informar\u00a0a\u00a0los\u00a0pacientes \u00a0y\u00a0recomendarles \u00a0que,\u00a0en\u00a0\npresencia \u00a0de\u00a0estos\u00a0s\u00edntomas, \u00a0eviten\u00a0tareas\u00a0peligrosas \u00a0como\u00a0conducir\u00a0o\u00a0usar\u00a0m\u00e1quinas \u00a0\npesadas.\u00a0Asimismo \u00a0deber\u00eda\u00a0evitarse\u00a0en\u00a0pacientes \u00a0con\u00a0antecedentes \u00a0psiqui\u00e1tricos \u00a0\ngraves.\u00a0\n3)\u00a0EFV\u00a0est\u00e1\u00a0disponible \u00a0para\u00a0su\u00a0uso\u00a0en\u00a0coformulaci\u00f3n \u00a0junto\u00a0a\u00a0TDF+FTC\u00a0en\u00a0un\u00a0\u00fanico\u00a0\ncomprimido \u00a0de\u00a0administraci\u00f3n \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0\n4)\u00a0La\u00a0NVP\u00a0puede\u00a0producir\u00a0exantema \u00a0cut\u00e1neo,\u00a0con\u00a0o\u00a0sin\u00a0fiebre\u00a0y\u00a0s\u00edntomas\u00a0\npseudogripales. \u00a0Se\u00a0han\u00a0descrito\u00a0eventos\u00a0hep\u00e1ticos \u00a0graves\u00a0e\u00a0incluso\u00a0fatales\u00a0durante\u00a0las\u00a0\nprimeras\u00a0semanas\u00a0de\u00a0tratamiento, \u00a0por\u00a0lo\u00a0que\u00a0NVP\u00a0debe\u00a0administrarse \u00a0con\u00a0precauci\u00f3n \u00a0\nen\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0y\u00a0transaminasas \u00a0elevadas\u00a0(contraindicada \u00a0si\u00a0las\u00a0\ntransaminasas \u00a0est\u00e1n\u00a0por\u00a0encima\u00a0de\u00a0cinco\u00a0veces\u00a0el\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0la\u00a0normalidad). \u00a0\nLos\u00a0eventos\u00a0hep\u00e1ticos \u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0el\u00a0primer\u00a0tratamiento \u00a0de\u00a0mujeres\u00a0con\u00a0\nCD4\u00a0>250\u00a0c\u00e9lulas/\u00b5L \u00a0(11%\u00a0frente\u00a0a\u00a00,9%)\u00a0o\u00a0de\u00a0hombres\u00a0con\u00a0CD4\u00a0>400\u00a0c\u00e9lulas/\u00b5L \u00a0(6,3%\u00a0\nfrente\u00a0a\u00a01,2%).\u00a0En\u00a0pacientes \u00a0que\u00a0reciben\u00a0metadona \u00a0debe\u00a0tenerse\u00a0especial\u00a0cuidado\u00a0ya\u00a0\nque,\u00a0tanto\u00a0EFV\u00a0como\u00a0NVP,\u00a0suelen\u00a0inducir\u00a0su\u00a0metabolismo \u00a0y\u00a0producir\u00a0s\u00edndrome \u00a0de\u00a0\nabstinencia. \u00a0\n5)\u00a0La\u00a0NVP\u00a0ha\u00a0demostrado \u00a0no\u00a0inferioridad \u00a0con\u00a0respecto\u00a0a\u00a0ATV/r,\u00a0incluso\u00a0con\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0>100.000 \u00a0copias/mL. \u00a0\n6)\u00a0Existe\u00a0muy\u00a0escasa\u00a0experiencia \u00a0en\u00a0cuanto\u00a0a\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0\nABC+3TC+NVP. \u00a0Tanto\u00a0ABC\u00a0como\u00a0NVP\u00a0pueden\u00a0presentar \u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad. \u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0NN\u00a0\n\u0083 En\u00a0general\u00a0se\u00a0recomienda \u00a0EFV\u00a0frente\u00a0a\u00a0NVP,\u00a0por\u00a0el\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0estudios\u00a0y\u00a0\nexperiencia \u00a0(nivel\u00a0C)\u00a0\n\u0083 EFV\u00a0est\u00e1\u00a0contraindicado \u00a0durante\u00a0el\u00a0primer\u00a0trimestre \u00a0de\u00a0la\u00a0gestaci\u00f3n. \u00a0Se\u00a0\u00a0\nrecomienda \u00a0considerar \u00a0otras\u00a0opciones\u00a0en\u00a0mujeres\u00a0que\u00a0no\u00a0utilicen\u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0eficaces.\u00a0As\u00ed\u00a0mismo,\u00a0se\u00a0debe\u00a0evitar\u00a0en\u00a0pacientes \u00a0que\u00a0realicen\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 33tareas\u00a0peligrosas \u00a0si\u00a0presentan \u00a0s\u00edntomas\u00a0de\u00a0somnolencia, \u00a0mareos\u00a0y/o\u00a0trastornos \u00a0de\u00a0\nla\u00a0concentraci\u00f3n. \u00a0\n\u0083 Se\u00a0desaconseja \u00a0el\u00a0uso\u00a0de\u00a0NVP\u00a0en\u00a0mujeres\u00a0con\u00a0recuento\u00a0de\u00a0CD4\u00a0>250\u00a0c\u00e9lulas/\u03bcL\u00a0\u00a0y\u00a0\nen\u00a0varones\u00a0con\u00a0recuento\u00a0de\u00a0CD4\u00a0>400\u00a0c\u00e9lulas/\u03bcL\u00a0\n\u00a0\n\u00a0\n4.5.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0\nEn\u00a0Espa\u00f1a\u00a0se\u00a0han\u00a0comercializado \u00a09\u00a0IP:\u00a0saquinavir \u00a0(SQV),\u00a0indinavir\u00a0(IDV),\u00a0ritonavir\u00a0(RTV),\u00a0\nnelfinavir \u00a0(NFV),\u00a0fosamprenavir \u00a0(FPV),\u00a0lopinavir\u00a0(LPV),\u00a0atazanavir \u00a0(ATV),\u00a0tipranavir \u00a0(TPV)\u00a0\ny\u00a0darunavir \u00a0(DRV).\u00a0TPV/r\u00a0est\u00e1\u00a0aprobado \u00a0por\u00a0la\u00a0European \u00a0Medicines \u00a0Agency\u00a0(EMA)\u00a0\nsolamente \u00a0en\u00a0pacientes \u00a0pretratados. \u00a0Sus\u00a0principales \u00a0caracter\u00edsticas \u00a0se\u00a0muestran \u00a0en\u00a0la\u00a0\nTabla\u00a07.\u00a0Los\u00a0IP\u00a0son\u00a0inductores \u00a0e\u00a0inhibidores \u00a0del\u00a0citocromo \u00a0P450\u00a0y\u00a0frecuentemente \u00a0\npueden\u00a0originar\u00a0interacciones \u00a0farmacocin\u00e9ticas. \u00a0La\u00a0elecci\u00f3n\u00a0final\u00a0del\u00a0IP\u00a0se\u00a0basar\u00e1\u00a0en\u00a0\ndatos\u00a0de\u00a0eficacia,\u00a0tolerancia, \u00a0interacciones, \u00a0posolog\u00eda \u00a0y\u00a0farmacocin\u00e9tica. \u00a0LPV/r\u00a0se\u00a0\nadministra \u00a0en\u00a0comprimidos \u00a0coformulados \u00a0que\u00a0no\u00a0precisan\u00a0\u00a0refrigeraci\u00f3n. \u00a0Para\u00a0el\u00a0resto\u00a0\nde\u00a0IP/r\u00a0se\u00a0recomienda \u00a0mantener \u00a0las\u00a0c\u00e1psulas\u00a0de\u00a0ritonavir\u00a0refrigeradas \u00a0(la\u00a0ficha\u00a0t\u00e9cnica\u00a0\ninforma\u00a0que\u00a0pueden\u00a0permanecer \u00a0hasta\u00a030\u00a0d\u00edas\u00a0a\u00a0temperatura \u00a0no\u00a0superior\u00a0a\u00a025\u00b0C).\u00a0\n\u00a0Combinaciones \u00a0de\u00a0TAR\u00a0que\u00a0incluyan\u00a0IP\u00a0potenciados \u00a0\nSe\u00a0entiende\u00a0por\u00a0IP\u00a0potenciado \u00a0la\u00a0coadministraci\u00f3n \u00a0de\u00a0un\u00a0IP\u00a0con\u00a0dosis\n\u00a0reducidas \u00a0de\u00a0RTV.\u00a0\nEl\u00a0RTV\u00a0tiene\u00a0un\u00a0potente\u00a0efecto\u00a0inhibidor\u00a0del\u00a0citocromo \u00a0P450\u00a0que\u00a0inhibe\u00a0el\u00a0\nmetabolismo \u00a0del\u00a0segundo\u00a0IP\u00a0mejorando \u00a0su\u00a0perfil\u00a0farmacocin\u00e9tico \u00a0y\u00a0el\u00a0cociente\u00a0\nCmin/CI50,\u00a0reduciendo \u00a0el\u00a0riesgo\u00a0de\u00a0aparici\u00f3n \u00a0de\u00a0resistencias. \u00a0Adem\u00e1s\u00a0al\u00a0potenciar \u00a0un\u00a0IP\u00a0\nse\u00a0reduce\u00a0el\u00a0n\u00famero\u00a0de\u00a0comprimidos, \u00a0la\u00a0frecuencia \u00a0de\u00a0dosis\u00a0y\u00a0las\u00a0restricciones \u00a0\ndiet\u00e9ticas \u00a0lo\u00a0que\u00a0favorece\u00a0la\u00a0adherencia. \u00a0La\u00a0formulaci\u00f3n \u00a0de\u00a0RTV\u00a0disponible \u00a0en\u00a0Espa\u00f1a\u00a0\nrequiere\u00a0condiciones \u00a0especiales \u00a0de\u00a0conservaci\u00f3n \u00a0(nevera).\u00a0Se\u00a0ha\u00a0aprobado \u00a0la\u00a0\ncomercializaci\u00f3n \u00a0de\u00a0RTV\u00a0en\u00a0una\u00a0nueva\u00a0presentaci\u00f3n \u00a0(comprimidos \u00a0recubiertos \u00a0con\u00a0\npel\u00edcula)\u00a0que\u00a0no\u00a0requiere\u00a0las\u00a0precauciones \u00a0mencionadas. \u00a0En\u00a0la\u00a0Tabla\u00a07\u00a0est\u00e1n\u00a0las\u00a0\ncombinaciones \u00a0m\u00e1s\u00a0importantes \u00a0de\u00a0IP\u00a0y\u00a0sus\u00a0dosificaciones \u00a0basadas\u00a0en\u00a0estudios\u00a0\nfarmacocin\u00e9ticos. \u00a0\u00a0\n\u00a0\nEnsayos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0IP\u00a0\nComparaciones \u00a0entre\u00a0IP\u00a0\nM98\u2010863\u00a0\nEl\u00a0M98\u2010863\u00a0es\u00a0un\u00a0ensayo\u00a0aleatorizado, \u00a0doble\u00a0ciego,\u00a0multic\u00e9ntrico \u00a0que\u00a0compar\u00f3\u00a0LPV/r\u00a0\n(400/100\u00a0mg\u00a0BID;\u00a0n=326)\u00a0frente\u00a0a\u00a0NFV\u00a0(750\u00a0mg\u00a0TID;\u00a0n=327)\u00a0junto\u00a0a\u00a0d4T+3TC. \u00a0En\u00a0la\u00a0\nsemana\u00a060,\u00a0se\u00a0observ\u00f3\u00a0mejor\u00a0respuesta \u00a0virol\u00f3gica \u00a0(ITT)\u00a0en\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0\nLPV/r\u00a0(CVP\u00a0<50\u00a0copias/mL, \u00a064%\u00a0y\u00a052%,\u00a0respectivamente, \u00a0p\u00a0=0,001)262.\u00a0\n\u00a0\nAbbott\u00a0418\u00a0\u00a0\nEn\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0Abbott\u00a0418\u00a0se\u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0LPV/r\u00a0BID\u00a0frente\u00a0a\u00a0\nLPV/r\u00a0QD\u00a0combinados \u00a0con\u00a0TDF\u00a0y\u00a0FTC.\u00a0Se\u00a0incluyeron \u00a0190\u00a0pacientes \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 34CD4\u00a0de\u00a0214\u2010232\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0de\u00a0CVP\u00a0de\u00a04,6\u20104,8\u00a0log10\u00a0en\u00a0cada\u00a0grupo.\u00a0A\u00a0la\u00a0semana\u00a048\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0(ITT)\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0similar\u00a0(70%\u00a0y\u00a064%\u00a0seg\u00fan\u00a0\npauta,\u00a0LPV/r\u00a0QD\u00a0o\u00a0LPV/r\u00a0BID)263.\u00a0\n\u00a0\nKLEAN\u00a0\nEl\u00a0estudio\u00a0KLEAN\u00a0compar\u00f3\u00a0FPV/r\u00a0(700/100\u00a0mg\u00a0BID)\u00a0con\u00a0LPV/r\u00a0(300/100\u00a0mg\u00a0BID,\u00a0\nc\u00e1psulas)\u00a0ambos\u00a0con\u00a0ABC/3TC\u00a0coformulados, \u00a0en\u00a0887\u00a0pacientes. \u00a0En\u00a0la\u00a0semana\u00a048\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a066%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0FPV/r\u00a0y\u00a0\n65%\u00a0en\u00a0el\u00a0de\u00a0LPV/r,\u00a0demostrando \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0FPV/r\u00a0frente\u00a0a\u00a0las\u00a0c\u00e1psulas\u00a0de\u00a0\nLPV/r.\u00a0No\u00a0hubo\u00a0diferencia \u00a0significativa \u00a0en\u00a0cuanto\u00a0a\u00a0tolerancia \u00a0digestiva\u00a0(n\u00e1useas, \u00a0\nv\u00f3mitos,\u00a0diarrea)\u00a0ni\u00a0alteraciones \u00a0lip\u00eddicas233.\u00a0\u00a0\n\u00a0\nAPV30001 \u00a0\u2010\u00a0NEAT\u00a0\nEn\u00a0el\u00a0estudio\u00a0NEAT\u00a0se\u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0FPV\u00a0(1400\u00a0mg\u00a0BID)\u00a0frente\u00a0a\u00a0\nNFV,\u00a0ambos\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0ABC\u00a0y\u00a03TC.\u00a0Se\u00a0aleatorizaron \u00a0166\u00a0pacientes \u00a0a\u00a0FPV\u00a0y\u00a083\u00a0\na\u00a0NFV.\u00a0\u00a0A\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0fue\u00a0\nmayor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\u00a0FPV\u00a0que\u00a0en\u00a0el\u00a0de\u00a0NFV\u00a0(66%\u00a0y\u00a051%;\u00a0ITT).\u00a0En\u00a0el\u00a0grupo\u00a0de\u00a0CVP\u00a0\nelevada\u00a0(>100.000 \u00a0copias/mL) \u00a0la\u00a0proporci\u00f3n \u00a0fue\u00a0de\u00a067%\u00a0y\u00a035%\u00a0respectivamente \u00a0\n(p<0,05)264.\u00a0\n\u00a0\nAPV30002 \u00a0\u2010\u00a0SOLO\u00a0\nEl\u00a0SOLO\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0en\u00a0el\u00a0que\u00a0compararon \u00a0322\u00a0pacientes \u00a0tratados\u00a0\ncon\u00a0FPV/r\u00a0QD\u00a0(1400/200 \u00a0mg)\u00a0con\u00a0327\u00a0pacientes \u00a0con\u00a0NFV,\u00a0ambos\u00a0asociados \u00a0a\u00a0ABC+3TC. \u00a0\nLa\u00a0mediana\u00a0de\u00a0CD4\u00a0fue\u00a0170\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0la\u00a0CVP\u00a04,8\u00a0log10.\u00a0El\u00a020%\u00a0de\u00a0los\u00a0pacientes \u00a0ten\u00edan\u00a0\n<50\u00a0CD4/\u00b5L.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0no\u00a0hubo\u00a0diferencias \u00a0(ITT)\u00a0en\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0(69%,\u00a0FPV/r\u00a0frente\u00a068%,\u00a0NFV)\u00a0ni\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(55\u00a0\nfrente\u00a0a\u00a053%).\u00a0Sin\u00a0embargo, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0presentaron \u00a0fallo\u00a0\nvirol\u00f3gico \u00a0fue\u00a0superior\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0NFV\u00a0(17%)\u00a0que\u00a0en\u00a0la\u00a0de\u00a0FPV/r\u00a0(7%)265.\u00a0\u00a0\n\u00a0\nCOL100758 \u00a0\nEl\u00a0estudio\u00a0COL100758 \u00a0compar\u00f3\u00a0FPV/r\u00a0(1400/100 \u00a0mg)\u00a0y\u00a0FPV/r\u00a0(1400/200 \u00a0mg)\u00a0\u00a0ambos\u00a0\nQD\u00a0junto\u00a0con\u00a0ABC/3TC\u00a0coformulados. \u00a0Se\u00a0incluyeron \u00a0115\u00a0pacientes. \u00a0A\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a079%\u00a0(FPV/r\u00a0100\u00a0mg)\u00a0y\u00a063%\u00a0\n(FPV/r\u00a0200\u00a0mg),\u00a0\u00a0p=0,061.\u00a0La\u00a0adherencia \u00a0fue\u00a0mejor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0100\u00a0mg\u00a0de\u00a0RTV266.\u00a0En\u00a0\nvoluntarios \u00a0sanos\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0FPV\u00a0(1400\u00a0mg\u00a0QD)\u00a0\nno\u00a0difieren\u00a0si\u00a0se\u00a0potencia\u00a0con\u00a0100\u00a0o\u00a0200\u00a0mg\u00a0de\u00a0RTV267.\u00a0\u00a0\n\u00a0ARTEMIS \u00a0\nEl\u00a0estudio\u00a0ARTEMIS\u00a0compar\u00f3\u00a0DRV/r\u00a0(800/100\u00a0mg,\u00a0QD)\u00a0frente\u00a0a\u00a0LPV/r\u00a0(BID\u00a0y\u00a0QD)\u00a0en\u00a0689\u00a0\npacientes \u00a0que\u00a0recibieron \u00a0adem\u00e1s\u00a0TDF/FTC\u00a0coformulados. \u00a0La\u00a0dosificaci\u00f3n \u00a0de\u00a0LPV/r\u00a0fue\u00a0\nvariable:\u00a077%\u00a0recibieron \u00a0el\u00a0LPV/r\u00a0BID,\u00a015%\u00a0QD\u00a0y,\u00a0adem\u00e1s,\u00a0el\u00a07%\u00a0cambi\u00f3\u00a0de\u00a0BID\u00a0a\u00a0QD\u00a0\ndurante\u00a0el\u00a0estudio.\u00a0El\u00a015%\n\u00a0recibi\u00f3\u00a0LPV/r\u00a0en\u00a0c\u00e1psulas,\u00a0el\u00a02%\u00a0en\u00a0comprimidos \u00a0y\u00a0el\u00a083%\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 35cambiaron \u00a0de\u00a0c\u00e1psulas\u00a0a\u00a0comprimidos \u00a0durante\u00a0el\u00a0estudio.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0\nproporci\u00f3n \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a084%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0DRV/r\u00a0y\u00a078%\u00a0en\u00a0el\u00a0de\u00a0\nLPV/r\u00a0(IC\u00a095%,\u00a0\u22120,3\u00a0a\u00a011,2;\u00a0p=0,062)\u00a0demostrando \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0DRV/r\u00a0frente\u00a0a\u00a0\nLPV/r,\u00a0Los\u00a0pacientes \u00a0tratados\u00a0con\u00a0DRV/r\u00a0presentaron \u00a0menos\u00a0diarrea\u00a0grado\u00a02\u20104\u00a0que\u00a0los\u00a0\ntratados\u00a0con\u00a0LPV/r\u00a0(4%\u00a0frente\u00a010%)\u00a0y\u00a0las\u00a0elevaciones \u00a0lip\u00eddicas\u00a0fueron\u00a0menores\u00a0\n(triglic\u00e9ridos \u00a0y\u00a0colesterol \u00a0total)268.\u00a0A\u00a0las\u00a096\u00a0semanas, \u00a0un\u00a079%\u00a0de\u00a0los\u00a0pacientes \u00a0en\u00a0la\u00a0\nrama\u00a0de\u00a0DRV/r\u00a0y\u00a0un\u00a071%\u00a0en\u00a0la\u00a0LPV/r\u00a0ten\u00edan\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0confirmando \u00a0no\u00a0s\u00f3lo\u00a0la\u00a0\nno\u00a0inferioridad \u00a0(diferencia \u00a0estimada: \u00a08,4%;\u00a0IC\u00a095%,\u00a01,9\u00a0a\u00a014,8;\u00a0p\u00a0<0,001),\u00a0sino\u00a0tambi\u00e9n\u00a0\nla\u00a0superioridad \u00a0de\u00a0DRV/r\u00a0sobre\u00a0LPV/r\u00a0(ITT,\u00a0P\u00a0=\u00a00,012).\u00a0Dado\u00a0que\u00a0se\u00a0trata\u00a0de\u00a0un\u00a0objetivo\u00a0\nsecundario \u00a0y\u00a0de\u00a0un\u00a0estudio\u00a0abierto,\u00a0estas\u00a0diferencias \u00a0deben\u00a0ser\u00a0interpretadas \u00a0con\u00a0\nprecauci\u00f3n. \u00a0Un\u00a04%\u00a0de\u00a0los\u00a0pacientes \u00a0de\u00a0la\u00a0rama\u00a0de\u00a0DRV/r\u00a0y\u00a0un\u00a09%\u00a0de\u00a0los\u00a0la\u00a0rama\u00a0de\u00a0\nLPV/r\u00a0abandonaron \u00a0el\u00a0tratamiento \u00a0asignado269.\u00a0A\u00a0las\u00a0192\u00a0semanas, \u00a0el\u00a068,8%\u00a0de\u00a0los\u00a0\npacientes \u00a0con\u00a0DRV/r\u00a0y\u00a0el\u00a057,2%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0LPV/r\u00a0mostraron \u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0corroborando \u00a0la\u00a0no\u00a0inferioridad \u00a0y\u00a0superioridad \u00a0del\u00a0DRV/r.\u00a0Se\u00a0confirma\u00a0as\u00ed\u00a0el\u00a0\nbuen\u00a0perfil\u00a0de\u00a0tolerabilidad \u00a0del\u00a0DRV\u00a0tras\u00a04\u00a0a\u00f1os\u00a0de\u00a0tratamiento270.\u00a0\n\u00a0GEMINI\u00a0\nEl\u00a0estudio\u00a0GEMINI\u00a0compar\u00f3\u00a0SQV/r\u00a0(1000/100 \u00a0mg,\u00a0BID)\u00a0frente\u00a0a\u00a0LPV/r\u00a0(300/100\u00a0mg\u00a0BID,\u00a0\nc\u00e1psulas)\u00a0en\u00a0337\u00a0pacientes. \u00a0Todos\u00a0recibieron \u00a0adem\u00e1s\u00a0TDF/FTC\u00a0coformulados. \u00a0A\u00a0las\u00a048\u00a0\nsemanas\u00a0la\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a064,7%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0SQV/r\u00a0y\u00a0\nde\u00a063,5%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0LPV/r\n\u00a0(IC\u00a095%,\u00a0\u20139,6\u00a0a\u00a0\u201311,9).\u00a0El\u00a0estudio\u00a0demostr\u00f3 \u00a0no\u00a0\ninferioridad \u00a0de\u00a0SQV/r\u00a0frente\u00a0a\u00a0LPV/r.\u00a0Las\u00a0elevaciones \u00a0lip\u00eddicas\u00a0fueron\u00a0similares\u00a0con\u00a0un\u00a0\nincremento \u00a0mayor\u00a0de\u00a0triglic\u00e9ridos \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0LPV/r\u00a0y\u00a0de\u00a0C\u2010LDL\u00a0en\u00a0el\u00a0de\u00a0SQV/r271.\u00a0\n\u00a0BMS\u2010089\u00a0\nEl\u00a0estudio\u00a0BMS\u00a0089\u00a0compar\u00f3\u00a0ATV\u00a0(400\u00a0mg\u00a0QD)\u00a0frente\u00a0a\u00a0ATV/r\u00a0(300/100\u00a0mg,\u00a0QD).\u00a0Se\u00a0\nincluyeron \u00a0200\u00a0pacientes \u00a0que\u00a0recibieron \u00a0adem\u00e1s\u00a0d4T\u00a0de\u00a0liberaci\u00f3n \u00a0retardada \u00a0(100\u00a0mg\u00a0\nQD)\u00a0y\u00a03TC\u00a0(300\u00a0mg\u00a0QD).\u00a0A\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(ITT)\u00a0fue\n\u00a075%\u00a0(ATV/r)\u00a0y\u00a070%\u00a0(ATV).\u00a0En\u00a0este\u00a0estudio\u00a0se\u00a0demostr\u00f3 \u00a0la\u00a0no\u00a0\ninferioridad \u00a0de\u00a0ATV/r\u00a0frente\u00a0a\u00a0ATV\u00a0sin\u00a0potenciar. \u00a0Las\u00a0causas\u00a0de\u00a0fracaso\u00a0terap\u00e9utico \u00a0\nfueron\u00a0diferentes \u00a0en\u00a0los\u00a0dos\u00a0brazos.\u00a0Hubo\u00a0m\u00e1s\u00a0fracasos\u00a0virol\u00f3gicos \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV\u00a0\nno\u00a0potenciado \u00a0(10\u00a0frente\u00a0a\u00a03;\u00a0p:\u00a0ns).\u00a0Los\u00a0que\u00a0fracasaron \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV/r\u00a0no\u00a0\ntuvieron\u00a0mutaciones \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa\u00a0mientras\u00a0que\u00a0se\u00a0detectaron \u00a0en\u00a03\u00a0de\u00a0los\u00a0\n10\u00a0que\u00a0fracasaron \u00a0con\u00a0ATV\u00a0sin\u00a0potenciar. \u00a0Tambi\u00e9n\u00a0hubo\u00a0m\u00e1s\u00a0mutaciones \u00a0a\u00a03TC\u00a0en\u00a0el\u00a0\ngrupo\u00a0no\u00a0potenciado \u00a0(7\u00a0de\u00a010,\u00a0frente\u00a0a\u00a01\u00a0de\u00a03).\u00a0Las\u00a0suspensiones \u00a0de\u00a0tratamiento \u00a0por\u00a0\nhiperbilirrubinemia \u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0con\u00a0ATV/r.\u00a0El\u00a0estudio\u00a0pone\u00a0de\u00a0manifiesto \u00a0la\u00a0\nmayor\u00a0eficacia\u00a0virol\u00f3gica \u00a0y\u00a0barrera\u00a0gen\u00e9tica\u00a0de\u00a0ATV/r272.\u00a0\u00a0\n\u00a0Estudio\u00a01182.33\u00a0\u00a0\nEl\u00a0estudio\u00a01182.33\u00a0intent\u00f3\u00a0comparar \u00a0dos\u00a0dosis\u00a0de\u00a0TPV/r\u00a0(500/100\u00a0BID\u00a0y\u00a0500/200\u00a0BID)\u00a0\nfrente\u00a0a\u00a0LPV/r\u00a0(400/100\u00a0BID).\u00a0El\u00a0comit\u00e9\u00a0de\u00a0vigilancia\u00a0decidi\u00f3\u00a0parar\u00a0el\u00a0estudio\u00a0por\u00a0mayor\u00a0\ntasa\u00a0de\u00a0elevaci\u00f3n \u00a0asintom\u00e1tica \u00a0de\u00a0enzimas\u00a0hep\u00e1ticas \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TPV/r\u00a0\u00a0500/200\u00a0BID\u00a0\ny\u00a0por\u00a0no\u00a0alcanzar\u00a0el\n\u00a0criterio\u00a0de\u00a0no\u00a0inferioridad \u00a0a\u00a0la\u00a0semana\u00a060\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TPV/r\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 36500/100\u00a0BID.\u00a0Debido\u00a0a\u00a0estos\u00a0resultados \u00a0no\u00a0se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0TPV/r\u00a0en\u00a0terapias\u00a0\nde\u00a0inicio\u00a0(N\u00famero\u00a0de\u00a0identificaci\u00f3n \u00a0en\u00a0ClinicalTrials.gov \u00a0NCT00144105) \u00a0\n\u00a0Estudio\u00a0730\u00a0\nLa\u00a0combinaci\u00f3n \u00a0TDF+FTC+ \u00a0LPV/r\u00a0(comprimidos, \u00a0BID)\u00a0se\u00a0ha\u00a0comparado \u00a0con\u00a0la\u00a0\ncombinaci\u00f3n \u00a0TDF+FTC+LPV/r \u00a0(comprimidos, \u00a0QD)\u00a0en\u00a0664\u00a0pacientes \u00a0que\u00a0recib\u00edan\u00a0el\u00a0\nprimer\u00a0tratamiento. \u00a0Este\u00a0ensayo\u00a0cl\u00ednico\n\u00a0demuestra \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0LPV/r\u00a0\ncomprimidos \u00a0administrado \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0frente\u00a0a\u00a0LPV/r\u00a0comprimidos \u00a0administrados \u00a0\ndos\u00a0veces\u00a0al\u00a0d\u00eda.\u00a0\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0cargas\u00a0virales\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a0\ndel\u00a077%\u00a0en\u00a0el\u00a0grupo\u00a0QD\u00a0y\u00a0del\u00a076%\u00a0en\u00a0el\u00a0grupo\u00a0BID.\u00a0Durante\u00a0las\u00a0primeras\u00a08\u00a0semanas\u00a0del\u00a0\nestudio\u00a0los\u00a0pacientes \u00a0en\u00a0cada\u00a0grupo\u00a0fueron\u00a0aleatorizados \u00a0adem\u00e1s\u00a0a\u00a0recibir\u00a0las\u00a0c\u00e1psulas\u00a0\no\u00a0los\u00a0comprimidos \u00a0de\u00a0LPV/r\u00a0sin\u00a0encontrar \u00a0diferencias \u00a0entre\u00a0ambas\u00a0presentaciones \u00a0\nrespecto\u00a0a\u00a0la\u00a0incidencia \u00a0de\u00a0efectos\u00a0adversos\u00a0o\u00a0a\u00a0discontinuaciones \u00a0por\u00a0toxicidad263.\u00a0\u00a0\n\u00a0\nEstudio\u00a0CASTLE\u00a0\u00a0\nEste\u00a0ensayo\u00a0compara\u00a0la\u00a0combinaci\u00f3n \u00a0TDF+FTC+ATV/r \u00a0QD\u00a0con\u00a0la\u00a0combinaci\u00f3n \u00a0\nTDF+FTC+LPV/r \u00a0(c\u00e1psulas) \u00a0BID\u00a0en\u00a0883\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo,\u00a0demostrando \u00a0\nla\u00a0no\u2010inferioridad \u00a0de\u00a0ATV/r\u00a0frente\u00a0a\u00a0LPV/r\u00a0en\u00a0su\u00a0forma\u00a0de\u00a0c\u00e1psulas.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0cargas\u00a0virales\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a0de\u00a078%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ATV/r\u00a0y\u00a0de\u00a0\n76%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0LPV/r.\u00a0ATV/r\u00a0mostr\u00f3\u00a0mejor\u00a0perfil\u00a0lip\u00eddico\u00a0(colesterol \u00a0total,\u00a0\ntriglic\u00e9ridos \u00a0y\u00a0colesterol \u00a0no\u2010HDL).\u00a0La\u00a0ictericia\u00a0e\u00a0hiperbilirrubinemia \u00a0fueron\u00a0m\u00e1s\u00a0\nfrecuentes \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ATV/r\u00a0mientras\u00a0que\u00a0la\u00a0diarrea\u00a0y\u00a0las\u00a0n\u00e1useas\u00a0lo\u00a0fueron\u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0LPV/r273.\u00a0A\u00a0las\u00a096\u00a0semanas, \u00a0el\u00a074%\u00a0frente\u00a0a\u00a068%\u00a0de\u00a0los\u00a0pacientes \u00a0en\u00a0las\u00a0ramas\u00a0\nde\u00a0ATV/r\u00a0y\u00a0de\u00a0LPV/r,\u00a0respectivamente \u00a0ten\u00edan\u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT,\u00a0p\u00a0<0,05),\u00a0con\u00a0\nlo\u00a0que\u00a0se\u00a0confirmaba \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ATV/r\u00a0con\u00a0respecto\u00a0a\u00a0LPV/R.\u00a0Los\u00a0abandonos \u00a0\nen\u00a0ambas\u00a0ramas\u00a0fueron\u00a0del\u00a07%274.\u00a0\n\u00a0\nResumen \u00a0sobre\u00a0ensayos\u00a0de\u00a0IP\u00a0en\u00a0pacientes \u00a0sin\u00a0terapia\u00a0previa\u00a0\nLos\u00a0estudios\u00a0han\u00a0demostrado \u00a0que\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0un\u00a0IP\u00a0(LPV,\u00a0SQV,\u00a0FPV,\u00a0ATV,\u00a0DRV)\u00a0\npotenciado \u00a0tiene\u00a0ventajas\u00a0de\u00a0eficacia\u00a0y\u00a0barrera\u00a0gen\u00e9tica\u00a0respecto\u00a0a\u00a0los\u00a0IP\u00a0no\u00a0\npotenciados \u00a0y\u00a0el\u00a0principal\u00a0inconveniente \u00a0de\u00a0la\u00a0potenciaci\u00f3n \u00a0es\u00a0el\u00a0aumento\u00a0de\u00a0efectos\u00a0\nadversos. \u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0IP\u00a0\n\u0083 Como\u00a0IP\u00a0de\u00a0primera\u00a0elecci\u00f3n\u00a0se\u00a0recomienda \u00a0ATV/r\u00a0QD,\u00a0DRV/r\u00a0QD,\u00a0LPV/r\u00a0BID\u00a0o\u00a0QD\u00a0\n(nivel\u00a0A).\u00a0Los\u00a0tres\u00a0IP,\u00a0que\u00a0se\u00a0han\u00a0ordenado \u00a0alfab\u00e9ticamente, \u00a0tienen\u00a0una\u00a0potencia\u00a0\nantiviral\u00a0similar\u00a0y\u00a0diferencias \u00a0en\u00a0tolerancia \u00a0y\u00a0perfil\u00a0metab\u00f3lico \u00a0(nivel\u00a0A)\u00a0\n\u0083 FPV/r\u00a0o\u00a0SAQ/r\u00a0se\u00a0pueden\u00a0utilizar\u00a0como\u00a0pautas\u00a0alternativas. \u00a0Ambos\u00a0f\u00e1rmacos \u00a0est\u00e1n\u00a0\nrespaldados \u00a0por\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0comparativo \u00a0con\u00a0LPV/r\u00a0y\u00a0est\u00e1n\u00a0aprobados \u00a0por\u00a0la\u00a0\nEMA\u00a0(nivel\u00a0A)\u00a0\n\u0083 Tambi\u00e9n\u00a0se\u00a0deben\u00a0considerar \u00a0alternativas \u00a0otras\u00a0dosificaciones \u00a0de\u00a0IP/r\u00a0o\u00a0IP\u00a0no\u00a0\npotenciados: \u00a0ATV\u00a0(200\u00a0mg\u00a0BID),\u00a0FPV/r\u00a0(1400/200) \u00a0QD\u00a0o\u00a0FPV/r\u00a0(1400/100) \u00a0QD.\u00a0Estas\u00a0\ndosificaciones \u00a0carecen\u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0con\u00a0tama\u00f1o\u00a0muestral\u00a0adecuado \u00a0que\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 37valoren\u00a0su\u00a0eficacia\u00a0frente\u00a0a\u00a0un\u00a0IP\u00a0de\u00a0primera\u00a0elecci\u00f3n\u00a0y\u00a0no\u00a0han\u00a0sido\u00a0aprobadas \u00a0por\u00a0\nla\u00a0EMA\u00a0\u00a0\n\u0083 La\u00a0combinaci\u00f3n \u00a0ddI+FTC+ATV \u00a0(no\u00a0potenciado) \u00a0no\u00a0debe\u00a0utilizarse\u00a0en\u00a0pacientes \u00a0sin\u00a0\nTAR\u00a0previo\u00a0por\u00a0riesgo\u00a0elevado\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0(nivel\u00a0A)\u00a0\n\u0083 NFV,\u00a0IDV/r,\u00a0TPV/r\u00a0y\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas\u00a0no\u00a0deben\u00a0utilizarse\u00a0en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo\u00a0(nivel\u00a0A)\u00a0\n\u00a0\n4.6.\u00a0Inhibidores \u00a0del\u00a0correceptor \u00a0CCR5\u00a0\nLos\u00a0inhibidores \u00a0del\u00a0correceptor \u00a0CCR5\u00a0act\u00faan\u00a0bloqueando \u00a0la\u00a0entrada\u00a0de\u00a0VIH\u00a0en\u00a0la\u00a0c\u00e9lula\u00a0\ndiana.\u00a0Estos\u00a0f\u00e1rmacos \u00a0son\u00a0activos\u00a0solamente \u00a0si\u00a0el\u00a0virus\u00a0tiene\u00a0tropismo\u00a0R5.\u00a0\nMVC\u00a0es\u00a0el\u00a0inhibidor\u00a0del\u00a0correceptor \u00a0CCR5\u00a0que\u00a0ha\u00a0sido\u00a0aprobado \u00a0para\u00a0tratamientos \u00a0en\u00a0\npacientes \u00a0pretratados \u00a0con\u00a0tropismo\u00a0R5\u00a0(Tabla\u00a08).\u00a0\u00a0\u00a0\n\u00a0\nEnsayo\u00a0que\u00a0avala\u00a0la\u00a0recomendaci\u00f3n \u00a0de\u00a0inhibidores \u00a0de\u00a0CCR5\u00a0\nMERIT\u00a0\nEl\u00a0estudio\u00a0MERIT\u00a0es\u00a0un\u00a0ensayo\u00a0que\u00a0compar\u00f3\u00a0MVC\u00a0(300\u00a0mg,\u00a0BID),\u00a0con\u00a0MVC\u00a0(600\u00a0mg,\u00a0\nQD)\u00a0con\u00a0EFV\u00a0(600\u00a0mg,\u00a0QD)\u00a0en\u00a0pacientes \u00a0infectados \u00a0por\u00a0VIH\u00a0R5\u2010tr\u00f3pico\u00a0y\u00a0sin\u00a0terapia\u00a0\nprevia.\u00a0Los\u00a0pacientes \u00a0recibieron \u00a0adem\u00e1s\u00a0ZDV+3TC. \u00a0El\u00a0grupo\u00a0de\u00a0MVC\u00a0QD\u00a0fue\u00a0\ninterrumpido \u00a0a\u00a0la\u00a0semana\u00a016\u00a0por\u00a0no\u00a0alcanzar\u00a0el\u00a0criterio\u00a0virol\u00f3gico \u00a0definido\u00a0en\u00a0el\u00a0\nprotocolo. \u00a0\nA\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a065,3%\u00a0y\u00a0\n69,3%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0MVC\u00a0y\u00a0de\u00a0EFV\u00a0(l\u00edmite\u00a0inferior\u00a0del\u00a0IC\u00a097,5%,\u00a0\u201310,9%).\u00a0\u00a0La\u00a0\nproporci\u00f3n \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar)\u00a0fue\u00a070,6\u00a0%\u00a0y\u00a0\n73,1%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0MVC\u00a0y\u00a0de\u00a0EFV\u00a0(l\u00edmite\u00a0inferior\u00a0del\u00a0IC\u00a097,5%\u00a0\u22649,5%).\u00a0El\u00a0l\u00edmite\u00a0\ninferior\u00a0del\u00a0IC\u00a0al\u00a097,5%,\u00a0de\u00a0no\u00a0inferioridad, \u00a0que\u00a0se\u00a0estableci\u00f3 \u00a0para\u00a0este\u00a0ensayo\u00a0cl\u00ednico\u00a0\nfue\u00a0de\u00a0\u201010%.\u00a0Por\u00a0lo\u00a0tanto\u00a0el\u00a0estudio\u00a0demostr\u00f3 \u00a0la\u00a0no\u2010inferioridad \u00a0de\u00a0MVC\u00a0para\u00a0el\u00a0criterio\u00a0\nde\u00a0400\u00a0copias/mL \u00a0pero\u00a0no\u00a0para\u00a0el\u00a0de\u00a050\u00a0copias/mL. \u00a0La\u00a0discontinuaci\u00f3n \u00a0del\u00a0TAR\u00a0por\u00a0\nfalta\u00a0de\u00a0eficacia\u00a0fue\u00a0m\u00e1s\u00a0frecuente \u00a0con\u00a0MVC\u00a0(11,9%)\u00a0que\u00a0con\u00a0EFV\u00a0(4,2%),\u00a0pero\u00a0por\u00a0\nefectos\u00a0adversos\u00a0la\u00a0discontinuaci\u00f3n \u00a0fue\u00a0mayor\u00a0con\u00a0EFV\u00a0(13,6%)\u00a0que\u00a0con\u00a0MVC\u00a0(4,2%).\u00a0La\u00a0\nrecuperaci\u00f3n \u00a0inmunol\u00f3gica \u00a0fue\u00a0mayor\u00a0con\u00a0MVC\u00a0(170\u00a0frente\u00a0144\u00a0c\u00e9lulas/\u00b5L)275,\u00a0276.\u00a0En\u00a0\nun\u00a0rean\u00e1lisis \u00a0post\u2010hoc\u00a0en\u00a0el\u00a0que\u00a0se\u00a0excluyeron \u00a0107\u00a0pacientes \u00a0(15%),\u00a0con\u00a0virus\u00a0no\u2010R5\u00a0\ncon\u00a0un\u00a0ensayo\u00a0de\u00a0tropismo\u00a0m\u00e1s\u00a0sensible,\u00a0el\u00a0l\u00edmite\u00a0inferior\u00a0de\u00a0no\u00a0inferioridad \u00a0al\u00a097,5%\u00a0\npara\u00a0la\u00a0diferencia \u00a0entre\u00a0tratamientos \u00a0se\u00a0situ\u00f3\u00a0por\u00a0encima\u00a0de\u00a0\u201010%\u00a0para\u00a0cada\u00a0\nobjetivo276.\u00a0\u00a0\n\u00a0\nRecomendaci\u00f3n \u00a0sobre\u00a0inhibidores \u00a0correceptor \u00a0CCR5\u00a0\n\u0083 Este\u00a0comit\u00e9\u00a0considera \u00a0que\u00a0MVC\u00a0s\u00f3lo\u00a0debe\u00a0emplearse \u00a0como\u00a0tratamiento \u00a0de\u00a0inicio\u00a0\nen\u00a0pacientes \u00a0con\u00a0virus\u00a0R5\u00a0tr\u00f3pico\u00a0y\u00a0cuando\u00a0no\u00a0sea\u00a0posible\u00a0un\u00a0tratamiento \u00a0con\u00a0NN\u00a0o\u00a0\ncon\u00a0un\u00a0IP.\u00a0MVC\u00a0no\u00a0est\u00e1\u00a0aprobado \u00a0por\u00a0la\u00a0EMA\u00a0para\u00a0su\u00a0uso\u00a0en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo;\u00a0la\u00a0recomendaci\u00f3n \u00a0se\u00a0basa\u00a0en\u00a0resultados \u00a0del\u00a0estudio\u00a0MERIT\u00a0\n\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 384.7.\u00a0Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nLos\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0act\u00faan\u00a0alterando \u00a0la\u00a0integrasa \u00a0viral\u00a0que\u00a0no\u00a0pueden\u00a0unir\u00a0\nlos\u00a0extremos \u00a0reactivos\u00a0del\u00a0ADN\u00a0viral\u00a0al\u00a0ADN\u00a0celular\u00a0(Tabla\u00a08).\u00a0\u00a0\u00a0\n\u00a0\nEnsayo\u00a0que\u00a0avala\u00a0la\u00a0recomendaci\u00f3n \u00a0de\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nSTARTMRK \u00a0\nEl\u00a0estudio\u00a0STARTMRK \u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico,\u00a0aleatorizado, \u00a0doble\u00a0ciego,\u00a0multic\u00e9ntrico \u00a0e\u00a0\ninternacional \u00a0que\u00a0compara\u00a0EFV\u00a0con\u00a0RAL,\u00a0ambos\u00a0combinados \u00a0con\u00a0TDF/FTC\u00a0en\u00a0566\u00a0\npacientes \u00a0sin\u00a0TAR\u00a0previo277.\u00a0El\u00a0objetivo\u00a0primario\u00a0de\u00a0eficacia\u00a0fue\u00a0la\u00a0consecuci\u00f3n \u00a0de\u00a0una\u00a0\nCVP\u00a0<50\u00a0copias/mL \u00a0a\u00a0la\u00a0semana\u00a048.\u00a0El\u00a0margen\u00a0de\u00a0no\u00a0inferioridad \u00a0fue\u00a0del\u00a012%.\u00a0El\u00a053%\u00a0\nde\u00a0los\u00a0pacientes \u00a0ten\u00edan\u00a0carga\u00a0viral\u00a0basal\u00a0>100.000 \u00a0copias/mL \u00a0y\u00a0un\u00a047%\u00a0un\u00a0recuento\u00a0de\u00a0\nCD4\u00a0<200\u00a0c\u00e9lulas/\u00b5L. \u00a0El\u00a0objetivo\u00a0primario\u00a0del\u00a0estudio\u00a0se\u00a0consigui\u00f3 \u00a0en\u00a0un\u00a086,1%\u00a0de\u00a0los\u00a0\npacientes \u00a0del\u00a0grupo\u00a0de\u00a0RAL\u00a0y\u00a0en\u00a0el\u00a081,9%\u00a0del\u00a0grupo\u00a0de\u00a0EFV\u00a0(diferencia \u00a04,2%;\u00a0IC\u00a095%,\u00a0\u2010\n1,9\u00a0a\u00a010,3).\u00a0El\u00a0grupo\u00a0de\u00a0RAL\u00a0tard\u00f3\u00a0menos\u00a0tiempo\u00a0en\u00a0alcanzar\u00a0la\u00a0indetectabilidad \u00a0que\u00a0el\u00a0\ngrupo\u00a0de\u00a0EFV\u00a0(p\u00a0<\u00a00,0001).\u00a0Los\u00a0efectos\u00a0adversos\u00a0relacionados \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0fueron\u00a0\nm\u00e1s\u00a0frecuentes \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0EFV\u00a0que\u00a0en\u00a0el\u00a0de\u00a0RAL\u00a0(p\u00a0<0,0001)277.\u00a0\u00a0\n\u00a0\nRecomendaci\u00f3n \u00a0sobre\u00a0inhibidores \u00a0integrasa \u00a0\n\u0083 Este\u00a0comit\u00e9\u00a0considera \u00a0que\u00a0RAL\u00a0s\u00f3lo\u00a0debe\u00a0emplearse \u00a0como\u00a0tratamiento \u00a0de\u00a0inicio\u00a0\ncuando\u00a0no\u00a0sea\u00a0posible\u00a0un\u00a0tratamiento \u00a0con\u00a0NN\u00a0o\u00a0IP\u00a0(debido\u00a0a\u00a0su\u00a0precio\u00a0elevado)\u00a0\n\u00a0\n\u00a0\n4.8.\u00a0Pautas\u00a0libres\u00a0de\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sidos \u00a0\nLa\u00a0toxicidad\u00a0inherente \u00a0a\u00a0los\u00a0diversos\u00a0AN\u00a0ha\u00a0llevado\u00a0a\u00a0la\u00a0implementaci\u00f3n \u00a0de\u00a0pautas\u00a0que\u00a0\nintenten\u00a0ahorrar\u00a0al\u00a0paciente\u00a0dicha\u00a0toxicidad. \u00a0Aunque\u00a0en\u00a0\u00e9pocas\u00a0anteriores, \u00a0algunos\u00a0\nensayos\u00a0como\u00a0el\u00a0DMP\u00a0006\u00a0incluyeron \u00a0pautas\u00a0de\u00a0TAR\u00a0que\u00a0inclu\u00edan\u00a0s\u00f3lo\u00a0un\u00a0IP\u00a0potenciado \u00a0\ncon\u00a0un\u00a0NN,\u00a0e\u00a0incluso\u00a0ensayos\u00a0recientes\u00a0como\u00a0el\u00a0ACTG\u00a05142\u00a0han\u00a0incluido\u00a0una\u00a0pauta\u00a0de\u00a0\nLPV/r+EFV. \u00a0Dichas\u00a0pautas\u00a0presentaban \u00a0una\u00a0eficacia\u00a0aceptable, \u00a0pero\u00a0en\u00a0general\u00a0se\u00a0\nacompa\u00f1aban \u00a0de\u00a0un\u00a0exceso\u00a0de\u00a0toxicidad\u00a0metab\u00f3lica \u00a0que\u00a0las\u00a0hac\u00eda\u00a0desaconsejables. \u00a0La\u00a0\naparici\u00f3n \u00a0de\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa, \u00a0f\u00e1rmacos \u00a0con\u00a0una\u00a0actividad\u00a0metab\u00f3lica \u00a0\npr\u00e1cticamente \u00a0neutra,\u00a0ha\u00a0permitido \u00a0retomar\u00a0el\u00a0dise\u00f1o\u00a0de\u00a0pautas\u00a0basadas\u00a0en\u00a0un\u00a0\nIP/r+IInt.\u00a0Existen\u00a0resultados \u00a0preliminares \u00a0de\u00a0un\u00a0estudio\u00a0que\u00a0ha\u00a0evaluado\u00a0la\u00a0factibilidad \u00a0\nde\u00a0dicha\u00a0combinaci\u00f3n \u00a0\n\u00a0\u00a0\u00a0\u00a0\nEnsayo\u00a0que\u00a0avala\u00a0la\u00a0recomendaci\u00f3n \u00a0de\u00a0pautas\u00a0libres\u00a0de\u00a0AN\u00a0\n\u00a0El\u00a0estudio\u00a0PROGRESS \u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico,\u00a0aleatorizado, \u00a0multic\u00e9ntrico \u00a0e\u00a0internacional \u00a0\nque\u00a0compara\u00a0LPV/r+RAL \u00a0con\u00a0LPV/r+TDF/FTC \u00a0en\u00a0206\u00a0pacientes \u00a0sin\u00a0TAR\u00a0previo.\u00a0El\u00a0\nobjetivo\u00a0primario\u00a0de\u00a0eficacia\u00a0fue\u00a0la\u00a0consecuci\u00f3n \u00a0de\u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0a\u00a0la\u00a0semana\u00a0\n48\u00aa\u00a0por\u00a0ITT\u00a0TLOVR.\u00a0El\u00a0margen\u00a0de\u00a0no\u00a0inferioridad \u00a0se\u00a0estableci\u00f3 \u00a0en\u00a0el\u00a0\u201020%\u00a0y\u00a0se\u00a0\nestableci\u00f3 \u00a0tambi\u00e9n\u00a0que\u00a0si\u00a0se\u00a0demostraba \u00a0a\u00a0ese\u00a0respecto, \u00a0se\u00a0evaluar\u00eda\u00a0la\u00a0no\u00a0inferioridad \u00a0\ncon\u00a0respecto\u00a0a\u00a0un\u00a0margen\u00a0del\u00a0\u201012%.\u00a0El\u00a0objetivo\u00a0primario\u00a0del\u00a0estudio\u00a0se\u00a0consigui\u00f3 \u00a0en\u00a0un\u00a0\n83,2%\u00a0de\u00a0los\u00a0pacientes \u00a0del\u00a0grupo\u00a0de\u00a0LPV/r+RAL \u00a0y\u00a0en\u00a0el\u00a084,8%\u00a0del\u00a0grupo\u00a0de\u00a0LPV/r\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 39(diferencia \u00a0\u20101,6%;\u00a0IC\u00a095%,\u00a0\u201012,0\u00a0a\u00a0\u20108,8).\u00a0El\u00a0grupo\u00a0con\u00a0RAL\u00a0tard\u00f3\u00a0menos\u00a0tiempo\u00a0en\u00a0\nalcanzar\u00a0la\u00a0indetectabilidad \u00a0que\u00a0el\u00a0grupo\u00a0con\u00a0TDF/FTC\u00a0(p\u00a0<0,001).\u00a0Los\u00a0efectos\u00a0adversos\u00a0\nrelacionados \u00a0con\u00a0el\u00a0TAR\u00a0que\u00a0obligaron \u00a0a\u00a0interrumpirlo \u00a0fueron\u00a0del\u00a02,0%\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0\nLPV/r+RAL \u00a0y\u00a0del\u00a01,9%\u00a0en\u00a0la\u00a0de\u00a0LPV/r+TDF/FTC278.\u00a0\u00a0\n\u00a0\nRecomendaci\u00f3n \u00a0sobre\u00a0pautas\u00a0libres\u00a0de\u00a0AN\u00a0\n\u0083 Este\u00a0comit\u00e9\u00a0considera \u00a0que\u00a0las\u00a0combinaciones \u00a0de\u00a0IP/r\u00a0con\u00a0IInt\u00a0est\u00e1n\u00a0en\u00a0fase\u00a0de\u00a0\nestudio\u00a0y\u00a0por\u00a0tanto,\u00a0s\u00f3lo\u00a0debe\u00a0considerarse \u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0inicio\u00a0cuando\u00a0no\u00a0\nsea\u00a0posible\u00a0un\u00a0tratamiento \u00a0que\u00a0incluya\u00a0AN.\u00a0RAL\u00a0est\u00e1\u00a0aprobado \u00a0por\u00a0la\u00a0EMA\u00a0para\u00a0\ntratamiento \u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0AN.\u00a0Este\u00a0\ncomit\u00e9\u00a0considera \u00a0que\u00a0a\u00a0la\u00a0combinaci\u00f3n \u00a0objeto\u00a0de\u00a0estudio\u00a0debe\u00a0aplicarse\u00a0la\u00a0misma\u00a0\nrestricci\u00f3n \u00a0que\u00a0a\u00a0la\u00a0de\u00a0RAL\u00a0con\u00a0dos\u00a0AN,\u00a0en\u00a0cuanto\u00a0a\u00a0su\u00a0coste.\u00a0Dicha\u00a0limitaci\u00f3n \u00a0se\u00a0\nbasa\u00a0de\u00a0forma\u00a0exclusiva\u00a0en\u00a0razones\u00a0de\u00a0coste/beneficio, \u00a0pero\u00a0no\u00a0en\u00a0razones\u00a0de\u00a0\neficacia\u00a0virol\u00f3gica \u00a0o\u00a0de\u00a0seguridad. \u00a0\u00a0\n\u00a0\n4.9.\u00a0Tratamiento \u00a0antirretroviral \u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0con\u00a0eventos\u00a0C\u00a0\nVarios\u00a0ensayos\u00a0cl\u00ednicos\u00a0han\u00a0estudiado \u00a0el\u00a0momento \u00a0id\u00f3neo\u00a0de\u00a0iniciar\u00a0del\u00a0TAR\u00a0en\u00a0\npacientes \u00a0con\u00a0infecciones \u00a0oportunistas \u00a0diagn\u00f3sticas \u00a0de\u00a0sida.\u00a0El\u00a0ACTG\u00a0A5164279\u00a0incluy\u00f3\u00a0\na\u00a0pacientes \u00a0con\u00a0infecciones \u00a0oportunistas \u00a0diferentes \u00a0de\u00a0la\u00a0tuberculosis \u00a0y\u00a0demostr\u00f3 \u00a0que\u00a0\nel\u00a0TAR\u00a0precoz\u00a0(administrado \u00a0antes\u00a0de\u00a0las\u00a02\u00a0semanas\u00a0del\u00a0inicio\u00a0del\u00a0tratamiento \u00a0del\u00a0\nevento\u00a0oportunista) \u00a0redujo\u00a0de\u00a0forma\u00a0significativa \u00a0(49%)\u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0cl\u00ednica\u00a0\n(nueva\u00a0infecci\u00f3n\u00a0oportunista \u00a0o\u00a0muerte)\u00a0con\u00a0respecto\u00a0a\u00a0diferir\u00a0el\u00a0tratamiento \u00a0\nantirretroviral \u00a0(entre\u00a030\u00a0y\u00a0270\u00a0d\u00edas).\u00a0Con\u00a0respecto\u00a0a\u00a0la\u00a0tuberculosis, \u00a0se\u00a0conocen\u00a0los\u00a0\nresultados \u00a0de\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0efectuados \u00a0en\u00a0\u00c1frica.\u00a0El\u00a0ensayo\u00a0cl\u00ednico\u00a0SAPIT280\u00a0\ndemostr\u00f3 \u00a0que\u00a0el\u00a0TAR\u00a0debe\u00a0iniciarse\u00a0durante\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0tuberculosis, \u00a0ya\u00a0que\u00a0\nlos\u00a0pacientes \u00a0que\u00a0lo\u00a0iniciaron\u00a0despu\u00e9s\u00a0de\u00a0haberlo\u00a0finalizado \u00a0tuvieron\u00a0una\u00a0mayor\u00a0\nmortalidad \u00a0(12.1\u00a0frente\u00a0a\u00a05.4\u00a0muertes\u00a0por\u00a0100\u00a0pacientes \u2010a\u00f1o).\u00a0El\u00a0ensayo\u00a0cl\u00ednico\u00a0\nCAMELIA281\u00a0demostr\u00f3 \u00a0en\u00a0pacientes \u00a0con\u00a0tuberculosis \u00a0que\u00a0estaban\u00a0muy\u00a0\ninmunodeprimidos \u00a0(mediana \u00a0de\u00a0linfocitos\u00a0CD4\u00a0de\u00a025\u00a0c\u00e9lulas/\u00b5L) \u00a0que\u00a0el\u00a0TAR\u00a0precoz\u00a0\n(administrado \u00a0antes\u00a0de\u00a0las\u00a02\u00a0semanas\u00a0del\u00a0inicio\u00a0del\u00a0tratamiento \u00a0de\u00a0la\u00a0tuberculosis) \u00a0\ntambi\u00e9n\u00a0redujo\u00a0de\u00a0forma\u00a0significativa \u00a0la\u00a0mortalidad \u00a0(8.3%\u00a0frente\u00a0a\u00a013.8%)\u00a0con\u00a0respecto\u00a0\nal\u00a0inicio\u00a0del\u00a0TAR\u00a0a\u00a0partir\u00a0de\u00a0las\u00a08\u00a0semanas\u00a0de\u00a0iniciado\u00a0el\u00a0tratamiento \u00a0antituberculoso. \u00a0\nEn\u00a0todos\u00a0estos\u00a0ensayos\u00a0cl\u00ednicos\u00a0el\u00a0TAR\u00a0precoz\u00a0se\u00a0acompa\u00f1\u00f3 \u00a0de\u00a0una\u00a0mayor\u00a0incidencia \u00a0\ndel\u00a0s\u00edndrome \u00a0inflamatorio \u00a0de\u00a0reconstituci\u00f3n \u00a0inmune\u00a0(SIRI)\u00a0pero\u00a0sin\u00a0mortalidad. \u00a0Estos\u00a0\nexcelentes \u00a0resultados \u00a0del\u00a0TAR\u00a0precoz\u00a0en\u00a0pacientes \u00a0con\u00a0infecciones \u00a0oportunistas \u00a0no\u00a0se\u00a0\nhan\u00a0podido\u00a0confirmar \u00a0en\u00a0la\u00a0meningitis \u00a0tuberculosa \u00a0y\u00a0criptoc\u00f3cica. \u00a0Dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0\nefectuados \u00a0respectivamente \u00a0en\u00a0Vietnam\u00a0y\u00a0en\u00a0Uganda\u00a0demostraron \u00a0que\u00a0el\u00a0TAR\u00a0precoz\u00a0\nno\u00a0redujo\u00a0la\u00a0mortalidad \u00a0de\u00a0la\u00a0meningitis \u00a0tuberculosa282\u00a0y\u00a0la\u00a0aument\u00f3\u00a0en\u00a0la\u00a0meningitis \u00a0\ncriptoc\u00f3cica283.\u00a0Se\u00a0desconocen \u00a0las\u00a0causas,\u00a0pero\u00a0probablemente \u00a0el\u00a0peor\u00a0manejo\u00a0cl\u00ednico\u00a0\nde\u00a0estas\u00a0dos\u00a0infecciones \u00a0oportunistas \u00a0en\u00a0pa\u00edses\u00a0pobres\u00a0y\u00a0el\u00a0SIRI\u00a0en\u00a0un\u00a0compartimento \u00a0\ncerrado\u00a0como\u00a0el\u00a0SNC\u00a0podr\u00edan\u00a0justificarlo. \u00a0\u00a0\n\u00a0\nCon\u00a0respecto\u00a0a\u00a0las\u00a0neoplasias \u00a0asociadas \u00a0al\u00a0Sida\u00a0(SK,\u00a0linfoma\u00a0y\u00a0carcinoma \u00a0de\u00a0c\u00e9rvix)\u00a0el\u00a0\nTAR\u00a0debe\u00a0iniciarse\u00a0de\u00a0forma\u00a0precoz\u00a0evitando\u00a0en\u00a0lo\u00a0posible\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0reciban\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 40quimioterapia \u00a0la\u00a0utilizaci\u00f3n \u00a0de\u00a0pautas\u00a0con\u00a0inhibidores \u00a0de\u00a0la\u00a0proteasas \u00a0debido\u00a0a\u00a0que\u00a0\naumentan \u00a0su\u00a0toxicidad. \u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0TAR\u00a0en\u00a0pacientes \u00a0con\u00a0eventos\u00a0tipo\u00a0C\u00a0\n\u0083 En\u00a0pacientes \u00a0que\u00a0se\u00a0diagnostican \u00a0con\u00a0eventos\u00a0C\u00a0el\u00a0TAR\u00a0debe\u00a0administrarse \u00a0de\u00a0\nforma\u00a0precoz\u00a0(en\u00a0el\u00a0primer\u00a0mes\u00a0e\u00a0idealmente \u00a0en\u00a0las\u00a0primeras\u00a0dos\u00a0semanas) \u00a0(nivel\u00a0\nA)\u00a0\n\u0083 Las\u00a0excepciones \u00a0son\u00a0\u00a0los\u00a0pacientes \u00a0con\u00a0meningitis \u00a0tuberculosa \u00a0y\u00a0criptoc\u00f3cica \u00a0en\u00a0los\u00a0\nque\u00a0se\u00a0desconoce \u00a0cu\u00e1l\u00a0es\u00a0el\u00a0mejor\u00a0momento \u00a0para\u00a0iniciarlo\u00a0y\u00a0los\u00a0pacientes \u00a0con\u00a0\ntuberculosis \u00a0con\u00a0cifras\u00a0de\u00a0CD4\u00a0mayores\u00a0de\u00a0100\u00a0c\u00e9lulas/\u00b5L \u00a0en\u00a0los\u00a0que\u00a0ensayos\u00a0\ncl\u00ednicos\u00a0que\u00a0est\u00e1n\u00a0en\u00a0marcha\u00a0indicar\u00e1n \u00a0si\u00a0el\u00a0TAR\u00a0debe\u00a0administrase \u00a0de\u00a0forma\u00a0\nprecoz\u00a0o\u00a0puede\u00a0diferirse\u00a0a\u00a0las\u00a08\u00a0semanas, \u00a0cuando\u00a0se\u00a0inicia\u00a0la\u00a0fase\u00a0de\u00a0\nmantenimiento \u00a0de\u00a0la\u00a0tuberculosis. \u00a0\n\u00a0\n5.\u00a0MODIFICACI\u00d3N \u00a0DEL\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\n5.1.\u00a0Fracaso\u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0\nEl\u00a0fracaso\u00a0del\u00a0TAR\u00a0se\u00a0puede\u00a0entender \u00a0desde\u00a0tres\u00a0puntos\u00a0de\u00a0vista:\u00a0virol\u00f3gico, \u00a0\ninmunol\u00f3gico \u00a0y\u00a0cl\u00ednico.\u00a0\nLa\u00a0incidencia \u00a0de\u00a0fracaso\u00a0virol\u00f3gico, \u00a0sus\u00a0causas\u00a0y\u00a0el\u00a0perfil\u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0\nseleccionadas \u00a0han\u00a0cambiado \u00a0desde\u00a0el\u00a0inicio\u00a0de\u00a0TAR\u00a0paralelamente \u00a0a\u00a0los\u00a0reg\u00edmenes \u00a0de\u00a0\nTAR\u00a0utilizados. \u00a0Tras\u00a0la\u00a0introducci\u00f3n \u00a0de\u00a0los\u00a0NN\u00a0y\u00a0los\u00a0IP/r,\u00a0y\u00a0la\u00a0sustituci\u00f3n \u00a0de\u00a0los\u00a0AN\u00a0\ntimid\u00ednicos \u00a0se\u00a0ha\u00a0reducido\u00a0sustancialmente \u00a0no\u00a0solo\u00a0la\u00a0incidencia \u00a0del\u00a0fracaso\u00a0al\u00a0primer\u00a0\nTAR\u00a0sino\u00a0tambi\u00e9n\u00a0el\u00a0tipo\u00a0de\u00a0mutaciones \u00a0emergentes \u00a0con\u00a0reducci\u00f3n \u00a0de\u00a0las\u00a0TAMs\u00a0y\u00a0las\u00a0\nmutaciones \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa189.\u00a0La\u00a0toxicidad\u00a0fue\u00a0inicialmente \u00a0la\u00a0causa\u00a0m\u00e1s\u00a0\nfrecuente \u00a0de\u00a0fracaso\u00a0terap\u00e9utico \u00a0por\u00a0retirada\u00a0del\u00a0tratamiento. \u00a0Con\u00a0los\u00a0reg\u00edmenes \u00a0\nusados\u00a0actualmente \u00a0se\u00a0ha\u00a0reducido\u00a0dr\u00e1sticamente \u00a0la\u00a0frecuencia \u00a0de\u00a0fracaso\u00a0terap\u00e9utico \u00a0\ny\u00a0las\u00a0tasas\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0(definido\u00a0como\u00a0>50\u00a0copias/mL) \u00a0en\u00a0primeras\u00a0l\u00edneas\u00a0de\u00a0\ntratamiento \u00a0est\u00e1n\u00a0entre\u00a0el\u00a020\u201040%,\u00a0aunque\u00a0al\u00a0menos\u00a0en\u00a0una\u00a0cuarta\u00a0parte\u00a0de\u00a0ellos\u00a0no\u00a0se\u00a0\nconsigue\u00a0amplificar \u00a0el\u00a0estudio\u00a0de\u00a0resistencias \u00a0genot\u00edpico \u00a0debido\u00a0a\u00a0la\u00a0presencia \u00a0de\u00a0\ncargas\u00a0virales\u00a0bajas\u00a0(<500\u00a0copias/mL)254,\u00a0284.\u00a0\nEn\u00a0la\u00a0\u00e9poca\u00a0moderna\u00a0se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0pautas\u00a0de\u00a0gran\u00a0eficacia,\u00a0sencillas\u00a0y\u00a0con\u00a0\nescasa\u00a0toxicidad\u00a0que\u00a0combinan \u00a0AN\u00a0coformulados \u00a0no\u00a0timid\u00ednicos \u00a0y\u00a0NN,\u00a0IP/r\u00a0o\u00a0RAL.\u00a0\u00a0\nLos\u00a0sucesivos \u00a0fracasos\u00a0terap\u00e9uticos \u00a0con\u00a0acumulaci\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencias \u00a0\nfrente\u00a0a\u00a0diferentes \u00a0familias\u00a0de\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0limitan\u00a0las\u00a0posibilidades \u00a0de\u00a0\n\u00e9xito\u00a0del\u00a0TAR,\u00a0obligan\u00a0al\u00a0uso\u00a0de\u00a0reg\u00edmenes \u00a0m\u00e1s\u00a0caros\u00a0y\u00a0complejos \u00a0y\u00a0se\u00a0asocian\u00a0con\u00a0y\u00a0\nmayor\u00a0incidencia \u00a0de\u00a0sida\u00a0y\u00a0muerte285.\u00a0\n\u00a0Factores\u00a0que\u00a0influyen\u00a0en\u00a0el\u00a0fracaso\u00a0terap\u00e9utico \u00a0\nEstos\u00a0pueden\u00a0clasificarse \u00a0en\u00a03\u00a0grupos\u00a0seg\u00fan\u00a0dependan \u00a0del\u00a0paciente, \u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0o\u00a0\ndel\u00a0virus.\u00a0\u00a0\nEntre\u00a0los\u00a0primeros, \u00a0el\u00a0m\u00e1s\u00a0importante \u00a0es\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento \u00a0que\u00a0es\u00a0el\u00a0mejor\u00a0\npredictor \u00a0de\u00a0respuesta \u00a0terap\u00e9utica\n286\u2010288.\u00a0Si\u00a0se\u00a0detecta\u00a0un\u00a0fracaso\u00a0virol\u00f3gico \u00a0sin\u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0debe\u00a0valorarse \u00a0la\u00a0falta\u00a0de\u00a0adherencia \u00a0como\u00a0causa\u00a0m\u00e1s\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 41probable. \u00a0La\u00a0ausencia\u00a0de\u00a0mutaciones \u00a0en\u00a0este\u00a0escenario, \u00a0no\u00a0excluye\u00a0que\u00a0puedan\u00a0existir\u00a0\nen\u00a0poblaciones \u00a0virales\u00a0minoritarias \u00a0no\u00a0detectables \u00a0por\u00a0las\u00a0pruebas\u00a0de\u00a0detecci\u00f3n \u00a0de\u00a0\nresistencia \u00a0genot\u00edpicas \u00a0convencionales, \u00a0especialmente \u00a0frente\u00a0a\u00a0f\u00e1rmacos\u00a0de\u00a0baja\u00a0\nbarrera\u00a0gen\u00e9tica\u00a0(3TC/FTC, \u00a0NN\u00a0de\u00a0primera\u00a0generaci\u00f3n \u00a0e\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa). \u00a0\nEntre\u00a0los\u00a0factores\u00a0que\u00a0dependen \u00a0del\u00a0f\u00e1rmaco\u00a0se\u00a0considera \u00a0en\u00a0primer\u00a0lugar\u00a0la\u00a0potencia\u00a0\ndel\u00a0r\u00e9gimen\u00a0terap\u00e9utico, \u00a0la\u00a0falta\u00a0de\u00a0niveles\u00a0en\u00a0sangre\u00a0por\u00a0malabsorci\u00f3n \u00a0o\u00a0interacciones \u00a0\nmedicamentosas \u00a0y\u00a0los\u00a0errores\u00a0de\u00a0dosificaci\u00f3n. \u00a0\nEntre\u00a0los\u00a0factores\u00a0que\u00a0dependen \u00a0del\u00a0VIH,\u00a0el\u00a0m\u00e1s\u00a0importante \u00a0es\u00a0la\u00a0resistencia \u00a0a\u00a0los\u00a0FAR\u00a0\nque\u00a0resulta\u00a0de\u00a0la\u00a0interacci\u00f3n \u00a0de\u00a0la\u00a0capacidad \u00a0replicativa \u00a0y\u00a0diversidad \u00a0del\u00a0virus\u00a0y\u00a0la\u00a0\npresi\u00f3n\u00a0farmacol\u00f3gica. \u00a0La\u00a0resistencia \u00a0a\u00a0los\u00a0FAR\u00a0puede\u00a0ser\u00a0transmitida \u00a0a\u00a0otras\u00a0personas, \u00a0\nes\u00a0variable\u00a0seg\u00fan\u00a0\u00e1rea\u00a0o\u00a0colectivo\u00a0de\u00a0pacientes \u00a0estudiados \u00a0y\u00a0m\u00e9todo\u00a0empleado. \u00a0Las\u00a0\ncifras\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0virus\u00a0resistentes \u00a0var\u00edan\u00a0entre\u00a0\u00a0en\u00a0un\u00a07,7\u00a0y\u00a019,2\u00a0%289,\u00a0290.\u00a0\nSe\u00a0estima\u00a0que\u00a0en\u00a0nuestro\u00a0medio\u00a0entre\u00a09\u201012\u00a0%\u00a0las\u00a0infecciones \u00a0recientes\u00a0por\u00a0VIH\u00a0tienen\u00a0\nmutaciones \u00a0de\u00a0resistencia85,\u00a088,\u00a0291\u2010293.\u00a0Las\u00a0mutaciones \u00a0\u00fanicas\u00a0que\u00a0confieren \u00a0con\u00a0\nresistencia \u00a0a\u00a0NN,\u00a0algunas\u00a0de\u00a0las\u00a0que\u00a0confieren \u00a0resistencia \u00a0a\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0\nintegrasa \u00a0o\u00a0determinadas \u00a0mutaciones \u00a0frente\u00a0a\u00a0AN\u00a0comprometen \u00a0la\u00a0eficacia\u00a0de\u00a0los\u00a0\ntratamientos \u00a0de\u00a0primera\u00a0l\u00ednea293.\u00a0El\u00a0uso\u00a0de\u00a0t\u00e9cnicas\u00a0ultrasensibles \u00a0que\u00a0permiten \u00a0\ndetectar\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0en\u00a0variantes\u00a0virales\u00a0minoritarias \u00a0no\u00a0detectables \u00a0con\u00a0\nlas\u00a0t\u00e9cnicas\u00a0convencionales \u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante) \u00a0podr\u00eda\u00a0explicar\u00a0algunos\u00a0de\u00a0los\u00a0\nfracasos\u00a0virol\u00f3gicos \u00a0en\u00a0pacientes \u00a0que\u00a0inician\u00a0un\u00a0TAR\u00a0potencialmente \u00a0eficaz94,\u00a095.\u00a0Dos\u00a0\nestudios\u00a0de\u00a0cohortes\u00a0han\u00a0coincidido \u00a0al\u00a0describir\u00a0que\u00a0si\u00a0se\u00a0logra\u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0\nen\u00a0el\u00a0primer\u00a0TAR,\u00a0el\u00a0rebrote\u00a0de\u00a0la\u00a0CVP\u00a0suele\u00a0asociarse \u00a0a\u00a0mal\u00a0cumplimiento \u00a0o\u00a0toxicidad\u00a0y\u00a0\nen\u00a0muy\u00a0escasas\u00a0ocasiones \u00a0puede\u00a0atribuirse \u00a0a\u00a0falta\u00a0de\u00a0potencia, \u00a0interacciones \u00a0\nmedicamentosas \u00a0o\u00a0\u00a0problemas \u00a0de\u00a0absorci\u00f3n45,\u00a0294.\u00a0\nEl\u00a0fen\u00f3meno \u00a0de\u00a0la\u00a0inmigraci\u00f3n \u00a0obliga\u00a0a\u00a0valorar\u00a0el\u00a0origen\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0\npor\u00a0VIH\u00a0en\u00a0situaci\u00f3n\u00a0de\u00a0fracaso\u00a0virol\u00f3gico. \u00a0El\u00a0uso\u00a0de\u00a0NVP\u00a0en\u00a0dosis\u00a0\u00fanica\u00a0como\u00a0profilaxis\u00a0\nde\u00a0transmisi\u00f3n \u00a0materno\u2010infantil,\u00a0el\u00a0TAR\u00a0poco\u00a0potente,\u00a0la\u00a0escasa\u00a0monitorizaci\u00f3n \u00a0o\u00a0\nproblemas \u00a0de\u00a0distribuci\u00f3n \u00a0y\u00a0almacenaje \u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0\u00a0explican\u00a0el\u00a0aumento\u00a0de\u00a0\nincidencia \u00a0de\u00a0\u00a0fracaso\u00a0virol\u00f3gico \u00a0determinados \u00a0pa\u00edses\u00a0desfavorecidos295\u2010297.\u00a0\u00a0Una\u00a0\nelevada\u00a0proporci\u00f3n \u00a0de\u00a0estos\u00a0pacientes \u00a0son\u00a0portadores \u00a0de\u00a0VIH\u00a0diferentes \u00a0al\u00a0subtipo\u00a0B\u00a0y\u00a0\npor\u00a0lo\u00a0tanto\u00a0con\u00a0patrones\u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0potencialmente \u00a0distintos.\u00a0\nExiste\u00a0una\u00a0mayor\u00a0predisposici\u00f3n \u00a0a\u00a0seleccionar \u00a0la\u00a0mutaci\u00f3n \u00a0K65R\u00a0en\u00a0el\u00a0subtipo\u00a0C298\u00a0y\u00a0en\u00a0\ngeneral\u00a0hay\u00a0menos\u00a0experiencia \u00a0con\u00a0FAR\u00a0en\u00a0subtipos\u00a0no\u00a0B299,\u00a0300.\u00a0Por\u00a0otra\u00a0parte,\u00a0algunos\u00a0\npacientes \u00a0de\u00a0origen\u00a0subsahariano \u00a0padecen\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u20102\u00a0o\u00a0infecci\u00f3n\u00a0dual\u00a0por\u00a0\nVIH\u20101\u00a0y\u00a0VIH\u20102.\u00a0EL\u00a0VIH\u20102\u00a0desarrolla \u00a0patrones\u00a0diferentes \u00a0de\u00a0mutaciones \u00a0tras\u00a0exposici\u00f3n \u00a0a\u00a0\nAN301.\u00a0\u00a0\u00a0\n\u00a0Criterios\u00a0de\u00a0cambio\u00a0de\u00a0TAR\u00a0por\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nLas\u00a0definici\u00f3n \u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0se\u00a0ha\u00a0indicado\u00a0previamente \u00a0(v\u00e9ase\u00a0apartado\u00a02.2).\u00a0\nAnte\u00a0un\u00a0fracaso\u00a0virol\u00f3gico \u00a0es\u00a0recomendable \u00a0repetir\u00a0la\u00a0CVP\u00a0para\u00a0confirmarlo \u00a0y\u00a0cambiar\u00a0\nel\u00a0TAR\u00a0lo\u00a0antes\u00a0posible\u00a0para\u00a0evitar\u00a0el\u00a0ac\u00famulo\u00a0de\u00a0mutaciones \u00a0y\u00a0la\u00a0elevaci\u00f3n \u00a0de\u00a0la\u00a0CVP,\n\u00a0\nfacilitando \u00a0de\u00a0este\u00a0modo\u00a0la\u00a0respuesta \u00a0al\u00a0nuevo\u00a0tratamiento. \u00a0\u00a0\nLos\u00a0\u201cblips\u201d\u00a0son\u00a0rebrotes\u00a0o\u00a0elevaciones \u00a0transitorias \u00a0de\u00a0la\u00a0CVP\u00a0cerca\u00a0del\u00a0umbral\u00a0de\u00a0\ndetecci\u00f3n \u00a0en\u00a0pacientes \u00a0en\u00a0TAR\u00a0y\u00a0con\u00a0CVP\u00a0suprimida. \u00a0En\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estudios\u00a0los\u00a0\n\u201cblips\u201d\u00a0aislados\u00a0no\u00a0se\u00a0asocian\u00a0a\u00a0mayor\u00a0riesgo\u00a0de\u00a0fracaso44,\u00a046,\u00a047,\u00a0302,\u00a0303\u00a0aunque\u00a0otros\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 42estudios\u00a0s\u00ed\u00a0que\u00a0han\u00a0relacionado \u00a0los\u00a0\u201cblips\u201d\u00a0con\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico42,\u00a049\u00a0e\u00a0\nincluso\u00a0se\u00a0ha\u00a0observado \u00a0evoluci\u00f3n \u00a0gen\u00e9tica\u00a0y\u00a0selecci\u00f3n\u00a0de\u00a0resistencias \u00a0en\u00a0los\u00a0\u201cblips\u201d\u00a0\nfrecuentes46,\u00a0302.\u00a0En\u00a0un\u00a0paciente\u00a0con\u00a0\u201cblips\u201d\u00a0frecuentes \u00a0debe\u00a0evaluarse \u00a0la\u00a0potencia\u00a0del\u00a0\nTAR\u00a0y\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento. \u00a0\u00a0\nEl\u00a0fracaso\u00a0inmunol\u00f3gico \u00a0puede\u00a0ir\u00a0precedido \u00a0de\u00a0un\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Algunos\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0indetectable \u00a0presentan \u00a0permanentemente \u00a0un\u00a0n\u00famero\u00a0bajo\u00a0de\u00a0CD\u00a0con\u00a0mayor\u00a0\nriesgo\u00a0de\u00a0morbimortalidad \u00a0secundaria \u00a0a\u00a0sida304\u00a0y\u00a0otros\u00a0procesos. \u00a0Esta\u00a0situaci\u00f3n, \u00a0\nconocida\u00a0como\u00a0discordancia \u00a0inmunol\u00f3gica, \u00a0no\u00a0est\u00e1\u00a0relacionada \u00a0con\u00a0insuficiente \u00a0\npotencia\u00a0del\u00a0TAR.\u00a0En\u00a0estos\u00a0casos\u00a0no\u00a0existe\u00a0ninguna\u00a0prueba\u00a0que\u00a0demuestre \u00a0que\u00a0un\u00a0\ncambio\u00a0de\u00a0tratamiento \u00a0consiga\u00a0una\u00a0mayor\u00a0recuperaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0CD4,\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0\nse\u00a0recomienda \u00a0cambiar\u00a0el\u00a0TAR,\u00a0salvo\u00a0cuando\u00a0incluya\u00a0combinaciones \u00a0que\u00a0se\u00a0asocian\u00a0a\u00a0\ndescenso \u00a0de\u00a0CD4\u00a0(p.e.\u00a0\u00a0ZDV\u00a0o\u00a0TDF\u00a0+\u00a0ddI).\u00a0\u00a0\nEl\u00a0fracaso\u00a0cl\u00ednico\u00a0en\u00a0un\u00a0paciente\u00a0en\u00a0TAR,\u00a0es\u00a0decir\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0eventos\u00a0cl\u00ednicos\u00a0B\u00a0o\u00a0C,\u00a0\nno\u00a0siempre\u00a0se\u00a0asocia\u00a0a\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Puede\u00a0aparecer\u00a0en\u00a0los\u00a0primeros\u00a0meses\u00a0de\u00a0\ninstauraci\u00f3n \u00a0del\u00a0TAR\u00a0en\u00a0pacientes \u00a0muy\u00a0inmunodeprimidos, \u00a0o\u00a0relacionarse \u00a0con\u00a0\nfen\u00f3menos \u00a0de\u00a0restauraci\u00f3n \u00a0inmunol\u00f3gica \u00a0pudiendo \u00a0obligar\u00a0a\u00a0modificar \u00a0el\u00a0TAR305.\u00a0\u00a0\n\u00a0\nObjetivo\u00a0del\u00a0tratamiento \u00a0tras\u00a0un\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nEl\u00a0objetivo\u00a0terap\u00e9utico \u00a0es\u00a0conseguir \u00a0de\u00a0nuevo\u00a0la\u00a0supresi\u00f3n \u00a0viral\u00a0mantenida \u00a0(<50\u00a0\ncopias/mL). \u00a0Para\u00a0ello,\u00a0se\u00a0debe\u00a0instaurar\u00a0un\u00a0nuevo\u00a0r\u00e9gimen\u00a0con\u00a0tres\u00a0f\u00e1rmacos\u00a0\nplenamente \u00a0activos\u00a0siempre\u00a0que\u00a0esto\u00a0sea\u00a0posible.\u00a0No\u00a0hay\u00a0ning\u00fan\u00a0dato\u00a0respecto\u00a0a\u00a0\npautas\u00a0con\u00a0s\u00f3lo\u00a0dos\u00a0f\u00e1rmacos\u00a0activos\u00a0en\u00a0TAR\u00a0de\u00a0rescate,\u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0\npotencialmente \u00a0podr\u00edan\u00a0ser\u00a0suficientes \u00a0en\u00a0algunos\u00a0escenarios \u00a0de\u00a0rescate\u00a0precoz\u00a0con\u00a0\nescasa\u00a0resistencia \u00a0y\u00a0siempre\u00a0que\u00a0incluyan\u00a0un\u00a0IP/r\u00a0activo.\u00a0Cuando\u00a0no\u00a0pueda\u00a0disponerse \u00a0\nde\u00a03\u00a0f\u00e1rmacos\u00a0activos\u00a0se\u00a0contar\u00e1\u00a0con\u00a0otros\u00a0que\u00a0conserven \u00a0la\u00a0mayor\u00a0actividad\u00a0residual\u00a0\n(estudio\u00a0de\u00a0resistencias) \u00a0y\u00a0con\u00a0la\u00a0mejor\u00a0tolerancia \u00a0posible.\u00a0\u00a0\nNo\u00a0se\u00a0debe\u00a0retrasar\u00a0el\u00a0cambio\u00a0de\u00a0tratamiento. \u00a0A\u00a0partir\u00a0de\u00a0datos\u00a0de\u00a0los\u00a0estudios\u00a0TORO\u00a0\nse\u00a0han\u00a0establecido \u00a0cuatro\u00a0factores\u00a0asociados \u00a0a\u00a0eficacia\u00a0virol\u00f3gica \u00a0del\u00a0TAR\u00a0de\u00a0rescate:\u00a0\nrecuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0\u2265\u00a0100\u00a0c\u00e9lulas/\u00b5L \u00a0(OR\u00a02,1;\u00a0IC\u00a095%,\u00a01,5\u00a0a\u00a03,1),\u00a0CVP\u00a0basal\u00a0<5\u00a0\nlog10\u00a0(OR\u00a01,8;\u00a0IC\u00a095%,\u00a01,2\u00a0a\u00a02,6),\u00a0haber\u00a0recibido\u00a0\u226410\u00a0FAR\u00a0(OR\u00a02,4;\u00a0IC\u00a095%,\u00a01,6\u00a0a\u00a03,4)\u00a0y\u00a0\ndisponer\u00a0\u22652\u00a0f\u00e1rmacos \u00a0activos\u00a0en\u00a0el\u00a0nuevo\u00a0TAR\u00a0(OR\u00a02,3;\u00a0IC\u00a095%,\u00a01,6\u00a0a\u00a03,3)306.\u00a0En\u00a0todos\u00a0\nlos\u00a0estudios\u00a0de\u00a0rescate\u00a0se\u00a0han\u00a0identificado \u00a0como\u00a0factores\u00a0de\u00a0mala\u00a0respuesta, \u00a0la\u00a0CVP\u00a0\nelevada\u00a0(habitualmente \u00a0definida\u00a0como\u00a0>100.000 \u00a0copias/mL) \u00a0y\u00a0las\u00a0cifras\u00a0bajas\u00a0de\u00a0\nc\u00e9lulas\u00a0CD4307\u2010316.\u00a0\nPara\u00a0conseguir \u00a0el\u00a0objetivo\u00a0de\u00a0CVP\u00a0indetectable \u00a0pueden\u00a0ser\u00a0\u00fatiles\u00a0algunas\u00a0estrategias \u00a0\ncomo:\u00a0\n\u2022 Facilitar\u00a0la\u00a0adherencia \u00a0al\u00a0TAR.\u00a0La\u00a0mala\u00a0adherencia \u00a0suele\u00a0ser\u00a0la\u00a0causa\u00a0de\u00a0la\u00a0mayor\u00eda\u00a0\nde\u00a0los\u00a0fracasos\u00a0virol\u00f3gicos. \u00a0Antes\u00a0de\u00a0iniciar\u00a0el\u00a0TAR\u00a0de\u00a0rescate\u00a0hay\u00a0que\u00a0identificar \u00a0las\u00a0\ncausas\u00a0de\u00a0mala\u00a0adherencia \u00a0y\u00a0se\u00a0deben\u00a0tomar\u00a0medidas\u00a0para\u00a0corregirlas, \u00a0pues\u00a0en\u00a0\ncaso\u00a0contrario\u00a0se\u00a0reproducir\u00e1n \u00a0tras\u00a0el\u00a0nuevo\u00a0TAR\u00a0de\u00a0rescate.\u00a0El\u00a0nuevo\u00a0tratamiento \u00a0\ndebe\u00a0ser\u00a0lo\u00a0m\u00e1s\u00a0c\u00f3modo\u00a0y\u00a0bien\u00a0tolerado\u00a0posible.\u00a0En\u00a0algunos\u00a0grupos\u00a0de\u00a0pacientes \u00a0\ncon\u00a0mala\u00a0adherencia \u00a0al\u00a0TAR\u00a0se\u00a0debe\u00a0procurar\u00a0que\u00a0el\u00a0tratamiento \u00a0sea\u00a0directamente \u00a0\nobservado \u00a0y\u00a0basado\u00a0en\u00a0pautas\u00a0QD317,\u00a0318.\u00a0Sin\u00a0embargo, \u00a0no\u00a0hay\u00a0datos\u00a0que\u00a0confirmen \u00a0\nque\u00a0la\u00a0adherencia \u00a0sea\u00a0mejor\u00a0con\u00a0pautas\u00a0de\u00a0rescate\u00a0QD\u00a0que\u00a0con\u00a0pautas\u00a0BID\u00a0por\u00a0lo\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 43que\u00a0nunca\u00a0debe\u00a0escogerse \u00a0una\u00a0pauta\u00a0QD,\u00a0si\u00a0no\u00a0es\u00a0la\u00a0\u00f3ptima\u00a0para\u00a0esa\u00a0situaci\u00f3n\u00a0de\u00a0\nrescate,\u00a0s\u00f3lo\u00a0para\u00a0facilitar\u00a0la\u00a0adherencia. \u00a0\n\u2022 Pruebas\u00a0de\u00a0resistencia. \u00a0La\u00a0realizaci\u00f3n \u00a0de\u00a0una\u00a0prueba\u00a0de\u00a0resistencia \u00a0genot\u00edpica \u00a0o\u00a0\nfenot\u00edpica \u00a0en\u00a0cada\u00a0fracaso,\u00a0optimiza\u00a0el\u00a0nuevo\u00a0tratamiento, \u00a0aumenta\u00a0su\u00a0eficacia\u00a0y\u00a0\nmejora\u00a0el\u00a0pron\u00f3stico \u00a0de\u00a0los\u00a0pacientes284,\u00a0319,\u00a0320.\u00a0Los\u00a0resultados \u00a0m\u00e1s\u00a0\u00fatiles\u00a0se\u00a0\nobtienen\u00a0si\u00a0esta\u00a0prueba\u00a0se\u00a0realiza\u00a0mientras\u00a0el\u00a0paciente\u00a0se\u00a0encuentra \u00a0con\u00a0el\u00a0\ntratamiento \u00a0que\u00a0ha\u00a0fracasado. \u00a0En\u00a0Espa\u00f1a\u00a0se\u00a0usa\u00a0habitualmente \u00a0el\u00a0genotipo. \u00a0En\u00a0su\u00a0\ninterpretaci\u00f3n \u00a0debe\u00a0tenerse\u00a0en\u00a0cuenta\u00a0que\u00a0las\u00a0mutaciones \u00a0detectadas \u00a0est\u00e1n\u00a0\npresentes \u00a0con\u00a0seguridad. \u00a0Sin\u00a0embargo, \u00a0las\u00a0no\u00a0detectadas \u00a0pueden\u00a0encontrarse \u00a0en\u00a0\npoblaciones \u00a0minoritarias \u00a0(menores \u00a0al\u00a015%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0total)\u00a0y\u00a0pueden\u00a0no\u00a0\ndetectarse \u00a0en\u00a0el\u00a0genotipo\u00a0poblacional. \u00a0Cuanto\u00a0m\u00e1s\u00a0tiempo\u00a0transcurra \u00a0desde\u00a0la\u00a0\nsuspensi\u00f3n \u00a0del\u00a0TAR\u00a0y\u00a0la\u00a0realizaci\u00f3n \u00a0del\u00a0genotipo\u00a0m\u00e1s\u00a0f\u00e1cil\u00a0es\u00a0que\u00a0desaparezcan \u00a0las\u00a0\nmutaciones, \u00a0especialmente \u00a0las\u00a0que\u00a0causan\u00a0mayor\u00a0deterioro \u00a0en\u00a0la\u00a0fitness\u00a0viral.\u00a0En\u00a0\naquellos\u00a0casos\u00a0en\u00a0los\u00a0que\u00a0se\u00a0disponga\u00a0de\u00a0estudios\u00a0genot\u00edpicos \u00a0previos\u00a0es\u00a0muy\u00a0\nimportante \u00a0valorar\u00a0la\u00a0suma\u00a0de\u00a0todos\u00a0los\u00a0genotipos \u00a0(genotipo \u00a0acumulado), \u00a0que\u00a0ha\u00a0\ndemostrado \u00a0mejorar\u00a0la\u00a0eficacia\u00a0en\u00a0la\u00a0elecci\u00f3n\u00a0del\u00a0nuevo\u00a0r\u00e9gimen\u00a0antirretroviral88.\u00a0\nEn\u00a0pacientes \u00a0multitratados \u00a0puede\u00a0establecerse \u00a0el\u00a0\u00cdndice\u00a0de\u00a0Susceptibilidad \u00a0\nFenot\u00edpica/Genot\u00edpica \u00a0\u2010ISF/G\u2010\u00a0(n\u00famero\u00a0de\u00a0f\u00e1rmacos \u00a0activos\u00a0seg\u00fan\u00a0la\u00a0prueba\u00a0de\u00a0\nresistencias \u00a0genot\u00edpica \u00a0o\u00a0fenot\u00edpica) \u00a0\u00a0como\u00a0predictor \u00a0de\u00a0respuesta \u00a0al\u00a0\ntratamiento321.\u00a0Existen\u00a0ciertas\u00a0discordancias \u00a0seg\u00fan\u00a0el\u00a0sistema\u00a0en\u00a0el\u00a0que\u00a0se\u00a0realiza\u00a0la\u00a0\ninterpretaci\u00f3n \u00a0de\u00a0resistencias \u00a0lo\u00a0que\u00a0puede\u00a0suponer\u00a0una\u00a0limitaci\u00f3n \u00a0en\u00a0el\u00a0uso\u00a0del\u00a0\nISG\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica.\u00a0La\u00a0concordancia \u00a0mayor\u00a0se\u00a0observa\u00a0en\u00a0los\u00a0NN\u00a0(93%)\u00a0y\u00a0en\u00a0\nlos\u00a0IP\u00a0(84%),\u00a0en\u00a0cambio\u00a0para\u00a0los\u00a0AN\u00a0s\u00f3lo\u00a0es\u00a0del\u00a076%322.\u00a0\u00a0\n\u2022 Tropismo .\u00a0Debe\u00a0determinarse \u00a0sistem\u00e1ticamente \u00a0el\u00a0tropismo\u00a0del\u00a0VIH\u20101\u00a0en\u00a0cada\u00a0\nfracaso\u00a0virol\u00f3gico, \u00a0exceptuando \u00a0los\u00a0casos\u00a0en\u00a0que\u00a0previamente \u00a0ya\u00a0se\u00a0haya\u00a0\ndocumentado \u00a0la\u00a0existencia \u00a0de\u00a0tropismo\u00a0no\u00a0R5.\u00a0La\u00a0determinaci\u00f3n \u00a0debe\u00a0realizarse \u00a0\nsimult\u00e1neamente \u00a0al\u00a0genotipo\u00a0est\u00e1ndar\u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa,\u00a0proteasa\u00a0(e\u00a0\nintegrasa \u00a0si\u00a0procede). \u00a0\n\u2022 \u00cdndice\u00a0ponderado \u00a0(score )\u00a0de\u00a0resistencia \u00a0genot\u00edpica \u00a0a\u00a0IP.\u00a0La\u00a0interpretaci\u00f3n \u00a0de\u00a0las\u00a0\npruebas\u00a0genot\u00edpicas \u00a0a\u00a0IP\u00a0depende\u00a0del\u00a0n\u00famero,\u00a0tipo\u00a0y\u00a0patr\u00f3n\u00a0de\u00a0mutaciones \u00a0\nseleccionadas. \u00a0En\u00a0la\u00a0actualidad \u00a0se\u00a0han\u00a0desarrollado \u00a0\u00edndices\u00a0ponderados \u00a0(scores)\u00a0\nque\u00a0definen\u00a0la\u00a0sensibilidad \u00a0a\u00a0determinados \u00a0IP\u00a0(ATV/r323,\u00a0SQV/r324,\u00a0LPV/r325,\u00a0\nDRV/r326\u00a0y\u00a0TPV/r327)\u00a0y\u00a0a\u00a0la\u00a0ETR\u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante) \u00a0basados\u00a0en\u00a0datos\u00a0extra\u00eddos \u00a0de\u00a0\nestudios\u00a0realizados \u00a0en\u00a0la\u00a0vida\u00a0real.\u00a0Algunos\u00a0algoritmos \u00a0de\u00a0interpretaci\u00f3n, \u00a0como\u00a0el\u00a0\nespa\u00f1ol\u00a0de\u00a0la\u00a0RIS\u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0abajo)\u00a0o\u00a0el\u00a0de\u00a0REGAa,\u00a0ponderan \u00a0el\u00a0peso\u00a0de\u00a0las\u00a0\nmutaciones \u00a0para\u00a0todos\u00a0los\u00a0antirretrovirales, \u00a0incluidos\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0\nintegrasa. \u00a0Estos\u00a0scores\u00a0\u00a0marcan\u00a0el\u00a0\u201cpeso\u201d\u00a0de\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0mutaciones \u00a0seg\u00fan\u00a0el\u00a0\ngrado\u00a0de\u00a0resistencia \u00a0(valores\u00a0negativos) \u00a0o\u00a0de\u00a0susceptibilidad \u00a0o\u00a0hipersusceptibilidad \u00a0\n(valores\u00a0positivos). \u00a0Los\u00a0scores\u00a0punt\u00faan\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0mutaciones \u00a0y\u00a0finalmente \u00a0se\u00a0\nobtiene\u00a0un\u00a0resultado \u00a0de\u00a0mayor\u00a0o\u00a0menor\u00a0susceptibilidad \u00a0al\u00a0f\u00e1rmaco.\u00a0\n\u2022 Cociente\u00a0inhibitorio \u00a0genot\u00edpico. \u00a0El\u00a0cociente\u00a0inhibitorio \u00a0genot\u00edpico \u00a0(CIG)\u00a0es\u00a0la\u00a0raz\u00f3n\u00a0\nentre\u00a0las\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0del\u00a0f\u00e1rmaco\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0mutaciones \u00a0\nrelevantes \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa. \u00a0Se\u00a0considera \u00a0un\u00a0marcador \u00a0predictivo \u00a0de\u00a0\n                                                 \na http://regaweb.med.kuleuven.be/software/rega_algorithm  \n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 44respuesta \u00a0a\u00a0un\u00a0IP\u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0todas\u00a0las\u00a0mutaciones \u00a0cuentan\u00a0por\u00a0igual328\u2010330.\u00a0Otra\u00a0\naproximaci\u00f3n \u00a0es\u00a0el\u00a0coeficiente \u00a0inhibitorio \u00a0normalizado \u00a0que\u00a0calcula\u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0\nlas\u00a0concentraciones \u00a0m\u00ednimas\u00a0plasm\u00e1ticas \u00a0del\u00a0f\u00e1rmaco\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0veces\u00a0por\u00a0\nencima\u00a0de\u00a0la\u00a0IC50\u00a0obtenido\u00a0en\u00a0el\u00a0fenotipo\u00a0viral331.\u00a0\n\u2022 Pruebas\u00a0de\u00a0resistencia \u00a0genot\u00edpicas \u00a0con\u00a0mayor\u00a0sensibilidad: \u00a0PCR\u00a0alelo\u2010espec\u00edfica, \u00a0\nensayo\u00a0de\u00a0ligaci\u00f3n\u00a0de\u00a0oligonucle\u00f3tidos, \u00a0Ultradeep \u2010sequencing \u00a0\u00a0o\u00a0secuenciaci\u00f3n \u00a0de\u00a0\ngenomas\u00a0individuales \u00a0\u2013SGI\u2010\u00a0(Single\u00a0genome\u00a0sequencing \u00a0analysis).\u00a0Son\u00a0\u00a0\nmetodolog\u00edas \u00a0actualmente \u00a0en\u00a0investigaci\u00f3n \u00a0que\u00a0permiten \u00a0conocer\u00a0el\u00a0papel\u00a0que\u00a0\njuegan\u00a0en\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0las\u00a0variantes\u00a0virales\u00a0minoritarias \u00a0con\u00a0mutaciones \u00a0de\u00a0\nresistencia \u00a0(especialmente \u00a0NN)\u00a0y\u00a0que\u00a0est\u00e1n\u00a0presentes \u00a0antes\u00a0del\u00a0inicio\u00a0del\u00a0\ntratamiento \u00a0pero\u00a0que\u00a0no\u00a0son\u00a0detectadas \u00a0por\u00a0los\u00a0genotipos \u00a0poblacionales \u00a0\nconvencionales96,\u00a098.\u00a0Las\u00a0t\u00e9cnicas\u00a0basadas\u00a0en\u00a0PCR\u00a0tienen\u00a0la\u00a0mayor\u00a0sensibilidad \u00a0\nte\u00f3rica\u00a0para\u00a0detectar\u00a0variantes\u00a0minoritarias \u00a0puntuales, \u00a0pero\u00a0presentan \u00a0bastantes \u00a0\nlimitaciones. \u00a0Las\u00a0t\u00e9cnicas\u00a0ultrasensibles \u00a0basadas\u00a0en\u00a0la\u00a0secuenciaci\u00f3n \u00a0aumentan \u00a0la\u00a0\nsensibilidad \u00a0de\u00a0detecci\u00f3n \u00a0de\u00a0mutaciones \u00a0minoritarias \u00a0y,\u00a0al\u00a0disponer\u00a0de\u00a0secuencias \u00a0\ncompletas \u00a0independientes, \u00a0permite\u00a0establecer \u00a0n\u00edtidamente \u00a0su\u00a0asociaci\u00f3n, \u00a0realizar\u00a0\nestudios\u00a0filogen\u00e9ticos \u00a0m\u00e1s\u00a0completos \u00a0y\u00a0estudiar\u00a0la\u00a0evoluci\u00f3n \u00a0en\u00a0el\u00a0tiempo\u00a0de\u00a0las\u00a0\ndiferentes \u00a0poblaciones. \u00a0Est\u00e1\u00a0bien\u00a0establecido \u00a0actualmente \u00a0que\u00a0las\u00a0mutaciones \u00a0\nminoritarias \u00a0condicionan \u00a0la\u00a0respuesta \u00a0a\u00a0un\u00a0TAR\u00a0basado\u00a0en\u00a0NN\u00a0de\u00a0primera\u00a0\ngeneraci\u00f3n \u00a0(NVP\u00a0o\u00a0EFV).\u00a0Esto\u00a0es\u00a0debido\u00a0a\u00a0que\u00a0la\u00a0presencia \u00a0de\u00a0una\u00a0sola\u00a0mutaci\u00f3n \u00a0\nproduce\u00a0resistencia \u00a0de\u00a0alto\u00a0nivel\u00a0al\u00a0f\u00e1rmaco.\u00a0Es\u00a0la\u00a0\u00fanica\u00a0situaci\u00f3n\u00a0en\u00a0que\u00a0hasta\u00a0\nahora\u00a0se\u00a0ha\u00a0podido\u00a0demostrar \u00a0el\u00a0impacto\u00a0cl\u00ednico\u00a0de\u00a0las\u00a0mutaciones \u00a0minoritarias91\u2010\n98,\u00a0332.\u00a0Es\u00a0de\u00a0esperar\u00a0que\u00a0acabe\u00a0confirm\u00e1ndose \u00a0asimismo \u00a0el\u00a0impacto\u00a0de\u00a0las\u00a0\nmutaciones \u00a0minoritarias \u00a0frente\u00a0a\u00a0otros\u00a0f\u00e1rmacos \u00a0de\u00a0baja\u00a0barrera\u00a0gen\u00e9tica,\u00a0\nespecialmente \u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0y\u00a03TC/FTC.\u00a0Asimismo, \u00a0es\u00a0posible\u00a0que\u00a0\nsean\u00a0determinantes \u00a0respecto\u00a0a\u00a0f\u00e1rmacos\u00a0con\u00a0mayor\u00a0barrera\u00a0gen\u00e9tica,\u00a0en\u00a0aquellas\u00a0\nsituaciones \u00a0en\u00a0que,\u00a0existiendo \u00a0ya\u00a0alguna\u00a0mutaci\u00f3n \u00a0que\u00a0comporte \u00a0una\u00a0resistencia \u00a0\nde\u00a0nivel\u00a0bajo/intermedio, \u00a0la\u00a0detecci\u00f3n \u00a0\u00a0de\u00a0otras\u00a0mutaciones \u00a0(aunque\u00a0por\u00a0debajo\u00a0\ndel\u00a015\u201020%)\u00a0pueda\u00a0comportar \u00a0un\u00a0incremento \u00a0significativo \u00a0de\u00a0la\u00a0resistencia, \u00a0por\u00a0\nejemplo\u00a0frente\u00a0a\u00a0ETR333.\u00a0Contrariamente, \u00a0la\u00a0presencia \u00a0de\u00a0mutaciones \u00a0minoritarias \u00a0\nno\u00a0tiene\u00a0impacto\u00a0en\u00a0la\u00a0respuesta \u00a0a\u00a0pautas\u00a0basadas\u00a0con\u00a0IP/r\u00a0en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo334.\u00a0\n\u2022 Monitorizaci\u00f3n \u00a0plasm\u00e1tica \u00a0de\u00a0f\u00e1rmacos. \u00a0Poco\u00a0\u00fatil\u00a0en\u00a0la\u00a0actualidad \u00a0en\u00a0la\u00a0\noptimizaci\u00f3n \u00a0de\u00a0un\u00a0TAR\u00a0de\u00a0rescate\u00a0debido\u00a0a\u00a0la\u00a0existencia \u00a0de\u00a0datos\u00a0cl\u00ednicos\u00a0muy\u00a0\ns\u00f3lidos\u00a0con\u00a0las\u00a0pautas\u00a0actuales\u00a0de\u00a0rescate,\u00a0la\u00a0variabilidad \u00a0interindividual. \u00a0En\u00a0casos\u00a0\nseleccionados, \u00a0puede\u00a0ayudar\u00a0a\u00a0optimizar \u00a0el\u00a0tratamiento \u00a0mejorando \u00a0as\u00ed\u00a0su\u00a0eficacia\u00a0\n(v\u00e9ase\u00a0apartado\u00a0de\u00a0farmacocin\u00e9tica) \u00a0317,\u00a0335,\u00a0336.\u00a0\n\u00a05.1.1.\u00a0Cambio\u00a0de\u00a0TAR\u00a0tras\u00a0fracaso\u00a0precoz\u00a0\u00a0\nLos\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados \u00a0que\u00a0han\u00a0evaluado\u00a0la\u00a0eficacia\u00a0de\u00a0diferentes \u00a0\ncombinaciones \u00a0de\u00a0FAR\u00a0en\u00a0tratamientos \u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0son\u00a0escasos.\u00a0El\u00a0objetivo\u00a0\nterap\u00e9utico \u00a0es\u00a0la\u00a0resupresi\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0(CVP\u00a0<50\u00a0copias/mL). \u00a0Los\u00a0cambios\u00a0precoces\u00a0\nevitan\u00a0ac\u00famulo\u00a0de\u00a0mutaciones \u00a0y\u00a0permiten \u00a0secuenciar\n\u00a0FAR\u00a0incluso\u00a0dentro\u00a0de\u00a0cada\u00a0\nfamilia.\u00a0Con\u00a0los\u00a0FAR\u00a0actualmente \u00a0disponibles \u00a0resulta\u00a0sencillo\u00a0dise\u00f1ar\u00a0un\u00a0TAR\u00a0de\u00a0rescate\u00a0\naunque\u00a0siempre\u00a0se\u00a0debe\u00a0contar\u00a0con\u00a0una\u00a0prueba\u00a0de\u00a0resistencias \u00a0y\u00a0tropismo\u00a0del\u00a0VIH.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 45En\u00a0el\u00a0caso\u00a0de\u00a0pacientes \u00a0que\u00a0iniciaran\u00a0el\u00a0tratamiento \u00a0con\u00a0tres\u00a0AN,\u00a0la\u00a0mutaci\u00f3n \u00a0m\u00e1s\u00a0\nfrecuente \u00a0es\u00a0la\u00a0M184V241\u00a0con\u00a0TAMs\u00a0si\u00a0el\u00a0esquema\u00a0inclu\u00eda\u00a0AN\u00a0timid\u00ednicos \u00a0o\u00a0la\u00a0K65R\u00a0\n(TDF)\u00a0o\u00a0L74V\u00a0y\u00a0Y115F\u00a0(ABC)\u00a0si\u00a0el\u00a0TAR\u00a0inclu\u00eda\u00a0AN\u00a0no\u00a0timid\u00ednicos337\u2010339.\u00a0\u00a0\nSi\u00a0el\u00a0fracaso\u00a0es\u00a0con\u00a0una\u00a0pauta\u00a0con\u00a02AN\u00a0y\u00a01NN\u00a0una\u00a0\u00fanica\u00a0mutaci\u00f3n \u00a0(p.e.\u00a0K103N)\u00a0es\u00a0\ncapaz\u00a0de\u00a0generar\u00a0resistencia \u00a0de\u00a0alto\u00a0nivel\u00a0a\u00a0EFV\u00a0y\u00a0NVP340.\u00a0El\u00a0patr\u00f3n\u00a0de\u00a0mutaciones \u00a0es\u00a0\nligeramente \u00a0distinto\u00a0seg\u00fan\u00a0la\u00a0pauta\u00a0incluyera\u00a0NVP\u00a0(Y181C,\u00a0K103N,\u00a0G190A,\u00a0K101E,\u00a0\nA98G)\u00a0o\u00a0EFV\u00a0(K103N,\u00a0L100I,\u00a0Y188L,\u00a0G190A,\u00a0K101E)341.\u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0se\u00a0\nacompa\u00f1a \u00a0de\u00a0otras\u00a0mutaciones \u00a0a\u00a0AN\u00a0(M184V,\u00a0L74V\u00a0o\u00a0K65R)\u00a0con\u00a0una\u00a0incidencia \u00a0\nsuperior\u00a0a\u00a0lo\u00a0que\u00a0ocurre\u00a0cuando\u00a0el\u00a0primer\u00a0r\u00e9gimen\u00a0est\u00e1\u00a0compuesto \u00a0por\u00a02\u00a0AN\u00a0y\u00a01\u00a0IP/r\u00a0\n342.\u00a0\u00a0Un\u00a0cambio\u00a0precoz\u00a0evitar\u00eda\u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0que\u00a0\ncomprometiera \u00a0la\u00a0eficacia\u00a0de\u00a0los\u00a0NN\u00a0de\u00a0nueva\u00a0generaci\u00f3n. \u00a0En\u00a0este\u00a0escenario \u00a0la\u00a0\nutilizaci\u00f3n \u00a0de\u00a0ETR\u00a0puede\u00a0estar\u00a0comprometida \u00a0seg\u00fan\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0mutaciones \u00a0\nseleccionado, \u00a0especialmente \u00a0si\u00a0existen\u00a0\u22653\u00a0mutaciones \u00a0frente\u00a0a\u00a0NN\u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0\nadelante)343.\u00a0Aunque\u00a0ha\u00a0existido\u00a0debate\u00a0sobre\u00a0si\u00a0los\u00a0fracasos\u00a0a\u00a0NVP\u00a0seleccionan \u00a0mayor\u00a0\nresistencia \u00a0frente\u00a0a\u00a0ETR\u00a0que\u00a0los\u00a0fracasos\u00a0a\u00a0EFV,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0con\u00a0mayor\u00a0poder\u00a0\nestad\u00edstico \u00a0realizado\u00a0sobre\u00a0un\u00a0estudio\u00a0aleatorizado \u00a0(estudios\u00a0DUET,\u00a0con\u00a0599\u00a0pacientes \u00a0\ntratados)\u00a0los\u00a0fracasos\u00a0previos\u00a0a\u00a0NVP\u00a0no\u00a0se\u00a0asociaron \u00a0con\u00a0peor\u00a0respuesta \u00a0a\u00a0ETR\u00a0que\u00a0los\u00a0\nfracasos\u00a0a\u00a0EFV307.\u00a0\nEl\u00a0uso\u00a0de\u00a0IP/r\u00a0en\u00a0el\u00a0primer\u00a0TAR\u00a0ha\u00a0reducido\u00a0significativamente \u00a0el\u00a0n\u00famero\u00a0de\u00a0fracasos\u00a0\nvirol\u00f3gicos \u00a0y\u00a0la\u00a0selecci\u00f3n\u00a0de\u00a0mutaciones \u00a0frente\u00a0a\u00a0los\u00a0IP\u00a0y\u00a0los\u00a0f\u00e1rmacos \u00a0acompa\u00f1antes. \u00a0\nTodos\u00a0los\u00a0IP/r\u00a0tienen\u00a0una\u00a0barrera\u00a0gen\u00e9tica\u00a0elevada\u00a0y,\u00a0de\u00a0hecho,\u00a0s\u00f3lo\u00a0excepcionalmente \u00a0\naparecen \u00a0mutaciones \u00a0primarias \u00a0o\u00a0secundarias \u00a0frente\u00a0al\u00a0IP\u00a0en\u00a0un\u00a0primer\u00a0fracaso\u00a0\nvirol\u00f3gico344.\u00a0El\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0en\u00a0los\u00a0IP\u00a0es\u00a0un\u00a0proceso\u00a0gradual\u00a0que\u00a0requiere\u00a0\nel\u00a0ac\u00famulo\u00a0de\u00a0varias\u00a0mutaciones \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa76.\u00a0Existen\u00a0mutaciones \u00a0\nseleccionadas \u00a0espec\u00edficamente \u00a0por\u00a0un\u00a0IP\u00a0(no\u00a0potenciado) \u00a0que\u00a0no\u00a0presentan \u00a0\nresistencias \u00a0cruzadas\u00a0(se\u00a0consideran \u00a0mutaciones \u00a0espec\u00edficas, \u00a0signature \u00a0mutations ,\u00a0de\u00a0\ncada\u00a0IP):\u00a0D30N\u00a0(NFV)106,\u00a0I47A\u00a0y\u00a0L76V\u00a0(LPV)345,\u00a0346,\u00a0G48V\u00a0(SQV)347,\u00a0I50L\u00a0(ATV)348\u00a0o\u00a0I50V\u00a0\n(FPV\u00a0y\u00a0DRV349)\u00a0y\u00a0alguna\u00a0de\u00a0ellas\u00a0puede,\u00a0por\u00a0el\u00a0contrario, \u00a0producir\u00a0hipersusceptibilidad \u00a0a\u00a0\notros\u00a0IP:\u00a0la\u00a047A\u00a0confiere\u00a0elevada\u00a0resistencia \u00a0fenot\u00edpica \u00a0a\u00a0LPV\u00a0(>100\u00a0veces),\u00a0resistencia \u00a0\ncruzada\u00a0con\u00a0FPV\u00a0e\u00a0hipersusceptibilidad \u00a0a\u00a0SQV\u00a0345;\u00a0la\u00a050L\u00a0causa\u00a0hipersusceptibilidad \u00a0a\u00a0\ntodos\u00a0los\u00a0IP\u00a0excepto\u00a0ATV350,\u00a0o\u00a0la\u00a050V\u00a0causa\u00a0resistencia \u00a0a\u00a0LPV,\u00a0FPV\u00a0y\u00a0DRV\u00a0e\u00a0\nhipersusceptibilidad \u00a0a\u00a0TPV.\u00a0\u00a0La\u00a0continua\u00a0aparici\u00f3n \u00a0de\u00a0nuevas\u00a0mutaciones \u00a0obliga\u00a0a\u00a0\nconsultar \u00a0las\u00a0bases\u00a0de\u00a0datos\u00a0espec\u00edficas \u00a0con\u00a0informaci\u00f3n \u00a0actualizada \u00a0sobre\u00a0patrones\u00a0de\u00a0\nresistencia \u00a0y\u00a0su\u00a0significado \u00a0cl\u00ednico\u00a0(Los\u00a0\u00c1lamosb,\u00a0Universidad \u00a0de\u00a0Stanfordc\u00a0o\u00a0la\u00a0\nPlataforma \u00a0de\u00a0Resistencias \u00a0de\u00a0la\u00a0RISd).\u00a0El\u00a0rescate\u00a0de\u00a0un\u00a0tratamiento \u00a0a\u00a0dos\u00a0AN\u00a0m\u00e1s\u00a0un\u00a0\nIP/r\u00a0debe\u00a0realizarse \u00a0con\u00a03\u00a0f\u00e1rmacos \u00a0activos\u00a0que\u00a0pueden\u00a0incluir\u00a0NN,\u00a0AN,\u00a0IP/r\u00a0y\u00a0otros\u00a0de\u00a0\nlas\u00a0nuevas\u00a0familias.\u00a0Si\u00a0se\u00a0pretende\u00a0utilizar\u00a0un\u00a0IP,\u00a0DRV/r\u00a0ha\u00a0demostrado \u00a0ser\u00a0m\u00e1s\u00a0eficaz\u00a0\nque\u00a0LPV/r\u00a0cuando\u00a0existen\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0frente\u00a0a\u00a0IP\u00a0o\u00a0no\u00a0existen\u00a0suficientes \u00a0\nf\u00e1rmacos \u00a0activos\u00a0(ensayo\u00a0TITAN,\u00a0v\u00e9ase\u00a0m\u00e1s\u00a0adelante). \u00a0\nCon\u00a0frecuencia, \u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0del\u00a0primer\u00a0tratamiento \u00a0antirretroviral \u00a0selecciona \u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0(M184V,\u00a0K65R,\u00a0L74V,\u00a0etc.)337\u00a0que\u00a0obliga\u00a0\u00a0utilizar\u00a0otros\u00a0AN\u00a0\n(AZT\u00a0o\u00a0d4T)\u00a0en\u00a0los\u00a0tratamientos \u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0que\u00a0inducen\u00a0toxicidad\u00a0cr\u00f3nica\u00a0y\u00a0a\u00a0\nmenudo\u00a0irreparable \u00a0(toxicidad \u00a0mitocondrial, \u00a0lipoatrofia, \u00a0resistencia \u00a0insul\u00ednica \u00a0y\u00a0otras\u00a0\n                                                 \nb\u00a0http://resdb.lanl.gov/ Resist_DB/default.htm \u00a0\nc\u00a0http://hivdb6.stanford.edu/asi/deployed/hiv_cen tral.pl?program=hivdb&action=showMutationForm \u00a0\nd\u00a0http://www.retic \u2010ris.net/default_principal.asp?idx=&cidioma=2   \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 46alteraciones \u00a0metab\u00f3licas). \u00a0En\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica,\u00a0lo\u00a0usual\u00a0es\u00a0evitar\u00a0el\u00a0uso\u00a0de\u00a0estos\u00a0\nan\u00e1logos\u00a0y\u00a0utilizar\u00a0f\u00e1rmacos\u00a0de\u00a0las\u00a0nuevas\u00a0familias\u00a0en\u00a0su\u00a0lugar.\u00a0\n\u00a05.1.2.\u00a0Cambio\u00a0de\u00a0TAR\u00a0en\u00a0el\u00a0fracaso\u00a0avanzado \u00a0(TAR\u00a0de\u00a0rescate)\u00a0\nEl\u00a0tratamiento \u00a0tras\u00a0el\u00a0fracaso\u00a0de\u00a0al\u00a0menos\u00a0dos\u00a0l\u00edneas\u00a0de\u00a0TAR\u00a0se\u00a0ha\u00a0denominado \u00a0terapia\u00a0\nde\u00a0rescate\u00a0avanzado. \u00a0En\u00a0esta\u00a0situaci\u00f3n\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0enfermos \u00a0han\u00a0experimentado \u00a0\nfracaso\u00a0con\u00a0las\u00a0tres\u00a0familias\u00a0de\u00a0FAR\u00a0m\u00e1s\u00a0utilizados: \u00a0AN,\u00a0NN\u00a0e\u00a0IP.\u00a0Sin\u00a0embargo, \u00a0en\u00a0los\u00a0\nestudios\u00a0genot\u00edpicos, \u00a0todav\u00eda\u00a0existen\u00a0algunos\u00a0FAR\u00a0que\u00a0conservan \u00a0actividad\u00a0moderada \u00a0o\u00a0\nelevada\u00a0frente\u00a0al\u00a0VIH.\u00a0\u00a0\u00a0\nExisten\u00a0numerosos \u00a0ensayos\u00a0cl\u00ednicos\u00a0que\u00a0han\u00a0comparado \u00a0diferentes \u00a0tratamientos \u00a0de\u00a0\nrescate.\u00a0En\u00a0todos\u00a0ellos\u00a0se\u00a0han\u00a0utilizado\u00a0IP/r\u00a0o\u00a0f\u00e1rmacos\u00a0nuevos.\u00a0Son\u00a0estudios\u00a0\ndif\u00edcilmente \u00a0comparables \u00a0entre\u00a0s\u00ed\u00a0por\u00a0la\u00a0heterogeneidad \u00a0de\u00a0la\u00a0poblaci\u00f3n, \u00a0tratamientos \u00a0\nprevios,\u00a0criterios\u00a0de\u00a0eficacia,\u00a0tiempo\u00a0de\u00a0seguimiento \u00a0y\u00a0tipo\u00a0de\u00a0terapia\u00a0optimizada \u00a0\nutilizada\u00a0dependiendo \u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0disponibles \u00a0comercialmente \u00a0en\u00a0la\u00a0\u00e9poca\u00a0de\u00a0\nrealizaci\u00f3n \u00a0del\u00a0estudio.\u00a0\u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0potenciados \u00a0\nLopinavir/r \u00a0\nLa\u00a0experiencia \u00a0de\u00a0LPV/r\u00a0en\u00a0terapia\u00a0de\u00a0rescate\u00a0se\u00a0ha\u00a0obtenido\u00a0de\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0\nrealizados \u00a0por\u00a0el\u00a0resto\u00a0de\u00a0IP/r,\u00a0que\u00a0utilizan\u00a0LPV/r\u00a0como\u00a0IP\u00a0comparador \u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0\nadelante). \u00a0Tanto\u00a0TPV/r\u00a0como\u00a0DRV/r\u00a0han\u00a0demostrado \u00a0superioridad \u00a0respecto\u00a0a\u00a0LPV/r\u00a0en\u00a0\neste\u00a0escenario. \u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\nFosamprenavir \u00a0\nCONTEXT \u00a0\nEl\u00a0CONTEXT \u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0abierto\u00a0de\u00a0fase\u00a0III\u00a0que\u00a0compar\u00f3\u00a0la\u00a0\neficacia\u00a0de\u00a0FPV/r\u00a0frente\u00a0a\u00a0LPV/r\u00a0ambos\u00a0con\u00a02\u00a0AN\u00a0en\u00a0pacientes \u00a0tratados\u00a0previamente \u00a0\ncon\u00a01\u00a0\u00f3\u00a02\u00a0IP.\u00a0Se\u00a0incluyeron \u00a0300\u00a0pacientes \u00a0que\u00a0se\u00a0asignaron \u00a0a\u00a0recibir\u00a0FPV/r\u00a01400/200 \u00a0\nmg,\u00a0QD,\u00a0FPV/r\u00a0700/100\u00a0mg,\u00a0BID\u00a0o\u00a0LPV/r\u00a0BID\u00a0(400/100\u00a0mg,\u00a0BID).\u00a0Los\u00a0resultados \u00a0\nmostraron \u00a0que\u00a0FPV/r\u00a0QD\u00a0era\u00a0inferior\u00a0a\u00a0LPV/r\u00a0y\u00a0no\u00a0se\u00a0pudo\u00a0demostrar \u00a0la\u00a0no\u2010inferioridad \u00a0\nde\u00a0FPV/r\u00a0BID\u00a0frente\u00a0a\u00a0LPV/r.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0y\u00a0<50\u00a0copias/mL \u00a0\na\u00a0las\u00a048\u00a0semanas\u00a0fue\u00a050%\u00a0y\u00a037%\u00a0para\u00a0FPV/r\u00a0QD,\u00a058%\u00a0y\u00a046%\u00a0para\u00a0FPV/r\u00a0BID\u00a0y\u00a061%\u00a0y\u00a050%\u00a0\npara\u00a0LPV/r351.\u00a0FPV/r\u00a0no\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0de\u00a0elecci\u00f3n\u00a0en\u00a0TAR\u00a0de\u00a0rescate.\u00a0\n\u00a0\nSaquinavir \u00a0\nMaxCmin2 \u00a0\nEl\u00a0estudio\u00a0MaxCmin2 \u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0de\u00a0SQV/r\u00a0(1000/100mg, \u00a0BID)\u00a0frente\u00a0a\u00a0LPV/r\u00a0\n(400/100\u00a0mg,\u00a0BID)\u00a0en\u00a0un\u00a0estudio\u00a0abierto\u00a0y\u00a0aleatorizado \u00a0que\u00a0incluy\u00f3\u00a0339\u00a0pacientes. \u00a0A\u00a0\nlas\u00a048\u00a0semanas\u00a0(ITT,\u00a0interrupci\u00f3n \u00a0=\u00a0fracaso)\u00a0el\u00a025%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0LPV/r\u00a0y\u00a0el\u00a039%\u00a0\nde\u00a0los\u00a0tratados\u00a0con\u00a0SQV/r\u00a0presentaron \u00a0fracaso\u00a0terap\u00e9utico \u00a0definido\u00a0como\u00a0CVP\u00a0\u2265200\u00a0\ncopias/mL \u00a0en\u00a0cualquier \u00a0momento \u00a0del\u00a0estudio\u00a0\u00a0(p=0,005). \u00a0El\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0fue\u00a0\nsimilar\u00a0con\u00a0ambas\u00a0pautas\u00a0(p=0,27)\u00a0352.\u00a0\u00a0En\u00a0este\u00a0estudio\u00a0se\u00a0utilizaron \u00a0c\u00e1psulas\u00a0duras\u00a0con\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 47200\u00a0mg\u00a0de\u00a0SQV\u00a0y\u00a0la\u00a0adherencia, \u00a0los\u00a0efectos\u00a0adversos\u00a0y\u00a0el\u00a0dise\u00f1o\u00a0abierto\u00a0\nprobablemente \u00a0resultaron \u00a0negativos \u00a0para\u00a0el\u00a0brazo\u00a0con\u00a0SQV/r.\u00a0SQV/r\u00a0no\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0\nde\u00a0elecci\u00f3n\u00a0en\u00a0TAR\u00a0de\u00a0rescate.\u00a0\n\u00a0\nAtazanavir \u00a0\nAI424\u00a0045\u00a0\nEl\u00a0estudio\u00a0AI424\u00a0045\u00a0compar\u00f3\u00a0ATV/r,\u00a0frente\u00a0a\u00a0ATV\u00a0m\u00e1s\u00a0SQV\u00a0y\u00a0frente\u00a0a\u00a0LPV/r\u00a0en\u00a0\npacientes \u00a0en\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Se\u00a0requer\u00eda\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0que\u00a0hubieran\u00a0\nllevado\u00a0al\u00a0menos\u00a02\u00a0reg\u00edmenes \u00a0previos\u00a0y\u00a0experiencia \u00a0con\u00a0alg\u00fan\u00a0f\u00e1rmaco\u00a0de\u00a0las\u00a0tres\u00a0\nclases\u00a0(AN,\u00a0NN\u00a0e\u00a0IP).\u00a0Todos\u00a0los\u00a0pacientes \u00a0recibieron \u00a0adem\u00e1s\u00a0TDF\u00a0y\u00a0otro\u00a0AN.\u00a0\u00a0A\u00a0la\u00a0\nsemana\u00a024\u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0eficacia\u00a0del\u00a0brazo\u00a0que\u00a0combinaba \u00a0ATV\u00a0y\u00a0SQV\u00a0era\u00a0\ninferior\u00a0a\u00a0LPV/r,\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0dio\u00a0opci\u00f3n\u00a0de\u00a0cambiar\u00a0el\u00a0tratamiento. \u00a0Tanto\u00a0a\u00a0las\u00a024\u00a0\ncomo\u00a048\u00a0semanas, \u00a0ATV/r\u00a0result\u00f3\u00a0no\u00a0inferior\u00a0a\u00a0LPV/r\u00a0respecto\u00a0al\u00a0criterio\u00a0de\u00a0valoraci\u00f3n \u00a0\nprimario\u00a0(reducci\u00f3n \u00a0de\u00a0CVP)\u00a0y\u00a0la\u00a0consecuci\u00f3n \u00a0de\u00a0CVP\u00a0<50\u00a0\u00f3\u00a0<400\u00a0copias/mL. \u00a0Sin\u00a0\nembargo, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias\u00a0fue\u00a038%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ATV/r\u00a0\nfrente\u00a0a\u00a045%\u00a0en\u00a0el\u00a0de\u00a0LPV/r353.\u00a0A\u00a0las\u00a096\u00a0semanas\u00a0el\u00a0criterio\u00a0de\u00a0valoraci\u00f3n \u00a0primario\u00a0\ndemostr\u00f3 \u00a0una\u00a0eficacia\u00a0similar\u00a0de\u00a0ATV/r\u00a0(\u20102,29\u00a0log10)\u00a0frente\u00a0a\u00a0LPV/r\u00a0(\u20102,08\u00a0log10).\u00a0En\u00a0los\u00a0\npacientes \u00a0en\u00a0tratamiento, \u00a0la\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0indetectable \u00a0fue\u00a0similar\u00a0en\u00a0ambos\u00a0\nbrazos,\u00a0pero\u00a0el\u00a0estudio\u00a0carece\u00a0de\u00a0poder\u00a0estad\u00edstico \u00a0para\u00a0demostrar \u00a0diferencias \u00a0para\u00a0\neste\u00a0objetivo\u00a0secundario. \u00a0En\u00a0un\u00a0subestudio354\u00a0que\u00a0analiz\u00f3\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0a\u00a0las\u00a0\n48\u00a0semanas\u00a0seg\u00fan\u00a0la\u00a0presencia \u00a0de\u00a0mutaciones \u00a0en\u00a0las\u00a0posiciones \u00a0D30,\u00a0V32,\u00a0M36,\u00a0M46,\u00a0\nI47,\u00a0G48,\u00a0I50,\u00a0F53,\u00a0I54,\u00a0A71,\u00a0G73,\u00a0V77,\u00a0V82,\u00a0I84,\u00a0N88\u00a0y\u00a0L90,\u00a0la\u00a0respuesta \u00a0fue\u00a0similar\u00a0si\u00a0\nhab\u00eda\u00a0\u22644\u00a0mutaciones. \u00a0Sin\u00a0embargo\u00a0cuando\u00a0el\u00a0n\u00famero\u00a0era\u00a0\u2265\u00a05,\u00a0ning\u00fan\u00a0paciente\u00a0(0/9)\u00a0del\u00a0\ngrupo\u00a0de\u00a0ATV/r\u00a0y\u00a05/18\u00a0(28%)\u00a0de\u00a0los\u00a0de\u00a0LPV/r\u00a0lograron\u00a0indetectabilidad. \u00a0Por\u00a0otra\u00a0parte\u00a0\nse\u00a0identificaron \u00a0mutaciones \u00a0asociadas \u00a0a\u00a0resistencia \u00a0a\u00a0ambos\u00a0f\u00e1rmacos. \u00a0Las\u00a0mutaciones \u00a0\nen\u00a0las\u00a0posiciones \u00a0M46,\u00a0I54,\u00a0I84,\u00a0o\u00a0L90\u00a0reducen\u00a0la\u00a0eficacia\u00a0de\u00a0ATV/r\u00a0a\u00a0menos\u00a0de\u00a0un\u00a030%,\u00a0\nal\u00a0igual\u00a0que\u00a0las\u00a0posiciones \u00a0M46,\u00a0I54\u00a0o\u00a0I84\u00a0en\u00a0LPV/r.\u00a0\u00a0\nATV/r\u00a0no\u00a0parece\u00a0ser\u00a0un\u00a0buen\u00a0f\u00e1rmaco\u00a0en\u00a0pacientes \u00a0con\u00a0experiencia \u00a0a\u00a0m\u00faltiples \u00a0\nf\u00e1rmacos \u00a0y\u00a0mutaciones \u00a0acumuladas \u00a0a\u00a0IP.\u00a0\u00a0\n\u00a0\nTipranavir \u00a0\nRESIST\u00a01\u00a0y\u00a02\u00a0\nLos\u00a0estudios\u00a0RESIST\u00a0son\u00a0estudios\u00a0fase\u00a0III\u00a0en\u00a0los\u00a0que\u00a0se\u00a0compar\u00f3\u00a0TPV/r\u00a0con\u00a0otro\u00a0IP/r\u00a0\nelegido\u00a0por\u00a0cada\u00a0investigador \u00a0(IP/rC).\u00a0Los\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0exig\u00edan\u00a0llevar\u00a0una\u00a0pauta\u00a0\ncon\u00a0IP,\u00a0estar\u00a0en\u00a0fracaso\u00a0virol\u00f3gico \u00a0(CVP\u00a0>1000\u00a0copias/mL) \u00a0y\u00a0en\u00a0el\u00a0estudio\u00a0genot\u00edpico \u00a0\ndeb\u00eda\u00a0haber\u00a0\u22651\u00a0mutaciones \u00a0primarias \u00a0en\u00a0los\u00a0codones\u00a030,\u00a046,\u00a048,\u00a050,\u00a082,\u00a084\u00a0o\u00a090,\u00a0y\u00a0\u22642\u00a0\nen\u00a0los\u00a0codones\u00a033,\u00a082,\u00a084\u00a0\u00f3\u00a090.\u00a0Los\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0a\u00a0TPV/r\u00a0o\u00a0un\u00a0IP/r\u00a0\ncomparador \u00a0(IP/rC).\u00a0\u00a0A\u00a0todos\u00a0los\u00a0pacientes \u00a0se\u00a0les\u00a0administr\u00f3 \u00a0un\u00a0tratamiento \u00a0optimizado \u00a0\nque\u00a0s\u00f3lo\u00a0pod\u00eda\u00a0incluir\u00a0ENF\u00a0en\u00a0cuanto\u00a0a\u00a0nuevos\u00a0f\u00e1rmacos. \u00a0Los\u00a0pacientes \u00a0part\u00edan\u00a0de\u00a0CVP\u00a0\nelevadas\u00a0(mediana \u00a0de\u00a04,8\u00a0log10\u00a0copias/mL) \u00a0y\u00a0CD4\u00a0bajos\u00a0(mediana \u00a0<200\u00a0c\u00e9lulas/\u00b5L). \u00a0En\u00a0\nel\u00a0RESIST\u20101\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0pacientes \u00a0del\u00a0IP/rC\u00a0recibieron \u00a0LPV/r\u00a0(61%),\u00a0mientras\u00a0que\u00a0\nen\u00a0el\u00a0RESIST\u20102\u00a0los\u00a0m\u00e1s\u00a0usados\u00a0fueron\u00a0APV/r\u00a0(40%)\u00a0y\u00a0LPV/r\u00a0(38%).\u00a0La\u00a0ENF\u00a0se\u00a0indic\u00f3\u00a0en\u00a0el\u00a0\n36%\u00a0del\u00a0RESIST\u20101\u00a0y\u00a0el\u00a012%\u00a0del\u00a0RESIST\u20102\u00a0(hab\u00eda\u00a0pacientes \u00a0tratados\u00a0previamente \u00a0con\u00a0este\u00a0\nf\u00e1rmaco)310.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 48Los\u00a0resultados \u00a0conjuntos \u00a0de\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0mostraron \u00a0una\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0del\u00a022,8%\u00a0y\u00a010,2%\u00a0con\u00a0TPV/r\u00a0y\u00a0con\u00a0\nIP/rC\u00a0respectivamente. \u00a0El\u00a0uso\u00a0de\u00a0ENF\u00a0mejor\u00f3\u00a0los\u00a0resultados \u00a0en\u00a0ambos\u00a0brazos,\u00a0\nalcanzando \u00a0el\u00a052%\u00a0(<400\u00a0copias/mL) \u00a0y\u00a035,8%\u00a0(50\u00a0copias/mL) \u00a0en\u00a0el\u00a0brazo\u00a0del\u00a0TPV/r\u00a0310.\u00a0\u00a0\n\u00a0\nMutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0TPV\u00a0\nSe\u00a0han\u00a0identificado \u00a019\u00a0mutaciones \u00a0en\u00a014\u00a0posiciones \u00a0de\u00a0amino\u00e1cidos \u00a0(L10V,\u00a0L24I,\u00a0M36I,\u00a0\nK43T,\u00a0M46L,\u00a0I47V,\u00a0I50L/V,\u00a0I54A/L/M/V, \u00a0I54L,\u00a0Q58E,\u00a0T74P,\u00a0L76V,\u00a0V82L/T,\u00a0N83D,\u00a0y\u00a0I84V)\u00a0\nasociadas \u00a0a\u00a0resistencia \u00a0a\u00a0TPV.\u00a0Seg\u00fan\u00a0el\u00a0peso\u00a0en\u00a0la\u00a0respuesta \u00a0al\u00a0tratamiento \u00a0con\u00a0TPV\u00a0\n(favorezcan \u00a0la\u00a0respuesta, \u00a0tengan\u00a0impacto\u00a0reducido\u00a0o\u00a0gran\u00a0impacto\u00a0en\u00a0la\u00a0resistencia) \u00a0se\u00a0\nles\u00a0ha\u00a0dado\u00a0un\u00a0valor\u00a0en\u00a0el\u00a0score\u00a0actualizado \u00a0(L10V,\u00a01;\u00a0L24I,\u00a0\u20102;\u00a0M36I,\u00a02;\u00a0K43T,\u00a02;\u00a0M46L,\u00a0\n1;\u00a0I47V,\u00a06;\u00a0I50L/V,\u00a0\u20104;\u00a0I54A/M/V, \u00a03;\u00a0I54L,\u00a0\u20107;\u00a0Q58E,\u00a05;\u00a0T74P,\u00a06;\u00a0L76V,\u00a0\u20102;\u00a0V82L/T,\u00a05;\u00a0\nN83D,\u00a04;\u00a0y\u00a0I84V,\u00a02).\u00a0En\u00a0la\u00a0elaboraci\u00f3n \u00a0de\u00a0este\u00a0score\u00a0se\u00a0ha\u00a0tenido\u00a0en\u00a0cuenta\u00a0la\u00a0eficacia\u00a0\nde\u00a0la\u00a0medicaci\u00f3n \u00a0que\u00a0acompa\u00f1aba \u00a0al\u00a0TPV.\u00a0Cuando\u00a0el\u00a0score\u00a0era\u00a0\u22643\u00a0la\u00a0respuesta \u00a0en\u00a0las\u00a0\nsemanas\u00a08\u00a0y\u00a048\u00a0es\u00a0m\u00e1xima\u00a0y\u00a0m\u00ednima\u00a0si\u00a0el\u00a0score\u00a0es\u00a0>10.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0\nrespond\u00edan \u00a0aumentaba \u00a0cuanto\u00a0mayor\u00a0era\u00a0la\u00a0eficacia\u00a0del\u00a0r\u00e9gimen\u00a0acompa\u00f1ante355.\u00a0\n\u00a0Darunavir \u00a0\nEste\u00a0IP\u00a0presenta\u00a0una\u00a0alta\u00a0afinidad\u00a0por\u00a0la\u00a0proteasa\u00a0y\u00a0es\u00a0muy\u00a0potente\u00a0in\u00a0vitro\u00a0e\u00a0in\u00a0vivo\u00a0\nfrente\u00a0a\u00a0la\u00a0cepa\u00a0salvaje\u00a0y\u00a0mutantes \u00a0con\u00a0resistencias \u00a0a\u00a0m\u00faltiples \u00a0FAR\u00a0incluyendo \u00a0IP\n356,\u00a0\n357.\u00a0\u00a0\nPOWER\u00a01\u00a0y\u00a02\u00a0\nLos\u00a0ensayos\u00a0POWER\u00a0compararon \u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0diferentes \u00a0dosis\u00a0de\u00a0DRV/r\u00a0\n(fase\u00a0II)\u00a0frente\u00a0a\u00a0un\u00a0IP/r\u00a0comparador \u00a0(IP/rC)\u00a0asociados \u00a0ambos\u00a0a\u00a0una\u00a0selecci\u00f3n\u00a0\noptimizada \u00a0de\u00a0f\u00e1rmacos. \u00a0Los\u00a0pacientes \u00a0incluidos\u00a0ten\u00eda\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0hab\u00edan\u00a0\nsido\u00a0tratados\u00a0previamente \u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0las\u00a0tres\u00a0familias\u00a0y\u00a0ten\u00edan\u00a0\u22651\u00a0mutaciones \u00a0\nprimarias \u00a0a\u00a0IP.\u00a0La\u00a0aleatorizaci\u00f3n \u00a0se\u00a0estratific\u00f3 \u00a0por\u00a0el\u00a0n\u00famero\u00a0de\u00a0mutaciones, \u00a0la\u00a0CVP\u00a0y\u00a0el\u00a0\nuso\u00a0de\u00a0ENF.\u00a0A\u00a0las\u00a024\u00a0semanas, \u00a0la\u00a0dosis\u00a0de\u00a0\u00a0DRV/r\u00a0se\u00a0unific\u00f3\u00a0a\u00a0600/100\u00a0mg\u00a0BID.\u00a0\u00a0En\u00a0el\u00a0\nan\u00e1lisis\u00a0combinado \u00a0de\u00a0ambos\u00a0estudios,\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0se\u00a0incluyeron \u00a0solamente \u00a0los\u00a0\npacientes \u00a0que\u00a0recibieron \u00a0la\u00a0dosis\u00a0de\u00a0DRV/r\u00a0de\u00a0600/100\u00a0mg\u00a0BID\u00a0desde\u00a0el\u00a0principio\u00a0\n(n=131)\u00a0frente\u00a0al\u00a0grupo\u00a0control\u00a0(n=120).\u00a0La\u00a0variable\u00a0principal\u00a0de\u00a0eficacia\u00a0fue\u00a0la\u00a0\nrespuesta \u00a0virol\u00f3gica \u00a0confirmada \u00a0(reducci\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0\u22651\u00a0log10\u00a0copias/mL \u00a0y\u00a0tiempo\u00a0\nhasta\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0respuesta \u00a0virol\u00f3gica, \u00a0TLOVR).\u00a0En\u00a0cuanto\u00a0a\u00a0eficacia,\u00a0la\u00a0reducci\u00f3n \u00a0de\u00a0\nla\u00a0CVP\u00a0se\u00a0alcanz\u00f3\u00a0en\u00a061%\u00a0de\u00a0los\u00a0pacientes \u00a0del\u00a0grupo\u00a0de\u00a0DRV/r\u00a0y\u00a0en\u00a015%\u00a0del\u00a0grupo\u00a0\ncomparador \u00a0(diferencia \u00a046%;\u00a0IC\u00a095%,\u00a035\u00a0a\u00a057;\u00a0p<0,0001). \u00a0La\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(ITT\u2010TLOVR)\u00a0fue\u00a045%\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0DRV/r\u00a0y\u00a010%\u00a0en\u00a0el\u00a0grupo\u00a0control.\u00a0La\u00a0\neficacia\u00a0superior\u00a0de\u00a0DRV/r\u00a0frente\u00a0al\u00a0IP/r\u00a0comparador \u00a0se\u00a0mantuvo\u00a0independientemente \u00a0\ndel\u00a0uso\u00a0de\u00a0ENF,\u00a0de\u00a0la\u00a0CVP\u00a0basal,\u00a0mutaciones \u00a0primarias \u00a0frente\u00a0a\u00a0IP\u00a0o\u00a0n\u00famero\u00a0de\u00a0FAR\u00a0\nactivos\u00a0en\u00a0la\u00a0terapia\u00a0optimizada. \u00a0Tambi\u00e9n\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0discontinuaciones \u00a0(fracaso\u00a0\no\u00a0abandono \u00a0por\u00a0cualquier \u00a0motivo)\u00a0fue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0DRV/r\u00a0(21%\u00a0frente\u00a0a\u00a0\n81%)308.\u00a0En\u00a0la\u00a0semana\u00a096\u00a0el\u00a039%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0DRV/r\u00a0y\u00a0el\u00a09%\u00a0del\u00a0grupo\u00a0\ncomparador \u00a0persist\u00edan \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(p<0,001, \u00a0ITT\u2010TLOVR)315.\u00a0\u00a0\nEl\u00a0estudio\u00a0POWER\u00a03\u00a0se\u00a0dise\u00f1\u00f3\u00a0para\u00a0incrementar \u00a0los\u00a0datos\u00a0de\u00a0eficacia,\u00a0seguridad \u00a0y\u00a0\ntolerancia \u00a0de\u00a0DRV/r\u00a0(dosis\u00a0de\u00a0600/100\u00a0mg,\u00a0BID)\u00a0ratificando \u00a0los\u00a0resultados \u00a0obtenidos \u00a0en\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 49los\u00a0estudios\u00a0POWER\u00a01\u00a0y\u00a02\u00a0y\u00a0no\u00a0dispone\u00a0de\u00a0rama\u00a0control358.\u00a0En\u00a0la\u00a0semana\u00a0144,\u00a0el\u00a037%\u00a0y\u00a0\nel\u00a09%\u00a0de\u00a0los\u00a0pacientes \u00a0respectivamente \u00a0persist\u00edan \u00a0con\u00a0CVP\u00a0<\u00a050\u00a0copias/mL359.\u00a0\n\u00a0TITAN\u00a0\nEl\u00a0TITAN\u00a0es\u00a0un\u00a0ensayo\u00a0fase\u00a0III,\u00a0aleatorizado, \u00a0que\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0de\u00a0DRV/r\u00a0frente\u00a0a\u00a0\nLPV/r,\u00a0ambos\u00a0con\u00a0un\u00a0tratamiento \u00a0optimizado, \u00a0en\u00a0pacientes \u00a0en\u00a0fracaso\u00a0virol\u00f3gico \u00a0pero\u00a0\ncon\u00a0menor\u00a0experiencia \u00a0en\u00a0tratamientos \u00a0que\u00a0en\u00a0los\u00a0estudios\u00a0POWER.\u00a0Los\u00a0criterios\u00a0de\u00a0\ninclusi\u00f3n\u00a0fueron\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0duraci\u00f3n\u00a0de\u00a0TAR\n\u00a0\u226512\u00a0semanas\u00a0y\u00a0que\u00a0nunca\u00a0\nhubieran\u00a0recibido\u00a0LPV/r.\u00a0Los\u00a0datos\u00a0deber\u00edan\u00a0analizarse \u00a0con\u00a0criterios\u00a0de\u00a0no\u2010inferioridad. \u00a0\nNo\u00a0obstante, \u00a0con\u00a0la\u00a0finalidad\u00a0de\u00a0realizar\u00a0una\u00a0comparaci\u00f3n \u00a0entre\u00a0ambas\u00a0opciones\u00a0\nterap\u00e9uticas, \u00a0el\u00a0dise\u00f1o\u00a0del\u00a0estudio\u00a0recog\u00eda,\u00a0a\u00a0priori,\u00a0que\u00a0se\u00a0realizar\u00eda\u00a0un\u00a0estudio\u00a0de\u00a0\nsuperioridad \u00a0por\u00a0ITT\u00a0en\u00a0caso\u00a0de\u00a0cumplirse \u00a0la\u00a0no\u2010inferioridad. \u00a0Se\u00a0incluyeron \u00a0595\u00a0\npacientes. \u00a0A\u00a0las\u00a048\u00a0semanas\u00a0se\u00a0observ\u00f3\u00a0(ITT)\u00a0que\u00a077%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0DRV/r\u00a0y\u00a067%\u00a0\ndel\u00a0grupo\u00a0LPV/r\u00a0alcanzaron \u00a0la\u00a0variable\u00a0principal\u00a0del\u00a0estudio:\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0\n(diferencia \u00a0media\u00a0estimada\u00a010%;\u00a0IC\u00a095%\u00a02\u00a0a\u00a017,\u00a0p\u00a0<0,001);\u00a0DRV/r\u00a0cumpl\u00eda\u00a0por\u00a0tanto\u00a0\ncriterios\u00a0de\u00a0superioridad \u00a0frente\u00a0a\u00a0LPV/r.\u00a0Tambi\u00e9n\u00a0se\u00a0observaron \u00a0diferencias \u00a0con\u00a0\ncriterios\u00a0de\u00a0superioridad \u00a0de\u00a0DRV/r\u00a0cuando\u00a0se\u00a0analiz\u00f3\u00a0la\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(71%\u00a0frente\u00a0a\u00a060%,\u00a0diferencia \u00a0media\u00a0estimada\u00a011%;\u00a0IC\u00a095%,\u00a03\u00a0a\u00a019;\u00a0\np=0,005). \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0subgrupos \u00a0respecto\u00a0a\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0DRV/r\u00a0result\u00f3\u00a0\ntambi\u00e9n\u00a0superior\u00a0a\u00a0LPV/r\u00a0si\u00a0los\u00a0CD4\u00a0basales\u00a0eran\u00a0bajos,\u00a0CVP\u00a0>100000\u00a0copias/mL, \u00a0\npresencia \u00a0de\u00a0\u22651\u00a0mutaciones \u00a0primarias \u00a0a\u00a0IP,\u00a0fold\u2010change\u00a0de\u00a0LPV/r\u00a0>10\u00a0o\u00a0\u00a0fold\u2010change\u00a0a\u00a0\nDRV\u00a0<10.\u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0de\u00a010%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0DRV/r\u00a0y\u00a0de\u00a022%\u00a0con\u00a0LPV/r.\u00a0En\u00a0\nel\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0mutaciones \u00a0de\u00a0resistencia, \u00a0s\u00f3lo\u00a0el\u00a021%\u00a0(6/28)\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0\nfracasaron \u00a0con\u00a0DRV/r\u00a0desarrollaron \u00a0mutaciones \u00a0adicionales \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa\u00a0\nmientras\u00a0que\u00a0s\u00ed\u00a0lo\u00a0hizo\u00a0el\u00a036%\u00a0(20/56)\u00a0del\u00a0grupo\u00a0LPV/r.\u00a0Las\u00a0mutaciones \u00a0frente\u00a0a\u00a0AN\u00a0\nfueron\u00a0menos\u00a0frecuentes \u00a0en\u00a0el\u00a0grupo\u00a0con\u00a0DRV/r\u00a0(14%\u00a0frente\u00a0a\u00a027%).\u00a0La\u00a0seguridad \u00a0y\u00a0\ntolerancia \u00a0de\u00a0DRV/r\u00a0fue\u00a0comparable \u00a0a\u00a0LPV/r,\u00a0con\u00a0menos\u00a0diarrea\u00a0de\u00a0grado\u00a02\u20104\u00a0y\u00a0mejor\u00a0\nperfil\u00a0lip\u00eddico360.\u00a0\u00a0\u00a0\u00a0\n\u00a0\nGRACE\u00a0\nEl\u00a0estudio\u00a0GRACE\u00a0(Gender,\u00a0Race\u00a0and\u00a0Clinical\u00a0Experience )\u00a0es\u00a0un\u00a0estudio\u00a0en\u00a0fase\u00a0IIIb,\u00a0\nmultic\u00e9ntrico \u00a0y\u00a0abierto\u00a0que\u00a0incluy\u00f3\u00a0pacientes \u00a0con\u00a0experiencia \u00a0previa\u00a0a\u00a0f\u00e1rmacos\u00a0\nantirretrovirales \u00a0y\u00a0con\u00a0CVP\u00a0\u22651000\u00a0copias/mL. \u00a0Todos\u00a0los\u00a0pacientes \u00a0recibieron \u00a0DRV/r\u00a0\n600/100mg \u00a0BID\u00a0con\u00a0un\u00a0tratamiento \u00a0optimizado \u00a0que\u00a0inclu\u00eda\u00a0AN\u00a0y\u00a0NN,\u00a0incluida\u00a0ETR.\u00a0El\u00a0\nobjetivo\u00a0principal\u00a0fue\u00a0evaluar\u00a0si\u00a0hab\u00eda\u00a0diferencias \u00a0seg\u00fan\u00a0el\u00a0g\u00e9nero\u00a0o\u00a0la\u00a0raza\u00a0de\u00a0los\u00a0\npacientes \u00a0respecto\u00a0a\u00a0la\u00a0eficacia\u00a0(CVP\u00a0<50\u00a0copias/mL) \u00a0del\u00a0tratamiento \u00a0a\u00a0las\u00a048\u00a0semanas. \u00a0\nSe\u00a0incluyeron \u00a0429\u00a0pacientes, \u00a0de\u00a0los\u00a0cuales\u00a0un\u00a067%\u00a0eran\u00a0mujeres\u00a0y\u00a0un\u00a084%\u00a0eran\u00a0de\u00a0raza\u00a0\nnegra.\u00a0Un\u00a032,8%\u00a0de\u00a0las\u00a0mujeres\u00a0suspendieron \u00a0el\u00a0TAR\u00a0frente\u00a0a\u00a0un\u00a023,2%\u00a0de\u00a0los\u00a0hombres\u00a0\n(p\u00a0<0,05).\u00a0En\u00a0la\u00a0semana\u00a048,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0en\u00a0ITT\u2010TLOVR,\u00a0un\u00a050,9%\u00a0de\u00a0las\u00a0mujeres\u00a0y\u00a0un\u00a0\n58,5%\u00a0de\u00a0los\u00a0hombres\u00a0alcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0Las\u00a0diferencias \u00a0en\u00a0la\u00a0\nrespuesta \u00a0virol\u00f3gica \u00a0ajustada\u00a0por\u00a0la\u00a0CVP\u00a0y\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0basales\u00a0fue:\u00a0\u20109,6\u00a0\n(IC\u00a095%,\u00a0\u201019,85\u00a0a\u00a00,68).\u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0en\u00a0ITT\u2010TLOVR\u00a0en\u00a0el\u00a0que\u00a0se\u00a0censuraron \u00a0los\u00a0\npacientes \u00a0que\u00a0fracasaron \u00a0por\u00a0causas\u00a0diferentes \u00a0al\u00a0fracaso\u00a0virol\u00f3gico, \u00a0un\u00a073%\u00a0y\u00a0un\u00a0\n73,5%\u00a0de\u00a0las\u00a0mujeres\u00a0y\u00a0hombres\u00a0alcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0diferencia \u00a0\u20103,9\u00a0(IC\u00a0\n95%,\u00a0\u201013,89\u00a0a\u00a06,02).\u00a0Los\u00a0autores\u00a0resaltan\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0DRV/r\u00a0en\u00a0los\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 50tratamientos \u00a0de\u00a0rescate\u00a0tanto\u00a0en\u00a0hombres\u00a0como\u00a0en\u00a0mujeres,\u00a0aunque\u00a0una\u00a0elevada\u00a0\nproporci\u00f3n \u00a0de\u00a0mujeres\u00a0abandonan \u00a0el\u00a0TAR\u00a0por\u00a0razones\u00a0distintas\u00a0al\u00a0fracaso\u00a0virol\u00f3gico361,\u00a0\n362.\u00a0\u00a0\u00a0\n\u00a0\nODIN\u00a0\nEs\u00a0un\u00a0estudio\u00a0fase\u00a0IIIb\u00a0que\u00a0ha\u00a0comparado \u00a0las\u00a0dosis\u00a0de\u00a0DRV/r\u00a0800/100\u00a0QD\u00a0frente\u00a0a\u00a0\n600/100\u00a0BID\u00a0junto\u00a0a\u00a0un\u00a0r\u00e9gimen\u00a0de\u00a0rescate\u00a0que\u00a0s\u00f3lo\u00a0inclu\u00eda\u00a0AN\u00a0en\u00a0pacientes \u00a0con\u00a0\nfracaso\u00a0a\u00a0un\u00a0TAR\u00a0y\u00a0que\u00a0no\u00a0presentaran \u00a0ninguna\u00a0mutaci\u00f3n \u00a0frente\u00a0a\u00a0DRV\u00a0(score\u00a0de\u00a0la\u00a0IAS\u2010\nUSA)363.\u00a0Ha\u00a0incluido\u00a0590\u00a0pacientes \u00a0con\u00a0CVP\u00a01000\u00a0copias/mL \u00a0y\u00a0un\u00a0recuento\u00a0de\u00a0CD4\u00a0>50\u00a0\nc\u00e9lulas.\u00a0El\u00a0objetivo\u00a0primario\u00a0fue\u00a0la\u00a0demostraci\u00f3n \u00a0de\u00a0la\u00a0no\u2010inferioridad \u00a0de\u00a0la\u00a0dosis\u00a0QD\u00a0de\u00a0\nDRV/r\u00a0en\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<\u00a050\u00a0copias/mL \u00a0(ITT\u2010TLOVR,\u00a0delta\u00a0\npredefinido \u00a0del\u00a012%).\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0el\u00a0porcentaje \u00a0fue\u00a0del\u00a072,1%\u00a0para\u00a0la\u00a0dosis\u00a0QD\u00a0y\u00a0\ndel\u00a070,9%\u00a0para\u00a0la\u00a0dosis\u00a0BID\u00a0(diferencia \u00a01,2%;\u00a0IC\u00a095%,\u00a0\u20136,1%\u00a0a\u00a08,5%),\u00a0cumpliendo \u00a0la\u00a0no\u2010\ninferioridad. \u00a0La\u00a0evoluci\u00f3n \u00a0del\u00a0recuento\u00a0de\u00a0c\u00e9lulas\u00a0CD4\u00a0fue\u00a0similar\u00a0entre\u00a0ambas\u00a0ramas.\u00a0\nSolo\u00a01/294\u00a0pacientes \u00a0desarroll\u00f3 \u00a0una\u00a0mutaci\u00f3n \u00a0de\u00a0resistencia \u00a0a\u00a0DRV\u00a0en\u00a0el\u00a0fracaso\u00a0\n(ninguno\u00a0en\u00a0la\u00a0rama\u00a0BID).\u00a0La\u00a0tasa\u00a0de\u00a0efectos\u00a0adversos\u00a0de\u00a0grados\u00a03/4\u00a0se\u00a0redujo\u00a0a\u00a0la\u00a0\nmitad\u00a0en\u00a0el\u00a0grupo\u00a0QD\u00a0(7,8%\u00a0frente\u00a0a\u00a015,2%)\u00a0y\u00a0los\u00a0niveles\u00a0de\u00a0colesterol \u00a0total,\u00a0LDL\u00a0y\u00a0\ntriglic\u00e9ridos \u00a0fueron\u00a0significativamente \u00a0menores\u00a0en\u00a0la\u00a0rama\u00a0QD.\u00a0Debe\u00a0destacarse \u00a0que\u00a0\nen\u00a0realidad\u00a0el\u00a046%\u00a0de\u00a0los\u00a0pacientes \u00a0incluidos\u00a0no\u00a0hab\u00eda\u00a0recibido\u00a0ning\u00fan\u00a0IP\u00a0y\u00a0que\u00a0la\u00a0\nmediana\u00a0de\u00a0mutaciones \u00a0primarias \u00a0para\u00a0IP\u00a0fue\u00a0de\u00a00,\u00a0por\u00a0lo\u00a0que\u00a0la\u00a0aplicaci\u00f3n \u00a0de\u00a0los\u00a0\nresultados \u00a0de\u00a0este\u00a0estudio\u00a0en\u00a0pacientes \u00a0con\u00a0varias\u00a0mutaciones \u00a0primarias \u00a0en\u00a0la\u00a0proteasa\u00a0\npuede\u00a0ser\u00a0limitada364.\u00a0En\u00a0funci\u00f3n\u00a0de\u00a0los\u00a0resultados \u00a0los\u00a0autores\u00a0sugieren\u00a0que\u00a0DRV/r\u00a0QD\u00a0\npodr\u00eda\u00a0ser\u00a0una\u00a0opci\u00f3n\u00a0terap\u00e9utica \u00a0en\u00a0pacientes \u00a0que\u00a0han\u00a0fracasado \u00a0a\u00a0un\u00a0tratamiento \u00a0\nprevio\u00a0y\u00a0no\u00a0tengan\u00a0mutaciones \u00a0espec\u00edficas \u00a0a\u00a0DRV.\u00a0\u00a0\n\u00a0\nMutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0DRV\u00a0\nSe\u00a0han\u00a0identificado \u00a011\u00a0mutaciones \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa\u00a0(V11I,\u00a0V32I,\u00a0L33F,\u00a0I47V,\u00a0\nI50V,\u00a0I54L\u00a0o\u00a0M,\u00a0T74P,\u00a0L76V,\u00a0I84V,\u00a0L89V)\u00a0relacionadas \u00a0con\u00a0p\u00e9rdida\u00a0de\u00a0sensibilidad \u00a0a\u00a0\nDRV.\u00a0La\u00a0respuesta \u00a0virol\u00f3gica \u00a0a\u00a0DRV/r\u00a0en\u00a0TAR\u00a0de\u00a0rescate\u00a0se\u00a0va\u00a0reduciendo \u00a0\nparalelamente \u00a0al\u00a0n\u00famero\u00a0de\u00a0estas\u00a0mutaciones, \u00a0al\u00a0igual\u00a0que\u00a0sucede\u00a0con\u00a0todos\u00a0los\u00a0IP/r.\u00a0\nLos\u00a0porcentajes \u00a0de\u00a0respuesta \u00a0con\u00a00,\u00a01,\u00a02\u00a0y\u00a03\u00a0mutaciones \u00a0fue\u00a0del\u00a072%,\u00a053%,\u00a037%\u00a0y\u00a029%\u00a0\nrespectivamente \u00a0en\u00a0los\u00a0estudios\u00a0POWER\u00a0(7%\u00a0con\u00a0\u22654\u00a0mutaciones)365.\u00a0\u00a0\nEste\u00a0dato\u00a0debe\u00a0ser\u00a0muy\u00a0tenido\u00a0en\u00a0cuenta\u00a0para\u00a0valorar\u00a0el\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos\u00a0\nacompa\u00f1antes \u00a0en\u00a0el\u00a0r\u00e9gimen\u00a0de\u00a0rescate\u00a0seg\u00fan\u00a0la\u00a0actividad\u00a0residual\u00a0de\u00a0DRV\u00a0cuando\u00a0\n\u00e9sta\u00a0est\u00e9\u00a0comprometida. \u00a0\n\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\nEtravirina \u00a0\u00a0\nEtravirina \u00a0es\u00a0un\u00a0NN\u00a0de\u00a0segunda\u00a0generaci\u00f3n \u00a0activo\u00a0en\u00a0determinados \u00a0casos\u00a0con\u00a0infecci\u00f3n\u00a0\nVIH\u00a0con\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0frente\u00a0a\u00a0EFV\u00a0y\u00a0NVP.\u00a0\u00a0\n\u00a0\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 51Estudio\u00a0TMC125\u2010C227\u00a0\nFue\u00a0un\u00a0estudio\u00a0aleatorizado \u00a0abierto\u00a0en\u00a0fase\u00a0II\u00a0en\u00a0donde\u00a0se\u00a0intent\u00f3\u00a0evaluar\u00a0la\u00a0utilidad\u00a0\nde\u00a0ETR\u00a0en\u00a0fases\u00a0tempranas \u00a0de\u00a0tratamiento. \u00a0Se\u00a0incluyeron \u00a0116\u00a0pacientes \u00a0que\u00a0nunca\u00a0\nhab\u00edan\u00a0estado\u00a0expuestos \u00a0a\u00a0IP\u00a0pero\u00a0que\u00a0ten\u00edan\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0NN\u00a0por\u00a0\nfracaso\u00a0de\u00a0un\u00a0tratamiento \u00a0previo\u00a0con\u00a0NN,\u00a0interrupci\u00f3n \u00a0de\u00a0un\u00a0NN\u00a0o\u00a0profilaxis\u00a0de\u00a0\ntransmisi\u00f3n \u00a0vertical\u00a0con\u00a0NN.\u00a0Se\u00a0utiliz\u00f3\u00a0una\u00a0dosis\u00a0de\u00a0ETR\u00a0de\u00a0800\u00a0mg\u00a0BID\u00a0de\u00a0una\u00a0\nformulaci\u00f3n \u00a0anterior\u00a0a\u00a0la\u00a0actual,\u00a0que\u00a0ofrec\u00eda\u00a0una\u00a0farmacocin\u00e9tica \u00a0similar\u00a0a\u00a0la\u00a0obtenida\u00a0\ncon\u00a0los\u00a0200\u00a0mg\u00a0BID\u00a0actuales.\u00a0Los\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0a\u00a0recibir\u00a0ETR\u00a0o\u00a0el\u00a0IP\u00a0\n(potenciado \u00a0o\u00a0no)\u00a0seleccionado \u00a0por\u00a0el\u00a0investigador, \u00a0siempre\u00a0junto\u00a0a\u00a0dos\u00a0AN.\u00a0Si\u00a0bien\u00a0\nhubo\u00a0una\u00a0respuesta \u00a0inicial\u00a0en\u00a0ambas\u00a0ramas,\u00a0se\u00a0observ\u00f3\u00a0un\u00a0repunte\u00a0de\u00a0la\u00a0CVP\u00a0en\u00a0la\u00a0\nrama\u00a0de\u00a0ETR\u00a0y\u00a0el\u00a0estudio\u00a0fue\u00a0suspendido \u00a0prematuramente. \u00a0Los\u00a0pacientes \u00a0ten\u00edan\u00a0hasta\u00a0\n7\u00a0mutaciones \u00a0de\u00a0AN\u00a0y\u00a04\u00a0de\u00a0NN343.\u00a0Este\u00a0estudio\u00a0es\u00a0un\u00a0ejemplo\u00a0de\u00a0la\u00a0necesidad \u00a0de\u00a0\nutilizar\u00a0m\u00e1s\u00a0de\u00a0dos\u00a0f\u00e1rmacos\u00a0activos\u00a0y\u00a0evitar\u00a0la\u00a0monoterapia \u00a0funcional \u00a0en\u00a0pacientes \u00a0\npretratados. \u00a0\u00a0\u00a0\n\u00a0DUET\u00a01\u00a0y\u00a02\u00a0\u00a0\u00a0\nLos\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0fase\u00a0III\u00a0DUET\u00a0se\u00a0dise\u00f1aron \u00a0para\u00a0analizar\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\nde\u00a0ETR\u00a0en\u00a0pacientes \u00a0con\u00a0experiencia \u00a0previa\u00a0a\u00a0FAR.\u00a0Con\u00a0un\u00a0dise\u00f1o\u00a0similar,\u00a0DUET\u00a01\u00a0y\u00a02,\u00a0\nson\u00a0ensayos\u00a0multinacionales, \u00a0paralelos, \u00a0aleatorizados \u00a0y\u00a0doble\u00a0ciego\u00a0de\u00a0ETR\u00a0frente\u00a0a\u00a0\nplacebo.\u00a0Los\n\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0eran:\u00a0CVP\u00a0>5000\u00a0copias/mL, \u00a0TAR\u00a0estable\u00a0durante\u00a0\u22658\u00a0\nsemanas, \u00a0presencia \u00a0de\u00a0\u22651\u00a0mutaci\u00f3n \u00a0frente\u00a0a\u00a0NN\u00a0y\u00a0\u22653\u00a0mutaciones \u00a0frente\u00a0a\u00a0IP.\u00a0Todos\u00a0los\u00a0\npacientes \u00a0recibieron \u00a0DRV/r\u00a0y\u00a0AN\u00a0seg\u00fan\u00a0terapia\u00a0optimizada. \u00a0El\u00a0uso\u00a0de\u00a0ENF\u00a0fue\u00a0opcional.\u00a0\nLa\u00a0variable\u00a0principal\u00a0del\u00a0estudio\u00a0era\u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0la\u00a0semana\u00a024\u00a0(an\u00e1lisis\u00a0\npor\u00a0ITT\u00a0y\u00a0TLOVR).\u00a0Se\u00a0incluyeron \u00a0612\u00a0pacientes \u00a0en\u00a0el\u00a0DUET\u20101\u00a0y\u00a0591\u00a0en\u00a0el\u00a0DUET\u20102.\u00a0Los\u00a0\nresultados \u00a0fueron:\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0tratados\u00a0con\u00a0ETR,\u00a056%\u00a0y\u00a062%\u00a0(DUET\u20101\u00a0y\u00a0\nDUET\u20102)\u00a0\u00a0frente\u00a0a\u00a039%\u00a0y\u00a044%\u00a0(en\u00a0grupos\u00a0placebo)\u00a0respectivamente \u00a0(p<0,01\u00a0y\u00a0p\u00a0<0,001).\u00a0\nLa\u00a0CVP\u00a0se\u00a0redujo\u00a0en\u00a02,4\u00a0y\u00a02,3\u00a0log10\u00a0en\u00a0los\u00a0grupos\u00a0con\u00a0ETR\u00a0y\u00a02,3\u00a0y\u00a01,7\u00a0log10\u00a0en\u00a0los\u00a0de\u00a0\nplacebo\u00a0(diferencia \u00a0no\u00a0significativa). \u00a0Entre\u00a0los\u00a0pacientes \u00a0que\u00a0recibieron \u00a0ETR\u00a0y\u00a0ENF\u00a0en\u00a0el\u00a0\ntratamiento \u00a0optimizado, \u00a060%\u00a0y\u00a073%\u00a0alcanzaron \u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0frente\u00a0a\u00a056%\u00a0y\u00a068%\u00a0\nen\u00a0los\u00a0del\u00a0grupo\u00a0placebo313,\u00a0314.\u00a0Los\u00a0resultados \u00a0conjuntos \u00a0de\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a048\u00a0\nsemanas\u00a0confirman \u00a0los\u00a0datos\u00a0previos\u00a0con\u00a061%\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0ETR\u00a0alcanzaron \u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0frente\u00a0al\u00a040%\u00a0de\u00a0los\u00a0pacientes \u00a0asignados \u00a0al\u00a0grupo\u00a0placebo\u00a0(p<0,0001); \u00a0el\u00a0\ndescenso \u00a0de\u00a0la\u00a0CVP\u00a0era\u00a0de\u00a0\u20102,25\u00a0log10\u00a0y\u00a0\u20131,49\u00a0log10\u00a0respectivamente307.\u00a0En\u00a0la\u00a0semana\u00a0\n96,\u00a0el\u00a0an\u00e1lisis\u00a0combinado \u00a0de\u00a0ambos\u00a0estudios\u00a0se\u00f1ala\u00a0que\u00a0la\u00a0eficacia\u00a0de\u00a0ETR\u00a0m\u00e1s\u00a0terapia\u00a0\noptimizada \u00a0fue\u00a0superior\u00a0al\u00a0grupo\u00a0comparador: \u00a057%\u00a0frente\u00a0al\u00a036%\u00a0respectivamente \u00a0\n(p<0,001). \u00a0El\u00a091%\u00a0de\u00a0los\u00a0pacientes \u00a0asignados \u00a0a\u00a0ETR\u00a0que\u00a0alcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0copias\u00a0\nen\u00a0la\u00a0semana\u00a048\u00a0persist\u00edan \u00a0con\u00a0la\u00a0misma\u00a0eficacia\u00a0virol\u00f3gica \u00a0en\u00a0la\u00a0semana\u00a096366.\u00a0Por\u00a0otra\u00a0\nparte\u00a0el\u00a0n\u00famero\u00a0de\u00a0eventos\u00a0cl\u00ednicos\u00a0asociados \u00a0a\u00a0sida\u00a0o\u00a0muerte\u00a0fue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0\nque\u00a0recibi\u00f3\u00a0ETR\u00a0(p=0,06)\u00a0y\u00a0alcanz\u00f3\u00a0diferencias \u00a0estad\u00edsticamente \u00a0significativas \u00a0cuando\u00a0\nse\u00a0compararon \u00a0los\u00a0pacientes \u00a0de\u00a0ambos\u00a0grupos\u00a0que\u00a0adem\u00e1s\u00a0utilizaban \u00a0ENF\u00a0habi\u00e9ndola \u00a0\nutilizado\u00a0previamente \u00a0(5,9%\u00a0en\u00a0el\u00a0grupo\u00a0ETR\u00a0frente\u00a010,1%\u00a0en\u00a0el\u00a0grupo\u00a0placebo,\u00a0\np=0,02)367.\u00a0\u00a0\nLa\u00a0tolerancia \u00a0a\u00a0la\u00a0ETR\u00a0fue\u00a0buena,\u00a0el\u00a0efecto\u00a0secundario \u00a0m\u00e1s\u00a0frecuente \u00a0fue\u00a0un\u00a0exantema \u00a0\nleve\u00a0o\u00a0moderado. \u00a0Lo\u00a0manifestaron \u00a0el\u00a019%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0ETR\u00a0frente\u00a0al\u00a012%\u00a0del\u00a0\ngrupo\u00a0control\u00a0(p<0,0001); \u00a0apareci\u00f3\u00a0en\u00a0las\u00a0primeras\u00a0semanas, \u00a0la\u00a0mayor\u00eda\u00a0de\u00a0grado\u00a0leve\u2010\nmoderado \u00a0(el\u00a01%\u00a0se\u00a0consider\u00f3 \u00a0grado\u00a03)\u00a0y\u00a0s\u00f3lo\u00a0en\u00a0el\u00a02%\u00a0se\u00a0retir\u00f3\u00a0el\u00a0tratamiento. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 52La\u00a0ETR\u00a0tiene\u00a0pocas\u00a0interacciones \u00a0medicamentosas \u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante). \u00a0\n\u00a0\nMutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0ETR\u00a0\u00a0\nEl\u00a0fabricante \u00a0ha\u00a0identificado \u00a017\u00a0mutaciones \u00a0en\u00a0su\u00a0score\u00a0ponderado \u00a0que\u00a0pueden\u00a0\ndisminuir \u00a0la\u00a0respuesta \u00a0a\u00a0ETR:\u00a0V90I,\u00a0A98G,\u00a0L100I,\u00a0K101E/H/P, \u00a0V106I,\u00a0E138A,\u00a0\u00a0V179D/F/T, \u00a0\nY181C/I/V, \u00a0G190A/S\u00a0y\u00a0M230L.\u00a0Entre\u00a0estas\u00a0mutaciones, \u00a0la\u00a0presencia \u00a0de\u00a0la\u00a0Y181I\u00a0o\u00a0la\u00a0\nY181V\u00a0seguidas\u00a0de\u00a0la\u00a0L100I,\u00a0K101P,\u00a0Y181C\u00a0y\u00a0M230L\u00a0son\u00a0las\u00a0que\u00a0generan\u00a0una\u00a0mayor\u00a0\nresistencia \u00a0a\u00a0ETR.\u00a0Estas\u00a0mutaciones \u00a0tienen,\u00a0en\u00a0general,\u00a0una\u00a0baja\u00a0prevalencia \u00a0en\u00a0la\u00a0\npoblaci\u00f3n \u00a0VIH\u00a0con\u00a0fracaso\u00a0virol\u00f3gico \u00a0a\u00a0NN\u00a0de\u00a0primera\u00a0generaci\u00f3n, \u00a0aunque\u00a0siempre\u00a0que\u00a0\nvaya\u00a0a\u00a0usarse\u00a0ETR\u00a0debe\u00a0evaluarse \u00a0su\u00a0actividad\u00a0si\u00a0existen\u00a0mutaciones \u00a0para\u00a0NN368.\u00a0La\u00a0\npuntuaci\u00f3n \u00a0obtenida\u00a0con\u00a0la\u00a0suma\u00a0de\u00a0cada\u00a0mutaci\u00f3n \u00a0se\u00a0ha\u00a0correlacionado \u00a0con\u00a0\nrespuesta \u00a0virol\u00f3gica \u00a0observada \u00a0en\u00a0los\u00a0estudios\u00a0DUET.\u00a0\u00a0\u00a0\nPor\u00a0otra\u00a0parte\u00a0Monogram \u00a0ha\u00a0desarrollado \u00a0un\u00a0score\u00a0que\u00a0asigna\u00a0a\u00a0cada\u00a0mutaci\u00f3n \u00a0un\u00a0\nvalor\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0su\u00a0peso\u00a0(Valor\u00a04:\u00a0L100I,\u00a0K101P,\u00a0Y181C/I/V; \u00a0valor\u00a03:\u00a0E138A/G, \u00a0\nV179E,\u00a0G190Q,\u00a0M230L,\u00a0K238N,\u00a0valor\u00a02:\u00a0K101E,\u00a0V106A/I,\u00a0E138K,\u00a0V179L,\u00a0Y188L,\u00a0G190S;\u00a0y\u00a0\nvalor\u00a01:\u00a0V90I,\u00a0A98G,\u00a0K101H,\u00a0K103R,\u00a0V106M,\u00a0E138Q,\u00a0V179D/F/I/M/T, \u00a0Y181F,\u00a0Y189I,\u00a0\nG190A/E/T, \u00a0H221Y,\u00a0P225H,\u00a0K238T).\u00a0En\u00a0este\u00a0score\u00a0la\u00a0puntuaci\u00f3n \u00a0obtenida\u00a0con\u00a0la\u00a0suma\u00a0\nde\u00a0los\u00a0puntos\u00a0de\u00a0cada\u00a0mutaci\u00f3n \u00a0se\u00a0correlaciona \u00a0con\u00a0el\u00a0fenotipo.\u00a0Si\u00a0el\u00a0resultado \u00a0es\u00a0\ninferior\u00a0a\u00a04,\u00a0la\u00a0ETR\u00a0tiene\u00a0un\u00a090%\u00a0de\u00a0probabilidades \u00a0de\u00a0ser\u00a0eficaz\u00a0(\u201cfold\u00a0change\u201d\u00a0<2,9)369,\u00a0\n370.\u00a0La\u00a0Plataforma \u00a0de\u00a0resistencias \u00a0de\u00a0la\u00a0Red\u00a0de\u00a0Investigaci\u00f3n \u00a0en\u00a0sida\u00a0(RIS),\u00a0adjudica\u00a02\u00a0\npuntos\u00a0a\u00a0las\u00a0mutaciones \u00a0Y181C/I/V, \u00a0L100I,\u00a0K101P,\u00a0V179F,\u00a0G190E,\u00a0M230L\u00a0y\u00a0\u00a0un\u00a0punto\u00a0al\u00a0\nresto,\u00a0considerando \u00a0resistencia \u00a0un\u00a0score\u00a0\u22653368.\u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0uni\u00f3n\u00a0\nEnfuvirtida \u00a0\nLa\u00a0ENF\u00a0inhibe\u00a0la\u00a0fusi\u00f3n\u00a0del\u00a0VIH\u00a0evitando\u00a0su\u00a0penetraci\u00f3n \u00a0y\u00a0replicaci\u00f3n. \u00a0Se\u00a0administra \u00a0por\u00a0\nv\u00eda\u00a0subcut\u00e1nea \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda\u00a0y\u00a0su\u00a0principal\u00a0efecto\u00a0adverso\u00a0es\u00a0la\u00a0reacci\u00f3n\u00a0en\u00a0el\u00a0punto\u00a0\nde\u00a0inyecci\u00f3n \u00a0(Tabla\u00a09).\u00a0\u00a0\u00a0\u00a0\nTORO\u00a0I\u00a0y\u00a0II\u00a0\nLos\u00a0estudios\u00a0TORO\u00a0son\u00a0dos\u00a0ensayos\u00a0fase\u00a0III\u00a0en\u00a0los\u00a0que\u00a0se\u00a0compar\u00f3\u00a0la\u00a0actividad\u00a0antiviral\u00a0\nde\u00a0la\u00a0ENF\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0una\u00a0pauta\u00a0optimizada \u00a0frente\u00a0a\u00a0una\u00a0pauta\u00a0optimizada \u00a0en\u00a0\npacientes \u00a0en\u00a0fracaso\u00a0viral\u00a0con\u00a0m\u00faltiples \u00a0tratamientos \u00a0previos.\u00a0Se\u00a0incluyeron \u00a0alrededor \u00a0\nde\u00a01000\u00a0pacientes, \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0CVP\u00a0basal\u00a0>100000\u00a0copias/mL \u00a0y\u00a0de\u00a0CD4\u00a0<100\u00a0\nc\u00e9lulas/\u00b5L. \u00a0A\u00a0las\u00a024\u00a0semanas\u00a0el\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0\u00a0tratados\u00a0con\u00a0ENF\u00a0\nque\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0la\u00a0pauta\u00a0optimizada. \u00a0ENF\u00a0produjo\u00a0un\u00a0descenso \u00a0de\u00a0CVP\u00a0de\u00a0\u20100,93\u00a0\nlog10\u00a0(TORO\u00a0I)\u00a0y\u00a0\u20100,78\u00a0log10\u00a0(TORO\u00a0II)\u00a0\u00a0(p<0,0001)311,\u00a0312.\u00a0A\u00a0la\u00a0semana\u00a048,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0\ncombinado \u00a0de\u00a0los\u00a0dos\u00a0estudios,\u00a0el\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0fue\u00a0de\u00a0\u20101,48\u00a0log10\u00a0copias/mL \u00a0\n(ENF)\u00a0y\u00a0\u20100,63\u00a0log10\u00a0copias/mL \u00a0en\u00a0el\u00a0tratamiento \u00a0optimizado \u00a0(p<0,0001). \u00a0La\u00a0probabilidad \u00a0\nde\u00a0alcanzar\u00a0una\u00a0respuesta \u00a0virol\u00f3gica \u00a0fue\u00a0m\u00e1s\u00a0del\u00a0doble\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ENF\u00a0(descenso \u00a0\nCVP\u00a0>1\u00a0log10\u00a037%\u00a0frente\u00a017%;\u00a0CVP\u00a0<400\u00a0copias/mL, \u00a030%\u00a0frente\u00a012%\u00a0y\u00a0CVP\u00a0<50\u00a0\ncopias/mL, \u00a018%\u00a0frente\u00a0a\u00a08%\u00a0(p<0,0001)). \u00a0El\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0del\u00a0grupo\u00a0con\u00a0ENF\u00a0\ntriplic\u00f3\u00a0al\u00a0grupo\u00a0control\u00a0(32\u00a0y\u00a011\u00a0semanas, \u00a0p<0,0001)371.\u00a0Es\u00a0decir,\u00a0tanto\u00a0el\u00a0an\u00e1lisis\u00a0\nprimario\u00a0de\u00a0eficacia\u00a0como\u00a0el\u00a0resto\u00a0de\u00a0an\u00e1lisis\u00a0secundarios \u00a0predefinidos, \u00a0demostraron \u00a0\nque\u00a0el\u00a0tratamiento \u00a0de\u00a0rescate\u00a0era\u00a0m\u00e1s\u00a0eficaz\u00a0cuando\u00a0se\u00a0utilizaba\u00a0ENF.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 53Se\u00a0han\u00a0identificado \u00a0mutaciones \u00a0en\u00a0la\u00a0regi\u00f3n\u00a0HR1\u00a0de\u00a0la\u00a0gp41\u00a0del\u00a0virus\u00a0que\u00a0reducen\u00a0la\u00a0\nsensibilidad \u00a0al\u00a0ENF\u00a0(G36D/S,\u00a0I37V,\u00a0V38A/M/E, \u00a0Q39R,\u00a0Q40H,\u00a0N42T,\u00a0N43D.\u00a0Otras\u00a0\nmutaciones \u00a0o\u00a0polimorfismos \u00a0en\u00a0otras\u00a0regiones\u00a0de\u00a0la\u00a0envoltura, \u00a0como\u00a0por\u00a0ejemplo\u00a0la\u00a0\nregi\u00f3n\u00a0HR2)\u00a0podr\u00edan\u00a0disminuir \u00a0la\u00a0sensibilidad \u00a0a\u00a0ENF349.\u00a0Por\u00a0ello,\u00a0secuenciar \u00a0s\u00f3lo\u00a0las\u00a0\nmutaciones \u00a0de\u00a0la\u00a0regi\u00f3n\u00a0HR1\u00a0podr\u00eda\u00a0ser\u00a0inadecuado \u00a0cuando\u00a0se\u00a0sospecha \u00a0resistencia \u00a0a\u00a0\nENF.\u00a0La\u00a0barrera\u00a0gen\u00e9tica\u00a0de\u00a0ENF\u00a0es\u00a0t\u00edpicamente \u00a0baja,\u00a0desarrollando \u00a0resistencia \u00a0al\u00a0\nf\u00e1rmaco\u00a0con\u00a0solo\u00a0una\u00a0mutaci\u00f3n. \u00a0\nUn\u00a0consenso \u00a0espa\u00f1ol\u00a0recomienda \u00a0su\u00a0uso\u00a0en\u00a0pacientes \u00a0en\u00a0los\u00a0que\u00a0no\u00a0se\u00a0pueda\u00a0\nconfeccionar \u00a0un\u00a0tratamiento \u00a0\u00f3ptimo\u00a0con\u00a03\u00a0f\u00e1rmacos \u00a0activos372.\u00a0\n\u00a0\nInhibidores \u00a0del\u00a0correceptor \u00a0CCR5\u00a0\nMaraviroc \u00a0\nMVC\u00a0es\u00a0un\u00a0antagonista \u00a0del\u00a0correceptor \u00a0CCR5\u00a0e\u00a0impide\u00a0la\u00a0entrada\u00a0del\u00a0virus\u00a0con\u00a0\ntropismo\u00a0R5.\u00a0Presenta\u00a0una\u00a0actividad\u00a0potente\u00a0frente\u00a0a\u00a0cepas\u00a0con\u00a0tropismo\u00a0R5\u00a0tanto\u00a0\nsilvestres \u00a0como\u00a0con\u00a0mutaciones \u00a0para\u00a0AN,\u00a0NN\u00a0o\u00a0IP373.\u00a0\u00a0\nMOTIVATE \u00a01\u00a0y\u00a02\u00a0\nLos\u00a0estudios\u00a0MOTIVATE \u00a0(1\u00a0y\u00a02)\u00a0son\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0fase\u00a0III,\u00a0paralelos\u00a0y\u00a0doble\u00a0\nciego,\u00a0donde\u00a0se\u00a0aleatoriz\u00f3 \u00a0a\u00a0los\u00a0pacientes \u00a0incluidos\u00a0a\u00a0recibir\u00a0MVC\u00a0(QD\u00a0o\u00a0BID)\u00a0frente\u00a0a\u00a0\nplacebo\u00a0y\u00a0a\u00f1adiendo \u00a0a\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a0brazos\u00a0un\u00a0tratamiento \u00a0optimizado. \u00a0Los\u00a0criterios\u00a0\nde\u00a0inclusi\u00f3n\u00a0fueron\u00a0CVP\u00a0>5000\u00a0copias/mL, \u00a0tropismo\u00a0R5\u00a0y\u00a0resistencia \u00a0a\u00a0\u22651\u00a0FAR\u00a0o\u00a0\u22652\u00a0IP.\u00a0\nLos\u00a0pacientes \u00a0se\u00a0estratificaron \u00a0seg\u00fan\u00a0uso\u00a0de\u00a0ENF\u00a0y\u00a0CVP.\u00a0Se\u00a0incluy\u00f3\u00a0a\u00a0m\u00e1s\u00a0de\u00a01000\u00a0\npacientes \u00a0de\u00a0los\u00a0que\u00a0209\u00a0recibieron \u00a0placebo,\u00a0414\u00a0MVC,\u00a0QD\u00a0(150\u00a0\u00f3\u00a0300\u00a0mg)\u00a0y\u00a0426\u00a0MVC\u00a0\nBID\u00a0(150\u00a0\u00f3\u00a0300\u00a0mg).\u00a0La\u00a0variable\u00a0principal\u00a0del\u00a0estudio\u00a0fue\u00a0la\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0en\u00a0la\u00a0\nsemana\u00a048\u00a0y\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0\u00f3\u00a050\u00a0copias/mL \u00a0fue\u00a0una\u00a0variable\u00a0\nsecundaria. \u00a0\nLos\u00a0resultados \u00a0combinados \u00a0de\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0muestran \u00a0que\u00a0el\u00a0\ndescenso \u00a0de\u00a0CVP\u00a0fue:\u00a0MVC\u00a0QD:\u00a0\u20101,68\u00a0log,\u00a0MVC\u00a0BID:\u00a0\u20101,84\u00a0log\u00a0y\u00a0grupo\u00a0placebo:\u00a0\u20100,78\u00a0\nlog;\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL: \u00a051,7%,\u00a056,1%\u00a0y\u00a022,5%\u00a0\nrespectivamente \u00a0(valor\u00a0p\u00a0frente\u00a0a\u00a0placebo\u00a0\u00a0<0,0001); \u00a0y\u00a0CVP\u00a0<50\u00a0copias/mL: \u00a043,2%,\u00a0\n45,5%\u00a0y\u00a016,7%\u00a0(valor\u00a0p\u00a0frente\u00a0a\u00a0placebo\u00a0<0,001).\u00a0El\u00a0incremento \u00a0de\u00a0linfocitos\u00a0CD4\u00a0fue\u00a0\ntambi\u00e9n\u00a0significativamente \u00a0mayor\u00a0y\u00a0m\u00e1s\u00a0precoz\u00a0en\u00a0los\u00a0grupos\u00a0que\u00a0recibieron \u00a0MVC374.\u00a0\nEsta\u00a0ventaja\u00a0en\u00a0la\u00a0recuperaci\u00f3n \u00a0inmunol\u00f3gica \u00a0ha\u00a0sido\u00a0tambi\u00e9n\u00a0demostrada \u00a0con\u00a0\nindependencia \u00a0de\u00a0la\u00a0eficacia\u00a0virol\u00f3gica375.\u00a0La\u00a0eficacia\u00a0(CVP\u00a0<50\u00a0copias/mL) \u00a0fue\u00a0tambi\u00e9n\u00a0\nsuperior\u00a0cuando\u00a0los\u00a0pacientes \u00a0recibieron \u00a0ENF\u00a0por\u00a0primera\u00a0vez:\u00a064%\u00a0y\u00a061%\u00a0en\u00a0los\u00a0\ngrupos\u00a0que\u00a0recibieron \u00a0MVC\u00a0y\u00a027%\u00a0en\u00a0los\u00a0grupos\u00a0que\u00a0recibieron \u00a0placebo\u00a0con\u00a0ENF376.\u00a0En\u00a0\nla\u00a0semana\u00a096,\u00a0el\u00a041,3%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0recibieron \u00a0MVC\u00a0en\u00a0pauta\u00a0BID\u00a0persist\u00edan \u00a0\ncon\u00a0una\u00a0CVP\u00a0<50\u00a0copias\u00a0frente\u00a0al\u00a07,2%\u00a0de\u00a0los\u00a0pacientes \u00a0del\u00a0grupo\u00a0placebo377.\u00a0En\u00a0cuanto\u00a0\nvariables\u00a0de\u00a0desenlace \u00a0cl\u00ednicas,\u00a0el\u00a0tratamiento \u00a0con\u00a0MVC\u00a0se\u00a0asoci\u00f3\u00a0de\u00a0manera\u00a0\nsignificativa \u00a0con\u00a0mayor\u00a0tiempo\u00a0hasta\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0eventos\u00a0de\u00a0categor\u00eda \u00a0C\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0el\u00a0placebo\u00a0(p=0,042)375;\u00a0siendo\u00a0hasta\u00a0la\u00a0fecha\u00a0el\u00a0\u00fanico\u00a0estudio\u00a0en\u00a0\nrescate\u00a0que\u00a0ha\u00a0podido\u00a0demostrar \u00a0este\u00a0beneficio \u00a0cl\u00ednico\u00a0incluyendo \u00a0solo\u00a0uno\u00a0de\u00a0los\u00a0\nnuevos\u00a0f\u00e1rmacos \u00a0activos.\u00a0\nLos\u00a0efectos\u00a0adversos\u00a0producidos \u00a0por\u00a0MVC\u00a0no\u00a0fueron\u00a0superiores \u00a0a\u00a0los\u00a0del\u00a0grupo\u00a0\nplacebo.\u00a0Los\u00a0temores\u00a0iniciales\u00a0acerca\u00a0de\u00a0un\u00a0posible\u00a0mayor\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0o\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 54de\u00a0una\u00a0mayor\u00a0incidencia \u00a0de\u00a0tumores,\u00a0asociada\u00a0al\u00a0bloqueo\u00a0del\u00a0correceptor \u00a0humano\u00a0\nCCR5,\u00a0no\u00a0solo\u00a0no\u00a0se\u00a0han\u00a0confirmado \u00a0sino\u00a0que\u00a0la\u00a0incidencia \u00a0de\u00a0determinados \u00a0eventos\u00a0\ncl\u00ednicos\u00a0es\u00a0menor\u00a0en\u00a0la\u00a0rama\u00a0tratada\u00a0con\u00a0MVC376,\u00a0378,\u00a0379\u00a0.\u00a0\u00a0\nSe\u00a0analiz\u00f3\u00a0retrospectivamente \u00a0la\u00a0relaci\u00f3n\u00a0del\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0los\u00a0pacientes \u00a0de\u00a0los\u00a0\nMOTIVATE \u00a0con\u00a0el\u00a0tropismo\u00a0viral.\u00a0Dos\u00a0tercios\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0MVC\u00a0que\u00a0fracasaron \u00a0\nten\u00edan\u00a0un\u00a0tropismo\u00a0dual\u00a0(R5/X4)\u00a0o\u00a0bien\u00a0el\u00a0tropismo\u00a0vari\u00f3\u00a0entre\u00a0la\u00a0selecci\u00f3n\u00a0y\u00a0el\u00a0inicio\u00a0\ndel\u00a0tratamiento. \u00a0El\u00a0cambio\u00a0de\u00a0tropismo\u00a0del\u00a0R5\u00a0a\u00a0dual\u00a0o\u00a0X4\u00a0se\u00a0observ\u00f3\u00a0en\u00a0el\u00a07,5%\u00a0de\u00a0los\u00a0\npacientes \u00a0que\u00a0fracasaban \u00a0con\u00a0MVC\u00a0y\u00a0s\u00f3lo\u00a0el\u00a01,9%\u00a0del\u00a0grupo\u00a0placebo.\u00a0No\u00a0se\u00a0observ\u00f3\u00a0\ncambio\u00a0de\u00a0tropismo\u00a0en\u00a0el\u00a04%\u00a0de\u00a0los\u00a0fracasos\u00a0a\u00a0MVC.\u00a0En\u00a0los\u00a0pacientes \u00a0que\u00a0fracasaron \u00a0en\u00a0\nlos\u00a0estudios\u00a0MOTIVATE, \u00a0los\u00a0sujetos\u00a0que\u00a0recibieron \u00a0MVC\u00a0asociado\u00a0a\u00a0\u22652\u00a0f\u00e1rmacos\u00a0activos\u00a0\npresentaron \u00a0una\u00a0tasa\u00a0de\u00a0cambio\u00a0de\u00a0tropismo\u00a0R5\u00a0a\u00a0D/M\u00a0o\u00a0X4\u00a0similar\u00a0a\u00a0los\u00a0tratados\u00a0con\u00a0\nplacebo.\u00a0Tras\u00a0la\u00a0retirada\u00a0del\u00a0MVC\u00a0las\u00a0cepas\u00a0revert\u00edan\u00a0r\u00e1pidamente \u00a0a\u00a0R5.\u00a0Todos\u00a0los\u00a0\npacientes \u00a0que\u00a0recib\u00edan\u00a0MVC\u00a0presentaron \u00a0un\u00a0incremento \u00a0significativo \u00a0de\u00a0los\u00a0linfocitos\u00a0\nCD4380.\u00a0\n\u00a0Resistencia \u00a0a\u00a0Maraviroc \u00a0\nLa\u00a0eficacia\u00a0de\u00a0MVC\u00a0exige\u00a0la\u00a0presencia \u00a0de\u00a0tropismo\u00a0viral\u00a0R5\u00a0y\u00a0no\u00a0es\u00a0activo\u00a0cuando\u00a0las\u00a0\npoblaciones \u00a0virales\u00a0presentan \u00a0tropismo\u00a0viral\u00a0X4\u00a0o\u00a0dual\u00a0(R5/X4).\u00a0Algunos\u00a0casos\u00a0de\u00a0FV\u00a0\ndurante\u00a0el\u00a0tratamiento \u00a0con\u00a0MVC\u00a0corresponden \u00a0a\u00a0un\u00a0sobre\u00a0crecimiento \u00a0de\u00a0poblaciones \u00a0\nvirales\u00a0con\u00a0tropismo\u00a0X4\u00a0preexistentes\n\u00a0y\u00a0no\u00a0detectadas \u00a0por\u00a0la\u00a0baja\u00a0sensibilidad \u00a0de\u00a0la\u00a0\nprueba\u00a0basal\u00a0(TrofileTM,\u00a0detectaba \u00a0virus\u00a0X4\u00a0con\u00a0una\u00a0certeza\u00a0del\u00a0100%\u00a0s\u00f3lo\u00a0cuando\u00a0la\u00a0\nproporci\u00f3n \u00a0era\u00a0\u226510\u00a0%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0y\u00a0la\u00a0CVP\u00a0>1000\u00a0copias/mL). \u00a0La\u00a0t\u00e9cnica\u00a0de\u00a0\nTrofileTM\u00a0ES\u00a0que\u00a0se\u00a0realiza\u00a0actualmente \u00a0detecta\u00a0poblaciones \u00a0minoritarias \u00a0con\u00a0tropismo\u00a0\nX4\u00a0hasta\u00a0en\u00a0una\u00a0proporci\u00f3n \u00a0del\u00a00,1%.\u00a0Asimismo \u00a0el\u00a0tropismo\u00a0puede\u00a0detectarse \u00a0por\u00a0\nm\u00e9todos\u00a0genot\u00edpicos. \u00a0Recientemente \u00a0se\u00a0ha\u00a0comunicado \u00a0una\u00a0predicci\u00f3n \u00a0del\u00a0tropismo\u00a0y\u00a0\nde\u00a0respuesta \u00a0a\u00a0MVC\u00a0similar\u00a0con\u00a0el\u00a0genotipo\u00a0poblacional \u00a0tanto\u00a0en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo\u00a0como\u00a0en\u00a0rescate123,\u00a0124.\u00a0\u00a0Se\u00a0han\u00a0redactado \u00a0unas\u00a0gu\u00edas\u00a0espa\u00f1olas \u00a0\npara\u00a0la\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0que\u00a0favorecen \u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0pruebas\u00a0\ngenot\u00edpicas \u00a0para\u00a0su\u00a0determinaci\u00f3n125.\u00a0\nAdem\u00e1s,\u00a0se\u00a0han\u00a0identificado \u00a0mutaciones \u00a0en\u00a0la\u00a0mol\u00e9cula\u00a0gp120\u00a0que\u00a0permite\u00a0al\u00a0virus\u00a0\nunirse\u00a0al\u00a0receptor\u00a0R5\u00a0en\u00a0presencia \u00a0de\u00a0MVC\u00a0sin\u00a0cambiar\u00a0de\u00a0tropismo\u00a0durante\u00a0el\u00a0\ntratamiento349.\u00a0El\u00a0perfil\u00a0de\u00a0mutaciones \u00a0seleccionadas \u00a0por\u00a0MVC\u00a0es\u00a0complejo \u00a0y\u00a0todav\u00eda\u00a0\nno\u00a0se\u00a0conoce\u00a0su\u00a0importancia \u00a0y\u00a0\u00a0frecuencia \u00a0de\u00a0aparici\u00f3n. \u00a0\u00a0\nMVC\u00a0es\u00a0un\u00a0substrato \u00a0de\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0y\u00a0su\u00a0metabolismo \u00a0se\u00a0realiza\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\nCYP3A4;\u00a0por\u00a0lo\u00a0que\u00a0presenta\u00a0un\u00a0potencial \u00a0importante \u00a0de\u00a0interacciones \u00a0con\u00a0f\u00e1rmacos \u00a0\nque\u00a0utilizan\u00a0la\u00a0misma\u00a0v\u00eda\u00a0metab\u00f3lica \u00a0(v\u00e9ase\u00a0cap\u00edtulo\u00a0interacciones). \u00a0\n\u00a0Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nRaltegravir \u00a0\nLa\u00a0integrasa \u00a0es\u00a0una\u00a0de\u00a0las\u00a0tres\u00a0enzimas\u00a0fundamentales \u00a0del\u00a0ciclo\u00a0de\u00a0replicaci\u00f3n \u00a0del\u00a0VIH.\u00a0\nSu\u00a0funci\u00f3n\u00a0es\u00a0catalizar\u00a0la\u00a0inserci\u00f3n\u00a0del\u00a0ADN\u00a0proviral\u00a0en\u00a0el\u00a0genoma\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0hu\u00e9sped.\u00a0\nEl\u00a0RAL\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0capaz\u00a0de\u00a0\ninhibir\u00a0la\u00a0integrasa, \u00a0es\u00a0activo\u00a0frente\u00a0a\u00a0cepas\u00a0de\u00a0VIH\u00a0con\u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0las\u00a0tres\u00a0familias\u00a0cl\u00e1sicas\u00a0y\u00a0frente\u00a0a\u00a0cepa\u00a0silvestre381.\u00a0\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 55BENCHMRK \u00a01\u00a0y\u00a02\u00a0\nLos\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0fase\u00a0III\u00a0BENCHMRK \u00a0(1\u00a0y\u00a02)\u00a0son\u00a0estudios\u00a0paralelos, \u00a0aleatorizados \u00a0\ny\u00a0doble\u00a0ciego\u00a0dise\u00f1ados \u00a0para\u00a0analizar\u00a0la\u00a0eficacia\u00a0de\u00a0RAL\u00a0en\u00a0rescate\u00a0de\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0m\u00faltiples \u00a0FAR\u00a0y\u00a0en\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Los\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0fueron\u00a0CVP\u00a0\n>1000\u00a0copias/mL, \u00a0resistencia \u00a0genot\u00edpica \u00a0o\u00a0fenot\u00edpica \u00a0al\u00a0menos\u00a0a\u00a0un\u00a0f\u00e1rmaco\u00a0de\u00a0cada\u00a0\nuna\u00a0de\u00a0las\u00a0tres\u00a0clases\u00a0(AN,\u00a0NN\u00a0e\u00a0IP).\u00a0Se\u00a0incluyeron \u00a0350\u00a0pacientes \u00a0(BENCHMRK \u20101)\u00a0y\u00a0349\u00a0\n(BENCHMRK \u20102)\u00a0en\u00a0situaci\u00f3n\u00a0cl\u00ednica\u00a0muy\u00a0avanzada \u00a0(82%\u00a0con\u00a0criterios\u00a0de\u00a0sida)\u00a0y\u00a0que\u00a0\nhab\u00edan\u00a0recibido\u00a0una\u00a0mediana\u00a0de\u00a012\u00a0FAR\u00a0durante\u00a09,9\u00a0a\u00f1os.\u00a0Los\u00a0pacientes \u00a0fueron\u00a0\naleatorizados \u00a0(2:1)\u00a0a\u00a0recibir\u00a0RAL\u00a0o\u00a0placebo\u00a0ambos\u00a0con\u00a0terapia\u00a0optimizada. \u00a0En\u00a0los\u00a0\nresultados \u00a0combinados \u00a0de\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0CVP\u00a0\n<400\u00a0copias/mL \u00a0fue\u00a0de\u00a072,1\u00a0%\u00a0en\u00a0el\u00a0grupo\u00a0RAL\u00a0y\u00a037,1\u00a0%\u00a0en\u00a0placebo\u00a0(p<0,001). \u00a0La\u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0fue\u00a0del\u00a062,1\u00a0%\u00a0en\u00a0el\u00a0grupo\u00a0RAL\u00a0y\u00a032,9\u00a0%\u00a0en\u00a0el\u00a0placebo\u00a0(p\u00a0<0,001)316.\u00a0La\u00a0\neficacia\u00a0de\u00a0RAL\u00a0fue\u00a0superior\u00a0a\u00a0placebo\u00a0independiente \u00a0de\u00a0la\u00a0CVP,\u00a0de\u00a0los\u00a0CD4+\u00a0o\u00a0del\u00a0\n\u00edndice\u00a0GSS/PSS\u00a0\u2265\u00a02.\u00a0\nCuando\u00a0en\u00a0la\u00a0terapia\u00a0optimizada \u00a0se\u00a0asoci\u00f3\u00a0DRV/r\u00a0y\u00a0ENF\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0CVP\u00a0<400\u00a0\ncopias/mL \u00a0fue\u00a098%\u00a0(RAL)\u00a0y\u00a0de\u00a087%\u00a0(placebo); \u00a0si\u00a0solamente \u00a0recib\u00edan\u00a0ENF\u00a0el\u00a090%\u00a0(rama\u00a0\nRAL)\u00a0y\u00a063%\u00a0(rama\u00a0placebo)\u00a0ten\u00edan\u00a0<400\u00a0copias/mL, \u00a0mientras\u00a0que\u00a0si\u00a0s\u00f3lo\u00a0recib\u00edan\u00a0DRV/r\u00a0\nlas\u00a0proporciones \u00a0fueron\u00a0de\u00a090%\u00a0y\u00a055%309.\u00a0La\u00a0seguridad \u00a0y\u00a0tolerabilidad \u00a0de\u00a0RAL\u00a0result\u00f3\u00a0\ncomparable \u00a0al\u00a0placebo.\u00a0Se\u00a0observ\u00f3\u00a0una\u00a0mayor\u00a0incidencia \u00a0de\u00a0neoplasias \u00a0en\u00a0el\u00a0grupo\u00a0\nasignado\u00a0a\u00a0RAL\u00a0(3,5%\u00a0frente\u00a0a\u00a01,7%),\u00a0aunque\u00a0no\u00a0fue\u00a0estad\u00edsticamente \u00a0significativa \u00a0ni\u00a0se\u00a0\nha\u00a0comunicado \u00a0ninguna\u00a0relaci\u00f3n\u00a0directa\u00a0con\u00a0el\u00a0f\u00e1rmaco.\u00a0Estudios\u00a0posteriores \u00a0que\u00a0\nanalizan\u00a0la\u00a0incidencia \u00a0de\u00a0neoplasias \u00a0en\u00a0ensayos\u00a0cl\u00ednicos\u00a0y\u00a0programas \u00a0de\u00a0acceso\u00a0\nexpandido \u00a0no\u00a0se\u00a0observa\u00a0una\u00a0mayor\u00a0incidencia \u00a0de\u00a0c\u00e1ncer\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0reciben\u00a0\nRAL382.\u00a0\u00a0\nEl\u00a0an\u00e1lisis\u00a0combinado \u00a0en\u00a0la\u00a0semana\u00a096\u00a0de\u00a0los\u00a0estudios\u00a0BENCHMRK \u00a0demostr\u00f3 \u00a0la\u00a0eficacia\u00a0\nduradera\u00a0de\u00a0RAL.\u00a0El\u00a058%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0recibieron \u00a0RAL\u00a0persist\u00edan \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0frente\u00a0al\u00a026%\u00a0de\u00a0los\u00a0pacientes \u00a0del\u00a0grupo\u00a0placebo.\u00a0Este\u00a0porcentaje \u00a0se\u00a0\nincrement\u00f3 \u00a0al\u00a079%\u00a0cuando\u00a0los\u00a0pacientes \u00a0recib\u00edan\u00a0adem\u00e1s\u00a0otros\u00a0f\u00e1rmacos \u00a0activos383.\u00a0\u00a0\nRAL\u00a0se\u00a0metaboliza \u00a0por\u00a0glucuronizaci\u00f3n \u00a0hep\u00e1tica; \u00a0no\u00a0es\u00a0inductor\u00a0o\u00a0inhibidor\u00a0de\u00a0los\u00a0\nisoenzimas \u00a0del\u00a0citocromo \u00a0P450\u00a0por\u00a0lo\u00a0que\u00a0su\u00a0potencial \u00a0de\u00a0interacciones \u00a0farmacol\u00f3gicas \u00a0\nes\u00a0bajo\u00a0(v\u00e9ase\u00a0cap\u00edtulo\u00a0interacciones) \u00a0\n\u00a0\nEstudio\u00a0TRIO\u00a0\nEstudio\u00a0abierto\u00a0no\u00a0comparativo \u00a0que\u00a0tiene\u00a0como\u00a0objetivo\u00a0evaluar\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\nde\u00a0un\u00a0tratamiento \u00a0antirretroviral \u00a0de\u00a0rescate\u00a0que\u00a0conten\u00eda\u00a0RAL\u00a0+\u00a0DRV/r\u00a0+\u00a0ETR.\u00a0Incluy\u00f3\u00a0\n103\u00a0pacientes \u00a0con:\u00a0edad\u00a0\u226518\u00a0a\u00f1os,\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0sin\u00a0tratamiento \u00a0previo\u00a0con\u00a0\nf\u00e1rmacos \u00a0en\u00a0investigaci\u00f3n, \u00a0con\u00a0historia\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0a\u00a0NN,\u00a0e\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0\nmultirresistente \u00a0definida\u00a0como:\u00a0\u22653\u00a0mutaciones \u00a0primarias \u00a0de\u00a0resistencia \u00a0a\u00a0IP;\u00a0\u22653\u00a0\nmutaciones \u00a0a\u00a0AN;\u00a0\u22643\u00a0mutaciones \u00a0a\u00a0DRV;\u00a0y\u00a0\u22643\u00a0mutaciones \u00a0a\u00a0NN.\u00a0En\u00a0la\u00a0semana\u00a024,\u00a093\u00a0\npacientes \u00a0(90%;\u00a0IC\u00a095%,\u00a085\u00a0a\u00a096%)\u00a0y\u00a0en\u00a0la\u00a0semana\u00a048,\u00a089\u00a0pacientes \u00a0(86%;\u00a0IC\u00a095%,\u00a080\u00a0a\u00a0\n93%)\u00a0lograron\u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0La\u00a0mediana\u00a0de\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0en\u00a0la\u00a0\nsemana\u00a048\u00a0respecto\u00a0al\u00a0valor\u00a0basal\u00a0fue\u00a0de\u00a0\u22122,4\u00a0log\u00a0(IQR,\u00a0\u20102,9\u00a0a\u00a0\u20101,9).\u00a0La\u00a0mediana\u00a0de\u00a0\nascenso\u00a0de\u00a0los\u00a0linfocitos\u00a0CD4\u00a0respecto\u00a0al\u00a0valor\u00a0basal\u00a0fue\u00a0de\u00a0108/\u00b5L\u00a0(IQR:\u00a058\u2010169).\u00a0\nDurante\u00a0el\u00a0periodo\u00a0del\u00a0estudio,\u00a0s\u00f3lo\u00a0un\u00a0paciente\u00a0tuvo\u00a0que\u00a0suspender \u00a0el\u00a0tratamiento \u00a0\npor\u00a0toxicidad384.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 56\u00a0\nMutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0RAL\u00a0\nEn\u00a0estudios\u00a0in\u00a0vitro\u00a0se\u00a0han\u00a0identificado \u00a0hasta\u00a041\u00a0mutaciones \u00a0del\u00a0gen\u00a0de\u00a0la\u00a0integrasa \u00a0\nasociadas \u00a0a\u00a0resistencia. \u00a0Un\u00a0total\u00a0de\u00a0105\u00a0pacientes \u00a0de\u00a0462\u00a0que\u00a0recibieron \u00a0RAL\u00a0en\u00a0los\u00a0\nestudios\u00a0BENCHMRK \u00a0desarrollaron \u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0la\u00a0semana\u00a048,\u00a0aunque\u00a0s\u00f3lo\u00a0en\u00a0\n94\u00a0se\u00a0pudo\u00a0realizar\u00a0estudio\u00a0de\u00a0resistencias. \u00a0En\u00a064/94\u00a0(68%)\u00a0se\u00a0detectaron \u00a0mutaciones \u00a0\nde\u00a0resistencia \u00a0RAL\u00a0con\u00a03\u00a0patrones\u00a0de\u00a0resistencia: \u00a0(1)\u00a0N155H\u00a0+\u00a0L74M,\u00a0E92Q,\u00a0T97A,\u00a0\nV151I,\u00a0G163R;\u00a0(2)\u00a0Q148K/R/H \u00a0+\u00a0G140S/A, \u00a0E138K\u00a0y\u00a0(3)\u00a0Y143R/C\u00a0+\u00a0L74A/I,\u00a0T97A,\u00a0I203M,\u00a0\nS230R.\u00a0RAL\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0de\u00a0barrera\u00a0gen\u00e9tica\u00a0baja\u00a0o\u00a0intermedia, \u00a0siendo\u00a0necesarias \u00a02\u00a0\nmutaciones \u00a0para\u00a0la\u00a0resistencia \u00a0completa. \u00a0\n\u00a0Opciones \u00a0de\u00a0tratamiento \u00a0en\u00a0pacientes \u00a0con\u00a0m\u00faltiples \u00a0fracasos\u00a0virol\u00f3gicos \u00a0y\u00a0sin\u00a0\nopciones\u00a0terap\u00e9uticas. \u00a0Tratamientos \u00a0con\u00a0pautas\u00a0de\u00a0TAR\u00a0\u00a0no\u00a0supresoras \u00a0\n\u00a0\nCon\u00a0los\u00a0f\u00e1rmacos \u00a0disponibles \u00a0actualmente \u00a0debe\u00a0perseguirse \u00a0siempre\u00a0la\u00a0supresi\u00f3n \u00a0\nvirol\u00f3gica \u00a0completa \u00a0y\u00a0duradera\u00a0(<50\u00a0copias/mL) \u00a0en\u00a0todos\u00a0los\u00a0pacientes \u00a0con\u00a0fracaso\u00a0\nvirol\u00f3gico, \u00a0por\u00a0avanzado \u00a0que\u00a0sea.\u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0el\u00a0paciente\u00a0multitratado \u00a0no\u00a0\nsiempre\u00a0conduce\u00a0de\u00a0forma\u00a0r\u00e1pida\u00a0al\u00a0fracaso\u00a0inmunol\u00f3gico \u00a0y\u00a0progresi\u00f3n \u00a0cl\u00ednica25,\u00a0385,\u00a0386.\u00a0\nDe\u00a0hecho,\u00a0muchos\u00a0pacientes \u00a0contin\u00faan \u00a0con\u00a0recuentos \u00a0de\u00a0CD4\u00a0relativamente \u00a0estables\u00a0y\u00a0\naproximadamente \u00a0s\u00f3lo\u00a0un\u00a0tercio\u00a0experimenta \u00a0un\u00a0descenso387.\u00a0Este\u00a0\u00faltimo\u00a0hecho\u00a0se\u00a0\nobserva\u00a0m\u00e1s\u00a0frecuentemente \u00a0cuando\u00a0la\u00a0CVP\u00a0es\u00a0elevada,\u00a0habitualmente \u00a0>10000\u201020000\u00a0\ncopias/mL. \u00a0\u00a0\nEn\u00a0un\u00a0paciente\u00a0en\u00a0el\u00a0que\u00a0resulte\u00a0imposible \u00a0construir\u00a0un\u00a0TAR\u00a0potencialmente \u00a0eficaz\u00a0con\u00a0\nal\u00a0menos\u00a0dos\u00a0f\u00e1rmacos\u00a0activos\u00a0m\u00e1s\u00a0otros\u00a0f\u00e1rmacos \u00a0activos\u00a0por\u00a0problemas \u00a0de\u00a0\nresistencia, \u00a0toxicidad, \u00a0comorbilidad \u00a0grave\u00a0o\u00a0problemas \u00a0de\u00a0adherencia \u00a0o\u00a0tolerancia, \u00a0\npueden\u00a0plantearse \u00a0otras\u00a0opciones\u00a0diferentes \u00a0al\u00a0tratamiento \u00a0de\u00a0rescate\u00a0si\u00a0la\u00a0situaci\u00f3n\u00a0\ninmunitaria \u00a0del\u00a0paciente\u00a0lo\u00a0permite.\u00a0\u00a0\nDiversos\u00a0estudios\u00a0han\u00a0demostrado \u00a0los\u00a0efectos\u00a0beneficiosos \u00a0de\u00a0mantener \u00a0un\u00a0\ntratamiento \u00a0no\u00a0supresor\u00a0en\u00a0caso\u00a0infecci\u00f3n\u00a0avanzada \u00a0multirresistente \u00a0sin\u00a0opciones\u00a0de\u00a0\niniciar\u00a0una\u00a0pauta\u00a0supresora388.\u00a0En\u00a0pacientes \u00a0con\u00a0un\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0<50/\u00b5L,\u00a0\nel\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0una\u00a0enfermedad \u00a0oportunista \u00a0tipo\u00a0sida\u00a0era\u00a0un\u00a022%\u00a0inferior\u00a0si\u00a0el\u00a0\npaciente\u00a0continuaba \u00a0con\u00a0el\u00a0TAR\u00a0a\u00a0pesar\u00a0de\u00a0presentar \u00a0fracaso\u00a0virol\u00f3gico \u00a0respecto\u00a0a\u00a0los\u00a0\nque\u00a0lo\u00a0suspendieron389.\u00a0Esto\u00a0se\u00a0relaciona \u00a0con\u00a0la\u00a0persistencia \u00a0de\u00a0una\u00a0poblaci\u00f3n \u00a0viral\u00a0\nVIH\u20101\u00a0con\u00a0baja\u00a0capacidad \u00a0replicativa \u00a0y\u00a0probablemente \u00a0menos\u00a0lesiva.\u00a0\nEl\u00a0tratamiento \u00a0de\u00a0un\u00a0paciente\u00a0con\u00a0escasas\u00a0opciones\u00a0terap\u00e9uticas \u00a0puede\u00a0ser\u00a0un\u00a0\ntratamiento \u00a0no\u00a0supresor. \u00a0Deben\u00a0ser\u00a0tratamientos \u00a0c\u00f3modos, \u00a0poco\u00a0t\u00f3xicos\u00a0y\u00a0que\u00a0\ndisminuyan \u00a0la\u00a0capacidad \u00a0replicativa \u00a0viral.\u00a0No\u00a0se\u00a0recomienda \u00a0continuar \u00a0con\u00a0pautas\u00a0no\u00a0\nsupresoras \u00a0que\u00a0contengan \u00a0IP,\u00a0NN\u00a0o\u00a0IInt,\u00a0ya\u00a0que\u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0resistencias \u00a0frente\u00a0a\u00a0\nestos\u00a0f\u00e1rmacos\u00a0dificultar\u00eda \u00a0la\u00a0eficacia\u00a0de\u00a0futuros\u00a0f\u00e1rmacos\u00a0de\u00a0estas\u00a0familias.\u00a0Pautas\u00a0con\u00a0\n2\u00a0\u00f3\u00a03\u00a0AN,\u00a0que\u00a0incluyan\u00a03TC\u00a0o\u00a0FTC,\u00a0podr\u00edan\u00a0resultar\u00a0parcialmente \u00a0eficaces\u00a0en\u00a0algunos\u00a0\npacientes, \u00a0aunque\u00a0obligar\u00eda\u00a0a\u00a0una\u00a0monitorizaci\u00f3n \u00a0frecuente \u00a0del\u00a0recuento\u00a0de\u00a0linfocitos\u00a0\nCD4\u00a0y\u00a0deben\u00a0reemplazarse \u00a0por\u00a0un\u00a0r\u00e9gimen\u00a0de\u00a0rescate\u00a0supresor\u00a0con\u00a03\u00a0f\u00e1rmacos \u00a0activos\u00a0\nen\u00a0cuanto\u00a0sea\u00a0posible390.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 57La\u00a0mutaci\u00f3n \u00a0M184V\u00a0compromete \u00a0la\u00a0capacidad \u00a0replicativa \u00a0del\u00a0VIH.\u00a0Un\u00a0ensayo\u00a0que\u00a0\ninclu\u00eda\u00a0pacientes \u00a0multirresistentes \u00a0con\u00a0esta\u00a0mutaci\u00f3n, \u00a0aleatorizados \u00a0a\u00a0continuar \u00a0s\u00f3lo\u00a0\ncon\u00a03TC\u00a0o\u00a0a\u00a0suspender \u00a0el\u00a0tratamiento, \u00a0mostr\u00f3\u00a0en\u00a0la\u00a0semana\u00a048,\u00a0que\u00a069%\u00a0(IC\u00a095%,\u00a051\u00a0a\u00a0\n83%)\u00a0del\u00a0grupo\u00a0que\u00a0interrumpi\u00f3 \u00a0frente\u00a0a\u00a041%\u00a0(IC\u00a095%,\u00a026\u00a0a\u00a059%)\u00a0de\u00a0los\u00a0que\u00a0\ncontinuaron \u00a0con\u00a03TC,\u00a0presentaron \u00a0un\u00a0evento\u00a0cl\u00ednico\u00a0o\u00a0fracaso\u00a0inmunol\u00f3gico. \u00a0En\u00a0los\u00a0que\u00a0\nrecib\u00edan\u00a03TC\u00a0el\u00a0fracaso\u00a0fue\u00a0m\u00e1s\u00a0tard\u00edo\u00a0(p=0,01)\u00a0y\u00a0el\u00a0descenso \u00a0de\u00a0CD4,\u00a0rebrote\u00a0de\u00a0CVP\u00a0y\u00a0\naumento\u00a0de\u00a0capacidad \u00a0replicativa \u00a0fueron\u00a0menores391.\u00a0En\u00a0funci\u00f3n\u00a0de\u00a0estos\u00a0estudios,\u00a0se\u00a0\npropone\u00a0que\u00a0el\u00a0tratamiento \u00a0de\u00a0pacientes \u00a0con\u00a0m\u00faltiples \u00a0fracasos\u00a0contenga \u00a03TC\u00a0o\u00a0FTC\u00a0\npara\u00a0mantener \u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0la\u00a0mutaci\u00f3n \u00a0M184V\u00a0y\u00a0reducir\u00a0su\u00a0capacidad \u00a0\nreplicativa392.\u00a0Sin\u00a0embargo, \u00a0este\u00a0dato\u00a0no\u00a0se\u00a0ha\u00a0confirmado \u00a0cuando\u00a0se\u00a0usan\u00a0pautas\u00a0de\u00a0\nrescate\u00a0supresoras \u00a0que\u00a0consiguen \u00a0CVP\u00a0indetectables. \u00a0\n\u00a0\nReplicaci\u00f3n \u00a0viral\u00a0baja\u00a0en\u00a0pacientes \u00a0multitratados \u00a0\u00a0\nCon\u00a0las\u00a0recomendaciones \u00a0actuales\u00a0sobre\u00a0tratamiento \u00a0antirretroviral, \u00a0dos\u00a0\ndeterminaciones \u00a0sucesivas \u00a0de\u00a0CVP\u00a0>50\u00a0copias/mL \u00a0tras\u00a06\u00a0meses\u00a0de\u00a0iniciado\u00a0el\u00a0TAR\u00a0o\u00a0tras\u00a0\nhaber\u00a0\u00a0conseguido \u00a0previamente \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0se\u00a0considera \u00a0fracaso\u00a0\nvirol\u00f3gico. \u00a0En\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0realizados \u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0como\u00a0\nen\u00a0los\u00a0realizados \u00a0en\u00a0pacientes \u00a0con\u00a0fracasos\u00a0virol\u00f3gicos, \u00a0un\u00a0n\u00famero\u00a0no\u00a0desde\u00f1able \u00a0de\u00a0\npacientes \u00a0consiguen \u00a0un\u00a0descenso \u00a0significativo \u00a0importante \u00a0de\u00a0la\u00a0CVP\u00a0(<400\u00a0copias/mL) \u00a0\npero\u00a0no\u00a0alcanzan\u00a0la\u00a0m\u00e1xima\u00a0supresi\u00f3n \u00a0viral.\u00a0Esta\u00a0proporci\u00f3n \u00a0se\u00a0incrementa \u00a0en\u00a0\npacientes \u00a0con\u00a0fracasos\u00a0previos\u00a0y\u00a0acumulaci\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0frente\u00a0a\u00a0\ndiferentes \u00a0FAR.\u00a0Con\u00a0frecuencia, \u00a0los\u00a0pacientes \u00a0con\u00a0replicaci\u00f3n \u00a0viral\u00a0baja\u00a0(RVB)\u00a0y\u00a0\npersistente \u00a0del\u00a0VIH\u00a0y\u00a0que\u00a0podemos \u00a0definir\u00a0como\u00a0una\u00a0CVP\u00a0entre\u00a050\u2010500/1000 \u00a0\ncopias/mL, \u00a0mantienen \u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4.\u00a0A\u00a0pesar\u00a0de\u00a0que\u00a0el\u00a0tratamiento \u00a0de\u00a0\nelecci\u00f3n\u00a0es\u00a0un\u00a0r\u00e9gimen\u00a0que\u00a0consiga\u00a0nuevamente \u00a0la\u00a0supresi\u00f3n \u00a0mantenida \u00a0por\u00a0debajo\u00a0de\u00a0\n50\u00a0copias/mL, \u00a0la\u00a0ausencia, \u00a0o\u00a0complejidad \u00a0de\u00a0otras\u00a0alternativas \u00a0terap\u00e9uticas, \u00a0la\u00a0\nconservaci\u00f3n \u00a0de\u00a0la\u00a0inmunidad \u00a0y\u00a0la\u00a0dificultad \u00a0de\u00a0obtener\u00a0resultados \u00a0v\u00e1lidos\u00a0con\u00a0pruebas\u00a0\nde\u00a0resistencia \u00a0genot\u00edpicas \u00a0o\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0viral\u00a0por\u00a0la\u00a0baja\u00a0viremia\u00a0\nplasm\u00e1tica \u00a0dificultan \u00a0el\u00a0manejo\u00a0de\u00a0estos\u00a0pacientes. \u00a0Si\u00a0la\u00a0pauta\u00a0presenta\u00a0una\u00a0barrera\u00a0\ngen\u00e9tica\u00a0elevada\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0selecci\u00f3n\u00a0de\u00a0resistencias \u00a0es\u00a0muy\u00a0bajo,\u00a0puede\u00a0en\u00a0\ndeterminados \u00a0casos\u00a0mantenerse \u00a0al\u00a0paciente\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento. \u00a0En\u00a0este\u00a0\nescenario \u00a0se\u00a0han\u00a0propuesto \u00a0diferentes \u00a0estrategias \u00a0terap\u00e9uticas, \u00a0aunque\u00a0ninguna\u00a0de\u00a0\nellas\u00a0ha\u00a0sido\u00a0evaluada\u00a0en\u00a0estudios\u00a0prospectivos \u00a0longitudinales \u00a0y\u00a0comparativos. \u00a0Algunos\u00a0\nautores\u00a0han\u00a0demostrado \u00a0que\u00a0la\u00a0intensificaci\u00f3n \u00a0de\u00a0la\u00a0terapia\u00a0podr\u00eda\u00a0conseguir \u00a0de\u00a0nuevo\u00a0\nvalores\u00a0de\u00a0CVP\u00a0<50\u00a0copias/mL393\u00a0aunque\u00a0podr\u00eda\u00a0constituir \u00a0un\u00a0tratamiento \u00a0sub\u00f3ptimo \u00a0al\u00a0\na\u00f1adir\u00a0un\u00a0solo\u00a0f\u00e1rmaco\u00a0activo\u00a0nuevo,\u00a0especialmente \u00a0si\u00a0se\u00a0utilizan\u00a0f\u00e1rmacos\u00a0con\u00a0barrera\u00a0\ngen\u00e9tica\u00a0baja.\u00a0Otra\u00a0posibilidad \u00a0consistir\u00eda \u00a0en\u00a0realizar\u00a0una\u00a0pruebas\u00a0m\u00e1s\u00a0sensibles\u00a0de\u00a0\nresistencias \u00a0genot\u00edpicas \u00a0que\u00a0permiten \u00a0detectar\u00a0mutaciones \u00a0a\u00a0pesar\u00a0de\u00a0la\u00a0CVP\u00a0baja394,\u00a0\n395.\u00a0Si\u00a0la\u00a0pauta\u00a0de\u00a0tratamiento \u00a0antirretroviral \u00a0presenta\u00a0una\u00a0baja\u00a0barrera\u00a0gen\u00e9tica\u00a0es\u00a0\nm\u00e1s\u00a0prudente \u00a0sustituirla \u00a0bajo\u00a0criterio\u00a0cl\u00ednico\u00a0por\u00a0otra\u00a0con\u00a0barrera\u00a0gen\u00e9tica\u00a0elevada\u00a0\nbasada\u00a0en\u00a0un\u00a0IP/r,\u00a0independientemente \u00a0de\u00a0que\u00a0no\u00a0se\u00a0consiga\u00a0demostrar \u00a0la\u00a0presencia \u00a0\nde\u00a0mutaciones. \u00a0No\u00a0est\u00e1\u00a0bien\u00a0establecida \u00a0cu\u00e1l\u00a0es\u00a0la\u00a0mejor\u00a0actitud\u00a0en\u00a0pacientes \u00a0con\u00a0RVB,\u00a0\naunque\u00a0se\u00a0conoce\u00a0que\u00a0los\u00a0\u00a0pacientes \u00a0con\u00a0RVB\u00a0pueden\u00a0seleccionar \u00a0nuevas\u00a0mutaciones \u00a0\nde\u00a0resistencia, \u00a0fracasos394,\u00a0395\u00a0y\u00a0contribuir \u00a0a\u00a0la\u00a0diseminaci\u00f3n \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0a\u00a0otras\u00a0\npersonas396.\u00a0La\u00a0tolerancia \u00a0al\u00a0tratamiento, \u00a0la\u00a0posibilidad \u00a0de\u00a0realizar\u00a0pruebas\u00a0de\u00a0\nresistencia \u00a0o\u00a0tropismo\u00a0viral,\u00a0las\u00a0alternativas \u00a0disponibles \u00a0y\u00a0sobretodo \u00a0la\u00a0posibilidad \u00a0de\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 58cambiar\u00a0el\u00a0TAR\u00a0a\u00a0un\u00a0r\u00e9gimen\u00a0que\u00a0incluya\u00a0al\u00a0menos\u00a0dos\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\nplenamente \u00a0activos\u00a0condicionan \u00a0la\u00a0actitud\u00a0del\u00a0cl\u00ednico\u00a0en\u00a0este\u00a0escenario \u00a0cl\u00ednico.\u00a0\u00a0\n\u00a0Suspensi\u00f3n \u00a0del\u00a0TAR\u00a0\u00a0\nLa\u00a0interrupci\u00f3n \u00a0del\u00a0tratamiento \u00a0en\u00a0pacientes \u00a0multirresistentes \u00a0se\u00a0plante\u00f3\u00a0ante\u00a0la\u00a0\nhip\u00f3tesis\u00a0de\u00a0que\u00a0la\u00a0reaparici\u00f3n \u00a0de\u00a0la\u00a0cepa\u00a0silvestre\u00a0permitir\u00eda \u00a0una\u00a0mejor\u00a0respuesta \u00a0tras\u00a0\nla\u00a0reintroducci\u00f3n \u00a0del\u00a0tratamiento. \u00a0Los\u00a0ensayos\u00a0cl\u00ednicos\u00a0realizados \u00a0para\u00a0evaluar\u00a0esta\u00a0\nestrategia\n\u00a0han\u00a0evidenciado \u00a0un\u00a0descenso \u00a0importante \u00a0del\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0durante\u00a0la\u00a0\ninterrupci\u00f3n \u00a0frente\u00a0a\u00a0los\u00a0que\u00a0contin\u00faan \u00a0con\u00a0TAR397,\u00a0398.\u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0cambio\u00a0de\u00a0TAR\u00a0por\u00a0fracaso\u00a0virol\u00f3gico \u00a0\u00a0\n\u0083 Se\u00a0debe\u00a0conseguir \u00a0CVP\u00a0indetectable \u00a0(<50\u00a0copias/mL) \u00a0en\u00a0cualquier \u00a0tratamiento \u00a0de\u00a0\nrescate\u00a0(nivel\u00a0A)\u00a0\n\u0083 El\u00a0TAR\u00a0nuevo\u00a0debe\u00a0contener\u00a03\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0totalmente \u00a0activos\u00a0(nivel\u00a0\nA)\u00a0\n\u0083 Se\u00a0debe\u00a0realizar\u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0y\u00a0una\u00a0prueba\u00a0de\u00a0tropismo\u00a0para\u00a0\nconfeccionar \u00a0el\u00a0mejor\u00a0r\u00e9gimen\u00a0alternativo \u00a0(nivel\u00a0B).\u00a0La\u00a0prueba\u00a0de\u00a0resistencias \u00a0debe\u00a0\nrealizarse \u00a0mientras\u00a0el\u00a0paciente\u00a0est\u00e1\u00a0recibiendo \u00a0el\u00a0tratamiento \u00a0fallido\u00a0o\u00a0lo\u00a0m\u00e1s\u00a0\nprecoz\u00a0tras\u00a0la\u00a0suspensi\u00f3n. \u00a0Si\u00a0se\u00a0dispone\u00a0de\u00a0tests\u00a0genot\u00edpicos \u00a0previos,\u00a0se\u00a0debe\u00a0tener\u00a0\nen\u00a0cuenta\u00a0el\u00a0conjunto\u00a0de\u00a0mutaciones \u00a0detectadas \u00a0(genotipo \u00a0acumulado) \u00a0\n\u0083 Si\u00a0es\u00a0imposible \u00a0dise\u00f1ar\u00a0un\u00a0TAR\u00a0de\u00a0rescate\u00a0con\u00a0tres\u00a0f\u00e1rmacos\u00a0activos,\u00a0la\u00a0combinaci\u00f3n \u00a0\nde\u00a0dos\u00a0plenamente \u00a0activos\u00a0y\u00a0otros\u00a0que\u00a0conserven \u00a0cierta\u00a0actividad\u00a0puede\u00a0resultar\u00a0\neficaz\u00a0en\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0\n\u0083 El\u00a0cambio\u00a0del\u00a0TAR\u00a0por\u00a0fracaso\u00a0virol\u00f3gico \u00a0debe\u00a0efectuarse \u00a0de\u00a0modo\u00a0precoz\u00a0para\u00a0\nevitar\u00a0el\u00a0ac\u00famulo\u00a0de\u00a0mutaciones \u00a0y\u00a0facilitar\u00a0la\u00a0respuesta \u00a0al\u00a0nuevo\u00a0tratamiento \u00a0(nivel\u00a0\nB)\u00a0\n\u0083 En\u00a0la\u00a0elecci\u00f3n\u00a0del\u00a0nuevo\u00a0TAR\u00a0se\u00a0deben\u00a0analizar\u00a0las\u00a0causas\u00a0que\u00a0motivaron \u00a0el\u00a0fracaso\u00a0\n(adherencia \u00a0o\u00a0interacciones \u00a0medicamentosas), \u00a0la\u00a0historia\u00a0farmacol\u00f3gica, \u00a0las\u00a0\ntoxicidades \u00a0que\u00a0haya\u00a0presentado \u00a0y\u00a0las\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0previas\u00a0(nivel\u00a0C)\u00a0\n\u0083 El\u00a0nuevo\u00a0TAR\u00a0debe\u00a0ser\u00a0c\u00f3modo,\u00a0bien\u00a0tolerado\u00a0por\u00a0el\u00a0paciente\u00a0y\u00a0lo\u00a0menos\u00a0t\u00f3xico\u00a0\nposible.\u00a0Debe\u00a0insistirse\u00a0en\u00a0la\u00a0adherencia \u00a0antes\u00a0de\u00a0iniciar\u00a0un\u00a0rescate\u00a0y\u00a0subsanar\u00a0\nespec\u00edficamente \u00a0las\u00a0causas\u00a0que\u00a0motivaron \u00a0el\u00a0fracaso\u00a0de\u00a0la\u00a0pauta\u00a0anterior\u00a0rescate\u00a0\n(nivel\u00a0C)\u00a0\n\u0083 Debe\u00a0evitarse\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0timidina,\u00a0especialmente \u00a0d4T,\u00a0si\u00a0existen\u00a0otras\u00a0\nalternativas \u00a0en\u00a0cualquiera \u00a0de\u00a0las\u00a0l\u00edneas\u00a0del\u00a0tratamiento \u00a0de\u00a0rescate\u00a0(nivel\u00a0C)\u00a0\n\u0083 No\u00a0se\u00a0deben\u00a0realizar\u00a0interrupciones \u00a0estructuradas \u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0\nen\u00a0situaciones \u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0aumentar \u00a0la\u00a0eficacia\u00a0del\u00a0\ntratamiento \u00a0de\u00a0rescate\u00a0\u00a0(nivel\u00a0A)\u00a0\n\u0083 No\u00a0se\u00a0recomienda \u00a0suspender \u00a0el\u00a0TAR\u00a0en\u00a0pacientes \u00a0en\u00a0situaci\u00f3n\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0\ny\u00a0sin\u00a0opciones\u00a0terap\u00e9uticas \u00a0de\u00a0rescate\u00a0(nivel\u00a0B).\u00a0En\u00a0esta\u00a0situaci\u00f3n\u00a0debe\u00a0buscarse\u00a0un\u00a0\ntratamiento \u00a0basado\u00a0en\u00a0f\u00e1rmacos\u00a0que\u00a0disminuyan \u00a0la\u00a0capacidad \u00a0replicativa \u00a0viral\u00a0y\u00a0no\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 59a\u00f1adan\u00a0m\u00e1s\u00a0resistencia \u00a0a\u00a0la\u00a0ya\u00a0existente\u00a0(p.e.\u00a03TC\u00a0o\u00a0FTC\u00a0o\u00a0TDF)\u00a0y\u00a0deben\u00a0vigilarse\u00a0\nestrechamente \u00a0\u00a0las\u00a0cifras\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0la\u00a0CVP\u00a0(nivel\u00a0C)\u00a0\n\u0083 Es\u00a0recomendable, \u00a0en\u00a0determinas \u00a0circunstancias, \u00a0consultar \u00a0con\u00a0un\u00a0cl\u00ednico\u00a0o\u00a0vir\u00f3logo\u00a0\ncon\u00a0experiencia \u00a0en\u00a0resistencias \u00a0y\u00a0TAR\u00a0de\u00a0rescate\u00a0o\u00a0remitir\u00a0al\u00a0paciente\u00a0a\u00a0otro\u00a0centro\u00a0\nhospitalario \u00a0que\u00a0disponga\u00a0de\u00a0experiencia \u00a0y\u00a0f\u00e1rmacos\u00a0suficientes \u00a0(en\u00a0ocasiones \u00a0de\u00a0\nuso\u00a0restringido \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0programas \u00a0de\u00a0acceso\u00a0expandido) \u00a0para\u00a0conseguir \u00a0un\u00a0TAR\u00a0\ncon\u00a0las\u00a0m\u00e1ximas\u00a0posibilidades \u00a0de\u00a0\u00e9xito\u00a0(nivel\u00a0C)\u00a0\n\u00a0\u00a0\n5.2.\u00a0SIMPLIFICACION \u00a0DEL\u00a0TAR\u00a0\nSe\u00a0entiende\u00a0por\u00a0simplificaci\u00f3n \u00a0del\u00a0TAR\u00a0el\u00a0cambio\u00a0de\u00a0un\u00a0esquema\u00a0terap\u00e9utico \u00a0que\u00a0ha\u00a0\nconseguido \u00a0la\u00a0supresi\u00f3n \u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0por\u00a0otro\u00a0m\u00e1s\u00a0sencillo\u00a0que\u00a0sigue\u00a0\nmanteniendo \u00a0dicha\u00a0supresi\u00f3n. \u00a0Sus\u00a0objetivos\u00a0son\u00a0mejorar\u00a0la\u00a0calidad\u00a0de\u00a0vida,\u00a0facilitar\u00a0la\u00a0\nadherencia \u00a0y\u00a0prevenir\u00a0o\u00a0revertir\u00a0algunos\u00a0efectos\u00a0adversos. \u00a0\u00a0\nCon\u00a0la\u00a0simplificaci\u00f3n \u00a0se\u00a0consigue\u00a0reducir\u00a0el\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0o\u00a0la\u00a0frecuencia \u00a0de\u00a0\ntomas,\u00a0aprovechar \u00a0la\u00a0comodidad \u00a0de\u00a0las\u00a0coformulaciones, \u00a0eliminar\u00a0las\u00a0restricciones \u00a0\nalimentarias, \u00a0mejorar\u00a0los\u00a0efectos\u00a0secundarios \u00a0y\u00a0reducir\u00a0o\u00a0eliminar\u00a0las\u00a0interacciones. \u00a0\u00a0\nEsta\u00a0estrategia \u00a0empez\u00f3\u00a0a\u00a0utilizarse\u00a0con\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0los\u00a0NN.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0\nestudios\u00a0de\u00a0simplificaci\u00f3n \u00a0iniciales\u00a0se\u00a0efectu\u00f3\u00a0a\u00a0partir\u00a0de\u00a0pautas\u00a0con\u00a0IP\u00a0no\u00a0potenciados. \u00a0\nLa\u00a0potenciaci\u00f3n \u00a0con\u00a0RTV\u00a0de\u00a0los\u00a0IP\u00a0fue\u00a0el\u00a0primer\u00a0paso\u00a0para\u00a0elaborar\u00a0reg\u00edmenes \u00a0\nterap\u00e9uticos \u00a0que\u00a0no\u00a0presentan \u00a0los\u00a0problemas \u00a0de\u00a0complejidad \u00a0y\u00a0tolerancia \u00a0de\u00a0los\u00a0IP\u00a0\niniciales.\u00a0Los\u00a0IP\u00a0de\u00a0segunda\u00a0generaci\u00f3n \u00a0y\u00a0las\u00a0nuevas\u00a0formulaciones \u00a0de\u00a0los\u00a0antiguos,\u00a0as\u00ed\u00a0\ncomo\u00a0las\u00a0coformulaciones \u00a0y\u00a0los\u00a0f\u00e1rmacos\u00a0de\u00a0nuevas\u00a0clases\u00a0han\u00a0contribuido \u00a0tambi\u00e9n\u00a0a\u00a0\nconstruir\u00a0tratamientos \u00a0sencillos.\u00a0\u00a0\nEn\u00a0la\u00a0actualidad \u00a0la\u00a0mayor\u00eda\u00a0de\u00a0pacientes \u00a0inician\u00a0tratamiento \u00a0con\u00a0combinaciones \u00a0\nsencillas\u00a0y\u00a0con\u00a0posterioridad, \u00a0cuando\u00a0\u00e9stas\u00a0fracasan,\u00a0pasan\u00a0a\u00a0tratamientos \u00a0m\u00e1s\u00a0\ncomplejos. \u00a0La\u00a0simplificaci\u00f3n \u00a0ha\u00a0sido\u00a0una\u00a0estrategia \u00a0muy\u00a0utilizada\u00a0durante\u00a0un\u00a0periodo\u00a0\nlargo\u00a0de\u00a0tiempo,\u00a0pero\u00a0en\u00a0la\u00a0actualidad \u00a0las\u00a0pautas\u00a0con\u00a0tratamientos \u00a0sencillos\u00a0desde\u00a0el\u00a0\nprincipio, \u00a0son\u00a0la\u00a0pr\u00e1ctica\u00a0habitual,\u00a0quedando \u00a0pocos\u00a0para\u00a0simplificar. \u00a0\nSe\u00a0puede\u00a0simplificar \u00a0el\u00a0TAR\u00a0reduciendo \u00a0el\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos, \u00a0el\u00a0n\u00famero\u00a0de\u00a0\ncomprimidos \u00a0o\u00a0el\u00a0n\u00famero\u00a0de\u00a0tomas.\u00a0\u00a0\n\u00a0Reducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos \u00a0\nLos\u00a0primeros\u00a0\nestudios\u00a0de\u00a0simplificaci\u00f3n \u00a0del\u00a0TAR\u00a0tuvieron\u00a0como\u00a0objetivo\u00a0la\u00a0reducci\u00f3n \u00a0\ndel\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos \u00a0en\u00a0lo\u00a0que\u00a0se\u00a0denomin\u00f3 \u00a0estrategia \u00a0de\u00a0inducci\u00f3n \u2010\nmantenimiento \u00a0consistente \u00a0en\u00a0una\u00a0primera\u00a0fase\u00a0de\u00a0inducci\u00f3n \u00a0con\u00a0tres\u00a0o\u00a0cuatro\u00a0\nantirretrovirales \u00a0seguida\u00a0del\u00a0mantenimiento \u00a0con\u00a0menos\u00a0de\u00a0tres\u00a0f\u00e1rmacos. \u00a0\u00a0\nEsta\u00a0estrategia \u00a0se\u00a0cuestion\u00f3 \u00a0por\u00a0el\u00a0fracaso\u00a0de\u00a0algunos\u00a0ensayos\u00a0iniciales.\u00a0Alg\u00fan\u00a0estudio\u00a0\nposterior\u00a0no\u00a0encontr\u00f3\u00a0diferencias \u00a0en\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0<50\u00a0copias/mL \u00a0\n(79%\u00a0frente\u00a077%)\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0entre\u00a0la\u00a0rama\u00a0de\u00a0simplificaci\u00f3n \u00a0y\u00a0la\u00a0de\u00a0\nmantenimiento \u00a0del\u00a0TAR\u00a0inicial,\u00a0las\u00a0reacciones \u00a0adversas\u00a0fueron\u00a0menos\u00a0frecuentes \u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0simplificaci\u00f3n \u00a0(15%,\u00a0frente\u00a0a\u00a06%)\u00a0y\u00a0mejor\u00f3\u00a0el\u00a0perfil\u00a0lip\u00eddico\u00a0y\u00a0la\u00a0adherencia399.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 60Se\u00a0ha\u00a0explorado \u00a0la\u00a0estrategia \u00a0de\u00a0simplificar \u00a0a\u00a0monoterapia \u00a0con\u00a0LPV/r,\u00a0tras\u00a0un\u00a0tiempo\u00a0\nde\u00a0inducci\u00f3n \u00a0con\u00a0triple\u00a0terapia\u00a0que\u00a0incluye\u00a0a\u00a0este\u00a0f\u00e1rmaco.\u00a0El\u00a0estudio\u00a0OK04\u00a0que\u00a0incluye\u00a0\na\u00a0205\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0durante\u00a0al\u00a0menos\u00a06\u00a0meses\u00a0(mediana \u00a0de\u00a028),\u00a0que\u00a0\nestaban\u00a0tomando\u00a0un\u00a0TAR\u00a0que\u00a0inclu\u00eda\u00a0LPV/r\u00a0asociado\u00a0a\u00a0dos\u00a0AN.\u00a0Es\u00a0un\u00a0estudio\u00a0\naleatorizado, \u00a0abierto,\u00a0de\u00a0no\u00a0inferioridad \u00a0que\u00a0comparaba \u00a0la\u00a0estrategia \u00a0de\u00a0continuaci\u00f3n \u00a0\ndel\u00a0tratamiento \u00a0triple\u00a0frente\u00a0a\u00a0la\u00a0monoterapia \u00a0con\u00a0LPV/r,\u00a0considerando \u00a0v\u00e1lida\u00a0la\u00a0\nreinducci\u00f3n \u00a0con\u00a02\u00a0AN\u00a0si\u00a0aparec\u00eda\u00a0rebrote\u00a0viral.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0el\u00a0porcentaje \u00a0de\u00a0\npacientes \u00a0sin\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0de\u00a090\u00a0y\u00a094%\u00a0respectivamente, \u00a0(diferencia, \u00a0\u20104%;\u00a0\nl\u00edmite\u00a0superior\u00a0del\u00a0IC\u00a095%\u00a0para\u00a0la\u00a0diferencia \u00a03,4%,\u00a0cumpliendo \u00a0el\u00a0criterio\u00a0de\u00a0no\u00a0\ninferioridad \u00a0de\u00a0la\u00a0monoterapia \u00a0con\u00a0o\u00a0sin\u00a0reintroducci\u00f3n \u00a0de\u00a0los\u00a0AN\u00a0frente\u00a0al\u00a0tratamiento \u00a0\ntriple).\u00a0El\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0a\u00a0las\u00a048\u00a0semanas\u00a0(ITT),\u00a0\nconsiderando \u00a0las\u00a0reinducciones \u00a0como\u00a0fallos,\u00a0fue\u00a0del\u00a085%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0monoterapia \u00a0y\u00a0\n90%\u00a0en\u00a0el\u00a0de\u00a0continuaci\u00f3n \u00a0(p=0,31).\u00a0Los\u00a0episodios \u00a0de\u00a0viremia\u00a0de\u00a0bajo\u00a0nivel,\u00a0entre\u00a050\u00a0y\u00a0\n500\u00a0copias/mL \u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0monoterapia \u00a0(4\u00a0\nfrente\u00a0a\u00a0ninguno)400.\u00a0\u00a0\nCon\u00a0los\u00a0pacientes \u00a0de\u00a0estos\u00a0dos\u00a0estudios\u00a0se\u00a0efectu\u00f3\u00a0un\u00a0an\u00e1lisis\u00a0multivariante \u00a0de\u00a0los\u00a0\nfactores\u00a0predictores \u00a0de\u00a0p\u00e9rdida\u00a0de\u00a0respuesta \u00a0virol\u00f3gica \u00a0del\u00a0grupo\u00a0tratado\u00a0con\u00a0LPV/r\u00a0en\u00a0\nmonoterapia. \u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0se\u00a0relacion\u00f3 \u00a0con\u00a0falta\u00a0de\u00a0adherencia, \u00a0niveles\u00a0bajos\u00a0\nde\u00a0hemoglobina \u00a0y\u00a0nadir\u00a0de\u00a0CD4\u00a0<100\u00a0c\u00e9lulas/\u00b5L401.\u00a0\u00a0\nEn\u00a0\u00a0otro\u00a0estudio\u00a0de\u00a0simplificaci\u00f3n \u00a0a\u00a0monoterapia \u00a0con\u00a0LPV/r\u00a0la\u00a0estrategia \u00a0fue\u00a0algo\u00a0\ndistinta.\u00a0Se\u00a0incluyeron \u00a0155\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriz\u00f3 \u00a02:1\u00a0\na\u00a0iniciar\u00a0tratamiento \u00a0con\u00a0ZDV/3TC\u00a0junto\u00a0con\u00a0LPV/r\u00a0(n=104)\u00a0o\u00a0con\u00a0EFV\u00a0(n=51).\u00a0Entre\u00a0las\u00a0\n24\u00a0y\u00a048\u00a0semanas\u00a0de\u00a0tratamiento \u00a0y\u00a0tras\u00a0al\u00a0menos\u00a03\u00a0controles \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0\nlos\u00a0pacientes \u00a0que\u00a0tomaban\u00a0LPV/r\u00a0pasaron\u00a0a\u00a0mantenimiento \u00a0con\u00a0LPV/r\u00a0en\u00a0monoterapia. \u00a0\nConsiderando \u00a0fracaso\u00a0a\u00a0cualquier \u00a0viremia\u00a0positiva,\u00a0a\u00a0las\u00a096\u00a0semanas\u00a0de\u00a0seguimiento, \u00a0\nun\u00a048%\u00a0de\u00a0los\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0LPV/r\u00a0y\u00a0un\u00a061%\u00a0con\u00a0EFV\u00a0presentaban \u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0(IC\u00a095%\u00a0de\u00a0la\u00a0diferencia, \u00a0\u201029%\u00a0a\u00a04%;\u00a0p=0,17).\u00a0En\u00a0un\u00a0nuevo\u00a0an\u00e1lisis\u00a0en\u00a0el\u00a0\nque\u00a0se\u00a0incluyeron \u00a0como\u00a0respondedores \u00a0a\u00a0los\u00a0pacientes \u00a0que\u00a0tras\u00a0reintroducir \u00a0los\u00a0\nmismos\u00a0AN\u00a0consiguieron \u00a0de\u00a0nuevo\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0el\u00a060%\u00a0de\u00a0pacientes \u00a0en\u00a0\ntratamiento \u00a0con\u00a0LPV/r\u00a0y\u00a0el\u00a063%\u00a0con\u00a0EFV\u00a0respondieron \u00a0al\u00a0tratamiento \u00a0(IC\u00a095%,\u00a0\u201019%\u00a0a\u00a0\n13%,\u00a0p=0,73).\u00a0Se\u00a0objetivaron \u00a0viremias\u00a0de\u00a0bajo\u00a0nivel\u00a0en\u00a0los\u00a0pacientes \u00a0en\u00a0monoterapia. \u00a0\nEn\u00a0cuanto\u00a0a\u00a0la\u00a0seguridad, \u00a0se\u00a0observ\u00f3\u00a0lipoatrofia \u00a0en\u00a0el\u00a05%\u00a0del\u00a0brazo\u00a0de\u00a0monoterapia, \u00a0\nfrente\u00a0a\u00a0un\u00a034%\u00a0del\u00a0grupo\u00a0de\u00a0EFV.\u00a0No\u00a0se\u00a0observaron \u00a0diferencias \u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0\nlipohipertrofia. \u00a0Las\u00a0alteraciones \u00a0lip\u00eddicas\u00a0grado\u00a03\u20104\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0el\u00a0grupo\u00a0\ndel\u00a0LPV/r402.\u00a0\u00a0\nEn\u00a0estos\u00a0dos\u00a0estudios\u00a0se\u00a0pone\u00a0de\u00a0manifiesto \u00a0la\u00a0importancia \u00a0del\u00a0periodo\u00a0durante\u00a0el\u00a0cual\u00a0\nla\u00a0CVP\u00a0permanece \u00a0indetectable \u00a0previo\u00a0al\u00a0paso\u00a0a\u00a0monoterapia. \u00a0Otros\u00a0estudios\u00a0como\u00a0el\u00a0\nKalMo\u00a0confirman \u00a0estos\u00a0resultados403,\u00a0pero\u00a0en\u00a0el\u00a0caso\u00a0del\u00a0MOST404\u00a0tuvo\u00a0que\u00a0detenerse \u00a0\nprecozmente. \u00a0Se\u00a0trataba\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0en\u00a0el\u00a0que\u00a0se\u00a0inclu\u00eda\u00a0a\u00a0pacientes \u00a0con\u00a0carga\u00a0\nviral\u00a0indetectable \u00a0que\u00a0se\u00a0aleatorizan \u00a0a\u00a0continuar \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0a\u00a0pasar\u00a0a\u00a0\nmonoterapia \u00a0con\u00a0LPV/r.\u00a0El\u00a0objetivo\u00a0primario\u00a0era\u00a0el\u00a0fallo\u00a0virol\u00f3gico \u00a0en\u00a0sistema\u00a0nervioso\u00a0\ncentral\u00a0y/o\u00a0tracto\u00a0genital.\u00a0El\u00a0fallo\u00a0virol\u00f3gico \u00a0a\u00a0nivel\u00a0sangu\u00edneo \u00a0se\u00a0defini\u00f3\u00a0como\u00a0la\u00a0\npresencia \u00a0de\u00a0dos\u00a0cargas\u00a0virales\u00a0consecutivas \u00a0superiores \u00a0a\u00a0400\u00a0c\u00e9lulas/\u00b5L. \u00a0Se\u00a0incluyeron \u00a0\n60\u00a0pacientes, \u00a06\u00a0pacientes \u00a0de\u00a0la\u00a0rama\u00a0de\u00a0monoterapia \u00a0presentaron \u00a0fallo\u00a0virol\u00f3gico, \u00a0\ntodos\u00a0ellos\u00a0con\u00a0nadir\u00a0de\u00a0CD4\u00a0<200\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0en\u00a0las\u00a0primeras\u00a024\u00a0semanas\u00a0de\u00a0\ntratamiento. \u00a0Adem\u00e1s\u00a05\u00a0de\u00a0ellos\u00a0ten\u00edan\u00a0CV\u00a0elevada\u00a0en\u00a0LCR\u00a0y\u00a04\u00a0sintomatolog\u00eda \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 61neurol\u00f3gica. \u00a0Los\u00a0autores\u00a0concluyeron \u00a0que\u00a0esta\u00a0es\u00a0una\u00a0estrategia \u00a0que\u00a0no\u00a0se\u00a0puede\u00a0\nrecomendar \u00a0de\u00a0forma\u00a0general\u00a0y\u00a0que\u00a0hay\u00a0que\u00a0seleccionar \u00a0a\u00a0los\u00a0pacientes \u00a0de\u00a0forma\u00a0\nadecuada. \u00a0\u00a0\nEsta\u00a0misma\u00a0estrategia \u00a0se\u00a0est\u00e1\u00a0explorando \u00a0con\u00a0ATV/r405\u00a0y\u00a0DRV/r406\u2010412.\u00a0\u00a0\nSe\u00a0han\u00a0publicado \u00a0los\u00a0resultados \u00a0a\u00a048\u00a0semanas\u00a0de\u00a0un\u00a0estudio\u00a0piloto,\u00a0abierto\u00a0de\u00a0un\u00a0solo\u00a0\nbrazo\u00a0de\u00a0simplificaci\u00f3n \u00a0a\u00a0ATV/r,\u00a0el\u00a0ACTG\u00a05201405.\u00a0Se\u00a0incluyeron \u00a0en\u00a0el\u00a0mismo\u00a0a\u00a034\u00a0\npacientes \u00a0que\u00a0hab\u00edan\u00a0iniciado\u00a0tratamiento \u00a0con\u00a02\u00a0AN\u00a0y\u00a0IP,\u00a0que\u00a0estaban\u00a0con\u00a0carga\u00a0viral\u00a0\nindetectable \u00a0(<50\u00a0copias/mL), \u00a0durante\u00a0al\u00a0menos\u00a048\u00a0semanas, \u00a0no\u00a0hab\u00edan\u00a0no\u00a0hab\u00edan\u00a0sido\u00a0\ntratados\u00a0con\u00a0NN\u00a0ni\u00a0fallo\u00a0virol\u00f3gico \u00a0previo\u00a0y\u00a0eran\u00a0HBsAg\u00a0negativos. \u00a0En\u00a0el\u00a0momento \u00a0de\u00a0\nentrar\u00a0en\u00a0el\u00a0estudio\u00a0se\u00a0sustitu\u00eda\u00a0el\u00a0IP\u00a0que\u00a0estaban\u00a0tomando\u00a0por\u00a0ATV/r\u00a0y\u00a06\u00a0semanas\u00a0\ndespu\u00e9s\u00a0se\u00a0suspend\u00edan \u00a0los\u00a0AN.\u00a0El\u00a0objetivo\u00a0primario\u00a0del\u00a0estudio\u00a0era\u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0\nfallo\u00a0virol\u00f3gico. \u00a0A\u00a0las\u00a048\u00a0semanas, \u00a030\u00a0pacientes \u00a0(88%)\u00a0segu\u00edan\u00a0con\u00a0carga\u00a0viral\u00a0\nindetectable. \u00a0En\u00a0los\u00a0que\u00a0presentaron \u00a0fallo\u00a0virol\u00f3gico \u00a0no\u00a0se\u00a0detectaron \u00a0mutaciones \u00a0de\u00a0\nresistencia. \u00a0Adem\u00e1s,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0la\u00a0viremia\u00a0residual\u00a0se\u00a0observ\u00f3\u00a0que\u00a0no\u00a0se\u00a0\nmodificaba \u00a0en\u00a0los\u00a0pacientes \u00a0en\u00a0los\u00a0que\u00a0no\u00a0hubo\u00a0fallo\u00a0virol\u00f3gico, \u00a0pero\u00a0aumentaba \u00a0\nprogresivamente \u00a0en\u00a0los\u00a0que\u00a0lo\u00a0tuvieron\u00a0detect\u00e1ndose \u00a0desde\u00a04\u201012\u00a0semanas\u00a0antes\u00a0de\u00a0\nque\u00a0se\u00a0confirmara \u00a0el\u00a0fracaso.\u00a0M\u00e1s\u00a0recientemente \u00a0se\u00a0han\u00a0comunicado \u00a0datos\u00a0del\u00a0estudio\u00a0\nOREY.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0estudio\u00a0piloto,\u00a0abierto,\u00a0multic\u00e9ntrico \u00a0de\u00a0brazo\u00a0\u00fanico\u00a0y\u00a096\u00a0semanas\u00a0\nde\u00a0seguimiento \u00a0que\u00a0eval\u00faa\u00a0la\u00a0monoterapia \u00a0con\u00a0ATV/r.\u00a0Se\u00a0incluyeron \u00a061\u00a0pacientes \u00a0que\u00a0\nestaban\u00a0recibiendo \u00a0TAR,\u00a0que\u00a0no\u00a0hab\u00edan\u00a0tenido\u00a0ning\u00fan\u00a0fracaso\u00a0previo\u00a0(CVP\u00a0<50\u00a0\ncopias/mL \u00a0al\u00a0menos\u00a024\u00a0semanas) \u00a0y\u00a0en\u00a0tratamiento \u00a0con\u00a0ATV/r\u00a0y\u00a02\u00a0AN\u00a0al\u00a0menos\u00a0las\u00a08\u00a0\nsemanas\u00a0antes\u00a0de\u00a0su\u00a0inclusi\u00f3n. \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0\npacientes \u00a0mantuvieron \u00a0la\u00a0supresi\u00f3n \u00a0virol\u00f3gica \u00a0(79%\u00a0<400\u00a0copias/mL) \u00a0tras\u00a0cambiar\u00a0a\u00a0\nmonoterapia, \u00a0la\u00a0reintroducci\u00f3n \u00a0de\u00a0la\u00a0triple\u00a0terapia\u00a0fue\u00a0generalmente \u00a0satisfactoria \u00a0(7\u00a0de\u00a0\n9\u00a0pacientes). \u00a0El\u00a0desarrollo \u00a0de\u00a0mutaciones \u00a0primarias \u00a0a\u00a0IP\u00a0fue\u00a0raro413.\u00a0\nEn\u00a0cuanto\u00a0al\u00a0DRV/r,\u00a0se\u00a0han\u00a0comunicado \u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0que\u00a0exploran\u00a0dos\u00a0\nescenarios \u00a0distintos\u00a0en\u00a0los\u00a0que\u00a0se\u00a0eval\u00faa\u00a0la\u00a0eficacia\u00a0y\u00a0la\u00a0seguridad \u00a0de\u00a0la\u00a0administraci\u00f3n \u00a0\nde\u00a0DRV/r\u00a0en\u00a0monoterapia. \u00a0El\u00a0estudio\u00a0MONET406\u00a0tiene\u00a0un\u00a0dise\u00f1o\u00a0similar\u00a0al\u00a0OK.\u00a0En\u00a0\u00e9l\u00a0se\u00a0\nincluyeron \u00a0256\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0antirretroviral \u00a0con\u00a02\u00a0AN\u00a0y\u00a0un\u00a0NN\u00a0o\u00a0un\u00a0IP/r\u00a0sin\u00a0\nexperiencia \u00a0previa\u00a0a\u00a0DRV/r\u00a0ni\u00a0historia\u00a0de\u00a0fallo\u00a0virol\u00f3gico, \u00a0con\u00a0carga\u00a0viral\u00a0indetectable \u00a0\n(<50\u00a0copias/mL) \u00a0durante\u00a0al\u00a0menos\u00a06\u00a0meses.\u00a0Se\u00a0les\u00a0aleatoriz\u00f3 \u00a0a\u00a0tomar\u00a0bien\u00a0DRV/r\u00a0\n(800/100\u00a0QD)\u00a0(n=\u00a0129)\u00a0e\u00a0monoterapia \u00a0o\u00a0junto\u00a0a\u00a02\u00a0AN\u00a0optimizados \u00a0(n=\u00a0127).\u00a0Se\u00a0trata\u00a0de\u00a0\nun\u00a0estudio\u00a0de\u00a0no\u00a0inferioridad \u00a0en\u00a0el\u00a0que\u00a0el\u00a0objetivo\u00a0primario\u00a0es\u00a0el\u00a0tiempo\u00a0hasta\u00a0la\u00a0\np\u00e9rdida\u00a0de\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0(TLOVR).\u00a0Se\u00a0defini\u00f3\u00a0fracaso\u00a0terap\u00e9utico \u00a0a\u00a0la\u00a0\npresencia \u00a0de\u00a0dos\u00a0determinaciones \u00a0consecutivas \u00a0de\u00a0cargas\u00a0virales\u00a0superiores \u00a0a\u00a050\u00a0\ncopias/mL \u00a0antes\u00a0de\u00a0la\u00a0semana\u00a048\u00a0o\u00a0por\u00a0la\u00a0suspensi\u00f3n \u00a0del\u00a0tratamiento \u00a0en\u00a0estudio.\u00a0En\u00a0el\u00a0\nan\u00e1lisis\u00a0a\u00a0la\u00a0semana\u00a048\u00a0se\u00a0confirmaba \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0la\u00a0rama\u00a0de\u00a0DRV/r\u00a0en\u00a0\nmonoterapia. \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar,\u00a0considerando \u00a0cambio\u00a0de\u00a0\ntratamiento \u00a0como\u00a0un\u00a0fracaso,\u00a0el\u00a085,3%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0tomaban\u00a0DRV/r\u00a0frente\u00a0al\u00a0\n84,3%\u00a0de\u00a0los\u00a0que\u00a0tomaban\u00a0adem\u00e1s\u00a02\u00a0AN\u00a0presentaban \u00a0CVP\u00a0indetectable \u00a0(\u20101;\u00a0l\u00edmite\u00a0del\u00a0\nIC\u00a095%,\u00a0\u20109,9).\u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias, \u00a0se\u00a0ha\u00a0detectado \u00a0un\u00a0paciente\u00a0por\u00a0\nrama\u00a0con\u00a0evidencia \u00a0de\u00a0resistencia \u00a0genot\u00edpica, \u00a0pero\u00a0no\u00a0fenot\u00edpica \u00a0a\u00a0DRV.\u00a0\nRecientemente \u00a0se\u00a0han\u00a0comunicado \u00a0los\u00a0resultados \u00a0a\u00a0la\u00a0semana\u00a096.\u00a0No\u00a0se\u00a0ha\u00a0podido\u00a0\ndemostrar \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0la\u00a0rama\u00a0de\u00a0monoterapia. \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0primario\u00a0de\u00a0\neficacia\u00a0se\u00a0ha\u00a0observado \u00a0una\u00a0tasa\u00a0de\u00a0blips\u00a0y\u00a0discontinuaciones \u00a0ligeramente \u00a0superior\u00a0en\u00a0\nla\u00a0rama\u00a0de\u00a0monoterapia, \u00a0si\u00a0bien\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos\u00a0se\u00a0observ\u00f3\u00a0una\u00a0resupresi\u00f3n \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 62posterior\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0tras\u00a0intensificaci\u00f3n407.En\u00a0un\u00a0an\u00e1lisis\u00a0\nmultivariante \u00a0de\u00a0los\u00a0factores\u00a0relacionados \u00a0con\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0respuesta \u00a0al\u00a0tratamiento, \u00a0\nel\u00a0\u00fanico\u00a0factor\u00a0encontrado \u00a0ha\u00a0sido\u00a0la\u00a0coinfecci\u00f3n \u00a0VIH\u2010VHC\u00a0.\u00a0\nEn\u00a0el\u00a0estudio\u00a0MONOI410\u00a0el\u00a0dise\u00f1o\u00a0es\u00a0distinto.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0\nabierto\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0a\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0recibido\u00a0tratamiento \u00a0\nantirretroviral \u00a0durante\u00a0al\u00a0menos\u00a018\u00a0meses,\u00a0que\u00a0presentaban \u00a0CVP\u00a0<400\u00a0copias/mL \u00a0\ndurante\u00a0los\u00a018\u00a0meses\u00a0previos\u00a0y\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0el\u00a0momento \u00a0de\u00a0la\u00a0inclusi\u00f3n, \u00a0que\u00a0\nno\u00a0hab\u00edan\u00a0presentado \u00a0fallo\u00a0virol\u00f3gico \u00a0a\u00a0IP\u00a0y\u00a0no\u00a0hab\u00edan\u00a0recibido\u00a0nunca\u00a0DRV/r.\u00a0Consta\u00a0de\u00a0\ndos\u00a0fases,\u00a0en\u00a0la\u00a0primera\u00a0se\u00a0introduce \u00a0en\u00a0el\u00a0tratamiento \u00a0DRV/r\u00a0en\u00a0la\u00a0semana\u00a0\u20108\u00a0y\u00a0en\u00a0la\u00a0\nsegunda\u00a0en\u00a0la\u00a0que\u00a0se\u00a0aleatoriza \u00a01:1\u00a0a\u00a0DRV/r\u00a0(600/100\u00a0mg\u00a0BID)\u00a0o\u00a0a\u00a0DRV/r\u00a0(600/100\u00a0BID)\u00a0\n+\u00a02\u00a0AN.\u00a0Es\u00a0un\u00a0estudio\u00a0de\u00a0no\u00a0inferioridad \u00a0de\u00a0la\u00a0pauta\u00a0de\u00a0monoterapia \u00a0frente\u00a0a\u00a0la\u00a0\ntriterapia \u00a0y\u00a0el\u00a0objetivo\u00a0primario\u00a0es\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0que\u00a0mantienen \u00a0respuesta \u00a0\nvirol\u00f3gica \u00a0en\u00a0la\u00a0semana\u00a048,\u00a0aunque\u00a0el\u00a0seguimiento \u00a0programado \u00a0es\u00a0m\u00e1s\u00a0prolongado. \u00a0En\u00a0\nla\u00a0fase\u00a0inicial\u00a0se\u00a0incluyeron \u00a0242\u00a0pacientes, \u00a0se\u00a0aleatorizaron \u00a0226.\u00a0Se\u00a0han\u00a0comunicado \u00a0los\u00a0\ndatos\u00a0a\u00a0la\u00a0semana\u00a048\u00a0(110\u00a0pacientes \u00a0en\u00a0triple\u00a0terapia\u00a0y\u00a0109\u00a0con\u00a0DRV/r).\u00a0En\u00a0los\u00a0\nresultados \u00a0por\u00a0protocolo \u00a0DRV/r\u00a0en\u00a0monoterapia \u00a0muestra\u00a0no\u00a0inferioridad \u00a0frente\u00a0a\u00a0la\u00a0\ntriple\u00a0terapia\u00a0(94,1%\u00a0frente\u00a0a\u00a099,0%\u00a0de\u00a0CVP\u00a0<50\u00a0copias/mL); \u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0por\u00a0ITT\u00a0se\u00a0\nobtienen\u00a0resultados \u00a0similares\u00a0(87,5%\u00a0frente\u00a0a\u00a092%):\u00a0Se\u00a0objetivaron \u00a0tres\u00a0fracasos\u00a0\nvirol\u00f3gicos \u00a0(>400\u00a0copias/mL) \u00a0en\u00a0pacientes \u00a0con\u00a0DRV/r\u00a0en\u00a0monoterapia, \u00a0sin\u00a0detectarse \u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0para\u00a0DRV,\u00a0y\u00a0con\u00a0posterior\u00a0resupresi\u00f3n \u00a0viral\u00a0tras\u00a0la\u00a0\nreintroducci\u00f3n \u00a0de\u00a0los\u00a0AN.\u00a0Si\u00a0bien\u00a02\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0presentaron \u00a0\ns\u00edntomas\u00a0neurol\u00f3gicos \u00a0(cefalea\u00a0y\u00a0crisis\u00a0convulsiva \u00a0en\u00a0un\u00a0paciente\u00a0con\u00a0epilepsia\u00a0no\u00a0\ntratada);\u00a0el\u00a0an\u00e1lisis\u00a0citobioqu\u00edmico \u00a0del\u00a0LCR\u00a0era\u00a0normal,\u00a0pero\u00a0la\u00a0carga\u00a0viral\u00a0era\u00a0\ndetectable \u00a0en\u00a0el\u00a0LCR.\u00a0Este\u00a0hallazgo\u00a0cuestiona \u00a0la\u00a0capacidad \u00a0de\u00a0la\u00a0monoterapia \u00a0para\u00a0\nmantener \u00a0la\u00a0supresi\u00f3n \u00a0del\u00a0VIH\u00a0en\u00a0sistema\u00a0nervioso\u00a0central.\u00a0\u00a0Recientemente \u00a0se\u00a0han\u00a0\npresentado \u00a0los\u00a0datos\u00a0de\u00a0redistribuci\u00f3n \u00a0de\u00a0grasa\u00a0corporal\u00a0observ\u00e1ndose \u00a0un\u00a0menor\u00a0\n\u00edndice\u00a0de\u00a0las\u00a0mismas\u00a0en\u00a0la\u00a0rama\u00a0que\u00a0no\u00a0llevaba\u00a0AN,\u00a0al\u00a0igual\u00a0que\u00a0en\u00a0otros\u00a0estudios410.\u00a0\u00a0\nIgualmente \u00a0se\u00a0han\u00a0presentado \u00a0datos\u00a0de\u00a0varios\u00a0estudios\u00a0en\u00a0los\u00a0que\u00a0se\u00a0explora\u00a0la\u00a0\nposibilidad \u00a0de\u00a0realizar\u00a0otro\u00a0tipo\u00a0de\u00a0inducci\u00f3n \u2010mantenimiento \u00a0que\u00a0consiste\u00a0en\u00a0iniciar\u00a0un\u00a0\ntratamiento \u00a0con\u00a0ATV/r\u00a0y\u00a0posteriormente \u00a0suspender \u00a0el\u00a0RTV.\u00a0Esta\u00a0estrategia \u00a0se\u00a0ha\u00a0\nplanteado \u00a0para\u00a0evitar\u00a0los\u00a0efectos\u00a0secundarios \u00a0que\u00a0produce\u00a0el\u00a0RTV\u00a0incluso\u00a0a\u00a0dosis\u00a0bajas.\u00a0\nLos\u00a0estudios\u00a0m\u00e1s\u00a0significativos \u00a0son\u00a0el\u00a0INDUMA\u00a0y\u00a0el\u00a0ARIES.\u00a0El\u00a0INDUMA414\u00a0es\u00a0un\u00a0estudio\u00a0\naleatorizado, \u00a0abierto,\u00a0multic\u00e9ntrico \u00a0de\u00a0no\u00a0inferioridad, \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0252\u00a0\npacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0que\u00a0iniciaron\u00a0tratamiento \u00a0de\u00a0inducci\u00f3n \u00a0con\u00a02AN\u00a0+\u00a0\nATV/r\u00a0y\u00a0que\u00a0en\u00a0la\u00a0semana\u00a026\u201030,\u00a0los\u00a0que\u00a0ten\u00edan\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0y\u00a0segu\u00edan\u00a0con\u00a0el\u00a0\ntratamiento \u00a0(172)\u00a0se\u00a0aleatorizan \u00a01:1\u00a0a\u00a0continuar \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0a\u00a0tomar\u00a02\u00a0\nAN\u00a0+\u00a0ATV\u00a0400\u00a0mg\u00a0QD\u00a0con\u00a0un\u00a0seguimiento \u00a0de\u00a048\u00a0semanas. \u00a0El\u00a0objetivo\u00a0primario\u00a0era\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0manten\u00edan \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0a\u00a0las\u00a048\u00a0semanas. \u00a0\nObjetivos \u00a0secundarios \u00a0eran\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL, \u00a0la\u00a0cifra\u00a0\nde\u00a0CD4\u00a0y\u00a0los\u00a0datos\u00a0de\u00a0seguridad. \u00a0La\u00a0mitad\u00a0de\u00a0los\u00a0pacientes \u00a0llevaban\u00a0como\u00a0pareja\u00a0de\u00a0\nAN,\u00a0ABC/3TC. \u00a0En\u00a0la\u00a0semana\u00a048\u00a0la\u00a0rama\u00a0de\u00a0ATV\u00a0demostr\u00f3 \u00a0no\u00a0inferioridad \u00a0con\u00a0respecto\u00a0a\u00a0\nla\u00a0de\u00a0ATV/r\u00a0(proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0es\u00a0de\u00a075\u00a0%\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0\nATV/r\u00a0(n=\u00a085)\u00a0y\u00a0de\u00a078%\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV\u00a0(n=87);\u00a0con\u00a0una\u00a0diferencia \u00a0de\u00a02,9\u00a0y\u00a0un\u00a0IC\u00a0\n95%,\u00a0\u20109,8\u00a0a\u00a015,5.\u00a0En\u00a0cuanto\u00a0al\u00a0perfil\u00a0de\u00a0seguridad, \u00a0se\u00a0produjeron \u00a0menos\u00a0casos\u00a0de\u00a0\nhiperbilirrubinemia \u00a0y\u00a0de\u00a0dislipemia \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV.\u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0\u00e9sta\u00a0\nes\u00a0una\u00a0opci\u00f3n\u00a0en\u00a0pacientes \u00a0que\u00a0no\u00a0toman\u00a0tenofovir. \u00a0No\u00a0se\u00a0detectaron \u00a0resistencias \u00a0\nfrente\u00a0a\u00a0IP\u00a0en\u00a0ninguno\u00a0de\u00a0los\u00a0brazos\u00a0entre\u00a0los\u00a0pacientes \u00a0que\u00a0presentaron \u00a0fracaso\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 63virol\u00f3gico. \u00a0El\u00a0estudio\u00a0ARIES415,\u00a0416\u00a0es\u00a0un\u00a0estudio\u00a0similar.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0\nabierto,\u00a0multic\u00e9ntrico, \u00a0de\u00a0no\u00a0inferioridad \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo\u00a0a\u00a0los\u00a0que\u00a0se\u00a0pauta\u00a0ABC/3TC\u00a0+\u00a0ATV/r\u00a0y\u00a0posteriormente, \u00a0en\u00a0la\u00a0\nsemana\u00a036,\u00a0se\u00a0aleatorizan \u00a0(1:1)\u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0a\u00a0suspender \u00a0el\u00a0\nritonavir\u00a0durante\u00a048\u00a0semanas, \u00a0si\u00a0su\u00a0CVP\u00a0es\u00a0<50\u00a0copias/mL \u00a0y\u00a0no\u00a0han\u00a0presentado \u00a0fallo\u00a0\nvirol\u00f3gico \u00a0previo.\u00a0Se\u00a0aleatorizaron \u00a0419\u00a0pacientes, \u00a0incluy\u00e9ndose \u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0a\u00a0los\u00a0379\u00a0\n(90%)\u00a0que\u00a0completaron \u00a0las\u00a084\u00a0semanas\u00a0de\u00a0seguimiento. \u00a0El\u00a0objetivo\u00a0primario\u00a0era\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP<\u00a050\u00a0copias/mL \u00a0en\u00a0la\u00a0semana\u00a084\u00a0(TLOVR).\u00a0Los\u00a0autores\u00a0\nobservan\u00a0que\u00a0la\u00a0eficacia\u00a0de\u00a0ambos\u00a0tratamientos \u00a0es\u00a0similar\u00a0y\u00a0sostenida \u00a0\nindependientemente \u00a0de\u00a0la\u00a0CVP\u00a0basal,\u00a0siendo\u00a0infrecuente \u00a0el\u00a0fallo\u00a0virol\u00f3gico \u00a0(2%)\u00a0que\u00a0se\u00a0\nmantiene \u00a0a\u00a0las\u00a0120\u00a0semanas417.\u00a0\u00a0\n\u00a0\nReducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0y/o\u00a0de\u00a0dosis\u00a0\nLa\u00a0reducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0y/o\u00a0de\u00a0dosis\u00a0se\u00a0consigue\u00a0sustituyendo \u00a0el\u00a0IP\u00a0\npor\u00a0un\u00a0f\u00e1rmaco\u00a0de\u00a0otro\u00a0grupo\u00a0o\u00a0incluso\u00a0utilizando \u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0presentan \u00a0\ncoformulados \u00a0en\u00a0un\u00a0n\u00famero\u00a0\u00fanico\u00a0o\u00a0reducido\u00a0de\u00a0comprimidos. \u00a0La\u00a0primera\u00a0estrategia, \u00a0\nampliamente \u00a0estudiada, \u00a0se\u00a0ha\u00a0evaluado\u00a0sustituci\u00f3n \u00a0del\u00a0IP/r\u00a0por\u00a0EFV,\u00a0NVP\u00a0o\u00a0ABC\u00a0y\u00a0\ntambi\u00e9n\u00a0por\u00a0otro\u00a0IP/r\u00a0que\u00a0se\u00a0pueda\u00a0administrar \u00a0en\u00a0QD.\u00a0\n\u00a0\nSimplificaci\u00f3n \u00a0con\u00a0EFV\u00a0\nSe\u00a0han\u00a0realizado\u00a0m\u00faltiples \u00a0estudios\u00a0al\u00a0respecto, \u00a0pero\u00a0pocos\u00a0de\u00a0ellos\u00a0son\u00a0comparativos. \u00a0\nEn\u00a0los\u00a0estudios\u00a0DMP\u2010049\u00a0y\u00a0\u2010027\u00a0se\u00a0aleatorizaron \u00a0a\u00a0pacientes \u00a0que\u00a0estaban\u00a0tomando\u00a0un\u00a0\nTAR\u00a0con\u00a0IP\u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0o\u00a0sustituirlo \u00a0por\u00a0EFV.\u00a0En\u00a0los\u00a0dos\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nfue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0EFV418,\u00a0419\u00a0.\u00a0\nEn\u00a0otro\u00a0estudio\u00a0se\u00a0compar\u00f3\u00a0el\u00a0cambio\u00a0de\u00a0IP\u00a0por\u00a0EFV\u00a0(n=25),\u00a0NVP\u00a0(n=26)\u00a0o\u00a0continuar \u00a0\ncon\u00a0el\u00a0IP\u00a0(n=26),\u00a0en\u00a0pacientes \u00a0en\u00a0TAR\u00a0con\u00a0IP\u00a0con\u00a0CD4\u00a0>300\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0<80\u00a0\ncopias/mL \u00a0mantenida \u00a0m\u00e1s\u00a0de\u00a09\u00a0meses.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0(ITT)\u00a0no\u00a0hubo\u00a0diferencia \u00a0en\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0con\u00a0EFV\u00a0(80%)\u00a0o\u00a0IP\u00a0(77%)420.\u00a0\u00a0\nEn\u00a0un\u00a0estudio\u00a0con\u00a0dise\u00f1o\u00a0combinado \u00a0(caso\u2010control\u00a0y\u00a0aleatorizado) \u00a0se\u00a0compar\u00f3\u00a0la\u00a0\nevoluci\u00f3n \u00a0de\u00a0167\u00a0pacientes \u00a0(a\u00a0los\u00a0que\u00a0tras\u00a0suspender \u00a0el\u00a0IP\u00a0se\u00a0aleatorizaron \u00a0a\u00a0EFV\u00a0o\u00a0\nABC),\u00a0con\u00a0otros\u00a0167\u00a0pacientes \u00a0que\u00a0continuaron \u00a0con\u00a0IP\u00a0(control). \u00a0A\u00a0las\u00a048\u00a0semanas\u00a0(ITT)\u00a0\nel\u00a070%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0EFV\u00a0y\u00a0el\u00a054%\u00a0con\u00a0IP\u00a0presentaban \u00a0CVP\u00a0<500\u00a0copias/mL \u00a0\n(p<0,05)421.\u00a0\u00a0\u00a0\nEn\u00a0un\u00a0estudio\u00a0que\u00a0incluy\u00f3\u00a0262\u00a0pacientes \u00a0en\u00a0TAR\u00a0basado\u00a0en\u00a0IP/r\u00a0y\u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL, \u00a0se\u00a0cambi\u00f3\u00a0el\u00a0TAR\u00a0a\u00a0EFV\u00a0en\u00a0una\u00a0pauta\u00a0QD\u00a0(EFV+ddI+3TC) \u00a0o\u00a0BID\u00a0(EFV\u00a0con\u00a0los\u00a0\nAN\u00a0de\u00a0base).\u00a0El\u00a0estudio\u00a0era\u00a0abierto,\u00a0aleatorizado \u00a0y\u00a0de\u00a0no\u00a0inferioridad \u00a0y\u00a0su\u00a0objetivo\u00a0\nprimario\u00a0era\u00a0el\u00a0mantenimiento \u00a0de\u00a0supresi\u00f3n \u00a0virol\u00f3gica \u00a0en\u00a0la\u00a0semana\u00a048.\u00a0La\u00a0pauta\u00a0QD\u00a0\nno\u00a0era\u00a0inferior\u00a0a\u00a0la\u00a0BID.\u00a0En\u00a0general,\u00a0ambas\u00a0pautas\u00a0se\u00a0asociaban \u00a0con\u00a0baja\u00a0tasa\u00a0de\u00a0fallo\u00a0\nvirol\u00f3gico \u00a0y\u00a0con\u00a0una\u00a0mejora\u00a0importante \u00a0en\u00a0la\u00a0satisfacci\u00f3n \u00a0de\u00a0los\u00a0pacientes, \u00a0en\u00a0la\u00a0\nadherencia \u00a0y\u00a0la\u00a0calidad\u00a0de\u00a0vida.\u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0el\u00a0cambio\u00a0de\u00a0un\u00a0IP/r\u00a0a\u00a0EFV\u00a0\nes\u00a0seguro\u00a0y\u00a0bien\u00a0tolerado422.\u00a0\n\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 64\u00a0Simplificaci\u00f3n \u00a0con\u00a0NVP\u00a0\nExisten\u00a0varios\u00a0estudios\u00a0aleatorizados \u00a0y\u00a0un\u00a0estudio\u00a0con\u00a0dise\u00f1o\u00a0caso\u2010control\u00a0en\u00a0los\u00a0que\u00a0\nse\u00a0compara\u00a0seguir\u00a0con\u00a0un\u00a0IP\u00a0con\u00a0cambiar\u00a0a\u00a0NVP.\u00a0\u00a0\nEn\u00a0varios\u00a0estudios\u00a0aleatorizados \u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0simplificar \u00a0a\u00a0IP,\u00a0la\u00a0\neficacia\u00a0terap\u00e9utica \u00a0a\u00a0las\u00a024\u201048\u00a0semanas, \u00a0fue\u00a0similar\u00a0en\u00a0las\u00a0dos\u00a0ramas\u00a0y\u00a0se\u00a0observ\u00f3\u00a0una\u00a0\nmejor\u00eda\u00a0del\u00a0perfil\u00a0lip\u00eddico423\u2010425.\u00a0En\u00a0uno\u00a0de\u00a0los\u00a0estudios\u00a0se\u00a0observ\u00f3\u00a0una\u00a0mayor\u00a0eficacia\u00a0\nvirol\u00f3gica \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0simplificaci\u00f3n426.\u00a0\nEn\u00a0un\u00a0estudio\u00a0caso\u2010control\u00a0de\u00a0una\u00a0cohorte\u00a0de\u00a0pacientes \u00a0que\u00a0recibieron \u00a0un\u00a0IP\u00a0en\u00a0su\u00a0\nprimer\u00a0TAR\u00a0y\u00a0que\u00a0sustituyeron \u00a0por\u00a0NVP\u00a0(n=125)\u00a0o\u00a0por\u00a0otro\u00a0IP\u00a0(cambio\u00a0a\u00a0nueva\u00a0\nformulaci\u00f3n \u00a0de\u00a0SQV\u00a0o\u00a0IP/r\u00a0(n=321),\u00a0se\u00a0encontr\u00f3\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0que\u00a0el\u00a0riesgo\u00a0relativo\u00a0\nde\u00a0fracasar\u00a0por\u00a0cambio\u00a0de\u00a0tratamiento \u00a0fue\u00a05\u00a0veces\u00a0superior\u00a0con\u00a0el\u00a0IP\u00a0que\u00a0con\u00a0NVP\u00a0sin\u00a0\nque\u00a0existieran \u00a0diferencias \u00a0en\u00a0el\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico427.\u00a0\u00a0\nCon\u00a0un\u00a0dise\u00f1o\u00a0distinto,\u00a0en\u00a0otro\u00a0estudio\u00a0espa\u00f1ol\u00a0(MULTINEKA) \u00a0se\u00a0aleatoriz\u00f3 \u00a0a\u00a067\u00a0\npacientes \u00a0en\u00a0tratamiento \u00a0estable\u00a0y\u00a0con\u00a0CVP<50\u00a0copias\u00a0durante\u00a0al\u00a0menos\u00a06\u00a0meses\u00a0a\u00a0\nrecibir\u00a0LPV/r\u00a0con\u00a0NVP\u00a0o\u00a0con\u00a0dos\u00a0AN.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0de\u00a0tratamiento, \u00a0no\u00a0se\u00a0detect\u00f3\u00a0\nfracaso\u00a0virol\u00f3gico \u00a0en\u00a0ninguno\u00a0de\u00a0los\u00a0pacientes. \u00a0Se\u00a0describi\u00f3\u00a0un\u00a0posible\u00a0beneficio \u00a0en\u00a0la\u00a0\ntoxicidad\u00a0mitocondrial, \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0NVP428.\u00a0\nLa\u00a0NVP\u00a0est\u00e1\u00a0contraindicada \u00a0en\u00a0mujeres\u00a0con\u00a0CD4\u00a0>250\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0en\u00a0varones\u00a0con\u00a0>400\u00a0\npor\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0grave.\u00a0Sin\u00a0embargo, \u00a0varios\u00a0estudios\u00a0independientes429\u2010\n435\u00a0coinciden \u00a0en\u00a0se\u00f1alar\u00a0que\u00a0no\u00a0se\u00a0ha\u00a0objetivado \u00a0un\u00a0incremento \u00a0de\u00a0la\u00a0hepatotoxicidad \u00a0\no\u00a0del\u00a0exantema \u00a0en\u00a0pacientes \u00a0en\u00a0los\u00a0que\u00a0se\u00a0introduce \u00a0NVP\u00a0como\u00a0estrategia \u00a0de\u00a0\nsimplificaci\u00f3n \u00a0o\u00a0sustituci\u00f3n \u00a0por\u00a0toxicidad\u00a0independientemente \u00a0del\u00a0n\u00famero\u00a0de\u00a0CD4.\u00a0\nEstos\u00a0resultados \u00a0son\u00a0muy\u00a0consistentes \u00a0por\u00a0el\u00a0n\u00famero\u00a0de\u00a0pacientes, \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0ha\u00a0\nmodificado \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0en\u00a0el\u00a0sentido\u00a0de\u00a0que\u00a0no\u00a0importa\u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0cuando\u00a0\nse\u00a0simplifica \u00a0un\u00a0TAR\u00a0a\u00a0NVP\u00a0(v\u00e9ase\u00a0ficha\u00a0t\u00e9cnica).\u00a0\u00a0\n\u00a0Simplificaci\u00f3n \u00a0con\u00a0abacavir\u00a0\n\u00a0Se\u00a0han\u00a0realizado\u00a0m\u00faltiples \u00a0estudios\u00a0aleatorizados \u00a0y\u00a0un\u00a0estudio\u00a0caso\u2010control\u00a0\nprospectivo \u00a0que\u00a0analizan\u00a0esta\u00a0estrategia. \u00a0Los\u00a0resultados \u00a0son\u00a0dispares.\u00a0\u00a0\nEn\u00a0uno\u00a0de\u00a0ellos\u00a0la\u00a0eficacia\u00a0terap\u00e9utica \u00a0fue\u00a0superior\u00a0en\u00a0la\u00a0rama\u00a0del\u00a0ABC.\u00a0En\u00a0los\u00a0otros,\u00a0\nincluido\u00a0\nel\u00a0estudio\u00a0TRIZAL\u00a0y\u00a0el\u00a0COLA30305, \u00a0la\u00a0eficacia\u00a0fue\u00a0similar,\u00a0pero\u00a0se\u00a0observ\u00f3\u00a0una\u00a0\nmayor\u00a0incidencia \u00a0de\u00a0fracasos\u00a0en\u00a0aquellos\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0pasado\u00a0a\u00a0tomar\u00a0ABC\u00a0y\u00a0\npreviamente \u00a0hab\u00edan\u00a0tomado\u00a0tratamientos \u00a0sub\u00f3ptimos421,\u00a0436\u2010438.\u00a0\nEn\u00a0el\u00a0estudio\u00a0de\u00a0dise\u00f1o\u00a0combinado \u00a0(caso\u2010control\u00a0y\u00a0aleatorizado) \u00a0que\u00a0comparaba \u00a0IP\u00a0con\u00a0\nEFV\u00a0o\u00a0ABC,\u00a0el\u00a065%\u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0ABC\u00a0y\u00a0el\u00a054%\u00a0de\u00a0los\u00a0que\u00a0continuaron \u00a0\ncon\u00a0IP\u00a0presentaron \u00a0CVP\u00a0<500\u00a0copias/mL \u00a0(p<0,05)\u00a0a\u00a0las\u00a048\u00a0semanas439.\u00a0\nEn\u00a0otro\u00a0estudio,\u00a0209\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0a\u00a0recibir\u00a0ZDV/3TC/ABC \u00a0en\u00a0\ncombinaci\u00f3n \u00a0fija\u00a0con\u00a0EFV\u00a0o\u00a0LPV/r,\u00a0durante\u00a024\u201036\u00a0semanas. \u00a0Los\u00a0pacientes \u00a0que\u00a0tuvieron\u00a0\nCVP\u00a0<50\u00a0copias\u00a0mL\u00a0en\u00a0ambos\u00a0brazos\u00a0continuaron \u00a0con\u00a0ZDV/3TC/ABC. \u00a0A\u00a0las\u00a072\u00a0semanas\u00a0\npor\u00a0intenci\u00f3n \u00a0de\u00a0tratamiento \u00a0un\u00a031%\u00a0y\u00a0un\u00a043%\u00a0mantuvieron \u00a0la\u00a0CVP\u00a0indetectable, \u00a0pero\u00a0\nel\u00a034%\u00a0y\u00a025%\u00a0de\u00a0ellos\u00a0cambiaron \u00a0la\u00a0pauta\u00a0por\u00a0toxicidad440.\u00a0\nEn\u00a0distintos\u00a0estudios\u00a0se\u00a0ha\u00a0puesto\u00a0de\u00a0manifiesto \u00a0la\u00a0existencia \u00a0de\u00a0un\u00a0riesgo\u00a0elevado\u00a0de\u00a0\nfracaso\u00a0terap\u00e9utico \u00a0y\u00a0desarrollo \u00a0de\u00a0mutaciones \u00a0a\u00a0AN\u00a0cuando\u00a0se\u00a0utilizan\u00a0pautas\u00a0de\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 65simplificaci\u00f3n \u00a0con\u00a03TC/ABC+TDF441\u00a0y\u00a03TC+ddI+TDF \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0desaconsejan \u00a0como\u00a0\nestrategia \u00a0de\u00a0simplificaci\u00f3n \u00a0pese\u00a0a\u00a0su\u00a0sencillez.\u00a0\n\u00a0Comparaci\u00f3n \u00a0directa\u00a0de\u00a0EFV,\u00a0NVP\u00a0y\u00a0ABC\u00a0en\u00a0simplificaci\u00f3n \u00a0de\u00a0TAR\u00a0\nEl\u00a0NEFA\u00a0es\u00a0un\u00a0estudio\u00a0prospectivo \u00a0en\u00a0el\u00a0que\u00a0se\u00a0aleatorizaron \u00a0460\u00a0pacientes \u00a0en\u00a0\ntratamiento \u00a0con\u00a0dos\u00a0AN\u00a0m\u00e1s\u00a0un\u00a0IP,\u00a0con\u00a0CVP<200\u00a0copias/mL \u00a0\ndurante\u00a0\u22656\u00a0meses442.\u00a0Se\u00a0\nsustitu\u00eda\u00a0el\u00a0IP\u00a0por\u00a0NVP\u00a0(n=155),\u00a0EFV\u00a0(n=156)\u00a0o\u00a0ABC\u00a0(n=149).\u00a0El\u00a050%,\u00a058%\u00a0y\u00a046%\u00a0de\u00a0\npacientes \u00a0respectivamente \u00a0hab\u00edan\u00a0recibido\u00a0tratamientos \u00a0previos\u00a0sub\u00f3ptimos \u00a0con\u00a0uno\u00a0\no\u00a0dos\u00a0AN.\u00a0La\u00a0eficacia\u00a0terap\u00e9utica \u00a0(ITT)\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0(CVP\u00a0<200\u00a0copias/mL) \u00a0fue\u00a0\nsimilar\u00a0en\u00a0los\u00a0tres\u00a0grupos\u00a0(77%,\u00a072%\u00a0y\u00a077%;\u00a0p=NS).\u00a0EL\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0superior\u00a0en\u00a0\nel\u00a0grupo\u00a0de\u00a0ABC\u00a0(6%,\u00a04%\u00a0y\u00a012%;\u00a0p<0,05)\u00a0y\u00a0ocurr\u00eda\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0recibido\u00a0\ntratamiento \u00a0sub\u00f3ptimo. \u00a0Estos\u00a0resultados \u00a0se\u00a0han\u00a0confirmado \u00a0a\u00a0los\u00a03\u00a0a\u00f1os443.\u00a0El\u00a0an\u00e1lisis\u00a0\ngenot\u00edpico \u00a0de\u00a0las\u00a0cepas\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0fracaso\u00a0virol\u00f3gico \u00a0evidenci\u00f3 \u00a0un\u00a0n\u00famero\u00a0\nmayor\u00a0de\u00a0mutaciones \u00a0de\u00a0resistencias \u00a0a\u00a0AN\u00a0en\u00a0los\u00a0que\u00a0recibieron \u00a0ABC444.\u00a0El\u00a0n\u00famero\u00a0de\u00a0\npacientes \u00a0que\u00a0suspendi\u00f3 \u00a0el\u00a0tratamiento \u00a0por\u00a0efectos\u00a0adversos\u00a0fue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\nABC\u00a0(17%,\u00a017%\u00a0y\u00a06%;\u00a0p<0,01).\u00a0La\u00a0simplificaci\u00f3n \u00a0a\u00a0cualquiera \u00a0de\u00a0los\u00a0NN,\u00a0sobre\u00a0todo\u00a0a\u00a0\nNVP,\u00a0produjo\u00a0beneficios \u00a0en\u00a0el\u00a0perfil\u00a0lip\u00eddico,\u00a0con\u00a0reducci\u00f3n \u00a0de\u00a0colesterol \u2010no\u2010HDL\u00a0con\u00a0\nABC.\u00a0Los\u00a0niveles\u00a0de\u00a0triglic\u00e9ridos \u00a0se\u00a0redujeron \u00a0en\u00a0los\u00a0tres\u00a0brazos.\u00a0Los\u00a0marcadores \u00a0de\u00a0\nresistencia \u00a0a\u00a0la\u00a0insulina\u00a0mostraron \u00a0una\u00a0tendencia \u00a0a\u00a0la\u00a0mejor\u00eda.\u00a0Sin\u00a0embargo, \u00a0no\u00a0\nmejoraron \u00a0las\u00a0alteraciones \u00a0en\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa445,\u00a0446.\u00a0\u00a0\nUn\u00a0estudio\u00a0de\u00a0cohortes\u00a0con\u00a0los\u00a0datos\u00a0de\u00a0la\u00a0French\u00a0Hospital\u00a0Database \u00a0on\u00a0HIV\u00a0trata\u00a0de\u00a0\nreproducir \u00a0los\u00a0datos\u00a0del\u00a0estudio\u00a0NEFA\u00a0pero\u00a0en\u00a0la\u00a0vida\u00a0real.\u00a0Se\u00a0incluyeron \u00a02462\u00a0\npacientes \u00a0seguidos\u00a0durante\u00a012\u00a0meses\u00a0y\u00a0en\u00a0los\u00a0que\u00a0el\u00a0primer\u00a0tratamiento \u00a0incluyera\u00a0un\u00a0\nIP;\u00a0se\u00a0cambi\u00f3\u00a0el\u00a0IP\u00a0por\u00a0EFV,\u00a0NVP\u00a0o\u00a0ABC.\u00a0Los\u00a0factores\u00a0predictivos \u00a0de\u00a0rebrote\u00a0de\u00a0la\u00a0CVP\u00a0\nfueron:\u00a0sexo\u00a0femenino, \u00a0menor\u00a0edad,\u00a0exposici\u00f3n \u00a0sub\u00f3ptima \u00a0previa\u00a0a\u00a0antirretrovirales, \u00a0\nCPV\u00a0elevada,\u00a0uso\u00a0de\u00a0ddI/d4T\u00a0tras\u00a0el\u00a0cambio\u00a0y\u00a0cambio\u00a0a\u00a0NVP\u00a0o\u00a0ABC\u00a0(si\u00a0se\u00a0hab\u00eda\u00a0recibido\u00a0\ntratamientos \u00a0sub\u00f3ptimos). \u00a0Las\u00a0diferencias \u00a0respecto\u00a0al\u00a0NEFA\u00a0probablemente \u00a0se\u00a0deban\u00a0a\u00a0\ndiferencias \u00a0metodol\u00f3gicas447.\u00a0\u00a0\u00a0\u00a0\nComparando \u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0tres\u00a0AN\u00a0(ZDV/3TC/ABC \u00a0coformulados) \u00a0frente\u00a0a\u00a0la\u00a0\ncombinaci\u00f3n \u00a0de\u00a0dos\u00a0AN\u00a0(ZDV/3TC \u00a0coformulados) \u00a0m\u00e1s\u00a0NVP,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0(ITT)\u00a0a\u00a0las\u00a048\u00a0\nsemanas\u00a0no\u00a0hubo\u00a0diferencias \u00a0significativas \u00a0en\u00a0cuanto\u00a0CVP\u00a0indetectable448.\u00a0\u00a0\n\u00a0Simplificaci\u00f3n \u00a0con\u00a0atazanavir \u00a0\nEl\u00a0ATV\u00a0es\u00a0un\u00a0IP\u00a0de\u00a0dosificaci\u00f3n \u00a0QD,\u00a0bien\u00a0tolerado,\u00a0con\u00a0buen\u00a0perfil\u00a0metab\u00f3lico \u00a0y\u00a0pocos\u00a0\ncomprimidos \u00a0que\u00a0ha\u00a0permitido \u00a0una\u00a0nueva\u00a0estrategia \u00a0de\u00a0simplificaci\u00f3n \u00a0en\u00a0la\u00a0que\u00a0un\u00a0IP\u00a0\nsustituye\u00a0a\u00a0otro.\u00a0\nEl\u00a0SWAN\u00a0es\u00a0un\u00a0estudio\u00a0abierto\u00a0en\u00a0fase\u00a0IIIb,\u00a0en\u00a0el\u00a0que\u00a0419\u00a0pacientes\n\u00a0en\u00a0tratamiento \u00a0\nestable\u00a0con\u00a0IP\u00a0(potenciado \u00a0o\u00a0no)\u00a0y\u00a0con\u00a0CVP\u00a0indetectable \u00a0se\u00a0aleatorizaron \u00a0(2:1)\u00a0a\u00a0ATV\u00a0\n400\u00a0mg\u00a0QD\u00a0(en\u00a0caso\u00a0de\u00a0tomar\u00a0TDF\u00a0se\u00a0paut\u00f3\u00a0ATV/r\u00a0300/100\u00a0mg)\u00a0(n=278)\u00a0o\u00a0continuar \u00a0\ncon\u00a0el\u00a0IP\u00a0(n=141).\u00a0A\u00a0la\u00a0semana\u00a048\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0menor\u00a0en\u00a0los\u00a0que\u00a0\nsimplificaron \u00a0(7%\u00a0frente\u00a0a\u00a016%;\u00a0p<0,01).\u00a0La\u00a0eficacia\u00a0virol\u00f3gica \u00a0fue\u00a0superior\u00a0en\u00a0los\u00a0\npacientes \u00a0que\u00a0pasaron\u00a0de\u00a0tomar\u00a0un\u00a0IP\u00a0no\u00a0potenciado \u00a0a\u00a0ATV\u00a0(22%\u00a0frente\u00a0a\u00a05%;\u00a0\np<0,001); \u00a0no\u00a0hubo\u00a0diferencias \u00a0entre\u00a0los\u00a0que\u00a0siguieron\u00a0con\u00a0IP/r\u00a0y\u00a0los\u00a0que\u00a0pasaron\u00a0de\u00a0\nIP/r\u00a0a\u00a0ATV\u00a0(11%\u00a0frente\u00a0a\u00a08%;\u00a0p=NS)449.\u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0seguridad, \u00a0la\u00a0suspensi\u00f3n \u00a0de\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 66tratamiento \u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0pacientes \u00a0del\u00a0grupo\u00a0control\u00a0(21%\u00a0frente\u00a0a\u00a034%;\u00a0p<0,01)\u00a0y\u00a0\nel\u00a0perfil\u00a0lip\u00eddico\u00a0fue\u00a0mejor\u00a0en\u00a0el\u00a0grupo\u00a0que\u00a0simplific\u00f3 \u00a0a\u00a0ATV.\u00a0Los\u00a0datos\u00a0de\u00a0los\u00a0estudios\u00a0\nATAZIP\u00a0y\u00a0SIMPATAZ \u00a0confirman \u00a0la\u00a0seguridad \u00a0y\u00a0eficacia\u00a0de\u00a0esta\u00a0estrategia \u00a0de\u00a0\nsimplificaci\u00f3n, \u00a0en\u00a0este\u00a0caso\u00a0cambiando \u00a0LPV/r\u00a0por\u00a0ATV/r450,\u00a0451.\u00a0\nEl\u00a0estudio\u00a0REAL,\u00a0del\u00a0que\u00a0se\u00a0han\u00a0presentado \u00a0datos\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0es\u00a0un\u00a0ensayo\u00a0\ncl\u00ednico\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a0pacientes \u00a0en\u00a0TAR\u00a0estable\u00a0al\u00a0menos\u00a0durante\u00a012\u00a0semanas\u00a0\nque\u00a0contiene\u00a0un\u00a0IP\u00a0administrado \u00a0BID,\u00a0con\u00a0CVP\u00a0indetectable \u00a0y\u00a0lipohipertrofia, \u00a0a\u00a0los\u00a0que\u00a0\nse\u00a0aleatoriza \u00a0a\u00a0continuar \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0cambiar\u00a0el\u00a0IP\u00a0a\u00a0ATV/r\u00a0\u00a0300/100\u00a0\nmg.\u00a0El\u00a0control\u00a0inmuno\u2010virol\u00f3gico \u00a0se\u00a0mantuvo, \u00a0se\u00a0observ\u00f3\u00a0una\u00a0mejor\u00eda\u00a0del\u00a0perfil\u00a0lip\u00eddico\u00a0\nen\u00a0la\u00a0rama\u00a0de\u00a0ATV\u00a0pero\u00a0no\u00a0se\u00a0objetivaron \u00a0diferencias \u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0composici\u00f3n \u00a0\ncorporal452.\u00a0\u00a0\u00a0\nOtra\u00a0estrategia \u00a0es\u00a0la\u00a0desarrollada \u00a0en\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0AI424\u2010067\u00a0a\u00a048\u00a0semanas453.\u00a0Se\u00a0\ntrata\u00a0de\u00a0un\u00a0estudio\u00a0aleatorizado, \u00a0abierto,\u00a0prospectivo, \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0246\u00a0\npacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0IP/r\u00a0y\u00a0con\u00a0hiperlipidemia \u00a0y\u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0Se\u00a0\naleatorizaron \u00a0los\u00a0pacientes \u00a0a\u00a0cambiar\u00a0a\u00a0ATV\u00a0(400\u00a0mg)\u00a0en\u00a0el\u00a0d\u00eda\u00a01\u00a0(cambio\u00a0inmediato) \u00a0o\u00a0\nmantener \u00a0su\u00a0tratamiento \u00a0y\u00a0cambiar\u00a0a\u00a0ATV\u00a0(400\u00a0mg)\u00a0a\u00a0las\u00a024\u00a0semanas\u00a0(cambio\u00a0\nretrasado). \u00a0A\u00a0las\u00a012\u00a0semanas\u00a0ambos\u00a0grupos\u00a0manten\u00edan \u00a0un\u00a0control\u00a0virol\u00f3gico \u00a0similar\u00a0y\u00a0\naquellos\u00a0pacientes \u00a0que\u00a0tomaban\u00a0ATV\u00a0mostraron \u00a0una\u00a0mejor\u00eda\u00a0significativa \u00a0de\u00a0las\u00a0cifras\u00a0\nde\u00a0LDL\u2010colesterol \u00a0(\u201015\u00a0y\u00a0+1%;\u00a0p<0,0001). \u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0el\u00a0cambio\u00a0\ninmediato \u00a0o\u00a0diferido\u00a0de\u00a0un\u00a0IP\u00a0potenciado \u00a0o\u00a0no\u00a0a\u00a0ATV\u00a0no\u00a0potenciado \u00a0en\u00a0pacientes \u00a0con\u00a0\nhiperlipemia \u00a0se\u00a0asocia\u00a0con\u00a0mejor\u00eda\u00a0en\u00a0los\u00a0par\u00e1metros \u00a0lip\u00eddicos\u00a0sin\u00a0p\u00e9rdida\u00a0de\u00a0supresi\u00f3n \u00a0\nvirol\u00f3gica. \u00a0\u00a0\n\u00a0\nSimplificaci\u00f3n \u00a0a\u00a0reg\u00edmenes \u00a0de\u00a0administraci\u00f3n \u00a0en\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0\nEl\u00a0cambio\u00a0a\u00a0un\u00a0r\u00e9gimen\u00a0QD\u00a0es\u00a0otra\u00a0forma\u00a0de\u00a0simplificaci\u00f3n \u00a0en\u00a0pacientes \u00a0que\u00a0est\u00e9n\u00a0bien\u00a0\ncontrolados. \u00a0Varios\u00a0ensayos\u00a0han\u00a0comprobado \u00a0la\u00a0validez\u00a0de\u00a0esta\u00a0estrategia. \u00a0\nEn\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0se\u00a0aleatorizaron \u00a0355\u00a0pacientes \u00a0a\u00a0seguir\u00a0con\u00a0su\u00a0TAR\u00a0o\u00a0cambiar\u00a0a\u00a0\nuna\u00a0terapia\u00a0QD\u00a0(ddI+FTC+EFV). \u00a0A\u00a0la\u00a0semana\u00a048\u00a0segu\u00edan\u00a0con\u00a0CVP\u00a0indetectable \u00a0el\u00a087%\u00a0de\u00a0\nla\u00a0rama\u00a0QD\u00a0y\u00a0el\u00a079%\u00a0de\u00a0los\u00a0que\u00a0no\u00a0hab\u00edan\u00a0cambiado \u00a0(p<0,05\u00a0)454.\u00a0En\u00a0otro\u00a0estudio\u00a0no\u00a0\naleatorizado \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0169\u00a0pacientes, \u00a084\u00a0siguieron\u00a0su\u00a0TAR\u00a0y\u00a085\u00a0se\u00a0\ncambiaron \u00a0a\u00a0ddI\u00a0+TDF+\u00a0NVP\u00a0QD;\u00a0la\u00a0eficacia\u00a0virol\u00f3gica \u00a0fue\u00a0buena\u00a0(76\u00a0frente\u00a0a\u00a086%,\u00a0ITT)\u00a0\npero\u00a0los\u00a0linfocitos\u00a0CD4\u00a0disminuyeron \u00a0en\u00a0la\u00a0rama\u00a0QD\u00a0con\u00a0un\u00a0decremento \u00a0medio\u00a0de\u00a095\u00a0\nc\u00e9lulas/\u00b5L455.\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ddI+TDF\u00a0ha\u00a0demostrado \u00a0eficacia\u00a0virol\u00f3gica \u00a0pero\u00a0pobre\u00a0recuperaci\u00f3n \u00a0de\u00a0\nlinfocitos\u00a0CD4\u00a0o\u00a0incluso\u00a0descenso \u00a0de\u00a0su\u00a0n\u00famero\u00a0aunque\u00a0la\u00a0CVP\u00a0est\u00e9\u00a0suprimida. \u00a0Este\u00a0\ndescenso \u00a0era\u00a0m\u00e1s\u00a0patente\u00a0cuando\u00a0se\u00a0administraban \u00a0las\u00a0dosis\u00a0est\u00e1ndar\u00a0(plenas)\u00a0de\u00a0\nddI456.\u00a0Los\u00a0reg\u00edmenes \u00a0de\u00a0administraci\u00f3n \u00a0QD\u00a0que\u00a0contengan \u00a0la\u00a0combinaci\u00f3n \u00a0ddI+TDF\u00a0\ndeben\u00a0evitarse.\u00a0De\u00a0hacerlo\u00a0se\u00a0debe\u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0ddI\u00a0a\u00a0250\u00a0mg/d\u00eda\u00a0en\u00a0pacientes \u00a0\ncon\u00a0m\u00e1s\u00a0de\u00a060\u00a0Kg\u00a0de\u00a0peso\u00a0y\u00a0a\u00a0200\u00a0mg/d\u00eda\u00a0en\u00a0pacientes \u00a0por\u00a0debajo\u00a0de\u00a0dicho\u00a0peso.\u00a0\nCon\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0las\u00a0combinaciones \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0AN\u00a0administrados \u00a0QD\u00a0se\u00a0ha\u00a0\nsimplificado \u00a0a\u00fan\u00a0m\u00e1s\u00a0la\u00a0situaci\u00f3n. \u00a0Est\u00e1\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0claro\u00a0su\u00a0papel\u00a0en\u00a0terapia\u00a0de\u00a0inicio\u00a0\ny\u00a0ya\u00a0se\u00a0han\u00a0puesto\u00a0en\u00a0marcha\u00a0ensayos\u00a0para\u00a0valorar\u00a0su\u00a0uso\u00a0en\u00a0reg\u00edmenes \u00a0m\u00e1s\u00a0sencillos.\u00a0\nEl\u00a0SWEET\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0en\u00a0el\u00a0que\u00a0234\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0durante\u00a0al\u00a0\nmenos\u00a06\u00a0meses\u00a0con\u00a0ZDV/3TC\u00a0(coformulados) \u00a0+\u00a0EFV\u00a0y\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0se\u00a0\naleatorizaron \u00a0a\u00a0TDF+FTC\u00a0(coformulados) \u00a0+\u00a0EFV\u00a0o\u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento. \u00a0A\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 67las\u00a024\u00a0semanas\u00a0se\u00a0observ\u00f3\u00a0una\u00a0mejor\u00eda\u00a0en\u00a0las\u00a0cifras\u00a0de\u00a0hemoglobina \u00a0y\u00a0en\u00a0el\u00a0perfil\u00a0\nlip\u00eddico\u00a0en\u00a0la\u00a0rama\u00a0TDF+FTC, \u00a0manteni\u00e9ndose \u00a0la\u00a0respuesta \u00a0al\u00a0tratamiento \u00a0(CVP\u00a0<50\u00a0\ncopias/mL, \u00a093%\u00a0frente\u00a0a\u00a088%;\u00a0p=0,26).\u00a0Recientemente \u00a0se\u00a0han\u00a0publicado \u00a0los\u00a0resultados \u00a0\na\u00a048\u00a0semanas457\u00a0a\u00a0las\u00a0que\u00a0han\u00a0llegado\u00a0206\u00a0pacientes. \u00a0Un\u00a05%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0\ncontinuaron \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0y\u00a0un\u00a03%\u00a0de\u00a0los\u00a0que\u00a0lo\u00a0cambiaron, \u00a0\ndiscontinuaron \u00a0el\u00a0estudio\u00a0por\u00a0efectos\u00a0adversos. \u00a0No\u00a0se\u00a0objetivaron \u00a0diferencias \u00a0\nsignificativas \u00a0entre\u00a0las\u00a0dos\u00a0ramas\u00a0(85%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0continuaron \u00a0el\u00a0tratamiento \u00a0\nfrente\u00a0al\u00a088%\u00a0de\u00a0los\u00a0que\u00a0cambiaron \u00a0ten\u00edan\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0ITT).\u00a0En\u00a0el\u00a0subestudio \u00a0\nde\u00a0100\u00a0pacientes \u00a0a\u00a0los\u00a0que\u00a0se\u00a0ha\u00a0realizado\u00a0DEXA\u00a0del\u00a0tejido\u00a0graso,\u00a0se\u00a0observa\u00a0que\u00a0la\u00a0\ngrasa\u00a0se\u00a0mantiene \u00a0o\u00a0aumenta\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0cambian\u00a0el\u00a0tratamiento, \u00a0pero\u00a0\ndisminuye \u00a0en\u00a0el\u00a0grupo\u00a0que\u00a0contin\u00faa\u00a0(diferencia \u00a0media\u00a0de\u00a0448\u00a0g;\u00a0IC\u00a095%,\u00a057\u00a0a\u00a0839\u00a0g;\u00a0\np=0,025). \u00a0Al\u00a0igual\u00a0que\u00a0en\u00a0otros\u00a0estudios,\u00a0el\u00a0incremento \u00a0de\u00a0grasa\u00a0es\u00a0menor\u00a0en\u00a0aquellos\u00a0\npacientes \u00a0que\u00a0tomaban\u00a0ZDV\u00a0y\u00a0en\u00a0los\u00a0que\u00a0presentaban \u00a0menor\u00a0cantidad\u00a0de\u00a0grasa\u00a0\nperif\u00e9rica. \u00a0No\u00a0se\u00a0observaron \u00a0diferencias \u00a0entre\u00a0grupos\u00a0en\u00a0cuanto\u00a0a\u00a0toxicidad\u00a0renal.\u00a0Los\u00a0\ninvestigadores \u00a0concluyen \u00a0que\u00a0el\u00a0cambio\u00a0de\u00a0ZDV/3TC\u00a0por\u00a0TDF/FTC\u00a0en\u00a0pacientes \u00a0en\u00a0\ntratamiento \u00a0con\u00a0EFV\u00a0y\u00a0respuesta \u00a0virol\u00f3gica \u00a0mantenida \u00a0es\u00a0seguro\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0\nvista\u00a0virol\u00f3gico \u00a0y\u00a0se\u00a0asocia\u00a0con\u00a0un\u00a0incremento \u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0hemoglobina \u00a0y\u00a0una\u00a0mejor\u00eda\u00a0\nde\u00a0los\u00a0par\u00e1metros \u00a0lip\u00eddicos\u00a0y\u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal.\u00a0\u00a0\u00a0\nEn\u00a0otro\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado, \u00a0abierto\u00a0que\u00a0incluye\u00a0a\u00a080\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0y\u00a0que\u00a0est\u00e1n\u00a0en\u00a0tratamiento \u00a0con\u00a0ZDV/3TC\u00a0(+\u00a0IP\u00a0\u00f3\u00a0NN),\u00a0\u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0\na\u00a0seguir\u00a0con\u00a0ZDV/3TC\u00a0o\u00a0cambiar\u00a0a\u00a0TDF/FTC\u00a0(RECOMB), \u00a0en\u00a0la\u00a0semana\u00a024\u00a0el\u00a085%\u00a0de\u00a0los\u00a0\npacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0TDF\u2010FTC,\u00a0presentaban \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0frente\u00a0a\u00a0un\u00a0\n80%\u00a0con\u00a0ZDV/3TC\u00a0(p=0,77)458.\u00a0Se\u00a0observ\u00f3\u00a0adem\u00e1s\u00a0un\u00a0incremento \u00a0significativo \u00a0de\u00a0grasa\u00a0\nen\u00a0las\u00a0extremidades \u00a0en\u00a0los\u00a0pacientes \u00a0cuya\u00a0masa\u00a0grasa\u00a0era\u00a0<7,2\u00a0kg\u00a0basalmente. \u00a0Por\u00a0\n\u00faltimo\u00a0mejoraron \u00a0las\u00a0cifras\u00a0de\u00a0colesterol \u2010LDL\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC.\u00a0En\u00a0los\u00a0datos\u00a0a\u00a072\u00a0\nsemanas459,\u00a0no\u00a0se\u00a0ha\u00a0observado \u00a0ning\u00fan\u00a0fallo\u00a0virol\u00f3gico; \u00a0el\u00a090%\u00a0de\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC\u00a0\nfrente\u00a0a\u00a0un\u00a083%\u00a0de\u00a0la\u00a0rama\u00a0de\u00a0AZT/3TC\u00a0presentan \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(p=\u00a00.52);\u00a0la\u00a0\nmediana\u00a0de\u00a0incremento \u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0fue\u00a0similar.\u00a0Adem\u00e1s,\u00a0en\u00a0estos\u00a0pacientes \u00a0se\u00a0\nobjetiva\u00a0una\u00a0mejor\u00eda\u00a0significativa, \u00a0incremento \u00a0progresivo \u00a0de\u00a0grasa\u00a0en\u00a0las\u00a0extremidades, \u00a0\nsobre\u00a0todo\u00a0si\u00a0el\u00a0IMC\u00a0basal\u00a0es\u00a0>25\u00a0Kg/m2\u00a0y\u00a0llevan\u00a0m\u00e1s\u00a0de\u00a05\u00a0a\u00f1os\u00a0con\u00a0AZT/3TC.\u00a0El\u00a0an\u00e1lisis\u00a0\nse\u00a0realiza\u00a0seg\u00fan\u00a0el\u00a0IMC\u00a0basal\u00a0sea\u00a0superior\u00a0o\u00a0no\u00a0a\u00a025\u00a0Kg/m2\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0a\u00f1os\u00a0en\u00a0\ntratamiento \u00a0con\u00a0AZT/3TC\u00a0y\u00a0en\u00a0todos\u00a0los\u00a0escenarios \u00a0la\u00a0mejor\u00eda\u00a0de\u00a0grasa\u00a0perif\u00e9rica \u00a0es\u00a0\nestad\u00edsticamente \u00a0significativa \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC.\u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0\u00e9sta\u00a0\nes\u00a0una\u00a0estrategia \u00a0segura\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0inmuno\u2010virol\u00f3gico \u00a0y\u00a0de\u00a0efectos\u00a0\nadversos, \u00a0que\u00a0mejora\u00a0la\u00a0lipoatrofia \u00a0y\u00a0distintos\u00a0par\u00e1metros \u00a0bioqu\u00edmicos \u00a0(hemoglobina, \u00a0\nhematocrito \u00a0y\u00a0colesterol \u2010LDL).\u00a0Otro\u00a0ensayo\u00a0similar\u00a0es\u00a0el\u00a0TOTEM,\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a0\n91\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0y\u00a0dislipemia, \u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0a\u00a0seguir\u00a0con\u00a0\nel\u00a0mismo\u00a0tratamiento \u00a0o\u00a0cambiar\u00a0a\u00a0TDF/FTC.\u00a0En\u00a0los\u00a0pacientes \u00a0que\u00a0cambiaron \u00a0se\u00a0observ\u00f3\u00a0\nuna\u00a0mejor\u00eda\u00a0significativa \u00a0en\u00a0el\u00a0perfil\u00a0lip\u00eddico\u00a0a\u00a0las\u00a012\u00a0semanas460.\u00a0Se\u00a0conoce\u00a0igualmente \u00a0\nlos\u00a0resultados \u00a0del\u00a0BICOMBO, \u00a0estudio\u00a0aleatorizado \u00a0y\u00a0abierto\u00a0que\u00a0incluy\u00f3\u00a0a\u00a0335\u00a0\npacientes \u00a0que\u00a0recib\u00edan\u00a0tratamiento \u00a0con\u00a0un\u00a0r\u00e9gimen\u00a0que\u00a0inclu\u00eda\u00a03TC,\u00a0con\u00a0supresi\u00f3n \u00a0\nvirol\u00f3gica \u00a0durante\u00a0\u22656\u00a0meses\u00a0y\u00a0que\u00a0fueron\u00a0aleatorizados \u00a0a\u00a0sustituir\u00a0los\u00a0AN\u00a0por\u00a0las\u00a0\ncombinaciones \u00a0coformuladas \u00a0ABC/3TC\u00a0(n=\u00a0167)\u00a0o\u00a0TDF/FTC\u00a0(n=\u00a0168)461.\u00a0El\u00a0estudio\u00a0se\u00a0\ndise\u00f1\u00f3\u00a0para\u00a0evaluar\u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ambas\u00a0combinaciones \u00a0respecto\u00a0a\u00a0fracaso\u00a0\nterap\u00e9utico \u00a0o\u00a0virol\u00f3gico. \u00a0En\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC, \u00a0el\u00a0fracaso\u00a0terap\u00e9utico \u00a0fue\u00a0de\u00a013,3%\u00a0\nfrente\u00a0a\u00a019,2%\u00a0en\u00a0el\u00a0de\u00a0ABC+3TC, \u00a0no\u00a0demostr\u00e1ndose \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ABC+3TC\u00a0\nfrente\u00a0a\u00a0TDF+FTC\u00a0(IC\u00a095%,\u00a0\u20102\u00a0a\u00a014%).\u00a0Sin\u00a0embargo\u00a0ABC+3TC\u00a0demostr\u00f3 \u00a0la\u00a0no\u00a0inferioridad \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 68frente\u00a0a\u00a0TDF+FTC\u00a0en\u00a0el\u00a0objetivo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0(2,4%\u00a0frente\u00a0a\u00a00%;\u00a0IC\u00a095%,\u00a00,05\u00a0a\u00a0\n6%).\u00a0Las\u00a0suspensiones \u00a0por\u00a0eventos\u00a0adversos\u00a0fueron\u00a0de\u00a010%\u00a0del\u00a0grupo\u00a0de\u00a0ABC+3TC\u00a0\nfrente\u00a0al\u00a05%\u00a0del\u00a0grupo\u00a0TDF+FTC\u00a0(p=0,004). \u00a0En\u00a0cuanto\u00a0al\u00a0perfil\u00a0lip\u00eddico,\u00a0las\u00a0reducciones \u00a0\nel\u00a0colesterol \u00a0total,\u00a0HDL,\u00a0LDL\u00a0y\u00a0triglic\u00e9ridos \u00a0fueron\u00a0mayores\u00a0en\u00a0la\u00a0rama\u00a0TDF+FTC. \u00a0El\u00a0\nincremento \u00a0en\u00a0la\u00a0grasa\u00a0perif\u00e9rica \u00a0y\u00a0las\u00a0alteraciones \u00a0en\u00a0la\u00a0funci\u00f3n\u00a0renal\u00a0\u00a0o\u00a0la\u00a0densidad\u00a0\nmineral\u00a0\u00f3sea\u00a0fueron\u00a0similares. \u00a0La\u00a0toxicidad\u00a0hep\u00e1tica\u00a0fue\u00a0muy\u00a0baja\u00a0en\u00a0ambos\u00a0grupos.\u00a0\nPor\u00a0el\u00a0contrario, \u00a0la\u00a0respuesta \u00a0inmunol\u00f3gica \u00a0fue\u00a0mejor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ABC+3TC. \u00a0La\u00a0\ndeterminaci\u00f3n \u00a0previa\u00a0del\u00a0HLA\u00a0B*5701\u00a0podr\u00eda\u00a0haber\u00a0modificado \u00a0estos\u00a0resultados. \u00a0\u00a0\nExiste\u00a0otro\u00a0estudio\u00a0aleatorizado, \u00a0abierto,\u00a0programado \u00a0para\u00a096\u00a0semanas, \u00a0en\u00a0el\u00a0que\u00a0se\u00a0\nha\u00a0realizado\u00a0el\u00a0HLA\u00a0B*5701\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0pacientes \u00a0HLA\u00a0B*5701\u00a0negativos \u00a0\ncon\u00a0CVP<50\u00a0copias/mL, \u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0a\u00a0sustituir\u00a0la\u00a0base\u00a0de\u00a0an\u00e1logos\u00a0por\u00a0los\u00a0\ncombos\u00a0ABC/3TC\u00a0o\u00a0TDF/FTC.\u00a0El\u00a0objetivo\u00a0primario\u00a0es\u00a0el\u00a0fallo\u00a0virol\u00f3gico \u00a0(dos\u00a0\ndeterminaciones \u00a0consecutivas \u00a0<400\u00a0copias/mL \u00a0en\u00a0ITT).\u00a0Los\u00a0objetivos\u00a0secundarios \u00a0\ninclu\u00edan\u00a0SIDA,\u00a0muerte,\u00a0efectos\u00a0adversos, \u00a0eventos\u00a0serios\u00a0no\u00a0SIDA,\u00a0alteraciones \u00a0\nmetab\u00f3licas \u00a0y\u00a0composici\u00f3n \u00a0corporal.\u00a0En\u00a0este\u00a0caso\u00a0se\u00a0incluye\u00a0a\u00a0357\u00a0pacientes, \u00a0el\u00a0fallo\u00a0\nvirol\u00f3gico \u00a0es\u00a0poco\u00a0frecuente \u00a0(5,6%\u00a0en\u00a0pacientes \u00a0con\u00a0ABC/3TC\u00a0y\u00a03,9%\u00a0con\u00a0TDF/FTC;\u00a0\np=ns).\u00a0La\u00a0combinaci\u00f3n \u00a0con\u00a0ABC/3TC\u00a0se\u00a0asoci\u00f3\u00a0con\u00a0eventos\u00a0no\u00a0SIDA\u00a0m\u00e1s\u00a0serios,\u00a0sobre\u00a0\ntodo\u00a0cardiovasculares462.\u00a0\u00a0\nEn\u00a0otro\u00a0ensayo\u00a0cl\u00ednico\u00a0prospectivo, \u00a0aleatorizado, \u00a0controlado, \u00a0abierto,\u00a0multic\u00e9ntrico, \u00a0se\u00a0\nincluye\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0CVP\u00a0indetectable \u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0a\u00a0seguir\u00a0\ncon\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0tomar\u00a0TDF/FTC/EFV \u00a0coformulados \u00a0con\u00a0un\u00a0seguimiento \u00a0a\u00a0\n48\u00a0semanas463,\u00a0demostrando \u00a0la\u00a0misma\u00a0eficacia\u00a0en\u00a0las\u00a0dos\u00a0ramas.\u00a0Se\u00a0incluy\u00f3\u00a0a\u00a0300\u00a0\npacientes \u00a0que\u00a0presentaban \u00a0CVP\u00a0<200\u00a0copias/mL \u00a0durante\u00a0>3\u00a0meses\u00a0y\u00a0sin\u00a0ning\u00fan\u00a0cambio\u00a0\nde\u00a0tratamiento. \u00a0Se\u00a0estatificaron \u00a0seg\u00fan\u00a0estuvieran \u00a0tomando\u00a0NN\u00a0o\u00a0IP\u00a0y\u00a0aleatorizaron \u00a02:1\u00a0\na\u00a0simplificar \u00a0el\u00a0tratamiento \u00a0(tomar\u00a0la\u00a0tableta\u00a0\u00fanica)\u00a0o\u00a0seguir\u00a0con\u00a0su\u00a0mismo\u00a0tratamiento. \u00a0\nSe\u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0la\u00a0seguridad \u00a0en\u00a0el\u00a0momento \u00a0basal\u00a0y\u00a0a\u00a0las\u00a0semanas\u00a04,\u00a012,\u00a024,\u00a036\u00a0y\u00a0\n48.\u00a0Adem\u00e1s\u00a0a\u00a0los\u00a0pacientes \u00a0se\u00a0les\u00a0realiz\u00f3\u00a0una\u00a0valoraci\u00f3n \u00a0de\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0as\u00ed\u00a0como\u00a0\nde\u00a0sus\u00a0preferencias \u00a0en\u00a0cuanto\u00a0a\u00a0los\u00a0f\u00e1rmacos. \u00a0De\u00a0los\u00a0300\u00a0pacientes \u00a0incluidos, \u00a097\u00a0\ncontinuaron \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento. \u00a0A\u00a0las\u00a048\u00a0semanas, \u00a0el\u00a089%\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0\nTDF/FTC/EFV \u00a0frente\u00a0a\u00a088%\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0presentaban \u00a0CVP\u00a0<200\u00a0copias/mL \u00a0\n(TLOVR;\u00a0IC\u00a095%)\u00a0con\u00a0una\u00a0diferencia \u00a0entre\u00a0ramas\u00a0de\u00a01,1%\u00a0(\u20106,7%\u00a0a\u00a08,8%),\u00a0indicando \u00a0no\u00a0\ninferioridad \u00a0de\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC/EFV. \u00a0El\u00a087%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0cambiaron \u00a0a\u00a0\nTDF/FTC/EFV \u00a0frente\u00a0a\u00a085%\u00a0de\u00a0los\u00a0que\u00a0no\u00a0cambiaron \u00a0el\u00a0tratamiento \u00a0presentaban \u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0analizados \u00a0de\u00a0la\u00a0misma\u00a0manera:\u00a0diferencia \u00a0entre\u00a0las\u00a0dos\u00a0ramas\u00a0de\u00a02,6%\u00a0\n(IC\u00a095%,\u00a0\u20105,9%\u00a0a\u00a011,1%).\u00a0Las\u00a0tasas\u00a0de\u00a0discontinuaci\u00f3n \u00a0fueron\u00a0similares, \u00a0aunque\u00a0la\u00a0\nsuspensi\u00f3n \u00a0por\u00a0efectos\u00a0adversos\u00a0fue\u00a0superior\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC/EFV \u00a0(5%\u00a0frente\u00a0a\u00a0\n1%),\u00a0sobre\u00a0todo\u00a0por\u00a0sintomatolog\u00eda \u00a0relacionada \u00a0con\u00a0el\u00a0SNC.\u00a0No\u00a0se\u00a0objetivaron \u00a0\ndiferencias \u00a0en\u00a0cuanto\u00a0a\u00a0tasa\u00a0de\u00a0filtrado\u00a0glomerular, \u00a0ni\u00a0en\u00a0la\u00a0adherencia. \u00a0S\u00ed\u00a0se\u00a0observ\u00f3\u00a0\nuna\u00a0mejor\u00eda\u00a0en\u00a0la\u00a0cifra\u00a0de\u00a0triglic\u00e9ridos \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC/EFV \u00a0(\u201020\u00a0frente\u00a0a\u00a0\u20103\u00a0\nmg/dl;\u00a0p=\u00a00,035).\u00a0En\u00a0cuanto\u00a0a\u00a0los\u00a0datos\u00a0de\u00a0calidad\u00a0de\u00a0vida464,\u00a0los\u00a0pacientes \u00a0que\u00a0\nsimplificaron \u00a0refer\u00edan\u00a0mejor\u00eda\u00a0en\u00a0muchos\u00a0de\u00a0los\u00a0s\u00edntomas\u00a0relacionados \u00a0con\u00a0el\u00a0VIH,\u00a0\nencontraban \u00a0el\u00a0nuevo\u00a0tratamiento \u00a0m\u00e1s\u00a0f\u00e1cil\u00a0de\u00a0tomar\u00a0y\u00a0seguir\u00a0\u00a0y\u00a0lo\u00a0prefer\u00edan \u00a0frente\u00a0a\u00a0\nlos\u00a0tratamientos \u00a0previos.\u00a0El\u00a0estudio\u00a0ADONE\u00a0confirma\u00a0estos\u00a0resultados465.\u00a0\nDesde\u00a0la\u00a0publicaci\u00f3n \u00a0del\u00a0estudio\u00a0NODY466\u00a0disponemos \u00a0de\u00a0una\u00a0nueva\u00a0opci\u00f3n\u00a0para\u00a0\nsimplificar \u00a0a\u00a0una\u00a0terapia\u00a0QD,\u00a0ya\u00a0que\u00a0ha\u00a0demostrado \u00a0la\u00a0eficacia\u00a0y\u00a0la\u00a0seguridad \u00a0de\u00a0la\u00a0\nsimplificaci\u00f3n \u00a0de\u00a0NVP\u00a0administrada \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda\u00a0a\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 69estudio\u00a0con\u00a0una\u00a0duraci\u00f3n\u00a0de\u00a048\u00a0semanas, \u00a0abierto,\u00a0aleatorizado, \u00a0multic\u00e9ntrico \u00a0en\u00a0el\u00a0que\u00a0\nse\u00a0incluyeron \u00a0298\u00a0pacientes \u00a0estables\u00a0que\u00a0estaban\u00a0tomando\u00a0nevirapina \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda\u00a0\ndurante\u00a0al\u00a0menos\u00a012\u201018\u00a0semanas\u00a0y\u00a0presentaban \u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0Estos\u00a0pacientes \u00a0se\u00a0\naleatorizaron \u00a0a\u00a0continuar \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0a\u00a0tomar\u00a0nevirapina \u00a0QD.\u00a0El\u00a0\nobjetivo\u00a0primario\u00a0del\u00a0estudio\u00a0era\u00a0valorar\u00a0la\u00a0seguridad \u00a0hep\u00e1tica\u00a0del\u00a0tratamiento \u00a0QD,\u00a0\nanalizando \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0ALT/AST\u00a0grado\u00a03\u20104;\u00a0y\u00a0los\u00a0objetivos\u00a0\nsecundarios \u00a0eran\u00a0el\u00a0desarrollo \u00a0de\u00a0hepatitis\u00a0cl\u00ednica\u00a0y\u00a0la\u00a0eficacia\u00a0inmuno\u2010virol\u00f3gica \u00a0y\u00a0\ncl\u00ednica.\u00a0El\u00a0estudio\u00a0demostr\u00f3 \u00a0no\u00a0inferioridad \u00a0\u00a0por\u00a0protocolo \u00a0frente\u00a0a\u00a0mantener \u00a0la\u00a0pauta\u00a0\ninicial,\u00a0habi\u00e9ndose \u00a0predefinido \u00a0la\u00a0no\u00a0inferioridad \u00a0como\u00a0un\u00a0margen\u00a0del\u00a010%\u00a0para\u00a0\nhepatotoxicidad \u00a0que\u00a0era\u00a0el\u00a0objetivo\u00a0primario.\u00a0\nUna\u00a0de\u00a0las\u00a0grandes\u00a0cuestiones \u00a0por\u00a0resolver\u00a0es\u00a0si\u00a0el\u00a0impacto\u00a0de\u00a0no\u00a0tomar\u00a0una\u00a0dosis\u00a0de\u00a0\nmedicaci\u00f3n \u00a0por\u00a0olvido\u00a0o\u00a0incumplimiento \u00a0puede\u00a0ser\u00a0mayor\u00a0en\u00a0un\u00a0r\u00e9gimen\u00a0QD\u00a0que\u00a0en\u00a0un\u00a0\nr\u00e9gimen\u00a0de\u00a0varias\u00a0dosis\u00a0diarias\u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0\nresistencia467.\u00a0En\u00a0la\u00a0actualidad \u00a0disponemos \u00a0de\u00a0m\u00faltiples \u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0pueden\u00a0\nadministrar \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda,\u00a0con\u00a0una\u00a0vida\u00a0media\u00a0suficientemente \u00a0larga\u00a0como\u00a0para\u00a0evitar\u00a0\neste\u00a0problema. \u00a0\n\u00a0\nOtros\u00a0tipos\u00a0de\u00a0simplificaci\u00f3n \u00a0\nCon\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0nuevos\u00a0f\u00e1rmacos \u00a0de\u00a0nuevas\u00a0familias,\u00a0se\u00a0ha\u00a0podido\u00a0simplificar \u00a0el\u00a0\ntratamiento \u00a0administrado \u00a0a\u00a0pacientes \u00a0multitratados. \u00a0Esta\u00a0simplificaci\u00f3n \u00a0no\u00a0radica\u00a0en\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0comprimidos \u00a0sino\u00a0en\u00a0la\u00a0forma\u00a0de\u00a0administraci\u00f3n \u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0As\u00ed\u00a0se\u00a0\nhan\u00a0presentado \u00a0ya\u00a0estudios\u00a0en\u00a0los\u00a0que\u00a0se\u00a0sustituye\u00a0el\u00a0ENF\u00a0por\u00a0RAL,\u00a0manteni\u00e9ndose \u00a0la\u00a0\neficacia\u00a0del\u00a0tratamiento468\u2010473.\u00a0Aunque\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0trabajos\u00a0son\u00a0observacionales, \u00a0ya\u00a0\nse\u00a0ha\u00a0realizado\u00a0un\u00a0ensayo\u00a0cl\u00ednico470\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluy\u00f3\u00a0a\u00a0170\u00a0pacientes \u00a0con\u00a0VIH\u00a0\nresistente \u00a0a\u00a0los\u00a0tres\u00a0grupos\u00a0de\u00a0f\u00e1rmacos \u00a0y\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0durante\u00a0al\u00a0menos\u00a03\u00a0\nmeses\u00a0en\u00a0tratamiento \u00a0con\u00a0ENF.\u00a0Se\u00a0les\u00a0aleatoriz\u00f3 \u00a01:1\u00a0a\u00a0seguir\u00a0con\u00a0ENF\u00a0o\u00a0cambiar\u00a0a\u00a0RAL.\u00a0\nEl\u00a0objetivo\u00a0primario\u00a0era\u00a0la\u00a0proporci\u00f3n \u00a0acumulada \u00a0de\u00a0pacientes \u00a0con\u00a0fallo\u00a0virol\u00f3gico \u00a0\ndefinido\u00a0como\u00a0CVP\u00a0\u2265400\u00a0copias/mL \u00a0hasta\u00a0la\u00a0semana\u00a024.\u00a0Se\u00a0observ\u00f3\u00a0fallo\u00a0virol\u00f3gico \u00a0en\u00a0\nun\u00a0paciente\u00a0por\u00a0rama.\u00a0La\u00a0conclusi\u00f3n \u00a0de\u00a0los\u00a0autores\u00a0es\u00a0que\u00a0el\u00a0cambio\u00a0a\u00a0raltegravir \u00a0es\u00a0\neficaz\u00a0y\u00a0bien\u00a0tolerado\u00a0a\u00a0las\u00a024\u00a0semanas\u00a0del\u00a0mismo,\u00a0que\u00a0ofrece\u00a0la\u00a0ventaja\u00a0de\u00a0la\u00a0\nsimplicidad, \u00a0un\u00a0mismo\u00a0perfil\u00a0de\u00a0seguridad \u00a0y\u00a0que\u00a0se\u00a0necesita\u00a0un\u00a0seguimiento \u00a0m\u00e1s\u00a0a\u00a0\nlargo\u00a0plazo.\u00a0No\u00a0se\u00a0podr\u00eda\u00a0utilizar\u00a0MVC\u00a0en\u00a0el\u00a0contexto\u00a0de\u00a0la\u00a0simplificaci\u00f3n, \u00a0en\u00a0estudios\u00a0\nsimilares\u00a0a\u00a0los\u00a0ya\u00a0realizados \u00a0ya\u00a0que\u00a0en\u00a0estas\u00a0circunstancias \u00a0no\u00a0se\u00a0puede\u00a0realizar\u00a0el\u00a0test\u00a0\nde\u00a0tropismo. \u00a0\nTambi\u00e9n\u00a0se\u00a0ha\u00a0explorado \u00a0con\u00a0\u00e9xito\u00a0la\u00a0sustituci\u00f3n \u00a0de\u00a0enfuvirtida \u00a0por\u00a0otros\u00a0f\u00e1rmacos \u00a0\ncomo\u00a0la\u00a0ETR474.\u00a0\u00a0\nPero\u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0veces\u00a0no\u00a0es\u00a0tan\u00a0sencilla\u00a0y\u00a0no\u00a0debe\u00a0realizarse \u00a0si\u00a0puede\u00a0\ncomprometer \u00a0la\u00a0eficacia\u00a0del\u00a0tratamiento. \u00a0Como\u00a0ejemplo,\u00a0destacan\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0\npresentados \u00a0recientemente, \u00a0SWITCHMRK \u00a01\u00a0y\u00a02475.\u00a0Se\u00a0trata\u00a0de\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0\nparalelos, \u00a0multic\u00e9ntricos, \u00a0doble\u00a0ciego,\u00a0aleatorizados \u00a0en\u00a0los\u00a0que\u00a0se\u00a0incluy\u00f3\u00a0a\u00a0pacientes \u00a0\nvirol\u00f3gicamente \u00a0controlados, \u00a0en\u00a0tratamiento \u00a0del\u00a0que\u00a0formaba\u00a0parte\u00a0lopinavir/r \u00a0de\u00a0\nforma\u00a0estable,\u00a0no\u00a0se\u00a0excluy\u00f3\u00a0a\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0fracasado \u00a0a\u00a0otros\u00a0reg\u00edmenes \u00a0\nterap\u00e9uticos, \u00a0siempre\u00a0que\u00a0en\u00a0el\u00a0momento \u00a0de\u00a0inclusi\u00f3n\u00a0presentaran \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0\ndurante\u00a0al\u00a0menos\u00a03\u00a0meses.\u00a0Los\u00a0pacientes \u00a0se\u00a0aleatorizaron \u00a01:1\u00a0a\u00a0mantener \u00a0LPV/r\u00a0o\u00a0\ncambiar\u00a0a\u00a0RAL,\u00a0con\u00a0la\u00a0misma\u00a0base\u00a0de\u00a0an\u00e1logos. \u00a0Los\u00a0objetivos\u00a0primarios \u00a0eran:\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 70porcentaje \u00a0de\u00a0cambio\u00a0en\u00a0las\u00a0cifras\u00a0de\u00a0l\u00edpidos\u00a0en\u00a0la\u00a0semana\u00a012,\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0la\u00a0semana\u00a024\u00a0as\u00ed\u00a0como\u00a0eficacia\u00a0y\u00a0seguridad \u00a0a\u00a0las\u00a024\u00a0\nsemanas. \u00a0En\u00a0el\u00a0SWITCHMRK \u00a02,\u00a0se\u00a0aleatorizaron \u00a0355\u00a0pacientes \u00a0y\u00a0se\u00a0trat\u00f3\u00a0a\u00a0354\u00a0(176\u00a0con\u00a0\nRAL\u00a0y\u00a0178\u00a0con\u00a0LPV/r).\u00a0Tras\u00a0el\u00a0cambio,\u00a0el\u00a0RAL\u00a0se\u00a0confirm\u00f3\u00a0como\u00a0bien\u00a0tolerado\u00a0y\u00a0se\u00a0\nprodujo\u00a0una\u00a0mejor\u00eda\u00a0significativa \u00a0de\u00a0los\u00a0par\u00e1metros \u00a0lip\u00eddicos,\u00a0pero\u00a0no\u00a0demostr\u00f3 \u00a0no\u00a0\ninferioridad \u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0virol\u00f3gico \u00a0en\u00a0la\u00a0semana\u00a024:\u00a0154\u00a0de\u00a0175\u00a0pacientes \u00a0\n(88%)\u00a0frente\u00a0a\u00a0167\u00a0de\u00a0178\u00a0(93,8%)\u00a0ten\u00edan\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0los\u00a0grupos\u00a0de\u00a0RAL\u00a0y\u00a0\nLPV/r\u00a0respectivamente; \u00a0la\u00a0diferencia \u00a0observada \u00a0entre\u00a0los\u00a0dos\u00a0tratamientos \u00a0es\u00a0de\u00a0\u20105,8\u00a0%\u00a0\n(IC\u00a095%,\u00a0\u201012,2\u00a0a\u00a00,22;\u00a0ITT).\u00a0Probablemente \u00a0estos\u00a0resultados \u00a0son\u00a0debidos\u00a0a\u00a0los\u00a0criterios\u00a0\nde\u00a0inclusi\u00f3n\u00a0de\u00a0los\u00a0pacientes \u00a0y\u00a0m\u00e1s\u00a0en\u00a0concreto\u00a0a\u00a0permitir\u00a0la\u00a0entrada\u00a0en\u00a0el\u00a0estudio\u00a0de\u00a0\npacientes \u00a0con\u00a0fracaso\u00a0virol\u00f3gico \u00a0previo\u00a0cuando\u00a0se\u00a0plantea\u00a0sustituir\u00a0el\u00a0LPV/R\u00a0por\u00a0RAL\u00a0\nque\u00a0tienen\u00a0distinta\u00a0barrera\u00a0gen\u00e9tica.\u00a0La\u00a0ense\u00f1anza \u00a0de\u00a0este\u00a0estudio\u00a0es\u00a0que\u00a0se\u00a0debe\u00a0\nelegir\u00a0muy\u00a0bien\u00a0a\u00a0los\u00a0pacientes \u00a0cuyo\u00a0tratamiento \u00a0se\u00a0simplifica \u00a0y\u00a0la\u00a0estrategia \u00a0de\u00a0\nsimplificaci\u00f3n \u00a0a\u00a0seguir.\u00a0\u00a0\u00a0\u00a0\nEn\u00a0el\u00a0estudio\u00a0SPIRAL\u00a0los\u00a0resultados \u00a0son\u00a0muy\u00a0distintos476.\u00a0En\u00a0este\u00a0caso\u00a0se\u00a0trata\u00a0de\u00a0un\u00a0\nensayo\u00a0cl\u00ednico\u00a0abierto,\u00a0multic\u00e9ntrico \u00a0a\u00a048\u00a0semanas, \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a0273\u00a0\npacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0un\u00a0r\u00e9gimen\u00a0que\u00a0contiene\u00a0IP/r\u00a0con\u00a0carga\u00a0viral\u00a0<50\u00a0\ncopias/mL \u00a0durante\u00a0al\u00a0menos\u00a06\u00a0meses,\u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a01:1\u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0\ntratamiento \u00a0o\u00a0cambiar\u00a0el\u00a0IP/r\u00a0a\u00a0raltegravir. \u00a0El\u00a0objetivo\u00a0primario\u00a0fue\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0sin\u00a0fallo\u00a0virol\u00f3gico \u00a0a\u00a0las\u00a048\u00a0semanas. \u00a0Es\u00a0un\u00a0estudio\u00a0de\u00a0no\u00a0inferioridad \u00a0con\u00a0un\u00a0\nmargen\u00a0de\u00a0\u201012,5%.\u00a0En\u00a0este\u00a0caso,\u00a0s\u00ed\u00a0que\u00a0se\u00a0cumpli\u00f3\u00a0el\u00a0criterio\u00a0de\u00a0no\u00a0inferioridad: \u00a0a\u00a0las\u00a0\n48\u00a0semanas\u00a0el\u00a089.2%\u00a0de\u00a0pacientes \u00a0con\u00a0raltegravir \u00a0y\u00a0el\u00a086,6%\u00a0de\u00a0pacientes \u00a0con\u00a0IP/r\u00a0no\u00a0\nhab\u00edan\u00a0fracasado \u00a0(diferencia \u00a02,6%;\u00a0IC\u00a095%,\u00a0\u20105,2\u00a0a\u00a010,6).\u00a0Adem\u00e1s\u00a0el\u00a0cambio\u00a0a\u00a0RAL\u00a0\nsupuso\u00a0una\u00a0mejor\u00eda\u00a0significativa \u00a0del\u00a0perfil\u00a0lip\u00eddico.\u00a0La\u00a0diferencia \u00a0entre\u00a0los\u00a0resultados \u00a0de\u00a0\nambos\u00a0estudios\u00a0se\u00a0relaciona\u00a0con\u00a0el\u00a0dise\u00f1o\u00a0y\u00a0sobre\u00a0todo\u00a0con\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0supresi\u00f3n \u00a0\nvirol\u00f3gica \u00a0previa\u00a0al\u00a0cambio\u00a0de\u00a0tratamiento. \u00a0\nTambi\u00e9n\u00a0se\u00a0ha\u00a0explorado \u00a0la\u00a0posibilidad \u00a0de\u00a0utilizar\u00a0el\u00a0RAL\u00a0s\u00f3lo\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0como\u00a0\nsimplificaci\u00f3n. \u00a0Se\u00a0ha\u00a0presentado \u00a0el\u00a0estudio\u00a0ODIS477\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a0222\u00a0pacientes \u00a0\nen\u00a0tratamiento \u00a0con\u00a0IP/r+TDF/FTC \u00a0o\u00a0ABC/3TC\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0al\u00a0menos\u00a024\u00a0\nsemanas, \u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0en\u00a0proporci\u00f3n \u00a01:2\u00a0a\u00a0sustituir\u00a0el\u00a0IP/r\u00a0por\u00a0RAL\u00a0400\u00a0mg\u00a0\nBID\u00a0(n=73)\u00a0o\u00a0RAL\u00a0800\u00a0mg\u00a0QD\u00a0(n=149).\u00a0Adem\u00e1s,\u00a0a\u00a0la\u00a0semana\u00a012,\u00a0si\u00a0no\u00a0exist\u00edan\u00a0\ndiferencias \u00a0entre\u00a0las\u00a0dos\u00a0ramas\u00a0en\u00a0cuanto\u00a0a\u00a0eficacia,\u00a0los\u00a0pacientes \u00a0incluidos\u00a0en\u00a0la\u00a0rama\u00a0\nBID\u00a0pod\u00edan\u00a0ser\u00a0de\u00a0nuevo\u00a0aleatorizados \u00a0a\u00a0seguir\u00a0BID\u00a0(n=35)\u00a0o\u00a0pasar\u00a0a\u00a0QD\u00a0(n=38).\u00a0Los\u00a0\ndatos\u00a0presentados \u00a0corresponden \u00a0a\u00a0las\u00a024\u00a0semanas. \u00a0Las\u00a0conclusiones \u00a0de\u00a0los\u00a0autores\u00a0son\u00a0\nque\u00a0en\u00a0pacientes \u00a0estables\u00a0en\u00a0tratamiento \u00a0con\u00a0IP,\u00a0la\u00a0sustituci\u00f3n \u00a0del\u00a0IP\u00a0por\u00a0raltegravir \u00a0se\u00a0\nasocia\u00a0con\u00a0bajo\u00a0riesgo\u00a0de\u00a0fallo\u00a0virol\u00f3gico \u00a0en\u00a0la\u00a0semana\u00a024\u00a0si\u00a0no\u00a0existe\u00a0historia\u00a0previa\u00a0de\u00a0\nresistencia \u00a0a\u00a0AN.\u00a0La\u00a0eficacia\u00a0y\u00a0la\u00a0seguridad \u00a0de\u00a0las\u00a0dos\u00a0ramas\u00a0son\u00a0similares. \u00a0Existe\u00a0mayor\u00a0\nriesgo\u00a0de\u00a0fallo\u00a0virol\u00f3gico \u00a0en\u00a0la\u00a0rama\u00a0QD\u00a0aunque\u00a0las\u00a0diferencias \u00a0no\u00a0son\u00a0estad\u00edsticamente \u00a0\nsignificativas. \u00a0Estos\u00a0resultados \u00a0ponen\u00a0de\u00a0nuevo\u00a0de\u00a0manifiesto \u00a0la\u00a0importancia \u00a0de\u00a0elegir\u00a0\nadecuadamente \u00a0los\u00a0pacientes \u00a0a\u00a0los\u00a0que\u00a0se\u00a0va\u00a0a\u00a0simplificar. \u00a0Este\u00a0mismo\u00a0an\u00e1lisis\u00a0es\u00a0\ndiscutido\u00a0en\u00a0una\u00a0editorial\u00a0que\u00a0acompa\u00f1a \u00a0la\u00a0publicaci\u00f3n \u00a0del\u00a0estudio\u00a0SWITCHMRK478.\u00a0\u00a0\u00a0\nSin\u00a0embargo, \u00a0el\u00a0estudio\u00a0fase\u00a0III\u00a0que\u00a0comparaba \u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0la\u00a0dosificaci\u00f3n \u00a0\nRAL\u00a0800\u00a0mg\u00a0QD\u00a0frente\u00a0a\u00a0RAL\u00a0400\u00a0mg\u00a0BID\u00a0(ambos\u00a0combinados \u00a0con\u00a0TDF/FTC)\u00a0en\u00a0\npacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0ha\u00a0sido\u00a0interrumpido \u00a0ya\u00a0que\u00a0RAL\u00a0QD\u00a0no\u00a0ha\u00a0podido\u00a0\ndemostrar \u00a0la\u00a0no\u00a0inferioridad \u00a0frente\u00a0a\u00a0la\u00a0dosificaci\u00f3n \u00a0BID\u00a0(identificador \u00a0de\u00a0\nClinicalTrials.gov \u00a0NCT00745823; \u00a0Nota\u00a0de\u00a0prensa\u00a0de\u00a0MERCK).\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 71\u00a0\nRecomendaciones \u00a0sobre\u00a0simplificaci\u00f3n \u00a0del\u00a0TAR\u00a0\n\u0083 Es\u00a0importante \u00a0seleccionar \u00a0muy\u00a0bien\u00a0los\u00a0pacientes \u00a0a\u00a0los\u00a0que\u00a0se\u00a0debe\u00a0simplificar \u00a0y\u00a0la\u00a0\nestrategia \u00a0a\u00a0seguir.\u00a0La\u00a0simplificaci\u00f3n \u00a0no\u00a0se\u00a0puede\u00a0realizar\u00a0a\u00a0costa\u00a0de\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0\neficacia\u00a0virol\u00f3gica. \u00a0S\u00f3lo\u00a0se\u00a0puede\u00a0plantear\u00a0una\u00a0simplificaci\u00f3n \u00a0si\u00a0no\u00a0ha\u00a0existido\u00a0\nfracaso\u00a0previo\u00a0o\u00a0si\u00a0se\u00a0utilizan\u00a0f\u00e1rmacos\u00a0plenamente \u00a0activos\u00a0para\u00a0mantener \u00a0el\u00a0\u00e9xito\u00a0\nvirol\u00f3gico479\u00a0(nivel\u00a0A)\u00a0\n\u0083 En\u00a0pacientes, \u00a0sin\u00a0historia\u00a0de\u00a0fracaso\u00a0previo\u00a0a\u00a0IP,\u00a0con\u00a0CVP\u00a0indetectable \u00a0al\u00a0menos\u00a06\u00a0\nmeses\u00a0y\u00a0signos\u00a0o\u00a0s\u00edntomas\u00a0de\u00a0toxicidad\u00a0por\u00a0los\u00a0AN\u00a0es\u00a0posible\u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0\nLPV/r\u00a0\u00a0(BID)\u00a0o\u00a0DRV/r\u00a0en\u00a0monoterapia402,\u00a0480\u2010482\u00a0(nivel\u00a0A)\u00a0\n\u0083 Si\u00a0no\u00a0ha\u00a0existido\u00a0fracaso\u00a0previo\u00a0a\u00a0AN\u00a0se\u00a0puede\u00a0sustituir\u00a0el\u00a0IP\u00a0por\u00a0EFV,\u00a0NVP\u00a0o\u00a0ABC.\u00a0\nNo\u00a0se\u00a0recomienda \u00a0simplificar \u00a0de\u00a0un\u00a0IP\u00a0a\u00a0ABC\u00a0si\u00a0el\u00a0paciente\u00a0ha\u00a0recibido\u00a0tratamientos \u00a0\nsub\u00f3ptimos \u00a0previos\u00a0con\u00a0AN\u00a0(Nivel\u00a0A)443\u00a0\n\u0083 Est\u00e1\u00a0contraindicada \u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0ABC\u00a0asociado\u00a0a\u00a0TDF\u00a0y\u00a03TC\u00a0o\u00a0a\u00a0TDF\u00a0y\u00a0ddI441,\u00a0\n455,\u00a0456,\u00a0483\u00a0(nivel\u00a0B)\u00a0\n\u0083 En\u00a0pacientes \u00a0con\u00a0riesgo\u00a0cardiovascular \u00a0elevado\u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0ATV\u00a0o\u00a0ATV/r,\u00a0NVP\u00a0\no\u00a0RAL\u00a0puede\u00a0a\u00f1adir\u00a0ventajas\u00a0metab\u00f3licas453,\u00a0455,\u00a0468,\u00a0484\u00a0(nivel\u00a0A)\u00a0\n\u0083 En\u00a0pacientes \u00a0en\u00a0su\u00a0primera\u00a0pauta\u00a0terap\u00e9utica \u00a0con\u00a0IP\u00a0y\u00a0con\u00a0CVP\u00a0indetectable \u00a0se\u00a0\npuede\u00a0simplificar \u00a0a\u00a0una\u00a0pauta\u00a0QD\u00a0como\u00a0EFV\u00a0+TDF+3TC \u00a0(o\u00a0FTC),\u00a0EFV+ddI+3TC \u00a0(o\u00a0\nFTC),\u00a0o\u00a0ATV/r\u00a0(o\u00a0ATV)+TDF+FTC449,\u00a0463\u00a0(nivel\u00a0A)\u00a0\n\u0083 La\u00a0sustituci\u00f3n \u00a0de\u00a0ENF\u00a0por\u00a0RAL\u00a0en\u00a0pacientes \u00a0suprimidos \u00a0virol\u00f3gicamente \u00a0se\u00a0ha\u00a0\ndemostrado \u00a0como\u00a0eficaz\u00a0y\u00a0segura472\u00a0(nivel\u00a0A)\u00a0\n\u0083 Otras\u00a0posibles\u00a0simplificaciones \u00a0deben\u00a0ser\u00a0realizadas \u00a0en\u00a0el\u00a0seno\u00a0de\u00a0ensayos\u00a0cl\u00ednicos,\u00a0\nno\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0(nivel\u00a0C)\u00a0\n\u00a0\n\u00a0\n6.\u00a0ADHERENCIA \u00a0\nSe\u00a0entiende\u00a0por\u00a0adherencia \u00a0al\u00a0TAR\u00a0la\u00a0capacidad \u00a0del\u00a0paciente\u00a0para\u00a0implicarse \u00a0\ncorrectamente \u00a0en\u00a0la\u00a0elecci\u00f3n,\u00a0inicio\u00a0y\u00a0cumplimiento \u00a0del\u00a0mismo\u00a0a\u00a0fin\u00a0de\u00a0conseguir \u00a0una\u00a0\nadecuada \u00a0supresi\u00f3n \u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral.\u00a0\u00a0\nEl\u00a0control\u00a0virol\u00f3gico \u00a0depende\u00a0de\u00a0m\u00faltiples \u00a0factores\u00a0pero\u00a0la\u00a0adherencia \u00a0incorrecta \u00a0es\u00a0la\u00a0\nprimera\u00a0causa\u00a0de\u00a0fracaso\u00a0terap\u00e9utico, \u00a0relacion\u00e1ndose \u00a0con\u00a0mala\u00a0respuesta \u00a0virol\u00f3gica485\u00a0\npeor\u00a0reconstituci\u00f3n \u00a0inmune486,\u00a0y\u00a0mayor\u00a0riesgo\u00a0de\u00a0mortalidad487,\u00a0488.\u00a0Por\u00a0tanto,\u00a0es\u00a0muy\u00a0\nimportante \u00a0que\u00a0los\u00a0pacientes \u00a0sean\u00a0conscientes \u00a0de\u00a0su\u00a0enfermedad, \u00a0entiendan \u00a0\nclaramente \u00a0el\u00a0objetivo\u00a0del\u00a0TAR,\u00a0participen \u00a0en\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0iniciarlo,\u00a0se\u00a0sientan\u00a0\ncapaces\u00a0de\u00a0cumplir\u00a0dicho\u00a0tratamiento \u00a0y\u00a0comprendan \u00a0la\u00a0enorme\u00a0importancia \u00a0que\u00a0tiene\u00a0\nuna\u00a0toma\u00a0continuada \u00a0y\u00a0correcta\u00a0de\u00a0la\u00a0medicaci\u00f3n. \u00a0\u00a0\nDurante\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0se\u00a0ha\u00a0intentado \u00a0conocer\u00a0los\u00a0factores\u00a0asociados \u00a0a\u00a0mala\u00a0\nadherencia. \u00a0Las\u00a0diferencias \u00a0entre\u00a0los\u00a0estudios,\u00a0muchos\u00a0de\u00a0ellos\u00a0carentes\u00a0del\u00a0adecuado \u00a0\nrigor\u00a0metodol\u00f3gico, \u00a0hacen\u00a0dif\u00edcil\u00a0realizar\u00a0generalizaciones \u00a0con\u00a0alto\u00a0grado\u00a0de\u00a0\nevidencia489.\u00a0Se\u00a0han\u00a0identificado \u00a0varios\u00a0factores\u00a0asociados \u00a0con\u00a0mala\u00a0adherencia, \u00a0entre\u00a0\nlos\u00a0que\u00a0destacan\u00a0la\u00a0mala\u00a0relaci\u00f3n\u00a0m\u00e9dico\u2010paciente, \u00a0consumo\u00a0activo\u00a0de\u00a0drogas,\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 72enfermedad \u00a0mental,\u00a0edad\u00a0m\u00e1s\u00a0joven,\u00a0nivel\u00a0educativo \u00a0del\u00a0paciente, \u00a0idioma,\u00a0falta\u00a0de\u00a0\napoyo\u00a0social,\u00a0complejidad \u00a0del\u00a0tratamiento, \u00a0efectos\u00a0secundarios \u00a0y,\u00a0m\u00e1s\u00a0recientemente, \u00a0\ntemor\u00a0acerca\u00a0de\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0alteraciones \u00a0metab\u00f3licas \u00a0y\u00a0morfol\u00f3gicas8,\u00a0490,\u00a0491.\u00a0Un\u00a0\ntema\u00a0controvertido \u00a0es\u00a0la\u00a0relaci\u00f3n\u00a0de\u00a0la\u00a0adherencia \u00a0con\u00a0la\u00a0edad;\u00a0su\u00a0importancia \u00a0va\u00a0ser\u00a0\ncreciente \u00a0dado\u00a0el\u00a0envejecimiento \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0infectada \u00a0por\u00a0el\u00a0VIH;\u00a0se\u00a0ha\u00a0\nencontrado \u00a0peor\u00a0cumplimiento \u00a0en\u00a0pacientes \u00a0muy\u00a0j\u00f3venes\u00a0y\u00a0mejor\u00a0cumplimiento \u00a0en\u00a0\npacientes \u00a0mayores\u00a0de\u00a065\u00a0a\u00f1os204.\u00a0El\u00a0uso\u00a0concomitante \u00a0de\u00a0otros\u00a0f\u00e1rmacos, \u00a0la\u00a0mayor\u00a0\nprevalencia \u00a0de\u00a0efectos\u00a0adversos, \u00a0de\u00a0interacciones, \u00a0la\u00a0depresi\u00f3n \u00a0y\u00a0las\u00a0alteraciones \u00a0de\u00a0\nmemoria\u00a0podr\u00edan\u00a0causar\u00a0menor\u00a0adherencia \u00a0en\u00a0los\u00a0mayores492.\u00a0Lo\u00a0que\u00a0parece\u00a0claro\u00a0es\u00a0\nque\u00a0los\u00a0trastornos \u00a0neurocognitivos, \u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0de\u00a0m\u00e1s\u00a0edad,\u00a0\nsuponen\u00a0un\u00a0factor\u00a0negativo\u00a0para\u00a0la\u00a0adherencia493\u00a0y\u00a0que\u00a0este\u00a0aspecto\u00a0deber\u00e1\u00a0ser\u00a0\nestudiado \u00a0y\u00a0atendido\u00a0en\u00a0los\u00a0pr\u00f3ximos \u00a0a\u00f1os . Por\u00a0el\u00a0contrario, \u00a0el\u00a0apoyo\u00a0emocional \u00a0y\u00a0vital,\u00a0\nla\u00a0capacidad \u00a0para\u00a0incluir\u00a0la\u00a0medicaci\u00f3n \u00a0en\u00a0las\u00a0actividades \u00a0de\u00a0la\u00a0vida\u00a0diaria\u00a0sin\u00a0ocultarla\u00a0\ny\u00a0la\u00a0comprensi\u00f3n \u00a0de\u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0adherencia \u00a0y\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0son\u00a0\nfactores\u00a0que\u00a0predicen\u00a0una\u00a0adherencia \u00a0correcta.\u00a0Corregir\u00a0los\u00a0primeros\u00a0e\u00a0incrementar \u00a0los\u00a0\nsegundos \u00a0forma\u00a0parte\u00a0de\u00a0la\u00a0optimizaci\u00f3n \u00a0del\u00a0TAR\u00a0y\u00a0debe\u00a0incorporarse \u00a0a\u00a0la\u00a0rutina\u00a0de\u00a0\nseguimientos \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0(Tabla\u00a010).\u00a0\nEl\u00a0inicio\u00a0del\u00a0TAR\u00a0no\u00a0es\u00a0urgente\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica.\u00a0Antes\u00a0de\u00a0iniciar\u00a0\nla\u00a0terapia\u00a0conviene\u00a0preparar\u00a0al\u00a0paciente, \u00a0identificar \u00a0las\u00a0situaciones \u00a0que\u00a0puedan\u00a0\ndificultar\u00a0la\u00a0adherencia \u00a0correcta\u00a0e\u00a0intentar\u00a0corregirlas494.\u00a0Es\u00a0importante \u00a0conocer\u00a0los\u00a0\nfactores\u00a0dependientes \u00a0del\u00a0paciente\u00a0(laborales, \u00a0restricciones \u00a0diet\u00e9ticas, \u00a0etc.)\u00a0para\u00a0\ndise\u00f1ar\u00a0un\u00a0TAR\u00a0a\u00a0la\u00a0medida.\u00a0Cuando\u00a0se\u00a0inicie\u00a0el\u00a0TAR\u00a0es\u00a0imprescindible \u00a0que\u00a0se\u00a0ofrezca\u00a0\nuna\u00a0informaci\u00f3n \u00a0detallada, \u00a0soporte\u00a0y\u00a0accesibilidad \u00a0en\u00a0los\u00a0aspectos\u00a0relacionados \u00a0con\u00a0el\u00a0\ntratamiento. \u00a0En\u00a0este\u00a0sentido\u00a0el\u00a0uso\u00a0de\u00a0un\u00a0tel\u00e9fono\u00a0directo\u00a0puede\u00a0facilitar\u00a0el\u00a0contacto\u00a0\nentre\u00a0el\u00a0paciente\u00a0y\u00a0los\u00a0profesionales. \u00a0\u00a0\nDurante\u00a0el\u00a0TAR\u00a0es\u00a0fundamental \u00a0evaluar\u00a0peri\u00f3dicamente \u00a0la\u00a0adherencia, \u00a0que\u00a0debe\u00a0\ntenerse\u00a0en\u00a0cuenta\u00a0en\u00a0las\u00a0decisiones \u00a0terap\u00e9uticas. \u00a0Dado\u00a0que\u00a0no\u00a0existe\u00a0un\u00a0m\u00e9todo\u00a0fiable\u00a0\nde\u00a0evaluaci\u00f3n, \u00a0se\u00a0recomienda \u00a0utilizar\u00a0varias\u00a0t\u00e9cnicas\u00a0como\u00a0la\u00a0entrevista, \u00a0pasar\u00a0un\u00a0\ncuestionario \u00a0estructurado \u00a0(existen\u00a0cuestionarios \u00a0disponibles \u00a0validados \u00a0en\u00a0Espa\u00f1a495,\u00a0\n496)\u00a0recuento\u00a0de\u00a0medicaci\u00f3n \u00a0sobrante\u00a0y\u00a0registro\u00a0de\u00a0recogida\u00a0de\u00a0la\u00a0medicaci\u00f3n \u00a0en\u00a0la\u00a0\nfarmacia\u00a0as\u00ed\u00a0como\u00a0la\u00a0evoluci\u00f3n \u00a0cl\u00ednica\u00a0y\u00a0virol\u00f3gica. \u00a0Para\u00a0ello\u00a0es\u00a0indispensable \u00a0que\u00a0exista\u00a0\nuna\u00a0buena\u00a0coordinaci\u00f3n \u00a0entre\u00a0todos\u00a0los\u00a0estamentos \u00a0implicados \u00a0y\u00a0en\u00a0particular \u00a0entre\u00a0\ncl\u00ednicos\u00a0y\u00a0farmac\u00e9uticos. \u00a0\u00a0\nLa\u00a0entrevista \u00a0y\u00a0los\u00a0cuestionarios \u00a0estructurados, \u00a0son\u00a0de\u00a0f\u00e1cil\u00a0acceso\u00a0en\u00a0cualquier \u00a0\u00e1mbito\u00a0\nasistencial, \u00a0sin\u00a0embargo, \u00a0no\u00a0son\u00a0muy\u00a0precisos,\u00a0y\u00a0en\u00a0determinadas \u00a0circunstancias \u00a0\npueden\u00a0arrojar\u00a0resultados \u00a0no\u00a0v\u00e1lidos.\u00a0Los\u00a0m\u00e9todos\u00a0m\u00e1s\u00a0sofisticados \u00a0y\u00a0caros\u00a0para\u00a0\nevaluar\u00a0la\u00a0adherencia \u00a0como\u00a0determinaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0f\u00e1rmacos497\u00a0o\u00a0\ndispositivos \u00a0electr\u00f3nicos \u00a0que\u00a0registran\u00a0la\u00a0toma\u00a0de\u00a0medicaci\u00f3n \u00a0(MEMS\u00a0o\u00a0Medication \u00a0\nEvent\u00a0Monitoring \u00a0System),\u00a0se\u00a0circunscriben \u00a0al\u00a0campo\u00a0de\u00a0la\u00a0investigaci\u00f3n498.\u00a0Con\u00a0\nninguno\u00a0de\u00a0ellos\u00a0hay\u00a0informaci\u00f3n \u00a0suficiente \u00a0como\u00a0para\u00a0recomendar \u00a0su\u00a0utilizaci\u00f3n \u00a0\nrutinaria\u00a0en\u00a0cl\u00ednica.\u00a0\nLas\u00a0caracter\u00edsticas \u00a0virol\u00f3gicas \u00a0del\u00a0VIH\u00a0determinan \u00a0que\u00a0cuando\u00a0existen\u00a0niveles\u00a0\nsubterap\u00e9uticos \u00a0de\u00a0los\u00a0FAR\u00a0el\u00a0virus\u00a0pueda\u00a0replicarse \u00a0y\u00a0desarrollar \u00a0resistencias. \u00a0Los\u00a0\ndatos\u00a0obtenidos \u00a0durante\u00a0los\u00a0primeros\u00a0tratamientos \u00a0combinados, \u00a0basados\u00a0en\u00a0IP\u00a0sin\u00a0\npotenciar \u00a0constataron \u00a0que\u00a0la\u00a0m\u00e1xima\u00a0eficacia\u00a0requer\u00eda\u00a0una\u00a0adherencia \u00a0pr\u00e1cticamente \u00a0\nperfecta,\u00a0cl\u00e1sicamente \u00a0>95%286.\u00a0Estudios\u00a0recientes\u00a0sugieren\u00a0que\u00a0con\u00a0niveles\u00a0menores\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 73se\u00a0pueden\u00a0alcanzar\u00a0los\u00a0objetivos\u00a0terap\u00e9uticos \u00a0en\u00a0reg\u00edmenes \u00a0basados\u00a0en\u00a0NN\u00a0o\u00a0IP/r,\u00a0\nespecialmente \u00a0en\u00a0pacientes \u00a0que\u00a0consiguen \u00a0viremias\u00a0indetectables499\u2010501.\u00a0Debe\u00a0\ndestacarse \u00a0que\u00a0no\u00a0s\u00f3lo\u00a0es\u00a0importante \u00a0el\u00a0porcentaje \u00a0de\u00a0dosis\u00a0omitidas\u00a0sino\u00a0tambi\u00e9n\u00a0los\u00a0\npatrones\u00a0de\u00a0adhesi\u00f3n\u00a0sub\u00f3ptima. \u00a0Las\u00a0interrupciones \u00a0de\u00a0tratamiento \u00a0(m\u00e1s\u00a0de\u00a0dos\u00a0d\u00edas\u00a0\nsin\u00a0tomar\u00a0ning\u00fan\u00a0f\u00e1rmaco)\u00a0presentan \u00a0mayor\u00a0repercusi\u00f3n \u00a0en\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0que\u00a0\nla\u00a0omisi\u00f3n\u00a0ocasional \u00a0de\u00a0dosis502.\u00a0En\u00a0terapia\u00a0de\u00a0inicio,\u00a0tambi\u00e9n\u00a0se\u00a0ha\u00a0demostrado \u00a0una\u00a0\nrelaci\u00f3n\u00a0lineal\u00a0entre\u00a0nivel\u00a0de\u00a0adherencia \u00a0y\u00a0efectividad: \u00a0en\u00a0tratamientos \u00a0basados\u00a0en\u00a0NN,\u00a0\npor\u00a0cada\u00a010\u00a0%\u00a0de\u00a0incremento \u00a0en\u00a0el\u00a0cumplimiento, \u00a0se\u00a0observ\u00f3\u00a0un\u00a010\u00a0%\u00a0\u00a0m\u00e1s\u00a0de\u00a0\npacientes \u00a0que\u00a0consiguen \u00a0viremias\u00a0indetectables \u00a0sostenidas503.\u00a0Tambi\u00e9n\u00a0pudieron\u00a0\nevidenciarse \u00a0diferencias \u00a0entre\u00a0distintos\u00a0IP/r\u00a0y\u00a0su\u00a0relaci\u00f3n\u00a0entre\u00a0adherencia \u00a0y\u00a0\nefectividad, \u00a0la\u00a0adherencia \u00a0sub\u00f3ptima \u00a0a\u00a0DRV/r\u00a0tuvo\u00a0un\u00a0impacto\u00a0menor\u00a0comparado \u00a0con\u00a0\nLPV/r\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0en\u00a0el\u00a0estudio\u00a0aleatorizado \u00a0ARTEMIS504.\u00a0\nLa\u00a0relaci\u00f3n\u00a0entre\u00a0adherencia \u00a0y\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0es\u00a0m\u00e1s\u00a0compleja\u00a0que\u00a0la\u00a0idea\u00a0\nestablecida \u00a0de\u00a0que\u00a0\u201cla\u00a0no\u00a0adherencia \u00a0aumenta\u00a0el\u00a0riesgo\u00a0de\u00a0resistencias\u201d. \u00a0Se\u00a0han\u00a0\nencontrado \u00a0diferencias \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0las\u00a0familias\u00a0de\u00a0f\u00e1rmacos; \u00a0as\u00ed\u00a0en\u00a0pautas\u00a0basadas\u00a0\nen\u00a0IP\u00a0no\u00a0potenciados \u00a0se\u00a0comprob\u00f3 \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0con\u00a0niveles\u00a0altos\u00a0de\u00a0\ncumplimiento, \u00a0mientras\u00a0que\u00a0en\u00a0pautas\u00a0con\u00a0NN\u00a0las\u00a0resistencias \u00a0son\u00a0inusuales \u00a0en\u00a0los\u00a0\npacientes \u00a0muy\u00a0cumplidores, \u00a0d\u00e1ndose\u00a0en\u00a0los\u00a0poco\u00a0adherentes \u00a0y\u00a0especialmente \u00a0en\u00a0los\u00a0\npacientes \u00a0con\u00a0interrupciones \u00a0prolongadas \u00a0del\u00a0tratamiento505;\u00a0por\u00a0el\u00a0contrario, \u00a0en\u00a0el\u00a0\ncaso\u00a0de\u00a0los\u00a0IP\u00a0potenciados, \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0es\u00a0mucho\u00a0m\u00e1s\u00a0dif\u00edcil\u00a0con\u00a0\ncualquier \u00a0nivel\u00a0de\u00a0adherencia \u00a0debido\u00a0a\u00a0su\u00a0elevada\u00a0barrera\u00a0gen\u00e9tica506,\u00a0507.\u00a0En\u00a0cualquier \u00a0\ncaso,\u00a0ante\u00a0un\u00a0paciente\u00a0con\u00a0alta\u00a0sospecha \u00a0de\u00a0presentar \u00a0dificultades \u00a0para\u00a0el\u00a0\ncumplimiento \u00a0terap\u00e9utico, \u00a0es\u00a0mejor\u00a0evitar\u00a0las\u00a0pautas\u00a0basadas\u00a0en\u00a0NN\u00a0e\u00a0iniciar\u00a0TAR\u00a0con\u00a0\npautas\u00a0basadas\u00a0en\u00a0IP/r,\u00a0que\u00a0evitan\u00a0el\u00a0riesgo\u00a0de\u00a0seleccionar \u00a0resistencias \u00a0relevantes \u00a0en\u00a0\ncaso\u00a0de\u00a0incumplimiento \u00a0y\u00a0fracaso\u00a0virol\u00f3gico. \u00a0\nSi\u00a0se\u00a0detecta\u00a0una\u00a0falta\u00a0de\u00a0adherencia \u00a0debe\u00a0intervenirse \u00a0de\u00a0forma\u00a0activa\u00a0para\u00a0corregirla. \u00a0\nLa\u00a0monitorizaci\u00f3n \u00a0de\u00a0la\u00a0adherencia \u00a0no\u00a0debe\u00a0utilizarse\u00a0para\u00a0explicar\u00a0un\u00a0fracaso\u00a0o\u00a0el\u00a0\ndesarrollo \u00a0de\u00a0resistencias, \u00a0sino\u00a0para\u00a0prevenir\u00a0que\u00a0\u00e9stos\u00a0se\u00a0produzcan \u00a0mediante \u00a0la\u00a0\ndetecci\u00f3n \u00a0precoz\u00a0de\u00a0los\u00a0problemas \u00a0e\u00a0implementar \u00a0r\u00e1pidamente \u00a0medidas\u00a0\ncorrectoras508.\u00a0A\u00a0modo\u00a0de\u00a0ejemplo,\u00a0cuando\u00a0se\u00a0analiz\u00f3\u00a0la\u00a0adherencia \u00a0f\u00e1rmaco\u00a0por\u00a0\nf\u00e1rmaco,\u00a0en\u00a0lugar\u00a0de\u00a0hacerlo\u00a0de\u00a0forma\u00a0global,\u00a0se\u00a0detect\u00f3\u00a0que\u00a0en\u00a0un\u00a030\u00a0%\u00a0de\u00a0los\u00a0\npacientes \u00a0ten\u00eda\u00a0falta\u00a0de\u00a0adherencia \u00a0diferencial, \u00a0es\u00a0decir\u00a0a\u00a0alguno\u00a0de\u00a0los\u00a0componentes \u00a0\ndel\u00a0tratamiento \u00a0y\u00a0esta\u00a0falta\u00a0de\u00a0adherencia \u00a0se\u00a0relacion\u00f3 \u00a0con\u00a0fracaso\u00a0virol\u00f3gico509.\u00a0La\u00a0\ncoformulaci\u00f3n \u00a0de\u00a0f\u00e1rmacos \u00a0simplifica \u00a0el\u00a0TAR\u00a0y\u00a0podr\u00eda\u00a0prevenir\u00a0y\u00a0corregir\u00a0este\u00a0\nproblema, \u00a0mejorando \u00a0la\u00a0adherencia \u00a0global510\u00a0e\u00a0impidiendo \u00a0la\u00a0adherencia \u00a0selectiva\u00a0en\u00a0\npacientes \u00a0que\u00a0reciben\u00a0tratamiento \u00a0triple.\u00a0De\u00a0este\u00a0modo\u00a0se\u00a0reducen\u00a0las\u00a0posibilidades \u00a0de\u00a0\nselecci\u00f3n\u00a0de\u00a0resistencias \u00a0por\u00a0monoterapia \u00a0encubierta. \u00a0\nLas\u00a0estrategias \u00a0son\u00a0m\u00faltiples, \u00a0algunas\u00a0basadas\u00a0en\u00a0teor\u00edas\u00a0psicol\u00f3gicas \u00a0y\u00a0la\u00a0mayor\u00eda\u00a0\ndirigidas\u00a0a\u00a0paliar\u00a0los\u00a0condicionantes \u00a0sociales\u00a0o\u00a0individuales \u00a0de\u00a0los\u00a0pacientes. \u00a0Desde\u00a0esta\u00a0\nperspectiva \u00a0cabe\u00a0analizar\u00a0las\u00a0intervenciones \u00a0sobre\u00a0adherencia \u00a0mediante \u00a0las\u00a0\ndenominadas \u00a0\u201centrevistas \u00a0motivacionales\u201d \u00a0511,\u00a0las\u00a0visitas\u00a0domiciliarias \u00a0y\u00a0la\u00a0intervenci\u00f3n \u00a0\nespec\u00edfica \u00a0sobre\u00a0la\u00a0pareja\u00a0del\u00a0paciente, \u00a0todas\u00a0ellas\u00a0relativamente \u00a0complejas, \u00a0sin\u00a0\nresultados \u00a0definitivos \u00a0y\u00a0sin\u00a0grandes\u00a0diferencias \u00a0frente\u00a0al\u00a0grupo\u00a0control\u00a0asesorado \u00a0\nacorde\u00a0a\u00a0una\u00a0buena\u00a0pr\u00e1ctica\u00a0cl\u00ednica.\u00a0Las\u00a0intervenciones \u00a0dirigidas\u00a0a\u00a0ciertas\u00a0poblaciones \u00a0\nespeciales \u00a0\u2013\u00a0mujeres,\u00a0latinos\u00a0en\u00a0EEUU,\u00a0y\u00a0pacientes \u00a0con\u00a0historia\u00a0previa\u00a0de\u00a0alcoholismo \u00a0\u2013\u00a0\nno\u00a0han\u00a0logrado\u00a0mejorar\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento489.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 74Las\u00a0intervenciones \u00a0sencillas\u00a0de\u00a0educaci\u00f3n \u00a0y\u00a0soporte\u00a0en\u00a0aspectos\u00a0pr\u00e1cticos\u00a0del\u00a0\ntratamiento \u00a0han\u00a0demostrado \u00a0ser\u00a0beneficiosas512.\u00a0Probablemente \u00a0la\u00a0intervenci\u00f3n \u00a0que\u00a0\nha\u00a0demostrado \u00a0mayor\u00a0eficacia\u00a0ha\u00a0sido\u00a0el\u00a0soporte\u00a0interpersonal \u00a0estructurado, \u00a0en\u00a0el\u00a0que\u00a0\npersonal\u00a0sanitario\u00a0entrenado \u00a0emplea\u00a0estrategias \u00a0individualizadas. \u00a0\u00a0\nRespecto\u00a0al\u00a0tratamiento \u00a0directamente \u00a0observado \u00a0(TDO),\u00a0en\u00a0un\u00a0metaan\u00e1lisis \u00a0de\u00a017\u00a0\nestudios\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0incrementa \u00a0la\u00a0probabilidad \u00a0de\u00a0conseguir \u00a0CVP\u00a0\nindetectable \u00a0(HR\u00a01,24;\u00a0IC\u00a095%,\u00a01,08\u00a0a\u00a01,41),\u00a0mayor\u00a0incremento \u00a0de\u00a0CD4,\u00a0y\u00a0adherencia \u00a0\n>95%.\u00a0Este\u00a0beneficio \u00a0es\u00a0incluso\u00a0mayor\u00a0cuando\u00a0se\u00a0aplica\u00a0a\u00a0determinadas \u00a0poblaciones \u00a0\ncon\u00a0grandes\u00a0dificultades \u00a0para\u00a0un\u00a0cumplimiento \u00a0\u00f3ptimo,\u00a0como\u00a0usuarios\u00a0de\u00a0drogas\u00a0o\u00a0en\u00a0\nprisiones, \u00a0pero\u00a0no\u00a0parece\u00a0mantenerse \u00a0a\u00a0largo\u00a0plazo\u00a0tras\u00a0cesar\u00a0la\u00a0intervenci\u00f3n513.\u00a0\u00a0\nLa\u00a0adhesi\u00f3n\u00a0al\u00a0tratamiento \u00a0puede\u00a0decaer\u00a0con\u00a0el\u00a0tiempo\u00a0y\u00a0por\u00a0tanto\u00a0las\u00a0estrategias \u00a0\ndise\u00f1adas \u00a0para\u00a0optimizarla \u00a0deben\u00a0dirigirse\u00a0no\u00a0s\u00f3lo\u00a0a\u00a0incrementarla \u00a0sino\u00a0a\u00a0mantenerla \u00a0\nconstante514.\u00a0\u00a0\nGESIDA\u00a0y\u00a0el\u00a0PNS,\u00a0conjuntamente \u00a0con\u00a0la\u00a0Sociedad\u00a0Espa\u00f1ola\u00a0de\u00a0Farmacia\u00a0Hospitalaria8\u00a0\nhan\u00a0revisado\u00a0los\u00a0factores\u00a0que\u00a0influyen\u00a0en\u00a0la\u00a0adherencia, \u00a0los\u00a0m\u00e9todos\u00a0de\u00a0evaluaci\u00f3n \u00a0y\u00a0\nlas\u00a0posibles\u00a0estrategias \u00a0de\u00a0intervenci\u00f3n \u00a0y\u00a0actuaci\u00f3n \u00a0de\u00a0un\u00a0equipo\u00a0multidisciplinar \u00a0que\u00a0\ndebe\u00a0ser\u00a0integrado \u00a0por\u00a0m\u00e9dicos,\u00a0farmac\u00e9uticos, \u00a0enfermeras, \u00a0psic\u00f3logos \u00a0y\u00a0personal\u00a0de\u00a0\nsoporte.\u00a0Remitimos \u00a0a\u00a0ese\u00a0documento \u00a0para\u00a0profundizar \u00a0en\u00a0el\u00a0tema\u00a0de\u00a0la\u00a0adherencia \u00a0al\u00a0\nTAR.\u00a0\u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0adherencia \u00a0\n\u0083 Antes\u00a0de\u00a0iniciar\u00a0el\u00a0TAR\u00a0se\u00a0debe\u00a0preparar\u00a0al\u00a0paciente, \u00a0identificar \u00a0y\u00a0corregir\u00a0las\u00a0causas\u00a0\nque\u00a0pueden\u00a0limitar\u00a0su\u00a0adherencia. \u00a0Si\u00a0el\u00a0paciente\u00a0no\u00a0est\u00e1\u00a0preparado, \u00a0en\u00a0general\u00a0es\u00a0\nmejor\u00a0retrasar\u00a0el\u00a0inicio\u00a0del\u00a0TAR\u00a0(nivel\u00a0C)\u00a0\n\u0083 Una\u00a0vez\u00a0iniciado\u00a0el\u00a0TAR\u00a0se\u00a0recomienda \u00a0efectuar\u00a0un\u00a0primer\u00a0control\u00a0a\u00a0las\u00a02\u20104\u00a0\nsemanas\u00a0para\u00a0corregir\u00a0los\u00a0factores\u00a0inherentes \u00a0al\u00a0tratamiento \u00a0o\u00a0del\u00a0propio\u00a0paciente\u00a0\nque\u00a0puedan\u00a0limitar\u00a0la\u00a0adherencia \u00a0(nivel\u00a0C)\u00a0\n\u0083 Si\u00a0la\u00a0adherencia \u00a0es\u00a0correcta,\u00a0debe\u00a0monitorizarse \u00a0y\u00a0reforzarse, \u00a0coincidiendo \u00a0con\u00a0las\u00a0\nvisitas\u00a0cl\u00ednicas\u00a0(nivel\u00a0C)\u00a0\n\u0083 El\u00a0control\u00a0de\u00a0la\u00a0adherencia \u00a0debe\u00a0realizarse \u00a0por\u00a0un\u00a0equipo\u00a0multidisciplinar, \u00a0y\u00a0en\u00a0\u00e9l\u00a0\ndeben\u00a0estar\u00a0implicados \u00a0no\u00a0s\u00f3lo\u00a0el\u00a0m\u00e9dico\u00a0sino\u00a0tambi\u00e9n\u00a0la\u00a0enfermer\u00eda, \u00a0los\u00a0\nprofesionales \u00a0de\u00a0apoyo\u00a0psicol\u00f3gico \u00a0y\u00a0la\u00a0farmacia\u00a0hospitalaria \u00a0(nivel\u00a0C)\u00a0\n\u0083 Cada\u00a0unidad\u00a0asistencial \u00a0debiera\u00a0realizar\u00a0un\u00a0seguimiento \u00a0peri\u00f3dico \u00a0de\u00a0la\u00a0adherencia, \u00a0\nno\u00a0s\u00f3lo\u00a0con\u00a0vistas\u00a0a\u00a0detectar\u00a0las\u00a0faltas\u00a0individuales \u00a0de\u00a0cumplimiento \u00a0sino\u00a0para\u00a0\nconocer\u00a0la\u00a0magnitud \u00a0del\u00a0problema \u00a0en\u00a0su\u00a0\u00e1mbito\u00a0de\u00a0trabajo;\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0los\u00a0datos\u00a0\npermitir\u00e1 \u00a0determinar \u00a0las\u00a0causas\u00a0de\u00a0los\u00a0problemas \u00a0detectados \u00a0(abandonos, \u00a0\nvacaciones \u00a0terap\u00e9uticas, \u00a0incumplimientos\u2026) \u00a0y\u00a0elaborar\u00a0estrategias \u00a0concretas \u00a0de\u00a0\nactuaci\u00f3n, \u00a0tanto\u00a0con\u00a0los\u00a0enfermos \u00a0como\u00a0en\u00a0la\u00a0estructura \u00a0y\u00a0funcionamiento \u00a0del\u00a0\nequipo\u00a0asistencial \u00a0(nivel\u00a0C)\u00a0\n\u0083 En\u00a0pacientes \u00a0con\u00a0cumplimiento \u00a0irregular\u00a0es\u00a0preferible \u00a0utilizar\u00a0pautas\u00a0basadas\u00a0en\u00a0\nIP/r\u00a0frente\u00a0a\u00a0las\u00a0que\u00a0se\u00a0basan\u00a0en\u00a0NN\u00a0para\u00a0dificultar\u00a0la\u00a0selecci\u00f3n\u00a0de\u00a0resistencias \u00a0\n(nivel\u00a0C)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 75\u00a0\n\u00a0\n7.\u00a0EFECTOS\u00a0ADVERSOS \u00a0DEL\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\nLos\u00a0FAR\u00a0pueden\u00a0producir\u00a0numerosos \u00a0efectos\u00a0secundarios \u00a0que\u00a0se\u00a0presentan \u00a0al\u00a0inicio\u00a0del\u00a0\ntratamiento \u00a0o\u00a0a\u00a0medio\u2010largo\u00a0plazo.\u00a0En\u00a0este\u00a0\u00faltimo\u00a0caso\u00a0suelen\u00a0asociarse \u00a0a\u00a0procesos\u00a0\nfisiol\u00f3gicos \u00a0o\u00a0comorbilidades \u00a0relacionados \u00a0con\u00a0el\u00a0envejecimiento. \u00a0Algunos\u00a0de\u00a0ellos\u00a0son\u00a0\nespec\u00edficos \u00a0de\u00a0f\u00e1rmacos\u00a0y\u00a0otros\u00a0de\u00a0grupo.\u00a0En\u00a0las\u00a0tablas\u00a011\u201015\u00a0se\u00a0muestra\u00a0la\u00a0toxicidad\u00a0\ncaracter\u00edstica \u00a0de\u00a0cada\u00a0familia\u00a0y\u00a0se\u00a0resume\u00a0la\u00a0toxicidad\u00a0por\u00a0\u00f3rganos\u00a0y\u00a0aparatos, \u00a0la\u00a0\npatogenia, \u00a0la\u00a0relaci\u00f3n\u00a0individual \u00a0con\u00a0cada\u00a0f\u00e1rmaco,\u00a0el\u00a0diagn\u00f3stico \u00a0y\u00a0el\u00a0tratamiento \u00a0de\u00a0\nlos\u00a0mismos.\u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0comentan \u00a0los\u00a0que,\u00a0por\u00a0su\u00a0frecuencia \u00a0y/o\u00a0potencial \u00a0\ngravedad, \u00a0tienen\u00a0mayor\u00a0relevancia \u00a0cl\u00ednica.\u00a0\n\u00a0Toxicidad \u00a0mitocondrial \u00a0\u00a0\nEn\u00a0la\u00a0Tabla\u00a011\u00a0se\u00a0exponen\u00a0los\u00a0posibles\u00a0efectos\u00a0adversos\u00a0debidos\u00a0al\u00a0da\u00f1o\u00a0mitocondrial \u00a0\nproducido \u00a0por\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0enzima\u00a0ADN\u2010polimerasa \u00a0mitocondrial. \u00a0El\u00a0m\u00e1s\u00a0grave\u00a0de\u00a0\nellos,\u00a0una\u00a0combinaci\u00f3n \u00a0de\u00a0acidosis\u00a0l\u00e1ctica\u00a0y\u00a0esteatosis \u00a0hep\u00e1tica\u00a0(ALEH),\u00a0es\u00a0inducido\u00a0por\u00a0\nd4T\u00a0y,\u00a0en\u00a0menor\u00a0medida,\u00a0por\u00a0ZDV\u00a0y\u00a0ddI.\u00a0Su\u00a0incidencia \u00a0es\u00a0baja,\u00a0pero\u00a0si\u00a0no\u00a0se\u00a0diagnostica \u00a0\na\u00a0tiempo\u00a0puede\u00a0ser\u00a0mortal515.\u00a0Las\u00a0manifestaciones \u00a0cl\u00ednicas,\u00a0subagudas \u00a0e\u00a0inespec\u00edficas \u00a0\n(astenia,\u00a0disnea\u00a0e\u00a0insuficiencia \u00a0hep\u00e1tica), \u00a0o\u00a0la\u00a0acidosis\u00a0aparecen \u00a0cuando\u00a0el\u00a0lactato\u00a0es\u00a0\n>5\u201010\u00a0mmol/L.\u00a0Debe\u00a0tenerse\u00a0un\u00a0alto\u00a0grado\u00a0de\u00a0sospecha \u00a0y\u00a0realizar\u00a0el\u00a0diagn\u00f3stico \u00a0antes\u00a0\nde\u00a0que\u00a0aparezca\u00a0acidosis,\u00a0pues\u00a0en\u00a0esta\u00a0fase\u00a0(hiperlactatemia \u00a0asintom\u00e1tica) \u00a0la\u00a0\nmortalidad \u00a0es\u00a0muy\u00a0inferior\u00a0a\u00a0la\u00a0de\u00a0la\u00a0ALEH.\u00a0Su\u00a0tratamiento \u00a0consiste\u00a0en\u00a0retirar\u00a0los\u00a0AN\u00a0\nresponsables \u00a0y\u00a0monitorizar \u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0lactato.\u00a0\u00a0\nLa\u00a0lipoatrofia, \u00a0aunque\u00a0tambi\u00e9n\u00a0es\u00a0secundaria \u00a0a\u00a0toxicidad\u00a0mitocondrial, \u00a0se\u00a0comenta\u00a0en\u00a0\nel\u00a0apartado\u00a0de\u00a0anomal\u00edas \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal516.\u00a0\u00a0\n\u00a0\nReacciones \u00a0de\u00a0hipersensibilidad \u00a0\u00a0\nAunque\u00a0todos\u00a0los\u00a0FAR\u00a0pueden\u00a0provocar\u00a0RHS,\u00a0que\u00a0son\u00a0mucho\u00a0m\u00e1s\u00a0frecuentes \u00a0con\u00a0ABC\u00a0y\u00a0\nlos\u00a0NN\u00a0(la\u00a0RHS\u00a0a\u00a0ABC\u00a0se\u00a0ha\u00a0descrito\u00a0m\u00e1s\u00a0arriba)\u00a0111,\u00a0517.\u00a0\u00a0\nLas\u00a0RHS\u00a0frente\u00a0a\u00a0los\u00a0NN\u00a0suelen\u00a0presentarse \u00a0con\u00a0un\u00a0exantema \u00a0cut\u00e1neo\u00a0y\u00a0rara\u00a0vez\u00a0con\u00a0un\u00a0\ncuadro\u00a0sist\u00e9mico \u00a0grave\u00a0o\u00a0con\u00a0s\u00edndrome \u00a0de\u00a0Stevens\u2010Johnson\u00a0o\u00a0necr\u00f3lisis \u00a0epid\u00e9rmica \u00a0\nt\u00f3xica\u00a0(Tabla\u00a012).\u00a0\u00a0\n\u00a0\nHepatotoxicidad \u00a0\nEs,\u00a0junto\u00a0al\u00a0exantema, \u00a0el\u00a0efecto\u00a0adverso\u00a0espec\u00edfico \u00a0de\u00a0grupo\u00a0m\u00e1s\u00a0importante \u00a0de\u00a0los\u00a0NN,\u00a0\nsi\u00a0bien\u00a0su\u00a0intensidad \u00a0suele\u00a0ser\u00a0leve\u00a0o\u00a0moderada \u00a0y\u00a0son\u00a0raros\u00a0los\u00a0casos\u00a0de\u00a0hepatitis\u00a0\nsintom\u00e1tica. \u00a0NVP\u00a0provoca\u00a0elevaci\u00f3n \u00a0de\u00a0transaminasas \u00a0con\u00a0mayor\u00a0frecuencia \u00a0y\u00a0se\u00a0\ndesaconseja \u00a0su\u00a0uso\u00a0en\u00a0mujeres\u00a0con\u00a0>250\u00a0CD4/\u00b5L\u00a0y\u00a0varones\u00a0con\u00a0>400\u00a0CD4/\u00b5L\u00a0debido\u00a0a\u00a0\nun\u00a0mayor\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0grave433,\u00a0435.\u00a0No\u00a0obstante, \u00a0parece\u00a0ser\u00a0que\u00a0los\u00a0\npacientes \u00a0pre\u2010tratados,\u00a0especialmente \u00a0en\u00a0el\u00a0contexto\u00a0de\u00a0una\u00a0simplificaci\u00f3n \u00a0del\u00a0TAR,\u00a0\ntienen\u00a0un\u00a0riesgo\u00a0similar\u00a0al\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0nunca\u00a0llevaron\u00a0TAR\u00a0con\u00a0\ninmunodepresi\u00f3n \u00a0m\u00e1s\u00a0profunda432,\u00a0518\u00a0lo\u00a0que\u00a0ha\u00a0llevado\u00a0a\u00a0un\u00a0cambio\u00a0en\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 76de\u00a0NVP.\u00a0Los\u00a0IP\u00a0potenciados \u00a0que\u00a0se\u00a0usan\u00a0actualmente \u00a0y\u00a0los\u00a0FAR\u00a0de\u00a0otras\u00a0familias\u00a0tienen\u00a0\nunas\u00a0tasas\u00a0de\u00a0hepatotoxicidad \u00a0m\u00e1s\u00a0reducidas \u00a0que\u00a0los\u00a0NN519\u2010521\u00a0(Tabla\u00a012).\u00a0\n\u00a0Trastornos \u00a0neuropsiqui\u00e1tricos \u00a0\nEFV\u00a0produce\u00a0diversos\u00a0s\u00edntomas\u00a0neuropsiqui\u00e1tricos \u00a0(mareo,\u00a0somnolencia, \u00a0insomnio, \u00a0\nsue\u00f1os\u00a0v\u00edvidos,\u00a0confusi\u00f3n, \u00a0ansiedad, \u00a0despersonalizaci\u00f3n, \u00a0etc.)\u00a0en\u00a0m\u00e1s\u00a0del\u00a050%\u00a0de\u00a0los\u00a0\ncasos,\u00a0los\u00a0cuales,\u00a0aunque\u00a0suelen\u00a0remitir\u00a0en\u00a0las\u00a0primeras\u00a02\u20104\u00a0semanas, \u00a0obligan\u00a0a\u00a0\ninterrumpir \u00a0el\u00a0tratamiento \u00a0en\u00a0un\u00a0peque\u00f1o\u00a0porcentaje \u00a0de\u00a0los\u00a0casos\n522,\u00a0523\u00a0(Tabla\u00a012).\u00a0Se\u00a0\naconseja\u00a0evitar\u00a0este\u00a0f\u00e1rmaco\u00a0en\u00a0pacientes \u00a0con\u00a0trastornos \u00a0psiqui\u00e1tricos \u00a0mayores,\u00a0\naunque\u00a0en\u00a0un\u00a0estudio\u00a0aleatorizado \u00a0el\u00a0riesgo\u00a0de\u00a0depresi\u00f3n \u00a0fue\u00a0similar\u00a0con\u00a0EFV\u00a0que\u00a0con\u00a0\nlos\u00a0IP524.\u00a0Aunque\u00a0otros\u00a0FAR,\u00a0como\u00a0ZDV,\u00a0pueden\u00a0provocar\u00a0s\u00edntomas\u00a0neurol\u00f3gicos, \u00a0\u00e9stos\u00a0\nson\u00a0mucho\u00a0menos\u00a0frecuentes \u00a0y\u00a0predecibles \u00a0que\u00a0los\u00a0de\u00a0EFV.\u00a0\n\u00a0\nNefrotoxicidad \u00a0\nTDF\u00a0puede\u00a0inducir\u00a0toxicidad\u00a0renal\u00a0en\u00a0una\u00a0peque\u00f1a\u00a0proporci\u00f3n \u00a0de\u00a0pacientes. \u00a0Su\u00a0\nincidencia \u00a0en\u00a0estudios\u00a0de\u00a0cohorte525,\u00a0526\u00a0es\u00a0mayor\u00a0que\u00a0la\u00a0observada \u00a0en\u00a0ensayos\u00a0cl\u00ednicos,\u00a0\nen\u00a0los\u00a0que\u00a0solamente \u00a0se\u00a0ha\u00a0encontrado \u00a0una\u00a0reducci\u00f3n \u00a0discreta\u00a0(\u224810%)\u00a0y\u00a0no\u00a0progresiva \u00a0\ndel\u00a0filtrado\u00a0glomerular216,\u00a0527.\u00a0Esta\u00a0complicaci\u00f3n \u00a0consiste\u00a0en\u00a0una\u00a0disfunci\u00f3n \u00a0tubular\u00a0y\u00a0se\u00a0\nmanifiesta \u00a0como\u00a0un\u00a0s\u00edndrome \u00a0de\u00a0Fanconi\u00a0acompa\u00f1ado \u00a0de\u00a0una\u00a0disminuci\u00f3n \u00a0del\u00a0filtrado\u00a0\nglomerular528.\u00a0Es\u00a0m\u00e1s\u00a0frecuente \u00a0cuando\u00a0coincide\u00a0con\u00a0otros\u00a0factores\u00a0de\u00a0riesgo\u00a0\n(insuficiencia \u00a0renal\u00a0previa\u00a0o\u00a0concomitante, \u00a0diabetes,\u00a0hipertensi\u00f3n \u00a0arterial,\u00a0f\u00e1rmacos \u00a0\nnefrot\u00f3xicos, \u00a0edad\u00a0avanzada, \u00a0bajo\u00a0peso\u00a0corporal\u00a0y\u00a0cifras\u00a0bajas\u00a0de\u00a0CD4)\u00a0214,\u00a0216,\u00a0219,\u00a0528,\u00a0529.\u00a0\nLa\u00a0nefrotoxicidad \u00a0por\u00a0TDF\u00a0suele\u00a0revertir\u00a0al\u00a0retirar\u00a0el\u00a0f\u00e1rmaco,\u00a0aunque\u00a0la\u00a0reversi\u00f3n \u00a0\npuede\u00a0no\u00a0ser\u00a0completa530.\u00a0IDV\u00a0y\u00a0ATV,\u00a0\u00e9ste\u00a0\u00faltimo\u00a0con\u00a0mucha\u00a0menor\u00a0frecuencia, \u00a0\nproducen \u00a0nefrolitiasis \u00a0por\u00a0dep\u00f3sito\u00a0tubular\u00a0de\u00a0cristales\u00a0(Tabla\u00a012).\u00a0\n\u00a0\nTrastornos \u00a0metab\u00f3licos \u00a0y\u00a0riesgo\u00a0cardiovascular \u00a0\nEste\u00a0grupo\u00a0de\u00a0trastornos \u00a0incluye\u00a0dislipemia, \u00a0resistencia \u00a0a\u00a0la\u00a0insulina\u00a0y\u00a0diabetes\u00a0mellitus,\u00a0\ntodos\u00a0los\u00a0cuales\u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0con\u00a0los\u00a0IP\u00a0cl\u00e1sicos\u00a0\u00a0que\u00a0con\u00a0los\u00a0IP\u00a0potenciados \u00a0\nactualmente \u00a0utilizados \u00a0y\u00a0con\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0timidina\u00a0que\u00a0con\u00a0los\u00a0dem\u00e1s\u00a0AN.\u00a0\nAsimismo, \u00a0todas\u00a0estas\u00a0anomal\u00edas \u00a0son\u00a0m\u00e1s\u00a0comunes\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0redistribuci\u00f3n \u00a0\nde\u00a0la\u00a0grasa\u00a0corporal.\u00a0\u00a0\nLa\u00a0dislipemia \u00a0caracterizada \u00a0por\u00a0aumento\u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0colesterol \u00a0total,\u00a0\ncolesterol \u2010LDL\u00a0y,\u00a0sobre\u00a0todo,\u00a0triglic\u00e9ridos, \u00a0es\u00a0la\u00a0anomal\u00eda\u00a0metab\u00f3lica \u00a0que\u00a0con\u00a0mayor\u00a0\nfrecuencia \u00a0se\u00a0asocia\u00a0al\u00a0TAR.\u00a0Aunque\u00a0tradicionalmente \u00a0se\u00a0ha\u00a0relacionado \u00a0esta\u00a0dislipemia \u00a0\ncon\u00a0los\u00a0IP,\u00a0no\u00a0todos\u00a0ellos\u00a0tienen\u00a0el\u00a0mismo\u00a0impacto\u00a0sobre\u00a0los\u00a0l\u00edpidos\u00a0y\u00a0otros\u00a0FAR,\u00a0\nespecialmente \u00a0los\u00a0an\u00e1logos\u00a0de\u00a0timidina,\u00a0tambi\u00e9n\u00a0inducen\u00a0dislipemia257,\u00a0272,\u00a0531\u2010533.\u00a0ABC\u00a0\no\u00a0la\u00a0formulaci\u00f3n \u00a0a\u00a0dosis\u00a0fija\u00a0ABC/3TC\u00a0aumenta\u00a0los\u00a0l\u00edpidos\u00a0plasm\u00e1ticos \u00a0mientras\u00a0que\u00a0TDF\u00a0\no\u00a0la\u00a0formulaci\u00f3n \u00a0a\u00a0dosis\u00a0fija\u00a0TDF/FTC\u00a0los\u00a0disminuye, \u00a0aunque\u00a0el\u00a0cociente\u00a0colesterol \u00a0\ntotal/colesterol \u2010HDL\u00a0se\u00a0mantiene \u00a0por\u00a0igual\u00a0con\u00a0ambos225,\u00a0534.\u00a0Respecto\u00a0a\u00a0los\u00a0IP,\u00a0diversos\u00a0\nensayos\u00a0cl\u00ednicos\u00a0han\u00a0revelado\u00a0que\u00a0ATV,\u00a0y\u00a0FPV,\u00a0sobre\u00a0todo\u00a0sin\u00a0potenciar, \u00a0tienen\u00a0un\u00a0\nmejor\u00a0perfil\u00a0lip\u00eddico;\u00a0ATV/r,\u00a0SQV/r\u00a0(1500/100 \u00a0BID\u00a0\u00f3\u00a01500/100 \u00a0QD)\u00a0y\u00a0DRV/r\u00a0(600/100\u00a0\nBID\u00a0u\u00a0800/100\u00a0QD)\u00a0presentan \u00a0perfiles\u00a0intermedios; \u00a0mientras\u00a0que\u00a0FPV/r\u00a0(1400/100 \u00a0QD\u00a0\no\u00a0700/100\u00a0BID),\u00a0LPV/r\u00a0(400/100\u00a0BID)\u00a0y\u00a0TPV/r\u00a0(500/200\u00a0BID)\u00a0tienen\u00a0perfiles\u00a0m\u00e1s\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 77desfavorables, \u00a0sobre\u00a0todo\u00a0en\u00a0lo\u00a0que\u00a0respecta\u00a0a\u00a0los\u00a0triglic\u00e9ridos233,\u00a0269,\u00a0273,\u00a0308,\u00a0313,\u00a0314,\u00a0353,\u00a0\n449,\u00a0535\u2010538.\u00a0El\u00a0manejo\u00a0de\u00a0la\u00a0dislipemia \u00a0se\u00a0comenta\u00a0en\u00a0las\u00a0tablas\u00a013\u201015539\u2010543.\u00a0\u00a0\nLos\u00a0IP\u00a0pueden\u00a0disminuir \u00a0la\u00a0disponibilidad \u00a0de\u00a0la\u00a0glucosa\u00a0perif\u00e9rica \u00a0y\u00a0la\u00a0secreci\u00f3n \u00a0\npancre\u00e1tica \u00a0de\u00a0insulina\u00a0de\u00a0forma\u00a0aguda\u00a0y\u00a0pueden\u00a0descompensar \u00a0o\u00a0desencadenar \u00a0una\u00a0\ndiabetes\u00a0en\u00a0pacientes \u00a0ya\u00a0diab\u00e9ticos \u00a0o\u00a0en\u00a0personas\u00a0predispuestas \u00a0a\u00a0serlo.\u00a0En\u00a0general,\u00a0\nestas\u00a0alteraciones \u00a0no\u00a0se\u00a0mantienen \u00a0a\u00a0medio\u2010largo\u00a0plazo,\u00a0por\u00a0lo\u00a0que\u00a0deben\u00a0existir\u00a0\nmecanismos \u00a0compensadores \u00a0de\u00a0las\u00a0mismas544,\u00a0545.\u00a0IDV\u00a0y\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas\u00a0son\u00a0los\u00a0que\u00a0\nse\u00a0han\u00a0relacionado \u00a0con\u00a0el\u00a0desarrollo \u00a0de\u00a0resistencia \u00a0a\u00a0la\u00a0insulina546\u2010548,\u00a0mientras\u00a0que\u00a0los\u00a0\ndem\u00e1s\u00a0IP\u00a0parecen\u00a0tener\u00a0poco\u00a0o\u00a0ning\u00fan\u00a0efecto\u00a0cl\u00ednicamente \u00a0significativo \u00a0sobre\u00a0la\u00a0\nhomeostasis \u00a0de\u00a0la\u00a0glucosa.\u00a0La\u00a0diabetes\u00a0mellitus\u00a0es\u00a0menos\u00a0com\u00fan\u00a0(Tabla\u00a014)\u00a0y\u00a0su\u00a0\nasociaci\u00f3n \u00a0con\u00a0los\u00a0IP\u00a0no\u00a0es\u00a0constante \u00a0en\u00a0todos\u00a0los\u00a0estudios544,\u00a0546,\u00a0548.\u00a0El\u00a0tratamiento \u00a0\ncon\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0timidina\u00a0(en\u00a0particular \u00a0d4T)\u00a0y\u00a0ddI,\u00a0constituye \u00a0un\u00a0factor\u00a0de\u00a0riesgo\u00a0\npara\u00a0el\u00a0desarrollo \u00a0de\u00a0resistencia \u00a0a\u00a0la\u00a0insulina\u00a0y\u00a0diabetes\u00a0mellitus549.\u00a0\u00a0Los\u00a0inhibidores \u00a0de\u00a0\nla\u00a0integrasa \u00a0y\u00a0los\u00a0antagonistas \u00a0del\u00a0CCR5\u00a0tienen\u00a0un\u00a0perfil\u00a0metab\u00f3lico \u00a0favorable277,\u00a0550.\u00a0\nAl\u00a0igual\u00a0que\u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0general,\u00a0los\u00a0factores\u00a0de\u00a0riesgo\u00a0tradicionales \u00a0son\u00a0los\u00a0que\u00a0\ndeterminan \u00a0principalmente \u00a0el\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0enfermedad \u00a0cardiovascular \u00a0en\u00a0los\u00a0\npacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH.\u00a0En\u00a0\u00e9stos,\u00a0no\u00a0obstante, \u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0no\u00a0\ncontrolada \u00a0y\u00a0ciertos\u00a0reg\u00edmenes \u00a0de\u00a0TAR\u00a0incrementan \u00a0tambi\u00e9n\u00a0dicho\u00a0riesgo,\u00a0aunque\u00a0es\u00a0\nmuy\u00a0probable\u00a0que\u00a0la\u00a0contribuci\u00f3n \u00a0de\u00a0estos\u00a0\u00faltimos\u00a0sea\u00a0menor\u00a0que\u00a0la\u00a0de\u00a0los\u00a0otros\u00a0\nfactores\u00a0anteriormente \u00a0mencionados. \u00a0Aunque\u00a0algunos\u00a0estudios\u00a0de\u00a0cohortes\u00a0han\u00a0\npuesto\u00a0de\u00a0manifiesto \u00a0que\u00a0la\u00a0duraci\u00f3n\u00a0del\u00a0tratamiento \u00a0con\u00a0IP\u00a0es\u00a0un\u00a0factor\u00a0de\u00a0riesgo\u00a0\nindependiente \u00a0para\u00a0el\u00a0desarrollo \u00a0de\u00a0cardiopat\u00eda \u00a0isqu\u00e9mica551\u2010553,\u00a0otros,\u00a0en\u00a0su\u00a0mayor\u00eda\u00a0\nretrospectivos \u00a0y\u00a0con\u00a0poco\u00a0tiempo\u00a0de\u00a0seguimiento, \u00a0han\u00a0obtenido\u00a0resultados \u00a0\ncontrapuestos \u00a0553\u2010556.\u00a0El\u00a0efecto\u00a0sobre\u00a0el\u00a0riesgo\u00a0cardiovascular \u00a0de\u00a0los\u00a0IP\u00a0como\u00a0familia\u00a0\nest\u00e1\u00a0mediado, \u00a0al\u00a0menos\u00a0en\u00a0parte,\u00a0por\u00a0la\u00a0dislipemia \u00a0asociada\u00a0con\u00a0el\u00a0uso\u00a0de\u00a0estos\u00a0\nf\u00e1rmacos. \u00a0Adem\u00e1s,\u00a0un\u00a0an\u00e1lisis\u00a0de\u00a0la\u00a0cohorte\u00a0D:A:D\u00a0ha\u00a0revelado\u00a0que\u00a0determinados \u00a0IP\u00a0\n(IDV,\u00a0LPV/r)\u00a0est\u00e1n\u00a0relacionados \u00a0con\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio, \u00a0que\u00a0no\u00a0\npuede\u00a0ser\u00a0exclusivamente \u00a0justificado \u00a0por\u00a0dicha\u00a0anomal\u00eda\u00a0metab\u00f3lica557.\u00a0Este\u00a0mismo\u00a0\nestudio\u00a0ha\u00a0mostrado \u00a0tambi\u00e9n\u00a0que\u00a0el\u00a0uso\u00a0reciente\u00a0(\u00faltimos\u00a0seis\u00a0meses)\u00a0de\u00a0ABC\u00a0o\u00a0ddI\u00a0se\u00a0\nasocia\u00a0con\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0infarto\u00a0agudo\u00a0de\u00a0miocardio, \u00a0especialmente \u00a0en\u00a0los\u00a0\npacientes \u00a0que\u00a0tienen\u00a0un\u00a0riesgo\u00a0cardiovascular \u00a0m\u00e1s\u00a0elevado557.\u00a0No\u00a0obstante, \u00a0la\u00a0relaci\u00f3n\u00a0\nentre\u00a0ABC\u00a0e\u00a0infarto\u00a0de\u00a0miocardio \u00a0es\u00a0un\u00a0motivo\u00a0de\u00a0controversia, \u00a0pues,\u00a0aunque\u00a0\u00a0ha\u00a0sido\u00a0\nconstatada \u00a0tambi\u00e9n\u00a0en\u00a0el\u00a0estudio\u00a0SMART231\u00a0y\u00a0en\u00a0sendos\u00a0estudios\u00a0de\u00a0casos\u00a0y\u00a0\ncontroles558,\u00a0559,\u00a0ni\u00a0un\u00a0an\u00e1lisis\u00a0conjunto\u00a0de\u00a052\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados \u00a0que\u00a0\ninclu\u00edan\u00a0un\u00a0brazo\u00a0de\u00a0tratamiento \u00a0con\u00a0ABC232\u00a0ni\u00a0otros\u00a0ensayos\u00a0cl\u00ednicos\u00a0y\u00a0estudios\u00a0de\u00a0\ncohorte\u00a0han\u00a0observado \u00a0tal\u00a0asociaci\u00f3n560\u2010562\u00a0as\u00ed\u00a0como\u00a0tampoco\u00a0ninguna\u00a0relaci\u00f3n\u00a0de\u00a0ABC\u00a0\ncon\u00a0potenciales \u00a0mecanismos \u00a0patog\u00e9nicos \u00a0que\u00a0pudieran\u00a0explicarla563\u2010565.\u00a0La\u00a0\ncontroversia \u00a0existente\u00a0pone\u00a0de\u00a0manifiesto \u00a0que\u00a0no\u00a0es\u00a0posible\u00a0controlar\u00a0de\u00a0forma\u00a0\nadecuada \u00a0posibles\u00a0sesgos\u00a0en\u00a0los\u00a0estudios\u00a0que\u00a0han\u00a0implicado \u00a0a\u00a0ABC\u00a0o\u00a0ddI\u00a0y\u00a0ponen\u00a0en\u00a0\nduda\u00a0la\u00a0contribuci\u00f3n \u00a0causal\u00a0de\u00a0los\u00a0mencionados \u00a0AN\u00a0en\u00a0el\u00a0desarrollo \u00a0de\u00a0la\u00a0enfermedad \u00a0\ncardiovascular. \u00a0\u00a0\n\u00a0\nAnomal\u00edas \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal\u00a0\nEl\u00a0s\u00edndrome \u00a0de\u00a0lipodistrofia \u00a0se\u00a0caracteriza \u00a0por\u00a0la\u00a0presencia, \u00a0combinada \u00a0o\u00a0no,\u00a0de\u00a0\np\u00e9rdida\u00a0de\u00a0grasa\u00a0perif\u00e9rica \u00a0(lipoatrofia) \u00a0y\u00a0de\u00a0ac\u00famulo\u00a0de\u00a0grasa\u00a0perivisceral \u00a0y/o\u00a0en\u00a0\nabdomen, \u00a0mamas\u00a0y\u00a0cuello\u00a0(lipoacumulaci\u00f3n). \u00a0La\u00a0lipoatrofia, \u00a0el\u00a0efecto\u00a0adverso\u00a0m\u00e1s\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 78temido\u00a0por\u00a0los\u00a0pacientes, \u00a0se\u00a0relaciona\u00a0particularmente \u00a0con\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0\ntimidina213,\u00a0214,\u00a0216,\u00a0219,\u00a0516,\u00a0531,\u00a0542,\u00a0543.\u00a0Aunque\u00a0en\u00a0su\u00a0aparici\u00f3n \u00a0pueden\u00a0influir\u00a0m\u00faltiples \u00a0\nfactores,\u00a0las\u00a0pautas\u00a0con\u00a0d4T\u00a0y\u00a0ZDV\u00a0(particularmente \u00a0junto\u00a0con\u00a0IP\u00a0cl\u00e1sicos\u00a0y\u00a0EFV)\u00a0han\u00a0\nevidenciado \u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0lipoatrofia \u00a0y\u00a0su\u00a0sustituci\u00f3n \u00a0por\u00a0ABC\u00a0o\u00a0TDF\u00a0o\u00a0por\u00a0pautas\u00a0\nsin\u00a0AN\u00a0se\u00a0asocia\u00a0a\u00a0una\u00a0mejor\u00eda\u00a0de\u00a0la\u00a0misma216,\u00a0219,\u00a0527,\u00a0529,\u00a0531,\u00a0537,\u00a0540\u2010543\u00a0(Tabla\u00a012).\u00a0Los\u00a0\nresultados \u00a0de\u00a0dos\u00a0estudios\u00a0comparativos \u00a0entre\u00a0EFV\u00a0y\u00a0LPV/r\u00a0sugieren\u00a0que\u00a0el\u00a0uso\u00a0de\u00a0EFV\u00a0\npuede\u00a0asociarse \u00a0a\u00a0una\u00a0mayor\u00a0p\u00e9rdida\u00a0de\u00a0grasa\u00a0subcut\u00e1nea \u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0LPV/r\u00a0\ncuando\u00a0el\u00a0r\u00e9gimen\u00a0incluye\u00a0an\u00e1logos\u00a0de\u00a0timidina402,\u00a0566.\u00a0Esta\u00a0diferencia \u00a0no\u00a0se\u00a0observa\u00a0en\u00a0\nel\u00a0estudio\u00a0ACTG\u00a05224s\u00a0(subestudio \u00a0metab\u00f3lico \u00a0del\u00a0ACTG\u00a05202)\u00a0que\u00a0compara\u00a0EFV\u00a0con\u00a0\nATV/r\u00a0asociado\u00a0a\u00a02\u00a0AN\u00a0(ABC/3TC \u00a0o\u00a0FTC/TDF)\u00a0en\u00a0el\u00a0que\u00a0hay\u00a0una\u00a0ganancia\u00a0global\u00a0de\u00a0\ngrasa,\u00a0pero\u00a0hasta\u00a0el\u00a016,3%\u00a0tiene\u00a0una\u00a0p\u00e9rdida\u00a0de\u00a0grasa\u00a0igual\u00a0o\u00a0superior\u00a0al\u00a010%,\u00a0pero\u00a0sin\u00a0\ndiferencias \u00a0en\u00a0funci\u00f3n\u00a0del\u00a0tratamiento567.\u00a0El\u00a0que\u00a0no\u00a0se\u00a0haya\u00a0observado \u00a0lipoatrofia \u00a0en\u00a0\notros\u00a0ensayos\u00a0en\u00a0los\u00a0que\u00a0EFV\u00a0tampoco\u00a0se\u00a0asociaba\u00a0a\u00a0an\u00e1logos\u00a0de\u00a0timidina216,\u00a0219,\u00a0527,\u00a0537,\u00a0\n543,\u00a0indica\u00a0que\u00a0EFV\u00a0no\u00a0parece\u00a0estar\u00a0directamente \u00a0implicado \u00a0en\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0\nlipoatrofia. \u00a0En\u00a0la\u00a0Tabla\u00a015\u00a0se\u00a0comentan \u00a0la\u00a0evaluaci\u00f3n \u00a0y\u00a0opciones\u00a0terap\u00e9uticas \u00a0para\u00a0las\u00a0\nanomal\u00edas \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal568\u2010571.\u00a0\n\u00a0Otros\u00a0efectos\u00a0adversos\u00a0\u00a0\nLa\u00a0osteopenia \u00a0y\u00a0la\u00a0osteoporosis \u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0los\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0\nVIH,\u00a0pero\u00a0se\u00a0desconoce \u00a0la\u00a0importancia \u00a0relativa\u00a0de\u00a0los\u00a0distintos\u00a0factores\u00a0invocados \u00a0\ncomo\u00a0favorecedores \u00a0de\u00a0la\u00a0misma,\u00a0entre\u00a0los\u00a0que\u00a0se\u00a0incluyen\u00a0el\u00a0propio\u00a0VIH\u00a0y\u00a0el\u00a0TAR.\u00a0\nAunque\u00a0el\u00a0TAR\u00a0podr\u00eda\u00a0jugar\u00a0un\u00a0papel\u00a0patog\u00e9nico \u00a0en\u00a0el\u00a0desarrollo \u00a0de\u00a0estos\u00a0trastornos \u00a0\nlos\u00a0datos\u00a0disponibles \u00a0no\u00a0son\u00a0concluyentes572,\u00a0573.\u00a0Al\u00a0iniciar\u00a0el\u00a0TAR\u00a0hay\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0\nosteopenia \u00a0que\u00a0posteriormente \u00a0se\u00a0recupera\u00a0en\u00a0parte.\u00a0Se\u00a0ha\u00a0comparado \u00a0el\u00a0efecto\u00a0de\u00a0\nTDF\u00a0y\u00a0ABC\u00a0sobre\u00a0la\u00a0densidad\u00a0mineral\u00a0\u00f3sea\u00a0y\u00a0el\u00a0TDF\u00a0produce\u00a0mayor\u00a0osteopenia \u00a0de\u00a0\ncadera567,\u00a0574.\u00a0La\u00a0presunta\u00a0relaci\u00f3n\u00a0entre\u00a0el\u00a0TAR\u00a0y\u00a0la\u00a0osteonecrosis \u00a0es\u00a0a\u00fan\u00a0m\u00e1s\u00a0\nambigua575.\u00a0\u00a0\nPor\u00a0\u00faltimo,\u00a0EFV\u00a0es\u00a0teratog\u00e9nico, \u00a0por\u00a0lo\u00a0que\u00a0est\u00e1\u00a0contraindicado \u00a0su\u00a0uso\u00a0durante\u00a0el\u00a0\nprimer\u00a0trimestre \u00a0de\u00a0la\u00a0gestaci\u00f3n.576\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0efectos\u00a0adversos\u00a0del\u00a0TAR\u00a0\n\u2022 Se\u00a0debe\u00a0monitorizar \u00a0la\u00a0tolerancia \u00a0y\u00a0las\u00a0reacciones \u00a0adversas\u00a0agudas\u00a0del\u00a0TAR\u00a0durante\u00a0\nlas\u00a0primeras\u00a02\u20104\u00a0semanas, \u00a0particularmente \u00a0en\u00a0aquellos\u00a0pacientes \u00a0que\u00a0tengan\u00a0\ncomorbilidades \u00a0predisponentes \u00a0o\u00a0tomen\u00a0concomitantemente \u00a0otros\u00a0f\u00e1rmacos \u00a0cuyas\u00a0\ninteracciones \u00a0puedan\u00a0tener\u00a0consecuencias \u00a0cl\u00ednicas,\u00a0y\u00a0llevar\u00a0a\u00a0cabo\u00a0una\u00a0eventual\u00a0\nmodificaci\u00f3n \u00a0del\u00a0tratamiento \u00a0seg\u00fan\u00a0la\u00a0gravedad \u00a0de\u00a0la\u00a0reacci\u00f3n\u00a0adversa\u00a0y\u00a0el\u00a0f\u00e1rmaco\u00a0\nimplicado. \u00a0Para\u00a0ello\u00a0debe\u00a0facilitarse \u00a0el\u00a0contacto\u00a0entre\u00a0el\u00a0paciente\u00a0y\u00a0los\u00a0\nprofesionales \u00a0(Nivel\u00a0C)\u00a0\n\u2022 Se\u00a0deben\u00a0evitar\u00a0f\u00e1rmacos\u00a0que\u00a0puedan\u00a0reagudizar \u00a0o\u00a0empeorar \u00a0enfermedades \u00a0\npreexistentes \u00a0(Nivel\u00a0C)\u00a0\n\u2022 Se\u00a0recomienda \u00a0monitorizar \u00a0la\u00a0glucemia\u00a0y\u00a0los\u00a0l\u00edpidos\u00a0plasm\u00e1ticos \u00a0(colesterol \u00a0total,\u00a0\ncolesterol \u2010HDL,\u00a0colesterol \u2010LDL\u00a0y\u00a0triglic\u00e9ridos) \u00a0en\u00a0ayunas\u00a0en\u00a0cada\u00a0visita\u00a0de\u00a0control\u00a0\n(nivel\u00a0C)541,\u00a0544,\u00a0577\u00a0\n\u2022 Se\u00a0recomienda \u00a0calcular\u00a0el\u00a0riesgo\u00a0cardiovascular \u00a0al\u00a0menos\u00a0una\u00a0vez\u00a0al\u00a0a\u00f1o\u00a0(nivel\u00a0C)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 79\u2022 Se\u00a0recomienda \u00a0efectuar\u00a0un\u00a0estudio\u00a0elemental \u00a0de\u00a0orina\u00a0con\u00a0proteinuria \u00a0y\u00a0calcular\u00a0la\u00a0\ntasa\u00a0de\u00a0filtrado\u00a0glomerular \u00a0renal\u00a0(f\u00f3rmula\u00a0MDRD\u00a0o\u00a0Cockroft\u2010Gault)\u00a0en\u00a0la\u00a0primera\u00a0\nvisita\u00a0y\u00a0luego\u00a0una\u00a0vez\u00a0al\u00a0a\u00f1o\u00a0si\u00a0no\u00a0hay\u00a0factores\u00a0de\u00a0riesgo\u00a0para\u00a0el\u00a0desarrollo \u00a0de\u00a0\nnefrotoxicidad \u00a0o\u00a0cada\u00a0seis\u00a0meses\u00a0si\u00a0\u00e9stos\u00a0est\u00e1n\u00a0presentes \u00a0as\u00ed\u00a0como\u00a0tambi\u00e9n\u00a0antes\u00a0\nde\u00a0iniciar\u00a0el\u00a0TAR\u00a0(nivel\u00a0A)578,\u00a0579.\u00a0En\u00a0los\u00a0pacientes \u00a0que\u00a0ya\u00a0reciben\u00a0TAR\u00a0se\u00a0recomienda \u00a0\nefectuar\u00a0este\u00a0estudio\u00a0en\u00a0todas\u00a0las\u00a0revisiones \u00a0(nivel\u00a0B),\u00a0en\u00a0especial\u00a0si\u00a0toman\u00a0TDF\u00a0\n(nivel\u00a0C)579.\u00a0Si\u00a0el\u00a0filtrado\u00a0glomerular \u00a0es\u00a0<50\u00a0mL/min\u00a0o\u00a0hay\u00a0proteinuria \u00a0manifiesta \u00a0no\u00a0\nse\u00a0deben\u00a0usar\u00a0TDF\u00a0ni\u00a0IDV\u00a0y\u00a0se\u00a0deben\u00a0ajustar\u00a0las\u00a0dosis\u00a0o\u00a0intervalos \u00a0de\u00a0los\u00a0AN\u00a0excepto\u00a0\nABC\u00a0(nivel\u00a0C)578,\u00a0579.\u00a0No\u00a0se\u00a0recomienda \u00a0usar\u00a0TDF\u00a0en\u00a0aquellos\u00a0pacientes \u00a0en\u00a0los\u00a0que\u00a0el\u00a0\ndeterioro \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0renal\u00a0sea\u00a0agudo\u00a0o\u00a0est\u00e9\u00a0directamente \u00a0relacionado \u00a0con\u00a0este\u00a0\nf\u00e1rmaco\u00a0(nivel\u00a0C)579\u00a0\u00a0\n\u00a0\n\u00a0\n8.\u00a0INTERACCIONES \u00a0FARMACOCIN\u00c9TICAS \u00a0Y\u00a0FARMACODIN\u00c1MICAS \u00a0\nLas\u00a0interacciones \u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0(FAR)\u00a0entre\u00a0s\u00ed\u00a0o\u00a0con\u00a0otros\u00a0\nmedicamentos \u00a0constituyen \u00a0un\u00a0problema \u00a0de\u00a0primera\u00a0magnitud \u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0los\u00a0\npacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0ya\u00a0que\u00a0sus\u00a0consecuencias \u00a0pueden\u00a0tener\u00a0una\u00a0\nimportante \u00a0repercusi\u00f3n \u00a0cl\u00ednica580\u2010583.\u00a0Las\u00a0m\u00e1s\u00a0relevantes \u00a0suelen\u00a0ser\u00a0las\u00a0interacciones \u00a0\nfarmacocin\u00e9ticas, \u00a0especialmente \u00a0a\u00a0nivel\u00a0del\u00a0metabolismo \u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0Diferentes \u00a0\nsistemas\u00a0enzim\u00e1ticos \u00a0est\u00e1n\u00a0implicados \u00a0en\u00a0dicho\u00a0metabolismo \u00a0y\u00a0en\u00a0todos\u00a0ellos\u00a0pueden\u00a0\nproducirse \u00a0interacciones. \u00a0Los\u00a0FAR\u00a0son\u00a0sustratos\u00a0de\u00a0uno\u00a0o\u00a0varios\u00a0de\u00a0estos\u00a0sistemas\u00a0\nenzim\u00e1ticos \u00a0y\u00a0a\u00a0la\u00a0vez\u00a0pueden\u00a0comportarse \u00a0como\u00a0inductores \u00a0y/o\u00a0inhibidores \u00a0de\u00a0\ncualquiera \u00a0de\u00a0ellos.\u00a0La\u00a0inducci\u00f3n \u00a0del\u00a0metabolismo \u00a0producir\u00e1 \u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0las\u00a0\nconcentraciones \u00a0del\u00a0f\u00e1rmaco\u00a0en\u00a0el\u00a0lugar\u00a0de\u00a0acci\u00f3n,\u00a0pudiendo \u00a0disminuir \u00a0la\u00a0eficacia\u00a0del\u00a0\ntratamiento, \u00a0mientras\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0ocasionar\u00e1 \u00a0un\u00a0aumento\u00a0de\u00a0las\u00a0concentraciones \u00a0\ncon\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0toxicidad. \u00a0En\u00a0general,\u00a0la\u00a0inducci\u00f3n \u00a0se\u00a0produce\u00a0por\u00a0un\u00a0aumento\u00a0\nde\u00a0la\u00a0s\u00edntesis\u00a0proteica\u00a0(enzimas), \u00a0siendo\u00a0un\u00a0proceso\u00a0lento\u00a0que\u00a0requiere\u00a0d\u00edas\u00a0o\u00a0semanas, \u00a0\nmientras\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0suele\u00a0ser\u00a0competitiva \u00a0y\u00a0se\u00a0produce\u00a0de\u00a0manera\u00a0r\u00e1pida,\u00a0\ndependiendo \u00a0de\u00a0la\u00a0concentraci\u00f3n \u00a0del\u00a0inhibidor, \u00a0pudiendo \u00a0aparecer\u00a0los\u00a0efectos\u00a0t\u00f3xicos\u00a0\nde\u00a0los\u00a0sustratos\u00a0en\u00a0pocas\u00a0horas.\u00a0Dado\u00a0que\u00a0ambos\u00a0mecanismos \u00a0son\u00a0diferentes \u00a0e\u00a0\nindependientes, \u00a0algunos\u00a0f\u00e1rmacos \u00a0pueden\u00a0ser\u00a0inhibidores \u00a0e\u00a0inductores \u00a0al\u00a0mismo\u00a0\ntiempo,\u00a0predominando \u00a0uno\u00a0u\u00a0otro\u00a0efecto.\u00a0\nEl\u00a0sistema\u00a0metab\u00f3lico \u00a0m\u00e1s\u00a0importante \u00a0es\u00a0el\u00a0citocromo \u00a0P450\u00a0(CYP)\u00a0y\u00a0su\u00a0principal\u00a0\nisoenzima \u00a0el\u00a0CYP3A4.\u00a0Muchos\u00a0FAR,\u00a0especialmente \u00a0los\u00a0IP\u00a0y\u00a0NN,\u00a0y\u00a0muchos\u00a0otros\u00a0\nf\u00e1rmacos \u00a0que\u00a0a\u00a0menudo\u00a0reciben\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0son\u00a0inhibidores \u00a0\no\u00a0inductores \u00a0de\u00a0diferentes \u00a0isoenzimas \u00a0de\u00a0CYP.\u00a0La\u00a0potente\u00a0inhibici\u00f3n \u00a0enzim\u00e1tica \u00a0que\u00a0\nproduce\u00a0RTV\u00a0se\u00a0utiliza\u00a0para\u00a0potenciar \u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0otros\u00a0IP\u00a0(substratos \u00a0de\u00a0\nCYP3A4),\u00a0logrando\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0m\u00e1s\u00a0eficaces\u00a0y\u00a0menos\u00a0susceptibles \u00a0al\u00a0\nefecto\u00a0inductor\u00a0de\u00a0otros\u00a0f\u00e1rmacos\u00a0(ej.\u00a0NN)\u00a0y\u00a0al\u00a0mismo\u00a0tiempo\u00a0pautas\u00a0m\u00e1s\u00a0simples,\u00a0con\u00a0\nmenos\u00a0restricciones \u00a0diet\u00e9ticas. \u00a0Se\u00a0est\u00e1n\u00a0investigando \u00a0nuevos\u00a0potenciadores \u00a0\nfarmacocin\u00e9ticos \u00a0que\u00a0carecen\u00a0de\u00a0eficacia\u00a0antirretroviral, \u00a0de\u00a0los\u00a0cuales\u00a0el\u00a0que\u00a0se\u00a0\nencuentra \u00a0en\u00a0fases\u00a0m\u00e1s\u00a0avanzadas \u00a0de\u00a0investigaci\u00f3n \u00a0es\u00a0el\u00a0cobicistat \u00a0(GS\u20109350).\u00a0La\u00a0\npotenciaci\u00f3n \u00a0ejercida\u00a0sobre\u00a0ATV\u00a0y\u00a0DRV\u00a0por\u00a0150\u00a0mg\u00a0c/24h\u00a0de\u00a0cobicistat \u00a0\u00a0fue\u00a0similar\u00a0a\u00a0la\u00a0\nobtenida\u00a0con\u00a0100\u00a0mg\u00a0c/24h\u00a0de\u00a0RTV.\u00a0Cobicistat \u00a0se\u00a0est\u00e1\u00a0desarrollando \u00a0\nfundamentalmente \u00a0como\u00a0potenciador \u00a0del\u00a0nuevo\u00a0inhibidor\u00a0de\u00a0la\u00a0integrasa \u00a0elvitegravir. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 80La\u00a0formulaci\u00f3n \u00a0QUAD\u00a0contiene\u00a0en\u00a0un\u00a0s\u00f3lo\u00a0comprimido \u00a0EVT\u00a0150\u00a0mg/GS\u20109350\u00a0150\u00a0\nmg/FTC\u00a0200\u00a0mg\u00a0y\u00a0TDF\u00a0300\u00a0mg584\u2010588.\u00a0\nOtra\u00a0v\u00eda\u00a0metab\u00f3lica \u00a0es\u00a0la\u00a0conjugaci\u00f3n \u00a0de\u00a0los\u00a0FAR\u00a0o\u00a0de\u00a0sus\u00a0metabolitos \u00a0procedentes \u00a0de\u00a0\nla\u00a0oxidaci\u00f3n \u00a0del\u00a0f\u00e1rmaco\u00a0por\u00a0el\u00a0CYP.\u00a0Diversos\u00a0FAR\u00a0son\u00a0inductores \u00a0o\u00a0inhibidores \u00a0del\u00a0\ncomplejo \u00a0enzim\u00e1tico \u00a0de\u00a0las\u00a0uridindifosfato \u2010glucuroniltransferasas \u00a0(UDPGT)\u00a0\n(glucuronizaci\u00f3n). \u00a0A\u00a0menudo\u00a0los\u00a0inductores \u00a0del\u00a0CYP\u00a0son\u00a0tambi\u00e9n\u00a0inductores \u00a0de\u00a0la\u00a0\nUDPGT\u00a0y\u00a0los\u00a0inhibidores \u00a0del\u00a0CYP\u00a0son\u00a0inhibidores \u00a0de\u00a0la\u00a0UDPGT,\u00a0pero\u00a0algunos\u00a0inhibidores \u00a0\ndel\u00a0CYP\u00a0son\u00a0inductores \u00a0de\u00a0la\u00a0glucuronizaci\u00f3n \u00a0y\u00a0viceversa. \u00a0As\u00ed,\u00a0por\u00a0ejemplo,\u00a0RTV\u00a0y,\u00a0en\u00a0\nmenor\u00a0medida,\u00a0NFV\u00a0inhiben\u00a0varias\u00a0subfamilias \u00a0del\u00a0citocromo \u00a0P450\u00a0y\u00a0son\u00a0inductores \u00a0de\u00a0\nlas\u00a0UDPGT.\u00a0La\u00a0combinaci\u00f3n \u00a0TPV/r\u00a0muestra\u00a0un\u00a0efecto\u00a0inductor\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n. \u00a0\nATV\u00a0inhibe\u00a0ambos\u00a0sistemas\u00a0enzim\u00e1ticos. \u00a0\nCada\u00a0vez\u00a0est\u00e1n\u00a0adquiriendo \u00a0mayor\u00a0protagonismo \u00a0una\u00a0serie\u00a0de\u00a0prote\u00ednas \u00a0\ntransportadoras \u00a0transmembrana, \u00a0tales\u00a0como\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0(P\u2010gp),\u00a0capaces\u00a0de\u00a0\nalterar\u00a0la\u00a0biodisponibilidad \u00a0de\u00a0diversos\u00a0FAR\u00a0y\u00a0su\u00a0distribuci\u00f3n \u00a0por\u00a0el\u00a0organismo. \u00a0Estas\u00a0\nprote\u00ednas \u00a0pueden\u00a0ser\u00a0inducidas \u00a0o\u00a0inhibidas\u00a0por\u00a0diversos\u00a0f\u00e1rmacos. \u00a0Habitualmente \u00a0la\u00a0\ninducci\u00f3n \u00a0o\u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0CYP\u00a0y\u00a0de\u00a0la\u00a0P\u2010gp\u00a0van\u00a0en\u00a0el\u00a0mismo\u00a0sentido,\u00a0pero\u00a0al\u00a0igual\u00a0que\u00a0\nsucede\u00a0con\u00a0la\u00a0glucuronizaci\u00f3n \u00a0ambos\u00a0efectos\u00a0pueden\u00a0ser\u00a0discordantes. \u00a0\nEn\u00a0las\u00a0Tablas\u00a05\u00a0a\u00a09\u00a0se\u00a0detallan\u00a0las\u00a0interacciones \u00a0de\u00a0los\u00a0diferentes \u00a0FAR:\u00a0\n\u0083 Los\u00a0AN\u00a0tienen\u00a0pocas\u00a0interacciones \u00a0metab\u00f3licas. \u00a0ZDV\u00a0y\u00a0ABC\u00a0se\u00a0glucuronizan. \u00a03TC,\u00a0\nFTC,\u00a0d4T\u00a0y\u00a0TDF\u00a0se\u00a0eliminan\u00a0principalmente \u00a0por\u00a0v\u00eda\u00a0renal\u00a0y\u00a0son\u00a0poco\u00a0susceptibles \u00a0de\u00a0\npadecer\u00a0interacciones \u00a0metab\u00f3licas \u00a0relevantes. \u00a0Se\u00a0ha\u00a0descrito\u00a0aumento\u00a0del\u00a0riesgo\u00a0\nde\u00a0toxicidad\u00a0renal\u00a0al\u00a0asociar\u00a0TDF\u00a0a\u00a0algunos\u00a0IP/r589\u2010595.\u00a0\n\u0083 En\u00a0cuanto\u00a0a\u00a0los\u00a0NN,\u00a0NVP\u00a0se\u00a0comporta \u00a0como\u00a0inductor\u00a0del\u00a0CYP3A\u00a0y\u00a0del\u00a0CYP2B6;\u00a0EFV\u00a0\nes\u00a0fundamentalmente \u00a0un\u00a0inductor\u00a0del\u00a0CYP3A4\u00a0y\u00a0de\u00a0la\u00a0UGT1A1596,\u00a0aunque\u00a0in\u00a0vitro\u00a0\nse\u00a0comporta \u00a0tambi\u00e9n\u00a0como\u00a0inhibidor\u00a0de\u00a0\u00e9ste\u00a0y\u00a0de\u00a0otros\u00a0isoenzimas \u00a0del\u00a0CYP\u00a0\n(CYP2C9,\u00a02C19).\u00a0ETR\u00a0act\u00faa\u00a0como\u00a0sustrato\u00a0e\u00a0inductor\u00a0del\u00a0CYP3A4\u00a0y\u00a0como\u00a0inhibidor\u00a0\ndel\u00a0CYP2C9\u00a0y\u00a02C19597,\u00a0598.\u00a0\n\u0083 Por\u00a0lo\u00a0que\u00a0respecta\u00a0a\u00a0los\u00a0IP,\u00a0RTV\u00a0es\u00a0un\u00a0potente\u00a0inhibidor\u00a0de\u00a0los\u00a0isoenzimas \u00a0CYP3A4,\u00a0\n2D6\u00a0y\u00a0tambi\u00e9n\u00a0tiene\u00a0un\u00a0efecto\u00a0inductor\u00a0de\u00a0varios\u00a0isoenzimas \u00a0del\u00a0CYP\u00a0(1A2,\u00a03A4,\u00a0\n2B6,\u00a02C9,\u00a02C19)599,\u00a0as\u00ed\u00a0como\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n; \u00a0adem\u00e1s\u00a0es\u00a0capaz\u00a0de\u00a0autoinducir \u00a0\nsu\u00a0propio\u00a0metabolismo. \u00a0NFV\u00a0es\u00a0inhibidor\u00a0del\u00a0CYP3A4\u00a0y\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0d\u00e9bil\u00a0de\u00a0\nCYP2C19, \u00a02D6,\u00a01A2\u00a0y\u00a02B6;\u00a0en\u00a0cambio,\u00a0es\u00a0inductor\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n. \u00a0IDV\u00a0es\u00a0un\u00a0\ninhibidor\u00a0del\u00a0CYP3A4.\u00a0SQV\u00a0es\u00a0un\u00a0inhibidor\u00a0d\u00e9bil\u00a0del\u00a0CYP3A4.\u00a0FPV\u00a0puede\u00a0ser\u00a0\ninhibidor\u00a0o\u00a0inductor\u00a0del\u00a0CYP3A4.\u00a0\u00a0LPV/r\u00a0inhibe\u00a0el\u00a0CYP3A4\u00a0in\u00a0vitro\u00a0y,\u00a0en\u00a0menor\u00a0\nproporci\u00f3n, \u00a0el\u00a0CYP\u00a02D6;\u00a0in\u00a0vivo\u00a0induce\u00a0su\u00a0propio\u00a0metabolismo, \u00a0los\u00a0CYP2C9\u00a0y\u00a02C19600\u00a0\ny\u00a0la\u00a0glucuronizaci\u00f3n. \u00a0ATV\u00a0es\u00a0inhibidor\u00a0del\u00a0CYP3A4\u00a0y\u00a0de\u00a0la\u00a0UDPGT1A1 \u00a0(enzima\u00a0\nencargado \u00a0de\u00a0la\u00a0glucuronizaci\u00f3n \u00a0de\u00a0la\u00a0bilirrubina). \u00a0\u00a0TPV/r\u00a0in\u00a0vivo\u00a0y\u00a0en\u00a0estado\u00a0de\u00a0\nequilibrio \u00a0es\u00a0un\u00a0inductor\u00a0de\u00a0CYP2C9,\u00a0CYP1A2\u00a0y\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n \u00a0e\u00a0inhibidor\u00a0del\u00a0\nCYP3A4\u00a0y\u00a02D6601.\u00a0Respecto\u00a0a\u00a0su\u00a0efecto\u00a0sobre\u00a0la\u00a0P\u2010pg,\u00a0los\u00a0datos\u00a0sugieren\u00a0que\u00a0el\u00a0\nefecto\u00a0neto\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0TPV/r\u00a0en\u00a0estado\u00a0de\u00a0equilibrio \u00a0es\u00a0de\u00a0inducci\u00f3n \u00a0leve\u00a0\nde\u00a0la\u00a0P\u2010gp.\u00a0Debido\u00a0al\u00a0efecto\u00a0antag\u00f3nico \u00a0de\u00a0inhibici\u00f3n \u00a0del\u00a0CYP3A4\u00a0e\u00a0inducci\u00f3n \u00a0de\u00a0la\u00a0\nP\u2010gp,\u00a0es\u00a0dif\u00edcil\u00a0predecir\u00a0el\u00a0efecto\u00a0neto\u00a0de\u00a0TPV/r\u00a0sobre\u00a0f\u00e1rmacos\u00a0que\u00a0sean\u00a0substratos \u00a0\nde\u00a0ambos.\u00a0\n\u0083 Inhibidores \u00a0del\u00a0correceptor \u00a0CCR5.\u00a0MVC\u00a0es\u00a0sustrato\u00a0de\u00a0CYP3A4,\u00a0pero\u00a0no\u00a0es\u00a0inhibidor\u00a0\nni\u00a0inductor602.\u00a0Los\u00a0inhibidores \u00a0e\u00a0inductores \u00a0de\u00a0CYP3A4\u00a0alteran\u00a0los\u00a0par\u00e1metros \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 81farmacocin\u00e9ticos \u00a0de\u00a0MVC,\u00a0recomend\u00e1ndose \u00a0cambios\u00a0en\u00a0su\u00a0dosis\u00a0(Tabla\u00a08).\u00a0\u00a0En\u00a0\ngeneral\u00a0se\u00a0ajustar\u00e1n \u00a0las\u00a0dosis\u00a0como\u00a0sigue:\u00a0150\u00a0mg\u00a0BID\u00a0cuando\u00a0se\u00a0administra \u00a0con\u00a0\ninhibidores \u00a0del\u00a0CYP3A4\u00a0como\u00a0por\u00a0ejemplo\u00a0IP/r\u00a0(con\u00a0excepci\u00f3n \u00a0de\u00a0TPV/r\u00a0y\u00a0FPV/r);\u00a0\n600\u00a0mg\u00a0BID\u00a0cuando\u00a0se\u00a0administra \u00a0con\u00a0f\u00e1rmacos \u00a0inductores \u00a0como\u00a0EFV\u00a0o\u00a0rifampicina \u00a0\n(con\u00a0excepci\u00f3n \u00a0de\u00a0NVP),\u00a0en\u00a0ausencia\u00a0de\u00a0inhibidores \u00a0potentes, \u00a0en\u00a0cuya\u00a0presencia \u00a0\npredomina \u00a0el\u00a0efecto\u00a0inhibidor\u00a0y\u00a0se\u00a0administrar\u00e1n \u00a0150\u00a0mg\u00a0BID;\u00a0300\u00a0mg\u00a0BID\u00a0con\u00a0otros\u00a0\nf\u00e1rmacos \u00a0(incluyendo \u00a0TPV/r\u00a0y\u00a0FPV/r)602\u2010605.\u00a0\u00a0\n\u0083 Inhibidores \u00a0de\u00a0la\u00a0integrasa. \u00a0RAL\u00a0no\u00a0es\u00a0sustrato\u00a0ni\u00a0influye\u00a0en\u00a0la\u00a0actividad\u00a0del\u00a0CYP.\u00a0Se\u00a0\nmetaboliza \u00a0por\u00a0glucuronizaci\u00f3n, \u00a0sin\u00a0inhibir\u00a0ni\u00a0inducir\u00a0esta\u00a0enzima.\u00a0Los\u00a0inhibidores \u00a0e\u00a0\ninductores \u00a0de\u00a0UGT1A1\u00a0modifican \u00a0los\u00a0par\u00e1metros \u00a0farmacocin\u00e9ticos \u00a0de\u00a0RAL,\u00a0pero\u00a0en\u00a0\nla\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos\u00a0no\u00a0se\u00a0recomienda \u00a0cambio\u00a0en\u00a0su\u00a0dosificaci\u00f3n \u00a0por\u00a0su\u00a0amplio\u00a0\nmargen\u00a0terap\u00e9utico \u00a0(Tabla\u00a08)606\u2010609.\u00a0\n\u0083 Inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n.\u00a0ENF\u00a0se\u00a0metaboliza \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0las\u00a0v\u00edas\u00a0catab\u00f3licas \u00a0de\u00a0las\u00a0\nprote\u00ednas \u00a0y\u00a0amino\u00e1cidos. \u00a0No\u00a0es\u00a0sustrato\u00a0ni\u00a0influye\u00a0en\u00a0la\u00a0actividad\u00a0de\u00a0ninguno\u00a0de\u00a0los\u00a0\nsistemas\u00a0metab\u00f3licos \u00a0de\u00a0los\u00a0otros\u00a0FAR.\u00a0No\u00a0es\u00a0susceptible \u00a0de\u00a0presentar \u00a0\ninteracciones \u00a0metab\u00f3licas \u00a0relevantes. \u00a0\nEn\u00a0las\u00a0tablas\u00a06\u00a0a\u00a08\u00a0se\u00a0especifican \u00a0las\u00a0dosis\u00a0de\u00a0los\u00a0FAR\u00a0cuando\u00a0se\u00a0administran \u00a0en\u00a0\ncombinaci\u00f3n \u00a0con\u00a0otros\u00a0FAR595,\u00a0610\u2010635,\u00a0antituberculosos636\u2010653,\u00a0metadona654\u2010662,\u00a0\nestatinas663\u2010672,\u00a0f\u00e1rmacos \u00a0para\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0C673\u2010680,\u00a0otros\u00a0f\u00e1rmacos583,\u00a0\n623,\u00a0681\u2010723,\u00a0productos \u00a0naturales724\u2010728\u00a0y\u00a0asociaciones \u00a0contraindicadas \u00a0o\u00a0no\u00a0\nrecomendadas)\u2217.\u00a0Debido\u00a0a\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0FAR\u00a0se\u00a0\nrenueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0\nactualizada \u00a0de\u00a0las\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0\u00a0\nEn\u00a0la\u00a0tabla\u00a016\u00a0se\u00a0especifican \u00a0los\u00a0ajustes\u00a0de\u00a0dosis\u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0caso\u00a0de\u00a0insuficiencia \u00a0\nrenal,\u00a0hemodi\u00e1lisis \u00a0o\u00a0di\u00e1lisis\u00a0peritoneal \u00a0o\u00a0insuficiencia \u00a0hep\u00e1tica729\u2010773.\u00a0\nAlgunas\u00a0interacciones \u00a0farmacodin\u00e1micas \u00a0son\u00a0de\u00a0inter\u00e9s,\u00a0como\u00a0el\u00a0antagonismo \u00a0en\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0intracelular \u00a0que\u00a0se\u00a0produce\u00a0entre\u00a0ZDV\u00a0y\u00a0d4T.\u00a0Desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0de\u00a0la\u00a0\ncoinfecci\u00f3n \u00a0con\u00a0el\u00a0VHC\u00a0tiene\u00a0inter\u00e9s\u00a0conocer\u00a0que\u00a0ribavirina \u00a0ha\u00a0mostrado \u00a0antagonismo \u00a0\nin\u00a0vitro\u00a0con\u00a0ZDV\u00a0y\u00a0d4T.\u00a0Sin\u00a0embargo\u00a0en\u00a0el\u00a0subestudio \u00a0farmacocin\u00e9tico \u00a0del\u00a0APRICOT\u00a0esta\u00a0\ninteracci\u00f3n \u00a0no\u00a0se\u00a0produjo\u00a0in\u00a0vivo.\u00a0\u00a0\nLa\u00a0ribavirina \u00a0y\u00a0ddI\u00a0producen \u00a0toxicidad\u00a0mitocondrial. \u00a0Su\u00a0incidencia \u00a0se\u00a0multiplic\u00f3 \u00a0por\u00a05\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0uso\u00a0de\u00a0ribavirina \u00a0y\u00a0otros\u00a0AN.\u00a0Tres\u00a0de\u00a0los\u00a023\u00a0casos\u00a0comunicados \u00a0a\u00a0la\u00a0\nFDA\u00a0fueron\u00a0mortales, \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0recomienda \u00a0evitar\u00a0esta\u00a0asociaci\u00f3n. \u00a0En\u00a0lo\u00a0posible\u00a0se\u00a0\nevitar\u00e1\u00a0tambi\u00e9n\u00a0el\u00a0uso\u00a0simult\u00e1neo \u00a0de\u00a0ribavirina \u00a0con\u00a0ZDV\u00a0o\u00a0d4T\u00a0por\u00a0toxicidad\u00a0\nhematol\u00f3gica \u00a0o\u00a0mitocondrial. \u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0interacciones \u00a0medicamentosas \u00a0\n\u0083 Se\u00a0debe\u00a0rese\u00f1ar\u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0todos\u00a0los\u00a0medicamentos, \u00a0productos \u00a0naturales \u00a0\ny\u00a0medicinas \u00a0alternativas, \u00a0para\u00a0evaluar\u00a0posibles\u00a0interacciones \u00a0\n\u0083 Se\u00a0deben\u00a0tener\u00a0en\u00a0cuenta\u00a0las\u00a0contraindicaciones \u00a0y\u00a0realizar\u00a0los\u00a0ajustes\u00a0de\u00a0dosis\u00a0\ncorrespondientes \u00a0cuando\u00a0sea\u00a0necesario \u00a0\n                                                 \n\u2217 Se\u00a0han\u00a0incluido\u00a0solamente \u00a0las\u00a0referencias \u00a0sobre\u00a0interacciones \u00a0de\u00a0los\u00a0\u00faltimos\u00a03\u00a0a\u00f1os,\u00a0el\u00a0resto\u00a0pueden\u00a0consultarse \u00a0en\u00a0la\u00a0p\u00e1gina\u00a0web\u00a0\nhttp://www.interaccioneshiv.com   \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 82\u0083 Se\u00a0debe\u00a0considerar \u00a0la\u00a0monitorizaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0se\u00a0\nadministren \u00a0dos\u00a0o\u00a0m\u00e1s\u00a0f\u00e1rmacos\u00a0con\u00a0posibles\u00a0interacciones \u00a0farmacocin\u00e9ticas \u00a0\nrelevantes \u00a0para\u00a0evitar\u00a0toxicidad\u00a0o\u00a0ineficacia \u00a0terap\u00e9utica \u00a0(nivel\u00a0C)\u00a0\n\u00a0\n9.\u00a0HEPATOPATIA \u00a0CRONICA \u00a0Y\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\nLa\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0por\u00a0virus\u00a0de\u00a0la\u00a0hepatitis\u00a0es\u00a0la\u00a0comorbilidad \u00a0m\u00e1s\u00a0relevante \u00a0que\u00a0\npresentan \u00a0los\u00a0sujetos\u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0Espa\u00f1a\u00a0por\u00a0su\u00a0frecuencia, \u00a0por\u00a0la\u00a0\nprogresi\u00f3n \u00a0a\u00a0enfermedad \u00a0hep\u00e1tica\u00a0terminal\u00a0y\u00a0por\u00a0aumentar \u00a0la\u00a0hepatotoxicidad \u00a0del\u00a0\nTAR.\u00a0\u00a0\n\u00a0\n9.\u00a01.\u00a0Infecci\u00f3n \u00a0VIH,\u00a0TAR\u00a0e\u00a0historia\u00a0natural\u00a0de\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0VHC\u00a0y\u00a0VHB\u00a0\nEn\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0virus\u00a0hepatotropos \u00a0la\u00a0buena\u00a0situaci\u00f3n\u00a0\ninmunol\u00f3gica, \u00a0el\u00a0control\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0del\u00a0VIH\u00a0y\u00a0el\u00a0recibir\u00a0TAR\u00a0se\u00a0asocian\u00a0con\u00a0\nun\u00a0mejor\u00a0pron\u00f3stico \u00a0global,\u00a0menor\u00a0velocidad \u00a0de\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0enfermedad \u00a0hep\u00e1tica\u00a0\ny\u00a0menor\u00a0riesgo\u00a0de\u00a0complicaciones \u00a0y\u00a0muerte\u00a0por\u00a0causa\u00a0hep\u00e1tica774\u2010781.\u00a0Se\u00a0ha\u00a0descrito\u00a0la\u00a0\ncapacidad \u00a0del\u00a0VIH\u00a0para\u00a0infectar\u00a0c\u00e9lulas\u00a0estrelladas \u00a0hep\u00e1ticas \u00a0y\u00a0promover \u00a0su\u00a0activaci\u00f3n \u00a0\ncon\u00a0incremento \u00a0de\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0col\u00e1geno, \u00a0lo\u00a0que\u00a0sugiere\u00a0que\u00a0la\u00a0replicaci\u00f3n \u00a0del\u00a0VIH\u00a0\npuede\u00a0contribuir \u00a0directamente \u00a0al\u00a0mayor\u00a0desarrollo \u00a0de\u00a0la\u00a0fibrosis\u00a0hep\u00e1tica\u00a0en\u00a0pacientes \u00a0\ncoinfectados782.\u00a0Por\u00a0ello,\u00a0aun\u00a0en\u00a0ausencia\u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0o\u00a0estudios\u00a0de\u00a0\nobservaci\u00f3n \u00a0prospectiva \u00a0que\u00a0valoren\u00a0el\u00a0impacto\u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0evoluci\u00f3n \u00a0de\u00a0la\u00a0fibrosis\u00a0\nhep\u00e1tica\u00a0en\u00a0cohortes\u00a0de\u00a0pacientes \u00a0coinfectados, \u00a0las\u00a0evidencias \u00a0anteriormente \u00a0descritas\u00a0\nrespaldan \u00a0el\u00a0control\u00a0precoz\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0del\u00a0VIH\u00a0y\u00a0el\u00a0mantenimiento \u00a0de\u00a0una\u00a0buena\u00a0\nsituaci\u00f3n\u00a0inmunol\u00f3gica \u00a0en\u00a0estos\u00a0pacientes. \u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0VIH,\u00a0TAR\u00a0e\u00a0historia\u00a0natural\u00a0de\u00a0las\u00a0hepatitis\u00a0\n\u2022 En\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0el\u00a0VHC\u00a0se\u00a0debe\u00a0recomendar \u00a0el\u00a0inicio\u00a0de\u00a0TAR\u00a0\nindependientemente \u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0T\u00a0CD4+\u00a0individualizando \u00a0la\u00a0decisi\u00f3n\u00a0en\u00a0\nfunci\u00f3n\u00a0de\u00a0variables\u00a0virol\u00f3gicas, \u00a0histol\u00f3gicas \u00a0y\u00a0de\u00a0motivaci\u00f3n \u00a0del\u00a0paciente\u00a0(nivel\u00a0C)\u00a0\n\u2022 En\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0el\u00a0VHB\u00a0el\u00a0TAR\u00a0se\u00a0debe\u00a0iniciar\u00a0independientemente \u00a0\nde\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0T\u00a0CD4\u00a0(nivel\u00a0C)\u00a0\n\u00a0\n9.\u00a02.\u00a0Toxicidad \u00a0hep\u00e1tica\u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0\nLa\u00a0toxicidad\u00a0hep\u00e1tica\u00a0se\u00a0ha\u00a0descrito\u00a0con\u00a0todas\u00a0las\u00a0familias\u00a0de\u00a0FAR\u00a0aunque\u00a0con\u00a0\nincidencia \u00a0y\u00a0mecanismos \u00a0patog\u00e9nicos \u00a0diferentes783\u2010786.\u00a0La\u00a0incidencia \u00a0real\u00a0es\u00a0dif\u00edcil\u00a0de\u00a0\nestimar\u00a0por\u00a0problemas \u00a0metodol\u00f3gicos787.\u00a0En\u00a0primer\u00a0lugar\u00a0el\u00a0diagn\u00f3stico \u00a0de\u00a0toxicidad\u00a0\nhep\u00e1tica\u00a0por\u00a0un\u00a0f\u00e1rmaco\u00a0implica\u00a0una\u00a0relaci\u00f3n\u00a0temporal\u00a0y\u00a0la\u00a0exclusi\u00f3n \u00a0de\u00a0otras\u00a0causas\u00a0\nde\u00a0elevaci\u00f3n \u00a0de\u00a0enzimas\u00a0hep\u00e1ticas \u00a0(EEH)\u00a0y\u00a0estos\u00a0criterios\u00a0no\u00a0se\u00a0cumplen\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0\nde\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0VHC/VHB \u00a0con\u00a0EEH.\u00a0En\u00a0segundo\u00a0lugar,\u00a0la\u00a0definici\u00f3n \u00a0\nde\u00a0los\u00a0distintos\u00a0grados\u00a0de\u00a0hepatotoxicidad \u00a0no\u00a0es\u00a0uniforme. \u00a0En\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0se\u00a0\nsuele\u00a0definir\u00a0como\u00a0hepatotoxicidad \u00a0grave\u00a0a\u00a0una\u00a0elevaci\u00f3n \u00a0mayor\u00a0de\u00a05\u00a0veces\u00a0el\u00a0l\u00edmite\u00a0\nsuperior\u00a0de\u00a0la\u00a0normalidad \u00a0de\u00a0ALT\u00a0y/o\u00a0AST788.\u00a0Sin\u00a0embargo\u00a0esta\u00a0definici\u00f3n \u00a0est\u00e1\u00a0limitada\u00a0\nal\u00a0no\u00a0considerar \u00a0el\u00a0fallo\u00a0hep\u00e1tico, \u00a0no\u00a0tener\u00a0en\u00a0cuenta\u00a0la\u00a0hepatotoxicidad \u00a0colest\u00e1sica \u00a0o\u00a0\nmixta\u00a0y\u00a0ser\u00a0m\u00e1s\u00a0sensible\u00a0para\u00a0detectar\u00a0hepatotoxicidad \u00a0en\u00a0pacientes \u00a0con\u00a0valores\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 83basales\u00a0de\u00a0transaminasas \u00a0elevados. \u00a0Para\u00a0resolver\u00a0este\u00a0\u00faltimo\u00a0problema \u00a0se\u00a0acepta\u00a0\nconsiderar \u00a0EEH\u00a0grave\u00a0asintom\u00e1tica \u00a0a\u00a0los\u00a0incrementos \u00a0de\u00a0ALT\u00a0y/o\u00a0AST\u00a0superiores \u00a0a\u00a03,5\u00a0\nveces\u00a0la\u00a0cifra\u00a0basal\u00a0para\u00a0los\u00a0pacientes \u00a0con\u00a0de\u00a0niveles\u00a0elevados\u00a0transaminasa \u00a0basales789.\u00a0\nEn\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0la\u00a0coinfecci\u00f3n \u00a0por\u00a0VHC/VHB \u00a0aumenta\u00a0de\u00a02\u00a0a\u00a010\u00a0\nveces\u00a0las\u00a0posibilidades \u00a0de\u00a0desarrollar \u00a0EEH\u00a0durante\u00a0el\u00a0TAR,\u00a0aunque\u00a0el\u00a0desarrollo \u00a0de\u00a0fallo\u00a0\nhep\u00e1tico\u00a0debido\u00a0a\u00a0la\u00a0hepatotoxicidad \u00a0por\u00a0TAR\u00a0es\u00a0raro,\u00a0y\u00a0generalmente \u00a0sucede\u00a0en\u00a0\npacientes \u00a0con\u00a0hepatopat\u00eda \u00a0avanzada \u00a0subyacente. \u00a0La\u00a0incidencia \u00a0de\u00a0hepatotoxicidad \u00a0\naumenta\u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0previa789\u2010791.\u00a0De\u00a0este\u00a0modo\u00a0en\u00a0pacientes \u00a0\ncoinfectados \u00a0por\u00a0VIH/VHC\u00a0tratados\u00a0con\u00a0TAR,\u00a0la\u00a0frecuencia \u00a0de\u00a0EEH\u00a0grave\u00a0asintom\u00e1tica \u00a0\nes\u00a0superior\u00a0en\u00a0los\u00a0que\u00a0presentan \u00a0una\u00a0fibrosis\u00a0avanzada \u00a0(estadios\u00a0F3\u00a0y\u00a0F4,\u00a0F\u22653)792.\u00a0\nEn\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0VHC\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0C\u00a0reduce\u00a0de\u00a0\nmodo\u00a0notable\u00a0el\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0hep\u00e1tica793,\u00a0794.\u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0hepatototoxicidad \u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0las\u00a0hepatitis\u00a0\n\u0083 No\u00a0se\u00a0puede\u00a0contraindicar \u00a0ning\u00fan\u00a0FAR\u00a0en\u00a0caso\u00a0de\u00a0coinfecci\u00f3n \u00a0con\u00a0VHC\u00a0o\u00a0VHB\u00a0si\u00a0la\u00a0\nfunci\u00f3n\u00a0hep\u00e1tica\u00a0est\u00e1\u00a0preservada \u00a0(nivel\u00a0B),\u00a0pero\u00a0se\u00a0debe\u00a0priorizar\u00a0el\u00a0uso\u00a0de\u00a0FAR\u00a0con\u00a0\nel\u00a0menor\u00a0potencial \u00a0de\u00a0hepatotoxicidad \u00a0(nivel\u00a0C)\u00a0783\u2010786\u00a0\n\u0083 Se\u00a0debe\u00a0retirar\u00a0el\u00a0TAR\u00a0en\u00a0caso\u00a0de\u00a0hepatitis\u00a0sintom\u00e1tica, \u00a0y\u00a0en\u00a0la\u00a0asintom\u00e1tica \u00a0si\u00a0se\u00a0\nsospecha \u00a0que\u00a0se\u00a0debe\u00a0a\u00a0toxicidad\u00a0mitocondrial, \u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad \u00a0o\u00a0\nhipertransaminemia \u00a0grado\u00a04\u00a0(nivel\u00a0C)\u00a0785,\u00a0786\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0hepatitis\u00a0asintom\u00e1tica \u00a0con\u00a0hipertransaminemia \u00a0grado\u00a03,\u00a0se\u00a0debe\u00a0\nconsiderar \u00a0la\u00a0suspensi\u00f3n \u00a0del\u00a0TAR\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0situaci\u00f3n\u00a0cl\u00ednica,\u00a0inmunol\u00f3gica \u00a0y\u00a0\nvirol\u00f3gica, \u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0utilizados \u00a0y\u00a0de\u00a0la\u00a0historia\u00a0previa\u00a0de\u00a0exposici\u00f3n \u00a0a\u00a0FAR\u00a0\n(nivel\u00a0C)\u00a0785,\u00a0786\u00a0\n\u00a0\n9.\u00a03.\u00a0Uso\u00a0de\u00a0antirretrovirales \u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0\nLa\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0puede\u00a0alterar\u00a0el\u00a0metabolismo \u00a0y\u00a0la\u00a0biodisponibilidad \u00a0de\u00a0los\u00a0FAR\u00a0\ncon\u00a0incremento \u00a0de\u00a0toxicidad\u00a0o\u00a0alteraci\u00f3n \u00a0de\u00a0la\u00a0actividad\u00a0antiviral731,\u00a0755,\u00a0764,\u00a0795\u2010799.\u00a0Se\u00a0\nsabe\u00a0que\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0sin\u00a0insuficiencia \u00a0hepatocelular \u00a0es\u00a0una\u00a0situaci\u00f3n\u00a0muy\u00a0\nfrecuente \u00a0y\u00a0la\u00a0experiencia \u00a0acumulada \u00a0sugiere\u00a0que\u00a0se\u00a0pueden\u00a0usar\u00a0los\u00a0FAR\u00a0a\u00a0las\u00a0dosis\u00a0\nhabituales \u00a0y\u00a0que\u00a0su\u00a0eficacia\u00a0no\u00a0est\u00e1\u00a0comprometida. \u00a0Sin\u00a0embargo\u00a0en\u00a0la\u00a0insuficiencia \u00a0\nhepatocelular \u00a0se\u00a0reduce\u00a0el\u00a0metabolismo \u00a0de\u00a0f\u00e1rmacos \u00a0v\u00eda\u00a0P450\u00a0y\u00a0la\u00a0\nglucuronoconjugaci\u00f3n. \u00a0No\u00a0hay\u00a0datos\u00a0sobre\u00a0el\u00a0TAR\u00a0en\u00a0casos\u00a0de\u00a0hepatitis\u00a0aguda.\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0uso\u00a0de\u00a0FAR\u00a0en\u00a0hepatopat\u00edas \u00a0\n\u0083 Se\u00a0debe\u00a0evaluar\u00a0el\u00a0grado\u00a0de\u00a0fibrosis\u00a0hep\u00e1tica\u00a0y\u00a0el\u00a0grado\u00a0de\u00a0funci\u00f3n\u00a0hep\u00e1tica\u00a0en\u00a0los\u00a0\npacientes \u00a0coinfectados \u00a0por\u00a0virus\u00a0hepatotropos \u00a0ya\u00a0que\u00a0pueden\u00a0condicionar \u00a0la\u00a0\nelecci\u00f3n\u00a0del\u00a0TAR,\u00a0las\u00a0dosis\u00a0prescritas \u00a0de\u00a0los\u00a0FAR\u00a0y\u00a0la\u00a0estrategia \u00a0de\u00a0monitorizaci\u00f3n \u00a0de\u00a0\nsu\u00a0eficacia\u00a0y\u00a0toxicidad\u00a0(nivel\u00a0C)789\u2010792\u00a0\n\u0083 Los\u00a0FAR\u00a0se\u00a0pueden\u00a0usar\u00a0a\u00a0las\u00a0dosis\u00a0habituales \u00a0en\u00a0caso\u00a0de\u00a0hepatitis\u00a0cr\u00f3nica\u00a0sin\u00a0\ninsuficiencia \u00a0hepatocelular \u00a0o\u00a0con\u00a0insuficiencia \u00a0hepatocelular \u00a0leve\u00a0(Child\u00a0\u00a0A)\u00a0\nextremando \u00a0la\u00a0vigilancia\u00a0por\u00a0el\u00a0mayor\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0(nivel\u00a0B)\u00a0731,\u00a0755,\u00a0764,\u00a0795\u2010799\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 84\u0083 En\u00a0caso\u00a0de\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0con\u00a0signos\u00a0de\u00a0insuficiencia \u00a0hepatocelular \u00a0se\u00a0deber\u00e1\u00a0\najustar\u00a0la\u00a0dosis\u00a0de\u00a0los\u00a0f\u00e1rmacos, \u00a0idealmente \u00a0mediante \u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0niveles\u00a0\u00a0\nplasm\u00e1ticos, \u00a0o\u00a0en\u00a0su\u00a0ausencia, \u00a0mediante \u00a0las\u00a0recomendaciones \u00a0de\u00a0la\u00a0Tabla\u00a016\u00a0(nivel\u00a0\nC)\u00a0731,\u00a0755,\u00a0764,\u00a0795\u2010799\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0hepatitis\u00a0aguda\u00a0grave\u00a0debe\u00a0interrumpirse \u00a0el\u00a0TAR\u00a0y\u00a0reintroducirlo \u00a0una\u00a0\nvez\u00a0superado \u00a0el\u00a0problema \u00a0(nivel\u00a0C)\u00a0731,\u00a0755,\u00a0764,\u00a0795\u2010799\u00a0\u00a0\n\u00a09.\u00a04.\u00a0TAR\u00a0en\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0\u00a0de\u00a0la\u00a0hepatitis\u00a0por\u00a0virus\u00a0C\u00a0\u00a0\nEl\u00a0tratamiento \u00a0recomendado \u00a0de\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0VHC\u00a0en\u00a0pacientes \u00a0coinfectados \u00a0\npor\u00a0el\u00a0VIH\u00a0es\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0interfer\u00f3n \u00a0pegilado\u00a0y\u00a0ribavirina\n800\u2010808.\u00a0Por\u00a0otro\u00a0lado,\u00a0se\u00a0\nhan\u00a0descrito\u00a0brotes\u00a0de\u00a0hepatitis\u00a0aguda\u00a0C\u00a0en\u00a0homosexuales \u00a0infectados \u00a0por\u00a0VIH809\u2010812,\u00a0\npara\u00a0cuyo\u00a0tratamiento \u00a0se\u00a0recomienda \u00a0interfer\u00f3n \u00a0pegilado,\u00a0en\u00a0caso\u00a0de\u00a0que\u00a0la\u00a0viremia\u00a0C\u00a0\npersista\u00a0detectable \u00a0a\u00a0las\u00a012\u00a0semanas813\u2010816.\u00a0La\u00a0duraci\u00f3n\u00a0\u00f3ptima\u00a0del\u00a0tratamiento \u00a0en\u00a0\nambos\u00a0casos\u00a0est\u00e1\u00a0por\u00a0definir815.\u00a0Un\u00a0aspecto\u00a0importante \u00a0cuando\u00a0se\u00a0inicia\u00a0tratamiento \u00a0\ncon\u00a0interfer\u00f3n \u00a0y\u00a0ribavirina \u00a0en\u00a0pacientes \u00a0coinfectados \u00a0es\u00a0la\u00a0selecci\u00f3n\u00a0de\u00a0los\u00a0FAR.\u00a0Estos\u00a0\npueden\u00a0contribuir \u00a0al\u00a0incremento \u00a0del\u00a0riesgo\u00a0de\u00a0los\u00a0efectos\u00a0adversos\u00a0por\u00a0la\u00a0v\u00eda\u00a0de\u00a0\ntoxicidades \u00a0aditivas\u00a0o\u00a0sin\u00e9rgicas \u00a0como\u00a0por\u00a0ejemplo\u00a0anemia\u00a0y/o\u00a0neutropenia \u00a0si\u00a0se\u00a0utiliza\u00a0\nzidovudina817,\u00a0818,\u00a0aumento\u00a0de\u00a0la\u00a0toxicidad\u00a0mitocondrial \u00a0con\u00a0la\u00a0didanosina \u00a0y\u00a0la\u00a0\nestavudina819\u2010821\u00a0pancreatitis, \u00a0acidosis\u00a0l\u00e1ctica\u00a0y\u00a0descompensaci\u00f3n \u00a0de\u00a0la\u00a0cirrosis\u00a0con\u00a0\ndidanosina820\u2010823.\u00a0Un\u00a0segundo\u00a0mecanismo \u00a0potencial \u00a0por\u00a0el\u00a0que\u00a0los\u00a0AN\u00a0pueden\u00a0influir\u00a0el\u00a0\ntratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0C\u00a0es\u00a0por\u00a0la\u00a0v\u00eda\u00a0de\u00a0interferencia \u00a0con\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0la\u00a0RBV\u00a0\nfrente\u00a0al\u00a0VHC.\u00a0En\u00a0este\u00a0contexto, \u00a0el\u00a0uso\u00a0de\u00a0abacavir\u00a0se\u00a0ha\u00a0visto\u00a0asociado\u00a0a\u00a0una\u00a0menor\u00a0\nrespuesta \u00a0al\u00a0tratamiento \u00a0con\u00a0interfer\u00f3n \u00a0pegilado\u00a0y\u00a0RBV\u00a0en\u00a0algunos\u00a0estudios824\u2010826,\u00a0pero\u00a0\nno\u00a0en\u00a0otros673,\u00a0827,\u00a0828.\u00a0\nLos\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0EFV\u00a0aumentan \u00a0en\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0por\u00a0encima\u00a0del\u00a0dintel\u00a0\nde\u00a0toxicidad\u00a0del\u00a0sistema\u00a0nervioso\u00a0central\u00a0en\u00a0un\u00a0alto\u00a0porcentaje \u00a0de\u00a0pacientes731,\u00a0829\u00a0por\u00a0\nlo\u00a0que,\u00a0si\u00a0se\u00a0usa\u00a0EFV\u00a0en\u00a0este\u00a0escenario, \u00a0deber\u00eda\u00a0hacerse\u00a0con\u00a0monitorizaci\u00f3n \u00a0de\u00a0niveles\u00a0\nde\u00a0f\u00e1rmaco,\u00a0para\u00a0evitar\u00a0la\u00a0sobreexposici\u00f3n \u00a0al\u00a0mismo.\u00a0Por\u00a0\u00faltimo\u00a0se\u00a0ha\u00a0comunicado \u00a0que\u00a0\nuna\u00a0sustancial \u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0estable\u00a0con\u00a0ATV\u00a0experimentan \u00a0\nhiperbilirrubinemia \u00a0e\u00a0ictericia\u00a0tras\u00a0el\u00a0inicio\u00a0de\u00a0tratamiento \u00a0para\u00a0la\u00a0hepatitis\u00a0C\u00a0con\u00a0\ninterfer\u00f3n \u00a0m\u00e1s\u00a0ribavirina. \u00a0Este\u00a0hecho\u00a0podr\u00eda\u00a0ser\u00a0debido\u00a0al\u00a0incremento \u00a0de\u00a0bilirrubina \u00a0\nasociado\u00a0a\u00a0la\u00a0hemolisis \u00a0por\u00a0ribavirina \u00a0y\u00a0al\u00a0compromiso \u00a0del\u00a0normal\u00a0aclaramiento \u00a0de\u00a0\nbilirrubina \u00a0debido\u00a0a\u00a0la\u00a0inhibici\u00f3n \u00a0competitiva \u00a0de\u00a0ATV830.\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0tratamiento \u00a0simult\u00e1neo \u00a0del\u00a0VIH\u00a0y\u00a0VHC\u00a0\n\u0083 El\u00a0TAR\u00a0no\u00a0debe\u00a0iniciarse\u00a0simult\u00e1neamente \u00a0con\u00a0el\u00a0tratamiento \u00a0del\u00a0VHC\u00a0(nivel\u00a0C)816\u00a0\n\u0083 Cuando\u00a0se\u00a0traten\u00a0simult\u00e1neamente \u00a0el\u00a0VIH\u00a0y\u00a0el\u00a0VHC,\u00a0debe\u00a0realizarse \u00a0un\u00a0seguimiento \u00a0\nestrecho\u00a0del\u00a0paciente\u00a0para\u00a0detectar\u00a0reacciones \u00a0adversas\u00a0(nivel\u00a0B)\u00a0815,\u00a0831,\u00a0832\u00a0\n\u0083 No\u00a0se\u00a0debe\u00a0asociar\u00a0la\u00a0ribavirina \u00a0con\u00a0ddI\u00a0(nivel\u00a0B)816\u00a0\n\u0083 Se\u00a0evitar\u00e1\u00a0el\u00a0uso\u00a0simult\u00e1neo \u00a0de\u00a0ribavirina \u00a0con\u00a0ZDV\u00a0(nivel\u00a0B)816\u00a0\n\u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 859.\u00a05.\u00a0Tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0B\u00a0en\u00a0pacientes \u00a0coinfectados \u00a0\u00a0\nLos\u00a0FAR\u00a0activos\u00a0frente\u00a0al\u00a0VIH\u00a0y\u00a0al\u00a0VHB\u00a0son\u00a03TC,\u00a0FTC\u00a0y\u00a0TDF781,\u00a0833\u2010841.\u00a0Si\u00a0alguno\u00a0de\u00a0ellos\u00a0se\u00a0\nretirara\u00a0de\u00a0un\u00a0TAR\u00a0que\u00a0fracase\u00a0puede\u00a0originar\u00a0en\u00a0coinfectados \u00a0por\u00a0VHB\u00a0un\u00a0rebrote\u00a0del\u00a0\nvirus\u00a0con\u00a0da\u00f1o\u00a0hepatocelular842.\u00a0El\u00a0tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0por\u00a0VHB\u00a0con\u00a03TC\u00a0o\u00a0FTC\u00a0\nen\u00a0monoterapia \u00a0facilita\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0al\u00a0VIH836\u2010841.\u00a0Entecavir, \u00a0f\u00e1rmaco\u00a0\nactivo\u00a0frente\u00a0al\u00a0VHB,\u00a0ha\u00a0demostrado \u00a0actividad\u00a0frente\u00a0a\u00a0VIH\u00a0y\u00a0capacidad \u00a0para\u00a0inducir\u00a0\nigualmente \u00a0\u00a0mutaciones, \u00a0como\u00a0la\u00a0M184V836,\u00a0838.\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0tratamiento \u00a0hepatitis\u00a0B\u00a0en\u00a0infectados \u00a0con\u00a0VIH\u00a0\n\u2022 Se\u00a0recomienda \u00a0iniciar\u00a0el\u00a0TAR\u00a0usando\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0TDF\u00a0+\u00a0FTC\u00a0(o\u00a03TC)\u00a0como\u00a0AN\u00a0en\u00a0\npacientes \u00a0coinfectados \u00a0que\u00a0requieran \u00a0tratamiento \u00a0de\u00a0VIH\u00a0o\u00a0VHB\u00a0(nivel\u00a0C)781,\u00a0838\u00a0\n\u2022 Si\u00a0se\u00a0requiere\u00a0tratamiento \u00a0del\u00a0VHB\u00a0y\u00a0se\u00a0decide\u00a0no\u00a0tratar\u00a0el\u00a0VIH\u00a0se\u00a0recomienda \u00a0\u00a0usar\u00a0\nf\u00e1rmacos \u00a0que\u00a0no\u00a0induzcan\u00a0resistencias \u00a0al\u00a0VIH\u00a0(nivel\u00a0C)781,\u00a0838\u00a0\n\u2022 No\u00a0debe\u00a0usarse\u00a0entecavir \u00a0en\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0salvo\u00a0que\u00a0su\u00a0\nreplicaci\u00f3n \u00a0est\u00e9\u00a0controlada \u00a0con\u00a0otros\u00a0f\u00e1rmacos \u00a0(Nivel\u00a0B)\u00a0781,\u00a0838\u00a0\u00a0\n\u2022 En\u00a0pacientes \u00a0coinfectados \u00a0en\u00a0los\u00a0que\u00a0por\u00a0cualquier \u00a0motivo\u00a0se\u00a0suspenda \u00a03TC,\u00a0FTC\u00a0o\u00a0\nTDF,\u00a0se\u00a0debe\u00a0incluir\u00a0en\u00a0el\u00a0TAR\u00a0otro\u00a0f\u00e1rmaco\u00a0con\u00a0actividad\u00a0anti\u2010VHB\u00a0(nivel\u00a0C)\u00a0781,\u00a0838\u00a0\u00a0\n\u00a0\n\u00a0\n10.\u00a0TAR\u00a0EN\u00a0LA\u00a0MUJER,\u00a0EN\u00a0EL\u00a0EMBARAZO \u00a0Y\u00a0COMO\u00a0PREVENCI\u00d3N \u00a0DE\u00a0LA\u00a0TRANSMISI\u00d3N \u00a0\nMATERNO \u2010FETAL\u00a0\u00a0\nM\u00e1s\u00a0del\u00a050%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0mundial\u00a0infectada \u00a0por\u00a0el\u00a0VIH\u00a0son\u00a0mujeres.\u00a0En\u00a0Europa\u00a0\nest\u00e1n\u00a0aumentando \u00a0las\u00a0nuevas\u00a0infecciones \u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0femenina, \u00a0sobre\u00a0todo\u00a0por\u00a0v\u00eda\u00a0\nsexual\u00a0y\u00a0en\u00a0los\u00a0estratos\u00a0sociales\u00a0m\u00e1s\u00a0desfavorecidos, \u00a0como\u00a0en\u00a0los\u00a0inmigrantes843.\u00a0En\u00a0\nEspa\u00f1a,\u00a0sin\u00a0embargo, \u00a0datos\u00a0recientes\u00a0de\u00a0la\u00a0cohorte\u00a0CoRis,\u00a0muestran \u00a0una\u00a0discreta\u00a0\ndisminuci\u00f3n \u00a0(24,3%)\u00a0en\u00a0los\u00a0nuevos\u00a0casos,\u00a0aunque\u00a0confirman \u00a0cambios\u00a0en\u00a0los\u00a0patrones\u00a0\nde\u00a0infecci\u00f3n, \u00a0afectando \u00a0especialmente \u00a0a\u00a0la\u00a0poblaci\u00f3n \u00a0inmigrante844.\u00a0\u00a0\nLas\u00a0inc\u00f3gnitas \u00a0por\u00a0resolver\u00a0son\u00a0muchas\u00a0dado\u00a0que\u00a0las\u00a0mujeres\u00a0no\u00a0han\u00a0sido\u00a0incorporadas \u00a0\na\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0hasta\u00a01993\u00a0y\u00a0a\u00fan\u00a0en\u00a0los\u00a0m\u00e1s\u00a0recientes\u00a0su\u00a0n\u00famero\u00a0no\u00a0sobrepasa \u00a0el\u00a0\n30%.\u00a0Las\u00a0diferencias \u00a0biol\u00f3gicas \u00a0y\u00a0de\u00a0composici\u00f3n \u00a0corporal,\u00a0por\u00a0citar\u00a0algunas,\u00a0podr\u00edan\u00a0\nsuponer\u00a0\u00a0cambios\u00a0tanto\u00a0en\u00a0la\u00a0evoluci\u00f3n \u00a0de\u00a0la\u00a0enfermedad, \u00a0como\u00a0en\u00a0la\u00a0respuesta \u00a0a\u00a0la\u00a0\nterapia\u00a0o\u00a0a\u00a0las\u00a0toxicidades \u00a0farmacol\u00f3gicas \u00a0que\u00a0no\u00a0han\u00a0sido\u00a0suficientemente \u00a0\nexploradas845,\u00a0846.\u00a0\u00a0\n\u00a0\n10.1\u00a0Consideraciones \u00a0especiales \u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0mujer\u00a0\nVarios\u00a0estudios\u00a0de\u00a0cohortes\u00a0han\u00a0descrito\u00a0en\u00a0las\u00a0mujeres\u00a0datos\u00a0discordantes, \u00a0tanto\u00a0en\u00a0\nlos\u00a0par\u00e1metros \u00a0inmuno\u2010\u00a0virol\u00f3gicos, \u00a0como\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0enfermedad847\u2010849.\u00a0No\u00a0\nobstante, \u00a0no\u00a0han\u00a0sido\u00a0observadas \u00a0diferencias \u00a0por\u00a0g\u00e9nero\u00a0en\u00a0la\u00a0eficacia\u00a0de\u00a0los\u00a0\nf\u00e1rmacos850.\u00a0El\u00a0inicio\u00a0y\u00a0la\u00a0elecci\u00f3n\u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0mujer\u00a0tienen\u00a0las\u00a0mismas\u00a0indicaciones \u00a0y\u00a0\nobjetivos\u00a0que\u00a0en\u00a0el\u00a0hombre,\u00a0con\u00a0la\u00a0\u00fanica\u00a0salvedad\u00a0del\u00a0\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0\u00a0\n(menor\u00a0de\u00a0250\u00a0c\u00e9lulas/\u00b5L), \u00a0si\u00a0la\u00a0combinaci\u00f3n \u00a0antirretroviral \u00a0incluye\u00a0NVP.\u00a0\nExisten,\u00a0sin\u00a0embargo, \u00a0aspectos\u00a0espec\u00edficos \u00a0de\u00a0g\u00e9nero\u00a0que\u00a0obligan\u00a0a\u00a0modificaciones \u00a0en\u00a0\nel\u00a0TAR\u00a0y\u00a0deben\u00a0ser\u00a0tenidos\u00a0en\u00a0cuenta.\u00a0Por\u00a0un\u00a0lado\u00a0hay\u00a0una\u00a0mayor\u00a0incidencia \u00a0de\u00a0ciertos\u00a0\nefectos\u00a0secundarios \u00a0a\u00a0los\u00a0f\u00e1rmacos \u00a0en\u00a0las\u00a0mujeres849\u00a0lo\u00a0que\u00a0conduce\u00a0a\u00a0un\u00a0abandono \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 86m\u00e1s\u00a0frecuente \u00a0del\u00a0TAR361.\u00a0Y\u00a0sobre\u00a0todo,\u00a0el\u00a0potencial \u00a0reproductivo \u00a0de\u00a0la\u00a0mujer,\u00a0en\u00a0sus\u00a0\ndistintas\u00a0etapas,\u00a0condiciona \u00a0una\u00a0cuidadosa \u00a0aproximaci\u00f3n \u00a0multidisciplinar, \u00a0con\u00a0el\u00a0fin\u00a0no\u00a0\nsolo\u00a0de\u00a0evitar\u00a0la\u00a0transmisi\u00f3n \u00a0vertical,\u00a0sino\u00a0adem\u00e1s\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0otras\u00a0ETS,\u00a0\nembarazos \u00a0no\u00a0deseados \u00a0y\u00a0comorbilidades \u00a0espec\u00edficas \u00a0(infecci\u00f3n \u00a0por\u00a0HPV\u00a0y\u00a0carcinoma \u00a0\nde\u00a0c\u00e9rvix),\u00a0y\u00a0las\u00a0alteraciones \u00a0asociadas \u00a0a\u00a0la\u00a0menopausia \u00a0que\u00a0se\u00a0agravadas \u00a0con\u00a0\nfrecuencia \u00a0por\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0con\u00a0su\u00a0terapia.\u00a0\n\u00a0\n10.2\u00a0Diferencias \u00a0en\u00a0efectos\u00a0adversos\u00a0\nLa\u00a0\u00a0mayor\u00a0incidencia \u00a0de\u00a0toxicidad\u00a0farmacol\u00f3gica \u00a0en\u00a0las\u00a0mujeres,\u00a0descrita\u00a0de\u00a0forma\u00a0casi\u00a0\nun\u00e1nime\u00a0por\u00a0los\u00a0investigadores, \u00a0y\u00a0es,\u00a0sin\u00a0duda,\u00a0un\u00a0tema\u00a0preocupante. \u00a0A\u00a0las\u00a0evidencias \u00a0\naportadas \u00a0por\u00a0el\u00a0grupo\u00a0ICONA\u00a0y\u00a0otras\u00a0cohortes845\u00a0se\u00a0suman\u00a0los\u00a0resultados \u00a0de\u00a0Ensayos\u00a0\nCl\u00ednicos\u00a0como\u00a0el\u00a0FIRST848.\u00a0\nDe\u00a0sobra\u00a0conocido\u00a0y\u00a0con\u00a0reflejo\u00a0espec\u00edfico \u00a0en\u00a0las\u00a0directrices, \u00a0es\u00a0el\u00a0incremento \u00a0de\u00a0la\u00a0\nsusceptibilidad \u00a0femenina \u00a0al\u00a0exantema \u00a0y\u00a0la\u00a0hepatotoxicidad \u00a0grave\u00a0con\u00a0NVP849,\u00a0851,\u00a0\u00a0la\u00a0\nmayor\u00a0incidencia \u00a0de\u00a0acidosis\u00a0l\u00e1ctica,\u00a0sobre\u00a0todo\u00a0durante\u00a0el\u00a0embarazo852\u00a0y\u00a0a\u00a0la\u00a0m\u00e1s\u00a0\nintensa\u00a0presencia \u00a0de\u00a0alteraciones \u00a0metab\u00f3licas853,\u00a0854,\u00a0incluida\u00a0la\u00a0resistencia \u00a0a\u00a0la\u00a0\ninsulina855\u00a0y\u00a0la\u00a0redistribuci\u00f3n \u00a0grasa856,\u00a0857,\u00a0con\u00a0caracter\u00edsticas \u00a0especiales \u00a0en\u00a0las\u00a0mujeres,\u00a0\ny\u00a0mayor\u00a0repercusi\u00f3n \u00a0psicol\u00f3gica858.\u00a0\nTambi\u00e9n\u00a0los\u00a0efectos\u00a0t\u00f3xicos\u00a0del\u00a0EFV\u00a0sobre\u00a0el\u00a0SNC\u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0las\u00a0mujeres\u00a0y\u00a0\ncondicionan, \u00a0en\u00a0ocasiones, \u00a0un\u00a0abandono \u00a0precoz\u00a0de\u00a0la\u00a0terapia859,\u00a0860.\u00a0\u00a0Adem\u00e1s,\u00a0no\u00a0\npodemos \u00a0\u00a0olvidar\u00a0que\u00a0tanto\u00a0la\u00a0depresi\u00f3n \u00a0como\u00a0otros\u00a0trastornos \u00a0psiqui\u00e1tricos \u00a0son\u00a0ya\u00a0\nm\u00e1s\u00a0comunes\u00a0en\u00a0las\u00a0mujeres\u00a0portadoras \u00a0del\u00a0VIH\u00a0respecto\u00a0a\u00a0la\u00a0poblaci\u00f3n \u00a0general861,\u00a0862.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nTeniendo \u00a0en\u00a0cuenta\u00a0que\u00a0la\u00a0osteoporosis/ \u00a0osteopenia, \u00a0se\u00a0asocia,\u00a0entre\u00a0otros\u00a0factores,\u00a0al\u00a0\u00a0\nbajo\u00a0IMC\u00a0e\u00a0hipertrigliceridemia, \u00a0m\u00e1s\u00a0comunes\u00a0en\u00a0las\u00a0personas\u00a0VIH+,\u00a0es\u00a0comprensible \u00a0el\u00a0\naumento\u00a0de\u00a0su\u00a0prevalencia \u00a0en\u00a0esta\u00a0poblaci\u00f3n863,\u00a0864.\u00a0En\u00a0las\u00a0mujeres\u00a0VIH+\u00a0la\u00a0densidad\u00a0\n\u00f3sea\u00a0es\u00a0menor\u00a0que\u00a0en\u00a0las\u00a0no\u00a0portadoras \u00a0del\u00a0virus\u00a0pero\u00a0es\u00a0cl\u00ednicamente \u00a0irrelevante \u00a0en\u00a0la\u00a0\npre\u00a0menopausia865\u2010867\u00a0cobrando \u00a0mayor\u00a0importancia \u00a0en\u00a0la\u00a0postmenopausia865.\u00a0\u00a0\u00a0Este\u00a0\naspecto\u00a0no\u00a0es\u00a0balad\u00ed\u00a0en\u00a0una\u00a0poblaci\u00f3n \u00a0que\u00a0envejece, \u00a0con\u00a0mayor\u00a0velocidad \u00a0y\u00a0con\u00a0mayor\u00a0\nconcomitancia \u00a0de\u00a0factores\u00a0de\u00a0riesgo,\u00a0que\u00a0la\u00a0de\u00a0referencia, \u00a0y\u00a0puede\u00a0determinar \u00a0cambios\u00a0\nen\u00a0el\u00a0TAR.\u00a0\n\u00a0\n10.3\u00a0Otras\u00a0diferencias \u00a0de\u00a0g\u00e9nero\u00a0que\u00a0pueden\u00a0afectar\u00a0la\u00a0eficacia\u00a0del\u00a0TAR\u00a0\nHan\u00a0sido\u00a0descritos\u00a0peores\u00a0resultados \u00a0en\u00a0cuanto\u00a0a\u00a0g\u00e9nero,\u00a0en\u00a0relaci\u00f3n\u00a0a\u00a0los\u00a0objetivos\u00a0\ndel\u00a0TAR361.\u00a0Podemos \u00a0identificar, \u00a0sin\u00a0embargo, \u00a0factores\u00a0de\u00a0confusi\u00f3n \u00a0potenciales \u00a0que\u00a0\nexplicar\u00edan \u00a0parte\u00a0de\u00a0estas\u00a0diferencias. \u00a0Aspectos\u00a0socio\u2010culturales, \u00a0(la\u00a0desigualdad \u00a0de\u00a0la\u00a0\nmujer\u00a0en\u00a0algunos\u00a0sectores\u00a0como\u00a0inmigrantes, \u00a0minor\u00edas\u00a0\u00e9tnicas,\u00a0etc.),\u00a0una\u00a0superior\u00a0\nincidencia \u00a0de\u00a0problemas \u00a0psicol\u00f3gicos/ \u00a0psiqui\u00e1tricos, \u00a0un\u00a0mayor\u00a0temor\u00a0a\u00a0la\u00a0\nestigmatizaci\u00f3n, \u00a0una\u00a0excesiva\u00a0preocupaci\u00f3n \u00a0por\u00a0la\u00a0confidencialidad\u2026 \u00a0Todo\u00a0lo\u00a0cual,\u00a0\ncontribuye \u00a0a\u00a0dificultades \u00a0en\u00a0el\u00a0acceso\u00a0al\u00a0sistema\u00a0sanitario, \u00a0al\u00a0retraso\u00a0en\u00a0el\u00a0inicio\u00a0del\u00a0\nTAR\u00a0y\u00a0a\u00a0una\u00a0peor\u00a0adherencia. \u00a0\u00a0\u00a0\n\u00a0\n10.4\u00a0\u00a0Mujer\u00a0en\u00a0periodo\u00a0f\u00e9rtil:\u00a0interacciones \u00a0con\u00a0anticonceptivos \u00a0hormonales \u00a0\nAproximadamente \u00a0el\u00a070%\u00a0de\u00a0las\u00a0mujeres\u00a0que\u00a0participan \u00a0en\u00a0estudios\u00a0sobre\u00a0el\u00a0VIH\u00a0son\u00a0\nsexualmente \u00a0activas,\u00a0muchas\u00a0de\u00a0ellas\u00a0en\u00a0edad\u00a0f\u00e9rtil.\u00a0El\u00a0uso\u00a0del\u00a0preservativo \u00a0es\u00a0el\u00a0\nm\u00e9todo\u00a0de\u00a0elecci\u00f3n,\u00a0tanto\u00a0por\u00a0su\u00a0eficacia\u00a0(con\u00a0una\u00a0tasa\u00a0de\u00a0fallos\u00a0del\u00a03%)868,\u00a0como\u00a0por\u00a0\nprevenci\u00f3n \u00a0simult\u00e1nea \u00a0de\u00a0otras\u00a0ETS.\u00a0En\u00a0la\u00a0pr\u00e1ctica\u00a0real,\u00a0el\u00a0uso\u00a0de\u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0es\u00a0variable\u00a0y\u00a0la\u00a0anticoncepci\u00f3n \u00a0hormonal \u00a0puede\u00a0ser\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 87muchas\u00a0pacientes \u00a0debido\u00a0a\u00a0influencias \u00a0culturales \u00a0u\u00a0otros\u00a0factores.\u00a0Adem\u00e1s,\u00a0en\u00a0\nocasiones \u00a0son\u00a0prescritos \u00a0sin\u00a0conocimiento \u00a0del\u00a0experto\u00a0en\u00a0VIH,\u00a0por\u00a0m\u00e9dicos\u00a0de\u00a0familia\u00a0o\u00a0\nginec\u00f3logos \u00a0desconocedores \u00a0de\u00a0los\u00a0riesgos\u00a0potenciales. \u00a0Los\u00a0m\u00e9todos\u00a0anticonceptivos \u00a0\nhormonales \u00a0e\u00a0intrauterinos \u00a0en\u00a0general\u00a0se\u00a0han\u00a0mostrado \u00a0seguros\u00a0en\u00a0mujeres\u00a0con\u00a0\ninfecci\u00f3n\u00a0VIH869\u2010872.\u00a0\u00a0\n\u00a0\nAunque\u00a0la\u00a0anticoncepci\u00f3n \u00a0hormonal \u00a0no\u00a0parece\u00a0interferir\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0\nenfermedad, \u00a0ni\u00a0con\u00a0la\u00a0eficacia\u00a0del\u00a0TAR871,\u00a0muchos\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0de\u00a0\nuso\u00a0com\u00fan,\u00a0interaccionan873\u2010879\u00a0con\u00a0los\u00a0anticonceptivos \u00a0hormonales \u00a0aumentando \u00a0o\u00a0\ndisminuyendo \u00a0los\u00a0niveles\u00a0en\u00a0sangre\u00a0del\u00a0etinilestradiol \u00a0y/o\u00a0de\u00a0noretindrona, \u00a0\nconduciendo \u00a0a\u00a0la\u00a0intensificaci\u00f3n \u00a0de\u00a0su\u00a0toxicidad\u00a0(como\u00a0por\u00a0ejemplo\u00a0el\u00a0\ntromboembolismo), \u00a0o\u00a0a\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0su\u00a0eficacia\u00a0respectivamente, \u00a0(para\u00a0m\u00e1s\u00a0\ndetalles\u00a0v\u00e9ase\u00a0el\u00a0cap\u00edtulo\u00a0de\u00a0interacciones \u00a0y\u00a0tablas\u00a05\u00a0a\u00a09).\u00a0Cuando\u00a0se\u00a0usan\u00a0estos\u00a0\nf\u00e1rmacos \u00a0se\u00a0recomienda \u00a0la\u00a0utilizaci\u00f3n \u00a0de\u00a0medios\u00a0alternativos \u00a0o\u00a0adicionales \u00a0de\u00a0\ncontracepci\u00f3n. \u00a0\nDeber\u00eda\u00a0considerarse \u00a0el\u00a0efecto\u00a0del\u00a0acetato\u00a0de\u00a0medroxiprogesterona \u00a0depot\u00a0(Depo\u2010\nProgevera) \u00a0en\u00a0pacientes \u00a0con\u00a0osteoporosis \u00a0establecida \u00a0o\u00a0con\u00a0factores\u00a0de\u00a0riesgo\u00a0para\u00a0\nsufrirla,\u00a0por\u00a0su\u00a0efecto\u00a0negativo\u00a0sobre\u00a0la\u00a0densidad\u00a0mineral\u00a0\u00f3sea880.\u00a0Aunque,\u00a0por\u00a0razones\u00a0\nno\u00a0aclaradas, \u00a0el\u00a0uso\u00a0de\u00a0este\u00a0f\u00e1rmaco\u00a0se\u00a0asocia\u00a0en\u00a0estudios\u00a0epidemiol\u00f3gicos, \u00a0con\u00a0un\u00a0\nmayor\u00a0riesgo\u00a0de\u00a0adquisici\u00f3n \u00a0de\u00a0VIH\u00a0en\u00a0mujeres\u00a0j\u00f3venes\u00a0(18\u201024\u00a0a\u00f1os)881.\u00a0\u00a0\n\u00a0\nHay\u00a0muy\u00a0pocos\u00a0datos\u00a0respecto\u00a0a\u00a0otros\u00a0tipos\u00a0de\u00a0anticoncepci\u00f3n \u00a0hormonal \u00a0combinada \u00a0\n(parches\u00a0de\u00a0larga\u00a0duraci\u00f3n, \u00a0anillos\u00a0vaginales \u00a0con\u00a0componente \u00a0hormonal, \u00a0etc.),\u00a0por\u00a0ello\u00a0\nse\u00a0recomienda \u00a0tambi\u00e9n\u00a0el\u00a0uso\u00a0de\u00a0medios\u00a0combinados \u00a0de\u00a0contracepci\u00f3n. \u00a0Tambi\u00e9n\u00a0son\u00a0\npocos\u00a0los\u00a0estudios\u00a0con\u00a0el\u00a0acetato\u00a0de\u00a0medroxiprogesterona \u00a0de\u00a0dep\u00f3sito\u00a0(DMPA),\u00a0que\u00a0no\u00a0\nparece\u00a0ver\u00a0afectados \u00a0sus\u00a0niveles\u00a0por\u00a0el\u00a0NFV,\u00a0la\u00a0NVP\u00a0o\u00a0el\u00a0EFV\u00a0882,\u00a0883.\u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0TAR\u00a0en\u00a0mujeres\u00a0\n\u25cfEl\u00a0inicio\u00a0y\u00a0los\u00a0objetivos\u00a0del\u00a0TAR\u00a0son\u00a0los\u00a0mismos\u00a0en\u00a0las\u00a0mujeres\u00a0que\u00a0en\u00a0los\u00a0hombres\u00a0\n(Nivel\u00a0A)\u00a0\n\u25cfLa\u00a0mayor\u00a0incidencia \u00a0de\u00a0toxicidades, \u00a0como\u00a0el\u00a0exantema \u00a0y\u00a0la\u00a0hepatotoxicidad \u00a0por\u00a0NVP\u00a0\ncondicionan \u00a0modificaciones \u00a0en\u00a0su\u00a0uso\u00a0en\u00a0mujeres\u00a0(CD4<250 \u00a0c\u00e9lulas/\u00b5L) \u00a0(Nivel\u00a0A)\u00a0\n\u25cf\u00a0La\u00a0prescripci\u00f3n \u00a0de\u00a0antirretrovirales \u00a0debe\u00a0tener\u00a0en\u00a0cuenta\u00a0el\u00a0uso\u00a0actual\u00a0o\u00a0planificado \u00a0\nde\u00a0anticonceptivos. \u00a0Los\u00a0contraceptivos \u00a0hormonales \u00a0interaccionan \u00a0con\u00a0muchos\u00a0\nf\u00e1rmacos \u00a0antirretrovirales \u00a0por\u00a0lo\u00a0que\u00a0deben\u00a0ser\u00a0sustituidos \u00a0o\u00a0complementados \u00a0por\u00a0\notros\u00a0m\u00e9todos\u00a0anticonceptivos \u00a0(Nivel\u00a0A)\u00a0\n\u00a0\n10.5\u00a0TAR\u00a0en\u00a0el\u00a0embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0materno\u2010fetal\u00a0\nLa\u00a0transmisi\u00f3n \u00a0materno\u2010fetal\u00a0es\u00a0la\u00a0causa\u00a0de\u00a0pr\u00e1cticamente \u00a0la\u00a0totalidad\u00a0de\u00a0los\u00a0casos\u00a0de\u00a0\ninfecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0ni\u00f1os.\u00a0El\u00a0periodo\u00a0fetal\u00a0m\u00e1s\u00a0vulnerable \u00a0es\u00a0durante\u00a0la\u00a0gestaci\u00f3n \u00a0\ntemprana, \u00a0por\u00a0lo\u00a0que\u00a0todas\u00a0las\u00a0mujeres\u00a0deben\u00a0recibir\u00a0informaci\u00f3n \u00a0previa\u00a0sobre\u00a0la\u00a0\nteratogenicidad \u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0como\u00a0parte\u00a0de\u00a0su\u00a0control\u00a0cl\u00ednico\u00a0y\u00a0adecuar\u00a0el\u00a0TAR\u00a0ante\u00a0\nel\u00a0deseo\u00a0de\u00a0embarazo884.\u00a0\u00a0\nA\u00a0continuaci\u00f3n \u00a0se\u00a0resumen\u00a0las\u00a0evidencias \u00a0sobre\u00a0las\u00a0que\u00a0se\u00a0basan\u00a0las\u00a0recomendaciones \u00a0\ndel\u00a0TAR\u00a0en\u00a0el\u00a0embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical.\u00a0Si\u00a0se\u00a0quiere\u00a0m\u00e1s\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 88informaci\u00f3n \u00a0se\u00a0aconseja\u00a0la\u00a0lectura\u00a0de\u00a0los\u00a0documentos \u00a0m\u00e1s\u00a0amplios\u00a0incluidos\u00a0en\u00a0la\u00a0\nbibliograf\u00eda884,\u00a0885.\u00a0\u00a0\nSe\u00a0recomienda \u00a0realizar\u00a0la\u00a0serolog\u00eda\u00a0frente\u00a0al\u00a0VIH\u00a0a\u00a0todas\u00a0las\u00a0embarazadas \u00a0\nindependientemente \u00a0de\u00a0sus\u00a0antecedentes \u00a0epidemiol\u00f3gicos. \u00a0El\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0\nvertical\u00a0depende\u00a0de\u00a0varios\u00a0factores\u00a0(maternos, \u00a0virales,\u00a0placentarios, \u00a0obst\u00e9tricos, \u00a0\nlactancia, \u00a0fetales,\u00a0neonatales, \u00a0etc.)\u00a0pero\u00a0la\u00a0CVP\u00a0de\u00a0la\u00a0madre\u00a0durante\u00a0el\u00a0embarazo \u00a0y\u00a0en\u00a0\nel\u00a0parto\u00a0es\u00a0el\u00a0factor\u00a0determinante, \u00a0sin\u00a0que\u00a0exista\u00a0un\u00a0dintel\u00a0m\u00ednimo\u00a0que\u00a0evite\u00a0la\u00a0\ntransmisi\u00f3n886.\u00a0\u00a0\nAnte\u00a0una\u00a0mujer\u00a0infectada \u00a0por\u00a0el\u00a0VIH,\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0se\u00a0basa\u00a0\nen\u00a0los\u00a0siguientes \u00a0principios: \u00a0el\u00a0TAR,\u00a0por\u00a0baja\u00a0que\u00a0sea\u00a0la\u00a0CVP,\u00a0el\u00a0test\u00a0de\u00a0resistencias, \u00a0el\u00a0\ntratamiento \u00a0con\u00a0AZT\u00a0endovenoso \u00a0durante\u00a0el\u00a0parto,\u00a0\u00a0la\u00a0ces\u00e1rea\u00a0programada \u00a0(cuando\u00a0la\u00a0\nCVP\u00a0es\u00a0>1000\u00a0copias/mL, \u00a0el\u00a0tratamiento \u00a0con\u00a0AZT\u00a0del\u00a0ni\u00f1o\u00a0durante\u00a06\u00a0semanas\u00a0y\u00a0evitar\u00a0la\u00a0\nlactancia884,\u00a0887.\u00a0\nEl\u00a0objetivo\u00a0del\u00a0TAR\u00a0en\u00a0el\u00a0embarazo \u00a0es\u00a0conseguir \u00a0y\u00a0mantener \u00a0CVP\u00a0indetectable.\u00a0\nEl\u00a0test\u00a0de\u00a0resistencia \u00a0genot\u00edpico \u00a0est\u00e1\u00a0recomendado \u00a0para\u00a0todas\u00a0las\u00a0embarazadas \u00a0antes\u00a0\nde\u00a0comenzar \u00a0el\u00a0TAR,\u00a0as\u00ed\u00a0como\u00a0para\u00a0aquellas\u00a0que,\u00a0estando\u00a0en\u00a0terapia,\u00a0tengan\u00a0CVP\u00a0\ndetectable. \u00a0En\u00a0ocasiones, \u00a0es\u00a0necesario \u00a0iniciar\u00a0el\u00a0TAR\u00a0a\u00fan\u00a0sin\u00a0disponer\u00a0del\u00a0resultado \u00a0del\u00a0\ntest,\u00a0sujeto\u00a0a\u00a0modificaci\u00f3n \u00a0posterior, \u00a0en\u00a0el\u00a0caso\u00a0de\u00a0que\u00a0\u00e9ste\u00a0refleje\u00a0mutaciones \u00a0de\u00a0\nresistencias \u00a0a\u00a0los\u00a0f\u00e1rmacos\u00a0elegidos884.\u00a0\n\u00a0\n10.6\u00a0Consideraciones \u00a0a\u00a0tener\u00a0en\u00a0cuenta\u00a0respecto\u00a0al\u00a0TAR\u00a0\u00a0\nEl\u00a0embarazo \u00a0en\u00a0la\u00a0mujer\u00a0VIH+\u00a0es\u00a0una\u00a0situaci\u00f3n\u00a0excepcional \u00a0que\u00a0no\u00a0debe\u00a0impedir\u00a0la\u00a0\noptimizaci\u00f3n \u00a0de\u00a0la\u00a0terapia,\u00a0pero\u00a0que\u00a0implica\u00a0unas\u00a0elecciones \u00a0espec\u00edficas \u00a0que\u00a0afectan\u00a0\ntanto\u00a0a\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0sus\u00a0dosis\u00a0(los\u00a0niveles\u00a0de\u00a0algunos\u00a0f\u00e1rmacos \u00a0disminuyen \u00a0en\u00a0el\u00a0\nsegundo\u00a0y\u00a0tercer\u00a0trimestre, \u00a0por\u00a0lo\u00a0que\u00a0pueden\u00a0tener\u00a0que\u00a0ser\u00a0aumentados, \u00a0\nrecomend\u00e1ndose \u00a0su\u00a0monitorizaci\u00f3n), \u00a0al\u00a0momento \u00a0del\u00a0inicio\u00a0del\u00a0TAR,\u00a0a\u00a0los\u00a0efectos\u00a0\nadversos\u00a0por\u00a0toxicidad\u00a0durante\u00a0el\u00a0embarazo \u00a0y\u00a0a\u00a0los\u00a0potenciales \u00a0riesgos\u00a0para\u00a0el\u00a0\nneonato,\u00a0muchos\u00a0de\u00a0los\u00a0cuales\u00a0son\u00a0desconocidos \u00a0con\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0\nLos\u00a0datos\u00a0de\u00a0seguridad \u00a0de\u00a0los\u00a0FAR\u00a0para\u00a0el\u00a0feto\u00a0son\u00a0limitados\u00a0(Tabla\u00a017).\u00a0De\u00a0los\u00a0datos\u00a0\ndisponibles, \u00a0se\u00a0puede\u00a0destacar:\u00a0\u00a0\n1)\u00a0ZDV\u00a0es\u00a0segura\u00a0al\u00a0menos\u00a0a\u00a0corto\u00a0y\u00a0medio\u00a0plazo,\u00a0aunque\u00a0un\u00a0estudio\u00a0sugiri\u00f3\u00a0riesgo\u00a0de\u00a0\ntoxicidad\u00a0mitocondrial \u00a0en\u00a0ni\u00f1os;\u00a0\u00a0\n2)\u00a0EFV\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0potencialmente \u00a0terat\u00f3geno, \u00a0por\u00a0lo\u00a0que\u00a0est\u00e1\u00a0contraindicado \u00a0al\u00a0\nmenos\u00a0durante\u00a0el\u00a0primer\u00a0trimestre; \u00a0\u00a0\n3)\u00a0Es\u00a0posible\u00a0que\u00a0los\u00a0IP\u00a0se\u00a0asocien\u00a0con\u00a0bajo\u00a0peso\u00a0al\u00a0nacer888\u00a0o\u00a0prematuridad889;\u00a0\n\u00a04)\u00a0La\u00a0seguridad \u00a0de\u00a0otros\u00a0f\u00e1rmacos \u00a0es\u00a0a\u00fan\u00a0peor\u00a0conocida, \u00a0y\u00a0aunque\u00a0se\u00a0catalogan \u00a0como\u00a0\ncategor\u00eda \u00a0\u201cB\u201d\u00a0o\u00a0\u201cC\u201d\u00a0de\u00a0la\u00a0FDA\u00a0(Tabla\u00a017),\u00a0los\u00a0datos\u00a0disponibles \u00a0de\u00a0seguridad, \u00a0\nespecialmente \u00a0a\u00a0largo\u00a0plazo,\u00a0son\u00a0limitados. \u00a0Se\u00a0tiene\u00a0escasa\u00a0informaci\u00f3n \u00a0de\u00a0TDF,\u00a0ATV,\u00a0\nFPV\u00a0e\u00a0IDV\u00a0y\u00a0muy\u00a0escasa\u00a0de\u00a0TPV,\u00a0DRV,\u00a0RAL890\u2010892,\u00a0ETR\u00a0y\u00a0MVC.\u00a0\u00a0Por\u00a0ello\u00a0se\u00a0deben\u00a0evitar\u00a0\nestos\u00a0f\u00e1rmacos, \u00a0salvo\u00a0en\u00a0pacientes \u00a0embarazadas \u00a0en\u00a0fracaso,\u00a0en\u00a0cuyo\u00a0caso\u00a0deberemos \u00a0\norientarnos \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0poca\u00a0informaci\u00f3n \u00a0disponible. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 89Existe\u00a0un\u00a0registro\u00a0establecido \u00a0en\u00a01989\u00a0que\u00a0recoge\u00a0de\u00a0forma\u00a0prospectiva \u00a0la\u00a0prevalencia \u00a0\nen\u00a0malformaciones \u00a0entre\u00a0los\u00a0expuestos \u00a0durante\u00a0el\u00a0primer\u00a0trimestre, \u00a0que\u00a0es\u00a0del\u00a02,9%,\u00a0\nsimilar\u00a0al\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0no\u00a0expuesta\u00a0(2,7%)889 . \u00a0\u00a0\nEn\u00a0cuanto\u00a0a\u00a0la\u00a0madre,\u00a0cabe\u00a0rese\u00f1ar\u00a0que\u00a0se\u00a0han\u00a0descrito\u00a0casos\u00a0de\u00a0toxicidad\u00a0\nmitocondrial \u00a0y\u00a0acidosis\u00a0l\u00e1ctica\u00a0en\u00a0gestantes, \u00a0las\u00a0cuales\u00a0pueden\u00a0estar\u00a0m\u00e1s\u00a0predispuestas \u00a0\na\u00a0esta\u00a0complicaci\u00f3n. \u00a0Estos\u00a0efectos\u00a0secundarios \u00a0se\u00a0asociaron \u00a0inicialmente \u00a0a\u00a0ZDV\u00a0pero\u00a0\nposteriormente \u00a0se\u00a0han\u00a0descrito\u00a0casos\u00a0relacionados \u00a0con\u00a0d4T.\u00a0La\u00a0FDA\u00a0ha\u00a0comunicado \u00a0\ntres\u00a0muertes\u00a0maternas \u00a0por\u00a0acidosis\u00a0l\u00e1ctica\u00a0y\u00a0tres\u00a0muertes\u00a0fetales\u00a0en\u00a0mujeres\u00a0tratadas\u00a0\ncon\u00a0d4T\u00a0y\u00a0ddI\u00a0como\u00a0AN,\u00a0por\u00a0lo\u00a0que\u00a0desaconseja \u00a0esta\u00a0combinaci\u00f3n. \u00a0La\u00a0acidosis\u00a0l\u00e1ctica\u00a0\ngrave,\u00a0no\u00a0letal,\u00a0se\u00a0ha\u00a0comunicado \u00a0con\u00a0otros\u00a0AN852.\u00a0\u00a0Adem\u00e1s\u00a0se\u00a0ha\u00a0descrito\u00a0que\u00a0la\u00a0\nhepatotoxicidad \u00a0por\u00a0NVP\u00a0ser\u00eda\u00a012\u00a0veces\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0gestantes \u00a0con\u00a0CD4\u00a0>250\u00a0\nc\u00e9lulas/\u00b5L893.\u00a0\nLa\u00a0elecci\u00f3n\u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0embarazada \u00a0y\u00a0sus\u00a0particularidades \u00a0se\u00a0explica\u00a0detalladamente \u00a0\nen\u00a0las\u00a0directrices \u00a0espec\u00edficas \u00a0nacionales \u00a0o\u00a0internacionales884,\u00a0885.\u00a0\nLos\u00a0datos\u00a0disponibles \u00a0de\u00a0la\u00a0eficacia\u00a0de\u00a0la\u00a0ces\u00e1rea\u00a0programada \u00a0(semana\u00a038)\u00a0como\u00a0\ninstrumento \u00a0potencial \u00a0para\u00a0reducir\u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0sugieren\u00a0que\u00a0si\u00a0en\u00a0el\u00a0\nmomento \u00a0del\u00a0parto\u00a0la\u00a0CVP\u00a0es\u00a0<1000\u00a0copias/mL \u00a0la\u00a0ces\u00e1rea\u00a0electiva\u00a0no\u00a0disminuye \u00a0el\u00a0\nriesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0parto\u00a0vaginal\u00a0(0,8%\u00a0frente\u00a0a\u00a00,7%)884,\u00a0893,\u00a0894.\u00a0La\u00a0morbilidad \u00a0\nrelacionada \u00a0con\u00a0la\u00a0ces\u00e1rea\u00a0en\u00a0los\u00a0pa\u00edses\u00a0desarrollados \u00a0no\u00a0parece\u00a0ser\u00a0importante895.\u00a0La\u00a0\nlactancia\u00a0est\u00e1\u00a0contraindicada. \u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0TAR\u00a0y\u00a0gestaci\u00f3n \u00a0\n\u0083 El\u00a0test\u00a0de\u00a0VIH\u00a0debe\u00a0efectuarse \u00a0a\u00a0toda\u00a0mujer\u00a0embarazada \u00a0(nivel\u00a0B).\u00a0Si\u00a0hay\u00a0pr\u00e1cticas\u00a0\nde\u00a0riesgo\u00a0debe\u00a0repetirse\u00a0en\u00a0el\u00a0tercer\u00a0trimestre \u00a0(nivel\u00a0C)\u00a0\n\u0083 En\u00a0las\u00a0mujeres\u00a0que\u00a0llegan\u00a0al\u00a0parto\u00a0sin\u00a0conocer\u00a0su\u00a0estado\u00a0respecto\u00a0al\u00a0VIH,\u00a0se\u00a0debe\u00a0\nhacer\u00a0un\u00a0test\u00a0r\u00e1pido,\u00a0ya\u00a0que\u00a0la\u00a0ces\u00e1rea\u00a0electiva\u00a0reduce\u00a0la\u00a0transmisi\u00f3n \u00a0un\u00a050%\u00a0(nivel\u00a0\nB)\u00a0\n\u0083 El\u00a0objetivo\u00a0del\u00a0TAR\u00a0es\u00a0conseguir \u00a0CVP\u00a0indetectable \u00a0(nivel\u00a0B).\u00a0Uno\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0a\u00a0\nincluir\u00a0en\u00a0el\u00a0TARGA,\u00a0siempre\u00a0que\u00a0no\u00a0haya\u00a0resistencia \u00a0o\u00a0toxicidad\u00a0severa\u00a0previa\u00a0\ndocumentadas, \u00a0o\u00a0dudas\u00a0respecto\u00a0a\u00a0la\u00a0adherencia \u00a0si\u00a0hay\u00a0que\u00a0cambiar\u00a0de\u00a0\u00a0otro\u00a0\nf\u00e1rmaco\u00a0posol\u00f3gicamente \u00a0m\u00e1s\u00a0c\u00f3modo,\u00a0debe\u00a0ser\u00a0ZDV\u00a0que\u00a0se\u00a0administrar\u00e1 \u00a0durante\u00a0\nel\u00a0embarazo, \u00a0en\u00a0el\u00a0parto\u00a0(v\u00eda\u00a0endovenosa) \u00a0y\u00a0al\u00a0reci\u00e9n\u00a0nacido\u00a0(nivel\u00a0A)\u00a0\n\u0083 Debe\u00a0ser\u00a0realizado\u00a0un\u00a0test\u00a0de\u00a0resistencias \u00a0en\u00a0todas\u00a0las\u00a0mujeres\u00a0VIH+\u00a0embarazadas \u00a0\nsin\u00a0TAR\u00a0o\u00a0en\u00a0las\u00a0que\u00a0la\u00a0CVP\u00a0sea\u00a0detectable \u00a0(nivel\u00a0A)\u00a0\n\u0083 Es\u00a0fundamental \u00a0planificar \u00a0el\u00a0control\u00a0de\u00a0la\u00a0CVP\u00a0antes\u00a0del\u00a0parto,\u00a0hacia\u00a0la\u00a0semana\u00a032\u2010\n36\u00a0para\u00a0decidir\u00a0si\u00a0se\u00a0va\u00a0a\u00a0realizar\u00a0ces\u00e1rea\u00a0electiva\u00a0o\u00a0no\u00a0(niveles\u00a0B\u00a0y\u00a0C)\u00a0\n\u0083 No\u00a0deben\u00a0utilizarse\u00a0f\u00e1rmacos\u00a0con\u00a0riesgo\u00a0teratog\u00e9nico \u00a0y\u00a0deben\u00a0evitarse,\u00a0en\u00a0la\u00a0\nmedida\u00a0de\u00a0lo\u00a0posible,\u00a0f\u00e1rmacos \u00a0cuyo\u00a0riesgo\u00a0no\u00a0es\u00a0bien\u00a0conocido\u00a0(FPV,\u00a0TDF,\u00a0ATV,\u00a0\nDRV,\u00a0TPV,\u00a0ENF,\u00a0MVC,\u00a0ETR\u00a0y\u00a0RAL)\u00a0(nivel\u00a0C)\u00a0\n\u0083 Se\u00a0desaconseja \u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0d4T+ddI\u00a0por\u00a0el\u00a0riesgo\u00a0de\u00a0acidosis\u00a0l\u00e1ctica\u00a0(nivel\u00a0B)\u00a0\n\u0083 Si\u00a0no\u00a0se\u00a0consigue\u00a0una\u00a0CVP\u00a0suficientemente \u00a0baja\u00a0(<1000\u00a0copias/mL) \u00a0se\u00a0debe\u00a0indicar\u00a0\nuna\u00a0ces\u00e1rea\u00a0programada \u00a0en\u00a0la\u00a0semana\u00a037\u201038\u00a0(nivel\u00a0A)\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 9011.\u00a0PREVENCION \u00a0DE\u00a0LA\u00a0TRANSMISI\u00d3N \u00a0DEL\u00a0VIH\u00a0\nLa\u00a0epidemia \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0VIH\u00a0sigue\u00a0en\u00a0expansi\u00f3n, \u00a0se\u00a0calcula\u00a0que\u00a0en\u00a0el\u00a0a\u00f1o\u00a02009\u00a0hubo\u00a0\n2.600.000 \u00a0nuevas\u00a0infecciones896.\u00a0A\u00a0lo\u00a0largo\u00a0de\u00a0las\u00a0\u00faltimas\u00a0d\u00e9cadas\u00a0se\u00a0han\u00a0realizado\u00a0\nm\u00faltiples \u00a0intervenciones \u00a0biom\u00e9dicas \u00a0para\u00a0disminuir \u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH.\u00a0Se\u00a0han\u00a0\nconseguido \u00a0algunos\u00a0\u00e9xitos\u00a0con\u00a0los\u00a0programas \u00a0de\u00a0intercambio \u00a0de\u00a0jeringuillas \u00a0y\u00a0\ntratamiento \u00a0sustitutivo \u00a0con\u00a0metadona \u00a0en\u00a0los\u00a0UDVP,\u00a0as\u00ed\u00a0como\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0\u00a0nuevas\u00a0\ninfecciones \u00a0en\u00a0un\u00a050\u201060%\u00a0en\u00a0varones\u00a0mediante \u00a0la\u00a0circuncisi\u00f3n \u00a0masculina, \u00a0la\u00a0difusi\u00f3n\u00a0\ndel\u00a0uso\u00a0del\u00a0preservativo, \u00a0el\u00a0control\u00a0de\u00a0las\u00a0ETS,\u00a0sobre\u00a0todo\u00a0del\u00a0HSV,\u00a0la\u00a0espectacular \u00a0\ndisminuci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical,\u00a0y\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0en\u00a0parejas\u00a0\nserodiscordantes897\u2010900.\u00a0\nSin\u00a0embargo, \u00a0las\u00a0actuaciones \u00a0destinadas \u00a0a\u00a0lograr\u00a0modificaciones \u00a0de\u00a0conducta \u00a0no\u00a0han\u00a0\nlogrado\u00a0sus\u00a0frutos,\u00a0fundamentalmente \u00a0por\u00a0la\u00a0diferente \u00a0percepci\u00f3n \u00a0del\u00a0riesgo,\u00a0sobre\u00a0\ntodo\u00a0a\u00a0nivel\u00a0heterosexual \u00a0en\u00a0los\u00a0pa\u00edses\u00a0en\u00a0v\u00edas\u00a0de\u00a0desarrollo \u00a0y\u00a0en\u00a0los\u00a0varones\u00a0que\u00a0\nrealizan\u00a0sexo\u00a0con\u00a0varones\u00a0en\u00a0los\u00a0pa\u00edses\u00a0desarrollados901.\u00a0Una\u00a0de\u00a0las\u00a0principales \u00a0\ndificultades \u00a0en\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0sexual\u00a0del\u00a0VIH\u00a0se\u00a0debe\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0\nVIH\u00a0aguda,\u00a0que\u00a0se\u00a0asocia\u00a0con\u00a0una\u00a0capacidad \u00a0de\u00a0transmisi\u00f3n \u00a0hasta\u00a026\u00a0veces\u00a0superior,\u00a0\nrelacionado \u00a0con\u00a0las\u00a0elevadas\u00a0CVP\u00a0comparada \u00a0con\u00a0la\u00a0infecci\u00f3n\u00a0en\u00a0el\u00a0per\u00edodo\u00a0\nasintom\u00e1tico902.\u00a0Sin\u00a0embrago\u00a0la\u00a0detecci\u00f3n \u00a0precoz\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0es\u00a0dif\u00edcil\u00a0en\u00a0la\u00a0\npr\u00e1ctica\u00a0m\u00e9dica.\u00a0As\u00ed\u00a0mismo\u00a0el\u00a0diagn\u00f3stico \u00a0tard\u00edo\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0VIH\u00a0en\u00a0los\u00a0pa\u00edses\u00a0\ndesarrollados \u00a0contribuye \u00a0a\u00a0la\u00a0transmisi\u00f3n \u00a0sexual903.\u00a0\n \nPapel\u00a0del\u00a0TAR\u00a0en\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0\nPor\u00a0las\u00a0mismas\u00a0razones\u00a0que\u00a0el\u00a0TAR\u00a0disminuy\u00f3 \u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0del\u00a0VIH\u00a0de\u00a0forma\u00a0\nespectacular904,\u00a0puede\u00a0disminuir \u00a0la\u00a0incidencia \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0heterosexual900.\u00a0As\u00ed\u00a0se\u00a0\nha\u00a0visto\u00a0como\u00a0el\u00a0TAR\u00a0tambi\u00e9n\u00a0disminuye \u00a0la\u00a0CVP\u00a0en\u00a0las\u00a0secreciones \u00a0genitales, \u00a0y\u00a0\ncontribuir\u00e1 \u00a0a\u00a0la\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0sexual.\u00a0En\u00a0un\u00a0meta\u2010an\u00e1lisis\u00a0se\u00a0observ\u00f3\u00a0un\u00a0\nriesgo\u00a0cero\u00a0con\u00a0una\u00a0CVP\u00a0<400\u00a0copias/mL. \u00a0El\u00a0riesgo\u00a0de\u00a0\u00a0transmisi\u00f3n \u00a0de\u00a0una\u00a0persona\u00a0en\u00a0\nTAR\u00a0es\u00a0de\u00a00,5\u00a0por\u00a0100\u00a0personas/a\u00f1o \u00a0y\u00a0de\u00a0un\u00a05,6\u00a0por\u00a0100\u00a0personas/a\u00f1o \u00a0de\u00a0los\u00a0pacientes \u00a0\nno\u00a0tratados209.\u00a0\nVarios\u00a0estudios\u00a0observacionales \u00a0realizados \u00a0en\u00a0\u00c1frica\u00a0han\u00a0demostrado \u00a0una\u00a0disminuci\u00f3n \u00a0\nde\u00a0la\u00a0transmisi\u00f3n \u00a0en\u00a0un\u00a080\u201092%\u00a0en\u00a06.374\u00a0parejas\u00a0serodiscordantes \u00a0tras\u00a0el\u00a0inicio\u00a0de\u00a0TAR\u00a0\nen\u00a0las\u00a0personas\u00a0infectadas905,\u00a0906\u00a0y\u00a0que\u00a0tiende\u00a0a\u00a0cero\u00a0en\u00a0una\u00a0cohorte\u00a0de\u00a0Madrid907.\u00a0En\u00a0la\u00a0\nactualidad \u00a0se\u00a0encuentra \u00a0en\u00a0marcha\u00a0un\u00a0estudio\u00a0aleatorizado \u00a0(HPTN\u00a0052)\u00a0con\u00a01.750\u00a0\nparejas\u00a0discordantes \u00a0para\u00a0recibir\u00a0TAR\u00a0o\u00a0no\u00a0en\u00a0pacientes \u00a0con\u00a0CD4:\u00a0350\u2010500/\u00b5L.\u00a0Este\u00a0\nestudio\u00a0pretende \u00a0responder \u00a0a\u00a0las\u00a0preguntas \u00a0sobre\u00a0el\u00a0efecto\u00a0de\u00a0TAR\u00a0precoz\u00a0y\u00a0la\u00a0\nprevenci\u00f3n \u00a0en\u00a0las\u00a0parejas\u00a0serodiscordantes \u00a0durante\u00a05\u00a0a\u00f1os908.\u00a0\u00a0\nEstos\u00a0datos\u00a0sugieren\u00a0que\u00a0una\u00a0difusi\u00f3n\u00a0amplia\u00a0de\u00a0TAR\u00a0podr\u00eda\u00a0reducir\u00a0la\u00a0transmisi\u00f3n \u00a0por\u00a0\nv\u00eda\u00a0sexual.\u00a0Un\u00a0modelo\u00a0matem\u00e1tico \u00a0basado\u00a0\u00a0en\u00a0la\u00a0detecci\u00f3n \u00a0precoz\u00a0de\u00a0la\u00a0infecci\u00f3n, \u00a0\u00a0\nmediante \u00a0una\u00a0prueba\u00a0universal\u00a0voluntaria, \u00a0\u00a0y\u00a0el\u00a0inicio\u00a0de\u00a0TAR\u00a0\u00a0precoz\u00a0en\u00a0todas\u00a0las\u00a0\npersonas\u00a0reci\u00e9n\u00a0diagnosticadas, \u00a0\u00a0mostr\u00f3\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0incidencia \u00a0y\u00a0de\u00a0la\u00a0\nmortalidad \u00a0a\u00a0<1\u00a0caso/1000 \u00a0personas/a\u00f1o \u00a0en\u00a010\u00a0a\u00f1os909.\u00a0Otro\u00a0modelo\u00a0similar\u00a0realizado\u00a0\nen\u00a0San\u00a0Francisco \u00a0en\u00a0varones\u00a0con\u00a0pr\u00e1cticas\u00a0sexuales\u00a0con\u00a0varones,\u00a0mostr\u00f3\u00a0una\u00a0\ndisminuci\u00f3n \u00a0del\u00a091%\u00a0en\u00a0la\u00a0incidencia \u00a0en\u00a010\u00a0a\u00f1os910.\u00a0Recientemente \u00a0se\u00a0han\u00a0comunicado \u00a0\nefectos\u00a0beneficiosos \u00a0indirectos \u00a0de\u00a0TAR\u00a0en\u00a0la\u00a0comunidad. \u00a0Tanto\u00a0en\u00a0San\u00a0Francisco \u00a0como\u00a0\nen\u00a0Vancouver \u00a0se\u00a0observ\u00f3\u00a0una\u00a0relaci\u00f3n\u00a0entre\u00a0la\u00a0generalizaci\u00f3n \u00a0del\u00a0TAR\u00a0y\u00a0la\u00a0disminuci\u00f3n \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 91de\u00a0nuevos\u00a0casos\u00a0de\u00a0infecci\u00f3n\u00a0VIH911,\u00a0912.\u00a0A\u00a0nivel\u00a0de\u00a0Salud\u00a0P\u00fablica,\u00a0se\u00a0deber\u00e1\u00a0determinar \u00a0\nel\u00a0beneficio \u00a0del\u00a0TAR\u00a0en\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0en\u00a0la\u00a0comunidad913,\u00a0914.\u00a0\n\u00a0\nProfilaxis \u00a0Pre\u2010Exposici\u00f3n \u00a0\nEn\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0se\u00a0est\u00e1\u00a0desarrollando \u00a0una\u00a0intensa\u00a0investigaci\u00f3n \u00a0sobre\u00a0la\u00a0\u00a0profilaxis\u00a0\nprimaria\u00a0con\u00a0FAR,\u00a0basada\u00a0fundamentalmente \u00a0en\u00a0la\u00a0evidencia \u00a0de\u00a0la\u00a0eficacia\u00a0de\u00a0la\u00a0\nprofilaxis\u00a0primaria\u00a0en\u00a0otras\u00a0\u00e1reas\u00a0m\u00e9dicas,\u00a0como\u00a0la\u00a0malaria,\u00a0tuberculosis, \u00a0profilaxis\u00a0\nantibi\u00f3tica \u00a0quir\u00fargica, \u00a0y\u00a0en\u00a0estudios\u00a0animales\u00a0realizados \u00a0sobre\u00a0todo\u00a0con\u00a0TDF.\u00a0Se\u00a0ha\u00a0\ndise\u00f1ado\u00a0una\u00a0estrategia \u00a0denominada \u00a0profilaxis\u00a0pre\u2010exposici\u00f3n \u00a0(PrEP)\u00a0con\u00a0TDF\u00a0o\u00a0con\u00a0\nTDF/FTC,\u00a0por\u00a0v\u00eda\u00a0oral\u00a0o\u00a0\u00a0t\u00f3pica,\u00a0en\u00a0grupos\u00a0espec\u00edficos \u00a0con\u00a0un\u00a0elevado\u00a0riesgo\u00a0de\u00a0\ntransmisi\u00f3n, \u00a0como\u00a0trabajadores \u00a0del\u00a0sexo,\u00a0mujeres\u00a0y\u00a0varones\u00a0en\u00a0parejas\u00a0discordantes, \u00a0\nvarones\u00a0que\u00a0realizan\u00a0sexo\u00a0con\u00a0varones\u00a0y\u00a0UDVP.\u00a0Han\u00a0sido\u00a0incluidos\u00a020.000\u00a0hombres\u00a0y\u00a0\nmujeres\u00a0no\u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0los\u00a0diferentes \u00a0estudios\u00a0que\u00a0finalizar\u00e1n \u00a0en\u00a0los\u00a0dos\u00a0\npr\u00f3ximos \u00a0a\u00f1os915.\u00a0Este\u00a0a\u00f1o\u00a0ha\u00a0tenido\u00a0una\u00a0importante \u00a0repercusi\u00f3n \u00a0medi\u00e1tica \u00a0la\u00a0\ncomunicaci\u00f3n \u00a0de\u00a0la\u00a0eficacia\u00a0de\u00a0TDF\u00a0al\u00a01%\u00a0en\u00a0gel,\u00a0utilizado\u00a0antes\u00a0y\u00a0despu\u00e9s\u00a0del\u00a0coito,\u00a0\ncon\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0incidencia \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0en\u00a0un\u00a039%\u00a0en\u00a0mujeres\u00a0\nde\u00a0alto\u00a0riesgo\u00a0en\u00a0Sud\u00e1frica \u00a0(estudio\u00a0CAPRISA\u00a0004)916.\u00a0Otro\u00a0estudio\u00a0\u00a0interesante \u00a0\ncompara\u00a0la\u00a0eficacia\u00a0de\u00a0TDF\u00a0al\u00a01%\u00a0en\u00a0gel\u00a0usado\u00a0diariamente \u00a0frente\u00a0a\u00a0TDF/FTC\u00a0por\u00a0v\u00eda\u00a0\noral\u00a0(estudio\u00a0VOICE,\u00a0Identificador \u00a0en\u00a0Clinicaltrials.gov \u00a0NCT00705679). \u00a0Un\u00a0estudio\u00a0de\u00a0\u00a0\nprofilaxis\u00a0pre\u2010exposici\u00f3n \u00a0publicado \u00a0recientemente \u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0pauta\u00a0de\u00a0TDF/FTC\u00a0\ndiaria\u00a0por\u00a0v\u00eda\u00a0oral\u00a0ten\u00eda\u00a0una\u00a0eficacia\u00a0global\u00a0del\u00a044%\u00a0frente\u00a0a\u00a0placebo\u00a0en\u00a0varones\u00a0con\u00a0\nrelaciones \u00a0homosexuales, \u00a0aunque\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento \u00a0era\u00a0muy\u00a0baja917.\u00a0\nLa\u00a0PrEP\u00a0\u00a0puede\u00a0ser\u00a0una\u00a0estrategia \u00a0\u00a0apropiada, \u00a0pero\u00a0\u00a0precisar\u00e1\u00a0una\u00a0valoraci\u00f3n \u00a0final\u00a0\ndespu\u00e9s\u00a0de\u00a0la\u00a0finalizaci\u00f3n \u00a0de\u00a0los\u00a0estudios,\u00a0aunque\u00a0\u00a0se\u00a0perfila\u00a0una\u00a0dificultad \u00a0en\u00a0su\u00a0\nimplementaci\u00f3n \u00a0a\u00a0largo\u00a0plazo,\u00a0sobre\u00a0todo\u00a0relacionado \u00a0con\u00a0los\u00a0posibles\u00a0cambios\u00a0en\u00a0las\u00a0\nconductas \u00a0sexuales,\u00a0la\u00a0adherencia, \u00a0el\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0y\u00a0su\u00a0coste\u2010\nefectividad918,\u00a0919.\u00a0Con\u00a0el\u00a0actual\u00a0estado\u00a0de\u00a0los\u00a0conocimientos \u00a0no\u00a0pueden\u00a0emitirse\u00a0\nrecomendaciones \u00a0concretas. \u00a0\n\u00a0Profilaxis \u00a0post\u2010exposici\u00f3n \u00a0ocupacional \u00a0\nEl\u00a0uso\u00a0de\u00a0TAR\u00a0tras\u00a0una\u00a0exposici\u00f3n \u00a0profesional \u00a0al\u00a0VIH\u00a0reduce\u00a0el\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0\nmismo,\u00a0aunque\u00a0se\u00a0han\u00a0documentado \u00a0transmisiones \u00a0a\u00a0pesar\u00a0de\u00a0una\u00a0PPE\u00a0correcta\u00a0con\u00a0\ntres\u00a0f\u00e1rmacos. \u00a0El\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0tras\u00a0exposici\u00f3n \u00a0percut\u00e1nea \u00a0a\u00a0sangre\u00a0\ninfectada \u00a0oscila\u00a0entre\n\u00a00,24\u00a0a\u00a00,65\u00a0%\u00a0y\u00a0es\u00a0del\u00a00,09%\u00a0tras\u00a0un\u00a0contacto\u00a0con\u00a0mucosas\u00a0o\u00a0piel\u00a0\nno\u00a0intacta920.\u00a0Los\u00a0factores\u00a0asociados \u00a0a\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0son:\u00a0\npinchazo\u00a0profundo \u00a0(OR\u00a015;\u00a0IC\u00a095%,\u00a06,0\u00a0a\u00a041),\u00a0con\u00a0sangre\u00a0visible\u00a0en\u00a0el\u00a0dispositivo \u00a0(OR\u00a0\n6,2;\u00a0IC\u00a095%,\u00a02,2\u00a0a\u00a021),\u00a0reci\u00e9n\u00a0extra\u00eddo\u00a0de\u00a0vena\u00a0o\u00a0arteria\u00a0(OR\u00a04,3;\u00a0IC\u00a095%,\u00a01,7\u00a0a\u00a012)\u00a0en\u00a0\npaciente\u00a0fuente\u00a0con\u00a0enfermedad \u00a0avanzada \u00a0(OR\u00a05,6;\u00a0IC\u00a095%,\u00a02\u00a0a\u00a016).\u00a0La\u00a0PPE\u00a0con\u00a0\nmonoterapia \u00a0(ZDV)\u00a0reduce\u00a0la\u00a0transmisi\u00f3n \u00a0un\u00a081%\u00a0(OR\u00a00,19;\u00a0IC\u00a095%,\u00a00,06\u00a0a\u00a00,52)921.\u00a0No\u00a0\nexisten\u00a0estudios\u00a0comparados \u00a0que\u00a0permitan\u00a0establecer \u00a0recomendaciones \u00a0firmes\u00a0sobre\u00a0\nel\u00a0momento \u00a0de\u00a0inicio,\u00a0la\u00a0duraci\u00f3n\u00a0o\u00a0los\u00a0f\u00e1rmacos \u00a0o\u00a0combinaciones \u00a0a\u00a0emplear\u00a0tras\u00a0una\u00a0\nexposici\u00f3n \u00a0accidental. \u00a0\u00a0\nPor\u00a0modelos\u00a0animales, \u00a0y\u00a0estudios\u00a0de\u00a0caso\u2010control\u00a0sabemos\u00a0que\u00a0la\u00a0PPE\u00a0es\u00a0tanto\u00a0m\u00e1s\u00a0\neficaz\u00a0cuanto\u00a0antes\u00a0se\u00a0inicie922.\u00a0Su\u00a0duraci\u00f3n\u00a0no\u00a0est\u00e1\u00a0establecida \u00a0pero\u00a0en\u00a0modelos\u00a0\nanimales\u00a0los\u00a0periodos\u00a0de\u00a03\u00a0\u00f3\u00a010\u00a0d\u00edas\u00a0son\u00a0menos\u00a0eficaces\u00a0que\u00a028\u00a0d\u00edas,\u00a0por\u00a0ello\u00a0se\u00a0ha\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 92consensuado \u00a0recomendar \u00a04\u00a0semanas. \u00a0No\u00a0existen\u00a0estudios\u00a0que\u00a0demuestren \u00a0que\u00a0la\u00a0PPE\u00a0\ncon\u00a03\u00a0f\u00e1rmacos \u00a0sea\u00a0mejor\u00a0que\u00a0con\u00a02,\u00a0aunque\u00a0prevalece \u00a0la\u00a0opci\u00f3n\u00a0de\u00a0indicar\u00a0triple\u00a0\nterapia\u00a0de\u00a0modo\u00a0similar\u00a0al\u00a0TAR\u00a0de\u00a0inicio.\u00a0La\u00a0elecci\u00f3n\u00a0de\u00a0los\u00a0FAR\u00a0depender\u00e1 \u00a0de\u00a0los\u00a0\nefectos\u00a0adversos\u00a0potenciales \u00a0y\u00a0de\u00a0las\u00a0preferencias \u00a0de\u00a0los\u00a0sanitarios \u00a0teniendo\u00a0en\u00a0cuenta\u00a0\nque\u00a0la\u00a0intolerancia \u00a0a\u00a0los\u00a0FAR\u00a0entre\u00a0el\u00a0personal\u00a0sanitario\u00a0es\u00a0muy\u00a0elevada\u00a0(50%)923,\u00a0924.\u00a0\u00a0\nPara\u00a0establecer \u00a0la\u00a0necesidad \u00a0de\u00a0profilaxis\u00a0debemos \u00a0conocer\u00a0el\u00a0tipo\u00a0de\u00a0exposici\u00f3n \u00a0y\u00a0\nsolicitar,\u00a0tras\u00a0consentimiento \u00a0informado, \u00a0serolog\u00eda\u00a0r\u00e1pida\u00a0frente\u00a0al\u00a0VIH,\u00a0VHB\u00a0y\u00a0VHC\u00a0del\u00a0\npaciente\u2010fuente\u00a0y\u00a0del\u00a0trabajador. \u00a0\nEn\u00a0las\u00a0exposiciones \u00a0que\u00a0precisen\u00a0profilaxis\u00a0se\u00a0recomienda \u00a0un\u00a0TAR\u00a0que\u00a0incluya\u00a0dos\u00a0AN,\u00a0\ncon\u00a0un\u00a0IP\u00a0potenciado. \u00a0En\u00a0los\u00a0casos\u00a0que\u00a0no\u00a0pueda\u00a0administrase \u00a0un\u00a0TAR\u00a0basado\u00a0en\u00a0IP,\u00a0o\u00a0\nque\u00a0sea\u00a0intolerante, \u00a0la\u00a0sustituci\u00f3n \u00a0de\u00a0\u00e9ste\u00a0por\u00a0EFV,\u00a0recordando \u00a0que\u00a0no\u00a0puede\u00a0\nadministrarse \u00a0en\u00a0embarazadas, \u00a0o\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0ZDV+3TC+TDF \u00a0podr\u00edan\u00a0ser\u00a0buenas\u00a0\nopciones210,\u00a0214,\u00a0923,\u00a0924.\u00a0La\u00a0NVP\u00a0no\u00a0es\u00a0aconsejable \u00a0por\u00a0las\u00a0posible\u00a0toxicidad\u00a0cut\u00e1nea\u00a0o\u00a0\nhep\u00e1tica925.\u00a0\u00a0\u00a0\nLas\u00a0recomendaciones \u00a0para\u00a0la\u00a0PPE\u00a0ocupacional \u00a0est\u00e1n\u00a0bien\u00a0implementadas \u00a0en\u00a0la\u00a0mayor\u00eda\u00a0\nde\u00a0los\u00a0pa\u00edses\u00a0occidentales, \u00a0sin\u00a0embargo\u00a0debemos \u00a0recordar\u00a0que\u00a0el\u00a0n\u00famero\u00a0de\u00a0\u00a0pacientes \u00a0\ncon\u00a0infecci\u00f3n\u00a0VIH\u00a0ha\u00a0aumentado \u00a0significativamente \u00a0y\u00a0\u00a0probablemente \u00a0tambi\u00e9n\u00a0se\u00a0\nincrementar\u00e1n \u00a0las\u00a0exposiciones \u00a0de\u00a0los\u00a0sanitarios \u00a0al\u00a0VIH.\u00a0La\u00a0transmisi\u00f3n \u00a0ocupacional \u00a0del\u00a0\nVIH\u00a0es\u00a0muy\u00a0rara\u00a0y\u00a0la\u00a0evidencia \u00a0muestra\u00a0que\u00a0la\u00a0PPE\u00a0modifica\u00a0los\u00a0riesgos\u00a0de\u00a0transmisi\u00f3n. \u00a0\nAunque\u00a0conviene\u00a0recordar\u00a0que\u00a0ninguna\u00a0pauta\u00a0de\u00a0PPE\u00a0ser\u00e1\u00a0eficaz\u00a0al\u00a0100%926.\u00a0En\u00a0el\u00a0\nReino\u00a0Unido,\u00a0\u00a0un\u00a0estudio\u00a0reciente\u00a0de\u00a0la\u00a0Health\u00a0Protection \u00a0Agency\u00a0(HPA),\u00a0mostr\u00f3\u00a0que\u00a0en\u00a0\nun\u00a020%\u00a0de\u00a0casos\u00a0con\u00a0exposici\u00f3n \u00a0manifiesta \u00a0a\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0VIH\u00a0no\u00a0se\u00a0realiz\u00f3\u00a0\nla\u00a0PPE.\u00a0\u00a0El\u00a0conocimiento \u00a0de\u00a0las\u00a0recomendaciones \u00a0por\u00a0parte\u00a0de\u00a0los\u00a0sanitarios \u00a0era\u00a0bueno,\u00a0\npero\u00a0exist\u00edan\u00a0diferencias \u00a0en\u00a0la\u00a0percepci\u00f3n \u00a0del\u00a0\u00a0riesgo\u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0\u00a0en\u00a0los\u00a0diversos\u00a0\nestamentos \u00a0sanitarios \u00a0a\u00a0la\u00a0hora\u00a0de\u00a0iniciar\u00a0una\u00a0PPE\u00a0tras\u00a0una\u00a0exposici\u00f3n927.\u00a0\nEn\u00a0caso\u00a0de\u00a0conocer\u00a0o\u00a0sospechar \u00a0que\u00a0el\u00a0paciente\u00a0fuente\u00a0tiene\u00a0un\u00a0virus\u00a0resistente, \u00a0se\u00a0\ndeben\u00a0seleccionar \u00a0FAR\u00a0sin\u00a0resistencia \u00a0cruzada.\u00a0Se\u00a0ha\u00a0demostrado \u00a0que\u00a0una\u00a0elevada\u00a0\nproporci\u00f3n \u00a0no\u00a0desde\u00f1able \u00a0de\u00a0virus\u00a0de\u00a0los\u00a0casos\u00a0fuente\u00a0pueden\u00a0presentar \u00a0mutaciones \u00a0\nde\u00a0resistencia, \u00a0especialmente \u00a0a\u00a0AN\u00a0y\u00a0NN928.\u00a0MVC,\u00a0RAL\u00a0o\u00a0T20\u00a0no\u00a0se\u00a0recomiendan \u00a0para\u00a0\nPPE,\u00a0salvo\u00a0en\u00a0casos\u00a0excepcionales \u00a0de\u00a0multirresistencia. \u00a0El\u00a0PNS/Gesida929\u00a0la\u00a0European \u00a0\nAIDS\u00a0Clinical\u00a0Society930,\u00a0los\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention \u00a0(CDC)931\u00a0y\u00a0otros\u00a0\norganismos \u00a0han\u00a0actualizado \u00a0las\u00a0recomendaciones \u00a0de\u00a0tratamiento \u00a0antirretroviral \u00a0\npostexposici\u00f3n \u00a0ocupacional \u00a0y\u00a0no\u00a0ocupacional \u00a0cuyo\u00a0texto\u00a0est\u00e1\u00a0disponible \u00a0en\u00a0sus\u00a0\nrespectivas \u00a0p\u00e1ginas\u00a0web.\u00a0\u00a0\nEl\u00a0estado\u00a0de\u00a0New\u00a0York\u00a0ha\u00a0realizado\u00a0recientemente \u00a0unas\u00a0recomendaciones \u00a0m\u00e1s\u00a0\nestrictas,\u00a0haciendo\u00a0\u00e9nfasis\u00a0en\u00a0el\u00a0inicio\u00a0de\u00a0la\u00a0PPE\u00a0antes\u00a0de\u00a0las\u00a0dos\u00a0horas\u00a0tras\u00a0la\u00a0\nexposici\u00f3n \u00a0y\u00a0no\u00a0efectuarla \u00a0m\u00e1s\u00a0all\u00e1\u00a0de\u00a0las\u00a036\u00a0horas.\u00a0Recomiendan \u00a0una\u00a0pauta\u00a0de\u00a0tres\u00a0\nFAR,\u00a0tres\u00a0AN\u00a0para\u00a0cualquier \u00a0exposici\u00f3n \u00a0significativa. \u00a0En\u00a0aras\u00a0a\u00a0mejorar\u00a0la\u00a0adherencia \u00a0\nrecomiendan \u00a0utilizar\u00a0las\u00a0asociaciones \u00a0coformuladas \u00a0(TDF/FTC+ZDV \u00a0o\u00a0AZT/3TC+TDF), \u00a0y\u00a0\nutilizan\u00a0los\u00a0IP/r\u00a0y\u00a0NN\u00a0en\u00a0los\u00a0usos\u00a0alternativos932.\u00a0\nA\u00a0toda\u00a0persona\u00a0que\u00a0se\u00a0haya\u00a0evaluado\u00a0por\u00a0PPE\u00a0debe\u00a0ofrec\u00e9rsele \u00a0un\u00a0plan\u00a0de\u00a0seguimiento \u00a0\nque\u00a0incluir\u00e1\u00a0informaci\u00f3n, \u00a0apoyo\u00a0psicol\u00f3gico \u00a0y\u00a0control\u00a0de\u00a0los\u00a0posibles\u00a0s\u00edntomas\u00a0de\u00a0\nprimoinfecci\u00f3n. \u00a0Si\u00a0se\u00a0prescribi\u00f3 \u00a0PPE\u00a0se\u00a0deben\u00a0controlar\u00a0dentro\u00a0de\u00a0las\u00a0primeras\u00a072\u00a0\nhoras\u00a0para\u00a0revalorar\u00a0la\u00a0necesidad \u00a0de\u00a0profilaxis\u00a0y\u00a0conocer\u00a0si\u00a0el\u00a0trabajador \u00a0ha\u00a0presentado \u00a0\nreacciones \u00a0adversas, \u00a0interacciones \u00a0y\u00a0problemas \u00a0de\u00a0adherencia. \u00a0Se\u00a0programar\u00e1n \u00a0\ncontroles \u00a0anal\u00edticos \u00a0y\u00a0serol\u00f3gicos \u00a0a\u00a0las\u00a04\u00a0semanas\u00a0y\u00a0a\u00a0los\u00a03\u00a0y\u00a06\u00a0meses.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 93\u00a0\nRecomendaciones \u00a0sobre\u00a0profilaxis \u00a0postexposici\u00f3n \u00a0ocupacional \u00a0\u00a0\n\u2022 Los\u00a0servicios\u00a0sanitarios \u00a0deben\u00a0disponer\u00a0de\u00a0un\u00a0manual\u00a0escrito\u00a0sobre\u00a0las\u00a0actuaciones \u00a0\ny\u00a0derivaciones \u00a0a\u00a0seguir\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0exposici\u00f3n \u00a0al\u00a0VIH,\u00a0profesional \u00a0o\u00a0no,\u00a0con\u00a0\ndisponibilidad \u00a0de\u00a0diagn\u00f3stico \u00a0serol\u00f3gico \u00a0r\u00e1pido\u00a0y\u00a0con\u00a0accesibilidad \u00a0de\u00a024\u00a0horas\u00a0a\u00a0\nlos\u00a0f\u00e1rmacos \u00a0utilizados \u00a0en\u00a0la\u00a0PPE\u00a0(Nivel\u00a0C)\u00a0\n\u2022 Se\u00a0debe\u00a0valorar\u00a0el\u00a0caso\u00a0fuente\u00a0(VIH\u00a0confirmado \u00a0o\u00a0sospechoso), \u00a0el\u00a0estado\u00a0serol\u00f3gico \u00a0\nde\u00a0la\u00a0persona\u00a0expuesta\u00a0y\u00a0las\u00a0caracter\u00edsticas \u00a0de\u00a0la\u00a0exposici\u00f3n \u00a0para\u00a0indicar\u00a0la\u00a0PPE\u00a0\n(Nivel\u00a0C)\u00a0\u00a0\u00a0\n\u2022 La\u00a0administraci\u00f3n \u00a0de\u00a0PPE\u00a0debe\u00a0iniciarse\u00a0lo\u00a0antes\u00a0posible,\u00a0mejor\u00a0en\u00a0las\u00a0primeras\u00a0\ncuatro\u00a0horas,\u00a0y\u00a0hasta\u00a0las\u00a072\u00a0horas.\u00a0No\u00a0est\u00e1\u00a0indicada\u00a0despu\u00e9s\u00a0de\u00a072\u00a0horas\u00a0y\u00a0su\u00a0\nduraci\u00f3n\u00a0ser\u00e1\u00a0de\u00a04\u00a0semanas\u00a0(Nivel\u00a0C)\u00a0\n\u2022 Cuando\u00a0est\u00e9\u00a0indicada\u00a0la\u00a0PPE\u00a0se\u00a0recomienda \u00a0una\u00a0pauta\u00a0convencional \u00a0con\u00a0tres\u00a0FAR.\u00a0\nSe\u00a0recomiendan \u00a0combinaciones \u00a0fijas\u00a0(TDF+FTC \u00a0\u00a0o\u00a0ZDV+3TC), \u00a0asociadas \u00a0a\u00a0un\u00a0IP/r.\u00a0Si\u00a0\nno\u00a0se\u00a0puede\u00a0administrar \u00a0TAR\u00a0basado\u00a0en\u00a0IP/r,\u00a0podr\u00eda\u00a0sustituirse \u00a0el\u00a0IP/r\u00a0por\u00a0EFV\u00a0o\u00a0\nbien\u00a0una\u00a0terapia\u00a0con\u00a03\u00a0AN:\u00a0ZDV/3TC\u00a0+\u00a0TDF\u00a0o\u00a0TDF/FTC+ZDV \u00a0(Nivel\u00a0B)\u00a0\n\u2022 Si\u00a0se\u00a0sospecha \u00a0que\u00a0el\u00a0virus\u00a0del\u00a0caso\u00a0\u00edndice\u00a0puede\u00a0tener\u00a0resistencia \u00a0a\u00a0uno\u00a0o\u00a0varios\u00a0\nf\u00e1rmacos, \u00a0la\u00a0profilaxis\u00a0no\u00a0debe\u00a0retrasarse \u00a0y\u00a0debe\u00a0incluir\u00a0medicamentos \u00a0sin\u00a0\nresistencia \u00a0cruzada\u00a0(Nivel\u00a0C)\u00a0\n\u2022 En\u00a0caso\u00a0de\u00a0duda\u00a0sobre\u00a0la\u00a0indicaci\u00f3n \u00a0de\u00a0la\u00a0PPE,\u00a0se\u00a0recomienda \u00a0administrar \u00a0la\u00a0\nprimera\u00a0dosis\u00a0de\u00a0forma\u00a0inmediata \u00a0y\u00a0valorar\u00a0su\u00a0continuidad \u00a0en\u00a0las\u00a024\u00a0h\u00a0posteriores \u00a0\npor\u00a0un\u00a0experto\u00a0en\u00a0infecci\u00f3n\u00a0VIH\u00a0(Nivel\u00a0C)\u00a0\n\u2022 El\u00a0seguimiento \u00a0debe\u00a0incluir\u00a0la\u00a0revaloraci\u00f3n \u00a0de\u00a0la\u00a0indicaci\u00f3n \u00a0a\u00a0las\u00a024\u201072\u00a0horas\u00a0del\u00a0\ninicio\u00a0del\u00a0TAR\u00a0y\u00a0control\u00a0del\u00a0cumplimiento \u00a0y\u00a0tolerabilidad \u00a0del\u00a0TAR\u00a0as\u00ed\u00a0como\u00a0serolog\u00eda\u00a0\nal\u00a0VIH,\u00a0VHB\u00a0y\u00a0VHC\u00a0(estos\u00a0en\u00a0caso\u00a0de\u00a0fuente\u00a0infectada \u00a0o\u00a0con\u00a0sospecha) \u00a0en\u00a0los\u00a0meses\u00a0\n1,\u00a03\u00a0y\u00a06\u00a0tras\u00a0la\u00a0exposici\u00f3n \u00a0(Nivel\u00a0C)\u00a0\n\u00a0\nProfilaxis \u00a0post\u2010exposici\u00f3n \u00a0no\u00a0ocupacional \u00a0\nLa\u00a0indicaci\u00f3n \u00a0de\u00a0la\u00a0PPE\u00a0no\u2010ocupacional \u00a0se\u00a0basa\u00a0en\u00a0la\u00a0patogenia \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0VIH,\u00a0en\u00a0\nestudios\u00a0observacionales \u00a0realizados \u00a0principalmente \u00a0en\u00a0mujeres\u00a0v\u00edctimas\u00a0de\u00a0\nviolaciones, \u00a0en\u00a0hombres\u00a0con\u00a0pr\u00e1cticas\u00a0sexuales\u00a0de\u00a0alto\u00a0riesgo\u00a0con\u00a0otros\u00a0hombres, \u00a0la\u00a0\ninformaci\u00f3n \u00a0procedente \u00a0de\u00a0otras\u00a0profilaxis\u00a0frente\u00a0al\u00a0VIH\u00a0(exposici\u00f3n \u00a0ocupacional, \u00a0\ntransmisi\u00f3n \u00a0vertical)\u00a0y\u00a0de\u00a0datos\u00a0de\u00a0experimentaci\u00f3n \u00a0animal.\u00a0No\u00a0hay\u00a0datos\u00a0sobre\u00a0la\u00a0\neficacia\u00a0de\u00a0esta\u00a0estrategia, \u00a0pero\u00a0los\u00a0datos\u00a0disponibles \u00a0sobre\u00a0\u00a0la\u00a0accesibilidad \u00a0y\u00a0\nseguridad \u00a0han\u00a0conducido \u00a0a\u00a0una\u00a0amplia\u00a0aceptaci\u00f3n933.\u00a0\nEl\u00a0mayor\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0es\u00a0la\u00a0relaci\u00f3n\u00a0anal\u00a0receptiva \u00a0no\u00a0protegida \u00a0(0,5\u20103%)\u00a0con\u00a0\nvar\u00f3n\u00a0VIH+,\u00a0seguido\u00a0del\u00a0intercambio \u00a0de\u00a0jeringuillas \u00a0(0,67%),\u00a0de\u00a0la\u00a0punci\u00f3n\u00a0percut\u00e1nea \u00a0\ncon\u00a0VIH+\u00a0(0,3%),\u00a0la\u00a0relaci\u00f3n\u00a0vaginal\u00a0receptiva \u00a0(0,05\u20100,8),\u00a0o\u00a0la\u00a0vaginal\u00a0o\u00a0anal\u00a0insertiva\u00a0\n(0,05\u20100,065).\u00a0La\u00a0relaci\u00f3n\u00a0orogenital \u00a0receptiva \u00a0e\u00a0insertiva\u00a0tiene\u00a0un\u00a0riesgo\u00a0menor\u00a0(0,005\u2010\n0,01)\u00a0929,\u00a0934,\u00a0935.\u00a0Sin\u00a0embargo\u00a0recientemente \u00a0se\u00a0ha\u00a0estudiado \u00a0el\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0\npor\u00a0acto\u00a0sexual\u00a0en\u00a01.381\u00a0varones\u00a0homosexuales \u00a0entre\u00a0los\u00a0a\u00f1os\u00a02001\u20102004.\u00a0La\u00a0\ntransmisi\u00f3n \u00a0en\u00a0la\u00a0relaci\u00f3n\u00a0anal\u00a0receptiva \u00a0fue\u00a0de\u00a01,43%\u00a0(IC\u00a095%,\u00a00,48\u00a0a\u00a02,85)\u00a0si\u00a0exist\u00eda\u00a0\neyaculaci\u00f3n \u00a0y\u00a0de\u00a00,65%\u00a0(C95%,\u00a00,15\u00a0a\u00a01,53)\u00a0en\u00a0caso\u00a0de\u00a0retirada\u00a0previa\u00a0a\u00a0la\u00a0eyaculaci\u00f3n. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 94La\u00a0probabilidad \u00a0de\u00a0transmisi\u00f3n \u00a0por\u00a0relaci\u00f3n\u00a0anal\u00a0insertiva\u00a0en\u00a0varones\u00a0circuncidados \u00a0fue\u00a0\n0,11%\u00a0(IC\u00a095%,\u00a00,02\u00a0a\u00a00,24)\u00a0y\u00a00,62%\u00a0(IC\u00a095%,\u00a00,07\u00a0a\u00a01,68)\u00a0en\u00a0pacientes \u00a0no\u00a0\ncircuncidados936.\u00a0Es\u00a0muy\u00a0importante \u00a0recordar\u00a0que\u00a0en\u00a0la\u00a0era\u00a0TAR,\u00a0la\u00a0probabilidad \u00a0de\u00a0\ntransmisi\u00f3n \u00a0del\u00a0VIH\u00a0por\u00a0una\u00a0relaci\u00f3n\u00a0anal\u00a0receptiva \u00a0con\u00a0eyaculaci\u00f3n \u00a0es\u00a0el\u00a0doble\u00a0que\u00a0sin\u00a0\neyaculaci\u00f3n \u00a0y\u00a010\u00a0veces\u00a0superior\u00a0a\u00a0la\u00a0observada \u00a0en\u00a0la\u00a0relaci\u00f3n\u00a0anal\u00a0insertiva\u00a0en\u00a0un\u00a0\npaciente\u00a0circundidado, \u00a0en\u00a0las\u00a0relaciones \u00a0heterosexuales \u00a0o\u00a0en\u00a0la\u00a0exposici\u00f3n \u00a0\nocupacional937.\u00a0El\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0est\u00e1\u00a0igualmente \u00a0aumentado \u00a0en\u00a0caso\u00a0de\u00a0ETS\u00a0o\u00a0\nen\u00a0las\u00a0agresiones \u00a0sexuales.\u00a0\nInicialmente \u00a0existi\u00f3\u00a0cierta\u00a0preocupaci\u00f3n \u00a0de\u00a0que\u00a0la\u00a0extensi\u00f3n \u00a0de\u00a0la\u00a0PPE\u00a0no\u00a0ocupacional \u00a0\npudiera\u00a0reducir\u00a0las\u00a0medidas\u00a0de\u00a0prevenci\u00f3n \u00a0primaria,\u00a0al\u00a0existir\u00a0una\u00a0supuesta\u00a0\u201cprofilaxis \u00a0\npara\u00a0el\u00a0d\u00eda\u00a0despu\u00e9s\u201d, \u00a0y\u00a0\u00a0relajar\u00a0la\u00a0seguridad \u00a0en\u00a0las\u00a0pr\u00e1cticas\u00a0sexuales\u00a0o\u00a0de\u00a0las\u00a0inyecci\u00f3n \u00a0\nde\u00a0drogas.\u00a0Sin\u00a0embargo, \u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0si\u00a0la\u00a0PPE\u00a0no\u00a0ocupacional \u00a0\u00a0se\u00a0acompa\u00f1a \u00a0\nde\u00a0la\u00a0oportuna \u00a0intervenci\u00f3n \u00a0educativa \u00a0se\u00a0pueden\u00a0reducir\u00a0las\u00a0pr\u00e1cticas\u00a0de\u00a0riesgo938.\u00a0Es\u00a0\nimportante \u00a0en\u00a0este\u00a0sentido\u00a0realizar\u00a0historia\u00a0sexual\u00a0en\u00a0la\u00a0primera\u00a0visita\u00a0y\u00a0de\u00a0forma\u00a0\nperi\u00f3dica, \u00a0junto\u00a0con\u00a0despistaje \u00a0de\u00a0ETS\u00a0y\u00a0discutir\u00a0con\u00a0el\u00a0paciente\u00a0los\u00a0m\u00e9todos\u00a0para\u00a0la\u00a0\nprevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0en\u00a0las\u00a0relaciones \u00a0sexuales.\u00a0Los\u00a0problemas \u00a0de\u00a0la\u00a0\nPPE\u00a0no\u2010ocupacional \u00a0son\u00a0que\u00a0a\u00a0menudo\u00a0no\u00a0se\u00a0conoce\u00a0la\u00a0situaci\u00f3n\u00a0serol\u00f3gica \u00a0de\u00a0la\u00a0\nfuente,\u00a0el\u00a0inicio\u00a0de\u00a0la\u00a0profilaxis\u00a0suele\u00a0ser\u00a0m\u00e1s\u00a0tard\u00edo\u00a0y\u00a0el\u00a0nivel\u00a0de\u00a0abandonos \u00a0suele\u00a0ser\u00a0\nm\u00e1s\u00a0alto,\u00a0ya\u00a0sea\u00a0por\u00a0efectos\u00a0adversos\u00a0de\u00a0los\u00a0FAR,\u00a0o\u00a0por\u00a0simples\u00a0p\u00e9rdidas\u00a0del\u00a0\nseguimiento923,\u00a0939,\u00a0940.\u00a0En\u00a0Espa\u00f1a,\u00a0al\u00a0igual\u00a0que\u00a0otros\u00a0pa\u00edses,\u00a0la\u00a0demanda \u00a0de\u00a0la\u00a0PPE\u00a0no\u00a0\nocupacional \u00a0ha\u00a0aumentado \u00a0y\u00a0en\u00a0ocasiones \u00a0se\u00a0utiliza\u00a0en\u00a0escenarios \u00a0no\u00a0previstos\u00a0en\u00a0las\u00a0\nrecomendaciones \u00a0existentes941.\u00a0Estudios\u00a0de\u00a0coste\u2010eficacia\u00a0demuestran \u00a0que\u00a0\n\u00fanicamente \u00a0las\u00a0relaciones \u00a0de\u00a0alto\u00a0riesgo\u00a0con\u00a0fuentes\u00a0documentadas \u00a0HIV\u00a0positivas\u00a0son\u00a0\ncoste\u2010efectivas942.\u00a0\u00a0\nEn\u00a0las\u00a0recomendaciones \u00a0de\u00a0los\u00a0CDC934\u00a0y\u00a0del\u00a0PNS/Gesida929\u00a0\u00a0se\u00a0insiste\u00a0en\u00a0dos\u00a0aspectos\u00a0\nclaves\u00a0de\u00a0la\u00a0PPE\u00a0no\u00a0ocupacional \u00a0:\u00a01)\u00a0la\u00a0actuaci\u00f3n \u00a0m\u00e9dica\u00a0no\u00a0debe\u00a0ce\u00f1irse\u00a0\nexclusivamente \u00a0a\u00a0valorar\u00a0la\u00a0indicaci\u00f3n \u00a0de\u00a0PPE\u00a0con\u00a0FAR,\u00a0sino\u00a0que\u00a0debe\u00a0contemplar \u00a0la\u00a0\noferta\u00a0de\u00a0la\u00a0prueba\u00a0para\u00a0el\u00a0VIH,\u00a0educaci\u00f3n \u00a0sanitaria\u00a0para\u00a0la\u00a0reducci\u00f3n \u00a0del\u00a0riesgo\u00a0de\u00a0\nadquisici\u00f3n \u00a0del\u00a0VIH,\u00a0valoraci\u00f3n \u00a0del\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0de\u00a0otras\u00a0infecciones \u00a0y\u00a0\nseguimiento \u00a0cl\u00ednico;\u00a0y,\u00a02)\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0llevar\u00a0a\u00a0cabo\u00a0PPE\u00a0con\u00a0FAR\u00a0ha\u00a0de\u00a0ser\u00a0tomada\u00a0por\u00a0\nel\u00a0m\u00e9dico\u00a0y\u00a0el\u00a0paciente\u00a0de\u00a0forma\u00a0individualizada, \u00a0valorando \u00a0sus\u00a0beneficios \u00a0y\u00a0riesgos\u00a0y\u00a0\ndesaconsej\u00e1ndola \u00a0en\u00a0personas\u00a0con\u00a0exposiciones \u00a0repetidas. \u00a0La\u00a0PPE\u00a0debe\u00a0considerase \u00a0\nteniendo\u00a0en\u00a0cuenta\u00a0el\u00a0nivel\u00a0de\u00a0riesgo,\u00a0la\u00a0v\u00eda\u00a0de\u00a0exposici\u00f3n, \u00a0el\u00a0estado\u00a0serol\u00f3gico \u00a0y/o\u00a0\npr\u00e1cticas\u00a0de\u00a0riesgo\u00a0de\u00a0la\u00a0persona\u00a0fuente,\u00a0as\u00ed\u00a0como\u00a0el\u00a0TAR\u00a0recibido\u00a0por\u00a0el\u00a0paciente\u00a0\nfuente\u00a0caso\u00a0de\u00a0estar\u00a0infectado \u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0la\u00a0existencia \u00a0de\u00a0factores\u00a0de\u00a0riesgo\u00a0a\u00f1adidos\u00a0\n(Tabla\u00a018).\u00a0\u00a0\nLa\u00a0elecci\u00f3n\u00a0de\u00a0los\u00a0FAR,\u00a0su\u00a0inicio\u00a0y\u00a0duraci\u00f3n\u00a0es\u00a0similar\u00a0a\u00a0la\u00a0PPE\u00a0ocupacional. \u00a0En\u00a0la\u00a0PPE\u00a0no\u00a0\nocupacional \u00a0se\u00a0deber\u00eda\u00a0valorar\u00a0las\u00a0concentraciones \u00a0que\u00a0alcanzan\u00a0los\u00a0FAR\u00a0en\u00a0las\u00a0\nsecreciones \u00a0genitales\u00a0respecto\u00a0a\u00a0las\u00a0plasm\u00e1ticas. \u00a0Las\u00a0concentraciones \u00a0de\u00a0los\u00a0AN\u00a0son\u00a0\nm\u00e1s\u00a0elevadas\u00a0que\u00a0las\u00a0plasm\u00e1ticas, \u00a0los\u00a0IP\u00a0alcanzan\u00a0niveles\u00a0inferiores \u00a0a\u00a0los\u00a0AN,\u00a0sobre\u00a0\ntodo\u00a0por\u00a0su\u00a0uni\u00f3n\u00a0a\u00a0las\u00a0prote\u00ednas, \u00a0y\u00a0en\u00a0los\u00a0NN\u00a0se\u00a0han\u00a0observado \u00a0diferencias, \u00a0NVP\u00a0\nalcanza\u00a0niveles\u00a0superiores \u00a0a\u00a0las\u00a0plasm\u00e1ticas, \u00a0y\u00a0con\u00a0la\u00a0salvedad\u00a0de\u00a0que\u00a0EFV\u00a0no\u00a0es\u00a0\naconsejable \u00a0por\u00a0su\u00a0baja\u00a0concentraci\u00f3n \u00a0en\u00a0las\u00a0secreciones \u00a0genitales\u00a0(inferior\u00a0al\u00a010%\u00a0de\u00a0\nlas\u00a0plasm\u00e1ticas) \u00a0y\u00a0su\u00a0posible\u00a0efecto\u00a0teratog\u00e9nico939,\u00a0943.\u00a0\u00a0\nHist\u00f3ricamente \u00a0la\u00a0tolerabilidad \u00a0y\u00a0la\u00a0adherencia \u00a0de\u00a0la\u00a0PPE\u00a0no\u00a0ocupacional \u00a0eran\u00a0muy\u00a0\nbajas,\u00a0con\u00a0abandonos \u00a0del\u00a022%\u201076%,\u00a0siendo\u00a0la\u00a0toxicidad\u00a0la\u00a0principal\u00a0causa\u00a0del\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 95abandono923,\u00a0924,\u00a0940.\u00a0Por\u00a0ello\u00a0las\u00a0gu\u00edas\u00a0americanas \u00a0y\u00a0de\u00a0la\u00a0OMS\u00a0optan\u00a0por\u00a0dos\u00a0\u00a0FAR\u00a0(dos\u00a0\nAN)\u00a0para\u00a0mejorar\u00a0la\u00a0adherencia \u00a0y\u00a0recomiendan \u00a0un\u00a0tercer\u00a0f\u00e1rmaco\u00a0en\u00a0los\u00a0casos\u00a0de\u00a0\nmayor\u00a0\u00a0riesgo.\u00a0En\u00a0cambio\u00a0las\u00a0gu\u00edas\u00a0europeas, \u00a0y\u00a0las\u00a0brit\u00e1nicas \u00a0\u00a0recomiendan \u00a0\nTDF/FTC+LPV/r930,\u00a0944.\u00a0La\u00a0tolerabilidad \u00a0ha\u00a0mejorado \u00a0con\u00a0las\u00a0nuevas\u00a0pautas924.\u00a0En\u00a0el\u00a0a\u00f1o\u00a0\n2010\u00a0se\u00a0ha\u00a0publicado \u00a0la\u00a0experiencia \u00a0francesa945\u00a0con\u00a0249\u00a0pacientes \u00a0tratados\u00a0con\u00a0\nTDF/FTC+LPV/r, \u00a0con\u00a0un\u00a022%\u00a0de\u00a0abandonos, \u00a0y\u00a0la\u00a0experiencia \u00a0holandesa946\u00a0con\u00a0139\u00a0\npacientes \u00a0con\u00a0ZDV/3TC+ATV/r \u00a0de\u00a0los\u00a0que\u00a0completaron \u00a0el\u00a0tratamiento \u00a0el\u00a091%,\u00a0aunque\u00a0\nen\u00a0las\u00a0dos\u00a0series\u00a0la\u00a0toxicidad\u00a0fue\u00a0elevada,\u00a0sobre\u00a0todo\u00a0la\u00a0gastrointestinal. \u00a0Sin\u00a0embargo, \u00a0\nla\u00a0toxicidad\u00a0no\u00a0es\u00a0el\u00a0\u00fanico\u00a0factor\u00a0relacionado \u00a0con\u00a0la\u00a0adherencia, \u00a0dado\u00a0que\u00a0en\u00a0la\u00a0\nexperiencia \u00a0holandesa \u00a0observaron \u00a0que\u00a0los\u00a0varones\u00a0homosexuales \u00a0que\u00a0hab\u00edan\u00a0tenido\u00a0\nuna\u00a0exposici\u00f3n \u00a0con\u00a0un\u00a0paciente\u00a0con\u00a0infecci\u00f3n\u00a0VIH\u00a0conocida\u00a0finalizaron \u00a0la\u00a0pauta,\u00a0a\u00a0pesar\u00a0\nde\u00a0que\u00a0algunos\u00a0presentaban \u00a0efectos\u00a0adversos\u00a0m\u00e1s\u00a0importantes \u00a0que\u00a0otros\u00a0que\u00a0\nsuspendieron. \u00a0Se\u00a0ha\u00a0comunicado \u00a0una\u00a0experiencia \u00a0espa\u00f1ola\u00a0con\u00a0255\u00a0pacientes \u00a0(91%\u00a0\ntras\u00a0una\u00a0exposici\u00f3n \u00a0sexual).\u00a0Fueron\u00a0aleatorizados \u00a0a\u00a0ZDV/3TC+LPV/r \u00a0o\u00a0ZDV/3TC+ATV \u00a0\n(400mg\u00a0QD).\u00a0Las\u00a0p\u00e9rdidas\u00a0de\u00a0seguimiento \u00a0fueron\u00a0elevadas. \u00a0De\u00a0los\u00a0178\u00a0pacientes \u00a0\nevaluados, \u00a0el\u00a07%\u00a0suspendi\u00f3 \u00a0el\u00a0tratamiento \u00a0por\u00a0toxicidad, \u00a07\u00a0pacientes \u00a0con\u00a0LPV/r\u00a0y\u00a06\u00a0con\u00a0\nATV\u00a0respectivamente947.\u00a0\u00a0\n\u00a0\nRecomendaciones \u00a0sobre\u00a0profilaxis \u00a0postexposici\u00f3n \u00a0no\u00a0ocupacional \u00a0\n\u0083 La\u00a0PPE\u00a0no\u00a0ocupacional \u00a0debe\u00a0individualizarse \u00a0y\u00a0llevarse\u00a0a\u00a0cabo\u00a0en\u00a0el\u00a0marco\u00a0de\u00a0una\u00a0\nintervenci\u00f3n \u00a0m\u00e9dica\u00a0integral\u00a0(Nivel\u00a0C)\u00a0\n\u0083 La\u00a0PPE\u00a0no\u00a0ocupacional \u00a0debe\u00a0recomendarse \u00a0en\u00a0las\u00a0situaciones \u00a0denominadas \u00a0de\u00a0\n\u201criesgo\u00a0apreciable\u201d \u00a0si\u00a0se\u00a0dan\u00a0las\u00a0siguientes \u00a0condiciones: \u00a0a)\u00a0instauraci\u00f3n \u00a0precoz\u00a0\n(similar\u00a0a\u00a0la\u00a0PPE\u00a0ocupacional), \u00a0b)\u00a0ausencia\u00a0de\u00a0contraindicaciones \u00a0para\u00a0tomar\u00a0FAR,\u00a0c)\u00a0\nexposici\u00f3n \u00a0excepcional \u00a0y\u00a0d)\u00a0garant\u00eda\u00a0de\u00a0seguimiento \u00a0cl\u00ednico\u00a0y\u00a0anal\u00edtico\u00a0del\u00a0paciente\u00a0\n(Nivel\u00a0C)\u00a0\n\u0083 Los\u00a0f\u00e1rmacos \u00a0a\u00a0emplear,\u00a0su\u00a0duraci\u00f3n\u00a0y\u00a0el\u00a0seguimiento \u00a0de\u00a0los\u00a0pacientes \u00a0ser\u00e1\u00a0igual\u00a0\nque\u00a0\u00a0en\u00a0la\u00a0PPE\u00a0ocupacional \u00a0(Nivel\u00a0C)\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0exposici\u00f3n \u00a0sexual\u00a0debe\u00a0valorarse\u00a0el\u00a0riesgo\u00a0de\u00a0ETS\u00a0y\u00a0embarazo \u00a0(Nivel\u00a0C)\u00a0\n\u00a0\n12.\u00a0OTRAS\u00a0ESTRATEGIAS \u00a0Y\u00a0NUEVOS\u00a0FARMACOS \u00a0\nInterrupciones \u00a0supervisadas \u00a0del\u00a0tratamiento \u00a0\nLas\u00a0interrupciones \u00a0supervisadas \u00a0del\u00a0TAR\u00a0(IST)\u00a0se\u00a0plantearon \u00a0inicialmente \u00a0con\u00a0algunos\u00a0\nde\u00a0los\u00a0siguientes \u00a0objetivos: \u00a01)\u00a0estimulaci\u00f3n \u00a0de\u00a0la\u00a0respuesta \u00a0inmune\u00a0celular\u00a0en\u00a0\npacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0(auto\u2010inmunizaci\u00f3n); \u00a02)\u00a0reversi\u00f3n \u00a0de\u00a0mutaciones \u00a0del\u00a0\nVIH,\u00a0en\u00a0pacientes \u00a0en\u00a0multifracaso \u00a0antes\u00a0del\u00a0TAR\u00a0de\u00a0rescate;\u00a0y,\u00a03)\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0\nexposici\u00f3n \u00a0al\u00a0TAR,\u00a0principalmente \u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable, \u00a0para\u00a0prevenir\u00a0o\u00a0\nrevertir\u00a0efectos\u00a0adversos, \u00a0mejorar\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0y\u00a0en\u00a0menor\u00a0grado,\u00a0disminuir \u00a0el\u00a0\ngasto\u00a0sanitario\u00a0(vacaciones \u00a0terap\u00e9uticas). \u00a0\nPr\u00e1cticamente \u00a0se\u00a0han\u00a0abandonado \u00a0los\u00a0dos\u00a0primeros\u00a0planteamientos \u00a0al\u00a0no\u00a0obtener\u00a0\nresultados \u00a0positivos948\u2010951.\u00a0El\u00a0planteamiento \u00a0te\u00f3rico\u00a0de\u00a0la\u00a0IST\u00a0para\u00a0la\u00a0auto\u2010inmunizaci\u00f3n \u00a0\nera\u00a0conseguir \u00a0mediante \u00a0brotes\u00a0de\u00a0replicaci\u00f3n \u00a0viral\u00a0intermitente, \u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0la\u00a0\nrespuesta \u00a0inmune\u00a0espec\u00edfica \u00a0frente\u00a0al\u00a0VIH\u00a0con\u00a0el\u00a0fin\u00a0de\u00a0conseguir \u00a0una\u00a0baja\u00a0replicaci\u00f3n \u00a0\nviral\u00a0que\u00a0permitiera \u00a0mantener \u00a0a\u00a0los\u00a0pacientes \u00a0libres\u00a0de\u00a0TAR\u00a0durante\u00a0per\u00edodos\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 96prolongados. \u00a0Algunos\u00a0estudios\u00a0demostraron \u00a0que\u00a0aunque\u00a0era\u00a0posible\u00a0inducir\u00a0una\u00a0\nrespuesta \u00a0inmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH,\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0que\u00a0controlaron \u00a0\nla\u00a0replicaci\u00f3n \u00a0viral\u00a0en\u00a0ausencia\u00a0de\u00a0TAR\u00a0fue\u00a0muy\u00a0bajo949\u2010951.\u00a0\u00a0\nLas\u00a0IST\u00a0previas\u00a0a\u00a0un\u00a0TAR\u00a0de\u00a0rescate\u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0revertir\u00a0las\u00a0resistencias \u00a0a\u00a0los\u00a0\nFAR952,\u00a0953\u00a0y\u00a0mejorar\u00a0la\u00a0respuesta \u00a0al\u00a0mismo\u00a0no\u00a0han\u00a0demostrado \u00a0beneficio \u00a0virol\u00f3gico \u00a0o\u00a0\ninmunol\u00f3gico397,\u00a0398,\u00a0954,\u00a0955\u00a0\u00a0y\u00a0durante\u00a0la\u00a0IST\u00a0existe\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0\ncl\u00ednica.\u00a0\u00a0\nEn\u00a0un\u00a0contexto\u00a0similar,\u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0detectable \u00a0y\u00a0en\u00a0multifracaso, \u00a0se\u00a0han\u00a0\nexperimentado \u00a0las\u00a0llamadas\u00a0interrupciones \u00a0parciales\u00a0de\u00a0tratamiento \u00a0(IPT).\u00a0Estas\u00a0\nconsisten \u00a0en\u00a0interrumpir \u00a0los\u00a0IP\u00a0manteniendo \u00a0los\u00a0AN\u00a0a\u00a0los\u00a0que\u00a0el\u00a0virus\u00a0es\u00a0resistente. \u00a0Con\u00a0\nesta\u00a0estrategia \u00a0se\u00a0perpetu\u00e1n \u00a0las\u00a0mutaciones \u00a0virales\u00a0que\u00a0condicionan \u00a0baja\u00a0capacidad \u00a0\nreplicativa \u00a0conteniendo \u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0y\u00a0preservando \u00a0los\u00a0CD4201,\u00a0955.\u00a0Por\u00a0lo\u00a0tanto,\u00a0\nesta\u00a0estrategia \u00a0de\u00a0IPT\u00a0podr\u00eda\u00a0plantearse \u00a0en\u00a0pacientes \u00a0seleccionados \u00a0hasta\u00a0disponer\u00a0de\u00a0\nnuevos\u00a0f\u00e1rmacos \u00a0de\u00a0rescate.\u00a0\nLas\u00a0IST\u00a0para\u00a0reducir\u00a0la\u00a0exposici\u00f3n \u00a0al\u00a0TAR\u00a0(vacaciones \u00a0terap\u00e9uticas) \u00a0tienen\u00a0como\u00a0\nobjetivo\u00a0evitar\u00a0o\u00a0revertir\u00a0toxicidades, \u00a0mejorar\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0y\u00a0reducir\u00a0costes\u00a0\nmanteniendo \u00a0la\u00a0eficacia\u00a0cl\u00ednica\u00a0e\u00a0inmunol\u00f3gica956\u2010966.\u00a0Los\u00a0riesgos\u00a0ser\u00edan\u00a0la\u00a0presentaci\u00f3n \u00a0\nde\u00a0un\u00a0s\u00edndrome \u00a0retroviral \u00a0agudo\u00a0con\u00a0rebrote\u00a0viral,\u00a0el\u00a0deterioro \u00a0inmunol\u00f3gico \u00a0y\u00a0\nprogresi\u00f3n \u00a0cl\u00ednica,\u00a0aparici\u00f3n \u00a0de\u00a0nuevas\u00a0mutaciones \u00a0(resistencia), \u00a0m\u00e1s\u00a0posibilidades \u00a0de\u00a0\ntransmisi\u00f3n \u00a0del\u00a0VIH\u00a0y\u00a0aumento\u00a0de\u00a0enfermedades \u00a0cardiovasculares \u00a0y\u00a0hep\u00e1ticas, \u00a0no\u00a0\ndiagn\u00f3sticas \u00a0de\u00a0sida958,\u00a0961.\u00a0\u00a0\u00a0\nNo\u00a0es\u00a0f\u00e1cil\u00a0comparar \u00a0los\u00a0resultados \u00a0de\u00a0los\u00a0estudios\u00a0publicados \u00a0o\u00a0comunicados \u00a0por\u00a0\ndiferencias \u00a0en\u00a0el\u00a0dise\u00f1o,\u00a0tipo\u00a0de\u00a0pacientes \u00a0incluidos, \u00a0criterios\u00a0para\u00a0suspender \u00a0o\u00a0\nreiniciar\u00a0el\u00a0tratamiento, \u00a0etc.\u00a0Algunos\u00a0estudios\u00a0han\u00a0mantenido \u00a0interrupciones \u00a0fijas958,\u00a0\n961,\u00a0967\u00a0\u00a0mientras\u00a0que\u00a0en\u00a0otros\u00a0las\u00a0IST\u00a0se\u00a0han\u00a0basado\u00a0en\u00a0las\u00a0cifras\u00a0de\u00a0CD4959,\u00a0962,\u00a0968,\u00a0e\u00a0\nincluso\u00a0de\u00a0la\u00a0CVP201.\u00a0En\u00a0el\u00a0mayor\u00a0estudio\u00a0aleatorizado \u00a0realizado\u00a0hasta\u00a0la\u00a0fecha,\u00a0el\u00a0\nSMART,\u00a0los\u00a0pacientes \u00a0con\u00a0IST\u00a0progresaron \u00a0m\u00e1s\u00a0a\u00a0sida\u00a0o\u00a0muerte,\u00a0y\u00a0adem\u00e1s\u00a0presentaron \u00a0\nen\u00a0mayor\u00a0proporci\u00f3n \u00a0eventos\u00a0cardiol\u00f3gicos \u00a0o\u00a0hep\u00e1ticos201.\u00a0Es\u00a0probable\u00a0que\u00a0la\u00a0cifra\u00a0de\u00a0\n250\u00a0CD4\u00a0como\u00a0criterio\u00a0de\u00a0reinicio\u00a0fuera\u00a0demasiado \u00a0baja\u00a0y\u00a0favoreciera \u00a0un\u00a0curso\u00a0\ndesfavorable. \u00a0As\u00ed\u00a0en\u00a0otros\u00a0estudios\u00a0en\u00a0los\u00a0que\u00a0el\u00a0TAR\u00a0se\u00a0reiniciaba \u00a0a\u00a0las\u00a0350\u00a0CD4/\u00b5L962,\u00a0\n964\u2010966,\u00a0968,\u00a0la\u00a0evoluci\u00f3n \u00a0fue\u00a0favorable, \u00a0especialmente \u00a0en\u00a0pacientes \u00a0cuyo\u00a0nadir\u00a0de\u00a0CD4\u00a0\nera\u00a0>200\u00a0c\u00e9lulas/\u00b5L964,\u00a0966.\u00a0Esta\u00a0estrategia \u00a0podr\u00eda\u00a0ser\u00a0de\u00a0utilidad\u00a0en\u00a0los\u00a0que\u00a0iniciaron\u00a0\nTAR\u00a0con\u00a0cifras\u00a0de\u00a0CD4\u00a0>350\u2010500\u00a0c\u00e9lulas/\u00b5L, \u00a0y\u00a0que\u00a0permanecen \u00a0con\u00a0CVP\u00a0indetectable, \u00a0si\u00a0\nno\u00a0han\u00a0presentado \u00a0trombocitopenia. \u00a0\u00a0\nEl\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0en\u00a0las\u00a0pautas\u00a0que\u00a0incluyen\u00a0un\u00a0NN957,\u00a0se\u00a0puede\u00a0\nreducir\u00a0interrumpiendo \u00a0la\u00a0NVP\u00a0o\u00a0EFV\u00a0una\u00a0semana\u00a0antes,\u00a0evitando\u00a0as\u00ed\u00a0la\u00a0\u201cmonoterapia\u201d \u00a0\ncon\u00a0f\u00e1rmacos\u00a0de\u00a0vida\u00a0media\u00a0prolongada962.\u00a0\nEn\u00a0cualquier \u00a0caso,\u00a0la\u00a0principal\u00a0raz\u00f3n\u00a0para\u00a0no\u00a0recomendar \u00a0en\u00a0la\u00a0actualidad \u00a0las\u00a0\nestrategias \u00a0de\u00a0\u201cvacaciones \u00a0terap\u00e9uticas\u201d, \u00a0es\u00a0el\u00a0hallazgo\u00a0en\u00a0el\u00a0estudio\u00a0SMART\u00a0de\u00a0un\u00a0\naumento\u00a0en\u00a0la\u00a0incidencia \u00a0de\u00a0enfermedades \u00a0cardiovasculares \u00a0y\u00a0hep\u00e1ticos201,\u00a0969.\u00a0En\u00a0\nsubestudios \u00a0del\u00a0SMART969\u00a0y\u00a0otros\u00a0estudios\u00a0como\u00a0el\u00a0STACCATO970\u00a0y\u00a0el\u00a0estudio\u00a0espa\u00f1ol\u00a0\nSTOPAR971\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0control\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0dar\u00eda\u00a0\nlugar\u00a0al\u00a0aumento\u00a0de\u00a0citoquinas \u00a0pro\u00a0inflamatorias \u00a0como\u00a0MCP\u20101,\u00a0sVCAM\u20101,\u00a0o\u00a0IL\u20106,\u00a0entre\u00a0\notras,\u00a0lo\u00a0que\u00a0contribuir\u00eda \u00a0al\u00a0aumento\u00a0del\u00a0riesgo\u00a0cardiovascular \u00a0tras\u00a0la\u00a0interrupci\u00f3n \u00a0del\u00a0\nTAR.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 97Por\u00a0otra\u00a0parte,\u00a0hay\u00a0que\u00a0comentar \u00a0que\u00a0se\u00a0est\u00e1n\u00a0llevando\u00a0a\u00a0cabo\u00a0estudios\u00a0de\u00a0IST\u00a0de\u00a0corta\u00a0\nduraci\u00f3n\u00a0(3\u20104\u00a0meses)\u00a0en\u00a0el\u00a0contexto\u00a0de\u00a0utilizaci\u00f3n \u00a0de\u00a0vacunas\u00a0terap\u00e9uticas, \u00a0con\u00a0la\u00a0\nhip\u00f3tesis\u00a0de\u00a0promover \u00a0con\u00a0estas\u00a0una\u00a0respuesta \u00a0inmunol\u00f3gica \u00a0\u2010y\u00a0virol\u00f3gica \u2010\u00a0suficiente \u00a0\nque\u00a0permita\u00a0suspender \u00a0de\u00a0forma\u00a0transitoria \u00a0o\u00a0permanente \u00a0el\u00a0TAR972.\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\nRecomendaciones \u00a0sobre\u00a0interrupciones \u00a0supervisadas \u00a0del\u00a0tratamiento \u00a0\n\u0083 No\u00a0se\u00a0recomienda \u00a0la\u00a0IST\u00a0como\u00a0forma\u00a0de\u00a0autoinmunizaci\u00f3n \u00a0(nivel\u00a0B),\u00a0ni\u00a0como\u00a0parte\u00a0\nde\u00a0una\u00a0estrategia \u00a0de\u00a0rescate\u00a0(nivel\u00a0A)\u00a0949\u2010951,\u00a0953,\u00a0953,\u00a0954\u00a0\n\u0083 Se\u00a0desaconseja \u00a0la\u00a0IST\u00a0guiada\u00a0por\u00a0CD4.\u00a0Si\u00a0se\u00a0plantea\u00a0en\u00a0una\u00a0situaci\u00f3n\u00a0muy\u00a0\nseleccionada, \u00a0se\u00a0deber\u00edan\u00a0cumplir\u00a0las\u00a0siguientes \u00a0condiciones: \u00a01)\u00a0el\u00a0paciente\u00a0no\u00a0est\u00e1\u00a0\ndispuesto \u00a0a\u00a0continuar \u00a0el\u00a0TAR\u00a0de\u00a0forma\u00a0indefinida; \u00a02)\u00a0tiene\u00a0CD4\u00a0>500\u00a0c\u00e9lulas/\u00b5L, \u00a0\u00a03)\u00a0\nnadir\u00a0de\u00a0CD4\u00a0>200\u00a0c\u00e9lulas/\u00b5L; \u00a04)\u00a0se\u00a0reiniciar\u00e1 \u00a0el\u00a0TAR\u00a0si\u00a0CD4\u00a0<350\u00a0c\u00e9lulas/\u00b5L; \u00a05)\u00a0el\u00a0\npaciente\u00a0debe\u00a0conocer\u00a0que\u00a0existe\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0de\u00a0enfermedades \u00a0\ncardiovasculares \u00a0y\u00a0hep\u00e1ticas \u00a0si\u00a0se\u00a0interrumpe \u00a0el\u00a0TAR\u00a0y\u00a0se\u00a0reinicia\u00a0cuando\u00a0los\u00a0CD4\u00a0\ndescienden \u00a0a\u00a0<250\u00a0c\u00e9lulas/\u00b5L; \u00a06)\u00a0el\u00a0paciente\u00a0es\u00a0consciente \u00a0de\u00a0que\u00a0la\u00a0replicaci\u00f3n \u00a0\nviral\u00a0y\u00a0el\u00a0aumento\u00a0de\u00a0la\u00a0CVP\u00a0suponen\u00a0m\u00e1s\u00a0posibilidades \u00a0de\u00a0transmitir \u00a0el\u00a0VIH\u00a0y\u00a0\ntomar\u00e1\u00a0las\u00a0medidas\u00a0adecuadas \u00a0(nivel\u00a0C)201,\u00a0956\u00a0\n\u00a0Tratamientos \u00a0inmunomediados \u00a0\nEl\u00a0TAR\u00a0suprime\u00a0de\u00a0forma\u00a0eficaz\u00a0la\u00a0replicaci\u00f3n \u00a0viral,\u00a0lo\u00a0que\u00a0se\u00a0sigue\u00a0de\u00a0una\u00a0\nreconstituci\u00f3n \u00a0importante \u00a0del\u00a0sistema\u00a0inmune.\u00a0Sin\u00a0embargo, \u00a0la\u00a0respuesta \u00a0\ninmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH\u00a0no\u00a0suele\u00a0recuperarse \u00a0y\u00a0adem\u00e1s\u00a0en\u00a0algunos\u00a0casos\u00a0la\u00a0\nreconstituci\u00f3n \u00a0inmunol\u00f3gica \u00a0es\u00a0parcial.\u00a0Para\u00a0el\u00a0primer\u00a0caso\u00a0se\u00a0han\u00a0ensayado \u00a0\nlas\u00a0\nvacunas\u00a0terap\u00e9uticas \u00a0y\u00a0en\u00a0el\u00a0segundo\u00a0caso\u00a0el\u00a0tratamiento \u00a0con\u00a0inmunomoduladores \u00a0\ncomo\u00a0la\u00a0interleuquina \u20102\u00a0(IL\u20102).\u00a0\u00a0\n\u00a0Citoquinas: \u00a0IL\u20102.\u00a0\nEn\u00a0alg\u00fan\u00a0ensayo\u00a0cl\u00ednico\u00a0y\u00a0series\u00a0prospectivas \u00a0\n973\u2010975\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0la\u00a0IL\u20102,\u00a0\nadministrada \u00a0de\u00a0forma\u00a0intermitente \u00a0por\u00a0v\u00eda\u00a0subcut\u00e1nea \u00a0(4,5\u00a0a\u00a07,5\u00a0MU\u00a0cada\u00a012\u00a0horas\u00a0\ndurante\u00a05\u00a0d\u00edas\u00a0cada\u00a08\u00a0semanas) \u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0TAR\u00a0aumentaba \u00a0de\u00a0forma\u00a0\nimportante \u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0se\u00a0asociaba\u00a0con\u00a0una\u00a0mejor\u00a0respuesta \u00a0\nvirol\u00f3gica \u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0el\u00a0TAR.\u00a0Para\u00a0saber\u00a0si\u00a0estos\u00a0cambios\u00a0inmunol\u00f3gicos \u00a0se\u00a0\ntraduc\u00edan \u00a0en\u00a0mejor\u00edas\u00a0cl\u00ednicas\u00a0se\u00a0llevaron\u00a0a\u00a0cabo\u00a0dos\u00a0grandes\u00a0ensayos\u00a0cl\u00ednicos\u00a0\u00a0\ndenominados \u00a0SILCAAT\u00a0(1695\u00a0sujetos\u00a0con\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0entre\u00a050\u00a0y\u00a0299\u00a0\nc\u00e9lulas/\u00b5L \u00a0y\u00a0ESPRIT\u00a0(4111\u00a0pacientes \u00a0con\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0superiores \u00a0a\u00a0300\u00a0\nc\u00e9lulas/\u00b5L) \u00a0cuyos\u00a0resultados \u00a0se\u00a0han\u00a0publicado976.\u00a0El\u00a0punto\u00a0final\u00a0de\u00a0evaluaci\u00f3n \u00a0era\u00a0el\u00a0\nmismo\u00a0en\u00a0ambos\u00a0estudios:\u00a0presencia \u00a0de\u00a0eventos\u00a0oportunistas \u00a0o\u00a0muerte.\u00a0A\u00a0pesar\u00a0de\u00a0\nque\u00a0en\u00a0ambos\u00a0se\u00a0evidenci\u00f3 \u00a0un\u00a0aumento\u00a0significativo \u00a0de\u00a0CD4\u00a0(una\u00a0diferencia \u00a0de\u00a059\u00a0\nc\u00e9lulas\u00a0a\u00a0favor\u00a0del\u00a0grupo\u00a0de\u00a0IL\u20102\u00a0en\u00a0el\u00a0SILCAAT\u00a0y\u00a0de\u00a0160\u00a0en\u00a0el\u00a0ESPRIT),\u00a0\nlamentablemente \u00a0ambos\u00a0estudios\u00a0demostraron \u00a0que\u00a0el\u00a0aumento\u00a0de\u00a0CD4\u00a0como\u00a0\nconsecuencia \u00a0del\u00a0uso\u00a0de\u00a0IL\u20102\u00a0no\u00a0se\u00a0asociaba\u00a0a\u00a0una\u00a0reducci\u00f3n \u00a0de\u00a0eventos\u00a0oportunistas \u00a0o\u00a0\nun\u00a0aumento\u00a0en\u00a0la\u00a0supervivencia \u00a0de\u00a0estos\u00a0pacientes. \u00a0El\u00a0riesgo\u00a0relativo\u00a0de\u00a0EO/muerte \u00a0\nfue\u00a0de\u00a00,91\u00a0(0,70\u20101,18)\u00a0p=0,47\u00a0y\u00a00,93\u00a0(0,75\u20101,16),\u00a0p=0,52,\u00a0respectivamente. \u00a0En\u00a0cambio,\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 98los\u00a0pacientes \u00a0de\u00a0las\u00a0ramas\u00a0de\u00a0IL\u20102\u00a0presentaron \u00a0mayor\u00a0toxicidad, \u00a0sobre\u00a0todo\u00a0grado\u00a04,\u00a0\ngastrointestinal \u00a0y\u00a0psiqui\u00e1trica. \u00a0Los\u00a0autores\u00a0concluyeron \u00a0que\u00a0los\u00a0linfocitos\u00a0CD4\u00a0\naumentados \u00a0tras\u00a0el\u00a0uso\u00a0de\u00a0IL\u20102\u00a0no\u00a0ser\u00edan\u00a0funcionalmente \u00a0equivalentes \u00a0a\u00a0los\u00a0CD4\u00a0\nresultantes \u00a0de\u00a0la\u00a0supresi\u00f3n \u00a0virol\u00f3gica \u00a0tras\u00a0el\u00a0uso\u00a0de\u00a0TAR.\u00a0\u00a0\u00a0\nHay\u00a0actualmente \u00a0en\u00a0marcha\u00a0un\u00a0estudio\u00a0fase\u00a0I/IIa\u00a0con\u00a0IL\u20107\u00a0en\u00a0pacientes \u00a0con\u00a0CD4\u00a0100\u2010\n400\u00a0y\u00a0cargas\u00a0virales\u00a0<50\u00a0copias/mL \u00a0tras\u00a0al\u00a0menos\u00a012\u00a0meses\u00a0de\u00a0TAR.\u00a0\n\u00a0\nRecomendaci\u00f3n \u00a0sobre\u00a0tratamientos \u00a0inmunomediados \u00a0\n\u0083 Los\u00a0resultados \u00a0de\u00a0dos\u00a0grandes\u00a0ensayos\u00a0cl\u00ednicos\u00a0desaconsejan \u00a0el\u00a0uso\u00a0de\u00a0IL\u20102\u00a0en\u00a0\npacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0aumentar \u00a0su\u00a0inmunidad, \u00a0porque\u00a0\nno\u00a0se\u00a0asocia\u00a0a\u00a0una\u00a0reducci\u00f3n \u00a0de\u00a0eventos\u00a0oportunistas \u00a0ni\u00a0de\u00a0mortalidad \u00a0y\u00a0s\u00ed\u00a0a\u00a0un\u00a0\naumento\u00a0de\u00a0toxicidad\u00a0(nivel\u00a0A)976\u00a0\n\u00a0Inmunizaciones \u00a0terap\u00e9uticas \u00a0\nEl\u00a0objetivo\u00a0de\u00a0las\u00a0inmunizaciones \u00a0terap\u00e9uticas \u00a0es\u00a0potenciar \u00a0la\u00a0respuesta \u00a0\ninmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH.\u00a0Se\u00a0han\u00a0realizado\u00a0varios\u00a0estudios\u00a0con\u00a0diferentes \u00a0\nvacunas\u00a0terap\u00e9uticas \u00a0en\u00a0los\u00a0que\u00a0se\u00a0ha\u00a0observado \u00a0una\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0\nvariable\u00a0frente\u00a0al\u00a0VIH,\u00a0pero\u00a0no\u00a0se\u00a0ha\u00a0observado \u00a0un\u00a0claro\u00a0beneficio \u00a0inmunol\u00f3gico, \u00a0\nvirol\u00f3gico \u00a0o\u00a0cl\u00ednico\n977.\u00a0\u00a0En\u00a0la\u00a0actualidad \u00a0las\u00a0vacunaciones \u00a0terap\u00e9uticas \u00a0est\u00e1n\u00a0en\u00a0el\u00a0\n\u00e1mbito\u00a0exclusivamente \u00a0experimental978,\u00a0979.\u00a0\n\u00a0Nuevos\u00a0antirretrovirales \u00a0\nA\u00a0pesar\u00a0de\u00a0la\u00a0larga\u00a0lista\u00a0de\u00a0FAR\u00a0disponibles \u00a0la\u00a0imposibilidad \u00a0de\u00a0erradicar\u00a0el\u00a0VIH,\u00a0los\u00a0\nrequerimientos \u00a0de\u00a0adherencia, \u00a0las\u00a0toxicidades \u00a0a\u00a0largo\u00a0plazo\u00a0y\u00a0el\u00a0desarrollo \u00a0de\u00a0\nresistencias \u00a0cruzadas\u00a0entre\u00a0clases\u00a0o\u00a0familias\u00a0de\u00a0FAR\u00a0obligan\u00a0a\u00a0buscar\u00a0nuevos\u00a0f\u00e1rmacos \u00a0\npara\u00a0el\u00a0control\u00a0duradero \u00a0de\u00a0la\u00a0infecci\u00f3n\n\u00a0por\u00a0el\u00a0VIH.\u00a0\u00a0\nExisten\u00a0f\u00e1rmacos\u00a0no\u00a0comercializados \u00a0pero\u00a0en\u00a0fases\u00a0avanzadas \u00a0de\u00a0investigaci\u00f3n: \u00a0el\u00a0NN\u00a0\nrilpivirina \u00a0(TMC278) \u00a0y\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0elvitegravir \u00a0(EVG)\u00a0y\u00a0GSK1349572. \u00a0\u00a0\nRilpivirina \u00a0es\u00a0un\u00a0nuevo\u00a0NN\u00a0con\u00a0una\u00a0eficacia\u00a0similar\u00a0a\u00a0EFV\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0\nprevio\u00a0y\u00a0con\u00a0menor\u00a0toxicidad\u00a0sobre\u00a0sistema\u00a0nervioso\u00a0central\u00a0y\u00a0un\u00a0perfil\u00a0lip\u00eddico\u00a0m\u00e1s\u00a0\nfavorable, \u00a0seg\u00fan\u00a0los\u00a0datos\u00a0a\u00a096\u00a0semanas\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0en\u00a0fase\u00a0IIb\u00a0que\u00a0inclu\u00eda\u00a0\n368\u00a0pacientes \u00a0y\u00a0donde\u00a0se\u00a0estudiaron \u00a03\u00a0dosis\u00a0de\u00a025,\u00a075\u00a0y\u00a0150\u00a0mg/d\u00eda980.\u00a0Otras\u00a0ventajas\u00a0\nde\u00a0este\u00a0f\u00e1rmaco\u00a0es\u00a0que\u00a0tiene\u00a0una\u00a0vida\u00a0media\u00a0larga\u00a0que\u00a0permite\u00a0su\u00a0administraci\u00f3n \u00a0una\u00a0\nvez\u00a0al\u00a0d\u00eda\u00a0y\u00a0presenta\u00a0una\u00a0barrera\u00a0gen\u00e9tica\u00a0m\u00e1s\u00a0elevada\u00a0que\u00a0los\u00a0NN\u00a0de\u00a0primera\u00a0\ngeneraci\u00f3n981.\u00a0Datos\u00a0conjuntos \u00a0a\u00a048\u00a0semanas\u00a0de\u00a02\u00a0estudios\u00a0en\u00a0fase\u00a0III\u00a0(THRIVE\u00a0y\u00a0ECHO)\u00a0\nque\u00a0inclu\u00edan\u00a0m\u00e1s\u00a0de\u00a01300\u00a0pacientes \u00a0y\u00a0que\u00a0comparaban \u00a0rilpivirina \u00a0frente\u00a0a\u00a0efavirenz, \u00a0\nambos\u00a0asociados \u00a0a\u00a02\u00a0AN,\u00a0demostraron \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0rilpivirina \u00a0(ITT\u2010TLOVR),\u00a0con\u00a0\ntasas\u00a0muy\u00a0elevadas\u00a0de\u00a0carga\u00a0viral\u00a0<\u00a050\u00a0copias/mL \u00a0en\u00a0ambas\u00a0ramas\u00a0(84,3%\u00a0frente\u00a0a\u00a0\n82,3%)\u00a0aunque\u00a0se\u00a0produjeron \u00a0m\u00e1s\u00a0fallos\u00a0virol\u00f3gicos \u00a0(9%\u00a0frente\u00a0a\u00a04,8%)\u00a0con\u00a0rilpivirina, \u00a0\nlo\u00a0que\u00a0se\u00a0compens\u00f3 \u00a0con\u00a0una\u00a0menor\u00a0toxicidad\u00a0(abandono \u00a0por\u00a0efectos\u00a0adversos: \u00a02%\u00a0\nfrente\u00a0a\u00a06,7%)982.\u00a0\u00a0\u00a0\u00a0\nEVG\u00a0es\u00a0un\u00a0nuevo\u00a0\u00a0inhibidor\u00a0de\u00a0la\u00a0integrasa \u00a0que\u00a0se\u00a0administra \u00a0en\u00a0dosis\u00a0de\u00a0125\u00a0mg/d\u00eda\u00a0\npotenciado \u00a0con\u00a0100\u00a0mg\u00a0de\u00a0RTV983.\u00a0Tiene\u00a0el\u00a0inconveniente \u00a0de\u00a0presentar \u00a0resistencia \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 99cruzada\u00a0con\u00a0RAL.\u00a0En\u00a0un\u00a0estudio\u00a0de\u00a0b\u00fasqueda \u00a0de\u00a0dosis,\u00a0parcialmente \u00a0ciego\u00a0y\u00a0con\u00a0\nresultados \u00a0a\u00a048\u00a0semanas\u00a0se\u00a0est\u00e1\u00a0evaluando \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0EVG\u00a0frente\u00a0a\u00a0un\u00a0IP/r\u00a0\nen\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0con\u00a0experiencia \u00a0previa\u00a0a\u00a0otros\u00a0FAR984.\u00a0A\u00a0las\u00a024\u00a0\nsemanas\u00a0el\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0fue\u00a0de\u00a0\u20101,4,\u00a0\u20101,7,\u00a0\u20101,2\u00a0log10\u00a0copias/mL \u00a0en\u00a0las\u00a0ramas\u00a0de\u00a0\u00a0\nEVG\u00a050\u00a0mg,\u00a0EVG\u00a0125mg\u00a0y\u00a0el\u00a0IP/r\u00a0comparador \u00a0respectivamente \u00a0(valor\u00a0de\u00a0p\u00a0significativa \u00a0\n0,02\u00a0dosis\u00a0de\u00a0125\u00a0mg\u00a0frente\u00a0al\u00a0IP/r\u00a0comparador). \u00a0EVG/r\u00a0fue\u00a0bien\u00a0tolerado\u00a0y\u00a0no\u00a0se\u00a0\nidentificaron \u00a0toxicidades \u00a0relacionadas \u00a0con\u00a0la\u00a0dosis\u00a0del\u00a0f\u00e1rmaco.\u00a0Est\u00e1n\u00a0en\u00a0marcha\u00a0\nestudios\u00a0con\u00a0una\u00a0formulaci\u00f3n \u00a0cu\u00e1druple \u00a0(QUAD)\u00a0que\u00a0incluye\u00a0TDF,\u00a0FTC,\u00a0EVG\u00a0y\u00a0un\u00a0nuevo\u00a0\npotenciador \u00a0llamada\u00a0cobicistat \u00a0(GS\u20109350)584,\u00a0585.\u00a0\u00a0\nEl\u00a0S/GSK\u00a01349572\u00a0es\u00a0un\u00a0inhibidor\u00a0de\u00a0la\u00a0integrasa \u00a0de\u00a0nueva\u00a0generaci\u00f3n \u00a0con\u00a0un\u00a0perfil\u00a0de\u00a0\nresistencias \u00a0diferente \u00a0a\u00a0RAL\u00a0y\u00a0que\u00a0presenta\u00a0actividad\u00a0in\u00a0vitro\u00a0\u00a0frente\u00a0a\u00a0cepas\u00a0de\u00a0VIH\u00a0\nresistentes \u00a0a\u00a0RAL985\u00a0(aunque\u00a0con\u00a0menor\u00a0respuesta \u00a0en\u00a0cepas\u00a0con\u00a0la\u00a0mutaci\u00f3n \u00a0\nQ148H/K/R \u00a0+\u00a0mutaciones \u00a0secundarias \u00a0que\u00a0en\u00a0las\u00a0que\u00a0presentan \u00a0mutaciones \u00a0de\u00a0las\u00a0v\u00edas\u00a0\nN155H\u00a0o\u00a0Y143H986).\u00a0En\u00a0un\u00a0an\u00e1lisis\u00a0interino\u00a0a\u00a016\u00a0semanas\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0fase\u00a0II\u00a0\n(SPRING\u00a01)\u00a0que\u00a0compara\u00a03\u00a0dosis\u00a0del\u00a0572\u00a0(10,\u00a025\u00a0y\u00a050\u00a0mg/d\u00eda)\u00a0frente\u00a0a\u00a0efavirenz, \u00a0el\u00a0\ntiempo\u00a0hasta\u00a0una\u00a0carga\u00a0viral\u00a0<50\u00a0copias/mL \u00a0fue\u00a0menor\u00a0con\u00a0el\u00a0inhibidor\u00a0de\u00a0la\u00a0integrasa \u00a0\n(66%\u00a0frente\u00a0a\u00a018%\u00a0de\u00a0pacientes \u00a0alcanzaron \u00a0CVP\u00a0indetectable, \u00a0p<0,001)987.\u00a0La\u00a0toxicidad\u00a0\nmoderada/severa \u00a0fue\u00a0mayor\u00a0con\u00a0efavirenz\u00a0(18%\u00a0frente\u00a0a\u00a06%).\u00a0Est\u00e1n\u00a0en\u00a0marcha\u00a0\nestudios\u00a0en\u00a0fase\u00a0III\u00a0con\u00a0la\u00a0dosis\u00a0de\u00a050\u00a0mg/d\u00eda\u00a0del\u00a0572\u00a0(SPRING\u00a02\u00a0y\u00a0SINGLE).\u00a0\u00a0\u00a0\nEl\u00a0desarrollo \u00a0del\u00a0antagonista \u00a0del\u00a0correceptor \u00a0CCR5\u00a0vicriviroc\u00a0se\u00a0ha\u00a0suspendido \u00a0por\u00a0falta\u00a0\nde\u00a0eficacia988\u2010990.\u00a0\u00a0\nTambi\u00e9n\u00a0est\u00e1n\u00a0en\u00a0fase\u00a0relativamente \u00a0avanzada \u00a0de\u00a0investigaci\u00f3n \u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0\nmaduraci\u00f3n991\u00a0(bevirimat, \u00a0en\u00a0tableta\u00a0de\u00a0100\u00a0mg)\u00a0y\u00a0hay\u00a0potenciales \u00a0avances\u00a0dentro\u00a0de\u00a0\nlas\u00a0familias\u00a0existentes \u00a0como\u00a0inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0con\u00a0un\u00a0nuevo\u00a0\nmecanismo \u00a0de\u00a0acci\u00f3n\u00a0o\u00a0inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0de\u00a0vida\u00a0media\u00a0prolongada. \u00a0Aunque\u00a0la\u00a0\ndescripci\u00f3n \u00a0de\u00a0estos\u00a0f\u00e1rmacos \u00a0escapa\u00a0a\u00a0los\u00a0objetivos\u00a0de\u00a0estas\u00a0gu\u00edas,\u00a0vale\u00a0la\u00a0pena\u00a0\ncomentar \u00a0que\u00a0es\u00a0probable\u00a0que\u00a0en\u00a0pocos\u00a0a\u00f1os\u00a0aumente\u00a0de\u00a0forma\u00a0considerable \u00a0el\u00a0\narsenal\u00a0terap\u00e9utico \u00a0frente\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH.\u00a0\u00a0\n\u00a0\n13.\u00a0COSTE\u00a0COMPARATIVO \u00a0DE\u00a0LAS\u00a0DIFERENTES \u00a0COMBINACIONES \u00a0DE\u00a0FAR\u00a0\nEn\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os,\u00a0gracias\u00a0al\u00a0TAR,\u00a0se\u00a0ha\u00a0reducido\u00a0la\u00a0mortalidad \u00a0relacionada \u00a0con\u00a0el\u00a0sida\u00a0\ny\u00a0mejorado \u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0de\u00a0los\u00a0pacientes. \u00a0Sin\u00a0embargo, \u00a0la\u00a0terapia\u00a0antirretroviral \u00a0\ntiene\u00a0un\u00a0elevado\u00a0coste\u00a0y,\u00a0en\u00a0un\u00a0entorno\u00a0donde\u00a0los\u00a0recursos\u00a0son\u00a0limitados, \u00a0es\u00a0necesario \u00a0\ngestionar \u00a0correctamente \u00a0el\u00a0gasto.\u00a0Por\u00a0ello,\u00a0se\u00a0considera \u00a0conveniente \u00a0introducir \u00a0en\u00a0\nestas\u00a0gu\u00edas\u00a0unas\u00a0tablas\u00a0comparativas \u00a0de\u00a0los\u00a0costes\u00a0de\u00a0las\u00a0diferentes \u00a0combinaciones \u00a0de\u00a0\nTAR\u00a0utilizadas \u00a0como\u00a0terapia\u00a0de\u00a0inicio,\u00a0ya\u00a0que\u00a0existen\u00a0diferencias \u00a0sustanciales \u00a0entre\u00a0\nellas\u00a0(Fig\u00a01):\u00a0el\u00a0gasto\u00a0mensual\u00a0con\u00a0pautas\u00a0de\u00a0eficacia\u00a0similar\u00a0puede\u00a0diferir\u00a0en\u00a0cantidades \u00a0\nde\u00a0hasta\u00a0600\u00a0euros.\u00a0En\u00a0la\u00a0Tabla\u00a019\u00a0se\u00a0indica\u00a0el\u00a0precio\u00a0de\u00a0venta\u00a0laboratorio \u00a0(PVL)\u00a0con\u00a0\nIVA\u00a0(4%)\u00a0de\u00a0los\u00a0antirretrovirales \u00a0disponibles \u00a0en\u00a0Espa\u00f1a\u00a0en\u00a0el\u00a02010.\u00a0\u00a0\nA\u00a0pesar\u00a0de\u00a0que\u00a0estas\u00a0tablas\u00a0solamente \u00a0ha\u00a0tenido\u00a0en\u00a0cuenta\u00a0el\u00a0precio\u00a0crudo\u00a0de\u00a0los\u00a0FAR,\u00a0\na\u00a0la\u00a0hora\u00a0de\u00a0utilizar\u00a0la\u00a0informaci\u00f3n \u00a0del\u00a0coste\u00a0hay\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0que\u00a0adem\u00e1s\u00a0de\u00a0\nlos\u00a0costes\u00a0directos,\u00a0cada\u00a0alternativa \u00a0posible\u00a0presenta\u00a0aspectos\u00a0espec\u00edficos, \u00a0como\u00a0\nn\u00famero\u00a0de\u00a0comprimidos, \u00a0diferente \u00a0perfil\u00a0de\u00a0reacciones \u00a0adversas, \u00a0distinta\u00a0adherencia \u00a0y\u00a0\notros\u00a0aspectos\u00a0relacionados \u00a0con\u00a0el\u00a0seguimiento \u00a0cl\u00ednico,\u00a0que\u00a0podr\u00edan\u00a0requerir\u00a0distinto\u00a0\nconsumo\u00a0de\u00a0recursos992.\u00a0Por\u00a0ello,\u00a0y\u00a0pesar\u00a0de\u00a0sus\u00a0limitaciones, \u00a0es\u00a0deseable\u00a0que\u00a0se\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 100incorpore \u00a0la\u00a0evaluaci\u00f3n \u00a0farmacoecon\u00f3mica \u00a0con\u00a0objeto\u00a0de\u00a0determinar \u00a0la\u00a0eficiencia \u00a0de\u00a0\nlas\u00a0nuevas\u00a0estrategias \u00a0o\u00a0de\u00a0los\u00a0nuevos\u00a0medicamentos. \u00a0Este\u00a0aspecto\u00a0es\u00a0especialmente \u00a0\nrelevante \u00a0en\u00a0el\u00a0momento \u00a0actual,\u00a0ya\u00a0que\u00a0disponemos \u00a0de\u00a0m\u00faltiples \u00a0alternativas \u00a0de\u00a0\nelevada\u00a0eficacia\u00a0para\u00a0el\u00a0control\u00a0cr\u00f3nico\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH.\u00a0Aunque\u00a0las\u00a0\ndecisiones \u00a0de\u00a0tratamiento \u00a0en\u00a0el\u00a0caso\u00a0de\u00a0la\u00a0terapia\u00a0de\u00a0rescate\u00a0est\u00e1n\u00a0muy\u00a0condicionadas \u00a0\npor\u00a0factores\u00a0tales\u00a0como\u00a0resistencias, \u00a0adherencia \u00a0o\u00a0toxicidad, \u00a0es\u00a0probable\u00a0que,\u00a0en\u00a0el\u00a0\ncaso\u00a0del\u00a0paciente\u00a0sin\u00a0fracaso\u00a0previo\u00a0o\u00a0en\u00a0situaci\u00f3n\u00a0de\u00a0primer\u00a0fracaso,\u00a0pudiera\u00a0incluirse\u00a0\nel\u00a0concepto \u00a0de\u00a0eficiencia \u00a0(relaci\u00f3n\u00a0entre\u00a0coste\u00a0y\u00a0resultados) \u00a0en\u00a0la\u00a0toma\u00a0de\u00a0decisiones \u00a0\npara\u00a0seleccionar \u00a0la\u00a0alternativa. \u00a0Esta\u00a0idea\u00a0se\u00a0ha\u00a0aplicado\u00a0por\u00a0algunos\u00a0autores\u00a0en\u00a0an\u00e1lisis\u00a0\nfarmacoecon\u00f3mico \u00a0aplicado\u00a0al\u00a0TAR.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 101\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n14.\u00a0Tablas\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 102\u00a0\n\u00a0\nTabla\u00a01.\u00a0Exploraciones \u00a0complementarias \u00a0en\u00a0la\u00a0valoraci\u00f3n \u00a0y\u00a0seguimiento \u00a0de\u00a0los\u00a0\npacientes \u00a0con\u00a0infecci\u00f3n \u00a0por\u00a0el\u00a0VIH\u00a0\n\u00a0\n\u00a0\n\u2022 Valoraci\u00f3n \u00a0inicial\u00a0\nExploraci\u00f3n \u00a0f\u00edsica\u00a0completa \u00a0\n\u00a0Tensi\u00f3n\u00a0arterial\u00a0\n\u00a0Medidas\u00a0antropom\u00e9tricas \u00a0(talla,\u00a0peso\u00a0y\u00a0cintura)\u00a0\nHematimetr\u00eda \u00a0\u00a0\nBioqu\u00edmica \u00a0(incluyendo \u00a0glucemia, \u00a0perfil\u00a0hep\u00e1tico\u00a0y\u00a0lip\u00eddico)\u00a0\nRutinario\u00a0de\u00a0orina\u00a0y\u00a0sedimento \u00a0\nSerolog\u00eda: \u00a0VHB,\u00a0VHC,\u00a0VHA,\u00a0L\u00faes,\u00a0CMV\u00a0y\u00a0Toxoplasma \u00a0\u00a0\nEstudio\u00a0de\u00a0poblaciones \u00a0linfoides\u00a0\nCarga\u00a0viral\u00a0VIH\u00a0\u00a0\nEstudio\u00a0genot\u00edpico \u00a0de\u00a0resistencias \u00a0\nHLA\u00a0B*5701\u00a0\nMantoux\u00a0(o\u00a0quantifer\u00f3n) \u00a0y\u00a0radiograf\u00eda \u00a0de\u00a0t\u00f3rax\u00a0\u00a0\nCitolog\u00eda\u00a0cervical\u00a0(en\u00a0la\u00a0mujer)\u00a0\nCitolog\u00eda\u00a0anal\u00a0(considerar) \u00a0\nValoraci\u00f3n \u00a0de\u00a0la\u00a0fibrosis\u00a0hep\u00e1tica* \u00a0\n\u2022 Previo\u00a0al\u00a0inicio\u00a0del\u00a0TARV\u00a0\nEstudio\u00a0de\u00a0resistencias \u00a0\n\u2022 Seguimiento \u00a0(4\u00a0semanas\u00a0post\u00a0inicio\u00a0y\u00a0c/3\u20106\u00a0meses)\u00a0\nHematimetr\u00eda \u00a0y\u00a0bioqu\u00edmica \u00a0de\u00a0rutina\u00a0(con\u00a0perfil\u00a0lip\u00eddico)\u00a0\nCarga\u00a0viral\u00a0VIH\u00a0y\u00a0estudio\u00a0de\u00a0poblaciones \u00a0linfoides\u00a0\nEstudio\u00a0de\u00a0resistencias, \u00a0si\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nTropismo \u00a0viral\u00a0(si\u00a0fracaso\u00a0virol\u00f3gico) \u00a0\n\u00a0\n*Si\u00a0hepatitis\u00a0cr\u00f3nica\u00a0(optativo) \u00a0\n\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 103\u00a0\n\u00a0\nTabla\u00a02.\u00a0Indicaciones \u00a0de\u00a0las\u00a0pruebas\u00a0de\u00a0resistencia \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0\n\u00a0\n\u00a0\n\u2022 En\u00a0el\u00a0momento \u00a0del\u00a0diagn\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH*\u00a0\n\u2022 Inicio\u00a0del\u00a0TARV*\u00a0\n\u2022 Mujeres\u00a0embarazadas \u00a0\u00a0\n\u2022 En\u00a0cada\u00a0fracaso\u00a0del\u00a0TARV\u00a0\n\u2022 Profilaxis\u00a0post\u2010exposici\u00f3n \u00a0(caso\u00a0fuente)\u00a0\n\u00a0\n*Todos\u00a0los\u00a0pacientes \u00a0debieran\u00a0tener\u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0genot\u00edpicas \u00a0en\u00a0el\u00a0momento \u00a0del\u00a0\ndiagn\u00f3stico \u00a0y\u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0si\u00a0se\u00a0difiere\u00a0\u00a0\n\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 104\u00a0\n\u00a0\nTabla\u00a03.\u00a0Indicaciones \u00a0de\u00a0TARV\u00a0en\u00a0pacientes \u00a0asintom\u00e1ticos \u00a0con\u00a0infecci\u00f3n \u00a0cr\u00f3nica\u00a0por\u00a0VIH\u00a0\n\u00a0\nLinfocitos \u00a0CD4\u00a0 Pacientes \u00a0asintom\u00e1ticos \u00a0 Nivel\u00a0evidencia \u00a0\n\u2264350\u00a0 Recomendar \u00a0 A\u00a0\n350\u2010500\u00a0Recomendar \u00a0\u00a0(salvo\u00a0determinadas \u00a0\nsituaciones)* \u00a0B\u00a0\n>500\u00a0Diferir\u00a0en\u00a0general.\u00a0Considerar \u00a0en\u00a0\ndeterminadas \u00a0ocasiones** \u00a0B\u00a0\n*\u00a0N\u00famero\u00a0de\u00a0CD4\u00a0estable,\u00a0CVP\u00a0baja,\u00a0poca\u00a0predisposici\u00f3n \u00a0del\u00a0paciente\u00a0\n**\u00a0Cirrosis\u00a0hep\u00e1tica,\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0VHC;\u00a0hepatitis\u00a0B\u00a0que\u00a0requiera\u00a0tratamiento; \u00a0\nCVP\u00a0>\u00a0105\u00a0copias/ml; \u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0<14%;\u00a0edad\u00a0>55\u00a0a\u00f1os;\u00a0riesgo\u00a0cardiovascular \u00a0\nelevado;\u00a0nefropat\u00eda \u00a0VIH.\u00a0Parejas\u00a0serodiscordantes \u00a0con\u00a0alto\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 105Tabla\u00a04a.\u00a0Combinaciones \u00a0preferentes \u00a0de\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0pacientes \u00a0sin\u00a0\nterapia\u00a0previa\u2020\u00a0\n\u00a0\nR\u00e9gimen\u00a0 Comentarios\u2021\u00a0Ensayos\u00a0\u00a0que\u00a0\nlo\u00a0avalan\u00a0\u00a0\nTDF/FTC/EFV \u00a0Pauta\u00a0de\u00a0elecci\u00f3n\u00a0si\u00a0no\u00a0existen\u00a0otros\u00a0condicionantes. \u00a0\u00a0\nEvitar\u00a0en\u00a0mujeres\u00a0que\u00a0planean\u00a0quedarse \u00a0embarazadas \u00a0y\u00a0en\u00a0pacientes \u00a0con\u00a0alteraciones \u00a0\nneuropsiqui\u00e1tricas \u00a0no\u00a0estabilizadas. \u00a0\u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0que\u00a0realicen\u00a0tareas\u00a0peligrosas \u00a0si\u00a0presentan \u00a0s\u00edntomas\u00a0\nde\u00a0somnolencia, \u00a0mareos\u00a0y/o\u00a0trastornos \u00a0de\u00a0la\u00a0concentraci\u00f3n. \u00a0\u00a0\u00a0\nEs\u00a0preciso\u00a0realizar\u00a0previamente \u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0que\u00a0descarte\u00a0mutaciones \u00a0de\u00a0\nresistencia \u00a0a\u00a0EFV.\u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0factores\u00a0de\u00a0insuficiencia \u00a0renal.\u00a0Contraindicado \u00a0si\u00a0\nIFG\u00a0<30\u00a0ml/min)\u00a0ECHO,\u00a0THRIVE,\u00a0\nSTARTMRK, \u00a02NN,\u00a0\nACTG\u00a05202,\u00a0\nASSERT,\u00a0934,\u00a0\nMERIT,\u00a0ACTG\u00a05142\u00a0\nTDF/FTC+DRV/r \u00a0\u00a0Usar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0factores\u00a0de\u00a0insuficiencia \u00a0renal.\u00a0Contraindicado \u00a0si\u00a0\nIFG\u00a0<30\u00a0ml/min)\u00a0ARTEMIS\u00a0\nTDF/FTC+ATV/r \u00a0Evitar\u00a0si\u00a0se\u00a0utilizan\u00a0Inhibidores \u00a0de\u00a0la\u00a0bomba\u00a0de\u00a0protones. \u00a0\u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0factores\u00a0de\u00a0insuficiencia \u00a0renal.\u00a0Contraindicado \u00a0si\u00a0\nIFG\u00a0<30\u00a0ml/min)\u00a0CASTLE,\u00a0ACTG\u00a0\n5202,\u00a0ARTEN\u00a0\nTDF/FTC+RAL* \u00a0El\u00a0coste\u00a0de\u00a0esta\u00a0pauta\u00a0es\u00a0muy\u00a0superior\u00a0al\u00a0de\u00a0las\u00a0otras\u00a0pautas\u00a0preferentes \u00a0\u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0factores\u00a0de\u00a0insuficiencia \u00a0renal.\u00a0Contraindicado \u00a0si\u00a0\nIFG\u00a0<30\u00a0ml/min)\u00a0STARTMRK \u00a0\nTDF/FTC+NVP* \u00a0No\u00a0iniciar\u00a0en\u00a0mujeres\u00a0con\u00a0CD4\u00a0>250\u00a0c\u00e9lulas/\u00b5L \u00a0ni\u00a0en\u00a0varones\u00a0con\u00a0CD4\u00a0>\u00a0400\u00a0c\u00e9lulas/\u00b5L. \u00a0\u00a0\nEs\u00a0preciso\u00a0realizar\u00a0previamente \u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0que\u00a0descarte\u00a0mutaciones \u00a0de\u00a0\nresistencia \u00a0a\u00a0NVP.\u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0factores\u00a0de\u00a0insuficiencia \u00a0renal.\u00a0Contraindicado \u00a0si\u00a0\nIFG\u00a0<\u00a030\u00a0ml/min)\u00a0ARTEN,\u00a0OCTANE\u00a0II\u00a0\nTDF/FTC+LPV/r* \u00a0Usar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0hiperlipidemia \u00a0y/o\u00a0riesgo\u00a0cardiovascular \u00a0elevado.\u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0factores\u00a0de\u00a0insuficiencia \u00a0renal.\u00a0Contraindicado \u00a0si\u00a0\nIFG\u00a0<30\u00a0ml/min)\u00a0ARTEMIS, \u00a0730,\u00a0\nCASTLE,\u00a0GEMINI,\u00a0\nOCTANE\u00a0II,\u00a0HEAT,\u00a0\nACTG\u00a05142;\u00a0\nABC/3TC+ATV/r* \u00a0Evitar\u00a0si\u00a0se\u00a0utilizan\u00a0Inhibidores \u00a0de\u00a0la\u00a0bomba\u00a0de\u00a0protones. \u00a0\u00a0\nEs\u00a0preciso\u00a0realizar\u00a0previamente \u00a0determinaci\u00f3n \u00a0de\u00a0HLA\u2010B5701.\u00a0No\u00a0utilizar\u00a0si\u00a0HLA\u2010B5701\u00a0\npositivo.\u00a0\nComparado \u00a0con\u00a0TDF/FTC+ATV/r, \u00a0mayor\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0pacientes \u00a0con\u00a0CV\u00a0\n>100.000 \u00a0copias/mL \u00a0\u00a0ACTG\u00a05202\u00a0\nABC/3TC+LPV/r* \u00a0Es\u00a0preciso\u00a0realizar\u00a0previamente \u00a0determinaci\u00f3n \u00a0de\u00a0HLA\u2010B5701.\u00a0No\u00a0utilizar\u00a0si\u00a0HLA\u2010B5701\u00a0\npositivo.\u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0hiperlipidemia \u00a0y/o\u00a0riesgo\u00a0cardiovascular \u00a0elevado.\u00a0KLEAN,\u00a0HEAT\u00a0\nABC/3TC+EFV* \u00a0Evitar\u00a0en\u00a0mujeres\u00a0que\u00a0planean\u00a0quedarse \u00a0embarazadas \u00a0y\u00a0en\u00a0pacientes \u00a0con\u00a0alteraciones \u00a0\nneuropsiqui\u00e1tricas \u00a0no\u00a0estabilizadas. \u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0que\u00a0realicen\u00a0tareas\u00a0peligrosas \u00a0si\u00a0presentan \u00a0s\u00edntomas\u00a0\nde\u00a0somnolencia, \u00a0mareos\u00a0y/o\u00a0trastornos \u00a0de\u00a0la\u00a0concentraci\u00f3n. \u00a0\u00a0\u00a0\nEs\u00a0preciso\u00a0realizar\u00a0previamente \u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0que\u00a0descarte\u00a0mutaciones \u00a0de\u00a0\nresistencia \u00a0a\u00a0EFV.\u00a0\nEs\u00a0preciso\u00a0realizar\u00a0previamente \u00a0determinaci\u00f3n \u00a0de\u00a0HLA\u2010B5701.\u00a0No\u00a0utilizar\u00a0si\u00a0HLA\u2010B5701\u00a0\npositivo.\u00a0\u00a0\nComparado \u00a0con\u00a0TDF/FTC/EFV \u00a0\u00a0mayor\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0pacientes \u00a0con\u00a0CV\u00a0\n>100.000 \u00a0copias/mL \u00a0ACTG\u00a05202,\u00a0\nASSERT,\u00a0CNA30024 \u00a0\n\u00a0\n\u2020\u00a0Se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0preparados \u00a0que\u00a0combinen \u00a0f\u00e1rmacos \u00a0a\u00a0dosis\u00a0fijas.\u00a0No\u00a0existe\u00a0en\u00a0la\u00a0actualidad \u00a0suficiente \u00a0informaci\u00f3n \u00a0que\u00a0\npermita\u00a0considerar \u00a0como\u00a0equivalentes \u00a0terap\u00e9uticos \u00a0a\u00a0FTC\u00a0y\u00a03TC,\u00a0por\u00a0lo\u00a0que\u00a0el\u00a0uso\u00a0de\u00a0uno\u00a0u\u00a0otro\u00a0f\u00e1rmaco\u00a0en\u00a0los\u00a0reg\u00edmenes \u00a0\nseleccionados \u00a0depende\u00a0fundamentalmente \u00a0de\u00a0la\u00a0experiencia \u00a0disponible \u00a0\u00a0en\u00a0su\u00a0uso\u00a0\u00a0con\u00a0los\u00a0otros\u00a0f\u00e1rmacos \u00a0de\u00a0la\u00a0combinaci\u00f3n. \u00a0\u00a0\n*\u00a0Estas\u00a0pautas\u00a0no\u00a0han\u00a0sido\u00a0respaldadas \u00a0como\u00a0\u00a0preferentes \u00a0por\u00a0la\u00a0totalidad\u00a0del\u00a0panel.\u00a0\u00a0\n\u2021\u00a0Los\u00a0comentarios \u00a0reflejan\u00a0aspectos\u00a0fundamentales \u00a0a\u00a0considerar \u00a0en\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0r\u00e9gimen,\u00a0pero\u00a0no\u00a0pretenden \u00a0ser\u00a0una\u00a0gu\u00eda\u00a0\nexhaustiva \u00a0de\u00a0las\u00a0precauciones \u00a0a\u00a0tomar\u00a0en\u00a0el\u00a0uso\u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0Para\u00a0mayor\u00a0informaci\u00f3n \u00a0se\u00a0recomienda \u00a0revisar\u00a0el\u00a0texto\u00a0del\u00a0\ndocumento \u00a0as\u00ed\u00a0como\u00a0las\u00a0fichas\u00a0t\u00e9cnicas\u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 106\u00a0\nTabla\u00a04b.\u00a0Combinaciones \u00a0alternativas \u00a0de\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0pacientes \u00a0sin\u00a0\nterapia\u00a0previa\u2020\u00a0\n\u00a0\nR\u00e9gimen\u00a0 Comentarios\u2021\u00a0Ensayos\u00a0que\u00a0\nlo\u00a0avalan\u00a0\nABC/3TC+FPV/r \u00a0Es\u00a0preciso\u00a0realizar\u00a0previamente \u00a0determinaci\u00f3n \u00a0de\u00a0HLA\u2010B5701.\u00a0No\u00a0utilizar\u00a0\nsi\u00a0HLA\u2010B5701\u00a0positivo.\u00a0\nEvitar\u00a0en\u00a0pacientes \u00a0con\u00a0hiperlipidemia \u00a0y/o\u00a0riesgo\u00a0cardiovascular \u00a0elevado.\u00a0\u00a0KLEAN\u00a0\nTDF/FTC+SAQ/r \u00a0El\u00a0uso\u00a0de\u00a0SAQ\u00a0se\u00a0ha\u00a0asociado\u00a0a\u00a0prolongaci\u00f3n \u00a0del\u00a0intervalo\u00a0QT\u00a0con\u00a0el\u00a0\nriesgo\u00a0potencial \u00a0de\u00a0arritmias. \u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0factores\u00a0de\u00a0insuficiencia \u00a0renal.\u00a0\nContraindicado \u00a0si\u00a0el\u00a0IFG\u00a0\u00a0<30\u00a0ml/min).\u00a0GEMINI\u00a0\nddI+3TC+EFV \u00a0Evitar\u00a0en\u00a0mujeres\u00a0que\u00a0planean\u00a0quedarse \u00a0embarazadas \u00a0y\u00a0en\u00a0pacientes \u00a0\ncon\u00a0alteraciones \u00a0neuropsiqui\u00e1tricas \u00a0no\u00a0estabilizadas. \u00a0\nUsar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0que\u00a0realicen\u00a0tareas\u00a0peligrosas \u00a0si\u00a0\npresentan \u00a0s\u00edntomas\u00a0de\u00a0somnolencia, \u00a0mareos\u00a0y/o\u00a0trastornos \u00a0de\u00a0la\u00a0\nconcentraci\u00f3n. \u00a0\u00a0\u00a0\nEs\u00a0preciso\u00a0realizar\u00a0previamente \u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0que\u00a0descarte\u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0EFV.\u00a0\nEl\u00a0uso\u00a0de\u00a0ddI\u00a0puede\u00a0asociarse \u00a0a\u00a0toxicidad\u00a0mitocondrial \u00a0GESIDA\u00a03903\u00a0\nAZT/3TC+EFV \u00a0\u00a0Usar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0que\u00a0realicen\u00a0tareas\u00a0peligrosas \u00a0si\u00a0\npresentan \u00a0s\u00edntomas\u00a0de\u00a0somnolencia, \u00a0mareos\u00a0y/o\u00a0trastornos \u00a0de\u00a0la\u00a0\nconcentraci\u00f3n. \u00a0\u00a0\u00a0\nEs\u00a0preciso\u00a0realizar\u00a0previamente \u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0que\u00a0descarte\u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0EFV.\u00a0\nEvitar\u00a0en\u00a0mujeres\u00a0que\u00a0planean\u00a0quedarse \u00a0embarazadas \u00a0y\u00a0en\u00a0pacientes \u00a0\ncon\u00a0alteraciones \u00a0neuropsiqui\u00e1tricas \u00a0no\u00a0estabilizadas. \u00a0\nEvitar\u00a0en\u00a0caso\u00a0de\u00a0anemia.\u00a0\nEsta\u00a0pauta\u00a0conlleva\u00a0mayor\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0lipoatrofia. \u00a0934,\u00a0CNA30024 \u00a0\nAZT/3TC+ABC \u00a0\n(c/s\u00a0TDF)\u00a0Es\u00a0preciso\u00a0realizar\u00a0previamente \u00a0determinaci\u00f3n \u00a0de\u00a0HLA\u2010B5701.\u00a0No\u00a0utilizar\u00a0\nsi\u00a0HLA\u2010B5701\u00a0positivo.\u00a0\nEvitar\u00a0en\u00a0caso\u00a0de\u00a0anemia.\u00a0\u00a0\nEsta\u00a0pauta\u00a0conlleva\u00a0mayor\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico. \u00a0\nEvitar\u00a0si\u00a0la\u00a0carga\u00a0viral\u00a0es\u00a0>100.000 \u00a0copias/mL. \u00a0\nEsta\u00a0pauta\u00a0conlleva\u00a0mayor\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0lipoatrofia. \u00a0ACTG\u00a0A5095\u00a0\nAZT/3TC+MVC \u00a0Es\u00a0preciso\u00a0realizar\u00a0previamente \u00a0determinaci\u00f3n \u00a0de\u00a0tropismo\u00a0viral.\u00a0No\u00a0\nutilizar\u00a0si\u00a0tropismo\u00a0X4\u00a0o\u00a0Dual\u2010Mixto.\u00a0\nEvitar\u00a0en\u00a0caso\u00a0de\u00a0anemia.\u00a0\u00a0\nEsta\u00a0pauta\u00a0conlleva\u00a0mayor\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0lipoatrofia. \u00a0MERIT\u00a0\n\u00a0\n\u2020\u00a0Se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0preparados \u00a0que\u00a0combinen \u00a0f\u00e1rmacos \u00a0a\u00a0dosis\u00a0fija.\u00a0No\u00a0existe\u00a0en\u00a0la\u00a0actualidad \u00a0suficiente \u00a0informaci\u00f3n \u00a0que\u00a0\npermita\u00a0considerar \u00a0como\u00a0equivalentes \u00a0terap\u00e9uticos \u00a0a\u00a0FTC\u00a0y\u00a03TC,\u00a0por\u00a0lo\u00a0que\u00a0el\u00a0uso\u00a0de\u00a0uno\u00a0u\u00a0otro\u00a0f\u00e1rmaco\u00a0en\u00a0los\u00a0reg\u00edmenes \u00a0\nseleccionados \u00a0depende\u00a0fundamentalmente \u00a0de\u00a0la\u00a0experiencia \u00a0disponible \u00a0\u00a0en\u00a0su\u00a0uso\u00a0con\u00a0los\u00a0otros\u00a0f\u00e1rmacos \u00a0de\u00a0la\u00a0combinaci\u00f3n. \u00a0\u00a0\n\u2021\u00a0Los\u00a0comentarios \u00a0reflejan\u00a0aspectos\u00a0fundamentales \u00a0a\u00a0considerar \u00a0en\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0r\u00e9gimen,\u00a0pero\u00a0no\u00a0pretenden \u00a0ser\u00a0una\u00a0gu\u00eda\u00a0\nexhaustiva \u00a0de\u00a0las\u00a0precauciones \u00a0a\u00a0tomar\u00a0en\u00a0el\u00a0uso\u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0Para\u00a0mayor\u00a0informaci\u00f3n \u00a0se\u00a0recomienda \u00a0revisar\u00a0el\u00a0texto\u00a0del\u00a0\ndocumento \u00a0as\u00ed\u00a0como\u00a0las\u00a0fichas\u00a0t\u00e9cnicas\u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 107 Tabla\u00a05.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0y\u00a0\u00a0de\u00a0nucle\u00f3tido \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina \u00a0\nddI\u00a0Estavudina \u00a0\nd4T\u00a0Lamivudina \u00a0\n3TC\u00a0Emtricitabina \u00a0\nFTC\u00a0Abacavir\u00a0\nABC\u00a0Tenofovir \u00a0\nTDF\u00a0\nNombre\u00a0\ncomercial \u00a0Retrovir\u00ae\u00a0\nZidovudinaCom \u00a0\nbinopharm\u00ae\u00a0\n*Combivir\u00ae\u00a0\n**Trizivir\u00ae\u00a0Videx\u00ae\u00a0 Zerit\u00ae\u00a0 Epivir\u00ae\u00a0\nLamivudina \u00a0\nNormon\u00ae \u00a0\n*Combivir\u00ae\u00a0\n**Trizivir\u00ae\u00a0\n***Kivexa\u00ae \u00a0Emtriva\u00ae\u00a0\n****Truvada\u00ae \u00a0\n*****\u00a0Atripla\u00ae\u00a0Ziagen\u00ae\u00a0\n**Trizivir\u00ae\u00a0\n***Kivexa\u00ae \u00a0Viread\u00ae\u00a0\n****Truvada\u00ae \u00a0\n*****\u00a0Atripla\u00ae\u00a0\nDosis\u00a0\nrecomendada \u00a0250\u2010300\u00a0mg\u00a0BID\u00a0<60\u00a0Kg.:\u00a0\n250\u00a0mg\u00a0QD\u00a0\u00f3\u00a0\n125\u00a0mg\u00a0BID\u00a0\n>60\u00a0Kg:\u00a0\u00a0\n400\u00a0mg\u00a0QD\u00a0\u00f3\u00a0\n\u00a0200\u00a0mg\u00a0BID\u00a0<60\u00a0Kg:\u00a0\n30\u00a0mg\u00a0BID\u00a0\n>60\u00a0mg:\u00a0\n40\u00a0mg\u00a0BID\u00a0150\u00a0mg\u00a0BID\u00a0\n300\u00a0mg\u00a0QD\u00a0200\u00a0mg\u00a0QD\u00a0 300\u00a0mg\u00a0BID\u00a0\n600\u00a0mg\u00a0QD\u00a0300\u00a0mg\u00a0QD\u00a0\nPresentaciones \u00a0\ncomerciales \u00a0caps.\u00a0100,\u00a0250\u00a0mg\u00a0\ny\u00a0comp./caps \u00a0300\u00a0\nmg.\u00a0\nsol.\u00a0oral\u00a010\u00a0mg/ml\u00a0\nvial\u00a0\u00a0i.v.\u00a0(10\u00a0mg/ml)\u00a0Comp.\u00a0,\u00a050,\u00a0100,\u00a0y\u00a0\n150\u00a0mg.\u00a0c\u00e1ps\u00a0\nent\u00e9ricas\u00a0de\u00a0125,\u00a0\n200,\u00a0250\u00a0y\u00a0400\u00a0mg\u00a0\ny\u00a0polvo\u00a0no\u00a0\ntamponado \u00a0para\u00a0\u00a0\nsol.\u00a0oral\u00a0(5\u00a0\u00f3\u00a010\u00a0\nmg/ml\u00a0seg\u00fan\u00a0el\u00a0\nvolumen\u00a0a\u00f1adido).caps.\u00a020,\u00a030\u00a0y\u00a040\u00a0\nmg\u00a0\nsol.\u00a0oral\u00a01mg/ml\u00a0comp.\u00a0150\u00a0mg\u00a0\ncomp.\u00a0300\u00a0mg\u00a0\nsol.\u00a0oral\u00a010\u00a0mg/ml\u00a0\u00a0c\u00e1ps\u00a0200\u00a0mg\u00a0\nsol.\u00a0oral\u00a010mg/ml\u00a0\n\u00a0comp.\u00a0300\u00a0mg\u00a0\nsol.\u00a0oral\u00a020\u00a0mg/ml\u00a0\u00a0comp.\u00a0300\u00a0mg\u00a0\u00a0\nBiodisponibilid. \u00a0\noral\u00a0\n\u00a064\u00b110%\u00a0a,\u00a0\u03c9\u00a042\u00a0(\u00b112)%\u00a0a,\u00a0\u2126\u00a0\n(comp.\u00a0\ntamponados) \u00a086\u00b118%\u00a0a,\u03c9\u00a0 80\u201085%\u00a0\u03c9\u00a0 93%\u00a0(c\u00e1ps)\u00a0\u03c9\u00a0\n75%\u00a0(sol\u00a0oral)\u00a0\u03c9\u00a083%\u00a0\u03c9\u00a0 25%\u00a0en\u00a0ayunas.\u2126\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 108 Efecto\u00a0de\u00a0los\u00a0\nalimentos \u00a0Los\u00a0alimentos \u00a0\ngrasos\u00a0pueden\u00a0\nreducir\u00a0la\u00a0Cm\u00e1x\u00a0un\u00a0\n50%,\u00a0sin\u00a0afectar\u00a0el\u00a0\nAUC.\u00a0\u00a0Videx\u00ae\u00a0en\u00a0c\u00e1psulas\u00a0\nde\u00a0liberaci\u00f3n \u00a0\nent\u00e9rica\u00a0debe\u00a0\nadministrarse \u00a02\u00a0\nhoras\u00a0despu\u00e9s\u00a0de\u00a0\ncomer\u00a0y\u00a0no\u00a0se\u00a0\ndebe\u00a0ingerir\u00a0\nning\u00fan\u00a0otro\u00a0\nalimento\u00a0hasta\u00a0\ndespu\u00e9s\u00a0de\u00a0otras\u00a0\n1.5\u00a0horas\u00a0(los\u00a0\nalimentos \u00a0reducen\u00a0\nun\u00a020\u201025%\u00a0sus\u00a0\nconcentraciones \u00a0\nplasm\u00e1ticas \u00a0y\u00a0un\u00a0\n23%\u00a0las\u00a0de\u00a0su\u00a0\nmetabolito \u00a0activo\u00a0\nintracelular \u00a0ddA\u2010\nTP).\u00a0\nProbablemente \u00a0\nescasa\u00a0repercusi\u00f3n \u00a0\nen\u00a0el\u00a0contexto\u00a0de\u00a0\nuna\u00a0terapia\u00a0triple.\u00a0Puede\u00a0\nadministrarse \u00a0con\u00a0\no\u00a0sin\u00a0alimentos. \u00a0Puede\u00a0tomarse\u00a0\ncon\u00a0o\u00a0sin\u00a0\nalimentos. \u00a0(Los\u00a0\nalimentos \u00a0\nprolongan \u00a0la\u00a0\nabsorci\u00f3n \u00a0de\u00a03TC\u00a0\npero\u00a0no\u00a0var\u00edan\u00a0su\u00a0\nbiodisponibilidad). \u00a0Puede\u00a0tomarse\u00a0\ncon\u00a0o\u00a0sin\u00a0\nalimentos. \u00a0Puede\u00a0tomarse\u00a0\ncon\u00a0o\u00a0sin\u00a0\nalimentos. \u00a0La\u00a0administraci\u00f3n \u00a0\ncon\u00a0una\u00a0comida\u00a0\nligera\u00a0en\u00a0grasa\u00a0no\u00a0\nmodific\u00f3\u00a0el\u00a0AUC,\u00a0\nmientras\u00a0que\u00a0una\u00a0\ncomida\u00a0rica\u00a0en\u00a0\ngrasa\u00a0aument\u00f3\u00a0un\u00a0\n40%\u00a0el\u00a0AUC.\u00a0\u2126\u00a0\nSemivida \u00a0\nplasm\u00e1tica \u00a00,5\u20103\u00a0horas\u00a0c,\u00a0\u03c9\u00a01,19\u00a0\u00b1\u00a00,21horasa,\u00a0\u21261,3\u00a0a\u00a02,3\u00a0horas\u00a0\u03c9\u00a05\u20107\u00a0horas\u00a0\u03c9\u00a0 10\u00a0horas\u00a0\u03c9\u00a0 1,5\u00a0horas\u00a0\u03c9\u00a0 12\u201018\u00a0horas\u00a0\u03c9\u00a0\nSemivida \u00a0\nintracelular \u00a0\n\u00a03\u00a0horas&\u00a0 \u00a025\u201040\u00a0horas&\u00a03,5\u00a0horas\u00a0\u03c9\u00a0\n\u00a0\u00a016\u201019\u00a0horas\u00a0\u03c9\u00a039\u00a0horas\u00a0\u03c9\u00a0 20,6\u00a0horas\u00a0\u03c9\u00a0\n(carbovir\u00a0\ntrifosfato) \u00a0PBMCs:\u00a010\u00a0horas\u00a0\n(en\u00a0c\u00e9lulas\u00a0\nactivadas); \u00a0\n50\u00a0horas\u00a0(en\u00a0\nc\u00e9lulas\u00a0en\u00a0\nreposo)\u03c9\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 109 \u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Zidovudina \u00a0\nAZT\u00a0Didanosina \u00a0\nddI\u00a0Estavudina \u00a0\nd4T\u00a0Lamivudina \u00a0\n3TC\u00a0Emtricitabina \u00a0\nFTC\u00a0Abacavir\u00a0\nABC\u00a0Tenofovir \u00a0\nTDF\u00a0\n\u00a0\nCmax\u00a0\u2010\u2010\u00a0\u00a0 \u00a00,9\u00a0microg/mL \u00a0\n\u00a0(3,8\u00a0microM)\u00a0&\u00a0536\u00b1146\u00a0nanog/ml \u00a0\n(con\u00a040\u00a0\nmg/12h)(VIH+)\u00a0a,\u03c9\u00a02,0\u00a0microg/ml \u00a0(300\u00a0\nmg/24h)\u00a0\u03c9\u00a0\n\u00a01,8\u00b10,7\u00a0microg/ml\u00a0\u03c9\u00a0\n\u00a0\u00a04,26\u00a0microg/ml \u00a0(600\u00a0\nmg/24h)\u00a0\u03c9\u00a0\n\u00a0\u00a0326\u00a0nanog/mL\u00a0\u03c9\u00a0\nCmin\u00a0 \u2010\u2010\u00a0 \u2010\u2010\u00a0 8\u00a0\u00b1\u00a09\u00a0nanog/ml \u00a0(con\u00a0\n40\u00a0mg/12h)\u00a0(VIH+)\u00a0\u2126\u00a00,04\u00a0microg/ml \u00a0(300\u00a0\nmg/24h)\u00a0\u03c9\u00a00,09\u00b10,07 \u00a0microg/ml\u00a0\n\u03c9\u00a0\u2010\u2010\u00a0 64,4\u00a0nanog/mL\u00a0\u03c9\u00a0\nAUC\u00a0 1400\u00b1200\u00a0\nnanog\u2219h/mL\u00a0a,\u00a0\u03c9\u00a02,65\u00a0\u00b1\u00a01,07\u00a0\nmicrog\u2219h/mLa,\u00a0\u2126\u00a0AUC0\u201012h:\u00a01284\u00b1\u00a0\n227\u00a0nanog.h/ml \u00a0(con\u00a0\n40\u00a0mg/12h)\u00a0(VIH+)\u00a0\u00a0\na,\u00a0\u03c9\u00a0AUC0\u201024h:\u00a0\u00a0\n8,9\u00a0microg\u2219h/ml\u00a0(300\u00a0\nmg/24h)\u00a0\u03c9\u00a010,0\u00b13,1\u00a0\nmicrog\u2219h/ml\u00a0\u03c9\u00a011,95\u00a0microg\u2219h/ml\u00a0\n600\u00a0mg/24h)\u00a0\u03c9\u00a0\n\u00a03324\u00a0nanog\u2219h/mL\u00a0\u03c9\u00a0\nCI50\u00a0frente\u00a0a\u00a0VIH\u20101\u00a0\nin\u00a0vitro\u00a0\n\u00a0CI50\u00a0:0,01\u00a0\u2013\u00a00,49\u00a0\nmicroM\u00a0c,\u00a0\u03c9\u00a0(0,00267\u2010\n0,13\u00a0microg/mL) \u00a0CI50\u00a0:0,01\u00a0to\u00a00,1\u00a0\nmicroM\u00a0c,\u00a0\u03c9\u00a0(0,00236\u2010\n0,0236\u00a0microg/mL) \u00a0CI50\u00a0:0,002\u20100,9\u00a0\nmicrog/mL \u00a0\n\u00a0(0,0089\u20104\u00a0microM)\u00a0\u2126\u00a0\n\u00a0\u00a0CI50\u00a0:0,003\u00a0to\u00a015\u00a0\nmicroM\u00a0\u00a0\n(1\u00a0\u03bcM\u00a0=\u00a00,23\u00a0\nmicrog/mL)\u00a0\u2126\u00a0CI50\u00a0:0,00032\u20100,124\u00a0\nmicrog/ml \u00a0(0,0013\u2010\n0,5\u00a0microM)\u00a0\nVHB:\u00a00,01\u00a0a\u00a00,04\u00a0\nmicroM.\u00a0\u03c9\u00a0CI50\u00a0:0,08\u00a0microg/ml \u00a0\n(0,26\u00a0microM)\u00a0\u03c9\u00a0\n\u00a0CI50\u00a0:VIH\u20101IIIB:\u00a01\u20106\u00a0\nmicroM\u00a0(0,635\u20103,81\u00a0\nmicrog/mL) \u00a0(c\u00e9lulas\u00a0\nlinfoides)\u00a0\u03c9\u00a0\n\u00a01,1\u00a0microM\u00a0(0,698\u00a0\nmicrog/mL) \u00a0(HIV\u20101\u00a0\nsubtipo\u00a0B\u00a0en\u00a0\nPBMCs).\u00a0\u03c9\u00a0\n\u00a0\nActividad \u00a0\n\u00a0\u00a0\nVIH\u20101,2\u00a0\u03c9\u00a0 VIH\u20101,2\u00a0\u03c9\u00a0\u00a0\nVIH\u20101,2\u00a0&\u00a0\u00a0\nVIH\u20101,2\u00a0\u03c9\u00a0\nVHB\u00a0\u03c9\u00a0\u00a0\nVIH\u20101,2\u00a0\u03c9\u00a0\nVHB\u00a0\u03c9\u00a0\u00a0\nVIH\u20101,2\u00a0\u03c9\u00a0\n\u00a0\u00a0\nVIH\u20101,2\u00a0\u03c9\u00a0\nVHB\u00a0\u03c9\u00a0\nPenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\n(LCR:plasma) \u00a0\n\u00a00,6\u00a0[0,04\u00a0\u20102,62]b,\u00a0\u03c9\u00a0\nGrado\u00a04\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0\n(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0\u00a021\u00a0(\u00b10,03)%\u00a0a\u00a0(tras\u00a0\nadmin.\u00a0IV)\u00a0.\u00a0\u2126\u00a0\nGrado\u00a02\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0\n(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0\u00a00,39\u00b10,06\u00a0\u03c9\u00a0\nGrado\u00a02\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0\n(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a00,12\u00a0\u03c9\u00a0\nGrado\u00a02\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0\n(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0No\u00a0se\u00a0dispone\u00a0de\u00a0\ndatos\u00a0\u03c9\u00a0\nGrado\u00a03\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0\n(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a030\u201044%\u00a0\u03c9\u00a0\nGrado\u00a03\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0\n(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a04%\u00a0\nGrado\u00a01\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0\n(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 110 \u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina \u00a0\nddI\u00a0Estavudina \u00a0\nd4T\u00a0Lamivudina \u00a0\n3TC\u00a0Emtricitabina \u00a0\nFTC\u00a0Abacavir\u00a0\nABC\u00a0Tenofovir \u00a0\nTDF\u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nExcreci\u00f3n \u00a0Glucuronidaci\u00f3n \u00a0\nhep\u00e1tica\u00a0\n\u00a0\n\u00a0\n\u00a0\nRenal\u00a0(15%\u00a0\ninalterado) \u00a0Hep\u00e1tica\u00a050%\u00a0\nRenal\u00a0(50%\u00a0\ninalterado) \u00a0Hep\u00e1tica\u00a050%\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nRenal\u00a0(50%\u00a0\ninalterado) \u00a0Hep\u00e1tica\u00a05\u201010%\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nRenal\u00a0(70%\u00a0\ninalterado) \u00a0Hep\u00e1tica\u00a013%\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nRenal\u00a0\u00a086%\u00a0Glucuronidaci\u00f3n \u00a0\nhep\u00e1tica\u00a0\nAlcohol\u00a0\ndeshidrogenasa \u00a0\n\u00a0\n\u00a0\nRenal\u00a083%\u00a0(2%\u00a0\ninalterado \u00a0y\u00a081%\u00a0\nmetabolitos) \u00a0El\u00a0TDF\u00a0(pro\u00a0\nf\u00e1rmaco)\u00a0\nes\u00a0\nr\u00e1pidamente \u00a0\nhidrolizado \u00a0a\u00a0\ntenofovir\u00a0por\u00a0las\u00a0\nesterasas \u00a0\nplasm\u00e1ticas. \u00a0\u00a0\n70\u201080%\u00a0renal\u00a0\ninalterado \u00a0\n\u00a0\nEfectos\u00a0adversos\u00a0Mielosupresi\u00f3n: \u00a0\nanemia\u00a0y/o\u00a0\nneutropenia \u00a0a\u00a0\ndosis\u00a0elevadas\u00a0\nCefalea\u00a0\nMareo\u00a0\nIntolerancia \u00a0\ngastrointestinal. \u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Pancreatitis \u00a0\nHiperuricemia \u00a0\nNeuropat\u00eda \u00a0\nperif\u00e9rica \u00a0\nDiarrea\u00a0\nN\u00e1useas\u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0con\u00a0\nesteatosis \u00a0\nhep\u00e1tica1\u00a0Neuropat\u00eda \u00a0\nperif\u00e9rica \u00a0\u00a0\nPancreatitis \u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Intolerancia \u00a0\ndigestiva\u00a0\nCefalea\u00a0\nFatiga\u00a0\nDolor\u00a0abdominal \u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1 \u00a0Cefalea\u00a0\nIntolerancia \u00a0\ndigestiva\u00a0\nExantema \u00a0cut\u00e1neo\nElevaci\u00f3n \u00a0CPK\u00a0\nAnemia/neutrope\nnia\u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Hipersensibilidad \u00a0\n(5\u20108%)\u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Intolerancia \u00a0\ndigestiva\u00a0\nCefalea\u00a0\nFatiga\u00a0\nDolor\u00a0abdominal \u00a0\nProteinuria \u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 111 \u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina \u00a0\nddI\u00a0Estavudina \u00a0\nd4T\u00a0Lamivudina \u00a0\n3tC\u00a0Emtricitabina \u00a0\nFTC\u00a0Abacavir\u00a0\nABC\u00a0Tenofovir \u00a0\nTDF3\u00a0\nInteracciones \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nAsociaciones \u00a0no\u00a0\nrecomendables \u00a0o\ncontraindicadas \u00a0D4T\u00a0\nPrecauci\u00f3n \u00a0en\u00a0la\u00a0\nasociaci\u00f3n \u00a0con\u00a0\nTPV/r\u00a0por\u00a0\ndisminuci\u00f3n \u00a0de\u00a0los\u00a0\nniveles\u00a0de\u00a0\nzidovudina \u00a0Ribavirina \u00a0\nd4T\u00a0\n\u00a0\nTDF\u00a0(ajustar\u00a0dosis\u00a0\nde\u00a0ddI)\u00a0AZT\u00a0\nddI\u00a0FTC\u00a0\nCotrimoxazol \u00a0\n(dosis\u00a0altas;\u00a0a\u00a0dosis\u00a0\nprofil\u00e1cticas \u00a0\nNRAD)\u00a03TC\u00a0\nddC\u00a0Precauci\u00f3n \u00a0en\u00a0\u00a0la\u00a0\nasociaci\u00f3n \u00a0con\u00a0\nTPV/r\u00a0por\u00a0\ndisminuci\u00f3n \u00a0de\u00a0los\u00a0\nniveles\u00a0de\u00a0abacavir\n\u00a0ATV\u00a0no\u00a0potenciado\n\u00a0\nddI\u00a0(ajustar\u00a0dosis\u00a0\nde\u00a0ddI)\u00a0\nInmuno\u2010\nsupresores \u00a0In\u00a0vitro,\u00a0el\u00a0\u00e1cido\u00a0micofen\u00f3lico \u00a0aument\u00f3\u00a0el\u00a0efecto\u00a0antirretroviral \u00a0de\u00a0ABC,\u00a0ddI\u00a0y\u00a0TDF\u00a0de\u00a0forma\u00a0dosis\u2010dependiente. \u00a0En\u00a0cambio,\u00a0el\u00a0\u00e1cido\u00a0micofen\u00f3lico \u00a0\nmostr\u00f3\u00a0antagonismo \u00a0in\u00a0vitro\u00a0con\u00a0AZT\u00a0y\u00a0d4T.\u00a0Se\u00a0desconoce \u00a0su\u00a0significado \u00a0cl\u00ednico.\u00a0Posible\u00a0aumento\u00a0de\u00a0nefrotoxicidad \u00a0con\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0TDF\u00a0a\u00a0\nciclosporina \u00a0\u00f3\u00a0tacrolimus. \u00a0\nInterferon/ \u00a0\nRibavirina \u00a0Se\u00a0recomienda \u00a0evitar\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0ddI\u00a0y\u00a0ribavirina, \u00a0ya\u00a0que\u00a0se\u00a0ha\u00a0descrito\u00a0aumento\u00a0de\u00a0toxicidad\u00a0mitocondrial \u00a0y\u00a0pancreatitis. \u00a0Ribavirina2\u00a0ha\u00a0\nmostrado \u00a0inhibir\u00a0in\u00a0vitro\u00a0la\u00a0fosforilaci\u00f3n \u00a0intracelular \u00a0de\u00a0AZT\u00a0y\u00a0d4T.\u00a0Sin\u00a0embargo, \u00a0en\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0VHC\u00a0no\u00a0se\u00a0ha\u00a0observado \u00a0\nesta\u00a0interacci\u00f3n \u00a0negativa\u00a0entre\u00a0ribavirina \u00a0y\u00a0AZT,\u00a0d4T\u00a0\u00f3\u00a03TC\u00a0(subestudio \u00a0del\u00a0APRICOT). \u00a0Se\u00a0evitar\u00e1\u00a0en\u00a0la\u00a0medida\u00a0de\u00a0lo\u00a0posible\u00a0el\u00a0uso\u00a0simult\u00e1neo \u00a0de\u00a0\nribavirina \u00a0con\u00a0ZDV\u00a0por\u00a0riesgo\u00a0de\u00a0anemia.\u00a0Sobre\u00a0la\u00a0posible\u00a0interacci\u00f3n \u00a0entre\u00a0ABC\u00a0\u00a0y\u00a0ribavirina, \u00a0los\u00a0resultados \u00a0son\u00a0contradictorios: \u00a0si\u00a0bien\u00a0algunos\u00a0\nestudios\u00a0han\u00a0sugerido\u00a0que\u00a0ABC\u00a0podr\u00eda\u00a0reducir\u00a0la\u00a0eficacia\u00a0de\u00a0ribavirina, \u00a0en\u00a0la\u00a0mayor\u00eda\u00a0\u00a0de\u00a0estudios,\u00a0entre\u00a0ellos\u00a0los\u00a0estudios\u00a03603\u00a0y\u00a05006\u00a0de\u00a0Gesida,\u00a0\nno\u00a0se\u00a0ha\u00a0observado \u00a0esta\u00a0interacci\u00f3n, \u00a0especialmente \u00a0cuando\u00a0la\u00a0dosis\u00a0de\u00a0ribavirina \u00a0se\u00a0ajustaba\u00a0a\u00a0peso.\u00a0Con\u00a0el\u00a0interfer\u00f3n \u00a0beta\u00a0(Avonex\u00ae, \u00a0Rebif\u00ae,\u00a0\nBetaferon\u00ae) \u00a0se\u00a0han\u00a0descrito\u00a0aumentos \u00a0de\u00a0la\u00a0semivida\u00a0AZT\u00a0hasta\u00a03\u00a0veces\u00a0y\u00a0con\u00a0interfer\u00f3n \u00a0alfa\u00a0(Intron\u00ae,PegIntron\u00ae, \u00a0Roferon\u00a0A\u00ae,\u00a0Wellferon\u00ae) \u00a0\n\u219136%\u00a0AUC\u00a0AZT\u00a0(\u2191\u00a0riesgo\u00a0toxicidad\u00a0hematol\u00f3gica). \u00a0Algunos\u00a0autores\u00a0recomiendan \u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0AZT\u00a0un\u00a050\u201075%\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0\ninterferon \u00a0beta.\u00a0\u00a0\n\u00a0\nMetadona \u00a0(MT)\u00a0\ny\u00a0otros\u00a0opi\u00e1ceos\u00a0Puede\u2191Cp\u00a0AZT\u00a0MT:\u00a0Interacci\u00f3n \u00a0\npoco\u00a0probable\u00a0\u00a0\nBuprenorfina: \u00a0No\u00a0\ninteracci\u00f3n \u00a0NRAD\u00a0(\u219327%\u00a0AUC\u00a0\nd4T)\u00a0MT:\u00a0Interacci\u00f3n \u00a0\npoco\u00a0probable\u00a0\u00a0\nBuprenorfina: \u00a0No\u00a0\ninteracci\u00f3n \u00a0Interacci\u00f3n \u00a0poco\u00a0\nprobable\u00a0Puede\u00a0requerir\u00a0un\u00a0\nligero\u00a0\u2191\u00a0MT\u00a0\n\u00a0MT:\u00a0Interacci\u00f3n \u00a0\npoco\u00a0probable\u00a0\u00a0\nBuprenorfina: \u00a0No\u00a0\ninteracci\u00f3n \u00a0\nF\u00e1rmacos \u00a0\nempleados \u00a0para\u00a0\ntratar\u00a0la\u00a0\ninfluenza \u00a0Se\u00a0considera \u00a0poco\u00a0probable\u00a0una\u00a0interacci\u00f3n \u00a0con\u00a0zanamivir, \u00a0dada\u00a0su\u00a0escasa\u00a0absorci\u00f3n. \u00a0\u00a0\nOseltamivir \u00a0y\u00a0amantadina \u00a0se\u00a0eliminan\u00a0por\u00a0v\u00eda\u00a0renal.\u00a0Oseltamivir \u00a0mediante \u00a0filtraci\u00f3n\u00a0glomerular \u00a0y\u00a0secreci\u00f3n \u00a0tubular.\u00a0Se\u00a0ha\u00a0observado \u00a0un\u00a0aumento\u00a0\ndel\u00a0doble\u00a0en\u00a0sus\u00a0Cp\u00a0al\u00a0asociarlo\u00a0con\u00a0probenecid, \u00a0f\u00e1rmaco\u00a0inhibidor\u00a0de\u00a0la\u00a0secreci\u00f3n \u00a0tubular.\u00a0Es\u00a0probable\u00a0que\u00a0en\u00a0la\u00a0eliminaci\u00f3n \u00a0de\u00a0amantadina \u00a0\nintervenga \u00a0tambi\u00e9n\u00a0la\u00a0secreci\u00f3n \u00a0tubular.\u00a0No\u00a0puede\u00a0descartarse \u00a0una\u00a0interacci\u00f3n \u00a0con\u00a0otros\u00a0f\u00e1rmacos\u00a0eliminados \u00a0mediante \u00a0esta\u00a0v\u00eda\u00a0como\u00a0\nlamivudina, \u00a0emtricitabina \u00a0y\u00a0tenofovir, \u00a0aunque\u00a0no\u00a0se\u00a0dispone\u00a0de\u00a0informaci\u00f3n \u00a0espec\u00edfica \u00a0al\u00a0respecto. \u00a0Se\u00a0recomienda \u00a0precauci\u00f3n \u00a0en\u00a0los\u00a0pacientes \u00a0\ncon\u00a0funci\u00f3n\u00a0renal\u00a0alterada\u00a0que\u00a0deban\u00a0recibir\u00a0oseltamivir \u00a0u\u00a0amantadina \u00a0junto\u00a0con\u00a0estos\u00a0ARV.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 112 \u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina \u00a0\nddI\u00a0Estavudina \u00a0\nd4T\u00a0Lamivudina \u00a0\n3tC\u00a0Emtricitabina \u00a0\nFTC\u00a0Abacavir\u00a0\nABC\u00a0Tenofovir \u00a0\nTDF3\u00a0\n\u00a0\nOtros\u00a0\u00a0\nGanciclovir: \u00a0\n\u2191riesgo\u00a0toxicidad\u00a0\nhematol\u00f3gica. \u00a0\u00a0\n\u00a0\nProbenecid: \u00a0evitar\u00a0\n\u00f3\u00a0reducir\u00a050%\u00a0AZT\u00a0\u00a0\nTDF:\u00a0evitar\u00a0la\u00a0\nasociaci\u00f3n, \u00a0por\u00a0\naumento\u00a0del\u00a0\nriesgo\u00a0de\u00a0fracaso\u00a0\nterap\u00e9utico. \u00a0En\u00a0\ncaso\u00a0necesario, \u00a0\najustar\u00a0dosis.\u00a0\n(\u219140%\u00a0AUC\u00a0ddI).\u00a0\nSin\u00a0cambios\u00a0TDF.\u00a0\nAjuste\u00a0de\u00a0dosis\u00a0\nddI:\u00a0\u226560\u00a0kg:\u00a0250\u00a0\nmg/d\u00eda;\u00a0<60\u00a0kg:\u00a0\n200\u00a0mg/d\u00eda\u00a0(en\u00a0\neste\u00a0caso\u00a0ddI\u00a0se\u00a0\npueden\u00a0\nadministrar \u00a0juntos\u00a0\nc/s\u00a0comida\u00a0ligera).\u00a0\n\u00a0\nCon\u00a0alopurinol, \u00a0\nreducir\u00a0la\u00a0dosis\u00a0de\u00a0\nddI\u00a0a\u00a0la\u00a0mitad\u00a0\n\u00a0\u00a0\n\u00a0Doxorrubicina \u00a0in\u00a0\nvitro\u00a0interfiere \u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0\nd4T.\u00a0Se\u00a0desconoce \u00a0\nla\u00a0importancia \u00a0\ncl\u00ednica,\u00a0pero\u00a0se\u00a0\nrecomienda \u00a0un\u00a0\ncontrol\u00a0estrecho\u00a0\nde\u00a0la\u00a0carga\u00a0viral.\u00a0\u00a0\nNefrot\u00f3xicos: \u00a0\nposible\u00a0\u2191Cp\u00a03TC\u00a0\nPrecauci\u00f3n \u00a0con\n\u00a0\nf\u00e1rmacos\u00a0que\u00a0se\u00a0\neliminen\u00a0por\u00a0v\u00eda\u00a0\nrenal\u00a0(secreci\u00f3n \u00a0\nactiva\u00a0por\u00a0el\u00a0\nsistema\u00a0de\u00a0\ntransporte \u00a0\ncati\u00f3nico\u00a0\norg\u00e1nico): \u00a0riesgo\u00a0\nde\u00a0ac\u00famulo\u00a0de\u00a0\nambos.\u00a0\u00a0\nNefrot\u00f3xicos: \u00a0\nposible\u00a0\u2191Cp\u00a0FTC\u00a0\nprecauci\u00f3n \u00a0con\u00a0\nf\u00e1rmacos\u00a0que\u00a0se\u00a0\neliminen\u00a0por\u00a0v\u00eda\u00a0\nrenal\u00a0(secreci\u00f3n \u00a0\ntubular\u00a0activa):\u00a0\nriesgo\u00a0de\u00a0ac\u00famulo\u00a0\nde\u00a0ambos.\u00a0FTC\u00a0no\u00a0\nha\u00a0mostrado \u00a0\nefecto\u00a0inhibidor\u00a0\nsobre\u00a0las\u00a0\nprincipales \u00a0\nisoenzimas \u00a0del\u00a0\ncitocromo \u00a0P450\u00a0ni\u00a0\nsobre\u00a0la\u00a0\nglucuronidaci\u00f3n, \u00a0\npor\u00a0lo\u00a0que\u00a0no\u00a0es\u00a0\nde\u00a0esperar\u00a0que\u00a0se\u00a0\nproduzcan \u00a0\ninteracciones \u00a0\nmetab\u00f3licas \u00a0\nimportantes \u00a0a\u00a0este\u00a0\nnivel.\u00a0\u00a0\nClorpromacina, \u00a0\ndisulfiram \u00a0e\u00a0\nisoniacida \u00a0\u2191\u00a0Cp\u00a0de\u00a0\nambos.\u00a0\nSe\u00a0ha\u00a0\u00a0descrito\u00a0un\u00a0\ncaso\u00a0de\u00a0\nrabdomiolisis \u00a0\ngrave\u00a0en\u00a0un\u00a0\npaciente\u00a0que\u00a0\npresent\u00f3\u00a0\nhipersensibilidad \u00a0a\u00a0\nABC\u00a0y\u00a0\u00a0recib\u00eda\u00a0\ntratamiento \u00a0con\u00a0\nfibratos\u00a0\n(ciprofibrato \u00a0100\u00a0\nmg/24\u00a0horas).\u00a0ddI:\u00a0evitar\u00a0la\u00a0\nasociaci\u00f3n. \u00a0En\u00a0caso\u00a0\nnecesario, \u00a0ajustar\u00a0\ndosis:\u00a0\u00a0Sin\u00a0cambios\u00a0\nTDF.\u00a0Ajuste\u00a0de\u00a0ddI:\u00a0\n\u226560\u00a0kg:\u00a0250\u00a0\nmg/d\u00eda;\u00a0<60\u00a0kg:\u00a0\n200\u00a0mg/d\u00eda\u00a0\n(pueden\u00a0\nadministrarse \u00a0\njuntos\u00a0c/s\u00a0comida)\nCon\u00a0ATV\u00a0utilizar\u00a0\nATV/r\u00a0\u00a0300/100\u00a0mg\u00a0\nc/24h.\u00a0\nTelaprevir: \u00a0NRAD\u00a0\nNefrot\u00f3xicos \u00a0,\u00a0\ninhibidores \u00a0o\u00a0\ncompetidores \u00a0por\u00a0\nla\u00a0secreci\u00f3n \u00a0\ntubular\u00a0renal\u00a0\npodr\u00edan\u00a0aumentar \u00a0\nla\u00a0toxicidad\u00a0de\u00a0\nambos.\u00a0Aumento \u00a0\nde\u00a0riesgo\u00a0de\u00a0\ntoxicidad\u00a0renal\u00a0con\u00a0\nIP.\u00a0\nProbenecid \u00a0podr\u00eda\u00a0\naumentar \u00a0las\u00a0\nconcentraciones \u00a0\nplasm\u00e1ticas \u00a0de\u00a0\nTDF.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 113 \u00a0\nAUC\u00a0:\u00a0Area\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0Concentraci\u00f3n \u00a0plasm\u00e1tica; \u00a0NRAD:\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0QD:\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda;\u00a0TID:\u00a0tres\u00a0veces\u00a0al\u00a0d\u00eda.\u00a0*Combivir \u00ae:\u00a0\nasociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0AZT\u00a0300\u00a0mg\u00a0y\u00a03TC\u00a0150\u00a0mg.**Trizivir\u00ae\u00a0:\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0AZT\u00a0300\u00a0mg,\u00a03TC\u00a0150\u00a0mg\u00a0y\u00a0abacavir\u00a0300\u00a0mg.\u00a0***Kivexa\u00ae: \u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0\nde\u00a03TC\u00a0300\u00a0mg\u00a0y\u00a0abacavir\u00a0600\u00a0mg;\u00a0****Truvada\u00ae: \u00a0\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0tenofovir\u00a0300\u00a0mg\u00a0y\u00a0emtricitabina \u00a0200\u00a0mg.\u00a0*****Atripla\u00ae: \u00a0\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0tenofovir\u00a0\n300\u00a0mg,\u00a0emtricitabina \u00a0200\u00a0mg\u00a0y\u00a0efavirenz\u00a0600\u00a0mg.\u00a0\n\u00a0\na\u00a0Expresado \u00a0como\u00a0media\u00a0\u00b1\u00a0DE\u00a0si\u00a0no\u00a0se\u00a0indica\u00a0lo\u00a0contrario\u00a0\nb\u00a0Expresado \u00a0como\u00a0mediana\u00a0\u00b1\u00a0rango\u00a0intercuartil \u00a0\u00a0\nc\u00a0Expresado \u00a0como\u00a0rango\u00a0\n\u00a0\n1\u00a0Reacci\u00f3n\u00a0poco\u00a0frecuente \u00a0aunque\u00a0potencialmente \u00a0muy\u00a0grave.\u00a0\n2cabe\u00a0recordar\u00a0que\u00a0cualquier \u00a0posible\u00a0interacci\u00f3n \u00a0con\u00a0ribavirina \u00a0puede\u00a0persistir\u00a0hasta\u00a02\u00a0meses\u00a0despu\u00e9s\u00a0de\u00a0interrumpir \u00a0el\u00a0tratamiento \u00a0con\u00a0Rebetol\u00ae\u00a0debido\u00a0a\u00a0la\u00a0larga\u00a0vida\u00a0\nmedia\u00a0de\u00a0este\u00a0f\u00e1rmaco.\u00a0\n3Tenofovir \u00a0se\u00a0elimina\u00a0mayoritariamente \u00a0por\u00a0v\u00eda\u00a0renal\u00a0y\u00a0no\u00a0act\u00faa\u00a0como\u00a0substrato, \u00a0inductor\u00a0\u00f3\u00a0inhibidor\u00a0del\u00a0citocromo \u00a0P\u2010450,\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0espera\u00a0que\u00a0tenga\u00a0interacciones \u00a0\nrelevantes \u00a0de\u00a0car\u00e1cter\u00a0metab\u00f3lico. \u00a0\n\u00a0\n\u03c9\u00a0Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0europea.\u00a0EPARS:\u00a0European \u00a0Public\u00a0Assessment \u00a0Reports.\u00a0Disponble \u00a0en:\u00a0\nhttp://www.ema.europa.eu/ema/index.jsp?curl =pages/includes/medicines/medicines_landing _page.jsp&murl=menus/m edicines/medicines. jsp&mid=.\u00a0Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n\u2126Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0americana \u00a0(fuentes:\u00a0FDA\u00a0and\u00a0First\u00a0Data\u00a0Bank,\u00a0Inc).\u00a0Disponible \u00a0en: http://www.rxlist.com/drugs/alpha_a.htm \u00a0.Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n\u00a0\nNOTA:\u00a0debido\u00a0a\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0\nf\u00e1rmacos\u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 114 Tabla\u00a06.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0\nNombre\u00a0comercial \u00a0 Viramune\u00ae\u00a0Sustiva\u00ae\u00a0\n*Atripla\u00ae\u00a0Intelence\u00ae\u00a0\nDosis\u00a0recomendada \u00a0\n\u00a0200\u00a0mg\u00a0QD\u00a0x\u00a014\u00a0d\u00edas\u00a0\nseguidas\u00a0de\u00a0200\u00a0mg\u00a0BID\u00a0600\u00a0mg\u00a0QD\u00a0 200\u00a0mg\u00a0BID\u00a0(dispersable \u00a0en\u00a0agua)\u00a0\nPresentaciones \u00a0\ncomerciales \u00a0comprimidos \u00a0200\u00a0mg\u00a0\nsuspensi\u00f3n \u00a010\u00a0mg/mL\u00a0c\u00e1psulas\u00a050,\u00a0100\u00a0y\u00a0200\u00a0mg\u00a0y\u00a0\u00a0comp.\u00a0600\u00a0mg\u00a0comprimidos \u00a0100\u00a0mg\u00a0\nBiodisponibilidad \u00a0oral\u00a0\n\u00a093\u00a0\u00b1\u00a09%a,\u03c9\u00a0(comprimidos)\u00a0\n91\u00a0\u00b1\u00a08%\u00a0a\u00a0(soluci\u00f3n\u00a0oral)\u00a022%\u00a0(dosis\u00a0unica\u00a0de\u00a0600\u00a0mg\u00a0con\u00a0comida\u00a0de\u00a0alto\u00a0\ncontenido \u00a0graso)\u00a0\u03c9\u00a0\n17%\u00a0(dosis\u00a0unica\u00a0de\u00a0600\u00a0mg\u00a0con\u00a0comida\u00a0normal)\u00a0\n\u03c9\u00a0No\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0\nbiodisponibilidad \u00a0absoluta\u00a0en\u00a0humanos\u00a0\n\u03c9\u00a0\nEfecto\u00a0de\u00a0los\u00a0\u00a0alimentos \u00a0Se\u00a0puede\u00a0administrar \u00a0con\u00a0o\u00a0sin\u00a0alimentos. \u00a0(Al\u00a0\nadministrar \u00a0nevirapina \u00a0con\u00a0un\u00a0desayuno \u00a0rico\u00a0\nen\u00a0grasas,\u00a0el\u00a0grado\u00a0de\u00a0absorci\u00f3n \u00a0fue\u00a0\ncomparable \u00a0al\u00a0observado \u00a0en\u00a0condiciones \u00a0de\u00a0\nayuno).\u00a0Evitar\u00a0las\u00a0comidas\u00a0ricas\u00a0en\u00a0grasa,\u00a0pues\u00a0la\u00a0\nbiodisponibilidad \u00a0aumenta\u00a0un\u00a050%\u00a0y\u00a0podr\u00eda\u00a0\naumentar \u00a0la\u00a0toxicidad. \u00a0Debe\u00a0administrarse \u00a0con\u00a0alimentos. \u00a0El\u00a0\nAUC\u00a0y\u00a0la\u00a0Cmax\u00a0de\u00a0la\u00a0formulaci\u00f3n \u00a0usada\u00a0\nen\u00a0estudios\u00a0de\u00a0Fase\u00a0III\u00a0(F060)\u00a0fueron\u00a0un\u00a0\n51\u00a0y\u00a0un\u00a044%\u00a0menores\u00a0cuando\u00a0se\u00a0\nadministr\u00f3 \u00a0en\u00a0ayunas,\u00a0y\u00a0un\u00a025\u00a0y\u00a038%\u00a0\nmenores\u00a0tras\u00a0un\u00a0desayuno \u00a0alto\u00a0en\u00a0fibra\u00a0\n(en\u00a0comparaci\u00f3n \u00a0con\u00a0un\u00a0desayuno \u00a0\nest\u00e1ndar). \u00a0Las\u00a0diferencias \u00a0en\u00a0las\u00a0\nconcentraciones \u00a0de\u00a0ETR\u00a0administrado \u00a0\ntras\u00a0una\u00a0comida\u00a0con\u00a0alto\u00a0contenido \u00a0\nlip\u00eddico,\u00a0tras\u00a0un\u00a0desayuno \u00a0est\u00e1ndar\u00a0o\u00a0\ntras\u00a0un\u00a0croissant\u00a0no\u00a0fueron\u00a0cl\u00ednicamente \u00a0\nsignificativas. \u00a0\nSemivida \u00a0plasm\u00e1tica \u00a025\u201030\u00a0horas\u00a0(tras\u00a0dosis\u00a0m\u00faltiples)\u00a0\u03c9\u00a0\n45\u00a0horas\u00a0tras\u00a0una\u00a0dosis\u00a0\u00fanica.\u00a0La\u00a0diferencia \u00a0se\u00a0\ndebe\u00a0a\u00a0la\u00a0autoinducci\u00f3n \u00a0de\u00a0su\u00a0propio\u00a0\nmetabolismo. \u00a040\u201055\u00a0horas\u00a0(tras\u00a0dosis\u00a0m\u00faltiples)\u00a0\u03c9\u00a0\n52\u201076\u00a0horas\u00a0tras\u00a0una\u00a0dosis\u00a0\u00fanica.\u00a0La\u00a0diferencia \u00a0\nse\u00a0debe\u00a0a\u00a0la\u00a0autoinducci\u00f3n \u00a0de\u00a0su\u00a0propio\u00a0\nmetabolismo.\u00a0\u2126\u00a030\u201040\u00a0horas\u00a0\u03c9\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 115 Cmax\u00a0\n\u00a05,74\u00a0microg/ml \u00a0(5,00\u20107,44)\u00a0(200\u00a0mg/12h)\u00a0\u03c9\u00a04,07\u00a0microg/ml \u00a0\u2126\u00a0\n12,9\u00a0\u00b1\u00a03,7\u00a0microM\u00a0(VIH+)a,\u00a0\u03c9\u00a0\n\u00a0\u2010\u2010\u00a0\nCmin\u00a0 3,73\u00a0microg/ml \u00a0(3,20\u20105,08)\u00a0(200\u00a0mg/12h)\u00a0\u03c9\u00a05,6\u00a0\u00b1\u00a03,2\u00a0microM\u00a0(1,77\u00a0microg/ml) \u00a0(VIH+)a,\u00a0\u03c9\u00a0\u00a0296,74\u00b1377,52 \u00a0nanog/mL \u00a0(VIH+)a,\u2126\u00a0\u00a0\nAUC\u00a0 109,0\u00a0microg.h/ml\u00a0\u03c9\u00a0(96,0\u2010143,5)\u00a0(200\u00a0mg/12h)\u00a0\n\u03c9\u00a0184\u00a0\u00b1\u00a073\u00a0microM\u2219h\u00a0(58,14\u00a0microg.h/mL)a,\u00a0\u03c9\u00a0\u00a04531,53\u00b14543,69 \u00a0nanog.h/mL(VIH+)\u00a0a,\u2126\u00a0\nCI50/90\u00a0frente\u00a0a\u00a0VIH\u20101\u00a0in\u00a0vitro\u00a0\n\u00a0\u00a0\nCI50\u00a0:0,063\u00a0microM\u00a0\u03c9\u00a0(0,017\u00a0microg/mL) \u00a0\n\u00a0CI90\u201095:\u00a0\u00a00,00014\u20100,0021\u00a0microg/ml \u00a0\u00a0\n\u00a0(0,00046\u20100,0068\u00a0microM)\u00a0\u03c9\u00a0CI50\u00a0:\u00a00,9\u00a0a\u00a05,5\u00a0nanoM.\u00a0(0,39\u20102,39\u00a0\nnanog/mL)\u03c9\u00a0\u00a0\nActividad \u00a0 VIH\u20101\u00a0\u03c9\u00a0 VIH\u20101\u00a0\u03c9\u00a0 VIH\u20101\u00a0\u03c9\u00a0\nPenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\n(LCR:plasma) \u00a045%\u00a0\u00b1\u00a05%\u00a0\u03c9\u00a0\nGrado\u00a04\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0la\u00a0\nclasificaci\u00f3n \u00a0del\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0\nmenor\u00a0a\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a00,69%\u00a0(entre\u00a00,26\u00a0y\u00a01,19%)\u00a0\u03c9\u00a0Las\u00a0\nconcentraciones \u00a0de\u00a0EFV\u00a0en\u00a0LCR\u00a0exceden\u00a0la\u00a0CI50\u00a0\npara\u00a0la\u00a0cepa\u00a0salvaje\u00a0del\u00a0virus:\u00a0LCR/plasma: \u00a00.005\u00a0\n(IQR\u00a00.0026\u20100.0076;\u00a0n\u001f=\u001f69).\u00a0CSF/\u00a0CI50:\u00a026\u00a0(IQR\u00a0\n8\u201041),\u00a0tomando\u00a0CI50\u00a0=0.51\u00a0ng/mL\u00a0(Best\u00a0BM.\u00a0J.\u00a0\nAntimicrob. \u00a0Chemother. \u00a0(2010)\u00a0doi:\u00a0\n10.1093/jac/dkq434) \u00a0\nGrado\u00a03\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0la\u00a0\nclasificaci\u00f3n \u00a0del\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0\nmenor\u00a0a\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0No\u00a0disponible\u00a0\u03c9\u00a0\nGrado\u00a02\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0la\u00a0\nclasificaci\u00f3n \u00a0del\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0\na\u00a04,\u00a0menor\u00a0a\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0\n430.\u00a0Croi\u00a02010)\u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0\n\u00a0\nExcreci\u00f3n \u00a0\n\u00a0Hep\u00e1tica\u00a0CYP3A4\u00a0\n(Inducci\u00f3n) \u00a0\n\u00a0\nRenal\u00a080%\u00a0(3%\u00a0inalterado) \u00a0\nHeces\u00a010%\u00a0Hep\u00e1tica\u00a0CYP3A4\u00a0\n(inducci\u00f3n \u2010inhibici\u00f3n) \u00a0\n\u00a0\nRenal\u00a034%\u00a0(1%\u00a0inalterado) \u00a0\nHeces\u00a016\u201061%\u00a0Hep\u00e1tica: \u00a0\n\u2010\u00a0inducci\u00f3n \u00a0de\u00a0CYP3A4;\u00a0\n\u2010\u00a0Inhibici\u00f3n: \u00a02C9,\u00a02C19\u00a0\n\u2010\u00a0glucuronidaci\u00f3n \u00a0\nRenal:\u00a0<\u00a01,2\u00a0%\u00a0\nExcrecci\u00f3n \u00a0fundamentalmente \u00a0por\u00a0\nheces\u00a0\nEfectos\u00a0adversos\u00a0\n\u00a0Exantema \u00a0\nAumento \u00a0de\u00a0transaminasas \u00a0y\u00a0\nHepatitis\u00a0aguda\u00a0Exantema \u00a0\nS\u00edntomas\u00a0neuropsiqui\u00e1tricos \u00a0\nAumento \u00a0de\u00a0las\u00a0transaminasas \u00a0\nTeratogenicidad \u00a0en\u00a0monos\u00a0Exantema \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 116 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0\nInteracciones \u00a0\nAsociaciones \u00a0\ncontraindicadas \u00a0\n\u00a0\u00a0\nAnticonceptivos \u00a0orales\u00a0\nETV\u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nKetoconazol \u00a0\nItraconazol \u00a0\nRifampicina \u00a0\nSaquinavir1\u00a0\nVoriconazol\u00a0\u00a0\u00a0\nAnticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nCarbamacepina \u00a0\nCisaprida\u00a0\nClaritromicina \u00a0\nDeriv.\u00a0Ergotamina \u00a0\nETV\u00a0\nHipericum \u00a0(hierba\u00a0de\u00a0S.\u00a0Juan)\u00a0\nItraconazol \u00a0\nMidazolam \u00a0\nPimozida\u00a0\nPosaconazol \u00a0\u00a0\nSaquinavir \u00a0(como\u00a0\u00fanico\u00a0IP)\u00a0\nTerfenadina \u00a0\nTriazolam \u00a0\nVoriconazol \u00a0(evitar/ajustar \u00a0dosis)\u00a0\u00a0\nCarbamacepina \u00a0\nEFV\u00a0\nFenitoina \u00a0\nFenobarbital \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nNVP\u00a0\nRifampicina \u00a0\nTPV/r\u00a0\nIP\u00a0no\u00a0potenciado \u00a0\nAnti\u00e1cidos \u00a0 No\u00a0se\u00a0ha\u00a0observado \u00a0interacci\u00f3n \u00a0significativa \u00a0No\u00a0se\u00a0ha\u00a0observado \u00a0interacci\u00f3n \u00a0significativa \u00a0Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0\ninteracci\u00f3n \u00a0significativa \u00a0\nInhibidores \u00a0de\u00a0la\u00a0\nbomba\u00a0de\u00a0protones\u00a0\n\u00a0Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0\nsignificativa \u00a0Ausencia\u00a0de\u00a0interacci\u00f3n. \u00a0 NRAD\u00a0(\u219141%\u00a0AUC\u00a0ETR)\u00a0\nAntihistam\u00ednicos \u00a0H2\u00a0Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0\nsignificativa \u00a0Ausencia\u00a0de\u00a0interacci\u00f3n. \u00a0 NRAD\u00a0(\u219314%\u00a0AUC\u00a0ETR)\u00a0\nAntimicobacterianos :\u00a0\n\u00a0\u2010 Rifampicina \u00a0\n\u00a0\u2193Cm\u00edn\u00a0y\u00a0AUC\u00a0NVP\u00a0del\u00a035\u00a0a\u00a0m\u00e1s\u00a0del\u00a050%.\u00a0\nResultados \u00a0cl\u00ednicos\u00a0discordantes. \u00a0No\u00a0aumentar \u00a0\nla\u00a0dosis\u00a0de\u00a0NVP\u00a0por\u00a0mayor\u00a0toxicidad. \u00a0No\u00a0\nemplear\u00a0pautas\u00a0de\u00a0NVP\u00a0QD\u00a0con\u00a0rifampicina. \u00a0\nPrecauci\u00f3n \u2010monitorizar \u00a0estrechamente \u00a0eficacia.\u00a0\u00a0\nNRAD\u00a0(\u219325%\u00a0AUC\u00a0EFV)\u00a0\u00a0\u00a0\n\u00a0\u00a0\nNo\u00a0hay\u00a0datos.\u00a0No\u00a0se\u00a0recomienda \u00a0\ndado\u00a0que\u00a0se\u00a0\nprev\u00e9\u00a0una\u00a0importante \u00a0reducci\u00f3n \u00a0de\u00a0las\u00a0\nconcentraciones \u00a0de\u00a0ETR\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 117 \u2010 Rifabutina \u00a0\n\u00a0NRAD\u00a0 450\u2010600\u00a0mg/d\u00eda\u00a0rifabutina \u00a0\u00f3\u00a0450\u2010600\u00a0mg\u00a0\n3veces\u00a0/semana\u00a0NRAD\u00a0(\u219337%\u00a0AUC\u00a0ETR)\u00a0\n\u2010 Claritromicina \u00a0\n\u00a0NRAD\u00a0 \u219339%\u00a0AUC\u00a0claritromicina \u00a0\nBuscar\u00a0alternativa \u00a0(azitromicina) \u00a0para\u00a0el\u00a0\ntratamiento \u00a0de\u00a0MAC\u00a0\u219339%\u00a0AUC\u00a0claritro,\u00a0\u219142%\u00a0AUC\u00a0ETR\u00a0\nBuscar\u00a0alternativa \u00a0(azitromicina) \u00a0para\u00a0el\u00a0\ntratamiento \u00a0de\u00a0MAC\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 118 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0\nAntiepil\u00e9pticos :\u00a0\n\u2010 Carbamazepina, \u00a0\u00a0\n\u2010 fenito\u00edna, \u00a0\nfenobarbital \u00a0Precauci\u00f3n. \u00a0Monitorizar \u00a0niveles\u00a0de\u00a0ambos\u00a0\nf\u00e1rmacos\u00a0Precauci\u00f3n. \u00a0Monitorizar \u00a0niveles\u00a0de\u00a0antiepil\u00e9ptico. \u00a0\nCarbamacepina: \u00a0no\u00a0recomendado \u00a0(\u219347%\u00a0Cmin\u00a0EFV\u00a0\ncon\u00a0400\u00a0mg\u00a0c/24h\u00a0de\u00a0CBZ;\u00a0\u219335%\u00a0Cmin\u00a0CBZ).\u00a0\nFenito\u00edna: \u00a0algun\u00a0caso\u00a0descrito\u00a0de\u00a0\u2191\u00a0fenito\u00edna\u00a0y\u00a0\u2193\u00a0EFV\u00a0\na\u00a0niveles\u00a0indetectables \u00a0(evitar\u00a0o\u00a0monitorizar \u00a0niveles\u00a0\nde\u00a0ambos).\u00a0No\u00a0hay\u00a0datos\u00a0\nAnticoagulantes \u00a0oralesTe\u00f3ricamente \u00a0NVP\u00a0podr\u00eda\u00a0aumentar \u00a0o\u00a0reducir\u00a0\nel\u00a0INR.\u00a0Monitorizar \u00a0estrechamente \u00a0Te\u00f3ricamente \u00a0EFV\u00a0podr\u00eda\u00a0aumentar \u00a0o\u00a0reducir\u00a0el\u00a0INR\u00a0\n(un\u00a0caso\u00a0descrito\u00a0que\u00a0requiri\u00f3\u00a0reducir\u00a0dosis\u00a0de\u00a0\nwarfarina). \u00a0Monitorizar \u00a0estrechamente \u00a0Te\u00f3ricamente \u00a0ETR\u00a0podr\u00eda\u00a0aumentar \u00a0o\u00a0\nreducir\u00a0el\u00a0INR.\u00a0Monitorizar \u00a0\nestrechamente \u00a0\nAnticonceptivos \u00a0\norales :\u00a0\u219319%\u00a0AUC\u00a0etinilestradiol. \u00a0\u00a0\nNo\u00a0debe\u00a0administrarse \u00a0junto\u00a0con\u00a0\nanticonceptivos \u00a0que\u00a0contengan \u00a0etinilestradiol \u00a0\no\u00a0noretindrona. \u00a0Deben\u00a0considerarse \u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0alternativos \u00a0o\u00a0adicionales. \u00a0\nNo\u00a0modifica\u00a0los\u00a0niveles\u00a0de\u00a0\nmedroxiprogesterona \u00a0(NRAD)\u00a0\n\u00a0Etinilestradiol \u00a0sin\u00a0cambios,\u00a0\u00a0\n\u219383%\u00a0AUC\u00a0levonorgestrel. \u00a0\u00a0\nNo\u00a0debe\u00a0administrarse \u00a0junto\u00a0con\u00a0anticonceptivos \u00a0\nque\u00a0contengan \u00a0etinilestradiol \u00a0o\u00a0noretindrona. \u00a0Deben\u00a0\nconsiderarse \u00a0m\u00e9todos\u00a0anticonceptivos \u00a0alternativos \u00a0o\u00a0\nadicionales. \u00a0\nNo\u00a0modifica\u00a0los\u00a0niveles\u00a0de\u00a0medroxiprogesterona \u00a0\u00a0\n(datos\u00a0preliminares) \u00a0\u219122%\u00a0AUC\u00a0etinilestradiol; \u00a0\u00a0\nnoretindrona, \u00a0AUC\u00a0sin\u00a0cambios.\u00a0\u00a0\nNRAD\u00a0\n\u00a0\n\u00a0Antif\u00fangicos \u00a0\n\u00a0Anfotericina \u00a0B:\u00a0NRAD.\u00a0\n\u00a0\nCaspofungina: \u00a0considerar \u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0\ndosis\u00a0de\u00a0mantenimiento \u00a0de\u00a0caspofungina \u00a0a\u00a070\u00a0\nmg/d.\u00a0\n\u00a0\nFluconazol: \u00a0No\u00a0recomendable \u00a0(\u2191100%\u00a0AUC\u00a0\nNVP\u00a0con\u00a0toxicidad). \u00a0\n\u00a0\nItraconazol, \u00a0ketoconazol \u00a0y\u00a0voriconazol: \u00a0\nContraindicados. \u00a0Anfotericina \u00a0B:\u00a0NRAD.\u00a0\nCaspofungina: \u00a0considerar \u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0dosis\u00a0de\u00a0\nmantenimiento \u00a0de\u00a0caspofungina \u00a0a\u00a070\u00a0mg/d.\u00a0\nFluconazol: \u00a0NRAD.\u00a0\nItraconazol: \u00a0No\u00a0recomendable \u00a0(s\u00f3lo\u00a0con\u00a0\nmonitorizaci\u00f3n \u00a0de\u00a0niveles\u00a0de\u00a0ambos\u00a0f\u00e1rmacos; \u00a0un\u00a0\ncaso\u00a0de\u00a0histoplasmosis \u00a0tratada\u00a0con\u00a0\u00e9xito\u00a0con\u00a0TDM\u00a0y\u00a0\najuste\u00a0a\u00a0800\u00a0mg/d\u00a0de\u00a0itraconazol \u00a0y\u00a0400\u00a0mg/d\u00a0de\u00a0EFV)\nPosaconazol: \u00a0contraindicado \u00a0(\u2193\u00a050%\u00a0AUC\u00a0posacon)\u00a0\nVoriconazol \u00a0:\u00a0No\u00a0recomendable \u00a0(solo\u00a0con\u00a0monitori\u2010\nzaci\u00f3n\u00a0de\u00a0niveles\u00a0de\u00a0ambos\u00a0f\u00e1rmacos)(aumentar \u00a0\ndosis\u00a0de\u00a0voriconazol \u00a0a\u00a0400mg/12 \u00a0y\u00a0posible\u00a0\ndisminuci\u00f3n \u00a0de\u00a0EFV\u00a0a\u00a0300\u00a0mg/d)\u00a0\u00a0Anfotericina \u00a0B:\u00a0NRAD.\u00a0\nLos\u00a0antif\u00fangicos \u00a0imidaz\u00f3licos \u00a0pueden\u00a0\naumentar \u00a0las\u00a0concentraciones \u00a0\nplasm\u00e1ticas \u00a0de\u00a0ETV.\u00a0ETV\u00a0podr\u00eda\u00a0reducir\u00a0\nlas\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0de\u00a0\nitraconazol \u00a0y\u00a0ketoconazol \u00a0por\u00a0aumento\u00a0\nde\u00a0su\u00a0metabolismo \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A4.\u00a0\u00a0\nFluconazol: \u00a0NRAD\u00a0(AUC\u00a0de\u00a0fluconazol \u00a0\nsin\u00a0cambios;\u00a0\u2191\u00a086%\u00a0AUC\u00a0ETR\u00a0\nVoriconazol: \u00a0\u2191\u00a036%\u00a0AUC\u00a0voriconazol; \u00a0\n\u219114%\u00a0AUC\u00a0ETR\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 119 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0\nEstatinas: \u00a0\u00a0 \u00a0\nCon\u00a0atorvastatina, \u00a0lovastatina \u00a0y\u00a0simvastatina, \u00a0\nmonitorizar \u00a0eficacia\u00a0estatina.\u00a0Con\u00a0fluvastatina \u00a0\ny\u00a0pravastatina \u00a0interacci\u00f3n \u00a0poco\u00a0probable\u00a0Se\u00a0han\u00a0descrito\u00a0reducciones \u00a0del\u00a058%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0\nsimvastatina, \u00a0del\u00a043%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0atorvastatina \u00a0y\u00a0\ndel\u00a040%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0pravastatina. \u00a0No\u00a0hay\u00a0datos\u00a0\npara\u00a0lovastatina \u00a0y\u00a0fluvastatina. \u00a0Algunos\u00a0pacientes \u00a0\npueden\u00a0requerir\u00a0aumento\u00a0de\u00a0dosis,\u00a0que\u00a0debe\u00a0\nrealizarse \u00a0de\u00a0forma\u00a0gradual.\u00a0\u00a0NRAD\u00a0(\u219337%\u00a0AUC\u00a0de\u00a0atorvastatina, \u00a0\n\u219127%\u00a0AUC\u00a02\u2010OH\u2010atorvastatina \u00a0).\u00a0\u00a0\nF\u00e1rmacos \u00a0empleados \u00a0\npara\u00a0tratar\u00a0la\u00a0\ninfluenza \u00a0Amantadina \u00a0/\u00a0oseltamivir \u00a0/\u00a0zanamivir: \u00a0te\u00f3ricamente \u00a0no\u00a0deben\u00a0esperarse \u00a0interacciones \u00a0\n\u00a0 \u00a0\u00a0\nInmunosupresores: \u00a0Posible\u00a0\u2193Cp\u00a0ciclosporina, \u00a0prednisona, \u00a0\ntacrolimus \u00a0y\u00a0sirolimus. \u00a0Monitorizar \u00a0\nniveles/eficacia \u00a0del\u00a0inmunosupresor. \u00a0La\u00a0dosis\u00a0\nde\u00a0ciclosporina \u00a0y\u00a0tacrolimus, \u00a0una\u00a0vez\u00a0ajustada,\u00a0\nse\u00a0mantiene \u00a0m\u00e1s\u00a0o\u00a0menos\u00a0constante \u00a0a\u00a0lo\u00a0largo\u00a0\ndel\u00a0tiempo.\u00a0En\u00a0pacientes \u00a0con\u00a0TOH,\u00a0la\u00a0dosis\u00a0de\u00a0\ntacrolimus \u00a0requerida \u00a0en\u00a0pacientes \u00a0tratados\u00a0\ncon\u00a0NVP\u00a0fue\u00a0similar\u00a0a\u00a0la\u00a0utilizada\u00a0en\u00a0VIH\u00a0\nnegativos. \u00a0Con\u00a0ciclosporina \u00a0una\u00a0vez\u00a0ajustada\u00a0la\u00a0dosis,\u00a0\u00e9sta\u00a0se\u00a0\nmantiene \u00a0m\u00e1s\u00a0o\u00a0menos\u00a0constante \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0\ntiempo.\u00a0Sin\u00a0embargo, \u00a0EFV\u00a0\u00a0redujo\u00a0de\u00a0forma\u00a0\nimportante \u00a0los\u00a0niveles\u00a0de\u00a0tacrolimus \u00a0en\u00a0pacientes \u00a0\ncon\u00a0TOH.\u00a0Con\u00a0el\u00a0resto,\u00a0te\u00f3ricamente \u00a0posible\u00a0\u2193Cp\u00a0\n(aunque\u00a0tambi\u00e9n\u00a0podr\u00eda\u00a0\u2191Cp)\u00a0de\u00a0prednisona \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0niveles/eficacia \u2010toxicidad\u00a0del\u00a0\ninmunosupresor. \u00a0No\u00a0hay\u00a0datos.\u00a0ETR\u00a0podr\u00eda\u00a0reducir\u00a0la\u00a0Cp\u00a0de\u00a0\nciclosporina, \u00a0tacrolimus \u00a0y\u00a0sirolimus\u00a0\n(monitorizar) \u00a0\nInterfer\u00f3n/ \u00a0Ribavirina \u00a0Ribavirina: \u00a0no\u00a0existe\u00a0evidencia \u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0no\u00a0nucle\u00f3sidos. \u00a0Interfer\u00f3n: \u00a0su\u00a0v\u00eda\u00a0de\u00a0\neliminaci\u00f3n \u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecida \u00a0as\u00ed\u00a0como\u00a0tampoco\u00a0su\u00a0posible\u00a0efecto\u00a0inhibidor\u00a0sobre\u00a0el\u00a0\ncitocromo \u00a0P\u2010450\u00a0(ha\u00a0mostrado \u00a0p.\u00a0ej.\u00a0\u2191Cp\u00a0de\u00a0teofilina\u00a0y\u00a0barbit\u00faricos). \u00a0No\u00a0hay\u00a0datos\u00a0con\u00a0respecto\u00a0a\u00a0\nposibles\u00a0interacciones \u00a0con\u00a0los\u00a0no\u00a0nucle\u00f3sidos. \u00a0Se\u00a0recomienda \u00a0una\u00a0monitorizaci\u00f3n \u00a0m\u00e1s\u00a0estrecha\u00a0de\u00a0\nlos\u00a0efectos\u00a0secundarios \u00a0a\u00a0nivel\u00a0de\u00a0SNC\u00a0con\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0EFV\u00a0\u00a0e\u00a0interfer\u00f3n. \u00a0\u00a0No\u00a0hay\u00a0datos.\u00a0Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0una\u00a0interacci\u00f3n \u00a0significativa \u00a0\nMetadona \u00a0\n\u00a0Posible\u00a0s\u00edndrome \u00a0abstinencia \u00a0\nPuede\u00a0requerir\u00a0\u2191\u00a0dosis\u00a0MT\u00a0del\u00a08\u00ba\u201010\u00ba\u00a0d\u00eda.\u00a0Posible\u00a0s\u00edndrome \u00a0abstinencia \u00a0\nPuede\u00a0requerir\u00a0\u2191\u00a0dosis\u00a0MT\u00a0del\u00a08\u00ba\u201010\u00ba\u00a0d\u00eda.\u00a0\nBuprenorfina \u00a0podr\u00eda\u00a0ser\u00a0una\u00a0alternativa \u00a0con\u00a0menor\u00a0\nriesgo\u00a0de\u00a0sd.\u00a0abstinencia \u00a0(datos\u00a0limitados). \u00a0\u00a0Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 120 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0\u00a0\nAntirretrovirales \u00a0IP\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u2010 IDV\u00a0\u219330%\u00a0AUC\u00a0IDV.\u00a0Valorar\u00a0\u2191\u00a01000\u00a0mg\u00a0c/8h\u00a0IDV\u00a0en\u00a0\nfunci\u00f3n\u00a0de\u00a0sus\u00a0Cp\u00a0(elevada\u00a0variabilidad \u00a0\ninterindividual) \u00a0\u00f3\u00a0usar\u00a0IDV/r\u00a0800/100\u00a0mg\u00a0c/12h.\u00a0\nNRAD\u00a0NVP\u00a0\u219331%\u00a0AUC\u00a0IDV\u00a0con\u00a0200\u00a0mg/d\u00eda\u00a0de\u00a0EFV.\u00a0\u00a0\u2191\u00a01000\u00a0\nmg\u00a0c/8h\u00a0IDV\u00a0\u00f3\u00a0usar\u00a0IDV/r\u00a0800/100\u00a0mg\u00a0c/12h.\u00a0\nNRAD\u00a0EFV\u00a0Evitar\u00a0el\u00a0uso\u00a0de\u00a0IDV\u00a0no\u00a0potenciado \u00a0con\u00a0ETR.\u00a0\nNo\u00a0hay\u00a0estudios\u00a0con\u00a0IDV/r.\u00a0\n\u00a0\n\u2010 RTV\u00a0\u00a0\nNRAD\u00a0\u00a0\nNRAD\u00a0(\u219118%\u00a0AUC\u00a0RTV)\u00a0NRAD\u00a0en\u00a0dosis\u00a0potenciaci\u00f3n. \u00a0\nContraindicado \u00a0con\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas\u00a0\n(\u219346%\u00a0AUC\u00a0ETV)\u00a0\u00a0\n\u2010 SQV\u00a0 No\u00a0recomendado \u00a0con\u00a0SQV\u00a0no\u00a0potenciado( \u219327%\u00a0\nAUC\u00a0SQV)1.\u00a0\u00a0\nNRAD\u00a0NVP\u00a0No\u00a0recomendado \u00a0con\u00a0SQV\u00a0no\u00a0potenciado \u00a0(\u219362%\u00a0\nAUC\u00a0SQV)2\u00a0NRAD\u00a0con\u00a0SQV\u00a0potenciado \u00a0\n\u00a0\n\u2010 NFV\u00a0\u00a0\nNRAD\u00a0Si\u00a0bien\u00a0los\u00a0estudios\u00a0en\u00a0voluntarios \u00a0sanos\u00a0no\u00a0\nmostraron \u00a0interacci\u00f3n, \u00a0un\u00a0estudio\u00a0en\u00a0pacientes \u00a0\nnaive\u00a0mostr\u00f3\u00a0a\u00a0las\u00a032\u00a0semanas\u00a0una\u00a0tendencia \u00a0no\u00a0\nsignificativa \u00a0a\u00a0\u2193Cm\u00e1x\u00a0y\u00a0AUC\u00a0NFV\u00a0\u00a0y\u00a0\u2193Cmin\u00a0NFV\u00a0\nsignificativa. \u00a0\u00a0\u00a0\nNo\u00a0hay\u00a0datos.\u00a0Asociaci\u00f3n \u00a0no\u00a0recomendada \u00a0\n\u2010 FPV\u00a0 \u00a0\nNRAD\u00a0(FPV/r\u00a0700/100\u00a0mg\u00a0c/12h)\u00a0\u00a0\nValorar\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0RTV\u00a0en\u00a0QD\u00a0(300\u00a0mg)\u00a0\nNRAD\u00a0(FPV/r\u00a0700/100\u00a0mg\u00a0c/12h)\u00a0\nValorar\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0RTV\u00a0en\u00a0QD\u00a0(300\u00a0mg)ETR\u00a0sin\u00a0cambios.\u00a0\u219169%\u00a0AUC\u00a0FPV\u00a0/r\u00a0\n(700/100\u00a0mg/12\u00a0h)(contrariamente \u00a0a\u00a0lo\u00a0\nesperado). \u00a0Considerar \u00a0reducci\u00f3n \u00a0de\u00a0dosis\u00a0\nde\u00a0FPV\u00a0(no\u00a0hay\u00a0informaci\u00f3n \u00a0suficiente \u00a0para\u00a0\nrecomendar \u00a0un\u00a0ajuste\u00a0de\u00a0dosis).\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 121 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0\n\u2010 LPV/r\u00a0\u219322%\u00a0AUC/\u219355%\u00a0Cmin\u00a0LPV.\u00a0Valorar\u00a0600/150\u00a0mg\u00a0\nc/12h\u00a0(variabilidad \u00a0interindividual \u00a0elevada.\u00a0Si\u00a0es\u00a0\nposible,\u00a0determinar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0LPV).\u00a0\u00a0\nNRAD\u00a0NVP\u00a0\n\u00a0\u219320\u201025%\u00a0AUC\u00a0LPV.\u00a0Valorar\u00a0600/150\u00a0mg\u00a0c/12h.\u00a0\n(variabilidad \u00a0interindividual \u00a0elevada.\u00a0Si\u00a0es\u00a0posible,\u00a0\ndeterminar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0LPV).\u00a0\u00a0\nNRAD\u00a0EFV\u00a0Formulaci\u00f3n \u00a0meltrex\u00a0de\u00a0LPV/r:\u00a0NRAD\u00a0(LPV\u00a0\nsin\u00a0cambios,\u00a0\u219335%\u00a0AUC\u00a0de\u00a0ETR)\u00a0\n\u2010 ATV/r\u00a0\u219333%\u00a0Cmin,\u00a0\u219360%\u00a0AUC\u00a0ATV.\u00a0No\u00a0se\u00a0recomienda \u00a0en\u00a0\npacientes \u00a0pretratados. \u00a0Ajuste\u00a0de\u00a0dosis\u00a0de\u00a0\u00a0ATV/r\u00a0en\u00a0\npacientes \u00a0naive\u00a0a\u00a0400/100\u00a0mg\u00a0c/24h.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0de\u00a0ATV.\u00a0\u219342%\u00a0Cmin\u00a0ATV.\u00a0No\u00a0se\u00a0recomienda \u00a0en\u00a0pacientes \u00a0\npretratados. \u00a0Ajuste\u00a0de\u00a0dosis\u00a0ATV/r\u00a0\u00a0en\u00a0pacientes \u00a0\nnaive\u00a0a\u00a0400/100\u00a0mg\u00a0/24h.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0de\u00a0ATV.\u00a0Utilizar\u00a0ATV/r\u00a0(\u219130%\u00a0AUC\u00a0ETR\u00a0y\u00a0\u219317%\u00a0\u00a0AUC\u00a0\nATV.\u00a0\n\u2010 TPV/r\u00a0\u00a0\nNRAD\u00a0\u00a0\nNRAD\u00a0\u00a0\nAsociaci\u00f3n \u00a0contraindicada \u00a0\u00a0(\u219376%\u00a0AUC\u00a0ETR\u00a0\ny\u00a0\u219118%\u00a0el\u00a0AUC\u00a0de\u00a0TPV)\u00a0\n\u2010 Darunavir/ \u00a0\nritonavir\u00a0DRV/r\u00a0600/100\u00a0mg/12h:\u00a0NRAD\u00a0 DRV/r\u00a0600/100\u00a0mg/12h:\u00a0NRAD\u00a0(\u219121%\u00a0AUC\u00a0EFV\u00a0y\u00a0\n\u219313%\u00a0\u00a0AUC\u00a0DRV)\u00a0\nDRV/r\u00a0900/100\u00a0mg/24h:\u00a0evitar\u00a0o\u00a0monitorizar \u00a0\nestrechamente \u00a0niveles\u00a0de\u00a0DRV.\u00a0\u219340%\u00a0AUC\u00a0\nDRV,\u219357%\u00a0Cmin\u00a0DRV.\u00a0\u00a0DRV/r\u00a0600/100\u00a0mg/12h:\u00a0NRAD\u00a0(\u219337%\u00a0AUC\u00a0\nETR\u00a0y\u00a0\u21916%\u00a0\u00a0AUC\u00a0DRV)\u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\n\u2010 RAL\u00a0 NRAD\u00a0 NRAD\u00a0(\u219336%\u00a0AUC\u00a0RAL)\u00a0 NRAD\u00a0(\u219310%\u00a0AUC\u00a0RAL,\u00a0\u2193\u00a034%\u00a0Cmin\u00a0de\u00a0RAL).\u00a0\nDebido\u00a0a\u00a0la\u00a0amplia\u00a0variabilidad \u00a0de\u00a0la\u00a0PK\u00a0de\u00a0\nRAL\u00a0se\u00a0han\u00a0descrito\u00a0Cmin\u00a0<CI95\u00a0(14,6\u00a0ng/mL)\u00a0\nen\u00a0algunos\u00a0pacientes. \u00a0Sin\u00a0embargo, \u00a0\u00a0los\u00a0\nbuenos\u00a0resultados \u00a0cl\u00ednicos\u00a0apoyan\u00a0el\u00a0uso\u00a0de\u00a0\nRAL+ETR+DRV/r \u00a0en\u00a0pacientes \u00a0pretratados \u00a0\n\u00a0(ANRS\u00a0139\u00a0TRIO).\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 122 \u00a0\nNombre\u00a0gen\u00e9rico Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0\n\u00a0\nInhibidores \u00a0del\u00a0correceptor \u00a0CCR5\u00a0\n\u00a0\nMVC\u00a0 NRAD En ausencia de inhibidores enzim\u00e1ticos potentes \ndebe aumentarse la dosis de MVC a 600 mg \nc/12h. Si se coadministran inhibdores (ej. IP/r) la \ndosis de MVC ser\u00e1 de 150 mg/12h 3. En ausencia de inhibidores enzim\u00e1ticos \npotentes debe aumentarse la dosis de \nMVC a 600 mg c/12h. Si se \ncoadministran inhibdores (ej. IP/r) la dosis de MVC ser\u00e1 de 150 mg/12h \n3. \n\u00a0\n\u2010 Otros\u00a0\n\u00a0\n\u00a0 \nBosentan: no modific\u00f3 los niveles de NVP \n(datos de un paciente) \n \nNVP puede \u2193 Cp de los f\u00e1rmacos \nmetabolizados a trav\u00e9s del CYP3A44. En \ncambio, a diferencia de lo esperado, NVP \naument\u00f3 un 56% el AUC de lumefantrina, sin \nque se observaran cambios en el intervalo \nQTcF.  \nAtovacuona / proguanilo: \u2193 68% AUC atovacuona \ny \u2193 58% AUC de proguanilo. Valorar aumento de \ndosis (datos limitados procedentes de la comparaci\u00f3n de datos de pacientes con datos \nhist\u00f3ricos de voluntarios sanos sin TARV \nPuede \u2191 Cp de los f\u00e1rmacos metabolizados a \ntrav\u00e9s del CYP3A4\n4 aunque es m\u00e1s probable \nque las \u2193.  Puede \u2191 Cp de los f\u00e1rmacos \nmetabolizados a trav\u00e9s del CYP3A44 \naunque es m\u00e1s probable que las \u2193.  \nSildenafilo: ( \u219341\u201357% AUC sildenafilo) \n(puede requerir aumento de dosis) \nParoxetina: ausencia de interacci\u00f3n. \nDigoxina: ausencia de interacciones \n\u00a0\nAUC\u00a0:\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva\u00a0de\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0frente\u00a0al\u00a0tiempo\u00a0(exposici\u00f3n \u00a0al\u00a0f\u00e1rmaco); \u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraci\u00f3n \u00a0\n\u00a0plasm\u00e1tica; \u00a0NRAD:\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0QD:\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda;\u00a0TDM:\u00a0monitorizaci\u00f3n \u00a0de\u00a0niveles\u00a0plasm\u00e1ticos; \u00a0TID:\u00a0tres\u00a0veces\u00a0al\u00a0d\u00eda.\u00a0\n*\u00a0Atripla\u00ae:\u00a0\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0tenofovir\u00a0300\u00a0mg,\u00a0emtricitabina \u00a0200\u00a0mg\u00a0y\u00a0EFV\u00a0600\u00a0mg.\u00a0\na\u00a0Expresado \u00a0como\u00a0media\u00a0\u00b1\u00a0DE\u00a0si\u00a0no\u00a0se\u00a0indica\u00a0lo\u00a0contrario\u00a0\n1\u00a0Saquinavir \u00a0en\u00a0c\u00e1psulas\u00a0duras\u00a0(Invirase\u00ae) \u00a0puede\u00a0asociarse \u00a0con\u00a0NVP\u00a0si\u00a0se\u00a0combina\u00a0con\u00a0ritonavir\u00a0(SQV/RTV \u00a01000/100 \u00a0mg\u00a0c/12h),\u00a0en\u00a0cuyo\u00a0caso\u00a0\u00a0\n\u00a0\u00a0datos\u00a0preliminares \u00a0han\u00a0mostrado \u00a0buenos\u00a0resultados. \u00a0\u00a0\n2\u00a0Saquinavir \u00a0puede\u00a0asociarse \u00a0con\u00a0la\u00a0dosis\u00a0habitual\u00a0de\u00a0EFV\u00a0si\u00a0se\u00a0combina\u00a0con\u00a0ritonavir\u00a0(1000/100 \u2010200\u00a0mg\u00a0c/12h).\u00a0\n3En\u00a0presencia \u00a0de\u00a0inhibidores \u00a0enzim\u00e1ticos \u00a0potentes\u00a0como\u00a0los\u00a0IP\u00a0(excepto\u00a0TPV/r\u00a0y\u00a0FPV/r),\u00a0antif\u00fangicos \u00a0imidaz\u00f3licos \u00a0(ketoconazol, \u00a0itraconazol), \u00a0macr\u00f3lidos \u00a0(eritromicina, \u00a0\nclaritromicina, \u00a0telitromicina) \u00a0o\u00a0nefazodona \u00a0el\u00a0efecto\u00a0inhibidor\u00a0predomina \u00a0sobre\u00a0el\u00a0efecto\u00a0inductor\u00a0enzim\u00e1tico \u00a0y\u00a0por\u00a0lo\u00a0tanto,\u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0\n150\u00a0mg\u00a0c/12h.\u00a0Maraviroc \u00a0no\u00a0debe\u00a0combinarse \u00a0con\u00a0dos\u00a0inductores \u00a0potentes\u00a0p.\u00a0ej.\u00a0rifampicina \u00a0+\u00a0efavrienz. \u00a0\n4\u00a0Principales \u00a0f\u00e1rmacos\u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A4:\u00a0alprazolam, \u00a0amiodarona, \u00a0amlodipino, \u00a0amprenavir, \u00a0ciclofosfamida, \u00a0\u00a0\nciclosporina, \u00a0clonacepam, \u00a0\u00a0\u00a0cloracepato, \u00a0dexametasona, \u00a0diazepam, \u00a0disopiramida, \u00a0estazolam, \u00a0etionamida, \u00a0fentanilo, \u00a0finasterida, \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 123 \u00a0fluracepam, \u00a0glipizida,\u00a0itraconazol, \u00a0lacidipino, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0meperidina, \u00a0nicardipino, \u00a0nifedipino, \u00a0nimodipino, \u00a0nitrendipino, \u00a0\u00a0\nprednisona, \u00a0quinidina, \u00a0sertralina, \u00a0sildenafilo, \u00a0vardenafilo, \u00a0tadalafilo, \u00a0tacrolimus, \u00a0vincristina \u00a0y\u00a0\u00a0\u00a0zolpidem. \u00a0\nCategorias \u00a0seguridad \u00a0embarazo \u00a0(FDA):\u00a0A=\u00a0ausencia\u00a0de\u00a0riesgos\u00a0para\u00a0el\u00a0feto;\u00a0B=\u00a0no\u00a0teratogenicidad \u00a0en\u00a0animales, \u00a0falta\u00a0de\u00a0estudios\u00a0en\u00a0humanos; \u00a0C=\u00a0no\u00a0datos\u00a0de\u00a0seguridad \u00a0\n\u00a0en\u00a0embarazadas \u00a0y\u00a0los\u00a0estudios\u00a0en\u00a0animales\u00a0muestran \u00a0toxicidad\u00a0fetal\u00a0o\u00a0no\u00a0se\u00a0han\u00a0realizado\u00a0y\u00a0no\u00a0deben\u00a0utilizarse\u00a0dichos\u00a0f\u00e1rmacos, \u00a0a\u00a0menos\u00a0que\u00a0el\u00a0beneficio \u00a0potencial \u00a0supere\u00a0\u00a0\n\u00a0\u00a0el\u00a0posible\u00a0riesgo\u00a0fetal.\u00a0\n\u03c9\u00a0Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0europea.\u00a0EPARS:\u00a0European \u00a0Public\u00a0Assessment \u00a0Reports.\u00a0Disponble \u00a0en:\u00a0\nhttp://www.ema.europa.eu/ema/index.jsp?curl =pages/includes/medicines/medicines_landing _page.jsp&murl=menus/m edicines/medicines. jsp&mid=\u00a0Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n\u2126Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0americana \u00a0(fuentes:\u00a0FDA\u00a0and\u00a0First\u00a0Data\u00a0Bank,\u00a0Inc).\u00a0Disponible \u00a0en: http://www.rxlist.com/drugs/alpha_a.htm \u00a0.Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n&Guardiola \u00a0JM,\u00a0Soriano\u00a0V\u00a0(Eds).\u00a0Tratamiento \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u2010SIDA.\u00a0F\u00e1rmacos \u00a0y\u00a0combinaciones. \u00a0D\u00e9cima\u00a0Edidi\u00f3n.\u00a0Barcelona: \u00a0Publicaciones \u00a0Permanyer \u00a02007.\u00a0\n\u00a0\n\u00a0\nNOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0\nf\u00e1rmacos\u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 124 Tabla\u00a07.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0(1\u00aa\u00a0parte):\u00a0indinavir, \u00a0ritonavir, \u00a0saquinavir, \u00a0nelfinavir \u00a0y\u00a0fosamprenavir \u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir \u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\n\u00a0\nNombre\u00a0comercial \u00a0\n\u00a0Crixivan\u00ae\u00a0 Norvir\u00ae\u00a0\u00a0\nInvirase\u00ae\u00a0\n\u00a0Viracept\u00ae\u00a0 Telzir\u00ae\u00a0\nDosis\u00a0\u00a0\n\u00a0\n\u00a0Recomendaci\u00f3n \u00a0\n\u00a0800\u00a0mg\u00a0TID\u00a0\nIDV/r\u00a0800/100\u00a0BID\u00a0\n\u00a0Si\u00a0no\u00a0potenciado, \u00a0debe\u00a0\ntomarse\u00a0con\u00a0est\u00f3mago \u00a0\nvac\u00edo\u00a0(restricci\u00f3n \u00a0diet\u00e9tica) \u00a0\n\u00a0Ingesta\u00a0abundante \u00a0de\u00a0\nl\u00edquidos\u00a0no\u00a0carb\u00f3nicos \u00a0\n\u00a0Como\u00a0potenciador \u00a0de\u00a0otros\u00a0\nIP\u00a0:\u00a0100\u00a0\u00f3\u00a0200\u00a0mg\u00a0con\u00a0cada\u00a0\ndosis\u00a0de\u00a0IP\u00a0\nComo\u00a0IP\u00a0(600\u00a0mg\u00a0BID)\u00a0se\u00a0\ndesaconseja \u00a0\n\u00a0\u00a0\u00a0SQV/r\u00a01000/100 \u00a0BID\n\u00a0\n\u00a0\nTomar\u00a0con\u00a0comida\u00a0grasa.\u00a0\u00a0750\u00a0mg\u00a0TID\u00a0\u00f3\u00a0\n1250\u00a0mg\u00a0BID\u00a0\n\u00a0Tomar\u00a0con\u00a0comida\u00a0grasa\u00a0FPV/r\u00a0\u00a0700/100\u00a0mg\u00a0c/12h\u00a0\u00a0\n\u00a0\nCon\u00a0\u00f3\u00a0sin\u00a0alimentos \u00a0\nPresentaci\u00f3n \u00a0comercial \u00a0c\u00e1ps.\u00a0200\u00a0y\u00a0400\u00a0mg\u00a0 sol.\u00a0oral\u00a080\u00a0mg/ml\u00a0\nc\u00e1ps.\u00a0100\u00a0mg\u00a0\u00a0\ncomp\u00a0100\u00a0mg\u00a0pr\u00f3xima\u00a0\ncomercializaci\u00f3n \u00a0comp\u00a0200\u00a0mg\u00a0\ncomp\u00a0500\u00a0mg\u00a0\n\u00a0comp\u00a0500\u00a0mg\u00a0\npolvo\u00a0(1\u00a0cuch\u00a01g\u00a0=50\u00a0mg\u00a0de\u00a0\nNFV)\u00a0comp\u00a0700\u00a0mg\u00a0\nsuspensi\u00f3n \u00a0oral\u00a050\u00a0mg/mL\u00a0\nBiodisponibilidad \u00a0Oral\u00a0\n\u00a065\u00a0%\u00a0(IC\u00a090\u00a0%,\u00a0\n58\u00a0a72\u00a0%),\u00a0tras\u00a0dosis\u00a0\u00fanica\u00a0\nde\u00a0800\u00a0mg.\u00a0\u03c9\u00a0No\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0\nbiodisponibilidad \u00a0absoluta\u00a0en\u00a0\nhumanos\u00a0\u03c9\u00a04%\u00a0(1\u20109%)c\u00a0en\u00a0ausencia\u00a0de\u00a0\nRTV\u00a0\u03c9\u00a0\nNo\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0\nbiodisponibilidad \u00a0absoluta\u00a0\nde\u00a0SQV\u00a0potenciado \u00a0con\u00a0\nRTV\u00a0en\u00a0humanos\u00a0\u03c9\u00a0No\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0\nbiodisponibilidad \u00a0absoluta\u00a0\nen\u00a0humanos\u00a0\u03c9\u00a0No\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0\nbiodisponibilidad \u00a0absoluta\u00a0\nen\u00a0humanos\u00a0\u03c9\u00a0\nEfecto\u00a0de\u00a0los\u00a0alimentos \u00a0No\u00a0potenciado \u00a0y\u00a0en\u00a0\npresencia \u00a0de\u00a0alimentos \u00a0\ngrasos\u00a0el\u00a0AUC\u00a0se\u00a0reduce\u00a0un\u00a0\n77%,\u00a0\u00a0por\u00a0lo\u00a0que\u00a0debe\u00a0\nadministrarse \u00a0en\u00a0ayunas\u00a0o\u00a0\ncon\u00a0una\u00a0comida\u00a0ligera\u00a0de\u00a0\nbajo\u00a0contenido \u00a0graso.\u00a0\nCuando\u00a0se\u00a0administra \u00a0\npotenciado \u00a0con\u00a0ritonavir\u00a0\npuede\u00a0tomarse\u00a0junto\u00a0con\u00a0En\u00a0presencia \u00a0de\u00a0alimentos \u00a0se\u00a0\nreduce\u00a0el\u00a0AUC\u00a0entre\u00a0un\u00a021\u00a0y\u00a0\nun\u00a023%.\u00a0\u2126\u00a0\nEl\u00a0sabor\u00a0amargo\u00a0de\u00a0Norvir\u00a0\nsoluci\u00f3n\u00a0puede\u00a0enmascararse \u00a0\nsi\u00a0se\u00a0mezcla\u00a0con\u00a0un\u00a0batido\u00a0de\u00a0\nchocolate.\u00a0\u03c9\u00a0En\u00a0voluntarios \u00a0sanos,\u00a0el\u00a0\nAUC\u00a0aument\u00f3\u00a0m\u00e1s\u00a0de\u00a06\u00a0\nveces\u00a0al\u00a0tomarlo\u00a0con\u00a0una\u00a0\ncomida\u00a0grasa,\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0su\u00a0\ningesta\u00a0en\u00a0ayunas.\u00a0Se\u00a0\nrecomienda \u00a0tomar\u00a0\nnelfinavir \u00a0dentro\u00a0de\u00a0las\u00a02h\u00a0\ndespu\u00e9s\u00a0de\u00a0comer.\u00a0\u2126\u00a0En\u00a0presencia \u00a0de\u00a0alimentos \u00a0\naumenta\u00a0el\u00a0AUC\u00a0entre\u00a02\u00a0y\u00a05\u00a0\nveces\u00a0(aumento \u00a0mayor\u00a0\ncuanto\u00a0mayor\u00a0contenido \u00a0\ncal\u00f3rico),\u00a0por\u00a0lo\u00a0que\u00a0\nnelfinavir \u00a0debe\u00a0\nadministrarse \u00a0con\u00a0comida.\u00a0\u2126Comprimidos: \u00a0la\u00a0\nadministraci\u00f3n \u00a0con\u00a0\nalimentos \u00a0no\u00a0modific\u00f3\u00a0\nsignificativamente \u00a0el\u00a0AUC,\u00a0\npor\u00a0lo\u00a0que\u00a0puede\u00a0ingerirse\u00a0\ncon\u00a0o\u00a0sin\u00a0alimentos. \u00a0\nSoluci\u00f3n\u00a0oral:\u00a0en\u00a0presencia \u00a0\nde\u00a0alimentos \u00a0el\u00a0AUC\u00a0se\u00a0\nredujo\u00a0un\u00a028%\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0su\u00a0ingesta\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 125 las\u00a0comidas.\u00a0\u2126\u00a0 en\u00a0ayunas.\u00a0En\u00a0adultos,\u00a0se\u00a0\nrecomienda \u00a0tomar\u00a0la\u00a0\nsoluci\u00f3n\u00a0en\u00a0ayunas\u00a0y\u00a0en\u00a0los\u00a0\nni\u00f1os\u00a0con\u00a0alimentos \u00a0porque\u00a0\nmejora\u00a0la\u00a0tolerabilidad.\u00a0\u2126\u00a0\nSemivida \u00a0plasm\u00e1tica \u00a0 1,8\u00a0\u00b1\u00a00,4\u00a0horasa,\u00a0\u03c9\u00a0 \u00a05\u00a0horas\u00a0(100\u00a0mg/24h)\u00a0\u03c9\u00a0\n\u00a05\u00a0horas\u00a0(100\u00a0mg/12h)\u00a0\u03c9\u00a0\n\u00a04\u00a0horas\u00a0(200\u00a0mg/24h)\u00a0\u03c9\u00a0\n\u00a08\u00a0horas\u00a0(200\u00a0mg/12h)\u00a0\u03c9\u00a07\u00a0horas\u00a0\u03c9\u00a0 3,5\u20105\u00a0horas\u00a0\u03c9\u00a0 7,7\u00a0horas\u00a0(FPV)\u00a0\u03c9\u00a0\n15\u00a0\u2013\u00a023\u00a0horas\u00a0(FPV/r)\u00a0\u03c9\u00a0\nCmax\u00a0\n\u00a0\u00a0\u00a0\n\u00a011144\u00a0(IC\u00a090%\u00a0=\u00a09192\u00a0a\u00a0\n13512)\u00a0nanoM\u00a0(=7,9\u00a0\nmicrog/mL) \u00a0con\u00a0IDV\u00a0800\u00a0\nmg/8h\u00a0\u03c9\u00a0\n19001\u00a0(IC\u00a090%\u00a0=\u00a017538\u00a0a\u00a0\n20588)\u00a0nanoM\u00a0(=13,5\u00a0\nmicrog/mL) \u00a0con\u00a0IDV/r\u00a0\n800/100\u00a0mg/12h\u00a0\u03c9\u00a0En\u00a0VIH+:\u00a0\n0,84\u00a0\u00b1\u00a00,39\u00a0microg/mla\u00a0(100\u00a0\nmg/24h)\u00a0\u03c9\u00a0\n0,89\u00a0microg/ml \u00a0(100\u00a0mg/12h)\n3,4\u00a0\u00b1\u00a01,3\u00a0microg/mla\u00a0(200\u00a0\nmg/24h)\u00a0\u03c9\u00a0\n4,5\u00a0\u00b1\u00a01,3\u00a0microg/mla\u00a0(200\u00a0\nmg/12h)\u00a0\u03c9\u00a0\u00a0En\u00a0VIH+:\u00a0\n5208\u00a0nanog/ml \u00a0(1.536\u2010\n14.369)c,\u00a0(SQV/r\u00a01000/100 \u00a0\nmg/12h\u00a0con\u00a0comida\u00a0rica\u00a0\nen\u00a0grasa)\u00a0\u03c9\u00a0\n\u00a03,0\u00a0\u00b1\u00a01,6\u00a0microg/ml \u00a0(750\u00a0\nmg/8h)\u00a0\u03c9\u00a0\n4,0\u00a0\u00b1\u00a00,8\u00a0microg/ml \u00a0(1250\u00a0\nmg/12h)\u00a0\u03c9\u00a0\n\u00a0FPV/r\u00a0700/100\u00a0mg\u00a0c/12h:\u00a0\n6,08\u00a0microg/ml  (IC95%:\u00a0\n5,38\u00a0a\u00a06,86)\u00a0\u03c9\u00a0\nFPV/r\u00a01400/100 \u00a0mg\u00a0c/24h:\u00a0\n7,93\u00a0microg/ml \u00a0(IC95%:7,25 \u00a0\na\u00a08,68)\u00a0\u2126\u00a0\nFPV/r\u00a01400/200 \u00a0mg\u00a0c/24h:\u00a0\n7,24microg/ml \u00a0(IC95%:6,32 \u00a0\na\u00a08,28)\u00a0\u2126\u00a0\nCmin\u00a0\n\u00a0\u00a0211\u00a0(IC\u00a090%\u00a0=\u00a0163\u00a0a\u00a0274)\u00a0\nnM\u00a0(0,15\u00a0microg/mL), \u00a0con\u00a0\nIDV\u00a0800\u00a0mg/8h\u00a0\u03c9\u00a0\n2274\u00a0(IC90%\u00a0=\u00a01701\u00a0a\u00a03042)\u00a0\nnM\u00a0(=1,6\u00a0microg/mL, \u00a0con\u00a0\nIDV/r\u00a0800/100\u00a0mg/12h\u00a0\u03c9\u00a0En\u00a0VIH+:\u00a0\n0,08\u00a0\u00b1\u00a00,04\u00a0microg/mla\u00a0(100\u00a0\nmg/24h)\u00a0\u03c9\u00a0\n0,22\u00a0microg/ml \u00a0(100\u00a0mg/12h)\n\u00a00,16\u00a0\u00b1\u00a00,10\u00a0microg/mla\u00a0(200\u00a0\nmg/24h)\u00a0\u03c9\u00a0\n\u00a00,6\u00a0\u00b1\u00a00,2\u00a0microg/mla\u00a0(200\u00a0\nmg/12h)\u00a0\u03c9\u00a0\nLas\u00a0Cmin\u00a0descienden \u00a0con\u00a0el\u00a0\ntiempo,\u00a0posiblemente \u00a0debido\u00a0\na\u00a0la\u00a0inducci\u00f3n \u00a0\nenzim\u00e1tica, \u00a0pero\u00a0parecen\u00a0\nestabilizarse \u00a0al\u00a0final\u00a0de\u00a02\u00a0\nsemanas.\u00a0\u03c9\u00a0\u00a0En\u00a0VIH+:\u00a0\n1179\u00a0nanog/ml \u00a0(334\u2010\n5.176)c\u00a0(SQV/r\u00a01000/100 \u00a0\nmg/12h\u00a0con\u00a0comida\u00a0rica\u00a0\nen\u00a0grasa)\u00a0\u03c9\u00a01,4\u00a0\u00b1\u00a00,6\u00a0microg/ml \u00a0con\u00a0la\u00a0\ndosis\u00a0de\u00a0la\u00a0ma\u00f1ana\u00a0\u00a0y\u00a01,0\u00a0\u00b1\u00a0\n0,5\u00a0microg/ml \u00a0con\u00a0la\u00a0de\u00a0la\u00a0\ntarde\u00a0(750\u00a0mg/8h)\u00a0\u03c9\u00a0\n2,2\u00a0\u00b1\u00a01,3\u00a0microg/ml \u00a0con\u00a0la\u00a0\ndosis\u00a0de\u00a0la\u00a0ma\u00f1ana\u00a0y\u00a00,7\u00a0\u00b1\u00a0\n0,4\u00a0microg/ml \u00a0con\u00a0la\u00a0de\u00a0la\u00a0\ntarde.\u00a0\u03c9\u00a0(1250\u00a0mg/12h)\u00a0\u03c9\u00a0\u00a0\nFPV/r\u00a0700/100\u00a0mg\u00a0c/12h:\u00a0\n2,12\u00a0microg/ml \u00a0(IC95%:1,77 \u00a0\na\u00a02,54)\u00a0\u03c9\u00a0\nFPV/r\u00a01400/100 \u00a0mg\u00a0c/24h:\u00a0\n0,86\u00a0microg/ml \u00a0(IC95%:0,74 \u00a0\na\u00a01,01)\u00a0\u2126\u00a0\nFPV/r\u00a01400/200 \u00a0mg\u00a0c/24h:\u00a0\n1,45\u00a0microg/ml \u00a0(IC95%:1,16 \u00a0\na\u00a01,81)\u00a0\u2126\u00a0\nAUC\u00a0 AUC0\u20108h\u00a0de\u00a0\n27813\u00a0nanoM*h \u00a0IC\u00a090%\u00a0=\u00a0\n22185\u00a0a\u00a034869)\u00a0(=19803\u00a0\nnanog*h/mL)(con \u00a0IDV\u00a0800\u00a0En\u00a0VIH+:\u00a0\nAUC24h\u00a06,6\u00a0\u00b1\u00a02,4\u00a0microg.h/mla\u00a0\n(100\u00a0mg/24h)\u00a0\u03c9\u00a0\nAUC12h\u00a06,2\u00a0microg.h/mla\u00a0(100\u00a0En\u00a0VIH+:\u00a0\nAUC0\u201012h\u00a0\u00a034926\u00a0\nnanog\u2219h/ml\u00a0(11826\u2010\n105992)c\u00a0(SQV/r\u00a01000/100 \u00a0AUC24h\u00a043,6\u00a0\u00b1\u00a017,8\u00a0\nmicrog\u2219h/ml\u00a0(750\u00a0mg/8h)\u00a0\u03c9\u00a0\nAUC24h\u00a052,8\u00a0\u00b1\u00a015,7\u00a0\nmicrog\u001fh/ml \u00a01250\u00a0FPV/r\u00a0700/100\u00a0mg\u00a0c/12h:\u00a0\nAUC0\u201012h\u00a039,6\u00a0(IC95%:34,5 \u00a0a\u00a0\n45,3)\u00a0microg\u00a0.h.\u00a0/ml\u00a0\u03c9\u00a0\nFPV/r\u00a01400/100 \u00a0mg\u00a0c/24h:\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 126 mg/8h.\u00a0\u03c9\u00a0\n116067\u00a0nanoM*h \u00a0(IC90%\u00a0=\u00a0\n101680\u00a0a\u00a0132490)\u00a0(=82639\u00a0\nnanog*h/mL)( \u00a0con\u00a0IDV/r\u00a0\n800/100\u00a0mg/12h.\u00a0\u03c9\u00a0mg/12h)\u00a0\u03c9\u00a0\nAUC24h\u00a020,0\u00a0\u00b1\u00a05,6\u00a0\nmicrog.h/mla\u00a0(200\u00a0mg/24h)\u00a0\u03c9\u00a0\nAUC12h\u00a021,92\u00a0\u00b1\u00a06,48\u00a0\nmicrog.h/mla\u00a0(200\u00a0mg/12h)\u00a0\u03c9\u00a0mg/12h\u00a0con\u00a0comida\u00a0rica\u00a0\nen\u00a0grasa)\u00a0\u03c9\u00a0mg/12h)\u03c9\u00a0 AUC0\u201024h\u00a066,4\u00a0microg.h/mL \u00a0\n(IC95%:61,1 \u00a0a72,1)\u00a0\u2126\u00a0\nFPV/r\u00a01400/200 \u00a0mg\u00a0c/24h:\u00a0\nAUC0\u201024h\u00a069,4\u00a0microg.h/mL \u00a0\n(IC95%:59,7 \u00a0a\u00a080,8)\u00a0\u2126\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 127 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir \u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\nCI50/90/95\u00a0frente\u00a0a\u00a0VIH\u20101\u00a0in\u00a0\nvitro\u00a0\n\u00a0CI95:\u00a050\u2010100\u00a0nanoM\u00a0\u03c9\u00a0\n(=35\u201071\u00a0nanog/mL) \u00a0\n\u00a0\u2010\u2010\u00a0\n\u00a0CI50:\u00a01\u201010\u00a0nM\u00a0\u03c9\u00a0(=0,76\u20107,6\u00a0\nnanog/mL) \u00a0\nCI50\u00a0ajustada\u00a0al\u00a0suero\u00a0(50\u00a0%\u00a0\nsuero\u00a0humano)\u00a025\u2010250\u00a0nM\u00a0\n(=19,2\u2010192\u00a0nanog/mL)\u00a0\n\u00a0CI90:\u00a05\u201050\u00a0nM\u00a0\u03c9(=3,8\u201038\u00a0\nnanog/mL) \u00a0CI95:\u00a058\u00a0nM\u00a0(7\u00a0\u2010\u00a0111\u00a0nM)c,\u00a0\u03c9\u00a0\n(=38,5\u00a0nanog/mL) \u00a0\n\u00a0CI50\u00a0entre\u00a00,012\u00a0a\u00a00,08\u00a0\u00a0\nmicroM\u00a0en\u00a0c\u00e9lulas\u00a0con\u00a0\ninfecci\u00f3n\u00a0aguda\u00a0y\u00a00,41\u00a0\nmicroM\u00a0en\u00a0c\u00e9lulas\u00a0con\u00a0\ninfecci\u00f3n\u00a0cr\u00f3nica\u00a0\u03c9\u00a0\nActividad \u00a0\n\u00a0VIH\u20101.2\u00a0\u03c9\u00a0 VIH\u20101,2,\u00a0aunque\u00a0en\u00a0la\u00a0\nactualidad \u00a0se\u00a0utiliza\u00a0como\u00a0\npotenciador \u00a0\nfarmacocin\u00e9tico.\u00a0\u03c9\u00a0VIH\u20101,2\u00a0\u03c9\u00a0 VIH\u20101,2\u00a0\u03c9\u00a0 VIH\u20101,2\u00a0\u03c9,\u00a0\u2126\u00a0\nPenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\n(LCR:plasma) \u00a0No\u00a0hay\u00a0datos\u00a0\u03c9\u00a0\nIDV\u00a0grado\u00a03\u00a0\u00a0e\u00a0IDV/r\u00a0\u00a0grado\u00a0\n4\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0del\u00a0\nestudio\u00a0CHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0\nmenor\u00a0a\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0\nPoster\u00a0430.\u00a0Croi\u00a02010)\u00a0Grado\u00a01\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0\nLCR\u00a0seg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0\na\u00a04,\u00a0menor\u00a0a\u00a0mayor)\u00a0\n(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0Insignificante \u00a0con\u00a0Invirase\u00a0\n600\u00a0mg/8h.\u00a0\u03c9\u00a0\nSQV\u00b1RTV: \u00a0grado\u00a01\u00a0de\u00a0\npenetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0\nla\u00a0clasificaci\u00f3n \u00a0del\u00a0estudio\u00a0\nCHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0\n430.\u00a0Croi\u00a02010)\u00a0Grado\u00a01\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0\nLCR\u00a0seg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0\na\u00a04,\u00a0menor\u00a0a\u00a0mayor)\u00a0\n(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0Penetraci\u00f3n \u00a0insignificante\u00a0\u03c9\u00a0\nGrado\u00a02\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0\nLCR\u00a0seg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0\na\u00a04,\u00a0menor\u00a0a\u00a0mayor)\u00a0\n(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a0\n2010)\u00a0\nMetabolizaci\u00f3n \u00a0 CYP3A4\u00a0 CYP3A4\u00a0 CYP3A4\u00a0 CYP3A4\u00a0 CYP3A4\u00a0\n\u00a0\nEfectos\u00a0\nAdversos \u00a0Nefrolitiasis \u00a0\nIntolerancia \u00a0G\u2010I.\u00a0\nHiperbilirrubinemia \u00a0\nHiperglucemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\nPosible\u00a0aumento\u00a0del\u00a0\nsangrado \u00a0en\u00a0hemof\u00edlicos \u00a0(En\u00a0dosis\u00a0reducidas \u00a0la\u00a0\nprevalencia \u00a0de\u00a0los\u00a0efectos\u00a0\nadversos\u00a0es\u00a0muy\u00a0baja)\u00a0\nIntolerancia \u00a0G\u2010I\u00a0\n(v\u00f3mitos, \u00a0diarrea)\u00a0\nParestesias \u00a0orales\u00a0\nHepatitis\u00a0\nHiperglucemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\n\u2010 Posible\u00a0aumento\u00a0del\u00a0\nsangrado \u00a0en\u00a0hemof\u00edlicos \u00a0\n\u00a0Intolerancia \u00a0G\u2010I\u00a0\n(diarrea)\u00a0\nCefalea\u00a0\n\u2191\u00a0transaminasas \u00a0\nHiperglucemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\nPosible\u00a0aumento\u00a0del\u00a0\nsangrado \u00a0en\u00a0hemof\u00edlicos \u00a0Diarrea\u00a0\nHiperglucemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\nPosible\u00a0aumento\u00a0del\u00a0\nsangrado \u00a0en\u00a0hemof\u00edlicos \u00a0Intolerancia \u00a0G\u2010I\u00a0\n(diarrea)\u00a0\nExantema \u00a0\nCefalea\u00a0\nHiperglucemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\nPosible\u00a0aumento\u00a0del\u00a0\nsangrado \u00a0en\u00a0hemof\u00edlicos \u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 128 \u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir \u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\n\u00a0\nInteracciones \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\n\u00a0\nAsociaciones \u00a0\ncontraindicadas \u00a0Alfuzosina \u00a0\nAmiodarona \u00a0\nAstemizol \u00a0\nAtazanavir \u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0\nhep\u00e1tica) \u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0fluvastatina \u00a0\ny\u00a0pravastatina) \u00a0\u00a0\nCisaprida\u00a0\nDeriv.\u00a0Ergotamina \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0\nJuan)\u00a0\nLumefantrina \u00a0\nMidazolam \u00a0oral10\u00a0\nPimozida\u00a0\nRifampicina \u00a0\nSalmeterol \u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0\npulmonar) \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam \u00a0\n\u00a0Alfuzosina \u00a0\nAmiodarona \u00a0\nAnticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nCisaprida\u00a0\nCloracepato \u00a0\nClozapina \u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0\nhep\u00e1tica) \u00a0\nDextropropoxif. \u00a0\nDiacepam \u00a0\nDeriv.\u00a0ergotamina \u00a0\nDisulfiram \u00a0\nEncainida \u00a0\nEstatinas\u00a0(excepto\u00a0\npravastatina) \u00a0\nEstazolam, \u00a0\u00a0\n\u00c9xtasis\u00a0\u00a0\nFlecainida \u00a0\nFluracepam \u00a0\nFluticasona \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0\nJuan)\u00a0\nLumefantrina \u00a0\nMeperidina \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral10\u00a0\nPimozida\u00a0\nPiroxicam \u00a0\nPropafenona \u00a0Ajo,\u00a0suplementos \u00a0(utilizar\u00a0\nSQV/r)\u00a0\nAlfuzosina \u00a0\nAstemizol \u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0fluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nCarbamacepina \u00a0\nCisaprida\u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0\nhep\u00e1tica) \u00a0\nDexametasona \u00a0\nDeriv.\u00a0ergotamina \u00a0\nEfavirenz\u00a0\u00a0\nFenito\u00edna \u00a0\nFenobarbital \u00a0\nFluticasona \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0\nJuan)\u00a0\nLumefantrina \u00a0\nMidazolam \u00a0oral10\u00a0\nNevirapina \u00a0\nPimozida\u00a0\nRifampicina \u00a0\nSalmeterol \u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0\npulmonar) \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam. \u00a0\n\u00a0Alfuzosina \u00a0\nAnticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nBupropion \u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0fluvastatina \u00a0\ny\u00a0pravastatina) \u00a0\u00a0\nCisaprida\u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0\nhep\u00e1tica) \u00a0\nDeriv.\u00a0Ergotamina \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0\nJuan)\u00a0\nLumefantrina \u00a0\nMidazolam \u00a0oral10\u00a0\nOmeprazol \u00a0y\u00a0afines\u00a0\nPimozida\u00a0\nRifampicina \u00a0\nSalmeterol \u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0\npulmonar) \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam \u00a0Alfuzosina \u00a0\nAnticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nCisaprida\u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0\nhep\u00e1tica) \u00a0\nDeriv.\u00a0ergotamina \u00a0\u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0fluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0\nJuan)\u00a0\nLumefantrina \u00a0\nLopinavir/r \u00a0\nMidazolam \u00a0oral10\u00a0\nPimozida\u00a0\u00a0\nRifampicina \u00a0\u00a0\nSalmeterol \u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0\npulmonar) \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 129 Quinidina \u00a0\u00a0\nSalmeterol \u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0\npulmonar) \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0\u00a0\u00a0\nVoriconazol \u00a0\nZolpidem \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 130 \u00a0\nNombre\u00a0gen\u00e9rico Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\nAnti\u00e1cidos \u00a0 Espaciarlos \u00a01h\u00a0 No\u00a0hay\u00a0datos\u00a0 No\u00a0hay\u00a0datos\u00a0 No\u00a0hay\u00a0datos\u00a0 Ausencia\u00a0de\u00a0interacciones  \u00a0\nInhibidores \u00a0de\u00a0la\u00a0\nbomba\u00a0de\u00a0protones\u00a0\n\u00a0Utilizar\u00a0IDV/r\u00a0(\u219347%\u00a0AUC\u00a0\nIDV)\u00a0No\u00a0hay\u00a0datos\u00a0 NRAD\u00a0(omeprazol \u00a040\u00a0mg/d\u00a0\n\u219180%\u00a0AUC\u00a0SQV\u00a0sin\u00a0toxicidad)Contraindicado \u00a0(\u219336%\u00a0AUc\u00a0\nNFV)\u00a0NRAD\u00a0(\u2193Cmax,\u00a0pero\u00a0AUC\u00a0y\u00a0\nCmin\u00a0FPV\u00a0sin\u00a0cambios). \u00a0\nAntihistam\u00ednicos \u00a0H2\u00a0No\u00a0hay\u00a0datos.\u00a0 No\u00a0hay\u00a0datos\u00a0 NRAD\u00a0 No\u00a0hay\u00a0datos\u00a0 NRAD\u00a0(\u219330%\u00a0AUC,\u00a0pero\u00a0Cmin\u00a0\nsin\u00a0cambios)\u00a0\nAntimicobact. \u00a0\n\u2010\u00a0Rifampicina \u00a0 Contraindicado \u00a0tanto\u00a0con\u00a0\nIDV\u00a0como\u00a0con\u00a0IDV/r\u00a0\u219335%\u00a0AUC\u00a0RTV.\u00a0NRAD\u00a0(RTV\u00a0a\u00a0\ndosis\u00a0plenas).\u00a0Monitorizar \u00a0\ntoxicidad\u00a0hep\u00e1tica\u00a0Contraindicado9\u00a0\u00a0 Contraindicado \u00a0 Contraindicado \u00a0\n\u2010\u00a0Rifabutina \u00a0(RFB)0\u00a01000\u00a0mg\u00a0c/8h\u00a0IDV.\u00a0\nRFB\u00a0150\u00a0mg\u00a0c/24h\u00a0\u00f3\u00a0300\u00a0mg\u00a0\n3veces/semana0.\u00a0\u00a0RFB\u00a0150\u2010300\u00a0mg\u00a0\u00a0\u00a03veces\u00a0\n/semana0\u00a0\u00a0Contraindicado \u00a0como\u00a0\u00fanico\u00a0\nIP\u00a00,2\u00a01000\u00a0mg\u00a0c/8h\u00a0\u00f3\u00a01250\u00a0mg\u00a0\nc/12h\u00a0NFV.\u00a0\nRFB\u00a0150\u00a0mg\u00a0c/24h\u00a0\u00f3\u00a0300\u00a0mg\u00a0\u00a0\n3veces\u00a0/semana0.\u00a0NRAD\u00a0FPV/r\u00a0\u00a0RFB\u00a0150\u2010300\u00a0\nmg\u00a0\u00a03veces\u00a0/semana0\u00a0\n\u00a0\n\u2010\u00a0Claritromicina \u00a0\u00a0\nNRAD\u00a0\nConsiderar \u00a0tratamientos \u00a0\nalternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0de\u00a0\nMAC\u00a0\nEn\u00a0presencia \u00a0de\u00a0RTV,\u00a0ajustar\u00a0\ndosis\u00a0de\u00a0claritro\u00a0si\u00a0funci\u00f3n\u00a0\nrenal\u00a0alterada1\u00a0\u00a0\nConsiderar \u00a0tratamientos \u00a0\nalternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0de\u00a0\nMAC\u00a0(100%\u00a0AUC\u00a014\u2010OH\u2010\nclaritromicina) \u00a0\nAjustar\u00a0dosis\u00a0claritro\u00a0si\u00a0func.\u00a0\nrenal\u00a0alterada1.\u00a0\u00a0\nNRAD\u00a0\nDado\u00a0que\u00a0se\u00a0administra \u00a0con\u00a0\nRTV,\u00a0considerar \u00a0tratamientos \u00a0\nalternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0de\u00a0\nMAC\u00a0\n\u00a0\u00a0\nNRAD\u00a0FPV\u00a0no\u00a0potenciado: \u00a0NRAD\u00a0\nFPV/r:\u00a0Considerar \u00a0\ntratamientos \u00a0alternativos \u00a0\npara\u00a0indicaciones \u00a0diferentes \u00a0\nde\u00a0MAC\u00a0\nAjustar\u00a0dosis\u00a0claritro\u00a0si\u00a0func.\u00a0\nrenal\u00a0alterada1.\u00a0\nAntiepil\u00e9pticos :\u00a0\n\u00a0\u2010 Carbamacepina, \u00a0\nfenito\u00edna, \u00a0\nfenobarbital \u00a0Posible\u00a0\u2193Cp\u00a0IDV.\u00a0\nMonitorizar \u00a0Cp\u00a0antiepil\u00e9ptico \u00a0\ny\u00a0ARV.\u00a0Con\u00a0carbamacepina \u00a0\n\u2193Cp\u00a0IDV\u00a0importantes. \u00a0Evitar\u00a0\nasociarlos \u00a0Monitorizar \u00a0Cp\u00a0antiepil\u00e9ptico \u00a0\ny\u00a0ARV.\u00a0RTV\u00a0puede\u00a0\u2193Cp\u00a0de\u00a0\nfenito\u00edna\u00a0y\u00a0lamotrigina. \u00a0\nDatos\u00a0iniciales\u00a0indican\u00a0que\u00a0\ntambi\u00e9n\u00a0podr\u00eda\u00a0\u2193Cp\u00a0de\u00a0\nvalproico. \u00a0\nVarios\u00a0casos\u00a0descritos\u00a0de\u00a0\ntoxicidad\u00a0por\u00a0\ncarbamacepina. \u00a0\u00a0\nNo\u00a0hay\u00a0datos.\u00a0Evitar\u00a0la\u00a0\ncombinaci\u00f3n \u00a0o\u00a0monito\u2010rizar\u00a0\nestrechamente \u00a0los\u00a0niveles\u00a0de\u00a0\nambos.\u00a0Posible\u00a0\u2193Cp\u00a0NFV.\u00a0\nMonitorizar \u00a0Cp\u00a0antiepil\u00e9ptico \u00a0\ny\u00a0ARV.\u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0\ntoxicidad\u00a0por\u00a0\ncarbamacepina. \u00a0Posible\u00a0\u2193Cp\u00a0APV.\u00a0\nMonitorizar \u00a0Cp\u00a0antiepil\u00e9ptico \u00a0\ny\u00a0ARV.\u00a0\nAnticoagulantes \u00a0orales\n\u00a0Los\u00a0IP\u00a0pueden\u00a0alterar\u00a0las\u00a0Cp\u00a0de\u00a0los\u00a0anticoagulantes. \u00a0Existen\u00a0casos\u00a0descritos\u00a0de\u00a0reducci\u00f3n \u00a0del\u00a0efecto\u00a0anticoagulante \u00a0con\u00a0requerimiento \u00a0de\u00a0aumento\u00a0de\u00a0\ndosis\u00a0de\u00a0acenocumarol \u00a0y\u00a0warfarina \u00a0al\u00a0asociarlos \u00a0a\u00a0RTV\u00a0\u00f3\u00a0IDV.\u00a0Monitorizar \u00a0estrictamente \u00a0el\u00a0tiempo\u00a0de\u00a0protrombina. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 131 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\nAnticonceptivos \u00a0\norales :\u00a0NRAD\u00a0 \u219340%\u00a0AUC\u00a0etinilestradiol. \u00a0\nNo\u00a0debe\u00a0administrarse \u00a0\njunto\u00a0con\u00a0anticonceptivos \u00a0\nque\u00a0contengan \u00a0\netinilestradiol \u00a0o\u00a0\nnoretindrona. \u00a0Deben\u00a0\nconsiderarse \u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0\nalternativos \u00a0o\u00a0adicionales. \u00a0\n\u00a0Disminuye \u00a0los\u00a0niveles\u00a0de\u00a0\netinilestradiol. \u00a0No\u00a0modifica\u00a0los\u00a0\nniveles\u00a0de\u00a0noretindrona. \u00a0No\u00a0\ndebe\u00a0administrarse \u00a0junto\u00a0con\u00a0\nanticonceptivos \u00a0que\u00a0contengan \u00a0\netinilestradiol \u00a0o\u00a0noretindrona. \u00a0\nDeben\u00a0considerarse \u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0alternativos \u00a0o\u00a0\nadicionales. \u00a0\u219347%\u00a0AUC\u00a0etinilestradiol. \u00a0No\u00a0debe\u00a0\nadministrarse \u00a0junto\u00a0con\u00a0\nanticonceptivos \u00a0que\u00a0contengan \u00a0\netinilestradiol \u00a0o\u00a0noretindrona. \u00a0\nDeben\u00a0considerarse \u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0alternativos \u00a0o\u00a0\nadicionales. \u00a0\nNo\u00a0modifica\u00a0los\u00a0niveles\u00a0de\u00a0\nmedroxiprogesterona \u00a0(datos\u00a0\npreliminares). \u00a0FPV/r\u00a0700/100\u00a0mg/12h:\u00a0\u00a0\n\u2193\u00a037%\u00a0AUC\u00a0etinilestradiol \u00a0\n\u2193\u00a034%\u00a0AUC\u00a0noretindrona. \u00a0No\u00a0\ndebe\u00a0administrarse \u00a0junto\u00a0con\u00a0\nanticonceptivos \u00a0que\u00a0contengan \u00a0\netinilestradiol \u00a0o\u00a0noretindrona. \u00a0\nDeben\u00a0considerarse \u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0alternativos \u00a0o\u00a0\nadicionales. \u00a0\nAntif\u00fangicos \u00a0\nimidaz\u00f3licos \u00a0Con\u00a0fluconazol \u00a0NRAD.\u00a0\n\u00a0\nCon\u00a0ketoconazol \u00a0\u2193IDV\u00a0600\u00a0mg\u00a0\nc/8h.\u00a0\n\u00a0\nCon\u00a0itraconazol \u00a0posible\u00a0\u2191Cp\u00a0\nIDV.\u00a0\u00a0\n\u00a0Con\u00a0fluconazol \u00a0NRAD\u00a0de\u00a0\nninguno.\u00a0\n\u00a0\nCon\u00a0voriconazol \u00a0+\u00a0IDV\u00a0800\u00a0mg\u00a0\nc/8h:\u00a0NRAD.Con \u00a0IDV/r\u00a0no\u00a0hay\u00a0\ndatos\u00a0(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0\nc/12h:\u00a0evitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0\nbalance\u00a0riesgo/beneficio \u00a0\njustifique\n\u00a0su\u00a0uso.\u00a0Ver\u00a0RTV).\u00a0\nMonitorizar \u00a0estrechamente. \u00a0\u00a0M\u00e1x\u00a0200\u00a0mg/d\u00eda\u00a0de\u00a0\nketoconazol \u00a0e\u00a0itraconazol. \u00a0\u00a0\n\u00a0Con\u00a0fluconazol \u00a0NRAD\u00a0de\u00a0\nninguno.\u00a0\n\u00a0Voriconazol \u00a0contraindicado \u00a0\n(estudio\u00a0con\u00a0400\u00a0mg\u00a0c/12h\u00a0\nde\u00a0RTV:\u00a0\u219382%\u00a0AUC\u00a0\nvoriconazol, \u00a0AUC\u00a0RTV\u00a0sin\u00a0\ncambios;\u00a0estudio\u00a0con\u00a0100\u00a0\nmg\u00a0c/12h\u00a0de\u00a0RTV:\u00a0\u219339%\u00a0\nAUC\u00a0voriconazol, \u00a0AUC\u00a0RTV\u00a0\nsin\u00a0cambios\u00a0importantes). \u00a0\u00a0\u00a0\nFluconazol: \u00a0NRAD\u00a0\n\u00a0Voriconazol \u00a0y\u00a0SQV+/\u2010RTV:\u00a0no\u00a0\nhay\u00a0datos\u00a0(RTV\u00a0400\u00a0mg\u00a0\nc/12h\u00a0\u00a0contraindicado; \u00a0RTV\u00a0\n100\u00a0mg\u00a0c/12h:\u00a0evitar\u00a0a\u00a0\nmenos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0justifique \u00a0su\u00a0\nuso.\u00a0Ver\u00a0RTV).\u00a0Se\u00a0\nrecomienda \u00a0monitorizar \u00a0\nestrechamente. \u00a0\n\u00a0ketoconazol \u00a0e\u00a0itraconazol \u00a0\nm\u00e1x\u00a0200\u00a0mg/d\u00eda.\u00a0No\u00a0se\u00a0han\u00a0descrito\u00a0\ninteracciones \u00a0cl\u00ednicamente \u00a0\nimportantes \u00a0con\u00a0fluconazol, \u00a0\nitraconazol, \u00a0\nketoconazol \u00a0\u00a0o\u00a0\ncaspofungina. \u00a0\n\u00a0Con\u00a0Voriconazol: \u00a0no\u00a0hay\u00a0datos.\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0\nestrechamente \u00a0(podr\u00eda\u00a0\naumentar \u00a0la\u00a0toxicidad\u00a0de\u00a0\nambos).\u00a0Con\u00a0FPV/r\u00a0no\u00a0sobrepasar \u00a0\n200\u00a0mg/d\u00eda\u00a0de\u00a0ketoconazol \u00a0e\u00a0\nitraconazol. \u00a0\nPosaconazol \u00a0+\u00a0FPV\u00a0no\u00a0\npotenciado: \u00a0evitar\u00a0(\u219323%\u00a0\nAUC\u00a0posaconazol). \u00a0No\u00a0hay\u00a0\ndatos\u00a0con\u00a0FPV/r.\u00a0\n\u2010 Con\u00a0voriconazol \u00a0y\u00a0\nFPV+/\u2010\u00a0RTV\u00a0no\u00a0hay\u00a0datos\u00a0\n(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0\nc/12h:\u00a0evitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0\nbalance\u00a0riesgo/beneficio \u00a0\njustifique \u00a0su\u00a0uso.\u00a0Ver\u00a0RTV).\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0\nestrechamente. \u00a0\u00a0\n\u00a0\n\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso \u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 132 Nombre\u00a0\ngen\u00e9rico\u00a0Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\nEstatinas: \u00a0 Lovastatina \u00a0y\u00a0simvastatina\u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0y\u00a0pravastatina \u00a0\ninteracci\u00f3n \u00a0poco\u00a0probable. \u00a0\nAtorvastatina: \u00a0asociar\u00a0con\u00a0\nprecauci\u00f3n \u00a0(iniciar\u00a0 con\u00a0dosis\u00a0\nbajas\u00a0m\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0Atorvastatina, \u00a0fluvastatina\u00a0\nlovastatina \u00a0y\u00a0simvastatina\u00a0\ncontraindicadas. \u00a0Con\u00a0\npravastatina \u00a0interacci\u00f3n \u00a0\npoco\u00a0probable. \u00a0\u00a0\u00a0\u00a0SQV/RTV \u00a0\n400/400\u00a0mg\u00a0c/12h\u00a0\uf0af50%\u00a0\npravastatina \u00a0\n(probablemente \u00a0NRAD)\u00a0y\u00a0\n\uf0adx4,5\u00a0AUC\u00a0 atorvastatina \u00a0\n(iniciar\u00a0con\u00a0dosis\u00a0bajas\u00a0\nm\u00e1ximo\u00a010\u00a0mg/ d\u00eda). \u00a0Lovastatina \u00a0y\u00a0simvastatina\u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0interac\u00a0poco\u00a0\nprobable. \u00a0Atorvastatina: \u00a0\nasociar\u00a0con\u00a0precauci\u00f3n \u00a0\n(iniciar\u00a0con\u00a0dosis\u00a0bajas\u00a0\nm\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0Con\u00a0\nSQV/RTV\u00a0400/400\u00a0mg\u00a0c/12h\u00a0\n\uf0af50%\u00a0pravastatina\u00a0\n(probablem\u00a0 NRAD)\u00a0y\u00a0\uf0adx4,5\u00a0\nAUC\u00a0 atorvastatina \u00a0\u00a0(iniciar\u00a0\ncon\u00a0dosis\u00a0bajas\u00a0m\u00e1ximo\u00a010\u00a0\nmg/d\u00eda).\u00a0Lovastatina \u00a0y\u00a0simvastatina\u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0interacci\u00f3n \u00a0poco\u00a0\nprobable. \u00a0Pravas\ntatina\u00a0es\u00a0\nsegura\u00a0pero\u00a0probablemente \u00a0\nrequiera\u00a0 aumento\u00a0de\u00a0dosis\u00a0\n(\uf0af47%\u00a0AUC).\u00a0Atorvastatina: \u00a0\nAsociar\u00a0con\u00a0precauci\u00f3n \u00a0(iniciar\u00a0\ncon\u00a0dosis\u00a0bajas\u00a0m\u00e1ximo\u00a010\u00a0\nmg/d\u00eda).). \u00a0Lovastatina \u00a0y\u00a0simvastatina \u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0y\u00a0pravastatina \u00a0\ninteracci\u00f3n \u00a0poco\u00a0probable. \u00a0\nFPV\u00a0aument\u00f3\u00a02,3\u00a0veces\u00a0 el\u00a0\nAUC\u00a0 de\u00a0atorvastatina\u00a0 (10\u00a0\nmg/d\u00eda):\u00a0asociar\u00a0con\u00a0\nprecauci\u00f3n \u00a0(iniciar\u00a0 con\u00a0dosis\u00a0\nbajas\u00a0m\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0\nEtanol:\u00a0 El\u00a0uso\u00a0agudo\u00a0o\u00a0cr\u00f3nico\u00a0de\u00a0etanol\u00a0alter\u00f3\u00a0m\u00ednimamente \u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0los\u00a0IP.\u00a0\nAntabus:\u00a0algunos\u00a0IP\u00a0podr\u00edan\u00a0dar\u00a0lugar\u00a0a\u00a0una\u00a0 reacci\u00f3n\u00a0de\u00a0tipo\u00a0disulfiram \u00a0por\u00a0su\u00a0contenido \u00a0en\u00a0etanol:\u00a0Norvir\u00ae\u00a0 soluci\u00f3n\u00a0oral\u00a0(43%\u00a0v/v);\u00a0Norvir\u00a0 c\u00e1psulas\u00a0(12%\u00a0\np/p);\u00a0 Kaletra\u00ae\u00a0soluci\u00f3n\u00a0oral\u00a0(42%);\u00a0 Aptivus\u00a0c\u00e1psulas\u00a0(7%\u00a0p/p\u00a0=100\u00a0mg/c\u00e1ps). \u00a0Kaletra\u00ae\u00a0en\u00a0comprimidos \u00a0no\u00a0contiene\u00a0alcohol.\u00a0Agenera se\u00ae\u00a0en\u00a0soluci\u00f3n\u00a0tiene\u00a0\nun\u00a0elevado\u00a0contenido\u00a0 de\u00a0propilenglicol \u00a0(550\u00a0 mg/mL),\u00a0que\u00a0se\u00a0metaboliza \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0alcohol\u00a0 deshidrogenasa, \u00a0por\u00a0lo\u00a0que\u00a0el\u00a0consumo\u00a0 de\u00a0etanol\u00a0junto\u00a0 con\u00a0\nestos\u00a0IPs\u00a0podr\u00eda\u00a0producir\u00a0toxicidad. \u00a0Kaletra\u00ae\u00a0en\u00a0c\u00e1psulas\u00a0y\u00a0Agenerase\u00ae \u00a0en\u00a0c\u00e1psulas\u00a0tambi\u00e9n\u00a0contienen \u00a0propilenglicol,\u00a0 pero\u00a0en\u00a0men or \u00a0cantidad. \u00a0\nF\u00e1rmacos \u00a0empleados\u00a0\npara\u00a0tratar\u00a0la\u00a0gota\u00a0Gota\u2010profilaxis: \u00a0colchicina \u00a0con\u00a0\u00a0IP\u00a0potenciado:\u00a0 0,3\u00a0mg\u00a0c/24h\u201048h;\u00a0colchicina \u00a0con\u00a0FPV\u00a0no\u00a0potenciado:\u00a0 0,3\u20100,6\u00a0mg/d\u00eda.\u00a0\nGota\u2010tratamiento: \u00a0Colchicina \u00a0con\u00a0IP\u00a0potenciado:\u00a0 0,6\u00a0mg\u00a0+\u00a00,3\u00a0mg\u00a01h\u00a0despu\u00e9s\u00a0 y\u00a0no\u00a0readministrar \u00a0antes\u00a0de\u00a03\u00a0dias.\u00a0Colchicina \u00a0con\u00a0FPV\u00a0no\u00a0potenciado:\u00a0 1,2\u00a0mg\u00a0\ny\u00a0no\u00a0readministrar \u00a0antes\u00a0de\u00a03\u00a0dias.\u00a0\u00a0\nFiebre\u00a0mediterr\u00e1nea\u00a0 familiar:\u00a0colchicina \u00a0con\u00a0IP\u00a0potenciado: \u00a0m\u00e1ximo\u00a00,3\u00a0mg/12h;\u00a0con\u00a0\u00a0FPV\u00a0no\u00a0potenciado:\u00a0 m\u00e1ximo\u00a00,6\u00a0mg/12h.\u00a0\u00a0\n(Seg\u00fan\u00a0recomendaciones \u00a0de\u00a0la\u00a0FDA;\u00a0de\u00a0las\u00a0\u00a0presentaciones\u00a0 disponibles \u00a0en\u00a0Espa\u00f1a,\u00a0la\u00a0\u00fanica\u00a0que\u00a0podr\u00eda\u00a0ajustarse\u00a0aproximadamente \u00a0ser\u00eda\u00a0el\u00a0Colchimax\u00ae \u00a0de\u00a0\n0,5\u00a0mg).\u00a0\nF\u00e1rmacos \u00a0empleados\u00a0\npara\u00a0tratar\u00a0la\u00a0\nhipertensi\u00f3n\u00a0\npulmonar \u00a0Bosentan \u00a0(Tracleer\u00ae): \u00a0si\u00a0el\u00a0paciente\u00a0recibe\u00a0IPs\u00a0e\u00a0inicia\u00a0bosentan: \u00a0iniciar\u00a062,5\u00a0 mg\u00a0c/24\u2010 48h.\u00a0Si\u00a0el\u00a0paciente\u00a0\u00a0recibe\u00a0bosentan \u00a0e\u00a0inicia\u00a0IPs:\u00a0suspender \u00a0bosentan \u00a0\nm\u00ednimo\u00a036\u00a0horas\u00a0antes\u00a0y\u00a0no\u00a0reiniciar\u00a0hasta\u00a010\u00a0d\u00edas\u00a0despu\u00e9s\u00a0de\u00a0iniciar\u00a0el\u00a0IP\u00a0a\u00a0una\u00a0 dosis\u00a0de\u00a062,5\u00a0 mg\u00a0c/24\u2010 48h.\u00a0\u00a0No\u00a0se\u00a0recomienda \u00a0asociar\u00a0bosentan \u00a0a\u00a0ATV\u00a0no\u00a0\npotenciado \u00a0por\u00a0riesgo\u00a0de\u00a0reducci\u00f3n \u00a0de\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0atazanavir. \u00a0\u00a0\nTadalafilo \u00a0(Cialis\u00ae):\u00a0si\u00a0el\u00a0paciente\u00a0recibe\u00a0IPs\u00a0e\u00a0inicia\u00a0tadalafilo: \u00a0iniciar\u00a020\u00a0mg\u00a0c/24h\u00a0y\u00a0aumentar \u00a0luego\u00a0a\u00a040\u00a0mg/d\u00eda\u00a0seg\u00fan\u00a0tolerabilidad. \u00a0Si\u00a0el\u00a0paciente\u00a0recibe\u00a0\ntadalafilo \u00a0y\u00a0debe\u00a0iniciar\u00a0IPs:\u00a0suspender \u00a0tadalafilo \u00a0minimo\u00a024h\u00a0antes\u00a0y\u00a0no\u00a0reiniciar\u00a0 hasta\u00a07\u00a0d\u00edas\u00a0despu\u00e9s\u00a0de\u00a0iniciar\u00a0el\u00a0IP\u00a0a\u00a0una\u00a0 dosis\u00a0de\u00a020\u00a0mg\u00a0c/24h,\u00a0luego\u00a0\naumentar \u00a0a\u00a040mg/dia. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nota:\u00a0En\u00a0esta\u00a0tabla\u00a0se\u00a0ha\u00a0corregido \u00a0el\u00a0error\u00a0del\u00a0nombre\u00a0comercial \u00a0de\u00a0bosentan\u00a0(Revatio \u00a0por\u00a0Tracleer) \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 133 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\nF\u00e1rmacos \u00a0empleados \u00a0\npara\u00a0tratar\u00a0la\u00a0\ninfluenza \u00a0Zanamivir/amantadina: \u00a0una\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0IPs\u00a0se\u00a0considera \u00a0poco\u00a0probable. \u00a0\nOseltamivir \u00a0se\u00a0ha\u00a0relacionado \u00a0con\u00a0efectos\u00a0adversos\u00a0neuropsiqui\u00e1tricos, \u00a0aunque\u00a0no\u00a0se\u00a0puede\u00a0descartar \u00a0que\u00a0\u00e9stos\u00a0sean\u00a0debidos,\u00a0al\u00a0menos\u00a0en\u00a0parte,\u00a0a\u00a0la\u00a0\npropia\u00a0enfermedad. \u00a0Los\u00a0IPs\u00a0al\u00a0bloquear\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0podr\u00edan\u00a0aumentar \u00a0la\u00a0penetraci\u00f3n \u00a0de\u00a0oseltamivir \u00a0en\u00a0el\u00a0SNC\u00a0y\u00a0empeorar \u00a0sus\u00a0efectos\u00a0adversos. \u00a0Se\u00a0\nrecomienda \u00a0asociarlos \u00a0con\u00a0pecauci\u00f3n \u00a0hasta\u00a0que\u00a0no\u00a0se\u00a0disponga\u00a0de\u00a0m\u00e1s\u00a0datos.\u00a0\u00a0\nInmunosupresores :\u00a0\n\u00a0\u00a0\u00a0\u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0RTV\u00a0puede\u00a0aumentar \u00a0\nhasta\u00a03\u00a0veces\u00a0Cp\u00a0\nciclosporina \u00a0y\u00a0tacrolimus. \u00a0\u00a0\n\u219130%\u00a0AUC\u00a0de\u00a0\nprednisolona \u00a0tras\u00a0la\u00a0\nadministraci\u00f3n \u00a0de\u00a0\nprednisona. \u00a0\nPosible\u00a0\u2191Cp\u00a0sirolimus. \u00a0\nMonitorizar \u00a0\nniveles/toxicidad \u00a0\ninmunosupresor. \u00a0\nMicofenolato \u00a0se\u00a0\nglucuronida \u00a0por\u00a0lo\u00a0que\u00a0RTV\u00a0\npodr\u00eda\u00a0\u2193\u00a0sus\u00a0Cp.\u00a0\nMonitorizar\n\u00a0\nniveles/eficacia. \u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0Un\u00a0paciente\u00a0\ncon\u00a0trasplante \u00a0de\u00a0h\u00edgado\u00a0\nrequiri\u00f3\u00a0una\u00a0reducci\u00f3n \u00a0muy\u00a0\nimportante \u00a0en\u00a0la\u00a0dosis\u00a0de\u00a0\ntacrolimus. \u00a0Las\u00a0Cp\u00a0NFV\u00a0no\u00a0se\u00a0\nalteraron. \u00a0Micofenolato \u00a0se\u00a0\nglucuronida \u00a0por\u00a0lo\u00a0que\u00a0NFV\u00a0\npodr\u00eda\u00a0\u2193\u00a0sus\u00a0Cp.\u00a0Monitorizar \u00a0\nniveles/eficacia. \u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0\nInmunosupresores :\u00a0La\u00a0dosis\u00a0de\u00a0ciclosporina \u00a0inicial\u00a0debe\u00a0ser\u00a0aprox\u00a01/10\u00a0de\u00a0la\u00a0habitual\u00a0y\u00a0puede\u00a0requerir\u00a0reducciones \u00a0progresivas \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0tiempo.\u00a0En\u00a0algunos\u00a0casos\u00a0la\u00a0dosis\u00a0\nal\u00a0cabo\u00a0de\u00a02\u00a0a\u00f1os\u00a0es\u00a0tan\u00a0s\u00f3lo\u00a0un\u00a025%\u00a0de\u00a0la\u00a0inicial\u00a0(probablemente \u00a0por\u00a0aumento\u00a0de\u00a0la\u00a0absorci\u00f3n \u00a0intestinal \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0tiempo).\u00a0\nTacrolimus: \u00a0se\u00a0ha\u00a0descrito\u00a0una\u00a0interacci\u00f3n \u00a0muy\u00a0importante \u00a0con\u00a0LPV/r\u00a0(pueden\u00a0ser\u00a0necesarios \u00a0menos\u00a0de\u00a01mg\u00a0de\u00a0tacrolimus \u00a0a\u00a0la\u00a0semana\u00a0y\u00a0puede\u00a0ser\u00a0\nnecesario \u00a0esperar\u00a0de\u00a03\u00a0a\u00a05\u00a0semanas\u00a0(seg\u00fan\u00a0funci\u00f3n\u00a0hep\u00e1tica) \u00a0antes\u00a0de\u00a0administrar \u00a0otra\u00a0dosis\u00a0de\u00a0tacrolimus \u00a0al\u00a0iniciar\u00a0LPV/r.\u00a0Tambi\u00e9n\u00a0se\u00a0ha\u00a0descrito\u00a0\ninteracci\u00f3n \u00a0con\u00a0otros\u00a0IP\u00a0(p.\u00a0ej\u00a0.\u00a0mayor\u00a0con\u00a0NFV\u00a0que\u00a0con\u00a0IDV,\u00a0requiri\u00e9ndose \u00a0en\u00a0un\u00a0estudio\u00a0unos\u00a00,6\u00a0mg\u00a0diarios\u00a0de\u00a0tacrolimus \u00a0con\u00a0estos\u00a0IP.\u00a0Tras\u00a0el\u00a0cambio\u00a0de\u00a0\nNFV\u00a0por\u00a0FPV\u00a0no\u00a0potenciado \u00a0pueden\u00a0requerirse \u00a0aumentos \u00a0de\u00a0dosis\u00a0(se\u00a0han\u00a0descrito\u00a0reducciones \u00a0del\u00a050%\u00a0de\u00a0sus\u00a0Cp)\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 134 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\nInterfer\u00f3n/ \u00a0\nRibavirina \u00a0Ribavirina: \u00a0no\u00a0existe\u00a0evidencia \u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0IP.\u00a0Interfer\u00f3n: \u00a0su\u00a0v\u00eda\u00a0de\u00a0eliminaci\u00f3n \u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecida \u00a0as\u00ed\u00a0como\u00a0tampoco\u00a0su\u00a0posible\u00a0\nefecto\u00a0inhibidor\u00a0sobre\u00a0el\u00a0citocromo \u00a0P\u2010450\u00a0(ha\u00a0mostrado \u00a0p.\u00a0ej.\u00a0\u2191Cp\u00a0de\u00a0teofilina\u00a0y\u00a0barbituratos). \u00a0No\u00a0hay\u00a0datos\u00a0con\u00a0respecto\u00a0a\u00a0posibles\u00a0interacciones \u00a0con\u00a0los\u00a0\nIP\u00a0\nMetadona(MT) \u00a0 in\u00a0vitro\u00a0\u219130%\u00a0AUC\u00a0MT.\u00a0\nProbablemente \u00a0\u00a0NRAD\u00a0Metadona: \u00a0in\u00a0vitro\u00a0x2\u00a0AUC\u00a0\nMT\u00a0\nin\u00a0vivo\u00a0\u219336%\u00a0AUC\u00a0MT.\u00a0\n\u2191dosis\u00a0MT.\u00a0\nOxicodona: \u00a0\u2191\u00a0x3\u00a0AUC\u00a0\noxicodona. \u00a0Puede\u00a0requerir\u00a0\nreducci\u00f3n \u00a0de\u00a0dosis.\u00a0NRAD\u00a0 \u219340\u201050%\u00a0Cp\u00a0MT\u00a0en\u00a0algunos\u00a0\npacientes. \u00a0\nSolo\u00a0requiere\u00a0peque\u00f1os \u00a0\n\u2191dosis.\u00a0Algunos\u00a0pacientes \u00a0pueden\u00a0\nrequerir\u00a0aumento\u00a0de\u00a0dosis\u00a0\nde\u00a0MT.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 135 Otros\u00a0f\u00e1rmacos \u00a0 Fluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0\nestudio\u00a0caso\u2010control,\u00a0una\u00a0\nelevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0\nRTV+fluticasona \u00a0(7/8;\u00a0\n88%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0\nfue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a0\n57%\u00a0de\u00a0los\u00a0casos.\u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0\nreducci\u00f3n \u00a0de\u00a0eficacia\u00a0de\u00a0\nL\u2010tiroxina.\u00a0\nIDV\u00a0\u00a0puede\u00a0aumentar \u00a04.4\u00a0\nveces\u00a0AUC\u00a0sildenafilo \u00a0\n(max\u00a025\u00a0mg\u00a0en\u00a0un\u00a0periodo\u00a0\nde\u00a048h).\u00a0Esta\u00a0interacci\u00f3n \u00a0\ntambi\u00e9n\u00a0se\u00a0produce\u00a0con\u00a0\nvardenafilo \u00a0(m\u00e1x\u00a02,5\u00a0mg\u00a0\nc/72h\u00a0si\u00a0asociado\u00a0a\u00a0RTV)\u00a0y\u00a0\ncon\u00a0tadalafilo \u00a0(iniciar\u00a0con\u00a0\n5\u00a0mg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0\nc/72h).\u00a0\nCon\u00a0omeprazol \u00a0espaciar\u00a0\n1h\u00a0(ausencia \u00a0de\u00a0\ninteracci\u00f3n \u00a0con\u00a0IDV/r)\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0\nneutropenia. \u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43.\u00a0Benzimidazoles \u00a0:\u00a0\u2193\u00a027%\u00a0AUC\u00a0\nalbendazol ,\u00a0\u219343%\u00a0AUC\u00a0\nmebendazol. \u00a0\nBupropi\u00f3n :\u00a0RTV\u00a0puede\u00a0\u2193Cp\u00a0\nbupropion. \u00a0\nDocetaxel :\u00a0casos\u00a0descritos\u00a0de\u00a0\u2191\u00a0\ntoxicidad. \u00a0\nFluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0estudio\u00a0\ncaso\u2010control,\u00a0una\u00a0elevada\u00a0\nproporci\u00f3n \u00a0de\u00a0los\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0fue\u00a0\nsintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0de\u00a0los\u00a0\ncasos.\u00a0\nFluoxetina :\u00a0se\u00a0han\u00a0descrito\u00a03\u00a0\ncasos\u00a0de\u00a0s\u00edndrome \u00a0\nserotonin\u00e9rgico. \u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0\nreducci\u00f3n \u00a0de\u00a0eficacia\u00a0de\u00a0L\u2010\ntiroxina.\u00a0\nQuinina:\u00a0\u2191\u00a0x4\u00a0AUC\u00a0quinina.\u00a0\nReducir\u00a0dosis\u00a0\nRTV\u00a0puede\u00a0aumentar \u00a011\u00a0veces\u00a0\nAUC\u00a0sildenafilo \u00a0(max\u00a025\u00a0mg\u00a0en\u00a0\nun\u00a0periodo\u00a0de\u00a048h).\u00a0Esta\u00a0\ninteracci\u00f3n \u00a0tambi\u00e9n\u00a0se\u00a0produce\u00a0\ncon\u00a0vardenafilo \u00a0(m\u00e1x\u00a02,5\u00a0mg\u00a0\nc/72h)\u00a0y\u00a0con\u00a0tadalafilo \u00a0(iniciar\u00a0\ncon\u00a05\u00a0mg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0\nc/72h).\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0\nneutropenia. \u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0que\u00a0\nse\u00a0metabolizan \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0los\u00a0\u00a0\nCYP3A44>2D65,\u00a0\u2191\u00f3\u2193\u00a0Cp\u00a0si\u00a02C96\u00a0y\u00a0\n\u2193\u00a0Cp\u00a0si\u00a0CYP1A27\u00a0y\u00a0\nglucuronidaci\u00f3n8.\u00a0Fluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0\nestudio\u00a0caso\u2010control,\u00a0una\u00a0\nelevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0\nRTV+fluticasona \u00a0(7/8;\u00a088%)\u00a0\npresentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0\nsintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0de\u00a0\nlos\u00a0casos.\u00a0\nDigoxina:\u00a0\u219149%AUC\u00a0de\u00a0\ndigoxina:\u00a0Monitorizar \u00a0\ndigoxinemia. \u00a0\u00a0\nSQV\u00a0\u00a0puede\u00a0aumentar \u00a03.1\u00a0\nveces\u00a0AUC\u00a0sildenafilo \u00a0(max\u00a0\n25\u00a0mg\u00a0en\u00a0un\u00a0periodo\u00a0de\u00a0\n48h).\u00a0Esta\u00a0interacci\u00f3n \u00a0\ntambi\u00e9n\u00a0se\u00a0produce\u00a0con\u00a0\nvardenafilo \u00a0(m\u00e1x\u00a02,5\u00a0mg\u00a0\nc/24h\u00a0y\u00a02,5\u00a0mg\u00a0c/72h\u00a0si\u00a0\nasociado\u00a0a\u00a0RTV)\u00a0y\u00a0con\u00a0\ntadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0mg\u00a0\ny\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0c/72h).\u00a0\n\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0\nneutropenia. \u00a0\n\u00a0El\u00a0zumo\u00a0de\u00a0pomelo\n\u00a0\naumenta\u00a0los\u00a0niveles\u00a0de\u00a0\nSQV.\u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43\u00a0Felodipino :\u00a0un\u00a0caso\u00a0descrito\u00a0\nde\u00a0interacci\u00f3n \u00a0(edema,\u00a0\nmareo,\u00a0hipotensi\u00f3n) \u00a0en\u00a0una\u00a0\nmujer\u00a0que\u00a0recib\u00eda\u00a050\u00a0mg/d\u00eda\u00a0\nde\u00a0metoprolol \u00a0y\u00a05\u00a0mg/d\u00eda\u00a0de\u00a0\nfelodipino. \u00a0\nPosible\u00a0aumento\u00a0Cp\u00a0\nsildenafilo \u00a0(max\u00a025\u00a0mg\u00a0en\u00a0un\u00a0\nperiodo\u00a0de\u00a048h).\u00a0Esta\u00a0\ninteracci\u00f3n \u00a0tambi\u00e9n\u00a0se\u00a0\nproduce\u00a0con\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/24h)\u00a0y\u00a0con\u00a0\ntadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0mg\u00a0y\u00a0\nno\u00a0exceder\u00a010\u00a0mg\u00a0c/72h).\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0\nneutropenia. \u00a0\n\u00a0\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0\nque\u00a0se\u00a0metabolizan \u00a0a\u00a0trav\u00e9s\u00a0\ndel\u00a0\u00a0CYP3A4\n3\u00a0\u00a0\u2193\u00a0Cp\u00a0de\u00a0los\u00a0\nque\u00a0sufren\u00a0glucuronidaci\u00f3n8\u00a0\n\u00a0Fluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0\nestudio\u00a0caso\u2010control,\u00a0una\u00a0\nelevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0\nRTV+fluticasona \u00a0(7/8;\u00a088%)\u00a0\npresentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0sintom\u00e1tica \u00a0\nen\u00a0un\u00a057%\u00a0de\u00a0los\u00a0casos.\u00a0\n\u00a0Posible\u00a0aumento\u00a0Cp\u00a0\nsildenafilo\n\u00a0(max\u00a025\u00a0mg\u00a0en\u00a0un\u00a0\nperiodo\u00a0de\u00a048h).\u00a0Esta\u00a0\ninteracci\u00f3n \u00a0tambi\u00e9n\u00a0se\u00a0\nproduce\u00a0con\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/24h\u00a0y\u00a02,5\u00a0mg\u00a0\nc/72h\u00a0si\u00a0asociado\u00a0a\u00a0RTV)\u00a0y\u00a0\ncon\u00a0tadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0\nmg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0\nc/72h).\u00a0\n\u00a0\nCon\u00a0FPV/r\u00a0700/100\u00a0mg\u00a0\nc/12h\u00a0se\u00a0redujo\u00a0aprox\u00a0un\u00a0\n50%\u00a0el\u00a0AUC\u00a0de\u00a0paroxetina \u00a0\n(20\u00a0mg/d\u00eda).\u00a0\u00a0\n\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0\nneutropenia. \u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0\u00f3\u00a0\u2193\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43,\u00a0ya\u00a0que\u00a0es\u00a0un\u00a0\ninhibidor\u00a0de\u00a0este\u00a0isoenzima \u00a0\npero\u00a0los\u00a0datos\u00a0tambi\u00e9n\u00a0\nsugieren\u00a0que\u00a0puede\u00a0\ninducirlo. \u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 136 \u00a0\n\u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\n\u00a0NN\u00a0 (ver\u00a0la\u00a0tabla\u00a0NN)\u00a0\u00a0 \u00a0 \u00a0 \u00a0\n\u00a0IP\u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0\n\u00a0\n\u2010\u00a0IDV\u00a0\u00a0 IDV/r:\u00a0800/100\u2010200\u00a0mg\u00a0c/12h.\u00a0\nEn\u00a0investigaci\u00f3n \u00a0pauta\u00a0IDV/r:\u00a0\n1200/200 \u00a0mg\u00a0c/24\u00a0h.\u00a0No\u00a0existen\u00a0\ndatos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0a\u00a0\nlargo\u00a0plazo\u00a0\u2191x4\u20108\u00a0AUC\u00a0SQV.\u00a0Sin\u00a0cambios\u00a0\nAUC\u00a0IDV.\u00a0No\u00a0hay\u00a0datos\u00a0sobre\u00a0\najuste\u00a0de\u00a0dosis\u00a0(antagonismo \u00a0\nin\u00a0vitro\u00a0y\u00a0complicado \u00a0de\u00a0\ndosificar). \u00a0NFV/IDV: \u00a01250/\u00a01200\u00a0mg\u00a0\nc/12h.\u00a0\n(datos\u00a0limitados) \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0No\u00a0hay\u00a0datos\u00a0suficientes \u00a0sobre\u00a0ajuste\u00a0de\u00a0\ndosis.\u00a0\n\u00a0\n\u2010\u00a0RTV\u00a0\u00a0\n\u00a0\u00a0 SQV/r:\u00a0400mg/400 \u00a0mg\u00a0BID\u00a0\nSQV/r:\u00a01000/100 \u00a0mg/12\u00a0h.\u00a0\u00a0\nEn\u00a0investigaci\u00f3n \u00a0en\u00a0pacientes \u00a0\nnaive\u00a0SQV/r\u00a01500/100 \u2010200\u00a0\nmg/24\u00a0h\u00a0(preferiblemente \u00a0en\u00a0\nel\u00a0desayuno). \u00a0RTV\u00a0100\u00a0\u00f3\u00a0200\u00a0mg\u00a0c/12h:\u00a0\n\u219130%\u00a0AUC\u00a0NFV.\u00a0\nSe\u00a0desaconseja \u00a0esta\u00a0\nasociaci\u00f3n. \u00a0FPV/r\u00a0700/100\u00a0mg\u00a0c/12h\u00a0\u00a0\u00a0\n(En\u00a0pacientes \u00a0naive\u00a0puede\u00a0administrarse \u00a0\nuna\u00a0vez\u00a0al\u00a0d\u00eda:\u00a0FPV/r\u00a01400/100 \u2010200\u00a0mg\u00a0\nc/24h.\u00a0No\u00a0se\u00a0recomienda \u00a0en\u00a0pacientes \u00a0\npretratados). \u00a0\n\u00a0\n\u2010\u00a0SQV\u00a0\u00a0 \u00a0 \u00a0 Se\u00a0desaconseja \u00a0esta\u00a0asociaci\u00f3n Datos\u00a0iniciales\u00a0sobre\u00a0ajuste\u00a0de\u00a0dosis:\u00a0\nSQV\u2010CGD/FPV/RTV \u00a01000/700/200 \u00a0mg\u00a0\nc/12h\u00a0(Se\u00a0recomienda \u00a0monitorizar \u00a0\nniveles\u00a0plasm\u00e1ticos). \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\na\u00a0largo\u00a0plazo\u00a0\n\u2010\u00a0NFV\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 No\u00a0hay\u00a0datos\u00a0\n\u00a0\nAUC:\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraciones \u00a0plasm\u00e1ticas; \u00a0\u00a0IT:\u00a0interacci\u00f3n; \u00a0NRAD:\u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0NS:\u00a0no\u00a0significativa; \u00a0QD:una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0\n\u00a0\na\u00a0Expresado \u00a0como\u00a0media\u00a0\u00b1\u00a0DE\u00a0si\u00a0no\u00a0se\u00a0indica\u00a0lo\u00a0contrario\u00a0\nb\u00a0Expresado \u00a0como\u00a0mediana\u00a0\u00b1\u00a0rango\u00a0intercuartil \u00a0\u00a0\nc\u00a0Expresado \u00a0como\u00a0rango\u00a0\n\u00a0\n0\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0estudios\u00a0han\u00a0sido\u00a0realizados \u00a0en\u00a0voluntarios \u00a0sanos\u00a0por\u00a0lo\u00a0que\u00a0en\u00a0los\u00a0pacientes \u00a0es\u00a0probable\u00a0que\u00a0las\u00a0dosis\u00a0recomendadas \u00a0inicialmente \u00a0con\u00a0IP/r\u00a0(150\u00a0mg\u00a0tres\u00a0veces\u00a0por\u00a0semana)\u00a0no\u00a0\nsean\u00a0suficientes. \u00a0Se\u00a0han\u00a0descrito\u00a0fracasos\u00a0de\u00a0tratamiento \u00a0antituberculoso \u00a0con\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0en\u00a0pacientes \u00a0con\u00a0imnunodepresi\u00f3n \u00a0avanzada \u00a0tratados\u00a0con\u00a0IP/r\u00a0y\u00a0rifabutina \u00a0150\u00a0mg\u00a0c/48\u00a0\nhoras\u00a0o\u00a0tres\u00a0veces\u00a0por\u00a0semana.\u00a0En\u00a0estos\u00a0casos\u00a0valorar\u00a0dosis\u00a0mayores: \u00a0rifabutina \u00a0300\u00a0mg\u00a0tres\u00a0veces\u00a0semana.\u00a0Dado\u00a0que\u00a0el\u00a0ajuste\u00a0de\u00a0dosis\u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecido \u00a0y\u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0\nniveles\u00a0de\u00a0rifabutina \u00a0no\u00a0est\u00e1\u00a0disponible \u00a0en\u00a0la\u00a0\u00a0mayor\u00eda\u00a0de\u00a0hospitales, \u00a0se\u00a0recomienda, \u00a0si\u00a0es\u00a0posible,\u00a0valorar\u00a0otras\u00a0alternativas \u00a0terap\u00e9uticas.\u00a0\n1\u00a0ClCr\u00a030\u201060\u00a0ml/min:\u00a0reducir\u00a0un\u00a050%,\u00a0ClCr\u00a0<30\u00a0ml/min:\u00a0reducir\u00a0un\u00a075%\u00a0(m\u00e1x.\u00a01g/d\u00eda).\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 137 2\u00a0\u00a0SQV\u00a0junto\u00a0con\u00a0RTV\u00a0(400/400\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a01000/100 \u00a0mg\u00a0c/12h)\u00a0pueden\u00a0administrarse \u00a0con\u00a0dosis\u00a0reducidas \u00a0de\u00a0rifabutina \u00a0(150\u00a0mg\u00a0\u00a03veces\u00a0/semana)(experiencia \u00a0limitada). \u00a0\u00a0\n3\u00a0Principales \u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A4:\u00a0alprazolam, \u00a0amiodarona, \u00a0amlodipino, \u00a0ciclofosfamida, \u00a0ciclosporina, \u00a0clonacepam, \u00a0cloracepato, \u00a0dextropropoxifeno, \u00a0diazepam, \u00a0\ndiltiazem, \u00a0disopiramida, \u00a0estazolam, \u00a0etionamida, \u00a0etosuximida, \u00a0felodipino, \u00a0fentanilo, \u00a0finasterida, \u00a0flunaricina, \u00a0fluracepam, \u00a0lacidipino, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0meperidina, \u00a0nicardipino, \u00a0nifedipino, \u00a0\nnimodipino, \u00a0nitrendipino, \u00a0prednisona, \u00a0quinidina, \u00a0quinina,\u00a0sertralina, \u00a0sildenafilo \u00a0(Viagra\u00ae),\u00a0vardenafilo, \u00a0tadalafilo, \u00a0tacrolimus, \u00a0verapamilo, \u00a0vincristina \u00a0y\u00a0zolpidem. \u00a0\n4\u00a0RTV\u00a0pueder\u00a0aumentar \u00a0hasta\u00a03\u00a0veces\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0siguiente\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A:\u00a0alfentanilo, \u00a0antagonistas \u00a0del\u00a0calcio\u00a0(amlodipino, \u00a0diltiazem, \u00a0felodipino, \u00a0nicardipino, \u00a0\nnifedipino, \u00a0nisoldipino, \u00a0verapamilo), \u00a0carbamacepina, \u00a0ciclosporina, \u00a0citost\u00e1ticos \u00a0(etop\u00f3sido, \u00a0docetaxel, \u00a0paclitaxel, \u00a0tamoxifeno, \u00a0vinblastina \u00a0y\u00a0vincristina), \u00a0clonacepam, \u00a0dexametasona, \u00a0\ndisopiramida, \u00a0eritromicina, \u00a0etosuximida, \u00a0fentanilo, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0nefazodona, \u00a0ondansetron, \u00a0prednisona, \u00a0quinina,\u00a0rifampicina, \u00a0sertralina, \u00a0tacrolimus, \u00a0taxol\u00a0\u00a0y\u00a0trazodona, \u00a0entre\u00a0otros.\u00a0\n5\u00a0Aumento \u00a0de\u00a01.5\u00a0a\u00a03\u00a0veces\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2D6:\u00a0amitriptilina, \u00a0clomipramina, \u00a0clorpromacina, \u00a0desipramina, \u00a0fluoxetina, \u00a0haloperidol, \u00a0imipramina, \u00a0\nmaprotilina, \u00a0metoprolol, \u00a0mexiletina, \u00a0nortriptilina, \u00a0paroxetina, \u00a0perfenazina, \u00a0pindolol,\u00a0propranolol, \u00a0risperidona, \u00a0timolol,\u00a0tioridacina, \u00a0tramadol\u00a0y\u00a0venlafaxina. \u00a0\n6\u00a0F\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2C9/19: \u00a0diclofenac, \u00a0ibuprofeno, \u00a0indometacina, \u00a0fenito\u00edna, \u00a0gliburida, \u00a0glipizida,\u00a0\u00a0lansoprazol, \u00a0losartan,\u00a0omeprazol, \u00a0proguanilo \u00a0y\u00a0tolbutamida. \u00a0\n7teofilina,\u00a0tacrina,\u00a0clozapina, \u00a0tacrina.\u00a0\n8\u00a0atovaquona, \u00a0clofibrato, \u00a0code\u00edna,\u00a0difenoxilato, \u00a0ketoprofeno, \u00a0ketorolaco, \u00a0lamotrigina, \u00a0loracepam, \u00a0metoclopramida, \u00a0morfina,\u00a0naproxeno, \u00a0oxacepam, \u00a0propofol, \u00a0temacepam \u00a0y\u00a0valproico. \u00a0\u00a0\n9\u00a0En\u00a0un\u00a0estudio\u00a0en\u00a0voluntarios \u00a0sanos\u00a0se\u00a0observ\u00f3\u00a0una\u00a0elevada\u00a0incidencia \u00a0de\u00a0hepatotoxicidad \u00a0con\u00a0esta\u00a0combinaci\u00f3n \u00a0(rifampicina \u00a0600\u00a0mg\u00a0c/24h\u00a0+\u00a0SQV/r\u00a01000/100 \u00a0mg\u00a0c/12h).\u00a0\u00a0\n10\u00a0Seg\u00fan\u00a0datos\u00a0iniciales\u00a0el\u00a0midazolam \u00a0intravenoso \u00a0podr\u00eda\u00a0administrarse \u00a0junto\u00a0con\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0reduciendo \u00a0la\u00a0dosis\u00a0y\u00a0bajo\u00a0estrecha\u00a0monitorizaci\u00f3n \u00a0cl\u00ednica\u00a0(UCI\u00a0o\u00a0similar).\u00a0\u00a0Sin\u00a0\nembargo, \u00a0el\u00a0midazolam \u00a0oral\u00a0est\u00e1\u00a0contraindicado. \u00a0\n\u00a0\n\u03c9\u00a0Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0europea.\u00a0EPARS:\u00a0European \u00a0Public\u00a0Assessment \u00a0Reports.\u00a0Disponble \u00a0en:\u00a0\nhttp://www.ema.europa.eu/ema/index.jsp?curl =pages/includes/medicines/medicines_landing _page.jsp&murl=menus/m edicines/medicines. jsp&mid=\u00a0Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n\u2126Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0americana \u00a0(fuentes:\u00a0FDA\u00a0and\u00a0First\u00a0Data\u00a0Bank,\u00a0Inc).\u00a0Disponible \u00a0en: http://www.rxlist.com/drugs/alpha_a.htm \u00a0.Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n&Guardiola \u00a0JM,\u00a0Soriano\u00a0V\u00a0(Eds).\u00a0Tratamiento \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u2010SIDA.\u00a0F\u00e1rmacos \u00a0y\u00a0combinaciones. \u00a0D\u00e9cima\u00a0Edidi\u00f3n.\u00a0Barcelona: \u00a0Publicaciones \u00a0Permanyer \u00a02007.\u00a0\n\u00a0\n\u00a0NOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0la\u00a0\ninformaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 138 Tabla\u00a07.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0(2\u00aa\u00a0parte):\u00a0lopinavir/r, \u00a0atazanavir, \u00a0darunavir, \u00a0tipranavir \u00a0\n\u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nNombre\u00a0comercial \u00a0\n\u00a0Kaletra\u00ae\u00a0 Reyataz\u00ae\u00a0 Prezista\u00ae\u00a0 Aptivus\u00ae\u00a0\nDosis\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0Recomendaci\u00f3n \u00a0400/100\u00a0mg\u00a0c/12h\u00a0\n800/200\u00a0mg\u00a0/24\u00a0h\u00a0\n\u00a0\u00a0\u00a0Tomar\u00a0con\u00a0o\u00a0sin\u00a0comida\u00a0300/100\u00a0mg\u00a0r/24\u00a0h\u00a0\u00f3\u00a0400\u00a0mg\u00a0c/24h\u00a0\nNota:\u00a0En\u00a0un\u00a0estudio\u00a0se\u00a0observ\u00f3\u00a0que\u00a0tan\u00a0\ns\u00f3lo\u00a0un\u00a038%\u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0\ncon\u00a0ATV\u00a0no\u00a0potenciado \u00a0alcanzaron \u00a0una\u00a0\nCmin>150 \u00a0ng/mL.\u00a0\u00a0\u00a0\nTomar\u00a0con\u00a0comida\u00a0600/100\u00a0mg\u00a0c/12h\n\u00a0(en\u00a0pacientes \u00a0\npretratados). \u00a0\u00a0\n800/100\u00a0QD\u00a0(en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo\u00a0\n\u00a0Tomar\u00a0con\u00a0comida\u00a0TPV/r\u00a0500/200\u00a0mg\u00a0c/12h\u00a0\n\u00a0\u00a0\u00a0\u00a0Tomar\u00a0con\u00a0comida\u00a0\nPresentaci\u00f3n \u00a0\ncomercial \u00a0comp\u00a0200/50\u00a0mg\u00a0\ncomp\u00a0100/25\u00a0mg\u00a0\nsol.\u00a0oral\u00a080/20\u00a0mg/ml\u00a0\u00a0c\u00e1ps\u00a0150,\u00a0200\u00a0y\u00a0300\u00a0mg\u00a0\u00a0 Comp\u00a0\u00a075,\u00a0150,\u00a0400\u00a0y\u00a0600\u00a0\u00a0mg\u00a0 c\u00e1ps\u00a0250\u00a0mg\u00a0\nBiodisponibilidad \u00a0\nOral\u00a0\n\u00a0No\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0\nbiodisponibilidad \u00a0absoluta\u00a0en\u00a0\nhumanos.\u00a0\u03c9\u00a068%\u00a0(57\u201080%)&\u00a0 37%\u00a0(DRV\u00a0solo,\u00a0dosis\u00a0\u00fanica\u00a0600\u00a0mg)\u00a0\n82%\u00a0(DRV/r\u00a0600/100\u00a0mg/12h).\u00a0\u03c9\u00a0No\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0biodisponibilidad \u00a0\nabsoluta\u00a0en\u00a0humanos.\u00a0\u2126\u00a0\nEfecto\u00a0de\u00a0los\u00a0\nalimentos \u00a0Se\u00a0recomienda \u00a0administrarlo \u00a0con\u00a0\nalimentos \u00a0para\u00a0reducir\u00a0la\u00a0\nvariabilidad \u00a0farmacocin\u00e9tica \u00a0y\u00a0\nmejorar\u00a0su\u00a0tolerabilidad.\u00a0\u2126\u00a0\nC\u00e1psulas: \u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0la\u00a0\nadministraci\u00f3n \u00a0en\u00a0ayunas,\u00a0la\u00a0\nadministraci\u00f3n \u00a0con\u00a0alimentos \u00a0de\u00a0\ncontenido \u00a0moderado \u00a0en\u00a0grasa\u00a0\naument\u00f3\u00a0un\u00a048%\u00a0el\u00a0AUC\u00a0y\u00a0los\u00a0\nalimentos \u00a0ricos\u00a0en\u00a0grasa\u00a0la\u00a0\naumentaron \u00a0un\u00a097%.\u00a0\u2126\u00a0\nSoluci\u00f3n:\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0la\u00a0\nadministraci\u00f3n \u00a0en\u00a0ayunas,\u00a0la\u00a0\nadministraci\u00f3n \u00a0con\u00a0alimentos \u00a0de\u00a0\ncontenido \u00a0moderado \u00a0en\u00a0grasa\u00a0\naument\u00f3\u00a0un\u00a080%\u00a0el\u00a0AUC\u00a0y\u00a0los\u00a0\nalimentos \u00a0ricos\u00a0en\u00a0grasa\u00a0la\u00a0\naumentaron \u00a0un\u00a0130%.\u00a0\u2126\u00a0ATV:\u00a0400\u00a0mg/24h:\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0\nla\u00a0administraci\u00f3n \u00a0en\u00a0ayunas,\u00a0la\u00a0\nadministraci\u00f3n \u00a0con\u00a0alimentos \u00a0de\u00a0\ncontenido \u00a0ligero\u00a0en\u00a0grasa\u00a0aument\u00f3\u00a0un\u00a0\n70%\u00a0el\u00a0AUC\u00a0y\u00a0los\u00a0alimentos \u00a0ricos\u00a0en\u00a0\ngrasa\u00a0la\u00a0aumentaron \u00a0un\u00a035%.\u00a0\u2126\u00a0\nATV/r:\u00a0300/100\u00a0mg/24h:\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0la\u00a0administraci\u00f3n \u00a0en\u00a0\nayunas,\u00a0la\u00a0administraci\u00f3n \u00a0con\u00a0alimentos \u00a0\nde\u00a0contenido \u00a0ligero\u00a0en\u00a0grasa\u00a0aument\u00f3\u00a0\nun\u00a033%\u00a0el\u00a0AUC\u00a0y\u00a0los\u00a0alimentos \u00a0ricos\u00a0en\u00a0\ngrasa\u00a0pr\u00e1cticamente \u00a0no\u00a0la\u00a0modificaron.\u00a0\u2126\n\u00a0Se\u00a0recomienda \u00a0administrarlo \u00a0con\u00a0\nalimentos. \u00a0Los\u00a0alimentos \u00a0aumentaron \u00a0un\u00a0\n30%\u00a0el\u00a0AUC,\u00a0sin\u00a0que\u00a0influyera\u00a0el\u00a0tipo\u00a0de\u00a0\nalimento.\u00a0\u2126\u00a0Los\u00a0alimentos \u00a0mejoran\u00a0la\u00a0tolerabilidad, \u00a0por\u00a0\nlo\u00a0que\u00a0TPV/r\u00a0debe\u00a0administrarse \u00a0con\u00a0\nalimentos.\u00a0\u03c9\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 139 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nSemivida \u00a0\nplasm\u00e1tica \u00a05\u20106\u00a0horas\u00a0\u03c9\u00a0 6,5\u00a0horas\u00a0(ATV\u00a0400\u00a0mg/24h)(VIH+)\u00a0\u2126\u00a0\n12\u00a0horas\u00a0(ATV/r\u00a0300/100\u00a0mg/24h)(VIH+)\u00a0\n\u03c9\u00a0\n\u00a015\u00a0\u00a0horas\u00a0(DRV/r\u00a0600/100\u00a0mg/12h)\u00a0\u03c9\u00a05,5\u00a0horas\u00a0\u00a0en\u00a0mujeres\u00a0y\u00a0\u00a06,0\u00a0horas\u00a0en\u00a0\nhombres\u00a0(TPV/r\u00a0500/200\u00a0mg/12h)\u00a0\u03c9\u00a0\n\u00a0\nCmax\u00a0\n\u00a0\u00a0\u00a0\n12,3\u00b1\u00a05,4\u00a0microg/ml \u00a0(400/100\u00a0\nmg/12h)\u00a0a,\u00a0\u03c9\u00a0\n9,8\u00a0\u00b1\u00a03,7\u00a0\u03bcg/mL(400/100 \u00a0\nmg/12h)(VIH+)\u00a0a,\u00a0\u2126\u00a0\n11,8\u00b1\u00a03,7\u00a0microg/ml \u00a0(800/200\u00a0\nmg/24h)(VIH+)\u00a0a,\u00a0\u2126\u00a0En\u00a0VIH+:\u00a0\n\u00a04466\u00a0nanog/ml\u00a0(ATV/r\u00a0300/100\u00a0\nmg/24h)\u03c9\u00a0\n3152\u00b12231 \u00a0nanog/ml \u00a0(ATV\u00a0400\u00a0\nmg/24h)\u2126\u00a0\u00a0\n\u2010\u2010\u00a0En\u00a0VIH+:\u00a0\n94,8\u00a0\u00b1\u00a022,8\u00a0microM\u00a0en\u00a0mujeres\u00a0(TPV/r\u00a0\n500/200\u00a0mg/12h)\u00a0\u03c9\u00a0\n77,6\u00a0\u00b1\u00a016,6\u00a0microM\u00a0en\u00a0hombres\u00a0\u00a0(TPV/r\u00a0\n500/200\u00a0mg/12h)\u00a0\u03c9\u00a0\n\u00a0\nCmin\u00a0\n\u00a0\u00a0\u00a0\n8,1\u00a0\u00b1\u00a05,7\u00a0microg/ml \u00a0(400/100\u00a0\nmg/12h)\u00a0\u00a0a,\u00a0\u03c9\u00a0\n7,1\u00a0\u00b1\u00a02,9\u00a0\u03bcg/mL(400/100 \u00a0\nmg/12)(VIH+)a,\u00a0\u2126\u00a0\n3,2\u00b1\u00a02,1\u00a0microg/ml \u00a0(800/200\u00a0\nmg/24h)\u00a0(VIH+)\u00a0a,\u00a0\u2126\u00a0\u00a0En\u00a0VIH+:\u00a0\n654\u00a0nanog/ml \u00a0(ATV/r\u00a0300/100\u00a0mg/24h)\u00a0\u03c9\n273\u00b1298a\u00a0\u00a0nanog/ml \u00a0(ATV\u00a0400\u00a0mg/24h)\u00a0\u2126\u00a0En\u00a0VIH+:\u00a0\n2282\u00b11168 \u00a0a\u00a0nanog/ml \u00a0(DRV/r\u00a0800/100\u00a0\nmg/24h)\u00a0\u2126\u00a0\n3578\u00b11151 \u00a0a\u00a0nanog/ml \u00a0(DRV/r\u00a0600/100\u00a0\nmg/12h)\u00a0\u2126\u00a0En\u00a0VIH+:\u00a0\n41,6\u00a0\u00b1\u00a024,3\u00a0microM\u00a0en\u00a0mujeres\u00a0(TPV/r\u00a0\n500/200\u00a0mg/12h)\u00a0\u03c9\u00a0\n35,6\u00a0\u00b1\u00a016,7\u00a0microM\u00a0en\u00a0hombres\u00a0(TPV/r\u00a0\n500/200\u00a0mg/12h)\u00a0\u03c9\u00a0\nAUC\u00a0 AUC0\u201012h:\u00a0113,2\u00a0\u00b1\u00a060,5\u00a0\nmicrog\u2022h/ml \u00a0(400/100\u00a0mg/12h)\u00a0\u00a0\u00a0\na,\u00a0\u03c9\u00a0\nAUC0\u201012h:\u00a092,6\u00a0\u00b1\u00a036,7\u00a0\u03bcg\u2022h/mL\u00a0\n(400/100\u00a0mg/12)(VIH+)a,\u00a0\u2126\u00a0\nAUC0\u201024h:\u00a0154,1\u00b1\u00a061,4\u00a0\nmicrog\u2022h/ml \u00a0(800/200\u00a0mg/24h)\u00a0\n(VIH+)\u00a0\u00a0\u00a0a,\u00a0\u2126\u00a0En\u00a0VIH+:\u00a0\nAUC0\u201024h:\u00a044185\u00a0nanog\u2022h/ml\u00a0(ATV/r\u00a0\n300/100\u00a0mg/24h)\u00a0\u03c9\u00a0\nAUC0\u201024h:\u00a022262\u00b120159 \u00a0a\u00a0nanog\u2022h/ml\u00a0\n(ATV\u00a0400\u00a0mg/24h)\u00a0\u2126\u00a0\n\u00a0En\u00a0VIH+:\u00a0\n93026\u00b127050 \u00a0a\u00a0nanog.h/ml \u00a0(DRV/r\u00a0\n800/100\u00a0mg/24h)\u00a0\u2126\u00a0\n124698\u00b132286 \u00a0a\u00a0nanog.h/ml \u00a0(DRV/r\u00a0\n600/100\u00a0mg/12h)\u00a0\u2126\u00a0En\u00a0VIH+:\u00a0\nAUC0\u201012h:\u00a0851\u00a0\u00b1\u00a0309\u00a0microM.h \u00a0en\u00a0mujeres\u00a0y\u00a0\n710\u00a0\u00b1\u00a0207\u00a0microM.h \u00a0\u00a0en\u00a0hombres\u00a0(TPV/r\u00a0\n500/200\u00a0mg/12h)\u00a0\u03c9\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 140 Nombre\u00a0\ngen\u00e9rico\u00a0Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\n\u00a0\nCI50/90\u00a0frente\u00a0a\u00a0\nVIH\u20101\u00a0(in\u00a0vitro)\u00a0\u00a0\nCI50\u00a0frente\u00a0a\u00a0VIH\u20101IIIB\u00a0en\u00a0c\u00e9lulas\u00a0\nMT4\u00a0fue\u00a017\u00a0nanoM\u00a0(10,6\u00a0\nmicrog/mL) \u00a0en\u00a0ausencia\u00a0de\u00a0suero\u00a0\nhumano\u00a0y\u00a0102\u00a0nanoM\u00a0(63,75\u00a0\nmicrog/mL) \u00a0en\u00a0presencia \u00a0de\u00a0\nsuero.\u00a0\u03c9\u00a0\nCI50\u00a0frente\u00a0a\u00a0varios\u00a0aislados\u00a0\ncl\u00ednicos\u00a0de\u00a0VIH\u20101\u00a0en\u00a0ausencia\u00a0de\u00a0\nsuero\u00a0\u00a06,5\u00a0nanoM\u00a0(4,6\u00a0\nmicrog/mL).\u00a0\u03c9\u00a0\u00a0\nCI50:0,002\u20100.004\u00a0microg/mL \u00a0\n(2,6\u00a0\u2013\u00a05,3\u00a0nanoM)\u00a0\u2126\u00a0\n\u00a0\u00a0\nCI50\u00a0:\u00a01,2\u00a0\u2010\u00a08,5\u00a0nanoM\u00a0(0,7\u00a0\u2010\u00a05,0\u00a0\nnanog/ml)\u00a0\u03c9\u00a0\u00a0\nCI50:\u00a00,03\u00a0a\u00a00,07\u00a0microM\u00a0(18\u201042\u00a0nanog/ml)\u00a0\n\u03c9\u00a0\nCI90:\u00a00,07\u00a0a\u00a00,18\u00a0microM\u00a0(42\u2010108\u00a0nanog/ml) \u00a0\n(La\u00a0actividad\u00a0antiviral\u00a0de\u00a0tipranavir \u00a0\ndisminuye \u00a03,75\u00a0veces\u00a0de\u00a0media\u00a0en\u00a0\npresencia \u00a0de\u00a0suero\u00a0humano).\u00a0\u03c9\u00a0\nActividad\u00a0frente\u00a0a\u00a0\nVIH\u20101\u00a0\n\u00a0VIH\u20101,2\u00a0\u03c9\u00a0 VIH\u20101,2\u00a0\u03c9\u00a0 VIH\u20101,2\u00a0\u03c9\u00a0 VIH\u20101,2\u00a0\u03c9\u00a0\nPenetraci\u00f3n \u00a0en\u00a0LCR\u00a0\n(LCR:plasma) \u00a0Grado\u00a03\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0\nseg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0del\u00a0estudio\u00a0\nCHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0\nmayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0\nCroi\u00a02010)\u00a0LCR/plasma: \u00a00,0021\u00a0a\u00a00,0226c,\u00a0\u2126\u00a0\nATV\u00a0\u00b1\u00a0RTV:\u00a0grado\u00a02\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0\nLCR\u00a0seg\u00fan\u00a0la\u00a0clasificaci\u00f3n \u00a0del\u00a0estudio\u00a0\nCHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0a\u00a0mayor)\u00a0\n(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a02010)\u00a0\nATV/r:\u00a0LCR:\u00a010,3\u00a0(<5\u201021\u00a0ng/mL)b\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a01278\u00a0(525\u20102265\u00a0\nng/mL)b\u00a0\u00a0\nATV:\u00a0LCR\u00a07,9\u00a0(6,6\u201022\u00a0ng/mL)\u00a0b\u00a0con\u00a0ATV,\u00a0\nen\u00a0comparaci\u00f3n \u00a0con\u00a0523\u00a0(283\u20101344\u00a0\nng/mL).\u00a0Concentraciones \u00a0en\u00a0LCR\u00a0bajas\u00a0\n(<1%)\u00a0y\u00a0muy\u00a0variables. \u00a0(Best\u00a0BM.\u00a0AIDS\u00a0\n2009;23(1):83 \u201087).\u00a0Grado\u00a03\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0la\u00a0\nclasificaci\u00f3n \u00a0del\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0\na\u00a04,\u00a0menor\u00a0a\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0\n430.\u00a0Croi\u00a02010)\u00a0No\u00a0hay\u00a0estudios\u00a0\u03c9\u00a0\nGrado\u00a01\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0la\u00a0\nclasificaci\u00f3n \u00a0del\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0\nmenor\u00a0a\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0\nCroi\u00a02010)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 141 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\n\u00a0\nMetabolizaci\u00f3n \u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\n\u00a0\nEfectos\u00a0\nAdversos \u00a0\u00a0\nIntolerancia \u00a0G\u2010I\u00a0\n(v\u00f3mitos, \u00a0diarrea)\u00a0\nCefalea\u00a0\nAstenia\u00a0\nHiperglicemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\nPosible\u00a0aumento\u00a0del\u00a0sangrado \u00a0\nen\u00a0hemof\u00edlicos \u00a0\u00a0\nHiperbilirrubinemia \u00a0\nIntolerancia \u00a0GI\u00a0(diarrea)\u00a0\nCefalea\u00a0\nLos\u00a0estudios\u00a0disponibles \u00a0a\u00a0las\u00a048\u00a0\nsemanas\u00a0no\u00a0muestran \u00a0alteraciones \u00a0\nlip\u00eddicas\u00a0relevantes \u00a0\nATV/r:\u00a0Dislipemia \u00a0leve\u00a0\nPosible\u00a0aumento\u00a0del\u00a0sangrado \u00a0en\u00a0\nhemof\u00edlicos \u00a0\u00a0\nIntolerancia \u00a0G\u2010I\u00a0(v\u00f3mitos, \u00a0diarrea)\u00a0\nCefalea\u00a0\nAstenia\u00a0\nDislipemia \u00a0leve\u00a0\nErupci\u00f3n\u00a0cut\u00e1nea,\u00a0que\u00a0suele\u00a0ser\u00a0\nmoderada \u00a0y\u00a0autolimitada. \u00a0\u00a0\nPosible\u00a0aumento\u00a0del\u00a0sangrado \u00a0en\u00a0\nhemof\u00edlicos \u00a0\u00a0Intolerancia \u00a0GI\u00a0(diarrea)\u00a0\nAlteraciones \u00a0SNC\u00a0(v\u00e9rtigo,\u00a0dificultad \u00a0de\u00a0\nconcentraci\u00f3n, \u00a0enlentecimiento, \u00a0cambios\u00a0de\u00a0\nhumor).\u00a0\nEn\u00a0combinaci\u00f3n \u00a0con\u00a0RTV,\u00a0aumento\u00a0de\u00a0\ntriglic\u00e9ridos \u00a0y\u00a0transaminasas. \u00a0\nSe\u00a0han\u00a0descrito\u00a014\u00a0casos\u00a0de\u00a0hemorragia \u00a0\nintracraneal, \u00a08\u00a0de\u00a0los\u00a0cuales\u00a0fueron\u00a0mortales, \u00a0\nentre\u00a06840\u00a0pacientes \u00a0incluidos\u00a0en\u00a0ensayos\u00a0\ncl\u00ednicos.\u00a0La\u00a0mayor\u00eda\u00a0ten\u00edan\u00a0factores\u00a0de\u00a0riesgo.\u00a0\n\u00a0\nAsociaciones \u00a0\ncontraindicadas \u00a0Alfuzosina \u00a0\nAnticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nCisaprida\u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0\nhep\u00e1tica) \u00a0\nDeriv.\u00a0ergotamina \u00a0\nEncainida \u00a0\nEstatinas\u00a0(excepto\u00a0atorvastatina, \u00a0\nfluvastatina \u00a0y\u00a0pravastatina) \u00a0\n\u00c9xtasis\u00a0\u00a0\nFluticasona \u00a0inh.\u00a0\nFPV\u00a0\nFlecainida \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nPimozida\u00a0\nPropafenona \u00a0Alfuzosina \u00a0\nAstemizol \u00a0\nBosentan \u00a0con\u00a0ATV\u00a0no\u00a0potenciado \u00a0\nEstatinas\u00a0(excepto\u00a0fluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nCisaprida\u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0hep\u00e1tica) \u00a0\nDeriv.\u00a0Ergotamina \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLumefantrina \u00a0\nIDV\u00a0\nIrinotecan \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nOmeprazol \u00a0y\u00a0afines\u00a09\u00a0\nPimozida\u00a0\nRifampicina \u00a0\nSalmeterol \u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0pulmonar) \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam \u00a0Alfuzosina \u00a0\nAmiodarona \u00a0\nAstemizol \u00a0\nCisaprida\u00a0\u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0hep\u00e1tica) \u00a0\nDeriv.\u00a0Ergotamina \u00a0\u00a0\nEstatinas\u00a0(simvastatina \u00a0y\u00a0lovastatina) \u00a0\nExtasis\u00a0\nFenobarbital \u00a0\nfenitoina\u00a0\nFluticasona \u00a0inh.\u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLidoca\u00edna \u00a0sist\u00e9mica \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nPimozida\u00a0\u00a0\nQuinidina \u00a0\u00a0\nRifampicina \u00a0\nSalmeterol \u00a0\nSertindol\u00a0Alfuzosina \u00a0\nAstemizol \u00a0\nCisaprida\u00a0\nColchicina \u00a0(si\u00a0insuf.\u00a0renal\u00a0o\u00a0hep\u00e1tica) \u00a0\nDeriv.\u00a0ergotamina \u00a0\nEncainida \u00a0\nEstatinas\u00a0(excepto\u00a0atorvastatina, \u00a0fluvastatina \u00a0\ny\u00a0pravastatina) \u00a0\nEtravirina \u00a0\n\u00c9xtasis\u00a0\u00a0\nFlecainida \u00a0\nFluticasona \u00a0inh\u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nPimozida\u00a0\nPropafenona \u00a0\nQuinidina \u00a0\u00a0\nRifampicina \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 142 Quinidina \u00a0\u00a0\nRifampicina \u00a0\nSalmeterol \u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0\npulmonar) \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0\u00a0\u00a0\n\u00a0Sildenafilo \u00a0(hipertensi\u00f3n \u00a0pulmonar) \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0\u00a0\u00a0Salmeterol \u00a0\nSQV\u00a0\nSildenafilo \u00a0(hipertensi\u00f3n \u00a0pulmonar) \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 143 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nAnti\u00e1cidos \u00a0\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0\u00a0 Espaciar\u00a01\u20102h\u00a0(primero\u00a0ATV)\u00a0\u00a0 Espaciar\u00a01\u20102h\u00a0(\u219325\u201029%\u00a0AUC\u00a0TPV)\u00a0\nInh.\u00a0bomba\u00a0protones Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 Contraindicado \u00a011\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0\nAntihist.\u00a0H2\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 Ensayado \u00a0con\u00a0famotidina12\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 No\u00a0hay\u00a0datos:\u00a0probablemente \u00a0ausencia\u00a0\nde\u00a0interacci\u00f3n \u00a0\nAntimicobact. \u00a0\u00a0\u00a0\u00a0 \u00a0\n\u2010\u00a0Rifampicina \u00a0 Contraindicado \u00a0 Contraindicado \u00a0 Contraindicado \u00a0 Contraindicado \u00a0(no\u00a0hay\u00a0datos)\u00a0\n\u2010\u00a0Rifabutina \u00a0(RFB)\u00a0RFB\u00a0150\u2010300\u00a0mg\u00a0\u00a03\u00a0veces\u00a0/semana0\u00a0NRAD\u00a0ATV\u00a0\n\u00a0RFB\u00a0150\u2010300\u00a0\u00a0mg\u00a03\u00a0veces\u00a0/semana. \u00a0NRAD\u00a0DRV/r\u00a0\n\u00a0RFB\u00a0150\u2010300\u00a0\u00a0mg\u00a03\u00a0veces\u00a0/semana0\u00a0RFB150\u2010300\u00a0mg\u00a0\u00a03\u00a0veces\u00a0/semana0\u00a0\n\u00a0\n\u2010\u00a0Claritromicina \u00a0Considerar \u00a0tratamientos \u00a0alternativos \u00a0\npara\u00a0indicaciones \u00a0diferentes \u00a0de\u00a0MAC.\u00a0\nAjustar\u00a0dosis\u00a0claritro\u00a0si\u00a0func.\u00a0renal\u00a0\nalterada1.\u00a0Reducir\u00a050%\u00a0la\u00a0dosis\u00a0de\u00a0claritro.\u00a0Se\u00a0\nreducen\u00a0las\u00a0concentraciones \u00a0de\u00a0su\u00a0\nmetabolito \u00a05\u2010hidroxi\u2010.\u00a0Considerar \u00a0\ntratamientos \u00a0alternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0de\u00a0MAC.\u00a0Considerar \u00a0tratamientos \u00a0\nalternativos \u00a0para\u00a0indicaciones \u00a0\ndiferentes \u00a0de\u00a0MAC\u00a0(niveles\u00a0de\u00a014\u2010\nOH\u2010claritromicina \u00a0inferiores \u00a0al\u00a0l\u00edmite\u00a0\nde\u00a0cuantificaci\u00f3n). \u00a0\nAjustar\u00a0dosis\u00a0claritro\u00a0si\u00a0func.\u00a0renal\u00a0\nalterada1.\u00a0Considerar \u00a0tratamientos \u00a0alternativos \u00a0\npara\u00a0indicaciones \u00a0diferentes \u00a0de\u00a0MAC.\u00a0\nTPV:\u219160%\u00a0AUC,\u00a0x2\u00a0Cm\u00edn;\u00a0Claritro:\u00a0\u219119%\u00a0\nAUC,\u00a0\u219168%\u00a0Cmin,\u00a0\u2193>95%\u00a014\u2010OH\u2010\nclaritromicina. \u00a0\n\u00a0\nAntiepil\u00e9pticos :\u00a0\n\u00a0\nCarbamazepina, \u00a0\nfenito\u00edna, \u00a0\nfenobarbital, \u00a0\nlamotrigina \u00a0Un\u00a0caso\u00a0descrito\u00a0de\u00a0intoxicaci\u00f3n \u00a0con\u00a0\ncarbamacepina \u00a0(tambien\u00a0podr\u00edan\u00a0\u2193Cp\u00a0\nLPV:\u00a0monitorizar \u00a0niveles\u00a0de\u00a0ambos).\u00a0\nCon\u00a0fenito\u00edna,\u00a0se\u00a0han\u00a0descrito\u00a0\u219330%\u00a0en\u00a0\nel\u00a0AUC\u00a0de\u00a0fenito\u00edna, \u00a0LPV\u00a0y\u00a0RTV\u00a0y\u00a0\u2193\u00a0\u2245\u00a0\n50%\u00a0Cmin\u00a0LPV\u00a0y\u00a0RTV.\u00a0Posible\u00a0\nrepercusi\u00f3n \u00a0cl\u00ednica.\u00a0Monitorizar \u00a0Cp\u00a0de\u00a0\nambos\u00a0f\u00e1rmacos. \u00a0\nCon\u00a0lamotrigina :\u00a0se\u00a0recomienda \u00a0duplicar\u00a0\nla\u00a0dosis\u00a0de\u00a0lamotrigina. \u00a0\nCon\u00a0\u00e1c\u00a0valproico:\u00a0datos\u00a0contradictorios \u00a0\n(\u219348%\u00a0niveles\u00a0valproico\u00a0en\u00a0un\u00a0paciente\u00a0\nversus\u00a0sin\u00a0cambios\u00a0en\u00a0otro\u00a0estudio\u00a0en\u00a0\nque\u00a0se\u00a0compar\u00f3\u00a0niv.\u00a0de\u00a0valproico\u00a0con\u00a0\ndatos\u00a0hist\u00f3ricos). \u00a0Precauci\u00f3n. \u00a0\u00a0Posible\u00a0\u2193Cp\u00a0ATV.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nantirretroviral \u00a0y\u00a0antiepil\u00e9ptico. \u00a0\n\u00a0Lamotrigina: \u00a0con\u00a0ATV\u00a0nopotenciado \u00a0\n\u219312%\u00a0AUC\u00a0lamotrigina; \u00a0con\u00a0ATV/r\u00a0\u219332%\n\u00a0\nAUC\u00a0lamotrigina. \u00a0\n\u00a0Carbamazepina \u00a0(200\u00a0mg/12h): \u00a0\u219145%\u00a0\nAUC\u00a0CBZ,\u00a0DRV\u00a0sin\u00a0cambios.\u00a0Valorar\u00a0\nreduccion \u00a0de\u00a0dosis\u00a0de\u00a0\ncarbamazepina \u00a0del\u00a025\u201050%.\u00a0Se\u00a0\nrecomienda \u00a0monitorizar \u00a0niveles\u00a0de\u00a0\ncarbamazepina. \u00a0\nFenobarbital \u00a0y\u00a0fenito\u00edna:\u00a0\ncontraindicados \u00a0por\u00a0riesgo\u00a0de\u00a0\nreducci\u00f3n \u00a0de\u00a0las\u00a0Cp\u00a0de\u00a0DRV.\u00a0\n\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0antirretroviral \u00a0y\u00a0\nantiepil\u00e9ptico. \u00a0\n\u00a0Un\u00a0caso\u00a0de\u00a0reducci\u00f3n \u00a0del\u00a050%\u00a0en\u00a0las\u00a0Cp\u00a0\nde\u00a0fenobarbital\n.\u00a0\nAnticoagulantes \u00a0\norales\u00a0\n\u00a0Los\u00a0IP\u00a0pueden\u00a0alterar\u00a0las\u00a0Cp\u00a0de\u00a0los\u00a0anticoagulantes. \u00a0Existen\u00a0casos\u00a0descritos\u00a0de\u00a0reducci\u00f3n \u00a0del\u00a0efecto\u00a0anticoagulante \u00a0con\u00a0requerimiento \u00a0de\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0\nacenocumarol \u00a0y\u00a0warfarina \u00a0al\u00a0asociarlos \u00a0a\u00a0RTV,\u00a0LPV/r\u00a0\u00f3\u00a0IDV.\u00a0Monitorizar \u00a0estrictamente \u00a0el\u00a0tiempo\u00a0de\u00a0protrombina. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 144 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nAnticonceptivos \u00a0\norales :\u00a0\u219342%\u00a0AUC\u00a0etinilestradiol. \u00a0\u00a0\nNo\u00a0debe\u00a0administrarse \u00a0junto\u00a0con\u00a0\nanticonceptivos \u00a0que\u00a0contengan \u00a0\netinilestradiol \u00a0o\u00a0noretindrona. \u00a0\nDeben\u00a0considerarse \u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0alternativos \u00a0o\u00a0\nadicionales \u00a0.\u00a0ATV\u00a0400\u00a0mg/24h:\u00a0\u2191\u00a048%\u00a0etinilestradiol, \u2191\u00a0x2\u00a0AUC\u00a0\nnoretindrona,. \u00a0Se\u00a0recomienda \u00a0que\u00a0el\u00a0\nanticonceptivo \u00a0oral\u00a0tenga\u00a0como\u00a0m\u00e1ximo\u00a030\u00a0mcg\u00a0\nde\u00a0etinilestradiol. \u00a0\nCon\u00a0ATV/r\u00a0300/100\u00a0mg\u00a0c/24h:\u00a0\u2193\u00a020%\u00a0\netinilestradiol, \u219185% AUC \u00a0norgestimato.Se \u00a0\nrecomienda \u00a0\u00a0que\u00a0el\u00a0anticonceptivo \u00a0oral\u00a0tenga,\u00a0\ncomo\u00a0m\u00ednimo\u00a030\u00a0mcg\u00a0de\u00a0etinilestradiol. \u00a0Con\u00a0\nambas\u00a0pautas\u00a0aumentan \u00a0los\u00a0niveles\u00a0de\u00a0\nprogest\u00e1geno, \u00a0pudiendo \u00a0aumentar \u00a0los\u00a0efectos\u00a0\nadversos. \u00a0\u00a0DRV/r 600/100 mg/12h: \u219344%\u00a0AUC\u00a0\u00a0\netinilestradiol \u00a0\u219314%,\u00a0AUC\u00a0\nnoretindrona. \u00a0No\u00a0debe\u00a0\nadministrarse \u00a0junto\u00a0con\u00a0\nanticonceptivos \u00a0que\u00a0contengan \u00a0\netinilestradiol \u00a0o\u00a0noretindrona. \u00a0\nDeben\u00a0considerarse \u00a0m\u00e9todos\u00a0\nanticonceptivos \u00a0alternativos \u00a0o\u00a0\nadicionales. \u00a0\u2193 50%\u00a0AUC\u00a0etinilestradiol. \u00a0Noretindrona \u00a0\nsin\u00a0cambios,\u00a0No\u00a0debe\u00a0administrarse \u00a0\njunto\u00a0con\u00a0anticonceptivos \u00a0que\u00a0\ncontengan \u00a0etinilestradiol \u00a0o\u00a0noretindrona \u00a0\n(disminuye \u00a0sus\u00a0niveles).\u00a0Deben\u00a0\nconsiderarse \u00a0m\u00e9todos\u00a0anticonceptivos \u00a0\nalternativos \u00a0o\u00a0adicionales. \u00a0\n\u00a0\nAntif\u00fangicos \u00a0\nimidaz\u00f3licos \u00a0No\u00a0se\u00a0han\u00a0descrito\u00a0interacciones \u00a0\ncl\u00ednicamente \u00a0importantes \u00a0con\u00a0\nfluconazol .\u00a0M\u00e1x\u00a0200\u00a0mg/d\u00eda\u00a0de\u00a0\nitraconazol \u00a0y\u00a0de\u00a0ketoconazol .\u00a0\nCon\u00a0voriconazol \u00a0y\u00a0LPV/r\u00a0no\u00a0hay\u00a0\ndatos\u00a0(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0c/12h:\u00a0\nevitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0justifique \u00a0su\u00a0uso.\u00a0\nVer\u00a0RTV).\u00a0Monitorizar \u00a0\nestrechamente. \u00a0\n\u00a0\n\u00a0Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0fluconazol .\u00a0\nPuede\u00a0administrarse \u00a0ATV\u00a0no\u00a0potenciado \u00a0con\u00a0\nketoconazol \u00a0junto\u00a0con\u00a0una\u00a0comida\u00a0ligera\u00a0sin\u00a0que\u00a0\nse\u00a0requiera\u00a0ajuste\u00a0de\u00a0dosis.\u00a0Con\u00a0ATV/r\u00a0no\u00a0\nexceder\u00a0200\u00a0mg/d\u00eda\u00a0de\u00a0ketoconazol. \u00a0\n\u00a0Con\u00a0voriconazol\n\u00a0y\u00a0ATV+/\u2010\u00a0RTV:\u00a0no\u00a0hay\u00a0datos\u00a0\n(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0contraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0\nc/12h:\u00a0evitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0justifique \u00a0su\u00a0uso.\u00a0Ver\u00a0RTV).\u00a0\nMonitorizar \u00a0estrechamente. \u00a0\n\u00a0\nPosaconazol \u00a0(400\u00a0mg/12h)\u00a0en\u00a0voluntarios \u00a0sanos\u00a0\naument\u00f3\u00a03,7\u00a0veces\u00a0el\u00a0AUC\u00a0de\u00a0ATV\u00a0no\u00a0\npotenciado \u00a0y\u00a02,5\u00a0veces\u00a0el\u00a0AUC\u00a0de\u00a0ATV/r.\u00a0Se\u00a0\nobservaron \u00a0aumentos \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0\nde\u00a0bilirrubina. \u00a0Ketoconazol: \u00a0+\u00a042%\u00a0AUC\u00a0DRV;\u00a0AUC\u00a0\nde\u00a0ketoconazol \u00a02\u00a0veces\u00a0mayor:\u00a0dosis\u00a0\nm\u00e1xima\u00a0de\u00a0ketoconazol \u00a0200\u00a0mg/d\u00eda.\u00a0\nItraconazol: \u00a0dosis\u00a0m\u00e1xima\u00a0de\u00a0\nitraconazol \u00a0200\u00a0mg/d\u00eda.\u00a0\nLa\u00a0coadministraci\u00f3n \u00a0de\u00a0voriconazol \u00a0y\u00a0\nDRV/r\u00a0no\u00a0ha\u00a0sido\u00a0estudiada \u00a0(RTV\u00a0400\u00a0\nmg\u00a0c/12h\u00a0\u00a0contraindicado; \u00a0RTV\u00a0100\u00a0\nmg\u00a0c/12h:\u00a0evitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0\nbalance\u00a0riesgo/beneficio \u00a0justifique \u00a0\nsu\u00a0uso.\u00a0Ver\u00a0RTV).\u00a0Monitorizar \u00a0\nestrechamente. \u00a0Con\u00a0fluconazol \u00a0(100\u00a0mg\u00a0c/24h),\u00a0posible\u00a0\naumento\u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nTPV\u00a0(datos\u00a0limitados). \u00a0Monitorizar \u00a0\ntoxicidad. \u00a0\nNo\u00a0se\u00a0recomienda \u00a0sobrepasar \u00a0los\u00a0200\u00a0\nmg/d\u00eda\u00a0de\u00a0fluconazol, \u00a0itraconazol \u00a0y\u00a0\nketoconazol. \u00a0\n\u00a0Con\u00a0voriconazol \u00a0\ny\u00a0TPV+/\u2010\u00a0RTV:\u00a0no\u00a0hay\u00a0\ndatos\u00a0(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0c/12h:\u00a0\nevitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0justifique \u00a0su\u00a0uso.\u00a0Ver\u00a0\nRTV).\u00a0Monitorizar \u00a0estrechamente. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso \u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 145 \u00a0\n\u00a0\u00a0\u00a0\nNombre\u00a0gen\u00e9rico Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nEstatinas \u00a0y\u00a0otros\u00a0\nhipolipemiantes \u00a0Lovastatina, \u00a0simvastatina\u00a0 y\u00a0fluvastatina \u00a0\ncontraindicadas. \u00a0\u00a0\nPravastatina: \u00a0NRAD\u00a0\nAtorvastatina: \u00a0asociar\u00a0con\u00a0precauci\u00f3n \u00a0\n(iniciar\u00a0con\u00a0m\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0\nRosuvastatina: \u00a0\uf0adx2\u00a0AUC\u00a0 rosuvastatina. \u00a0\nGemfibrozilo: \u00a0\u219341%\u00a0AUC\u00a0 gemfibrozilo. \u00a0\n\u00a0Lovastatina \u00a0y\u00a0simvastatina\u00a0\ncontraindicadas. \u00a0\u00a0\nFuvastatina \u00a0y\u00a0pravastatina \u00a0interacci\u00f3n \u00a0\npoco\u00a0probable. \u00a0\u00a0\nAtorvastatina: \u00a0asociar\u00a0con\u00a0precauci\u00f3n \u00a0\n(iniciar\u00a0con\u00a0m\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0Lovastatina, \u00a0simvastatina\u00a0 y\u00a0fluvastatina \u00a0\ncontraindicadas. \u00a0\nAtorvastatina \u00a0(\u2191x4\u00a0AUC\u00a0 atorvastatina):\u00a0\nse\u00a0recomienda \u00a0empezar\u00a0 con\u00a0una\u00a0 dosis\u00a0\nde\u00a0atorvastatina \u00a0de\u00a010\u00a0mg\u00a0al\u00a0d\u00eda\u00a0y\u00a0\naumentar \u00a0progresivamente\u00a0 en\u00a0f unci\u00f3n\u00a0\nde\u00a0la\u00a0respuesta\u00a0 cl\u00ednica.\u00a0\nRosuvastatina: \u00a0\uf0ad48%\u00a0AUC\u00a0\nrosuvastatina. \u00a0\nPravastatina: \u00a0en\u00a0un\u00a0estudio\u00a0 DRV/r\u00a0 no\u00a0\naument\u00f3\u00a0la\u00a0exposici\u00f3n \u00a0a\u00a0una\u00a0 dosis\u00a0\n\u00fanica\u00a0de\u00a0pravastatina, \u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\nsujetos,\u00a0aunque\u00a0\u00e9sta\u00a0se\u00a0multiplic\u00f3 \u00a05\u00a0\nveces\u00a0 s\u00f3lo\u00a0en\u00a0un\u00a0subgrupo \u00a0de\u00a0sujetos.\u00a0\nEn\u00a0otro\u00a0estudio\u00a0 se\u00a0observ\u00f3\u00a0 menos\u00a0\ninteracci\u00f3n: \u00a0\uf0ad21%\u00a0y\u00a0como\u00a0m\u00e1ximo\u00a0el\u00a0\nAUC\u00a0 se\u00a0duplic\u00f3.\u00a0Se\u00a0recomienda \u00a0iniciar\u00a0\ncon\u00a0dosis\u00a0bajas\u00a0de\u00a0pravastatina \u00a0e\u00a0\nincrementarlas \u00a0gradualmente \u00a0\u00a0hasta\u00a0\nconseguir \u00a0el\u00a0efecto\u00a0 cl\u00ednico\u00a0deseado\u00a0Lovastatina, \u00a0simvastatina\u00a0 y\u00a0fluvastatina \u00a0\ncontraindicadas. \u00a0\u00a0\nTPV/r\u00a0aument\u00f3\u00a09\u00a0veces\u00a0 el\u00a0AUC\u00a0 de\u00a0\natorvastatina. \u00a0\u00a0\nUtilizar\u00a0 preferiblemente\u00a0 pravastatina\u00a0\n(interacci\u00f3n \u00a0poco\u00a0probable). \u00a0\nRosuvastatina: \u00a0\uf0ad37%\u00a0AUC\u00a0\nrosuvastatina. \u00a0\nEtanol:\u00a0 El\u00a0uso\u00a0agudo\u00a0o\u00a0cr\u00f3nico\u00a0de\u00a0etanol\u00a0alter\u00f3\u00a0m\u00ednimamente \u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0los\u00a0IP.\u00a0\nAntabus:\u00a0algunos\u00a0IP\u00a0podr\u00edan\u00a0dar\u00a0lugar\u00a0a\u00a0una\u00a0 reacci\u00f3n\u00a0de\u00a0tipo\u00a0disulfiram \u00a0por\u00a0su\u00a0contenido \u00a0en\u00a0etanol:\u00a0Norvir\u00ae\u00a0 soluci\u00f3n\u00a0oral\u00a0(43%\u00a0v/v);\u00a0Norvir\u00a0 c\u00e1psulas\u00a0(12%\u00a0p/p);\u00a0\nKaletra\u00ae\u00a0soluci\u00f3n\u00a0oral\u00a0(42%);\u00a0 Aptivus\u00a0c\u00e1psulas\u00a0(7%\u00a0p/p\u00a0=100\u00a0mg/c\u00e1ps).\u00a0 Kaletra\u00ae\u00a0en\u00a0comprimidos \u00a0no\u00a0contiene\u00a0alco hol.\u00a0Agenerase\u00ae \u00a0en\u00a0soluci\u00f3n\u00a0tiene\u00a0un\u00a0elevado\u00a0\ncontenido \u00a0de\u00a0propilenglicol \u00a0(550\u00a0mg/mL),\u00a0que\u00a0se\u00a0metaboliza\u00a0 a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0alcohol\u00a0deshidrogenasa, \u00a0por\u00a0lo\u00a0que\u00a0el\u00a0consumo\u00a0de\u00a0etanol\u00a0junto\u00a0 con\u00a0estos\u00a0IPs\u00a0podr\u00eda\u00a0\nproducir\u00a0toxicidad. \u00a0Kaletra\u00ae\u00a0en\u00a0c\u00e1psulas\u00a0y\u00a0Agenerase\u00ae \u00a0en\u00a0c\u00e1psulas\u00a0tambi\u00e9n\u00a0contienen \u00a0propilenglicol, \u00a0pero\u00a0en\u00a0men or \u00a0cantidad. \u00a0\nF\u00e1rmacos \u00a0empleados\u00a0\npara\u00a0tratar\u00a0la\u00a0gota\u00a0Gota\u2010profilaxis: \u00a0colchicina \u00a0con\u00a0\u00a0IP\u00a0potenciado:\u00a0 0,3\u00a0mg\u00a0c/24h\u201048h;\u00a0colchicina \u00a0con\u00a0FPV\u00a0no\u00a0potenciado:\u00a0 0,3\u20100,6\u00a0mg/d\u00eda.\u00a0\nGota\u2010tratamiento: \u00a0Colchicina \u00a0con\u00a0IP\u00a0potenciado:\u00a0 0.6\u00a0mg\u00a0+\u00a00,3\u00a0mg\u00a01h\u00a0despu\u00e9s\u00a0 y\u00a0no\u00a0readministrar \u00a0antes\u00a0de\u00a03\u00a0dias.\u00a0Colchicina \u00a0con\u00a0FPV\u00a0no\u00a0potenciado:\u00a0\u00a0\n1,2\u00a0mg\u00a0y\u00a0no\u00a0readministrar \u00a0antes\u00a0de\u00a03\u00a0dias.\u00a0\u00a0\nFiebre\u00a0mediterr\u00e1nea\u00a0 familiar:\u00a0colchicina \u00a0con\u00a0IP\u00a0potenciado: \u00a0m\u00e1ximo\u00a00,3\u00a0mg/12h;\u00a0con\u00a0\u00a0FPV\u00a0no\u00a0potenciado:\u00a0 m\u00e1ximo\u00a00,6\u00a0mg/12h.\u00a0\u00a0\n(Seg\u00fan\u00a0recomendaciones \u00a0de\u00a0la\u00a0FDA;\u00a0de\u00a0las\u00a0\u00a0presentaciones\u00a0 disponibles \u00a0en\u00a0Espa\u00f1a,\u00a0la\u00a0\u00fanica\u00a0que\u00a0podr\u00eda\u00a0ajustarse\u00a0aproximadamente \u00a0ser\u00eda\u00a0el\u00a0Colchimax\u00ae \u00a0de\u00a00,5\u00a0mg).\u00a0\nF\u00e1rmacos \u00a0empleados\u00a0 Bosentan \u00a0(Tracleer\u00ae): \u00a0si\u00a0el\u00a0paciente\u00a0recibe\u00a0IPs\u00a0e\u00a0inicia\u00a0bosentan: \u00a0iniciar\u00a062,5\u00a0 mg\u00a0c/24\u2010 48h.\u00a0Si\u00a0el\u00a0paciente\u00a0\u00a0recibe\u00a0bosentan \u00a0e\u00a0inicia\u00a0IPs:\u00a0suspender \u00a0bosentan \u00a0m\u00ednimo\u00a0 \nDocumento \u00a0de\u00a0consenso \u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 146 para\u00a0tratar\u00a0la\u00a0\nhipertensi\u00f3n\u00a0 pulmonar \u00a036horas\u00a0antes\u00a0y\u00a0no\u00a0reiniciar\u00a0 hasta\u00a010\u00a0d\u00edas\u00a0despu\u00e9s\u00a0de\u00a0iniciar\u00a0el\u00a0IP\u00a0a\u00a0una\u00a0 dosis\u00a0de\u00a062,5\u00a0mg\u00a0c/24\u2010 48h.\u00a0\u00a0No\u00a0se\u00a0recomienda\u00a0 asociar\u00a0bosentan\u00a0 a\u00a0ATV\u00a0no\u00a0potenciado\u00a0 por\u00a0\nriesgo\u00a0de\u00a0reducci\u00f3n \u00a0de\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0ATV.\u00a0\u00a0\nTadalafilo \u00a0(Cialis\u00ae):\u00a0si\u00a0el\u00a0paciente\u00a0recibe\u00a0IPs\u00a0e\u00a0inicia\u00a0tadalafilo: \u00a0iniciar\u00a020\u00a0mg\u00a0c/24h\u00a0y\u00a0aumentar \u00a0luego\u00a0a\u00a040\u00a0mg/d\u00eda\u00a0seg\u00fan\u00a0tolerabilidad. \u00a0Si\u00a0el\u00a0paciente\u00a0recibe\u00a0tadalafilo \u00a0y\u00a0\ndebe\u00a0iniciar\u00a0IPs:\u00a0suspender \u00a0tadalafilo \u00a0minimo\u00a024h\u00a0antes\u00a0y\u00a0no\u00a0reiniciar\u00a0 hasta\u00a07\u00a0d\u00edas\u00a0despu\u00e9s\u00a0de\u00a0iniciar\u00a0el\u00a0IP\u00a0a\u00a0una\u00a0 dosis\u00a0de\u00a020\u00a0mg\u00a0c/24h,\u00a0luego\u00a0aumentar \u00a0a\u00a040mg/dia. \u00a0\nF\u00e1rmacos \u00a0empleados\u00a0\npara\u00a0tratar\u00a0la\u00a0influenza\u00a0Zanamivir/amantadina: \u00a0una\u00a0 interacci\u00f3n \u00a0con\u00a0los\u00a0IPs\u00a0se\u00a0considera \u00a0poco\u00a0probable. \u00a0\nOseltamivir \u00a0se\u00a0ha\u00a0relacionado \u00a0con\u00a0efectos\u00a0adversos\u00a0neuropsiqui\u00e1tricos, \u00a0aunque\u00a0no\u00a0se\u00a0puede\u00a0descartar \u00a0que\u00a0\u00e9stos\u00a0sean\u00a0 debidos,\u00a0al\u00a0menos\u00a0en\u00a0parte,\u00a0a\u00a0la\u00a0propia\u00a0\nenfermedad.\u00a0 Los\u00a0IPs\u00a0al\u00a0bloquear\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0podr\u00edan\u00a0aumentar \u00a0la\u00a0penetraci\u00f3n \u00a0de\u00a0oseltamivir \u00a0en\u00a0el\u00a0SNC\u00a0y\u00a0emp eorar\u00a0 sus\u00a0efectos\u00a0adversos.\u00a0 Se\u00a0recomienda \u00a0\nasociarlos \u00a0con\u00a0precauci\u00f3n \u00a0hasta\u00a0que\u00a0no\u00a0se\u00a0disponga\u00a0 de\u00a0m\u00e1s\u00a0datos.\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nota:\u00a0En\u00a0esta\u00a0tabla\u00a0se\u00a0ha\u00a0corregido \u00a0el\u00a0error\u00a0del\u00a0nombre\u00a0comercial \u00a0de\u00a0bosentan\u00a0(Revatio \u00a0por\u00a0Tracleer) \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 147 \u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nPosible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\u00a0prednisona, \u00a0\ntacrolimus \u00a0y\u00a0sirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0inmunosupresor. \u00a0\nMicofenolato \u00a0se\u00a0glucuronida \u00a0por\u00a0lo\u00a0\nque\u00a0RTV\u00a0podr\u00eda\u00a0\u2193\u00a0sus\u00a0Cp.\u00a0Monitorizar \u00a0\nniveles/eficacia. \u00a0En\u00a0un\u00a0paciente, \u00a0las\u00a0\ndosis\u00a0de\u00a0ciclosporina \u00a0tuvo\u00a0que\u00a0\nreducirse \u00a0a\u00a01/20\u00a0parte\u00a0al\u00a0a\u00f1adir\u00a0LPV/r.\u00a0\n\u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0prednisona, \u00a0\ntacrolimus \u00a0y\u00a0sirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0inmunosupresor. \u00a0\n\u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0prednisona, \u00a0\ntacrolimus \u00a0y\u00a0sirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0inmunosupresor. \u00a0\nTacrolimus: \u00a0un\u00a0caso\u00a0descrito\u00a0de\u00a0ajuste\u00a0\nhasta\u00a00,5\u00a0mg/semana. \u00a0No\u00a0hay\u00a0datos.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0estrechamente \u00a0los\u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0inmunosupresor. \u00a0\n\u00a0\u00a0Inmunosupresores :\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nLa\u00a0dosis\u00a0de\u00a0ciclosporina \u00a0inicial\u00a0debe\u00a0ser\u00a0aprox\u00a01/10\u00a0de\u00a0la\u00a0habitual\u00a0y\u00a0puede\u00a0requerir\u00a0reducciones \u00a0progresivas \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0\ntiempo.\u00a0En\u00a0algunos\u00a0casos\u00a0la\u00a0dosis\u00a0al\u00a0cabo\u00a0de\u00a02\u00a0a\u00f1os\u00a0es\u00a0tan\u00a0s\u00f3lo\u00a0un\u00a025%\u00a0de\u00a0la\u00a0inicial\u00a0(probablemente \u00a0por\u00a0aumento\u00a0de\u00a0la\u00a0\nabsorci\u00f3n \u00a0intestinal \u00a0a\u00a0lo\n\u00a0largo\u00a0del\u00a0tiempo).\u00a0\u00a0\nTacrolimus: \u00a0se\u00a0ha\u00a0descrito\u00a0una\u00a0interacci\u00f3n \u00a0muy\u00a0importante \u00a0con\u00a0LPV/r\u00a0(pueden\u00a0ser\u00a0necesarios \u00a0menos\u00a0de\u00a01mg\u00a0de\u00a0\ntacrolimus \u00a0a\u00a0la\u00a0semana\u00a0y\u00a0puede\u00a0ser\u00a0necesario \u00a0esperar\u00a0de\u00a03\u00a0a\u00a05\u00a0semanas\u00a0(seg\u00fan\u00a0funci\u00f3n\u00a0hep\u00e1tica) \u00a0antes\u00a0de\u00a0administrar \u00a0\notra\u00a0dosis\u00a0de\u00a0tacrolimus \u00a0al\u00a0iniciar\u00a0LPV/r.\u00a0Tambi\u00e9n\u00a0se\u00a0ha\u00a0descrito\u00a0interacci\u00f3n \u00a0con\u00a0otros\u00a0IP\u00a0(p.\u00a0ej\u00a0.\u00a0mayor\u00a0con\u00a0NFV\u00a0que\u00a0con\u00a0\nIDV,\u00a0requiri\u00e9ndose \u00a0en\u00a0un\u00a0estudio\u00a0unos\u00a00,6\u00a0mg\u00a0diarios\u00a0de\u00a0tacrolimus \u00a0con\u00a0estos\u00a0IP).\u00a0\u00a0\nInterfer\u00f3n/ \u00a0\nRibavirina \u00a0Ribavirina: \u00a0no\u00a0existe\u00a0evidencia \u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0IP.\u00a0\u00a0\nInterfer\u00f3n: \u00a0su\u00a0v\u00eda\u00a0de\u00a0eliminaci\u00f3n \u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecida \u00a0as\u00ed\u00a0como\u00a0tampoco\u00a0su\u00a0posible\u00a0efecto\u00a0inhibidor\u00a0sobre\u00a0el\u00a0citocromo \u00a0P\u2010450\u00a0(ha\u00a0mostrado \u00a0p.\u00a0ej.\u00a0\u2191Cp\u00a0\nde\u00a0teofilina\u00a0y\u00a0barbituratos). \u00a0No\u00a0hay\u00a0datos\u00a0con\u00a0respecto\u00a0a\u00a0posibles\u00a0interacciones \u00a0con\u00a0IP.\u00a0\nEn\u00a0pacientes \u00a0tratados\u00a0con\u00a0ATV\u00a0se\u00a0han\u00a0descrito\u00a0\u2191x2\u00a0bilirrubina. \u00a0\nMetadona(MT) \u00a0y\u00a0otros\u00a0\nopi\u00e1ceos\u00a0MT:\u219353%\u00a0AUC\u00a0MT.\u00a0Habitualmente \u00a0\nNRAD\u00a0de\u00a0metadona \u00a0\nBuprenorfina/naloxona: \u00a0NRAD.\u00a0\nOxicodona: \u2191x2,6\u00a0AUC\u00a0oxicodona. \u00a0\nPuede\u00a0requerir\u00a0reducci\u00f3n \u00a0de\u00a0dosis.\u00a0Metadona: \u00a0Probablemente \u00a0NRAD.\u00a0\nAusencia\u00a0de\u00a0interacci\u00f3n \u00a0\nfarmacocin\u00e9tica \u00a0con\u00a0ATV\u00a0400mg/d\u00eda. \u00a0\nSeg\u00fan\u00a0datos\u00a0iniciales\u00a0con\u00a0ATV/r\u00a0\n300/100\u00a0mg\u00a0c/24h\u00a0los\u00a0ajustes\u00a0de\u00a0dosis\u00a0\nde\u00a0MT,\u00a0si\u00a0se\u00a0requieren, \u00a0son\u00a0m\u00ednimos. \u00a0\nAlgunos\u00a0casos\u00a0descritos\u00a0de\u00a0\nintoxicaci\u00f3n \u00a0opi\u00e1cea\u00a0en\u00a0pacientes \u00a0\ntratados\u00a0con\u00a0ATV/r\u00a0y\u00a0buprenorfina, \u00a0\nresuelta\u00a0tras\u00a0reducir\u00a0la\u00a0dosis\u00a0del\u00a0\nopi\u00e1ceo.\u00a0Metadona: \u00a0no\u00a0se\u00a0requiere\u00a0ajustes\u00a0\ninicialmente. \u00a0Monitorizaci\u00f3n \u00a0cl\u00ednica\u00a0y\u00a0\najustar\u00a0dosis\u00a0posteriormente \u00a0en\u00a0caso\u00a0\nnecesario, \u00a0aunque\u00a0habitualmente \u00a0no\u00a0\nse\u00a0requiere.\u00a0\nBuprenorfina/naloxona: \u00a0buprenorfina \u00a0\nsin\u00a0cambios,\u00a0\u219146%\u00a0AUC\u00a0\nnorbuprenorfina. \u00a0S\u00edntomas\u00a0leves\u00a0de\u00a0\nexceso\u00a0de\u00a0opi\u00e1ceos\u00a0en\u00a0algunos\u00a0\npacientes \u00a0sin\u00a0requerir\u00a0\u2193dosis.\u00a0Metadona: \u00a0\u219348%\u00a0is\u00f3mero\u00a0activo\u00a0R\u2010\nmetadona: \u00a0puede\u00a0requerir\u00a0aumento\u00a0\nde\u00a0dosis.\u00a0\u00a0\n\u00a0Loperamida: \u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0TPV/r\u00a0\nact\u00faa\u00a0como\u00a0inhibidor\u00a0de\u00a0la\u00a0\nglicoprote\u00edna \u2010P,\u00a0no\u00a0se\u00a0observ\u00f3\u00a0\naumento\u00a0de\u00a0los\u00a0efectos\u00a0en\u00a0SNC\u00a0de\u00a0\nloperamida \u00a0(16\u00a0mg).\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 148 \u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nOtros\u00a0f\u00e1rmacos \u00a0 Artemeter/lumefantrina :\u00a0\u00a0\n\u2191\u00a0x2\u20103\u00a0AUC\u00a0lumefantrina, \u00a0\u219335%\u00a0\n%AUC\u00a0artemeter, \u00a0\u00a0LPV\u00a0sin\u00a0cambios.\u00a0\u00a0\nNRAD\u00a0monitorizar \u00a0toxicidad. \u00a0\nAtovaquona/proguanilo: \u00a0\u00a0\n\u219365%\u00a0AUC\u00a0atovaquona, \u00a0\u00a0\n\u219368%\u00a0AUC\u00a0proguanilo \u00a0(datos\u00a0limitados\u00a0\u00a0\nprocedentes \u00a0de\u00a0comparar \u00a0niveles\u00a0de\u00a0\npacientes \u00a0con\u00a0voluntarios \u00a0sanos\u00a0sin\u00a0\nTARV).\u00a0Valorar\u00a0aumento\u00a0de\u00a0dosis.\u00a0\nBupropi\u00f3n: \u00a0LPV/r\u00a0\u00a0\u219357%\u00a0AUCde\u00a0\nbupropi\u00f3n. \u00a0\nDigoxina:\u00a0\u219181%AUC\u00a0(0\u201012h)\u00a0de\u00a0una\u00a0\ndosis\u00a0\u00fanica\u00a0de\u00a00,5\u00a0mg\u00a0de\u00a0digoxina,\u00a0\nposiblemente \u00a0por\u00a0interacci\u00f3n \u00a0con\u00a0Pgp\u00a0\nintestinal. \u00a0Precauci\u00f3n \u00a0con\u00a0otros\u00a0\nf\u00e1rmacos \u00a0substrato \u00a0de\u00a0Pgp:\u00a0verapamilo, \u00a0\ndoxorrubicina. \u00a0\nEzetimiba \u00a0no\u00a0modific\u00f3\u00a0de\u00a0forma\u00a0\nsignificativa \u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0\nLPV/r\u00a0(no\u00a0se\u00a0evalu\u00f3\u00a0la\u00a0posible\u00a0\ninteracci\u00f3n \u00a0en\u00a0el\u00a0sentido\u00a0contrario, \u00a0\naunque\u00a0no\u00a0parece\u00a0probable\u00a0una\u00a0\ninteracci\u00f3n \u00a0importante). \u00a0\u00a0\nGemfibrozilo: \u00a0\u219341%\u00a0AUC\u00a0de\u00a0\ngemfibrozilo. \u00a0\n(sigue)\u00a0Atovaquona/proguanilo :\u00a0\u00a0\n\u219333%\u00a0AUC\u00a0atovaquona, \u00a0\u00a0\n\u219374%\u00a0AUC\u00a0proguanilo \u00a0(datos\u00a0limitados\u00a0\u00a0\nprocedentes \u00a0de\u00a0comparar \u00a0niveles\u00a0de\u00a0\npacientes \u00a0con\u00a0voluntarios \u00a0sanos\u00a0sin\u00a0\nTARV).\u00a0\n\u00a0\nCon\u00a0TDF:\u00a0utilizar\u00a0ATV/r\u00a0300/100\u00a0mg\u00a0\nc/24h.\u00a0\nReducir\u00a0dosis\u00a0de\u00a0diltiazem\u00a0a\u00a0la\u00a0mitad.\u00a0\nPosible\u00a0aumento\u00a0Cp\u00a0sildenafilo \u00a0(max\u00a025\u00a0\nmg\u00a0en\u00a0un\u00a0periodo\u00a0de\u00a048h),\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/72h\u00a0si\u00a0asociado\u00a0a\u00a0RTV)\u00a0y\u00a0\ntadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0mg\u00a0y\u00a0no\u00a0\nexceder\u00a010\u00a0mg\u00a0c/72h).\u00a0\n\u00a0\u00a0Fluticasona \u00a0inh\n.:\u00a0en\u00a0un\u00a0estudio\u00a0caso\u2010\ncontrol,\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0\nde\u00a0los\u00a0casos.\u00a0\n\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0neutropenia. \u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0CYP3A43\u00a0y\u00a0\u00a0\nUDP\u2010glucuroniltransferasa \u00a01A1.\u00a0\n\u00a0Digoxina:\u00a0DRV/r\u00a0aumenta\u00a0las\u00a0\nconcentraciones \u00a0plasm\u00e1ticas \u00a0de\u00a0\ndigoxina.\u00a0\n\u00a0Fluticasona \u00a0inh\n.:\u00a0en\u00a0un\u00a0estudio\u00a0caso\u2010\ncontrol,\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0\nde\u00a0los\u00a0casos.\u00a0\n\u00a0Inhibidores \u00a0de\u00a0la\u00a0recaptaci\u00f3n \u00a0de\u00a0\nserotonina :\u00a0las\u00a0AUC\u00a0sertralina \u00a0(50\u00a0\nmg/d\u00eda)\u00a0y\u00a0de\u00a0paroxetina \u00a0(20\u00a0mg/d\u00eda)\u00a0se\u00a0\nredujeron \u00a0aprox.\u00a0un\u00a050%\u00a0y\u00a040%,\u00a0\nrespectivamente, \u00a0tras\u00a07\u00a0d\u00edas\u00a0de\u00a0\ncoadministraci\u00f3n \u00a0con\u00a0DRV/r.\u00a0\n\u00a0\nSildenafilo :\u00a0el\u00a0AUC\u00a0de\u00a0sildenafilo \u00a0se\u00a0\nmultiplica \u00a0por\u00a04.\u00a0\u00a0Dosis\u00a0inicial:\u00a0no\u00a0\nexceder\u00a025\u00a0mg\u00a0en\u00a0un\u00a0periodo\u00a0de\u00a048h\u00a0\npara\u00a0sildenafilo, \u00a02,5\u00a0mg\u00a0en\u00a072h\u00a0para\u00a0\nvardenafilo \u00a0y\u00a010\u00a0mg\u00a0en\u00a072h\u00a0para\u00a0\ntadalafilo. \u00a0\n\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0neutropenia. \u00a0\n\u00a0\nEn\u00a0general\u00a0DRV/r\u00a0puede\u00a0aumentar \u00a0las\u00a0\nconcentraciones \u00a0plasm\u00e1ticas \u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0metabolizan \u00a0a\u00a0trav\u00e9s\u00a0\ndel\u00a0CYP3A43\u00a0\n\u00a0Bupropi\u00f3n :\u00a0se\u00a0reducen\u00a0las\u00a0\nconcentraciones \u00a0a\u00a0la\u00a0mitad\u00a0en\u00a0\npresencia \u00a0de\u00a0TPV/r.\u00a0\n\u00a0Fluticasona \u00a0inh\n.:\u00a0en\u00a0un\u00a0estudio\u00a0caso\u2010\ncontrol,\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0\nde\u00a0los\u00a0casos.\u00a0\n\u00a0Tadalafilo\n:\u00a0m\u00ednima\u00a0dosis\u00a0cuando\u00a0se\u00a0\nutiliza\u00a0los\u00a0primeros\u00a0d\u00edas\u00a0del\u00a0tratamiento \u00a0\ncon\u00a0TPV/r.\u00a0\u00a0Despu\u00e9s\u00a0de\u00a07\u201010\u00a0d\u00edas\u00a0de\u00a0\ntratamiento \u00a0con\u00a0TPV/r,\u00a0no\u00a0es\u00a0necesario \u00a0\najustar\u00a0la\u00a0dosis\u00a0de\u00a0tadalafilo. \u00a0\n\u00a0\nValaciclovir: \u00a0ausencia\u00a0de\u00a0interacci\u00f3n. \u00a0\n\u00a0\u00a0\nVinblastina :\u00a0\u2191\u00a0riesgo\u00a0de\u00a0neutropenia. \u00a0\n\u00a0Aunque\u00a0con\u00a0TPV/r\u00a0se\u00a0ha\u00a0visto\u00a0que\u00a0\npredomina \u00a0el\u00a0efecto\u00a0inhibidor\u00a0\nenzim\u00e1tico \u00a0de\u00a0RTV,\u00a0se\u00a0recomienda \u00a0\nmucha\u00a0precauci\u00f3n, \u00a0ya\u00a0que\u00a0TPV\u00a0ha\u00a0\nreducido\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nvarios\u00a0IP\u00a0a\u00fan\u00a0en\u00a0presencia \u00a0de\u00a0RTV.\u00a0\n((\u219368%\u00a0AUC\u00a0ATV,\u00a0\u219370%\u00a0AUC\u00a0de\u00a0SQV,\u00a0\u2193\u00a0\n45%\u00a0el\u00a0\nAUC\u00a0de\u00a0APV,\u00a0y\u00a0\u2193\u00a049%\u00a0el\u00a0AUC\u00a0de\u00a0\nLPV).\u00a0\u00a0Podr\u00eda\u00a0ocurrir\u00a0tambi\u00e9n\u00a0con\u00a0otros\u00a0\nf\u00e1rmacos. \u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 149  \nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\nOtros\u00a0f\u00e1rmacos \u00a0 Fluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0estudio\u00a0caso\u2010\ncontrol,\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0\nde\u00a0los\u00a0casos.\u00a0\u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0reducci\u00f3n \u00a0de\u00a0\neficacia\u00a0de\u00a0L\u2010tiroxina.\u00a0\nPosible\u00a0aumento\u00a0Cp\u00a0sildenafilo \u00a0(max\u00a025\u00a0\nmg\u00a0en\u00a0un\u00a0periodo\u00a0de\u00a048h),\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/72h)\u00a0y\u00a0\u00a0tadalafilo \u00a0(iniciar\u00a0\ncon\u00a05\u00a0mg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0c/72h).\u00a0\nVinblastina :\u00a0un\u00a0caso\u00a0de\u00a0interacci\u00f3n \u00a0\ngrave\u00a0con\u00a0LPV/r:\u00a0tras\u00a0una\u00a0dosis\u00a0de\u00a06\u00a0\nmg/m2\u00a0de\u00a0vinblastina \u00a0el\u00a0paciente\u00a0\ndesarroll\u00f3 \u00a0pancitopenia \u00a0de\u00a0grado\u00a04.\u00a0Se\u00a0\nresolvi\u00f3\u00a0reduciendo \u00a0la\u00a0dosis\u00a0a\u00a0la\u00a0mitad.\u00a0\nProductos \u00a0naturales: \u00a0ausencia\u00a0de\u00a0\ninteracci\u00f3n \u00a0PK\u00a0con\u00a0Ginkgo\u00a0biloba\u00a0y\u00a0\nEchinacea \u00a0purpurea.\u00a0\u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0CYP3A43.\u00a0\nPodr\u00eda\u00a0tambi\u00e9n\u00a0\u2191Cp\u00a0(aumento \u00a0mucho\u00a0\nmenor)\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a02D6.5\u00a0\u00a0\nPuede\u00a0\u2193Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2C9/19 \u00a06\u00a0\u00f3\u00a0\nsufren\u00a0glucuronidaci\u00f3n.8\u00a0\n\u00a0\u00a0 \u00a0 \u00a0\n \n  \n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 150 \u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\n\u00a0AN\u00a0\u00a0 (ver\u00a0tabla\u00a0AN)\u00a0\n\u00a0NN\u00a0\u00a0 (ver\u00a0tabla\u00a0NN)\u00a0\nMaraviroc \u00a0 (ver\u00a0tabla\u00a0antagonistas \u00a0del\u00a0correcetor \u00a0CCR5\u00a0e\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa). \u00a0\nRaltegravir \u00a0 (ver\u00a0tabla\u00a0antagonistas \u00a0del\u00a0correcetor \u00a0CCR5\u00a0e\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa). \u00a0\nIP\u00a0 \u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u2010\u00a0IDV\u00a0Datos\u00a0farmacocin\u00e9ticos \u00a0iniciales:\u00a0IDV\u00a0\n600\u2010800\u00a0mg\u00a0c/12h\u00a0\nLPV/r\u00a0NRAD\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0Al\u00a0igual\u00a0que\u00a0ATV,\u00a0IDV\u00a0se\u00a0ha\u00a0asociado\u00a0a\u00a0\nhiperbilirrubinemia \u00a0(aumento \u00a0de\u00a0la\u00a0Bi\u00a0\nindirecta) \u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0recomienda \u00a0\nasociar\u00a0ambos\u00a0IPs.\u00a0DRV/r\u00a0600/100\u00a0mg\u00a0c/12h.\u00a0\nIDV:\u00a0800\u00a0g\u00a0c/12h\u00a0(600\u00a0mg\u00a0c/12h\u00a0en\u00a0caso\u00a0\nde\u00a0intolerancia). \u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0\npuede\u00a0reducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0\nniveles\u00a0plasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP\u00a0\npotenciados \u00a0con\u00a0RTV.\u00a0\u00a0\n\u00a0\n\u2010\u00a0RTV\u00a0LPV/r\u00a0400/100\u00a0mg\u00a0c/12h.\u00a0\u00a0\nUna\u00a0dosis\u00a0adicional\u00a0de\u00a0RTV\u00a0100\u00a0mg\u00a0\nc/12h:\u00a0\u219146%\u00a0AUC\u00a0LPV\u00a0y\u00a0x2\u00a0Cmin\u00a0LPV.\u00a0\nCon\u00a0LPV/r,\u00a0las\u00a0Cmin\u00a0RTV\u00a0son\u00a03\u00a0veces\u00a0\nmenores\u00a0que\u00a0con\u00a0100\u00a0mg\u00a0RTV\u00a0c/12h\u00a0\nasociado\u00a0a\u00a0IDV\u00a0\u00f3\u00a0SQV\u00a0\u00a0ATV/r\u00a0300/100\u00a0mg\u00a0c/24h\u00a0\n\u00a0\u2191\u00a014\u00a0veces\u00a0AUC\u00a0DRV.\u00a0DRV\u00a0esta\u00a0indicado\u00a0\nsolamente \u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0RTV.\u00a0\nDosis\u00a0de\u00a0DRV/r\u00a0600/100\u00a0mg\u00a0c/12h\u00a0en\u00a0\npacientes \u00a0pretratados \u00a0y\u00a0800/100\u00a0mg\u00a0\nc/24h\u00a0en\u00a0pacientes \u00a0naive.\u00a0TPV/r\u00a0500/200\u00a0mg\u00a0c/12h.\u00a0\n\u00a0\n\u2010\u00a0SQV\u00a0SQV\u00a01000\u00a0mg\u00a0c/12h\u00a0+\u00a0LPV/R\u00a0dosis\u00a0\nhabitual\u00a0.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0Con\u00a0una\u00a0dosificaci\u00f3n \u00a0de\u00a0SQV/RTV/ATV \u00a0\n1500/100/300 \u00a0mg\u00a0c/24h\u00a0se\u00a0ha\u00a0\nobservado \u00a0que\u00a0algunos\u00a0pacientes \u00a0no\u00a0\nalcanzan\u00a0una\u00a0Cmin\u00a0adecuada \u00a0de\u00a0SQV,\u00a0\npor\u00a0lo\u00a0que\u00a0se\u00a0recomienda \u00a0restringir\u00a0su\u00a0\nuso\u00a0a\u00a0pacientes \u00a0naive\u00a0a\u00a0IP\u00a0con\u00a0CV\u00a0baja\u00a0a\u00a0\nintermedia. \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0No\u00a0recomendado \u00a0(SQV\u00a0sin\u00a0cambios;\u00a0\n\u219326%\u00a0AUC\u00a0de\u00a0DRV).\u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0\npuede\u00a0reducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0\nniveles\u00a0plasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP\u00a0\npotenciados \u00a0con\u00a0RTV\u00a0\u00a0(\u219370%\u00a0AUC\u00a0SQV).\u00a0\n\u2010\u00a0NFV\u00a0 NFV:\u00a01000\u20101250\u00a0mg\u00a0c/12h.\u00a0LPV/r:\u00a0\npacientes \u00a0con\u00a0susceptibilidad \u00a0reducida\u00a0\no\u00a0experiencia \u00a0previa\u00a0a\u00a0IP\u00a0pueden\u00a0\nrequerir\u00a0aumento\u00a0de\u00a0dosis.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0\u00a0\nNo\u00a0hay\u00a0datos\u00a0\u00a0\nNo\u00a0hay\u00a0datos\u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0\npuede\u00a0reducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0\nniveles\u00a0plasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP.\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 151 \u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir \u00a0 Atazanavir \u00a0 Darunavir \u00a0 Tipranavir \u00a0\n\u2010FPV\u00a0 Si\u00a0se\u00a0requiere\u00a0usar\u00a0esta\u00a0\ncombinaci\u00f3n, \u00a0se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0\n(como\u00a0dosis\u00a0inicial\u00a0puede\u00a0\nemplearse \u00a01400\u00a0mg\u00a0c/12h\u00a0de\u00a0FOS\u2010\nAPV\u00a0con\u00a0600/150\u00a0mg\u00a0c/12h\u00a0de\u00a0\nLPV/r.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0ATV\u00a0300\u2010400\u00a0mg\u00a0c/24h\u00a0(\u00f3\u00a0\nrepartidos \u00a0c/12h)\u00a0+\u00a0FPV/r\u00a0700/100\u00a0\nmg\u00a0c/12h\u00a0\u00f3\u00a01400/100 \u2010200\u00a0mg\u00a0c/24h\u00a0\n(datos\u00a0farmacocin\u00e9ticos \u00a0\u00a0iniciales). \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0\u00a0\nNo\u00a0hay\u00a0datos\u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0\nTPV\u00a0puede\u00a0reducir\u00a0de\u00a0forma\u00a0\nimportante \u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0\nde\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV.\u00a0\n(Algunos\u00a0autores\u00a0han\u00a0logrado\u00a0\nniveles\u00a0adecuados \u00a0monitorizando \u00a0y\u00a0\naumentando \u00a0la\u00a0dosis\u00a0de\u00a0FPV/r\u00a0a\u00a0\u00a0\n1400/200 \u00a0mg\u00a0c/12h\u00a0en\u00a0\ncombinaci\u00f3n \u00a0con\u00a0TPV\u00a0(500\u00a0mg\u00a0\nc/12h).\u00a0Sin\u00a0embargo, \u00a0dada\u00a0la\u00a0\nelevada\u00a0variabilidad \u00a0interindividual, \u00a0\nalgunos\u00a0pacientes \u00a0podr\u00edan\u00a0no\u00a0\nalcanzar\u00a0niveles\u00a0adecuados. \u00a0\nExperiencia \u00a0limitada). \u00a0\n\u2010\u00a0LPV/r\u00a0 \u00a0 Datos\u00a0farmacocin\u00e9ticos \u00a0iniciales:\u00a0\nATV\u00a0300\u00a0mg\u00a0c/24h\u00a0+\u00a0LPV/r\u00a0400/100\u00a0\nmg\u00a0c/12h.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0\nseguridad \u00a0a\u00a0largo\u00a0plazo\u00a0Contraindicado \u00a0(\u219340%\u00a0AUC\u00a0DRV).\u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0\nTPV\u00a0puede\u00a0reducir\u00a0de\u00a0forma\u00a0\nimportante \u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0\nde\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV\u00a0\n(\u219349%\u00a0AUC\u00a0LPV).\u00a0\u00a0\n(Algunos\u00a0autores\u00a0han\u00a0logrado\u00a0\nniveles\u00a0adecuados \u00a0monitorizando \u00a0y\u00a0\naumentando \u00a0la\u00a0dosis\u00a0de\u00a0LPV/r\u00a0a\u00a0\u00a0\n400/300\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a0533/233\u00a0mg\u00a0\nc/12h\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0TPV\u00a0(500\u00a0\nmg\u00a0c/12h).\u00a0Sin\u00a0embargo, \u00a0dada\u00a0la\u00a0\nelevada\u00a0variabilidad \u00a0interindividual, \u00a0\nalgunos\u00a0pacientes \u00a0podr\u00edan\u00a0no\u00a0\nalcanzar\u00a0niveles\u00a0adecuados. \u00a0\nExperiencia \u00a0limitada). \u00a0\n\u2010\u00a0ATV\u00a0 \u00a0 \u00a0 NRAD\u00a0 No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0\nTPV\u00a0puede\u00a0reducir\u00a0de\u00a0forma\u00a0\nimportante \u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0\nde\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV\u00a0\n(\u219368%\u00a0AUC\u00a0ATV)\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 152 \u00a0\n\u2010\u00a0DRV/r\u00a0 \u00a0 \u00a0 \u00a0 No\u00a0hay\u00a0datos\u00a0\n\u00a0\nAUC:\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraciones \u00a0plasm\u00e1ticas; \u00a0I:\u00a0Invirase\u00ae; \u00a0IT:\u00a0interacci\u00f3n; \u00a0NRAD:\u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0NS:\u00a0no\u00a0significativa; \u00a0QD:una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0\na\u00a0Expresado \u00a0como\u00a0media\u00a0\u00b1\u00a0DE\u00a0si\u00a0no\u00a0se\u00a0indica\u00a0lo\u00a0contrario\u00a0\nb\u00a0Expresado \u00a0como\u00a0mediana\u00a0\u00b1\u00a0rango\u00a0intercuartil \u00a0\u00a0\nc\u00a0Expresado \u00a0como\u00a0rango\u00a0\n\u00a0\n0\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0estudios\u00a0han\u00a0sido\u00a0realizados \u00a0en\u00a0voluntarios \u00a0sanos\u00a0por\u00a0lo\u00a0que\u00a0en\u00a0los\u00a0pacientes \u00a0es\u00a0probable\u00a0que\u00a0las\u00a0dosis\u00a0recomendadas \u00a0inicialmente \u00a0con\u00a0IP/r\u00a0(150\u00a0mg\u00a0tres\u00a0veces\u00a0por\u00a0semana)\u00a0no\u00a0\nsean\u00a0suficientes. \u00a0Se\u00a0han\u00a0descrito\u00a0fracasos\u00a0de\u00a0tratamiento \u00a0antituberculoso \u00a0con\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0en\u00a0pacientes \u00a0con\u00a0imnunodepresi\u00f3n \u00a0avanzada \u00a0tratados\u00a0con\u00a0IP/r\u00a0y\u00a0rifabutina \u00a0150\u00a0mg\u00a0c/48\u00a0\nhoras\u00a0o\u00a0tres\u00a0veces\u00a0por\u00a0semana.\u00a0En\u00a0estos\u00a0casos\u00a0valorar\u00a0dosis\u00a0mayores: \u00a0rifabutina \u00a0300\u00a0mg\u00a0tres\u00a0veces\u00a0semana.\u00a0Dado\u00a0que\u00a0el\u00a0ajuste\u00a0de\u00a0dosis\u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecido \u00a0y\u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0\nniveles\u00a0de\u00a0rifabutina \u00a0no\u00a0est\u00e1\u00a0disponible \u00a0en\u00a0la\u00a0\u00a0mayor\u00eda\u00a0de\u00a0hospitales, \u00a0se\u00a0recomienda, \u00a0si\u00a0es\u00a0posible,\u00a0valorar\u00a0otras\u00a0alternativas \u00a0terap\u00e9uticas. \u00a0\n1\u00a0ClCr\u00a030\u201060\u00a0ml/min:\u00a0reducir\u00a0un\u00a050%,\u00a0ClCr\u00a0<30\u00a0ml/min:\u00a0reducir\u00a0un\u00a075%\u00a0(m\u00e1x.\u00a01g/d\u00eda).\u00a0\u00a0\n2\u00a0SQV\u00a0(I\u00a0\u00f3\u00a0F)\u00a0junto\u00a0con\u00a0RTV\u00a0(400/400\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a01000/100 \u00a0mg\u00a0c/12h)\u00a0pueden\u00a0administrarse \u00a0con\u00a0la\u00a0dosis\u00a0habitual\u00a0de\u00a0rifampicina \u00a0o\u00a0dosis\u00a0reducidas \u00a0de\u00a0rifabutina \u00a0(150\u00a0mg\u00a0\u00a03veces\u00a0\n/semana)(experiencia \u00a0limitada\u00a0\n3\u00a0Principales \u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A4:\u00a0alprazolam, \u00a0amiodarona, \u00a0amlodipino, \u00a0ciclofosfamida, \u00a0ciclosporina, \u00a0clonacepam, \u00a0cloracepato, \u00a0dextropropoxifeno, \u00a0diazepam, \u00a0\ndiltiazem, \u00a0disopiramida, \u00a0estazolam, \u00a0etionamida, \u00a0etosuximida, \u00a0felodipino, \u00a0fentanilo, \u00a0finasterida, \u00a0flunaricina, \u00a0fluracepam, \u00a0lacidipino, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0meperidina, \u00a0nicardipino, \u00a0nifedipino, \u00a0\nnimodipino, \u00a0nitrendipino, \u00a0prednisona, \u00a0quinidina, \u00a0quinina,\u00a0sertralina, \u00a0sildenafilo \u00a0(Viagra\u00ae),\u00a0vardenafilo, \u00a0tadalafilo, \u00a0tacrolimus, \u00a0verapamilo, \u00a0vincristina \u00a0y\u00a0zolpidem. \u00a0\n4\u00a0RTV\u00a0pueder\u00a0aumentar \u00a0hasta\u00a03\u00a0veces\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0siguiente\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A:\u00a0alfentanilo, \u00a0antagonistas \u00a0del\u00a0calcio\u00a0(amlodipino, \u00a0diltiazem, \u00a0felodipino, \u00a0nicardipino, \u00a0\nnifedipino, \u00a0nisoldipino, \u00a0verapamilo), \u00a0carbamacepina, \u00a0ciclosporina, \u00a0citost\u00e1ticos \u00a0(etop\u00f3sido, \u00a0paclitaxel, \u00a0tamoxifeno, \u00a0vinblastina \u00a0y\u00a0vincristina), \u00a0clonacepam, \u00a0dexametasona, \u00a0disopiramida, \u00a0\neritromicina, \u00a0etosuximida, \u00a0fentanilo, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0nefazodona, \u00a0ondansetron, \u00a0prednisona, \u00a0quinina,\u00a0rifampicina, \u00a0sertralina, \u00a0sildenafilo, \u00a0tacrolimus, \u00a0taxol\u00a0y\u00a0trazodona, \u00a0entre\u00a0otros.\u00a0\n5\u00a0Aumento \u00a0de\u00a01.5\u00a0a\u00a03\u00a0veces\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2D6:\u00a0amitriptilina, \u00a0clomipramina, \u00a0clorpromacina, \u00a0desipramina, \u00a0fluoxetina, \u00a0haloperidol, \u00a0imipramina, \u00a0\nmaprotilina, \u00a0metoprolol, \u00a0mexiletina, \u00a0nortriptilina, \u00a0paroxetina, \u00a0perfenazina, \u00a0pindolol,\u00a0propranolol, \u00a0risperidona, \u00a0timolol,\u00a0tioridacina, \u00a0tramadol\u00a0y\u00a0venlafaxina. \u00a0\n6\u00a0F\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2C9/19: \u00a0diclofenac, \u00a0ibuprofeno, \u00a0indometacina, \u00a0fenito\u00edna, \u00a0gliburida, \u00a0glipizida,\u00a0\u00a0lansoprazol, \u00a0losartan,\u00a0omeprazol, \u00a0proguanilo \u00a0y\u00a0tolbutamida. \u00a0\n7teofilina,\u00a0tacrina,\u00a0clozapina, \u00a0tacrina.\u00a0\n8\u00a0atovaquona, \u00a0clofibrato, \u00a0code\u00edna,\u00a0difenoxilato, \u00a0ketoprofeno, \u00a0ketorolaco, \u00a0lamotrigina, \u00a0loracepam, \u00a0metoclopramida, \u00a0morfina,\u00a0naproxeno, \u00a0oxacepam, \u00a0propofol, \u00a0temacepam \u00a0y\u00a0valproico. \u00a0\u00a0\n9\u00a0Atazanavir/r \u00a0puede\u00a0administrarse \u00a0junto\u00a0con\u00a0antihistam\u00ednicos \u00a0H2\u00a0(estudio\u00a0realizado\u00a0con\u00a0famotidina) \u00a0sin\u00a0que\u00a0se\u00a0requiera\u00a0espaciarlos. \u00a0Si\u00a0el\u00a0ATV\u00a0no\u00a0se\u00a0potencia\u00a0con\u00a0RTV,\u00a0se\u00a0recomienda \u00a0\nadministrarlo \u00a02h\u00a0antes\u00a0del\u00a0antihistam\u00ednico \u00a0H2.\u00a0\u00a0\u00a0\n10\u00a0Seg\u00fan\u00a0datos\u00a0iniciales\u00a0el\u00a0midazolam \u00a0intravenoso \u00a0podr\u00eda\u00a0administrarse \u00a0junto\u00a0con\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0reduciendo \u00a0la\u00a0dosis\u00a0y\u00a0bajo\u00a0estrecha\u00a0monitorizaci\u00f3n \u00a0cl\u00ednica\u00a0(UCI\u00a0o\u00a0similar).\u00a0\u00a0Sin\u00a0\nembargo, \u00a0el\u00a0midazolam \u00a0oral\u00a0est\u00e1\u00a0contraindicado. \u00a0\n11\u00a0ATV\u00a0no\u00a0potenciado \u00a0nunca\u00a0debe\u00a0asociarse \u00a0a\u00a0IBP.\u00a0ATV/r\u00a0no\u00a0debe\u00a0asociarse \u00a0a\u00a0IBP\u00a0en\u00a0pacientes \u00a0pretratados. \u00a0En\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0podr\u00eda\u00a0emplearse \u00a0un\u00a0m\u00e1ximo\u00a0de\u00a020\u00a0mg\u00a0de\u00a0\nomeprazol \u00a0junto\u00a0con\u00a0ATV/r,\u00a0espaci\u00e1ndolos \u00a012\u00a0horas.\u00a0En\u00a0cualquier \u00a0caso\u00a0se\u00a0evitar\u00e1\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0ATV\u00a0en\u00a0las\u00a0primeras\u00a0horas\u00a0tras\u00a0administrar \u00a0un\u00a0IBP.\u00a0\n12\u00a0Con\u00a0ATV/r,\u00a0puede\u00a0emplearse \u00a0una\u00a0dosis\u00a0m\u00e1xima\u00a0de\u00a0famotidina \u00a0de\u00a040\u00a0mg\u00a0c/12h\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0\u00f3\u00a0de\u00a020\u00a0mg\u00a0c/12h\u00a0en\u00a0pacientes \u00a0pretratados \u00a0(el\u00a0ARV\u00a0se\u00a0administrar\u00e1 \u00a0\nsimult\u00e1neamente \u00a0a\u00a0fin\u00a0de\u00a0que\u00a0el\u00a0ATV/r\u00a0se\u00a0haya\u00a0absorbido \u00a0cuando\u00a0act\u00fae\u00a0el\u00a0anti\u2010H2,\u00a0o\u00a010\u00a0h\u00a0despu\u00e9s\u00a0del\u00a0anti\u2010H2).\u00a0Cuando\u00a0deba\u00a0emplearse \u00a0un\u00a0anti\u2010H2\u00a0junto\u00a0con\u00a0TDF\u00a0y\u00a0ATV/r\u00a0se\u00a0aumentar\u00e1 \u00a0la\u00a0dosis\u00a0\nde\u00a0ATV/r\u00a0a\u00a0400/100\u00a0mg\u00a0c/24h.\u00a0En\u00a0tratamiento \u00a0inicial,\u00a0si\u00a0s\u00f3lo\u00a0puede\u00a0emplearse \u00a0ATV\u00a0no\u00a0potenciado, \u00a0se\u00a0utilizar\u00e1\u00a0una\u00a0dosis\u00a0m\u00e1xima\u00a0de\u00a020\u00a0mg\u00a0en\u00a0una\u00a0toma\u00a0y\u00a020\u00a0mg\u00a0c/12h\u00a0en\u00a0total\u00a0de\u00a0famotidina \u00a0\n(ATV\u00a0se\u00a0administrar\u00e1 \u00a0en\u00a0este\u00a0caso\u00a02\u00a0horas\u00a0antes,\u00a0para\u00a0asegurar\u00a0su\u00a0absorci\u00f3n \u00a0en\u00a0ausencia\u00a0de\u00a0RTV,\u00a0\u00a0\u00f3\u00a010h\u00a0despu\u00e9s\u00a0del\u00a0anti\u2010H2).\u00a0En\u00a0cualquier \u00a0caso,\u00a0se\u00a0evitar\u00e1\u00a0la\u00a0administraci\u00f3n \u00a0del\u00a0ATV\u00a0dentro\u00a0de\u00a0\nlas\u00a0primeras\u00a0horas\u00a0tras\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0un\u00a0anti\u2010H2.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 153 \u00a0\n\u03c9\u00a0Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0europea.\u00a0EPARS:\u00a0European \u00a0Public\u00a0Assessment \u00a0Reports.\u00a0Disponble \u00a0en:\u00a0\nhttp://www.ema.europa.eu/ema/index.jsp?curl =pages/includes/medicines/medicines_landing _page.jsp&murl=menus/m edicines/medicines. jsp&mid=\u00a0Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n\u2126Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0americana \u00a0(fuentes:\u00a0FDA\u00a0and\u00a0First\u00a0Data\u00a0Bank,\u00a0Inc).\u00a0Disponible \u00a0en: http://www.rxlist.com/drugs/alpha_a.htm \u00a0.Con\u00a0acceso\u00a0\n[5/12/2010]. \u00a0\n&Guardiola \u00a0JM,\u00a0Soriano\u00a0V\u00a0(Eds).\u00a0Tratamiento \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u2010SIDA.\u00a0F\u00e1rmacos \u00a0y\u00a0combinaciones. \u00a0D\u00e9cima\u00a0Edidi\u00f3n.\u00a0Barcelona: \u00a0Publicaciones \u00a0Permanyer \u00a02007.\u00a0\n\u00a0\n\u00a0\nNOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0la\u00a0\ninformaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 154Tabla\u00a08.\u00a0Antagonistas \u00a0del\u00a0correceptor \u00a0CCR5\u00a0e\u00a0inhibidores \u00a0integrasa \u00a0\n\u00a0\nGrupo\u00a0terap\u00e9utico \u00a0 Antagonistas \u00a0correceptor \u00a0CCR5\u00a0 Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Maraviroc \u00a01\u00a0 Raltegravir \u00a0\n\u00a0\nNombre\u00a0comercial \u00a0\n\u00a0Celsentri\u00ae \u00a0 Isentress\u00ae \u00a0\nDosis\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nRecomendaci\u00f3n \u00a0150,\u00a0300\u00a0\u00f3\u00a0600\u00a0mg\u00a0BID\u00a0dependiendo \u00a0de\u00a0las\u00a0\ninteracciones \u00a0con\u00a0otros\u00a0f\u00e1rmacos. \u00a0300\u00a0mg\u00a0BID\u00a0en\u00a0\nausencia\u00a0de\u00a0inhibidores \u00a0o\u00a0inductores \u00a0de\u00a0CYP3A4.\u00a0\nPuede\u00a0tomarse\u00a0con\u00a0o\u00a0sin\u00a0alimentos. \u00a0\u00a0\n400\u00a0mg\u00a0BID\u00a0\n\u00a0\n\u00a0\nPuede\u00a0tomarse\u00a0con\u00a0o\u00a0sin\u00a0alimentos. \u00a0\nPresentaci\u00f3n \u00a0comercial \u00a0 Comp.\u00a0de\u00a0150\u00a0y\u00a0de\u00a0300\u00a0mg\u00a0 Comp..\u00a0de\u00a0400\u00a0mg\u00a0\nBiodisponibilidad \u00a0Oral\u00a0\n\u00a023\u201033%\u00a0\u03c9\u00a0\n23%\u00a0(dosis\u00a0\u00fanica\u00a0de\u00a0100\u00a0mg)\u00a0\u03c9\u00a0\n33%\u00a0(estimada \u00a0para\u00a0300\u00a0mg)\u00a0\u03c9\u00a0No\u00a0se\u00a0ha\u00a0determinado \u00a0su\u00a0biodisponibilidad \u00a0\nabsoluta\u00a0en\u00a0humanos\u00a0\u03c9\u00a0\nEfecto\u00a0de\u00a0los\u00a0alimentos \u00a0 Un\u00a0desayuno \u00a0rico\u00a0en\u00a0grasa\u00a0redujo\u00a0el\u00a0AUC\u00a0un\u00a033%.\u00a0\nSin\u00a0embargo, \u00a0dado\u00a0que\u00a0no\u00a0hubo\u00a0restricciones \u00a0\nalimentarias \u00a0en\u00a0los\u00a0estudios\u00a0de\u00a0eficacia,\u00a0puede\u00a0\nadministrarse \u00a0con\u00a0o\u00a0sin\u00a0alimentos.\u00a0\u2126\u00a0Una\u00a0comida\u00a0con\u00a0contenido \u00a0de\u00a0grasa\u00a0moderado \u00a0\naument\u00f3\u00a0el\u00a013%\u00a0el\u00a0AUC.\u00a0Una\u00a0comida\u00a0con\u00a0elevado\u00a0\ncontenido \u00a0graso\u00a0\u00a0duplic\u00f3\u00a0el\u00a0AUC.\u00a0En\u00a0general,\u00a0los\u00a0\nalimentos \u00a0aumentaron \u00a0la\u00a0variabilidad \u00a0\nfarmacocin\u00e9tica. \u00a0Sin\u00a0embargo, \u00a0dado\u00a0que\u00a0no\u00a0hubo\u00a0\nrestricciones \u00a0alimentarias \u00a0en\u00a0los\u00a0estudios\u00a0de\u00a0\neficacia,\u00a0puede\u00a0administrarse \u00a0con\u00a0o\u00a0sin\u00a0alimentos.\u00a0\n\u2126\u00a0\nSemivida \u00a0plasm\u00e1tica \u00a0 13,2\u00a0horas\u00a0\u03c9\u00a0 9\u00a0horas\u00a0\u03c9\u00a0\nCmax\u00a00,618\u00a0microg/mL \u00a0(VIH+asintom\u00e1ticos \u00a0con\u00a0300\u00a0\nmg/12h)\u2126\u00a04,5\u00a0microM\u00a0(IC90%:2,0 \u201010,2)\u00a0\u00a0(=2,17\u00a0microg/mL) \u00a0\nCmin\u00a00,034\u00a0microg/mL(VIH+asintom\u00e1ticos \u00a0con\u00a0300\u00a0\nmg/12h)\u00a0\u2126\u00a0\n\u00a00,14\u00a0microM\u2126\u00a0(=\u00a00,068\u00a0microg/mL) \u00a0\nAUC\u00a0AUC0\u201012h:\u00a02,550\u00a0microg.h/mL(VIH+asintom\u00e1ticos \u00a0\ncon\u00a0300\u00a0mg/12h)\u00a0\u2126\u00a0AUC0\u201012h:\u00a014,3\u00a0microM .h\u2126\u00a0(IC90%:7,6 \u00a0a\u00a026,6)\u00a0(=6,89\u00a0\nmicrog/mL) \u00a0\n\u00a0\nCI50/90\u00a0frente\u00a0a\u00a0VIH\u20101\u00a0in\u00a0\nvitro\u00a0\n\u00a0CI50:0,1\u00a0a\u00a04,5\u00a0nanoM\u00a0(0,05\u00a0to\u00a02,3\u00a0nanog/mL)\u00a0\u2126\u00a0\n(1\u00a0nanoM=0,5 \u00a0nanog/mL)\u00a0\u2126\u00a0\u00a0\nCI90:\u00a00,57\u00a0(0,06\u00a0\u2013\u00a010,7)\u00a0nanog/mL\u00a0\u03c9\u00a0\n\u00a0CI95:\u00a031\u00b1\u00a020\u00a0nanoM\u00a0\u03c9(=14,9\u00a0microg/mL)\u00a0\n\u00a0\nActividad \u00a0\n\u00a0VIH\u20101\u00a0tropismo\u00a0R5\u00a0 VIH\u20101\u00a0y\u00a0VIH\u20102,\u00a0tropismo\u00a0R5,\u00a0X4\u00a0y\u00a0dual\u00a0\nPenetraci\u00f3n \u00a0en\u00a0LCR\u00a0(LCR:plasma) \u00a0Grado\u00a03\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0la\u00a0\nclasificaci\u00f3n \u00a0del\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0\na\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a02010) Penetraci\u00f3n \u00a0insignificante\u00a0\u03c9\u00a0\u00a0\nLas\u00a0concentraciones \u00a0de\u00a0RAL\u00a0en\u00a0LCR\u00a0(LCR\u00a014,5\u00a0\nng/mL;\u00a0conc.\u00a0plasm\u00e1ticas \u00a0261\u00a0ng/mL)\u00a0fueron\u00a04,5\u00a0\nveces\u00a0superiores \u00a0a\u00a0la\u00a0CI50\u00a0para\u00a0la\u00a0cepa\u00a0salvaje\u00a0del\u00a0\nvirus,\u00a0tomando\u00a0como\u00a0CI50\u00a03,2\u00a0ng/mL\u00a0(Croteau\u00a0D.\u00a0\nAAC\u00a02010;54:5156 \u20105160)\u00a0\nGrado\u00a03\u00a0de\u00a0penetraci\u00f3n \u00a0en\u00a0LCR\u00a0seg\u00fan\u00a0la\u00a0\nclasificaci\u00f3n \u00a0del\u00a0estudio\u00a0CHARTER \u00a0(de\u00a01\u00a0a\u00a04,\u00a0menor\u00a0\na\u00a0mayor)\u00a0(Letendre\u00a0S\u00a0Poster\u00a0430.\u00a0Croi\u00a02010) \n\u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0CYP3A4\u00a0\n(No\u00a0inductor,\u00a0ni\u00a0inhibidor) \u00a0Glucuronidaci\u00f3n \u00a0(UGT1A1) \u00a0\n(No\u00a0inductor,\u00a0ni\u00a0inhibidor\u00a0de\u00a0CYP3A4\u00a0ni\u00a0de\u00a0\nUGT1A1)\u00a0\nEfectos\u00a0\nAdversos \u00a0N\u00e1useas,\u00a0v\u00f3mitos,\u00a0flatulencia, \u00a0dolor\u00a0abdominal \u00a0\nParestesia, \u00a0disgeusia. \u00a0\nErupci\u00f3n\u00a0cut\u00e1nea.\u00a0\nAstenia.\u00a0Diarrea,\u00a0nauseas.\u00a0\nCefalea\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 155\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Maraviroc \u00a0 Raltegravir \u00a0\n\u00a0\nInteracciones \u00a0\u00a0\u00a0\n\u00a0\nAsociaciones \u00a0contraindicadas \u00a0Hypericum \u00a0perforatum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0 No\u00a0se\u00a0han\u00a0descrito.\u00a0\nAnti\u00e1cidos \u00a0\n\u00a0\nAntihistam\u00ednicos \u00a0H2\u00a0\n\u00a0Inhibidores \u00a0Bomba\u00a0protones \u00a0\n\u00a0\n\u00a0No\u00a0hay\u00a0datos\u00a0\n\u00a0\nNo\u00a0hay\u00a0datos\u00a0\n\u00a0No\u00a0hay\u00a0datos\u00a0Anti\u00e1cidos: \u00a0AUC\u00a0RAL\u00a0sin\u00a0cambios,\u00a0\u219365%\u00a0Cmin\u00a0RAL..\u00a0\nSignificado \u00a0cl\u00ednico\u00a0incierto.\u00a0Por\u00a0precauci\u00f3n, \u00a0\nespaciar\u00a0como\u00a0m\u00ednimo\u00a02h\u00a0.\u00a0\n\u00a0\nAnti\u2010H2:\u00a0una\u00a0dosis\u00a0\u00fanica\u00a0de\u00a020\u00a0mg\u00a0de\u00a0famotina\u00a01h\u00a0\nantes\u00a0del\u00a0RAL\u00a0aument\u00f3\u00a0un\u00a045%\u00a0el\u00a0AUC\u00a0de\u00a0RAL\u00a0y\u00a0un\u00a0\n6%\u00a0su\u00a0Cmin.\u00a0Estos\u00a0cambios\u00a0no\u00a0se\u00a0considera \u00a0que\u00a0\npuedan\u00a0tener\u00a0importancia \u00a0cl\u00ednica.\u00a0\n\u00a0\nIBP\u00a0En\u00a0pacientes \u00a0\u219139%\u00a0AUC\u00a0RAL,\u219124%\u00a0Cmin.\u00a0Estos\u00a0\ncambios\u00a0no\u00a0se\u00a0considera \u00a0que\u00a0puedan\u00a0tener\u00a0\nimportancia \u00a0cl\u00ednica.\u00a0\n\u00a0\nAntimicobact. \u00a0\u00a0\u00a0\n\u2010\u00a0Rifampicina \u00a0 Dosis\u00a0de\u00a0MVC\u00a0600\u00a0mg\u00a0c/12h\u00a0en\u00a0ausencia\u00a0de\u00a0\ninhibidores \u00a0enzim\u00e1ticos \u00a0potentes. \u00a01\u00a0Rifampicina \u00a0redujo\u00a0un\u00a061%\u00a0la\u00a0Cmin\u00a0de\u00a0RAL\u00a0y\u00a0un\u00a0\n40%\u00a0el\u00a0AUC.\u00a0Valorar\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0RAL\u00a0a\u00a0\n800\u00a0mg\u00a0c/12h.\u00a0\n\u2010\u00a0Rifabutina \u00a0(RFB)\u00a0 No\u00a0hay\u00a0datos\u00a0 NRAD\u00a0\n\u00a0\n\u2010\u00a0Claritromicina \u00a0 Dosis\u00a0de\u00a0MVC\u00a0a\u00a0150\u00a0mg\u00a0c/12h\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0\nclaritromicina \u00a0o\u00a0eritromicina. \u00a0\u00a0\nAntiepil\u00e9pticos :\u00a0\n\u00a0\u2010 Carbamazepina, \u00a0fenito\u00edna, \u00a0\nfenobarbital, \u00a0lamotrigina \u00a0\u00a0\nDosis\u00a0de\u00a0MVC\u00a0600\u00a0mg\u00a0c/12h\u00a0en\u00a0ausencia\u00a0de\u00a0\ninhibidores \u00a0enzim\u00e1ticos \u00a0potentes. \u00a0\n1\u00a0Carbamacepina, \u00a0fenito\u00edna, \u00a0fenobarbital: \u00a0\nValorar\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0RAL\u00a0a\u00a0800\u00a0mg\u00a0c/12h\u00a0\n(no\u00a0es\u00a0una\u00a0recomendaci\u00f3n \u00a0formal\u00a0del\u00a0\nlaboratorio). \u00a0\nLamotrigina: \u00a0ausencia\u00a0de\u00a0interacci\u00f3n \u00a0PK\u00a0\nAnticoagulantes \u00a0orales\u00a0\n\u00a0No\u00a0hay\u00a0datos\u00a0 No\u00a0hay\u00a0datos\u00a0\nAnticonceptivos \u00a0orales :\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0\nAntif\u00fangicos \u00a0imidaz\u00f3licos \u00a0 Itraconazol \u00a0y\u00a0ketoconazol: \u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0\ndosis\u00a0de\u00a0MVC\u00a0a\u00a0150\u00a0mg\u00a0c/12h.\u00a0\nFluconazol: \u00a0los\u00a0estudios\u00a0farmacocin\u00e9ticos \u00a0\npoblacionales \u00a0sugieren\u00a0que\u00a0no\u00a0se\u00a0requiere\u00a0ajuste\u00a0de\u00a0\ndosis\u00a0de\u00a0MVC.\u00a0Sin\u00a0embargo, \u00a0MVC\u00a0300\u00a0mg\u00a0c/12h\u00a0debe\u00a0\nadministrarse \u00a0con\u00a0precauci\u00f3n \u00a0cuando\u00a0se\u00a0administre \u00a0\ncon\u00a0fluconazol \u00a0hasta\u00a0disponer\u00a0de\u00a0m\u00e1s\u00a0datos.\u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0RAL\u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0los\u00a0antif\u00fangicos \u00a0imidaz\u00f3licos. \u00a0\nEstatinas: \u00a0 No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0MVC\u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0las\u00a0estatinas. \u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0RAL\u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0las\u00a0estatinas. \u00a0\nF\u00e1rmacos \u00a0empleados \u00a0para\u00a0\ntratar\u00a0la\u00a0influenza \u00a0Amantadina \u00a0/\u00a0oseltamivir \u00a0/zanamivir: \u00a0Te\u00f3ricamente \u00a0no\u00a0deben\u00a0esperarse \u00a0interacciones \u00a0\nInmunosupresores :\u00a0\n\u00a0No\u00a0hay\u00a0datos\u00a0 Te\u00f3ricamente \u00a0con\u00a0RAL\u00a0no\u00a0caben\u00a0esperar\u00a0\ninteracciones. \u00a0Datos\u00a0iniciales\u00a0sobre\u00a0el\u00a0uso\u00a0seguro\u00a0\nde\u00a0RAL\u00a0con\u00a0sirolimus, \u00a0tacrolimus \u00a0y\u00a0ciclosporina. \u00a0\nInterfer\u00f3n/ \u00a0\nRibavirina \u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0MVC\u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0interferon \u00a0alfa\u00a0ni\u00a0con\u00a0ribavirina. \u00a0Te\u00f3ricamente \u00a0RAL\u00a0no\u00a0caben\u00a0esperar\u00a0interacciones \u00a0\nMetadona(MT) \u00a0y\u00a0otros\u00a0opi\u00e1ceos\u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0MVC\u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0la\u00a0metadona. \u00a0RAL\u00a0no\u00a0modifica\u00a0las\u00a0concentraciones \u00a0de\u00a0metadona \u00a0\nOtros\u00a0f\u00e1rmacos \u00a0 Cotrimoxazol: \u00a0ausencia\u00a0de\u00a0interacci\u00f3n \u00a0Midazolam: \u00a0\nausencia\u00a0de\u00a0interacci\u00f3n \u00a0\nNefazodona: \u00a0debido\u00a0al\u00a0efecto\u00a0inhibidor\u00a0enzim\u00e1tico \u00a0\npotente\u00a0de\u00a0nefazodona, \u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0\ndosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0c/12h)\u00a0Ezetimiba: \u00a0NRAD\u00a0\nMidazolam: \u00a0ausencia\u00a0de\u00a0interacci\u00f3n. \u00a0\u00a0\nUna\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0utilizados \u00a0para\u00a0la\u00a0\ndisfunci\u00f3n \u00a0er\u00e9ctil\u00a0(sildenafilo, \u00a0vardenafilo \u00a0o\u00a0\ntadalafilo) \u00a0es\u00a0poco\u00a0probable. \u00a0\n\u00a0AN\u00a0\u00a0 (ver\u00a0tabla\u00a0AN)\u00a0 (ver\u00a0tabla\u00a0AN)\u00a0\n\u00a0NN\u00a0\u00a0 (ver\u00a0tabla\u00a0NN)\u00a0 (ver\u00a0tabla\u00a0NN)\u00a0\nIP\u00a0 \u00a0\u00a0\n\u2010\u00a0RTV\u00a0 \u2010 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0o\u00a0cl\u00ednicamente \u00a0no\u00a0\nsignificativa \u00a0\n\u2010\u00a0IDV\u00a0 \u2010 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0Te\u00f3ricamente, \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0\nimportante. \u00a0\n\u2010\u00a0SQV\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0c/12h)\u00a0Te\u00f3ricamente, \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 156importante. \u00a0\n\u2010\u00a0NFV\u00a0 \u2010 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0\u2010 No\u00a0hay\u00a0datos\u00a0\n\u2010FPV\u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0 Un\u00a0estudio\u00a0en\u00a0voluntarios \u00a0sanos\u00a0ha\u00a0demostrado \u00a0\nuna\u00a0reducci\u00f3n \u00a0de\u00a0Cp\u00a0de\u00a0ambos\u00a0(RAL:\u00a0\u2193\u00a015\u201055%\u00a0\nAUC,\u00a0\u219325\u201068%\u00a0Cmin;\u00a0FPV:\u00a0\u2193\u00a00\u201036%\u00a0AUC,\u00a0\u2193\u00a017\u2010\n50%\u00a0Cmin).\u00a0Los\u00a0niveles\u00a0resultantes \u00a0fueron\u00a0\nsuperiores \u00a0a\u00a0x2\u00a0veces\u00a0la\u00a0IC90\u00a0para\u00a0ambos\u00a0\nf\u00e1rmacos, \u00a0pero\u00a0podr\u00eda\u00a0tener\u00a0importancia \u00a0en\u00a0\npretratados. \u00a0\n\u2010\u00a0LPV/r\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0c/12h)\u00a0NRAD\u00a0\n\u2010\u00a0ATV\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0c/12h)\u00a0NRAD\u00a0(Con\u00a0ATV/r\u00a0300/100\u00a0mg/24h\u00a0\u219141%\u00a0AUC\u00a0RAL\u00a0\nsin\u00a0toxicidad). \u00a0\u00a0\n\u2010TPV/r\u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0Monitorizar \u00a0\ntransaminasas \u00a0NRAD\u00a0(\u2193\u00a024%\u00a0AUC\u00a0y\u00a055%\u00a0Cmin\u00a0RAL,\u00a0pero\u00a0en\u00a0los\u00a0\nestudios\u00a0BENCHMRK \u00a0no\u00a0disminuy\u00f3 \u00a0la\u00a0eficacia)\u00a0\n\u2010DRV/r\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0c/12h)\u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0importante. \u00a0\nInhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\u00a0\u00a0\n\u2010RAL\u00a0 NRAD\u00a0 \u2010\u2010\u00a0\n\u00a0\nAUC:\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraciones \u00a0plasm\u00e1ticas; \u00a0F:\u00a0Fortovase\u00ae; \u00a0I:\u00a0Invirase\u00ae; \u00a0IT:\u00a0interacci\u00f3n; \u00a0NRAD:\u00a0\nno\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0NS:\u00a0no\u00a0significativa; \u00a0QD:una\u00a0vez\u00a0al\u00a0d\u00eda;\u00a0MVC,\u00a0maraviroc; \u00a0RAL,\u00a0raltegravir \u00a0\n\u00a0\n\u00a0\n1En\u00a0presencia \u00a0de\u00a0inhibidores \u00a0enzim\u00e1ticos \u00a0potentes\u00a0como\u00a0los\u00a0IP\u00a0(excepto\u00a0TPV/r\u00a0y\u00a0FPV/r),\u00a0antif\u00fangicos \u00a0imidaz\u00f3licos \u00a0(ketoconazol, \u00a0\nitraconazol), \u00a0macr\u00f3lidos \u00a0(eritromicina, \u00a0claritromicina), \u00a0nefazodona \u00a0\u00f3\u00a0telitromicina \u00a0el\u00a0efecto\u00a0inhibidor\u00a0predomina \u00a0sobre\u00a0el\u00a0efecto\u00a0\ninductor\u00a0enzim\u00e1tico \u00a0y\u00a0por\u00a0lo\u00a0tanto,\u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0MVC\u00a0a\u00a0150\u00a0mg\u00a0c/12h.\u00a0\u00a0\n\u00a0\n2F\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A:\u00a0alfentanilo, \u00a0antagonistas \u00a0del\u00a0calcio\u00a0(amlodipino, \u00a0diltiazem, \u00a0felodipino, \u00a0nicardipino, \u00a0\nnifedipino, \u00a0nisoldipino, \u00a0verapamilo), \u00a0carbamacepina, \u00a0ciclosporina, \u00a0citost\u00e1ticos \u00a0(etop\u00f3sido, \u00a0paclitaxel, \u00a0tamoxifeno, \u00a0vinblastina \u00a0y\u00a0\nvincristina), \u00a0clonacepam, \u00a0dexametasona, \u00a0disopiramida, \u00a0eritromicina, \u00a0etosuximida, \u00a0fentanilo, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0nefazodona, \u00a0\nondansetron, \u00a0prednisona, \u00a0quinina,\u00a0rifampicina, \u00a0sertralina, \u00a0sildenafilo, \u00a0tacrolimus \u00a0y\u00a0trazodona, \u00a0entre\u00a0otros.\u00a0\n\u00a0\n\u03c9\u00a0Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0europea.\u00a0EPARS:\u00a0European \u00a0Public\u00a0Assessment \u00a0Reports.\u00a0Disponble \u00a0en:\u00a0\nhttp://www.ema.europa.eu/ema/index.jsp?cu rl=pages/includes/medicine s/medicines_landing_page.j sp&murl=menus/medicines\n/medicines.jsp&mid =\u00a0Con\u00a0acceso\u00a0[5/12/2010]. \u00a0\n\u2126Informaci\u00f3n \u00a0procedente \u00a0de\u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0americana \u00a0(fuentes:\u00a0FDA\u00a0and\u00a0First\u00a0Data\u00a0Bank,\u00a0Inc).\u00a0Disponible \u00a0en: \nhttp://www.rxlist.com/drugs/alpha_a.htm \u00a0.Con\u00a0acceso\u00a0[5/12/2010]. \u00a0\n\u00a0NOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0\nrecomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0\nfarmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 157 Tabla\u00a09.\u00a0Inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Enfuvirtida \u00a0(T\u201020)\u00a0\nNombre\u00a0comercial \u00a0 Fuzeon\u00ae\u00a0\u00a0\nDosis\u00a0recomendada \u00a0 90\u00a0mg\u00a0c/12h\u00a0s.c.\u00a0\nPresentaciones \u00a0\ncomerciales \u00a0vial\u00a0de\u00a090\u00a0mg\u00a0\nSemivida \u00a0plasm\u00e1tica \u00a0 3,8\u00b10,6\u00a0horas\u00a0\u00a0\nBiodisponibilidad \u00a0 80%\u00a0(v\u00eda\u00a0s.c.)\u00a0\nSemivida \u00a0plasm\u00e1tica \u00a0 3,8\u00b10,6\u00a0horas\u00a0\u00a0\nCmax\u00a0 4,59\u00b11,5\u00a0microg/mL \u00a0(VIH+)\u00a0\u00a0\nCmin\u00a0 2,6\u00a0\u2013\u00a03,4\u00a0microg/mL(VIH+)\u00a0\u00a0\nAUC\u00a0 55,8\u00b112,1 \u00a0microg.h/mL(VIH+)\u00a0\u00a0\u00a0\nCI\u00a050\u00a0 CI50\u00a0:\u00a00,259\u00a0microg/mL \u00a0(media\u00a0geom\u00e9trica) \u00a0en\u00a0un\u00a0ensayo\u00a0de\u00a0entrada\u00a0de\u00a0recombinaci\u00f3n \u00a0de\u00a0genotipos \u00a0VIH.\u00a0\u00a0\nActividad \u00a0 VIH\u20101\u00a0\nMetabolizaci\u00f3n \u00a0\nExcreci\u00f3n \u00a0Catabolismo \u00a0en\u00a0sus\u00a0amino\u00e1cidos \u00a0constituyentes \u00a0\nNo\u00a0hay\u00a0datos\u00a0\nEfectos\u00a0adversos\u00a0 Reacciones \u00a0locales\u00a0leve\u2010moderadas \u00a0en\u00a0el\u00a0punto\u00a0de\u00a0inyecci\u00f3n, \u00a0dolor\u00a0de\u00a0cabeza\u00a0y\u00a0fiebre.\u00a0\nInteracciones \u00a0Escaso\u00a0riesgo\u00a0de\u00a0interacci\u00f3n \u00a0metab\u00f3lica. \u00a0Se\u00a0ha\u00a0observado \u00a0in\u00a0vitro\u00a0un\u00a0efecto\u00a0sin\u00e9gico\u00a0intenso\u00a0de\u00a0enfuvirtide \u00a0con\u00a0elvitegravir, \u00a0lopinavir\u00a0y\u00a0\ndarunavir \u00a0y\u00a0un\u00a0efecto\u00a0sin\u00e9rgico\u00a0moderado \u00a0con\u00a0efavirenz. \u00a0Estudios\u00a0in\u00a0vitro\u00a0e\u00a0in\u00a0vivo\u00a0con\u00a0una\u00a0amplia\u00a0variedad\u00a0de\u00a0isoenzimas \u00a0hep\u00e1ticos \u00a0no\u00a0\nhan\u00a0mostrado \u00a0efecto\u00a0inhibitorio \u00a0de\u00a0T\u201020\u00a0sobre\u00a0los\u00a0mismos.\u00a0Estudios\u00a0en\u00a0pacientes \u00a0no\u00a0se\u00a0ha\u00a0encontrado \u00a0interacci\u00f3n \u00a0de\u00a0T\u201020\u00a0con\u00a0\nrifampicina, \u00a0ETR,\u00a0RTV\u00a0y\u00a0SQV/r.\u00a0Tampoco \u00a0se\u00a0ha\u00a0observado \u00a0interacci\u00f3n \u00a0farmacocin\u00e9tica \u00a0de\u00a0T\u201020\u00a0con\u00a0tacrolimus \u00a0ni\u00a0con\u00a0DRV.\u00a0En\u00a0un\u00a0estudio\u00a0\nse\u00a0observ\u00f3\u00a0un\u00a0aumento\u00a0de\u00a0las\u00a0concentraciones \u00a0de\u00a0TPV\u00a0(\u219150%\u00a0Cmin)\u00a0y\u00a0de\u00a0RTV\u00a0(\u2191\u00a0volumen\u00a0de\u00a0distribuci\u00f3n \u00a0y\u00a0semivida\u00a0de\u00a0eliminaci\u00f3n \u00a0de\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 158 ambos)\u00a0en\u00a0presencia \u00a0de\u00a0enfuvurtida, \u00a0aunque\u00a0estos\u00a0resultados \u00a0no\u00a0han\u00a0podido\u00a0corroborarse \u00a0en\u00a0otro\u00a0estudio.\u00a0Seg\u00fan\u00a0un\u00a0suban\u00e1lisis \u00a0del\u00a0\nestudio\u00a0RESIST,\u00a0no\u00a0parece\u00a0que\u00a0el\u00a0aumento\u00a0en\u00a0las\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0de\u00a0TPV\u00a0se\u00a0relacione\u00a0con\u00a0un\u00a0aumento\u00a0del\u00a0riesgo\u00a0de\u00a0\nhepatotoxicidad. \u00a0\u00a0\n\u00a0\nNOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0la\u00a0\ninformaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 159Tabla\u00a010.\u00a0Causas\u00a0de\u00a0adherencia \u00a0incorrecta \u00a0\u00a0y\u00a0posibles\u00a0estrategias \u00a0de\u00a0intervenci\u00f3n \u00a0\n\u00a0\n\u00a0 Causas\u00a0potenciales \u00a0de\u00a0incumplimiento Posibles\u00a0intervenciones \u00a0\nFactores\u00a0\nsociales,\u00a0\necon\u00f3micos, \u00a0\neducativos. \u00a0Falta\u00a0de\u00a0apoyo\u00a0social\u00a0y/o\u00a0familiar.\u00a0\nEscasos\u00a0recursos.\u00a0\u00a0Bajo\u00a0nivel\u00a0\neducativo \u00a0Buscar\u00a0alianza\u00a0con\u00a0familia\u00a0y\u00a0allegados. \u00a0Conocer\u00a0\nnecesidades \u00a0sociales.\u00a0Reclutar\u00a0organizaciones \u00a0\ncomunitarias. \u00a0Educaci\u00f3n \u00a0intensiva, \u00a0explicaciones \u00a0\nclaras\u00a0y\u00a0comprensibles \u00a0y\u00a0adaptadas \u00a0\nFactores\u00a0del\u00a0\nequipo\u00a0\nasistencial \u00a0Falta\u00a0de\u00a0recursos.\u00a0Atenci\u00f3n\u00a0masificada \u00a0\ne\u00a0impersonal. \u00a0Ausencia\u00a0de\u00a0\ncoordinaci\u00f3n \u00a0entre\u00a0diferentes \u00a0\nservicios\u00a0de\u00a0apoyo\u00a0a\u00a0la\u00a0asistencia. \u00a0\nInsuficiente \u00a0formaci\u00f3n \u00a0en\u00a0terapia\u00a0\nantirretroviral. \u00a0Falta\u00a0de\u00a0accesibilidad. \u00a0\nDeficiente \u00a0formaci\u00f3n \u00a0en\u00a0relaci\u00f3n\u00a0\npersonal\u00a0sanitario\u2010paciente. \u00a0Accesibilidad \u00a0y\u00a0continuidad \u00a0de\u00a0la\u00a0asistencia. \u00a0\nEquipo\u00a0multidisciplinar. \u00a0Recursos\u00a0materiales \u00a0y\u00a0\nhumanos \u00a0suficientes \u00a0y\u00a0coordinados. \u00a0\u00a0\nFormaci\u00f3n \u00a0s\u00f3lida\u00a0en\u00a0terapia\u00a0antirretroviral \u00a0y\u00a0en\u00a0\natenci\u00f3n\u00a0al\u00a0paciente. \u00a0\nPlantear\u00a0terapia\u00a0directamente \u00a0observada \u00a0en\u00a0\ndeterminados \u00a0\u00e1mbitos\u00a0asistenciales. \u00a0\nFactores\u00a0\nrelacionados \u00a0\ncon\u00a0el\u00a0\ntratamiento \u00a0Efectos\u00a0adversos, \u00a0tama\u00f1o\u00a0y\u00a0\npalatabilidad \u00a0de\u00a0las\u00a0unidades\u00a0\ngal\u00e9nicas, \u00a0n\u00famero\u00a0de\u00a0dosis\u00a0diarias.\u00a0\nIntrusi\u00f3n\u00a0en\u00a0la\u00a0vida\u00a0del\u00a0paciente. \u00a0Falta\u00a0\nde\u00a0adaptaci\u00f3n \u00a0a\u00a0las\u00a0preferencias \u00a0y\u00a0\nnecesidades \u00a0del\u00a0paciente. \u00a0Simplificar \u00a0el\u00a0r\u00e9gimen\u00a0terap\u00e9utico. \u00a0Pautas\u00a0\nconvenientes \u00a0en\u00a0n\u00famero\u00a0y\u00a0dosificaci\u00f3n \u00a0de\u00a0\ncomprimidos, \u00a0emplear\u00a0f\u00e1rmacos\u00a0co\u2010formulados \u00a0\nIndividualizar \u00a0tratamiento: \u00a0Resistencias, \u00a0\ncomorbilidad, \u00a0preferencias, \u00a0interacciones. \u00a0\u00a0\nT\u00e9cnicas\u00a0especiales \u00a0para\u00a0la\u00a0toma\u00a0de\u00a0la\u00a0\nmedicaci\u00f3n. \u00a0Ayudar\u00a0a\u00a0desarrollar \u00a0mecanismos \u00a0de\u00a0\nreacci\u00f3n\u00a0(p.e.\u00a0anticipaci\u00f3n \u00a0y\u00a0manejo\u00a0de\u00a0efectos\u00a0\nadversos) \u00a0\nFactores\u00a0\nrelacionados \u00a0\ncon\u00a0el\u00a0paciente\u00a0No\u00a0aceptaci\u00f3n. \u00a0Rechazo\u00a0del\u00a0\ndiagn\u00f3stico. \u00a0Rechazo\u00a0del\u00a0tratamiento \u00a0\n(creencias \u00a0y\u00a0actitudes) \u00a0\nOlvidos\u00a0y\u00a0barreras.\u00a0Insuficiente \u00a0\ncomprensi\u00f3n \u00a0de\u00a0la\u00a0enfermedad \u00a0y\u00a0su\u00a0\ntratamiento. \u00a0Insuficiente \u00a0\nentendimiento \u00a0de\u00a0la\u00a0relaci\u00f3n\u00a0\nriesgo/beneficio. \u00a0\nMotivos\u00a0de\u00a0dosificaci\u00f3n \u00a0y\u00a0\ncumplimiento. \u00a0\nComorbilidad \u00a0psiqui\u00e1trica. \u00a0\nUso\u00a0y\u00a0abuso\u00a0de\u00a0drogas\u00a0Negociar\u00a0y\u00a0consensuar \u00a0el\u00a0plan\u00a0terap\u00e9utico. \u00a0\nFomentar \u00a0la\u00a0percepci\u00f3n \u00a0de\u00a0indicadores \u00a0de\u00a0la\u00a0\nnecesidad \u00a0de\u00a0\u00a0tratamiento. \u00a0Informar\u00a0sobre\u00a0\u00a0\nriesgos\u00a0y\u00a0beneficios \u00a0del\u00a0tratamiento. \u00a0Asociar\u00a0cada\u00a0\ntoma\u00a0con\u00a0actividades \u00a0cotidianas. \u00a0T\u00e9cnicas\u00a0\nespeciales \u00a0y\u00a0ayudas\u00a0para\u00a0el\u00a0cumplimiento \u00a0(diarios\u00a0\nde\u00a0medicaci\u00f3n, \u00a0alarmas,\u00a0tel\u00e9fonos, \u00a0etc).\u00a0Mejorar\u00a0\nla\u00a0comunicaci\u00f3n \u00a0paciente\u00a0\u2013\u00a0profesional \u00a0sanitario. \u00a0\nInformaci\u00f3n \u00a0referente \u00a0a\u00a0la\u00a0enfermedad \u00a0y\u00a0el\u00a0\ntratamiento, \u00a0motivo\u00a0de\u00a0la\u00a0dosificaci\u00f3n, \u00a0riesgo\u00a0del\u00a0\nincumplimiento. \u00a0Informaci\u00f3n \u00a0oral\u00a0y\u00a0escrita.\u00a0\nVerificar\u00a0comprensi\u00f3n. \u00a0Derivar\u00a0para\u00a0intervenci\u00f3n \u00a0\npsicol\u00f3gica \u00a0en\u00a0\u00a0\u00e1reas\u00a0disfuncionales \u00a0o\u00a0\nintervenci\u00f3n \u00a0psiqui\u00e1trica \u00a0si\u00a0se\u00a0detecta\u00a0patolog\u00eda \u00a0\npsiqui\u00e1trica. \u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 160 Tabla\u00a011.\u00a0Toxicidad \u00a0de\u00a0cada\u00a0familia\u00a0de\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\n\u00a0\nFamilia\u00a0 Toxicidad \u00a0 Prevalencia \u00a0 Cl\u00ednica\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0\ninversa\u00a0nucle\u00f3sidos \u00a0o\u00a0\nnucle\u00f3tidos1\u00a0Toxicidad \u00a0mitocondrial \u00a0 20\u201040%\u00a0 Neuropat\u00eda \u00a0perif\u00e9rica \u00a0\nMiopat\u00eda\u00a0\nCardiomiopat\u00eda \u00a0\nPancreatitis \u00a0\nHepatomegalia \u00a0\nEsteatosis \u00a0hep\u00e1tica\u00a0\nHepatitis\u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\nMielotoxicidad \u00a0\nAlteraci\u00f3n \u00a0tubular\u00a0proximal\u00a0renal\u00a0\nLipoatrofia \u00a0\nHiperlipemia \u00a0y\u00a0resistencia \u00a0insul\u00ednica \u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0\ninversa\u00a0no\u00a0nucle\u00f3sidos2\u00a0Hipersensibilidad \u00a0 10\u201020%\u00a0 Exantema \u00a0(extensi\u00f3n \u00a0y\u00a0gravedad \u00a0variable)\u00a0\nAfectaci\u00f3n \u00a0multiorg\u00e1nica \u00a0\nFiebre\u00a0\nInhibidores \u00a0de\u00a0la\u00a0proteasa3\u00a0Hiperlipemia \u00a0\u00a0\nResistencia \u00a0a\u00a0la\u00a0insulina\u00a0(IP\u00a0cl\u00e1sicos;\u00a0dif\u00edcil\u00a0\nde\u00a0separar\u00a0de\u00a0los\u00a0efectos\u00a0de\u00a0an\u00e1logos\u00a0de\u00a0\ntimidina)\u00a0y\u00a0lipodistrofia \u00a025\u201050%\u00a0 Hipertrigliceridemia \u00a0(especialmente) \u00a0\nHipercolesterolemia \u00a0\nDiabetes\u00a0mellitus\u00a0\nLipoacumulaci\u00f3n \u00a0intraabdominal \u00a0\nInhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n4\u00a0 Inflamaci\u00f3n \u00a0d\u00e9rmica\u00a0local\u00a0 60\u201070%\u00a0 Dolor\u00a0\nTumoraci\u00f3n \u00a0\nInhibidores \u00a0de\u00a0los\u00a0receptores \u00a0\nCCR55\u00a0Mecanismo \u00a0desconocido \u00a0(bloqueo\u00a0\nreceptor\u00a0CCR5?)\u00a0<2%\u00a0 \u2191\u00a0riesgo\u00a0de\u00a0infecciones \u00a0respiratorias \u00a0\n\u2191\u00a0riesgo\u00a0de\u00a0cardiopat\u00eda \u00a0isqu\u00e9mica?5\u00a0\nInhibidores \u00a0de\u00a0la\u00a0integrasa6\u00a0Mecanismo \u00a0desconocido \u00a0 5\u201010%6\u00a0 Elevaci\u00f3n \u00a0de\u00a0CPK6\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 161 Las\u00a0distintas\u00a0manifestaciones \u00a0de\u00a0la\u00a0toxicidad\u00a0se\u00a0suelen\u00a0presentar \u00a0de\u00a0forma\u00a0aislada.\u00a0Aparecen \u00a0generalmente \u00a0en\u00a0los\u00a0tres\u00a0primeros\u00a0meses\u00a0de\u00a0\ntratamiento, \u00a0aunque\u00a0algunas\u00a0expresiones \u00a0de\u00a0la\u00a0toxicidad\u00a0mitocondrial \u00a0(neuropat\u00eda, \u00a0miopat\u00eda, \u00a0acidosis\u00a0l\u00e1ctica\u00a0o\u00a0lipoatrofia) \u00a0suelen\u00a0aparecer\u00a0de\u00a0\nforma\u00a0tard\u00eda\u00a0(meses\u00a0o\u00a0a\u00f1os).\u00a0\n1.\u00a0ABC\u00a0constituye \u00a0una\u00a0excepci\u00f3n, \u00a0pues\u00a0su\u00a0toxicidad\u00a0est\u00e1\u00a0mediada\u00a0por\u00a0hipersensibilidad. \u00a0TDF\u00a0puede\u00a0inducir\u00a0nefrotoxicidad. \u00a0\n2.\u00a0Efavirenz\u00a0puede\u00a0inducir\u00a0toxicidad\u00a0neurops\u00edqui\u00e1trica \u00a0como\u00a0efecto\u00a0adverso\u00a0singular.\u00a0\n3.\u00a0Indinavir\u00a0puede\u00a0causar\u00a0nefrolitiasis \u00a0e\u00a0insuficiencia \u00a0renal\u00a0como\u00a0efectos\u00a0adversos\u00a0singulares. \u00a0Atazanavir \u00a0no\u00a0comporta \u00a0el\u00a0riesgo\u00a0de\u00a0alteraciones \u00a0\nmetab\u00f3licas, \u00a0como\u00a0otros\u00a0IP,\u00a0pero\u00a0puede\u00a0producir\u00a0hiperbilirrubinemia \u00a0y\u00a0nefrolitiasis \u00a0como\u00a0efectos\u00a0adversos\u00a0singulares. \u00a0\n4.\u00a0La\u00a0enfuvirtida \u00a0(T\u201020),\u00a0\u00fanico\u00a0representante \u00a0de\u00a0esta\u00a0familia\u00a0disponible \u00a0en\u00a0la\u00a0actualidad, \u00a0se\u00a0administra \u00a0por\u00a0v\u00eda\u00a0subcut\u00e1nea. \u00a0\n5.\u00a0Maraviroc \u00a0es\u00a0el\u00a0\u00fanico\u00a0representante \u00a0de\u00a0esta\u00a0familia\u00a0disponible \u00a0en\u00a0la\u00a0actualidad. \u00a0Los\u00a0efectos\u00a0indicados \u00a0est\u00e1n\u00a0incluidos\u00a0en\u00a0la\u00a0ficha\u00a0t\u00e9cnica.\u00a0\n6.\u00a0Raltegravir \u00a0es\u00a0el\u00a0\u00fanico\u00a0representante \u00a0de\u00a0esta\u00a0familia\u00a0disponible \u00a0en\u00a0la\u00a0actualidad. \u00a0En\u00a0estudio\u00a0BENCHMRK, \u00a0elevaci\u00f3n \u00a0de\u00a0CPK\u00a0grado\u00a03\u20104\u00a0\n(generalmente \u00a0asintom\u00e1tica), \u00a07%.\u00a0\u00a0CPK:\u00a0Creatinfosfoquinasa   \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 162 Tabla\u00a012.\u00a0Toxicidad \u00a0de\u00a0los\u00a0antirretrovirales \u00a0por\u00a0\u00f3rganos\u00a0y\u00a0aparatos\u00a0\n\u00a0\n \nToxicidad \u00a0 F\u00e1rmaco/s \u00a0 Diagn\u00f3stico \u00a0 Patogenia \u00a0 Actitud\u00a0\nAnemia\u00a0 AZT\u00a0(dosis\u2010dependiente) \u00a0S\u00edntomas \u00a0cl\u00ednicos\u00a0de\u00a0anemia\u00a0Inhibici\u00f3n \u00a0de\u00a0la\u00a0proliferaci\u00f3n \u00a0de\u00a0\nlas\u00a0c\u00e9lulas\u00a0progenitoras \u00a0eritroides \u00a0Suspensi\u00f3n \u00a0de\u00a0AZT\u00a0\nTransfusi\u00f3n \u00a0de\u00a0hemat\u00edes \u00a0(si\u00a0hemoglobina \u00a0<8g/dL\u00a0\u00f3\u00a0hay\u00a0s\u00edntomas\u00a0de\u00a0\nanemia)\u00a0\nMiopat\u00eda\u00a0 AZT\u00a0(dosis\u2010dependiente) \u00a0\nRAL\u00a0Despu\u00e9s\u00a0del\u00a0primer\u00a0semestre \u00a0\u00a0de\u00a0\ntratamiento \u00a0(AZT)\u00a0\nS\u00edntomas: \u00a0mialgias\u00a0o\u00a0debilidad \u00a0\nmuscular\u00a0proximal\u00a0y\u00a0elevaci\u00f3n \u00a0de\u00a0\nenzimas\u00a0musculares \u00a0(CPK,\u00a0LDH,\u00a0\u00a0\naldolasa)\u00a0Toxicidad \u00a0mitocondrial \u00a0(AZT)\u00a0\nMecanismo \u00a0desconocido \u00a0(RAL)\u00a0Suspensi\u00f3n \u00a0de\u00a0AZT\u00a0\u00f3\u00a0RAL\u00a0\nSi\u00a0cl\u00ednica\u00a0importante, \u00a0prednisona \u00a01\u20102\u00a0mg/kg/d\u00eda \u00a0(AZT)\u00a0\nNeuropat\u00eda \u00a0perif\u00e9rica \u00a0ddI\u00a0(13\u201034%)\u00a0\nd4T\u00a0(15\u201020%)\u00a0\n(dosis\u2010dependiente) \u00a0\n\u00a0Hipoestesia, \u00a0parestesia \u00a0o\u00a0dolor\u00a0\nen\u00a0zona\u00a0distal\u00a0de\u00a0extremidades \u00a0\n(especialmente \u00a0pies)\u00a0\nDiagn\u00f3stico \u00a0diferencial \u00a0con\u00a0la\u00a0\nneuropat\u00eda \u00a0por\u00a0el\u00a0propio\u00a0VIH\u00a0\n(aparece\u00a0en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0e\u00a0inmunodepresi\u00f3n \u00a0\ngrave)\u00a0Interacci\u00f3n \u00a0entre\u00a0citoquinas \u00a0y\u00a0\nfactores\u00a0de\u00a0crecimiento \u00a0neuronal\u00a0\nFavorecida \u00a0por\u00a0neuropat\u00eda \u00a0previa\u00a0\ny\u00a0\u00a0factores\u00a0predisponentes \u00a0\n(enolismo, \u00a0desnutrici\u00f3n, \u00a0\ndiabetes,\u00a0etc)\u00a0Evitar\u00a0asociaciones \u00a0de\u00a0f\u00e1rmacos \u00a0neurot\u00f3xicos \u00a0\nValorar\u00a0mantener \u00a0f\u00e1rmacos \u00a0potencialmente \u00a0implicados \u00a0si\u00a0la\u00a0cl\u00ednica\u00a0no\u00a0es\u00a0\ngrave\u00a0y\u00a0no\u00a0hay\u00a0alternativas \u00a0razonables \u00a0\nSuspender \u00a0los\u00a0f\u00e1rmacos \u00a0implicados \u00a0si\u00a0cl\u00ednica\u00a0progresiva \u00a0o\u00a0invalidante. \u00a0La\u00a0\nrecuperaci\u00f3n \u00a0es\u00a0lenta\u00a0(meses\u00a0o\u00a0a\u00f1os).\u00a0\nSi\u00a0dolor\u00a0leve:\u00a0analg\u00e9sicos \u00a0habituales. \u00a0\nSi\u00a0dolor\u00a0moderado \u2010intenso:\u00a0gabapentina, \u00a0\u00a0pregabalina \u00a0o\u00a0lamotrigina \u00a0con\u00a0\no\u00a0sin\u00a0benzodiacepinas; \u00a0si\u00a0no\u00a0eficacia,\u00a0valorar\u00a0carbamacepina \u00a0y/o\u00a0\namitriptilina \u00a0(producen \u00a0efectos\u00a0colin\u00e9rgicos) \u00a0\nSi\u00a0dolor\u00a0muy\u00a0intenso\u00a0o\u00a0refractario: \u00a0opi\u00e1ceos\u00a0\nToxicidad \u00a0\nneurops\u00edquica \u00a0EFV\u00a0(20\u201050%)\u00a0\u00a0\n(dosis\u2010dependiente; \u00a0m\u00e1s\u00a0\nprevalente \u00a0si\u00a0administraci\u00f3n \u00a0\ncon\u00a0alimentos) \u00a0Durante\u00a0el\u00a0primer\u00a0mes\u00a0de\u00a0\ntratamiento, \u00a0tras\u00a0lo\u00a0cual\u00a0\ndisminuye \u00a0o\u00a0desaparece. \u00a0\nEspectro\u00a0cl\u00ednico\u00a0variado:\u00a0mareo,\u00a0\nansiedad, \u00a0somnolencia, \u00a0\ntrastornos \u00a0del\u00a0sue\u00f1o,\u00a0\nagravamiento \u00a0de\u00a0problemas \u00a0\nps\u00edquicos \u00a0subyacentes, \u00a0y\u00a0\nalteraciones \u00a0motoras.\u00a0Desconocida. \u00a0 Evitar\u00a0en\u00a0pacientes \u00a0con\u00a0trastornos \u00a0psiqui\u00e1tricos \u00a0mayores. \u00a0\nValorar\u00a0individualmente \u00a0el\u00a0estilo\u00a0de\u00a0vida\u00a0y\u00a0la\u00a0actividad\u00a0del\u00a0paciente\u00a0antes\u00a0\nde\u00a0prescribirlo. \u00a0\nGeneralmente \u00a0no\u00a0es\u00a0necesaria \u00a0la\u00a0suspensi\u00f3n \u00a0de\u00a0efavirenz. \u00a0\nSuspender \u00a0en\u00a0casos\u00a0de\u00a0manifestaciones \u00a0graves\u00a0o\u00a0invalidantes. \u00a0\nAdministraci\u00f3n \u00a0por\u00a0la\u00a0noche,\u00a0al\u00a0menos\u00a01\u20102\u00a0horas\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0cena.\u00a0\nValorar\u00a0benzodiacepinas \u00a0o\u00a0neurol\u00e9pticos \u00a0si\u00a0alteraciones \u00a0del\u00a0sue\u00f1o\u00a0\npersistentes. \u00a0\nPuede\u00a0intentarse \u00a0ajuste\u00a0de\u00a0dosis\u00a0si\u00a0hay\u00a0posibilidad \u00a0de\u00a0estudio\u00a0\nfarmacocin\u00e9tico, \u00a0aunque\u00a0no\u00a0est\u00e1\u00a0definitivamente \u00a0probado\u00a0\n\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 163 Toxicidad \u00a0 F\u00e1rmaco/s \u00a0 Diagn\u00f3stico \u00a0 Patogenia \u00a0 Actitud\u00a0\nExantema \u00a0y/o\u00a0\nhipersensibilidad \u00a0No\u2010nucle\u00f3sidos \u00a0(m\u00e1s\u00a0\nfrecuente \u00a0NVP)\u00a0(<20%)\u00a0\u00a0\nInhibidores \u00a0de\u00a0proteasa\u00a0\n(m\u00e1s\u00a0frecuente \u00a0TPV\u00a0\u00a0(8\u2010\n14%),\u00a0DRV\u00a0y\u00a0FPV\u00a0(3\u20105%)\u00a0\nNucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nABC:\u00a05%\u00a0si\u00a0no\u00a0se\u00a0realiza\u00a0\ndeterminaci\u00f3n \u00a0de\u00a0HLA\u00a0\nB*5701;\u00a0si\u00a0se\u00a0realiza,\u00a0la\u00a0\nfrecuencia \u00a0es\u00a00%)\u00a0\n\u00a0Durante\u00a0los\u00a0primeros\u00a0dos\u00a0meses\u00a0\nde\u00a0tratamiento \u00a0\nExantema \u00a0maculo\u2010papular\u00a0(casos\u00a0\nleves).\u00a0\nFiebre,\u00a0afectaci\u00f3n \u00a0mucosa,\u00a0\npulmonar, \u00a0hep\u00e1tica\u00a0o\u00a0\nhematol\u00f3gica \u00a0(casos\u00a0graves)\u00a0\nLa\u00a0hipersensibilidad \u00a0se\u00a0manifiesta \u00a0\npor\u00a0afectaci\u00f3n \u00a0multi\u00f3rganica, \u00a0a\u00a0\nveces\u00a0con\u00a0escaso\u00a0o\u00a0nulo\u00a0\nexantema, \u00a0y\u00a0puede\u00a0haber\u00a0\neosinofilia. \u00a0Desconocida. \u00a0\nSe\u00a0ha\u00a0sugerido\u00a0una\u00a0reacci\u00f3n\u00a0\nant\u00edgeno\u2010anticuerpo \u00a0similar\u00a0a\u00a0la\u00a0\u00a0\nenfermedad \u00a0del\u00a0suero\u00a0o\u00a0una\u00a0\ntoxicidad\u00a0directa\u00a0por\u00a0metabolitos \u00a0\nintermediarios. \u00a0\nIdentificaci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nriesgo\u00a0gen\u00e9tico\u00a0elevado\u00a0de\u00a0\nhipersensibilidad \u00a0a\u00a0abacavir\u00a0(HLA\u2010\nB*5701)\u00a0Comienzo \u00a0escalonado \u00a0de\u00a0dosis\u00a0de\u00a0nevirapina. \u00a0No\u00a0dar\u00a0corticoides \u00a0\nprofil\u00e1cticos \u00a0(no\u00a0evitan\u00a0el\u00a0riesgo\u00a0e\u00a0incluso\u00a0lo\u00a0pueden\u00a0aumentar) \u00a0ni\u00a0\nantihistam\u00ednicos \u00a0\nSi\u00a0exantema \u00a0leve\u00a0sin\u00a0cl\u00ednica\u00a0de\u00a0hipersensibilidad \u00a0acompa\u00f1ante, \u00a0se\u00a0puede\u00a0\nmantener \u00a0el\u00a0tratamiento \u00a0y\u00a0realizar\u00a0una\u00a0vigilancia \u00a0estrecha. \u00a0\nEl\u00a0exantema \u00a0por\u00a0ETR,\u00a0\u00a0generalmente \u00a0leve\u2010moderado \u00a0y\u00a0raramente \u00a0obliga\u00a0\na\u00a0retirar\u00a0el\u00a0f\u00e1rmaco\u00a0\nSi\u00a0exantema \u00a0grave\u00a0o\u00a0cl\u00ednica\u00a0de\u00a0hipersensibilidad, \u00a0interrupci\u00f3n \u00a0\npermanente \u00a0del\u00a0f\u00e1rmaco.\u00a0\u00a0\nEn\u00a0los\u00a0casos\u00a0donde\u00a0pueda\u00a0estar\u00a0implicado \u00a0ABC\u00a0\u00a0y\u00a0la\u00a0cl\u00ednica\u00a0no\u00a0sea\u00a0clara,\u00a0\npuede\u00a0ser\u00a0razonable \u00a0mantener \u00a0el\u00a0tratamiento \u00a0durante\u00a024\u00a0horas\u00a0m\u00e1s\u00a0con\u00a0\nuna\u00a0vigilancia \u00a0estrecha\u00a0y\u00a0valorar\u00a0evoluci\u00f3n \u00a0antes\u00a0de\u00a0retirar\u00a0ABC.\u00a0\nTratamiento \u00a0sintom\u00e1tico \u00a0con\u00a0antihistam\u00ednicos \u00a0y/o\u00a0corticoides \u00a0una\u00a0vez\u00a0\ninterrumpido \u00a0el\u00a0f\u00e1rmaco\u00a0sospechoso \u00a0\nTratamiento \u00a0de\u00a0soporte\u00a0hemodin\u00e1mico, \u00a0o\u00a0respiratorio \u00a0en\u00a0casos\u00a0graves\u00a0\nque\u00a0lo\u00a0requieran \u00a0\nNO\u00a0REINTRODUCIR \u00a0NUNCA\u00a0UN\u00a0F\u00c1RMACO \u00a0RETIRADO \u00a0POR\u00a0SOSPECHA \u00a0DE\u00a0\nHIPERSENSIBILIDAD \u00a0\nHepatitis\u00a0 Nucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nAZT,\u00a0ddI\u00a0y\u00a0d4T).\u00a0No\u00a0\nnucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nNVP)\u00a0\nInhibidores \u00a0de\u00a0proteasa\u00a0\n(m\u00e1s\u00a0frecuente \u00a0RTV\u00a0a\u00a0dosis\u00a0\nplena)\u00a0\n\u00a0\n\u00a0El\u00a050%\u00a0de\u00a0los\u00a0casos\u00a0aparece\u00a0en\u00a0el\u00a0\nprimer\u00a0semestre. \u00a0\nAumento \u00a0de\u00a0transaminasas \u00a0sin\u00a0\ncl\u00ednica\u00a0(10\u201015%\u00a0de\u00a0pacientes). \u00a0\nHepatitis\u00a0cl\u00ednica\u00a0(<1%).\u00a0\nFactores\u00a0de\u00a0riesgo:\u00a0infecci\u00f3n\u00a0por\u00a0\nvirus\u00a0de\u00a0hepatitis\u00a0B\u00a0y\u00a0C\u00a0\u00a0Multifactorial: \u00a0toxicidad\u00a0\nmitocondrial \u00a0(nucle\u00f3sidos), \u00a0\nefecto\u00a0t\u00f3xico\u2010inmunol\u00f3gico \u00a0(no\u00a0\nnucle\u00f3sidos); \u00a0si\u00a0IP\u00a0efecto\u00a0mixto\u00a0\n(toxicidad \u00a0directa,\u00a0recuperaci\u00f3n \u00a0\ninmune\u00a0si\u00a0VHB\u00a0o\u00a0VHC),\u00a0rebrote\u00a0de\u00a0\nvirus\u00a0B\u00a0tras\u00a0suspender \u00a0TARV\u00a0con\u00a0\nefecto\u00a0anti\u2010VHB\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0Considerar \u00a0vigilancia \u00a0estrecha\u00a0y\u00a0potencial \u00a0suspensi\u00f3n \u00a0si\u00a0transaminasas \u00a0>5\u00a0\nveces\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0normalidad. \u00a0\nInterrumpir \u00a0si\u00a0transaminasas \u00a0>10\u00a0veces\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0normalidad, \u00a0\nmanifestaciones \u00a0cl\u00ednicas\u00a0de\u00a0hipersensibilidad \u00a0(fiebre\u00a0o\u00a0exantema), \u00a0de\u00a0\nfallo\u00a0hep\u00e1tico\u00a0\n(ictericia, \u00a0encefalopat\u00eda, \u00a0o\u00a0hemorragia) \u00a0o\u00a0acidosis\u00a0l\u00e1ctica.\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 164  \n \n \n \nToxicidad \u00a0 F\u00e1rmaco/s \u00a0 Diagn\u00f3stico \u00a0 Patogenia \u00a0 Actitud\u00a0\nToxicidad \u00a0\ngastrointestinal \u00a0Inhibidores \u00a0de\u00a0proteasa\u00a0\nsobre\u00a0todo\u00a0RTV\u00a0(a\u00a0dosis\u00a0\nplenas),\u00a0\u00a040%;\u00a0IDV,\u00a025%;\u00a0\u00a0\nNFV,\u00a025%\u00a0;\u00a0LPV/r,\u00a025%;\u00a0\u00a0\nSQV,\u00a05%\u00a0\nNucle\u00f3sidos \u00a0con\u00a0menor\u00a0\nfrecuencia \u00a0que\u00a0IP\u00a0\n(particularmente \u00a0AZT\u00a0y\u00a0TDF)\u00a0\u00a0\n\u00a0Sabor\u00a0desagradable \u00a0(RTV\u00a0\nsuspensi\u00f3n) \u00a0\nMolestias \u00a0digestivas \u00a0altas\u00a0(IDV\u00a0y\u00a0\nAPV)\u00a0\nDiarrea\u00a0(NFV\u00a0y\u00a0LPV/r)\u00a0Multifactorial. \u00a0\nInhibici\u00f3n \u00a0de\u00a0enzimas\u00a0\npancre\u00e1ticas \u00a0(inhibidores \u00a0de\u00a0\nproteasa). \u00a0\nIntolerancia \u00a0a\u00a0la\u00a0lactosa\u00a0que\u00a0\ncontienen \u00a0como\u00a0excipiente \u00a0\n(todos\u00a0los\u00a0antirretrovirales). \u00a0Raramente \u00a0grave,\u00a0pero\u00a0por\u00a0su\u00a0frecuencia \u00a0e\u00a0incomodidad \u00a0puede\u00a0limitar\u00a0la\u00a0\nadherencia \u00a0al\u00a0TAR.\u00a0\nPara\u00a0la\u00a0diarrea,\u00a0dietas\u00a0rica\u00a0en\u00a0alimentos \u00a0astringentes \u00a0o\u00a0fibra\u00a0soluble\u00a0o\u00a0\nf\u00e1rmacos \u00a0inhibidores \u00a0de\u00a0la\u00a0motilidad \u00a0intestinal \u00a0(loperamida). \u00a0\nSuspensi\u00f3n \u00a0del\u00a0f\u00e1rmaco\u00a0si\u00a0molestias \u00a0persistentes \u00a0o\u00a0intensas.\u00a0\nPancreatitis \u00a0 Nucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nddI\u00a0y\u00a0d4T).\u00a0\nAumento \u00a0de\u00a0riesgo\u00a0cuando\u00a0\nse\u00a0administra \u00a0hidroxiurea, \u00a0o\u00a0\nTDF\u00a0con\u00a0ddI.\u00a0\n\u00a0Generalmente, \u00a0asintom\u00e1tica. \u00a0\nPuede\u00a0haber\u00a0manifestaciones \u00a0\ncl\u00ednicas\u00a0de\u00a0dolor\u00a0abdominal \u00a0y\u00a0\ndiarrea.\u00a0Toxicidad \u00a0mitocondrial \u00a0 Retirar\u00a0el\u00a0f\u00e1rmaco\u00a0potencialmente \u00a0implicado. \u00a0\n\u00a0\u00a0\nInsuficiencia \u00a0renal\u00a0y\u00a0\ntubulopat\u00eda \u00a0TDF\u00a0\nIDV\u00a0\n\u00a0Elevaci\u00f3n \u00a0leve\u00a0o\u00a0moderada \u00a0de\u00a0la\u00a0\ncreatinina \u00a0con/sin\u00a0anomal\u00edas \u00a0\nanal\u00edticas \u00a0de\u00a0disfunci\u00f3n \u00a0tubular\u00a0\n(hipofosfatemia). \u00a0\u00a0\nNo\u00a0suele\u00a0acompa\u00f1arse \u00a0de\u00a0cl\u00ednica.\u00a0Alteraci\u00f3n \u00a0tubular\u00a0proximal\u00a0\u00a0\n(TDF)\u00a0\u00a0\nNefritis\u00a0intersticial \u00a0por\u00a0cristales\u00a0\n(IDV)\u00a0\n\u00a0Evitar\u00a0en\u00a0pacientes \u00a0con\u00a0insuficiencia \u00a0renal.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0\ncoadministraci\u00f3n \u00a0con\u00a0otros\u00a0f\u00e1rmacos \u00a0potencialmente \u00a0nefrot\u00f3xicos. \u00a0\nHidrataci\u00f3n \u00a0adecuada \u00a0para\u00a0prevenir\u00a0o\u00a0mejorar\u00a0la\u00a0elevaci\u00f3n \u00a0de\u00a0creatinina. \u00a0\nSuspensi\u00f3n \u00a0del\u00a0f\u00e1rmaco\u00a0si\u00a0el\u00a0filtrado\u00a0glomerular \u00a0es\u00a0<50\u00a0mL/min\u00a0\u00a0\nNefrolitiasis \u00a0 IDV\u00a0\nATV\u00a0\u00a0\n\u00a0Dolor\u00a0c\u00f3lico\u00a0lumbar.\u00a0\u00a0Hematuria \u00a0\nmicrosc\u00f3pica \u00a0y\u00a0ocasionalmente \u00a0\nmacrosc\u00f3pica. \u00a0Ocasionalmente, \u00a0\nfiebre\u00a0(diagn\u00f3stico \u00a0diferencial \u00a0\ncon\u00a0pielonefritis) \u00a0\nM\u00e1s\u00a0frecuente \u00a0en\u00a0ambientes \u00a0\ncalurosos \u00a0Precipitaci\u00f3n \u00a0de\u00a0indinavir\u00a0en\u00a0\norina\u00a0concentrada \u00a0(densidad \u00a0\n>1020)\u00a0\u00a0y\u00a0pH\u00a0b\u00e1sico\u00a0(>5).\u00a0Prevenci\u00f3n \u00a0mediante \u00a0ingesta\u00a0adecuada \u00a0de\u00a0l\u00edquido\u00a0(1500\u00a0ml\u00a0de\u00a0agua\u00a0al\u00a0\nd\u00eda\u00a0o\u00a0m\u00e1s\u00a0si\u00a0ambiente \u00a0caluroso\u00a0o\u00a0p\u00e9rdidas\u00a0extraordinarias \u00a0de\u00a0l\u00edquidos). \u00a0\nEvitar\u00a0bebidas\u00a0carb\u00f3nicas. \u00a0\nAnti\u2010inflamatorios \u00a0no\u00a0esteroideos \u00a0para\u00a0el\u00a0dolor.\u00a0\nSuspensi\u00f3n \u00a0transitoria \u00a0del\u00a0f\u00e1rmaco\u00a0responsable \u00a0si\u00a0dolor\u00a0intenso.\u00a0\nSuspensi\u00f3n \u00a0definitiva \u00a0del\u00a0f\u00e1rmaco\u00a0responsable \u00a0si\u00a0episodios \u00a0repetidos \u00a0sin\u00a0\ndesencadenante \u00a0evidente. \u00a0\u00a0\nAjuste\u00a0de\u00a0dosis\u00a0si\u00a0posibilidad \u00a0de\u00a0estudio\u00a0farmacocin\u00e9tico. \u00a0\n\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 165 Tabla\u00a013.\u00a0Evaluaci\u00f3n \u00a0y\u00a0tratamiento \u00a0de\u00a0la\u00a0dislipemia \u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0 Tratamiento \u00a0\nRealizar\u00a0anal\u00edtica\u00a0en\u00a0ayunas\u00a0\nDescartar \u00a0otras\u00a0causas\u00a0de\u00a0hiperlipemia \u00a0secundaria \u00a0\nTratamiento \u00a0encaminado \u00a0a\u00a0prevenir\u00a0la\u00a0enfermedad \u00a0\nateroscler\u00f3tica \u00a0y\u00a0a\u00a0evitar\u00a0las\u00a0complicaciones \u00a0inmediatas \u00a0\nde\u00a0la\u00a0hipertrigliceridemia \u00a0grave.\u00a0Objetivo\u00a0del\u00a0tratamiento: \u00a0\n\u2010 Conseguir \u00a0una\u00a0cifra\u00a0de\u00a0colesterol \u00a0LDL,\u00a0seg\u00fan\u00a0el\u00a0riesgo.\u00a0Si\u00a0enfermedad \u00a0coronaria \u00a0\no\u00a0riesgo\u00a0equivalente, \u00a0LDL\u00a0<70\u00a0mg/dL;\u00a0si\u00a0RCV\u00a0\u226520%\u00a0(Framingham), \u00a0LDL\u00a0<100\u00a0\nmg/dL\u00a0\n\u2010 Si\u00a0triglic\u00e9ridos \u00a0>500mg/dL, \u00a0se\u00a0tratar\u00e1\u00a0la\u00a0hipertrigliceridemia \u00a0\nindependientemente \u00a0la\u00a0concentraci\u00f3n \u00a0de\u00a0colesterol \u2010LDL\u00a0\nTratamiento: \u00a0\nEn\u00a0primer\u00a0lugar,\u00a0medidas\u00a0generales: \u00a0dieta\u00a0(consulta\u00a0a\u00a0experto\u00a0en\u00a0nutrici\u00f3n), \u00a0\nejercicio\u00a0f\u00edsico,\u00a0abstinencia \u00a0de\u00a0tabaco,\u00a0y\u00a0sobre\u00a0todo\u00a0valoraci\u00f3n \u00a0individualizada \u00a0de\u00a0la\u00a0\nretirada\u00a0de\u00a0IP\u00a0y/o\u00a0de\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0timidina.\u00a0\nTratamiento \u00a0farmacol\u00f3gico \u00a0(si\u00a0medidas\u00a0previas\u00a0no\u00a0son\u00a0eficaces): \u00a0\u00a0\n\u2010 Estatinas. \u00a0Utilizar\u00a0preferentemente \u00a0atorvastatina, \u00a0pravastatina \u00a0o\u00a0\nrosuvastatina; \u00a0precauci\u00f3n \u00a0por\u00a0interacciones \u00a0con\u00a0IPs.\u00a0Valorar\u00a0ezetimibe \u00a0o\u00a0la\u00a0\ncombinaci\u00f3n \u00a0\u00e1cido\u00a0nicot\u00ednico/ laropiprant solas (si no se pueden usar estatinas) o \nasociadas a estatinas (si no se consiguen los objetivos de tratamiento con estatinas \nsolas)\u00a0\n\u2010 Fibratos\u00a0si\u00a0hipertrigliceridemia \u00a0aislada\u00a0o\u00a0junto\u00a0a\u00a0elevaci\u00f3n \u00a0moderada \u00a0de\u00a0\ncolesterol \u2010LDL.\u00a0En\u00a0caso\u00a0de\u00a0hipertrigliceridemia \u00a0intensa\u00a0y\u00a0refractaria \u00a0puede\u00a0\na\u00f1adirse\u00a0\u00e1cidos\u00a0grasos\u00a0omega\u20103.\u00a0\n\u2010 Precauci\u00f3n \u00a0con\u00a0la\u00a0coadministraci\u00f3n \u00a0de\u00a0fibratos\u00a0y\u00a0estatinas\u00a0(mayor\u00a0riesgo\u00a0de\u00a0\ntoxicidad\u00a0muscular) \u00a0\n\u00a0\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 166 Tabla\u00a014.\u00a0Evaluaci\u00f3n \u00a0y\u00a0tratamiento \u00a0de\u00a0la\u00a0diabetes\u00a0mellitus\u00a0\n\u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0 Tratamiento \u00a0\nRealizar\u00a0anal\u00edtica\u00a0en\u00a0ayunas\u00a0\nPrueba\u00a0de\u00a0tolerancia \u00a0oral\u00a0a\u00a0la\u00a0glucosa\u00a0(si\u00a0glucosa\u00a0\nbasal\u00a0alterada)\u00a0\nTratamiento \u00a0encaminado \u00a0a\u00a0evitar\u00a0las\u00a0\ncomplicaciones \u00a0metab\u00f3licas \u00a0a\u00a0corto\u00a0plazo\u00a0\n(hipoglucemia, \u00a0cetosis,\u00a0cetoacidosis, \u00a0y\u00a0estado\u00a0\nhiperosmolar) \u00a0y\u00a0las\u00a0complicaciones \u00a0micro\u00a0y\u00a0macro\u2010\nvasculares \u00a0a\u00a0largo\u00a0plazo\u00a0Valorar\u00a0individualizadamente \u00a0la\u00a0sustituci\u00f3n \u00a0de\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0\ntimidina\u00a0y\u00a0otros\u00a0f\u00e1rmacos\u00a0no\u00a0antirretrovirales \u00a0que\u00a0pudieran\u00a0estar\u00a0\nimplicados \u00a0\nObjetivo\u00a0terap\u00e9utico \u00a0guiado\u00a0por\u00a0hemoglobina \u00a0glicosilada \u00a0(HbA1c)\u00a0\n<6.5%\u00a0\nConsulta\u00a0con\u00a0endocrin\u00f3logo \u00a0\nAntidiab\u00e9ticos \u00a0orales.\u00a0Metformina, \u00a0si\u00a0sobrepeso \u00a0u\u00a0obesidad\u00a0\nabdominal, \u00a0o\u00a0sulfonilureas. \u00a0Pioglitazona \u00a0si\u00a0lipoatrofia \u00a0\nInsulina\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0diabetes\u00a0de\u00a0inicio\u00a0e\u00a0insulinopenia \u00a0\n(cetosis\u00a0o\u00a0cetoacidosis), \u00a0p\u00e9rdida\u00a0de\u00a0peso\u00a0y\u00a0cuando\u00a0no\u00a0sea\u00a0posible\u00a0\nconseguir \u00a0el\u00a0objetivo\u00a0de\u00a0HbA1c\u00a0<\u00a07%\u00a0con\u00a0antidiab\u00e9ticos \u00a0orales.\u00a0\nDeber\u00eda\u00a0considerarse \u00a0la\u00a0administraci\u00f3n \u00a0de\u00a075\u2010150\u00a0mg/d\u00eda\u00a0de\u00a0AAS\u00a0\na\u00a0todos\u00a0los\u00a0pacientes \u00a0con\u00a0diabetes.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 167 Tabla\u00a015.\u00a0\u00a0Evaluaci\u00f3n \u00a0y\u00a0tratamiento \u00a0de\u00a0la\u00a0alteraci\u00f3n \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal* \u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0 Tratamiento \u00a0\nDiagn\u00f3stico \u00a0cl\u00ednico\u00a0\nSer\u00eda\u00a0deseable\u00a0la\u00a0realizaci\u00f3n \u00a0peri\u00f3dica \u00a0de\u00a0alguna\u00a0\nmedida\u00a0objetiva\u00a0de\u00a0la\u00a0composici\u00f3n \u00a0corporal\u00a0(seg\u00fan\u00a0\ndisponibilidad \u00a0y\u00a0posibilidades \u00a0econ\u00f3micas \u00a0de\u00a0cada\u00a0\ncentro)\u00a0\n\u00a0No\u00a0hay\u00a0ninguna\u00a0medida\u00a0que\u00a0haya\u00a0demostrado \u00a0resolver\u00a0satisfactoriamente \u00a0los\u00a0\ncambios\u00a0corporales. \u00a0Las\u00a0que\u00a0a\u00a0continuaci\u00f3n \u00a0se\u00a0describen \u00a0han\u00a0mostrado, \u00a0en\u00a0el\u00a0\nmejor\u00a0de\u00a0los\u00a0casos,\u00a0una\u00a0eficacia\u00a0parcial\u00a0y\u00a0algunas\u00a0de\u00a0ellas\u00a0no\u00a0est\u00e1n\u00a0exentas\u00a0de\u00a0\nriesgos:\u00a0\n\u2022 medidas\u00a0generales \u00a0(dieta,\u00a0ejercicio\u00a0f\u00edsico):\u00a0evitar\u00a0modificaciones \u00a0de\u00a0peso\u00a0>5%\u00a0\ndel\u00a0peso\u00a0ideal\u00a0;\u00a0el\u00a0ejercicio\u00a0f\u00edsico\u00a0aer\u00f3bico\u00a0mejora\u00a0las\u00a0alteraciones \u00a0metab\u00f3licas \u00a0\ny\u00a0la\u00a0lipoacumulaci\u00f3n \u00a0intraabdominal \u00a0\n\u2022 sustituci\u00f3n \u00a0de\u00a0FAR\u00a0(IP,\u00a0AN):\u00a0la\u00a0retirada\u00a0de\u00a0los\u00a0IP\u00a0cl\u00e1sicos\u00a0puede\u00a0mejorar\u00a0las\u00a0\nalteraciones \u00a0metab\u00f3licas \u00a0y\u00a0la\u00a0lipoacumulaci\u00f3n \u00a0intraabdominal; \u00a0la\u00a0retirada\u00a0de\u00a0\nan\u00e1logos\u00a0de\u00a0timidina\u00a0mejora\u00a0la\u00a0lipoatrofia \u00a0(existen\u00a0m\u00e1s\u00a0estudios\u00a0con\u00a0d4T\u00a0que\u00a0\ncon\u00a0AZT)\u00a0\u00a0\n\u2022 f\u00e1rmacos \u00a0con\u00a0efectos\u00a0metab\u00f3licos \u00a0(metformina, \u00a0glitazonas, \u00a0hormona\u00a0del\u00a0\ncrecimiento). \u00a0La\u00a0hormona\u00a0del\u00a0crecimiento \u00a0puede\u00a0disminuir \u00a0la\u00a0lipoacumulaci\u00f3n \u00a0\nintraabdominal \u00a0pero\u00a0provoca\u00a0hiperglucemia \u00a0y\u00a0otros\u00a0efectos\u00a0secundarios. \u00a0Se\u00a0\nhan\u00a0comunicado \u00a0buenos\u00a0resultados \u00a0en\u00a0la\u00a0lipoacumulaci\u00f3n \u00a0visceral\u00a0con\u00a0\ntesamorelina \u00a0(an\u00e1logo\u00a0del\u00a0factor\u00a0estimulante \u00a0de\u00a0la\u00a0hormona\u00a0de\u00a0crecimiento). \u00a0\nLos\u00a0efectos\u00a0de\u00a0todos\u00a0estos\u00a0f\u00e1rmacos \u00a0revierten\u00a0con\u00a0el\u00a0cese\u00a0del\u00a0mismo\u00a0y\u00a0ninguno\u00a0\nde\u00a0ellos\u00a0tiene\u00a0indicaci\u00f3n \u00a0para\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0lipodistrofia. \u00a0\n\u2022 cirug\u00eda\u00a0pl\u00e1stica\u00a0(relleno\u00a0facial\u00a0en\u00a0lipoatrofia, \u00a0cirug\u00eda\u00a0reductora \u00a0en\u00a0lipoac\u00famulos \u00a0\naccesibles): \u00a0es\u00a0el\u00a0\u00fanico\u00a0tratamiento \u00a0actual\u00a0con\u00a0resultados \u00a0inmediatos .\u00a0\n\u00a0\n*\u00a0La\u00a0alteraci\u00f3n \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal\u00a0es\u00a0una\u00a0complicaci\u00f3n \u00a0prevalente \u00a0y\u00a0limitante\u00a0de\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0reciben\u00a0TARV\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 168 Tabla\u00a016.\u00a0Ajuste\u00a0de\u00a0dosis\u00a0de\u00a0los\u00a0antirretrovirales \u00a0en\u00a0insuficiencia \u00a0renal\u00a0y\u00a0hep\u00e1tica\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nInhibidores \u00a0TI,\u00a0an\u00e1logos\u00a0nucle\u00f3sido \u00a0\nAbacavir\u00a0(ABC)\u00a0\u00a0\nNo\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\nNo\u00a0administrar \u00a0Combivir\u00ae\u00a0y\u00a0Trizivir\u00ae\u00a0en\u00a0\npacientes \u00a0con\u00a0Cl\u00a0<50\u00a0mL/min\u00a0\u00a0(por\u00a0\nseparado, \u00a0ajustar\u00a0dosis\u00a0\nadecuadamente) \u00a0\u00a0\nDosis\u00a0habitual.\u00a0\nHD:\u00a0administrar \u00a0independientemente \u00a0de\u00a0la\u00a0\nsesi\u00f3n\u00a0de\u00a0HD,\u00a0ya\u00a0que\u00a0se\u00a0elimina\u00a0m\u00ednimamente. \u00a0\u00a0\nIH\u00a0leve\u00a0(Child\u2010Pugh\u00a05\u00a0a\u00a06):\u00a0200\u00a0mg\u00a0c/12h.\u00a0Utilizar\u00a0\u00a0la\u00a0\nsoluci\u00f3n\u00a0oral\u00a0de\u00a0Ziagen\u00ae\u00a0(10\u00a0mL\u00a0c/12h).\u00a0\n\u00a0\nIH\u00a0moderada \u2010grave:\u00a0la\u00a0seguridad, \u00a0eficacia\u00a0y\u00a0propiedades \u00a0\nfarmacocin\u00e9ticas \u00a0no\u00a0han\u00a0sido\u00a0evaluadas. \u00a0Evitar\u00a0en\u00a0lo\u00a0\nposible\u00a0su\u00a0uso.\u00a0\n\u00a0\n\u2265\u00a060\u00a0Kg\u00a0\u00a0\u00a0\u00a0\nCl\u00a0\u226560:\u00a0400\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCl\u00a030\u201059:\u00a0200\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCl\u00a010\u201029:\u00a0125\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCl\u00a0<10:\u00a0125\u00a0mg\u00a0c/24h\u00a0\u00a0\nHD/CAPD: \u00a0125\u00a0mg\u00a0c/24h;\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD\u00a0\nadministrar \u00a0post\u2010HD/CAPD \u00a0(no\u00a0requiere\u00a0\nsuplemento). \u00a0Didanosina, \u00a0c\u00e1psulas\u00a0\nent\u00e9ricas\u00a0(ddI)\u00a0\n<60\u00a0kg\u00a0\nCl\u00a0\u226560:\u00a0250\u00a0mg\u00a0c/24h\u00a0\nCl\u00a030\u201059:\u00a0125\u00a0mg\u00a0c/24h\u00a0\nCl\u00a010\u201029:\u00a0125\u00a0mg\u00a0c/24h\u00a0\nCl\u00a0<10:\u00a0Emplear\u00a0Videx\u00ae\u00a0polvo\u00a0para\u00a0\nsoluci\u00f3n\u00a0pedi\u00e1trica \u00a075\u00a0mg/24h.\u00a0\u00a0\nHD/CAPD: \u00a0Emplear\u00a0Videx\u00ae\u00a0polvo\u00a0para\u00a0soluci\u00f3n\u00a0\npedi\u00e1trica \u00a075\u00a0mg/24h.\u00a0\u00a0\nRiesgo\u00a0elevado\u00a0de\u00a0toxicidad\u00a0hep\u00e1tica\u00a0y\u00a0descompensaci\u00f3n. \u00a0\u00a0\nEn\u00a0pacientes \u00a0cirr\u00f3ticos, \u00a0no\u00a0se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0\ndidanosina. \u00a0\n\u00a0\nEn\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0del\u00a0VHC\u00a0didanosina \u00a0no\u00a0debe\u00a0\nadministrarse \u00a0conjuntamente \u00a0con\u00a0ribavirina. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 169 \u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nEmtricitabina \u00a0(FTC)\u00a0En\u00a0c\u00e1psulas\u00a0\nCl\u00a0\u226550:\u00a0200\u00a0mg\u00a0c/24h\u00a0\u00a0\nCl\u00a030\u201049:\u00a0200\u00a0mg\u00a0c/48h\u00a0\nCl\u00a015\u201029:\u00a0200\u00a0mg\u00a0c/72h\u00a0\nCl\u00a0<15:\u00a0200\u00a0mg\u00a0c/96h\u00a0\u00a0\n\u00a0\nEn\u00a0soluci\u00f3n\u00a0(10\u00a0mg/ml)*:\u00a0\nCl\u00a0\u226550:\u00a0240\u00a0mg\u00a0(24\u00a0ml)\u00a0c/24h\u00a0\u00a0\nCl\u00a030\u201049:\u00a0120\u00a0mg\u00a0(12\u00a0ml)c/24h\u00a0\nCl\u00a015\u201029:\u00a080\u00a0mg\u00a0(8\u00a0ml)\u00a0c/24h\u00a0\nCl\u00a0<15:\u00a060\u00a0mg\u00a0(6\u00a0ml)\u00a0c/24h\u00a0\u00a0\n\u00a0\nTruvada\u00ae:\u00a0no\u00a0administrar \u00a0a\u00a0pacientes \u00a0\ncon\u00a0Cl\u00a0<\u00a030\u00a0mL/min\u00a0\u00a0\nHD:\u00a0en\u00a0comprimidos \u00a0200\u00a0mg\u00a0c/96h,\u00a0en\u00a0\nsoluci\u00f3n\u00a0(10\u00a0mg/ml)\u00a060\u00a0mg\u00a0(6\u00a0ml)\u00a0c/24h.\nLos\u00a0d\u00edas\u00a0de\u00a0HD\u00a0administrar \u00a0post\u2010HD\u00a0\nNo\u00a0se\u00a0ha\u00a0estudiado \u00a0en\u00a0di\u00e1lisis\u00a0\nperitoneal. \u00a0\nTruvada\u00ae:\u00a0no\u00a0administrar \u00a0a\u00a0pacientes \u00a0\nen\u00a0HD\u00a0(administrar \u00a0los\u00a0componentes \u00a0\npor\u00a0separado, \u00a0ajustando \u00a0dosis\u00a0\nadecuadamente) \u00a0\u00a0\nDosis\u00a0habitual\u00a0(no\u00a0hay\u00a0datos,\u00a0pero\u00a0en\u00a0base\u00a0a\u00a0su\u00a0m\u00ednimo\u00a0\nmetabolismo \u00a0hep\u00e1tico, \u00a0es\u00a0poco\u00a0probable\u00a0que\u00a0requiera\u00a0ajuste\u00a0de\u00a0\ndosis).\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u2265\u00a060\u00a0Kg\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0Cl\u00a0\u226550:\u00a040\u00a0mg\u00a0c/12h\u00a0\u00a0\u00a0\u00a0\nCl\u00a026\u201049:\u00a020\u00a0mg\u00a0c/12h\u00a0\u00a0\u00a0\u00a0\nCl\u00a0\u226425:\u00a020\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0\u00a0\nHD:\u00a0\u00a020\u00a0mg\u00a0c/24h;\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD\u00a0\nadministrar \u00a0post\u2010HD\u00a0Estavudina \u00a0(d4T)\u00a0\n\u00a0\n<60\u00a0kg\u00a0\nCl\u00a0\u226550:\u00a030\u00a0mg\u00a0c/12h\u00a0\nCl\u00a026\u201049:\u00a015\u00a0mg\u00a0c/12h\u00a0\nCl\u00a0\u226425:\u00a015\u00a0mg\u00a0c/24h\u00a0\u00a0\nHD:\u00a0\u00a015\u00a0mg\u00a0c/24h;\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD\u00a0\nadministrar \u00a0post\u2010HD\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nDosis\u00a0habitual.\u00a0\u00a0Utilizar\u00a0con\u00a0precauci\u00f3n \u00a0por\u00a0el\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0\nmitocondrial \u00a0y\u00a0esteatosis \u00a0hep\u00e1tica.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 170 \u00a0\n\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nLamivudina \u00a0(3TC)\u00a0\n\u00a0Cl\u00a0\u2265\u00a050:\u00a0150\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a0300\u00a0mg\u00a0c/24h\u00a0\nCl\u00a030\u201049:\u00a0150\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a0de\u00a0150\u00a0mg)\u00a0\nCl\u00a015\u201029:\u00a0100\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a0150\u00a0mg)\u00a0\nCl\u00a05\u201014:\u00a050\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a0150\u00a0mg)\u00a0\nCl\u00a0<5:\u00a025\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a050\u00a0mg)\u00a0\nNo\u00a0administrar \u00a0Combivir\u00ae\u00a0y\u00a0Trizivir\u00ae\u00a0si\u00a0\u00a0Cl\u00a0<50\u00a0mL/min\u00a0\u00a0\n(administrar \u00a0los\u00a0componentes \u00a0por\u00a0separado, \u00a0ajustando \u00a0\ndosis\u00a0adecuadamente) \u00a0HD:\u00a025\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a050\u00a0mg)\u00a0Los\u00a0\nd\u00edas\u00a0de\u00a0la\u00a0HD,\u00a0administrar \u00a0post\u2010HD.\u00a0\n\u00a0\u00a0Dosis\u00a0habitual\u00a0\nTenofovir \u00a0(TDF)\u00a0Cl\u00a0\u2265\u00a050:\u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\nCl\u00a030\u201049:\u00a0300\u00a0mg\u00a0c/48h\u00a0\nCl\u00a010\u201029:\u00a0300\u00a0mg\u00a0c/72\u00a0a\u00a096h\u00a0\nNo\u00a0hay\u00a0recomendaciones \u00a0disponibles \u00a0para\u00a0pacientes \u00a0con\u00a0\nCl\u00a0<10\u00a0sin\u00a0HD\u00a0\n\u00a0HD:\u00a0habitualmente \u00a0300\u00a0mg\u00a0una\u00a0vez\u00a0por\u00a0\nsemana,\u00a0despu\u00e9s\u00a0de\u00a0una\u00a0de\u00a0las\u00a0sesiones\u00a0\n(asumiendo \u00a03\u00a0sesiones\u00a0de\u00a0di\u00e1lisis\u00a0semanales \u00a0\nde\u00a04h)\u00a0Dosis\u00a0habitual\u00a0\nZidovudina \u00a0(AZT)\u00a0Puede\u00a0acumularse \u00a0el\u00a0metabolito \u00a0glucur\u00f3nido \u00a0(GAZT)\u00a0\n\u00a0\nCl\u00a010\u201050:\u00a0250\u2010300\u00a0mg\u00a0c/12h.\u00a0\nCl\u00a0<10:\u00a0250\u2010300\u00a0mg\u00a0c/24h.\u00a0\u00a0\n\u00a0\nNo\u00a0administrar \u00a0Combivir\u00ae\u00a0y\u00a0Trizivir\u00ae\u00a0en\u00a0pacientes \u00a0con\u00a0Cl\u00a0\n<50\u00a0mL/min\u00a0\u00a0(administrar \u00a0los\u00a0componentes \u00a0por\u00a0\nseparado, \u00a0ajustando \u00a0dosis\u00a0adecuadamente) \u00a0\n\u00a0300\u00a0mg\u00a0c/24h.\u00a0\nHD/CAPD: \u00a0no\u00a0afecta\u00a0la\u00a0eliminaci\u00f3n \u00a0de\u00a0AZT\u00a0y\u00a0\naumenta\u00a0la\u00a0eliminaci\u00f3n \u00a0de\u00a0GAZT.\u00a0Por\u00a0\nprecauci\u00f3n, \u00a0se\u00a0recomienda \u00a0administrar \u00a0la\u00a0dosis\u00a0\ndiaria\u00a0post\u2010HD/CAPD. \u00a0Se\u00a0ha\u00a0observado \u00a0una\u00a0reducci\u00f3n \u00a0del\u00a0\naclaramiento \u00a0oral\u00a0de\u00a0zidovudina \u00a0el\u00a032%,\u00a0\n63%\u00a0\u00a0y\u00a070%,\u00a0respectivamente, \u00a0en\u00a0\npacientes \u00a0con\u00a0IH\u00a0leve,\u00a0moderada \u2010grave\u00a0\n\u00f3\u00a0cirrosis\u00a0comprobada \u00a0por\u00a0biopsia,\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0sujetos\u00a0sin\u00a0alteraci\u00f3n \u00a0\nhep\u00e1tica.\u00a0\u00a0\n\u00a0\nAlgunos\u00a0autores\u00a0sugieren\u00a0reducir\u00a0la\u00a0\ndosis\u00a0a\u00a0200\u00a0mg\u00a0c/12h\u00a0en\u00a0pacientes \u00a0con\u00a0\nIH\u00a0grave.\u00a0Se\u00a0recomienda \u00a0monitorizar \u00a0\nestrechamente \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0toxicidad\u00a0\nhematol\u00f3gica. \u00a0\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 171  \nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nInhibidores \u00a0de\u00a0la\u00a0TI,\u00a0no\u00a0an\u00e1logos\u00a0\nEfavirenz\u00a0(EFV)\u00a0\u00a0\nNo\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\n\u00a0Atripla\u00ae:\u00a0en\u00a0pacientes \u00a0con\u00a0Cl\u00a0<50\u00a0\nml/min,\u00a0utilizar\u00a0los\u00a0principios \u00a0activos\u00a0\npor\u00a0separado. \u00a0\u00a0\u00a0\nHD:\u00a0no\u00a0parece\u00a0necesario \u00a0ajustar\u00a0la\u00a0\ndosis.\u00a0\u00a0\n\u00a0\nCAPD:\u00a0un\u00a0estudio\u00a0farmacocin\u00e9tico \u00a0\npreliminar \u00a0indica\u00a0que\u00a0no\u00a0se\u00a0requiere\u00a0\najuste\u00a0de\u00a0dosis\u00a0(datos\u00a0de\u00a0un\u00a0solo\u00a0\npaciente). \u00a0IH\u00a0leve\u00a0a\u00a0moderada :\u00a0\ndosis\u00a0habitual.\u00a0Dada\u00a0la\u00a0elevada\u00a0variabilidad \u00a0\ninterindividual, \u00a0se\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0y\u00a0\naparici\u00f3n \u00a0de\u00a0efectos\u00a0adversos, \u00a0especialmente \u00a0a\u00a0nivel\u00a0de\u00a0SNC.\u00a0\u00a0\n\u00a0\nIH\u00a0grave:\u00a0datos\u00a0escasos.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso/\u00a0monitorizar \u00a0\nniveles\u00a0plasm\u00e1ticos. \u00a0En\u00a0un\u00a0paciente\u00a0con\u00a0Child\u00a0Pugh\u00a0grado\u00a0C,\u00a0la\u00a0\nsemivida\u00a0de\u00a0EFV\u00a0se\u00a0duplic\u00f3.\u00a0En\u00a0dos\u00a0pacientes \u00a0con\u00a0IH\u00a0(uno\u00a0de\u00a0\nellos\u00a0con\u00a0cirrosis)\u00a0el\u00a0AUC\u00a0de\u00a0EFV\u00a0aument\u00f3\u00a04\u00a0veces.\u00a0\u00a0En\u00a03\u00a0\npacientes \u00a0con\u00a0fibrosis\u00a0>12\u00a0kPa\u00a0(Fibroscan\u00ae) \u00a0la\u00a0Cmin\u00a0fue\u00a02,5\u00a0veces\u00a0\nsuperior\u00a0a\u00a0la\u00a0obtenida\u00a0en\u00a015\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VHC\u00a0con\u00a0\nfibrosis\u00a0<12kPa.\u00a0\u00a0\nEn\u00a0otro\u00a0estudio\u00a0el\u00a031%\u00a0de\u00a0los\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0presentaron \u00a0\nunas\u00a0concentraciones \u00a0>\u00a04000\u00a0ng/mL,\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0un\u00a03%\u00a0\nen\u00a0los\u00a0coinfectados \u00a0no\u00a0cirr\u00f3ticos. \u00a0\n\u00a0\nEtravirina \u00a0(ETV)\u00a0NRAD\u00a0 HD/CAPD: \u00a0por\u00a0su\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0\nque\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0de\u00a0\nHD/CAPD. \u00a0\n\u00a0IH\u00a0leve\u00a0o\u00a0moderada: \u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos;\u00a0evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 172 \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nNevirapina \u00a0(NVP)\u00a0\u00a0\nNo\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\nHD:\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD,\u00a0se\u00a0recomienda \u00a0\nadministrar \u00a0la\u00a0dosis\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0HD\u00a0\u00f3\u00a0\nun\u00a0suplemento \u00a0de\u00a0200\u00a0mg\u00a0post\u2010\nhemodi\u00e1lisis. \u00a0\u00a0\u00a0\nIH\u00a0leve\u00a0a\u00a0moderada \u00a0(Child\u2010Pugh\u00a0\u22647):\u00a0dosis\u00a0habitual.\u00a0Sin\u00a0embargo, \u00a0en\u00a0\npacientes \u00a0con\u00a0IH\u00a0moderada, \u00a0se\u00a0recomienda \u00a0monitorizar \u00a0\nestrechamente \u00a0niveles\u00a0plasm\u00e1ticos \u00a0y\u00a0aparici\u00f3n \u00a0de\u00a0efectos\u00a0adversos. \u00a0\nEn\u00a0un\u00a0estudio\u00a0en\u00a04\u00a0pacientes \u00a0con\u00a0\u00a0IH\u00a0moderada \u00a0(Child\u2010Pugh\u00a0B),\u00a0el\u00a0\nAUC\u00a0de\u00a0NVP\u00a0aument\u00f3\u00a041%.\u00a0\u00a0\n\u00a0\nIH\u00a0grave:\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso\u00a0(hepatotoxicidad). \u00a0\u00a0\u00a0\u00a0\n\u00a0\nEn\u00a0el\u00a0estudio\u00a0NEVADOSE \u00a066%\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0un\u00a0mayor\u00a0grado\u00a0\nde\u00a0fibrosis\u00a0(F4;\u00a0Fibroscan\u00ae) \u00a0presentaron \u00a0una\u00a0Cmin\u00a0de\u00a0NVP\u00a0por\u00a0\nencima\u00a0del\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0normalidad \u00a0(>6000\u00a0ng/mL).\u00a0En\u00a0otro\u00a0\nestudio\u00a0el\u00a050%\u00a0de\u00a0los\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0presentaron \u00a0unas\u00a0\nconcentraciones \u00a0>\u00a08000\u00a0ng/mL,\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0un\u00a027%\u00a0en\u00a0los\u00a0\ncoinfectados \u00a0no\u00a0cirr\u00f3ticos. \u00a0\n\u00a0\nSe\u00a0ha\u00a0observado \u00a0un\u00a0aumento\u00a0de\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0en\u00a0\npacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0con\u00a0CD4\u00a0>250\u00a0c\u00e9ls/\u00b5L\u00a0(mujeres) \u00a0o\u00a0\u00a0\n>400\u00a0c\u00e9ls/\u00b5L\u00a0(hombres) \u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 173 \u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nInhibidores \u00a0de\u00a0la\u00a0\u00a0proteasa\u00a0\nAtazanavir \u00a0(ATV)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0\n\u00a0\nHD/CAPD: \u00a0por\u00a0su\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0\nque\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0de\u00a0\nHD/CAPD. \u00a0\n\u00a0\nHD:\u00a0se\u00a0recomienda \u00a0su\u00a0uso\u00a0potenciado \u00a0(\u00a0\nATV/r\u00a0300/100)\u00a0para\u00a0compensar \u00a0el\u00a0\ndescenso \u00a0de\u00a0concentraci\u00f3n \u00a0de\u00a0ATV\u00a0\n(reducci\u00f3n \u00a0del\u00a028%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0ATV\u00a0los\u00a0\nd\u00edas\u00a0sin\u00a0HD\u00a0y\u00a0del\u00a042%\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD;\u00a0la\u00a0\neliminaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0HD\u00a0es\u00a0de\u00a0s\u00f3lo\u00a0el\u00a0\n2%).\u00a0Monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0\ncuando\u00a0sea\u00a0posible.\u00a0\u00a0IH\u00a0leve:\u00a0seg\u00fan\u00a0un\u00a0estudio\u00a0en\u00a0pacientes \u00a0coinfectados \u00a0con\u00a0VHC\u00a0con\u00a0IH\u00a0\nleve\u00a0a\u00a0moderada, \u00a0el\u00a0ATV\u00a0no\u00a0potenciado \u00a0(400\u00a0mg/24h)\u00a0puede\u00a0no\u00a0\nllegar\u00a0a\u00a0alcanzar\u00a0la\u00a0Cm\u00edn\u00a0deseada\u00a0(6/9\u00a0pacientes \u00a0con\u00a0niveles\u00a0\nsubterap\u00e9uticos). \u00a0Se\u00a0recomienda \u00a0usar\u00a0ATV\u00a0potenciado \u00a0con\u00a0RTV\u00a0\n(300/100\u00a0mg\u00a0/24h),\u00a0\u00a0\n\u00a0\nIH\u00a0moderada \u2010grave:\u00a0la\u00a0Agencia\u00a0Europea\u00a0del\u00a0Medicamento \u00a0\ndesaconseja \u00a0el\u00a0uso\u00a0de\u00a0atazanavir \u00a0potenciado \u00a0en\u00a0este\u00a0contexto\u00a0por\u00a0\nfalta\u00a0de\u00a0datos.\u00a0\nEn\u00a09\u00a0pacientes \u00a0con\u00a0fibrosis\u00a0>12\u00a0kPa\u00a0(Fibroscan\u00ae) \u00a0que\u00a0recibieron \u00a0\nATV/r,\u00a0la\u00a0Cmin\u00a0fue\u00a0comparable \u00a0a\u00a0la\u00a0obtenida\u00a0en\u00a026\u00a0pacientes \u00a0\ncoinfectados \u00a0por\u00a0VHC\u00a0con\u00a0fibrosis<12 \u00a0kPa.\u00a0Un\u00a0\u00a0estudio\u00a0en\u00a012\u00a0\npacientes \u00a0coinfectados \u00a0por\u00a0VHC\u00a0tratados\u00a0con\u00a0ATV/r,\u00a0el\u00a0AUC\u00a0fue\u00a0solo\u00a0\nun\u00a036%\u00a0superior\u00a0en\u00a0los\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0(n=7)\u00a0\u00a0\n\u00a0\n\u00a0Monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\nDarunavir \u00a0(DRV)\u00a0IR\u00a0leve,\u00a0moderada \u00a0o\u00a0grave:\u00a0no\u00a0\nrequiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\n\u00a0\u00a0\nHD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0\nque\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0de\u00a0\nHD/CAPD. \u00a0\u00a0\nIH\u00a0leve\u00a0o\u00a0moderada: \u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0\n\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos;\u00a0evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 174  \nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nFosamprenavir \u00a0(FPV)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0\ndosis\u00a0\u00a0\n\u00a0\nHD/CAPD: \u00a0debido\u00a0a\u00a0su\u00a0elevada\u00a0uni\u00f3n\u00a0\na\u00a0prote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0\nde\u00a0HD/CAPD. \u00a0\u00a0IH\u00a0leve\u00a0(Child\u00a0Pugh\u00a05\u20106):\u00a0FPV\u00a0700\u00a0mg\u00a0c/12h\u00a0+\u00a0RTV\u00a0100\u00a0mg\u00a0c/24h\u00a0\nIH\u00a0moderada \u00a0(Child\u00a0Pugh\u00a07\u20109):\u00a0FPV\u00a0450\u00a0mg\u00a0c/12h\u00a0+\u00a0RTV\u00a0100\u00a0mg\u00a0c/24h\u00a0\nEn\u00a0IH\u00a0grave\u00a0(Child\u00a0Pugh\u00a010\u201015):\u00a0FPV\u00a0300\u00a0mg\u00a0c/12h\u00a0+\u00a0RTV\u00a0100\u00a0mg\u00a0c/24h\u00a0(usar\u00a0\nsoluci\u00f3n\u00a0oral\u00a0de\u00a0FPV)\u00a0\n\u00a0\nEn\u00a0un\u00a0estudio\u00a0los\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0(n=6)\u00a0presentaron \u00a0una\u00a0Cmin\u00a02\u00a0veces\u00a0\u00a0mayor\u00a0\ny\u00a0AUC\u00a043%\u00a0mayor.\u00a0En\u00a0otro\u00a0estudio,\u00a0en\u00a02\u00a0pacientes \u00a0con\u00a0fibrosis\u00a0>12\u00a0kPa\u00a0\n(Fibroscan\u00ae) \u00a0la\u00a0Cmin\u00a0fue\u00a0comparable \u00a0a\u00a0la\u00a0obtenida\u00a0en\u00a06\u00a0pacientes \u00a0coinfectados \u00a0\npor\u00a0VHC\u00a0con\u00a0fibrosis<12 \u00a0kPa.\u00a0\u00a0\nSe\u00a0recomienda \u00a0la\u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\nIndinavir\u00a0(IDV)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0\ndosis\u00a0\u00a0\nHD:\u00a0probablemente \u00a0no\u00a0requiera\u00a0\najuste\u00a0de\u00a0dosis\u00a0si\u00a0funci\u00f3n\u00a0hep\u00e1tica\u00a0\nconservada \u00a0(datos\u00a0de\u00a0un\u00a0solo\u00a0\npaciente). \u00a0Se\u00a0elimina\u00a0m\u00ednimamente \u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0HD.\u00a0IDV\u00a0(no\u00a0potenciado): \u00a0\nIH\u00a0leve\u00a0a\u00a0moderada: \u00a0600\u00a0mg\u00a0c/8h.\u00a0\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos.\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\u00a0\n\u00a0IDV/r:\u00a0\u00a0\nAlgunos\u00a0pacientes \u00a0coinfectados \u00a0con\u00a0VHC\u00a0pueden\u00a0requerir\u00a0reducci\u00f3n \u00a0de\u00a0dosis,\u00a0\nhabitualmente \u00a0IDV/r\u00a0\u00a0400/100\u00a0mg\u00a0C/12h\u00a0o,\u00a0incluso\u00a0IDV/r\u00a0200/100\u00a0mg\u00a0c/12h.\u00a0\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 175 Lopinavir\u00a0(LPV/r)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0\ndosis\u00a0\u00a0\nHD:\u00a0El\u00a0AUC\u00a0de\u00a0LPV/r\u00a0en\u00a013\u00a0pacientes \u00a0\nen\u00a0HD\u00a0fue\u00a0equivalente \u00a0a\u00a0la\u00a0de\u00a0\npacientes \u00a0con\u00a0funci\u00f3n\u00a0renal\u00a0normal.\u00a0\nNo\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\n\u00a0\nCAPD:\u00a0no\u00a0hay\u00a0datos.\u00a0Debido\u00a0a\u00a0la\u00a0\nelevada\u00a0uni\u00f3n\u00a0a\u00a0prote\u00ednas \u00a0plasm\u00e1ticas \u00a0\nde\u00a0lopinavir\u00a0y\u00a0ritonavir,\u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0\nde\u00a0CAPD.\u00a0\n\u00a0\u00a0\nEn\u00a0un\u00a0estudio\u00a0los\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VHC\u00a0con\u00a0cirrosis\u00a0hep\u00e1tica\u00a0sin\u00a0signos\u00a0\nde\u00a0IH\u00a0(n=7)\u00a0presentaron \u00a0un\u00a0aumento\u00a0del\u00a0100%\u00a0en\u00a0el\u00a0AUC\u00a0y\u00a0la\u00a0Cmin\u00a0de\u00a0ritonavir,\u00a0\npero\u00a0sin\u00a0diferencias \u00a0en\u00a0la\u00a0exposici\u00f3n \u00a0\u00a0a\u00a0lopinavir. \u00a0\nUn\u00a0estudio\u00a0en\u00a0pacientes \u00a0con\u00a0IH\u00a0leve\u00a0(n=6)\u00a0o\u00a0moderada \u00a0(n=6)\u00a0mostr\u00f3\u00a0un\u00a0aumento\u00a0\nsignificativo \u00a0en\u00a0la\u00a0exposici\u00f3n \u00a0tanto\u00a0a\u00a0lopinavir\u00a0como\u00a0a\u00a0ritonavir.\u00a0Sin\u00a0embargo, \u00a0la\u00a0\nrelevancia \u00a0cl\u00ednica\u00a0de\u00a0estos\u00a0cambios\u00a0no\u00a0est\u00e1\u00a0clara\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0aconseja\u00a0\nmodificar \u00a0las\u00a0dosis\u00a0de\u00a0lopinavir. \u00a0\u00a0\n\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 176 \u00a0\n\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nNelfinavir \u00a0(NFV)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0HD:\u00a0no\u00a0es\u00a0probable\u00a0que\u00a0NFV\u00a0se\u00a0elimine\u00a0\nsignificativamente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0HD.\u00a0Datos\u00a0\nde\u00a0un\u00a0paciente\u00a0con\u00a0ERCA\u00a0e\u00a0IH\u00a0mostraron \u00a0la\u00a0\nausencia\u00a0de\u00a0eliminaci\u00f3n \u00a0de\u00a0NFV\u00a0durante\u00a0\nuna\u00a0sesi\u00f3n\u00a0de\u00a0HD\u00a0de\u00a04\u00a0horas.\u00a0\u00a0\n\u00a0\nCAPD:\u00a0no\u00a0es\u00a0probable\u00a0que\u00a0NFV\u00a0se\u00a0elimine\u00a0\nsignificativamente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0CAPD.\u00a0En\u00a0\nun\u00a0paciente\u00a0tratado\u00a0con\u00a01250\u00a0mg\u00a0c/12h\u00a0de\u00a0\nNFV,\u00a0las\u00a0concentraciones \u00a0en\u00a0el\u00a0l\u00edquido\u00a0de\u00a0\ndi\u00e1lisis\u00a0fueron\u00a0inferiores \u00a0al\u00a0l\u00edmite\u00a0de\u00a0\ndetecci\u00f3n. \u00a0\u00a0\u00a0\nDosis\u00a0habitual\u00a0\u00a0\n(aunque\u00a0en\u00a0presencia \u00a0de\u00a0IH\u00a0aumenta\u00a0el\u00a0AUC\u00a0de\u00a0NFV\u00a0entre\u00a0un\u00a049\u00a0%\u00a0y\u00a0\nun\u00a069\u00a0%,\u00a0los\u00a0datos\u00a0no\u00a0parecen\u00a0indicar\u00a0que\u00a0se\u00a0produzca\u00a0un\u00a0aumento\u00a0\nde\u00a0toxicidad). \u00a0\u00a0\u00a0\n\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\n\u00a0\nRitonavir\u00a0(RTV)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\n\u00a0\u00a0\nHD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas \u00a0de\u00a0ritonavir,\u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0de\u00a0\nHD/CAPD \u00a0\n\u00a0No\u00a0usar\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas\u00a0por\u00a0el\u00a0riesgo\u00a0de\u00a0hepatotoxicidad. \u00a0\n\u00a0\nRitonavir\u00a0como\u00a0potenciador \u00a0farmacocin\u00e9tico: \u00a0\u00a0\nIH\u00a0leve\u00a0a\u00a0moderada: \u00a0dosis\u00a0habitual.\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso.\u00a0\n\u00a0\nConsultar \u00a0datos\u00a0espec\u00edficos \u00a0sobre\u00a0el\u00a0inhibidor\u00a0de\u00a0la\u00a0proteasa\u00a0\npotenciado \u00a0con\u00a0el\u00a0ritonavir.\u00a0\nSaquinavir \u00a0(SQV)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\n\u00a0\u00a0HD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas \u00a0de\u00a0ritonavir,\u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0de\u00a0\nHD/CAPD. \u00a0Datos\u00a0de\u00a0un\u00a0paciente\u00a0indican\u00a0\nescasa\u00a0eliminaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0HD.\u00a0\n\u00a0\u00a0\nIH\u00a0leve\u2010moderada: \u00a0dosis\u00a0habitual.\u00a0\n\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso.\u00a0Contraindicado \u00a0\nen\u00a0pacientes \u00a0con\u00a0insuficiencia \u00a0hep\u00e1tica\u00a0descompensada. \u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 177 \u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nTipranavir \u00a0(TPV)\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\nHD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas \u00a0de\u00a0TPV/RTV, \u00a0no\u00a0es\u00a0\nde\u00a0esperar\u00a0que\u00a0se\u00a0eliminen\u00a0en\u00a0las\u00a0\nsesiones\u00a0de\u00a0HD/CAPD. \u00a0\n\u00a0Datos\u00a0limitados. \u00a0Elevado\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0hep\u00e1tica: \u00a0TPV/r\u00a0se\u00a0ha\u00a0\nrelacionado \u00a0con\u00a0casos\u00a0de\u00a0hepatitis\u00a0cl\u00ednica\u00a0y\u00a0descompensaci\u00f3n \u00a0\nhep\u00e1tica,\u00a0incluyendo \u00a0algunos\u00a0casos\u00a0mortales. \u00a0Se\u00a0recomienda \u00a0un\u00a0\nestrecho\u00a0seguimiento \u00a0de\u00a0los\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VHB\u00a0\u00f3\u00a0VHC,\u00a0\npor\u00a0el\u00a0aumento\u00a0de\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0que\u00a0presentan. \u00a0\u00a0\n\u00a0IH\u00a0leve\u00a0(Child\u2010Pugh\u00a0A):\u00a0\u00a0dosis\u00a0habitual.\u00a0\u00a0\nIH\u00a0moderada \u00a0o\u00a0grave\u00a0(Child\u2010Pugh\u00a0B\u00a0y\u00a0C):\u00a0contraindicado. \u00a0\u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\nEnfuvirtida \u00a0(T\u201020)\u00a0\u00a0\nNo\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\nHD:\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0\nNo\u00a0hay\u00a0datos.\u00a0Algunos\u00a0autores\u00a0recomiendan \u00a0utilizar\u00a0la\u00a0dosis\u00a0\nhabitual.\u00a0\u00a0\u00a0\nInhibidores \u00a0de\u00a0la\u00a0Integrasa \u00a0\nRAL\u00a0(raltegravir) \u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0 \u00a0\nHD:\u00a0no\u00a0es\u00a0probable\u00a0que\u00a0RAL\u00a0se\u00a0elimine\u00a0\nsignificativamente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0HD.\u00a0\nDatos\u00a0de\u00a0dos\u00a0pacientes \u00a0con\u00a0ERCA\u00a0\nmostraron \u00a0la\u00a0ausencia\u00a0de\u00a0eliminaci\u00f3n \u00a0de\u00a0\nRAL\u00a0durante\u00a0una\u00a0sesi\u00f3n\u00a0de\u00a0HD\u00a0de\u00a04\u00a0horas.\u00a0\u00a0\n\u00a0\u00a0\nIH\u00a0leve\u2010moderada: \u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0estudios.\u00a0Utilizar\u00a0con\u00a0precauci\u00f3n. \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 178 \u00a0\n\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0 Insuficiencia \u00a0hep\u00e1tica\u00a0\nInhibidores \u00a0correceptor \u00a0CCR5\u00a0\nMVR\u00a0(maraviroc) \u00a0En\u00a0ausencia\u00a0de\u00a0inhibidores \u00a0potentes\u00a0del\u00a0\nCYP3A4\u00a0probablemente \u00a0no\u00a0requiera\u00a0\najuste\u00a0de\u00a0dosis.\u00a0\nS\u00f3lo\u00a0se\u00a0recomienda \u00a0un\u00a0ajuste\u00a0de\u00a0dosis\u00a0\nen\u00a0pacientes \u00a0con\u00a0Cl\u00a0<80\u00a0ml/min\u00a0y\u00a0que\u00a0\nest\u00e1n\u00a0recibiendo \u00a0inhibidores \u00a0potentes\u00a0\ndel\u00a0CYP3A4,\u00a0como\u00a0los\u00a0IPs\u00a0\u00a0(excepto\u00a0\nTPV/r),\u00a0ketoconazol, \u00a0itraconazol, \u00a0\nclaritromicina \u00a0o\u00a0telitromicina: \u00a0en\u00a0estos\u00a0\ncasos\u00a0administrar \u00a0150\u00a0mg\u00a0c/24h.\u00a0Si\u00a0el\u00a0Cl\u00a0\nes\u00a0<30\u00a0ml/min\u00a0se\u00a0recomienda \u00a0mucha\u00a0\nprecauci\u00f3n \u00a0debido\u00a0al\u00a0aumento\u00a0de\u00a0\nriesgo\u00a0de\u00a0hipotensi\u00f3n \u00a0postural.\u00a0\nCon\u00a0Cl\u00a0<80\u00a0ml/min\u00a0y\u00a0en\u00a0combinaci\u00f3n \u00a0\ncon\u00a0FPV/r\u00a0administrar \u00a0150\u00a0mg\u00a0c/12h.\u00a0\n\u00a0(Estos\u00a0ajustes\u00a0de\u00a0dosis\u00a0se\u00a0recomiendan \u00a0\nbas\u00e1ndose \u00a0en\u00a0los\u00a0datos\u00a0de\u00a0un\u00a0estudio\u00a0\nen\u00a0insuficiencia \u00a0renal\u00a0y\u00a0simulaciones \u00a0\nfarmacocin\u00e9ticas, \u00a0sin\u00a0que\u00a0su\u00a0seguridad \u00a0\ny\u00a0eficacia\u00a0hayan\u00a0sido\u00a0evaluadas \u00a0\ncl\u00ednicamente, \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0recomienda \u00a0\nuna\u00a0estrecha\u00a0monitorizaci\u00f3n). \u00a0\u00a0\nHD:\u00a0en\u00a0ausencia\u00a0de\u00a0inhibidores \u00a0\npotentes\u00a0del\u00a0CYP3A4\u00a0no\u00a0se\u00a0requiere\u00a0\najuste\u00a0de\u00a0dosis.\u00a0En\u00a0presencia \u00a0de\u00a0los\u00a0\nmismos,\u00a0dosificar\u00a0igual\u00a0que\u00a0para\u00a0Cl\u00a0\n<80\u00a0ml/min\u00a0(datos\u00a0limitados) \u00a0\u00a0\u00a0\nDatos\u00a0de\u00a0un\u00a0estudio\u00a0con\u00a0dosis\u00a0\u00fanicas\u00a0de\u00a0300\u00a0mg\u00a0MVR.\u00a0En\u00a0\ncomparaci\u00f3n \u00a0con\u00a0los\u00a0voluntarios \u00a0con\u00a0funci\u00f3n\u00a0hep\u00e1tica\u00a0normal:\u00a0\nIH\u00a0leve:\u00a0+25%\u00a0AUC\u00a0\nIH\u00a0moderada: \u00a0+45%\u00a0AUC\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos\u00a0\nSe\u00a0desconoce \u00a0la\u00a0importancia \u00a0cl\u00ednica\u00a0que\u00a0estos\u00a0aumentos \u00a0pueden\u00a0\nsuponer.\u00a0\u00a0\n\u00a0\nSe\u00a0ha\u00a0descrito\u00a0un\u00a0caso\u00a0de\u00a0posible\u00a0hepatotoxicidad \u00a0precedido \u00a0de\u00a0una\u00a0\nreacci\u00f3n\u00a0al\u00e9rgica\u00a0sist\u00e9mica. \u00a0\u00a0\n\u00a0\n*Las\u00a0c\u00e1psulas\u00a0y\u00a0la\u00a0soluci\u00f3n\u00a0oral\u00a0de\u00a0emtricitabina \u00a0tienen\u00a0diferente \u00a0biodisponibilidad, \u00a0de\u00a0forma\u00a0que\u00a0con\u00a0240\u00a0mg\u00a0de\u00a0la\u00a0soluci\u00f3n\u00a0oral\u00a0(24\u00a0ml)\u00a0se\u00a0alcanzan\u00a0unas\u00a0concentraciones \u00a0\nplasm\u00e1ticas \u00a0similares\u00a0a\u00a0las\u00a0alcanzadas \u00a0con\u00a0200\u00a0mg\u00a0en\u00a0c\u00e1psulas.\u00a0\nAN:\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sidos; \u00a0ANt:\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3tidos, \u00a0CH:\u00a0cirrosis\u00a0hep\u00e1tica; \u00a0Cl:\u00a0aclaramiento \u00a0de\u00a0creatinina \u00a0en\u00a0ml/min;\u00a0ERCA:\u00a0enfermedad \u00a0renal\u00a0cr\u00f3nica\u00a0avanzada, \u00a0HD:\u00a0\nhemodi\u00e1lisis; \u00a0IH:\u00a0insuficiencia \u00a0hep\u00e1tica; \u00a0IP:\u00a0inhibidores \u00a0de\u00a0la\u00a0proteasa; \u00a0IR:\u00a0insuficiencia \u00a0renal;\u00a0NN:\u00a0inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sidos. \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 179Tabla\u00a017.\u00a0Seguridad \u00a0de\u00a0los\u00a0antirretrovirales \u00a0en\u00a0el\u00a0embarazo \u00a0\n\u00a0\nF\u00e1rmaco\u00a0 FDA*\u00a0Paso\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0placenta\u00a0\n(Cociente \u00a0RN/madre) \u00a0Carcinogenicidad \u00a0\n(animales) \u00a0Teratogenicidad \u00a0\n(animales) \u00a0\nZidovudina \u00a0 C\u00a0 0,85\u00a0 S\u00ed\u00a0 Si\u00a0\nDidanosina \u00a0 B\u00a0 0,5\u00a0 No\u00a0 No\u00a0\nEstavudina \u00a0 C\u00a0 0,76\u00a0 S\u00ed\u00a0 No\u00a0\nLamivudina \u00a0 C\u00a0 1\u00a0 No\u00a0 No\u00a0\nAbacavir\u00a0 C\u00a0 Si\u00a0(ratas)\u00a0 S\u00ed\u00a0 Si\u00a0\nTenofovir \u00a0 B\u00a0 0,95\u20100\u201099\u00a0 S\u00ed\u00a0 No\u00a0\nEmtricitabina \u00a0 B\u00a0 0,4\u20100,5\u00a0 No\u00a0 No\u00a0\nSaquinavir \u00a0 B\u00a0 M\u00ednimo\u00a0 No\u00a0 No\u00a0\nIndinavir\u00a0 C\u00a0 M\u00ednimo\u00a0 S\u00ed\u00a0 No\u00a0\nRitonavir\u00a0 B\u00a0 M\u00ednimo\u00a0 S\u00ed\u00a0 Si\u00a0\nNelfinavir \u00a0 B\u00a0 M\u00ednimo/Variable \u00a0 S\u00ed\u00a0 No\u00a0\nFosamprenavir \u00a0 C\u00a0 \u00bf?\u00a0 S\u00ed\u00a0 No\u00a0\nLopinavir\u00a0 C\u00a0 0,2+/\u20100,13\u00a0 S\u00ed\u00a0 Si\u00a0\nAtazanavir \u00a0 B\u00a0 M\u00ednimo/Variable \u00a0 S\u00ed\u00a0 No\u00a0\nTipranavir \u00a0 C\u00a0 \u00bf?\u00a0 No\u00a0completado \u00a0 No\u00a0\nDarunavir \u00a0 C\u00a0 \u00bf?\u00a0 S\u00ed\u00a0 No\u00a0\nNevirapina \u00a0 B\u00a0 1\u00a0 S\u00ed\u00a0 No\u00a0\nEfavirenz\u00a0 D\u00a0 1\u00a0 S\u00ed\u00a0 Si\u00a0\nEtravirina \u00a0 B\u00a0 \u00bf?\u00a0 No\u00a0completado \u00a0 No\u00a0\nEnfuvirtida \u00a0 B\u00a0No\u00a0(basado\u00a0en\u00a0muy\u00a0pocos\u00a0\ndatos)\u00a0No\u00a0realizado\u00a0 No\u00a0\nMaraviroc \u00a0 B\u00a0 \u00bf?\u00a0 No\u00a0 No\u00a0\nRaltegravir \u00a0 C\u00a0Ratas\u00a0(1,5\u20102,5)\u00a0\nConejos\u00a0(0,02)\u00a0No\u00a0completado \u00a0 No\u00a0\n\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 180 Tabla\u00a018.\u00a0Recomendaciones \u00a0de\u00a0profilaxis \u00a0postexposici\u00f3n \u00a0\u00a0\n \n\u00a0PPE\u00a0recomendada \u00a0si:\u00a0\nExposici\u00f3n \u00a0a:\u00a0Tipo\u00a0exposici\u00f3n \u00a0 Fuente\u00a0\nPenetraci\u00f3n \u00a0SC\u00a0o\u00a0IM\u00a0con\u00a0aguja\u00a0IM/IV\u00a0o\u00a0sistema\u00a0IV\u00a0 VIH+,\u00a0o\u00a0desconocido \u00a0pero\u00a0con\u00a0factores\u00a0de\u00a0riesgo\u00a0Sangre\u00a0u\u00a0otros\u00a0\nfluidos\u00a0\npotencialmente \u00a0\ninfectivos \u00a0Accidente \u00a0percut\u00e1neo \u00a0con\u00a0instrumento \u00a0cortante\u00a0o\u00a0aguja\u00a0\nIM/SC\u00a0o\u00a0sutura\u00a0\nContacto\u00a0>\u00a015min\u00a0con\u00a0mucosas\u00a0o\u00a0piel\u00a0no\u00a0intacta.\u00a0VIH+\u00a0\nSexo\u00a0anal\u00a0o\u00a0vaginal\u00a0 VIH+,\u00a0o\u00a0desconocido \u00a0pero\u00a0con\u00a0factores\u00a0de\u00a0riesgo\u00a0Secreciones \u00a0\nGenitales \u00a0\nSexo\u00a0oral\u00a0receptivo \u00a0con\u00a0eyaculaci\u00f3n \u00a0 VIH+\u00a0\nUDVP\u00a0Intercambio \u00a0de\u00a0jeringuilla \u00a0o\u00a0\u00a0agujas\u00a0 VIH+\u00a0\nR\u00e9gimen\u00a0terap\u00e9utico: \u00a0\nTDF/FTC\u00a0+\u00a0IP/r\u00a0(ver\u00a0tabla\u00a04)\u00a0\u00a0\nAlternativas*: \u00a0\nAZT+3TC\u00a0+\u00a0IP/r\u00a0\nTDF/FTC\u00a0\u00a0+\u00a0RAL\u00a0\n\u00a0AZT/3TC\u00a0+\u00a0RAL\u00a0\nAZT/3TC\u00a0+\u00a0TDF\u00a0\n*\u00a0En\u00a0casos\u00a0de\u00a0intolerancia \u00a0o\u00a0imposibilidad \u00a0de\u00a0usar\u00a0TARV\u00a0basados\u00a0en\u00a0IP/r\u00a0\n \n\u00a0\n\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 181 \u00a0\nTabla\u00a019.\u00a0Coste\u00a0mensual\u00a0(PVL+IVA, \u00a0en\u00a0\u20ac)\u00a0de\u00a0los\u00a0antirretrovirales \u00a0de\u00a0uso\u00a0m\u00e1s\u00a0frecuente \u00a0\n\u00a0\n\u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nAn\u00e1logos \u00a0de\u00a0nucle\u00f3sido \u00a0y\u00a0nucle\u00f3tido \u00a0\nAbacavir\u00a0ZIAGEN\u00a0 300\u00a0MG\u00a060\u00a0COMP\u00a0234,72 3,91 60234,72 234,72 ABC\u00a0300\u00a0mg/12h\u00a0\nDidanosina \u00a0VIDEX\u00a0 400\u00a0MG\u00a030\u00a0CAPS\u00a0160,56 5,35 30160,56 \u00a0160,56 ddI\u00a0400\u00a0mg/24h\u00a0\nDidanosina \u00a0VIDEX\u00a0 250\u00a0MG\u00a030\u00a0CAPS\u00a0100,34 3,34 30100,34 100,34 ddI\u00a0250\u00a0mg/24h\u00a0\nEmtricitabina \u00a0EMTRIVA \u00a0 200\u00a0MG\u00a030\u00a0CAPS\u00a0153,24 5,11 30153,24 153,24 FTC\u00a0200\u00a0mg/24h\u00a0\nEstavudina \u00a0ZERIT\u00a0 40\u00a0MG\u00a0448\u00a0CAPS\u00a01213,84 2,71 60162,57 162,57 d4T\u00a040\u00a0mg/12h\u00a0\nEstavudina \u00a0ZERIT\u00a0 30\u00a0MG\u00a0448\u00a0CAPS\u00a01174,65 2,62 60157,32 \u00a0157,32 d4T\u00a030\u00a0mg/12h\u00a0\nLamivudina \u00a0EPIVIR\u00a0 300\u00a0MG\u00a030\u00a0COMP\u00a0146,81 4,89 30146,81 146,81 3TC\u00a0300\u00a0mg/24h\u00a0\nLamivudina \u00a0LAMIVUDINA \u00a0\nNORMON \u00a0300\u00a0MG\u00a030\u00a0COMP\u00a065,27 2,17 3065,27 65,27 3TC\u00a0300\u00a0mg/24h\u00a0\nTenofovir \u00a0VIREAD\u00a0 245\u00a0MG\u00a030\u00a0COMP\u00a0300,25 10,00 30300,25 300,25 TDF\u00a0300\u00a0mg/24h\u00a0\nZidovudina \u00a0RETROVIR \u00a0 300\u00a0MG\u00a0300\u00a0COMP\u00a0820,20 2,73 60164,04 164,04 AZT\u00a0300\u00a0mg/12h\u00a0\nZidovudina \u00a0ZIDOVUDINA \u00a0\nCOMBINOPHARM \u00a0300\u00a0MG\u00a0300\u00a0CAPS\u00a0430,62 1,44 6086,12 86,12 AZT\u00a0300\u00a0mg/12h\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 182 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nAn\u00e1logos \u00a0de\u00a0nucle\u00f3sido \u00a0y\u00a0nucle\u00f3tido \u00a0en\u00a0combinaci\u00f3n \u00a0\nAbacavir+ \u00a0\nLamivudina \u00a0KIVEXA\u00a0600/300\u00a0MG\u00a0\u00a0\n30\u00a0COMP\u00a0369,76 12,33 30369,77 369,76 Kivexa\u00a01c/24h\u00a0\nEmtricitabina+ \u00a0\nTenofovir \u00a0TRUVADA \u00a0200/245\u00a0MG\u00a0\n30\u00a0COMP\u00a0450,04 15,00 30450,04 450,04 Truvada\u00a01c/24h\u00a0\nZidovudina+ \u00a0\nLamivudina \u00a0COMBIVIR \u00a0150/300\u00a0MG\u00a0\u00a0\n60\u00a0COMP\u00a0302,03 5,03 60302,03 302,03 Combivir\u00a01c/12h\u00a0\nZidovudina+ \u00a0\nLamivudina+ \u00a0\nAbacavir\u00a0TRIZIVIR\u00a0300/150/300 \u00a0MG\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n60\u00a0COMP\u00a0509,93 8,50 60509,93 509,93 TZV\u00a01c/12h\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\nEfavirenz\u00a0SUSTIVA\u00a0 600\u00a0MG\u00a030\u00a0COMP\u00a0275,63 9,19 30275,63 \u00a0275,63 EFV\u00a0600\u00a0mg/24h\u00a0\nNevirapina \u00a0VIRAMUNE \u00a0 200\u00a0MG\u00a060\u00a0COMP\u00a0207,68 3,46 60207,68 207,68 NVP\u00a0200\u00a0mg/12h\u00a0\nEtravirina \u00a0INTELENCE \u00a0 100\u00a0MG\u00a0120\u00a0COMP\u00a0468,00 3,9 120468,00 468,00 ETR\u00a0200\u00a0MG/12\u00a0H\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0an\u00e1logos \u00a0de\u00a0nucle\u00f3sidos \u00a0y\u00a0nucle\u00f3tidos \u00a0\nEfavirenz\u00a0+\u00a0\nEmtricitabina+ \u00a0\nTenofovir \u00a0ATRIPLA\u00a0600\u00a0MG\u00a0\n200\u00a0MG\u00a0\n245\u00a0MG\u00a0COMP\u00a0729,12 24.30 30729,12 729,12 Atripla\u00a01c/24h\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 183  \nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nInhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0\nAtazanavir \u00a0REYATAZ\u00a0 200\u00a0MG\u00a060\u00a0CAPS\u00a0454,05 7,57 60454,05 454,05 ATV\u00a0400\u00a0mg/24h\u00a0\nAtazanavir \u00a0REYATAZ\u00a0 300\u00a0MG\u00a030\u00a0CAPS\u00a0454,05 7,57 60454,05 23,36 477,42 ATV/r\u00a0300/100\u00a0mg/24h\u00a0\nDarunavir \u00a0PREZISTA \u00a0 600\u00a0MG\u00a060\u00a0COMP\u00a0666,44 11,11 60666,44 46,72 713,16DRV/r\u00a0600/100\u00a0mg/12h\u00a0\nDarunavir \u00a0PREZISTA \u00a0 400\u00a0MG\u00a060\u00a0COMP\u00a0444,30 7,40 60444,30 23,36 467,66DRV/r\u00a0800/100\u00a0mg/24h\u00a0\nFosamprenavir \u00a0TELZIR\u00a0 700\u00a0MG\u00a060\u00a0COMP\u00a0329,57 5,49 60329,57 46,72 376,29 FPV/r\u00a0700/100\u00a0mg/12h\u00a0\nIndinavir\u00a0CRIXIVAN \u00a0 400\u00a0MG\u00a0180\u00a0CAPS\u00a0272,22 1,51 120181,48 46,72 228,20 IDV/r\u00a0800/100\u00a0mg/12h\u00a0\nLopinavir+ \u00a0\nRitonavir\u00a0comp\u00a0KALETRA\u00a0 120\u00a0COMP\u00a0 416,02 3,47 120416,02 416,02 LPV/r\u00a02\u00a0comp/12h \u00a0\nNelfinavir \u00a0VIRACEPT \u00a0 250\u00a0MG\u00a0270\u00a0COMP\u00a0306,91 1,14 300341,02 \u00a0341,02 NFV\u00a01250\u00a0mg/12h\u00a0\nSaquinavir \u00a0INVIRASE \u00a0 500\u00a0MG\u00a0120\u00a0COMP\u00a0316,11 2,63 120316,12 46,72 362,84SQV/r\u00a01000/100 \u00a0\nmg/12h\u00a0\nRitonavir\u00a0NORVIR\u00a0 100\u00a0MG\u00a084\u00a0CAPS\u00a0 65,42 0,78 6046,72 46,72 46,72 RTV\u00a0100\u00a0mg/12h\u00a0\nTipranavir \u00a0APTIVUS\u00a0 250\u00a0MG\u00a0120\u00a0CAPS\u00a0733,20 6,11 120733,20 93,44 826,64 TPV/r\u00a0500/200\u00a0mg/12h\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 184  \nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nInhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\nEnfuvirtida \u00a0FUZEON\u00a090\u00a0MG/ML\u00a0\u00a0\n60\u00a0VIALES\u00a01586,38 26,44 601586,37 1586,37 T20\u00a090\u00a0mg/12h\u00a0\nInhibidores \u00a0de\u00a0la\u00a0uni\u00f3n\u00a0\nMaraviroc \u00a0CELSENTRI \u00a0150\u00a0Y\u00a0300\u00a0MG\u00a0\nCOMP\u00a0735,07 12,25 60735,07 735,07MVC\u00a0300\u00a0(\u00f3\u00a0150)\u00a0\nmg/12\u00a0h\u00a0\nInhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nRaltegravir \u00a0\u00a0ISENTRESS \u00a0 400\u00a0MG\u00a060\u00a0COMP\u00a0717,60 11,96 60717,60 717,60 RAL\u00a0400\u00a0mg/12h\u00a0\n\u00a0\n \n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso \u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 185 \u00a0\nFigura\u00a01.\u00a0Coste\u00a0mensual\u00a0de\u00a0los\u00a0tratamientos\u00a0 preferentes \u00a0(seg\u00fan\u00a0Tabla\u00a04)\n725,67917,7 927,461167,64\n657,72866,06 847,18\n785,78\n645,39\n200400600800100012001400\nTDF/FTC+EFV\nTDF/FTC\n+DRV/r\nTDF/FTC+\nATV/r\nTDF/FT\nC+RAL*\nTDF/F\nTC+NV\nP*\nTDF/F\nTC+LPV/r*\nABC/3TC+ATV/r*\nABC\n/3TC\n+LPV/r*\nABC/3TC+EFV*\nPrecio en PVL+IVA en \u20ac  (se ha calculado el precio bas \u00e1ndose en los combos Truvada\u00ae y Kivexa\u00ae). Las pautas \nmarcadas con asterisco (*) no han sido consideradas  preferentes por la totalidad del panel Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 186REFERENCIAS \u00a0BIBLIOGRAFICAS \u00a0\n\u00a0\n\u00a0 1.\u00a0\u00a0Consejo\u00a0Asesor\u00a0Cl\u00ednico\u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0SIDA.\u00a0Tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(4\u00aa\u00a0\nedici\u00f3n).\u00a0Madrid.\u00a0Ministerio \u00a0de\u00a0Sanidad\u00a0y\u00a0Consumo, \u00a01997:\u00a0(10)\u00a01\u201016.\u00a0\u00a0\n\u00a0 2.\u00a0\u00a0Panel\u00a0de\u00a0expertos\u00a0de\u00a0Gesida\u00a0y\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0sida.\u00a0Documento \u00a0de\u00a0consenso \u00a0de\u00a0Gesida/Plan \u00a0\nNacional\u00a0sobre\u00a0el\u00a0Sida\u00a0respecto\u00a0al\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0adultos\u00a0infectados \u00a0por\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0\ninmunodeficiencia \u00a0humana\u00a0(Actualizaci\u00f3n \u00a0enero\u00a02010).\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02010;\u00a028(6):362 \u00a0\ne1\u201091\u00a0\n\u00a0 3.\u00a0\u00a0Thompson \u00a0MA,\u00a0Aberg\u00a0JA,\u00a0Cahn\u00a0P,\u00a0Montaner \u00a0JS,\u00a0Rizzardini \u00a0G,\u00a0Telenti\u00a0A\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0treatment \u00a0of\u00a0\nadult\u00a0HIV\u00a0infection: \u00a02010\u00a0recommendations \u00a0of\u00a0the\u00a0International \u00a0AIDS\u00a0Society\u2010USA\u00a0panel.\u00a0JAMA\u00a02010;\u00a0\n304(3):321 \u2010333\u00a0\n\u00a0 4.\u00a0\u00a0Panel\u00a0on\u00a0Antiretroviral \u00a0Guidelines \u00a0for\u00a0Adults\u00a0and\u00a0Adolescents. \u00a0Guidelines \u00a0for\u00a0the\u00a0use\u00a0of\u00a0\u00a0antiretroviral \u00a0\nagents\u00a0in\u00a0HIV\u20101\u2010infected\u00a0adults\u00a0and\u00a0adolescents. \u00a0Department \u00a0of\u00a0Health\u00a0and\u00a0Human\u00a0Services.\u00a0December \u00a0\n1,\u00a02009.\u00a0Disponible \u00a0en:\u00a0www.aidsinfo.nih.gov/ContentF iles/AdultandAdolescentGL.pdf \u00a0(Acceso\u00a0\n14.12.2010). \u00a0\n\u00a0 5.\u00a0\u00a0Kish\u00a0MA.\u00a0Guide\u00a0to\u00a0development \u00a0of\u00a0practice\u00a0guidelines. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02001;\u00a032(6):851 \u2010854\u00a0\n\u00a0 6.\u00a0\u00a0Mocroft\u00a0A,\u00a0Vella\u00a0S,\u00a0Benfield\u00a0TL,\u00a0Chiesi\u00a0A,\u00a0Miller\u00a0V,\u00a0Gargalianos \u00a0P\u00a0et\u00a0al.\u00a0Changing \u00a0patterns\u00a0of\u00a0mortality\u00a0\nacross\u00a0Europe\u00a0in\u00a0patients\u00a0infected\u00a0with\u00a0HIV\u20101.\u00a0EuroSIDA \u00a0Study\u00a0Group.\u00a0Lancet\u00a01998;\u00a0352(9142):1725 \u201030\u00a0\n\u00a0 7.\u00a0\u00a0Palella\u00a0FJ,\u00a0Jr.,\u00a0Delaney\u00a0KM,\u00a0Moorman \u00a0AC,\u00a0Loveless\u00a0MO,\u00a0Fuhrer\u00a0J,\u00a0Satten\u00a0GA\u00a0et\u00a0al.\u00a0Declining\u00a0morbidity \u00a0\nand\u00a0mortality\u00a0among\u00a0patients\u00a0with\u00a0advanced \u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0HIV\u00a0Outpatient \u00a0\nStudy\u00a0Investigators. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01998;\u00a0338(13):853 \u201060\u00a0\n\u00a0 8.\u00a0\u00a0Knobel\u00a0H,\u00a0Polo\u00a0R,\u00a0Escobar\u00a0I,\u00a0(Coordinadores). \u00a0Recomendaciones \u00a0Gesida\u00a0/\u00a0SEFH\u00a0/\u00a0PNS\u00a0para\u00a0mejorar\u00a0la\u00a0\nadherencia \u00a0al\u00a0tratamiento \u00a0antirretroviral \u00a0(Actualizaci\u00f3n \u00a0junio\u00a0de\u00a02008).\u00a0Disponible \u00a0en:\u00a0\nwww.gesida.seimc.org/pcientifica/fuentes /DcyRc/Gesida_dcyrc 2008_adherenciaTAR.pdf \u00a0(Acceso\u00a0\n14.12.2010). \u00a0\n\u00a0 9.\u00a0\u00a0Sterne\u00a0JA,\u00a0May\u00a0M,\u00a0Costagliola \u00a0D,\u00a0de\u00a0WF,\u00a0Phillips\u00a0AN,\u00a0Harris\u00a0R\u00a0et\u00a0al.\u00a0Timing\u00a0of\u00a0initiation\u00a0of\u00a0antiretroviral \u00a0\ntherapy\u00a0in\u00a0AIDS\u2010free\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a0a\u00a0collaborative \u00a0analysis\u00a0of\u00a018\u00a0HIV\u00a0cohort\u00a0studies.\u00a0Lancet\u00a0\n2009;\u00a0373(9672):1352 \u20101363\u00a0\n\u00a0 10.\u00a0\u00a0Jaen\u00a0A,\u00a0Esteve\u00a0A,\u00a0Miro\u00a0JM,\u00a0Tural\u00a0C,\u00a0Montoliu \u00a0A,\u00a0Ferrer\u00a0E\u00a0et\u00a0al.\u00a0Determinants \u00a0of\u00a0HIV\u00a0progression \u00a0and\u00a0\nassessment \u00a0of\u00a0the\u00a0optimal\u00a0time\u00a0to\u00a0initiate\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0PISCIS\u00a0Cohort\u00a0(Spain).\u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(2):212 \u2010220\u00a0\n\u00a0 11.\u00a0\u00a0Autran\u00a0B,\u00a0Carcelain\u00a0G,\u00a0Li\u00a0TS,\u00a0Blanc\u00a0C,\u00a0Mathez\u00a0D,\u00a0Tubiana\u00a0R\u00a0et\u00a0al.\u00a0Positive\u00a0effects\u00a0of\u00a0combined \u00a0\nantiretroviral \u00a0therapy\u00a0on\u00a0CD4+\u00a0T\u00a0cell\u00a0homeostasis \u00a0and\u00a0function\u00a0in\u00a0advanced \u00a0HIV\u00a0disease.\u00a0Science\u00a01997;\u00a0\n277(5322):112 \u20106\u00a0\n\u00a0 12.\u00a0\u00a0Kelleher\u00a0AD,\u00a0Carr\u00a0A,\u00a0Zaunders \u00a0J,\u00a0Cooper\u00a0DA.\u00a0Alterations \u00a0in\u00a0the\u00a0immune\u00a0response\u00a0of\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0(HIV)\u2010infected\u00a0subjects\u00a0treated\u00a0with\u00a0an\u00a0HIV\u2010specific\u00a0protease\u00a0inhibitor,\u00a0\nritonavir.\u00a0J\u00a0Infect\u00a0Dis\u00a01996;\u00a0173(2):321 \u20109\u00a0\n\u00a0 13.\u00a0\u00a0Montessori \u00a0V,\u00a0Press\u00a0N,\u00a0Harris\u00a0M,\u00a0Akagi\u00a0L,\u00a0Montaner \u00a0JS.\u00a0Adverse\u00a0effects\u00a0of\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0HIV\u00a0\ninfection. \u00a0CMAJ\u00a02004;\u00a0170(2):229 \u2010238\u00a0\n\u00a0 14.\u00a0\u00a0Hirsch\u00a0MS,\u00a0Gunthard \u00a0HF,\u00a0Schapiro\u00a0JM,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Hammer\u00a0SM\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0drug\u00a0\nresistance \u00a0testing\u00a0in\u00a0adult\u00a0HIV\u20101\u00a0infection: \u00a02008\u00a0recommendations \u00a0of\u00a0an\u00a0International \u00a0AIDS\u00a0Society\u2010USA\u00a0\npanel.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a047(2):266 \u2010285\u00a0\n\u00a0 15.\u00a0\u00a0Finzi\u00a0D,\u00a0Blankson\u00a0J,\u00a0Siliciano\u00a0JD,\u00a0Margolick \u00a0JB,\u00a0Chadwick \u00a0K,\u00a0Pierson\u00a0T\u00a0et\u00a0al.\u00a0Latent\u00a0infection\u00a0of\u00a0CD4+\u00a0T\u00a0\ncells\u00a0provides\u00a0a\u00a0mechanism \u00a0for\u00a0lifelong\u00a0persistence \u00a0of\u00a0HIV\u20101,\u00a0even\u00a0in\u00a0patients\u00a0on\u00a0effective\u00a0combination \u00a0\ntherapy.\u00a0Nat\u00a0Med\u00a01999;\u00a05(5):512\u20107\u00a0\n\u00a0 16.\u00a0\u00a0Josefsson \u00a0L,\u00a0Dahl\u00a0V,\u00a0Palmer\u00a0S.\u00a0Can\u00a0HIV\u00a0infection\u00a0be\u00a0eradicated \u00a0through\u00a0use\u00a0of\u00a0potent\u00a0antiviral\u00a0agents?\u00a0\nCurr\u00a0Opin\u00a0Infect\u00a0Dis\u00a02010;\u00a023(6):628 \u2010632\u00a0\n\u00a0 17.\u00a0\u00a0Garcia\u00a0F,\u00a0de\u00a0LE,\u00a0Plana\u00a0M,\u00a0Castro\u00a0P,\u00a0Mestre\u00a0G,\u00a0Nomdedeu \u00a0M\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0CD4+\u00a0T\u2010cell\u00a0response\u00a0to\u00a0\nhighly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0according \u00a0to\u00a0baseline\u00a0CD4+\u00a0T\u2010cell\u00a0count.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02004;\u00a036(2):702 \u2010713\u00a0\n\u00a0 18.\u00a0\u00a0Plana\u00a0M,\u00a0Garcia\u00a0F,\u00a0Gallart\u00a0T,\u00a0Miro\u00a0JM,\u00a0Gatell\u00a0JM.\u00a0Lack\u00a0of\u00a0T\u2010cell\u00a0proliferative \u00a0response\u00a0to\u00a0HIV\u20101\u00a0antigens\u00a0\nafter\u00a01\u00a0year\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0treatment \u00a0in\u00a0early\u00a0HIV\u20101\u00a0disease.\u00a0Immunology \u00a0Study\u00a0Group\u00a0of\u00a0\nSpanish\u00a0EARTH\u20101\u00a0Study.\u00a0Lancet\u00a01998;\u00a0352(9135):1194 \u20105\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 187\u00a0 19.\u00a0\u00a0Landon\u00a0BE,\u00a0Wilson\u00a0IB,\u00a0McInnes\u00a0K,\u00a0Landrum\u00a0MB,\u00a0Hirschhorn \u00a0LR,\u00a0Marsden\u00a0PV\u00a0et\u00a0al.\u00a0Physician \u00a0\nspecialization \u00a0and\u00a0the\u00a0quality\u00a0of\u00a0care\u00a0for\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0Arch\u00a0Intern\u00a0Med\u00a0\n2005;\u00a0165(10):1133 \u20101139\u00a0\n\u00a0 20.\u00a0\u00a0Li\u00a0TS,\u00a0Tubiana\u00a0R,\u00a0Katlama\u00a0C,\u00a0Calvez\u00a0V,\u00a0Ait\u00a0Mohand\u00a0H,\u00a0Autran\u00a0B.\u00a0Long\u2010lasting\u00a0recovery\u00a0in\u00a0CD4\u00a0T\u2010cell\u00a0\nfunction\u00a0and\u00a0viral\u2010load\u00a0reduction \u00a0after\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0advanced \u00a0HIV\u20101\u00a0disease.\u00a0\nLancet\u00a01998;\u00a0351(9117):1682 \u20106\u00a0\n\u00a0 21.\u00a0\u00a0Kostense\u00a0S,\u00a0Raaphorst \u00a0FM,\u00a0Notermans \u00a0DW,\u00a0Joling\u00a0J,\u00a0Hooibrink \u00a0B,\u00a0Pakker\u00a0NG\u00a0et\u00a0al.\u00a0Diversity\u00a0of\u00a0the\u00a0T\u2010cell\u00a0\nreceptor\u00a0BV\u00a0repertoire \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0reflects\u00a0the\u00a0biphasic\u00a0CD4+\u00a0T\u2010cell\u00a0repopulation \u00a0kinetics\u00a0\nduring\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a01998;\u00a012(18):235 \u201040\u00a0\n\u00a0 22.\u00a0\u00a0Pe\u00f1a\u00a0JM,\u00a0Miro\u00a0JM.\u00a0Restauraci\u00f3n \u00a0inmunol\u00f3gica \u00a0en\u00a0pacientes \u00a0con\u00a0Sida.\u00a0\u00bfRequiem \u00a0por\u00a0las\u00a0profilaxis? \u00a0Med\u00a0\nClin\u00a0(Barc)\u00a01999;\u00a0113(10):375 \u20108\u00a0\n\u00a0 23.\u00a0\u00a0Lopez\u00a0Bernaldo\u00a0de\u00a0Quiros\u00a0JC,\u00a0Miro\u00a0JM,\u00a0Pena\u00a0JM,\u00a0Podzamczer \u00a0D,\u00a0Alberdi\u00a0JC,\u00a0Martinez\u00a0E\u00a0et\u00a0al.\u00a0A\u00a0\nrandomized \u00a0trial\u00a0of\u00a0the\u00a0discontinuation \u00a0of\u00a0primary\u00a0and\u00a0secondary \u00a0prophylaxis \u00a0against\u00a0Pneumocystis \u00a0\ncarinii\u00a0pneumonia \u00a0after\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection. \u00a0Grupo\u00a0de\u00a0\nEstudio\u00a0del\u00a0SIDA\u00a004/98.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02001;\u00a0344(3):159 \u2010167\u00a0\n\u00a0 24.\u00a0\u00a0Deeks\u00a0SG,\u00a0Hecht\u00a0FM,\u00a0Swanson\u00a0M,\u00a0Elbeik\u00a0T,\u00a0Loftus\u00a0R,\u00a0Cohen\u00a0PT\u00a0et\u00a0al.\u00a0HIV\u00a0RNA\u00a0and\u00a0CD4\u00a0cell\u00a0count\u00a0\nresponse\u00a0to\u00a0protease\u00a0inhibitor\u00a0therapy\u00a0in\u00a0an\u00a0urban\u00a0AIDS\u00a0clinic:\u00a0response\u00a0to\u00a0both\u00a0initial\u00a0and\u00a0salvage\u00a0\ntherapy.\u00a0AIDS\u00a01999;\u00a013(6):35\u201043\u00a0\n\u00a0 25.\u00a0\u00a0Deeks\u00a0SG,\u00a0Barbour\u00a0JD,\u00a0Martin\u00a0JN,\u00a0Swanson\u00a0MS,\u00a0Grant\u00a0RM.\u00a0Sustained \u00a0CD4+\u00a0T\u00a0cell\u00a0response\u00a0after\u00a0virologic\u00a0\nfailure\u00a0of\u00a0protease\u00a0inhibitor\u2010based\u00a0regimens \u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0J\u00a0\nInfect\u00a0Dis\u00a02000;\u00a0181(3):946 \u201053\u00a0\n\u00a0 26.\u00a0\u00a0Kaufmann \u00a0D,\u00a0Pantaleo\u00a0G,\u00a0Sudre\u00a0P,\u00a0Telenti\u00a0A.\u00a0CD4\u2010cell\u00a0count\u00a0in\u00a0HIV\u20101\u2010infected\u00a0individuals \u00a0remaining \u00a0\nviraemic\u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0(HAART).\u00a0Swiss\u00a0HIV\u00a0Cohort\u00a0Study.\u00a0Lancet\u00a01998;\u00a0\n351(9104):723 \u20104\u00a0\n\u00a0 27.\u00a0\u00a0Garcia\u00a0F,\u00a0Vidal\u00a0C,\u00a0Plana\u00a0M,\u00a0Cruceta\u00a0A,\u00a0Gallart\u00a0MT,\u00a0Pumarola \u00a0T\u00a0et\u00a0al.\u00a0Residual\u00a0low\u2010level\u00a0viral\u00a0replication \u00a0\ncould\u00a0explain\u00a0discrepancies \u00a0between\u00a0viral\u00a0load\u00a0and\u00a0CD4+\u00a0cell\u00a0response\u00a0in\u00a0human\u00a0immunodeficiency \u00a0\nvirus\u2010infected\u00a0patients\u00a0receiving\u00a0antiretroviral \u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02000;\u00a030(2):392 \u20104\u00a0\n\u00a0 28.\u00a0\u00a0Dronda\u00a0F,\u00a0Moreno\u00a0S,\u00a0Moreno\u00a0A,\u00a0Casado\u00a0JL,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Antela\u00a0A.\u00a0Long\u2010term\u00a0outcomes \u00a0among\u00a0\nantiretroviral \u2010naive\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0with\u00a0small\u00a0increases \u00a0in\u00a0CD4+\u00a0cell\u00a0\ncounts\u00a0after\u00a0successful \u00a0virologic\u00a0suppression. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02002;\u00a035(8):1005 \u20101009\u00a0\n\u00a0 29.\u00a0\u00a0Gandhi\u00a0RT.\u00a0Cirrhosis\u00a0is\u00a0associated \u00a0with\u00a0low\u00a0CD4+\u00a0T\u00a0cell\u00a0counts:\u00a0implications \u00a0for\u00a0HIV\u2010infected\u00a0patients\u00a0\nwith\u00a0liver\u00a0disease.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(3):438 \u2010440\u00a0\n\u00a0 30.\u00a0\u00a0McGovern \u00a0BH,\u00a0Golan\u00a0Y,\u00a0Lopez\u00a0M,\u00a0Pratt\u00a0D,\u00a0Lawton\u00a0A,\u00a0Moore\u00a0G\u00a0et\u00a0al.\u00a0The\u00a0impact\u00a0of\u00a0cirrhosis\u00a0on\u00a0CD4+\u00a0T\u00a0\ncell\u00a0counts\u00a0in\u00a0HIV\u2010seronegative \u00a0patients.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(3):431 \u2010437\u00a0\n\u00a0 31.\u00a0\u00a0Bongiovanni \u00a0M,\u00a0Gori\u00a0A,\u00a0Lepri\u00a0AC,\u00a0Antinori\u00a0A,\u00a0De\u00a0LA,\u00a0Pagano\u00a0G\u00a0et\u00a0al.\u00a0Is\u00a0the\u00a0CD4\u00a0cell\u00a0percentage \u00a0a\u00a0better\u00a0\nmarker\u00a0of\u00a0immunosuppression \u00a0than\u00a0the\u00a0absolute\u00a0CD4\u00a0cell\u00a0count\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0cirrhosis? \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02007;\u00a045(5):650 \u2010653\u00a0\n\u00a0 32.\u00a0\u00a0D'Egidio\u00a0GE,\u00a0Kravcik\u00a0S,\u00a0Cooper\u00a0CL,\u00a0Cameron\u00a0DW,\u00a0Fergusson \u00a0DA,\u00a0Angel\u00a0JB.\u00a0Pneumocystis \u00a0jiroveci\u00a0\npneumonia \u00a0prophylaxis \u00a0is\u00a0not\u00a0required\u00a0with\u00a0a\u00a0CD4+\u00a0T\u2010cell\u00a0count\u00a0<\u00a0200\u00a0cells/microl \u00a0when\u00a0viral\u00a0replication \u00a0\nis\u00a0suppressed. \u00a0AIDS\u00a02007;\u00a021(13):1711 \u20101715\u00a0\n\u00a0 33.\u00a0\u00a0Brambilla \u00a0D,\u00a0Reichelderfer \u00a0PS,\u00a0Bremer\u00a0JW,\u00a0Shapiro\u00a0DE,\u00a0Hershow\u00a0RC,\u00a0Katzenstein \u00a0DA\u00a0et\u00a0al.\u00a0The\u00a0\ncontribution \u00a0of\u00a0assay\u00a0variation\u00a0and\u00a0biological \u00a0variation\u00a0to\u00a0the\u00a0total\u00a0variability \u00a0of\u00a0plasma\u00a0HIV\u20101\u00a0RNA\u00a0\nmeasurements. \u00a0The\u00a0Women\u00a0Infant\u00a0Transmission \u00a0Study\u00a0Clinics.\u00a0Virology\u00a0Quality\u00a0Assurance \u00a0Program.\u00a0\nAIDS\u00a01999;\u00a013(16):2269 \u201079\u00a0\n\u00a0 34.\u00a0\u00a0Lopez\u00a0A,\u00a0Caragol\u00a0I,\u00a0Candeias\u00a0J,\u00a0Villamor\u00a0N,\u00a0Echaniz\u00a0P,\u00a0Ortuno\u00a0F\u00a0et\u00a0al.\u00a0Enumeration \u00a0of\u00a0CD4(+)\u00a0T\u2010cells\u00a0in\u00a0the\u00a0\nperipheral \u00a0blood\u00a0of\u00a0HIV\u2010infected\u00a0patients:\u00a0an\u00a0interlaboratory \u00a0study\u00a0of\u00a0the\u00a0FACSCount \u00a0system.\u00a0\nCytometry \u00a01999;\u00a038(5):231 \u2010237\u00a0\n\u00a0 35.\u00a0\u00a0Kempf\u00a0DJ,\u00a0Rode\u00a0RA,\u00a0Xu\u00a0Y,\u00a0Sun\u00a0E,\u00a0Heath\u2010Chiozzi\u00a0ME,\u00a0Valdes\u00a0J\u00a0et\u00a0al.\u00a0The\u00a0duration\u00a0of\u00a0viral\u00a0suppression \u00a0\nduring\u00a0protease\u00a0inhibitor\u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infection\u00a0is\u00a0predicted \u00a0by\u00a0plasma\u00a0HIV\u20101\u00a0RNA\u00a0at\u00a0the\u00a0nadir.\u00a0\nAIDS\u00a01998;\u00a012(5):9\u201014\u00a0\n\u00a0 36.\u00a0\u00a0Raboud\u00a0JM,\u00a0Montaner \u00a0JS,\u00a0Conway\u00a0B,\u00a0Rae\u00a0S,\u00a0Reiss\u00a0P,\u00a0Vella\u00a0S\u00a0et\u00a0al.\u00a0Suppression \u00a0of\u00a0plasma\u00a0viral\u00a0load\u00a0below\u00a0\n20\u00a0copies/ml \u00a0is\u00a0required\u00a0to\u00a0achieve\u00a0a\u00a0long\u2010term\u00a0response\u00a0to\u00a0therapy.\u00a0AIDS\u00a01998;\u00a012(13):1619 \u201024\u00a0\n\u00a0 37.\u00a0\u00a0Demeter\u00a0LM,\u00a0Hughes\u00a0MD,\u00a0Coombs\u00a0RW,\u00a0Jackson\u00a0JB,\u00a0Grimes\u00a0JM,\u00a0Bosch\u00a0RJ\u00a0et\u00a0al.\u00a0Predictors \u00a0of\u00a0virologic\u00a0\nand\u00a0clinical\u00a0outcomes \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0receiving\u00a0concurrent \u00a0treatment \u00a0with\u00a0indinavir, \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 188zidovudine, \u00a0and\u00a0lamivudine. \u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0Protocol\u00a0320.\u00a0Ann\u00a0Intern\u00a0Med\u00a02001;\u00a0135(11):954 \u2010\n64\u00a0\n\u00a0 38.\u00a0\u00a0Huang\u00a0W,\u00a0De\u00a0G,\u00a0V,\u00a0Fischl\u00a0M,\u00a0Hammer\u00a0S,\u00a0Richman\u00a0D,\u00a0Havlir\u00a0D\u00a0et\u00a0al.\u00a0Patterns\u00a0of\u00a0plasma\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0type\u00a01\u00a0RNA\u00a0response\u00a0to\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02001;\u00a0183(10):1455 \u2010\n1465\u00a0\n\u00a0 39.\u00a0\u00a0Hicks\u00a0C,\u00a0King\u00a0MS,\u00a0Gulick\u00a0RM,\u00a0White\u00a0Jr\u00a0AC,\u00a0Eron\u00a0Jr\u00a0JJ,\u00a0Kessler\u00a0HA\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0safety\u00a0and\u00a0durable\u00a0\nantiretroviral \u00a0activity\u00a0of\u00a0lopinavir/ritonavir \u00a0in\u00a0treatment \u2010naive\u00a0patients:\u00a04\u00a0year\u00a0follow\u2010up\u00a0study.\u00a0AIDS\u00a0\n2004;\u00a018(5):775 \u2010779\u00a0\n\u00a0 40.\u00a0\u00a0Siliciano\u00a0RF.\u00a0Scientific\u00a0rationale\u00a0for\u00a0antiretroviral \u00a0therapy\u00a0in\u00a02005:\u00a0viral\u00a0reservoirs \u00a0and\u00a0resistance \u00a0\nevolution. \u00a0Top\u00a0HIV\u00a0Med\u00a02005;\u00a013(3):96\u2010100\u00a0\n\u00a0 41.\u00a0\u00a0Nettles\u00a0RE,\u00a0Kieffer\u00a0TL,\u00a0Simmons\u00a0RP,\u00a0Cofrancesco \u00a0J,\u00a0Jr.,\u00a0Moore\u00a0RD,\u00a0Gallant\u00a0JE\u00a0et\u00a0al.\u00a0Genotypic \u00a0resistance \u00a0\nin\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0persistently \u00a0detectable \u00a0low\u2010level\u00a0viremia\u00a0while\u00a0receiving\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a039(7):1030 \u20101037\u00a0\n\u00a0 42.\u00a0\u00a0Greub\u00a0G,\u00a0Cozzi\u2010Lepri\u00a0A,\u00a0Ledergerber \u00a0B,\u00a0Staszewski \u00a0S,\u00a0Perrin\u00a0L,\u00a0Miller\u00a0V\u00a0et\u00a0al.\u00a0Intermittent \u00a0and\u00a0sustained \u00a0\nlow\u2010level\u00a0HIV\u00a0viral\u00a0rebound\u00a0in\u00a0patients\u00a0receiving\u00a0potent\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a02002;\u00a016(14):1967 \u2010\n9\u00a0\n\u00a0 43.\u00a0\u00a0Jones\u00a0LE,\u00a0Perelson\u00a0AS.\u00a0Transient \u00a0viremia,\u00a0plasma\u00a0viral\u00a0load,\u00a0and\u00a0reservoir\u00a0replenishment \u00a0in\u00a0HIV\u2010infected\u00a0\npatients\u00a0on\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045(5):483 \u2010493\u00a0\n\u00a0 44.\u00a0\u00a0Havlir\u00a0DV,\u00a0Bassett\u00a0R,\u00a0Levitan\u00a0D,\u00a0Gilbert\u00a0P,\u00a0Tebas\u00a0P,\u00a0Collier\u00a0AC\u00a0et\u00a0al.\u00a0Prevalence \u00a0and\u00a0predictive \u00a0value\u00a0of\u00a0\nintermittent \u00a0viremia\u00a0with\u00a0combination \u00a0HIV\u00a0therapy.\u00a0JAMA\u00a02001;\u00a0286(2):171 \u20109\u00a0\n\u00a0 45.\u00a0\u00a0Lampe\u00a0FC,\u00a0Johnson\u00a0MA,\u00a0Lipman\u00a0M,\u00a0Loveday\u00a0C,\u00a0Youle\u00a0M,\u00a0Ransom\u00a0D\u00a0et\u00a0al.\u00a0Viral\u00a0breakthrough \u00a0after\u00a0\nsuppression \u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0experience \u00a0from\u00a0233\u00a0individuals \u00a0with\u00a0viral\u00a0loads\u00a0of\u00a0\nless\u00a0than\u00a050\u00a0copies/ml \u00a0followed\u00a0for\u00a0up\u00a0to\u00a04\u00a0years.\u00a0AIDS\u00a02003;\u00a017(5):768 \u201070\u00a0\n\u00a0 46.\u00a0\u00a0Mira\u00a0JA,\u00a0Macias\u00a0J,\u00a0Nogales\u00a0C,\u00a0Fernandez \u2010Rivera\u00a0J,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0Ramos\u00a0A\u00a0et\u00a0al.\u00a0Transient \u00a0rebounds \u00a0of\u00a0\nlow\u2010level\u00a0viraemia\u00a0among\u00a0HIV\u2010infected\u00a0patients\u00a0under\u00a0HAART\u00a0are\u00a0not\u00a0associated \u00a0with\u00a0virological \u00a0or\u00a0\nimmunological \u00a0failure.\u00a0Antivir\u00a0Ther\u00a02002;\u00a07(4):251\u2010256\u00a0\n\u00a0 47.\u00a0\u00a0Lee\u00a0PK,\u00a0Kieffer\u00a0TL,\u00a0Siliciano\u00a0RF,\u00a0Nettles\u00a0RE.\u00a0HIV\u20101\u00a0viral\u00a0load\u00a0blips\u00a0are\u00a0of\u00a0limited\u00a0clinical\u00a0significance. \u00a0J\u00a0\nAntimicrob \u00a0Chemother \u00a02006;\u00a057(5):803 \u2010805\u00a0\n\u00a0 48.\u00a0\u00a0Macias\u00a0J,\u00a0Palomares \u00a0JC,\u00a0Mira\u00a0JA,\u00a0Torres\u00a0MJ,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0Rodriquez \u00a0JM\u00a0et\u00a0al.\u00a0Transient \u00a0rebounds \u00a0of\u00a0\nHIV\u00a0plasma\u00a0viremia\u00a0are\u00a0associated \u00a0with\u00a0the\u00a0emergence \u00a0of\u00a0drug\u00a0resistance \u00a0mutations \u00a0in\u00a0patients\u00a0on\u00a0\nhighly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a02005;\u00a051(3):195 \u2010200\u00a0\n\u00a0 49.\u00a0\u00a0Garcia\u2010Gasco\u00a0P,\u00a0Maida\u00a0I,\u00a0Blanco\u00a0F,\u00a0Barreiro\u00a0P,\u00a0Martin\u2010Carbonero \u00a0L,\u00a0Vispo\u00a0E\u00a0et\u00a0al.\u00a0Episodes\u00a0of\u00a0low\u2010level\u00a0\nviral\u00a0rebound\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0on\u00a0antiretroviral \u00a0therapy:\u00a0frequency, \u00a0predictors \u00a0and\u00a0outcome. \u00a0J\u00a0\nAntimicrob \u00a0Chemother \u00a02008;\u00a061(3):699 \u2010704\u00a0\n\u00a0 50.\u00a0\u00a0Saag\u00a0MS,\u00a0Holodniy\u00a0M,\u00a0Kuritzkes\u00a0DR,\u00a0O'Brien\u00a0WA,\u00a0Coombs\u00a0R,\u00a0Poscher\u00a0ME\u00a0et\u00a0al.\u00a0HIV\u00a0viral\u00a0load\u00a0markers\u00a0in\u00a0\nclinical\u00a0practice.\u00a0Nat\u00a0Med\u00a01996;\u00a02(6):625\u20109\u00a0\n\u00a0 51.\u00a0\u00a0Khoo\u00a0SH,\u00a0Gibbons\u00a0SE,\u00a0Back\u00a0DJ.\u00a0Therapeutic \u00a0drug\u00a0monitoring \u00a0as\u00a0a\u00a0tool\u00a0in\u00a0treating\u00a0HIV\u00a0infection. \u00a0AIDS\u00a0\n2001;\u00a015\u00a0Suppl\u00a05:171\u201081\u00a0\n\u00a0 52.\u00a0\u00a0Nettles\u00a0RE,\u00a0Kieffer\u00a0TL,\u00a0Parsons\u00a0T,\u00a0Johnson\u00a0J,\u00a0Cofrancesco \u00a0J,\u00a0Jr.,\u00a0Gallant\u00a0JE\u00a0et\u00a0al.\u00a0Marked\u00a0intraindividual \u00a0\nvariability \u00a0in\u00a0antiretroviral \u00a0concentrations \u00a0may\u00a0limit\u00a0the\u00a0utility\u00a0of\u00a0therapeutic \u00a0drug\u00a0monitoring. \u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02006;\u00a042(8):1189 \u20101196\u00a0\n\u00a0 53.\u00a0\u00a0Schapiro\u00a0JM,\u00a0Winters\u00a0MA,\u00a0Stewart\u00a0F,\u00a0Efron\u00a0B,\u00a0Norris\u00a0J,\u00a0Kozal\u00a0MJ\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0high\u2010dose\u00a0saquinavir \u00a0\non\u00a0viral\u00a0load\u00a0and\u00a0CD4+\u00a0T\u2010cell\u00a0counts\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0Ann\u00a0Intern\u00a0Med\u00a01996;\u00a0124(12):1039 \u201050\u00a0\n\u00a0 54.\u00a0\u00a0Hoetelmans \u00a0RM,\u00a0Reijers\u00a0MH,\u00a0Weverling \u00a0GJ,\u00a0Ten\u00a0Kate\u00a0RW,\u00a0Wit\u00a0FW,\u00a0Mulder\u00a0JW\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0plasma\u00a0\ndrug\u00a0concentrations \u00a0on\u00a0HIV\u20101\u00a0clearance \u00a0rate\u00a0during\u00a0quadruple \u00a0drug\u00a0therapy.\u00a0AIDS\u00a01998;\u00a012(11):111 \u20105\u00a0\n\u00a0 55.\u00a0\u00a0Casado\u00a0JL,\u00a0Moreno\u00a0S,\u00a0Hertogs\u00a0K,\u00a0Dronda\u00a0F,\u00a0Antela\u00a0A,\u00a0Dehertogh \u00a0P\u00a0et\u00a0al.\u00a0Plasma\u00a0drug\u00a0levels,\u00a0genotypic \u00a0\nresistance, \u00a0and\u00a0virological \u00a0response\u00a0to\u00a0a\u00a0nelfinavir \u00a0plus\u00a0saquinavir \u2010containing \u00a0regimen.\u00a0AIDS\u00a02002;\u00a0\n16(1):47\u201052\u00a0\n\u00a0 56.\u00a0\u00a0Harris\u00a0M,\u00a0Durakovic \u00a0C,\u00a0Rae\u00a0S,\u00a0Raboud\u00a0J,\u00a0Fransen\u00a0S,\u00a0Shillington \u00a0A\u00a0et\u00a0al.\u00a0A\u00a0pilot\u00a0study\u00a0of\u00a0nevirapine, \u00a0\nindinavir, \u00a0and\u00a0lamivudine \u00a0among\u00a0patients\u00a0with\u00a0advanced \u00a0human\u00a0immunodeficiency \u00a0virus\u00a0disease\u00a0who\u00a0\nhave\u00a0had\u00a0failure\u00a0of\u00a0combination \u00a0nucleoside \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a01998;\u00a0177(6):1514 \u201020\u00a0\n\u00a0 57.\u00a0\u00a0Fatkenheuer \u00a0G,\u00a0Hoetelmans \u00a0RM,\u00a0Hunn\u00a0N,\u00a0Schwenk\u00a0A,\u00a0Franzen\u00a0C,\u00a0Reiser\u00a0M\u00a0et\u00a0al.\u00a0Salvage\u00a0therapy\u00a0with\u00a0\nregimens \u00a0containing \u00a0ritonavir\u00a0and\u00a0saquinavir \u00a0in\u00a0extensively \u00a0pretreated \u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a0\n1999;\u00a013(12):1485 \u20109\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 189\u00a0 58.\u00a0\u00a0Veldkamp \u00a0AI,\u00a0Weverling \u00a0GJ,\u00a0Lange\u00a0JM,\u00a0Montaner \u00a0JS,\u00a0Reiss\u00a0P,\u00a0Cooper\u00a0DA\u00a0et\u00a0al.\u00a0High\u00a0exposure \u00a0to\u00a0\nnevirapine \u00a0in\u00a0plasma\u00a0is\u00a0associated \u00a0with\u00a0an\u00a0improved \u00a0virological \u00a0response\u00a0in\u00a0HIV\u20101\u2010infected\u00a0individuals. \u00a0\nAIDS\u00a02001;\u00a015(9):1089 \u201095\u00a0\n\u00a0 59.\u00a0\u00a0DiCenzo\u00a0R,\u00a0Forrest\u00a0A,\u00a0Fischl\u00a0MA,\u00a0Collier\u00a0A,\u00a0Feinberg\u00a0J,\u00a0Ribaudo\u00a0H\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0indinavir\u00a0and\u00a0\nnelfinavir \u00a0in\u00a0treatment \u2010naive,\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0subjects.\u00a0Antimicrob \u00a0Agents\u00a0\nChemother \u00a02004;\u00a048(3):918 \u2010923\u00a0\n\u00a0 60.\u00a0\u00a0Csajka\u00a0C,\u00a0Marzolini \u00a0C,\u00a0Fattinger\u00a0K,\u00a0Decosterd \u00a0LA,\u00a0Fellay\u00a0J,\u00a0Telenti\u00a0A\u00a0et\u00a0al.\u00a0Population \u00a0pharmacokinetics \u00a0\nand\u00a0effects\u00a0of\u00a0efavirenz\u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0Clin\u00a0Pharmacol \u00a0Ther\u00a0\n2003;\u00a073(1):20\u201030\u00a0\n\u00a0 61.\u00a0\u00a0Dieleman \u00a0JP,\u00a0Gyssens\u00a0IC,\u00a0Van\u00a0Der\u00a0Ende\u00a0ME,\u00a0de\u00a0Marie\u00a0S,\u00a0Burger\u00a0DM.\u00a0Urological \u00a0complaints \u00a0in\u00a0relation\u00a0to\u00a0\nindinavir\u00a0plasma\u00a0concentrations \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a01999;\u00a013(4):473 \u20108\u00a0\n\u00a0 62.\u00a0\u00a0Gonzalez\u00a0de\u00a0Requena\u00a0D,\u00a0Nunez\u00a0M,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Soriano\u00a0V.\u00a0Liver\u00a0toxicity\u00a0caused\u00a0by\u00a0nevirapine. \u00a0\nAIDS\u00a02002;\u00a016(2):290 \u20101\u00a0\n\u00a0 63.\u00a0\u00a0Gonzalez\u2010Requena\u00a0D,\u00a0Nunez\u00a0M,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Gonzalez\u2010Lahoz\u00a0J,\u00a0Soriano\u00a0V.\u00a0Short\u00a0communication: \u00a0\nliver\u00a0toxicity\u00a0of\u00a0lopinavir\u2010containing \u00a0regimens \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0or\u00a0without\u00a0hepatitis\u00a0C\u00a0\ncoinfection. \u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a02004;\u00a020(7):698 \u2010700\u00a0\n\u00a0 64.\u00a0\u00a0Gutierrez \u00a0F,\u00a0Padilla\u00a0S,\u00a0Navarro\u00a0A,\u00a0Masia\u00a0M,\u00a0Hernandez \u00a0I,\u00a0Ramos\u00a0J\u00a0et\u00a0al.\u00a0Lopinavir\u00a0plasma\u00a0concentrations \u00a0\nand\u00a0changes\u00a0in\u00a0lipid\u00a0levels\u00a0during\u00a0salvage\u00a0therapy\u00a0with\u00a0lopinavir/ritonavir \u2010containing \u00a0regimens. \u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02003;\u00a033(5):594 \u2010600\u00a0\n\u00a0 65.\u00a0\u00a0Gonzalez\u00a0de\u00a0Requena\u00a0D,\u00a0Blanco\u00a0F,\u00a0Garcia\u2010Benayas\u00a0T,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Gonzalez\u2010Lahoz\u00a0J,\u00a0Soriano\u00a0V.\u00a0\nCorrelation \u00a0between\u00a0lopinavir\u00a0plasma\u00a0levels\u00a0and\u00a0lipid\u00a0abnormalities \u00a0in\u00a0patients\u00a0taking\u00a0\nlopinavir/ritonavir. \u00a0AIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02003;\u00a017(9):443 \u2010445\u00a0\n\u00a0 66.\u00a0\u00a0Gallego\u00a0L,\u00a0Barreiro\u00a0P,\u00a0del\u00a0Rio\u00a0R,\u00a0Gonzalez\u00a0de\u00a0Requena\u00a0D,\u00a0Rodriguez \u2010Albarino\u00a0A,\u00a0Gonzalez\u2010Lahoz\u00a0J\u00a0et\u00a0al.\u00a0\nAnalyzing \u00a0sleep\u00a0abnormalities \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0Efavirenz. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a0\n38(3):430 \u2010432\u00a0\n\u00a0 67.\u00a0\u00a0Gutierrez \u00a0F,\u00a0Navarro\u00a0A,\u00a0Padilla\u00a0S,\u00a0Anton\u00a0R,\u00a0Masia\u00a0M,\u00a0Borras\u00a0J\u00a0et\u00a0al.\u00a0Prediction \u00a0of\u00a0neuropsychiatric \u00a0\nadverse\u00a0events\u00a0associated \u00a0with\u00a0long\u2010term\u00a0efavirenz\u00a0therapy,\u00a0using\u00a0plasma\u00a0drug\u00a0level\u00a0monitoring. \u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02005;\u00a041(11):1648 \u20101653\u00a0\n\u00a0 68.\u00a0\u00a0Drake\u00a0JW.\u00a0Rates\u00a0of\u00a0spontaneous \u00a0mutation \u00a0among\u00a0RNA\u00a0viruses.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0USA\u00a01993;\u00a0\n90(9):4171 \u20105\u00a0\n\u00a0 69.\u00a0\u00a0Drake\u00a0JW,\u00a0Charlesworth \u00a0B,\u00a0Charlesworth \u00a0D,\u00a0Crow\u00a0JF.\u00a0Rates\u00a0of\u00a0spontaneous \u00a0mutation. \u00a0Genetics\u00a01998;\u00a0\n148(4):1667 \u201086\u00a0\n\u00a0 70.\u00a0\u00a0Mansky\u00a0LM,\u00a0Temin\u00a0HM.\u00a0Lower\u00a0in\u00a0vivo\u00a0mutation \u00a0rate\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0than\u00a0that\u00a0\npredicted \u00a0from\u00a0the\u00a0fidelity\u00a0of\u00a0purified\u00a0reverse\u00a0transcriptase. \u00a0J\u00a0Virol\u00a01995;\u00a069(8):5087 \u201094\u00a0\n\u00a0 71.\u00a0\u00a0Ho\u00a0DD,\u00a0Neumann \u00a0AU,\u00a0Perelson\u00a0AS,\u00a0Chen\u00a0W,\u00a0Leonard\u00a0JM,\u00a0Markowitz \u00a0M.\u00a0Rapid\u00a0turnover\u00a0of\u00a0plasma\u00a0\nvirions\u00a0and\u00a0CD4\u00a0lymphocytes \u00a0in\u00a0HIV\u20101\u00a0infection. \u00a0Nature\u00a01995;\u00a0373(6510):123 \u20106\u00a0\n\u00a0 72.\u00a0\u00a0Wei\u00a0X,\u00a0Ghosh\u00a0SK,\u00a0Taylor\u00a0ME,\u00a0Johnson\u00a0VA,\u00a0Emini\u00a0EA,\u00a0Deutsch\u00a0P\u00a0et\u00a0al.\u00a0Viral\u00a0dynamics \u00a0in\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0type\u00a01\u00a0infection. \u00a0Nature\u00a01995;\u00a0373(6510):117 \u201022\u00a0\n\u00a0 73.\u00a0\u00a0Coffin\u00a0JM.\u00a0HIV\u00a0population \u00a0dynamics \u00a0in\u00a0vivo:\u00a0implications \u00a0for\u00a0genetic\u00a0variation, \u00a0pathogenesis, \u00a0and\u00a0\ntherapy.\u00a0Science\u00a01995;\u00a0267(5197):483 \u20109\u00a0\n\u00a0 74.\u00a0\u00a0Perelson\u00a0AS,\u00a0Neumann \u00a0AU,\u00a0Markowitz \u00a0M,\u00a0Leonard\u00a0JM,\u00a0Ho\u00a0DD.\u00a0HIV\u20101\u00a0dynamics \u00a0in\u00a0vivo:\u00a0virion\u00a0clearance \u00a0\nrate,\u00a0infected\u00a0cell\u00a0life\u2010span,\u00a0and\u00a0viral\u00a0generation \u00a0time.\u00a0Science\u00a01996;\u00a0271(5255):1582 \u20106\u00a0\n\u00a0 75.\u00a0\u00a0Schuurman \u00a0R,\u00a0Nijhuis\u00a0M,\u00a0van\u00a0Leeuwen\u00a0R,\u00a0Schipper\u00a0P,\u00a0de\u00a0Jong\u00a0D,\u00a0Collis\u00a0P\u00a0et\u00a0al.\u00a0Rapid\u00a0changes\u00a0in\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0type\u00a01\u00a0RNA\u00a0load\u00a0and\u00a0appearance \u00a0of\u00a0drug\u2010resistant\u00a0virus\u00a0populations \u00a0in\u00a0persons\u00a0\ntreated\u00a0with\u00a0lamivudine \u00a0(3TC).\u00a0J\u00a0Infect\u00a0Dis\u00a01995;\u00a0171(6):1411 \u20109\u00a0\n\u00a0 76.\u00a0\u00a0Molla\u00a0A,\u00a0Korneyeva \u00a0M,\u00a0Gao\u00a0Q,\u00a0Vasavanonda \u00a0S,\u00a0Schipper\u00a0PJ,\u00a0Mo\u00a0HM\u00a0et\u00a0al.\u00a0Ordered\u00a0accumulation \u00a0of\u00a0\nmutations \u00a0in\u00a0HIV\u00a0protease\u00a0confers\u00a0resistance \u00a0to\u00a0ritonavir.\u00a0Nat\u00a0Med\u00a01996;\u00a02(7):760\u20106\u00a0\n\u00a0 77.\u00a0\u00a0Johnson\u00a0VA,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Kuritzkes\u00a0DR,\u00a0Pillay\u00a0D,\u00a0Schapiro\u00a0JM\u00a0et\u00a0al.\u00a0Update\u00a0of\u00a0drug\u00a0\nresistance \u00a0mutations \u00a0in\u00a0HIV\u20101:\u00a0Fall\u00a02006.\u00a0Top\u00a0HIV\u00a0Med\u00a02006;\u00a014(3):125 \u2010130\u00a0\n\u00a0 78.\u00a0\u00a0Hirsch\u00a0MS,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Conway\u00a0B,\u00a0Kuritzkes\u00a0DR,\u00a0D'Aquila\u00a0RT\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0drug\u00a0\nresistance \u00a0testing\u00a0in\u00a0adults\u00a0infected\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01:\u00a02003\u00a0\nrecommendations \u00a0of\u00a0an\u00a0International \u00a0AIDS\u00a0Society\u2010USA\u00a0Panel.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02003;\u00a037(1):113 \u2010128\u00a0\n\u00a0 79.\u00a0\u00a0Devereux \u00a0HL,\u00a0Youle\u00a0M,\u00a0Johnson\u00a0MA,\u00a0Loveday\u00a0C.\u00a0Rapid\u00a0decline\u00a0in\u00a0detectability \u00a0of\u00a0HIV\u20101\u00a0drug\u00a0resistance \u00a0\nmutations \u00a0after\u00a0stopping\u00a0therapy.\u00a0AIDS\u00a01999;\u00a013(18):123 \u20107\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 190\u00a0 80.\u00a0\u00a0Qari\u00a0SH,\u00a0Respess\u00a0R,\u00a0Weinstock \u00a0H,\u00a0Beltrami\u00a0EM,\u00a0Hertogs\u00a0K,\u00a0Larder\u00a0BA\u00a0et\u00a0al.\u00a0Comparative \u00a0analysis\u00a0of\u00a0two\u00a0\ncommercial \u00a0phenotypic \u00a0assays\u00a0for\u00a0drug\u00a0susceptibility \u00a0testing\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01.\u00a0J\u00a0\nClin\u00a0Microbiol \u00a02002;\u00a040(1):31\u201035\u00a0\n\u00a0 81.\u00a0\u00a0Larder\u00a0BA,\u00a0Kemp\u00a0SD,\u00a0Hertogs\u00a0K.\u00a0Quantitative \u00a0prediction \u00a0of\u00a0HIV\u20101\u00a0phenotypic \u00a0drug\u00a0resistance \u00a0from\u00a0\ngenotypes: \u00a0the\u00a0virtual\u00a0phenotype \u00a0(VirtualPhenopyte). \u00a0Antivir\u00a0Ther\u00a02000;\u00a05(Suppl\u00a03):49\u00a0\n\u00a0 82.\u00a0\u00a0Novak\u00a0RM,\u00a0Chen\u00a0L,\u00a0MacArthur \u00a0RD,\u00a0Baxter\u00a0JD,\u00a0Huppler\u00a0HK,\u00a0Peng\u00a0G\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0antiretroviral \u00a0drug\u00a0\nresistance \u00a0mutations \u00a0in\u00a0chronically \u00a0HIV\u2010infected,\u00a0treatment \u2010naive\u00a0patients:\u00a0implications \u00a0for\u00a0routine\u00a0\nresistance \u00a0screening \u00a0before\u00a0initiation\u00a0of\u00a0antiretroviral \u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(3):468 \u2010474\u00a0\n\u00a0 83.\u00a0\u00a0Wensing\u00a0AM,\u00a0van\u00a0d,\u00a0V,\u00a0Angarano \u00a0G,\u00a0Asjo\u00a0B,\u00a0Balotta\u00a0C,\u00a0Boeri\u00a0E\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0\nvariants\u00a0in\u00a0untreated \u00a0individuals \u00a0in\u00a0Europe:\u00a0implications \u00a0for\u00a0clinical\u00a0management. \u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0\n192(6):958 \u2010966\u00a0\n\u00a0 84.\u00a0\u00a0Cane\u00a0P,\u00a0Chrystie\u00a0I,\u00a0Dunn\u00a0D,\u00a0Evans\u00a0B,\u00a0Geretti\u00a0AM,\u00a0Green\u00a0H\u00a0et\u00a0al.\u00a0Time\u00a0trends\u00a0in\u00a0primary\u00a0resistance \u00a0to\u00a0HIV\u00a0\ndrugs\u00a0in\u00a0the\u00a0United\u00a0Kingdom: \u00a0multicentre \u00a0observational \u00a0study.\u00a0BMJ\u00a02005;\u00a0331(7529):1368 \u00a0\n\u00a0 85.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Rodriguez \u00a0C,\u00a0Colomina \u00a0J,\u00a0Tuset\u00a0C,\u00a0Garcia\u00a0F,\u00a0Eiros\u00a0JM\u00a0et\u00a0al.\u00a0Resistance \u00a0to\u00a0nonnucleoside \u00a0\nreverse\u2010transcriptase \u00a0inhibitors \u00a0and\u00a0prevalence \u00a0of\u00a0HIV\u00a0type\u00a01\u00a0non\u2010B\u00a0subtypes\u00a0are\u00a0increasing \u00a0among\u00a0\npersons\u00a0with\u00a0recent\u00a0infection\u00a0in\u00a0Spain.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(9):1350 \u20101354\u00a0\n\u00a0 86.\u00a0\u00a0Palacios\u00a0R,\u00a0Viciana\u00a0I,\u00a0P\u00e9rez\u00a0de\u00a0Pedro\u00a0I,\u00a0De\u00a0la\u00a0TJ,\u00a0Ropero\u00a0F,\u00a0Fern\u00e1ndez \u00a0S\u00a0et\u00a0al.\u00a0Prevalencia \u00a0de\u00a0mutaciones \u00a0\nde\u00a0resistencia \u00a0primaria\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos \u00a0de\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0la\u00a0provincia\u00a0de\u00a0M\u00e1laga.\u00a0\nEnferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02008;\u00a026:141\u2010145\u00a0\n\u00a0 87.\u00a0\u00a0S\u00e1nchez\u00a0O\u00f1oro\u00a0M.,\u00a0Lopez\u00a0MJ,\u00a0Santana\u00a0MA,\u00a0Andes\u00a0JM,\u00a0Campelo\u00a0FA.\u00a0Resistencias \u00a0primarias \u00a0a\u00a0los\u00a0\nf\u00e1rmacos \u00a0antirretrovirales \u00a0en\u00a0los\u00a0pacientes \u00a0diagnosticados \u00a0de\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0Gran\u00a0Canaria\u00a0entre\u00a0\nlos\u00a0a\u00f1os\u00a02002\u20102005.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02007;\u00a025(7):437 \u2010440\u00a0\n\u00a0 88.\u00a0\u00a0Garcia\u00a0F,\u00a0Perez\u2010Cachafeiro \u00a0S,\u00a0Guillot\u00a0V,\u00a0Alvarez\u00a0M,\u00a0Perez\u00a0P,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0et\u00a0al.\u00a0Transmisi\u00f3n \u00a0de\u00a0\nresistencias \u00a0primarias \u00a0y\u00a0distribuci\u00f3n \u00a0de\u00a0subtipos\u00a0del\u00a0VIH\u20101\u00a0en\u00a0la\u00a0cohorte\u00a0espa\u00f1ola\u00a0de\u00a0pacientes \u00a0naive\u00a0\n(CoRIS).\u00a02\u00ba\u00a0Congreso \u00a0de\u00a0Gesida,\u00a0Madrid,\u00a030\u00a0Noviembre \u20103\u00a0diciembre \u00a02010.\u00a0Abstract\u00a0OR\u201011.\u00a0\n\u00a0 89.\u00a0\u00a0Sax\u00a0PE,\u00a0Islam\u00a0R,\u00a0Walensky \u00a0RP,\u00a0Losina\u00a0E,\u00a0Weinstein \u00a0MC,\u00a0Goldie\u00a0SJ\u00a0et\u00a0al.\u00a0Should\u00a0resistance \u00a0testing\u00a0be\u00a0\nperformed \u00a0for\u00a0treatment \u2010naive\u00a0HIV\u2010infected\u00a0patients? \u00a0A\u00a0cost\u2010effectiveness \u00a0analysis.\u00a0Clin\u00a0Infect\u00a0Dis\u00a0\n2005;\u00a041(9):1316 \u20101323\u00a0\n\u00a0 90.\u00a0\u00a0Hecht\u00a0FM,\u00a0Grant\u00a0RM.\u00a0Resistance \u00a0testing\u00a0in\u00a0drug\u2010naive\u00a0HIV\u2010infected\u00a0patients:\u00a0is\u00a0it\u00a0time?\u00a0Clin\u00a0Infect\u00a0Dis\u00a0\n2005;\u00a041(9):1324 \u20101325\u00a0\n\u00a0 91.\u00a0\u00a0Mitsuya\u00a0Y,\u00a0Varghese \u00a0V,\u00a0Wang\u00a0C,\u00a0Liu\u00a0TF,\u00a0Holmes\u00a0SP,\u00a0Jayakumar \u00a0P\u00a0et\u00a0al.\u00a0Minority\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0type\u00a01\u00a0variants\u00a0in\u00a0antiretroviral \u2010naive\u00a0persons\u00a0with\u00a0reverse\u00a0transcriptase \u00a0codon\u00a0\n215\u00a0revertant \u00a0mutations. \u00a0J\u00a0Virol\u00a02008;\u00a082(21):10747 \u201010755\u00a0\n\u00a0 92.\u00a0\u00a0Balduin\u00a0M,\u00a0Oette\u00a0M,\u00a0Daumer\u00a0MP,\u00a0Hoffmann \u00a0D,\u00a0Pfister\u00a0HJ,\u00a0Kaiser\u00a0R.\u00a0Prevalence \u00a0of\u00a0minor\u00a0variants\u00a0of\u00a0HIV\u00a0\nstrains\u00a0at\u00a0reverse\u00a0transcriptase \u00a0position\u00a0103\u00a0in\u00a0therapy\u2010naive\u00a0patients\u00a0and\u00a0their\u00a0impact\u00a0on\u00a0the\u00a0\nvirological \u00a0failure.\u00a0J\u00a0Clin\u00a0Virol\u00a02009;\u00a045(1):34\u201038\u00a0\n\u00a0 93.\u00a0\u00a0Geretti\u00a0AM,\u00a0Fox\u00a0ZV,\u00a0Booth\u00a0CL,\u00a0Smith\u00a0CJ,\u00a0Phillips\u00a0AN,\u00a0Johnson\u00a0M\u00a0et\u00a0al.\u00a0Low\u2010frequency \u00a0K103N\u00a0strengthens \u00a0\nthe\u00a0impact\u00a0of\u00a0transmitted \u00a0drug\u00a0resistance \u00a0on\u00a0virologic\u00a0responses \u00a0to\u00a0first\u2010line\u00a0efavirenz\u00a0or\u00a0nevirapine \u2010\nbased\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a052(5):569 \u2010573\u00a0\n\u00a0 94.\u00a0\u00a0Simen\u00a0BB,\u00a0Simons\u00a0JF,\u00a0Hullsiek\u00a0KH,\u00a0Novak\u00a0RM,\u00a0MacArthur \u00a0RD,\u00a0Baxter\u00a0JD\u00a0et\u00a0al.\u00a0Low\u2010abundance \u00a0drug\u2010\nresistant\u00a0viral\u00a0variants\u00a0in\u00a0chronically \u00a0HIV\u2010infected,\u00a0antiretroviral \u00a0treatment \u2010naive\u00a0patients\u00a0significantly \u00a0\nimpact\u00a0treatment \u00a0outcomes. \u00a0J\u00a0Infect\u00a0Dis\u00a02009;\u00a0199(5):693 \u2010701\u00a0\n\u00a0 95.\u00a0\u00a0Metzner\u00a0KJ,\u00a0Giulieri\u00a0SG,\u00a0Knoepfel\u00a0SA,\u00a0Rauch\u00a0P,\u00a0Burgisser \u00a0P,\u00a0Yerly\u00a0S\u00a0et\u00a0al.\u00a0Minority\u00a0quasispecies \u00a0of\u00a0drug\u2010\nresistant\u00a0HIV\u20101\u00a0that\u00a0lead\u00a0to\u00a0early\u00a0therapy\u00a0failure\u00a0in\u00a0treatment \u2010naive\u00a0and\u00a0\u2010adherent\u00a0patients.\u00a0Clin\u00a0Infect\u00a0\nDis\u00a02009;\u00a048(2):239 \u2010247\u00a0\n\u00a0 96.\u00a0\u00a0Coovadia \u00a0A,\u00a0Hunt\u00a0G,\u00a0Abrams\u00a0EJ,\u00a0Sherman\u00a0G,\u00a0Meyers\u00a0T,\u00a0Barry\u00a0G\u00a0et\u00a0al.\u00a0Persistent \u00a0minority\u00a0K103N\u00a0\nmutations \u00a0among\u00a0women\u00a0exposed\u00a0to\u00a0single\u2010dose\u00a0nevirapine \u00a0and\u00a0virologic\u00a0response\u00a0to\u00a0nonnucleoside \u00a0\nreverse\u2010transcriptase \u00a0inhibitor\u2010based\u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a048(4):462 \u2010472\u00a0\n\u00a0 97.\u00a0\u00a0Peuchant \u00a0O,\u00a0Thiebaut\u00a0R,\u00a0Capdepont \u00a0S,\u00a0Lavignolle \u2010Aurillac\u00a0V,\u00a0Neau\u00a0D,\u00a0Morlat\u00a0P\u00a0et\u00a0al.\u00a0Transmission \u00a0of\u00a0HIV\u2010\n1\u00a0minority\u2010resistant\u00a0variants\u00a0and\u00a0response\u00a0to\u00a0first\u2010line\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a02008;\u00a022(12):1417 \u2010\n1423\u00a0\n\u00a0 98.\u00a0\u00a0Johnson\u00a0JA,\u00a0Li\u00a0JF,\u00a0Wei\u00a0X,\u00a0Lipscomb \u00a0J,\u00a0Irlbeck\u00a0D,\u00a0Craig\u00a0C\u00a0et\u00a0al.\u00a0Minority\u00a0HIV\u20101\u00a0drug\u00a0resistance \u00a0mutations \u00a0\nare\u00a0present\u00a0in\u00a0antiretroviral \u00a0treatment \u2010naive\u00a0populations \u00a0and\u00a0associate\u00a0with\u00a0reduced\u00a0treatment \u00a0\nefficacy.\u00a0PLoS\u00a0Med\u00a02008;\u00a05(7):e158 \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 191\u00a0 99.\u00a0\u00a0Havlir\u00a0DV,\u00a0Marschner \u00a0IC,\u00a0Hirsch\u00a0MS,\u00a0Collier\u00a0AC,\u00a0Tebas\u00a0P,\u00a0Bassett\u00a0RL\u00a0et\u00a0al.\u00a0Maintenance \u00a0antiretroviral \u00a0\ntherapies \u00a0in\u00a0HIV\u00a0infected\u00a0patients\u00a0with\u00a0undetectable \u00a0plasma\u00a0HIV\u00a0RNA\u00a0after\u00a0triple\u2010drug\u00a0therapy.\u00a0AIDS\u00a0\nClinical\u00a0Trials\u00a0Group\u00a0Study\u00a0343\u00a0Team.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01998;\u00a0339(18):1261 \u20101268\u00a0\n\u00a0 100.\u00a0\u00a0Huisman\u00a0MT,\u00a0Smit\u00a0JW,\u00a0Schinkel\u00a0AH.\u00a0Significance \u00a0of\u00a0P\u2010glycoprotein \u00a0for\u00a0the\u00a0pharmacology \u00a0and\u00a0clinical\u00a0use\u00a0\nof\u00a0HIV\u00a0protease\u00a0inhibitors. \u00a0AIDS\u00a02000;\u00a014(3):237 \u201042\u00a0\n\u00a0 101.\u00a0\u00a0Baxter\u00a0JD,\u00a0Mayers\u00a0DL,\u00a0Wentworth \u00a0DN,\u00a0Neaton\u00a0JD,\u00a0Hoover\u00a0ML,\u00a0Winters\u00a0MA\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0study\u00a0of\u00a0\nantiretroviral \u00a0management \u00a0based\u00a0on\u00a0plasma\u00a0genotypic \u00a0antiretroviral \u00a0resistance \u00a0testing\u00a0in\u00a0patients\u00a0\nfailing\u00a0therapy.\u00a0CPCRA\u00a0046\u00a0Study\u00a0Team\u00a0for\u00a0the\u00a0Terry\u00a0Beirn\u00a0Community \u00a0Programs \u00a0for\u00a0Clinical\u00a0Research\u00a0\non\u00a0AIDS.\u00a0AIDS\u00a02000;\u00a014(9):83\u201093\u00a0\n\u00a0 102.\u00a0\u00a0Clevenbergh \u00a0P,\u00a0Durant\u00a0J,\u00a0Halfon\u00a0P,\u00a0del\u00a0Giudice\u00a0P,\u00a0Mondain\u00a0V,\u00a0Montagne \u00a0N\u00a0et\u00a0al.\u00a0Persisting \u00a0long\u2010term\u00a0\nbenefit\u00a0of\u00a0genotype \u2010guided\u00a0treatment \u00a0for\u00a0HIV\u2010infected\u00a0patients\u00a0failing\u00a0HAART.\u00a0The\u00a0Viradapt\u00a0Study:\u00a0\nweek\u00a048\u00a0follow\u2010up.\u00a0Antivir\u00a0Ther\u00a02000;\u00a05(1):65\u201070\u00a0\n\u00a0 103.\u00a0\u00a0Tural\u00a0C,\u00a0Ruiz\u00a0L,\u00a0Holtzer\u00a0C,\u00a0Schapiro\u00a0J,\u00a0Viciana\u00a0P,\u00a0Gonzalez\u00a0J\u00a0et\u00a0al.\u00a0Clinical\u00a0utility\u00a0of\u00a0HIV\u20101\u00a0genotyping \u00a0and\u00a0\nexpert\u00a0advice:\u00a0the\u00a0Havana\u00a0trial.\u00a0AIDS\u00a02002;\u00a016(2):209 \u2010218\u00a0\n\u00a0 104.\u00a0\u00a0Cohen\u00a0CJ,\u00a0Hunt\u00a0S,\u00a0Sension\u00a0M,\u00a0Farthing\u00a0C,\u00a0Conant\u00a0M,\u00a0Jacobson\u00a0S\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0assessing \u00a0the\u00a0\nimpact\u00a0of\u00a0phenotypic \u00a0resistance \u00a0testing\u00a0on\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a02002;\u00a016(4):579 \u201088\u00a0\n\u00a0 105.\u00a0\u00a0Cingolani\u00a0A,\u00a0Antinori\u00a0A,\u00a0Rizzo\u00a0MG,\u00a0Murri\u00a0R,\u00a0Ammassari \u00a0A,\u00a0Baldini\u00a0F\u00a0et\u00a0al.\u00a0Usefulness \u00a0of\u00a0monitoring \u00a0HIV\u00a0\ndrug\u00a0resistance \u00a0and\u00a0adherence \u00a0in\u00a0individuals \u00a0failing\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0a\u00a0randomized \u00a0\nstudy\u00a0(ARGENTA). \u00a0AIDS\u00a02002;\u00a016(3):369 \u201079\u00a0\n\u00a0 106.\u00a0\u00a0Kemper\u00a0CA,\u00a0Witt\u00a0MD,\u00a0Keiser\u00a0PH,\u00a0Dube\u00a0MP,\u00a0Forthal\u00a0DN,\u00a0Leibowitz \u00a0M\u00a0et\u00a0al.\u00a0Sequencing \u00a0of\u00a0protease\u00a0\ninhibitor\u00a0therapy:\u00a0insights\u00a0from\u00a0an\u00a0analysis\u00a0of\u00a0HIV\u00a0phenotypic \u00a0resistance \u00a0in\u00a0patients\u00a0failing\u00a0protease\u00a0\ninhibitors. \u00a0AIDS\u00a02001;\u00a015(5):609 \u201015\u00a0\n\u00a0 107.\u00a0\u00a0Meynard\u00a0JL,\u00a0Vray\u00a0M,\u00a0Morand\u2010Joubert\u00a0L,\u00a0Race\u00a0E,\u00a0Descamps \u00a0D,\u00a0Peytavin\u00a0G\u00a0et\u00a0al.\u00a0Phenotypic \u00a0or\u00a0genotypic \u00a0\nresistance \u00a0testing\u00a0for\u00a0choosing\u00a0antiretroviral \u00a0therapy\u00a0after\u00a0treatment \u00a0failure:\u00a0a\u00a0randomized \u00a0trial.\u00a0AIDS\u00a0\n2002;\u00a016(5):727 \u201036\u00a0\n\u00a0 108.\u00a0\u00a0Mazzotta \u00a0F,\u00a0Lo\u00a0CS,\u00a0Torti\u00a0C,\u00a0Tinelli\u00a0C,\u00a0Pierotti\u00a0P,\u00a0Castelli\u00a0F\u00a0et\u00a0al.\u00a0Real\u00a0versus\u00a0virtual\u00a0phenotype \u00a0to\u00a0guide\u00a0\ntreatment \u00a0in\u00a0heavily\u00a0pretreated \u00a0patients:\u00a048\u2010week\u00a0follow\u2010up\u00a0of\u00a0the\u00a0Genotipo \u2010Fenotipo\u00a0di\u00a0Resistenza \u00a0\n(GenPheRex) \u00a0trial.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02003;\u00a032(3):268 \u2010280\u00a0\n\u00a0 109.\u00a0\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Garcia\u2010Arota\u00a0I,\u00a0Munoz\u00a0V,\u00a0Santos\u00a0I,\u00a0Sanz\u00a0J,\u00a0Abraira\u00a0V\u00a0et\u00a0al.\u00a0Phenotype \u00a0or\u00a0virtual\u00a0phenotype \u00a0\nfor\u00a0choosing\u00a0antiretroviral \u00a0therapy\u00a0after\u00a0failure:\u00a0a\u00a0prospective, \u00a0randomized \u00a0study.\u00a0Antivir\u00a0Ther\u00a02003;\u00a0\n8(6):577\u2010584\u00a0\n\u00a0 110.\u00a0\u00a0Torre\u00a0D,\u00a0Tambini\u00a0R.\u00a0Antiretroviral \u00a0drug\u00a0resistance \u00a0testing\u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0infection: \u00a0A\u00a0meta\u2010\nanalysis\u00a0study.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02002;\u00a03(1):1\u20108\u00a0\n\u00a0 111.\u00a0\u00a0Hughes\u00a0CA,\u00a0Foisy\u00a0MM,\u00a0Dewhurst \u00a0N,\u00a0Higgins\u00a0N,\u00a0Robinson \u00a0L,\u00a0Kelly\u00a0DV\u00a0et\u00a0al.\u00a0Abacavir\u00a0hypersensitivity \u00a0\nreaction:\u00a0an\u00a0update.\u00a0Ann\u00a0Pharmacother \u00a02008;\u00a042(3):387 \u2010396\u00a0\n\u00a0 112.\u00a0\u00a0Mallal\u00a0S,\u00a0Phillips\u00a0E,\u00a0Carosi\u00a0G,\u00a0Molina\u00a0JM,\u00a0Workman \u00a0C,\u00a0Tomazic\u00a0J\u00a0et\u00a0al.\u00a0HLA\u2010B*5701\u00a0screening \u00a0for\u00a0\nhypersensitivity \u00a0to\u00a0abacavir.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0358(6):568 \u2010579\u00a0\n\u00a0 113.\u00a0\u00a0Saag\u00a0M,\u00a0Balu\u00a0R,\u00a0Phillips\u00a0E,\u00a0Brachman \u00a0P,\u00a0Martorell \u00a0C,\u00a0Burman\u00a0W\u00a0et\u00a0al.\u00a0High\u00a0sensitivity \u00a0of\u00a0human\u00a0leukocyte \u00a0\nantigen\u2010B*5701\u00a0as\u00a0a\u00a0marker\u00a0for\u00a0immunologically \u00a0confirmed \u00a0abacavir\u00a0hypersensitivity \u00a0in\u00a0white\u00a0and\u00a0black\u00a0\npatients.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a046(7):1111 \u20101118\u00a0\n\u00a0 114.\u00a0\u00a0Moore\u00a0JP,\u00a0Kitchen\u00a0SG,\u00a0Pugach\u00a0P,\u00a0Zack\u00a0JA.\u00a0The\u00a0CCR5\u00a0and\u00a0CXCR4\u00a0coreceptors \u2010\u2010central\u00a0to\u00a0understanding \u00a0\nthe\u00a0transmission \u00a0and\u00a0pathogenesis \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0infection. \u00a0AIDS\u00a0Res\u00a0Hum\u00a0\nRetroviruses \u00a02004;\u00a020(1):111 \u2010126\u00a0\n\u00a0 115.\u00a0\u00a0Connor\u00a0RI,\u00a0Sheridan\u00a0KE,\u00a0Ceradini\u00a0D,\u00a0Choe\u00a0S,\u00a0Landau\u00a0NR.\u00a0Change\u00a0in\u00a0coreceptor \u00a0use\u00a0coreceptor \u00a0use\u00a0\ncorrelates \u00a0with\u00a0disease\u00a0progression \u00a0in\u00a0HIV\u20101\u2010\u2010infected\u00a0individuals. \u00a0J\u00a0Exp\u00a0Med\u00a01997;\u00a0185(4):621 \u2010628\u00a0\n\u00a0 116.\u00a0\u00a0Hunt\u00a0PW,\u00a0Harrigan\u00a0PR,\u00a0Huang\u00a0W,\u00a0Bates\u00a0M,\u00a0Williamson \u00a0DW,\u00a0McCune\u00a0JM\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0CXCR4\u00a0\ntropism\u00a0among\u00a0antiretroviral \u2010treated\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0detectable \u00a0viremia.\u00a0J\u00a0Infect\u00a0Dis\u00a02006;\u00a0\n194(7):926 \u2010930\u00a0\n\u00a0 117.\u00a0\u00a0Wilkin\u00a0TJ,\u00a0Su\u00a0Z,\u00a0Kuritzkes\u00a0DR,\u00a0Hughes\u00a0M,\u00a0Flexner\u00a0C,\u00a0Gross\u00a0R\u00a0et\u00a0al.\u00a0HIV\u00a0type\u00a01\u00a0chemokine \u00a0coreceptor \u00a0use\u00a0\namong\u00a0antiretroviral \u2010experienced \u00a0patients\u00a0screened\u00a0for\u00a0a\u00a0clinical\u00a0trial\u00a0of\u00a0a\u00a0CCR5\u00a0inhibitor:\u00a0AIDS\u00a0Clinical\u00a0\nTrial\u00a0Group\u00a0A5211.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(4):591 \u2010595\u00a0\n\u00a0 118.\u00a0\u00a0Whitcomb \u00a0JM,\u00a0Huang\u00a0W,\u00a0Fransen\u00a0S,\u00a0Limoli\u00a0K,\u00a0Toma\u00a0J,\u00a0Wrin\u00a0T\u00a0et\u00a0al.\u00a0Development \u00a0and\u00a0characterization \u00a0of\u00a0\na\u00a0novel\u00a0single\u2010cycle\u00a0recombinant \u2010virus\u00a0assay\u00a0to\u00a0determine \u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0\ncoreceptor \u00a0tropism.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02007;\u00a051(2):566 \u2010575\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 192\u00a0 119.\u00a0\u00a0Low\u00a0AJ,\u00a0Dong\u00a0W,\u00a0Chan\u00a0D,\u00a0Sing\u00a0T,\u00a0Swanstrom \u00a0R,\u00a0Jensen\u00a0M\u00a0et\u00a0al.\u00a0Current\u00a0V3\u00a0genotyping \u00a0algorithms \u00a0are\u00a0\ninadequate \u00a0for\u00a0predicting \u00a0X4\u00a0co\u2010receptor\u00a0usage\u00a0in\u00a0clinical\u00a0isolates.\u00a0AIDS\u00a02007;\u00a021(14):F17 \u2010F24\u00a0\n\u00a0 120.\u00a0\u00a0Chueca\u00a0N,\u00a0Garrido\u00a0C,\u00a0Alvarez\u00a0M,\u00a0Poveda\u00a0E,\u00a0de\u00a0Dios\u00a0LJ,\u00a0Zahonero \u00a0N\u00a0et\u00a0al.\u00a0Improvement \u00a0in\u00a0the\u00a0\ndetermination \u00a0of\u00a0HIV\u20101\u00a0tropism\u00a0using\u00a0the\u00a0V3\u00a0gene\u00a0sequence \u00a0and\u00a0a\u00a0combination \u00a0of\u00a0bioinformatic \u00a0tools.\u00a0J\u00a0\nMed\u00a0Virol\u00a02009;\u00a081(5):763 \u2010767\u00a0\n\u00a0 121.\u00a0\u00a0Poveda\u00a0E,\u00a0Seclen\u00a0E,\u00a0Gonzalez\u00a0MM,\u00a0Garcia\u00a0F,\u00a0Chueca\u00a0N,\u00a0Aguilera\u00a0A\u00a0et\u00a0al.\u00a0Design\u00a0and\u00a0validation \u00a0of\u00a0new\u00a0\ngenotypic \u00a0tools\u00a0for\u00a0easy\u00a0and\u00a0reliable\u00a0estimation \u00a0of\u00a0HIV\u00a0tropism\u00a0before\u00a0using\u00a0CCR5\u00a0antagonists. \u00a0J\u00a0\nAntimicrob \u00a0Chemother \u00a02009;\u00a063(5):1006 \u20101010\u00a0\n\u00a0 122.\u00a0\u00a0Seclen\u00a0E,\u00a0Garrido\u00a0C,\u00a0Gonzalez\u00a0MM,\u00a0Gonzalez\u2010Lahoz\u00a0J,\u00a0de\u00a0MC,\u00a0Soriano\u00a0V\u00a0et\u00a0al.\u00a0High\u00a0sensitivity \u00a0of\u00a0specific\u00a0\ngenotypic \u00a0tools\u00a0for\u00a0detection \u00a0of\u00a0X4\u00a0variants\u00a0in\u00a0antiretroviral \u2010experienced \u00a0patients\u00a0suitable\u00a0to\u00a0be\u00a0treated\u00a0\nwith\u00a0CCR5\u00a0antagonists. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02010;\u00a065(7):1486 \u20101492\u00a0\n\u00a0 123.\u00a0\u00a0McGovern \u00a0RA,\u00a0Thielen\u00a0A,\u00a0Mo\u00a0T,\u00a0Dong\u00a0W,\u00a0Woods\u00a0CK,\u00a0Chapman \u00a0D\u00a0et\u00a0al.\u00a0Population \u2010based\u00a0V3\u00a0genotypic \u00a0\ntropism\u00a0assay:\u00a0a\u00a0retrospective \u00a0analysis\u00a0using\u00a0screening \u00a0samples\u00a0from\u00a0the\u00a0A4001029 \u00a0and\u00a0MOTIVATE \u00a0\nstudies.\u00a0AIDS\u00a02010;\u00a024(16):2517 \u20102525\u00a0\n\u00a0 124.\u00a0\u00a0McGovern \u00a0R,\u00a0Dong\u00a0W,\u00a0Zhong\u00a0X,\u00a0Knapp\u00a0D,\u00a0Thielen\u00a0A,\u00a0Chapman \u00a0D,\u00a0et\u00a0al.\u00a0Population \u2010based\u00a0sequencing \u00a0of\u00a0\nthe\u00a0V3\u2010loop\u00a0is\u00a0comparable \u00a0to\u00a0the\u00a0enhanced \u00a0sensitivity \u00a0trofile\u00a0assay\u00a0in\u00a0predicting \u00a0virologic\u00a0response\u00a0to\u00a0\nmaraviroc \u00a0of\u00a0treatment \u2010naive\u00a0patients\u00a0in\u00a0the\u00a0MERIT\u00a0trial.\u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a092.\u00a0\n\u00a0 125.\u00a0\u00a0Poveda\u00a0E,\u00a0Alcami\u00a0J,\u00a0Paredes\u00a0R,\u00a0Cordoba\u00a0J,\u00a0Gutierrez \u00a0F,\u00a0Llibre\u00a0JM\u00a0et\u00a0al.\u00a0Genotypic \u00a0determination \u00a0of\u00a0HIV\u00a0\ntropism\u00a0\u2010\u00a0clinical\u00a0and\u00a0methodological \u00a0recommendations \u00a0to\u00a0guide\u00a0the\u00a0therapeutic \u00a0use\u00a0of\u00a0CCR5\u00a0\nantagonists. \u00a0AIDS\u00a0Rev\u00a02010;\u00a012(3):135 \u2010148\u00a0\n\u00a0 126.\u00a0\u00a0Stekler\u00a0J,\u00a0Collier\u00a0A.\u00a0Treatment \u00a0of\u00a0primary\u00a0HIV.\u00a0Curr\u00a0Infect\u00a0Dis\u00a0Rep\u00a02002;\u00a04(1):81\u201087\u00a0\n\u00a0 127.\u00a0\u00a0Pilcher\u00a0CD,\u00a0Eron\u00a0JJ,\u00a0Jr.,\u00a0Galvin\u00a0S,\u00a0Gay\u00a0C,\u00a0Cohen\u00a0MS.\u00a0Acute\u00a0HIV\u00a0revisited: \u00a0new\u00a0opportunities \u00a0for\u00a0treatment \u00a0\nand\u00a0prevention. \u00a0J\u00a0Clin\u00a0Invest\u00a02004;\u00a0113(7):937 \u2010945\u00a0\n\u00a0 128.\u00a0\u00a0Kassutto\u00a0S,\u00a0Rosenberg \u00a0E.\u00a0Primary\u00a0HIV\u00a0Type\u00a01\u00a0Infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a038:1452\u20101458\u00a0\n\u00a0 129.\u00a0\u00a0Weintrob \u00a0AC,\u00a0Giner\u00a0J,\u00a0Menezes\u00a0P,\u00a0Patrick\u00a0E,\u00a0Benjamin \u00a0DK,\u00a0Jr.,\u00a0Lennox\u00a0J\u00a0et\u00a0al.\u00a0Infrequent \u00a0diagnosis \u00a0of\u00a0\nprimary\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection: \u00a0missed\u00a0opportunities \u00a0in\u00a0acute\u00a0care\u00a0settings.\u00a0Arch\u00a0\nIntern\u00a0Med\u00a02003;\u00a0163(17):2097 \u20102100\u00a0\n\u00a0 130.\u00a0\u00a0Miro\u00a0JM,\u00a0Sued\u00a0O,\u00a0Plana\u00a0M,\u00a0Pumarola \u00a0T,\u00a0Gallart\u00a0T.\u00a0Avances\u00a0en\u00a0el\u00a0diagn\u00f3stico \u00a0y\u00a0tratamiento \u00a0de\u00a0la\u00a0\ninfecci\u00f3n\u00a0aguda\u00a0por\u00a0el\u00a0VIH\u20101.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02004;\u00a022(10):643 \u2010659\u00a0\n\u00a0 131.\u00a0\u00a0Lindback\u00a0S,\u00a0Thorstensson \u00a0R,\u00a0Karlsson\u00a0AC,\u00a0von\u00a0Sydow\u00a0M,\u00a0Flamholc\u00a0L,\u00a0Blaxhult\u00a0A\u00a0et\u00a0al.\u00a0Diagnosis \u00a0of\u00a0\nprimary\u00a0HIV\u20101\u00a0infection\u00a0and\u00a0duration\u00a0of\u00a0follow\u2010up\u00a0after\u00a0HIV\u00a0exposure. \u00a0Karolinska \u00a0Institute\u00a0Primary\u00a0HIV\u00a0\nInfection\u00a0Study\u00a0Group.\u00a0AIDS\u00a02000;\u00a014(15):2333 \u20109\u00a0\n\u00a0 132.\u00a0\u00a0Daar\u00a0ES,\u00a0Little\u00a0S,\u00a0Pitt\u00a0J,\u00a0Santangelo \u00a0J,\u00a0Ho\u00a0P,\u00a0Harawa\u00a0N\u00a0et\u00a0al.\u00a0Diagnosis \u00a0of\u00a0primary\u00a0HIV\u20101\u00a0infection. \u00a0Los\u00a0\nAngeles\u00a0County\u00a0Primary\u00a0HIV\u00a0Infection\u00a0Recruitment \u00a0Network. \u00a0Ann\u00a0Intern\u00a0Med\u00a02001;\u00a0134(1):25 \u20109\u00a0\n\u00a0 133.\u00a0\u00a0Lavreys\u00a0L,\u00a0Baeten\u00a0JM,\u00a0Chohan\u00a0V,\u00a0McClelland \u00a0RS,\u00a0Hassan\u00a0WM,\u00a0Richardson \u00a0BA\u00a0et\u00a0al.\u00a0Higher\u00a0set\u00a0point\u00a0\nplasma\u00a0viral\u00a0load\u00a0and\u00a0more\u2010severe\u00a0acute\u00a0HIV\u00a0type\u00a01\u00a0(HIV\u20101)\u00a0illness\u00a0predict\u00a0mortality\u00a0among\u00a0high\u2010risk\u00a0\nHIV\u20101\u2010infected\u00a0African\u00a0women.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(9):1333 \u20101339\u00a0\n\u00a0 134.\u00a0\u00a0Goujard\u00a0C,\u00a0Bonarek\u00a0M,\u00a0Meyer\u00a0L,\u00a0Bonnet\u00a0F,\u00a0Chaix\u00a0ML,\u00a0Deveau\u00a0C\u00a0et\u00a0al.\u00a0CD4\u00a0cell\u00a0count\u00a0and\u00a0HIV\u00a0DNA\u00a0level\u00a0\nare\u00a0independent \u00a0predictors \u00a0of\u00a0disease\u00a0progression \u00a0after\u00a0primary\u00a0HIV\u00a0type\u00a01\u00a0infection\u00a0in\u00a0untreated \u00a0\npatients.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(5):709 \u2010715\u00a0\n\u00a0 135.\u00a0\u00a0Fidler\u00a0S,\u00a0Fox\u00a0J,\u00a0Porter\u00a0K,\u00a0Weber\u00a0J.\u00a0Primary\u00a0HIV\u00a0infection: \u00a0to\u00a0treat\u00a0or\u00a0not\u00a0to\u00a0treat?\u00a0Curr\u00a0Opin\u00a0Infect\u00a0Dis\u00a0\n2008;\u00a021(1):4\u201010\u00a0\n\u00a0 136.\u00a0\u00a0Rieder\u00a0P,\u00a0Joos\u00a0B,\u00a0von\u00a0W,\u00a0V,\u00a0Kuster\u00a0H,\u00a0Grube\u00a0C,\u00a0Leemann \u00a0C\u00a0et\u00a0al.\u00a0HIV\u20101\u00a0transmission \u00a0after\u00a0cessation \u00a0of\u00a0\nearly\u00a0antiretroviral \u00a0therapy\u00a0among\u00a0men\u00a0having\u00a0sex\u00a0with\u00a0men.\u00a0AIDS\u00a02010;\u00a024(8):1177 \u20101183\u00a0\n\u00a0 137.\u00a0\u00a0Altfeld\u00a0M,\u00a0Rosenberg \u00a0ES,\u00a0Shankarappa \u00a0R,\u00a0Mukherjee \u00a0JS,\u00a0Hecht\u00a0FM,\u00a0Eldridge\u00a0RL\u00a0et\u00a0al.\u00a0Cellular\u00a0immune\u00a0\nresponses \u00a0and\u00a0viral\u00a0diversity\u00a0in\u00a0individuals \u00a0treated\u00a0during\u00a0acute\u00a0and\u00a0early\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0Exp\u00a0Med\u00a0\n2001;\u00a0193(2):169 \u201080\u00a0\n\u00a0 138.\u00a0\u00a0Cohen\u00a0DE,\u00a0Walker\u00a0BD.\u00a0Human\u00a0immunodeficiency \u00a0virus\u00a0pathogenesis \u00a0and\u00a0prospects \u00a0for\u00a0immune\u00a0control\u00a0\nin\u00a0patients\u00a0with\u00a0established \u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02001;\u00a032(12):1756 \u201068\u00a0\n\u00a0 139.\u00a0\u00a0Oxenius\u00a0A,\u00a0Yerly\u00a0S,\u00a0Ramirez\u00a0E,\u00a0Phillips\u00a0RE,\u00a0Price\u00a0DA,\u00a0Perrin\u00a0L.\u00a0Distribution \u00a0of\u00a0functional \u00a0HIV\u2010specific\u00a0CD8\u00a0T\u00a0\nlymphocytes \u00a0between\u00a0blood\u00a0and\u00a0secondary \u00a0lymphoid \u00a0organs\u00a0after\u00a08\u201018\u00a0months\u00a0of\u00a0antiretroviral \u00a0\ntherapy\u00a0in\u00a0acutely\u00a0infected\u00a0patients.\u00a0AIDS\u00a02001;\u00a015(13):1653 \u20106\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 193\u00a0 140.\u00a0\u00a0Oxenius\u00a0A,\u00a0Fidler\u00a0S,\u00a0Brady\u00a0M,\u00a0Dawson\u00a0SJ,\u00a0Ruth\u00a0K,\u00a0Easterbrook \u00a0PJ\u00a0et\u00a0al.\u00a0Variable\u00a0fate\u00a0of\u00a0virus\u2010specific\u00a0\nCD4(+)\u00a0T\u00a0cells\u00a0during\u00a0primary\u00a0HIV\u20101\u00a0infection. \u00a0Eur\u00a0J\u00a0Immunol\u00a02001;\u00a031(12):3782 \u20108\u00a0\n\u00a0 141.\u00a0\u00a0Rosenberg \u00a0ES,\u00a0Altfeld\u00a0M,\u00a0Poon\u00a0SH,\u00a0Phillips\u00a0MN,\u00a0Wilkes\u00a0BM,\u00a0Eldridge\u00a0RL\u00a0et\u00a0al.\u00a0Immune\u00a0control\u00a0of\u00a0HIV\u20101\u00a0\nafter\u00a0early\u00a0treatment \u00a0of\u00a0acute\u00a0infection. \u00a0Nature\u00a02000;\u00a0407(6803):523 \u20106\u00a0\n\u00a0 142.\u00a0\u00a0Mehandru \u00a0S,\u00a0Poles\u00a0MA,\u00a0Tenner\u2010Racz\u00a0K,\u00a0Jean\u2010Pierre\u00a0P,\u00a0Manuelli\u00a0V,\u00a0Lopez\u00a0P\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0mucosal\u00a0immune\u00a0\nreconstitution \u00a0during\u00a0prolonged \u00a0treatment \u00a0of\u00a0acute\u00a0and\u00a0early\u00a0HIV\u20101\u00a0infection. \u00a0PLoS\u00a0One\u00a02006;\u00a0\n3(12):e484 \u00a0\n\u00a0 143.\u00a0\u00a0Smith\u00a0DE,\u00a0Walker\u00a0BD,\u00a0Cooper\u00a0DA,\u00a0Rosenberg \u00a0ES,\u00a0Kaldor\u00a0JM.\u00a0Is\u00a0antiretroviral \u00a0treatment \u00a0of\u00a0primary\u00a0HIV\u00a0\ninfection\u00a0clinically\u00a0justified\u00a0on\u00a0the\u00a0basis\u00a0of\u00a0current\u00a0evidence? \u00a0AIDS\u00a02004;\u00a018(5):709 \u2010718\u00a0\n\u00a0 144.\u00a0\u00a0Kinloch\u2010de\u00a0LS.\u00a0Treatment \u00a0of\u00a0acute\u00a0HIV\u20101\u00a0infection: \u00a0is\u00a0it\u00a0coming\u00a0of\u00a0age?\u00a0J\u00a0Infect\u00a0Dis\u00a02006;\u00a0194(6):721 \u2010724\u00a0\n\u00a0 145.\u00a0\u00a0Voirin\u00a0N,\u00a0Routy\u00a0JP,\u00a0Smith\u00a0D,\u00a0Baratin\u00a0D,\u00a0Trepo\u00a0C,\u00a0Cotte\u00a0L\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0early\u00a0initiation\u00a0of\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy\u00a0on\u00a0CD4\u00a0cell\u00a0count\u00a0and\u00a0HIV\u2010RNA\u00a0viral\u00a0load\u00a0trends\u00a0within\u00a024\u00a0months\u00a0of\u00a0the\u00a0onset\u00a0of\u00a0\nacute\u00a0retroviral \u00a0syndrome. \u00a0HIV\u00a0Med\u00a02008;\u00a09(6):440\u2010444\u00a0\n\u00a0 146.\u00a0\u00a0Kassutto\u00a0S,\u00a0Maghsoudi \u00a0K,\u00a0Johnston\u00a0MN,\u00a0Robbins\u00a0GK,\u00a0Burgett\u00a0NC,\u00a0Sax\u00a0PE\u00a0et\u00a0al.\u00a0Longitudinal \u00a0analysis\u00a0of\u00a0\nclinical\u00a0markers\u00a0following \u00a0antiretroviral \u00a0therapy\u00a0initiated\u00a0during\u00a0acute\u00a0or\u00a0early\u00a0HIV\u00a0type\u00a01\u00a0infection. \u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02006;\u00a042(7):1024 \u20101031\u00a0\n\u00a0 147.\u00a0\u00a0Sued\u00a0O,\u00a0Miro\u00a0JM,\u00a0Alquezar\u00a0A,\u00a0Claramonte \u00a0X,\u00a0Garcia\u00a0F,\u00a0Plana\u00a0M\u00a0et\u00a0al.\u00a0Primary\u00a0human\u00a0immunodeficiency \u00a0\nvirus\u00a0type\u00a01\u00a0infection: \u00a0clinical,\u00a0virological \u00a0and\u00a0immunological \u00a0characteristics \u00a0of\u00a075\u00a0patients\u00a0(1997\u20102003).\u00a0\nEnferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02006;\u00a024(4):238 \u2010244\u00a0\n\u00a0 148.\u00a0\u00a0Fidler\u00a0S,\u00a0Oxenius\u00a0A,\u00a0Brady\u00a0M,\u00a0Clarke\u00a0J,\u00a0Cropley\u00a0I,\u00a0Babiker\u00a0A\u00a0et\u00a0al.\u00a0Virological \u00a0and\u00a0immunological \u00a0effects\u00a0of\u00a0\nshort\u00a0course\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02002;\u00a016:2049\u20102054\u00a0\n\u00a0 149.\u00a0\u00a0Fidler\u00a0S,\u00a0Fraser\u00a0C,\u00a0Fox\u00a0J,\u00a0Tamm\u00a0N,\u00a0Griffin\u00a0JT,\u00a0Weber\u00a0J.\u00a0Comparative \u00a0potency\u00a0of\u00a0three\u00a0antiretroviral \u00a0\ntherapy\u00a0regimes\u00a0in\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02006;\u00a020(2):247 \u2010252\u00a0\n\u00a0 150.\u00a0\u00a0Apuzzo\u00a0LG,\u00a0Vaida\u00a0F,\u00a0Gallant\u00a0JE,\u00a0Ernstrom \u00a0KB,\u00a0Little\u00a0SJ,\u00a0Routy\u00a0JP\u00a0et\u00a0al.\u00a0Tolerability \u00a0and\u00a0efficacy\u00a0of\u00a0PI\u00a0versus\u00a0\nNNRTI\u2010based\u00a0regimens \u00a0in\u00a0subjects\u00a0receiving\u00a0HAART\u00a0during\u00a0acute\u00a0or\u00a0early\u00a0HIV\u00a0infection. \u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr\u00a02009;\u00a050(3):267 \u2010275\u00a0\n\u00a0 151.\u00a0\u00a0Markowitz \u00a0M,\u00a0Mohri\u00a0H,\u00a0Mehandru \u00a0S,\u00a0Shet\u00a0A,\u00a0Berry\u00a0L,\u00a0Kalyanaraman \u00a0R\u00a0et\u00a0al.\u00a0Infection\u00a0with\u00a0multidrug \u00a0\nresistant, \u00a0dual\u2010tropic\u00a0HIV\u20101\u00a0and\u00a0rapid\u00a0progression \u00a0to\u00a0AIDS:\u00a0a\u00a0case\u00a0report.\u00a0Lancet\u00a02005;\u00a0365(9464):1031 \u2010\n1038\u00a0\n\u00a0 152.\u00a0\u00a0Gottlieb\u00a0GS,\u00a0Nickle\u00a0DC,\u00a0Jensen\u00a0MA,\u00a0Wong\u00a0KG,\u00a0Grobler\u00a0J,\u00a0Li\u00a0F\u00a0et\u00a0al.\u00a0Dual\u00a0HIV\u20101\u00a0infection\u00a0associated \u00a0with\u00a0\nrapid\u00a0disease\u00a0progression. \u00a0Lancet\u00a02004;\u00a0363(9409):619 \u2010622\u00a0\n\u00a0 153.\u00a0\u00a0Dalmau\u00a0J,\u00a0Puertas\u00a0MC,\u00a0Azuara\u00a0M,\u00a0Marino\u00a0A,\u00a0Frahm\u00a0N,\u00a0Mothe\u00a0B\u00a0et\u00a0al.\u00a0Contribution \u00a0of\u00a0immunological \u00a0and\u00a0\nvirological \u00a0factors\u00a0to\u00a0extremely \u00a0severe\u00a0primary\u00a0HIV\u00a0type\u00a01\u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a048(2):229 \u2010238\u00a0\n\u00a0 154.\u00a0\u00a0Chaix\u00a0ML,\u00a0Descamps \u00a0D,\u00a0Wirden\u00a0M,\u00a0Bocket\u00a0L,\u00a0Delaugerre \u00a0C,\u00a0Tamalet\u00a0C\u00a0et\u00a0al.\u00a0Stable\u00a0frequency \u00a0of\u00a0HIV\u20101\u00a0\ntransmitted \u00a0drug\u00a0resistance \u00a0in\u00a0patients\u00a0at\u00a0the\u00a0time\u00a0of\u00a0primary\u00a0infection\u00a0over\u00a01996\u20102006\u00a0in\u00a0France.\u00a0AIDS\u00a0\n2009;\u00a023(6):717 \u2010724\u00a0\n\u00a0 155.\u00a0\u00a0Goujard\u00a0C,\u00a0Boufassa\u00a0F,\u00a0Deveau\u00a0C,\u00a0Laskri\u00a0D,\u00a0Meyer\u00a0L.\u00a0Incidence \u00a0of\u00a0clinical\u00a0lipodystrophy \u00a0in\u00a0HIV\u2010infected\u00a0\npatients\u00a0treated\u00a0during\u00a0primary\u00a0infection. \u00a0AIDS\u00a02001;\u00a015(2):282 \u20104\u00a0\n\u00a0 156.\u00a0\u00a0Miller\u00a0J,\u00a0Carr\u00a0A,\u00a0Smith\u00a0D,\u00a0Emery\u00a0S,\u00a0Law\u00a0MG,\u00a0Grey\u00a0P\u00a0et\u00a0al.\u00a0Lipodystrophy \u00a0following \u00a0antiretroviral \u00a0therapy\u00a0\nof\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02000;\u00a014(15):2406 \u20107\u00a0\n\u00a0 157.\u00a0\u00a0Narciso\u00a0P,\u00a0Tozzi\u00a0V,\u00a0D'Offizi\u00a0G,\u00a0De\u00a0Carli\u00a0G,\u00a0Orchi\u00a0N,\u00a0Galati\u00a0V\u00a0et\u00a0al.\u00a0Metabolic \u00a0and\u00a0morphologic \u00a0disorders \u00a0in\u00a0\npatients\u00a0treated\u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0since\u00a0primary\u00a0HIV\u00a0infection. \u00a0Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci\u00a0\n2001;\u00a0946:214\u201022\u00a0\n\u00a0 158.\u00a0\u00a0Streeck\u00a0H,\u00a0Jessen\u00a0H,\u00a0Alter\u00a0G,\u00a0Teigen\u00a0N,\u00a0Waring\u00a0MT,\u00a0Jessen\u00a0A\u00a0et\u00a0al.\u00a0Immunological \u00a0and\u00a0virological \u00a0impact\u00a0\nof\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0initiated\u00a0during\u00a0acute\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02006;\u00a0\n194(6):734 \u2010739\u00a0\n\u00a0 159.\u00a0\u00a0Markowitz \u00a0M,\u00a0Jin\u00a0X,\u00a0Hurley\u00a0A,\u00a0Simon\u00a0V,\u00a0Ramratnam \u00a0B,\u00a0Louie\u00a0M\u00a0et\u00a0al.\u00a0Discontinuation \u00a0of\u00a0antiretroviral \u00a0\ntherapy\u00a0commenced \u00a0early\u00a0during\u00a0the\u00a0course\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0infection, \u00a0with\u00a0or\u00a0\nwithout\u00a0adjunctive \u00a0vaccination. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0186(5):634 \u2010643\u00a0\n\u00a0 160.\u00a0\u00a0Desquilbet \u00a0L,\u00a0Goujard\u00a0C,\u00a0Rouzioux\u00a0C,\u00a0Sinet\u00a0M,\u00a0Deveau\u00a0C,\u00a0Chaix\u00a0ML\u00a0et\u00a0al.\u00a0Does\u00a0transient\u00a0HAART\u00a0during\u00a0\nprimary\u00a0HIV\u20101\u00a0infection\u00a0lower\u00a0the\u00a0virological \u00a0set\u2010point?\u00a0AIDS\u00a02004;\u00a018(18):2361 \u20102369\u00a0\n\u00a0 161.\u00a0\u00a0Hecht\u00a0FM,\u00a0Wang\u00a0L,\u00a0Collier\u00a0A,\u00a0Little\u00a0S,\u00a0Markowitz \u00a0M,\u00a0Margolick \u00a0J\u00a0et\u00a0al.\u00a0A\u00a0multicenter \u00a0observational \u00a0study\u00a0\nof\u00a0the\u00a0potential\u00a0benefits\u00a0of\u00a0initiating\u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0during\u00a0acute\u00a0HIV\u00a0infection. \u00a0J\u00a0\nInfect\u00a0Dis\u00a02006;\u00a0194(6):725 \u2010733\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 194\u00a0 162.\u00a0\u00a0Steingrover \u00a0R,\u00a0Bezemer\u00a0D,\u00a0Fernandez \u00a0Garcia\u00a0E,\u00a0Kroon\u00a0F,\u00a0de\u00a0Wolf\u00a0F,\u00a0Prins\u00a0M,\u00a0Lange\u00a0J,\u00a0Prins\u00a0J.\u00a0Early\u00a0\ntreatment \u00a0of\u00a0primary\u00a0HIV\u20101\u00a0infection\u00a0lowers\u00a0the\u00a0viral\u00a0set\u00a0point.\u00a014th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Los\u00a0Angeles,\u00a0February\u00a025\u201028\u00a02007.\u00a0Abstract\u00a0124LB.\u00a0\n\u00a0 163.\u00a0\u00a0Koegl\u00a0C,\u00a0Wolf\u00a0E,\u00a0Jessen\u00a0H,\u00a0Schewe\u00a0K,\u00a0Rausch\u00a0M,\u00a0Goelz\u00a0J,\u00a0Goetzenic \u00a0A,\u00a0Knechten \u00a0H,\u00a0Jaeger\u00a0H,\u00a0et\u00a0al.\u00a0No\u00a0\nBenefit\u00a0from\u00a0Early\u00a0Treatment \u00a0in\u00a0Primary\u00a0HIV\u2010Infection? \u00a014th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Los\u00a0Angeles,\u00a0February\u00a025\u201028\u00a02007.\u00a0Abstract\u00a0125LB.\u00a0\n\u00a0 164.\u00a0\u00a0Seng\u00a0R,\u00a0Goujard\u00a0C,\u00a0Desquilbet \u00a0L,\u00a0Sinet\u00a0M,\u00a0Deveau\u00a0C,\u00a0Boufassa\u00a0F,\u00a0et\u00a0al.\u00a0CD4\u00a0T\u2010cell\u00a0Count\u00a0Increase\u00a0during\u00a0\nHAART\u00a0Initiated\u00a0in\u00a0Primary\u00a0Infection\u00a0In\u00a0Transient \u00a0after\u2010Long\u00a0term\u00a0HAART\u00a0Interruption. \u00a014th\u00a0Conference \u00a0\non\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Los\u00a0Angeles,\u00a0February\u00a025\u201028\u00a02007.\u00a0Abstract\u00a0347.\u00a0\n\u00a0 165.\u00a0\u00a0Lampe\u00a0FC,\u00a0Porter\u00a0K,\u00a0Kaldor\u00a0J,\u00a0Law\u00a0M,\u00a0Kinloch\u2010de\u00a0LS,\u00a0Phillips\u00a0AN.\u00a0Effect\u00a0of\u00a0transient\u00a0antiretroviral \u00a0\ntreatment \u00a0during\u00a0acute\u00a0HIV\u00a0infection: \u00a0comparison \u00a0of\u00a0the\u00a0Quest\u00a0trial\u00a0results\u00a0with\u00a0CASCADE \u00a0natural\u00a0\nhistory\u00a0study.\u00a0Antivir\u00a0Ther\u00a02007;\u00a012(2):189 \u2010193\u00a0\n\u00a0 166.\u00a0\u00a0Stekler\u00a0J,\u00a0Holte\u00a0S,\u00a0Maenza\u00a0J,\u00a0Stevens\u00a0C,\u00a0Collier\u00a0A.\u00a0Clinical\u00a0outcomes \u00a0of\u00a0ART\u00a0initiated\u00a0during\u00a0primary\u00a0HIV\u00a0\ninfection. \u00a014th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Los\u00a0Angeles,\u00a0February\u00a025\u201028\u00a0\n2007.\u00a0Abstract\u00a0346.\u00a0\n\u00a0 167.\u00a0\u00a0Prazuck\u00a0T,\u00a0Lafeuillade \u00a0A,\u00a0Hocqueloux \u00a0L,\u00a0Viard\u00a0JP,\u00a0Avettand\u00a0V,\u00a0Rouzoux\u00a0C.\u00a0Can\u00a0HAART\u00a0Initiation\u00a0at\u00a0Early\u00a0\nAcute\u00a0HIV\u00a0Infection\u00a0Benefit\u00a0the\u00a0Immune\u2010virology\u00a0Outcome \u00a0Despite\u00a0Subsequent \u00a0Treatment \u00a0Cessation? \u00a0\nThe\u00a0ANRS\u00a0Reservoirs \u00a0Study\u00a0Group.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0\nBoston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0695.\u00a0\n\u00a0 168.\u00a0\u00a0Desquilbet \u00a0L,\u00a0Hoen\u00a0B,\u00a0Goujard\u00a0C,\u00a0Deveau\u00a0C,\u00a0Warszawski \u00a0J,\u00a0Meyer\u00a0L,\u00a0et\u00a0al.\u00a0Early\u00a0Short\u2010course\u00a0HAART\u00a0\nInitiated\u00a0at\u00a0the\u00a0Time\u00a0of\u00a0Primary\u00a0HIV\u00a0Infection\u00a0Provides\u00a0No\u00a0Sustained \u00a0Benefit\u00a0in\u00a0Terms\u00a0of\u00a0Time\u00a0to\u00a0CD4\u00a0\nDecline\u00a0below\u00a0350/mm3:\u00a0Results\u00a0of\u00a0a\u00a0Propensity \u00a0Analysis\u00a0within\u00a0the\u00a0ANRS\u00a0PRIMO\u00a0Cohort.\u00a015th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0694.\u00a0\n\u00a0 169.\u00a0\u00a0Fox\u00a0J,\u00a0Scriba\u00a0TJ,\u00a0Robinson \u00a0N,\u00a0Weber\u00a0JN,\u00a0Phillips\u00a0RE,\u00a0Fidler\u00a0S.\u00a0Human\u00a0immunodeficiency \u00a0virus\u00a0(HIV)\u2010\nspecific\u00a0T\u00a0helper\u00a0responses \u00a0fail\u00a0to\u00a0predict\u00a0CD4+\u00a0T\u00a0cell\u00a0decline\u00a0following \u00a0short\u2010course\u00a0treatment \u00a0at\u00a0\nprimary\u00a0HIV\u20101\u00a0infection. \u00a0Clin\u00a0Exp\u00a0Immunol\u00a02008;\u00a0152(3):532 \u2010537\u00a0\n\u00a0 170.\u00a0\u00a0Pantazis\u00a0N,\u00a0Touloumi \u00a0G,\u00a0Vanhems \u00a0P,\u00a0Gill\u00a0J,\u00a0Bucher\u00a0HC,\u00a0Porter\u00a0K.\u00a0The\u00a0effect\u00a0of\u00a0antiretroviral \u00a0treatment \u00a0of\u00a0\ndifferent\u00a0durations \u00a0in\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02008;\u00a022(18):2441 \u20102450\u00a0\n\u00a0 171.\u00a0\u00a0Kaufmann \u00a0DE,\u00a0Lichterfeld \u00a0M,\u00a0Altfeld\u00a0M,\u00a0Addo\u00a0MM,\u00a0Johnston\u00a0MN,\u00a0Lee\u00a0PK\u00a0et\u00a0al.\u00a0Limited\u00a0durability \u00a0of\u00a0viral\u00a0\ncontrol\u00a0following \u00a0treated\u00a0acute\u00a0HIV\u00a0infection. \u00a0PLoS\u00a0Med\u00a02004;\u00a01(2):e36\u00a0\n\u00a0 172.\u00a0\u00a0Miro\u00a0JM,\u00a0Plana\u00a0M,\u00a0Garcia\u00a0F,\u00a0Ortiz\u00a0GM,\u00a0Maleno\u00a0MJ,\u00a0Arnedo\u00a0M,\u00a0et\u00a0al.\u00a0Structured \u00a0Treatment \u00a0Interruptions \u00a0\nin\u00a0Patients\u00a0Receiving \u00a0HAART\u00a0within\u00a090\u00a0days\u00a0after\u00a0onset\u00a0of\u00a0Primary\u00a0HIV\u20101\u00a0Infection\u00a0Symptoms: \u00a0\nSpontaneous \u00a0Control\u00a0of\u00a0Viremia\u00a0in\u00a0only\u00a0one\u00a0Third\u00a0of\u00a0Cases\u00a0after\u00a0Four\u00a0Cycles\u00a0Off\u00a0Therapy.\u00a014th\u00a0\nInternational \u00a0AIDS\u00a0Conference, \u00a0Barcelona, \u00a0July\u00a07\u201012\u00a02002.\u00a0Abstract\u00a0ThOrB1437. \u00a0\n\u00a0 173.\u00a0\u00a0Tremblay \u00a0CL,\u00a0Hicks\u00a0JL,\u00a0Sutton\u00a0L,\u00a0Giguel\u00a0F,\u00a0Flynn\u00a0T,\u00a0Johnston\u00a0M\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0resistance \u00a0associated \u00a0\nwith\u00a0supervised \u00a0treatment \u00a0interruptions \u00a0in\u00a0treated\u00a0acute\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02003;\u00a017:1086\u20101089\u00a0\n\u00a0 174.\u00a0\u00a0Hoen\u00a0B,\u00a0Fournier\u00a0I,\u00a0Lacabaratz \u00a0C,\u00a0Burgard\u00a0M,\u00a0Charreau\u00a0I,\u00a0Chaix\u00a0ML\u00a0et\u00a0al.\u00a0Structured \u00a0treatment \u00a0\ninterruptions \u00a0in\u00a0primary\u00a0HIV\u20101\u00a0infection: \u00a0the\u00a0ANRS\u00a0100\u00a0PRIMSTOP \u00a0trial.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2005;\u00a040(3):307 \u2010316\u00a0\n\u00a0 175.\u00a0\u00a0Emilie\u00a0D,\u00a0Burgard\u00a0M,\u00a0Lascoux\u00a0Combre\u00a0C,\u00a0Lauglin\u00a0M,\u00a0Krzyiek\u00a0R,\u00a0Pignosn\u00a0C\u00a0et\u00a0al.\u00a0Early\u00a0control\u00a0of\u00a0HIV\u00a0\nreplication \u00a0in\u00a0primary\u00a0HIV\u2010Infection\u00a0treated\u00a0with\u00a0antiretroviral \u00a0drugs\u00a0and\u00a0pegylated \u00a0IFN\u00a0alpha:\u00a0results\u00a0\nfrom\u00a0the\u00a0Primoferon \u00a0A\u00a0(ANRS\u00a0086)\u00a0Study.\u00a0AIDS\u00a02001;\u00a015(1435):1437 \u00a0\n\u00a0 176.\u00a0\u00a0Dybul\u00a0M,\u00a0Hidalgo\u00a0B,\u00a0Chun\u00a0TW,\u00a0Belson\u00a0M,\u00a0Migueles\u00a0SA,\u00a0Justement \u00a0JS\u00a0et\u00a0al.\u00a0Pilot\u00a0study\u00a0of\u00a0the\u00a0effects\u00a0of\u00a0\nintermittent \u00a0interleukin \u20102\u00a0on\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0specific\u00a0responses \u00a0in\u00a0patients\u00a0treated\u00a0\nduring\u00a0recently\u00a0acquired\u00a0HIV\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0185:61\u201068\u00a0\n\u00a0 177.\u00a0\u00a0Miro\u00a0JM,\u00a0Plana\u00a0M,\u00a0Garcia\u00a0F,\u00a0Ortiz\u00a0GM,\u00a0Maleno\u00a0MJ,\u00a0Sued\u00a0O,\u00a0et\u00a0al.\u00a0Low\u2010dose\u00a0daily\u00a0IL\u20102\u00a0combined \u00a0with\u00a0\nstructured \u00a0treatment \u00a0interruptions \u00a0did\u00a0not\u00a0increase\u00a0the\u00a0HIV\u20101\u2010specific\u00a0T\u2010cell\u00a0responses \u00a0in\u00a0patients\u00a0\nreceiving\u00a0HAART\u00a0with\u00a090\u00a0days\u00a0after\u00a0onset\u00a0primary\u00a0HIV\u20101\u00a0infection\u00a0symptoms. \u00a015th\u00a0International \u00a0AIDS\u00a0\nConference, \u00a0Bangkok,\u00a0July\u00a011\u201016\u00a02004.\u00a0Abstract\u00a0WePeB5690. \u00a0\n\u00a0 178.\u00a0\u00a0Adalid\u2010Peralta\u00a0L,\u00a0Godot\u00a0V,\u00a0Colin\u00a0C,\u00a0Krzysiek\u00a0R,\u00a0Tran\u00a0T,\u00a0Poignard\u00a0P\u00a0et\u00a0al.\u00a0Stimulation \u00a0of\u00a0the\u00a0primary\u00a0anti\u2010\nHIV\u00a0antibody\u00a0response\u00a0by\u00a0IFN\u2010alpha\u00a0in\u00a0patients\u00a0with\u00a0acute\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0Leukoc\u00a0Biol\u00a02008;\u00a0\n83(4):1060 \u20101067\u00a0\n\u00a0 179.\u00a0\u00a0Ravot\u00a0E,\u00a0Tambussi \u00a0G,\u00a0Jessen\u00a0H,\u00a0Tinelli\u00a0C,\u00a0Lazzarin\u00a0A,\u00a0Lisziexicz\u00a0J\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0hidroxiurea \u00a0on\u00a0T\u00a0cell\u00a0\ncount\u00a0changes\u00a0during\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02000;\u00a014:619\u2010622\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 195\u00a0 180.\u00a0\u00a0Rizzardi\u00a0GP,\u00a0Harari\u00a0A,\u00a0Capiluppi \u00a0B,\u00a0Tambussi \u00a0G,\u00a0Ellfsen\u00a0K,\u00a0Ciuffreda\u00a0D\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0primary\u00a0HIV\u20101\u00a0\ninfection\u00a0with\u00a0ciclosporin \u00a0A\u00a0coupled\u00a0with\u00a0HAART.\u00a0J\u00a0Clin\u00a0Invest\u00a02002;\u00a0109:681\u2010688\u00a0\n\u00a0 181.\u00a0\u00a0Markowitz \u00a0M,\u00a0Vaida\u00a0F,\u00a0Little\u00a0S,\u00a0Hare\u00a0C,\u00a0Balfour\u00a0H,\u00a0Ferguson \u00a0E,\u00a0et\u00a0al.\u00a0An\u00a0Open\u2010label\u00a0Randomized \u00a0Trial\u00a0to\u00a0\nDetermine \u00a0the\u00a0Virologic\u00a0and\u00a0Immunologic \u00a0Effects\u00a0of\u00a04\u2010Weeks\u00a0of\u00a0Cyclosporine \u00a0A\u00a0Given\u00a0in\u00a0Combination \u00a0\nwith\u00a0ART\u00a0during\u00a0Acute\u00a0and\u00a0Early\u00a0Infection. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0698c.\u00a0\n\u00a0 182.\u00a0\u00a0Miro\u00a0JM,\u00a0Lopez\u2010Dieguez\u00a0M,\u00a0Plana\u00a0M,\u00a0Pumarola \u00a0T,\u00a0Brunet\u00a0M,\u00a0Tuset\u00a0M,\u00a0Mu\u00f1oz\u2010Fernandez \u00a0MA,\u00a0Gatell\u00a0JM,\u00a0\nGallanr\u00a0J.\u00a0Randomized \u00a0clinical\u00a0trial\u00a0with\u00a0immune\u2010based\u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0primary\u00a0HIV\u20101\u00a0infection. \u00a0\n16th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0\n531.\u00a0\n\u00a0 183.\u00a0\u00a0Shiver\u00a0JW,\u00a0Fu\u00a0TM,\u00a0Chen\u00a0L,\u00a0Casimiro\u00a0DR,\u00a0Davies\u00a0ME,\u00a0Evans\u00a0RK\u00a0et\u00a0al.\u00a0Replication \u2010incompetent \u00a0adenoviral \u00a0\nvaccine\u00a0vector\u00a0elicits\u00a0effective\u00a0anti\u2010immunodeficiency \u2010virus\u00a0immunity. \u00a0Nature\u00a02002;\u00a0415(6869):331 \u2010335\u00a0\n\u00a0 184.\u00a0\u00a0Lu\u00a0W,\u00a0Wu\u00a0X,\u00a0Lu\u00a0Y,\u00a0Guo\u00a0W,\u00a0Andrieu\u00a0JM.\u00a0Therapeutic \u00a0dendritic\u2010cell\u00a0vaccine\u00a0for\u00a0simian\u00a0AIDS.\u00a0Nat\u00a0Med\u00a0\n2003;\u00a09(1):27\u201032\u00a0\n\u00a0 185.\u00a0\u00a0Kinloch\u2010de\u00a0LS,\u00a0Hoen\u00a0B,\u00a0Smith\u00a0DE,\u00a0Autran\u00a0B,\u00a0Lampe\u00a0FC,\u00a0Phillips\u00a0AN\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0therapeutic \u00a0\nimmunization \u00a0on\u00a0HIV\u20101\u00a0viremia\u00a0after\u00a0discontinuation \u00a0of\u00a0antiretroviral \u00a0therapy\u00a0initiated\u00a0during\u00a0acute\u00a0\ninfection. \u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0192(4):607 \u2010617\u00a0\n\u00a0 186.\u00a0\u00a0Emery\u00a0S,\u00a0Workman \u00a0C,\u00a0Puls\u00a0RL,\u00a0Bloch\u00a0M,\u00a0Baker\u00a0D,\u00a0Bodsworth \u00a0N\u00a0et\u00a0al.\u00a0Randomized, \u00a0placebo\u2010controlled, \u00a0\nphase\u00a0I/IIa\u00a0evaluation \u00a0of\u00a0the\u00a0safety\u00a0and\u00a0immunogenicity \u00a0of\u00a0fowlpox\u00a0virus\u00a0expressing \u00a0HIV\u00a0gag\u2010pol\u00a0and\u00a0\ninterferon \u2010gamma\u00a0in\u00a0HIV\u20101\u00a0infected\u00a0subjects.\u00a0Hum\u00a0Vaccin\u00a02005;\u00a01(6):232\u2010238\u00a0\n\u00a0 187.\u00a0\u00a0Rosenberg \u00a0ES,\u00a0Graham\u00a0BS,\u00a0Chan\u00a0ES,\u00a0Bosch\u00a0RJ,\u00a0Stocker\u00a0V,\u00a0Maenza\u00a0J\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0immunogenicity \u00a0of\u00a0\ntherapeutic \u00a0DNA\u00a0vaccination \u00a0in\u00a0individuals \u00a0treated\u00a0with\u00a0antiretroviral \u00a0therapy\u00a0during\u00a0acute/early \u00a0HIV\u20101\u00a0\ninfection. \u00a0PLoS\u00a0One\u00a02010;\u00a05(5):e10555 \u00a0\n\u00a0 188.\u00a0\u00a0Paul\u00a0S,\u00a0Gilbert\u00a0HM,\u00a0Ziecheck\u00a0W,\u00a0Jacobs\u00a0J,\u00a0Sepkowitz \u00a0KA.\u00a0The\u00a0impact\u00a0of\u00a0potent\u00a0antiretroviral \u00a0therapy\u00a0on\u00a0\nthe\u00a0characteristics \u00a0of\u00a0hospitalized \u00a0patients\u00a0with\u00a0HIV\u00a0infection. \u00a0AIDS\u00a01999;\u00a013(3):415 \u20108\u00a0\n\u00a0 189.\u00a0\u00a0Lampe\u00a0FC,\u00a0Gatell\u00a0JM,\u00a0Staszewski \u00a0S,\u00a0Johnson\u00a0MA,\u00a0Pradier\u00a0C,\u00a0Gill\u00a0MJ\u00a0et\u00a0al.\u00a0Changes\u00a0over\u00a0time\u00a0in\u00a0risk\u00a0of\u00a0\ninitial\u00a0virological \u00a0failure\u00a0of\u00a0combination \u00a0antiretroviral \u00a0therapy:\u00a0a\u00a0multicohort \u00a0analysis,\u00a01996\u00a0to\u00a02002.\u00a0\nArch\u00a0Intern\u00a0Med\u00a02006;\u00a0166(5):521 \u2010528\u00a0\n\u00a0 190.\u00a0\u00a0Lohse\u00a0N,\u00a0Hansen\u00a0AB,\u00a0Pedersen \u00a0G,\u00a0Kronborg \u00a0G,\u00a0Gerstoft\u00a0J,\u00a0Sorensen \u00a0HT\u00a0et\u00a0al.\u00a0Survival\u00a0of\u00a0persons\u00a0with\u00a0\nand\u00a0without\u00a0HIV\u00a0infection\u00a0in\u00a0Denmark, \u00a01995\u20102005.\u00a0Ann\u00a0Intern\u00a0Med\u00a02007;\u00a0146(2):87 \u201095\u00a0\n\u00a0 191.\u00a0\u00a0Life\u00a0expectancy \u00a0of\u00a0individuals \u00a0on\u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0in\u00a0high\u2010income\u00a0countries: \u00a0a\u00a0\ncollaborative \u00a0analysis\u00a0of\u00a014\u00a0cohort\u00a0studies.\u00a0Lancet\u00a02008;\u00a0372(9635):293 \u2010299\u00a0\n\u00a0 192.\u00a0\u00a0Lewden\u00a0C,\u00a0Chene\u00a0G,\u00a0Morlat\u00a0P,\u00a0Raffi\u00a0F,\u00a0Dupon\u00a0M,\u00a0Dellamonica \u00a0P\u00a0et\u00a0al.\u00a0HIV\u2010infected\u00a0adults\u00a0with\u00a0a\u00a0CD4\u00a0cell\u00a0\ncount\u00a0greater\u00a0than\u00a0500\u00a0cells/mm3 \u00a0on\u00a0long\u2010term\u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0reach\u00a0same\u00a0\nmortality\u00a0rates\u00a0as\u00a0the\u00a0general\u00a0population. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a046(1):72\u201077\u00a0\n\u00a0 193.\u00a0\u00a0Marschner \u00a0IC,\u00a0Collier\u00a0AC,\u00a0Coombs\u00a0RW,\u00a0D'Aquila\u00a0RT,\u00a0DeGruttola \u00a0V,\u00a0Fischl\u00a0MA\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0changes\u00a0in\u00a0\nplasma\u00a0levels\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0RNA\u00a0to\u00a0assess\u00a0the\u00a0clinical\u00a0benefit\u00a0of\u00a0\nantiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a01998;\u00a0177(1):40 \u20107\u00a0\n\u00a0 194.\u00a0\u00a0Mellors\u00a0JW,\u00a0Munoz\u00a0A,\u00a0Giorgi\u00a0JV,\u00a0Margolick \u00a0JB,\u00a0Tassoni\u00a0CJ,\u00a0Gupta\u00a0P\u00a0et\u00a0al.\u00a0Plasma\u00a0viral\u00a0load\u00a0and\u00a0CD4+\u00a0\nlymphocytes \u00a0as\u00a0prognostic \u00a0markers\u00a0of\u00a0HIV\u20101\u00a0infection. \u00a0Ann\u00a0Intern\u00a0Med\u00a01997;\u00a0126(12):946 \u201054\u00a0\n\u00a0 195.\u00a0\u00a0The\u00a0SMART\u00a0Study\u00a0Group.\u00a0Major\u00a0Clinical\u00a0Outcomes \u00a0in\u00a0Antiretroviral \u00a0Therapy\u00a0(ART)\u2010Naive\u00a0Participants \u00a0\nand\u00a0in\u00a0Those\u00a0Not\u00a0Receiving \u00a0ART\u00a0at\u00a0Baseline\u00a0in\u00a0the\u00a0SMART\u00a0Study.\u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0197(8):1133 \u20101144\u00a0\n\u00a0 196.\u00a0\u00a0Kitahata\u00a0MM,\u00a0Gange\u00a0SJ,\u00a0Abraham\u00a0AG,\u00a0Merriman \u00a0B,\u00a0Saag\u00a0MS,\u00a0Justice\u00a0AC\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0early\u00a0versus\u00a0\ndeferred\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0HIV\u00a0on\u00a0survival.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02009;\u00a0360(18):1815 \u20101826\u00a0\n\u00a0 197.\u00a0\u00a0Severe\u00a0P,\u00a0Juste\u00a0MA,\u00a0Ambroise \u00a0A,\u00a0Eliacin\u00a0L,\u00a0Marchand \u00a0C,\u00a0Apollon\u00a0S\u00a0et\u00a0al.\u00a0Early\u00a0versus\u00a0standard\u00a0\nantiretroviral \u00a0therapy\u00a0for\u00a0HIV\u2010infected\u00a0adults\u00a0in\u00a0Haiti.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02010;\u00a0363(3):257 \u2010265\u00a0\n\u00a0 198.\u00a0\u00a0Baker\u00a0JV,\u00a0Peng\u00a0G,\u00a0Rapkin\u00a0J,\u00a0Abrams\u00a0DI,\u00a0Silverberg \u00a0MJ,\u00a0MacArthur \u00a0RD\u00a0et\u00a0al.\u00a0CD4+\u00a0count\u00a0and\u00a0risk\u00a0of\u00a0non\u2010\nAIDS\u00a0diseases\u00a0following\u00a0initial\u00a0treatment \u00a0for\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02008;\u00a022(7):841 \u2010848\u00a0\n\u00a0 199.\u00a0\u00a0Monforte \u00a0A,\u00a0Abrams\u00a0D,\u00a0Pradier\u00a0C,\u00a0Weber\u00a0R,\u00a0Reiss\u00a0P,\u00a0Bonnet\u00a0F\u00a0et\u00a0al.\u00a0HIV\u2010induced\u00a0immunodeficiency \u00a0and\u00a0\nmortality\u00a0from\u00a0AIDS\u2010defining\u00a0and\u00a0non\u2010AIDS\u2010defining\u00a0malignancies. \u00a0AIDS\u00a02008;\u00a022(16):2143 \u20102153\u00a0\n\u00a0 200.\u00a0\u00a0Marin\u00a0B,\u00a0Thiebaut\u00a0R,\u00a0Bucher\u00a0HC,\u00a0Rondeau\u00a0V,\u00a0Costagliola \u00a0D,\u00a0Dorrucci\u00a0M\u00a0et\u00a0al.\u00a0Non\u2010AIDS\u2010defining\u00a0deaths\u00a0\nand\u00a0immunodeficiency \u00a0in\u00a0the\u00a0era\u00a0of\u00a0combination \u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a02009;\u00a023(13):1743 \u20101753\u00a0\n\u00a0 201.\u00a0\u00a0El\u2010Sadr\u00a0WM,\u00a0Lundgren \u00a0JD,\u00a0Neaton\u00a0JD,\u00a0Gordin\u00a0F,\u00a0Abrams\u00a0D,\u00a0Arduino\u00a0RC\u00a0et\u00a0al.\u00a0CD4+\u00a0count\u2010guided\u00a0\ninterruption \u00a0of\u00a0antiretroviral \u00a0treatment. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02006;\u00a0355(22):2283 \u20102296\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 196\u00a0 202.\u00a0\u00a0Bhaskaran \u00a0K,\u00a0Hamouda \u00a0O,\u00a0Sannes\u00a0M,\u00a0Boufassa\u00a0F,\u00a0Johnson\u00a0AM,\u00a0Lambert\u00a0PC\u00a0et\u00a0al.\u00a0Changes\u00a0in\u00a0the\u00a0risk\u00a0of\u00a0\ndeath\u00a0after\u00a0HIV\u00a0seroconversion \u00a0compared \u00a0with\u00a0mortality\u00a0in\u00a0the\u00a0general\u00a0population. \u00a0JAMA\u00a02008;\u00a0\n300(1):51 \u201059\u00a0\n\u00a0 203.\u00a0\u00a0May\u00a0M,\u00a0Sterne\u00a0JA,\u00a0Sabin\u00a0C,\u00a0Costagliola \u00a0D,\u00a0Justice\u00a0AC,\u00a0Thiebaut\u00a0R\u00a0et\u00a0al.\u00a0Prognosis \u00a0of\u00a0HIV\u20101\u2010infected\u00a0\npatients\u00a0up\u00a0to\u00a05\u00a0years\u00a0after\u00a0initiation\u00a0of\u00a0HAART:\u00a0collaborative \u00a0analysis\u00a0of\u00a0prospective \u00a0studies.\u00a0AIDS\u00a02007;\u00a0\n21(9):1185 \u20101197\u00a0\n\u00a0 204.\u00a0\u00a0Bra\u00f1as\u00a0F,\u00a0Berenguer \u00a0J,\u00a0Sanchez\u2010Conde\u00a0M,\u00a0Lopez\u2010Bernaldo\u00a0de\u00a0Quiros\u00a0JC,\u00a0Miralles\u00a0P,\u00a0Cosin\u00a0J\u00a0et\u00a0al.\u00a0The\u00a0\neldest\u00a0of\u00a0older\u00a0adults\u00a0living\u00a0with\u00a0HIV:\u00a0response\u00a0and\u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0\nAm\u00a0J\u00a0Med\u00a02008;\u00a0121(9):820 \u2010824\u00a0\n\u00a0 205.\u00a0\u00a0Moore\u00a0DM,\u00a0Hogg\u00a0RS,\u00a0Yip\u00a0B,\u00a0Craib\u00a0K,\u00a0Wood\u00a0E,\u00a0Montaner \u00a0JS.\u00a0CD4\u00a0percentage \u00a0is\u00a0an\u00a0independent \u00a0predictor\u00a0\nof\u00a0survival\u00a0in\u00a0patients\u00a0starting\u00a0antiretroviral \u00a0therapy\u00a0with\u00a0absolute\u00a0CD4\u00a0cell\u00a0counts\u00a0between\u00a0200\u00a0and\u00a0\n350\u00a0cells/microL. \u00a0HIV\u00a0Med\u00a02006;\u00a07(6):383\u2010388\u00a0\n\u00a0 206.\u00a0\u00a0Gras\u00a0L,\u00a0Kesselring \u00a0AM,\u00a0Griffin\u00a0JT,\u00a0van\u00a0Sighem\u00a0AI,\u00a0Fraser\u00a0C,\u00a0Ghani\u00a0AC\u00a0et\u00a0al.\u00a0CD4\u00a0cell\u00a0counts\u00a0of\u00a0800\u00a0\ncells/mm3 \u00a0or\u00a0greater\u00a0after\u00a07\u00a0years\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0are\u00a0feasible\u00a0in\u00a0most\u00a0patients\u00a0\nstarting\u00a0with\u00a0350\u00a0cells/mm3 \u00a0or\u00a0greater.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045(2):183 \u2010192\u00a0\n\u00a0 207.\u00a0\u00a0Mocroft\u00a0A,\u00a0Phillips\u00a0AN,\u00a0Gatell\u00a0J,\u00a0Ledergerber \u00a0B,\u00a0Fisher\u00a0M,\u00a0Clumeck\u00a0N\u00a0et\u00a0al.\u00a0Normalisation \u00a0of\u00a0CD4\u00a0counts\u00a0\nin\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0infection\u00a0and\u00a0maximum \u00a0virological \u00a0suppression \u00a0who\u00a0are\u00a0taking\u00a0combination \u00a0\nantiretroviral \u00a0therapy:\u00a0an\u00a0observational \u00a0cohort\u00a0study.\u00a0Lancet\u00a02007;\u00a0370(9585):407 \u2010413\u00a0\n\u00a0 208.\u00a0\u00a0Lichtenstein \u00a0KA,\u00a0Armon\u00a0C,\u00a0Buchacz\u00a0K,\u00a0Chmiel\u00a0JS,\u00a0Moorman \u00a0AC,\u00a0Wood\u00a0KC\u00a0et\u00a0al.\u00a0Initiation\u00a0of\u00a0antiretroviral \u00a0\ntherapy\u00a0at\u00a0CD4\u00a0cell\u00a0counts\u00a0>/=350\u00a0cells/mm3 \u00a0does\u00a0not\u00a0increase\u00a0incidence \u00a0or\u00a0risk\u00a0of\u00a0peripheral \u00a0\nneuropathy, \u00a0anemia,\u00a0or\u00a0renal\u00a0insufficiency. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(1):27\u201035\u00a0\n\u00a0 209.\u00a0\u00a0Attia\u00a0S,\u00a0Egger\u00a0M,\u00a0Muller\u00a0M,\u00a0Zwahlen\u00a0M,\u00a0Low\u00a0N.\u00a0Sexual\u00a0transmission \u00a0of\u00a0HIV\u00a0according \u00a0to\u00a0viral\u00a0load\u00a0and\u00a0\nantiretroviral \u00a0therapy:\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0AIDS\u00a02009;\u00a023(11):1397 \u20101404\u00a0\n\u00a0 210.\u00a0\u00a0Bartlett\u00a0JA,\u00a0Fath\u00a0MJ,\u00a0DeMasi\u00a0R,\u00a0Hermes\u00a0A,\u00a0Quinn\u00a0J,\u00a0Mondou\u00a0E\u00a0et\u00a0al.\u00a0An\u00a0updated\u00a0systematic \u00a0overview\u00a0of\u00a0\ntriple\u00a0combination \u00a0therapy\u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u2010infected\u00a0adults.\u00a0AIDS\u00a02006;\u00a020(16):2051 \u20102064\u00a0\n\u00a0 211.\u00a0\u00a0Gatell\u00a0JM,\u00a0Clotet\u00a0B,\u00a0Mallolas\u00a0J,\u00a0Podzamczer \u00a0D,\u00a0Mir\u00f3\u00a0JM.\u00a0Gu\u00eda\u00a0Practica\u00a0del\u00a0SIDA.\u00a0Cl\u00ednica,\u00a0diagnostico \u00a0y\u00a0\ntratamiento. \u00a0Barcelona: \u00a0Antares;\u00a02010.\u00a0\n\u00a0 212.\u00a0\u00a0Coffey\u00a0S.\u00a0HIV\u00a0InSite\u00a0Knowledge \u00a0Base.\u00a0Antiretroviral \u00a0drug\u00a0profiles.\u00a0Disponible \u00a0en:\u00a0\nhttp://hivinsite.ucs f.edu/InSite?page=ar \u2010drugs\u00a0(Acceso\u00a014.12.2010). \u00a0\n\u00a0 213.\u00a0\u00a0Gallant\u00a0JE,\u00a0Staszewski \u00a0S,\u00a0Pozniak\u00a0AL,\u00a0DeJesus\u00a0E,\u00a0Suleiman\u00a0JM,\u00a0Miller\u00a0MD\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\ntenofovir\u00a0DF\u00a0vs\u00a0stavudine \u00a0in\u00a0combination \u00a0therapy\u00a0in\u00a0antiretroviral \u2010naive\u00a0patients:\u00a0a\u00a03\u2010year\u00a0randomized \u00a0\ntrial.\u00a0JAMA\u00a02004;\u00a0292(2):191 \u2010201\u00a0\n\u00a0 214.\u00a0\u00a0Gallant\u00a0JE,\u00a0DeJesus\u00a0E,\u00a0Arribas\u00a0JR,\u00a0Pozniak\u00a0AL,\u00a0Gazzard\u00a0B,\u00a0Campo\u00a0RE\u00a0et\u00a0al.\u00a0Tenofovir \u00a0DF,\u00a0emtricitabine, \u00a0\nand\u00a0efavirenz\u00a0vs.\u00a0zidovudine, \u00a0lamivudine, \u00a0and\u00a0efavirenz\u00a0for\u00a0HIV.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02006;\u00a0354(3):251 \u2010260\u00a0\n\u00a0 215.\u00a0\u00a0Margot\u00a0NA,\u00a0Enejosa\u00a0J,\u00a0Cheng\u00a0AK,\u00a0Miller\u00a0MD,\u00a0McColl\u00a0DJ.\u00a0Development \u00a0of\u00a0HIV\u20101\u00a0drug\u00a0resistance \u00a0through\u00a0\n144\u00a0weeks\u00a0in\u00a0antiretroviral \u2010naive\u00a0subjects\u00a0on\u00a0emtricitabine, \u00a0tenofovir\u00a0disoproxil \u00a0fumarate, \u00a0and\u00a0\nefavirenz\u00a0compared \u00a0with\u00a0lamivudine/zidovudine \u00a0and\u00a0efavirenz\u00a0in\u00a0study\u00a0GS\u201001\u2010934.\u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr\u00a02009;\u00a052(2):209 \u2010221\u00a0\n\u00a0 216.\u00a0\u00a0Arribas\u00a0JR,\u00a0Pozniak\u00a0AL,\u00a0Gallant\u00a0JE,\u00a0DeJesus\u00a0E,\u00a0Gazzard\u00a0B,\u00a0Campo\u00a0RE\u00a0et\u00a0al.\u00a0Tenofovir \u00a0disoproxil \u00a0fumarate, \u00a0\nemtricitabine, \u00a0and\u00a0efavirenz\u00a0compared \u00a0with\u00a0zidovudine/lamivudine \u00a0and\u00a0efavirenz\u00a0in\u00a0treatment \u2010naive\u00a0\npatients:\u00a0144\u2010week\u00a0analysis.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(1):74\u201078\u00a0\n\u00a0 217.\u00a0\u00a0DeJesus\u00a0E,\u00a0Herrera\u00a0G,\u00a0Teofilo\u00a0E,\u00a0Gerstoft\u00a0J,\u00a0Buendia\u00a0CB,\u00a0Brand\u00a0JD\u00a0et\u00a0al.\u00a0Abacavir\u00a0versus\u00a0zidovudine \u00a0\ncombined \u00a0with\u00a0lamivudine \u00a0and\u00a0efavirenz, \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0antiretroviral \u2010naive\u00a0HIV\u2010infected\u00a0adults.\u00a0\nClin\u00a0Infect\u00a0Dis\u00a02004;\u00a039(7):1038 \u20101046\u00a0\n\u00a0 218.\u00a0\u00a0Moyle\u00a0GJ,\u00a0DeJesus\u00a0E,\u00a0Cahn\u00a0P,\u00a0Castillo\u00a0SA,\u00a0Zhao\u00a0H,\u00a0Gordon\u00a0DN\u00a0et\u00a0al.\u00a0Abacavir\u00a0once\u00a0or\u00a0twice\u00a0daily\u00a0\ncombined \u00a0with\u00a0once\u2010daily\u00a0lamivudine \u00a0and\u00a0efavirenz\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0antiretroviral \u2010naive\u00a0HIV\u2010\ninfected\u00a0adults:\u00a0results\u00a0of\u00a0the\u00a0Ziagen\u00a0Once\u00a0Daily\u00a0in\u00a0Antiretroviral \u00a0Combination \u00a0Study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr\u00a02005;\u00a038(4):417 \u2010425\u00a0\n\u00a0 219.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Ferrer\u00a0E,\u00a0Sanchez\u00a0P,\u00a0Gatell\u00a0JM,\u00a0Crespo\u00a0M,\u00a0Fisac\u00a0C\u00a0et\u00a0al.\u00a0Less\u00a0lipoatrophy \u00a0and\u00a0better\u00a0lipid\u00a0\nprofile\u00a0with\u00a0abacavir\u00a0as\u00a0compared \u00a0to\u00a0stavudine: \u00a096\u2010week\u00a0results\u00a0of\u00a0a\u00a0randomized \u00a0study.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02007;\u00a044(2):139 \u2010147\u00a0\n\u00a0 220.\u00a0\u00a0Saag\u00a0MS,\u00a0Cahn\u00a0P,\u00a0Raffi\u00a0F,\u00a0Wolff\u00a0M,\u00a0Pearce\u00a0D,\u00a0Molina\u00a0JM\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0emtricitabine \u00a0vs\u00a0\nstavudine \u00a0in\u00a0combination \u00a0therapy\u00a0in\u00a0antiretroviral \u2010naive\u00a0patients:\u00a0a\u00a0randomized \u00a0trial.\u00a0JAMA\u00a02004;\u00a0\n292(2):180 \u2010189\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 197\u00a0 221.\u00a0\u00a0Berenguer \u00a0J,\u00a0Gonzalez\u00a0J,\u00a0Ribera\u00a0E,\u00a0Domingo\u00a0P,\u00a0Santos\u00a0J,\u00a0Miralles\u00a0P\u00a0et\u00a0al.\u00a0Didanosine, \u00a0lamivudine, \u00a0and\u00a0\nefavirenz\u00a0versus\u00a0zidovudine, \u00a0lamivudine, \u00a0and\u00a0efavirenz\u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u00a0type\u00a01\u00a0infection: \u00a0\nfinal\u00a0analysis\u00a0(48\u00a0weeks)\u00a0of\u00a0a\u00a0prospective, \u00a0randomized, \u00a0noninferiority \u00a0clinical\u00a0trial,\u00a0GESIDA\u00a03903.\u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02008;\u00a047(8):1083 \u20101092\u00a0\n\u00a0 222.\u00a0\u00a0Robbins\u00a0GK,\u00a0De\u00a0Gruttola\u00a0V,\u00a0Shafer\u00a0RW,\u00a0Smeaton\u00a0LM,\u00a0Snyder\u00a0SW,\u00a0Pettinelli\u00a0C\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0\nsecuential \u00a0three\u2010drug\u00a0regimens \u00a0as\u00a0inicial\u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infecti\u00f3n. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0349:2293 \u20102303\u00a0\n\u00a0 223.\u00a0\u00a0Shafer\u00a0RW,\u00a0Smeaton\u00a0MS,\u00a0Robbins\u00a0GK,\u00a0De\u00a0Gruttola\u00a0V,\u00a0Snyder\u00a0SW,\u00a0D'\u00a0Aquila\u00a0RT\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0four\u2010\ndrug\u00a0regimens \u00a0and\u00a0pairs\u00a0of\u00a0sequential \u00a0three\u2010drugs\u00a0regimens \u00a0as\u00a0inicial\u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infection. \u00a0N\u00a0Engl\u00a0\nJ\u00a0Med\u00a02003;\u00a0349:2304 \u20102315\u00a0\n\u00a0 224.\u00a0\u00a0Campbell \u00a0T,\u00a0Smeaton\u00a0L,\u00a0De\u00a0Gruttola\u00a0V,\u00a0(for\u00a0ACTG\u00a0A5175\u00a0study\u00a0group).\u00a0PEARLS\u00a0(ACTG\u00a0A5175):\u00a0a\u00a0\nmultinational \u00a0study\u00a0of\u00a0didanosine \u2010EC,\u00a0emtricitabine \u00a0and\u00a0atazanavir \u00a0vs.\u00a0co\u2010formulated \u00a0\nzidovudine/lamivudine \u00a0and\u00a0efavirenz\u00a0for\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection. \u00a017th\u00a0International \u00a0AIDS\u00a0\nConference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0THAB0404. \u00a0\n\u00a0 225.\u00a0\u00a0Smith\u00a0KY,\u00a0Patel\u00a0P,\u00a0Fine\u00a0D,\u00a0Bellos\u00a0N,\u00a0Sloan\u00a0L,\u00a0Lackey\u00a0P\u00a0et\u00a0al.\u00a0Randomized, \u00a0double\u2010blind,\u00a0placebo\u2010matched, \u00a0\nmulticenter \u00a0trial\u00a0of\u00a0abacavir/lamivudine \u00a0or\u00a0tenofovir/emtricitabine \u00a0with\u00a0lopinavir/ritonavir \u00a0for\u00a0initial\u00a0\nHIV\u00a0treatment. \u00a0AIDS\u00a02009;\u00a023(12):1547 \u20101556\u00a0\n\u00a0 226.\u00a0\u00a0Sax\u00a0PE,\u00a0Tierney\u00a0C,\u00a0Collier\u00a0AC,\u00a0Fischl\u00a0MA,\u00a0Mollan\u00a0K,\u00a0Peeples\u00a0L\u00a0et\u00a0al.\u00a0Abacavir\u2010lamivudine \u00a0versus\u00a0tenofovir\u2010\nemtricitabine \u00a0for\u00a0initial\u00a0HIV\u20101\u00a0therapy.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02009;\u00a0361(23):2230 \u20102240\u00a0\n\u00a0 227.\u00a0\u00a0Daar\u00a0E,\u00a0Tiemey\u00a0C,\u00a0Fischl\u00a0MA,\u00a0Collier\u00a0A,\u00a0Mollan\u00a0K,\u00a0Budhathoki \u00a0C,\u00a0et\u00a0al.\u00a0ACTG\u00a05202:\u00a0Final\u00a0results\u00a0of\u00a0\nABC/3TC\u00a0or\u00a0TDF/FTC\u00a0with\u00a0either\u00a0EFV\u00a0or\u00a0ATV/r\u00a0in\u00a0treatment \u2010naive\u00a0HIV\u2010infected\u00a0patients.\u00a017th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0\nAbstract\u00a059LB.\u00a0\n\u00a0 228.\u00a0\u00a0Hill\u00a0A,\u00a0Sawyer\u00a0W.\u00a0Effects\u00a0of\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0backbone \u00a0on\u00a0the\u00a0efficacy\u00a0of\u00a0first\u2010\nline\u00a0boosted\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0based\u00a0on\u00a0protease\u00a0inhibitors: \u00a0meta\u2010regression \u00a0analysis\u00a0\nof\u00a012\u00a0clinical\u00a0trials\u00a0in\u00a05168\u00a0patients.\u00a0HIV\u00a0Med\u00a02009;\u00a010(9):527 \u2010535\u00a0\n\u00a0 229.\u00a0\u00a0Post\u00a0FA,\u00a0Moyle\u00a0GJ,\u00a0Stellbrink \u00a0HJ,\u00a0Domingo\u00a0P,\u00a0Podzamczer \u00a0D,\u00a0Fisher\u00a0M\u00a0et\u00a0al.\u00a0Randomized \u00a0comparison \u00a0of\u00a0\nrenal\u00a0effects,\u00a0efficacy,\u00a0and\u00a0safety\u00a0with\u00a0once\u2010daily\u00a0abacavir/lamivudine \u00a0versus\u00a0tenofovir/emtricitabine, \u00a0\nadministered \u00a0with\u00a0efavirenz, \u00a0in\u00a0antiretroviral \u2010naive,\u00a0HIV\u20101\u2010infected\u00a0adults:\u00a048\u2010week\u00a0results\u00a0from\u00a0the\u00a0\nASSERT\u00a0study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a055(1):49\u201057\u00a0\n\u00a0 230.\u00a0\u00a0Sabin\u00a0CA,\u00a0Worm\u00a0SW,\u00a0Weber\u00a0R,\u00a0Reiss\u00a0P,\u00a0El\u2010Sadr\u00a0W,\u00a0Dabis\u00a0F\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0\ninhibitors \u00a0and\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0enrolled\u00a0in\u00a0the\u00a0D:A:D\u00a0study:\u00a0a\u00a0multi\u2010\ncohort\u00a0collaboration. \u00a0Lancet\u00a02008;\u00a0371(9622):1417 \u20101426\u00a0\n\u00a0 231.\u00a0\u00a0The\u00a0SMART\u2010INSIGHT\u00a0and\u00a0the\u00a0D:A:D\u00a0Study\u00a0Groups.\u00a0Use\u00a0of\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0and\u00a0\nrisk\u00a0of\u00a0myocardial \u00a0infarction \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a02008;\u00a022(14):F17 \u2010F24\u00a0\n\u00a0 232.\u00a0\u00a0Brothers\u00a0CH,\u00a0Hernandez \u00a0JE,\u00a0Cutrell\u00a0AG,\u00a0Curtis\u00a0L,\u00a0it\u2010Khaled\u00a0M,\u00a0Bowlin\u00a0SJ\u00a0et\u00a0al.\u00a0Risk\u00a0of\u00a0myocardial \u00a0\ninfarction \u00a0and\u00a0abacavir\u00a0therapy:\u00a0no\u00a0increased \u00a0risk\u00a0across\u00a052\u00a0GlaxoSmithKline \u2010sponsored \u00a0clinical\u00a0trials\u00a0in\u00a0\nadult\u00a0subjects.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(1):20\u201028\u00a0\n\u00a0 233.\u00a0\u00a0Eron\u00a0J,\u00a0Jr.,\u00a0Yeni\u00a0P,\u00a0Gathe\u00a0J,\u00a0Jr.,\u00a0Estrada\u00a0V,\u00a0DeJesus\u00a0E,\u00a0Staszewski \u00a0S\u00a0et\u00a0al.\u00a0The\u00a0KLEAN\u00a0study\u00a0of\u00a0\nfosamprenavir \u2010ritonavir\u00a0versus\u00a0lopinavir\u2010ritonavir,\u00a0each\u00a0in\u00a0combination \u00a0with\u00a0abacavir\u2010lamivudine, \u00a0for\u00a0\ninitial\u00a0treatment \u00a0of\u00a0HIV\u00a0infection\u00a0over\u00a048\u00a0weeks:\u00a0a\u00a0randomised \u00a0non\u2010inferiority \u00a0trial.\u00a0Lancet\u00a02006;\u00a0\n368(9534):476 \u2010482\u00a0\n\u00a0 234.\u00a0\u00a0Hicks\u00a0CB,\u00a0DeJesus\u00a0E,\u00a0Sloan\u00a0LM,\u00a0Sension\u00a0MG,\u00a0Wohl\u00a0DA,\u00a0Liao\u00a0Q\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0once\u2010daily\u00a0\nfosamprenavir \u00a0boosted\u00a0with\u00a0either\u00a0100\u00a0or\u00a0200\u00a0mg\u00a0of\u00a0ritonavir,\u00a0in\u00a0combination \u00a0with\u00a0\nabacavir/lamivudine: \u00a096\u2010week\u00a0results\u00a0from\u00a0COL100758. \u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a02009;\u00a025(4):395 \u2010\n403\u00a0\n\u00a0 235.\u00a0\u00a0Elion\u00a0R,\u00a0DeJesus\u00a0E,\u00a0Sension\u00a0M,\u00a0Berger\u00a0D,\u00a0Towner\u00a0W,\u00a0Richmond \u00a0G\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0abacavir/lamivudine \u00a0\nand\u00a0ritonavir\u2010boosted\u00a0atazanavir \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection\u00a0in\u00a0antiretroviral \u2010naive\u00a0patients:\u00a0a\u00a0\n48\u2010week\u00a0pilot\u00a0study.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02008;\u00a09(3):152\u2010163\u00a0\n\u00a0 236.\u00a0\u00a0Leon\u00a0A,\u00a0Martinez\u00a0E,\u00a0Mallolas\u00a0J,\u00a0Laguno\u00a0M,\u00a0Blanco\u00a0JL,\u00a0Pumarola \u00a0T\u00a0et\u00a0al.\u00a0Early\u00a0virological \u00a0failure\u00a0in\u00a0\ntreatment \u2010naive\u00a0HIV\u2010infected\u00a0adults\u00a0receiving\u00a0didanosine \u00a0and\u00a0tenofovir\u00a0plus\u00a0efavirenz\u00a0or\u00a0nevirapine. \u00a0\nAIDS\u00a02005;\u00a019(2):213 \u2010215\u00a0\n\u00a0 237.\u00a0\u00a0Negredo\u00a0E,\u00a0Bonjoch\u00a0A,\u00a0Paredes\u00a0R,\u00a0Puig\u00a0J,\u00a0Clotet\u00a0B.\u00a0Compromised \u00a0immunologic \u00a0recovery\u00a0in\u00a0treatment \u2010\nexperienced \u00a0patients\u00a0with\u00a0HIV\u00a0infection\u00a0receiving\u00a0both\u00a0tenofovir\u00a0disoproxil \u00a0fumarate \u00a0and\u00a0didanosine \u00a0in\u00a0\nthe\u00a0TORO\u00a0studies.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(6):901 \u2010905\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 198\u00a0 238.\u00a0\u00a0Martinez\u00a0E,\u00a0Milinkovic \u00a0A,\u00a0de\u00a0Lazzari\u00a0E,\u00a0Ravasi\u00a0G,\u00a0Blanco\u00a0JL,\u00a0Larrousse \u00a0M\u00a0et\u00a0al.\u00a0Pancreatic \u00a0toxic\u00a0effects\u00a0\nassociated \u00a0with\u00a0the\u00a0co\u2010administration \u00a0of\u00a0didanosine \u00a0and\u00a0tenofovir\u00a0in\u00a0HIV\u2010infected\u00a0adults.\u00a0Lancet\u00a02004;\u00a0\n364:65\u201067\u00a0\n\u00a0 239.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Ferrer\u00a0E,\u00a0Gatell\u00a0JM,\u00a0Niubo\u00a0J,\u00a0Dalmau\u00a0D,\u00a0Leon\u00a0A\u00a0et\u00a0al.\u00a0Early\u00a0virological \u00a0failure\u00a0with\u00a0a\u00a0\ncombination \u00a0of\u00a0tenofovir, \u00a0didanosine \u00a0and\u00a0efavirenz. \u00a0Antivir\u00a0Ther\u00a02005;\u00a010(1):171 \u2010177\u00a0\n\u00a0 240.\u00a0\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Moreno\u00a0S,\u00a0Gutierrez \u00a0C,\u00a0Lopez\u00a0D,\u00a0Abraira\u00a0V,\u00a0Moreno\u00a0A\u00a0et\u00a0al.\u00a0High\u00a0virological \u00a0failure\u00a0rate\u00a0in\u00a0\nHIV\u00a0patients\u00a0after\u00a0switching \u00a0to\u00a0a\u00a0regimen\u00a0with\u00a0two\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0plus\u00a0\ntenofovir. \u00a0AIDS\u00a02005;\u00a019(7):695 \u2010698\u00a0\n\u00a0 241.\u00a0\u00a0Gulick\u00a0RM,\u00a0Ribaudo\u00a0HJ,\u00a0Shikuma\u00a0CM,\u00a0Lustgarten \u00a0S,\u00a0Squires\u00a0KE,\u00a0Meyer\u00a0III\u00a0WA\u00a0et\u00a0al.\u00a0Triple\u2010Nucleoside \u00a0\nRegimens \u00a0versus\u00a0Efavirenz\u2010Containing \u00a0Regimens \u00a0for\u00a0the\u00a0Initial\u00a0Treatment \u00a0of\u00a0HIV\u20101\u00a0Infection. \u00a0N\u00a0Engl\u00a0J\u00a0\nMed\u00a02004;\u00a0350:1850 \u20101861\u00a0\n\u00a0 242.\u00a0\u00a0Gulick\u00a0RM,\u00a0Ribaudo\u00a0HJ,\u00a0Shikuma\u00a0CM,\u00a0Lalama\u00a0C,\u00a0Schackman \u00a0BR,\u00a0Meyer\u00a0WA,\u00a0III\u00a0et\u00a0al.\u00a0Three\u2010\u00a0vs\u00a0four\u2010drug\u00a0\nantiretroviral \u00a0regimens \u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection: \u00a0a\u00a0randomized \u00a0controlled \u00a0trial.\u00a0JAMA\u00a0\n2006;\u00a0296(7):769 \u2010781\u00a0\n\u00a0 243.\u00a0\u00a0Staszewski \u00a0S,\u00a0Keiser\u00a0P,\u00a0Montaner \u00a0J,\u00a0Raffi\u00a0F,\u00a0Gathe\u00a0J,\u00a0Brotas\u00a0V\u00a0et\u00a0al.\u00a0Abacavir\u2010lamivudine \u2010zidovudine \u00a0vs\u00a0\nindinavir\u2010lamivudine \u2010zidovudine \u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u2010infected\u00a0adults:\u00a0A\u00a0randomized \u00a0equivalence \u00a0\ntrial.\u00a0JAMA\u00a02001;\u00a0285(9):1155 \u201063\u00a0\n\u00a0 244.\u00a0\u00a0Bartlett\u00a0JA,\u00a0Johnson\u00a0J,\u00a0Herrera\u00a0G,\u00a0Sosa\u00a0N,\u00a0Rodriguez \u00a0A,\u00a0Liao\u00a0Q\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0results\u00a0of\u00a0initial\u00a0therapy\u00a0\nwith\u00a0abacavir\u00a0and\u00a0Lamivudine \u00a0combined \u00a0with\u00a0Efavirenz, \u00a0Amprenavir/Ritonavir, \u00a0or\u00a0Stavudine. \u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02006;\u00a043(3):284 \u2010292\u00a0\n\u00a0 245.\u00a0\u00a0Gallant\u00a0JE,\u00a0Rodriguez \u00a0AE,\u00a0Weinberg \u00a0WG,\u00a0Young\u00a0B,\u00a0Berger\u00a0DS,\u00a0Lim\u00a0ML\u00a0et\u00a0al.\u00a0Early\u00a0virologic\u00a0nonresponse \u00a0\nto\u00a0tenofovir, \u00a0abacavir,\u00a0and\u00a0lamivudine \u00a0in\u00a0HIV\u2010infected\u00a0antiretroviral \u2010naive\u00a0subjects.\u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0\n192(11):1921 \u20101930\u00a0\n\u00a0 246.\u00a0\u00a0Gerstoft\u00a0J,\u00a0Kirk\u00a0O,\u00a0Obel\u00a0N,\u00a0Pedersen \u00a0C,\u00a0Mathiesen \u00a0L,\u00a0Nielsen\u00a0H.\u00a0Low\u00a0efficacy\u00a0and\u00a0high\u00a0frequency \u00a0of\u00a0\nadverse\u00a0events\u00a0in\u00a0a\u00a0randomized \u00a0trial\u00a0of\u00a0the\u00a0triple\u00a0NRTI\u00a0regimen\u00a0abacavir,\u00a0stavudine \u00a0and\u00a0didanosine. \u00a0\nAIDS\u00a02003;\u00a017:2045\u20102052\u00a0\n\u00a0 247.\u00a0\u00a0Ferrer\u00a0E,\u00a0Gatell\u00a0JM,\u00a0Sanchez\u00a0P,\u00a0Domingo\u00a0P,\u00a0Puig\u00a0T,\u00a0Niubo\u00a0J\u00a0et\u00a0al.\u00a0Zidovudine/lamivudine/abacavir \u00a0plus\u00a0\ntenofovir\u00a0in\u00a0HIV\u2010infected\u00a0naive\u00a0patients:\u00a0a\u00a096\u2010week\u00a0prospective \u00a0one\u2010arm\u00a0pilot\u00a0study.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0\nRetroviruses \u00a02008;\u00a024(7):931 \u2010934\u00a0\n\u00a0 248.\u00a0\u00a0Moyle\u00a0G,\u00a0Higgs\u00a0C,\u00a0Teague\u00a0A,\u00a0Mandalia \u00a0S,\u00a0Nelson\u00a0M,\u00a0Johnson\u00a0M\u00a0et\u00a0al.\u00a0An\u00a0open\u2010label,\u00a0randomized \u00a0\ncomparative \u00a0pilot\u00a0study\u00a0of\u00a0a\u00a0single\u2010class\u00a0quadruple \u00a0therapy\u00a0regimen\u00a0versus\u00a0a\u00a02\u2010class\u00a0triple\u00a0therapy\u00a0\nregimen\u00a0for\u00a0individuals \u00a0initiating\u00a0antiretroviral \u00a0therapy.\u00a0Antivir\u00a0Ther\u00a02006;\u00a011(1):73\u201078\u00a0\n\u00a0 249.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Ferrer\u00a0E,\u00a0Consiglio\u00a0E,\u00a0Gatell\u00a0JM,\u00a0Perez\u00a0P,\u00a0Perez\u00a0JL\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0clinical\u00a0trial\u00a0\ncomparing \u00a0nelfinavir \u00a0or\u00a0nevirapine \u00a0associated \u00a0to\u00a0zidovudine/lamivudine \u00a0in\u00a0HIV\u2010infected\u00a0naive\u00a0patients\u00a0\n(the\u00a0Combine\u00a0Study).\u00a0Antivir\u00a0Ther\u00a02002;\u00a07(2):81\u201090\u00a0\n\u00a0 250.\u00a0\u00a0Raffi\u00a0F,\u00a0Reliquet\u00a0V,\u00a0Podzamczer \u00a0D,\u00a0Pollard\u00a0RB.\u00a0Efficacy\u00a0of\u00a0nevirapine \u2010based\u00a0HAART\u00a0in\u00a0HIV\u20101\u2010infected,\u00a0\ntreatment \u2010naive\u00a0persons\u00a0with\u00a0high\u00a0and\u00a0low\u00a0baseline\u00a0viral\u00a0loads.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02001;\u00a02(4):317\u201022\u00a0\n\u00a0 251.\u00a0\u00a0Soriano\u00a0V,\u00a0K\u00f6ppe\u00a0S,\u00a0Mingrone \u00a0H,\u00a0Lutz\u00a0T,\u00a0Opravil\u00a0M,\u00a0Andrade\u2010Villanueva \u00a0J,\u00a0et\u00a0al.\u00a0Prospective \u00a0comparison \u00a0\nof\u00a0nevirapine \u00a0and\u00a0atazanavir/ritonavir \u00a0both\u00a0combined \u00a0with\u00a0tenofovir\u00a0DF/emtricitabine \u00a0in\u00a0treatment \u2010\nna\u00efve\u00a0HIV\u20101\u00a0infected\u00a0patients:\u00a0ARTEN\u00a0study\u00a0week\u00a048\u00a0results.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0\nTreatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0LBPEB07. \u00a0\n\u00a0 252.\u00a0\u00a0Lockman\u00a0S,\u00a0Hughes\u00a0MD,\u00a0McIntyre\u00a0J,\u00a0Zheng\u00a0Y,\u00a0Chipato\u00a0T,\u00a0Conradie\u00a0F\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0therapies \u00a0in\u00a0\nwomen\u00a0after\u00a0single\u2010dose\u00a0nevirapine \u00a0exposure. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02010;\u00a0363(16):1499 \u20101509\u00a0\n\u00a0 253.\u00a0\u00a0McIntyre\u00a0J,\u00a0Hughes\u00a0M,\u00a0Mellors\u00a0J,\u00a0Zheng\u00a0Y,\u00a0Hakim\u00a0J,\u00a0Asmelash \u00a0A,\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0ART\u00a0with\u00a0NVP+TDF/FTC \u00a0\nvs\u00a0LPV/r+TDF/FTC \u00a0among\u00a0antiretroviral \u00a0na\u00efve\u00a0womwn\u00a0in\u00a0Africa:\u00a0OCTANE\u00a0trial\u00a02/ACTG\u00a0A5208.\u00a017th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0\nAbstract\u00a0153LB.\u00a0\n\u00a0 254.\u00a0\u00a0Riddler\u00a0SA,\u00a0Haubrich\u00a0R,\u00a0DiRienzo\u00a0AG,\u00a0Peeples\u00a0L,\u00a0Powderly \u00a0WG,\u00a0Klingman \u00a0KL\u00a0et\u00a0al.\u00a0Class\u2010sparing\u00a0regimens \u00a0\nfor\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0358(20):2095 \u20102106\u00a0\n\u00a0 255.\u00a0\u00a0Staszewski \u00a0S,\u00a0Morales\u2010Ramirez\u00a0J,\u00a0Tashima\u00a0KT,\u00a0Rachlis\u00a0A,\u00a0Skiest\u00a0D,\u00a0Stanford\u00a0J\u00a0et\u00a0al.\u00a0Efavirenz\u00a0plus\u00a0\nzidovudine \u00a0and\u00a0lamivudine, \u00a0efavirenz\u00a0plus\u00a0indinavir, \u00a0and\u00a0indinavir\u00a0plus\u00a0zidovudine \u00a0and\u00a0lamivudine \u00a0in\u00a0the\u00a0\ntreatment \u00a0of\u00a0HIV\u20101\u00a0infection\u00a0in\u00a0adults.\u00a0Study\u00a0006\u00a0Team.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01999;\u00a0341(25):1865 \u201073\u00a0\n\u00a0 256.\u00a0\u00a0Montaner \u00a0JS,\u00a0Schutz\u00a0M,\u00a0Schwartz\u00a0R,\u00a0Jayaweera \u00a0DT,\u00a0Burnside\u00a0AF,\u00a0Walmsley \u00a0S\u00a0et\u00a0al.\u00a0Efficacy,\u00a0safety\u00a0and\u00a0\npharmacokinetics \u00a0of\u00a0once\u2010daily\u00a0saquinavir \u00a0soft\u2010gelatin\u00a0capsule/ritonavir \u00a0in\u00a0antiretroviral \u2010naive,\u00a0HIV\u2010\ninfected\u00a0patients.\u00a0MedGenMed \u00a02006;\u00a08(2):36\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 199\u00a0 257.\u00a0\u00a0Squires\u00a0K,\u00a0Lazzarin\u00a0A,\u00a0Gatell\u00a0JM,\u00a0Powderly \u00a0WG,\u00a0Pokrovskiy \u00a0V,\u00a0Delfraissy \u00a0JF\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0once\u2010\ndaily\u00a0atazanavir \u00a0with\u00a0efavirenz, \u00a0each\u00a0in\u00a0combination \u00a0with\u00a0fixed\u2010dose\u00a0zidovudine \u00a0and\u00a0lamivudine, \u00a0as\u00a0\ninitial\u00a0therapy\u00a0for\u00a0patients\u00a0infected\u00a0with\u00a0HIV.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02004;\u00a036(5):1011 \u20101019\u00a0\n\u00a0 258.\u00a0\u00a0Van\u00a0Leth\u00a0F,\u00a0Phanuphak \u00a0P,\u00a0Ruxrungtham \u00a0K,\u00a0Baraldi\u00a0E,\u00a0Miller\u00a0S,\u00a0Gazzard\u00a0B\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0first\u2010line\u00a0\nantiretroviral \u00a0therapy\u00a0with\u00a0regimens \u00a0including\u00a0nevirapine, \u00a0efavirenz, \u00a0or\u00a0both\u00a0drugs,\u00a0plus\u00a0stavudine \u00a0and\u00a0\nlamivudine: \u00a0a\u00a0randomised \u00a0open\u2010label\u00a0trial,\u00a0the\u00a02NN\u00a0Study.\u00a0Lancet\u00a02004;\u00a0363(9417):1253 \u20101263\u00a0\n\u00a0 259.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0JR,\u00a0Miro\u00a0JM,\u00a0Costa\u00a0MA,\u00a0Gonz\u00e1lez\u00a0J,\u00a0Rubio\u00a0R\u00a0et\u00a0al.\u00a0Clinical,\u00a0virologic,\u00a0and\u00a0immunologic \u00a0\nresponse\u00a0to\u00a0efavirenz\u00a0or\u00a0protease\u00a0inhibitor\u00a0based\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0a\u00a0cohort\u00a0of\u00a0\nantiretroviral \u2010naive\u00a0patients\u00a0with\u00a0advanced \u00a0HIV\u00a0infection\u00a0(EfaVIP\u00a02\u00a0Study).\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2004;\u00a035(4):343 \u2010350\u00a0\n\u00a0 260.\u00a0\u00a0Sierra\u2010Madero\u00a0J,\u00a0Villasis\u2010Keever\u00a0A,\u00a0Mendez\u00a0P,\u00a0Mosqueda \u2010Gomez\u00a0JL,\u00a0Torres\u2010Escobar\u00a0I,\u00a0Gutierrez \u2010\nEscolano\u00a0F\u00a0et\u00a0al.\u00a0Prospective, \u00a0randomized, \u00a0open\u00a0label\u00a0trial\u00a0of\u00a0Efavirenz\u00a0vs\u00a0Lopinavir/Ritonavir \u00a0in\u00a0HIV+\u00a0\ntreatment \u2010naive\u00a0subjects\u00a0with\u00a0CD4+<200 \u00a0cell/mm3 \u00a0in\u00a0Mexico.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a0\n53(5):582 \u2010588\u00a0\n\u00a0 261.\u00a0\u00a0Dybul\u00a0M,\u00a0Chun\u00a0TW,\u00a0Ward\u00a0DJ,\u00a0Hertogs\u00a0K,\u00a0Larder\u00a0B,\u00a0Fox\u00a0CH\u00a0et\u00a0al.\u00a0Evaluation \u00a0of\u00a0lymph\u00a0node\u00a0virus\u00a0burden\u00a0in\u00a0\nhuman\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0receiving\u00a0efavirenz\u2010based\u00a0protease\u00a0inhibitor\u2010\u2010sparing\u00a0\nhighly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02000;\u00a0181(4):1273 \u20109\u00a0\n\u00a0 262.\u00a0\u00a0Walmsley \u00a0S,\u00a0Bernstein \u00a0B,\u00a0King\u00a0M,\u00a0Arribas\u00a0J,\u00a0Beall\u00a0G,\u00a0Ruane\u00a0P\u00a0et\u00a0al.\u00a0Lopinavir\u2010ritonavir\u00a0versus\u00a0nelfinavir \u00a0\nfor\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02002;\u00a0346(26):2039 \u20102046\u00a0\n\u00a0 263.\u00a0\u00a0Gathe\u00a0J,\u00a0da\u00a0Silva\u00a0BA,\u00a0Cohen\u00a0DE,\u00a0Loutfy\u00a0MR,\u00a0Podzamczer \u00a0D,\u00a0Rubio\u00a0R\u00a0et\u00a0al.\u00a0A\u00a0once\u2010daily\u00a0lopinavir/ritonavir \u2010\nbased\u00a0regimen\u00a0is\u00a0noninferior \u00a0to\u00a0twice\u2010daily\u00a0dosing\u00a0and\u00a0results\u00a0in\u00a0similar\u00a0safety\u00a0and\u00a0tolerability \u00a0in\u00a0\nantiretroviral \u2010naive\u00a0subjects\u00a0through\u00a048\u00a0weeks.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a050(5):474 \u2010481\u00a0\n\u00a0 264.\u00a0\u00a0Rodriguez \u2010French\u00a0A,\u00a0Boghossian \u00a0J,\u00a0Gray\u00a0GE,\u00a0Nadler\u00a0JP,\u00a0Quinones \u00a0AR,\u00a0Sepulveda \u00a0GE\u00a0et\u00a0al.\u00a0The\u00a0NEAT\u00a0\nStudy:\u00a0A\u00a048\u2010week\u00a0open\u2010label\u00a0study\u00a0to\u00a0compare\u00a0the\u00a0antiviral\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0GW433908 \u00a0versus\u00a0\nnelfinavir \u00a0in\u00a0antiretroviral \u00a0therapy\u00a0na\u00efve\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02004;\u00a0\n35(1):22\u201032\u00a0\n\u00a0 265.\u00a0\u00a0Gathe\u00a0JC,\u00a0Ive\u00a0P,\u00a0Wood\u00a0R,\u00a0Schurmann \u00a0D,\u00a0Bellos\u00a0NC,\u00a0DeJesus\u00a0E\u00a0et\u00a0al.\u00a0SOLO:\u00a048\u2010week\u00a0efficacy\u00a0and\u00a0safety\u00a0\ncomparison \u00a0of\u00a0once\u2010daily\u00a0fosamprenavir \u00a0/ritonavir \u00a0versus\u00a0twice\u2010daily\u00a0nelfinavir \u00a0in\u00a0naive\u00a0HIV\u20101\u2010infected\u00a0\npatients.\u00a0AIDS\u00a02004;\u00a018(11):1529 \u20101537\u00a0\n\u00a0 266.\u00a0\u00a0Wohl\u00a0D,\u00a0Lancaster \u00a0T,\u00a0DeJesus\u00a0E,\u00a0Sloan\u00a0L,\u00a0Sension\u00a0M,\u00a0Liao\u00a0Q,\u00a0Hicks\u00a0C.\u00a0Determination \u00a0of\u00a0body\u00a0composition \u00a0\nchanges\u00a0by\u00a0total\u00a0body\u00a0DEXA\u00a0after\u00a048\u00a0weeks\u00a0of\u00a0treatment \u00a0with\u00a0once\u2010daily\u00a0fosamprenavir \u00a0(FPV)\u00a0boosted\u00a0\nwith\u00a0two\u00a0different\u00a0doses\u00a0of\u00a0ritonavir(r) \u00a0plus\u00a0abacavir\u00a0(ABC)/lamivudine(3TC): \u00a0COL100758. \u00a04th\u00a0IAS\u00a0\nConference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a0July\u00a022\u201025\u00a02007.\u00a0Abstract\u00a0\nTUPEB080. \u00a0\n\u00a0 267.\u00a0\u00a0Ruane\u00a0PJ,\u00a0Luber\u00a0AD,\u00a0Wire\u00a0MB,\u00a0Lou\u00a0Y,\u00a0Shelton\u00a0MJ,\u00a0Lancaster \u00a0CT\u00a0et\u00a0al.\u00a0Plasma\u00a0amprenavir \u00a0\npharmacokinetics \u00a0and\u00a0tolerability \u00a0following \u00a0administration \u00a0of\u00a01,400\u00a0milligrams \u00a0of\u00a0fosamprenavir \u00a0once\u00a0\ndaily\u00a0in\u00a0combination \u00a0with\u00a0either\u00a0100\u00a0or\u00a0200\u00a0milligrams \u00a0of\u00a0ritonavir\u00a0in\u00a0healthy\u00a0volunteers. \u00a0Antimicrob \u00a0\nAgents\u00a0Chemother \u00a02007;\u00a051(2):560 \u2010565\u00a0\n\u00a0 268.\u00a0\u00a0Ortiz\u00a0R,\u00a0DeJesus\u00a0E,\u00a0Khanlou\u00a0H,\u00a0Voronin\u00a0E,\u00a0van\u00a0LJ,\u00a0ndrade\u2010Villanueva \u00a0J\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0once\u2010\ndaily\u00a0darunavir/ritonavir \u00a0versus\u00a0lopinavir/ritonavir \u00a0in\u00a0treatment \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0at\u00a0week\u00a0\n48.\u00a0AIDS\u00a02008;\u00a022(12):1389 \u20101397\u00a0\n\u00a0 269.\u00a0\u00a0Mills\u00a0AM,\u00a0Nelson\u00a0M,\u00a0Jayaweera \u00a0D,\u00a0Ruxrungtham \u00a0K,\u00a0Cassetti\u00a0I,\u00a0Girard\u00a0PM\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0\ndarunavir/ritonavir \u00a0vs.\u00a0lopinavir/ritonavir \u00a0in\u00a0treatment \u2010naive,\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a096\u2010week\u00a0analysis.\u00a0\nAIDS\u00a02009;\u00a023(13):1679 \u20101688\u00a0\n\u00a0 270.\u00a0\u00a0Orkin\u00a0C,\u00a0DeJesus\u00a0E,\u00a0Khanlou\u00a0H,\u00a0Stoehr\u00a0A,\u00a0Supparatpinyo \u00a0K,\u00a0Van\u00a0de\u00a0Casteele\u00a0T,\u00a0et\u00a0al.\u00a0ARTEMIS: \u00a0192\u2010week\u00a0\nefficacy\u00a0and\u00a0safety\u00a0of\u00a0once\u2010daily\u00a0darunavir/ritonavir \u00a0vs\u00a0\u00a0lopinavir/r \u00a0in\u00a0treatment \u2010na\u00efve\u00a0HIV\u20101\u2010infected\u00a0\nadults.\u00a010th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a0November \u00a07\u201011\u00a02010.\u00a0\nAbstract\u00a0P3.\u00a0\n\u00a0 271.\u00a0\u00a0Walmsley \u00a0S,\u00a0Avihingsanon \u00a0A,\u00a0Slim\u00a0J,\u00a0Ward\u00a0DJ,\u00a0Ruxrungtham \u00a0K,\u00a0Brunetta\u00a0J\u00a0et\u00a0al.\u00a0Gemini:\u00a0a\u00a0noninferiority \u00a0\nstudy\u00a0of\u00a0saquinavir/ritonavir \u00a0versus\u00a0lopinavir/ritonavir \u00a0as\u00a0initial\u00a0HIV\u20101\u00a0therapy\u00a0in\u00a0adults.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02009;\u00a050(4):367 \u2010374\u00a0\n\u00a0 272.\u00a0\u00a0Malan\u00a0DR,\u00a0Krantz\u00a0E,\u00a0David\u00a0N,\u00a0Wirtz\u00a0V,\u00a0Hammond \u00a0J,\u00a0McGrath\u00a0D.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0atazanavir, \u00a0with\u00a0or\u00a0\nwithout\u00a0ritonavir,\u00a0as\u00a0part\u00a0of\u00a0once\u2010daily\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0regimens \u00a0in\u00a0antiretroviral \u2010\nnaive\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(2):161 \u2010167\u00a0\n\u00a0 273.\u00a0\u00a0Molina\u00a0JM,\u00a0Andrade\u2010Villanueva \u00a0J,\u00a0Echevarria \u00a0J,\u00a0Chetchotisakd \u00a0P,\u00a0Corral\u00a0J,\u00a0David\u00a0N\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0\natazanavir/ritonavir \u00a0versus\u00a0twice\u2010daily\u00a0lopinavir/ritonavir, \u00a0each\u00a0in\u00a0combination \u00a0with\u00a0tenofovir\u00a0and\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 200emtricitabine, \u00a0for\u00a0management \u00a0of\u00a0antiretroviral \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a048\u00a0week\u00a0efficacy\u00a0and\u00a0\nsafety\u00a0results\u00a0of\u00a0the\u00a0CASTLE\u00a0study.\u00a0Lancet\u00a02008;\u00a0372(9639):646 \u2010655\u00a0\n\u00a0 274.\u00a0\u00a0Molina\u00a0JM,\u00a0Andrade\u2010Villanueva \u00a0J,\u00a0Echevarria \u00a0J,\u00a0Chetchotisakd \u00a0P,\u00a0Corral\u00a0J,\u00a0David\u00a0N\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0\natazanavir/ritonavir \u00a0compared \u00a0with\u00a0twice\u2010daily\u00a0lopinavir/ritonavir, \u00a0each\u00a0in\u00a0combination \u00a0with\u00a0tenofovir\u00a0\nand\u00a0emtricitabine, \u00a0for\u00a0management \u00a0of\u00a0antiretroviral \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a096\u2010week\u00a0efficacy\u00a0\nand\u00a0safety\u00a0results\u00a0of\u00a0the\u00a0CASTLE\u00a0study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a053(3):323 \u2010332\u00a0\n\u00a0 275.\u00a0\u00a0Saag\u00a0M,\u00a0Ive\u00a0P,\u00a0Heera\u00a0J,\u00a0Tawadrous \u00a0M,\u00a0DeJesus\u00a0E,\u00a0Clumeck\u00a0N,\u00a0et\u00a0al.\u00a0A\u00a0multicenter, \u00a0randomized, \u00a0double\u2010\nblind,\u00a0comparative \u00a0trial\u00a0of\u00a0a\u00a0novel\u00a0CCR5\u00a0antagonist, \u00a0maraviroc \u00a0versus\u00a0efavirenz, \u00a0both\u00a0in\u00a0combination \u00a0\nwith\u00a0Combivir\u00a0(zidovudine \u00a0/\u00a0lamivudine), \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0antiretroviral \u00a0na\u00efve\u00a0patients\u00a0infected\u00a0with\u00a0\nR5\u00a0HIV\u20101:\u00a0week\u00a048\u00a0results\u00a0of\u00a0the\u00a0MERIT\u00a0study.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Sydney,\u00a0July\u00a022\u201025\u00a02007.\u00a0Abstract\u00a0WESS104. \u00a0\n\u00a0 276.\u00a0\u00a0Cooper\u00a0DA,\u00a0Heera\u00a0J,\u00a0Goodrich\u00a0J,\u00a0Tawadrous \u00a0M,\u00a0Saag\u00a0M,\u00a0DeJesus\u00a0E\u00a0et\u00a0al.\u00a0Maraviroc \u00a0versus\u00a0efavirenz, \u00a0\nboth\u00a0in\u00a0combination \u00a0with\u00a0zidovudine \u2010lamivudine, \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0antiretroviral \u2010naive\u00a0subjects\u00a0with\u00a0\nCCR5\u2010tropic\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02010;\u00a0201(6):803 \u2010813\u00a0\n\u00a0 277.\u00a0\u00a0Lennox\u00a0JL,\u00a0DeJesus\u00a0E,\u00a0Lazzarin\u00a0A,\u00a0Pollard\u00a0RB,\u00a0Madruga\u00a0JV,\u00a0Berger\u00a0DS\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0\nraltegravir \u2010based\u00a0versus\u00a0efavirenz\u2010based\u00a0combination \u00a0therapy\u00a0in\u00a0treatment \u2010naive\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0\ninfection: \u00a0a\u00a0multicentre, \u00a0double\u2010blind\u00a0randomised \u00a0controlled \u00a0trial.\u00a0Lancet\u00a02009;\u00a0374(9692):796 \u2010806\u00a0\n\u00a0 278.\u00a0\u00a0Reynes\u00a0J,\u00a0Lawal\u00a0A,\u00a0Pulido\u00a0F,\u00a0Soto\u2010Malave\u00a0R,\u00a0Gathe\u00a0J,\u00a0Tian\u00a0M,\u00a0et\u00a0al.\u00a0Combined \u00a0with\u00a0raltegravir \u00a0\ndemonstrated \u00a0similar\u00a0antiviral\u00a0efficacy\u00a0and\u00a0safety\u00a0as\u00a0LPV/r\u00a0combined \u00a0with\u00a0tenofovir\u00a0disoproxil \u00a0\nfumarate/emtricitabine \u00a0in\u00a0treatment \u2010na\u00efve\u00a0HIV\u20101\u2010infected\u00a0subjects:\u00a0PROGRESS \u00a048\u00a0week\u00a0results.\u00a018th\u00a0\nInternational \u00a0AIDS\u00a0Conference, \u00a0Vienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0MOAB0101. \u00a0\n\u00a0 279.\u00a0\u00a0Zolopa\u00a0A,\u00a0Andersen \u00a0J,\u00a0Powderly \u00a0W,\u00a0Sanchez\u00a0A,\u00a0Sanne\u00a0I,\u00a0Suckow\u00a0C\u00a0et\u00a0al.\u00a0Early\u00a0antiretroviral \u00a0therapy\u00a0\nreduces\u00a0AIDS\u00a0progression/death \u00a0in\u00a0individuals \u00a0with\u00a0acute\u00a0opportunistic \u00a0infections: \u00a0a\u00a0multicenter \u00a0\nrandomized \u00a0strategy\u00a0trial.\u00a0PLoS\u00a0One\u00a02009;\u00a04(5):e5575 \u00a0\n\u00a0 280.\u00a0\u00a0Abdool\u00a0Karim\u00a0SS,\u00a0Naidoo\u00a0K,\u00a0Grobler\u00a0A,\u00a0Padayatchi \u00a0N,\u00a0Baxter\u00a0C,\u00a0Gray\u00a0A\u00a0et\u00a0al.\u00a0Timing\u00a0of\u00a0initiation\u00a0of\u00a0\nantiretroviral \u00a0drugs\u00a0during\u00a0tuberculosis \u00a0therapy.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02010;\u00a0362(8):697 \u2010706\u00a0\n\u00a0 281.\u00a0\u00a0Blanc\u00a0X,\u00a0Sok\u00a0T,\u00a0Laureillard \u00a0D,\u00a0Borand\u00a0L,\u00a0Rekacewicz \u00a0C,\u00a0Nerrienet \u00a0E,\u00a0et\u00a0al.\u00a0Significant \u00a0enhancement \u00a0in\u00a0\nsurvival\u00a0with\u00a0early\u00a0(2\u00a0weeks)\u00a0vs.\u00a0late\u00a0(8\u00a0weeks)\u00a0initiation\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0treatment \u00a0in\u00a0\nseverely\u00a0immunosuppressed \u00a0HIV\u2010infected\u00a0adults\u00a0with\u00a0newly\u00a0diagnosed \u00a0tuberculosis. \u00a018th\u00a0International \u00a0\nAIDS\u00a0Conference, \u00a0Vienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0THLBB106. \u00a0\n\u00a0 282.\u00a0\u00a0Torok\u00a0ME,\u00a0Yen\u00a0NTB,\u00a0Chau\u00a0TTH,\u00a0et\u00a0al.\u00a0Randomised \u00a0controlled \u00a0trial\u00a0of\u00a0immediate \u00a0versus\u00a0deferred\u00a0\u00a0\nantiretroviral \u00a0therapy\u00a0in\u00a0HIV\u2010associated \u00a0tuberculous \u00a0meningitis. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0\nAntimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0H\u20101224.\u00a0\n\u00a0 283.\u00a0\u00a0Makadzange \u00a0AT,\u00a0Ndhlovu\u00a0CE,\u00a0Takarinda \u00a0K,\u00a0Reid\u00a0M,\u00a0Kurangwa \u00a0M,\u00a0Gona\u00a0P\u00a0et\u00a0al.\u00a0Early\u00a0versus\u00a0delayed\u00a0\ninitiation\u00a0of\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0concurrent \u00a0HIV\u00a0infection\u00a0and\u00a0cryptococcal \u00a0meningitis \u00a0in\u00a0sub\u2010\nsaharan\u00a0Africa.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02010;\u00a050(11):1532 \u20101538\u00a0\n\u00a0 284.\u00a0\u00a0Llibre\u00a0JM,\u00a0Schapiro\u00a0JM,\u00a0Clotet\u00a0B.\u00a0Clinical\u00a0implications \u00a0of\u00a0genotypic \u00a0resistance \u00a0to\u00a0the\u00a0newer\u00a0antiretroviral \u00a0\ndrugs\u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0virological \u00a0failure.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02010;\u00a050(6):872 \u2010881\u00a0\n\u00a0 285.\u00a0\u00a0Cozzi\u2010Lepri\u00a0A,\u00a0Phillips\u00a0AN,\u00a0Clotet\u00a0B,\u00a0Mocroft\u00a0A,\u00a0Ruiz\u00a0L,\u00a0Kirk\u00a0O\u00a0et\u00a0al.\u00a0Detection \u00a0of\u00a0HIV\u00a0drug\u00a0resistance \u00a0\nduring\u00a0antiretroviral \u00a0treatment \u00a0and\u00a0clinical\u00a0progression \u00a0in\u00a0a\u00a0large\u00a0European \u00a0cohort\u00a0study.\u00a0AIDS\u00a02008;\u00a0\n22(16):2187 \u20102198\u00a0\n\u00a0 286.\u00a0\u00a0Paterson\u00a0DL,\u00a0Swindells \u00a0S,\u00a0Mohr\u00a0J,\u00a0Brester\u00a0M,\u00a0Vergis\u00a0EN,\u00a0Squier\u00a0C\u00a0et\u00a0al.\u00a0Adherence \u00a0to\u00a0protease\u00a0inhibitor\u00a0\ntherapy\u00a0and\u00a0outcomes \u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection. \u00a0Ann\u00a0Intern\u00a0Med\u00a02000;\u00a0133(1):21 \u201030\u00a0\n\u00a0 287.\u00a0\u00a0Chesney\u00a0MA,\u00a0Ickovics\u00a0J,\u00a0Hecht\u00a0FM,\u00a0Sikipa\u00a0G,\u00a0Rabkin\u00a0J.\u00a0Adherence: \u00a0a\u00a0necessity\u00a0for\u00a0successful \u00a0HIV\u00a0\ncombination \u00a0therapy.\u00a0AIDS\u00a01999;\u00a013(Suppl\u00a0A):271\u20108\u00a0\n\u00a0 288.\u00a0\u00a0Haubrich\u00a0RH,\u00a0Little\u00a0SJ,\u00a0Currier\u00a0JS,\u00a0Forthal\u00a0DN,\u00a0Kemper\u00a0CA,\u00a0Beall\u00a0GN\u00a0et\u00a0al.\u00a0The\u00a0value\u00a0of\u00a0patient\u2010reported\u00a0\nadherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0predicting \u00a0virologic\u00a0and\u00a0immunologic \u00a0response. \u00a0California \u00a0\nCollaborative \u00a0Treatment \u00a0Group.\u00a0AIDS\u00a01999;\u00a013(9):1099 \u2010107\u00a0\n\u00a0 289.\u00a0\u00a0Shet\u00a0A,\u00a0Berry\u00a0L,\u00a0Mohri\u00a0H,\u00a0Mehandru \u00a0S,\u00a0Chung\u00a0C,\u00a0Kim\u00a0A\u00a0et\u00a0al.\u00a0Tracking\u00a0the\u00a0prevalence \u00a0of\u00a0transmitted \u00a0\nantiretroviral \u00a0drug\u2010resistant\u00a0HIV\u20101:\u00a0a\u00a0decade\u00a0of\u00a0experience. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a0\n41(4):439 \u2010446\u00a0\n\u00a0 290.\u00a0\u00a0Yerly\u00a0S,\u00a0von\u00a0W,\u00a0V,\u00a0Ledergerber \u00a0B,\u00a0Boni\u00a0J,\u00a0Schupbach \u00a0J,\u00a0Burgisser \u00a0P\u00a0et\u00a0al.\u00a0Transmission \u00a0of\u00a0HIV\u20101\u00a0drug\u00a0\nresistance \u00a0in\u00a0Switzerland: \u00a0a\u00a010\u2010year\u00a0molecular \u00a0epidemiology \u00a0survey.\u00a0AIDS\u00a02007;\u00a021(16):2223 \u20102229\u00a0\n\u00a0 291.\u00a0\u00a0Little\u00a0SJ,\u00a0Holte\u00a0S,\u00a0Routy\u00a0JP,\u00a0Daar\u00a0ES,\u00a0Markowitz \u00a0M,\u00a0Collier\u00a0AC\u00a0et\u00a0al.\u00a0Antiretroviral \u2010drug\u00a0resistance \u00a0among\u00a0\npatients\u00a0recently\u00a0infected\u00a0with\u00a0HIV.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02002;\u00a0347(6):385 \u201094\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 201\u00a0 292.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Rodriguez \u00a0C,\u00a0Garcia\u00a0F,\u00a0Eiros\u00a0JM,\u00a0Ruiz\u00a0L,\u00a0Caballero \u00a0E\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0X4\u00a0tropic\u00a0viruses\u00a0\nin\u00a0patients\u00a0recently\u00a0infected\u00a0with\u00a0HIV\u20101\u00a0and\u00a0lack\u00a0of\u00a0association \u00a0with\u00a0transmission \u00a0of\u00a0drug\u00a0resistance. \u00a0J\u00a0\nAntimicrob \u00a0Chemother \u00a02007;\u00a059(4):698 \u2010704\u00a0\n\u00a0 293.\u00a0\u00a0SPREAD\u00a0Programme. \u00a0Transmission \u00a0of\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0in\u00a0Europe\u00a0remains\u00a0limited\u00a0to\u00a0single\u00a0classes.\u00a0\nAIDS\u00a02008;\u00a022(5):625 \u2010635\u00a0\n\u00a0 294.\u00a0\u00a0Phillips\u00a0AN,\u00a0Miller\u00a0V,\u00a0Sabin\u00a0C,\u00a0Cozzi\u00a0Lepri\u00a0A,\u00a0Klauke\u00a0S,\u00a0Bickel\u00a0M\u00a0et\u00a0al.\u00a0Durability \u00a0of\u00a0HIV\u20101\u00a0viral\u00a0suppression \u00a0\nover\u00a03.3\u00a0years\u00a0with\u00a0multi\u2010drug\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0previously \u00a0drug\u2010naive\u00a0individuals. \u00a0AIDS\u00a02001;\u00a0\n15(18):2379 \u201084\u00a0\n\u00a0 295.\u00a0\u00a0Sungkanuparph \u00a0S,\u00a0Manosuthi \u00a0W,\u00a0Kiertiburanakul \u00a0S,\u00a0Piyavong\u00a0B,\u00a0Chumpathat \u00a0N,\u00a0Chantratita \u00a0W.\u00a0Options\u00a0\nfor\u00a0a\u00a0second\u2010line\u00a0antiretroviral \u00a0regimen\u00a0for\u00a0HIV\u00a0type\u00a01\u2010infected\u00a0patients\u00a0whose\u00a0initial\u00a0regimen\u00a0of\u00a0a\u00a0\nfixed\u2010dose\u00a0combination \u00a0of\u00a0stavudine, \u00a0lamivudine, \u00a0and\u00a0nevirapine \u00a0fails.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(3):447 \u2010\n452\u00a0\n\u00a0 296.\u00a0\u00a0Lockman\u00a0S,\u00a0Shapiro\u00a0RL,\u00a0Smeaton\u00a0LM,\u00a0Wester\u00a0C,\u00a0Thior\u00a0I,\u00a0Stevens\u00a0L\u00a0et\u00a0al.\u00a0Response \u00a0to\u00a0antiretroviral \u00a0\ntherapy\u00a0after\u00a0a\u00a0single,\u00a0peripartum \u00a0dose\u00a0of\u00a0nevirapine. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02007;\u00a0356(2):135 \u2010147\u00a0\n\u00a0 297.\u00a0\u00a0Gupta\u00a0RK,\u00a0Hill\u00a0A,\u00a0Sawyer\u00a0AW,\u00a0Cozzi\u2010Lepri\u00a0A,\u00a0von\u00a0W,\u00a0V,\u00a0Yerly\u00a0S\u00a0et\u00a0al.\u00a0Virological \u00a0monitoring \u00a0and\u00a0resistance \u00a0\nto\u00a0first\u2010line\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0adults\u00a0infected\u00a0with\u00a0HIV\u20101\u00a0treated\u00a0under\u00a0WHO\u00a0\nguidelines: \u00a0a\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0Lancet\u00a0Infect\u00a0Dis\u00a02009;\u00a09(7):409\u2010417\u00a0\n\u00a0 298.\u00a0\u00a0Brenner\u00a0BG,\u00a0Oliveira\u00a0M,\u00a0Doualla\u2010Bell\u00a0F,\u00a0Moisi\u00a0DD,\u00a0Ntemgwa \u00a0M,\u00a0Frankel\u00a0F\u00a0et\u00a0al.\u00a0HIV\u20101\u00a0subtype\u00a0C\u00a0viruses\u00a0\nrapidly\u00a0develop\u00a0K65R\u00a0resistance \u00a0to\u00a0tenofovir\u00a0in\u00a0cell\u00a0culture.\u00a0AIDS\u00a02006;\u00a020(9):F9\u201013\u00a0\n\u00a0 299.\u00a0\u00a0Dierynck\u00a0I,\u00a0De\u00a0Meyer\u00a0S,\u00a0Lathouwers \u00a0E,\u00a0Abeele\u00a0CV,\u00a0Van\u00a0de\u00a0Casteele\u00a0T,\u00a0DeMasi\u00a0R,\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0DRV/r\u00a0\nin\u00a0the\u00a0randomised, \u00a0controlled, \u00a0phase\u00a0III\u00a0Artemis\u00a0trial\u00a0in\u00a0treatment \u2010na\u00efve,\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0is\u00a0\nindependent \u00a0of\u00a0HIV\u20101\u00a0subtype.\u00a06th\u00a0European \u00a0HIV\u00a0Drug\u00a0Resistance \u00a0Workshop, \u00a0Budapest, \u00a0March\u00a026\u201028\u00a0\n2008.\u00a0Abstract\u00a057.\u00a0\n\u00a0 300.\u00a0\u00a0Bethel\u00a0R,\u00a0Hall\u00a0BD,\u00a0Baxter\u00a0J,\u00a0Schapiro\u00a0JM,\u00a0Boucher\u00a0C,\u00a0Scherer\u00a0J.\u00a0No\u00a0effect\u00a0of\u00a0subtype\u00a0on\u00a0susceptibility \u00a0and\u00a0\nvirologic\u00a0response\u00a0to\u00a0TPV/r\u00a0for\u00a0treatment \u00a0experienced \u00a0patients.\u00a0Antivir\u00a0Ther\u00a02010;\u00a013\u00a0(suppl\u00a03):A\u00a0121\u00a0\n(Abstract\u00a0111)\u00a0\n\u00a0 301.\u00a0\u00a0Smith\u00a0RA,\u00a0Anderson \u00a0DJ,\u00a0Pyrak\u00a0CL,\u00a0Preston\u00a0BD,\u00a0Gottlieb\u00a0GS.\u00a0Antiretroviral \u00a0drug\u00a0resistance \u00a0in\u00a0HIV\u20102:\u00a0three\u00a0\namino\u00a0acid\u00a0changes\u00a0are\u00a0sufficient \u00a0for\u00a0classwide \u00a0nucleoside \u00a0analogue\u00a0resistance. \u00a0J\u00a0Infect\u00a0Dis\u00a02009;\u00a0\n199(9):1323 \u20101326\u00a0\n\u00a0 302.\u00a0\u00a0Cohen\u00a0Stuart\u00a0JW,\u00a0Wensing\u00a0AM,\u00a0Kovacs\u00a0C,\u00a0Righart\u00a0M,\u00a0de\u00a0Jong\u00a0D,\u00a0Kaye\u00a0S\u00a0et\u00a0al.\u00a0Transient \u00a0relapses\u00a0(\"blips\")\u00a0\nof\u00a0plasma\u00a0HIV\u00a0RNA\u00a0levels\u00a0during\u00a0HAART\u00a0are\u00a0associated \u00a0with\u00a0drug\u00a0resistance. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02001;\u00a028(2):105 \u201013\u00a0\n\u00a0 303.\u00a0\u00a0Sungkanuparph \u00a0S,\u00a0Overton\u00a0ET,\u00a0Seyfried\u00a0W,\u00a0Groger\u00a0RK,\u00a0Fraser\u00a0VJ,\u00a0Powderly \u00a0WG.\u00a0Intermittent \u00a0episodes\u00a0of\u00a0\ndetectable \u00a0HIV\u00a0viremia\u00a0in\u00a0patients\u00a0receiving\u00a0nonnucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitor\u2010based\u00a0or\u00a0\nprotease\u00a0inhibitor\u2010based\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0regimens \u00a0are\u00a0equivalent \u00a0in\u00a0incidence \u00a0and\u00a0\nprognosis. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(9):1326 \u20101332\u00a0\n\u00a0 304.\u00a0\u00a0Tan\u00a0R,\u00a0Westfall\u00a0AO,\u00a0Willig\u00a0JH,\u00a0Mugavero \u00a0MJ,\u00a0Saag\u00a0MS,\u00a0Kaslow\u00a0RA\u00a0et\u00a0al.\u00a0Clinical\u00a0outcome\u00a0of\u00a0HIV\u2010infected\u00a0\nantiretroviral \u2010naive\u00a0patients\u00a0with\u00a0discordant \u00a0immunologic \u00a0and\u00a0virologic\u00a0responses \u00a0to\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(5):553 \u2010558\u00a0\n\u00a0 305.\u00a0\u00a0Berenguer \u00a0J,\u00a0Ribera\u00a0Santasusana \u00a0J,\u00a0Rubio\u00a0R,\u00a0Miralles\u00a0P,\u00a0Mahillo\u00a0B,\u00a0T\u00e9llez\u00a0M,\u00a0Lopez\u00a0Aldeguer\u00a0J,\u00a0Valencia\u00a0E,\u00a0\nSantos\u00a0J,\u00a0Rodriguez \u00a0Arrondo\u00a0FJ,\u00a0GESIDA\u00a0Lymphoma \u00a0Study\u00a0Group.\u00a0Characteristics \u00a0and\u00a0outcome\u00a0of\u00a0AIDS\u2010\nrelated\u00a0non\u2010Hodgkin's \u00a0lymphoma \u00a0in\u00a0patients\u00a0treated\u00a0with\u00a0HAART.\u00a013th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006.\u00a0Abstract\u00a0829.\u00a0\n\u00a0 306.\u00a0\u00a0Montaner \u00a0J,\u00a0Guimaraes \u00a0D,\u00a0Chung\u00a0J,\u00a0Gafoor\u00a0Z,\u00a0Salgo\u00a0M,\u00a0DeMasi\u00a0R.\u00a0Prognostic \u00a0staging\u00a0of\u00a0extensively \u00a0\npretreated \u00a0patients\u00a0with\u00a0advanced \u00a0HIV\u20101\u00a0disease.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02005;\u00a06(6):281\u2010290\u00a0\n\u00a0 307.\u00a0\u00a0Cahn\u00a0P,\u00a0Molina\u00a0JM,\u00a0Towner\u00a0W,\u00a0Peeters\u00a0M,\u00a0Vingerhoets \u00a0J,\u00a0Beets\u00a0G.\u00a048\u2010week\u00a0pooled\u00a0analysis\u00a0of\u00a0DUET\u20101\u00a0\nand\u00a0DUET\u20102:\u00a0the\u00a0impact\u00a0of\u00a0baseline\u00a0characteristics \u00a0on\u00a0virological \u00a0response\u00a0to\u00a0etravirine \u00a0(TMC125; \u00a0ETR).\u00a0\n17th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0TUPE0047. \u00a0\n\u00a0 308.\u00a0\u00a0Clotet\u00a0B,\u00a0Bellos\u00a0N,\u00a0Molina\u00a0JM,\u00a0Cooper\u00a0D,\u00a0Goffard\u00a0JC,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0darunavir \u2010\nritonavir\u00a0at\u00a0week\u00a048\u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0with\u00a0HIV\u20101\u00a0infection\u00a0in\u00a0POWER\u00a01\u00a0and\u00a02:\u00a0a\u00a0\npooled\u00a0subgroup \u00a0analysis\u00a0of\u00a0data\u00a0from\u00a0two\u00a0randomised \u00a0trials.\u00a0Lancet\u00a02007;\u00a0369(9568):1169 \u20101178\u00a0\n\u00a0 309.\u00a0\u00a0Cooper\u00a0DA,\u00a0Steigbigel \u00a0RT,\u00a0Gatell\u00a0JM,\u00a0Rockstroh \u00a0JK,\u00a0Katlama\u00a0C,\u00a0Yeni\u00a0P\u00a0et\u00a0al.\u00a0Subgroup \u00a0and\u00a0resistance \u00a0\nanalyses\u00a0of\u00a0raltegravir \u00a0for\u00a0resistant\u00a0HIV\u20101\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0359(4):355 \u2010365\u00a0\n\u00a0 310.\u00a0\u00a0Hicks\u00a0CB,\u00a0Cahn\u00a0P,\u00a0Cooper\u00a0DA,\u00a0Walmsley \u00a0SL,\u00a0Katlama\u00a0C,\u00a0Clotet\u00a0B\u00a0et\u00a0al.\u00a0Durable\u00a0efficacy\u00a0of\u00a0tipranavir \u2010\nritonavir\u00a0in\u00a0combination \u00a0with\u00a0an\u00a0optimised \u00a0background \u00a0regimen\u00a0of\u00a0antiretroviral \u00a0drugs\u00a0for\u00a0treatment \u2010Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 202experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0at\u00a048\u00a0weeks\u00a0in\u00a0the\u00a0Randomized \u00a0Evaluation \u00a0of\u00a0Strategic\u00a0Intervention \u00a0\nin\u00a0multi\u2010drug\u00a0reSistant\u00a0patients\u00a0with\u00a0Tipranavir \u00a0(RESIST)\u00a0studies:\u00a0an\u00a0analysis\u00a0of\u00a0combined \u00a0data\u00a0from\u00a0two\u00a0\nrandomised \u00a0open\u2010label\u00a0trials.\u00a0Lancet\u00a02006;\u00a0368(9534):466 \u2010475\u00a0\n\u00a0 311.\u00a0\u00a0Lalezari\u00a0JP,\u00a0Henry\u00a0K,\u00a0O'Hearn\u00a0M,\u00a0Montaner \u00a0JS,\u00a0Piliero\u00a0PJ,\u00a0Trottier\u00a0B\u00a0et\u00a0al.\u00a0Enfuvirtide, \u00a0an\u00a0HIV\u20101\u00a0fusion\u00a0\ninhibitor,\u00a0for\u00a0drug\u2010resistant\u00a0HIV\u00a0infection\u00a0in\u00a0North\u00a0and\u00a0South\u00a0America.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0\n348(22):2175 \u201085\u00a0\n\u00a0 312.\u00a0\u00a0Lazzarin\u00a0A,\u00a0Clotet\u00a0B,\u00a0Cooper\u00a0D,\u00a0Reynes\u00a0J,\u00a0Arasteh\u00a0K,\u00a0Nelson\u00a0M\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0enfuvirtide \u00a0in\u00a0patients\u00a0\ninfected\u00a0with\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0in\u00a0Europe\u00a0and\u00a0Australia. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0348(22):2186 \u201095\u00a0\n\u00a0 313.\u00a0\u00a0Lazzarin\u00a0A,\u00a0Campbell \u00a0T,\u00a0Clotet\u00a0B,\u00a0Johnson\u00a0M,\u00a0Katlama\u00a0C,\u00a0Moll\u00a0A\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0TMC125\u00a0\n(etravirine) \u00a0in\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0in\u00a0DUET\u20102:\u00a024\u2010week\u00a0results\u00a0from\u00a0a\u00a0\nrandomised, \u00a0double\u2010blind,\u00a0placebo\u2010controlled \u00a0trial.\u00a0Lancet\u00a02007;\u00a0370(9581):39 \u201048\u00a0\n\u00a0 314.\u00a0\u00a0Madruga\u00a0JV,\u00a0Cahn\u00a0P,\u00a0Grinsztejn \u00a0B,\u00a0Haubrich\u00a0R,\u00a0Lalezari\u00a0J,\u00a0Mills\u00a0A\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0TMC125\u00a0\n(etravirine) \u00a0in\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0in\u00a0DUET\u20101:\u00a024\u2010week\u00a0results\u00a0from\u00a0a\u00a0\nrandomised, \u00a0double\u2010blind,\u00a0placebo\u2010controlled \u00a0trial.\u00a0Lancet\u00a02007;\u00a0370(9581):29 \u201038\u00a0\n\u00a0 315.\u00a0\u00a0Pozniak\u00a0A,\u00a0Jayaweera \u00a0D,\u00a0Hoy\u00a0J,\u00a0de\u00a0Meyer\u00a0S,\u00a0De\u00a0Paepe\u00a0E,\u00a0Tomaka\u00a0F,\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0darunavir/ritonavir \u00a0\nin\u00a0treatment \u2010experienced \u00a0patients\u00a0at\u00a096\u00a0weeks\u00a0in\u00a0the\u00a0POWER\u00a01\u00a0and\u00a02\u00a0trials.\u00a011th\u00a0European \u00a0AIDS\u00a0\nConference, \u00a0Madrid,\u00a0October\u00a024\u201027\u00a02007.\u00a0Abstract\u00a0P7.2/07.\u00a0\n\u00a0 316.\u00a0\u00a0Steigbigel \u00a0RT,\u00a0Cooper\u00a0DA,\u00a0Kumar\u00a0PN,\u00a0Eron\u00a0JE,\u00a0Schechter \u00a0M,\u00a0Markowitz \u00a0M\u00a0et\u00a0al.\u00a0Raltegravir \u00a0with\u00a0\noptimized \u00a0background \u00a0therapy\u00a0for\u00a0resistant\u00a0HIV\u20101\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0359(4):339 \u2010354\u00a0\n\u00a0 317.\u00a0\u00a0Elzi\u00a0L,\u00a0Hirsch\u00a0HH,\u00a0Battegay\u00a0M.\u00a0Once\u2010daily\u00a0directly\u00a0observed \u00a0therapy\u00a0lopinavir/ritonavir \u00a0plus\u00a0indinavir\u00a0as\u00a0a\u00a0\nprotease\u00a0inhibitor\u2010only\u00a0salvage\u00a0therapy\u00a0in\u00a0heavily\u00a0pretreated \u00a0HIV\u20101\u2010infected\u00a0patients:\u00a0a\u00a0pilot\u00a0study.\u00a0AIDS\u00a0\n2006;\u00a020(1):129 \u2010131\u00a0\n\u00a0 318.\u00a0\u00a0Mitty\u00a0J,\u00a0Mwamburi \u00a0D,\u00a0Macalino\u00a0G,\u00a0Caliendo\u00a0A,\u00a0Bazerman \u00a0L,\u00a0Flanigan\u00a0T.\u00a0Improved \u00a0virologic\u00a0outcomes \u00a0\nand\u00a0less\u00a0HIV\u00a0resistance \u00a0for\u00a0HAART\u2010experienced \u00a0substance \u00a0users\u00a0receiving\u00a0modified\u00a0directly\u00a0observed \u00a0\ntherapy:\u00a0results\u00a0from\u00a0a\u00a0randomized \u00a0controlled \u00a0trial.\u00a013th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006.\u00a0Abstract\u00a0622a.\u00a0\n\u00a0 319.\u00a0\u00a0Palella\u00a0F,\u00a0Armon\u00a0C,\u00a0Cmiel\u00a0J,\u00a0Buchacz\u00a0K,\u00a0Novak\u00a0R,\u00a0Moorman \u00a0A,\u00a0et\u00a0al.\u00a0Enhanced \u00a0survival\u00a0associated \u00a0with\u00a0\nuse\u00a0of\u00a0HIV\u00a0susceptibility \u00a0testing\u00a0among\u00a0HAART\u2010experienced \u00a0patients\u00a0in\u00a0the\u00a0HIV\u00a0Outpatient \u00a0Study\u00a0\n(HOPS).\u00a013th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006.\u00a0\nAbstract\u00a0654.\u00a0\n\u00a0 320.\u00a0\u00a0Paredes\u00a0R,\u00a0Lalama\u00a0CM,\u00a0Ribaudo\u00a0HJ,\u00a0Schackman \u00a0BR,\u00a0Shikuma\u00a0C,\u00a0Giguel\u00a0F\u00a0et\u00a0al.\u00a0Pre\u2010existing\u00a0minority\u00a0drug\u2010\nresistant\u00a0HIV\u20101\u00a0variants,\u00a0adherence, \u00a0and\u00a0risk\u00a0of\u00a0antiretroviral \u00a0treatment \u00a0failure.\u00a0J\u00a0Infect\u00a0Dis\u00a02010;\u00a0\n201(5):662 \u2010671\u00a0\n\u00a0 321.\u00a0\u00a0Lawrence \u00a0J,\u00a0Huppler\u00a0HK,\u00a0Coakley\u00a0E,\u00a0Bates\u00a0M,\u00a0Weidler\u00a0J,\u00a0Lie\u00a0Y,\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0phenotypic \u00a0\nsusceptibility \u00a0score\u00a0as\u00a0a\u00a0predictor \u00a0of\u00a0treatment \u00a0response\u00a0in\u00a0persons\u00a0with\u00a0multi\u2010drug\u2010resistant\u00a0HIV\u20101.\u00a0\n13th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006.\u00a0Abstract\u00a0\n651.\u00a0\n\u00a0 322.\u00a0\u00a0Snoeck\u00a0J,\u00a0Kantor\u00a0R,\u00a0Shafer\u00a0RW,\u00a0Van\u00a0LK,\u00a0Deforche\u00a0K,\u00a0Carvalho\u00a0AP\u00a0et\u00a0al.\u00a0Discordances \u00a0between\u00a0\ninterpretation \u00a0algorithms \u00a0for\u00a0genotypic \u00a0resistance \u00a0to\u00a0protease\u00a0and\u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0of\u00a0\nhuman\u00a0immunodeficiency \u00a0virus\u00a0are\u00a0subtype\u00a0dependent. \u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02006;\u00a0\n50(2):694 \u2010701\u00a0\n\u00a0 323.\u00a0\u00a0Vora\u00a0S,\u00a0Marcelin\u00a0AG,\u00a0Gunthard \u00a0HF,\u00a0Flandre\u00a0P,\u00a0Hirsch\u00a0HH,\u00a0Masquelier \u00a0B\u00a0et\u00a0al.\u00a0Clinical\u00a0validation \u00a0of\u00a0\natazanavir/ritonavir \u00a0genotypic \u00a0resistance \u00a0score\u00a0in\u00a0protease\u00a0inhibitor\u2010experienced \u00a0patients.\u00a0AIDS\u00a02006;\u00a0\n20(1):35\u201040\u00a0\n\u00a0 324.\u00a0\u00a0Marcelin\u00a0AG,\u00a0Flandre\u00a0P,\u00a0de\u00a0MC,\u00a0Roquebert \u00a0B,\u00a0Peytavin\u00a0G,\u00a0Valer\u00a0L\u00a0et\u00a0al.\u00a0Clinical\u00a0validation \u00a0of\u00a0\nsaquinavir/ritonavir \u00a0genotypic \u00a0resistance \u00a0score\u00a0in\u00a0protease\u2010inhibitor\u2010experienced \u00a0patients.\u00a0Antivir\u00a0Ther\u00a0\n2007;\u00a012(2):247 \u2010252\u00a0\n\u00a0 325.\u00a0\u00a0King\u00a0MS,\u00a0Rode\u00a0R,\u00a0Cohen\u2010Codar\u00a0I,\u00a0Calvez\u00a0V,\u00a0Marcelin\u00a0AG,\u00a0Hanna\u00a0GJ\u00a0et\u00a0al.\u00a0Predictive \u00a0genotypic \u00a0algorithm \u00a0\nfor\u00a0virologic\u00a0response\u00a0to\u00a0lopinavir\u2010ritonavir\u00a0in\u00a0protease\u00a0inhibitor\u2010experienced \u00a0patients.\u00a0Antimicrob \u00a0\nAgents\u00a0Chemother \u00a02007;\u00a051(9):3067 \u20103074\u00a0\n\u00a0 326.\u00a0\u00a0Winters\u00a0B,\u00a0Van\u00a0der\u00a0Borght\u00a0K,\u00a0van\u00a0Craenenbroeck \u00a0E,\u00a0et\u00a0al.\u00a0Darunavir \u00a0phenotype \u00a0predicts\u00a0response\u00a0better\u00a0\nthan\u00a0genotype. \u00a05th\u00a0European \u00a0HIV\u00a0Drug\u00a0Resistance \u00a0Workshop, \u00a0Cascais,\u00a0March\u00a028\u201030\u00a02007.\u00a0Abstract\u00a072.\u00a0\n\u00a0 327.\u00a0\u00a0Naeger\u00a0LK,\u00a0Struble\u00a0KA.\u00a0Food\u00a0and\u00a0Drug\u00a0Administration \u00a0analysis\u00a0of\u00a0tipranavir \u00a0clinical\u00a0resistance \u00a0in\u00a0HIV\u20101\u2010\ninfected\u00a0treatment \u2010experienced \u00a0patients.\u00a0AIDS\u00a02007;\u00a021(2):179 \u2010185\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 203\u00a0 328.\u00a0\u00a0Barreiro\u00a0P,\u00a0Camino\u00a0N,\u00a0de\u00a0MC,\u00a0Valer\u00a0L,\u00a0Nunez\u00a0M,\u00a0Martin\u2010Carbonero \u00a0L\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0the\u00a0efficacy,\u00a0\nsafety\u00a0and\u00a0predictive \u00a0value\u00a0of\u00a0HIV\u00a0genotyping \u00a0using\u00a0distinct\u00a0ritonavir\u2010boosted\u00a0protease\u00a0inhibitors. \u00a0Int\u00a0J\u00a0\nAntimicrob \u00a0Agents\u00a02002;\u00a020(6):438 \u2010443\u00a0\n\u00a0 329.\u00a0\u00a0Gonzalez\u00a0de\u00a0RD,\u00a0Gallego\u00a0O,\u00a0Valer\u00a0L,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Soriano\u00a0V.\u00a0Prediction \u00a0of\u00a0virological \u00a0response\u00a0to\u00a0\nlopinavir/ritonavir \u00a0using\u00a0the\u00a0genotypic \u00a0inhibitory \u00a0quotient. \u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a02004;\u00a020(3):275 \u2010\n278\u00a0\n\u00a0 330.\u00a0\u00a0Hoefnagel \u00a0JG,\u00a0Van\u00a0der\u00a0Lee\u00a0MJ,\u00a0Koopmans \u00a0PP,\u00a0Schuurman \u00a0R,\u00a0Jurriaans\u00a0S,\u00a0van\u00a0Sighem\u00a0AI\u00a0et\u00a0al.\u00a0The\u00a0\ngenotypic \u00a0inhibitory \u00a0quotient\u00a0and\u00a0the\u00a0(cumulative) \u00a0number\u00a0of\u00a0mutations \u00a0predict\u00a0the\u00a0response\u00a0to\u00a0\nlopinavir\u00a0therapy.\u00a0AIDS\u00a02006;\u00a020(7):1069 \u20101071\u00a0\n\u00a0 331.\u00a0\u00a0Winston\u00a0A,\u00a0Hales\u00a0G,\u00a0Amin\u00a0J,\u00a0van\u00a0SE,\u00a0Cooper\u00a0DA,\u00a0Emery\u00a0S.\u00a0The\u00a0normalized \u00a0inhibitory \u00a0quotient\u00a0of\u00a0boosted\u00a0\nprotease\u00a0inhibitors \u00a0is\u00a0predictive \u00a0of\u00a0viral\u00a0load\u00a0response\u00a0in\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0\nindividuals. \u00a0AIDS\u00a02005;\u00a019(13):1393 \u20101399\u00a0\n\u00a0 332.\u00a0\u00a0Hernandez \u2010Novoa\u00a0B,\u00a0Page\u00a0C,\u00a0Gutierrez \u00a0C,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Casado\u00a0JL,\u00a0Dronda\u00a0F,\u00a0et\u00a0al.\u00a0Mutant\u00a0HIV\u00a0\nminority\u00a0variants\u00a0detected\u00a0by\u00a0ultradeep \u00a0sequencing \u00a0do\u00a0not\u00a0condition \u00a0virological \u00a0failure\u00a0in\u00a0patients\u00a0\nstarting\u00a0ARV\u00a0therapy\u00a0including\u00a0low\u00a0genetic\u00a0barrier\u00a0drugs.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0\nTreatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0WEPEB208. \u00a0\n\u00a0 333.\u00a0\u00a0Varghese \u00a0V,\u00a0Shahriar\u00a0R,\u00a0Rhee\u00a0SY,\u00a0Simen\u00a0BB,\u00a0Egholm\u00a0M,\u00a0Gharizadeh \u00a0B\u00a0et\u00a0al.\u00a0Minority\u00a0drug\u00a0resistance \u00a0\nmutations \u00a0associated \u00a0with\u00a0the\u00a0NNRTI\u00a0mutation \u00a0K103N\u00a0in\u00a0ART\u2010na\u00efve\u00a0and\u00a0NNRTI\u2010treated\u00a0HIV\u20101\u00a0infected\u00a0\npatients\u00a0(18th\u00a0International \u00a0Drug\u00a0Resistance \u00a0Workshop; \u00a0Fort\u00a0Lauderdale, \u00a0Florida,\u00a0USA;\u00a02009).\u00a0Antivir\u00a0\nTher\u00a02009;\u00a014\u00a0(Suppl\u00a01):A143\u00a0\n\u00a0 334.\u00a0\u00a0Lataillade \u00a0M,\u00a0Chiarella\u00a0J,\u00a0Yang\u00a0R,\u00a0Schnittman \u00a0S,\u00a0Wirtz\u00a0V,\u00a0Uy\u00a0J\u00a0et\u00a0al.\u00a0Prevalence \u00a0and\u00a0clinical\u00a0significance \u00a0of\u00a0\nHIV\u00a0drug\u00a0resistance \u00a0mutations \u00a0by\u00a0ultra\u2010deep\u00a0sequencing \u00a0in\u00a0antiretroviral \u2010naive\u00a0subjects\u00a0in\u00a0the\u00a0CASTLE\u00a0\nstudy.\u00a0PLoS\u00a0One\u00a02010;\u00a05(6):e10952 \u00a0\n\u00a0 335.\u00a0\u00a0Boffito\u00a0M,\u00a0Arnaudo\u00a0I,\u00a0Raiteri\u00a0R,\u00a0Bonora\u00a0S,\u00a0Sinicco\u00a0A,\u00a0Di\u00a0Garbo\u00a0A\u00a0et\u00a0al.\u00a0Clinical\u00a0use\u00a0of\u00a0lopinavir/ritonavir \u00a0in\u00a0\na\u00a0salvage\u00a0therapy\u00a0setting:\u00a0pharmacokinetics \u00a0and\u00a0pharmacodynamics. \u00a0AIDS\u00a02002;\u00a016(15):2081 \u20103\u00a0\n\u00a0 336.\u00a0\u00a0Best\u00a0BM,\u00a0Goicoechea \u00a0M,\u00a0Witt\u00a0MD,\u00a0Miller\u00a0L,\u00a0Daar\u00a0ES,\u00a0Diamond\u00a0C\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0controlled \u00a0trial\u00a0of\u00a0\ntherapeutic \u00a0drug\u00a0monitoring \u00a0in\u00a0treatment \u2010naive\u00a0and\u00a0\u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02007;\u00a046(4):433 \u2010442\u00a0\n\u00a0 337.\u00a0\u00a0Wainberg \u00a0MA,\u00a0Turner\u00a0D.\u00a0Resistance \u00a0issues\u00a0with\u00a0new\u00a0nucleoside/nucleotide \u00a0backbone \u00a0options.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02004;\u00a037\u00a0Suppl\u00a01:S36\u2010S43\u00a0\n\u00a0 338.\u00a0\u00a0Jemsek\u00a0J,\u00a0Hutcherson \u00a0P,\u00a0Harper\u00a0E.\u00a0Poor\u00a0virologic\u00a0responses \u00a0and\u00a0early\u00a0emergence \u00a0of\u00a0resistance \u00a0in\u00a0\ntreatment \u00a0naive,\u00a0HIV\u2010infected\u00a0patients\u00a0receiving\u00a0a\u00a0once\u00a0daily\u00a0triple\u00a0nucleoside \u00a0regimen\u00a0of\u00a0didanosine, \u00a0\nlamivudine, \u00a0and\u00a0tenofovir\u00a0DF.\u00a011th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0\nFrancisco, \u00a0February\u00a08\u2010\u201011\u00a02004.\u00a0Abstract\u00a051.\u00a0\n\u00a0 339.\u00a0\u00a0Landman \u00a0R,\u00a0Peytavin\u00a0G,\u00a0Descamps \u00a0D,\u00a0Brun\u00a0Vezinet\u00a0F,\u00a0Benech\u00a0H,\u00a0Benalisherif \u00a0A,\u00a0Trylesinski \u00a0A,\u00a0Katlama\u00a0C,\u00a0\nGirard\u00a0PM,\u00a0Raffi\u00a0F,\u00a0Yeni\u00a0P,\u00a0Bentata\u00a0M,\u00a0Jarrousse \u00a0B,\u00a0Michelet\u00a0C,\u00a0Flandre\u00a0P.\u00a0Low\u00a0genetic\u00a0barrier\u00a0to\u00a0\nresistance \u00a0is\u00a0a\u00a0possible\u00a0cause\u00a0of\u00a0early\u00a0virologic\u00a0failures\u00a0in\u00a0once\u2010daily\u00a0regimen\u00a0of\u00a0abacavir,\u00a0lamivudine, \u00a0\nand\u00a0tenofovir: \u00a0The\u00a0Tonus\u00a0study.\u00a011th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0\nFrancisco, \u00a0February\u00a08\u2010\u201011\u00a02004.\u00a0Abstract\u00a052.\u00a0\n\u00a0 340.\u00a0\u00a0Shafer\u00a0RW,\u00a0Stevenson \u00a0D,\u00a0Chan\u00a0B.\u00a0Human\u00a0Immunodeficiency \u00a0Virus\u00a0Reverse\u00a0Transcriptase \u00a0and\u00a0Protease\u00a0\nSequence \u00a0Database. \u00a0Nucleic\u00a0Acids\u00a0Res\u00a01999;\u00a027(1):348 \u201052\u00a0\n\u00a0 341.\u00a0\u00a0Llibre\u00a0JM,\u00a0Santos\u00a0JR,\u00a0Puig\u00a0T,\u00a0Molto\u00a0J,\u00a0Ruiz\u00a0L,\u00a0Paredes\u00a0R\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0etravirine \u2010associated \u00a0\nmutations \u00a0in\u00a0clinical\u00a0samples\u00a0with\u00a0resistance \u00a0to\u00a0nevirapine \u00a0and\u00a0efavirenz. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a0\n2008;\u00a062(5):909 \u2010913\u00a0\n\u00a0 342.\u00a0\u00a0Gupta\u00a0R,\u00a0Hill\u00a0A,\u00a0Sawyer\u00a0AW,\u00a0Pillay\u00a0D.\u00a0Emergence \u00a0of\u00a0drug\u00a0resistance \u00a0in\u00a0HIV\u00a0type\u00a01\u2010infected\u00a0patients\u00a0after\u00a0\nreceipt\u00a0of\u00a0first\u2010line\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0a\u00a0systematic \u00a0review\u00a0of\u00a0clinical\u00a0trials.\u00a0Clin\u00a0Infect\u00a0\nDis\u00a02008;\u00a047(5):712 \u2010722\u00a0\n\u00a0 343.\u00a0\u00a0Ruxrungtham \u00a0K,\u00a0Pedro\u00a0RJ,\u00a0Latiff\u00a0GH,\u00a0Conradie\u00a0F,\u00a0Domingo\u00a0P,\u00a0Lupo\u00a0S\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0reverse\u00a0\ntranscriptase \u00a0resistance \u00a0on\u00a0the\u00a0efficacy\u00a0of\u00a0TMC125\u00a0(etravirine) \u00a0with\u00a0two\u00a0nucleoside \u00a0reverse\u00a0\ntranscriptase \u00a0inhibitors \u00a0in\u00a0protease\u00a0inhibitor\u2010naive,\u00a0nonnucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u2010\nexperienced \u00a0patients:\u00a0study\u00a0TMC125\u2010C227.\u00a0HIV\u00a0Med\u00a02008;\u00a09(10):883 \u2010896\u00a0\n\u00a0 344.\u00a0\u00a0Llibre\u00a0JM.\u00a0First\u2010line\u00a0boosted\u00a0protease\u00a0inhibitor\u2010based\u00a0regimens \u00a0in\u00a0treatment \u2010naive\u00a0HIV\u20101\u2010infected\u00a0\npatients\u2010\u2010making\u00a0a\u00a0good\u00a0thing\u00a0better.\u00a0AIDS\u00a0Rev\u00a02009;\u00a011(4):215 \u2010222\u00a0\n\u00a0 345.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Valer\u00a0L,\u00a0Bacheler\u00a0L,\u00a0Pattery\u00a0T,\u00a0Corral\u00a0A,\u00a0Soriano\u00a0V.\u00a0Prevalence \u00a0of\u00a0the\u00a0HIV\u20101\u00a0protease\u00a0\nmutation \u00a0I47A\u00a0in\u00a0clinical\u00a0practice\u00a0and\u00a0association \u00a0with\u00a0lopinavir\u00a0resistance. \u00a0AIDS\u00a02006;\u00a020(7):1071 \u20101074\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 204\u00a0 346.\u00a0\u00a0Nijhuis\u00a0M,\u00a0Wensing\u00a0AM,\u00a0Bierman\u00a0WF,\u00a0de\u00a0JD,\u00a0Kagan\u00a0R,\u00a0Fun\u00a0A\u00a0et\u00a0al.\u00a0Failure\u00a0of\u00a0treatment \u00a0with\u00a0first\u2010line\u00a0\nlopinavir\u00a0boosted\u00a0with\u00a0ritonavir\u00a0can\u00a0be\u00a0explained \u00a0by\u00a0novel\u00a0resistance \u00a0pathways \u00a0with\u00a0protease\u00a0mutation \u00a0\n76V.\u00a0J\u00a0Infect\u00a0Dis\u00a02009;\u00a0200(5):698 \u2010709\u00a0\n\u00a0 347.\u00a0\u00a0Turner\u00a0D,\u00a0Schapiro\u00a0JM,\u00a0Brenner\u00a0BG,\u00a0Wainberg \u00a0MA.\u00a0The\u00a0influence \u00a0of\u00a0protease\u00a0inhibitor\u00a0resistance \u00a0\nprofiles\u00a0on\u00a0selection\u00a0of\u00a0HIV\u00a0therapy\u00a0in\u00a0treatment \u2010naive\u00a0patients.\u00a0Antivir\u00a0Ther\u00a02004;\u00a09(3):301\u2010314\u00a0\n\u00a0 348.\u00a0\u00a0Colonno\u00a0R,\u00a0Rose\u00a0R,\u00a0McLaren\u00a0C,\u00a0Thiry\u00a0A,\u00a0Parkin\u00a0N,\u00a0Friborg\u00a0J.\u00a0Identification \u00a0of\u00a0I50L\u00a0as\u00a0the\u00a0signature \u00a0\natazanavir \u00a0(ATV)\u2010resistance \u00a0mutation\u00a0in\u00a0treatment \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0receiving\u00a0ATV\u2010\ncontaining \u00a0regimens. \u00a0J\u00a0Infect\u00a0Dis\u00a02004;\u00a0189(10):1802 \u20101810\u00a0\n\u00a0 349.\u00a0\u00a0Johnson\u00a0VA,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Gunthard \u00a0HF,\u00a0Kuritzkes\u00a0DR,\u00a0Pillay\u00a0D\u00a0et\u00a0al.\u00a0Update\u00a0of\u00a0the\u00a0Drug\u00a0\nResistance \u00a0Mutations \u00a0in\u00a0HIV\u20101:\u00a0Spring\u00a02008.\u00a0Top\u00a0HIV\u00a0Med\u00a02008;\u00a016(1):62\u201068\u00a0\n\u00a0 350.\u00a0\u00a0Weinheimer \u00a0S,\u00a0Discotto\u00a0L,\u00a0Friborg\u00a0J,\u00a0Yang\u00a0H,\u00a0Colonno\u00a0R.\u00a0Atazanavir \u00a0signature \u00a0I50L\u00a0resistance \u00a0\nsubstitution \u00a0accounts\u00a0for\u00a0unique\u00a0phenotype \u00a0of\u00a0increased \u00a0susceptibility \u00a0to\u00a0other\u00a0protease\u00a0inhibitors \u00a0in\u00a0a\u00a0\nvariety\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0genetic\u00a0backbones. \u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a0\n2005;\u00a049(9):3816 \u20103824\u00a0\n\u00a0 351.\u00a0\u00a0Marcelin\u00a0AG,\u00a0Flandre\u00a0P,\u00a0Molina\u00a0JM,\u00a0Katlama\u00a0C,\u00a0Yeni\u00a0P,\u00a0Raffi\u00a0F\u00a0et\u00a0al.\u00a0Genotypic \u00a0resistance \u00a0analysis\u00a0of\u00a0the\u00a0\nvirological \u00a0response\u00a0to\u00a0fosamprenavir \u2010ritonavir\u00a0in\u00a0protease\u00a0inhibitor\u2010experienced \u00a0patients\u00a0in\u00a0CONTEXT \u00a0\nand\u00a0TRIAD\u00a0clinical\u00a0trials.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02008;\u00a052(12):4251 \u20104257\u00a0\n\u00a0 352.\u00a0\u00a0Dragsted\u00a0UB,\u00a0Gerstoft\u00a0J,\u00a0Youle\u00a0M,\u00a0Fox\u00a0Z,\u00a0Losso\u00a0M,\u00a0Benetucci \u00a0J\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0to\u00a0evaluate\u00a0\nlopinavir/ritonavir \u00a0versus\u00a0saquinavir/ritonavir \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a0the\u00a0MaxCmin2 \u00a0trial.\u00a0Antivir\u00a0\nTher\u00a02005;\u00a010(6):735 \u2010743\u00a0\n\u00a0 353.\u00a0\u00a0Johnson\u00a0M,\u00a0Grinsztejn \u00a0B,\u00a0Rodriguez \u00a0C,\u00a0Coco\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0Atazanavir \u00a0plus\u00a0ritonavir\u00a0or\u00a0\nsaquinavir, \u00a0and\u00a0lopinavir/ritonavir \u00a0in\u00a0patients\u00a0experiencing \u00a0multiple\u00a0virological \u00a0failures.\u00a0AIDS\u00a02005;\u00a0\n19(2):153 \u2010162\u00a0\n\u00a0 354.\u00a0\u00a0Naeger\u00a0LK,\u00a0Struble\u00a0KA.\u00a0Effect\u00a0of\u00a0baseline\u00a0protease\u00a0genotype \u00a0and\u00a0phenotype \u00a0on\u00a0HIV\u00a0response\u00a0to\u00a0\natazanavir/ritonavir \u00a0in\u00a0treatment \u2010experienced \u00a0patients.\u00a0AIDS\u00a02006;\u00a020(6):847 \u2010853\u00a0\n\u00a0 355.\u00a0\u00a0Scherer\u00a0J,\u00a0Schapiro\u00a0JM,\u00a0Maggiolo \u00a0F,\u00a0Perno\u00a0CF,\u00a0Boucher\u00a0CA,\u00a0Baxter\u00a0J,\u00a0et\u00a0al.\u00a0Improved \u00a0tipranavir \u00a0weighted \u00a0\nscore\u00a0predics\u00a0virologic\u00a0response\u00a0in\u00a0diverse\u00a0treatment \u2010experienced \u00a0patient\u00a0population. \u00a07th\u00a0European \u00a0\nHIV\u00a0Drug\u00a0Resistance \u00a0Workshop, \u00a0Stockholm, \u00a0March\u00a025\u201027\u00a02009.\u00a0Abstract\u00a094.\u00a0\n\u00a0 356.\u00a0\u00a0Arasteh\u00a0K,\u00a0Clumeck\u00a0N,\u00a0Pozniak\u00a0A,\u00a0Lazzarin\u00a0A,\u00a0De\u00a0MS,\u00a0Muller\u00a0H\u00a0et\u00a0al.\u00a0TMC114/ritonavir \u00a0substitution \u00a0for\u00a0\nprotease\u00a0inhibitor(s) \u00a0in\u00a0a\u00a0non\u2010suppressive \u00a0antiretroviral \u00a0regimen:\u00a0a\u00a014\u2010day\u00a0proof\u2010of\u2010principle\u00a0trial.\u00a0AIDS\u00a0\n2005;\u00a019(9):943 \u2010947\u00a0\n\u00a0 357.\u00a0\u00a0de\u00a0Meyer\u00a0S.,\u00a0Azijn\u00a0H,\u00a0Surleraux \u00a0D,\u00a0Jochmans \u00a0D,\u00a0Tahri\u00a0A,\u00a0Pauwels\u00a0R\u00a0et\u00a0al.\u00a0TMC114,\u00a0a\u00a0novel\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0type\u00a01\u00a0protease\u00a0inhibitor\u00a0active\u00a0against\u00a0protease\u00a0inhibitor\u2010resistant\u00a0viruses,\u00a0\nincluding\u00a0a\u00a0broad\u00a0range\u00a0of\u00a0clinical\u00a0isolates.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02005;\u00a049(6):2314 \u20102321\u00a0\n\u00a0 358.\u00a0\u00a0Saag\u00a0M,\u00a0Falcon\u00a0R,\u00a0Lefebre\u00a0E.\u00a0Efficacy\u00a0and\u00a0safety\u00a0results\u00a0of\u00a0darunavir/r \u00a0in\u00a0treatment \u2010experienced \u00a0\npatients:\u00a0POWER\u00a03.\u00a044th\u00a0Annual\u00a0meeting\u00a0of\u00a0the\u00a0Infectious \u00a0Disease\u00a0Society\u00a0of\u00a0America,\u00a0Toronto,\u00a0October\u00a0\n11\u201015\u00a02006.\u00a0Abstract\u00a0957.\u00a0\n\u00a0 359.\u00a0\u00a0Pozniak\u00a0A,\u00a0Arasteh\u00a0K,\u00a0Molina\u00a0JM,\u00a0Grinsztejn \u00a0B,\u00a0De\u00a0Meyer\u00a0S,\u00a0de\u00a0Casteele\u00a0T,\u00a0et\u00a0al.\u00a0Power\u00a03\u00a0analysis:\u00a0144\u2010\nweek\u00a0efficacy\u00a0and\u00a0safety\u00a0results\u00a0for\u00a0darunavir/ritonavir \u00a0600/100mg \u00a0bid\u00a0in\u00a0treatment \u2010experienced \u00a0HIV\u00a0\npatients.\u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a0November \u00a09\u201013\u00a02008.\u00a0\nAbstract\u00a0S1\u2010P24.\u00a0\n\u00a0 360.\u00a0\u00a0Madruga\u00a0JV,\u00a0Berger\u00a0D,\u00a0McMurchie \u00a0M,\u00a0Suter\u00a0F,\u00a0Banhegyi\u00a0D,\u00a0Ruxrungtham \u00a0K\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\ndarunavir \u2010ritonavir\u00a0compared \u00a0with\u00a0that\u00a0of\u00a0lopinavir\u2010ritonavir\u00a0at\u00a048\u00a0weeks\u00a0in\u00a0treatment \u2010experienced, \u00a0\nHIV\u2010infected\u00a0patients\u00a0in\u00a0TITAN:\u00a0a\u00a0randomised \u00a0controlled \u00a0phase\u00a0III\u00a0trial.\u00a0Lancet\u00a02007;\u00a0370(9581):49 \u201058\u00a0\n\u00a0 361.\u00a0\u00a0Squires\u00a0KE,\u00a0Currier\u00a0J,\u00a0Bridge\u00a0D,\u00a0Hagins\u00a0D,\u00a0Zorrilla\u00a0C,\u00a0Ryan\u00a0R,\u00a0et\u00a0al.\u00a0GRACE\u00a0(Gender,\u00a0Race\u00a0And\u00a0Clinical\u00a0\nExperience): \u00a048\u2010week\u00a0results\u00a0of\u00a0darunavir/r \u2010based\u00a0therapy\u00a0in\u00a0the\u00a0largest\u00a0trial\u00a0in\u00a0North\u00a0America\u00a0focused\u00a0\non\u00a0treatment \u2010experienced \u00a0women.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0MOPEB042. \u00a0\n\u00a0 362.\u00a0\u00a0Currier\u00a0J,\u00a0Averitt\u00a0BD,\u00a0Hagins\u00a0D,\u00a0Zorrilla\u00a0CD,\u00a0Feinberg\u00a0J,\u00a0Ryan\u00a0R\u00a0et\u00a0al.\u00a0Sex\u2010based\u00a0outcomes \u00a0of\u00a0darunavir \u2010\nritonavir\u00a0therapy:\u00a0a\u00a0single\u2010group\u00a0trial.\u00a0Ann\u00a0Intern\u00a0Med\u00a02010;\u00a0153(6):349 \u2010357\u00a0\n\u00a0 363.\u00a0\u00a0Cahn\u00a0P,\u00a0Fourie\u00a0J,\u00a0Grinsztejn \u00a0B,\u00a0Hodder\u00a0S,\u00a0Molina\u00a0JM,\u00a0Ruxrungtham \u00a0K,\u00a0et\u00a0al.\u00a0ODIN:\u00a0efficacy\u00a0and\u00a0safety\u00a0at\u00a0\n48\u00a0weeks\u00a0of\u00a0once\u2010daily\u00a0versus\u00a0twice\u2010daily\u00a0darunavir/ritonavir \u00a0in\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0\npatients\u00a0with\u00a0no\u00a0darunavir \u00a0resistance \u2010associated \u00a0mutations. \u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a057.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 205\u00a0 364.\u00a0\u00a0Lathouwers \u00a0E,\u00a0de\u00a0la\u00a0Rosa\u00a0G,\u00a0Van\u00a0de\u00a0Casteele\u00a0T,\u00a0De\u00a0Doncker\u00a0P,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0Meyer\u00a0S,\u00a0et\u00a0al.\u00a048\u2010\nweek\u00a0resistance \u00a0and\u00a0efficacy\u00a0subgroup \u00a0analysis\u00a0of\u00a0once\u2010\u00a0versus\u00a0twice\u2010daily\u00a0darunavir/ritonavir \u00a0in\u00a0ODIN.\u00a0\n50th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0Boston,\u00a0September \u00a012\u201015\u00a0\n2010.\u00a0Abstract\u00a0H\u20101811.\u00a0\n\u00a0 365.\u00a0\u00a0De\u00a0Meyer\u00a0S,\u00a0Dierynck\u00a0I,\u00a0Lathouwers \u00a0E,\u00a0van\u00a0Baelen\u00a0B,\u00a0Vangeneugden \u00a0T,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0et\u00a0al.\u00a0\nPhenotypic \u00a0and\u00a0genotypic \u00a0determinants \u00a0of\u00a0resistance \u00a0to\u00a0darunavir: \u00a0analysis\u00a0of\u00a0data\u00a0from\u00a0treatment \u2010\nexperienced \u00a0patients\u00a0in\u00a0POWER\u00a01,\u00a02,\u00a03\u00a0and\u00a0DUET\u20101\u00a0and\u00a0DUET\u20102.\u00a017th\u00a0International \u00a0HIV\u00a0Drug\u00a0Resistance \u00a0\nWorkshop, \u00a0Sitges,\u00a0June\u00a010\u201014\u00a02008.\u00a0Poster\u00a031.\u00a0\n\u00a0 366.\u00a0\u00a0Trottier\u00a0B,\u00a0Mills\u00a0A,\u00a0Cahn\u00a0P,\u00a0Clotet\u00a0B,\u00a0Grinsztejn \u00a0B,\u00a0Towner\u00a0W,\u00a0et\u00a0al.\u00a0Durable\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0\netravirine \u00a0in\u00a0treatment \u2010experienced, \u00a0HIV\u20101\u2010infected\u00a0patients:\u00a0pooled\u00a0week\u00a096\u00a0results\u00a0from\u00a0the\u00a0Phase\u00a0III\u00a0\nDUET\u20101\u00a0and\u00a0DUET\u20102\u00a0trials.\u00a018th\u00a0Annual\u00a0Canadian \u00a0Conference \u00a0on\u00a0HIV/AIDS\u00a0Research, \u00a0Vancouver, \u00a0April\u00a0\n23\u201026,\u00a02009.\u00a0Abstract\u00a0PI\u201048.\u00a0\n\u00a0 367.\u00a0\u00a0Eron\u00a0J,\u00a0Haubrich\u00a0R,\u00a0Reiss\u00a0P,\u00a0Thompson \u00a0M,\u00a0Weber\u00a0R,\u00a0Nijs\u00a0S,\u00a0et\u00a0al.\u00a0Clinical\u00a0endpoints \u00a0reduced\u00a0through\u00a0\netravirine \u00a0use\u00a0in\u00a0treatment \u2010experienced, \u00a0HIV\u2010infected\u00a0patients:\u00a0pooled\u00a096\u2010week\u00a0results\u00a0from\u00a0the\u00a0Phase\u00a0\nIII\u00a0Duet\u00a0trials.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u2010\n22\u00a02009.\u00a0Abstract\u00a0MOPEB043. \u00a0\n\u00a0 368.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Anta\u00a0L,\u00a0Garcia\u00a0F,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Gutierrez \u00a0F,\u00a0Llibre\u00a0JM\u00a0et\u00a0al.\u00a0HIV\u20101\u00a0genotypic \u00a0drug\u00a0\nresistance \u00a0interpretation \u00a0rules\u00a0\u2010\u00a02009\u00a0Spanish\u00a0guidelines. \u00a0AIDS\u00a0Rev\u00a02009;\u00a011(1):39\u201051\u00a0\n\u00a0 369.\u00a0\u00a0Benhamida \u00a0J,\u00a0Chappey\u00a0C,\u00a0Coakley\u00a0E,\u00a0Parkin\u00a0NT.\u00a0Monogram \u00a0HIV\u20101\u00a0Genotype \u00a0Algorithms \u00a0for\u00a0Prediction \u00a0of\u00a0\nEtravirine \u00a0Susceptibility: \u00a0Novel\u00a0Mutations \u00a0and\u00a0Weighting \u00a0Factors\u00a0Identified \u00a0Through\u00a0Correlations \u00a0to\u00a0\nPhenotype. \u00a017th\u00a0International \u00a0HIV\u00a0Drug\u00a0Resistance \u00a0Workshop, \u00a0Sitges,\u00a0June\u00a010\u201014\u00a02008.\u00a0Abstract\u00a0130.\u00a0\n\u00a0 370.\u00a0\u00a0Haddad\u00a0M,\u00a0Stawiski\u00a0E,\u00a0Benhamida \u00a0J,\u00a0Coakley\u00a0E.\u00a0Improved \u00a0genotypic \u00a0algorithm \u00a0for\u00a0predicting \u00a0etravirine \u00a0\nsusceptibility: \u00a0Comprehensive \u00a0list\u00a0of\u00a0mutations \u00a0identified \u00a0through\u00a0correlation \u00a0with\u00a0matched\u00a0phenotype. \u00a0\n17th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a0\n2010.\u00a0Abstract\u00a0574.\u00a0\n\u00a0 371.\u00a0\u00a0Nelson\u00a0M,\u00a0Arasteh\u00a0K,\u00a0Clotet\u00a0B,\u00a0Cooper\u00a0DA,\u00a0Henry\u00a0K,\u00a0Katlama\u00a0C\u00a0et\u00a0al.\u00a0Durable\u00a0efficacy\u00a0of\u00a0enfuvirtide \u00a0over\u00a0\n48\u00a0weeks\u00a0in\u00a0heavily\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0in\u00a0the\u00a0T\u201020\u00a0versus\u00a0optimized \u00a0\nbackground \u00a0regimen\u00a0only\u00a01\u00a0and\u00a02\u00a0clinical\u00a0trials.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a040(4):404 \u2010412\u00a0\n\u00a0 372.\u00a0\u00a0Ribera\u00a0E,\u00a0Moreno\u00a0S,\u00a0Viciana\u00a0P,\u00a0Echevarria \u00a0S,\u00a0Flores\u00a0J,\u00a0Frances\u00a0A\u00a0et\u00a0al.\u00a0Recomendaciones \u00a0espa\u00f1olas \u00a0para\u00a0\nel\u00a0uso\u00a0adecuado \u00a0de\u00a0la\u00a0enfuvirtida. \u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02007;\u00a025(2):131 \u2010142\u00a0\n\u00a0 373.\u00a0\u00a0Dorr\u00a0P,\u00a0Westby\u00a0M,\u00a0Dobbs\u00a0S,\u00a0Griffin\u00a0P,\u00a0Irvine\u00a0B,\u00a0Macartney \u00a0M\u00a0et\u00a0al.\u00a0Maraviroc \u00a0(UK\u2010427,857), \u00a0a\u00a0potent,\u00a0\norally\u00a0bioavailable, \u00a0and\u00a0selective\u00a0small\u2010molecule\u00a0inhibitor\u00a0of\u00a0chemokine \u00a0receptor\u00a0CCR5\u00a0with\u00a0broad\u2010\nspectrum \u00a0anti\u2010human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0activity.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02005;\u00a0\n49(11):4721 \u20104732\u00a0\n\u00a0 374.\u00a0\u00a0Gulick\u00a0RM,\u00a0Lalezari\u00a0J,\u00a0Goodrich\u00a0J,\u00a0Clumeck\u00a0N,\u00a0DeJesus\u00a0E,\u00a0Horban\u00a0A\u00a0et\u00a0al.\u00a0Maraviroc \u00a0for\u00a0Previously \u00a0\nTreated\u00a0Patients\u00a0with\u00a0R5\u00a0HIV\u20101\u00a0Infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0359(14):1429 \u20101441\u00a0\n\u00a0 375.\u00a0\u00a0Ashmuth\u00a0D,\u00a0Goodrich\u00a0J,\u00a0Cooper\u00a0D,\u00a0et\u00a0al.\u00a0CD4+\u00a0cell\u00a0restoration \u00a0after\u00a048\u00a0weeks\u00a0in\u00a0the\u00a0maraviroc \u00a0\ntreatment \u2010experienced \u00a0trials\u00a0MOTIVATE \u00a01\u00a0and\u00a02.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0\nAugust\u00a02008.\u00a0Abstract\u00a0TUPE0050. \u00a0\n\u00a0 376.\u00a0\u00a0Fatkenheuer \u00a0G,\u00a0Nelson\u00a0M,\u00a0Lazzarin\u00a0A,\u00a0Konourina \u00a0I,\u00a0Hoepelman \u00a0AIM,\u00a0Lampiris\u00a0H\u00a0et\u00a0al.\u00a0Subgroup \u00a0Analyses\u00a0\nof\u00a0Maraviroc \u00a0in\u00a0Previously \u00a0Treated\u00a0R5\u00a0HIV\u20101\u00a0Infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0359(14):1442 \u20101455\u00a0\n\u00a0 377.\u00a0\u00a0Hardy\u00a0WD,\u00a0Gulick\u00a0R,\u00a0Mayer\u00a0H,\u00a0F\u00e4lkenheuer \u00a0G,\u00a0Nelson\u00a0M,\u00a0Heera\u00a0J,\u00a0et\u00a0al.\u00a0Efficay\u00a0and\u00a0safety\u00a0of\u00a0Maraviroc \u00a0\nin\u00a0treatment \u2010experienced \u00a0patients\u00a0infected\u00a0with\u00a0R5\u00a0HIV\u20101:\u00a096\u00a0week\u00a0combined \u00a0an\u00e1lisis\u00a0of\u00a0the\u00a0MOTIVATE \u00a0\n1\u00a0and\u00a02\u00a0Studies.\u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a0November \u00a09\u201013\u00a0\n2008.\u00a0Abstract\u00a0425.\u00a0\n\u00a0 378.\u00a0\u00a0Ayoub\u00a0A,\u00a0Goodrich\u00a0J,\u00a0Tressler\u00a0R,\u00a0van\u00a0der\u00a0Ryst\u00a0E,\u00a0Rajicic\u00a0N,\u00a0Butelli\u00a0S,\u00a0et\u00a0al.\u00a0Incidence \u00a0of\u00a0infections \u00a0in\u00a0\ntreatment \u2010experienced \u00a0patients\u00a0infected\u00a0with\u00a0R5\u00a0HIV\u20101\u00a0in\u00a0the\u00a0MOTIVATE \u00a0stuides\u00a0of\u00a0maraviroc \u00a0in\u00a0\ncombination \u00a0with\u00a0optimized \u00a0background \u00a0therapy.\u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0\nInfection, \u00a0Glasgow,\u00a0November \u00a09\u201013\u00a02008.\u00a0Abstract\u00a0154.\u00a0\n\u00a0 379.\u00a0\u00a0Ayoub\u00a0A,\u00a0Walmsley \u00a0S,\u00a0Campo\u00a0R,\u00a0Goodrich\u00a0J,\u00a0Heera\u00a0J,\u00a0Valdez\u00a0H,\u00a0et\u00a0al.\u00a0Incidence \u00a0and\u00a0risk\u00a0factors\u00a0for\u00a0\nmalignancies \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0in\u00a0the\u00a0MOTIVATE \u00a0Studies\u00a0of\u00a0Maraviroc \u00a0+\u00a0optimized \u00a0\nbackground \u00a0therapy:\u00a096\u2010week\u00a0follow\u2010up.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0WEPEB255. \u00a0\n\u00a0 380.\u00a0\u00a0Van\u00a0der\u00a0Ryst\u00a0E,\u00a0Westby\u00a0M.\u00a0Changes\u00a0in\u00a0HIV\u20101\u00a0co\u2010receptor\u00a0tropism\u00a0for\u00a0patients\u00a0participating \u00a0in\u00a0the\u00a0\nmaraviroc \u00a0MOTIVATE \u00a01\u00a0and\u00a02\u00a0clinical\u00a0trials.\u00a047th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0\nChemotherapy, \u00a0Chicago,\u00a0September \u00a017\u201020\u00a02007.\u00a0Abstract\u00a0H\u2010715.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 206\u00a0 381.\u00a0\u00a0Cahn\u00a0P,\u00a0Sued\u00a0O.\u00a0Raltegravir: \u00a0a\u00a0new\u00a0antiretroviral \u00a0class\u00a0for\u00a0salvage\u00a0therapy.\u00a0Lancet\u00a02007;\u00a0\n369(9569):1235 \u20101236\u00a0\n\u00a0 382.\u00a0\u00a0Cooper\u00a0D,\u00a0Steigbigel \u00a0R,\u00a0Lennox\u00a0J,\u00a0Grinsztejn \u00a0B,\u00a0Markowitz \u00a0M,\u00a0Sklar\u00a0P,\u00a0et\u00a0al.\u00a0Review\u00a0of\u00a0cancer\u00a0incidence \u00a0in\u00a0\nraltegravir \u00a0clinical\u00a0trials.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0\nFebruary\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0859.\u00a0\n\u00a0 383.\u00a0\u00a0Steigbigel \u00a0RT,\u00a0Cooper\u00a0DA,\u00a0Teppler\u00a0H,\u00a0Eron\u00a0JJ,\u00a0Gatell\u00a0JM,\u00a0Kumar\u00a0PN\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nRaltegravir \u00a0combined \u00a0with\u00a0optimized \u00a0background \u00a0therapy\u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0with\u00a0drug\u2010\nresistant\u00a0HIV\u00a0infection: \u00a0week\u00a096\u00a0results\u00a0of\u00a0the\u00a0BENCHMRK \u00a01\u00a0and\u00a02\u00a0Phase\u00a0III\u00a0trials.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02010;\u00a0\n50(4):605 \u2010612\u00a0\n\u00a0 384.\u00a0\u00a0Fagard\u00a0C,\u00a0Descapms \u00a0D,\u00a0Dubar\u00a0V,\u00a0Colin\u00a0C,\u00a0Taburet\u00a0AM,\u00a0Roquebert \u00a0B,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nraltegravir \u00a0plus\u00a0etravirine \u00a0and\u00a0darunavir/ritonavir \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0with\u00a0multidrug \u2010\nresistant\u00a0virus:\u00a048\u2010week\u00a0results\u00a0from\u00a0the\u00a0ANRS\u00a0139\u00a0TRIO\u00a0trial.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0\nTreatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0TUPDB204. \u00a0\n\u00a0 385.\u00a0\u00a0Grabar\u00a0S,\u00a0Le\u00a0Moing\u00a0V,\u00a0Goujard\u00a0C,\u00a0Leport\u00a0C,\u00a0Kazatchkine \u00a0MD,\u00a0Costagliola \u00a0D\u00a0et\u00a0al.\u00a0Clinical\u00a0outcome\u00a0of\u00a0\npatients\u00a0with\u00a0HIV\u20101\u00a0infection\u00a0according \u00a0to\u00a0immunologic \u00a0and\u00a0virologic\u00a0response\u00a0after\u00a06\u00a0months\u00a0of\u00a0highly\u00a0\nactive\u00a0antiretroviral \u00a0therapy.\u00a0Ann\u00a0Intern\u00a0Med\u00a02000;\u00a0133(6):401 \u201010\u00a0\n\u00a0 386.\u00a0\u00a0Ledergerber \u00a0B,\u00a0Egger\u00a0M,\u00a0Opravil\u00a0M,\u00a0Telenti\u00a0A,\u00a0Hirschel\u00a0B,\u00a0Battegay\u00a0M\u00a0et\u00a0al.\u00a0Clinical\u00a0progression \u00a0and\u00a0\nvirological \u00a0failure\u00a0on\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0HIV\u20101\u00a0patients:\u00a0a\u00a0prospective \u00a0cohort\u00a0study.\u00a0\nSwiss\u00a0HIV\u00a0Cohort\u00a0Study.\u00a0Lancet\u00a01999;\u00a0353(9156):863 \u20108\u00a0\n\u00a0 387.\u00a0\u00a0Deeks\u00a0SG,\u00a0Barbour\u00a0JD,\u00a0Grant\u00a0RM,\u00a0Martin\u00a0JN.\u00a0Duration\u00a0and\u00a0predictors \u00a0of\u00a0CD4\u00a0T\u2010cell\u00a0gains\u00a0in\u00a0patients\u00a0who\u00a0\ncontinue\u00a0combination \u00a0therapy\u00a0despite\u00a0detectable \u00a0plasma\u00a0viremia.\u00a0AIDS\u00a02002;\u00a016(2):201 \u20107\u00a0\n\u00a0 388.\u00a0\u00a0Gandhi\u00a0T,\u00a0Wei\u00a0W,\u00a0Amin\u00a0K,\u00a0Kazanjian \u00a0P.\u00a0Effect\u00a0of\u00a0maintaining \u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0on\u00a0AIDS\u00a0\nevents\u00a0among\u00a0patients\u00a0with\u00a0late\u2010stage\u00a0HIV\u00a0infection\u00a0and\u00a0inadequate \u00a0response\u00a0to\u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a0\n2006;\u00a042(6):878 \u2010884\u00a0\n\u00a0 389.\u00a0\u00a0Kousignian \u00a0I,\u00a0Abgrall\u00a0S,\u00a0Grabar\u00a0S,\u00a0Mahamat \u00a0A,\u00a0Teicher\u00a0E,\u00a0Rouveix\u00a0E\u00a0et\u00a0al.\u00a0Maintaining \u00a0antiretroviral \u00a0\ntherapy\u00a0reduces\u00a0the\u00a0risk\u00a0of\u00a0AIDS\u2010defining\u00a0events\u00a0in\u00a0patients\u00a0with\u00a0uncontrolled \u00a0viral\u00a0replication \u00a0and\u00a0\nprofound \u00a0immunodeficiency. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a046(2):296 \u2010304\u00a0\n\u00a0 390.\u00a0\u00a0Deeks\u00a0SG,\u00a0Hoh\u00a0R,\u00a0Neilands\u00a0TB,\u00a0Liegler\u00a0T,\u00a0Aweeka\u00a0F,\u00a0Petropoulos \u00a0CJ\u00a0et\u00a0al.\u00a0Interruption \u00a0of\u00a0treatment \u00a0with\u00a0\nindividual \u00a0therapeutic \u00a0drug\u00a0classes\u00a0in\u00a0adults\u00a0with\u00a0multidrug \u2010resistant\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0\n192(9):1537 \u20101544\u00a0\n\u00a0 391.\u00a0\u00a0Castagna\u00a0A,\u00a0Danise\u00a0A,\u00a0Menzo\u00a0S,\u00a0Galli\u00a0L,\u00a0Gianotti\u00a0N,\u00a0Carini\u00a0E\u00a0et\u00a0al.\u00a0Lamivudine \u00a0monotherapy \u00a0in\u00a0HIV\u20101\u2010\ninfected\u00a0patients\u00a0harbouring \u00a0a\u00a0lamivudine \u2010resistant\u00a0virus:\u00a0a\u00a0randomized \u00a0pilot\u00a0study\u00a0(E\u2010184V\u00a0study).\u00a0AIDS\u00a0\n2006;\u00a020(6):795 \u2010803\u00a0\n\u00a0 392.\u00a0\u00a0Anderson \u00a0AM,\u00a0Bartlett\u00a0JA.\u00a0Changing \u00a0antiretroviral \u00a0therapy\u00a0in\u00a0the\u00a0setting\u00a0of\u00a0virologic\u00a0relapse:\u00a0review\u00a0of\u00a0\nthe\u00a0current\u00a0literature. \u00a0Curr\u00a0HIV/AIDS\u00a0Rep\u00a02006;\u00a03(2):79\u201085\u00a0\n\u00a0 393.\u00a0\u00a0Chaix\u00a0ML,\u00a0Sahali\u00a0S,\u00a0Pallier\u00a0C,\u00a0Barrail\u2010Tran\u00a0A,\u00a0Delfraissy \u00a0JF,\u00a0Ghosn\u00a0J.\u00a0Switching \u00a0to\u00a0darunavir/ritonavir \u00a0\nachieves\u00a0viral\u00a0suppression \u00a0in\u00a0patients\u00a0with\u00a0persistent \u00a0low\u00a0replication \u00a0on\u00a0first\u2010line\u00a0lopinavir/ritonavir. \u00a0\nAIDS\u00a02008;\u00a022(17):2405 \u20102407\u00a0\n\u00a0 394.\u00a0\u00a0Verhofstede \u00a0C,\u00a0Van\u00a0WF,\u00a0Van\u00a0Der\u00a0GB,\u00a0Pelgrom\u00a0J,\u00a0Vandekerckhove \u00a0L,\u00a0Plum\u00a0J\u00a0et\u00a0al.\u00a0Detection \u00a0of\u00a0drug\u00a0\nresistance \u00a0mutations \u00a0as\u00a0a\u00a0predictor \u00a0of\u00a0subsequent \u00a0virological \u00a0failure\u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0viral\u00a0\nrebounds \u00a0of\u00a0less\u00a0than\u00a01,000\u00a0RNA\u00a0copies/ml. \u00a0J\u00a0Med\u00a0Virol\u00a02007;\u00a079(9):1254 \u20101260\u00a0\n\u00a0 395.\u00a0\u00a0Parra\u2010Ruiz\u00a0J,\u00a0Alvarez\u00a0M,\u00a0Chueca\u00a0N,\u00a0Pena\u00a0A,\u00a0Pasquau\u00a0J,\u00a0Lopez\u2010Ruz\u00a0MA\u00a0et\u00a0al.\u00a0Resistencias \u00a0genot\u00edpicas \u00a0en\u00a0\npacientes \u00a0con\u00a0VIH\u20101\u00a0y\u00a0grados\u00a0de\u00a0viremia\u00a0persistentemente \u00a0bajos.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02009;\u00a0\n27(2):75\u201080\u00a0\n\u00a0 396.\u00a0\u00a0Neely\u00a0MN,\u00a0Benning\u00a0L,\u00a0Xu\u00a0J,\u00a0Strickler\u00a0HD,\u00a0Greenblatt \u00a0RM,\u00a0Minkoff\u00a0H\u00a0et\u00a0al.\u00a0Cervical\u00a0shedding\u00a0of\u00a0HIV\u20101\u00a0RNA\u00a0\namong\u00a0women\u00a0with\u00a0low\u00a0levels\u00a0of\u00a0viremia\u00a0while\u00a0receiving\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02007;\u00a044(1):38\u201042\u00a0\n\u00a0 397.\u00a0\u00a0Lawrence \u00a0J,\u00a0Mayers\u00a0DL,\u00a0Hullsiek\u00a0KH,\u00a0Collins\u00a0G,\u00a0Abrams\u00a0DI,\u00a0Reisler\u00a0RB\u00a0et\u00a0al.\u00a0Structured \u00a0treatment \u00a0\ninterruption \u00a0in\u00a0patients\u00a0with\u00a0multidrug \u2010resistant\u00a0human\u00a0immunodeficiency \u00a0virus.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0\n349(9):837 \u2010846\u00a0\n\u00a0 398.\u00a0\u00a0Deeks\u00a0SG,\u00a0Wrin\u00a0T,\u00a0Liegler\u00a0T,\u00a0Hoh\u00a0R,\u00a0Hayden\u00a0M,\u00a0Barbour\u00a0JD\u00a0et\u00a0al.\u00a0Virologic\u00a0and\u00a0immunologic \u00a0\nconsequences \u00a0of\u00a0discontinuing \u00a0combination \u00a0antiretroviral \u2010drug\u00a0therapy\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0\ndetectable \u00a0viremia.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02001;\u00a0344(7):472 \u201080\u00a0\n\u00a0 399.\u00a0\u00a0Markowitz \u00a0M,\u00a0Hill\u2010Zabala\u00a0C,\u00a0Lang\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Liao\u00a0Q,\u00a0Lanier\u00a0ER\u00a0et\u00a0al.\u00a0Induction \u00a0with\u00a0\nabacavir/lamivudine/zidovudine \u00a0plus\u00a0efavirenz\u00a0for\u00a048\u00a0weeks\u00a0followed\u00a0by\u00a048\u2010week\u00a0maintenance \u00a0with\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 207abacavir/lamivudine/zidovudine \u00a0alone\u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr\u00a02005;\u00a039(3):257 \u2010264\u00a0\n\u00a0 400.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0JR,\u00a0Delgado\u00a0R,\u00a0Cabrero\u00a0E,\u00a0Gonzalez\u2010Garcia\u00a0J,\u00a0Perez\u2010Elias\u00a0MJ\u00a0et\u00a0al.\u00a0Lopinavir\u2010ritonavir\u00a0\nmonotherapy \u00a0versus\u00a0lopinavir\u2010ritonavir\u00a0and\u00a0two\u00a0nucleosides \u00a0for\u00a0maintenance \u00a0therapy\u00a0of\u00a0HIV.\u00a0AIDS\u00a0\n2008;\u00a022(2):F1\u2010F9\u00a0\n\u00a0 401.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0J,\u00a0Gonzalez\u2010Garcia\u00a0J,\u00a0L\u00f3pez\u00a0Aldeguer\u00a0J,\u00a0Domingo\u00a0P,\u00a0Estrada\u00a0V,\u00a0et\u00a0al.\u00a0Risk\u00a0factors\u00a0for\u00a0loss\u00a0\nof\u00a0virological \u00a0supression \u00a0at\u00a048\u00a0weeks\u00a0in\u00a0patients\u00a0receiving\u00a0Lopinavir/ritonavir \u00a0monotherapy \u00a0in\u00a02\u00a0clinical\u00a0\ntrials\u00a0comparing \u00a0LPV/r\u00a0monotherapy \u00a0vs\u00a0triple\u00a0therapy\u00a0with\u00a0LPV/r\u00a0(OK\u00a0and\u00a0OK04\u00a0trials).\u00a014th\u00a0Conference \u00a0\non\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Los\u00a0Angeles,\u00a0February\u00a025\u201028\u00a02007.\u00a0Abstract\u00a0513.\u00a0\n\u00a0 402.\u00a0\u00a0Cameron\u00a0DW,\u00a0da\u00a0Silva\u00a0BA,\u00a0Arribas\u00a0JR,\u00a0Myers\u00a0RA,\u00a0Bellos\u00a0NC,\u00a0Gilmore\u00a0N\u00a0et\u00a0al.\u00a0A\u00a096\u2010week\u00a0comparison \u00a0of\u00a0\nlopinavir\u2010ritonavir\u00a0combination \u00a0therapy\u00a0followed\u00a0by\u00a0lopinavir\u2010ritonavir\u00a0monotherapy \u00a0versus\u00a0efavirenz\u00a0\ncombination \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0198(2):234 \u2010240\u00a0\n\u00a0 403.\u00a0\u00a0Nunes\u00a0EP,\u00a0Santini\u00a0de\u00a0OM,\u00a0Mercon\u00a0M,\u00a0Zajdenverg \u00a0R,\u00a0Faulhaber \u00a0JC,\u00a0Pilotto\u00a0JH\u00a0et\u00a0al.\u00a0Monotherapy \u00a0with\u00a0\nLopinavir/Ritonavir \u00a0as\u00a0maintenance \u00a0after\u00a0HIV\u20101\u00a0viral\u00a0suppression: \u00a0results\u00a0of\u00a0a\u00a096\u2010week\u00a0randomized, \u00a0\ncontrolled, \u00a0open\u2010label,\u00a0pilot\u00a0trial\u00a0(KalMo\u00a0study).\u00a0HIV\u00a0Clin\u00a0Trials\u00a02009;\u00a010(6):368 \u2010374\u00a0\n\u00a0 404.\u00a0\u00a0Gutmann \u00a0C,\u00a0Cusini\u00a0A,\u00a0Gunthard \u00a0HF,\u00a0Fux\u00a0C,\u00a0Hirschel\u00a0B,\u00a0Decosterd \u00a0LA\u00a0et\u00a0al.\u00a0Randomized \u00a0controlled \u00a0study\u00a0\ndemonstrating \u00a0failure\u00a0of\u00a0LPV/r\u00a0monotherapy \u00a0in\u00a0HIV:\u00a0the\u00a0role\u00a0of\u00a0compartment \u00a0and\u00a0CD4\u2010nadir.\u00a0AIDS\u00a0\n2010;\u00a024(15):2347 \u20102354\u00a0\n\u00a0 405.\u00a0\u00a0Wilkin\u00a0TJ,\u00a0McKinnon \u00a0JE,\u00a0DiRienzo\u00a0AG,\u00a0Mollan\u00a0K,\u00a0Fletcher\u00a0CV,\u00a0Margolis\u00a0DM\u00a0et\u00a0al.\u00a0Regimen\u00a0simplification \u00a0\nto\u00a0atazanavir \u2010ritonavir\u00a0alone\u00a0as\u00a0maintenance \u00a0antiretroviral \u00a0therapy:\u00a0final\u00a048\u2010week\u00a0clinical\u00a0and\u00a0virologic\u00a0\noutcomes. \u00a0J\u00a0Infect\u00a0Dis\u00a02009;\u00a0199(6):866 \u2010871\u00a0\n\u00a0 406.\u00a0\u00a0Arribas\u00a0JR,\u00a0Horban\u00a0A,\u00a0Gerstoft\u00a0J,\u00a0Fatkenheuer \u00a0G,\u00a0Nelson\u00a0M,\u00a0Clumeck\u00a0N\u00a0et\u00a0al.\u00a0The\u00a0MONET\u00a0trial:\u00a0\ndarunavir/ritonavir \u00a0with\u00a0or\u00a0without\u00a0nucleoside \u00a0analogues, \u00a0for\u00a0patients\u00a0with\u00a0HIV\u00a0RNA\u00a0below\u00a050\u00a0\ncopies/ml. \u00a0AIDS\u00a02010;\u00a024(2):223 \u2010230\u00a0\n\u00a0 407.\u00a0\u00a0Rieger\u00a0A,\u00a0Banhegyi\u00a0D,\u00a0Schmidt\u00a0W,\u00a0Arribas\u00a0JR,\u00a0Hill\u00a0A,\u00a0van\u00a0Delft,\u00a0Y,\u00a0Moecklinghoff \u00a0C.\u00a0The\u00a0MONET\u00a0trial\u00a096\u00a0\nweek\u00a0analysis:\u00a0darunavir/r \u00a0monotherapy \u00a0versus\u00a0darunavir/r \u00a0+\u00a02NRTIs,\u00a0for\u00a0patients\u00a0with\u00a0HIV\u00a0RNA\u00a0<\u00a050\u00a0\ncopies/mL \u00a0at\u00a0baseline.\u00a018th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Vienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0\nTBLBB209. \u00a0\n\u00a0 408.\u00a0\u00a0Katlama\u00a0C,\u00a0Valantin\u00a0MA,\u00a0Algarte\u2010Genin\u00a0M,\u00a0Duvivier\u00a0C,\u00a0Lambert\u2010Niclot\u00a0S,\u00a0Girard\u00a0PM,\u00a0et\u00a0al.\u00a0MONOI\u00a0ANRS\u00a0\n136A\u00a0randomized \u00a0multicenter \u00a0study\u00a0to\u00a0compare\u00a0the\u00a0efficacy\u00a0of\u00a0a\u00a0\u00a0monotherapy \u00a0of\u00a0\u00a0darunavir \u00a0to\u00a0a\u00a0triple\u00a0\ntherapy\u00a0with\u00a0\u00a02\u00a0nucleosides \u00a0analogues \u00a0combined \u00a0to\u00a0darunavir/r \u00a0in\u00a0HIV\u00a0infected\u00a0patients\u00a0with\u00a0full\u00a0viral\u00a0\nsuppression. \u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u2010\n22\u00a02009.\u00a0Abstract\u00a0WELBB102. \u00a0\n\u00a0 409.\u00a0\u00a0Molto\u00a0J,\u00a0Valle\u00a0M,\u00a0Santos\u00a0JR,\u00a0Mothe\u00a0B,\u00a0Miranda\u00a0C,\u00a0Cedeno\u00a0S\u00a0et\u00a0al.\u00a0Treatment \u00a0simplification \u00a0to\u00a0once\u00a0daily\u00a0\ndarunavir/ritonavir \u00a0guided\u00a0by\u00a0the\u00a0darunavir \u00a0inhibitory \u00a0quotient\u00a0in\u00a0heavily\u00a0pretreated \u00a0HIV\u2010infected\u00a0\npatients.\u00a0Antivir\u00a0Ther\u00a02010;\u00a015(2):219 \u2010225\u00a0\n\u00a0 410.\u00a0\u00a0Valentin\u00a0MA,\u00a0Flandre\u00a0P,\u00a0Kolta\u00a0S,\u00a0Duvivier\u00a0C,\u00a0Algarte\u2010Genin\u00a0M,\u00a0Ponscarme \u00a0D,\u00a0Slama\u00a0L,\u00a0Cuzin\u00a0L,\u00a0et\u00a0al.\u00a0Fat\u00a0\ntissue\u00a0distribution \u00a0changes\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0viral\u00a0suppression \u00a0treated\u00a0with\u00a0DRV/r\u00a0\nMonotherapy \u00a0vs\u00a02\u00a0NRTI+DRV/r \u00a0in\u00a0the\u00a0MONOI\u2010ANRS\u00a0136\u00a0randomized \u00a0trial:\u00a0results\u00a0at\u00a048\u00a0weeks.\u00a017th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0\nAbstract\u00a0721.\u00a0\n\u00a0 411.\u00a0\u00a0Cahn\u00a0P,\u00a0Fourie\u00a0J,\u00a0Grinsztejn \u00a0B,\u00a0Hodder\u00a0S,\u00a0Molina\u00a0JM,\u00a0Ruxrungtham \u00a0K,\u00a0Workman \u00a0C,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0\nsafety\u00a0at\u00a048\u00a0weeks\u00a0of\u00a0one\u2010daily\u00a0vs\u00a0twice\u00a0daily\u00a0DRV/r\u00a0in\u00a0treatment \u00a0experienced \u00a0HIV\u20101\u00a0+\u00a0patients\u00a0woth\u00a0no\u00a0\nDRV/\u00a0resistance \u00a0associated \u00a0mutations: \u00a0the\u00a0ODIN\u2010trial.\u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a057.\u00a0\n\u00a0 412.\u00a0\u00a0Curran\u00a0A,\u00a0Gutirerrez \u00a0M,\u00a0Deig\u00a0E,\u00a0Mateo\u00a0G,\u00a0Lopez\u00a0RM,\u00a0Imaz\u00a0A\u00a0et\u00a0al.\u00a0Efficacy,\u00a0safety\u00a0and\u00a0pharmacokinetics \u00a0\nof\u00a0900/100\u00a0mg\u00a0of\u00a0darunavir/ritonavir \u00a0once\u00a0daily\u00a0in\u00a0treatment \u2010experienced \u00a0patients.\u00a0J\u00a0Antimicrob \u00a0\nChemother \u00a02010;\u00a065(10):2195 \u20102203\u00a0\n\u00a0 413.\u00a0\u00a0Pulido\u00a0F,\u00a0Serrano\u00a0O,\u00a0Rivero\u00a0A,\u00a0Montes\u00a0ML,\u00a0Rubio\u00a0R,\u00a0L\u00f3pez\u00a0Bernaldo\u00a0de\u00a0Quir\u00f3s\u00a0JC,\u00a0et\u00a0al.\u00a0\nAtazanavir/ritonavir \u00a0en\u00a0monoterapia \u00a0como\u00a0mantenimiento \u00a0en\u00a0pacientes \u00a0con\u00a0supresi\u00f3n \u00a0virol\u00f3gica: \u00a0\nAn\u00e1lisis\u00a0primario\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0del\u00a0estudio\u00a0OREY.\u00a01er\u00a0Congreso \u00a0Nacional\u00a0de\u00a0Gesida,\u00a0Madrid,\u00a021\u201024\u00a0\noctubre\u00a02009.\u00a0PO\u201070.\u00a0\n\u00a0 414.\u00a0\u00a0Ghosn\u00a0J,\u00a0Carosi\u00a0G,\u00a0Moreno\u00a0S,\u00a0Pokrovsky \u00a0V,\u00a0Lazzarin\u00a0A,\u00a0Pialoux\u00a0G\u00a0et\u00a0al.\u00a0Unboosted \u00a0atazanavir \u2010based\u00a0\ntherapy\u00a0maintains \u00a0control\u00a0of\u00a0HIV\u00a0type\u20101\u00a0replication \u00a0as\u00a0effectively \u00a0as\u00a0a\u00a0ritonavir\u2010boosted\u00a0regimen.\u00a0Antivir\u00a0\nTher\u00a02010;\u00a015(7):993 \u20101002\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 208\u00a0 415.\u00a0\u00a0Squires\u00a0KE,\u00a0Young\u00a0B,\u00a0DeJesus\u00a0E,\u00a0Bellos\u00a0N,\u00a0Murphy\u00a0D,\u00a0Sutherland \u2010Phillips\u00a0DH\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0a\u00a0\n36\u2010week\u00a0induction \u00a0regimen\u00a0of\u00a0abacavir/lamivudine \u00a0and\u00a0ritonavir\u2010boosted\u00a0atazanavir \u00a0in\u00a0HIV\u2010infected\u00a0\npatients.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02010;\u00a011(2):69\u201079\u00a0\n\u00a0 416.\u00a0\u00a0Squires\u00a0KE,\u00a0Young\u00a0B,\u00a0DeJesus\u00a0E,\u00a0Bellos\u00a0N,\u00a0Murphy\u00a0D,\u00a0Zhao\u00a0HH\u00a0et\u00a0al.\u00a0Similar\u00a0efficacy\u00a0and\u00a0tolerability \u00a0of\u00a0\natazanavir \u00a0compared \u00a0with\u00a0atazanavir/ritonavir, \u00a0each\u00a0with\u00a0abacavir/lamivudine \u00a0after\u00a0initial\u00a0suppression \u00a0\nwith\u00a0abacavir/lamivudine \u00a0plus\u00a0ritonavir\u2010boosted\u00a0atazanavir \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a02010;\u00a0\n24(13):2019 \u20102027\u00a0\n\u00a0 417.\u00a0\u00a0Squires\u00a0KE,\u00a0DeJesus\u00a0E,\u00a0Bellos\u00a0N,\u00a0Ward\u00a0D,\u00a0Murphy\u00a0D,\u00a0Young\u00a0B,\u00a0et\u00a0al.\u00a0Sustained \u00a0virologic\u00a0efficacy\u00a0of\u00a0\natazanavir \u00a0vs\u00a0atazanavir/ritonavir \u00a0each\u00a0in\u00a0combination \u00a0with\u00a0abacavir/lamivudine \u00a0over\u00a0120\u00a0weeks:\u00a0the\u00a0\nARIES\u00a0trial.\u00a050th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0Boston,\u00a0\nSeptember \u00a012\u201015\u00a02010.\u00a0Abstract\u00a0H\u2010204.\u00a0\n\u00a0 418.\u00a0\u00a0Becker\u00a0S,\u00a0Rachlis\u00a0A,\u00a0Gill\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Pierone\u00a0G,\u00a0Kirkland\u00a0L,\u00a0Koosian\u00a0S,\u00a0Farina\u00a0D,\u00a0Labriola\u00a0D,\u00a0Ruiz\u00a0N,\u00a0\nBessen\u00a0L,\u00a0Villano\u00a0S.\u00a0Successful \u00a0substitution \u00a0of\u00a0protease\u00a0inhibitors \u00a0with\u00a0efavirenz\u00a0in\u00a0patients\u00a0with\u00a0\nundetectable \u00a0viral\u00a0loads:\u00a0A\u00a0prospective, \u00a0randomized, \u00a0multicenter, \u00a0open\u2010label\u00a0study\u00a0(DMP\u00a0049).\u00a08th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Chicago,\u00a0February\u00a04\u20108\u00a02001.\u00a0Abstract\u00a020.\u00a0\n\u00a0 419.\u00a0\u00a0Katlama\u00a0C,\u00a0Stazewsky \u00a0S,\u00a0Clumeck\u00a0N,\u00a0Arasteh\u00a0K,\u00a0Dellamonica \u00a0P,\u00a0Molina\u00a0JM,\u00a0et\u00a0al.\u00a0Successful \u00a0substitution \u00a0\nof\u00a0protease\u00a0inhibitors \u00a0with\u00a0Sustiva\u00a0(efavirenz) \u00a0in\u00a0patients\u00a0with\u00a0undetectable \u00a0plasma\u00a0HIV\u20101\u00a0RNA:\u00a0results\u00a0\nof\u00a0a\u00a0prospective, \u00a0randomized, \u00a0multicenter, \u00a0open\u2010label\u00a0study\u00a0(DMP\u00a0006\u2010027).\u00a0XIII\u00a0International \u00a0AIDS\u00a0\nConference, \u00a0Durban,\u00a0South\u00a0Africa,\u00a02000\u00a0(Abstract\u00a0LbPeB7044). \u00a0\n\u00a0 420.\u00a0\u00a0Negredo\u00a0E,\u00a0Cruz\u00a0L,\u00a0Paredes\u00a0R,\u00a0Ruiz\u00a0L,\u00a0Fumaz\u00a0CR,\u00a0Bonjoch\u00a0A\u00a0et\u00a0al.\u00a0Virological, \u00a0immunological, \u00a0and\u00a0clinical\u00a0\nimpact\u00a0of\u00a0switching \u00a0from\u00a0protease\u00a0inhibitors \u00a0to\u00a0nevirapine \u00a0or\u00a0to\u00a0efavirenz\u00a0in\u00a0patients\u00a0with\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0infection\u00a0and\u00a0long\u2010lasting\u00a0viral\u00a0suppression. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02002;\u00a034(4):504 \u201010\u00a0\n\u00a0 421.\u00a0\u00a0Maggiolo \u00a0F,\u00a0Ripamonti \u00a0D,\u00a0Ravasio\u00a0L,\u00a0Gregis\u00a0G,\u00a0Quinzan\u00a0G,\u00a0Callegaro \u00a0A\u00a0et\u00a0al.\u00a0Outcome \u00a0of\u00a02\u00a0simplification \u00a0\nstrategies \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02003;\u00a0\n37(1):41\u201049\u00a0\n\u00a0 422.\u00a0\u00a0Campo\u00a0RE,\u00a0Cohen\u00a0C,\u00a0Grimm\u00a0K,\u00a0Shangguan \u00a0T,\u00a0Maa\u00a0J,\u00a0Seekins\u00a0D.\u00a0Switch\u00a0from\u00a0protease\u00a0inhibitor\u2010\u00a0to\u00a0\nefavirenz\u2010based\u00a0antiretroviral \u00a0therapy\u00a0improves \u00a0quality\u00a0of\u00a0life,\u00a0treatment \u00a0satisfaction \u00a0and\u00a0adherence \u00a0\nwith\u00a0low\u00a0rates\u00a0of\u00a0virological \u00a0failure\u00a0in\u00a0virologically \u00a0suppressed \u00a0patients.\u00a0Int\u00a0J\u00a0STD\u00a0AIDS\u00a02010;\u00a021(3):166 \u2010\n171\u00a0\n\u00a0 423.\u00a0\u00a0Ruiz\u00a0L,\u00a0Negredo\u00a0E,\u00a0Domingo\u00a0P,\u00a0Paredes\u00a0R,\u00a0Francia\u00a0E,\u00a0Balague\u00a0M\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0treatment \u00a0\nsimplification \u00a0with\u00a0nevirapine \u00a0in\u00a0protease\u00a0inhibitor\u2010experienced \u00a0patients\u00a0with\u00a0hiv\u2010associated \u00a0\nlipodystrophy: \u00a01\u2010year\u00a0prospective \u00a0follow\u2010up\u00a0of\u00a0a\u00a0multicenter, \u00a0randomized, \u00a0controlled \u00a0study.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02001;\u00a027(3):229 \u201036\u00a0\n\u00a0 424.\u00a0\u00a0Negredo\u00a0E,\u00a0Ribalta\u00a0J,\u00a0Paredes\u00a0R,\u00a0Ferre\u00a0R,\u00a0Sirera\u00a0G,\u00a0Ruiz\u00a0L\u00a0et\u00a0al.\u00a0Reversal\u00a0of\u00a0atherogenic \u00a0lipoprotein \u00a0profile\u00a0\nin\u00a0HIV\u20101\u00a0infected\u00a0patients\u00a0with\u00a0lipodystrophy \u00a0after\u00a0replacing\u00a0protease\u00a0inhibitors \u00a0by\u00a0nevirapine. \u00a0AIDS\u00a0\n2002;\u00a016(10):1383 \u20101389\u00a0\n\u00a0 425.\u00a0\u00a0Arranz\u00a0Caso\u00a0JA,\u00a0Lopez\u00a0JC,\u00a0Santos\u00a0I,\u00a0Estrada\u00a0V,\u00a0Castilla\u00a0V,\u00a0Sanz\u00a0J\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0controlled \u00a0trial\u00a0\ninvestigating \u00a0the\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0switching \u00a0from\u00a0a\u00a0protease\u00a0inhibitor\u00a0to\u00a0nevirapine \u00a0in\u00a0patients\u00a0\nwith\u00a0undetectable \u00a0viral\u00a0load.\u00a0HIV\u00a0Med\u00a02005;\u00a06(5):353\u2010359\u00a0\n\u00a0 426.\u00a0\u00a0Barreiro\u00a0P,\u00a0Soriano\u00a0V,\u00a0Blanco\u00a0F,\u00a0Casimiro\u00a0C,\u00a0de\u00a0la\u00a0Cruz\u00a0JJ,\u00a0Gonzalez\u2010Lahoz\u00a0J.\u00a0Risks\u00a0and\u00a0benefits\u00a0of\u00a0\nreplacing\u00a0protease\u00a0inhibitors \u00a0by\u00a0nevirapine \u00a0in\u00a0HIV\u2010infected\u00a0subjects\u00a0under\u00a0long\u2010term\u00a0successful \u00a0triple\u00a0\ncombination \u00a0therapy.\u00a0AIDS\u00a02000;\u00a014(7):807 \u201012\u00a0\n\u00a0 427.\u00a0\u00a0Dieleman \u00a0JP,\u00a0Sturkenboom \u00a0MC,\u00a0Wit\u00a0FW,\u00a0Jambroes \u00a0M,\u00a0Mulder\u00a0JW,\u00a0Ten\u00a0Veen\u00a0JH\u00a0et\u00a0al.\u00a0Low\u00a0risk\u00a0of\u00a0\ntreatment \u00a0failure\u00a0after\u00a0substitution \u00a0of\u00a0nevirapine \u00a0for\u00a0protease\u00a0inhibitors \u00a0among\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0with\u00a0virus\u00a0suppression. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0185(9):1261 \u20101268\u00a0\n\u00a0 428.\u00a0\u00a0Negredo\u00a0E,\u00a0Miro\u00a0O,\u00a0Rodriguez \u2010Santiago\u00a0B,\u00a0Garrabou \u00a0G,\u00a0Estany\u00a0C,\u00a0Masabeu \u00a0A\u00a0et\u00a0al.\u00a0Improvement \u00a0of\u00a0\nmitochondrial \u00a0toxicity\u00a0in\u00a0patients\u00a0receiving\u00a0a\u00a0nucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitor\u2010sparing\u00a0\nstrategy:\u00a0results\u00a0from\u00a0the\u00a0Multicenter \u00a0Study\u00a0with\u00a0Nevirapine \u00a0and\u00a0Kaletra\u00a0(MULTINEKA). \u00a0Clin\u00a0Infect\u00a0Dis\u00a0\n2009;\u00a049(6):892 \u2010900\u00a0\n\u00a0 429.\u00a0\u00a0Clumeck\u00a0N,\u00a0Goebel\u00a0F,\u00a0Rozenbaum \u00a0W,\u00a0Gerstoft\u00a0J,\u00a0Staszewski \u00a0S,\u00a0Montaner \u00a0J\u00a0et\u00a0al.\u00a0Simplification \u00a0with\u00a0\nabacavir\u2010based\u00a0triple\u00a0nucleoside \u00a0therapy\u00a0versus\u00a0continued \u00a0protease\u00a0inhibitor\u2010based\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy\u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0undetectable \u00a0plasma\u00a0HIV\u20101\u00a0RNA.\u00a0AIDS\u00a02001;\u00a0\n15(12):1517 \u201026\u00a0\n\u00a0 430.\u00a0\u00a0Manfredi \u00a0R,\u00a0Calza\u00a0L.\u00a0Nevirapine \u00a0versus\u00a0efavirenz\u00a0in\u00a0742\u00a0patients:\u00a0no\u00a0link\u00a0of\u00a0liver\u00a0toxicity\u00a0with\u00a0female\u00a0sex,\u00a0\nand\u00a0a\u00a0baseline\u00a0CD4\u00a0cell\u00a0count\u00a0greater\u00a0than\u00a0250\u00a0cells/microl. \u00a0AIDS\u00a02006;\u00a020(17):2233 \u20102236\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 209\u00a0 431.\u00a0\u00a0Wolf\u00a0E,\u00a0Koegl\u00a0C,\u00a0Theobald \u00a0T,\u00a0jaegel\u2010Guedes\u00a0E,\u00a0Jaeger\u00a0H.\u00a0Nevirapine \u2010associated \u00a0hepatotoxicity: \u00a0no\u00a0\nincreased \u00a0risk\u00a0for\u00a0females\u00a0or\u00a0high\u00a0CD4\u00a0count\u00a0in\u00a0a\u00a0single\u2010centre\u00a0HIV\u00a0cohort.\u00a046th\u00a0Interscience \u00a0Conference \u00a0\non\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a02\u201030\u00a02006.\u00a0Abstract\u00a0H\u20101063.\u00a0\n\u00a0 432.\u00a0\u00a0de\u00a0Lazzari\u00a0E,\u00a0Leon\u00a0A,\u00a0Arnaiz\u00a0JA,\u00a0Martinez\u00a0E,\u00a0Knobel\u00a0H,\u00a0Negredo\u00a0E\u00a0et\u00a0al.\u00a0Hepatotoxicity \u00a0of\u00a0nevirapine \u00a0in\u00a0\nvirologically \u00a0suppressed \u00a0patients\u00a0according \u00a0to\u00a0gender\u00a0and\u00a0CD4\u00a0cell\u00a0counts.\u00a0HIV\u00a0Med\u00a02008;\u00a09(4):221\u2010226\u00a0\n\u00a0 433.\u00a0\u00a0Mocroft\u00a0A,\u00a0Staszewski \u00a0S,\u00a0Weber\u00a0R,\u00a0Gatell\u00a0J,\u00a0Rockstroh \u00a0J,\u00a0Gasiorowski \u00a0J\u00a0et\u00a0al.\u00a0Risk\u00a0of\u00a0discontinuation \u00a0of\u00a0\nnevirapine \u00a0due\u00a0to\u00a0toxicities\u00a0in\u00a0antiretroviral \u2010naive\u00a0and\u00a0\u2010experienced \u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0high\u00a0and\u00a0\nlow\u00a0CD4+\u00a0T\u2010cell\u00a0counts.\u00a0Antivir\u00a0Ther\u00a02007;\u00a012(3):325 \u2010333\u00a0\n\u00a0 434.\u00a0\u00a0Antela\u00a0A,\u00a0Ocampo\u00a0A,\u00a0Gomez\u00a0R,\u00a0Lopez\u00a0MJ,\u00a0Marino\u00a0A,\u00a0Losada\u00a0E\u00a0et\u00a0al.\u00a0Liver\u00a0toxicity\u00a0after\u00a0switching \u00a0or\u00a0\nsimplifying \u00a0to\u00a0nevirapine \u2010based\u00a0therapy\u00a0is\u00a0not\u00a0related\u00a0to\u00a0CD4\u00a0cell\u00a0counts:\u00a0results\u00a0of\u00a0the\u00a0TOSCANA \u00a0study.\u00a0\nHIV\u00a0Clin\u00a0Trials\u00a02010;\u00a011(1):11\u201017\u00a0\n\u00a0 435.\u00a0\u00a0Wit\u00a0FW,\u00a0Kesselring \u00a0AM,\u00a0Gras\u00a0L,\u00a0Richter\u00a0C,\u00a0Van\u00a0Der\u00a0Ende\u00a0ME,\u00a0Brinkman \u00a0K\u00a0et\u00a0al.\u00a0Discontinuation \u00a0of\u00a0\nnevirapine \u00a0because\u00a0of\u00a0hypersensitivity \u00a0reactions \u00a0in\u00a0patients\u00a0with\u00a0prior\u00a0treatment \u00a0experience, \u00a0compared \u00a0\nwith\u00a0treatment \u2010naive\u00a0patients:\u00a0the\u00a0ATHENA\u00a0cohort\u00a0study.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a046(6):933 \u2010940\u00a0\n\u00a0 436.\u00a0\u00a0Katlama\u00a0C,\u00a0Fenske\u00a0S,\u00a0Gazzard\u00a0B,\u00a0Lazzarin\u00a0A,\u00a0Clumeck\u00a0N,\u00a0Mallolas\u00a0J\u00a0et\u00a0al.\u00a0TRIZAL\u00a0study:\u00a0switching \u00a0from\u00a0\nsuccessful \u00a0HAART\u00a0to\u00a0Trizivir\u00a0(abacavir\u2010lamivudine \u2010zidovudine \u00a0combination \u00a0tablet):\u00a048\u00a0weeks\u00a0efficacy,\u00a0\nsafety\u00a0and\u00a0adherence \u00a0results.\u00a0HIV\u00a0Med\u00a02003;\u00a04(2):79\u201086\u00a0\n\u00a0 437.\u00a0\u00a0Opravil\u00a0M,\u00a0Hirschel\u00a0B,\u00a0Lazzarin\u00a0A,\u00a0Furrer\u00a0H,\u00a0Chave\u00a0JP,\u00a0Yerly\u00a0S\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0of\u00a0simplified \u00a0\nmaintenance \u00a0therapy\u00a0with\u00a0abacavir,\u00a0lamivudine, \u00a0and\u00a0zidovudine \u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0\ninfection. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0185(9):1251 \u20101260\u00a0\n\u00a0 438.\u00a0\u00a0Pulvirenti \u00a0J,\u00a0Goodwin\u00a0D,\u00a0Slater\u00a0L.\u00a0Simplification \u00a0of\u00a0protease\u00a0inhibitor\u2010\u00a0containing \u00a0HAART\u00a0regimens \u00a0with\u00a0\nabacavir\u00a0maintains \u00a0viral\u00a0suppression \u00a0and\u00a0favourable \u00a0adherence \u00a0in\u00a0HIV\u20101\u00a0infected\u00a0adults\u00a0(COLA30305). \u00a0\n39th\u00a0Annual\u00a0Meeting\u00a0of\u00a0the\u00a0Infectious \u00a0Disease\u00a0Society\u00a0of\u00a0America,\u00a0San\u00a0Francisco, \u00a0october\u00a025\u201028\u00a02001.\u00a0\nAbstract\u00a0620.\u00a0\n\u00a0 439.\u00a0\u00a0Mallolas\u00a0J,\u00a0Pich\u00a0J,\u00a0Penaranda \u00a0M,\u00a0Domingo\u00a0P,\u00a0Knobel\u00a0H,\u00a0Pedrol\u00a0E\u00a0et\u00a0al.\u00a0Induction \u00a0therapy\u00a0with\u00a0trizivir\u00a0plus\u00a0\nefavirenz\u00a0or\u00a0lopinavir/ritonavir \u00a0followed\u00a0by\u00a0trizivir\u00a0alone\u00a0in\u00a0naive\u00a0HIV\u20101\u2010infected\u00a0adults.\u00a0AIDS\u00a02008;\u00a0\n22(3):377 \u2010384\u00a0\n\u00a0 440.\u00a0\u00a0d'Ettorre\u00a0G,\u00a0Zaffiri\u00a0L,\u00a0Ceccarelli \u00a0G,\u00a0Andreotti \u00a0M,\u00a0Massetti\u00a0AP,\u00a0Vella\u00a0S\u00a0et\u00a0al.\u00a0Simplified \u00a0maintenance \u00a0\ntherapy\u00a0with\u00a0abacavir/lamivudine/zidovudine \u00a0plus\u00a0tenofovir\u00a0after\u00a0sustained \u00a0HIV\u00a0load\u00a0suppression: \u00a0four\u00a0\nyears\u00a0of\u00a0follow\u2010up.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(3):182\u2010188\u00a0\n\u00a0 441.\u00a0\u00a0Hoogewerf \u00a0M,\u00a0Regez\u00a0RM,\u00a0Schouten \u00a0WE,\u00a0Weigel\u00a0HM,\u00a0Frissen\u00a0PH,\u00a0Brinkman \u00a0K.\u00a0Change\u00a0to\u00a0abacavir\u2010\nlamivudine \u2010tenofovir\u00a0combination \u00a0treatment \u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0who\u00a0had\u00a0complete \u00a0virological \u00a0\nsuppression. \u00a0Lancet\u00a02003;\u00a0362(9400):1979 \u20101980\u00a0\n\u00a0 442.\u00a0\u00a0Martinez\u00a0E,\u00a0Arnaiz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Dalmau\u00a0D,\u00a0Ribera\u00a0E,\u00a0Domingo\u00a0P\u00a0et\u00a0al.\u00a0Substitution \u00a0of\u00a0nevirapine, \u00a0\nefavirenz, \u00a0or\u00a0abacavir\u00a0for\u00a0protease\u00a0inhibitors \u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0\nN\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0349(11):1036 \u20101046\u00a0\n\u00a0 443.\u00a0\u00a0Martinez\u00a0E,\u00a0Arnaiz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Dalmau\u00a0D,\u00a0Ribera\u00a0E,\u00a0Domingo\u00a0P\u00a0et\u00a0al.\u00a0Three\u2010year\u00a0follow\u2010up\u00a0of\u00a0\nprotease\u00a0inhibitor\u2010based\u00a0regimen\u00a0simplification \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a02007;\u00a021(3):367 \u2010369\u00a0\n\u00a0 444.\u00a0\u00a0Ochoa\u00a0de\u00a0EA,\u00a0Arnedo\u00a0M,\u00a0Xercavins \u00a0M,\u00a0Martinez\u00a0E,\u00a0Roson\u00a0B,\u00a0Ribera\u00a0E\u00a0et\u00a0al.\u00a0Genotypic \u00a0and\u00a0phenotypic \u00a0\nresistance \u00a0patterns\u00a0at\u00a0virological \u00a0failure\u00a0in\u00a0a\u00a0simplification \u00a0trial\u00a0with\u00a0nevirapine, \u00a0efavirenz\u00a0or\u00a0abacavir.\u00a0\nAIDS\u00a02005;\u00a019(13):1385 \u20101391\u00a0\n\u00a0 445.\u00a0\u00a0Fisac\u00a0C,\u00a0Fumero\u00a0E,\u00a0Crespo\u00a0M,\u00a0Roson\u00a0B,\u00a0Ferrer\u00a0E,\u00a0Virgili\u00a0N\u00a0et\u00a0al.\u00a0Metabolic \u00a0benefits\u00a024\u00a0months\u00a0after\u00a0\nreplacing\u00a0a\u00a0protease\u00a0inhibitor\u00a0with\u00a0abacavir,\u00a0efavirenz\u00a0or\u00a0nevirapine. \u00a0AIDS\u00a02005;\u00a019(9):917 \u2010925\u00a0\n\u00a0 446.\u00a0\u00a0Martinez\u00a0E,\u00a0Gatell\u00a0JM.\u00a0Considerations \u00a0on\u00a0the\u00a0effectiveness \u00a0of\u00a0nevirapine \u00a0in\u00a0protease\u00a0inhibitor\u2010based\u00a0\nregimen\u00a0simplification. \u00a0AIDS\u00a02007;\u00a021(13):1829 \u20101830\u00a0\n\u00a0 447.\u00a0\u00a0Abgrall\u00a0S,\u00a0Yeni\u00a0PG,\u00a0Bouchaud \u00a0O,\u00a0Costagliola \u00a0D.\u00a0Switch\u00a0from\u00a0a\u00a0first\u00a0virologically \u00a0effective\u00a0protease\u00a0\ninhibitor\u2010containing \u00a0regimen\u00a0to\u00a0a\u00a0regimen\u00a0containing \u00a0efavirenz, \u00a0nevirapine \u00a0or\u00a0abacavir.\u00a0AIDS\u00a02006;\u00a0\n20(16):2099 \u20102106\u00a0\n\u00a0 448.\u00a0\u00a0Bonjoch\u00a0A,\u00a0Paredes\u00a0R,\u00a0Galvez\u00a0J,\u00a0Miralles\u00a0C,\u00a0Videla\u00a0S,\u00a0Martinez\u00a0E\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0treatment \u00a0\nsimplification \u00a0with\u00a03\u00a0NRTIs\u00a0or\u00a02\u00a0NRTIs\u00a0plus\u00a0nevirapine \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0successful \u00a0\nfirst\u2010line\u00a0HAART.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a039(3):313 \u2010316\u00a0\n\u00a0 449.\u00a0\u00a0Gatell\u00a0J,\u00a0Salmon\u2010Ceron\u00a0D,\u00a0Lazzarin\u00a0A,\u00a0van\u00a0WE,\u00a0Antunes\u00a0F,\u00a0Leen\u00a0C\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0atazanavir \u2010\nbased\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0virologic\u00a0suppression \u00a0switched\u00a0from\u00a0a\u00a0stable,\u00a0\nboosted\u00a0or\u00a0unboosted \u00a0protease\u00a0inhibitor\u00a0treatment \u00a0regimen:\u00a0the\u00a0SWAN\u00a0Study\u00a0(AI424\u2010097)\u00a048\u2010week\u00a0\nresults.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(11):1484 \u20101492\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 210\u00a0 450.\u00a0\u00a0Mallolas\u00a0J,\u00a0Podzamczer \u00a0D,\u00a0Milinkovic \u00a0A,\u00a0Domingo\u00a0P,\u00a0Clotet\u00a0B,\u00a0Ribera\u00a0E\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nswitching \u00a0from\u00a0boosted\u00a0lopinavir\u00a0to\u00a0boosted\u00a0atazanavir \u00a0in\u00a0patients\u00a0with\u00a0virological \u00a0suppression \u00a0\nreceiving\u00a0a\u00a0LPV/r\u2010containing \u00a0HAART:\u00a0the\u00a0ATAZIP\u00a0study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(1):29\u201036\u00a0\n\u00a0 451.\u00a0\u00a0Rubio\u00a0R,\u00a0Serrano\u00a0O,\u00a0Carmena\u00a0J,\u00a0Asensi\u00a0V,\u00a0Echevarria \u00a0S,\u00a0Flores\u00a0J\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0simplification \u00a0from\u00a0\nprotease\u00a0inhibitors \u00a0to\u00a0boosted\u00a0atazanavir \u2010based\u00a0regimens \u00a0in\u00a0real\u2010life\u00a0conditions. \u00a0HIV\u00a0Med\u00a02010;\u00a0\n11(9):545 \u2010553\u00a0\n\u00a0 452.\u00a0\u00a0Moyle\u00a0G,\u00a0Girard\u00a0JM,\u00a0Andrade\u00a0J,\u00a0Salvato\u00a0P,\u00a0Bogner\u00a0JR,\u00a0Hay\u00a0P,\u00a0et\u00a0al.\u00a0Continuation \u00a0of\u00a0BID\u00a0boosted\u00a0PI\u00a0vs\u00a0\nswitch\u00a0to\u00a0once\u2010daily\u00a0ATV/RTV\u00a0for\u00a0the\u00a0management \u00a0of\u00a0lipodystrophy: \u00a048\u00a0week\u00a0primary\u00a0analysis\u00a0of\u00a0the\u00a096\u00a0\nweek\u00a0multicenter, \u00a0open\u2010label,\u00a0randomized, \u00a0prospective \u00a0ReAL\u00a0study.\u00a017th\u00a0International \u00a0AIDS\u00a0\nConference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0MOPDB103. \u00a0\n\u00a0 453.\u00a0\u00a0Sension\u00a0M,\u00a0ndrade\u00a0Neto\u00a0JL,\u00a0Grinsztejn \u00a0B,\u00a0Molina\u00a0JM,\u00a0Zavala\u00a0I,\u00a0Gonzalez\u2010Garcia\u00a0J\u00a0et\u00a0al.\u00a0Improvement \u00a0in\u00a0\nlipid\u00a0profiles\u00a0in\u00a0antiretroviral \u2010experienced \u00a0HIV\u2010positive\u00a0patients\u00a0with\u00a0hyperlipidemia \u00a0after\u00a0a\u00a0switch\u00a0to\u00a0\nunboosted \u00a0atazanavir. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(2):153 \u2010162\u00a0\n\u00a0 454.\u00a0\u00a0Molina\u00a0JM,\u00a0Journot\u00a0V,\u00a0Morand\u2010Joubert\u00a0L,\u00a0Yeni\u00a0P,\u00a0Rozenbaum \u00a0W,\u00a0Rancinan\u00a0C\u00a0et\u00a0al.\u00a0Simplification \u00a0therapy\u00a0\nwith\u00a0once\u2010daily\u00a0emtricitabine, \u00a0didanosine, \u00a0and\u00a0efavirenz\u00a0in\u00a0HIV\u20101\u2010infected\u00a0adults\u00a0with\u00a0viral\u00a0suppression \u00a0\nreceiving\u00a0a\u00a0protease\u00a0inhibitor\u2010based\u00a0regimen:\u00a0a\u00a0randomized \u00a0trial.\u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0191(6):830 \u2010839\u00a0\n\u00a0 455.\u00a0\u00a0Negredo\u00a0E,\u00a0Molto\u00a0J,\u00a0Munoz\u2010Moreno\u00a0JA,\u00a0Pedrol\u00a0E,\u00a0Ribera\u00a0E,\u00a0Viciana\u00a0P\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0once\u2010\ndaily\u00a0didanosine, \u00a0tenofovir\u00a0and\u00a0nevirapine \u00a0as\u00a0a\u00a0simplification \u00a0antiretroviral \u00a0approach. \u00a0Antivir\u00a0Ther\u00a02004;\u00a0\n9(3):335\u2010342\u00a0\n\u00a0 456.\u00a0\u00a0Barrios\u00a0A,\u00a0Rendon\u00a0A,\u00a0Negredo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Garcia\u2010Benayas\u00a0T,\u00a0Labarga\u00a0P\u00a0et\u00a0al.\u00a0Paradoxical \u00a0CD4+\u00a0T\u2010cell\u00a0\ndecline\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0complete \u00a0virus\u00a0suppression \u00a0taking\u00a0tenofovir\u00a0and\u00a0didanosine. \u00a0AIDS\u00a0\n2005;\u00a019(6):569 \u2010575\u00a0\n\u00a0 457.\u00a0\u00a0Fisher\u00a0M,\u00a0Moyle\u00a0GJ,\u00a0Shahmanesh \u00a0M,\u00a0Orkin\u00a0C,\u00a0Kingston\u00a0M,\u00a0Wilkins\u00a0E\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0comparative \u00a0\ntrial\u00a0of\u00a0continued \u00a0zidovudine/lamivudine \u00a0or\u00a0replacement \u00a0with\u00a0tenofovir\u00a0disoproxil \u00a0\nfumarate/emtricitabine \u00a0in\u00a0efavirenz\u2010treated\u00a0HIV\u20101\u2010infected\u00a0individuals. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2009;\u00a051(5):562 \u2010568\u00a0\n\u00a0 458.\u00a0\u00a0Mart\u00ednez\u00a0E,\u00a0Ribera\u00a0E,\u00a0Pulido\u00a0F,\u00a0Rubio\u00a0R,\u00a0Negredo\u00a0E,\u00a0Sanz\u00a0J\u00a0et\u00a0al.\u00a0Early\u00a0improvement \u00a0of\u00a0limb\u00a0fat\u00a0content\u00a0in\u00a0\npatients\u00a0switching \u00a0from\u00a0AZT/3TC\u00a0to\u00a0FTC/TDF\u00a0(TVD):\u00a0a\u00a024\u00a0week\u00a0interim\u00a0analysis\u00a0of\u00a0the\u00a0RECOMB\u00a0Trial.\u00a0\n17th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0MOPDB102. \u00a0\n\u00a0 459.\u00a0\u00a0Ribera\u00a0E,\u00a0Martinez\u00a0E,\u00a0Clotet\u00a0B,\u00a0Estrada\u00a0V,\u00a0Sanz\u00a0J,\u00a0Berenguer \u00a0J,\u00a0et\u00a0al.\u00a072\u00a0week\u00a0outcomes \u00a0following \u00a0switch\u00a0\nfrom\u00a0AZT/3TC\u00a0to\u00a0FTC/TDF\u00a0(TVD)\u00a0vs\u00a0continuing \u00a0on\u00a0AZT/3TC.\u00a0Final\u00a0results\u00a0of\u00a0the\u00a0RECOMB\u00a0trial.\u00a05th\u00a0IAS\u00a0\nConference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0\nCDB091.\u00a0\n\u00a0 460.\u00a0\u00a0Valantin\u00a0MA,\u00a0Bittar\u00a0R,\u00a0de\u00a0TP,\u00a0Bollens\u00a0D,\u00a0Slama\u00a0L,\u00a0Giral\u00a0P\u00a0et\u00a0al.\u00a0Switching \u00a0the\u00a0nucleoside \u00a0reverse\u00a0\ntranscriptase \u00a0inhibitor\u00a0backbone \u00a0to\u00a0tenofovir\u00a0disoproxil \u00a0fumarate \u00a0+\u00a0emtricitabine \u00a0promptly\u00a0improves \u00a0\ntriglycerides \u00a0and\u00a0low\u2010density\u00a0lipoprotein \u00a0cholesterol \u00a0in\u00a0dyslipidaemic \u00a0patients.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a0\n2010;\u00a065(3):556 \u2010561\u00a0\n\u00a0 461.\u00a0\u00a0Martinez\u00a0E,\u00a0Arranz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Lonca\u00a0M,\u00a0Sanz\u00a0J,\u00a0Barragan\u00a0P\u00a0et\u00a0al.\u00a0A\u00a0simplification \u00a0trial\u00a0switching \u00a0\nfrom\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0to\u00a0once\u2010daily\u00a0fixed\u2010dose\u00a0abacavir/lamivudine \u00a0or\u00a0\ntenofovir/emtricitabine \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0virological \u00a0suppression. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02009;\u00a051(3):290 \u2010297\u00a0\n\u00a0 462.\u00a0\u00a0Martin\u00a0A,\u00a0Bloch\u00a0M,\u00a0Amin\u00a0J,\u00a0Baker\u00a0D,\u00a0Cooper\u00a0DA,\u00a0Emery\u00a0S\u00a0et\u00a0al.\u00a0Simplification \u00a0of\u00a0antiretroviral \u00a0therapy\u00a0\nwith\u00a0tenofovir\u2010emtricitabine \u00a0or\u00a0abacavir\u2010Lamivudine: \u00a0a\u00a0randomized, \u00a096\u2010week\u00a0trial.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a0\n49(10):1591 \u20101601\u00a0\n\u00a0 463.\u00a0\u00a0DeJesus\u00a0E,\u00a0Young\u00a0B,\u00a0Morales\u2010Ramirez\u00a0JO,\u00a0Sloan\u00a0L,\u00a0Ward\u00a0DJ,\u00a0Flaherty\u00a0JF\u00a0et\u00a0al.\u00a0Simplification \u00a0of\u00a0\nantiretroviral \u00a0therapy\u00a0to\u00a0a\u00a0single\u2010tablet\u00a0regimen\u00a0consisting \u00a0of\u00a0efavirenz, \u00a0emtricitabine, \u00a0and\u00a0tenofovir\u00a0\ndisoproxil \u00a0fumarate \u00a0versus\u00a0unmodified \u00a0antiretroviral \u00a0therapy\u00a0in\u00a0virologically \u00a0suppressed \u00a0HIV\u20101\u2010infected\u00a0\npatients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(2):163 \u2010174\u00a0\n\u00a0 464.\u00a0\u00a0Hodder\u00a0SL,\u00a0Mounzer\u00a0K,\u00a0DeJesus\u00a0E,\u00a0Ebrahimi\u00a0R,\u00a0Grimm\u00a0K,\u00a0Esker\u00a0S\u00a0et\u00a0al.\u00a0Patient\u2010reported\u00a0outcomes \u00a0in\u00a0\nvirologically \u00a0suppressed, \u00a0HIV\u20101\u2010Infected\u00a0subjects\u00a0after\u00a0switching \u00a0to\u00a0a\u00a0simplified, \u00a0single\u2010tablet\u00a0regimen\u00a0of\u00a0\nefavirenz, \u00a0emtricitabine, \u00a0and\u00a0tenofovir\u00a0DF.\u00a0AIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02010;\u00a024(2):87\u201096\u00a0\n\u00a0 465.\u00a0\u00a0Airoldi\u00a0M,\u00a0Zaccarelli \u00a0M,\u00a0Bisi\u00a0L,\u00a0Bini\u00a0T,\u00a0Antinori\u00a0A,\u00a0Mussini\u00a0C\u00a0et\u00a0al.\u00a0One\u2010pill\u00a0once\u2010a\u2010day\u00a0HAART:\u00a0a\u00a0\nsimplification \u00a0strategy\u00a0that\u00a0improves \u00a0adherence \u00a0and\u00a0quality\u00a0of\u00a0life\u00a0of\u00a0HIV\u2010infected\u00a0subjects.\u00a0Patient\u00a0\nPrefer\u00a0Adherence \u00a02010;\u00a04:115\u2010125\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 211\u00a0 466.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Olmo\u00a0M,\u00a0Sanz\u00a0J,\u00a0Boix\u00a0V,\u00a0Negredo\u00a0E,\u00a0Knobel\u00a0H\u00a0et\u00a0al.\u00a0Safety\u00a0of\u00a0switching \u00a0nevirapine \u00a0twice\u00a0\ndaily\u00a0to\u00a0nevirapine \u00a0once\u00a0daily\u00a0in\u00a0virologically \u00a0suppressed \u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a0\n50(4):390 \u2010396\u00a0\n\u00a0 467.\u00a0\u00a0Pollard\u00a0RB.\u00a0Can\u00a0HIV\u00a0infection\u00a0be\u00a0treated\u00a0successfully \u00a0with\u00a0a\u00a0once\u2010daily\u00a0regimen? \u00a0AIDS\u00a0Read\u00a02002;\u00a0\n12(11):489 \u20108,\u00a0500,\u00a0508\u00a0\n\u00a0 468.\u00a0\u00a0Towner\u00a0W,\u00a0Klein\u00a0D,\u00a0Kerrigan\u00a0HL,\u00a0Follansbee \u00a0S,\u00a0Yu\u00a0K,\u00a0Horberg\u00a0M.\u00a0Virologic\u00a0outcomes \u00a0of\u00a0changing\u00a0\nenfuvirtide \u00a0to\u00a0raltegravir \u00a0in\u00a0HIV\u20101\u00a0patients\u00a0well\u00a0controlled \u00a0on\u00a0an\u00a0enfuvirtide \u00a0based\u00a0regimen:\u00a024\u2010week\u00a0\nresults\u00a0of\u00a0the\u00a0CHEER\u00a0study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(4):367 \u2010373\u00a0\n\u00a0 469.\u00a0\u00a0Harris\u00a0M,\u00a0Larsen\u00a0G,\u00a0Montaner \u00a0JSG.\u00a0Outcomes \u00a0of\u00a0patients\u00a0switched\u00a0from\u00a0Raltegravir \u00a0within\u00a0a\u00a0\nvirologocally \u00a0suppressive \u00a0regimen.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0\nBoston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0799.\u00a0\n\u00a0 470.\u00a0\u00a0De\u00a0Castro\u00a0N,\u00a0Braun\u00a0J,\u00a0Charreau\u00a0I,\u00a0Pialoux\u00a0G,\u00a0Cotte\u00a0L,\u00a0Katlama\u00a0C,\u00a0et\u00a0al.\u00a0Switch\u00a0from\u00a0Enfuvirtide \u00a0to\u00a0\nRaltegravir \u00a0in\u00a0highly\u00a0treatment \u2010experienced \u00a0patients:\u00a0a\u00a0randomized \u00a0open\u00a0label\u00a0non\u2010inferiority \u00a0trial,\u00a0\nEasier\u2010ANRS\u00a0138.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u2010\n11\u00a02009.\u00a0Abstract\u00a0572.\u00a0\n\u00a0 471.\u00a0\u00a0Gatti\u00a0F,\u00a0Matti\u00a0A,\u00a0Nasta\u00a0P,\u00a0Cologni\u00a0G,\u00a0Costarelli \u00a0S,\u00a0Carosi\u00a0G.\u00a0Switch\u00a0from\u00a0enfuvirtide \u00a0to\u00a0raltegravir: \u00a0a\u00a0\nsimplification \u00a0option\u00a0for\u00a0heavily\u00a0pretreated \u00a0patients.\u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0\nInfection, \u00a0Glasgow,\u00a0November \u00a09\u201013\u00a02008.\u00a0Abstract\u00a0P52.\u00a0\n\u00a0 472.\u00a0\u00a0Talbot\u00a0A,\u00a0Machouf\u00a0N,\u00a0Thomas\u00a0R,\u00a0Marcotte \u00a0S,\u00a0Therrien\u00a0R,\u00a0Lessard\u00a0B\u00a0et\u00a0al.\u00a0Switch\u00a0from\u00a0enfuvirtide \u00a0to\u00a0\nraltegravir \u00a0in\u00a0patients\u00a0with\u00a0undetectable \u00a0viral\u00a0load:\u00a0efficacy\u00a0and\u00a0safety\u00a0at\u00a024\u00a0weeks\u00a0in\u00a0a\u00a0Montreal \u00a0\ncohort.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(3):362 \u2010364\u00a0\n\u00a0 473.\u00a0\u00a0Santos\u00a0JR,\u00a0Llibre\u00a0JM,\u00a0Ferrer\u00a0E,\u00a0Domingo\u00a0P,\u00a0Imaz\u00a0A,\u00a0Molto\u00a0J\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0switching \u00a0from\u00a0\nenfuvirtide \u00a0to\u00a0raltegravir \u00a0in\u00a0patients\u00a0with\u00a0virological \u00a0suppression. \u00a0HIV\u00a0Clin\u00a0Trials\u00a02009;\u00a010(6):432 \u2010438\u00a0\n\u00a0 474.\u00a0\u00a0Loutfy\u00a0M,\u00a0Ribera\u00a0E,\u00a0Florence\u00a0E,\u00a0De\u00a0WS,\u00a0Castagna\u00a0A,\u00a0Ryan\u00a0R\u00a0et\u00a0al.\u00a0Sustained \u00a0HIV\u00a0RNA\u00a0suppression \u00a0after\u00a0\nswitching \u00a0from\u00a0enfuvirtide \u00a0to\u00a0etravirine \u00a0in\u00a0the\u00a0early\u00a0access\u00a0programme. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02009;\u00a0\n64(6):1341 \u20101344\u00a0\n\u00a0 475.\u00a0\u00a0Eron\u00a0JJ,\u00a0Young\u00a0B,\u00a0Cooper\u00a0DA,\u00a0Youle\u00a0M,\u00a0DeJesus\u00a0E,\u00a0ndrade\u2010Villanueva \u00a0J\u00a0et\u00a0al.\u00a0Switch\u00a0to\u00a0a\u00a0raltegravir \u2010based\u00a0\nregimen\u00a0versus\u00a0continuation \u00a0of\u00a0a\u00a0lopinavir\u2010ritonavir\u2010based\u00a0regimen\u00a0in\u00a0stable\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0\nsuppressed \u00a0viraemia\u00a0(SWITCHMRK \u00a01\u00a0and\u00a02):\u00a0two\u00a0multicentre, \u00a0double\u2010blind,\u00a0randomised \u00a0controlled \u00a0\ntrials.\u00a0Lancet\u00a02010;\u00a0375(9712):396 \u2010407\u00a0\n\u00a0 476.\u00a0\u00a0Martinez\u00a0E,\u00a0Larrousse \u00a0M,\u00a0Llibre\u00a0JM,\u00a0Gutierrez \u00a0F,\u00a0Saumoy\u00a0M,\u00a0Antela\u00a0A\u00a0et\u00a0al.\u00a0Substitution \u00a0of\u00a0raltegravir \u00a0for\u00a0\nritonavir\u2010boosted\u00a0protease\u00a0inhibitors \u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0the\u00a0SPIRAL\u00a0study.\u00a0AIDS\u00a02010;\u00a0\n24(11):1697 \u20101707\u00a0\n\u00a0 477.\u00a0\u00a0Vispo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Maida\u00a0I,\u00a0Mena\u00a0A,\u00a0Blanco\u00a0F,\u00a0Rodriguez \u2010Novoa\u00a0S,\u00a0et\u00a0al.\u00a0Simplification \u00a0from\u00a0protease\u00a0\ninhibitors \u00a0to\u00a0once\u00a0or\u00a0twice\u00a0daily\u00a0raltegravir: \u00a0the\u00a0ODIS\u00a0trial.\u00a018th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Vienna,\u00a0\nJuly\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0MOAB0102. \u00a0\n\u00a0 478.\u00a0\u00a0Kilby\u00a0JM.\u00a0Switching \u00a0HIV\u00a0therapies: \u00a0competing \u00a0host\u00a0and\u00a0viral\u00a0factors.\u00a0Lancet\u00a02010;\u00a0375(9712):352 \u2010354\u00a0\n\u00a0 479.\u00a0\u00a0Eron\u00a0J,\u00a0Andrade\u00a0J,\u00a0Zajdenverg \u00a0R,\u00a0Workman \u00a0C,\u00a0Cooper\u00a0D,\u00a0Young\u00a0B,\u00a0et\u00a0al.\u00a0Switching \u00a0from\u00a0stable\u00a0\nlopinavir/ritonavir \u2010based\u00a0to\u00a0raltegravir \u2010based\u00a0combination \u00a0ART\u00a0resulted\u00a0in\u00a0a\u00a0superior\u00a0lipid\u00a0profile\u00a0at\u00a0\nweek\u00a012\u00a0but\u00a0did\u00a0not\u00a0demonstrate \u00a0non\u2010inferior\u00a0virologic\u00a0efficacy\u00a0at\u00a0week\u00a024.\u00a016th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a070aLB.\u00a0\n\u00a0 480.\u00a0\u00a0Arribas\u00a0JR,\u00a0Delgado\u00a0R,\u00a0Arranz\u00a0A,\u00a0Munoz\u00a0R,\u00a0Portilla\u00a0J,\u00a0Pasquau\u00a0J\u00a0et\u00a0al.\u00a0Lopinavir\u2010ritonavir\u00a0monotherapy \u00a0\nversus\u00a0lopinavir\u2010ritonavir\u00a0and\u00a02\u00a0nucleosides \u00a0for\u00a0maintenance \u00a0therapy\u00a0of\u00a0HIV:\u00a096\u2010week\u00a0analysis.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(2):147 \u2010152\u00a0\n\u00a0 481.\u00a0\u00a0Pulido\u00a0F,\u00a0Matarranz \u00a0M,\u00a0Rodriguez \u2010Rivera\u00a0V,\u00a0Fiorante\u00a0S,\u00a0Hernando \u00a0A.\u00a0Boosted\u00a0protease\u00a0inhibitor\u00a0\nmonotherapy. \u00a0What\u00a0have\u00a0we\u00a0learnt\u00a0after\u00a0seven\u00a0years\u00a0of\u00a0research? \u00a0AIDS\u00a0Rev\u00a02010;\u00a012(3):127 \u2010134\u00a0\n\u00a0 482.\u00a0\u00a0Arribas\u00a0JR,\u00a0Horban\u00a0A,\u00a0Gerstoft\u00a0J,\u00a0F\u00e4lkenheuer \u00a0G,\u00a0Nelson\u00a0M,\u00a0Clumeck\u00a0N,\u00a0Pulido\u00a0F,\u00a0et\u00a0al.\u00a0The\u00a0MONET\u00a0trial:\u00a0\ndarunavir/ritonavir \u00a0monotherapy \u00a0shows\u00a0non\u2010inferior\u00a0efficacy\u00a0to\u00a0standard\u00a0HAART,\u00a0for\u00a0patients\u00a0with\u00a0HIV\u00a0\nRNA\u00a0<50\u00a0copies/mL \u00a0at\u00a0baseline.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0\nCape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abastract \u00a0TUAB106 \u2010LB.\u00a0\n\u00a0 483.\u00a0\u00a0Barrios\u00a0A,\u00a0Negredo\u00a0E,\u00a0Domingo\u00a0P,\u00a0Estrada\u00a0V,\u00a0Labarga\u00a0P,\u00a0Asensi\u00a0V\u00a0et\u00a0al.\u00a0Simplification \u00a0therapy\u00a0with\u00a0once\u2010\ndaily\u00a0didanosine, \u00a0tenofovir\u00a0and\u00a0efavirenz\u00a0in\u00a0HIV\u20101\u2010infected\u00a0adults\u00a0with\u00a0viral\u00a0suppression \u00a0receiving\u00a0a\u00a0\nmore\u00a0complex\u00a0antiretroviral \u00a0regimen:\u00a0final\u00a0results\u00a0of\u00a0the\u00a0EFADITE\u00a0trial.\u00a0Antivir\u00a0Ther\u00a02005;\u00a010(7):825 \u2010832\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 212\u00a0 484.\u00a0\u00a0Rubio\u00a0R,\u00a0Carmena\u00a0J,\u00a0Asensi\u00a0V,\u00a0Echevarria \u00a0S,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0simplification \u00a0from\u00a0protease\u00a0inhibitors \u00a0to\u00a0\nboosted\u00a0atazanavir \u00a0based\u00a0regimens \u00a0in\u00a0real\u00a0life\u00a0conditions: \u00a0final\u00a01\u00a0year\u00a0results\u00a0of\u00a0GESIDA\u00a044/04\u00a0\nSIMPATAZ \u00a0study.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0TUPE0111. \u00a0\n\u00a0 485.\u00a0\u00a0Nieuwkerk \u00a0PT,\u00a0Oort\u00a0FJ.\u00a0Self\u2010reported\u00a0adherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infection\u00a0and\u00a0\nvirologic\u00a0treatment \u00a0response: \u00a0a\u00a0meta\u2010analysis.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a038(4):445 \u2010448\u00a0\n\u00a0 486.\u00a0\u00a0Wood\u00a0E,\u00a0Hogg\u00a0RS,\u00a0Yip\u00a0B,\u00a0Harrigan\u00a0PR,\u00a0O'Shaughnessy \u00a0MV,\u00a0Montaner \u00a0JS.\u00a0The\u00a0impact\u00a0of\u00a0adherence \u00a0on\u00a0\nCD4\u00a0cell\u00a0count\u00a0responses \u00a0among\u00a0HIV\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02004;\u00a035(3):261 \u2010\n268\u00a0\n\u00a0 487.\u00a0\u00a0Lima\u00a0VD,\u00a0Harrigan\u00a0R,\u00a0Bangsberg \u00a0DR,\u00a0Hogg\u00a0RS,\u00a0Gross\u00a0R,\u00a0Yip\u00a0B\u00a0et\u00a0al.\u00a0The\u00a0combined \u00a0effect\u00a0of\u00a0modern\u00a0highly\u00a0\nactive\u00a0antiretroviral \u00a0therapy\u00a0regimens \u00a0and\u00a0adherence \u00a0on\u00a0mortality\u00a0over\u00a0time.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02009;\u00a050(5):529 \u2010536\u00a0\n\u00a0 488.\u00a0\u00a0Garcia\u00a0de\u00a0Olalla\u00a0P,\u00a0Knobel\u00a0H,\u00a0Carmona\u00a0A,\u00a0Guelar\u00a0A,\u00a0Lopez\u2010Colomes\u00a0JL,\u00a0Cayla\u00a0JA.\u00a0Impact\u00a0of\u00a0adherence \u00a0\nand\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0on\u00a0survival\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02002;\u00a030(1):105 \u2010110\u00a0\n\u00a0 489.\u00a0\u00a0Rueda\u00a0S,\u00a0Park\u2010Wyllie\u00a0LY,\u00a0Bayoumi\u00a0AM,\u00a0Tynan\u00a0AM,\u00a0Antoniou \u00a0TA,\u00a0Rourke\u00a0SB,\u00a0Glazier\u00a0RH.\u00a0Patient\u00a0support\u00a0\nand\u00a0education \u00a0for\u00a0promoting \u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0HIV/AIDS. \u00a0Cochrane \u00a0\nDatabase \u00a0Syst\u00a0Rev\u00a0Issue\u00a03.\u00a0Art.\u00a0No.:\u00a0CD001442. \u00a0DOI:\u00a010.1002/14651858.CD001442.pub2. \u00a0\n\u00a0 490.\u00a0\u00a0Mills\u00a0EJ,\u00a0Nachega\u00a0JB,\u00a0Bangsberg \u00a0DR,\u00a0Singh\u00a0S,\u00a0Rachlis\u00a0B,\u00a0Wu\u00a0P\u00a0et\u00a0al.\u00a0Adherence \u00a0to\u00a0HAART:\u00a0a\u00a0systematic \u00a0\nreview\u00a0of\u00a0developed \u00a0and\u00a0developing \u00a0nation\u00a0patient\u2010reported\u00a0barriers\u00a0and\u00a0facilitators. \u00a0PLoS\u00a0One\u00a02006;\u00a0\n3(11):e438 \u00a0\n\u00a0 491.\u00a0\u00a0Glass\u00a0TR,\u00a0De\u00a0GS,\u00a0Weber\u00a0R,\u00a0Vernazza\u00a0PL,\u00a0Rickenbach \u00a0M,\u00a0Furrer\u00a0H\u00a0et\u00a0al.\u00a0Correlates \u00a0of\u00a0self\u2010reported\u00a0\nnonadherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0the\u00a0Swiss\u00a0HIV\u00a0Cohort\u00a0Study.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02006;\u00a041(3):385 \u2010392\u00a0\n\u00a0 492.\u00a0\u00a0Pardi\u00a0GR,\u00a0Nunes\u00a0MA,\u00a0Preto\u00a0R,\u00a0Canassa\u00a0PG,\u00a0Correia\u00a0D.\u00a0Profile\u00a0of\u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0\ntherapy\u00a0of\u00a0patients\u00a0older\u00a0than\u00a050\u00a0years\u00a0old.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a052(2):301 \u2010303\u00a0\n\u00a0 493.\u00a0\u00a0Ettenhofer \u00a0ML,\u00a0Hinkin\u00a0CH,\u00a0Castellon\u00a0SA,\u00a0Durvasula \u00a0R,\u00a0Ullman\u00a0J,\u00a0Lam\u00a0M\u00a0et\u00a0al.\u00a0Aging,\u00a0neurocognition, \u00a0and\u00a0\nmedication \u00a0adherence \u00a0in\u00a0HIV\u00a0infection. \u00a0Am\u00a0J\u00a0Geriatr\u00a0Psychiatry \u00a02009;\u00a017(4):281 \u2010290\u00a0\n\u00a0 494.\u00a0\u00a0Stone\u00a0VE.\u00a0Strategies \u00a0for\u00a0optimizing \u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0lessons\u00a0from\u00a0\nresearch\u00a0and\u00a0clinical\u00a0practice.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02001;\u00a033(6):865 \u201072\u00a0\n\u00a0 495.\u00a0\u00a0Mu\u00f1oz\u2010Moreno\u00a0JA,\u00a0Fumaz\u00a0CR,\u00a0Ferrer\u00a0MJ,\u00a0Tuldra\u00a0A,\u00a0Rovira\u00a0T,\u00a0Viladrich\u00a0C\u00a0et\u00a0al.\u00a0Assessing \u00a0self\u2010reported\u00a0\nadherence \u00a0to\u00a0HIV\u00a0therapy\u00a0by\u00a0questionnaire: \u00a0the\u00a0SERAD\u00a0(Self\u2010Reported \u00a0Adherence) \u00a0Study.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0\nRetroviruses \u00a02007;\u00a023(10):1166 \u20101175\u00a0\n\u00a0 496.\u00a0\u00a0Knobel\u00a0H,\u00a0Alonso\u00a0J,\u00a0Casado\u00a0JL,\u00a0Collazos\u00a0J,\u00a0Gonzalez\u00a0J,\u00a0Ruiz\u00a0I\u00a0et\u00a0al.\u00a0Validation \u00a0of\u00a0a\u00a0simplified \u00a0medication \u00a0\nadherence \u00a0questionnaire \u00a0in\u00a0a\u00a0large\u00a0cohort\u00a0of\u00a0HIV\u2010infected\u00a0patients:\u00a0the\u00a0GEEMA\u00a0Study.\u00a0AIDS\u00a02002;\u00a0\n16(4):605 \u2010613\u00a0\n\u00a0 497.\u00a0\u00a0Duong\u00a0M,\u00a0Golzi\u00a0A,\u00a0Peytavin\u00a0G,\u00a0Piroth\u00a0L,\u00a0Froidure\u00a0M,\u00a0Grappin\u00a0M\u00a0et\u00a0al.\u00a0Usefulness \u00a0of\u00a0therapeutic \u00a0drug\u00a0\nmonitoring \u00a0of\u00a0antiretrovirals \u00a0in\u00a0routine\u00a0clinical\u00a0practice.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02004;\u00a05(4):216\u2010223\u00a0\n\u00a0 498.\u00a0\u00a0Deschamps \u00a0AE,\u00a0Graeve\u00a0VD,\u00a0van\u00a0WE,\u00a0De\u00a0S,\u00a0V,\u00a0Vandamme \u00a0AM,\u00a0van\u00a0VK\u00a0et\u00a0al.\u00a0Prevalence \u00a0and\u00a0correlates \u00a0of\u00a0\nnonadherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0a\u00a0population \u00a0of\u00a0HIV\u00a0patients\u00a0using\u00a0Medication \u00a0Event\u00a0\nMonitoring \u00a0System.\u00a0AIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02004;\u00a018(11):644 \u2010657\u00a0\n\u00a0 499.\u00a0\u00a0Bangsberg \u00a0DR.\u00a0Less\u00a0than\u00a095%\u00a0adherence \u00a0to\u00a0nonnucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitor\u00a0therapy\u00a0can\u00a0\nlead\u00a0to\u00a0viral\u00a0suppression. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a043(7):939 \u2010941\u00a0\n\u00a0 500.\u00a0\u00a0Maggiolo \u00a0F,\u00a0Ravasio\u00a0L,\u00a0Ripamonti \u00a0D,\u00a0Gregis\u00a0G,\u00a0Quinzan\u00a0G,\u00a0Arici\u00a0C\u00a0et\u00a0al.\u00a0Similar\u00a0adherence \u00a0rates\u00a0favor\u00a0\ndifferent\u00a0virologic\u00a0outcomes \u00a0for\u00a0patients\u00a0treated\u00a0with\u00a0nonnucleoside \u00a0analogues \u00a0or\u00a0protease\u00a0inhibitors. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(1):158 \u2010163\u00a0\n\u00a0 501.\u00a0\u00a0Cohen\u00a0CJ,\u00a0Colson\u00a0AE,\u00a0Sheble\u2010Hall\u00a0AG,\u00a0McLaughlin \u00a0KA,\u00a0Morse\u00a0GD.\u00a0Pilot\u00a0study\u00a0of\u00a0a\u00a0novel\u00a0short\u2010cycle\u00a0\nantiretroviral \u00a0treatment \u00a0interruption \u00a0strategy:\u00a048\u2010week\u00a0results\u00a0of\u00a0the\u00a0five\u2010days\u2010on,\u00a0two\u2010days\u2010off\u00a0(FOTO)\u00a0\nstudy.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(1):19\u201023\u00a0\n\u00a0 502.\u00a0\u00a0Knobel\u00a0H,\u00a0Urbina\u00a0O,\u00a0Gonzalez\u00a0A,\u00a0Sorli\u00a0ML,\u00a0Montero\u00a0M,\u00a0Carmona\u00a0A\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0different\u00a0patterns\u00a0of\u00a0\nnonadherence \u00a0on\u00a0the\u00a0outcome\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0long\u2010term\u00a0follow\u2010\nup.\u00a0HIV\u00a0Med\u00a02009;\u00a010(6):364 \u2010369\u00a0\n\u00a0 503.\u00a0\u00a0Nachega\u00a0JB,\u00a0Hislop\u00a0M,\u00a0Dowdy\u00a0DW,\u00a0Chaisson\u00a0RE,\u00a0Regensberg \u00a0L,\u00a0Maartens \u00a0G.\u00a0Adherence \u00a0to\u00a0\nnonnucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u2010based\u00a0HIV\u00a0therapy\u00a0and\u00a0virologic\u00a0outcomes. \u00a0Ann\u00a0Intern\u00a0\nMed\u00a02007;\u00a0146(8):564 \u2010573\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 213\u00a0 504.\u00a0\u00a0Nelson\u00a0M,\u00a0Girard\u00a0PM,\u00a0DeMasi\u00a0R,\u00a0Chen\u00a0L,\u00a0Smets\u00a0E,\u00a0Sekar\u00a0V\u00a0et\u00a0al.\u00a0Suboptimal \u00a0adherence \u00a0to\u00a0\ndarunavir/ritonavir \u00a0has\u00a0minimal\u00a0effect\u00a0on\u00a0efficacy\u00a0compared \u00a0with\u00a0lopinavir/ritonavir \u00a0in\u00a0treatment \u2010naive,\u00a0\nHIV\u2010infected\u00a0patients:\u00a096\u00a0week\u00a0ARTEMIS\u00a0data.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02010;\u00a065(7):1505 \u20101509\u00a0\n\u00a0 505.\u00a0\u00a0Parienti\u00a0JJ,\u00a0Das\u2010Douglas\u00a0M,\u00a0Massari\u00a0V,\u00a0Guzman\u00a0D,\u00a0Deeks\u00a0SG,\u00a0Verdon\u00a0R\u00a0et\u00a0al.\u00a0Not\u00a0all\u00a0missed\u00a0doses\u00a0are\u00a0the\u00a0\nsame:\u00a0sustained \u00a0NNRTI\u00a0treatment \u00a0interruptions \u00a0predict\u00a0HIV\u00a0rebound\u00a0at\u00a0low\u2010to\u2010moderate \u00a0adherence \u00a0\nlevels.\u00a0PLoS\u00a0One\u00a02008;\u00a03(7):e2783 \u00a0\n\u00a0 506.\u00a0\u00a0Bangsberg \u00a0DR,\u00a0Kroetz\u00a0DL,\u00a0Deeks\u00a0SG.\u00a0Adherence \u2010resistance \u00a0relationships \u00a0to\u00a0combination \u00a0HIV\u00a0\nantiretroviral \u00a0therapy.\u00a0Curr\u00a0HIV/AIDS\u00a0Rep\u00a02007;\u00a04(2):65\u201072\u00a0\n\u00a0 507.\u00a0\u00a0Maggiolo \u00a0F,\u00a0Airoldi\u00a0M,\u00a0Kleinloog \u00a0HD,\u00a0Callegaro \u00a0A,\u00a0Ravasio\u00a0V,\u00a0Arici\u00a0C\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0adherence \u00a0to\u00a0HAART\u00a0\non\u00a0virologic\u00a0outcome\u00a0and\u00a0on\u00a0the\u00a0selection\u00a0of\u00a0resistance \u2010conferring \u00a0mutations \u00a0in\u00a0N.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a0\n8(5):282\u2010292\u00a0\n\u00a0 508.\u00a0\u00a0Bangsberg \u00a0DR.\u00a0Preventing \u00a0HIV\u00a0antiretroviral \u00a0resistance \u00a0through\u00a0better\u00a0monitoring \u00a0of\u00a0treatment \u00a0\nadherence. \u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0197\u00a0Suppl\u00a03:S272\u2010S278\u00a0\n\u00a0 509.\u00a0\u00a0Gardner\u00a0EM,\u00a0Sharma\u00a0S,\u00a0Peng\u00a0G,\u00a0Hullsiek\u00a0KH,\u00a0Burman\u00a0WJ,\u00a0MacArthur \u00a0RD\u00a0et\u00a0al.\u00a0Differential \u00a0adherence \u00a0to\u00a0\ncombination \u00a0antiretroviral \u00a0therapy\u00a0is\u00a0associated \u00a0with\u00a0virological \u00a0failure\u00a0with\u00a0resistance. \u00a0AIDS\u00a02008;\u00a0\n22(1):75\u201082\u00a0\n\u00a0 510.\u00a0\u00a0Bangsberg \u00a0DR,\u00a0Ragland\u00a0K,\u00a0Monk\u00a0A,\u00a0Deeks\u00a0SG.\u00a0A\u00a0single\u00a0tablet\u00a0regimen\u00a0is\u00a0associated \u00a0with\u00a0higher\u00a0\nadherence \u00a0and\u00a0viral\u00a0suppression \u00a0than\u00a0multiple\u00a0tablet\u00a0regimens \u00a0in\u00a0HIV+\u00a0homeless \u00a0and\u00a0marginally \u00a0housed\u00a0\npeople.\u00a0AIDS\u00a02010;\u00a024(18):2835 \u20102840\u00a0\n\u00a0 511.\u00a0\u00a0Golin\u00a0CE,\u00a0Earp\u00a0J,\u00a0Tien\u00a0HC,\u00a0Stewart\u00a0P,\u00a0Porter\u00a0C,\u00a0Howie\u00a0L.\u00a0A\u00a02\u2010arm,\u00a0randomized, \u00a0controlled \u00a0trial\u00a0of\u00a0a\u00a0\nmotivational \u00a0interviewing \u2010based\u00a0intervention \u00a0to\u00a0improve\u00a0adherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0(ART)\u00a0\namong\u00a0patients\u00a0failing\u00a0or\u00a0initiating\u00a0ART.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a042(1):42\u201051\u00a0\n\u00a0 512.\u00a0\u00a0Simoni\u00a0JM,\u00a0Amico\u00a0KR,\u00a0Smith\u00a0L,\u00a0Nelson\u00a0K.\u00a0Antiretroviral \u00a0adherence \u00a0interventions: \u00a0translating \u00a0research\u00a0\nfindings\u00a0to\u00a0the\u00a0real\u00a0world\u00a0clinic.\u00a0Curr\u00a0HIV/AIDS\u00a0Rep\u00a02010;\u00a07(1):44\u201051\u00a0\n\u00a0 513.\u00a0\u00a0Hart\u00a0JE,\u00a0Jeon\u00a0CY,\u00a0Ivers\u00a0LC,\u00a0Behforouz \u00a0HL,\u00a0Caldas\u00a0A,\u00a0Drobac\u00a0PC\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0directly\u00a0observed \u00a0therapy\u00a0\nfor\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0on\u00a0virologic,\u00a0immunologic, \u00a0and\u00a0adherence \u00a0outcomes: \u00a0a\u00a0meta\u2010\nanalysis\u00a0and\u00a0systematic \u00a0review.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a054(2):167 \u2010179\u00a0\n\u00a0 514.\u00a0\u00a0Kleeberger \u00a0CA,\u00a0Buechner \u00a0J,\u00a0Palella\u00a0F,\u00a0Detels\u00a0R,\u00a0Riddler\u00a0S,\u00a0Godfrey\u00a0R\u00a0et\u00a0al.\u00a0Changes\u00a0in\u00a0adherence \u00a0to\u00a0highly\u00a0\nactive\u00a0antiretroviral \u00a0therapy\u00a0medications \u00a0in\u00a0the\u00a0Multicenter \u00a0AIDS\u00a0Cohort\u00a0Study.\u00a0AIDS\u00a02004;\u00a018(4):683 \u2010\n688\u00a0\n\u00a0 515.\u00a0\u00a0Falco\u00a0V,\u00a0Rodriguez \u00a0D,\u00a0Ribera\u00a0E,\u00a0Martinez\u00a0E,\u00a0Miro\u00a0JM,\u00a0Domingo\u00a0P\u00a0et\u00a0al.\u00a0Severe\u00a0nucleoside \u2010associated \u00a0\nlactic\u00a0acidosis\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients:\u00a0report\u00a0of\u00a012\u00a0cases\u00a0and\u00a0review\u00a0of\u00a0the\u00a0\nliterature. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02002;\u00a034(6):838 \u201046\u00a0\n\u00a0 516.\u00a0\u00a0Waters\u00a0L,\u00a0Nelson\u00a0M.\u00a0Long\u2010term\u00a0complications \u00a0of\u00a0antiretroviral \u00a0therapy:\u00a0lipoatrophy. \u00a0Int\u00a0J\u00a0Clin\u00a0Pract\u00a0\n2007;\u00a061(6):999 \u20101014\u00a0\n\u00a0 517.\u00a0\u00a0Hetherington \u00a0S,\u00a0McGuirk\u00a0S,\u00a0Powell\u00a0G,\u00a0Cutrell\u00a0A,\u00a0Naderer\u00a0O,\u00a0Spreen\u00a0B\u00a0et\u00a0al.\u00a0Hypersensitivity \u00a0reactions \u00a0\nduring\u00a0therapy\u00a0with\u00a0the\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0abacavir.\u00a0Clin\u00a0Ther\u00a02001;\u00a0\n23(10):1603 \u20101614\u00a0\n\u00a0 518.\u00a0\u00a0Kesselring \u00a0AM,\u00a0Wit\u00a0FW,\u00a0Sabin\u00a0CA,\u00a0Lundgren \u00a0JD,\u00a0Gill\u00a0MJ,\u00a0Gatell\u00a0JM\u00a0et\u00a0al.\u00a0Risk\u00a0factors\u00a0for\u00a0treatment \u2010\nlimiting\u00a0toxicities\u00a0in\u00a0patients\u00a0starting\u00a0nevirapine \u2010containing \u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a02009;\u00a0\n23(13):1689 \u20101699\u00a0\n\u00a0 519.\u00a0\u00a0Sulkowski \u00a0MS.\u00a0Drug\u2010induced\u00a0liver\u00a0injury\u00a0associated \u00a0with\u00a0antiretroviral \u00a0therapy\u00a0that\u00a0includes\u00a0HIV\u20101\u00a0\nprotease\u00a0inhibitors. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a038\u00a0Suppl\u00a02:S90\u2010S97\u00a0\n\u00a0 520.\u00a0\u00a0Pineda\u00a0JA,\u00a0Palacios\u00a0R,\u00a0Rivero\u00a0A,\u00a0bdel\u2010Kader\u00a0L,\u00a0Marquez\u00a0M,\u00a0Cano\u00a0P\u00a0et\u00a0al.\u00a0Low\u00a0incidence \u00a0of\u00a0severe\u00a0liver\u00a0\ntoxicity\u00a0in\u00a0patients\u00a0receiving\u00a0antiretroviral \u00a0combinations \u00a0including\u00a0atazanavir. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a0\n2006;\u00a057(5):1016 \u20101017\u00a0\n\u00a0 521.\u00a0\u00a0Palacios\u00a0R,\u00a0Vergara\u00a0S,\u00a0Rivero\u00a0A,\u00a0Aguilar\u00a0I,\u00a0Macias\u00a0J,\u00a0Camacho \u00a0A\u00a0et\u00a0al.\u00a0Low\u00a0incidence \u00a0of\u00a0severe\u00a0liver\u00a0events\u00a0\nin\u00a0HIV\u00a0patients\u00a0with\u00a0and\u00a0without\u00a0hepatitis\u00a0C\u00a0or\u00a0B\u00a0coinfection \u00a0receiving\u00a0lopinavir/ritonavir. \u00a0HIV\u00a0Clin\u00a0Trials\u00a0\n2006;\u00a07(6):319\u2010323\u00a0\n\u00a0 522.\u00a0\u00a0Clifford\u00a0DB,\u00a0Evans\u00a0S,\u00a0Yang\u00a0Y,\u00a0Acosta\u00a0EP,\u00a0Goodkin\u00a0K,\u00a0Tashima\u00a0K\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0efavirenz\u00a0on\u00a0\nneuropsychological \u00a0performance \u00a0and\u00a0symptoms \u00a0in\u00a0HIV\u2010infected\u00a0individuals. \u00a0Ann\u00a0Intern\u00a0Med\u00a02005;\u00a0\n143(10):714 \u2010721\u00a0\n\u00a0 523.\u00a0\u00a0Blanch\u00a0J,\u00a0Martinez\u00a0E,\u00a0Rousaud\u00a0A,\u00a0Blanco\u00a0JL,\u00a0Garcia\u2010Viejo\u00a0MA,\u00a0Peri\u00a0JM\u00a0et\u00a0al.\u00a0Preliminary \u00a0data\u00a0of\u00a0a\u00a0\nprospective \u00a0study\u00a0on\u00a0neuropsychiatric \u00a0side\u00a0effects\u00a0after\u00a0initiation\u00a0of\u00a0efavirenz. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02001;\u00a027(4):336 \u201043\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 214\u00a0 524.\u00a0\u00a0Journot\u00a0V,\u00a0Chene\u00a0G,\u00a0De\u00a0CN,\u00a0Rancinan\u00a0C,\u00a0Cassuto\u00a0JP,\u00a0Allard\u00a0C\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0efavirenz\u00a0is\u00a0not\u00a0associated \u00a0with\u00a0\na\u00a0higher\u00a0risk\u00a0of\u00a0depressive \u00a0disorders: \u00a0a\u00a0substudy\u00a0of\u00a0the\u00a0randomized \u00a0clinical\u00a0trial\u00a0ALIZE\u2010ANRS\u00a0099.\u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02006;\u00a042(12):1790 \u20101799\u00a0\n\u00a0 525.\u00a0\u00a0Gallant\u00a0JE,\u00a0Parish\u00a0MA,\u00a0Keruly\u00a0JC,\u00a0Moore\u00a0RD.\u00a0Changes\u00a0in\u00a0renal\u00a0function\u00a0associated \u00a0with\u00a0tenofovir\u00a0\ndisoproxil \u00a0fumarate \u00a0treatment, \u00a0compared \u00a0with\u00a0nucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitor\u00a0treatment. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(8):1194 \u20101198\u00a0\n\u00a0 526.\u00a0\u00a0Nelson\u00a0MR,\u00a0Katlama\u00a0C,\u00a0Montaner \u00a0JS,\u00a0Cooper\u00a0DA,\u00a0Gazzard\u00a0B,\u00a0Clotet\u00a0B\u00a0et\u00a0al.\u00a0The\u00a0safety\u00a0of\u00a0tenofovir\u00a0\ndisoproxil \u00a0fumarate \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u00a0infection\u00a0in\u00a0adults:\u00a0the\u00a0first\u00a04\u00a0years.\u00a0AIDS\u00a02007;\u00a0\n21(10):1273 \u20101281\u00a0\n\u00a0 527.\u00a0\u00a0Cassetti\u00a0I,\u00a0Madruga\u00a0JV,\u00a0Suleiman\u00a0JM,\u00a0Etzel\u00a0A,\u00a0Zhong\u00a0L,\u00a0Cheng\u00a0AK\u00a0et\u00a0al.\u00a0The\u00a0safety\u00a0and\u00a0efficacy\u00a0of\u00a0\ntenofovir\u00a0DF\u00a0in\u00a0combination \u00a0with\u00a0lamivudine \u00a0and\u00a0efavirenz\u00a0through\u00a06\u00a0years\u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u2010\n1\u2010infected\u00a0patients.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(3):164\u2010172\u00a0\n\u00a0 528.\u00a0\u00a0Gupta\u00a0SK.\u00a0Tenofovir \u2010associated \u00a0Fanconi\u00a0syndrome: \u00a0review\u00a0of\u00a0the\u00a0FDA\u00a0adverse\u00a0event\u00a0reporting \u00a0system.\u00a0\nAIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02008;\u00a022(2):99\u2010103\u00a0\n\u00a0 529.\u00a0\u00a0Moyle\u00a0GJ,\u00a0Sabin\u00a0CA,\u00a0Cartledge \u00a0J,\u00a0Johnson\u00a0M,\u00a0Wilkins\u00a0E,\u00a0Churchill\u00a0D\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0comparative \u00a0trial\u00a0\nof\u00a0tenofovir\u00a0DF\u00a0or\u00a0abacavir\u00a0as\u00a0replacement \u00a0for\u00a0a\u00a0thymidine \u00a0analogue\u00a0in\u00a0persons\u00a0with\u00a0lipoatrophy. \u00a0AIDS\u00a0\n2006;\u00a020(16):2043 \u20102050\u00a0\n\u00a0 530.\u00a0\u00a0Wever\u00a0K,\u00a0van\u00a0Agtmael\u00a0MA,\u00a0Carr\u00a0A.\u00a0Incomplete \u00a0reversibility \u00a0of\u00a0tenofovir\u2010related\u00a0renal\u00a0toxicity\u00a0in\u00a0HIV\u2010\ninfected\u00a0men.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a055(1):78\u201081\u00a0\n\u00a0 531.\u00a0\u00a0Hicks\u00a0C,\u00a0Cahn\u00a0P,\u00a0Ward\u00a0D,\u00a0Lazzarin\u00a0A,\u00a0Jelaska\u00a0A,\u00a0Drulak\u00a0M,\u00a0et\u00a0al.\u00a0Tripranavir/r \u00a0mantains \u00a0long\u00a0term\u00a0\nvirological \u00a0suppression \u00a0in\u00a0highly\u00a0treatment \u00a0experienced \u00a0patients\u00a0\u2013Three\u00a0year\u00a0follow\u2010up\u00a0RESIST.\u00a011th\u00a0\nEuropean \u00a0AIDS\u00a0Conference, \u00a0Madrid,\u00a0October\u00a024\u201027\u00a02007.\u00a0Abstract\u00a0P7.3/25.\u00a0\n\u00a0 532.\u00a0\u00a0Moyle\u00a0G.\u00a0Metabolic \u00a0issues\u00a0associated \u00a0with\u00a0protease\u00a0inhibitors. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045\u00a0\nSuppl\u00a01:S19\u2010S26\u00a0\n\u00a0 533.\u00a0\u00a0Smith\u00a0KY,\u00a0Weinberg \u00a0WG,\u00a0DeJesus\u00a0E,\u00a0Fischl\u00a0MA,\u00a0Liao\u00a0Q,\u00a0Ross\u00a0LL\u00a0et\u00a0al.\u00a0Fosamprenavir \u00a0or\u00a0atazanavir \u00a0once\u00a0\ndaily\u00a0boosted\u00a0with\u00a0ritonavir\u00a0100\u00a0mg,\u00a0plus\u00a0tenofovir/emtricitabine, \u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u00a0\ninfection: \u00a048\u2010week\u00a0results\u00a0of\u00a0ALERT.\u00a0AIDS\u00a0Res\u00a0Ther\u00a02008;\u00a05:5\u00a0\n\u00a0 534.\u00a0\u00a0Martinez\u00a0E,\u00a0Arranz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Lonca\u00a0M,\u00a0Sanz\u00a0J,\u00a0Barragan\u00a0P\u00a0et\u00a0al.\u00a0A\u00a0simplification \u00a0trial\u00a0switching \u00a0\nfrom\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0to\u00a0once\u2010daily\u00a0fixed\u2010dose\u00a0abacavir/lamivudine \u00a0or\u00a0\ntenofovir/emtricitabine \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0virological \u00a0suppression. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02009;\u00a051(3):290 \u2010297\u00a0\n\u00a0 535.\u00a0\u00a0Walmsley \u00a0S,\u00a0Ruxrungtham \u00a0K,\u00a0Slim\u00a0J,\u00a0et\u00a0al.\u00a0Saquinavir/r \u00a0BiD\u00a0versus\u00a0lopinavir/r \u00a0BiD,\u00a0plus\u00a0\nemtricitabine/tenofovir \u00a0QD\u00a0as\u00a0initial\u00a0therapy\u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients:\u00a0the\u00a0GEMINI\u00a0study.\u00a011th\u00a0\nEuropean \u00a0AIDS\u00a0Conference, \u00a0Madrid,\u00a0October\u00a024\u201027\u00a02007.\u00a0Abstract\u00a0PS1/4.\u00a0\n\u00a0 536.\u00a0\u00a0Mallolas\u00a0J,\u00a0Podzamczer \u00a0D,\u00a0Domingo\u00a0P,\u00a0Clotet\u00a0B,\u00a0Ribera\u00a0E,\u00a0Guti\u00e9rrez \u00a0F.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0switching \u00a0\nfrom\u00a0boosted\u00a0lopinavir\u00a0(LPV/r)\u00a0to\u00a0boosted\u00a0atazanavir \u00a0(ATV/r)\u00a0in\u00a0patients\u00a0with\u00a0virologic\u00a0suppression \u00a0\nreceiving\u00a0a\u00a0LPV/r\u2010containing \u00a0HAART:\u00a0the\u00a0AZATIP\u00a0study.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0\nTreatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a0July\u00a022\u201025\u00a02007.\u00a0Abstract\u00a0WEPEB117LB. \u00a0\n\u00a0 537.\u00a0\u00a0Martinez\u00a0E,\u00a0Arranz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Ribera\u00a0E,\u00a0Roca\u00a0V,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0NRTI's\u00a0switch\u00a0to\u00a0\ntenofovir\u00a0plus\u00a0emtricitabine \u00a0(Truvada) \u00a0vs.\u00a0abacavir\u00a0plus\u00a0lamivudine \u00a0(Kivexa)\u00a0in\u00a0patients\u00a0with\u00a0virologic\u00a0\nsuppression \u00a0receiving\u00a0a\u00a0lamivudine \u00a0containing \u00a0HAART:\u00a0The\u00a0BICOMBO \u00a0study.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0\nPathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a0July\u00a022\u201025\u00a02007.\u00a0Abstract\u00a0WESS102. \u00a0\n\u00a0 538.\u00a0\u00a0Tomaka\u00a0F,\u00a0Lefebvre\u00a0E,\u00a0Sekar\u00a0V,\u00a0Van\u00a0BB,\u00a0Vangeneugden \u00a0T,\u00a0Vandevoorde \u00a0A\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0ritonavir\u2010\nboosted\u00a0darunavir \u00a0vs.\u00a0ritonavir\u2010boosted\u00a0atazanavir \u00a0on\u00a0lipid\u00a0and\u00a0glucose\u00a0parameters \u00a0in\u00a0HIV\u2010negative,\u00a0\nhealthy\u00a0volunteers. \u00a0HIV\u00a0Med\u00a02009;\u00a010(5):318 \u2010327\u00a0\n\u00a0 539.\u00a0\u00a0Lundgren \u00a0JD,\u00a0Battegay\u00a0M,\u00a0Behrens\u00a0G,\u00a0De\u00a0WS,\u00a0Guaraldi\u00a0G,\u00a0Katlama\u00a0C\u00a0et\u00a0al.\u00a0European \u00a0AIDS\u00a0Clinical\u00a0Society\u00a0\n(EACS)\u00a0guidelines \u00a0on\u00a0the\u00a0prevention \u00a0and\u00a0management \u00a0of\u00a0metabolic \u00a0diseases\u00a0in\u00a0HIV.\u00a0HIV\u00a0Med\u00a02008;\u00a0\n9(2):72\u201081\u00a0\n\u00a0 540.\u00a0\u00a0Polo\u00a0R,\u00a0Galindo\u00a0MJ,\u00a0Martinez\u00a0E,\u00a0Alvarez\u00a0J,\u00a0Arevalo\u00a0JM,\u00a0Asensi\u00a0V\u00a0et\u00a0al.\u00a0Recomendaciones \u00a0de\u00a0GEAM/SPNS \u00a0\nsobre\u00a0el\u00a0tratamiento \u00a0de\u00a0las\u00a0alteraciones \u00a0metab\u00f3licas \u00a0y\u00a0morfol\u00f3gicas \u00a0en\u00a0el\u00a0paciente\u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0\nVIH.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02006;\u00a024(2):96\u2010117\u00a0\n\u00a0 541.\u00a0\u00a0Llibre\u00a0JM,\u00a0Domingo\u00a0P,\u00a0Palacios\u00a0R,\u00a0Santos\u00a0J,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Sanchez\u2010de\u00a0la\u00a0RR\u00a0et\u00a0al.\u00a0Sustained \u00a0\nimprovement \u00a0of\u00a0dyslipidaemia \u00a0in\u00a0HAART\u2010treated\u00a0patients\u00a0replacing\u00a0stavudine \u00a0with\u00a0tenofovir. \u00a0AIDS\u00a0\n2006;\u00a020(10):1407 \u20101414\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 215\u00a0 542.\u00a0\u00a0Madruga\u00a0JR,\u00a0Cassetti\u00a0I,\u00a0Suleiman\u00a0JM,\u00a0Etzel\u00a0A,\u00a0Zhong\u00a0L,\u00a0Holmes\u00a0CB\u00a0et\u00a0al.\u00a0The\u00a0safety\u00a0and\u00a0efficacy\u00a0of\u00a0\nswitching \u00a0stavudine \u00a0to\u00a0tenofovir\u00a0DF\u00a0in\u00a0combination \u00a0with\u00a0lamivudine \u00a0and\u00a0efavirenz\u00a0in\u00a0hiv\u20101\u2010infected\u00a0\npatients:\u00a0three\u2010year\u00a0follow\u2010up\u00a0after\u00a0switching \u00a0therapy.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(6):381\u2010390\u00a0\n\u00a0 543.\u00a0\u00a0Moyle\u00a0G,\u00a0Fisher\u00a0M,\u00a0and\u00a0the\u00a0SWEET\u00a0study\u00a0group.\u00a0Switching \u00a0from\u00a0Combivir\u00a0to\u00a0Truvada\u00a0preserved \u00a0limb\u00a0fat:\u00a0\nresults\u00a0of\u00a0a\u00a0DEXA\u00a0sub\u2010study\u00a0of\u00a0a\u00a048\u2010week\u00a0randomized \u00a0study.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0938.\u00a0\n\u00a0 544.\u00a0\u00a0Blumer\u00a0RM,\u00a0van\u00a0Vonderen \u00a0MG,\u00a0Sutinen\u00a0J,\u00a0Hassink\u00a0E,\u00a0Ackermans \u00a0M,\u00a0van\u00a0Agtmael\u00a0MA\u00a0et\u00a0al.\u00a0\nZidovudine/lamivudine \u00a0contributes \u00a0to\u00a0insulin\u00a0resistance \u00a0within\u00a03\u00a0months\u00a0of\u00a0starting\u00a0combination \u00a0\nantiretroviral \u00a0therapy.\u00a0AIDS\u00a02008;\u00a022(2):227 \u2010236\u00a0\n\u00a0 545.\u00a0\u00a0Carr\u00a0A,\u00a0Ritzhaupt \u00a0A,\u00a0Zhang\u00a0W,\u00a0Zajdenverg \u00a0R,\u00a0Workman \u00a0C,\u00a0Gatell\u00a0JM\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0boosted\u00a0tipranavir \u00a0\nand\u00a0lopinavir\u00a0on\u00a0body\u00a0composition, \u00a0insulin\u00a0sensitivity \u00a0and\u00a0adipocytokines \u00a0in\u00a0antiretroviral \u2010naive\u00a0adults.\u00a0\nAIDS\u00a02008;\u00a022(17):2313 \u20102321\u00a0\n\u00a0 546.\u00a0\u00a0Brown\u00a0TT,\u00a0Li\u00a0X,\u00a0Cole\u00a0SR,\u00a0Kingsley\u00a0LA,\u00a0Palella\u00a0FJ,\u00a0Riddler\u00a0SA\u00a0et\u00a0al.\u00a0Cumulative \u00a0exposure\u00a0to\u00a0nucleoside \u00a0\nanalogue\u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0is\u00a0associated \u00a0with\u00a0insulin\u00a0resistance \u00a0markers\u00a0in\u00a0the\u00a0\nMulticenter \u00a0AIDS\u00a0Cohort\u00a0Study.\u00a0AIDS\u00a02005;\u00a019(13):1375 \u20101383\u00a0\n\u00a0 547.\u00a0\u00a0De\u00a0Wit\u00a0S.,\u00a0Sabin\u00a0CA,\u00a0Weber\u00a0R,\u00a0Worm\u00a0SW,\u00a0Reiss\u00a0P,\u00a0Cazanave \u00a0C\u00a0et\u00a0al.\u00a0Incidence \u00a0and\u00a0risk\u00a0factors\u00a0for\u00a0new\u2010\nonset\u00a0diabetes\u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0the\u00a0Data\u00a0Collection \u00a0on\u00a0Adverse\u00a0Events\u00a0of\u00a0Anti\u2010HIV\u00a0Drugs\u00a0\n(D:A:D)\u00a0study.\u00a0Diabetes\u00a0Care\u00a02008;\u00a031(6):1224 \u20101229\u00a0\n\u00a0 548.\u00a0\u00a0Ledergerber \u00a0B,\u00a0Furrer\u00a0H,\u00a0Rickenbach \u00a0M,\u00a0Lehmann \u00a0R,\u00a0Elzi\u00a0L,\u00a0Hirschel\u00a0B\u00a0et\u00a0al.\u00a0Factors\u00a0associated \u00a0with\u00a0the\u00a0\nincidence \u00a0of\u00a0type\u00a02\u00a0diabetes\u00a0mellitus\u00a0in\u00a0HIV\u2010infected\u00a0participants \u00a0in\u00a0the\u00a0Swiss\u00a0HIV\u00a0Cohort\u00a0Study.\u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02007;\u00a045(1):111 \u2010119\u00a0\n\u00a0 549.\u00a0\u00a0Fleischman \u00a0A,\u00a0Johnsen\u00a0S,\u00a0Systrom\u00a0DM,\u00a0Hrovat\u00a0M,\u00a0Farrar\u00a0CT,\u00a0Frontera\u00a0W\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0a\u00a0nucleoside \u00a0\nreverse\u00a0transcriptase \u00a0inhibitor,\u00a0stavudine, \u00a0on\u00a0glucose\u00a0disposal\u00a0and\u00a0mitochondrial \u00a0function\u00a0in\u00a0muscle\u00a0of\u00a0\nhealthy\u00a0adults.\u00a0Am\u00a0J\u00a0Physiol\u00a0Endocrinol \u00a0Metab\u00a02007;\u00a0292(6):E1666 \u2010E1673\u00a0\n\u00a0 550.\u00a0\u00a0Heera\u00a0J,\u00a0Ive\u00a0P,\u00a0Botes\u00a0M,\u00a0DeJesus\u00a0E,\u00a0Mayer\u00a0H,\u00a0Goodrich\u00a0J,\u00a0et\u00a0al.\u00a0The\u00a0MERIT\u00a0study\u00a0of\u00a0Maraviroc \u00a0in\u00a0\nantiretroviral \u2010na\u00efve\u00a0patients\u00a0with\u00a0R5\u00a0HIV\u20101:\u00a096\u2010week\u00a0results.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0\nTreatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0TuAB103. \u00a0\n\u00a0 551.\u00a0\u00a0Bozzette\u00a0SA,\u00a0Ake\u00a0CF,\u00a0Tam\u00a0HK,\u00a0Phippard\u00a0A,\u00a0Cohen\u00a0D,\u00a0Scharfstein \u00a0DO\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0survival\u00a0and\u00a0serious\u00a0\ncardiovascular \u00a0events\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(3):338 \u2010341\u00a0\n\u00a0 552.\u00a0\u00a0Holmberg \u00a0SD,\u00a0Moorman \u00a0AC,\u00a0Williamson \u00a0JM,\u00a0Tong\u00a0TC,\u00a0Ward\u00a0DJ,\u00a0Wood\u00a0KC\u00a0et\u00a0al.\u00a0Protease\u00a0inhibitors \u00a0and\u00a0\ncardiovascular \u00a0outcomes \u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101.\u00a0Lancet\u00a02002;\u00a0360(9347):1747 \u20101748\u00a0\n\u00a0 553.\u00a0\u00a0Mary\u2010Krause\u00a0M,\u00a0Cotte\u00a0L,\u00a0Simon\u00a0A,\u00a0Partisani\u00a0M,\u00a0Costagliola \u00a0D,\u00a0Clinical\u00a0Epidemiology \u00a0Group\u00a0from\u00a0the\u00a0\nFrench\u00a0Hospital\u00a0Database. \u00a0Increased \u00a0risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0with\u00a0duration\u00a0of\u00a0protease\u00a0inhibitor\u00a0\ntherapy\u00a0in\u00a0HIV\u2010infected\u00a0men.\u00a0AIDS\u00a02003;\u00a017:2479\u20102486\u00a0\n\u00a0 554.\u00a0\u00a0Bongiovanni \u00a0M,\u00a0Casana\u00a0M,\u00a0Cicconi\u00a0P,\u00a0Pisacreta\u00a0M,\u00a0Codemo\u00a0R,\u00a0Pelucchi\u00a0M\u00a0et\u00a0al.\u00a0Predictive \u00a0factors\u00a0of\u00a0\nvascular\u00a0intima\u00a0media\u00a0thickness \u00a0in\u00a0HIV\u2010positive\u00a0subjects.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02008;\u00a061(1):195 \u2010199\u00a0\n\u00a0 555.\u00a0\u00a0Currier\u00a0JS,\u00a0Kendall\u00a0MA,\u00a0Henry\u00a0WK,\u00a0ston\u2010Smith\u00a0B,\u00a0Torriani\u00a0FJ,\u00a0Tebas\u00a0P\u00a0et\u00a0al.\u00a0Progression \u00a0of\u00a0carotid\u00a0artery\u00a0\nintima\u2010media\u00a0thickening \u00a0in\u00a0HIV\u2010infected\u00a0and\u00a0uninfected \u00a0adults.\u00a0AIDS\u00a02007;\u00a021(9):1137 \u20101145\u00a0\n\u00a0 556.\u00a0\u00a0Currier\u00a0JS,\u00a0Lundgren \u00a0JD,\u00a0Carr\u00a0A,\u00a0Klein\u00a0D,\u00a0Sabin\u00a0CA,\u00a0Sax\u00a0PE\u00a0et\u00a0al.\u00a0Epidemiological \u00a0evidence\u00a0for\u00a0\ncardiovascular \u00a0disease\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0and\u00a0relationship \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0\nCirculation \u00a02008;\u00a0118(2):e29 \u2010e35\u00a0\n\u00a0 557.\u00a0\u00a0Lundgren \u00a0JD,\u00a0Reiss\u00a0P,\u00a0Worms\u00a0S,\u00a0Weber\u00a0R,\u00a0El\u2010Sadr\u00a0W,\u00a0De\u00a0Wit\u00a0S,\u00a0et\u00a0al.\u00a0Risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0with\u00a0\nexposure \u00a0to\u00a0specific\u00a0ARV\u00a0from\u00a0the\u00a0PI,\u00a0NNRTI,\u00a0and\u00a0NRTI\u00a0classes:\u00a0The\u00a0D:A:D\u00a0study.\u00a016th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a044LB.\u00a0\n\u00a0 558.\u00a0\u00a0Lang\u00a0S,\u00a0Mary\u2010Krause\u00a0M,\u00a0Cotte\u00a0L,\u00a0Gilquin\u00a0J,\u00a0Partisani\u00a0M,\u00a0Simon\u00a0A,\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0specific\u00a0NRTI\u00a0and\u00a0PI\u00a0\nexposure \u00a0on\u00a0the\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction: \u00a0a\u00a0cese\u2010control\u00a0stydy\u00a0nested\u00a0with\u00a0FHDH\u00a0ANRS\u00a0CO4.\u00a016th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a043LB.\u00a0\n\u00a0 559.\u00a0\u00a0Durand\u00a0M,\u00a0Sheehy\u00a0O,\u00a0Baril\u00a0JG,\u00a0Lelonier\u00a0J,\u00a0Tremblay \u00a0C.\u00a0Relation\u00a0between\u00a0use\u00a0of\u00a0nucleosidic \u00a0reverse\u00a0\ntranscriptase \u00a0inhibitors \u00a0and\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction: \u00a0a\u00a0nested\u00a0case\u00a0control\u00a0study\u00a0using\u00a0Quebec's\u00a0\nPublic\u00a0Health\u00a0Insurance \u00a0Database. \u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0\nCape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0TuPEB175. \u00a0\n\u00a0 560.\u00a0\u00a0Lichtenstein \u00a0K,\u00a0Buckner\u00a0K,\u00a0Armon\u00a0C,\u00a0Tedalti\u00a0E,\u00a0Chmiel\u00a0J,\u00a0Wood\u00a0K,\u00a0et\u00a0al.\u00a0Low\u00a0CD4\u00a0count\u00a0is\u00a0an\u00a0important \u00a0\nrisk\u00a0factor\u00a0for\u00a0cardiovascular \u00a0disease\u00a0in\u00a0the\u00a0HIV\u00a0Outpatient \u00a0Study\u00a0(HOPS)\u00a0in\u00a0U.S.\u00a017th\u00a0International \u00a0AIDS\u00a0\nConference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0THPE0236. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 216\u00a0 561.\u00a0\u00a0Benson\u00a0C,\u00a0Ribaudo\u00a0H,\u00a0Zheng\u00a0E,\u00a0Koletar\u00a0S,\u00a0Smurzynski \u00a0M,\u00a0Bosch\u00a0R,\u00a0et\u00a0al.\u00a0No\u00a0association \u00a0of\u00a0abacavir\u00a0use\u00a0\nwith\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0or\u00a0severe\u00a0cardiovascular \u00a0disease\u00a0events:\u00a0results\u00a0from\u00a0ACTG\u00a0A5001.\u00a0\n16th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0\n721.\u00a0\n\u00a0 562.\u00a0\u00a0Bedimo\u00a0R,\u00a0Westfall\u00a0A,\u00a0Drechsler, \u00a0H,\u00a0Tebas\u00a0P.\u00a0Abacavir\u00a0use\u00a0and\u00a0risk\u00a0of\u00a0acute\u00a0myocardial \u00a0infarction \u00a0and\u00a0\ncerebrovascular \u00a0disease\u00a0in\u00a0the\u00a0HAART\u00a0era.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0MoAb202. \u00a0\n\u00a0 563.\u00a0\u00a0McComsey \u00a0G,\u00a0Smith\u00a0KY,\u00a0Patel\u00a0P,\u00a0Bellos\u00a0NC,\u00a0Sloan\u00a0L,\u00a0Lackey\u00a0P,\u00a0et\u00a0al.\u00a0Similar\u00a0reductions \u00a0in\u00a0markers\u00a0of\u00a0\ninflammation \u00a0and\u00a0endothelial \u00a0activation \u00a0after\u00a0initiation\u00a0of\u00a0abacavir/lamivudine \u00a0(ABC/3TC) \u00a0or\u00a0\ntenofovir/emtricitabine \u00a0(TDF/FTC) \u00a0in\u00a0the\u00a0HEAT\u00a0study.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0732.\u00a0\n\u00a0 564.\u00a0\u00a0Martinez\u00a0E,\u00a0Larrousse \u00a0M,\u00a0Perez\u00a0I,\u00a0Lonca\u00a0M,\u00a0Podzamczer \u00a0D,\u00a0Gutierez\u00a0F,\u00a0et\u00a0al.\u00a0No\u00a0evidence\u00a0for\u00a0recent\u00a0\nabacavir/ \u00a0lamivudine \u00a0use\u00a0in\u00a0promoting \u00a0inflammation, \u00a0endothelial \u00a0dysfunction, \u00a0hypercoagulability, \u00a0or\u00a0\ninsulin\u00a0resistance \u00a0in\u00a0virologically \u00a0suppressed \u00a0HIV\u2010infected\u00a0patients:\u00a0a\u00a0substudy\u00a0of\u00a0the\u00a0BICOMBO \u00a0\nrandomized \u00a0clinical\u00a0trial\u00a0(ISRCTN\u00a06189).\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0MoAb203. \u00a0\n\u00a0 565.\u00a0\u00a0Martin\u00a0A,\u00a0Amin\u00a0J,\u00a0Cooper\u00a0DA,\u00a0Carr\u00a0A,\u00a0Kelleher\u00a0AD,\u00a0Bloch\u00a0M\u00a0et\u00a0al.\u00a0Abacavir\u00a0does\u00a0not\u00a0affect\u00a0circulating \u00a0\nlevels\u00a0of\u00a0inflammatory \u00a0or\u00a0coagulopathic \u00a0biomarkers \u00a0in\u00a0suppressed \u00a0HIV:\u00a0a\u00a0randomized \u00a0clinical\u00a0trial.\u00a0AIDS\u00a0\n2010;\u00a024(17):2657 \u20102663\u00a0\n\u00a0 566.\u00a0\u00a0Haubrich\u00a0RH,\u00a0Riddler\u00a0SA,\u00a0DiRienzo\u00a0AG,\u00a0Komarow \u00a0L,\u00a0Powderly \u00a0WG,\u00a0Klingman \u00a0K\u00a0et\u00a0al.\u00a0Metabolic \u00a0outcomes \u00a0\nin\u00a0a\u00a0randomized \u00a0trial\u00a0of\u00a0nucleoside, \u00a0nonnucleoside \u00a0and\u00a0protease\u00a0inhibitor\u2010sparing\u00a0regimens \u00a0for\u00a0initial\u00a0\nHIV\u00a0treatment. \u00a0AIDS\u00a02009;\u00a023(9):1109 \u20101118\u00a0\n\u00a0 567.\u00a0\u00a0McComsey \u00a0G,\u00a0Kitch\u00a0D,\u00a0Daar\u00a0E,\u00a0Tiemey\u00a0C,\u00a0Jahed\u00a0N,\u00a0Tebas\u00a0P,\u00a0et\u00a0al.\u00a0Bone\u00a0and\u00a0limb\u00a0fat\u00a0outcomes \u00a0of\u00a0ACTG\u00a0\nA5224s,\u00a0a\u00a0substudy\u00a0of\u00a0ACTG\u00a0A5202:\u00a0A\u00a0prospective, \u00a0randomized, \u00a0partially\u00a0blinded\u00a0phese\u00a0III\u00a0trial\u00a0of\u00a0\nABC/3TC\u00a0or\u00a0TDF/FTC\u00a0with\u00a0EFV\u00a0or\u00a0ATV/r\u00a0for\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u00a0infection. \u00a017th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0106LB.\u00a0\n\u00a0 568.\u00a0\u00a0Falutz\u00a0J,\u00a0Allas\u00a0S,\u00a0Mamputu \u00a0JC,\u00a0Potvin\u00a0D,\u00a0Kotler\u00a0D,\u00a0Somero\u00a0M\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0safety\u00a0and\u00a0effects\u00a0of\u00a0\ntesamorelin, \u00a0a\u00a0growth\u00a0hormone \u2010releasing\u00a0factor\u00a0analogue, \u00a0in\u00a0HIV\u00a0patients\u00a0with\u00a0abdominal \u00a0fat\u00a0\naccumulation. \u00a0AIDS\u00a02008;\u00a022(14):1719 \u20101728\u00a0\n\u00a0 569.\u00a0\u00a0Guaraldi\u00a0G,\u00a0Orlando\u00a0G,\u00a0De\u00a0FD,\u00a0De\u00a0L,\u00a0I,\u00a0Rottino\u00a0A,\u00a0De\u00a0SG\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0three\u00a0different\u00a0\ninterventions \u00a0for\u00a0the\u00a0correction \u00a0of\u00a0HIV\u2010associated \u00a0facial\u00a0lipoatrophy: \u00a0a\u00a0prospective \u00a0study.\u00a0Antivir\u00a0Ther\u00a0\n2005;\u00a010(6):753 \u2010759\u00a0\n\u00a0 570.\u00a0\u00a0Lo\u00a0J,\u00a0You\u00a0SM,\u00a0Canavan\u00a0B,\u00a0Liebau\u00a0J,\u00a0Beltrani\u00a0G,\u00a0Koutkia\u00a0P\u00a0et\u00a0al.\u00a0Low\u2010dose\u00a0physiological \u00a0growth\u00a0hormone \u00a0in\u00a0\npatients\u00a0with\u00a0HIV\u00a0and\u00a0abdominal \u00a0fat\u00a0accumulation: \u00a0a\u00a0randomized \u00a0controlled \u00a0trial.\u00a0JAMA\u00a02008;\u00a0\n300(5):509 \u2010519\u00a0\n\u00a0 571.\u00a0\u00a0Moyle\u00a0GJ,\u00a0Lysakova\u00a0L,\u00a0Brown\u00a0S,\u00a0Sibtain\u00a0N,\u00a0Healy\u00a0J,\u00a0Priest\u00a0C\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0open\u2010label\u00a0study\u00a0of\u00a0\nimmediate \u00a0versus\u00a0delayed\u00a0polylactic \u00a0acid\u00a0injections \u00a0for\u00a0the\u00a0cosmetic\u00a0management \u00a0of\u00a0facial\u00a0lipoatrophy \u00a0\nin\u00a0persons\u00a0with\u00a0HIV\u00a0infection. \u00a0HIV\u00a0Med\u00a02004;\u00a05(2):82\u201087\u00a0\n\u00a0 572.\u00a0\u00a0McComsey \u00a0GA,\u00a0Tebas\u00a0P,\u00a0Shane\u00a0E,\u00a0Yin\u00a0MT,\u00a0Overton\u00a0ET,\u00a0Huang\u00a0JS\u00a0et\u00a0al.\u00a0Bone\u00a0disease\u00a0in\u00a0HIV\u00a0infection: \u00a0a\u00a0\npractical\u00a0review\u00a0and\u00a0recommendations \u00a0for\u00a0HIV\u00a0care\u00a0providers. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02010;\u00a051(8):937 \u2010946\u00a0\n\u00a0 573.\u00a0\u00a0Grupo\u00a0de\u00a0expertos\u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0y\u00a0Gesida.\u00a0Documento \u00a0de\u00a0consenso \u00a0sobre\u00a0alteraciones \u00a0\nosteoarticulares \u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0(Junio\u00a02010).\u00a0Disponible \u00a0en:\u00a0\nwww.gesida.seimc.org/pcientifica /fuentes/DcyRc/gesidadcyrc2010 \u2010altoseas.pdf \u00a0(Acceso\u00a014.12.2010). \u00a0\n\u00a0 574.\u00a0\u00a0Stellbrink \u00a0HJ,\u00a0Orkin\u00a0C,\u00a0Arribas\u00a0JR,\u00a0Compston \u00a0J,\u00a0Gerstoft\u00a0J,\u00a0van\u00a0WE\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0changes\u00a0in\u00a0bone\u00a0\ndensity\u00a0and\u00a0turnover\u00a0with\u00a0abacavir\u2010lamivudine \u00a0versus\u00a0tenofovir\u2010emtricitabine \u00a0in\u00a0HIV\u2010infected\u00a0adults:\u00a0\n48\u2010week\u00a0results\u00a0from\u00a0the\u00a0ASSERT\u00a0study.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02010;\u00a051(8):963 \u2010972\u00a0\n\u00a0 575.\u00a0\u00a0Gutierrez \u00a0F,\u00a0Padilla\u00a0S,\u00a0Masia\u00a0M,\u00a0Flores\u00a0J,\u00a0Boix\u00a0V,\u00a0Merino\u00a0E\u00a0et\u00a0al.\u00a0Osteonecrosis \u00a0in\u00a0patients\u00a0infected\u00a0with\u00a0\nHIV:\u00a0clinical\u00a0epidemiology \u00a0and\u00a0natural\u00a0history\u00a0in\u00a0a\u00a0large\u00a0case\u00a0series\u00a0from\u00a0Spain.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02006;\u00a042(3):286 \u2010292\u00a0\n\u00a0 576.\u00a0\u00a0Dear\u00a0Health\u00a0Care\u00a0Provider.\u00a0Important \u00a0Change\u00a0in\u00a0SUSTIVA\u00ae \u00a0(efavirenz) \u00a0Package\u00a0Insert\u00a0.\u00a0Change\u00a0from\u00a0\nPregnancy \u00a0Category\u00a0C\u00a0to\u00a0D.\u00a0Bristol\u2010Myers\u00a0Squibb\u00a0Company.March \u00a02005\u00a0.\u00a0\n\u00a0 577.\u00a0\u00a0Stein\u00a0JH.\u00a0Managing \u00a0cardiovascular \u00a0risk\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a0\n38(2):115 \u2010123\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 217\u00a0 578.\u00a0\u00a0Gupta\u00a0SK,\u00a0Eustace\u00a0JA,\u00a0Winston\u00a0JA,\u00a0Boydstun \u00a0II,\u00a0Ahuja\u00a0TS,\u00a0Rodriguez \u00a0RA\u00a0et\u00a0al.\u00a0Guidelines \u00a0for\u00a0the\u00a0\nmanagement \u00a0of\u00a0chronic\u00a0kidney\u00a0disease\u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0recommendations \u00a0of\u00a0the\u00a0HIV\u00a0Medicine \u00a0\nAssociation \u00a0of\u00a0the\u00a0Infectious \u00a0Diseases\u00a0Society\u00a0of\u00a0America.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(11):1559 \u20101585\u00a0\n\u00a0 579.\u00a0\u00a0Panel\u00a0de\u00a0GESIDA\u00a0y\u00a0Plan\u00a0Nacional\u00a0del\u00a0Sida.\u00a0Recomendaciones \u00a0de\u00a0GESIDA/SPNS \u00a0para\u00a0la\u00a0evaluaci\u00f3n \u00a0y\u00a0el\u00a0\ntratamiento \u00a0de\u00a0las\u00a0alteraciones \u00a0renales\u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0(2009).\u00a0Disponible \u00a0en:\u00a0\nwww\u00a0gesida\u00a0seimc\u00a0org/pcientifica/dcconsensos \u00a02009;\u00a0\n\u00a0 580.\u00a0\u00a0Tuset\u00a0M,\u00a0Mir\u00f3\u00a0JM,\u00a0Codina\u00a0C,\u00a0Ribas\u00a0J,\u00a0(Editores). \u00a0Gu\u00eda\u00a0de\u00a0interacciones \u00a0farmacol\u00f3gicas \u00a0en\u00a0VIH.\u00a0Disponible \u00a0\nen:\u00a0www.interaccioneshiv.com \u00a0(Acceso\u00a014.12.2010). \u00a0\n\u00a0 581.\u00a0\u00a0Evans\u2010Jones\u00a0JG,\u00a0Cottle\u00a0LE,\u00a0Back\u00a0DJ,\u00a0Gibbons\u00a0S,\u00a0Beeching\u00a0NJ,\u00a0Carey\u00a0PB\u00a0et\u00a0al.\u00a0Recognition \u00a0of\u00a0risk\u00a0for\u00a0\nclinically\u00a0significant \u00a0drug\u00a0interactions \u00a0among\u00a0HIV\u2010infected\u00a0patients\u00a0receiving\u00a0antiretroviral \u00a0therapy.\u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02010;\u00a050(10):1419 \u20101421\u00a0\n\u00a0 582.\u00a0\u00a0Dickinson \u00a0L,\u00a0Khoo\u00a0S,\u00a0Back\u00a0D.\u00a0Pharmacokinetics \u00a0and\u00a0drug\u2010drug\u00a0interactions \u00a0of\u00a0antiretrovirals: \u00a0an\u00a0update.\u00a0\nAntiviral\u00a0Res\u00a02010;\u00a085(1):176 \u2010189\u00a0\n\u00a0 583.\u00a0\u00a0Back\u00a0D,\u00a0Gibbons\u00a0S,\u00a0Wilkins\u00a0E,\u00a0Burger\u00a0D,\u00a0Shapiro\u00a0J,\u00a0Marzolini \u00a0C\u00a0et\u00a0al.\u00a0HIV\u00a0Drug\u00a0Interactions \u00a0website.\u00a0\nDisponible \u00a0e:\u00a0www\u00a0hiv\u2010druginteractions \u00a0org\u00a02010;\u00a0(Acceso\u00a014.12.2010) \u00a0\n\u00a0 584.\u00a0\u00a0Cohen\u00a0C,\u00a0Shamblaw \u00a0D,\u00a0Ruane\u00a0P,\u00a0Lion\u00a0R,\u00a0DeJesus\u00a0E,\u00a0Liu\u00a0H,\u00a0et\u00a0al.\u00a0Single\u2010tablet,\u00a0fixed\u2010dose\u00a0regimen\u00a0of\u00a0\nelvitegravir/emtricitabine/tenofovir \u00a0disoproxil \u00a0fumarate/GS \u20109350\u00a0achieves\u00a0a\u00a0high\u00a0rate\u00a0of\u00a0virologic\u00a0\nsuppression \u00a0and\u00a0GS\u20109350\u00a0is\u00a0an\u00a0effective\u00a0booster.\u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a058LB.\u00a0\n\u00a0 585.\u00a0\u00a0German\u00a0P,\u00a0Warren\u00a0D,\u00a0West\u00a0S,\u00a0Hui\u00a0J,\u00a0Kearney\u00a0BP.\u00a0Pharmacokinetics \u00a0and\u00a0bioavailability \u00a0of\u00a0an\u00a0integrase \u00a0\nand\u00a0novel\u00a0pharmacoenhancer \u2010containing \u00a0single\u2010tablet\u00a0fixed\u2010dose\u00a0combination \u00a0regimen\u00a0for\u00a0the\u00a0\ntreatment \u00a0of\u00a0HIV.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a055(3):323 \u2010329\u00a0\n\u00a0 586.\u00a0\u00a0Mathias\u00a0A,\u00a0Liu\u00a0HC,\u00a0Warren\u00a0D,\u00a0Sekar\u00a0V,\u00a0Kearney\u00a0BP.\u00a0Relative\u00a0bioavailability \u00a0and\u00a0pharmacokinetics \u00a0of\u00a0\nDarunavir \u00a0when\u00a0boosted\u00a0with\u00a0the\u00a0pharmacoenhancer \u00a0GS\u20109350\u00a0versus\u00a0ritonavir.\u00a011th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a028.\u00a0\n\u00a0 587.\u00a0\u00a0Mathias\u00a0AA,\u00a0German\u00a0P,\u00a0Murray\u00a0BP,\u00a0Wei\u00a0L,\u00a0Jain\u00a0A,\u00a0West\u00a0S\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0and\u00a0\npharmacodynamics \u00a0of\u00a0GS\u20109350:\u00a0a\u00a0novel\u00a0pharmacokinetic \u00a0enhancer \u00a0without\u00a0anti\u2010HIV\u00a0activity.\u00a0Clin\u00a0\nPharmacol \u00a0Ther\u00a02010;\u00a087(3):322 \u2010329\u00a0\n\u00a0 588.\u00a0\u00a0Ramanathan \u00a0S,\u00a0Warren\u00a0D,\u00a0Wei\u00a0L,\u00a0Kearney\u00a0B.\u00a0Pharmacokinetic \u00a0Boosting\u00a0of\u00a0Atazanavir \u00a0with\u00a0the\u00a0\nPharmacoenhancer \u00a0GS\u20109350\u00a0versus\u00a0Ritonavir. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0\nand\u00a0Chemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0A1\u20101301.\u00a0\n\u00a0 589.\u00a0\u00a0Ray\u00a0AS,\u00a0Tong\u00a0L,\u00a0Robinson \u00a0LK,\u00a0Kearney\u00a0B,\u00a0Rhodes\u00a0GR.\u00a0Role\u00a0of\u00a0intestinal \u00a0absorption \u00a0in\u00a0increased \u00a0tenofovir\u00a0\nexposure \u00a0when\u00a0tenofovir\u00a0disoproxil \u00a0fumarate \u00a0is\u00a0co\u2010administered \u00a0with\u00a0atazanavir \u00a0or\u00a0lopinavir/ritonavir. \u00a0\n7th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Lisbon,\u00a0April\u00a020\u201022\u00a02006.\u00a0Abstract\u00a0\n49.\u00a0\n\u00a0 590.\u00a0\u00a0Ray\u00a0AS,\u00a0Cihlar\u00a0T,\u00a0Robinson \u00a0LK,\u00a0Tong\u00a0L,\u00a0Vela\u00a0JE,\u00a0Wieman\u00a0ML,\u00a0et\u00a0al.\u00a0Mechanism \u00a0of\u00a0active\u00a0tubular\u00a0secretion \u00a0\nof\u00a0eenofovir \u00a0and\u00a0potential\u00a0for\u00a0a\u00a0renal\u00a0drug\u2010drug\u00a0interactions \u00a0with\u00a0HIV\u00a0protease\u00a0inhibitors. \u00a07th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Lisbon,\u00a0April\u00a020\u201022\u00a02006.\u00a0Abstract\u00a039.\u00a0\n\u00a0 591.\u00a0\u00a0Crane\u00a0h,\u00a0Harrington \u00a0R,\u00a0Van\u00a0Rompaey \u00a0SE,\u00a0Kitahata\u00a0M.\u00a0Didanosine \u00a0and\u00a0lower\u00a0baseline\u00a0body\u00a0weight\u00a0are\u00a0\nassociated \u00a0with\u00a0declining\u00a0renal\u00a0function\u00a0among\u00a0patients\u00a0receiving\u00a0tenofovir. \u00a013th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006.\u00a0Abstract\u00a0780.\u00a0\n\u00a0 592.\u00a0\u00a0Jao\u00a0J,\u00a0Wyatt\u00a0CM.\u00a0Antiretroviral \u00a0medications: \u00a0adverse\u00a0effects\u00a0on\u00a0the\u00a0kidney.\u00a0Adv\u00a0Chronic\u00a0Kidney\u00a0Dis\u00a0\n2010;\u00a017(1):72\u201082\u00a0\n\u00a0 593.\u00a0\u00a0Zimmermann \u00a0AE,\u00a0Pizzoferrato \u00a0T,\u00a0Bedford\u00a0J,\u00a0Morris\u00a0A,\u00a0Hoffman\u00a0R,\u00a0Braden\u00a0G.\u00a0Tenofovir \u2010associated \u00a0acute\u00a0\nand\u00a0chronic\u00a0kidney\u00a0disease:\u00a0a\u00a0case\u00a0of\u00a0multiple\u00a0drug\u00a0interactions. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(2):283 \u2010290\u00a0\n\u00a0 594.\u00a0\u00a0Kearney\u00a0BP,\u00a0Mathias\u00a0A,\u00a0Mittan\u00a0A,\u00a0Sayre\u00a0J,\u00a0Ebrahimi\u00a0R,\u00a0Cheng\u00a0AK.\u00a0Pharmacokinetics \u00a0and\u00a0safety\u00a0of\u00a0\ntenofovir\u00a0disoproxil \u00a0fumarate \u00a0on\u00a0coadministration \u00a0with\u00a0lopinavir/ritonavir. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2006;\u00a043(3):278 \u2010283\u00a0\n\u00a0 595.\u00a0\u00a0Fux\u00a0C,\u00a0Opravil\u00a0M,\u00a0Cavassini\u00a0M,\u00a0Calmy\u00a0A,\u00a0Flepp\u00a0M,\u00a0Gurtner\u2010Delafuente \u00a0V,\u00a0et\u00a0al.\u00a0Tenofovir \u00a0and\u00a0PI\u00a0use\u00a0are\u00a0\nassociated \u00a0with\u00a0an\u00a0increased \u00a0prevalence \u00a0of\u00a0proximal\u00a0renal\u00a0tubular\u00a0dysfunction \u00a0in\u00a0the\u00a0Swiss\u00a0HIV\u00a0cohort\u00a0\nstudy.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0\nAbstract\u00a0743.\u00a0\n\u00a0 596.\u00a0\u00a0Lee\u00a0L,\u00a0Soon\u00a0GH,\u00a0Shen\u00a0P,\u00a0Young\u00a0EL,\u00a0Flexner\u00a0C,\u00a0Pham\u00a0P.\u00a0Effect\u00a0of\u00a0efavirenz\u00a0and\u00a0darunavir/ritonavir \u00a0on\u00a0\nbilirubun\u00a0levels\u00a0in\u00a0healthy\u00a0adult\u00a0volunters: \u00a0role\u00a0of\u00a0induction \u00a0of\u00a0UGT1A1\u00a0and\u00a0bile\u00a0efflux\u00a0transporters. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 21811th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0\nAbstract\u00a027.\u00a0\n\u00a0 597.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0TN,\u00a0Stevens\u00a0T,\u00a0Aharchi\u00a0F,\u00a0de\u00a0Smedlt\u00a0G,\u00a0Peeters\u00a0M,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0etravirine \u00a0on\u00a0\ncytochrome \u00a0P450\u00a0isozymes\u00a0assessed\u00a0by\u00a0the\u00a0Cooperstown \u00a05+1\u00a0cocktail.\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0\nAnnual\u00a0Meeting,\u00a0Washington \u00a0DC,\u00a0October\u00a025\u201028\u00a02008.\u00a0Abstract\u00a0A\u2010955.\u00a0\n\u00a0 598.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0TN,\u00a0Raoof\u00a0A,\u00a0de\u00a0SG,\u00a0Hoetelmans \u00a0RM.\u00a0Clinical\u00a0pharmacokinetics \u00a0and\u00a0\npharmacodynamics \u00a0of\u00a0etravirine. \u00a0Clin\u00a0Pharmacokinet \u00a02009;\u00a048(9):561 \u2010574\u00a0\n\u00a0 599.\u00a0\u00a0Kharasch\u00a0ED,\u00a0Mitchell\u00a0D,\u00a0Coles\u00a0R,\u00a0Blanco\u00a0R.\u00a0Rapid\u00a0clinical\u00a0induction \u00a0of\u00a0hepatic\u00a0cytochrome \u00a0P4502B6\u00a0\nactivity\u00a0by\u00a0ritonavir.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02008;\u00a052(5):1663 \u20101669\u00a0\n\u00a0 600.\u00a0\u00a0Yeh\u00a0RF,\u00a0Gaver\u00a0VE,\u00a0Patterson \u00a0KB,\u00a0Rezk\u00a0NL,\u00a0Baxter\u2010Meheux\u00a0F,\u00a0Blake\u00a0MJ\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0induces\u00a0\nthe\u00a0hepatic\u00a0activity\u00a0of\u00a0cytochrome \u00a0P450\u00a0enzymes\u00a0CYP2C9,\u00a0CYP2C19, \u00a0and\u00a0CYP1A2\u00a0but\u00a0inhibits\u00a0the\u00a0\nhepatic\u00a0and\u00a0intestinal \u00a0activity\u00a0of\u00a0CYP3A\u00a0as\u00a0measured \u00a0by\u00a0a\u00a0phenotyping \u00a0drug\u00a0cocktail\u00a0in\u00a0healthy\u00a0\nvolunteers. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a042(1):52\u201060\u00a0\n\u00a0 601.\u00a0\u00a0Vourvahis \u00a0M,\u00a0Dumond\u00a0J,\u00a0Patterson \u00a0K,\u00a0Rezk\u00a0N,\u00a0Tien\u00a0H,\u00a0Li\u00a0J,\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0tipranavir/ritonavir \u00a0(TPV/r)\u00a0on\u00a0\nthe\u00a0activity\u00a0of\u00a0cytochrome \u00a0p450\u00a0(CYP)\u00a0enzymes\u00a01A2,\u00a02C9,\u00a0and\u00a02D6\u00a0in\u00a0healthy\u00a0volunteers. \u00a08th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Budapest, \u00a0April\u00a016\u201018\u00a02007.\u00a0Abstract\u00a0\n52.\u00a0\n\u00a0 602.\u00a0\u00a0Carter\u00a0NJ,\u00a0Keating\u00a0GM.\u00a0Maraviroc. \u00a0Drugs\u00a02007;\u00a067(15):2277 \u20102288\u00a0\n\u00a0 603.\u00a0\u00a0Hyland\u00a0R,\u00a0Dickins\u00a0M,\u00a0Collins\u00a0C,\u00a0Jones\u00a0H,\u00a0Jones\u00a0B.\u00a0Maraviroc: \u00a0in\u00a0vitro\u00a0assessment \u00a0of\u00a0drug\u2010drug\u00a0interaction \u00a0\npotential. \u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a066(4):498 \u2010507\u00a0\n\u00a0 604.\u00a0\u00a0Yost\u00a0R,\u00a0Pasquale\u00a0TR,\u00a0Sahloff\u00a0EG.\u00a0Maraviroc: \u00a0a\u00a0coreceptor \u00a0CCR5\u00a0antagonist \u00a0for\u00a0management \u00a0of\u00a0HIV\u00a0\ninfection. \u00a0Am\u00a0J\u00a0Health\u00a0Syst\u00a0Pharm\u00a02009;\u00a066(8):715 \u2010726\u00a0\n\u00a0 605.\u00a0\u00a0Perry\u00a0CM.\u00a0Maraviroc: \u00a0a\u00a0review\u00a0of\u00a0its\u00a0use\u00a0in\u00a0the\u00a0management \u00a0of\u00a0CCR5\u2010tropic\u00a0HIV\u20101\u00a0infection. \u00a0Drugs\u00a02010;\u00a0\n70(9):1189 \u20101213\u00a0\n\u00a0 606.\u00a0\u00a0Raltegravir. \u00a0Merck\u00a0Sharp\u00a0&\u00a0Dohme\u00a0Ltd.\u00a0Hertfordshire, \u00a0Reino\u00a0Unido.\u00a0Septiembre \u00a02010.\u00a0Disponible \u00a0en:\u00a0\nwww.ema.europa.eu/docs/es_ ES/document_library/EPAR_ \u2010_Product_Information/human/ \u00a0\n000860/WC500037405.pdf \u00a0Acceso:\u00a021.10.2010. \u00a0\n\u00a0 607.\u00a0\u00a0Burger\u00a0DM.\u00a0Raltegravir: \u00a0a\u00a0review\u00a0of\u00a0its\u00a0pharmacokinetics, \u00a0pharmacology \u00a0and\u00a0clinical\u00a0studies.\u00a0Expert\u00a0\nOpin\u00a0Drug\u00a0Metab\u00a0Toxicol\u00a02010;\u00a06(9):1151 \u20101160\u00a0\n\u00a0 608.\u00a0\u00a0Croxtall\u00a0JD,\u00a0Lyseng\u2010Williamson \u00a0KA,\u00a0Perry\u00a0CM.\u00a0Raltegravir. \u00a0Drugs\u00a02008;\u00a068(1):131 \u2010138\u00a0\n\u00a0 609.\u00a0\u00a0Evering\u00a0TH,\u00a0Markowitz \u00a0M.\u00a0Raltegravir \u00a0(MK\u20100518):\u00a0an\u00a0integrase \u00a0inhibitor\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u20101.\u00a0\nDrugs\u00a0Today\u00a0(Barc)\u00a02007;\u00a043(12):865 \u2010877\u00a0\n\u00a0 610.\u00a0\u00a0Iwamoto\u00a0M,\u00a0Wenning\u00a0LA,\u00a0Mistry\u00a0GC,\u00a0Petry\u00a0AS,\u00a0Liou\u00a0SY,\u00a0Ghosh\u00a0K\u00a0et\u00a0al.\u00a0Atazanavir \u00a0modestly \u00a0increases \u00a0\nplasma\u00a0levels\u00a0of\u00a0raltegravir \u00a0in\u00a0healthy\u00a0subjects.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a047(1):137 \u2010140\u00a0\n\u00a0 611.\u00a0\u00a0Ofotokun \u00a0I,\u00a0Acosta\u00a0EP,\u00a0Lennox\u00a0JL,\u00a0Pan\u00a0Y,\u00a0Easley\u00a0KA.\u00a0Pharmacokinetics \u00a0of\u00a0an\u00a0indinavir\u2010ritonavir\u2010\nfosamprenavir \u00a0regimen\u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus.\u00a0Pharmacotherapy \u00a02008;\u00a0\n28(1):74\u201081\u00a0\n\u00a0 612.\u00a0\u00a0Peytavin\u00a0G,\u00a0Chazallon \u00a0C,\u00a0Descamps \u00a0D,\u00a0Capitant\u00a0C,\u00a0Katlama\u00a0C,\u00a0Pialoux\u00a0G,\u00a0et\u00a0al.\u00a0Pharmacokinetic, \u00a0safety\u00a0\nand\u00a0efficacy\u00a0of\u00a0two\u00a0dual\u00a0PI\u00a0regimens \u00a0(FPV/r\u00a0bid/ATV\u00a0qd\u00a0and\u00a0SQV/ATV/r \u00a0qd)\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0\nantiretroviral \u2010na\u00efve\u00a0HIV\u20101\u00a0subjects:\u00a0a\u00a0randomized \u00a0pilot\u00a0study\u00a0(ANRS\u00a0127).\u00a09th\u00a0International \u00a0Workshop \u00a0\non\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0New\u00a0Orleans,\u00a0April\u00a07\u20109\u00a02008.\u00a0Abstract\u00a0P39.\u00a0\n\u00a0 613.\u00a0\u00a0Molt\u00f3\u00a0J,\u00a0Llibre\u00a0JM,\u00a0Valle\u00a0M,\u00a0Miranda\u00a0C,\u00a0Cede\u00f1o\u00a0S,\u00a0P\u00e9rez\u00a0Alvarez\u00a0N,\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0nevirapine \u00a0on\u00a0the\u00a0\nsteady\u2010state\u00a0through\u00a0concentrations \u00a0of\u00a0atazanavir/ritonavir. \u00a09th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0\nPharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0New\u00a0Orleans,\u00a0April\u00a07\u20109\u00a02008.\u00a0Abstract\u00a0P20.\u00a0\n\u00a0 614.\u00a0\u00a0Rhame\u00a0F,\u00a0Long\u00a0M,\u00a0Acosta\u00a0E.\u00a0RAL\u2010KAL:\u00a0Pharmacokinetics \u00a0of\u00a0coadministered \u00a0Raltegravir \u00a0and\u00a0Lopinavir\u2010\nRitonavir\u00a0in\u00a0healthy\u00a0adults.\u00a09th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0New\u00a0\nOrleans,\u00a0April\u00a07\u20109\u00a02008.\u00a0Abstract\u00a0O19.\u00a0\n\u00a0 615.\u00a0\u00a0Ng\u00a0J,\u00a0Klein\u00a0C,\u00a0Xiong\u00a0J,\u00a0Chiu\u00a0YL,\u00a0Doan\u00a0T,\u00a0Rolle\u00a0C,\u00a0et\u00a0al.\u00a0Lopinavir/Ritonavir \u00a0500/125\u00a0mg\u00a0Twice\u2010daily\u00a0+\u00a0\nEfavirenz\u00a0Approximate \u00a0the\u00a0Pharmacokinetic \u00a0Exposure\u00a0of\u00a0LPV/r\u00a0400/100\u00a0mg\u00a0Twice\u2010daily\u00a0Administered \u00a0\nAlone\u00a0in\u00a0Healthy\u00a0Adult\u00a0Subjects.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0\nFebruary\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0765.\u00a0\n\u00a0 616.\u00a0\u00a0Khanlou\u00a0H,\u00a0Allavena\u00a0C,\u00a0Billaud\u00a0E,\u00a0McKellar\u00a0M,\u00a0Reliquet\u00a0V.\u00a0Development \u00a0of\u00a0hepatic\u00a0cytolysis\u00a0alter\u00a0\nswitching \u00a0from\u00a0enfuvirtide \u00a0to\u00a0raltegravir \u00a0in\u00a0virologically \u00a0suppressed \u00a0patients\u00a0treated\u00a0with\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 219tipranavir/ritonavir. \u00a017th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0\nTUPE0087. \u00a0\n\u00a0 617.\u00a0\u00a0Hanley\u00a0WD,\u00a0Wenning\u00a0LA,\u00a0Moreau\u00a0A,\u00a0Kost\u00a0JT,\u00a0Mangin\u00a0E,\u00a0Shamp\u00a0T\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0tipranavir \u2010ritonavir\u00a0on\u00a0\npharmacokinetics \u00a0of\u00a0raltegravir. \u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02009;\u00a053(7):2752 \u20102755\u00a0\n\u00a0 618.\u00a0\u00a0Luber\u00a0A,\u00a0Condoluci \u00a0D,\u00a0Slowinski \u00a0P,\u00a0Loui\u00a0S,\u00a0Morwinkin \u00a0N,\u00a0Pappa\u00a0K,\u00a0et\u00a0al.\u00a0Steady\u2010state\u00a0pharmacokinetics \u00a0of\u00a0\nmaraviroc \u00a0and\u00a0amprenavir \u00a0alone\u00a0and\u00a0in\u00a0combination \u00a0after\u00a0maraviroc \u00a0is\u00a0given\u00a0BID\u00a0with\u00a0unboosted \u00a0or\u00a0\nritonavir\u00a0boosted\u00a0fosamprenavir \u00a0once\u2010\u00a0or\u00a0twice\u2010daily\u00a0in\u00a0fasted\u00a0healthy\u00a0volunteers. \u00a010th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Amsterdam, \u00a0April\u00a015\u201017,\u00a02009.\u00a0Abstract\u00a0P\u201031.\u00a0\n\u00a0 619.\u00a0\u00a0Lee\u00a0LS,\u00a0Soon\u00a0GH,\u00a0Shen\u00a0P,\u00a0Flexner\u00a0C,\u00a0Pham\u00a0P.\u00a0Pharmacokinetics \u00a0of\u00a0darunavir \u00a0900\u00a0mg\u00a0and\u00a0ritonavir\u00a0100\u00a0\nmg\u00a0once\u00a0daily\u00a0when\u00a0co\u2010administered \u00a0with\u00a0efavirenz\u00a0600\u00a0mg\u00a0once\u00a0daily\u00a0in\u00a0healthy\u00a0adult\u00a0volunteers. \u00a010th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Amsterdam, \u00a0April\u00a015\u201017,\u00a02009.\u00a0\nAbstract\u00a0P\u201029.\u00a0\n\u00a0 620.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Akuma\u00a0SH,\u00a0DeClerq\u00a0I,\u00a0De\u00a0Smedt\u00a0G,\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interaction \u00a0\nbetween\u00a0etravirine \u00a0and\u00a0lopinavir/ritonavir. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0\nChemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0A1\u20101298.\u00a0\n\u00a0 621.\u00a0\u00a0Luber\u00a0A,\u00a0Slovinski\u00a0D,\u00a0Acosta\u00a0E,\u00a0Pakes\u00a0G,\u00a0Pappa\u00a0K,\u00a0Condoluci \u00a0D,\u00a0et\u00a0al.\u00a0Steady\u2010state\u00a0pharmacokinetics \u00a0of\u00a0\nfosamprenavir \u00a0and\u00a0raltegravir \u00a0alone\u00a0and\u00a0combined \u00a0with\u00a0unboosted \u00a0and\u00a0ritonavir\u2010boosted\u00a0\nfosamprenavir. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0San\u00a0\nFrancisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0A1\u20101297.\u00a0\n\u00a0 622.\u00a0\u00a0Wittkop\u00a0L,\u00a0Breilh\u00a0D,\u00a0Da\u00a0SD,\u00a0Duffau\u00a0P,\u00a0Mercie\u00a0P,\u00a0Raymond \u00a0I\u00a0et\u00a0al.\u00a0Virological \u00a0and\u00a0immunological \u00a0response\u00a0\nin\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0multiple\u00a0treatment \u00a0failures\u00a0receiving\u00a0raltegravir \u00a0and\u00a0optimized \u00a0\nbackground \u00a0therapy,\u00a0ANRS\u00a0CO3\u00a0Aquitaine \u00a0Cohort.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02009;\u00a063(6):1251 \u20101255\u00a0\n\u00a0 623.\u00a0\u00a0Sekar\u00a0V,\u00a0Lefebvre\u00a0E,\u00a0Marien\u00a0K,\u00a0De\u00a0PM,\u00a0Vangeneugden \u00a0T,\u00a0Pozniak\u00a0A\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interaction \u00a0\nbetween\u00a0nevirapine \u00a0and\u00a0darunavir \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0Br\u00a0J\u00a0Clin\u00a0\nPharmacol \u00a02009;\u00a068(1):116 \u2010119\u00a0\n\u00a0 624.\u00a0\u00a0Anderson \u00a0MS,\u00a0Kakuda\u00a0TN,\u00a0Hanley\u00a0W,\u00a0Miller\u00a0J,\u00a0Kost\u00a0JT,\u00a0Stoltz\u00a0R\u00a0et\u00a0al.\u00a0Minimal\u00a0pharmacokinetic \u00a0\ninteraction \u00a0between\u00a0the\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0nonnucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0\netravirine \u00a0and\u00a0the\u00a0integrase \u00a0inhibitor\u00a0raltegravir \u00a0in\u00a0healthy\u00a0subjects.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a0\n2008;\u00a052(12):4228 \u20104232\u00a0\n\u00a0 625.\u00a0\u00a0Andrews\u00a0E,\u00a0Glue\u00a0P,\u00a0Fang\u00a0J,\u00a0Crownover \u00a0P,\u00a0Tressler\u00a0R,\u00a0Damle\u00a0B.\u00a0Assessment \u00a0of\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0co\u2010\nadministered \u00a0maraviroc \u00a0and\u00a0raltegravir. \u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02010;\u00a069(1):51\u201057\u00a0\n\u00a0 626.\u00a0\u00a0Baroncelli \u00a0S,\u00a0Villani\u00a0P,\u00a0Weimer\u00a0LE,\u00a0Ladisa\u00a0N,\u00a0Francisci\u00a0D,\u00a0Tommasi\u00a0C\u00a0et\u00a0al.\u00a0Raltegravir \u00a0plasma\u00a0\nconcentrations \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0receiving\u00a0salvage\u00a0regimens \u00a0based\u00a0on\u00a0raltegravir \u00a0with\u00a0\nand\u00a0without\u00a0maraviroc \u00a0coadministration. \u00a0Ann\u00a0Pharmacother \u00a02010;\u00a044(5):838 \u2010843\u00a0\n\u00a0 627.\u00a0\u00a0Barrail\u2010Tran\u00a0A,\u00a0Yazdanpanah \u00a0Y,\u00a0Fagard\u00a0C,\u00a0Colin\u00a0C,\u00a0Piketti\u00a0C,\u00a0Katlama\u00a0C,\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0Interaction \u00a0between\u00a0\nEtravirine \u00a0and\u00a0Raltegravir \u00a0plus\u00a0Darunavir/Ritonavir \u00a0When\u00a0Combined \u00a0in\u00a0Treatment \u2010experienced \u00a0Patients:\u00a0\nA\u00a0Substudy\u00a0of\u00a0the\u00a0ANRS\u00a0139\u00a0TRIO\u00a0Trial.\u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0\nSan\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0606.\u00a0\n\u00a0 628.\u00a0\u00a0Fagard\u00a0C,\u00a0Descamps \u00a0D,\u00a0Dubar\u00a0V,\u00a0Colin\u00a0C,\u00a0Taburet\u00a0AM,\u00a0Roquebert \u00a0B,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nraltegravir \u00a0plus\u00a0etravirine \u00a0and\u00a0darunavir/ritonavir \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0with\u00a0multidrug \u2010\nresistant\u00a0virus:\u00a048\u2010week\u00a0results\u00a0from\u00a0the\u00a0ANRS\u00a0139\u00a0TRIO\u00a0trial.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0\nTreatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0TUPDB204. \u00a0\n\u00a0 629.\u00a0\u00a0Imaz\u00a0A,\u00a0del\u00a0Saz\u00a0SV,\u00a0Ribas\u00a0MA,\u00a0Curran\u00a0A,\u00a0Caballero \u00a0E,\u00a0Falco\u00a0V\u00a0et\u00a0al.\u00a0Raltegravir, \u00a0etravirine, \u00a0and\u00a0ritonavir\u2010\nboosted\u00a0darunavir: \u00a0a\u00a0safe\u00a0and\u00a0successful \u00a0rescue\u00a0regimen\u00a0for\u00a0multidrug \u2010resistant\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a052(3):382 \u2010386\u00a0\n\u00a0 630.\u00a0\u00a0la\u00a0Porte\u00a0CJ,\u00a0Sabo\u00a0JP,\u00a0Beique\u00a0L,\u00a0Cameron\u00a0DW.\u00a0Lack\u00a0of\u00a0effect\u00a0of\u00a0efavirenz\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0\ntipranavir \u2010ritonavir\u00a0in\u00a0healthy\u00a0volunteers. \u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02009;\u00a053(11):4840 \u20104844\u00a0\n\u00a0 631.\u00a0\u00a0Menard\u00a0A,\u00a0Solas\u00a0C,\u00a0Mokthari\u00a0S,\u00a0Bregigeon \u00a0S,\u00a0Drogoul\u00a0MP,\u00a0Tamalet\u00a0C\u00a0et\u00a0al.\u00a0Etravirine \u2010raltegravir, \u00a0a\u00a0\nmarked\u00a0interaction \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a0about\u00a0four\u00a0cases.\u00a0AIDS\u00a02009;\u00a023(7):869 \u2010871\u00a0\n\u00a0 632.\u00a0\u00a0Muret\u00a0P,\u00a0Piedoux\u00a0S,\u00a0Foltzer\u00a0A,\u00a0Beguinot\u00a0I,\u00a0Boyer\u00a0L,\u00a0Burty\u00a0C,\u00a0et\u00a0al.\u00a0Pk/pd\u00a0of\u00a0raltegravir, \u00a0etravirine \u00a0and\u00a0\ndarunavir/r \u00a0when\u00a0used\u00a0in\u00a0combination \u00a0as\u00a0salvage\u00a0therapy.\u00a012th\u00a0European \u00a0AIDS\u00a0Conference, \u00a0Cologne,\u00a0\nNovember \u00a011\u201014\u00a02009.\u00a0Abstract\u00a0PE4.1/5.\u00a0\n\u00a0 633.\u00a0\u00a0Soon\u00a0GH,\u00a0Shen\u00a0P,\u00a0Yong\u00a0EL,\u00a0Pham\u00a0P,\u00a0Flexner\u00a0C,\u00a0Lee\u00a0L.\u00a0Pharmacokinetics \u00a0of\u00a0darunavir \u00a0at\u00a0900\u00a0milligrams \u00a0\nand\u00a0ritonavir\u00a0at\u00a0100\u00a0milligrams \u00a0once\u00a0daily\u00a0when\u00a0coadministered \u00a0with\u00a0efavirenz\u00a0at\u00a0600\u00a0milligrams \u00a0once\u00a0\ndaily\u00a0in\u00a0healthy\u00a0volunteers. \u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02010;\u00a054(7):2775 \u20102780\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 220\u00a0 634.\u00a0\u00a0Tommasi\u00a0C,\u00a0Tempestilli \u00a0M,\u00a0Bellagamba \u00a0R,\u00a0Notari\u00a0S,\u00a0Nicastri\u00a0E,\u00a0Pucillo\u00a0LP,\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0\ndarunavir/ritonavir, \u00a0raltegravir \u00a0and\u00a0etravirine \u00a0co\u2010administered \u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients.\u00a010th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Amsterdam, \u00a0April\u00a015\u201017,\u00a02009.\u00a0\nAbstract\u00a0O\u201011.\u00a0\n\u00a0 635.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Lefebvre\u00a0E,\u00a0De\u00a0MT,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0PM,\u00a0De\u00a0PE\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0darunavir \u00a0\n(TMC114) \u00a0and\u00a0atazanavir \u00a0during\u00a0coadministration \u00a0in\u00a0HIV\u2010negative,\u00a0healthy\u00a0volunteers. \u00a0Drugs\u00a0R\u00a0D\u00a02007;\u00a0\n8(4):241\u2010248\u00a0\n\u00a0 636.\u00a0\u00a0Haas\u00a0D,\u00a0Koletar\u00a0S,\u00a0Laughlin\u00a0L,\u00a0Kendall\u00a0M,\u00a0Suckow\u00a0C,\u00a0Gerber\u00a0J,\u00a0et\u00a0al.\u00a0Hepatic\u00a0Transaminase \u00a0Elevations \u00a0and\u00a0\nGastrointestinal \u00a0Intolerance \u00a0when\u00a0HIV\u2010negative\u00a0Healthy\u00a0Volunteers \u00a0on\u00a0Rifampin\u00a0add\u00a0Twice\u2010daily\u00a0\nAtazanavir \u00a0(300\u00a0mg)/Ritonavir \u00a0(100\u00a0mg):\u00a0ACTG\u00a0Protocol\u00a0A5213.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0766b.\u00a0\n\u00a0 637.\u00a0\u00a0Nijland\u00a0HM,\u00a0L'homme \u00a0RF,\u00a0Rongen\u00a0GA,\u00a0van\u00a0UP,\u00a0van\u00a0CR,\u00a0Boeree\u00a0MJ\u00a0et\u00a0al.\u00a0High\u00a0incidence \u00a0of\u00a0adverse\u00a0events\u00a0\nin\u00a0healthy\u00a0volunteers \u00a0receiving\u00a0rifampicin \u00a0and\u00a0adjusted\u00a0doses\u00a0of\u00a0lopinavir/ritonavir \u00a0tablets.\u00a0AIDS\u00a02008;\u00a0\n22(8):931 \u2010935\u00a0\n\u00a0 638.\u00a0\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention. \u00a0Managing \u00a0drug\u00a0interactions \u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u2010related\u00a0\ntuberculosis \u00a0(online).\u00a0Disponible \u00a0en:\u00a0\nwww.cdc.gov/tb/publications/guide lines/TB_HIV_Drugs/PDF/tbhiv.pdf \u00a0(Acceso\u00a014.12.2010). \u00a0\n\u00a0 639.\u00a0\u00a0Wenning\u00a0LA,\u00a0Hanley\u00a0WD,\u00a0Brainard\u00a0DM,\u00a0Petry\u00a0AS,\u00a0Ghosh\u00a0K,\u00a0Jin\u00a0B\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0rifampin,\u00a0a\u00a0potent\u00a0\ninducer\u00a0of\u00a0drug\u2010metabolizing \u00a0enzymes, \u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0raltegravir. \u00a0Antimicrob \u00a0Agents\u00a0\nChemother \u00a02009;\u00a053(7):2852 \u20102856\u00a0\n\u00a0 640.\u00a0\u00a0Khachi\u00a0H,\u00a0O'Connell \u00a0R,\u00a0Ladenheim \u00a0D,\u00a0Orkin\u00a0C.\u00a0Pharmacokinetic \u00a0interactions \u00a0between\u00a0rifabutin\u00a0and\u00a0\nlopinavir/ritonavir \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0mycobacterial \u00a0co\u2010infection. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a0\n2009;\u00a064(4):871 \u2010873\u00a0\n\u00a0 641.\u00a0\u00a0Brainard\u00a0DM,\u00a0Petry\u00a0AS,\u00a0Hanley\u00a0WD,\u00a0Wenning\u00a0LA,\u00a0Jin\u00a0B,\u00a0Breidinger \u00a0S,\u00a0et\u00a0al.\u00a0Doubling\u00a0the\u00a0dose\u00a0of\u00a0\nraltegravir \u00a0does\u00a0not\u00a0increase\u00a0trough\u00a0levels\u00a0in\u00a0the\u00a0presence\u00a0of\u00a0rifampin.\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0\nAnnual\u00a0Meeting,\u00a0Washington \u00a0DC,\u00a0October\u00a025\u201028\u00a02008.\u00a0Abstract\u00a0A\u2010964.\u00a0\n\u00a0 642.\u00a0\u00a0Swaminathan \u00a0S,\u00a0Padmapriyadarsini \u00a0C,\u00a0Venkatesan \u00a0P,\u00a0Narendran \u00a0G,\u00a0Kumar\u00a0R,\u00a0Iliayas\u00a0S,\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0\nnevirapine \u00a0vs\u00a0efavirenz\u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0TB:\u00a0A\u00a0randomized \u00a0clinical\u00a0trial.\u00a0\n16th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0\n35.\u00a0\n\u00a0 643.\u00a0\u00a0Bonora\u00a0S,\u00a0Di\u00a0PG.\u00a0Interactions \u00a0between\u00a0antiretroviral \u00a0agents\u00a0and\u00a0those\u00a0used\u00a0to\u00a0treat\u00a0tuberculosis. \u00a0Curr\u00a0\nOpin\u00a0HIV\u00a0AIDS\u00a02008;\u00a03(3):306\u2010312\u00a0\n\u00a0 644.\u00a0\u00a0Ello\u00a0F,\u00a0Bissagnene \u00a0E,\u00a0Eholi\u00e9\u00a0S,\u00a0Polneau\u00a0S,\u00a0Moutom\u00e9 \u00a0K,\u00a0Tanon\u00a0A,\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0clinical\u00a0trial\u00a0of\u00a0\nefavirenz\u00a0600mg/day \u00a0versus\u00a0800mg/day \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0tuberculosis \u00a0receiving\u00a0rifampicin \u00a0\nin\u00a0Abidjan\u00a0(Cote\u00a0d'Ivoire).\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Cape\u00a0\nTown,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0TUPEB142. \u00a0\n\u00a0 645.\u00a0\u00a0Boulle\u00a0A,\u00a0van\u00a0CG,\u00a0Cohen\u00a0K,\u00a0Hilderbrand \u00a0K,\u00a0Mathee\u00a0S,\u00a0Abrahams \u00a0M\u00a0et\u00a0al.\u00a0Outcomes \u00a0of\u00a0nevirapine \u2010\u00a0and\u00a0\nefavirenz\u2010based\u00a0antiretroviral \u00a0therapy\u00a0when\u00a0coadministered \u00a0with\u00a0rifampicin \u2010based\u00a0antitubercular \u00a0\ntherapy.\u00a0JAMA\u00a02008;\u00a0300(5):530 \u2010539\u00a0\n\u00a0 646.\u00a0\u00a0Brainard\u00a0DM,\u00a0Petry\u00a0AS,\u00a0Fang\u00a0L,\u00a0Lui\u00a0C,\u00a0Breidinger \u00a0SA,\u00a0Denoia\u00a0EP,\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0a\u00a0clinically\u00a0important \u00a0effect\u00a0\nof\u00a0rifabutin\u00a0on\u00a0raltegravir \u00a0pharmacokinetics. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0\nChemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0A1\u20101296.\u00a0\n\u00a0 647.\u00a0\u00a0Jenny\u2010Avital\u00a0ER,\u00a0Joseph\u00a0K.\u00a0Rifamycin \u2010resistant\u00a0Mycobacterium \u00a0tuberculosis \u00a0in\u00a0the\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy\u00a0era:\u00a0a\u00a0report\u00a0of\u00a03\u00a0relapses\u00a0with\u00a0acquired\u00a0rifampin\u00a0resistance \u00a0following \u00a0alternate\u2010\nday\u00a0rifabutin\u00a0and\u00a0boosted\u00a0protease\u00a0inhibitor\u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a048(10):1471 \u20101474\u00a0\n\u00a0 648.\u00a0\u00a0Manosuthi \u00a0W,\u00a0Sungkanuparph \u00a0S,\u00a0Tantanathip \u00a0P,\u00a0Lueangniyomkul \u00a0A,\u00a0Mankatitham \u00a0W,\u00a0Prasithsirskul \u00a0W\u00a0\net\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0comparing \u00a0plasma\u00a0drug\u00a0concentrations \u00a0and\u00a0efficacies \u00a0between\u00a02\u00a0\nnonnucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitor\u2010based\u00a0regimens \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0receiving\u00a0\nrifampicin: \u00a0the\u00a0N2R\u00a0Study.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a048(12):1752 \u20101759\u00a0\n\u00a0 649.\u00a0\u00a0Boulanger \u00a0C,\u00a0Hollender \u00a0E,\u00a0Farrell\u00a0K,\u00a0Stambaugh \u00a0JJ,\u00a0Maasen\u00a0D,\u00a0Ashkin\u00a0D\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0evaluation \u00a0\nof\u00a0rifabutin\u00a0in\u00a0combination \u00a0with\u00a0lopinavir\u2010ritonavir\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection\u00a0and\u00a0active\u00a0\ntuberculosis. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a049(9):1305 \u20101311\u00a0\n\u00a0 650.\u00a0\u00a0Decloedt\u00a0EH,\u00a0Maartens \u00a0G,\u00a0Smith\u00a0P,\u00a0Merry\u00a0C,\u00a0McIlleron \u00a0H.\u00a0The\u00a0pharmacokinetics \u00a0of\u00a0Lopinavir\u00a0in\u00a0South\u00a0\nAfrican\u00a0HIV\u2010infected\u00a0volunteers \u00a0receiving\u00a0rifampicin \u00a0with\u00a0adjusted\u00a0doses\u00a0of\u00a0Lopinavir/ritonavir. \u00a011th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a047.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 221\u00a0 651.\u00a0\u00a0Klein\u00a0R,\u00a0Struble\u00a0K.\u00a0U.S.\u00a0Food\u00a0and\u00a0Drug\u00a0Administration. \u00a0New\u00a0label\u00a0information \u00a0affecting\u00a0all\u00a0approved \u00a0\nprotease\u00a0inhibitors \u00a0for\u00a0treatment \u00a0of\u00a0HIV.\u00a0HIV\u00a0Update\u00a0April\u00a027,\u00a02010\u00a0\n\u00a0 652.\u00a0\u00a0Cohen\u00a0K,\u00a0Grant\u00a0A,\u00a0Dandara\u00a0C,\u00a0McIlleron \u00a0H,\u00a0Pemba\u00a0L,\u00a0Fielding\u00a0K\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0rifampicin \u2010based\u00a0\nantitubercular \u00a0therapy\u00a0and\u00a0the\u00a0cytochrome \u00a0P450\u00a02B6\u00a0516G>T\u00a0polymorphism \u00a0on\u00a0efavirenz\u00a0\nconcentrations \u00a0in\u00a0adults\u00a0in\u00a0South\u00a0Africa.\u00a0Antivir\u00a0Ther\u00a02009;\u00a014(5):687 \u2010695\u00a0\n\u00a0 653.\u00a0\u00a0Cohen\u00a0K,\u00a0Meintjes\u00a0G.\u00a0Management \u00a0of\u00a0individuals \u00a0requiring\u00a0antiretroviral \u00a0therapy\u00a0and\u00a0TB\u00a0treatment. \u00a0\nCurr\u00a0Opin\u00a0HIV\u00a0AIDS\u00a02010;\u00a05(1):61\u201069\u00a0\n\u00a0 654.\u00a0\u00a0Bruce\u00a0RD,\u00a0Altice\u00a0FL,\u00a0Moody\u00a0DE,\u00a0Morse\u00a0GD,\u00a0Andrews\u00a0L,\u00a0Lin\u00a0SN\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interactions \u00a0\nbetween\u00a0buprenorphine/naloxone \u00a0and\u00a0once\u2010daily\u00a0lopinavir/ritonavir. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2010;\u00a054(5):511 \u2010514\u00a0\n\u00a0 655.\u00a0\u00a0Bruce\u00a0RD,\u00a0Kresina\u00a0TF,\u00a0Cance\u2010Katz\u00a0EF.\u00a0Medication \u2010assisted\u00a0treatment \u00a0and\u00a0HIV/AIDS: \u00a0aspects\u00a0in\u00a0treating\u00a0\nHIV\u2010infected\u00a0drug\u00a0users.\u00a0AIDS\u00a02010;\u00a024(3):331 \u2010340\u00a0\n\u00a0 656.\u00a0\u00a0Nieminen \u00a0TH,\u00a0Hagelberg \u00a0NM,\u00a0Saari\u00a0TI,\u00a0Neuvonen \u00a0M,\u00a0Neuvonen \u00a0PJ,\u00a0Laine\u00a0K\u00a0et\u00a0al.\u00a0Oxycodone \u00a0\nconcentrations \u00a0are\u00a0greatly\u00a0increased \u00a0by\u00a0the\u00a0concomitant \u00a0use\u00a0of\u00a0ritonavir\u00a0or\u00a0lopinavir/ritonavir. \u00a0Eur\u00a0J\u00a0Clin\u00a0\nPharmacol \u00a02010;\u00a066(10):977 \u2010985\u00a0\n\u00a0 657.\u00a0\u00a0Anderson \u00a0MS,\u00a0Luk\u00a0JM,\u00a0Hanley\u00a0WD,\u00a0Jin\u00a0B,\u00a0Reisenberg \u00a0RA,\u00a0Wenning\u00a0LA,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0raltegravir \u00a0on\u00a0the\u00a0\npharmacokinetics \u00a0of\u00a0methadone. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0\nChemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0A1\u20101295.\u00a0\n\u00a0 658.\u00a0\u00a0Baker\u00a0J,\u00a0Gruber\u00a0VA,\u00a0Moody\u00a0DE,\u00a0Morse\u00a0GD,\u00a0Ma\u00a0Q,\u00a0Arenander \u00a0JN,\u00a0et\u00a0al.\u00a0Interactions \u00a0between\u00a0\nbuprenorphine \u00a0and\u00a0antiretrovirals: \u00a0Nucleos(t)ide \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0didanosine, \u00a0\nlamivudine \u00a0and\u00a0tenofovir. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0\nSan\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0A1\u20101306.\u00a0\n\u00a0 659.\u00a0\u00a0Bruce\u00a0R,\u00a0Altice\u00a0F,\u00a0Moody\u00a0D,\u00a0Lin\u00a0S,\u00a0Fanf\u00a0W,\u00a0Sabo\u00a0JS,\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interactions \u00a0between\u00a0\nbuprenorphine/naloxone \u00a0and\u00a0tipranavir/ritonavir \u00a0in\u00a0HIV\u2010negative\u00a0subjects\u00a0chronically \u00a0receiving\u00a0\nbuprenorphine/naloxone. \u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting,\u00a0Washington \u00a0DC,\u00a0October\u00a025\u2010\n28\u00a02008.\u00a0Abstract\u00a0A\u2010967a.\u00a0\n\u00a0 660.\u00a0\u00a0Gallagher \u00a0DP,\u00a0Kieran\u00a0J,\u00a0Sheehan\u00a0G,\u00a0Lambert\u00a0J,\u00a0Mahon\u00a0N,\u00a0Mallon\u00a0PW.\u00a0Ritonavir\u2010boosted\u00a0atazanavir, \u00a0\nmethadone, \u00a0and\u00a0ventricular \u00a0tachycardia: \u00a02\u00a0case\u00a0reports.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a047(3):e36 \u2010e38\u00a0\n\u00a0 661.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0van\u00a0den\u00a0BW,\u00a0Kakuda\u00a0TN,\u00a0Woodfall\u00a0B,\u00a0de\u00a0SG,\u00a0Vanaken\u00a0H\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0and\u00a0\npharmacodynamic \u00a0study\u00a0of\u00a0the\u00a0concomitant \u00a0administration \u00a0of\u00a0methadone \u00a0and\u00a0TMC125\u00a0in\u00a0HIV\u2010negative\u00a0\nvolunteers. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a048(3):322 \u2010329\u00a0\n\u00a0 662.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Tomaka\u00a0F,\u00a0Meyvisch \u00a0P,\u00a0De\u00a0Pauw\u00a0M,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0Vangeneugden \u00a0T,\u00a0Ettenhofer \u00a0ML.\u00a0\nPharmacokinetic \u00a0interaction \u00a0between\u00a0darunavir \u00a0in\u00a0combination \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0and\u00a0\nbuprenorphine/naloxone. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0\nSan\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0H\u2010232.\u00a0\n\u00a0 663.\u00a0\u00a0Busti\u00a0AJ,\u00a0Bain\u00a0AM,\u00a0Hall\u00a0RG,\u00a0Bedimo\u00a0RG,\u00a0Leff\u00a0RD,\u00a0Meek\u00a0C\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0atazanavir/ritonavir \u00a0or\u00a0\nfosamprenavir/ritonavir \u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0rosuvastatin. \u00a0J\u00a0Cardiovasc \u00a0Pharmacol \u00a02008;\u00a0\n51(6):605 \u2010610\u00a0\n\u00a0 664.\u00a0\u00a0van\u00a0der\u00a0Lee\u00a0M,\u00a0Sankatsing \u00a0R,\u00a0Schippers \u00a0E,\u00a0Vogel\u00a0M,\u00a0Fatkenheuer \u00a0G,\u00a0van\u00a0d,\u00a0V\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0and\u00a0\npharmacodynamics \u00a0of\u00a0combined \u00a0use\u00a0of\u00a0lopinavir/ritonavir \u00a0and\u00a0rosuvastatin \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0\nAntivir\u00a0Ther\u00a02007;\u00a012(7):1127 \u20101132\u00a0\n\u00a0 665.\u00a0\u00a0Kiser\u00a0JJ,\u00a0Gerber\u00a0JG,\u00a0Predhomme \u00a0JA,\u00a0Wolfe\u00a0P,\u00a0Flynn\u00a0DM,\u00a0Hoody\u00a0DW.\u00a0Drug/Drug \u00a0interaction \u00a0between\u00a0\nlopinavir/ritonavir \u00a0and\u00a0rosuvastatin \u00a0in\u00a0healthy\u00a0volunteers. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a0\n47(5):570 \u2010578\u00a0\n\u00a0 666.\u00a0\u00a0Van\u00a0Luin\u00a0M,\u00a0Colbers\u00a0A,\u00a0van\u00a0Ewijk\u2010Beneken\u2010Kolmer\u00a0EW,\u00a0Verweij\u2010Van\u00a0Wissen\u00a0C,\u00a0Schouwenberg \u00a0B,\u00a0\nHoitsma\u00a0A,\u00a0et\u00a0al.\u00a0Drug\u2010drug\u00a0interactions \u00a0between\u00a0raltegravir \u00a0and\u00a0pravastatin \u00a0in\u00a0healthy\u00a0volunteers. \u00a011th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a029.\u00a0\n\u00a0 667.\u00a0\u00a0Aquilante \u00a0C,\u00a0Kiser\u00a0JJ,\u00a0Anderson \u00a0P,\u00a0Christians \u00a0U,\u00a0Kosmiski\u00a0L,\u00a0Schniedewinnd \u00a0B,\u00a0et\u00a0al.\u00a0Influence \u00a0of\u00a0SLCO1B1\u00a0\npolymorphisms \u00a0on\u00a0pharmacokinetic \u00a0variability \u00a0in\u00a0the\u00a0drug\u2010drug\u00a0interaction \u00a0between\u00a0darunavir/ritonavir \u00a0\nand\u00a0pravastatin. \u00a050th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0Boston,\u00a0\nSeptember \u00a012\u201015\u00a02010.\u00a0Abstract\u00a0A1\u20102007.\u00a0\n\u00a0 668.\u00a0\u00a0Fichtenbaum \u00a0CJ,\u00a0Samineri\u00a0D,\u00a0Moore\u00a0E,\u00a0Sharma\u00a0S,\u00a0Sallans\u00a0L,\u00a0Desai\u00a0P,\u00a0et\u00a0al.\u00a0Darunavir/ritonavir \u00a0(DRV/rtv) \u00a0\nincreases \u00a0rosuvastatin \u00a0(RSV)\u00a0concentrations \u00a0but\u00a0does\u00a0not\u00a0alter\u00a0lipid\u2010lowering\u00a0effect\u00a0in\u00a0healthy\u00a0\nvolunteers. \u00a018th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Vienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0WEPE0101. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 222\u00a0 669.\u00a0\u00a0Busse\u00a0KH,\u00a0Hadigan\u00a0C,\u00a0Chairez\u00a0C,\u00a0Alfaro\u00a0RM,\u00a0Formentini \u00a0E,\u00a0Kovacs\u00a0JA\u00a0et\u00a0al.\u00a0Gemfibrozil \u00a0concentrations \u00a0are\u00a0\nsignificantly \u00a0decreased \u00a0in\u00a0the\u00a0presence\u00a0of\u00a0lopinavir\u2010ritonavir.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a0\n52(2):235 \u2010239\u00a0\n\u00a0 670.\u00a0\u00a0Pham\u00a0PA,\u00a0la\u00a0Porte\u00a0CJ,\u00a0Lee\u00a0LS,\u00a0van\u00a0HR,\u00a0Sabo\u00a0JP,\u00a0Elgadi\u00a0MM\u00a0et\u00a0al.\u00a0Differential \u00a0effects\u00a0of\u00a0tipranavir \u00a0plus\u00a0\nritonavir\u00a0on\u00a0atorvastatin \u00a0or\u00a0rosuvastatin \u00a0pharmacokinetics \u00a0in\u00a0healthy\u00a0volunteers. \u00a0Antimicrob \u00a0Agents\u00a0\nChemother \u00a02009;\u00a053(10):4385 \u20104392\u00a0\n\u00a0 671.\u00a0\u00a0Kostapanos \u00a0MS,\u00a0Milionis\u00a0HJ,\u00a0Elisaf\u00a0MS.\u00a0Rosuvastatin \u2010associated \u00a0adverse\u00a0effects\u00a0and\u00a0drug\u2010drug\u00a0\ninteractions \u00a0in\u00a0the\u00a0clinical\u00a0setting\u00a0of\u00a0dyslipidemia. \u00a0Am\u00a0J\u00a0Cardiovasc \u00a0Drugs\u00a02010;\u00a010(1):11\u201028\u00a0\n\u00a0 672.\u00a0\u00a0Jackson\u00a0A,\u00a0Moyle\u00a0G,\u00a0Watson\u00a0V,\u00a0Back\u00a0D,\u00a0Khoo\u00a0S,\u00a0Higgs\u00a0C,\u00a0et\u00a0al.\u00a0Variability \u00a0in\u00a0steady\u00a0state\u00a0raltegravir \u00a0\npharmacokinetics, \u00a0impact\u00a0of\u00a0ezetimibe? \u00a010th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0\nTherapy,\u00a0Amsterdam, \u00a0April\u00a015\u201017,\u00a02009.\u00a0Abstract\u00a0P\u201025.\u00a0\n\u00a0 673.\u00a0\u00a0Berenguer \u00a0J,\u00a0Von\u00a0Wichmann \u00a0MA,\u00a0Quereda\u00a0C,\u00a0Miralles\u00a0P,\u00a0Mallolas\u00a0J,\u00a0L\u00f3pez\u00a0Aldeguer\u00a0J,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0\naccompanying \u00a0antiretroviral \u00a0drugs\u00a0on\u00a0virologic\u00a0response\u00a0to\u00a0PEG\u2010IFN\u00a0and\u00a0ribavirin\u00a0in\u00a0HIV/HCV\u2010coinfected \u00a0\npatients.\u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010\nMarch\u00a02\u00a02010.\u00a0Abstract\u00a0663.\u00a0\n\u00a0 674.\u00a0\u00a0Rodriguez \u2010Torres\u00a0M,\u00a0Slim\u00a0J,\u00a0Bhatti\u00a0L,\u00a0Sterling\u00a0R,\u00a0Sulkowski \u00a0M,\u00a0Hassanein \u00a0T,\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0zidovudine \u00a0on\u00a0\nhematologic \u00a0parameters \u00a0during\u00a0treatment \u00a0with\u00a0peginterferon \u00a0alfa\u20102a\u00a0plus\u00a0ribavirin\u00a0for\u00a0chronic\u00a0hepatitis\u00a0\nC\u00a0in\u00a0HIV/HCV\u00a0co\u2010infected\u00a0patients\u00a0enrolled\u00a0in\u00a0a\u00a0large\u00a0randomized \u00a0double\u2010blind\u00a0study.\u00a017th\u00a0Conference \u00a0\non\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0664.\u00a0\n\u00a0 675.\u00a0\u00a0Amorosa\u00a0V,\u00a0Slim\u00a0J,\u00a0Mounzer\u00a0K,\u00a0Bruno\u00a0C,\u00a0Hoffman\u2010Terry\u00a0M,\u00a0Dorey\u2010Stein\u00a0Z,\u00a0et\u00a0al.\u00a0Abacavir\u00a0use\u00a0is\u00a0not\u00a0\nassociated \u00a0with\u00a0lack\u00a0of\u00a0virologic\u00a0response\u00a0in\u00a0ARV\u2010treated\u00a0HIV/HCV\u2010co\u2010infected\u00a0patients\u00a0receiving\u00a0\npegylated \u00a0interferon \u00a0and\u00a0ribavirin.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0\nMontreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0850.\u00a0\n\u00a0 676.\u00a0\u00a0van\u00a0Heeswijk\u00a0R,\u00a0Gysen\u00a0V,\u00a0Boogaerts \u00a0G,\u00a0De\u00a0Paepe\u00a0E,\u00a0Vangeneugden \u00a0T,\u00a0De\u00a0Backer\u00a0K,\u00a0et\u00a0al.\u00a0The\u00a0\npharmacokinetic \u00a0interaction \u00a0between\u00a0tenofovir\u00a0disoproxil \u00a0fumarate \u00a0and\u00a0the\u00a0investigational \u00a0HCV\u00a0\nprotease\u00a0inhibitor\u00a0telaprevir. \u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting,\u00a0Washington \u00a0DC,\u00a0October\u00a0\n25\u201028\u00a02008.\u00a0Abstract\u00a0A\u2010966.\u00a0\n\u00a0 677.\u00a0\u00a0Vispo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Pineda\u00a0JA,\u00a0Mira\u00a0JA,\u00a0Gir\u00f3n\u00a0JA.\u00a0Higher\u00a0rate\u00a0of\u00a0failure\u00a0to\u00a0pegylated \u2010interferon \u00a0plus\u00a0\nribavirin\u00a0in\u00a0HIV+\u00a0patients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0C\u00a0receiving\u00a0abacavir.\u00a0Antivir\u00a0Ther\u00a02008;\u00a013:428\u2010437\u00a0\n\u00a0 678.\u00a0\u00a0Gonz\u00e1lez\u2010Garc\u00eda\u00a0JJ,\u00a0Berenguer \u00a0J,\u00a0Condes\u00a0E,\u00a0Quereda\u00a0C,\u00a0Labarga\u00a0P,\u00a0Laguno\u00a0M,\u00a0et\u00a0al.\u00a0The\u00a0use\u00a0of\u00a0TDF+\u00a03TC/\u00a0\nFTC\u00a0is\u00a0associated \u00a0with\u00a0an\u00a0improved \u00a0response\u00a0to\u00a0pegylated \u00a0interferon \u00a0+\u00a0ribavirin\u00a0in\u00a0HIV/HCV\u2010co\u2010infected\u00a0\npatients\u00a0receiving\u00a0HAART:\u00a0The\u00a0Gesida\u00a050/06\u00a0study.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a01076.\u00a0\n\u00a0 679.\u00a0\u00a0Mira\u00a0J,\u00a0L\u00f3pez\u2010Cort\u00e9s\u00a0L,\u00a0Barreiro\u00a0P,\u00a0Tural\u00a0C,\u00a0Torres\u2010Tortosa\u00a0M,\u00a0de\u00a0los\u00a0Santos\u00a0Gil\u00a0I,\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0\nPegylated \u00a0Interferon \u00a0+\u00a0Ribavirin\u00a0Treatment \u00a0in\u00a0HIV/HCV\u2010co\u2010infected\u00a0Patients\u00a0Receiving \u00a0Abacavir\u00a0+\u00a0\nLamivudine \u00a0or\u00a0Tenofovir \u00a0+\u00a0either\u00a0Lamivudine \u00a0or\u00a0Emtricitabine \u00a0as\u00a0Nucleoside \u00a0Analogue \u00a0Backbone. \u00a015th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a01074.\u00a0\n\u00a0 680.\u00a0\u00a0Moreno\u00a0A,\u00a0Quereda\u00a0C,\u00a0Muriel\u00a0A,\u00a0P\u00e9rez\u2010Elias\u00a0M,\u00a0Casado\u00a0J,\u00a0Dronda\u00a0F,\u00a0et\u00a0al.\u00a0Does\u00a0the\u00a0Choice\u00a0of\u00a0NRTI\u00a0Have\u00a0\na\u00a0Significant \u00a0Influence \u00a0on\u00a0the\u00a0Outcome \u00a0of\u00a0pegIFN\u00a0plus\u00a0Ribavirin\u00a0among\u00a0HIV/HCV\u2010co\u2010infected\u00a0Patients? \u00a0\n15th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0\n1075.\u00a0\n\u00a0 681.\u00a0\u00a0Vfend\u00ae\u00a0(voriconazol). \u00a0Informaci\u00f3n \u00a0t\u00e9cnica\u00a0del\u00a0producto. \u00a0Agencia\u00a0Europea\u00a0del\u00a0Medicamento \u00a0(EMA).\u00a0\nRevisado: \u00a023/09/2010. \u00a0Disponible \u00a0en:\u00a0www.ema.europa.eu/docs/es_ ES/document_library/EPAR_ \u2010\n_Product_Information/human/000387/WC500049756.pdf \u00a0(Acceso\u00a013.11.2010). \u00a0\n\u00a0 682.\u00a0\u00a0Br\u00fcggermann \u00a0R,\u00a0Van\u00a0Luin\u00a0M,\u00a0van\u00a0den\u00a0Dungen\u00a0M,\u00a0Colbers\u00a0A,\u00a0Schouwenberg \u00a0B,\u00a0le\u00a0Blanc\u00a0R,\u00a0et\u00a0al.\u00a0\nBidirectional \u00a0pharmacokinetic \u00a0interaction \u00a0between\u00a0posaconazole \u00a0and\u00a0fosamprenavir. \u00a017th\u00a0Conference \u00a0\non\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0621.\u00a0\n\u00a0 683.\u00a0\u00a0Carten\u00a0M,\u00a0Kiser\u00a0JJ,\u00a0Kwara\u00a0A,\u00a0MaWhinney \u00a0S,\u00a0Cu\u2010Uvin\u00a0S.\u00a0Pharmacokinetic \u00a0interactions \u00a0between\u00a0the\u00a0\nhormonal \u00a0emergency \u00a0contraception, \u00a0levonorgestrel, \u00a0and\u00a0efavirenz. \u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0\nand\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0934.\u00a0\n\u00a0 684.\u00a0\u00a0Cingolani\u00a0A,\u00a0Torti\u00a0L,\u00a0Pinnetti\u00a0C,\u00a0de\u00a0Gaetano\u00a0DK,\u00a0Murri\u00a0R,\u00a0Tacconelli \u00a0E\u00a0et\u00a0al.\u00a0Detrimental \u00a0clinical\u00a0\ninteraction \u00a0between\u00a0ritonavir\u2010boosted\u00a0protease\u00a0inhibitors \u00a0and\u00a0vinblastine \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0\nHodgkin's \u00a0lymphoma. \u00a0AIDS\u00a02010;\u00a024(15):2408 \u20102412\u00a0\n\u00a0 685.\u00a0\u00a0Corti\u00a0N,\u00a0Heck\u00a0A,\u00a0Rentsch\u00a0K,\u00a0Zingg\u00a0W,\u00a0Jetter\u00a0A,\u00a0Stieger\u00a0B\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0ritonavir\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0\nof\u00a0the\u00a0benzimidazoles \u00a0albendazole \u00a0and\u00a0mebendazole: \u00a0an\u00a0interaction \u00a0study\u00a0in\u00a0healthy\u00a0volunteers. \u00a0Eur\u00a0J\u00a0\nClin\u00a0Pharmacol \u00a02009;\u00a065(10):999 \u20101006\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 223\u00a0 686.\u00a0\u00a0Hardy\u00a0H,\u00a0Backman\u00a0ES,\u00a0Farber\u00a0HW.\u00a0Successful \u00a0bosentan \u00a0and\u00a0nonnucleoside \u00a0reverse\u00a0transcriptase \u00a0\ninhibitor\u2010based\u00a0therapy\u00a0in\u00a0a\u00a0patient\u00a0with\u00a0acquired\u00a0immunodeficiency \u00a0syndrome \u00a0and\u00a0pulmonary \u00a0arterial\u00a0\nhypertension. \u00a0Pharmacotherapy \u00a02010;\u00a030(4):139e \u2010144e\u00a0\n\u00a0 687.\u00a0\u00a0Kredo\u00a0T,\u00a0Van\u00a0der\u00a0Walt\u00a0JS,\u00a0Mauff\u00a0K,\u00a0Smith\u00a0P,\u00a0Cohen\u00a0K,\u00a0Maartens \u00a0G,\u00a0et\u00a0al.\u00a0Nevirapine \u00a0increases \u00a0\nlumefantrine \u00a0exposure\u00a0in\u00a0HIV\u2010infected\u00a0patient.\u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0San\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0603.\u00a0\n\u00a0 688.\u00a0\u00a0Liedtke\u00a0MD,\u00a0Rathbun\u00a0RC.\u00a0Drug\u00a0interactions \u00a0with\u00a0antiretrovirals \u00a0and\u00a0warfarin.\u00a0Expert\u00a0Opin\u00a0Drug\u00a0Saf\u00a0\n2010;\u00a09(2):215\u2010223\u00a0\n\u00a0 689.\u00a0\u00a0Marfo\u00a0K,\u00a0Greenstein \u00a0S.\u00a0Antiretroviral \u00a0and\u00a0immunosuppressive \u00a0drug\u2010drug\u00a0interactions \u00a0in\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u2010infected\u00a0liver\u00a0and\u00a0kidney\u00a0transplant \u00a0recipients. \u00a0Transplant \u00a0Proc\u00a02009;\u00a0\n41(9):3796 \u20103799\u00a0\n\u00a0 690.\u00a0\u00a0Mir\u00a0O,\u00a0ssard\u2010Diana\u00a0B,\u00a0Louet\u00a0AL,\u00a0Loulergue \u00a0P,\u00a0Viard\u00a0JP,\u00a0Langlois\u00a0A\u00a0et\u00a0al.\u00a0Severe\u00a0toxicity\u00a0related\u00a0to\u00a0a\u00a0\npharmacokinetic \u00a0interaction \u00a0between\u00a0docetaxel \u00a0and\u00a0ritonavir\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0Br\u00a0J\u00a0Clin\u00a0\nPharmacol \u00a02010;\u00a069(1):99\u2010101\u00a0\n\u00a0 691.\u00a0\u00a0Mounier\u00a0N,\u00a0Katlama\u00a0C,\u00a0Costagliola \u00a0D,\u00a0Chichmanian \u00a0RM,\u00a0Spano\u00a0JP.\u00a0Drug\u00a0interactions \u00a0between\u00a0\nantineoplastic \u00a0and\u00a0antiretroviral \u00a0therapies: \u00a0Implications \u00a0and\u00a0management \u00a0for\u00a0clinical\u00a0practice.\u00a0Crit\u00a0Rev\u00a0\nOncol\u00a0Hematol\u00a02009;\u00a072(1):10\u201020\u00a0\n\u00a0 692.\u00a0\u00a0Pollack\u00a0TM,\u00a0McCoy\u00a0C,\u00a0Stead\u00a0W.\u00a0Clinically\u00a0significant \u00a0adverse\u00a0events\u00a0from\u00a0a\u00a0drug\u00a0interaction \u00a0between\u00a0\nquetiapine \u00a0and\u00a0atazanavir \u2010ritonavir\u00a0in\u00a0two\u00a0patients.\u00a0Pharmacotherapy \u00a02009;\u00a029(11):1386 \u20101391\u00a0\n\u00a0 693.\u00a0\u00a0Soyinka\u00a0JO,\u00a0Onyeji\u00a0CO,\u00a0Omoruyi\u00a0SI,\u00a0Owolabi\u00a0AR,\u00a0Sarma\u00a0PV,\u00a0Cook\u00a0JM.\u00a0Pharmacokinetic \u00a0interactions \u00a0\nbetween\u00a0ritonavir\u00a0and\u00a0quinine\u00a0in\u00a0healthy\u00a0volunteers \u00a0following \u00a0concurrent \u00a0administration. \u00a0Br\u00a0J\u00a0Clin\u00a0\nPharmacol \u00a02010;\u00a069(3):262 \u2010270\u00a0\n\u00a0 694.\u00a0\u00a0van\u00a0LM,\u00a0Colbers\u00a0A,\u00a0Verwey\u2010van\u00a0Wissen\u00a0CP,\u00a0van\u00a0Ewijk\u2010Beneken\u2010Kolmer\u00a0EW,\u00a0van\u00a0der\u00a0KM,\u00a0Hoitsma\u00a0A\u00a0et\u00a0al.\u00a0\nThe\u00a0effect\u00a0of\u00a0raltegravir \u00a0on\u00a0the\u00a0glucuronidation \u00a0of\u00a0lamotrigine. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02009;\u00a049(10):1220 \u20101227\u00a0\n\u00a0 695.\u00a0\u00a0Back\u00a0D,\u00a0Sekar\u00a0V,\u00a0Hoetelmans \u00a0RM.\u00a0Darunavir: \u00a0pharmacokinetics \u00a0and\u00a0drug\u00a0interactions. \u00a0Antivir\u00a0Ther\u00a02008;\u00a0\n13(1):1\u201013\u00a0\n\u00a0 696.\u00a0\u00a0Brown\u00a0KC,\u00a0Paul\u00a0S,\u00a0Kashuba\u00a0AD.\u00a0Drug\u00a0interactions \u00a0with\u00a0new\u00a0and\u00a0investigational \u00a0antiretrovirals. \u00a0Clin\u00a0\nPharmacokinet \u00a02009;\u00a048(4):211 \u2010241\u00a0\n\u00a0 697.\u00a0\u00a0Burger\u00a0DM,\u00a0Huisman\u00a0A,\u00a0Van\u00a0EN,\u00a0Neisingh\u00a0H,\u00a0van\u00a0UP,\u00a0Rongen\u00a0GA\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0atazanavir \u00a0and\u00a0\natazanavir/ritonavir \u00a0on\u00a0UDP\u2010glucuronosyltransferase \u00a0using\u00a0lamotrigine \u00a0as\u00a0a\u00a0phenotypic \u00a0probe.\u00a0Clin\u00a0\nPharmacol \u00a0Ther\u00a02008;\u00a084(6):698 \u2010703\u00a0\n\u00a0 698.\u00a0\u00a0Ciraci\u00a0E,\u00a0Villani\u00a0P,\u00a0Stano\u00a0F,\u00a0Cusato\u00a0M,\u00a0Heichen\u00a0M,\u00a0Monno\u00a0L,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0TDM\u2010assisted\u00a0\ncombination \u00a0therapy\u00a0with\u00a0voriconazole \u00a0plus\u00a0efavirenz\u00a0in\u00a0AIDS\u00a0patients\u00a0with\u00a0cryptococcosis. \u00a09th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0New\u00a0Orleans,\u00a0April\u00a07\u20109\u00a02008.\u00a0Abstract\u00a0\u00a0\nP18.\u00a0\n\u00a0 699.\u00a0\u00a0Corona\u00a0G,\u00a0Vaccher\u00a0E,\u00a0Sandron\u00a0S,\u00a0Sartor\u00a0I,\u00a0Tirelli\u00a0U,\u00a0Innocenti \u00a0F\u00a0et\u00a0al.\u00a0Lopinavir\u2010ritonavir\u00a0dramatically \u00a0\naffects\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0irinotecan \u00a0in\u00a0HIV\u00a0patients\u00a0with\u00a0Kaposi's\u00a0sarcoma.\u00a0Clin\u00a0Pharmacol \u00a0Ther\u00a0\n2008;\u00a083(4):601 \u2010606\u00a0\n\u00a0 700.\u00a0\u00a0Di\u00a0Biagio\u00a0A.,\u00a0Rosso\u00a0R,\u00a0Siccardi\u00a0M,\u00a0D'Avolio\u00a0A,\u00a0Bonora\u00a0S,\u00a0Viscoli\u00a0C.\u00a0Lack\u00a0of\u00a0interaction \u00a0between\u00a0raltegravir \u00a0\nand\u00a0cyclosporin \u00a0in\u00a0an\u00a0HIV\u2010infected\u00a0liver\u00a0transplant \u00a0recipient. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02009;\u00a064(4):874 \u2010\n875\u00a0\n\u00a0 701.\u00a0\u00a0Fang\u00a0AF,\u00a0Damle\u00a0BD,\u00a0LaBadie\u00a0RR,\u00a0Crownover \u00a0PH,\u00a0Hewlett\u00a0D,\u00a0Jr.,\u00a0Glue\u00a0PW.\u00a0Significant \u00a0decrease\u00a0in\u00a0\nnelfinavir \u00a0systemic\u00a0exposure \u00a0after\u00a0omeprazole \u00a0coadministration \u00a0in\u00a0healthy\u00a0subjects.\u00a0Pharmacotherapy \u00a0\n2008;\u00a028(1):42\u201050\u00a0\n\u00a0 702.\u00a0\u00a0Foisy\u00a0MM,\u00a0Yakiwchuk \u00a0EM,\u00a0Chiu\u00a0I,\u00a0Singh\u00a0AE.\u00a0Adrenal\u00a0suppression \u00a0and\u00a0Cushing's \u00a0syndrome \u00a0secondary \u00a0to\u00a0\nan\u00a0interaction \u00a0between\u00a0ritonavir\u00a0and\u00a0fluticasone: \u00a0a\u00a0review\u00a0of\u00a0the\u00a0literature. \u00a0HIV\u00a0Med\u00a02008;\u00a09(6):389\u2010\n396\u00a0\n\u00a0 703.\u00a0\u00a0German\u00a0P,\u00a0Parikh\u00a0S,\u00a0Lawrence \u00a0J,\u00a0Dorsey\u00a0G,\u00a0Rosenthal \u00a0PJ,\u00a0Havlir\u00a0D\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0affects\u00a0\npharmacokinetic \u00a0exposure \u00a0of\u00a0artemether/lumefantrine \u00a0in\u00a0HIV\u2010uninfected \u00a0healthy\u00a0volunteers. \u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(4):424 \u2010429\u00a0\n\u00a0 704.\u00a0\u00a0Guaraldi\u00a0G,\u00a0Cocchi\u00a0S,\u00a0Ciaffi\u00a0S,\u00a0Motta\u00a0A,\u00a0Pinetti\u00a0D,\u00a0Codeluppi \u00a0M,\u00a0et\u00a0al.\u00a0Different\u00a0Dose\u00a0Adjustments \u00a0of\u00a0\nImmunosuppresants \u00a0are\u00a0Necessary \u00a0after\u00a0Initiating\u00a0Boosted\u00a0or\u00a0Unboosted \u00a0First\u00a0Protease\u00a0Inhibitors \u00a0\nRegimen\u00a0Post\u2010liver\u00a0Transplantation. \u00a011th\u00a0European \u00a0AIDS\u00a0Conference, \u00a0Madrid,\u00a0October\u00a024\u201027\u00a02007.\u00a0\nAbstract\u00a0P4.2/04.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 224\u00a0 705.\u00a0\u00a0Iwamoto\u00a0M,\u00a0Wenning\u00a0LA,\u00a0Moreau\u00a0AR,\u00a0Hanley\u00a0WD,\u00a0Jin\u00a0B,\u00a0Breidinger \u00a0SA,\u00a0et\u00a0al.\u00a0Omeprazole \u00a0increases \u00a0\nplasma\u00a0levels\u00a0of\u00a0raltegravir \u00a0in\u00a0healthy\u00a0subjects.\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting,\u00a0\nWashington \u00a0DC,\u00a0October\u00a025\u201028\u00a02008.\u00a0Abstract\u00a0A\u2010963.\u00a0\n\u00a0 706.\u00a0\u00a0Iwamoto\u00a0M,\u00a0Kassahun \u00a0K,\u00a0Troyer\u00a0MD,\u00a0Hanley\u00a0WD,\u00a0Lu\u00a0P,\u00a0Rhoton\u00a0A\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0a\u00a0pharmacokinetic \u00a0effect\u00a0\nof\u00a0raltegravir \u00a0on\u00a0midazolam: \u00a0in\u00a0vitro/in\u00a0vivo\u00a0correlation. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a048(2):209 \u2010214\u00a0\n\u00a0 707.\u00a0\u00a0Ji\u00a0P,\u00a0Damle\u00a0B,\u00a0Xie\u00a0J,\u00a0Unger\u00a0SE,\u00a0Grasela\u00a0DM,\u00a0Kaul\u00a0S.\u00a0Pharmacokinetic \u00a0interaction \u00a0between\u00a0efavirenz\u00a0and\u00a0\ncarbamazepine \u00a0after\u00a0multiple\u2010dose\u00a0administration \u00a0in\u00a0healthy\u00a0subjects.\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a0\n48(8):948 \u2010956\u00a0\n\u00a0 708.\u00a0\u00a0Knoll\u00a0BM,\u00a0Vento\u00a0S,\u00a0Temesgen \u00a0Z.\u00a0Etravirine. \u00a0Drugs\u00a0Today\u00a0(Barc\u00a0)\u00a02008;\u00a044(1):23\u201033\u00a0\n\u00a0 709.\u00a0\u00a0Krishna\u00a0G,\u00a0Moton\u00a0A,\u00a0Ma\u00a0L,\u00a0Martinho \u00a0M,\u00a0Seiberling \u00a0M,\u00a0McLeod\u00a0J.\u00a0Effects\u00a0of\u00a0oral\u00a0posaconazole \u00a0on\u00a0the\u00a0\npharmacokinetics \u00a0of\u00a0atazanavir \u00a0alone\u00a0and\u00a0with\u00a0ritonavir\u00a0or\u00a0with\u00a0efavirenz\u00a0in\u00a0healthy\u00a0adult\u00a0volunteers. \u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(4):437 \u2010444\u00a0\n\u00a0 710.\u00a0\u00a0Mertz\u00a0D,\u00a0Battegay\u00a0M,\u00a0Marzolini \u00a0C,\u00a0Mayr\u00a0M.\u00a0Drug\u2010drug\u00a0interaction \u00a0in\u00a0a\u00a0kidney\u00a0transplant \u00a0recipient\u00a0\nreceiving\u00a0HIV\u00a0salvage\u00a0therapy\u00a0and\u00a0tacrolimus. \u00a0Am\u00a0J\u00a0Kidney\u00a0Dis\u00a02009;\u00a054(1):e1\u2010e4\u00a0\n\u00a0 711.\u00a0\u00a0Moreno\u00a0A,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Casado\u00a0JL,\u00a0Fortun\u00a0J,\u00a0Quereda\u00a0C,\u00a0B\u00e1rcena\u00a0R,\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0effectiveness \u00a0of\u00a0\nraltegravir \u2010based\u00a0HAART\u00a0in\u00a0HIV\u2010subjects\u00a0after\u00a0solid\u00a0organ\u00a0transplantation. \u00a049th\u00a0Interscience \u00a0Conference \u00a0\non\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0H\u2010913.\u00a0\n\u00a0 712.\u00a0\u00a0Moreno\u00a0A,\u00a0Barcena\u00a0R,\u00a0Quereda\u00a0C,\u00a0Casado\u00a0JL,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Fortun\u00a0J\u00a0et\u00a0al.\u00a0Safe\u00a0use\u00a0of\u00a0raltegravir \u00a0and\u00a0\nsirolimus\u00a0in\u00a0an\u00a0HIV\u2010infected\u00a0patient\u00a0with\u00a0renal\u00a0impairment \u00a0after\u00a0orthotopic \u00a0liver\u00a0transplantation. \u00a0AIDS\u00a0\n2008;\u00a022(4):547 \u2010548\u00a0\n\u00a0 713.\u00a0\u00a0Oostendorp \u00a0RL,\u00a0Huitema\u00a0A,\u00a0Rosing\u00a0H,\u00a0Jansen\u00a0RS,\u00a0Ter\u00a0HR,\u00a0Keessen\u00a0M\u00a0et\u00a0al.\u00a0Coadministration \u00a0of\u00a0ritonavir\u00a0\nstrongly\u00a0enhances \u00a0the\u00a0apparent\u00a0oral\u00a0bioavailability \u00a0of\u00a0docetaxel \u00a0in\u00a0patients\u00a0with\u00a0solid\u00a0tumors.\u00a0Clin\u00a0\nCancer\u00a0Res\u00a02009;\u00a015(12):4228 \u20104233\u00a0\n\u00a0 714.\u00a0\u00a0Sabo\u00a0JP,\u00a0Cong\u00a0XJ,\u00a0Haas\u00a0D,\u00a0Eskoetter \u00a0H,\u00a0Kraft\u00a0M,\u00a0Mauss\u00a0S.\u00a0Lack\u00a0of\u00a0a\u00a0pharmacokinetic \u00a0effect\u00a0between\u00a0\nsteady\u2010state\u00a0tipranavir/ritonavir \u00a0and\u00a0single\u2010dose\u00a0valacyclovir \u00a0in\u00a0healthy\u00a0volunteers. \u00a048th\u00a0Annual\u00a0\nICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting,\u00a0Washington \u00a0DC,\u00a0October\u00a025\u201028\u00a02008.\u00a0Abstract\u00a0A\u2010967.\u00a0\n\u00a0 715.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Van\u00a0Solingen\u2010Ristea\u00a0RM,\u00a0Onkelinx\u00a0J,\u00a0De\u00a0Smedt\u00a0G,\u00a0Peeters\u00a0M,\u00a0et\u00a0al.\u00a0No\u00a0\nclinically\u00a0relevant\u00a0effect\u00a0of\u00a0etravirine \u00a0on\u00a0digoxin\u00a0pharmacokinetics \u00a0in\u00a0HIV\u2010negative\u00a0volunteers. \u00a09th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0New\u00a0Orleans,\u00a0April\u00a07\u20109\u00a02008.\u00a0Abstract\u00a0\nP22.\u00a0\n\u00a0 716.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Van\u00a0Solingen\u2010Ristea\u00a0RM,\u00a0Aharchi\u00a0F,\u00a0De\u00a0Smedt\u00a0G,\u00a0Witek\u00a0J,\u00a0et\u00a0al.\u00a0\nPharmacokinetic \u00a0interaction \u00a0between\u00a0etravirine \u00a0and\u00a0fluconazole \u00a0or\u00a0voriconazole \u00a0in\u00a0HIV\u2010negative\u00a0\nvolunteers. \u00a049th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0San\u00a0Francisco, \u00a0\nSeptember \u00a012\u201015\u00a02009.\u00a0Abstract\u00a0A1\u20101299.\u00a0\n\u00a0 717.\u00a0\u00a0Sekar\u00a0V,\u00a0Tomaka\u00a0F,\u00a0Lavreys\u00a0L,\u00a0Meyvisch \u00a0P,\u00a0Bleys\u00a0C,\u00a0Da\u00a0Pawn\u00a0M,\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interaction \u00a0\nbetween\u00a0darunavir \u00a0in\u00a0combination \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0and\u00a0carbamazepine. \u00a017th\u00a0International \u00a0AIDS\u00a0\nConference, \u00a0Mexico\u00a0DF,\u00a03\u20108\u00a0August\u00a02008.\u00a0Abstract\u00a0TUPE0083. \u00a0\n\u00a0 718.\u00a0\u00a0Sekar\u00a0V,\u00a0Lefebvre\u00a0E,\u00a0De\u00a0MT,\u00a0De\u00a0PM,\u00a0De\u00a0PE,\u00a0Vangeneugden \u00a0T\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0repeated\u00a0doses\u00a0of\u00a0darunavir \u00a0\nplus\u00a0low\u2010dose\u00a0ritonavir\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0sildenafil\u00a0in\u00a0healthy\u00a0male\u00a0subjects:\u00a0phase\u00a0I\u00a0\nrandomized, \u00a0open\u2010label,\u00a0two\u2010way\u00a0crossover \u00a0study.\u00a0Clin\u00a0Drug\u00a0Investig\u00a02008;\u00a028(8):479 \u2010485\u00a0\n\u00a0 719.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0PE,\u00a0De\u00a0PM,\u00a0Vangeneugden \u00a0T,\u00a0Lefebvre\u00a0E\u00a0et\u00a0al.\u00a0Darunavir/ritonavir \u00a0\npharmacokinetics \u00a0following \u00a0coadministration \u00a0with\u00a0clarithromycin \u00a0in\u00a0healthy\u00a0volunteers. \u00a0J\u00a0Clin\u00a0\nPharmacol \u00a02008;\u00a048(1):60\u201065\u00a0\n\u00a0 720.\u00a0\u00a0Spak\u00a0CW,\u00a0Dhanireddy \u00a0S,\u00a0Kosel\u00a0BW.\u00a0Clinical\u00a0interaction \u00a0between\u00a0efavirenz\u00a0and\u00a0phenytoin. \u00a0AIDS\u00a02008;\u00a0\n22(1):164 \u2010165\u00a0\n\u00a0 721.\u00a0\u00a0Tappouni \u00a0HL,\u00a0Rublein\u00a0JC,\u00a0Donovan\u00a0BJ,\u00a0Hollowell \u00a0SB,\u00a0Tien\u00a0HC,\u00a0Min\u00a0SS\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0omeprazole \u00a0on\u00a0the\u00a0\nplasma\u00a0concentrations \u00a0of\u00a0indinavir\u00a0when\u00a0administered \u00a0alone\u00a0and\u00a0in\u00a0combination \u00a0with\u00a0ritonavir.\u00a0Am\u00a0J\u00a0\nHealth\u00a0Syst\u00a0Pharm\u00a02008;\u00a065(5):422 \u2010428\u00a0\n\u00a0 722.\u00a0\u00a0Tricot\u00a0L,\u00a0Teicher\u00a0E,\u00a0Peytavin\u00a0G,\u00a0Zucman\u00a0D,\u00a0Conti\u00a0F,\u00a0Calmus\u00a0Y\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0raltegravir \u00a0in\u00a0\nHIV\u2010infected\u00a0transplant \u00a0patients\u00a0cotreated \u00a0with\u00a0immunosuppressive \u00a0drugs.\u00a0Am\u00a0J\u00a0Transplant \u00a02009;\u00a0\n9(8):1946 \u20101952\u00a0\n\u00a0 723.\u00a0\u00a0Van\u00a0Luin\u00a0M,\u00a0Van\u00a0Der\u00a0Ende\u00a0ME,\u00a0Richter\u00a0C,\u00a0Visser\u00a0M,\u00a0Farag\u00a0D,\u00a0Van\u00a0der\u00a0Ven\u00a0A,\u00a0et\u00a0al.\u00a0Drug\u00a0interactions \u00a0\nbetween\u00a0atovaquone/proguanil \u00a0and\u00a0antiretroviral \u00a0agents.\u00a010th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0\nPharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Amsterdam, \u00a0April\u00a015\u201017,\u00a02009.\u00a0Abstract\u00a0O\u201019.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 225\u00a0 724.\u00a0\u00a0Ribera\u00a0E,\u00a0Ju\u00e1rez\u00a0JC,\u00a0Montoro\u00a0JB,\u00a0(Editores). \u00a0Fitoterapia \u00a0e\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH.\u00a0Interacciones \u00a0entre\u00a0\nf\u00e1rmacos \u00a0antirretrovirales \u00a0y\u00a0plantas\u00a0medicinales. \u00a0Madrid:\u00a0Gr\u00e1ficas\u00a0Enar\u00a0S\u00a0A,\u00a02007\u00a0\u00a0\n\u00a0 725.\u00a0\u00a0Robertson \u00a0SM,\u00a0Davey\u00a0RT,\u00a0Voell\u00a0J,\u00a0Formentini \u00a0E,\u00a0Alfaro\u00a0RM,\u00a0Penzak\u00a0SR.\u00a0Effect\u00a0of\u00a0Ginkgo\u00a0biloba\u00a0extract\u00a0on\u00a0\nlopinavir, \u00a0midazolam \u00a0and\u00a0fexofenadine \u00a0pharmacokinetics \u00a0in\u00a0healthy\u00a0subjects.\u00a0Curr\u00a0Med\u00a0Res\u00a0Opin\u00a02008;\u00a0\n24(2):591 \u2010599\u00a0\n\u00a0 726.\u00a0\u00a0Malati\u00a0CY,\u00a0Robertson \u00a0SM,\u00a0Hunt\u00a0JD,\u00a0Chairez\u00a0C,\u00a0Alfaro\u00a0RA,\u00a0Kovacs\u00a0JA,\u00a0et\u00a0al.\u00a0Echinacea \u00a0purpurea\u00a0does\u00a0not\u00a0\nalter\u00a0the\u00a0steady\u00a0state\u00a0pharmacokinetics \u00a0of\u00a0lopinavir\u00a0or\u00a0ritonavir\u00a0in\u00a0healthy\u00a0human\u00a0volunteers. \u00a049th\u00a0\nInterscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0San\u00a0Francisco, \u00a0September \u00a012\u201015\u00a0\n2009.\u00a0Abstract\u00a0A1\u20101307.\u00a0\n\u00a0 727.\u00a0\u00a0MacDonald \u00a0L,\u00a0Murty\u00a0M,\u00a0Foster\u00a0BC.\u00a0Antiviral\u00a0drug\u00a0disposition \u00a0and\u00a0natural\u00a0health\u00a0products: \u00a0risk\u00a0of\u00a0\ntherapeutic \u00a0alteration \u00a0and\u00a0resistance. \u00a0Expert\u00a0Opin\u00a0Drug\u00a0Metab\u00a0Toxicol\u00a02009;\u00a05(6):563\u2010578\u00a0\n\u00a0 728.\u00a0\u00a0Izzo\u00a0AA,\u00a0Ernst\u00a0E.\u00a0Interactions \u00a0between\u00a0herbal\u00a0medicines \u00a0and\u00a0prescribed \u00a0drugs:\u00a0an\u00a0updated\u00a0systematic \u00a0\nreview.\u00a0Drugs\u00a02009;\u00a069(13):1777 \u20101798\u00a0\n\u00a0 729.\u00a0\u00a0Abel\u00a0S,\u00a0Ridgway\u00a0C,\u00a0Hamlin\u00a0J,\u00a0Davis\u00a0J.\u00a0An\u00a0open,\u00a0parallel\u00a0group\u00a0study\u00a0to\u00a0compare\u00a0the\u00a0pharmacokinetics, \u00a0\nsafety\u00a0and\u00a0toleration \u00a0of\u00a0a\u00a0single\u00a0oral\u00a0dose\u00a0of\u00a0Maraviroc \u00a0in\u00a0subjects\u00a0with\u00a0mild\u00a0and\u00a0moderate \u00a0hepatic\u00a0\nimpairment \u00a0with\u00a0subjects\u00a0with\u00a0normal\u00a0hepatic\u00a0function.\u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0\nPharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Budapest, \u00a0April\u00a016\u201018\u00a02007.\u00a0Abstract\u00a08.\u00a0\n\u00a0 730.\u00a0\u00a0Agarwala \u00a0S,\u00a0Eley\u00a0T,\u00a0Child\u00a0M,\u00a0Wang\u00a0Y,\u00a0Persson\u00a0A,\u00a0Filoramo\u00a0D,\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0Atazanavir \u00a0in\u00a0\nseverely\u00a0renally\u00a0impaired\u00a0subjects\u00a0including\u00a0those\u00a0on\u00a0hemodialysis. \u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0\nClinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Budapest, \u00a0April\u00a016\u201018\u00a02007.\u00a0Abstract\u00a02.\u00a0\n\u00a0 731.\u00a0\u00a0Barreiro\u00a0P,\u00a0Rodriguez \u2010Novoa\u00a0S,\u00a0Labarga\u00a0P,\u00a0Ruiz\u00a0A,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Martin\u2010Carbonero \u00a0L\u00a0et\u00a0al.\u00a0Influence \u00a0\nof\u00a0liver\u00a0fibrosis\u00a0stage\u00a0on\u00a0plasma\u00a0levels\u00a0of\u00a0antiretroviral \u00a0drugs\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0chronic\u00a0\nhepatitis\u00a0C.\u00a0J\u00a0Infect\u00a0Dis\u00a02007;\u00a0195(7):973 \u2010979\u00a0\n\u00a0 732.\u00a0\u00a0Bossi\u00a0P,\u00a0Peytavin\u00a0G,\u00a0Lamotte\u00a0C,\u00a0Calvez\u00a0V,\u00a0Bricaire\u00a0F,\u00a0Costagliola \u00a0D\u00a0et\u00a0al.\u00a0High\u00a0indinavir\u00a0plasma\u00a0\nconcentrations \u00a0in\u00a0HIV\u2010positive\u00a0patients\u00a0co\u2010infected\u00a0with\u00a0hepatitis\u00a0B\u00a0or\u00a0C\u00a0virus\u00a0treated\u00a0with\u00a0low\u00a0doses\u00a0of\u00a0\nindinavir\u00a0and\u00a0ritonavir\u00a0(400/100\u00a0mg\u00a0twice\u00a0a\u00a0day)\u00a0plus\u00a0two\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitors. \u00a0\nAIDS\u00a02003;\u00a017(7):1108 \u20101110\u00a0\n\u00a0 733.\u00a0\u00a0Breilh\u00a0D,\u00a0Guinguene \u00a0S,\u00a0de\u00a0Ledinghen \u00a0V,\u00a0Toutain\u00a0J,\u00a0Pellegrin\u00a0JL,\u00a0Trimoulet \u00a0P,\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0\nBoosted\u00a0PI\u00a0and\u00a0NNRTI\u00a0in\u00a0HCV/HIV\u2010co\u2010infected\u00a0Patients.\u00a014th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Los\u00a0Angeles,\u00a0February\u00a025\u201028\u00a02007.\u00a0Abstract\u00a0946.\u00a0\n\u00a0 734.\u00a0\u00a0Chen\u00a0L,\u00a0Sabo\u00a0JP,\u00a0Philip\u00a0E,\u00a0Mao\u00a0Y,\u00a0Norris\u00a0SH,\u00a0MacGregor \u00a0TR\u00a0et\u00a0al.\u00a0Steady\u2010state\u00a0disposition \u00a0of\u00a0the\u00a0\nnonpeptidic \u00a0protease\u00a0inhibitor\u00a0tipranavir \u00a0when\u00a0coadministered \u00a0with\u00a0ritonavir.\u00a0Antimicrob \u00a0Agents\u00a0\nChemother \u00a02007;\u00a051(7):2436 \u20102444\u00a0\n\u00a0 735.\u00a0\u00a0Damle\u00a0B,\u00a0Hewlett\u00a0D,\u00a0Jr.,\u00a0Hsyu\u00a0PH,\u00a0Becker\u00a0M,\u00a0Petersen\u00a0A.\u00a0Pharmacokinetics \u00a0of\u00a0nelfinavir \u00a0in\u00a0subjects\u00a0with\u00a0\nhepatic\u00a0impairment. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02006;\u00a046(11):1241 \u20101249\u00a0\n\u00a0 736.\u00a0\u00a0Dominguez \u00a0S,\u00a0Benhamou \u00a0Y,\u00a0Katlama\u00a0C,\u00a0Peytavin\u00a0G.\u00a0Nevirapine \u00a0plasma\u00a0concentrations \u00a0in\u00a0HIV/HCV\u00a0and\u00a0\nHIV\u00a0infected\u00a0patients,\u00a0a\u00a0case\u00a0control\u00a0study:\u00a0NEVADOSE. \u00a07th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0\nPharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Lisbon,\u00a0April\u00a020\u201022\u00a02006.\u00a0Abstract\u00a021.\u00a0\n\u00a0 737.\u00a0\u00a0Dragovic\u00a0G,\u00a0Smith\u00a0CJ,\u00a0Jevtovic\u00a0D,\u00a0Grbovic\u00a0L,\u00a0Ypole\u00a0M.\u00a0The\u00a0impact\u00a0of\u00a0HCV/HIV\u00a0co\u2010infection\u00a0on\u00a0nevirapine \u00a0\nplasma\u00a0concentration \u00a0in\u00a0a\u00a0cohort\u00a0of\u00a0patients\u00a0in\u00a0Belgrade. \u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0\nPharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Budapest, \u00a0April\u00a016\u201018\u00a02007.\u00a0Abstract\u00a04.\u00a0\n\u00a0 738.\u00a0\u00a0Gatti\u00a0F,\u00a0Nasta\u00a0P,\u00a0Matti\u00a0A,\u00a0Loregian\u00a0A,\u00a0Pagni\u00a0S,\u00a0Prestini\u00a0K,\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0atazanavir \u00a0in\u00a0HIV\u20101\u2010\nHCV\u00a0co\u2010infected\u00a0patients.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a0\nJuly\u00a022\u201025\u00a02007.\u00a0Abstract\u00a0WEPEB008. \u00a0\n\u00a0 739.\u00a0\u00a0Gatti\u00a0F,\u00a0Pagni\u00a0S,\u00a0Nasta\u00a0P,\u00a0Boldrin\u00a0C,\u00a0Matti\u00a0A,\u00a0Loregian\u00a0A,\u00a0et\u00a0al.\u00a0Potential\u00a0role\u00a0of\u00a0TDM\u00a0in\u00a0dosing\u00a0protease\u00a0\ninhibitors \u00a0in\u00a0HIV\u2010HCV\u00a0co\u2010infected\u00a0patients\u00a0with\u00a0or\u00a0without\u00a0cirrhosis.\u00a025th\u00a0International \u00a0Congress\u00a0of\u00a0\nChemotherapy, \u00a0Munich,\u00a0March\u00a031\u00a0\u2010\u00a0April\u00a03\u00a02007\u00a0Abstract.\u00a0\n\u00a0 740.\u00a0\u00a0Gill\u00a0MJ,\u00a0Ostrop\u00a0NJ,\u00a0Fiske\u00a0WD,\u00a0Brennan\u00a0JM.\u00a0Efavirenz\u00a0dosing\u00a0in\u00a0patients\u00a0receiving\u00a0continuous \u00a0ambulatory \u00a0\nperitoneal \u00a0dialysis.\u00a0AIDS\u00a02000;\u00a014(8):1062 \u20101064\u00a0\n\u00a0 741.\u00a0\u00a0Guaraldi\u00a0G,\u00a0Cocchi\u00a0S,\u00a0Motta\u00a0A,\u00a0Ciaffi\u00a0S,\u00a0Codeluppi \u00a0M,\u00a0Bonora\u00a0S\u00a0et\u00a0al.\u00a0A\u00a0pilot\u00a0study\u00a0on\u00a0the\u00a0efficacy,\u00a0\npharmacokinetics \u00a0and\u00a0safety\u00a0of\u00a0atazanavir \u00a0in\u00a0patients\u00a0with\u00a0end\u2010stage\u00a0liver\u00a0disease.\u00a0J\u00a0Antimicrob \u00a0\nChemother \u00a02008;\u00a0\n\u00a0 742.\u00a0\u00a0Gupta\u00a0SK,\u00a0Rosenkranz \u00a0SL,\u00a0Cramer\u00a0YS,\u00a0Koletar\u00a0SL,\u00a0Szczech\u00a0LA,\u00a0Amorosa\u00a0V\u00a0et\u00a0al.\u00a0The\u00a0pharmacokinetics \u00a0and\u00a0\npharmacogenomics \u00a0of\u00a0efavirenz\u00a0and\u00a0lopinavir/ritonavir \u00a0in\u00a0HIV\u2010infected\u00a0persons\u00a0requiring\u00a0hemodialysis. \u00a0\nAIDS\u00a02008;\u00a022(15):1919 \u20101927\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 226\u00a0 743.\u00a0\u00a0Hermida\u00a0Donate\u00a0JM,\u00a0Quereda\u00a0C,\u00a0Moreno\u00a0A,\u00a0Hernandez \u00a0B,\u00a0Rodriguez \u00a0MA,\u00a0Dronda\u00a0F,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0\nsafety\u00a0of\u00a0atazanavir \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0liver\u00a0cirrhosis.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0\nPathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a0July\u00a022\u201025\u00a02007.\u00a0Abstract\u00a0MOPEB060. \u00a0\n\u00a0 744.\u00a0\u00a0Izzedine\u00a0H,\u00a0Launay\u2010Vacher\u00a0V,\u00a0Jullien\u00a0V,\u00a0Aymard\u00a0G,\u00a0Duvivier\u00a0C,\u00a0Deray\u00a0G.\u00a0Pharmacokinetics \u00a0of\u00a0tenofovir\u00a0in\u00a0\nhaemodialysis. \u00a0Nephrol\u00a0Dial\u00a0Transplant \u00a02003;\u00a018(9):1931 \u20101933\u00a0\n\u00a0 745.\u00a0\u00a0Jayasekara \u00a0D,\u00a0Aweeka\u00a0FT,\u00a0Rodriguez \u00a0R,\u00a0Kalayjian\u00a0RC,\u00a0Humphreys \u00a0MH,\u00a0Gambertoglio \u00a0JG.\u00a0Antiviral\u00a0therapy\u00a0\nfor\u00a0HIV\u00a0patients\u00a0with\u00a0renal\u00a0insufficiency. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a01999;\u00a021(5):384 \u201095\u00a0\n\u00a0 746.\u00a0\u00a0Katsounas \u00a0A,\u00a0Frank\u00a0A,\u00a0Klinker\u00a0H,\u00a0Langmann \u00a0P.\u00a0Efavirenz\u2010therapy\u00a0in\u00a0HIV\u2010patients\u00a0with\u00a0underlying \u00a0liver\u00a0\ndisease:\u00a0importance \u00a0of\u00a0continuous \u00a0TDM\u00a0of\u00a0EFV.\u00a0Eur\u00a0J\u00a0Med\u00a0Res\u00a02007;\u00a012(8):331 \u2010336\u00a0\n\u00a0 747.\u00a0\u00a0Kearney\u00a0BP,\u00a0Yale\u00a0K,\u00a0Shah\u00a0J,\u00a0Zhong\u00a0L,\u00a0Flaherty\u00a0JF.\u00a0Pharmacokinetics \u00a0and\u00a0dosing\u00a0recommendations \u00a0of\u00a0\ntenofovir\u00a0disoproxil \u00a0fumarate \u00a0in\u00a0hepatic\u00a0or\u00a0renal\u00a0impairment. \u00a0Clin\u00a0Pharmacokinet \u00a02006;\u00a045(11):1115 \u2010\n1124\u00a0\n\u00a0 748.\u00a0\u00a0King\u00a0JR,\u00a0Acosta\u00a0EP.\u00a0Tipranavir: \u00a0a\u00a0novel\u00a0nonpeptidic \u00a0protease\u00a0inhibitor\u00a0of\u00a0HIV.\u00a0Clin\u00a0Pharmacokinet \u00a02006;\u00a0\n45(7):665 \u2010682\u00a0\n\u00a0 749.\u00a0\u00a0Mallolas\u00a0J,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Ortega\u00a0E,\u00a0Guti\u00e9rrez \u00a0F,\u00a0Felizarta\u00a0F,\u00a0Bleiber\u00a0G,\u00a0et\u00a0al.\u00a0Fosamprenavir \u00a0/\u00a0ritonavir\u00a0\ndose\u00a0adjustment \u00a0for\u00a0patients\u00a0with\u00a0mild\u00a0and\u00a0moderate \u00a0hepatic\u00a0impairment \u00a0(APV10017). \u00a08th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Budapest, \u00a0April\u00a016\u201018\u00a02007.\u00a0Abstract\u00a0\n1.\u00a0\n\u00a0 750.\u00a0\u00a0Micheli\u00a0V,\u00a0Regazzi\u00a0M,\u00a0Dickinson \u00a0L,\u00a0Meraviglia \u00a0P,\u00a0Villani\u00a0P,\u00a0Khoo\u00a0SH\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\npharmacokinetics \u00a0in\u00a0HIV/HCV\u2010coinfected \u00a0patients\u00a0with\u00a0or\u00a0without\u00a0cirrhosis.\u00a0Ther\u00a0Drug\u00a0Monit\u00a02008;\u00a0\n30(3):306 \u2010313\u00a0\n\u00a0 751.\u00a0\u00a0Molto\u00a0J,\u00a0Valle\u00a0M,\u00a0Blanco\u00a0A,\u00a0Negredo\u00a0E,\u00a0Delavarga \u00a0M,\u00a0Miranda\u00a0C\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\npharmacokinetics \u00a0in\u00a0HIV\u00a0and\u00a0hepatitis\u00a0C\u00a0virus\u00a0co\u2010infected\u00a0patients\u00a0without\u00a0liver\u00a0function\u00a0impairment: \u00a0\ninfluence \u00a0of\u00a0liver\u00a0fibrosis.\u00a0Clin\u00a0Pharmacokinet \u00a02007;\u00a046(1):85\u201092\u00a0\n\u00a0 752.\u00a0\u00a0Molto\u00a0J,\u00a0Negredo\u00a0E,\u00a0Kaeser\u00a0B,\u00a0Gel\u00a0S,\u00a0Abt\u00a0M,\u00a0Becker\u00a0M,\u00a0et\u00a0al.\u00a0Nelfinavir \u00a0pharmacokinetics \u00a0in\u00a0patients\u00a0with\u00a0\nHIV\u00a0mono\u2010\u00a0and\u00a0HIV\u2010HCV\u00a0co\u2010infection. \u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0\nTherapy,\u00a0Budapest, \u00a0April\u00a016\u201018\u00a02007.\u00a0Abstract\u00a09.\u00a0\n\u00a0 753.\u00a0\u00a0Morello\u00a0J,\u00a0Garc\u00eda\u2010Gasc\u00f3\u00a0P,\u00a0Blanco\u00a0F,\u00a0Rodriguez \u2010Novoa\u00a0S,\u00a0Barreiro\u00a0P,\u00a0Maida\u00a0I,\u00a0et\u00a0al.\u00a0Higher\u00a0plasma\u00a0levels\u00a0\nof\u00a0Tipranavir \u00a0in\u00a0patients\u00a0with\u00a0more\u00a0significant \u00a0liver\u00a0fibrosis\u00a0and\u00a0risk\u00a0of\u00a0liver\u00a0toxicity.\u00a08th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Budapest, \u00a0April\u00a016\u201018\u00a02007.\u00a0Abstract\u00a035.\u00a0\n\u00a0 754.\u00a0\u00a0Paci\u2010Bonaventure \u00a0S,\u00a0Hafi\u00a0A,\u00a0Vincent\u00a0I,\u00a0Quertainmont \u00a0Y,\u00a0Goujard\u00a0C,\u00a0Charpentier \u00a0B\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0removal\u00a0\nof\u00a0nelfinavir \u00a0during\u00a0a\u00a0haemodialysis \u00a0session\u00a0in\u00a0an\u00a0HIV\u20101\u00a0infected\u00a0patient\u00a0with\u00a0hepatic\u00a0and\u00a0renal\u00a0\ninsufficiency. \u00a0Nephrol\u00a0Dial\u00a0Transplant \u00a02001;\u00a016:642\u2010643\u00a0\n\u00a0 755.\u00a0\u00a0Peng\u00a0JZ,\u00a0Pulido\u00a0F,\u00a0Causemaker \u00a0SJ,\u00a0Li\u00a0J,\u00a0Lorenzo\u00a0A,\u00a0Cepeda\u00a0C\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0lopinavir/ritonavir \u00a0\nin\u00a0HIV/hepatitis \u00a0C\u00a0virus\u2010coinfected \u00a0subjects\u00a0with\u00a0hepatic\u00a0impairment. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02006;\u00a046(3):265 \u2010\n274\u00a0\n\u00a0 756.\u00a0\u00a0Pereira\u00a0SA,\u00a0Caixas\u00a0U,\u00a0Branco\u00a0T,\u00a0Germano \u00a0I,\u00a0Lampreia \u00a0F,\u00a0Papoila\u00a0AL\u00a0et\u00a0al.\u00a0Efavirenz\u00a0concentrations \u00a0in\u00a0HIV\u2010\ninfected\u00a0patients\u00a0with\u00a0and\u00a0without\u00a0viral\u00a0hepatitis. \u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a066(4):551 \u20105\u00a0\n\u00a0 757.\u00a0\u00a0Pineda\u00a0JA,\u00a0Santos\u00a0J,\u00a0Rivero\u00a0A,\u00a0bdel\u2010Kader\u00a0L,\u00a0Palacios\u00a0R,\u00a0Camacho \u00a0A\u00a0et\u00a0al.\u00a0Liver\u00a0toxicity\u00a0of\u00a0antiretroviral \u00a0\ncombinations \u00a0including\u00a0atazanavir/ritonavir \u00a0in\u00a0patients\u00a0co\u2010infected\u00a0with\u00a0HIV\u00a0and\u00a0hepatitis\u00a0viruses:\u00a0\nimpact\u00a0of\u00a0pre\u2010existing\u00a0liver\u00a0fibrosis.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02008;\u00a061(4):925 \u2010932\u00a0\n\u00a0 758.\u00a0\u00a0Regazzi\u00a0M,\u00a0Tinelli\u00a0C,\u00a0Villani\u00a0P,\u00a0Cusato\u00a0M,\u00a0De\u00a0Silvestri\u00a0A,\u00a0Zucchi\u00a0P,\u00a0et\u00a0al.\u00a0Predictability \u00a0of\u00a0individual \u00a0\nNelfinavir \u00a0concentrations \u00a0at\u00a0different\u00a0time\u00a0points\u00a0for\u00a0total\u00a0systemic\u00a0exposure \u00a0in\u00a0HIV\u00a0and\u00a0HIV/HCV\u00a0co\u2010\ninfected\u00a0patients,\u00a0with\u00a0and\u00a0without\u00a0cirrhosis.\u00a06th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0\nHIV\u00a0Therapy,\u00a0Quebec,\u00a0April\u00a028\u201030\u00a02005.\u00a0Abstract\u00a061.\u00a0\n\u00a0 759.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0De\u00a0Smedt\u00a0G,\u00a0Woodfall\u00a0B,\u00a0Berckmans \u00a0C,\u00a0Peeters\u00a0M,\u00a0et\u00a0al.\u00a0\nPharmacokinetics \u00a0of\u00a0TMC125\u00a0in\u00a0HIV\u2010negative\u00a0volunteers \u00a0with\u00a0mild\u00a0and\u00a0moderate \u00a0hepatic\u00a0impairment. \u00a0\n47th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0Chicago,\u00a0September \u00a017\u201020\u00a0\n2007.\u00a0Abstract\u00a0A\u20101428.\u00a0\n\u00a0 760.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0Paepe\u00a0E,\u00a0Stevens\u00a0T,\u00a0Tomaka\u00a0F,\u00a0De\u00a0Pauw\u00a0M,\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0\nmultiple\u2010dose\u00a0darunavir \u00a0in\u00a0combination \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0in\u00a0individuals \u00a0with\u00a0impaired\u00a0hepatic\u00a0\nfunction.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a0July\u00a022\u201025\u00a02007.\u00a0\nAbstract\u00a0TUPDB05. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 227\u00a0 761.\u00a0\u00a0Spagnuolo \u00a0V,\u00a0Gentilini\u00a0G,\u00a0De\u00a0BA,\u00a0Galli\u00a0L,\u00a0Uberti\u2010Foppa\u00a0C,\u00a0Soldarini\u00a0A\u00a0et\u00a0al.\u00a0Liver\u00a0function\u00a0parameters \u00a0in\u00a0\nHIV/HCV\u00a0co\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0amprenavir \u00a0and\u00a0ritonavir\u00a0and\u00a0correlation \u00a0with\u00a0plasma\u00a0levels.\u00a0\nNew\u00a0Microbiol \u00a02007;\u00a030(3):279 \u2010282\u00a0\n\u00a0 762.\u00a0\u00a0Taburet\u00a0AM,\u00a0Naveau\u00a0S,\u00a0Zorza\u00a0G,\u00a0Colin\u00a0JN,\u00a0Delfraissy \u00a0JF,\u00a0Chaput\u00a0JC\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0zidovudine \u00a0\nin\u00a0patients\u00a0with\u00a0liver\u00a0cirrhosis.\u00a0Clin\u00a0Pharmacol \u00a0Ther\u00a01990;\u00a047(6):731 \u20109\u00a0\n\u00a0 763.\u00a0\u00a0Tebas\u00a0P,\u00a0Bellos\u00a0N,\u00a0Lucasti\u00a0C,\u00a0Richmond \u00a0G,\u00a0Godofsky \u00a0E,\u00a0Patel\u00a0I,\u00a0et\u00a0al.\u00a0Enfuvirtide \u00a0does\u00a0not\u00a0require\u00a0dose\u2010\nadjustment \u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0renal\u00a0failure:\u00a0the\u00a0results\u00a0of\u00a0a\u00a0pharmacokinetic \u00a0study\u00a0on\u00a0enfuvirtide \u00a0\nin\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0inpaired\u00a0renal\u00a0function\u00a0(NP17586). \u00a014th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Los\u00a0Angeles,\u00a0February\u00a025\u201028\u00a02007.\u00a0Abstract\u00a0572.\u00a0\n\u00a0 764.\u00a0\u00a0Veronese \u00a0L,\u00a0Rautaureau \u00a0J,\u00a0Sadler\u00a0BM,\u00a0Gillotin\u00a0C,\u00a0Petite\u00a0JP,\u00a0Pillegand\u00a0B\u00a0et\u00a0al.\u00a0Single\u2010dose\u00a0\npharmacokinetics \u00a0of\u00a0amprenavir, \u00a0a\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0protease\u00a0inhibitor,\u00a0in\u00a0subjects\u00a0\nwith\u00a0normal\u00a0or\u00a0impaired\u00a0hepatic\u00a0function.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02000;\u00a044(4):821 \u20106\u00a0\n\u00a0 765.\u00a0\u00a0Wyles\u00a0DL,\u00a0Gerber\u00a0JG.\u00a0Antiretroviral \u00a0drug\u00a0pharmacokinetics \u00a0in\u00a0hepatitis\u00a0with\u00a0hepatic\u00a0dysfunction. \u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02005;\u00a040(1):174 \u2010181\u00a0\n\u00a0 766.\u00a0\u00a0Crespo\u00a0M,\u00a0Pou\u00a0L,\u00a0Esteban\u00a0JI,\u00a0Falco\u00a0V,\u00a0Ribera\u00a0E,\u00a0L\u00f3pez\u00a0R\u00a0et\u00a0al.\u00a0Early\u00a0monitoring \u00a0of\u00a0ribavirin\u00a0serum\u00a0\nconcentration \u00a0is\u00a0not\u00a0useful\u00a0to\u00a0optimize\u00a0hepatitis\u00a0C\u00a0virus\u00a0treatment \u00a0in\u00a0HIV\u2010coinfected \u00a0patients.\u00a0Antivir\u00a0\nTher\u00a02007;\u00a012(8):1217 \u20101223\u00a0\n\u00a0 767.\u00a0\u00a0Vouvahis\u00a0M,\u00a0Fang\u00a0J,\u00a0Checcio\u00a0T,\u00a0Weatherley \u00a0B,\u00a0Heera\u00a0J.\u00a0Pharmacokinetics, \u00a0safety,\u00a0and\u00a0tolerability \u00a0of\u00a0\nmaraviroc \u00a0in\u00a0subjects\u00a0with\u00a0various\u00a0degrees\u00a0of\u00a0renal\u00a0impairment \u00a0and\u00a0normal\u00a0renal\u00a0function.\u00a011th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a015.\u00a0\n\u00a0 768.\u00a0\u00a0McFadyen \u00a0L,\u00a0Weatherley \u00a0B,\u00a0Vouvahis\u00a0M.\u00a0Population \u00a0modelling \u00a0of\u00a0maraviroc \u00a0pharmacokinetic \u00a0data\u00a0when\u00a0\nadministered \u00a0with\u00a0and\u00a0without\u00a0saquinavir/ritonavir \u00a0in\u00a0subjects\u00a0with\u00a0renal\u00a0dysfunctio. \u00a011th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a043.\u00a0\n\u00a0 769.\u00a0\u00a0Molto\u00a0J,\u00a0Sanz\u2010Moreno\u00a0J,\u00a0Valle\u00a0M,\u00a0Cede\u00f1o\u00a0S,\u00a0Bonal\u00a0J,\u00a0Bouarich\u00a0H,\u00a0Clotet\u00a0B.\u00a0Effect\u00a0of\u00a0hemodialysis \u00a0in\u00a0\nraltegravir \u00a0clearance \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0end\u00a0stage\u00a0renal\u00a0disease.\u00a011th\u00a0International \u00a0Workshop \u00a0\non\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a07.\u00a0\n\u00a0 770.\u00a0\u00a0Tommasi\u00a0C,\u00a0Nicastri\u00a0E,\u00a0Gallo\u00a0AL,\u00a0Tempestilli \u00a0M,\u00a0Bellagamba \u00a0R,\u00a0Fezza\u00a0R,\u00a0et\u00a0al.\u00a0Raltegravir \u00a0and\u00a0darunavir \u00a0\nplasma\u00a0pharmacokinetics \u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients\u00a0with\u00a0advanced \u00a0liver\u00a0disease.\u00a011th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a010.\u00a0\n\u00a0 771.\u00a0\u00a0Von\u00a0Hentig\u00a0N,\u00a0Khaykin\u00a0P,\u00a0Stephan\u00a0C,\u00a0Nisius\u00a0G,\u00a0Bickel\u00a0M,\u00a0Haberl\u00a0A,\u00a0et\u00a0al.\u00a0Hepatitis/HIV \u00a0co\u2010infection\u00a0\nwithout\u00a0hepatic\u00a0impairment \u00a0does\u00a0not\u00a0alter\u00a0lopinavir\u00a0plasma\u00a0concentrations \u00a0in\u00a0HIV\u20101\u00a0infeted\u00a0adults.\u00a011th\u00a0\nInternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy,\u00a0Sorrento, \u00a0April\u00a07\u20109\u00a02010.\u00a0Abstract\u00a057.\u00a0\n\u00a0 772.\u00a0\u00a0Chang\u00a0L,\u00a0Kreuzer\u00a0C,\u00a0Farha\u00a0R,\u00a0Abr\u00a0M,\u00a0Baher\u00a0L,\u00a0Tebas\u00a0P,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0moderate \u00a0liver\u00a0impairment \u00a0on\u00a0the\u00a0\nmultiple\u00a0dose\u00a0pharmacokinetics \u00a0of\u00a0ritonavir\u2010boosted\u00a0saquinavir \u00a0in\u00a0HIV\u00a0patient.\u00a018th\u00a0International \u00a0AIDS\u00a0\nConference, \u00a0Vienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0WEPE0093. \u00a0\n\u00a0 773.\u00a0\u00a0Sekar\u00a0V,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0PE,\u00a0Stevens\u00a0T,\u00a0Tomaka\u00a0F,\u00a0De\u00a0PM\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0multiple\u2010\ndose\u00a0darunavir \u00a0in\u00a0combination \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0in\u00a0individuals \u00a0with\u00a0mild\u2010to\u2010moderate \u00a0hepatic\u00a0\nimpairment. \u00a0Clin\u00a0Pharmacokinet \u00a02010;\u00a049(5):343 \u2010350\u00a0\n\u00a0 774.\u00a0\u00a0Bonacini\u00a0M,\u00a0Louie\u00a0S,\u00a0Bzowej\u00a0N,\u00a0Wohl\u00a0AR.\u00a0Survival\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection\u00a0and\u00a0viral\u00a0hepatitis\u00a0B\u00a0or\u00a0\nC:\u00a0a\u00a0cohort\u00a0study.\u00a0AIDS\u00a02004;\u00a018(15):2039 \u20102045\u00a0\n\u00a0 775.\u00a0\u00a0Garc\u00eda\u00a0Garc\u00eda\u00a0JA,\u00a0Aguilar\u2010Guisado\u00a0M,\u00a0Rivero\u00a0A,\u00a0Gir\u00f3n\u00a0Gonz\u00e1lez\u00a0J,\u00a0Gonz\u00e1lez\u00a0Serrano\u00a0M,\u00a0Merino\u00a0D,\u00a0et\u00a0al.\u00a0\nNatural\u00a0History\u00a0of\u00a0Compensated \u00a0Hepatitis\u00a0C\u00a0Virus\u2010related\u00a0Cirrhosis\u00a0in\u00a0HIV\u2010infected\u00a0Patients.\u00a015th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstrac\u00a01059.\u00a0\n\u00a0 776.\u00a0\u00a0Lopez\u2010Dieguez,\u00a0Gesida\u00a037/03\u2010FIPSE\u00a036465/03 \u00a0Study\u00a0Group.\u00a0Factors\u00a0Associated \u00a0with\u00a0Survival\u00a0and\u00a0First\u00a0\nHepatic\u00a0Decompensation \u00a0in\u00a0a\u00a0Large\u00a0Prospective \u00a0Cohort\u00a0of\u00a0HIV/HCV\u2010co\u2010infected\u00a0Patients\u00a0with\u00a0Liver\u00a0\nCirrhosis. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0\nAbstract\u00a01057.\u00a0\n\u00a0 777.\u00a0\u00a0Macias\u00a0J,\u00a0Mira\u00a0JA,\u00a0Lopez\u2010Cortes\u00a0LF,\u00a0Santos\u00a0I,\u00a0Giron\u2010Gonzalez\u00a0JA,\u00a0Gonzalez\u2010Serrano\u00a0M\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0\ntherapy\u00a0based\u00a0on\u00a0protease\u00a0inhibitors \u00a0as\u00a0a\u00a0protective \u00a0factor\u00a0against\u00a0liver\u00a0fibrosis\u00a0progression \u00a0in\u00a0patients\u00a0\nwith\u00a0chronic\u00a0hepatitis\u00a0C.\u00a0Antivir\u00a0Ther\u00a02006;\u00a011(7):839 \u2010846\u00a0\n\u00a0 778.\u00a0\u00a0Merchante \u00a0N,\u00a0Giron\u2010Gonzalez\u00a0JA,\u00a0Gonzalez\u2010Serrano\u00a0M,\u00a0Torre\u2010Cisneros\u00a0J,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0Arizcorreta \u00a0A\u00a0\net\u00a0al.\u00a0Survival\u00a0and\u00a0prognostic \u00a0factors\u00a0of\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0HCV\u2010related\u00a0end\u2010stage\u00a0liver\u00a0disease.\u00a0\nAIDS\u00a02006;\u00a020(1):49\u201057\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 228\u00a0 779.\u00a0\u00a0Qurishi\u00a0N,\u00a0Kreuzberg \u00a0C,\u00a0Luchters\u00a0G,\u00a0Effenberger \u00a0W,\u00a0Kupfer\u00a0B,\u00a0Sauerbruch \u00a0T\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0antiretroviral \u00a0\ntherapy\u00a0on\u00a0liver\u2010related\u00a0mortality\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0and\u00a0hepatitis\u00a0C\u00a0virus\u00a0coinfection. \u00a0Lancet\u00a02003;\u00a0\n362(9397):1708 \u20101713\u00a0\n\u00a0 780.\u00a0\u00a0Pineda\u00a0JA,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0guilar\u2010Guisado\u00a0M,\u00a0Rios\u2010Villegas\u00a0MJ,\u00a0Ruiz\u2010Morales\u00a0J,\u00a0Rivero\u00a0A\u00a0et\u00a0al.\u00a0Clinical\u00a0\nprogression \u00a0of\u00a0hepatitis\u00a0C\u00a0virus\u2010related\u00a0chronic\u00a0liver\u00a0disease\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0\npatients\u00a0undergoing \u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0Hepatology \u00a02007;\u00a046(3):622 \u2010630\u00a0\n\u00a0 781.\u00a0\u00a0Soriano\u00a0V,\u00a0Puoti\u00a0M,\u00a0Peters\u00a0M,\u00a0Benhamou \u00a0Y,\u00a0Sulkowski \u00a0M,\u00a0Zoulim\u00a0F\u00a0et\u00a0al.\u00a0Care\u00a0of\u00a0HIV\u00a0patients\u00a0with\u00a0\nchronic\u00a0hepatitis\u00a0B:\u00a0updated\u00a0recommendations \u00a0from\u00a0the\u00a0HIV\u2010Hepatitis\u00a0B\u00a0Virus\u00a0International \u00a0Panel.\u00a0AIDS\u00a0\n2008;\u00a022(12):1399 \u20101410\u00a0\n\u00a0 782.\u00a0\u00a0Tuyama\u00a0A,\u00a0Hong\u00a0F,\u00a0Mosoian\u00a0A,\u00a0Chen\u00a0P,\u00a0Chen\u00a0B,\u00a0Fiel\u00a0I,\u00a0e\u00a0al.\u00a0HIV\u00a0Entry\u00a0and\u00a0Replication \u00a0in\u00a0Stellate\u00a0Cells\u00a0\nPromotes \u00a0Cellular\u00a0Activation \u00a0and\u00a0Fibrogenesis: \u00a0Implications \u00a0for\u00a0Hepatic\u00a0Fibrosis\u00a0in\u00a0HIV/HCV\u00a0Co\u2010\ninfection. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0\nAbstract\u00a057.\u00a0\n\u00a0 783.\u00a0\u00a0Carr\u00a0A,\u00a0Cooper\u00a0DA.\u00a0Adverse\u00a0effects\u00a0of\u00a0antiretroviral \u00a0therapy.\u00a0Lancet\u00a02000;\u00a0356(9239):1423 \u201030\u00a0\n\u00a0 784.\u00a0\u00a0Reisler\u00a0RB,\u00a0Han\u00a0C,\u00a0Burman\u00a0WJ,\u00a0Tedaldi\u00a0EM,\u00a0Neaton\u00a0JD.\u00a0Grade\u00a04\u00a0events\u00a0are\u00a0as\u00a0important \u00a0as\u00a0AIDS\u00a0events\u00a0\nin\u00a0the\u00a0era\u00a0of\u00a0HAART.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02003;\u00a034(4):379 \u2010386\u00a0\n\u00a0 785.\u00a0\u00a0Rivero\u00a0A,\u00a0Mira\u00a0JA,\u00a0Pineda\u00a0JA.\u00a0Liver\u00a0toxicity\u00a0induced\u00a0by\u00a0non\u2010nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitors. \u00a0J\u00a0\nAntimicrob \u00a0Chemother \u00a02007;\u00a059(3):342 \u2010346\u00a0\n\u00a0 786.\u00a0\u00a0Nunez\u00a0M.\u00a0Hepatotoxicity \u00a0of\u00a0antiretrovirals: \u00a0incidence, \u00a0mechanisms \u00a0and\u00a0management. \u00a0J\u00a0Hepatol\u00a02006;\u00a0\n44(1\u00a0Suppl):S132 \u2010S139\u00a0\n\u00a0 787.\u00a0\u00a0Sabin\u00a0CA.\u00a0Pitfalls\u00a0of\u00a0assessing \u00a0hepatotoxicity \u00a0in\u00a0trials\u00a0and\u00a0observational \u00a0cohorts.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a038\u00a0\nSuppl\u00a02:S56\u2010S64\u00a0\n\u00a0 788.\u00a0\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group.\u00a0Table\u00a0of\u00a0grading\u00a0severity\u00a0of\u00a0adult\u00a0adverse\u00a0experiences. \u00a0Rockville, \u00a0MD:\u00a0US\u00a0\nDivision\u00a0of\u00a0AIDS,\u00a0National\u00a0Institute\u00a0of\u00a0Allergy\u00a0and\u00a0Infectious \u00a0Diseases,\u00a0Bethesda, \u00a01996.\u00a0\u00a0\n\u00a0 789.\u00a0\u00a0Sulkowski \u00a0MS,\u00a0Thomas\u00a0DL,\u00a0Chaisson\u00a0RE,\u00a0Moore\u00a0RD.\u00a0Hepatotoxicity \u00a0associated \u00a0with\u00a0antiretroviral \u00a0\ntherapy\u00a0in\u00a0adults\u00a0infected\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0and\u00a0the\u00a0role\u00a0of\u00a0hepatitis\u00a0C\u00a0or\u00a0B\u00a0virus\u00a0\ninfection. \u00a0JAMA\u00a02000;\u00a0283(1):74 \u201080\u00a0\n\u00a0 790.\u00a0\u00a0Saves\u00a0M,\u00a0Raffi\u00a0F,\u00a0Clevenbergh \u00a0P,\u00a0Marchou\u00a0B,\u00a0Waldner\u2010Combernoux \u00a0A,\u00a0Morlat\u00a0P.\u00a0Hepatitis\u00a0B\u00a0or\u00a0hepatitis\u00a0\nC\u00a0virus\u00a0infection\u00a0is\u00a0a\u00a0risk\u00a0factor\u00a0for\u00a0severe\u00a0hepatic\u00a0cytolysis\u00a0after\u00a0initiation\u00a0of\u00a0protease\u00a0inhibitor\u00a0\ncontaining \u00a0antiretroviral \u00a0regimen\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients.\u00a044:3451\u20103455.\u00a0\nAntimicrob \u00a0Agents\u00a0Chemother \u00a02000;\u00a044:3451\u20103455\u00a0\n\u00a0 791.\u00a0\u00a0Sulkowski \u00a0MS,\u00a0Thomas\u00a0DL,\u00a0Mehta\u00a0SH,\u00a0Chaisson\u00a0RE,\u00a0Moore\u00a0RD.\u00a0Hepatotoxicity \u00a0associated \u00a0with\u00a0\nnevirapine \u00a0or\u00a0efavirenz\u2010containing \u00a0antiretroviral \u00a0therapy:\u00a0role\u00a0of\u00a0hepatitis\u00a0C\u00a0and\u00a0B\u00a0infections. \u00a0\nHepatology \u00a02002;\u00a035(1):182 \u20109\u00a0\n\u00a0 792.\u00a0\u00a0Aranzabal \u00a0L,\u00a0Casado\u00a0JL,\u00a0Moya\u00a0J,\u00a0Quereda\u00a0C,\u00a0Diz\u00a0S,\u00a0Moreno\u00a0A\u00a0et\u00a0al.\u00a0Influence \u00a0of\u00a0liver\u00a0fibrosis\u00a0on\u00a0highly\u00a0\nactive\u00a0antiretroviral \u00a0therapy\u2010associated \u00a0hepatotoxicity \u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0and\u00a0hepatitis\u00a0C\u00a0virus\u00a0\ncoinfection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(4):588 \u2010593\u00a0\n\u00a0 793.\u00a0\u00a0McGovern \u00a0BH,\u00a0Birch\u00a0C,\u00a0Zaman\u00a0MT,\u00a0Bica\u00a0I,\u00a0Stone\u00a0D,\u00a0Quirk\u00a0JR\u00a0et\u00a0al.\u00a0Managing \u00a0symptomatic \u00a0drug\u2010induced\u00a0\nliver\u00a0injury\u00a0in\u00a0HIV\u2010hepatitis\u00a0C\u00a0virus\u2010coinfected \u00a0patients:\u00a0a\u00a0role\u00a0for\u00a0interferon. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a0\n45(10):1386 \u20101392\u00a0\n\u00a0 794.\u00a0\u00a0Labarga\u00a0P,\u00a0Soriano\u00a0V,\u00a0Vispo\u00a0ME,\u00a0Pinilla\u00a0J,\u00a0Martin\u2010Carbonero \u00a0L,\u00a0Castellares \u00a0C\u00a0et\u00a0al.\u00a0Hepatotoxicity \u00a0of\u00a0\nantiretroviral \u00a0drugs\u00a0is\u00a0reduced\u00a0after\u00a0successful \u00a0treatment \u00a0of\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0\nJ\u00a0Infect\u00a0Dis\u00a02007;\u00a0196(5):670 \u2010676\u00a0\n\u00a0 795.\u00a0\u00a0Moore\u00a0KH,\u00a0Raasch\u00a0RH,\u00a0Brouwer\u00a0KL,\u00a0Opheim\u00a0K,\u00a0Cheeseman \u00a0SH,\u00a0Eyster\u00a0E\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0and\u00a0\nbioavailability \u00a0of\u00a0zidovudine \u00a0and\u00a0its\u00a0glucuronidated \u00a0metabolite \u00a0in\u00a0patients\u00a0with\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0infection\u00a0and\u00a0hepatic\u00a0disease\u00a0(AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0protocol\u00a0062).\u00a0\nAntimicrob \u00a0Agents\u00a0Chemother \u00a01995;\u00a039(12):2732 \u20107\u00a0\n\u00a0 796.\u00a0\u00a0Johnson\u00a0MA,\u00a0Horak\u00a0J,\u00a0Breuel\u00a0P.\u00a0The\u00a0pharmacokinetics \u00a0of\u00a0lamivudine \u00a0in\u00a0patients\u00a0with\u00a0impaired\u00a0hepatic\u00a0\nfunction.\u00a0Eur\u00a0J\u00a0Clin\u00a0Pharmacol \u00a01998;\u00a054(4):363 \u20106\u00a0\n\u00a0 797.\u00a0\u00a0Schaad\u00a0HJ,\u00a0Petty\u00a0BG,\u00a0Grasela\u00a0DM,\u00a0Christofalo \u00a0B,\u00a0Raymond \u00a0R,\u00a0Stewart\u00a0M.\u00a0Pharmacokinetics \u00a0and\u00a0safety\u00a0of\u00a0\na\u00a0single\u00a0dose\u00a0of\u00a0stavudine \u00a0(d4T)\u00a0in\u00a0patients\u00a0with\u00a0severe\u00a0hepatic\u00a0impairment. \u00a0Antimicrob \u00a0Agents\u00a0\nChemother \u00a01997;\u00a041(12):2793 \u20106\u00a0\n\u00a0 798.\u00a0\u00a0Khaliq\u00a0Y,\u00a0Gallicano \u00a0K,\u00a0Seguin\u00a0I,\u00a0Fyke\u00a0K,\u00a0Carignan\u00a0G,\u00a0Bulman\u00a0D\u00a0et\u00a0al.\u00a0Single\u00a0and\u00a0multiple\u00a0dose\u00a0\npharmacokinetics \u00a0of\u00a0nelfinavir \u00a0and\u00a0CYP2C19\u00a0activity\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0\nwith\u00a0chronic\u00a0liver\u00a0disease.\u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02000;\u00a050(2):108 \u201015\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 229\u00a0 799.\u00a0\u00a0Arribas\u00a0J,\u00a0Pulido\u00a0F,\u00a0Peng\u00a0JZ,\u00a0Kemmis\u00a0S,\u00a0Li\u00a0JL,\u00a0Lorenzo\u00a0A.\u00a0Evaluation \u00a0of\u00a0the\u00a0multiple\u2010dose\u00a0\npharmacokinetics \u00a0of\u00a0lopinavir/ritonavir \u00a0(LPV/R)\u00a0in\u00a0HIV\u00a0and\u00a0HCV\u00a0co\u2010infected\u00a0subjects\u00a0with\u00a0mild\u00a0or\u00a0\nmoderate \u00a0hepatic\u00a0insufficiency. \u00a09th\u00a0European \u00a0AIDS\u00a0Conference \u00a0/\u00a01st\u00a0EACS\u00a0Resistance \u00a0&\u00a0Pharmacology \u00a0\nWorkshop, \u00a0Warsaw,\u00a0October\u00a025\u201029\u00a02003.\u00a0Abstract\u00a0F2/6.\u00a0\n\u00a0 800.\u00a0\u00a0Torriani\u00a0FJ,\u00a0Rodriguez \u2010Torres\u00a0M,\u00a0Rockstroh \u00a0JK,\u00a0Lissen\u00a0E,\u00a0Gonzalez\u2010Garcia\u00a0J,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0Peginterferon \u00a0\nAlfa\u20102a\u00a0plus\u00a0ribavirin\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0virus\u00a0infection\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02004;\u00a0\n351(5):438 \u2010450\u00a0\n\u00a0 801.\u00a0\u00a0Torriani\u00a0FJ,\u00a0Rockstroh \u00a0J,\u00a0Rodriguez \u2010Torres\u00a0M,\u00a0Lissen\u00a0E,\u00a0Gonzalez\u00a0J,\u00a0Lazzarin\u00a0A,\u00a0Carosi\u00a0G,\u00a0et\u00a0al.\u00a0Final\u00a0results\u00a0\nof\u00a0APRICOT: \u00a0A\u00a0randomized, \u00a0partially\u00a0blinded,\u00a0international \u00a0trial\u00a0evaluating \u00a0peginterferon \u2010alfa\u20102a\u00a0+\u00a0\nribavirin\u00a0vs\u00a0interferon \u2010alfa\u20102a\u00a0+\u00a0ribavirin\u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0HCV\u00a0in\u00a0HIV/HCV\u00a0co\u2010infection. \u00a011th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a08\u2010\u201011\u00a02004.\u00a0Abstract\u00a0\n112.\u00a0\n\u00a0 802.\u00a0\u00a0Perronne \u00a0C,\u00a0Carrat\u00a0F,\u00a0Bani\u2010Sadr\u00a0F,\u00a0Pol\u00a0S,\u00a0Rosenthal \u00a0E,\u00a0Lunel\u00a0F,\u00a0Morand\u00a0P,\u00a0Salmon\u00a0D,\u00a0et\u00a0al.\u00a0Final\u00a0results\u00a0of\u00a0\nANRS\u00a0HC02\u2010RIBAVIC:\u00a0A\u00a0randomized \u00a0controlled \u00a0trial\u00a0of\u00a0pegylated \u2010Interferon \u2010alfa\u20102b\u00a0plus\u00a0ribavirin\u00a0vs\u00a0\ninterferon \u2010alfa\u20102b\u00a0plus\u00a0ribavirin\u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u00a0co\u2010infected\u00a0\npatients.\u00a011th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a08\u2010\u201011\u00a0\n2004.\u00a0Abstract\u00a0117LB.\u00a0\n\u00a0 803.\u00a0\u00a0Perez\u2010Olmeda\u00a0M,\u00a0Soriano\u00a0V,\u00a0Asensi\u00a0V,\u00a0Morales\u00a0D,\u00a0Romero\u00a0M,\u00a0Ochoa\u00a0A\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0chronic\u00a0\nhepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0interferon \u00a0alpha\u20102b\u00a0plus\u00a0ribavirin.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a0\n2003;\u00a019(12):1083 \u20101089\u00a0\n\u00a0 804.\u00a0\u00a0Perez\u2010Olmeda\u00a0M,\u00a0Nunez\u00a0M,\u00a0Romero\u00a0M,\u00a0Gonzalez\u00a0J,\u00a0Castro\u00a0A,\u00a0Arribas\u00a0JR\u00a0et\u00a0al.\u00a0Pegylated \u00a0IFN\u2010alpha2b\u00a0\nplus\u00a0ribavirin\u00a0as\u00a0therapy\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a02003;\u00a017(7):1023 \u20101028\u00a0\n\u00a0 805.\u00a0\u00a0Laguno\u00a0M,\u00a0Murillas\u00a0J,\u00a0Blanco\u00a0JL,\u00a0Martinez\u00a0E,\u00a0Miquel\u00a0R,\u00a0Sanchez\u2010Tapias\u00a0JM\u00a0et\u00a0al.\u00a0Peginterferon \u00a0alfa\u20102b\u00a0\nplus\u00a0ribavirin\u00a0compared \u00a0with\u00a0interferon \u00a0alfa\u20102b\u00a0plus\u00a0ribavirin\u00a0for\u00a0treatment \u00a0of\u00a0HIV/HCV\u00a0co\u2010infected\u00a0\npatients.\u00a0AIDS\u00a02004;\u00a018(13):F27 \u2010F36\u00a0\n\u00a0 806.\u00a0\u00a0Chung\u00a0RT,\u00a0Andersen \u00a0J,\u00a0Volberding \u00a0P,\u00a0Robbins\u00a0GK,\u00a0Liu\u00a0T,\u00a0Sherman\u00a0KE\u00a0et\u00a0al.\u00a0Peginterferon \u00a0Alfa\u20102a\u00a0plus\u00a0\nribavirin\u00a0versus\u00a0interferon \u00a0alfa\u20102a\u00a0plus\u00a0ribavirin\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010coinfected \u00a0persons.\u00a0N\u00a0Engl\u00a0\nJ\u00a0Med\u00a02004;\u00a0351(5):451 \u2010459\u00a0\n\u00a0 807.\u00a0\u00a0Chung\u00a0R,\u00a0Andersen \u00a0J,\u00a0Volberding \u00a0P,\u00a0Robbins\u00a0G,\u00a0Liu\u00a0T,\u00a0Sherman\u00a0K,\u00a0et\u00a0al.\u00a0A\u00a0randomized, \u00a0controlled \u00a0trial\u00a0of\u00a0\nPEG\u2010interferon \u2010alfa\u20102a\u00a0plus\u00a0ribavirin\u00a0vs\u00a0interferon \u2010alfa\u20102a\u00a0plus\u00a0ribavirin\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0Vvrus\u00a0\ninfection\u00a0in\u00a0HIV\u2010co\u2010infected\u00a0persons:\u00a0Follow\u2010up\u00a0results\u00a0of\u00a0ACTG\u00a0A5071.\u00a011th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a08\u2010\u201011\u00a02004.\u00a0Abstract\u00a0110.\u00a0\n\u00a0 808.\u00a0\u00a0Carrat\u00a0F,\u00a0Bani\u2010Sadr\u00a0F,\u00a0Pol\u00a0S,\u00a0Rosenthal \u00a0E,\u00a0Lunel\u2010Fabiani\u00a0F,\u00a0Benzekri\u00a0A\u00a0et\u00a0al.\u00a0Pegylated \u00a0interferon \u00a0alfa\u20102b\u00a0\nvs\u00a0standard\u00a0interferon \u00a0alfa\u20102b,\u00a0plus\u00a0ribavirin,\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0a\u00a0\nrandomized \u00a0controlled \u00a0trial.\u00a0JAMA\u00a02004;\u00a0292(23):2839 \u20102848\u00a0\n\u00a0 809.\u00a0\u00a0Soriano\u00a0V,\u00a0Mocroft\u00a0A,\u00a0Rockstroh \u00a0J,\u00a0Ledergerber \u00a0B,\u00a0Knysz\u00a0B,\u00a0Chaplinskas \u00a0S\u00a0et\u00a0al.\u00a0Spontaneous \u00a0viral\u00a0\nclearance, \u00a0viral\u00a0load,\u00a0and\u00a0genotype \u00a0distribution \u00a0of\u00a0hepatitis\u00a0C\u00a0virus\u00a0(HCV)\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0\nanti\u2010HCV\u00a0antibodies \u00a0in\u00a0Europe.\u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0198(9):1337 \u20101344\u00a0\n\u00a0 810.\u00a0\u00a0Shores\u00a0NJ,\u00a0Maida\u00a0I,\u00a0Soriano\u00a0V,\u00a0Nunez\u00a0M.\u00a0Sexual\u00a0transmission \u00a0is\u00a0associated \u00a0with\u00a0spontaneous \u00a0HCV\u00a0\nclearance \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0J\u00a0Hepatol\u00a02008;\u00a049(3):323 \u2010328\u00a0\n\u00a0 811.\u00a0\u00a0Serpaggi\u00a0J,\u00a0Chaix\u00a0ML,\u00a0Batisse\u00a0D,\u00a0Dupont\u00a0C,\u00a0Vallet\u2010Pichard\u00a0A,\u00a0Fontaine\u00a0H\u00a0et\u00a0al.\u00a0Sexually\u00a0transmitted \u00a0acute\u00a0\ninfection\u00a0with\u00a0a\u00a0clustered \u00a0genotype \u00a04\u00a0hepatitis\u00a0C\u00a0virus\u00a0in\u00a0HIV\u20101\u2010infected\u00a0men\u00a0and\u00a0inefficacy \u00a0of\u00a0early\u00a0\nantiviral\u00a0therapy.\u00a0AIDS\u00a02006;\u00a020(2):233 \u2010240\u00a0\n\u00a0 812.\u00a0\u00a0Gotz\u00a0HM,\u00a0van\u00a0DG,\u00a0Niesters\u00a0HG,\u00a0den\u00a0Hollander \u00a0JG,\u00a0Thio\u00a0HB,\u00a0de\u00a0ZO.\u00a0A\u00a0cluster\u00a0of\u00a0acute\u00a0hepatitis\u00a0C\u00a0virus\u00a0\ninfection\u00a0among\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men\u2010\u2010results\u00a0from\u00a0contact\u00a0tracing\u00a0and\u00a0public\u00a0health\u00a0\nimplications. \u00a0AIDS\u00a02005;\u00a019(9):969 \u2010974\u00a0\n\u00a0 813.\u00a0\u00a0Santantonio \u00a0T,\u00a0Fasano\u00a0M.\u00a0Therapy\u00a0of\u00a0acute\u00a0hepatitis\u00a0C:\u00a0a\u00a0review\u00a0of\u00a0literature. \u00a0Curr\u00a0Pharm\u00a0Des\u00a02008;\u00a0\n14(17):1686 \u20101689\u00a0\n\u00a0 814.\u00a0\u00a0Jaeckel\u00a0E,\u00a0Cornberg \u00a0M,\u00a0Wedemeyer \u00a0H,\u00a0Santantonio \u00a0T,\u00a0Mayer\u00a0J,\u00a0Zankel\u00a0M\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0acute\u00a0\nhepatitis\u00a0C\u00a0with\u00a0interferon \u00a0alfa\u20102b.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02001;\u00a0345(20):1452 \u20101457\u00a0\n\u00a0 815.\u00a0\u00a0Vogel\u00a0M,\u00a0Nattermann \u00a0J,\u00a0Baumgarten \u00a0A,\u00a0Klausen\u00a0G,\u00a0Bieniek\u00a0B,\u00a0Schewe\u00a0K\u00a0et\u00a0al.\u00a0Pegylated \u00a0interferon \u2010alpha\u00a0\nfor\u00a0the\u00a0treatment \u00a0of\u00a0sexually\u00a0transmitted \u00a0acute\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0individuals. \u00a0Antivir\u00a0Ther\u00a0\n2006;\u00a011(8):1097 \u20101101\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 230\u00a0 816.\u00a0\u00a0Soriano\u00a0V,\u00a0Puoti\u00a0M,\u00a0Sulkowski \u00a0M,\u00a0Cargnel\u00a0A,\u00a0Benhamou \u00a0Y,\u00a0Peters\u00a0M\u00a0et\u00a0al.\u00a0Care\u00a0of\u00a0patients\u00a0coinfected \u00a0\nwith\u00a0HIV\u00a0and\u00a0hepatitis\u00a0C\u00a0virus:\u00a02007\u00a0updated\u00a0recommendations \u00a0from\u00a0the\u00a0HCV\u2010HIV\u00a0International \u00a0Panel.\u00a0\nAIDS\u00a02007;\u00a021(9):1073 \u20101089\u00a0\n\u00a0 817.\u00a0\u00a0Alvarez\u00a0D,\u00a0Dieterich\u00a0DT,\u00a0Brau\u00a0N,\u00a0Moorehead \u00a0L,\u00a0Ball\u00a0L,\u00a0Sulkowski \u00a0MS.\u00a0Zidovudine \u00a0use\u00a0but\u00a0not\u00a0weight\u2010\nbased\u00a0ribavirin\u00a0dosing\u00a0impacts\u00a0anaemia\u00a0during\u00a0HCV\u00a0treatment \u00a0in\u00a0HIV\u2010infected\u00a0persons.\u00a0J\u00a0Viral\u00a0Hepat\u00a0\n2006;\u00a013(10):683 \u2010689\u00a0\n\u00a0 818.\u00a0\u00a0Brau\u00a0N,\u00a0Rodriguez \u2010Torres\u00a0M,\u00a0Prokupek \u00a0D,\u00a0Bonacini\u00a0M,\u00a0Giffen\u00a0CA,\u00a0Smith\u00a0JJ\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0chronic\u00a0\nhepatitis\u00a0C\u00a0in\u00a0HIV/HCV\u2010coinfection \u00a0with\u00a0interferon \u00a0alpha\u20102b+\u00a0full\u2010course\u00a0vs.\u00a016\u2010week\u00a0delayed\u00a0ribavirin.\u00a0\nHepatology \u00a02004;\u00a039(4):989 \u2010998\u00a0\n\u00a0 819.\u00a0\u00a0Garcia\u2010Benayas\u00a0T,\u00a0Blanco\u00a0F,\u00a0Soriano\u00a0V.\u00a0Weight\u00a0loss\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02002;\u00a0\n347(16):1287 \u20101288\u00a0\n\u00a0 820.\u00a0\u00a0Lafeuillade \u00a0A,\u00a0Hittinger\u00a0G,\u00a0Chadapaud \u00a0S.\u00a0Increased \u00a0mitochondrial \u00a0toxicity\u00a0with\u00a0ribavirin\u00a0in\u00a0HIV/HCV\u00a0\ncoinfection. \u00a0Lancet\u00a02001;\u00a0357(9252):280 \u2010281\u00a0\n\u00a0 821.\u00a0\u00a0Moreno\u00a0A,\u00a0Quereda\u00a0C,\u00a0Moreno\u00a0L,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Muriel\u00a0A,\u00a0Casado\u00a0JL\u00a0et\u00a0al.\u00a0High\u00a0rate\u00a0of\u00a0didanosine \u2010\nrelated\u00a0mitochondrial \u00a0toxicity\u00a0in\u00a0HIV/HCV\u2010coinfected \u00a0patients\u00a0receiving\u00a0ribavirin.\u00a0Antivir\u00a0Ther\u00a02004;\u00a0\n9(1):133\u2010138\u00a0\n\u00a0 822.\u00a0\u00a0Mauss\u00a0S,\u00a0Larrey\u00a0D,\u00a0Valenti\u00a0W,\u00a0Torriani\u00a0F,\u00a0Dieterich\u00a0D,\u00a0Passe\u00a0S\u00a0et\u00a0al.\u00a0Risk\u00a0factors\u00a0for\u00a0hepatic\u00a0\ndecompensation \u00a0in\u00a0cirrhotic\u00a0patients\u00a0with\u00a0HIV/HCV\u00a0co\u2010infection\u00a0treated\u00a0with\u00a0pegylated \u00a0interferon \u2010\u00e1\u00a0or\u00a0\ninterferon \u2010\u00e1\u00a0and\u00a0rivbavirin, \u00a0or\u00a0placebo.\u00a0Antivir\u00a0Ther\u00a02003;\u00a08(L4)\u00a0\n\u00a0 823.\u00a0\u00a0Bani\u2010Sadr\u00a0F,\u00a0Carrat\u00a0F,\u00a0Pol\u00a0S,\u00a0Hor\u00a0R,\u00a0Rosenthal \u00a0E,\u00a0Goujard\u00a0C\u00a0et\u00a0al.\u00a0Risk\u00a0factors\u00a0for\u00a0symptomatic \u00a0\nmitochondrial \u00a0toxicity\u00a0in\u00a0HIV/hepatitis \u00a0C\u00a0virus\u2010coinfected \u00a0patients\u00a0during\u00a0interferon \u00a0plus\u00a0ribavirin\u2010based\u00a0\ntherapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a040(1):47\u201052\u00a0\n\u00a0 824.\u00a0\u00a0Bani\u2010Sadr\u00a0F,\u00a0Denoeud\u00a0L,\u00a0Morand\u00a0P,\u00a0Lunel\u2010Fabiani\u00a0F,\u00a0Pol\u00a0S,\u00a0Cacoub\u00a0P\u00a0et\u00a0al.\u00a0Early\u00a0virologic\u00a0failure\u00a0in\u00a0HIV\u2010\ncoinfected \u00a0hepatitis\u00a0C\u00a0patients\u00a0treated\u00a0with\u00a0the\u00a0peginterferon \u2010ribavirin\u00a0combination: \u00a0does\u00a0abacavir\u00a0play\u00a0\na\u00a0role?\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045(1):123 \u2010125\u00a0\n\u00a0 825.\u00a0\u00a0Vispo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Pineda\u00a0JA,\u00a0Mira\u00a0JA,\u00a0Maida\u00a0I,\u00a0Martin\u2010Carbonero \u00a0L\u00a0et\u00a0al.\u00a0Low\u00a0response\u00a0to\u00a0pegylated \u00a0\ninterferon \u00a0plus\u00a0ribavirin\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0C\u00a0treated\u00a0with\u00a0abacavir.\u00a0Antivir\u00a0\nTher\u00a02008;\u00a013(3):429 \u2010437\u00a0\n\u00a0 826.\u00a0\u00a0Mira\u00a0JA,\u00a0Lopez\u2010Cortes\u00a0LF,\u00a0Barreiro\u00a0P,\u00a0Tural\u00a0C,\u00a0Torres\u2010Tortosa\u00a0M,\u00a0de\u00a0Los\u00a0SG,\u00a0I\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0pegylated \u00a0\ninterferon \u00a0plus\u00a0ribavirin\u00a0treatment \u00a0in\u00a0HIV/hepatitis \u00a0C\u00a0virus\u00a0co\u2010infected\u00a0patients\u00a0receiving\u00a0abacavir\u00a0plus\u00a0\nlamivudine \u00a0or\u00a0tenofovir\u00a0plus\u00a0either\u00a0lamivudine \u00a0or\u00a0emtricitabine \u00a0as\u00a0nucleoside \u00a0analogue\u00a0backbone. \u00a0J\u00a0\nAntimicrob \u00a0Chemother \u00a02008;\u00a062(6):1365 \u20101373\u00a0\n\u00a0 827.\u00a0\u00a0Amorosa\u00a0VK,\u00a0Slim\u00a0J,\u00a0Mounzer\u00a0K,\u00a0Bruno\u00a0C,\u00a0Hoffman\u2010Terry\u00a0M,\u00a0Dorey\u2010Stein\u00a0Z\u00a0et\u00a0al.\u00a0The\u00a0influence \u00a0of\u00a0\nabacavir\u00a0and\u00a0other\u00a0antiretroviral \u00a0agents\u00a0on\u00a0virological \u00a0response\u00a0to\u00a0HCV\u00a0therapy\u00a0among\u00a0antiretroviral \u2010\ntreated\u00a0HIV\u2010infected\u00a0patients.\u00a0Antivir\u00a0Ther\u00a02010;\u00a015(1):91\u201099\u00a0\n\u00a0 828.\u00a0\u00a0Laufer\u00a0N,\u00a0Laguno\u00a0M,\u00a0Perez\u00a0I,\u00a0Cifuentes \u00a0C,\u00a0Murillas\u00a0J,\u00a0Vidal\u00a0F\u00a0et\u00a0al.\u00a0Abacavir\u00a0does\u00a0not\u00a0influence \u00a0the\u00a0rate\u00a0of\u00a0\nvirological \u00a0response\u00a0in\u00a0HIV\u2010HCV\u2010coinfected \u00a0patients\u00a0treated\u00a0with\u00a0pegylated \u00a0interferon \u00a0and\u00a0weight\u2010\nadjusted\u00a0ribavirin.\u00a0Antivir\u00a0Ther\u00a02008;\u00a013(7):953 \u2010957\u00a0\n\u00a0 829.\u00a0\u00a0Meynard\u00a0JL,\u00a0Lacombe\u00a0K,\u00a0Poirier\u00a0JM,\u00a0Legrand\u00a0J,\u00a0Morand\u2010Joubert\u00a0L,\u00a0Girard\u00a0PM.\u00a0Influence \u00a0of\u00a0liver\u00a0fibrosis\u00a0\nstage\u00a0on\u00a0plasma\u00a0levels\u00a0of\u00a0efavirenz\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0B\u00a0or\u00a0C.\u00a0J\u00a0Antimicrob \u00a0\nChemother \u00a02009;\u00a063(3):579 \u2010584\u00a0\n\u00a0 830.\u00a0\u00a0Rodriguez \u2010Novoa\u00a0S,\u00a0Morello\u00a0J,\u00a0Gonzalez\u00a0M,\u00a0Vispo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Gonzalez\u2010Pardo\u00a0G\u00a0et\u00a0al.\u00a0Increase\u00a0in\u00a0\nserum\u00a0bilirubin\u00a0in\u00a0HIV/hepatitis \u2010C\u00a0virus\u2010coinfected \u00a0patients\u00a0on\u00a0atazanavir \u00a0therapy\u00a0following \u00a0initiation\u00a0of\u00a0\npegylated \u2010interferon \u00a0and\u00a0ribavirin.\u00a0AIDS\u00a02008;\u00a022(18):2535 \u20102537\u00a0\n\u00a0 831.\u00a0\u00a0Glue\u00a0P.\u00a0The\u00a0clinical\u00a0pharmacology \u00a0of\u00a0ribavirin.\u00a0Semin\u00a0Liver\u00a0Dis\u00a01999;\u00a019\u00a0Suppl\u00a01:17\u201024\u00a0\n\u00a0 832.\u00a0\u00a0Japour\u00a0AJ,\u00a0Lertora\u00a0JJ,\u00a0Meehan\u00a0PM,\u00a0Erice\u00a0A,\u00a0Connor\u00a0JD,\u00a0Griffith\u00a0BP\u00a0et\u00a0al.\u00a0A\u00a0phase\u2010I\u00a0study\u00a0of\u00a0the\u00a0safety,\u00a0\npharmacokinetics, \u00a0and\u00a0antiviral\u00a0activity\u00a0of\u00a0combination \u00a0didanosine \u00a0and\u00a0ribavirin\u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0\ndisease.\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0231\u00a0Protocol\u00a0Team.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0Hum\u00a0Retrovirol \u00a0\n1996;\u00a013(3):235 \u201046\u00a0\n\u00a0 833.\u00a0\u00a0van\u00a0Bommel\u00a0F.,\u00a0Wunsche \u00a0T,\u00a0Mauss\u00a0S,\u00a0Reinke\u00a0P,\u00a0Bergk\u00a0A,\u00a0Schurmann \u00a0D\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0adefovir\u00a0and\u00a0\ntenofovir\u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0lamivudine \u2010resistant\u00a0hepatitis\u00a0B\u00a0virus\u00a0infection. \u00a0Hepatology \u00a02004;\u00a0\n40(6):1421 \u20101425\u00a0\n\u00a0 834.\u00a0\u00a0Dore\u00a0GJ,\u00a0Cooper\u00a0DA,\u00a0Pozniak\u00a0AL,\u00a0DeJesus\u00a0E,\u00a0Zhong\u00a0L,\u00a0Miller\u00a0MD\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0tenofovir\u00a0disoproxil \u00a0\nfumarate \u00a0in\u00a0antiretroviral \u00a0therapy\u2010naive\u00a0and\u00a0\u2010experienced \u00a0patients\u00a0coinfected \u00a0with\u00a0HIV\u20101\u00a0and\u00a0hepatitis\u00a0\nB\u00a0virus.\u00a0J\u00a0Infect\u00a0Dis\u00a02004;\u00a0189(7):1185 \u20101192\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 231\u00a0 835.\u00a0\u00a0Schildgen \u00a0O,\u00a0Schewe\u00a0CK,\u00a0Vogel\u00a0M,\u00a0Daumer\u00a0M,\u00a0Kaiser\u00a0R,\u00a0Weitner\u00a0L\u00a0et\u00a0al.\u00a0Successful \u00a0therapy\u00a0of\u00a0hepatitis\u00a0B\u00a0\nwith\u00a0tenofovir\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0failing\u00a0previous\u00a0adefovir\u00a0and\u00a0lamivudine \u00a0treatment. \u00a0AIDS\u00a02004;\u00a0\n18(17):2325 \u20102327\u00a0\n\u00a0 836.\u00a0\u00a0Lim\u00a0SG,\u00a0Ng\u00a0TM,\u00a0Kung\u00a0N,\u00a0Krastev\u00a0Z,\u00a0Volfova\u00a0M,\u00a0Husa\u00a0P\u00a0et\u00a0al.\u00a0A\u00a0double\u2010blind\u00a0placebo\u2010controlled \u00a0study\u00a0of\u00a0\nemtricitabine \u00a0in\u00a0chronic\u00a0hepatitis\u00a0B.\u00a0Arch\u00a0Intern\u00a0Med\u00a02006;\u00a0166(1):49 \u201056\u00a0\n\u00a0 837.\u00a0\u00a0Bang\u00a0LM,\u00a0Scott\u00a0LJ.\u00a0Emtricitabine: \u00a0an\u00a0antiretroviral \u00a0agent\u00a0for\u00a0HIV\u00a0infection. \u00a0Drugs\u00a02003;\u00a063(22):2413 \u2010\n2424\u00a0\n\u00a0 838.\u00a0\u00a0Thio\u00a0CL,\u00a0Locarnini\u00a0S.\u00a0Treatment \u00a0of\u00a0HIV/HBV\u00a0coinfection: \u00a0clinical\u00a0and\u00a0virologic\u00a0issues.\u00a0AIDS\u00a0Rev\u00a02007;\u00a0\n9(1):40\u201053\u00a0\n\u00a0 839.\u00a0\u00a0Ramos\u00a0B,\u00a0Nunez\u00a0M,\u00a0Martin\u2010Carbonero \u00a0L,\u00a0Sheldon\u00a0J,\u00a0Rios\u00a0P,\u00a0Labarga\u00a0P\u00a0et\u00a0al.\u00a0Hepatitis\u00a0B\u00a0virus\u00a0genotypes \u00a0\nand\u00a0lamivudine \u00a0resistance \u00a0mutations \u00a0in\u00a0HIV/hepatitis \u00a0B\u00a0virus\u2010coinfected \u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02007;\u00a044(5):557 \u2010561\u00a0\n\u00a0 840.\u00a0\u00a0Matthews \u00a0GV,\u00a0Bartholomeusz \u00a0A,\u00a0Locarnini\u00a0S,\u00a0Ayres\u00a0A,\u00a0Sasaduesz \u00a0J,\u00a0Seaberg\u00a0E\u00a0et\u00a0al.\u00a0Characteristics \u00a0of\u00a0\ndrug\u00a0resistant\u00a0HBV\u00a0in\u00a0an\u00a0international \u00a0collaborative \u00a0study\u00a0of\u00a0HIV\u2010HBV\u2010infected\u00a0individuals \u00a0on\u00a0extended \u00a0\nlamivudine \u00a0therapy.\u00a0AIDS\u00a02006;\u00a020(6):863 \u2010870\u00a0\n\u00a0 841.\u00a0\u00a0Suzuki\u00a0F,\u00a0Tsubota\u00a0A,\u00a0Arase\u00a0Y,\u00a0Suzuki\u00a0Y,\u00a0Akuta\u00a0N,\u00a0Hosaka\u00a0T\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0lamivudine \u00a0therapy\u00a0and\u00a0\nfactors\u00a0associated \u00a0with\u00a0emergence \u00a0of\u00a0resistance \u00a0in\u00a0chronic\u00a0hepatitis\u00a0B\u00a0virus\u00a0infection\u00a0in\u00a0Japan.\u00a0\nIntervirology \u00a02003;\u00a046(3):182 \u2010189\u00a0\n\u00a0 842.\u00a0\u00a0Bessesen\u00a0M,\u00a0Ives\u00a0D,\u00a0Condreay \u00a0L,\u00a0Lawrence \u00a0S,\u00a0Sherman\u00a0KE.\u00a0Chronic\u00a0active\u00a0hepatitis\u00a0B\u00a0exacerbations \u00a0in\u00a0\nhuman\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0following \u00a0development \u00a0of\u00a0resistance \u00a0to\u00a0or\u00a0withdrawal \u00a0\nof\u00a0lamivudine. \u00a0Clin\u00a0Infect\u00a0Dis\u00a01999;\u00a028(5):1032 \u20105\u00a0\n\u00a0 843.\u00a0\u00a0d'Arminio \u00a0MA,\u00a0Gonzalez\u00a0L,\u00a0Haberl\u00a0A,\u00a0Sherr\u00a0L,\u00a0Ssanyu\u2010Sseruma\u00a0W,\u00a0Walmsley \u00a0SL.\u00a0Better\u00a0mind\u00a0the\u00a0gap:\u00a0\naddressing \u00a0the\u00a0shortage\u00a0of\u00a0HIV\u2010positive\u00a0women\u00a0in\u00a0clinical\u00a0trials.\u00a0AIDS\u00a02010;\u00a024(8):1091 \u20101094\u00a0\n\u00a0 844.\u00a0\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Muriel\u00a0A,\u00a0Moreno\u00a0A,\u00a0Arazo\u00a0P,\u00a0Leal\u00a0M,\u00a0Navarro\u00a0G,\u00a0et\u00a0al.\u00a0Relevant\u00a0changes\u00a0in\u00a0features\u00a0at\u00a0\npresentation \u00a0among\u00a0HIV\u00a0infected\u00a0women\u00a0in\u00a0the\u00a0Spanish\u00a0AIDS\u00a0research\u00a0network\u00a0cohort\u00a0(CoRis,\u00a01996\u2010\n2008).\u00a018th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Vienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0CDC0280. \u00a0\n\u00a0 845.\u00a0\u00a0Nicastri\u00a0E,\u00a0Leone\u00a0S,\u00a0Angeletti\u00a0C,\u00a0Palmisano \u00a0L,\u00a0Sarmati\u00a0L,\u00a0Chiesi\u00a0A\u00a0et\u00a0al.\u00a0Sex\u00a0issues\u00a0in\u00a0HIV\u20101\u2010infected\u00a0\npersons\u00a0during\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0a\u00a0systematic \u00a0review.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02007;\u00a0\n60(4):724 \u2010732\u00a0\n\u00a0 846.\u00a0\u00a0Hirsch\u00a0JS.\u00a0Gender,\u00a0sexuality, \u00a0and\u00a0antiretroviral \u00a0therapy:\u00a0using\u00a0social\u00a0science\u00a0to\u00a0enhance\u00a0outcomes \u00a0and\u00a0\ninform\u00a0secondary \u00a0prevention \u00a0strategies. \u00a0AIDS\u00a02007;\u00a021\u00a0Suppl\u00a05:S21\u2010S29\u00a0\n\u00a0 847.\u00a0\u00a0Collazos\u00a0J,\u00a0Asensi\u00a0V,\u00a0Carton\u00a0JA.\u00a0Sex\u00a0differences \u00a0in\u00a0the\u00a0clinical,\u00a0immunological \u00a0and\u00a0virological \u00a0parameters \u00a0\nof\u00a0HIV\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0HAART.\u00a0AIDS\u00a02007;\u00a021(7):835 \u2010843\u00a0\n\u00a0 848.\u00a0\u00a0Tedaldi\u00a0EM,\u00a0Absalon\u00a0J,\u00a0Thomas\u00a0AJ,\u00a0Shlay\u00a0JC,\u00a0van\u00a0dB\u2010W.\u00a0Ethnicity, \u00a0race,\u00a0and\u00a0gender.\u00a0Differences \u00a0in\u00a0\nserious\u00a0adverse\u00a0events\u00a0among\u00a0participants \u00a0in\u00a0an\u00a0antiretroviral \u00a0initiation\u00a0trial:\u00a0results\u00a0of\u00a0CPCRA\u00a0058\u00a0\n(FIRST\u00a0Study).\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(4):441 \u2010448\u00a0\n\u00a0 849.\u00a0\u00a0Prins\u00a0M,\u00a0Meyer\u00a0L,\u00a0Hessol\u00a0NA.\u00a0Sex\u00a0and\u00a0the\u00a0course\u00a0of\u00a0HIV\u00a0infection\u00a0in\u00a0the\u00a0pre\u2010\u00a0and\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy\u00a0eras.\u00a0AIDS\u00a02005;\u00a019(4):357 \u2010370\u00a0\n\u00a0 850.\u00a0\u00a0Struble\u00a0K,\u00a0Soon\u00a0GH,\u00a0Min\u00a0M,\u00a0Chan\u2010Tack\u00a0K,\u00a0Murray\u00a0J,\u00a0Birnkrant \u00a0D,\u00a0et\u00a0al.\u00a0Meta\u2010analysis\u00a0of\u00a0efficacy\u00a0\noutcomes \u00a0for\u00a0treatment \u2010na\u00efve\u00a0and\u00a0treatment \u2010experienced \u00a0HIV\u2010infected\u00a0women\u00a0in\u00a0randomized \u00a0\ncontrolled \u00a0clinical\u00a0trials:\u00a02000\u00a0to\u00a02008.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0\nMontreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0987b.\u00a0\n\u00a0 851.\u00a0\u00a0Nicastri\u00a0E,\u00a0Angeletti\u00a0C,\u00a0Palmisano \u00a0L,\u00a0Sarmati\u00a0L,\u00a0Chiesi\u00a0A,\u00a0Geraci\u00a0A\u00a0et\u00a0al.\u00a0Gender\u00a0differences \u00a0in\u00a0clinical\u00a0\nprogression \u00a0of\u00a0HIV\u20101\u2010infected\u00a0individuals \u00a0during\u00a0long\u2010term\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a0\n2005;\u00a019(6):577 \u2010583\u00a0\n\u00a0 852.\u00a0\u00a0Sarner\u00a0L,\u00a0Fakoya\u00a0A.\u00a0Acute\u00a0onset\u00a0lactic\u00a0acidosis\u00a0and\u00a0pancreatitis \u00a0in\u00a0the\u00a0third\u00a0trimester \u00a0of\u00a0pregnancy \u00a0in\u00a0\nHIV\u20101\u00a0positive\u00a0women\u00a0taking\u00a0antiretroviral \u00a0medication. \u00a0Sex\u00a0Transm\u00a0Infect\u00a02002;\u00a078(1):58\u201059\u00a0\n\u00a0 853.\u00a0\u00a0Pernerstorfer \u2010Schoen\u00a0H,\u00a0Jilma\u00a0B,\u00a0Perschler \u00a0A,\u00a0Wichlas\u00a0S,\u00a0Schindler \u00a0K,\u00a0Schindl\u00a0A\u00a0et\u00a0al.\u00a0Sex\u00a0differences \u00a0in\u00a0\nHAART\u2010associated \u00a0dyslipidaemia. \u00a0AIDS\u00a02001;\u00a015(6):725 \u2010734\u00a0\n\u00a0 854.\u00a0\u00a0Kumar\u00a0PN,\u00a0Rodriguez \u2010French\u00a0A,\u00a0Thompson \u00a0MA,\u00a0Tashima\u00a0KT,\u00a0Averitt\u00a0D,\u00a0Wannamaker \u00a0PG\u00a0et\u00a0al.\u00a0A\u00a0\nprospective, \u00a096\u2010week\u00a0study\u00a0of\u00a0the\u00a0impact\u00a0of\u00a0Trizivir,\u00a0Combivir/nelfinavir, \u00a0and\u00a0\nlamivudine/stavudine/nelfinavir \u00a0on\u00a0lipids,\u00a0metabolic \u00a0parameters \u00a0and\u00a0efficacy\u00a0in\u00a0antiretroviral \u2010naive\u00a0\npatients:\u00a0effect\u00a0of\u00a0sex\u00a0and\u00a0ethnicity. \u00a0HIV\u00a0Med\u00a02006;\u00a07(2):85\u201098\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 232\u00a0 855.\u00a0\u00a0Dube\u00a0MP,\u00a0Lipshultz\u00a0SE,\u00a0Fichtenbaum \u00a0CJ,\u00a0Greenberg \u00a0R,\u00a0Schecter\u00a0AD,\u00a0Fisher\u00a0SD.\u00a0Effects\u00a0of\u00a0HIV\u00a0infection\u00a0\nand\u00a0antiretroviral \u00a0therapy\u00a0on\u00a0the\u00a0heart\u00a0and\u00a0vasculature. \u00a0Circulation \u00a02008;\u00a0118(2):e36 \u2010e40\u00a0\n\u00a0 856.\u00a0\u00a0Barzon\u00a0L,\u00a0Zamboni\u00a0M,\u00a0Pacenti\u00a0M,\u00a0Milan\u00a0G,\u00a0Bosello\u00a0O,\u00a0Federspil\u00a0G\u00a0et\u00a0al.\u00a0Do\u00a0oestrogen \u00a0receptors \u00a0play\u00a0a\u00a0\nrole\u00a0in\u00a0the\u00a0pathogenesis \u00a0of\u00a0HIV\u2010associated \u00a0lipodystrophy? \u00a0AIDS\u00a02005;\u00a019(5):531 \u2010533\u00a0\n\u00a0 857.\u00a0\u00a0Mulligan\u00a0K,\u00a0Anastos\u00a0K,\u00a0Justman\u00a0J,\u00a0Freeman\u00a0R,\u00a0Wichienkuer \u00a0P,\u00a0Robison\u00a0E\u00a0et\u00a0al.\u00a0Fat\u00a0distribution \u00a0in\u00a0HIV\u2010\ninfected\u00a0women\u00a0in\u00a0the\u00a0United\u00a0States:\u00a0DEXA\u00a0substudy\u00a0in\u00a0the\u00a0Women's \u00a0Interagency \u00a0HIV\u00a0Study.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02005;\u00a038(1):18\u201022\u00a0\n\u00a0 858.\u00a0\u00a0From\u00a0the\u00a0Study\u00a0of\u00a0Fat\u00a0Redistribution \u00a0and\u00a0Metabolic \u00a0Change\u00a0in\u00a0HIV\u00a0Infection. \u00a0Fat\u00a0distribution \u00a0in\u00a0women\u00a0\nwith\u00a0HIV\u00a0infection. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a042(5):562 \u2010571\u00a0\n\u00a0 859.\u00a0\u00a0Cespedes \u00a0MS,\u00a0Aberg\u00a0JA.\u00a0Neuropsychiatric \u00a0complications \u00a0of\u00a0antiretroviral \u00a0therapy.\u00a0Drug\u00a0Saf\u00a02006;\u00a0\n29(10):865 \u2010874\u00a0\n\u00a0 860.\u00a0\u00a0Smith\u00a0CJ,\u00a0Sabin\u00a0CA,\u00a0Youle\u00a0MS,\u00a0Lampe\u00a0FC,\u00a0Bhagani\u00a0S,\u00a0Madge\u00a0S\u00a0et\u00a0al.\u00a0Response \u00a0to\u00a0efavirenz\u2010containing \u00a0\nregimens \u00a0in\u00a0previously \u00a0antiretroviral \u2010naive\u00a0HIV\u2010positive\u00a0patients:\u00a0the\u00a0role\u00a0of\u00a0gender.\u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr\u00a02007;\u00a046(1):62\u201067\u00a0\n\u00a0 861.\u00a0\u00a0Morrison\u00a0MF,\u00a0Petitto\u00a0JM,\u00a0Ten\u00a0HT,\u00a0Gettes\u00a0DR,\u00a0Chiappini \u00a0MS,\u00a0Weber\u00a0AL\u00a0et\u00a0al.\u00a0Depressive \u00a0and\u00a0anxiety\u00a0\ndisorders \u00a0in\u00a0women\u00a0with\u00a0HIV\u00a0infection. \u00a0Am\u00a0J\u00a0Psychiatry \u00a02002;\u00a0159(5):789 \u2010796\u00a0\n\u00a0 862.\u00a0\u00a0Ickovics\u00a0JR,\u00a0Hamburger \u00a0ME,\u00a0Vlahov\u00a0D,\u00a0Schoenbaum \u00a0EE,\u00a0Schuman\u00a0P,\u00a0Boland\u00a0RJ\u00a0et\u00a0al.\u00a0Mortality, \u00a0CD4\u00a0cell\u00a0\ncount\u00a0decline,\u00a0and\u00a0depressive \u00a0symptoms \u00a0among\u00a0HIV\u2010seropositive \u00a0women:\u00a0longitudinal \u00a0analysis\u00a0from\u00a0\nthe\u00a0HIV\u00a0Epidemiology \u00a0Research\u00a0Study.\u00a0JAMA\u00a02001;\u00a0285(11):1466 \u20101474\u00a0\n\u00a0 863.\u00a0\u00a0Dolan\u00a0SE,\u00a0Carpenter \u00a0S,\u00a0Grinspoon \u00a0S.\u00a0Effects\u00a0of\u00a0weight,\u00a0body\u00a0composition, \u00a0and\u00a0testosterone \u00a0on\u00a0bone\u00a0\nmineral\u00a0density\u00a0in\u00a0HIV\u2010infected\u00a0women.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045(2):161 \u2010167\u00a0\n\u00a0 864.\u00a0\u00a0Dolan\u00a0SE,\u00a0Huang\u00a0JS,\u00a0Killilea\u00a0KM,\u00a0Sullivan\u00a0MP,\u00a0Aliabadi\u00a0N,\u00a0Grinspoon \u00a0S.\u00a0Reduced\u00a0bone\u00a0density\u00a0in\u00a0HIV\u2010\ninfected\u00a0women.\u00a0AIDS\u00a02004;\u00a018(3):475 \u2010483\u00a0\n\u00a0 865.\u00a0\u00a0Yin\u00a0MT,\u00a0Lu\u00a0D,\u00a0Cremers\u00a0S,\u00a0Tien\u00a0PC,\u00a0Cohen\u00a0MH,\u00a0Shi\u00a0Q\u00a0et\u00a0al.\u00a0Short\u2010term\u00a0bone\u00a0loss\u00a0in\u00a0HIV\u2010infected\u00a0\npremenopausal \u00a0women.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a053(2):202 \u2010208\u00a0\n\u00a0 866.\u00a0\u00a0Yin\u00a0MT,\u00a0Shane\u00a0E.\u00a0Low\u00a0bone\u2010mineral\u00a0density\u00a0in\u00a0patients\u00a0with\u00a0HIV:\u00a0pathogenesis \u00a0and\u00a0clinical\u00a0significance. \u00a0\nCurr\u00a0Opin\u00a0Endocrinol \u00a0Diabetes\u00a02006;\u00a013(6):497 \u2010502\u00a0\n\u00a0 867.\u00a0\u00a0Arnsten\u00a0JH,\u00a0Freeman\u00a0R,\u00a0Howard\u00a0AA,\u00a0Floris\u2010Moore\u00a0M,\u00a0Santoro\u00a0N,\u00a0Schoenbaum \u00a0EE.\u00a0HIV\u00a0infection\u00a0and\u00a0\nbone\u00a0mineral\u00a0density\u00a0in\u00a0middle\u2010aged\u00a0women.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(7):1014 \u20101020\u00a0\n\u00a0 868.\u00a0\u00a0Cejtin\u00a0HE.\u00a0Gynecologic \u00a0issues\u00a0in\u00a0the\u00a0HIV\u2010infected\u00a0woman.\u00a0Infect\u00a0Dis\u00a0Clin\u00a0North\u00a0Am\u00a02008;\u00a022(4):709 \u201039\u00a0\n\u00a0 869.\u00a0\u00a0Curtis\u00a0KM,\u00a0Nanda\u00a0K,\u00a0Kapp\u00a0N.\u00a0Safety\u00a0of\u00a0hormonal \u00a0and\u00a0intrauterine \u00a0methods\u00a0of\u00a0contraception \u00a0for\u00a0women\u00a0\nwith\u00a0HIV/AIDS: \u00a0a\u00a0systematic \u00a0review.\u00a0AIDS\u00a02009;\u00a023\u00a0Suppl\u00a01:S55\u2010S67\u00a0\n\u00a0 870.\u00a0\u00a0Waters\u00a0L,\u00a0Barton\u00a0S.\u00a0Contraception \u00a0and\u00a0HIV:\u00a0what\u00a0do\u00a0we\u00a0know\u00a0and\u00a0what\u00a0needs\u00a0to\u00a0be\u00a0done?\u00a0J\u00a0Fam\u00a0Plann\u00a0\nReprod\u00a0Health\u00a0Care\u00a02006;\u00a032(1):10\u201014\u00a0\n\u00a0 871.\u00a0\u00a0Heikinheimo \u00a0O,\u00a0Lahteenmaki \u00a0P.\u00a0Contraception \u00a0and\u00a0HIV\u00a0infection\u00a0in\u00a0women.\u00a0Hum\u00a0Reprod\u00a0Update\u00a02009;\u00a0\n15(2):165 \u2010176\u00a0\n\u00a0 872.\u00a0\u00a0Mitchell\u00a0HS,\u00a0Stephens \u00a0E.\u00a0Contraception \u00a0choice\u00a0for\u00a0HIV\u00a0positive\u00a0women.\u00a0Sex\u00a0Transm\u00a0Infect\u00a02004;\u00a0\n80(3):167 \u2010173\u00a0\n\u00a0 873.\u00a0\u00a0Sevinsky\u00a0H,\u00a0Eley\u00a0T,\u00a0He\u00a0B,\u00a0Persson\u00a0A,\u00a0Garner\u00a0D,\u00a0Yones\u00a0C,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0efavirenz\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0\nof\u00a0ethinyl\u00a0estradiol\u00a0and\u00a0norgestimate \u00a0in\u00a0healthy\u00a0female\u00a0subjects.\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0\nMeeting,\u00a0Washington \u00a0DC,\u00a0October\u00a025\u201028\u00a02008.\u00a0Abstract\u00a0A598.\u00a0\n\u00a0 874.\u00a0\u00a0El\u2010Ibiary\u00a0SY,\u00a0Cocohoba \u00a0JM.\u00a0Effects\u00a0of\u00a0HIV\u00a0antiretrovirals \u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0hormonal \u00a0\ncontraceptives. \u00a0Eur\u00a0J\u00a0Contracept \u00a0Reprod\u00a0Health\u00a0Care\u00a02008;\u00a013(2):123 \u2010132\u00a0\n\u00a0 875.\u00a0\u00a0Chu\u00a0JH,\u00a0Gange\u00a0SJ,\u00a0Anastos\u00a0K,\u00a0Minkoff\u00a0H,\u00a0Cejtin\u00a0H,\u00a0Bacon\u00a0M\u00a0et\u00a0al.\u00a0Hormonal \u00a0contraceptive \u00a0use\u00a0and\u00a0the\u00a0\neffectiveness \u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0Am\u00a0J\u00a0Epidemiol \u00a02005;\u00a0161(9):881 \u2010890\u00a0\n\u00a0 876.\u00a0\u00a0Mildvan\u00a0D,\u00a0Yarrish\u00a0R,\u00a0Marshak\u00a0A,\u00a0Hutman\u00a0HW,\u00a0McDonough \u00a0M,\u00a0Lamson\u00a0M\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0\ninteraction \u00a0between\u00a0nevirapine \u00a0and\u00a0ethinyl\u00a0estradiol/norethindrone \u00a0when\u00a0administered \u00a0concurrently \u00a0\nto\u00a0HIV\u2010infected\u00a0women.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02002;\u00a029(5):471 \u2010477\u00a0\n\u00a0 877.\u00a0\u00a0Ouellet\u00a0D,\u00a0Hsu\u00a0A,\u00a0Qian\u00a0J,\u00a0Locke\u00a0CS,\u00a0Eason\u00a0CJ,\u00a0Cavanaugh \u00a0JH\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0ritonavir\u00a0on\u00a0the\u00a0\npharmacokinetics \u00a0of\u00a0ethinyl\u00a0oestradiol \u00a0in\u00a0healthy\u00a0female\u00a0volunteers. \u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a01998;\u00a0\n46(2):111 \u2010116\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 233\u00a0 878.\u00a0\u00a0Anderson \u00a0MS,\u00a0Wenning\u00a0LA,\u00a0Moreau\u00a0A,\u00a0Kost\u00a0JT,\u00a0Bieberdorf \u00a0FA,\u00a0Stone\u00a0JA,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0raltegravir \u00a0on\u00a0the\u00a0\npharmacokinetics \u00a0of\u00a0oral\u00a0contraceptives. \u00a047th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0\nChemotherapy, \u00a0Chicago,\u00a0September \u00a017\u201020\u00a02007.\u00a0Abstract\u00a0A\u20101425.\u00a0\n\u00a0 879.\u00a0\u00a0Zhang\u00a0J,\u00a0Chung\u00a0E,\u00a0Eley\u00a0T,\u00a0Yones\u00a0C,\u00a0Persson\u00a0A,\u00a0Xu\u00a0X,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0atazanavir/ritonavir \u00a0on\u00a0the\u00a0\npharmacokinetics \u00a0of\u00a0ethinyl\u00a0estradiol\u00a0and\u00a017\u2010deacetyl\u00a0norgestimate \u00a0in\u00a0healthy\u00a0female\u00a0subjects.\u00a047th\u00a0\nInterscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0Chicago,\u00a0September \u00a017\u201020\u00a02007.\u00a0\nAbstract\u00a0A\u20101415.\u00a0\n\u00a0 880.\u00a0\u00a0Beksinska \u00a0ME,\u00a0Smit\u00a0JA,\u00a0Ramkissoon \u00a0A.\u00a0Progestogen \u2010only\u00a0injectable \u00a0hormonal \u00a0contraceptive \u00a0use\u00a0should\u00a0\nbe\u00a0considered \u00a0in\u00a0analysis\u00a0of\u00a0studies\u00a0addressing \u00a0the\u00a0loss\u00a0of\u00a0bone\u00a0mineral\u00a0density\u00a0in\u00a0HIV\u2010positive\u00a0women.\u00a0\nJ\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02010;\u00a054(4):e5\u00a0\n\u00a0 881.\u00a0\u00a0Morrison\u00a0CS,\u00a0Chen\u00a0PL,\u00a0Kwok\u00a0C,\u00a0Richardson \u00a0BA,\u00a0Chipato\u00a0T,\u00a0Mugerwa \u00a0R\u00a0et\u00a0al.\u00a0Hormonal \u00a0contraception \u00a0and\u00a0\nHIV\u00a0acquisition: \u00a0reanalysis \u00a0using\u00a0marginal\u00a0structural \u00a0modeling. \u00a0AIDS\u00a02010;\u00a024(11):1778 \u20101781\u00a0\n\u00a0 882.\u00a0\u00a0Watts\u00a0DH,\u00a0Park\u00a0JG,\u00a0Cohn\u00a0SE,\u00a0Yu\u00a0S,\u00a0Hitti\u00a0J,\u00a0Stek\u00a0A\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0tolerability \u00a0of\u00a0depot\u00a0\nmedroxyprogesterone \u00a0acetate\u00a0among\u00a0HIV\u2010infected\u00a0women\u00a0on\u00a0antiretroviral \u00a0therapy:\u00a0ACTG\u00a0A5093.\u00a0\nContraception \u00a02008;\u00a077(2):84\u201090\u00a0\n\u00a0 883.\u00a0\u00a0Nanda\u00a0K,\u00a0Amaral\u00a0E,\u00a0Hays\u00a0M,\u00a0Viscola\u00a0MA,\u00a0Mehta\u00a0N,\u00a0Bahamondes \u00a0L.\u00a0Pharmacokinetic \u00a0interactions \u00a0\nbetween\u00a0depot\u00a0medroxyprogesterone \u00a0acetate\u00a0and\u00a0combination \u00a0antiretroviral \u00a0therapy.\u00a0Fertil\u00a0Steril\u00a0\n2008;\u00a090(4):965 \u2010971\u00a0\n\u00a0 884.\u00a0\u00a0Public\u00a0Health\u00a0Service\u00a0Task\u00a0Force.\u00a0Recommendations \u00a0for\u00a0use\u00a0of\u00a0antiretroviral \u00a0drugs\u00a0in\u00a0pregnant\u00a0HIV\u20101\u2010\ninfected\u00a0women\u00a0for\u00a0maternal\u00a0health\u00a0and\u00a0interventions \u00a0to\u00a0reduce\u00a0perinatal\u00a0HIV\u00a0transmission \u00a0in\u00a0the\u00a0\nUnited\u00a0States\u00a0(May\u00a024,\u00a02010).\u00a0Disponible \u00a0en:\u00a0http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf \u00a0\n(Acceso\u00a014/12/2010). \u00a0\n\u00a0 885.\u00a0\u00a0Polo\u00a0R,\u00a0Iribarren\u00a0JA,\u00a0de\u00a0Jos\u00e9\u00a0MI,\u00a0Mu\u00f1oz\u00a0G\u00e1lligo\u00a0E,\u00a0(Coordinadores). \u00a0Recomendaciones \u00a0de\u00a0la\u00a0Secretar\u00eda \u00a0\ndel\u00a0PNS,\u00a0el\u00a0GeSida,\u00a0la\u00a0SEGO\u00a0y\u00a0la\u00a0AEP\u00a0para\u00a0el\u00a0seguimiento \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0con\u00a0relaci\u00f3n\u00a0a\u00a0la\u00a0\nreproducci\u00f3n, \u00a0el\u00a0embarazo \u00a0y\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0(diciembre \u00a02007).\u00a0Accesible \u00a0en:\u00a0\nhttp://www.gesida.seimc.org/ \u00a0(Acceso\u00a014.12.2010). \u00a0\n\u00a0 886.\u00a0\u00a0Ioannidis\u00a0JP,\u00a0Abrams\u00a0EJ,\u00a0Ammann\u00a0A,\u00a0Bulterys\u00a0M,\u00a0Goedert\u00a0JJ,\u00a0Gray\u00a0L\u00a0et\u00a0al.\u00a0Perinatal\u00a0transmission \u00a0of\u00a0\nhuman\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0by\u00a0pregnant\u00a0women\u00a0with\u00a0RNA\u00a0virus\u00a0loads\u00a0<1000\u00a0copies/ml. \u00a0J\u00a0\nInfect\u00a0Dis\u00a02001;\u00a0183(4):539 \u201045\u00a0\n\u00a0 887.\u00a0\u00a0Connor\u00a0EM,\u00a0Sperling\u00a0RS,\u00a0Gelber\u00a0R,\u00a0Kiselev\u00a0P,\u00a0Scott\u00a0G,\u00a0O'Sullivan \u00a0MJ\u00a0et\u00a0al.\u00a0Reduction \u00a0of\u00a0maternal\u2010infant\u00a0\ntransmission \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0with\u00a0zidovudine \u00a0treatment. \u00a0Pediatric\u00a0AIDS\u00a0\nClinical\u00a0Trials\u00a0Group\u00a0Protocol\u00a0076\u00a0Study\u00a0Group.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01994;\u00a0331(18):1173 \u201080\u00a0\n\u00a0 888.\u00a0\u00a0Cotter\u00a0AM,\u00a0Garcia\u00a0AG,\u00a0Duthely\u00a0ML,\u00a0Luke\u00a0B,\u00a0O'Sullivan \u00a0MJ.\u00a0Is\u00a0antiretroviral \u00a0therapy\u00a0during\u00a0pregnancy \u00a0\nassociated \u00a0with\u00a0an\u00a0increased \u00a0risk\u00a0of\u00a0preterm\u00a0delivery,\u00a0low\u00a0birth\u00a0weight,\u00a0or\u00a0stillbirth? \u00a0J\u00a0Infect\u00a0Dis\u00a02006;\u00a0\n193(9):1195 \u20101201\u00a0\n\u00a0 889.\u00a0\u00a0Antiretroviral \u00a0Pregnancy \u00a0Registry\u00a0Steering\u00a0Committee. \u00a0Antiretroviral \u00a0pregnancy \u00a0registry\u00a0international \u00a0\ninterim\u00a0report\u00a0for\u00a01\u00a0January\u00a01989\u00a0through\u00a031\u00a0January\u00a02010.\u00a0Accesible \u00a0en:\u00a0www.apregistry.com \u00a0(Acceso\u00a0\n14.12.2010). \u00a0\n\u00a0 890.\u00a0\u00a0Best\u00a0BM,\u00a0Capparelli \u00a0EV,\u00a0Stek\u00a0A,\u00a0Burchett\u00a0SK,\u00a0Huo\u00a0Y,\u00a0Aweeka\u00a0F,\u00a0et\u00a0al.\u00a0Raltegravir \u00a0pharmacokinetics \u00a0during\u00a0\npregnancy. \u00a050th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0Boston,\u00a0\nSeptember \u00a012\u201015\u00a02010.\u00a0Abstract\u00a0H\u20101668a.\u00a0\n\u00a0 891.\u00a0\u00a0Garrido\u00a0C,\u00a0Soriano\u00a0V,\u00a0de\u00a0MC.\u00a0New\u00a0therapeutic \u00a0strategies \u00a0for\u00a0raltegravir. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02010;\u00a0\n65(2):218 \u2010223\u00a0\n\u00a0 892.\u00a0\u00a0McKeown \u00a0DA,\u00a0Rosenvinge \u00a0M,\u00a0Donaghy\u00a0S,\u00a0Sharland\u00a0M,\u00a0Holt\u00a0DW,\u00a0Cormack\u00a0I\u00a0et\u00a0al.\u00a0High\u00a0neonatal\u00a0\nconcentrations \u00a0of\u00a0raltegravir \u00a0following \u00a0transplacental \u00a0transfer\u00a0in\u00a0HIV\u20101\u00a0positive\u00a0pregnant\u00a0women.\u00a0AIDS\u00a0\n2010;\u00a024(15):2416 \u20102418\u00a0\n\u00a0 893.\u00a0\u00a0Hitti\u00a0J,\u00a0Frenkel\u00a0LM,\u00a0Stek\u00a0AM,\u00a0Nachman \u00a0SA,\u00a0Baker\u00a0D,\u00a0Gonzalez\u2010Garcia\u00a0A\u00a0et\u00a0al.\u00a0Maternal\u00a0toxicity\u00a0with\u00a0\ncontinuous \u00a0nevirapine \u00a0in\u00a0pregnancy: \u00a0results\u00a0from\u00a0PACTG\u00a01022.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02004;\u00a0\n36(3):772 \u2010776\u00a0\n\u00a0 894.\u00a0\u00a0Fiore\u00a0S,\u00a0Newell\u00a0ML,\u00a0Thorne\u00a0C.\u00a0Higher\u00a0rates\u00a0of\u00a0post\u2010partum\u00a0complications \u00a0in\u00a0HIV\u2010infected\u00a0than\u00a0in\u00a0\nuninfected \u00a0women\u00a0irrespective \u00a0of\u00a0mode\u00a0of\u00a0delivery.\u00a0AIDS\u00a02004;\u00a018(6):933 \u2010938\u00a0\n\u00a0 895.\u00a0\u00a0Achievements \u00a0in\u00a0public\u00a0health.\u00a0Reduction \u00a0in\u00a0perinatal\u00a0transmission \u00a0of\u00a0HIV\u00a0infection\u2010\u2010United\u00a0States,\u00a0\n1985\u20102005.\u00a0MMWR\u00a0Morb\u00a0Mortal\u00a0Wkly\u00a0Rep\u00a02006;\u00a055(21):592 \u2010597\u00a0\n\u00a0 896.\u00a0\u00a0UNAIDS.\u00a0AIDS\u00a0epidemic\u00a0update\u00a02010.\u00a0Disponible \u00a0en:\u00a0www\u00a0unaids\u00a0org/globalreport/default \u00a0htm\u00a02010;\u00a0\n(Acceso\u00a014.12.2010) \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 234\u00a0 897.\u00a0\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention. \u00a0Incorporating \u00a0HIV\u00a0prevention \u00a0into\u00a0the\u00a0medical\u00a0care\u00a0of\u00a0\npersons\u00a0living\u00a0with\u00a0HIV.\u00a0Recommendations \u00a0of\u00a0CDC,\u00a0the\u00a0Health\u00a0Resources \u00a0and\u00a0Services\u00a0Administration, \u00a0\nthe\u00a0National\u00a0Institutes \u00a0of\u00a0Health,\u00a0and\u00a0the\u00a0HIV\u00a0Medicine \u00a0Association \u00a0of\u00a0the\u00a0Infectious \u00a0Diseases\u00a0Society\u00a0of\u00a0\nAmerica.\u00a0MMWR\u00a0Recomm\u00a0Rep\u00a02003;\u00a052(RR\u201012):1\u201024\u00a0\n\u00a0 898.\u00a0\u00a0Padian\u00a0NS,\u00a0Buve\u00a0A,\u00a0Balkus\u00a0J,\u00a0Serwadda \u00a0D,\u00a0Cates\u00a0W,\u00a0Jr.\u00a0Biomedical \u00a0interventions \u00a0to\u00a0prevent\u00a0HIV\u00a0infection: \u00a0\nevidence, \u00a0challenges, \u00a0and\u00a0way\u00a0forward.\u00a0Lancet\u00a02008;\u00a0372(9638):585 \u2010599\u00a0\n\u00a0 899.\u00a0\u00a0Piot\u00a0P,\u00a0Bartos\u00a0M,\u00a0Larson\u00a0H,\u00a0Zewdie\u00a0D,\u00a0Mane\u00a0P.\u00a0Coming\u00a0to\u00a0terms\u00a0with\u00a0complexity: \u00a0a\u00a0call\u00a0to\u00a0action\u00a0for\u00a0HIV\u00a0\nprevention. \u00a0Lancet\u00a02008;\u00a0372(9641):845 \u2010859\u00a0\n\u00a0 900.\u00a0\u00a0Quinn\u00a0TC,\u00a0Wawer\u00a0MJ,\u00a0Sewankambo \u00a0N,\u00a0Serwadda \u00a0D,\u00a0Li\u00a0C,\u00a0Wabwire\u2010Mangen\u00a0F\u00a0et\u00a0al.\u00a0Viral\u00a0load\u00a0and\u00a0\nheterosexual \u00a0transmission \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01.\u00a0Rakai\u00a0Project\u00a0Study\u00a0Group.\u00a0N\u00a0Engl\u00a0J\u00a0\nMed\u00a02000;\u00a0342(13):921 \u2010929\u00a0\n\u00a0 901.\u00a0\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention. \u00a02009\u00a0Compendium \u00a0of\u00a0evidence\u2010based\u00a0HIV\u00a0prevention \u00a0\ninterventions. \u00a0Available\u00a0at:\u00a0www.cdc.gov/hiv/topics/ research/prs/evidence \u2010based\u2010interventions.htm \u00a0\n(Acceso:\u00a020.10.2010). \u00a0\n\u00a0 902.\u00a0\u00a0Hollingsworth \u00a0TD,\u00a0Anderson \u00a0RM,\u00a0Fraser\u00a0C.\u00a0HIV\u20101\u00a0transmission, \u00a0by\u00a0stage\u00a0of\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0\n198(5):687 \u2010693\u00a0\n\u00a0 903.\u00a0\u00a0Moreno\u00a0S,\u00a0Mocroft\u00a0A,\u00a0Monforte \u00a0A.\u00a0Medical\u00a0and\u00a0societal\u00a0consequences \u00a0of\u00a0late\u00a0presentation. \u00a0Antivir\u00a0Ther\u00a0\n2010;\u00a015\u00a0Suppl\u00a01:9\u201015\u00a0\n\u00a0 904.\u00a0\u00a0Watts\u00a0DH.\u00a0Management \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection\u00a0in\u00a0pregnancy. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02002;\u00a0\n346(24):1879 \u20101891\u00a0\n\u00a0 905.\u00a0\u00a0Donnell\u00a0D,\u00a0Baeten\u00a0JM,\u00a0Kiarie\u00a0J,\u00a0Thomas\u00a0KK,\u00a0Stevens\u00a0W,\u00a0Cohen\u00a0CR\u00a0et\u00a0al.\u00a0Heterosexual \u00a0HIV\u20101\u00a0transmission \u00a0\nafter\u00a0initiation\u00a0of\u00a0antiretroviral \u00a0therapy:\u00a0a\u00a0prospective \u00a0cohort\u00a0analysis.\u00a0Lancet\u00a02010;\u00a0375(9731):2092 \u2010\n2098\u00a0\n\u00a0 906.\u00a0\u00a0Sullivan\u00a0P,\u00a0Kayitenkore \u00a0K,\u00a0Chomba\u00a0E,\u00a0Karita\u00a0E,\u00a0Mwananyanda \u00a0L,\u00a0Vwalika\u00a0C,\u00a0et\u00a0al.\u00a0Reduction \u00a0of\u00a0HIV\u00a0\nTransmission \u00a0Risk\u00a0and\u00a0High\u00a0Risk\u00a0Sex\u00a0while\u00a0Prescribed \u00a0ART:\u00a0Results\u00a0from\u00a0Discordant \u00a0Couples\u00a0in\u00a0Rwanda\u00a0\nand\u00a0Zambia.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a0\n2009.\u00a0Abstract\u00a052bLB.\u00a0\n\u00a0 907.\u00a0\u00a0Del\u00a0Romero\u00a0J.,\u00a0Castilla\u00a0J,\u00a0Hernando \u00a0V,\u00a0Rodriguez \u00a0C,\u00a0Garcia\u00a0S.\u00a0Combined \u00a0antiretroviral \u00a0treatment \u00a0and\u00a0\nheterosexual \u00a0transmission \u00a0of\u00a0HIV\u20101:\u00a0cross\u00a0sectional\u00a0and\u00a0prospective \u00a0cohort\u00a0study.\u00a0BMJ\u00a02010;\u00a0340:c2205 \u00a0\n\u00a0 908.\u00a0\u00a0National\u00a0Institute\u00a0of\u00a0Allergy\u00a0and\u00a0Infectious \u00a0Diseases.\u00a0Preventing \u00a0sexual\u00a0transmission \u00a0of\u00a0HIV\u00a0with\u00a0anti\u2010\nVIH\u00a0drugs.\u00a0Disponible \u00a0en:\u00a0http://clinicaltrials \u00a0gov/ct2/show/NCT00074581 \u00a02010;\u00a0(Acceso\u00a014.12.2010) \u00a0\n\u00a0 909.\u00a0\u00a0Granich\u00a0RM,\u00a0Gilks\u00a0CF,\u00a0Dye\u00a0C,\u00a0De\u00a0Cock\u00a0KM,\u00a0Williams\u00a0BG.\u00a0Universal \u00a0voluntary \u00a0HIV\u00a0testing\u00a0with\u00a0immediate \u00a0\nantiretroviral \u00a0therapy\u00a0as\u00a0a\u00a0strategy\u00a0for\u00a0elimination \u00a0of\u00a0HIV\u00a0transmission: \u00a0a\u00a0mathematical \u00a0model.\u00a0Lancet\u00a0\n2009;\u00a0373(9657):48 \u201057\u00a0\n\u00a0 910.\u00a0\u00a0Charlebois \u00a0E,\u00a0Porco\u00a0T,\u00a0Das\u2010Douglas\u00a0M,\u00a0Havlir\u00a0D.\u00a0Effect\u00a0of\u00a0expanded \u00a0ART\u00a0strategies \u00a0on\u00a0the\u00a0MSM\u00a0VIH\u00a0\nepidemic\u00a0in\u00a0San\u00a0Francisco. \u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0\nFrancisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0996.\u00a0\n\u00a0 911.\u00a0\u00a0Das\u00a0M,\u00a0Chu\u00a0PL,\u00a0Santos\u00a0GM,\u00a0Scheer\u00a0S,\u00a0Vittinghoff \u00a0E,\u00a0McFarland \u00a0W\u00a0et\u00a0al.\u00a0Decreases \u00a0in\u00a0community \u00a0viral\u00a0\nload\u00a0are\u00a0accompanied \u00a0by\u00a0reductions \u00a0in\u00a0new\u00a0HIV\u00a0infections \u00a0in\u00a0San\u00a0Francisco. \u00a0PLoS\u00a0One\u00a02010;\u00a05(6):e11068 \u00a0\n\u00a0 912.\u00a0\u00a0Montaner \u00a0JS,\u00a0Lima\u00a0VD,\u00a0Barrios\u00a0R,\u00a0Yip\u00a0B,\u00a0Wood\u00a0E,\u00a0Kerr\u00a0T\u00a0et\u00a0al.\u00a0Association \u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0\ntherapy\u00a0coverage, \u00a0population \u00a0viral\u00a0load,\u00a0and\u00a0yearly\u00a0new\u00a0HIV\u00a0diagnoses \u00a0in\u00a0British\u00a0Columbia, \u00a0Canada:\u00a0a\u00a0\npopulation \u2010based\u00a0study.\u00a0Lancet\u00a02010;\u00a0376(9740):532 \u2010539\u00a0\n\u00a0 913.\u00a0\u00a0Dieffenbach \u00a0CW,\u00a0Fauci\u00a0AS.\u00a0Universal \u00a0voluntary \u00a0testing\u00a0and\u00a0treatment \u00a0for\u00a0prevention \u00a0of\u00a0HIV\u00a0\ntransmission. \u00a0JAMA\u00a02009;\u00a0301(22):2380 \u20102382\u00a0\n\u00a0 914.\u00a0\u00a0Cohen\u00a0MS,\u00a0Gay\u00a0CL.\u00a0Treatment \u00a0to\u00a0prevent\u00a0transmission \u00a0of\u00a0HIV\u20101.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02010;\u00a050\u00a0Suppl\u00a03:S85\u2010S95\u00a0\n\u00a0 915.\u00a0\u00a0Hillier\u00a0S.\u00a0Pre\u2010Exposure\u00a0Prophylaxis: \u00a0Could\u00a0It\u00a0Work?\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0Montreal, \u00a0February\u00a08\u201011\u00a02009.\u00a0Abstract\u00a073.\u00a0\n\u00a0 916.\u00a0\u00a0Abdool\u00a0KQ,\u00a0bdool\u00a0Karim\u00a0SS,\u00a0Frohlich\u00a0JA,\u00a0Grobler\u00a0AC,\u00a0Baxter\u00a0C,\u00a0Mansoor\u00a0LE\u00a0et\u00a0al.\u00a0Effectiveness \u00a0and\u00a0safety\u00a0\nof\u00a0tenofovir\u00a0gel,\u00a0an\u00a0antiretroviral \u00a0microbicide, \u00a0for\u00a0the\u00a0prevention \u00a0of\u00a0HIV\u00a0infection\u00a0in\u00a0women.\u00a0Science\u00a0\n2010;\u00a0329(5996):1168 \u20101174\u00a0\n\u00a0 917.\u00a0\u00a0Grant\u00a0RM,\u00a0Lama\u00a0JR,\u00a0Anderson \u00a0PL,\u00a0McMahan \u00a0V,\u00a0Liu\u00a0AY,\u00a0Vargas\u00a0L\u00a0et\u00a0al.\u00a0Preexposure \u00a0Chemoprophylaxis \u00a0for\u00a0\nHIV\u00a0Prevention \u00a0in\u00a0Men\u00a0Who\u00a0Have\u00a0Sex\u00a0with\u00a0Men.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02010\u00a0(doi:\u00a010.1065/NEJMoa1011205) \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 235\u00a0 918.\u00a0\u00a0Kim\u00a0SC,\u00a0Becker\u00a0S,\u00a0Dieffenbach \u00a0C,\u00a0Hanewall \u00a0BS,\u00a0Hankins\u00a0C,\u00a0Lo\u00a0YR\u00a0et\u00a0al.\u00a0Planning\u00a0for\u00a0pre\u2010exposure\u00a0\nprophylaxis \u00a0to\u00a0prevent\u00a0HIV\u00a0transmission: \u00a0challenges \u00a0and\u00a0opportunities. \u00a0J\u00a0Int\u00a0AIDS\u00a0Soc\u00a02010;\u00a013(26):24 \u2010\n33\u00a0\n\u00a0 919.\u00a0\u00a0Underhill\u00a0K,\u00a0Operario\u00a0D,\u00a0Mimiaga\u00a0MJ,\u00a0Skeer\u00a0MR,\u00a0Mayer\u00a0KH.\u00a0Implementation \u00a0science\u00a0of\u00a0pre\u2010exposure\u00a0\nprophylaxis: \u00a0preparing \u00a0for\u00a0public\u00a0use.\u00a0Curr\u00a0HIV/AIDS\u00a0Rep\u00a02010;\u00a07(4):210\u2010219\u00a0\n\u00a0 920.\u00a0\u00a0Baggaley\u00a0RF,\u00a0Boily\u00a0MC,\u00a0White\u00a0RG,\u00a0Alary\u00a0M.\u00a0Risk\u00a0of\u00a0HIV\u20101\u00a0transmission \u00a0for\u00a0parenteral \u00a0exposure \u00a0and\u00a0blood\u00a0\ntransfusion: \u00a0a\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0AIDS\u00a02006;\u00a020(6):805 \u2010812\u00a0\n\u00a0 921.\u00a0\u00a0Cardo\u00a0DM,\u00a0Culver\u00a0DH,\u00a0Ciesielski\u00a0CA,\u00a0Srivastava \u00a0PU,\u00a0Marcus\u00a0R,\u00a0Abiteboul \u00a0D\u00a0et\u00a0al.\u00a0A\u00a0case\u2010control\u00a0study\u00a0of\u00a0\nHIV\u00a0seroconversion \u00a0in\u00a0health\u00a0care\u00a0workers\u00a0after\u00a0percutaneous \u00a0exposure. \u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0\nand\u00a0Prevention \u00a0Needlestick \u00a0Surveillance \u00a0Group.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01997;\u00a0337(21):1485 \u201090\u00a0\n\u00a0 922.\u00a0\u00a0Grob\u00a0PM,\u00a0Cao\u00a0Y,\u00a0Muchmore \u00a0E,\u00a0Ho\u00a0DD,\u00a0Norris\u00a0S,\u00a0Pav\u00a0JW\u00a0et\u00a0al.\u00a0Prophylaxis \u00a0against\u00a0HIV\u20101\u00a0infection\u00a0in\u00a0\nchimpanzees \u00a0by\u00a0nevirapine, \u00a0a\u00a0nonnucleoside \u00a0inhibitor\u00a0of\u00a0reverse\u00a0transcriptase. \u00a0Nat\u00a0Med\u00a01997;\u00a03(6):665\u2010\n70\u00a0\n\u00a0 923.\u00a0\u00a0Luque\u00a0A,\u00a0Hulse\u00a0S,\u00a0Wang\u00a0D,\u00a0Shahzad\u00a0U,\u00a0Tanzman\u00a0E,\u00a0Antenozzi \u00a0S\u00a0et\u00a0al.\u00a0Assessment \u00a0of\u00a0adverse\u00a0events\u00a0\nassociated \u00a0with\u00a0antiretroviral \u00a0regimens \u00a0for\u00a0postexposure \u00a0prophylaxis \u00a0for\u00a0occupational \u00a0and\u00a0\nnonoccupational \u00a0exposures \u00a0to\u00a0prevent\u00a0transmission \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus.\u00a0Infect\u00a0Control\u00a0\nHosp\u00a0Epidemiol \u00a02007;\u00a028(6):695 \u2010701\u00a0\n\u00a0 924.\u00a0\u00a0Rabaud\u00a0C,\u00a0Burty\u00a0C,\u00a0Grandidier \u00a0M,\u00a0Christian\u00a0B,\u00a0Penalba\u00a0C,\u00a0Beguinot\u00a0I\u00a0et\u00a0al.\u00a0Tolerability \u00a0of\u00a0postexposure \u00a0\nprophylaxis \u00a0with\u00a0the\u00a0combination \u00a0of\u00a0zidovudine \u2010lamivudine \u00a0and\u00a0lopinavir\u2010ritonavir\u00a0for\u00a0HIV\u00a0infection. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(2):303 \u2010305\u00a0\n\u00a0 925.\u00a0\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention. \u00a0Serious\u00a0adverse\u00a0events\u00a0attributed \u00a0to\u00a0nevirapine \u00a0regimens \u00a0\nfor\u00a0postexposure \u00a0prophylaxis \u00a0after\u00a0HIV\u00a0exposures \u2010\u2010worldwide, \u00a01997\u20102000.\u00a0MMWR\u00a0Morb\u00a0Mortal\u00a0Wkly\u00a0\nRep\u00a02001;\u00a049(51\u201052):1153\u20106\u00a0\n\u00a0 926.\u00a0\u00a0Young\u00a0T,\u00a0Arens\u00a0FJ,\u00a0Kenndy\u00a0GE,\u00a0Laurie\u00a0JV,\u00a0Rutherford \u00a0GW.\u00a0Antiretroviral \u00a0post\u2010exposure \u00a0prophylaxis \u00a0for\u00a0\noccupational \u00a0HIV\u00a0exposure. \u00a0Cochrane \u00a0Database \u00a0Syst\u00a0Rev\u00a02007;\u00a02007(1):Art. \u00a0No.:\u00a0CD002835. \u00a0\nDOI:10.1002/14651858.CD002835.pub3. \u00a0\n\u00a0 927.\u00a0\u00a0Zenner\u00a0D,\u00a0Tomkins\u00a0S,\u00a0Charlett\u00a0A,\u00a0Wellings\u00a0K,\u00a0Ncube\u00a0F.\u00a0HIV\u00a0prone\u00a0occupational \u00a0exposures: \u00a0epidemiology \u00a0\nand\u00a0factors\u00a0associated \u00a0with\u00a0initiation\u00a0of\u00a0post\u2010exposure\u00a0prophylaxis. \u00a0J\u00a0Epidemiol \u00a0Community \u00a0Health\u00a0\n2009;\u00a063(5):373 \u2010378\u00a0\n\u00a0 928.\u00a0\u00a0Beltrami\u00a0EM,\u00a0Cheingsong \u00a0R,\u00a0Heneine\u00a0WM,\u00a0Respess\u00a0RA,\u00a0Orelien\u00a0JG,\u00a0Mendelson \u00a0MH\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0\ndrug\u00a0resistance \u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0source\u00a0patients\u00a0for\u00a0occupational \u00a0exposures \u00a0\nto\u00a0healthcare \u00a0workers.\u00a0Infect\u00a0Control\u00a0Hosp\u00a0Epidemiol \u00a02003;\u00a024(10):724 \u2010730\u00a0\n\u00a0 929.\u00a0\u00a0Polo\u00a0R,\u00a0Aguirrebengoa \u00a0K,\u00a0Vives\u00a0N,\u00a0(Coordinadores). \u00a0Recomendaciones \u00a0del\u00a0SPNS,\u00a0Gesida,\u00a0CEESCAT, \u00a0SEIP\u00a0y\u00a0\nAEP\u00a0sobre\u00a0profilaxis\u00a0postexposici\u00f3n \u00a0frente\u00a0al\u00a0VIH,\u00a0VHB\u00a0y\u00a0VHC\u00a0en\u00a0adultos\u00a0y\u00a0ni\u00f1os.\u00a0Ministerio \u00a0Sanidad\u00a0y\u00a0\nConsumo \u00a02008.\u00a0\n\u00a0 930.\u00a0\u00a0Clumeck\u00a0N,\u00a0Dedes\u00a0N,\u00a0Pozniak\u00a0A,\u00a0Raffi\u00a0F.\u00a0European \u00a0AIDS\u00a0Clinical\u00a0Society.\u00a0Guidelines. \u00a0Clinical\u00a0manegement \u00a0\nand\u00a0treatment \u00a0of\u00a0HIV\u00a0infected\u00a0adults\u00a0in\u00a0Europe.\u00a0Disponible \u00a0en:\u00a0www\u00a0europeanaidsclinicalsociety \u00a0\norg/guidelinespdf/EACS \u2010EuroGuidelines_FullVersion \u00a0pdf\u00a02009;\u00a0(Acceso:\u00a020.10.2010) \u00a0\n\u00a0 931.\u00a0\u00a0Panlilio\u00a0AL,\u00a0Cardo\u00a0DM,\u00a0Grohskopf \u00a0LA,\u00a0Heneine\u00a0W,\u00a0Ross\u00a0CS.\u00a0Updated\u00a0U.S.\u00a0Public\u00a0Health\u00a0Service\u00a0guidelines \u00a0\nfor\u00a0the\u00a0management \u00a0of\u00a0occupational \u00a0exposures \u00a0to\u00a0HIV\u00a0and\u00a0recommendations \u00a0for\u00a0postexposure \u00a0\nprophylaxis. \u00a0MMWR\u00a0Recomm\u00a0Rep\u00a02005;\u00a054(RR\u20109):1\u201017\u00a0\n\u00a0 932.\u00a0\u00a0New\u00a0York\u00a0State\u00a0Department \u00a0of\u00a0Health\u00a0AIDS\u00a0Institute.\u00a0HIV\u00a0prophylaxis \u00a0following \u00a0occupational \u00a0exposure. \u00a0\nMay\u00a02010\u00a0Update.\u00a0Disponible \u00a0en:\u00a0www\u00a0hivguidelines \u00a0org\u00a02010;\u00a0(Acceso:\u00a019.10.2010) \u00a0\n\u00a0 933.\u00a0\u00a0Landovitz \u00a0RJ,\u00a0Currier\u00a0JS.\u00a0Postexposure \u00a0prophylaxis \u00a0for\u00a0HIV\u00a0infection\u00a0(clinical\u00a0practice). \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0\n2009;\u00a0361(18):1768 \u20101775\u00a0\n\u00a0 934.\u00a0\u00a0Smith\u00a0DK,\u00a0Grohskopf \u00a0LA,\u00a0Black\u00a0RJ,\u00a0Auerbach \u00a0JD,\u00a0Veronese \u00a0F,\u00a0Struble\u00a0KA\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0\npostexposure \u00a0prophylaxis \u00a0after\u00a0sexual,\u00a0injection\u2010drug\u00a0use,\u00a0or\u00a0other\u00a0nonoccupational \u00a0exposure \u00a0to\u00a0HIV\u00a0in\u00a0\nthe\u00a0United\u00a0States:\u00a0recommendations \u00a0from\u00a0the\u00a0U.S.\u00a0Department \u00a0of\u00a0Health\u00a0and\u00a0Human\u00a0Services.\u00a0MMWR\u00a0\nRecomm\u00a0Rep\u00a02005;\u00a054(RR\u20102):1\u201020\u00a0\n\u00a0 935.\u00a0\u00a0Boily\u00a0MC,\u00a0Baggaley\u00a0RF,\u00a0Wang\u00a0L,\u00a0Masse\u00a0B,\u00a0White\u00a0RG,\u00a0Hayes\u00a0RJ\u00a0et\u00a0al.\u00a0Heterosexual \u00a0risk\u00a0of\u00a0HIV\u20101\u00a0infection\u00a0\nper\u00a0sexual\u00a0act:\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis\u00a0of\u00a0observational \u00a0studies.\u00a0Lancet\u00a0Infect\u00a0Dis\u00a02009;\u00a0\n9(2):118\u2010129\u00a0\n\u00a0 936.\u00a0\u00a0Jin\u00a0F,\u00a0Jansson\u00a0J,\u00a0Law\u00a0M,\u00a0Prestage\u00a0GP,\u00a0Zablotska \u00a0I,\u00a0Imrie\u00a0JC\u00a0et\u00a0al.\u00a0Per\u2010contact\u00a0probability \u00a0of\u00a0HIV\u00a0\ntransmission \u00a0in\u00a0homosexual \u00a0men\u00a0in\u00a0Sydney\u00a0in\u00a0the\u00a0era\u00a0of\u00a0HAART.\u00a0AIDS\u00a02010;\u00a024(6):907 \u2010913\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 236\u00a0 937.\u00a0\u00a0Barber\u00a0TJ,\u00a0Benn\u00a0PD.\u00a0Postexposure \u00a0prophylaxis \u00a0for\u00a0HIV\u00a0following \u00a0sexual\u00a0exposure. \u00a0Curr\u00a0Opin\u00a0HIV\u00a0AIDS\u00a0\n2010;\u00a05(4):322\u2010326\u00a0\n\u00a0 938.\u00a0\u00a0Martin\u00a0JN,\u00a0Roland\u00a0ME,\u00a0Neilands\u00a0TB,\u00a0Krone\u00a0MR,\u00a0Bamberger \u00a0JD,\u00a0Kohn\u00a0RP\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0postexposure \u00a0\nprophylaxis \u00a0against\u00a0HIV\u00a0infection\u00a0following \u00a0sexual\u00a0exposure \u00a0does\u00a0not\u00a0lead\u00a0to\u00a0increases \u00a0in\u00a0high\u2010risk\u00a0\nbehavior. \u00a0AIDS\u00a02004;\u00a018(5):787 \u2010792\u00a0\n\u00a0 939.\u00a0\u00a0Dumond\u00a0JB,\u00a0Yeh\u00a0RF,\u00a0Patterson \u00a0KB,\u00a0Corbett\u00a0AH,\u00a0Jung\u00a0BH,\u00a0Rezk\u00a0NL\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0drug\u00a0exposure\u00a0in\u00a0\nthe\u00a0female\u00a0genital\u00a0tract:\u00a0implications \u00a0for\u00a0oral\u00a0pre\u2010\u00a0and\u00a0post\u2010exposure\u00a0prophylaxis. \u00a0AIDS\u00a02007;\u00a0\n21(14):1899 \u20101907\u00a0\n\u00a0 940.\u00a0\u00a0Bryant\u00a0J,\u00a0Baxter\u00a0L,\u00a0Hird\u00a0S.\u00a0Non\u2010occupational \u00a0postexposure \u00a0prophylaxis \u00a0for\u00a0HIV:\u00a0a\u00a0systematic \u00a0review.\u00a0\nHealth\u00a0Technol\u00a0Assess\u00a02009;\u00a013(14):iii, \u00a0ix\u201060\u00a0\n\u00a0 941.\u00a0\u00a0Vives\u00a0N,\u00a0Almeda\u00a0J,\u00a0Contreras \u00a0CA,\u00a0Garcia\u00a0F,\u00a0Campins\u00a0M,\u00a0Casabona \u00a0J.\u00a0Demanda \u00a0y\u00a0prescripci\u00f3n \u00a0de\u00a0la\u00a0\nprofilaxis\u00a0postexposici\u00f3n \u00a0no\u00a0ocupacional \u00a0al\u00a0VIH\u00a0en\u00a0Espa\u00f1a\u00a0(2001\u20102005).\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a0\n2008;\u00a026(9):546 \u2010551\u00a0\n\u00a0 942.\u00a0\u00a0Guinot\u00a0D,\u00a0Ho\u00a0MT,\u00a0Poynten\u00a0IM,\u00a0McAllister \u00a0J,\u00a0Pierce\u00a0A,\u00a0Pell\u00a0C\u00a0et\u00a0al.\u00a0Cost\u2010effectiveness \u00a0of\u00a0HIV\u00a0\nnonoccupational \u00a0post\u2010exposure\u00a0prophylaxis \u00a0in\u00a0Australia. \u00a0HIV\u00a0Med\u00a02009;\u00a010(4):199 \u2010208\u00a0\n\u00a0 943.\u00a0\u00a0Taylor\u00a0S,\u00a0Davies\u00a0S.\u00a0Antiretroviral \u00a0drug\u00a0concentrations \u00a0in\u00a0the\u00a0male\u00a0and\u00a0female\u00a0genital\u00a0tract:\u00a0implications \u00a0\nfor\u00a0the\u00a0sexual\u00a0transmission \u00a0of\u00a0HIV.\u00a0Curr\u00a0Opin\u00a0HIV\u00a0AIDS\u00a02010;\u00a05(4):335\u2010343\u00a0\n\u00a0 944.\u00a0\u00a0Fisher\u00a0M,\u00a0Benn\u00a0P,\u00a0Evans\u00a0B,\u00a0Pozniak\u00a0A,\u00a0Jones\u00a0M,\u00a0Maclean\u00a0S\u00a0et\u00a0al.\u00a0UK\u00a0Guideline \u00a0for\u00a0the\u00a0use\u00a0of\u00a0post\u2010\nexposure \u00a0prophylaxis \u00a0for\u00a0HIV\u00a0following \u00a0sexual\u00a0exposure. \u00a0Int\u00a0J\u00a0STD\u00a0AIDS\u00a02006;\u00a017(2):81\u201092\u00a0\n\u00a0 945.\u00a0\u00a0Tosini\u00a0W,\u00a0Muller\u00a0P,\u00a0Prazuck\u00a0T,\u00a0Benabdelmoumen \u00a0G,\u00a0Peyrouse \u00a0E,\u00a0Christian\u00a0B\u00a0et\u00a0al.\u00a0Tolerability \u00a0of\u00a0HIV\u00a0\npostexposure \u00a0prophylaxis \u00a0with\u00a0tenofovir/emtricitabine \u00a0and\u00a0lopinavir/ritonavir \u00a0tablet\u00a0formulation. \u00a0AIDS\u00a0\n2010;\u00a024(15):2375 \u20102380\u00a0\n\u00a0 946.\u00a0\u00a0Sonder\u00a0GJ,\u00a0Prins\u00a0JM,\u00a0Regez\u00a0RM,\u00a0Brinkman \u00a0K,\u00a0Mulder\u00a0JW,\u00a0Veenstra\u00a0J\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0Two\u00a0HIV\u00a0\nPostexposure \u00a0Prophylaxis \u00a0Regimens \u00a0Among\u00a0Men\u00a0Who\u00a0Have\u00a0Sex\u00a0With\u00a0Men\u00a0in\u00a0Amsterdam: \u00a0Adverse\u00a0\nEffects\u00a0Do\u00a0Not\u00a0Influence \u00a0Compliance. \u00a0Sex\u00a0Transm\u00a0Dis\u00a02010;\u00a037(11):681 \u2010686\u00a0\n\u00a0 947.\u00a0\u00a0Diaz\u2010Brito\u00a0V,\u00a0Le\u00f3n\u00a0A,\u00a0Knobel\u00a0H,\u00a0Peraire\u00a0J,\u00a0Domingo\u00a0P,\u00a0Clotet\u00a0B,\u00a0et\u00a0al.\u00a0An\u00a0open\u00a0randomized \u00a0multicenter \u00a0\nclinical\u00a0trial\u00a0comparing \u00a0Zidovudine/Lamivudine \u00a0plus\u00a0Lopinavir/Ritonavir \u00a0or\u00a0plus\u00a0Atazanavir \u00a0used\u00a0as\u00a0post\u2010\nexposure \u00a0prophylaxis \u00a0for\u00a0HIV\u00a0infection. \u00a017th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0\nSan\u00a0Francisco, \u00a0February\u00a027\u2010March\u00a02\u00a02010.\u00a0Abstract\u00a0956.\u00a0\n\u00a0 948.\u00a0\u00a0Dybul\u00a0M,\u00a0Chun\u00a0TW,\u00a0Yoder\u00a0C,\u00a0Hidalgo\u00a0B,\u00a0Belson\u00a0M,\u00a0Hertogs\u00a0K\u00a0et\u00a0al.\u00a0Short\u2010cycle\u00a0structured \u00a0intermittent \u00a0\ntreatment \u00a0of\u00a0chronic\u00a0HIV\u00a0infection\u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0effects\u00a0on\u00a0virologic,\u00a0\nimmunologic, \u00a0and\u00a0toxicity\u00a0parameters. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0USA\u00a02001;\u00a098(26):15161 \u20106\u00a0\n\u00a0 949.\u00a0\u00a0Garcia\u00a0F,\u00a0Plana\u00a0M,\u00a0Ortiz\u00a0GM,\u00a0Bonhoeffer \u00a0S,\u00a0Soriano\u00a0A,\u00a0Vidal\u00a0C\u00a0et\u00a0al.\u00a0The\u00a0virological \u00a0and\u00a0immunological \u00a0\nconsequences \u00a0of\u00a0structured \u00a0treatment \u00a0interruptions \u00a0in\u00a0chronic\u00a0HIV\u20101\u00a0infection. \u00a0\u00a0AIDS\u00a02001;\u00a015:F29\u201040\u00a0\n\u00a0 950.\u00a0\u00a0Ruiz\u00a0L,\u00a0Carcelain\u00a0G,\u00a0Martinez\u2010Picado\u00a0J,\u00a0Frost\u00a0S,\u00a0Marfil\u00a0S,\u00a0Paredes\u00a0R\u00a0et\u00a0al.\u00a0HIV\u00a0dynamics \u00a0and\u00a0Tcell\u00a0\nimmunity \u00a0after\u00a0three\u00a0structured \u00a0treatment \u00a0interruptions \u00a0in\u00a0chronic\u00a0HIV\u20101\u00a0infection. \u00a0\u00a0AIDS\u00a02001;\u00a015:F19\u2010\n27\u00a0\n\u00a0 951.\u00a0\u00a0Fagard\u00a0C,\u00a0Oxenius\u00a0A,\u00a0Gunthard \u00a0H,\u00a0Garcia\u00a0F,\u00a0Le\u00a0Braz\u00a0M,\u00a0Mestre\u00a0G\u00a0et\u00a0al.\u00a0A\u00a0prospective \u00a0trial\u00a0of\u00a0structured \u00a0\ntreatment \u00a0interruptions \u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0Arch\u00a0Intern\u00a0Med\u00a02003;\u00a0163:1220 \u2010\n1226\u00a0\n\u00a0 952.\u00a0\u00a0Miller\u00a0V,\u00a0Sabin\u00a0C,\u00a0Hertogs\u00a0K,\u00a0Bloor\u00a0S,\u00a0Martinez\u2010Picado\u00a0J,\u00a0D'Aquila\u00a0R\u00a0et\u00a0al.\u00a0Virological \u00a0and\u00a0immunological \u00a0\neffects\u00a0of\u00a0treatment \u00a0interruptions \u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients\u00a0with\u00a0treatment \u00a0failure.\u00a0AIDS\u00a02000;\u00a0\n14(18):2857 \u201067\u00a0\n\u00a0 953.\u00a0\u00a0Walmsley \u00a0SL,\u00a0Thorne\u00a0A,\u00a0Loutfy\u00a0MR,\u00a0LaPierre\u00a0N,\u00a0MacLeod\u00a0J,\u00a0Harrigan\u00a0R\u00a0et\u00a0al.\u00a0A\u00a0prospective \u00a0randomized \u00a0\ncontrolled \u00a0trial\u00a0of\u00a0structured \u00a0treatment \u00a0interruption \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0failing\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy\u00a0(Canadian \u00a0HIV\u00a0Trials\u00a0Network\u00a0Study\u00a0164).\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a0\n45(4):418 \u2010425\u00a0\n\u00a0 954.\u00a0\u00a0Ruiz\u00a0L,\u00a0Ribera\u00a0E,\u00a0Bonjoch\u00a0A,\u00a0Romeu\u00a0J,\u00a0Martinez\u2010Picado\u00a0J,\u00a0Paredes\u00a0R\u00a0et\u00a0al.\u00a0Role\u00a0of\u00a0structured \u00a0treatment \u00a0\ninterruption \u00a0before\u00a0a\u00a05\u2010drug\u00a0salvage\u00a0antiretroviral \u00a0regimen:\u00a0the\u00a0Retrogene \u00a0Study.\u00a0J\u00a0Infect\u00a0Dis\u00a02003;\u00a0\n188:977\u2010985\u00a0\n\u00a0 955.\u00a0\u00a0Deeks\u00a0SG,\u00a0Hoh\u00a0R,\u00a0Grant\u00a0RM,\u00a0Wrin\u00a0T,\u00a0Barbour\u00a0JD,\u00a0Narvaez\u00a0A\u00a0et\u00a0al.\u00a0CD4+\u00a0T\u00a0Cell\u00a0Kinetics\u00a0and\u00a0Activation \u00a0in\u00a0\nHuman\u00a0Immunodeficiency \u00a0Virus\u2010Infected\u00a0Patients\u00a0Who\u00a0Remain\u00a0Viremic\u00a0Despite\u00a0Long\u2010Term\u00a0Treatment \u00a0\nwith\u00a0Protease\u00a0Inhibitor\u2010Based\u00a0Therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0185(3):315 \u201023\u00a0\n\u00a0 956.\u00a0\u00a0Ananworanich \u00a0J,\u00a0Hirschel\u00a0B.\u00a0Intermittent \u00a0therapy\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0chronic\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02007;\u00a0\n21(2):123 \u2010134\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 237\u00a0 957.\u00a0\u00a0Arnedo\u2010Valero\u00a0M,\u00a0Garc\u00eda\u00a0F,\u00a0Gil\u00a0C,\u00a0Castro\u00a0P,\u00a0Blanco\u00a0JL,\u00a0Miro\u00a0JM,\u00a0Pumarola \u00a0T,\u00a0Gatell\u00a0JM.\u00a0Risk\u00a0of\u00a0developing \u00a0\nselected\u00a0de\u00a0novo\u00a0resistance \u00a0mutations \u00a0during\u00a0structured \u00a0therapy\u00a0interruption \u00a0in\u00a0chronic\u00a0HIV\u20101\u00a0\ninfection. \u00a011th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a08\u2010\u201011\u00a0\n2004.\u00a0Abstract\u00a0668.\u00a0\n\u00a0 958.\u00a0\u00a0Cardiello\u00a0PG,\u00a0Hassink\u00a0E,\u00a0Ananworanich \u00a0J,\u00a0Srasuebkul \u00a0P,\u00a0Samor\u00a0T,\u00a0Mahanontharit \u00a0A\u00a0et\u00a0al.\u00a0A\u00a0prospective, \u00a0\nrandomized \u00a0trial\u00a0of\u00a0structured \u00a0treatment \u00a0interruption \u00a0for\u00a0patients\u00a0with\u00a0chronic\u00a0HIV\u00a0type\u00a01\u00a0infection. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(4):594 \u2010600\u00a0\n\u00a0 959.\u00a0\u00a0Danel\u00a0C,\u00a0Moh\u00a0R,\u00a0Minga\u00a0A,\u00a0Anzian\u00a0A,\u00a0Ba\u2010Gomis\u00a0O,\u00a0Kanga\u00a0C\u00a0et\u00a0al.\u00a0CD4\u2010guided\u00a0structured \u00a0antiretroviral \u00a0\ntreatment \u00a0interruption \u00a0strategy\u00a0in\u00a0HIV\u2010infected\u00a0adults\u00a0in\u00a0west\u00a0Africa\u00a0(Trivacan\u00a0ANRS\u00a01269\u00a0trial):\u00a0a\u00a0\nrandomised \u00a0trial.\u00a0Lancet\u00a02006;\u00a0367(9527):1981 \u20101989\u00a0\n\u00a0 960.\u00a0\u00a0Jacobson\u00a0JM,\u00a0Turner\u00a0BJ,\u00a0Abrutyn\u00a0E.\u00a0Trials\u00a0that\u00a0matter:\u00a0CD4+\u00a0T\u2010lymphocyte \u00a0count\u2010guided\u00a0interruption \u00a0of\u00a0\nantiretroviral \u00a0therapy\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0Ann\u00a0Intern\u00a0Med\u00a02007;\u00a0146(9):682 \u2010683\u00a0\n\u00a0 961.\u00a0\u00a0Marchou\u00a0B,\u00a0Tangre\u00a0P,\u00a0Charreau\u00a0I,\u00a0Izopet\u00a0J,\u00a0Girard\u00a0PM,\u00a0May\u00a0T,\u00a0et\u00a0al.\u00a0Structured \u00a0treatment \u00a0interruptions \u00a0\nin\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0high\u00a0CD4\u00a0cell\u00a0counts\u00a0and\u00a0virologic\u00a0suppression: \u00a0Results\u00a0of\u00a0a\u00a0prospective, \u00a0\nrandomized, \u00a0open\u2010label\u00a0trial\u00a0(Window\u00a0\u2010\u00a0ANRS\u00a0106).\u00a013th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006.\u00a0Abstract\u00a0104.\u00a0\n\u00a0 962.\u00a0\u00a0Olmo\u00a0M,\u00a0Podzamczer \u00a0D,\u00a0Pe\u00f1aranda \u00a0M,\u00a0Guti\u00e9rrez \u00a0F,\u00a0Nubi\u00f3\u00a0J,\u00a0Romeu\u00a0J,\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0of\u00a0CD4\u2010\nguided\u00a0haart\u00a0interruption \u00a0in\u00a0patients\u00a0receiving\u00a0mostly\u00a0NRTI\u2010based\u00a0regimens: \u00a096\u2010week\u00a0results.\u00a011th\u00a0\nEuropean \u00a0AIDS\u00a0Conference, \u00a0Madrid,\u00a0October\u00a024\u201027\u00a02007.\u00a0Abstract\u00a0P7.6/02.\u00a0\n\u00a0 963.\u00a0\u00a0Olmo\u00a0M,\u00a0Podzamczer \u00a0D,\u00a0Pe\u00f1aranda \u00a0M,\u00a0Guti\u00e9rrez \u00a0F,\u00a0Nubi\u00f3\u00a0J,\u00a0Romeu\u00a0J,\u00a0et\u00a0al.\u00a0PBMC\u00a0and\u00a0plasma\u00a0genotypic \u00a0\nresistance \u00a0during\u00a0a\u00a0CD4\u2010guided\u00a0HAART\u00a0interruption \u00a0randomized \u00a0study.\u00a096\u2010week\u00a0follow\u2010up.\u00a011th\u00a0\nEuropean \u00a0AIDS\u00a0Conference, \u00a0Madrid,\u00a0October\u00a024\u201027\u00a02007.\u00a0Abstract\u00a0P3.4/04.\u00a0\n\u00a0 964.\u00a0\u00a0Pogany\u00a0K,\u00a0van\u00a0V,\u00a0I,\u00a0Prins\u00a0JM,\u00a0Nieuwkerk \u00a0PT,\u00a0van\u00a0dE,\u00a0I,\u00a0Kauffmann \u00a0RH\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0active\u00a0treatment \u00a0\ndiscontinuation \u00a0in\u00a0patients\u00a0with\u00a0a\u00a0CD4+\u00a0T\u2010cell\u00a0nadir\u00a0greater\u00a0than\u00a0350\u00a0cells/mm3: \u00a048\u2010week\u00a0Treatment \u00a0\nInterruption \u00a0in\u00a0Early\u00a0Starters\u00a0Netherlands \u00a0Study\u00a0(TRIESTAN). \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a0\n44(4):395 \u2010400\u00a0\n\u00a0 965.\u00a0\u00a0Ruiz\u00a0L,\u00a0Paredes\u00a0R,\u00a0Gomez\u00a0G,\u00a0Romeu\u00a0J,\u00a0Domingo\u00a0P,\u00a0Perez\u2010Alvarez\u00a0N\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0therapy\u00a0\ninterruption \u00a0guided\u00a0by\u00a0CD4\u00a0cell\u00a0counts\u00a0and\u00a0plasma\u00a0HIV\u20101\u00a0RNA\u00a0levels\u00a0in\u00a0chronically \u00a0HIV\u20101\u2010infected\u00a0\npatients.\u00a0AIDS\u00a02007;\u00a021(2):169 \u2010178\u00a0\n\u00a0 966.\u00a0\u00a0Skiest\u00a0DJ,\u00a0Su\u00a0Z,\u00a0Havlir\u00a0DV,\u00a0Robertson \u00a0KR,\u00a0Coombs\u00a0RW,\u00a0Cain\u00a0P\u00a0et\u00a0al.\u00a0Interruption \u00a0of\u00a0antiretroviral \u00a0\ntreatment \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0preserved \u00a0immune\u00a0function\u00a0is\u00a0associated \u00a0with\u00a0a\u00a0low\u00a0rate\u00a0of\u00a0\nclinical\u00a0progression: \u00a0a\u00a0prospective \u00a0study\u00a0by\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a05170.\u00a0J\u00a0Infect\u00a0Dis\u00a02007;\u00a0\n195(10):1426 \u20101436\u00a0\n\u00a0 967.\u00a0\u00a0Ananworanich \u00a0J,\u00a0Gayet\u2010Ageron\u00a0A,\u00a0Le\u00a0Braz\u00a0M,\u00a0Prasithsirikul \u00a0W,\u00a0Chetchotisakd \u00a0P,\u00a0Kiertiburanakul \u00a0S,\u00a0\nPhanuphak \u00a0P,\u00a0Cooper\u00a0D,\u00a0Hirschel\u00a0B,\u00a0the\u00a0Staccato\u00a0Study\u00a0Group.\u00a0CD4\u2010guided\u00a0scheduled \u00a0treatments \u00a0\ninterruptions \u00a0compared \u00a0to\u00a0continuous \u00a0therapy:\u00a0Results\u00a0of\u00a0the\u00a0Staccato\u00a0trial.\u00a013th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006.\u00a0Abatract\u00a0102.\u00a0\n\u00a0 968.\u00a0\u00a0Ananworanich \u00a0J,\u00a0Gayet\u2010Ageron\u00a0A,\u00a0Le\u00a0BM,\u00a0Prasithsirikul \u00a0W,\u00a0Chetchotisakd \u00a0P,\u00a0Kiertiburanakul \u00a0S\u00a0et\u00a0al.\u00a0CD4\u2010\nguided\u00a0scheduled \u00a0treatment \u00a0interruptions \u00a0compared \u00a0with\u00a0continuous \u00a0therapy\u00a0for\u00a0patients\u00a0infected\u00a0with\u00a0\nHIV\u20101:\u00a0results\u00a0of\u00a0the\u00a0Staccato\u00a0randomised \u00a0trial.\u00a0Lancet\u00a02006;\u00a0368(9534):459 \u2010465\u00a0\n\u00a0 969.\u00a0\u00a0Kuller\u00a0L,\u00a0SMART\u00a0Study\u00a0Group.\u00a0Elevated\u00a0levels\u00a0of\u00a0interleukin \u20106\u00a0and\u00a0D\u2010dimer\u00a0are\u00a0associated \u00a0with\u00a0an\u00a0\nincreased \u00a0risk\u00a0of\u00a0death\u00a0in\u00a0patients\u00a0with\u00a0HIV.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0\nInfections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0139.\u00a0\n\u00a0 970.\u00a0\u00a0Calmy\u00a0A,\u00a0Nguyen\u00a0A,\u00a0Montecucco \u00a0F,\u00a0Gayet\u2010Ageron\u00a0A,\u00a0Burger\u00a0F,\u00a0Mach\u00a0F,\u00a0et\u00a0al.\u00a0HIV\u00a0activates\u00a0markers\u00a0of\u00a0\ncardiovascular \u00a0risk\u00a0in\u00a0a\u00a0randomized \u00a0treatment \u00a0interruption \u00a0trial:\u00a0STACCATO. \u00a015th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0February\u00a03\u20106\u00a02008.\u00a0Abstract\u00a0140.\u00a0\n\u00a0 971.\u00a0\u00a0Olmo\u00a0M,\u00a0Alonso\u00a0Villaverde \u00a0C,\u00a0Penaranda \u00a0M,\u00a0Gutierrez \u00a0F,\u00a0Romeu\u00a0J,\u00a0Larrousse \u00a0M,\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0HAART\u00a0\ninterruption \u00a0on\u00a0plasma\u00a0inflammatory \u00a0markers\u00a0associated \u00a0with\u00a0cardiovascular \u00a0disease.\u00a024\u2010month\u00a0results\u00a0\nfrom\u00a0a\u00a0randomized \u00a0study.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Montreal, \u00a0\nFebruary\u00a08\u201011\u00a02009.\u00a0Abstract\u00a0738.\u00a0\n\u00a0 972.\u00a0\u00a0Schooley\u00a0RT,\u00a0Spritzler\u00a0J,\u00a0Wang\u00a0H,\u00a0Lederman \u00a0MM,\u00a0Havlir\u00a0D,\u00a0Kuritzkes\u00a0DR\u00a0et\u00a0al.\u00a0AIDS\u00a0clinical\u00a0trials\u00a0group\u00a0\n5197:\u00a0a\u00a0placebo\u2010controlled \u00a0trial\u00a0of\u00a0immunization \u00a0of\u00a0HIV\u20101\u2010infected\u00a0persons\u00a0with\u00a0a\u00a0replication \u2010deficient\u00a0\nadenovirus \u00a0type\u00a05\u00a0vaccine\u00a0expressing \u00a0the\u00a0HIV\u20101\u00a0core\u00a0protein.\u00a0J\u00a0Infect\u00a0Dis\u00a02010;\u00a0202(5):705 \u2010716\u00a0\n\u00a0 973.\u00a0\u00a0Davey\u00a0RT,\u00a0Jr.,\u00a0Murphy\u00a0RL,\u00a0Graziano\u00a0FM,\u00a0Boswell\u00a0SL,\u00a0Pavia\u00a0AT,\u00a0Cancio\u00a0M\u00a0et\u00a0al.\u00a0Immunologic \u00a0and\u00a0virologic\u00a0\neffects\u00a0of\u00a0subcutaneous \u00a0interleukin \u00a02\u00a0in\u00a0combination \u00a0with\u00a0antiretroviral \u00a0therapy:\u00a0A\u00a0randomized \u00a0\ncontrolled \u00a0trial.\u00a0JAMA\u00a02000;\u00a0284(2):183 \u20109\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 238\u00a0 974.\u00a0\u00a0Emery\u00a0S,\u00a0Capra\u00a0WB,\u00a0Cooper\u00a0DA,\u00a0Mitsuyasu \u00a0RT,\u00a0Kovacs\u00a0JA,\u00a0Vig\u00a0P\u00a0et\u00a0al.\u00a0Pooled\u00a0analysis\u00a0of\u00a03\u00a0randomized, \u00a0\ncontrolled \u00a0trials\u00a0of\u00a0interleukin \u20102\u00a0therapy\u00a0in\u00a0adult\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0disease.\u00a0J\u00a0Infect\u00a0\nDis\u00a02000;\u00a0182(2):428 \u201034\u00a0\n\u00a0 975.\u00a0\u00a0Katlama\u00a0C,\u00a0Carcelain\u00a0G,\u00a0Duvivier\u00a0C,\u00a0Chouquet \u00a0C,\u00a0Tubiana\u00a0R,\u00a0De\u00a0Sa\u00a0M\u00a0et\u00a0al.\u00a0Interleukin \u00a0\u20102\u00a0accelerates \u00a0CD4\u00a0\ncell\u00a0reconstitution \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0severe\u00a0immunosuppression \u00a0despite\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy:\u00a0the\u00a0ILSTIM\u00a0study\u2010\u2010ANRS\u00a0082.\u00a0AIDS\u00a02002;\u00a016:2027\u20102034\u00a0\n\u00a0 976.\u00a0\u00a0The\u00a0INSIGHT\u2010ESPRIT\u00a0Study\u00a0Group\u00a0and\u00a0SILCAAT\u00a0Scientific\u00a0Committee. \u00a0Interleukin \u20102\u00a0Therapy\u00a0in\u00a0Patients\u00a0\nwith\u00a0HIV\u00a0Infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02009;\u00a0361(16):1548 \u20101559\u00a0\n\u00a0 977.\u00a0\u00a0Kahn\u00a0JO,\u00a0Cherng\u00a0DW,\u00a0Mayer\u00a0K,\u00a0Murray\u00a0H,\u00a0Lagakos\u00a0S.\u00a0Evaluation \u00a0of\u00a0HIV\u20101\u00a0immunogen, \u00a0an\u00a0immunologic \u00a0\nmodifier,\u00a0administered \u00a0to\u00a0patients\u00a0infected\u00a0with\u00a0HIV\u00a0having\u00a0300\u00a0to\u00a0549\u00a0x\u00a010(6)/L\u00a0CD4\u00a0cell\u00a0counts:\u00a0A\u00a0\nrandomized \u00a0controlled \u00a0trial.\u00a0JAMA\u00a02000;\u00a0284(17):2193 \u2010202\u00a0\n\u00a0 978.\u00a0\u00a0Garcia\u00a0F,\u00a0Lejeune\u00a0M,\u00a0Climent\u00a0N,\u00a0Gil\u00a0C,\u00a0Alcami\u00a0J,\u00a0Morente\u00a0V\u00a0et\u00a0al.\u00a0Therapeutic \u00a0immunization \u00a0with\u00a0\ndendritic\u00a0cells\u00a0loaded\u00a0with\u00a0heat\u2010inactivated \u00a0autologous \u00a0HIV\u20101\u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0\nInfect\u00a0Dis\u00a02005;\u00a0191(10):1680 \u20101685\u00a0\n\u00a0 979.\u00a0\u00a0Fernandez \u2010Cruz\u00a0E,\u00a0Moreno\u00a0S,\u00a0Navarro\u00a0J,\u00a0Clotet\u00a0B,\u00a0Bouza\u00a0E,\u00a0Carbone\u00a0J\u00a0et\u00a0al.\u00a0Therapeutic \u00a0immunization \u00a0\nwith\u00a0an\u00a0inactivated \u00a0HIV\u20101\u00a0Immunogen \u00a0plus\u00a0antiretrovirals \u00a0versus\u00a0antiretroviral \u00a0therapy\u00a0alone\u00a0in\u00a0\nasymptomatic \u00a0HIV\u2010infected\u00a0subjects.\u00a0Vaccine\u00a02004;\u00a022(23\u201024):2966\u20102973\u00a0\n\u00a0 980.\u00a0\u00a0Pozniak\u00a0AL,\u00a0Morales\u2010Ramirez\u00a0J,\u00a0Katabira\u00a0E,\u00a0Steyn\u00a0D,\u00a0Lupo\u00a0SH,\u00a0Santoscoy \u00a0M\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nTMC278\u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u20101\u00a0patients:\u00a0week\u00a096\u00a0results\u00a0of\u00a0a\u00a0phase\u00a0IIb\u00a0randomized \u00a0trial.\u00a0AIDS\u00a0\n2010;\u00a024(1):55\u201065\u00a0\n\u00a0 981.\u00a0\u00a0Azijn\u00a0H,\u00a0Tirry\u00a0I,\u00a0Vingerhoets \u00a0J,\u00a0de\u00a0Bethune\u00a0MP,\u00a0Kraus\u00a0G,\u00a0Boven\u00a0K\u00a0et\u00a0al.\u00a0TMC278,\u00a0a\u00a0next\u2010generation \u00a0\nnonnucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0(NNRTI),\u00a0active\u00a0against\u00a0wild\u2010type\u00a0and\u00a0NNRTI\u2010resistant\u00a0\nHIV\u20101.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02010;\u00a054(2):718 \u2010727\u00a0\n\u00a0 982.\u00a0\u00a0Cohen\u00a0C,\u00a0Molina\u00a0JM,\u00a0Cahn\u00a0P,\u00a0Clotet\u00a0B,\u00a0Fouriee\u00a0J,\u00a0Grinsztejn \u00a0B,\u00a0et\u00a0al.\u00a0Pooled\u00a0Week\u00a048\u00a0efficacy\u00a0and\u00a0safety\u00a0\nresults\u00a0from\u00a0ECHO\u00a0and\u00a0THRIVE,\u00a0two\u00a0double\u2010blind,\u00a0randomised, \u00a0Phase\u00a0III\u00a0trials\u00a0comparing \u00a0TMC278\u00a0\nversus\u00a0efavirenz\u00a0in\u00a0treatment \u2010na\u00efve,\u00a0\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a018th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0\nVienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0abstract\u00a0\u00a0THLBB206. \u00a0\n\u00a0 983.\u00a0\u00a0Shimura\u00a0K,\u00a0Kodama\u00a0E,\u00a0Sakagami \u00a0Y,\u00a0Matsuzaki \u00a0Y,\u00a0Watanabe \u00a0W,\u00a0Yamataka \u00a0K\u00a0et\u00a0al.\u00a0Broad\u00a0antiretroviral \u00a0\nactivity\u00a0and\u00a0resistance \u00a0profile\u00a0of\u00a0the\u00a0novel\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0integrase \u00a0inhibitor\u00a0\nelvitegravir \u00a0(JTK\u2010303/GS\u20109137).\u00a0J\u00a0Virol\u00a02008;\u00a082(2):764 \u2010774\u00a0\n\u00a0 984.\u00a0\u00a0Zolopa\u00a0AR,\u00a0Berger\u00a0DS,\u00a0Lampiris\u00a0H,\u00a0Zhong\u00a0L,\u00a0Chuck\u00a0SL,\u00a0Enejosa\u00a0JV\u00a0et\u00a0al.\u00a0Activity\u00a0of\u00a0elvitegravir, \u00a0a\u00a0once\u2010\ndaily\u00a0integrase \u00a0inhibitor,\u00a0against\u00a0resistant\u00a0HIV\u00a0Type\u00a01:\u00a0results\u00a0of\u00a0a\u00a0phase\u00a02,\u00a0randomized, \u00a0controlled, \u00a0\ndose\u2010ranging\u00a0clinical\u00a0trial.\u00a0J\u00a0Infect\u00a0Dis\u00a02010;\u00a0201(6):814 \u2010822\u00a0\n\u00a0 985.\u00a0\u00a0Underwood \u00a0M,\u00a0Johns\u00a0B,\u00a0Sato\u00a0A,\u00a0Fujiwara\u00a0T,\u00a0Spreen\u00a0W.\u00a0S/GSK1349572: \u00a0a\u00a0next\u00a0generation \u00a0integrase \u00a0\ninhibitor\u00a0with\u00a0activity\u00a0against\u00a0integrase \u00a0inhibitor\u00a0clinical\u00a0isolates\u00a0from\u00a0patients\u00a0experiencing \u00a0virologic\u00a0\nfailure\u00a0while\u00a0on\u00a0raltegravir \u00a0therapy.\u00a05th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Cape\u00a0Town,\u00a0July\u00a019\u201022\u00a02009.\u00a0Abstract\u00a0WePeAO98. \u00a0\n\u00a0 986.\u00a0\u00a0Eron\u00a0J,\u00a0Durant\u00a0J,\u00a0Poizot\u2010Martin\u00a0I,\u00a0Reynes\u00a0J,\u00a0Soriano\u00a0V,\u00a0Kumar\u00a0P\u00a0et\u00a0al.\u00a0Activity\u00a0of\u00a0a\u00a0next\u00a0generation \u00a0\nintegrase \u00a0inhibitor,\u00a0S/GSK1349572, \u00a0in\u00a0subjects\u00a0with\u00a0HIV\u00a0exhibiting \u00a0raltegravir \u00a0resistance: \u00a0initial\u00a0results\u00a0of\u00a0\nVIKING\u00a0study\u00a0(ING112961). \u00a018th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Vienna,\u00a0July\u00a018\u201023\u00a02010.\u00a0Abstract\u00a0\nMOAB0105. \u00a0\n\u00a0 987.\u00a0\u00a0Arribas\u00a0JR,\u00a0Lazzarin\u00a0A,\u00a0Raffi,\u00a0F,\u00a0Rakhmanova \u00a0A,\u00a0Richmond \u00a0G,\u00a0Rockstroh \u00a0J,\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0S/GSK1349572 \u00a0\nas\u00a0part\u00a0of\u00a0combination \u00a0therapy\u00a0in\u00a0antiretroviral \u00a0na\u00efve\u00a0adults:\u00a0rapid\u00a0and\u00a0potent\u00a0antiviral\u00a0responses \u00a0in\u00a0the\u00a0\ninterim\u00a016\u2010week\u00a0analysis\u00a0from\u00a0SPRING\u20101\u00a0(ING112276). \u00a018th\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Vienna,\u00a0July\u00a0\n18\u201023\u00a02010.\u00a0Abstract\u00a0THLBB205. \u00a0\n\u00a0 988.\u00a0\u00a0Gulick\u00a0RM,\u00a0Su\u00a0Z,\u00a0Flexner\u00a0C,\u00a0Hughes\u00a0MD,\u00a0Skolnik\u00a0PR,\u00a0Wilkin\u00a0TJ\u00a0et\u00a0al.\u00a0Phase\u00a02\u00a0study\u00a0of\u00a0the\u00a0safety\u00a0and\u00a0\nefficacy\u00a0of\u00a0vicriviroc, \u00a0a\u00a0CCR5\u00a0inhibitor,\u00a0in\u00a0HIV\u20101\u2010Infected,\u00a0treatment \u2010experienced \u00a0patients:\u00a0AIDS\u00a0clinical\u00a0\ntrials\u00a0group\u00a05211.\u00a0J\u00a0Infect\u00a0Dis\u00a02007;\u00a0196(2):304 \u2010312\u00a0\n\u00a0 989.\u00a0\u00a0McNicholas \u00a0P,\u00a0Wei\u00a0Y,\u00a0Whitcomb \u00a0J,\u00a0Greaves\u00a0W,\u00a0Black\u00a0TA,\u00a0Tremblay \u00a0CL\u00a0et\u00a0al.\u00a0Characterization \u00a0of\u00a0emergent \u00a0\nHIV\u00a0resistance \u00a0in\u00a0treatment \u2010naive\u00a0subjects\u00a0enrolled\u00a0in\u00a0a\u00a0vicriviroc\u00a0phase\u00a02\u00a0trial.\u00a0J\u00a0Infect\u00a0Dis\u00a02010;\u00a0\n201(10):1470 \u20101480\u00a0\n\u00a0 990.\u00a0\u00a0Wilkin\u00a0TJ,\u00a0Su\u00a0Z,\u00a0Krambrink \u00a0A,\u00a0Long\u00a0J,\u00a0Greaves\u00a0W,\u00a0Gross\u00a0R\u00a0et\u00a0al.\u00a0Three\u2010year\u00a0safety\u00a0and\u00a0efficacy\u00a0of\u00a0\nvicriviroc, \u00a0a\u00a0CCR5\u00a0antagonist, \u00a0in\u00a0HIV\u20101\u2010infected\u00a0treatment \u2010experienced \u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02010;\u00a054(5):470 \u2010476\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02011)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 239\u00a0 991.\u00a0\u00a0McCallister \u00a0S,\u00a0Doto\u00a0J,\u00a0Allaway\u00a0G,\u00a0Martin\u00a0DE.\u00a0Multiple\u00a0dosing\u00a0of\u00a0the\u00a0novel\u00a0HIV\u20101\u00a0maturation \u00a0inhibitor\u00a0\nbevirimat: \u00a0aggregate \u00a0adverse\u00a0event\u00a0(AE)\u00a0and\u00a0laboratory \u00a0data\u00a0from\u00a0four\u00a0short\u2010term\u00a0studies.\u00a04th\u00a0IAS\u00a0\nConference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a0July\u00a022\u201025\u00a02007.\u00a0Abstract\u00a0\nWEPEA110. \u00a0\n\u00a0 992.\u00a0\u00a0Llibre\u00a0JM,\u00a0Antela\u00a0A,\u00a0Arribas\u00a0JR,\u00a0Domingo\u00a0P,\u00a0Gatell\u00a0JM,\u00a0Lopez\u2010Aldeguer\u00a0J\u00a0et\u00a0al.\u00a0El\u00a0papel\u00a0de\u00a0las\u00a0\ncombinaciones \u00a0de\u00a0antirretrovirales \u00a0a\u00a0dosis\u00a0fijas.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02010;\u00a028(9):615 \u2010620\u00a0\n\u00a0\n\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}